wsi_fname,part_description,processed_date,text_data_clindx,text_data_final
H23-852;S12;MSKW - 2023-06-15 16.42.50.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Lymphoma, Mantle Cell\par Clinical Hx/Op Findings: pre-treatment\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\par      - Involvement by mantle cell lymphoma (approximately 10% with CD20 immunohistochemistry)\par      - Hypercellular marrow with trilineage maturing hematopoiesis.\par\par See comment.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT:\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b  \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  The intrasinusoidal infiltrative pattern of the lymphoma is unusual but is reported in mantle cell lymphoma.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy shows hypercellular bone marrow (60% cellularity). There is\~trilineage maturing hematopoiesis and interstitial small lymphocytes.  The aspirate smears are hypercellular and show increased small lymphocytes.  \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Immunostain for CD20 highlights an interstitial and predominantly intrasinusoidal lymphoid infiltrate taking up 10% of the cellularity.  The lymphoid infiltrate shows CD5 and weak CyclinD1 expression.  CD3 highlights the T-cells.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-1200)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Abnormal B cell population detected. \par The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)\par Abnormal B cell population represents 19.7% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD43 (positive), CD79b (dim), ROR1 (positive), CD19 (dim)\par Normal: CD20, CD81, CD40, CD45, CD38\par Negative: CD23, CD200, CD10, CD3\par\par Number of cells acquired: 552 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (01/31/2023):\par WBC 13.6 H [4.0-11.0 K/mcL] \par RBC 4.96 [3.80-5.00 M/mcL] \par HGB 14.5 [11.2-15.4 g/dL] \par HCT 43.7 [34.3-46.0 %] \par MCV 88 [80-98 fL] \par MCH 29.2 [27.0-33.0 pg] \par MCHC 33.2 [31.0-36.5 g/dL] \par RDW 12.7 [12.2-15.1 %] \par Platelets 269 [160-400 K/mcL] \par\par Neutrophil 19.0 L [32.5-74.8 %] \par Mono 4.0 [0.0-12.3 %] \par Eos 8.0 H [0.0-4.9 %] \par Baso 2.0 H [0.0-1.5 %] \par Lymph 22.0 [12.2-47.4 %] \par Abnormal Lymphoid Cells 45.0 H [0.0-0.0 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 2.6 [1.5-7.5 K/mcL] \par Abs Mono 0.5 [0.0-1.3 K/mcL] \par Absolute Eosinophil 1.1 H [0.0-0.7 K/mcL] \par Absolute Basophil 0.3 H [0.0-0.2 K/mcL] \par Abs Lymph 9.1 H [0.9-3.2 K/mcL] \par\par Morphology:  Lymphocytosis of predominantly small lymphocytes\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Not available\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Not available\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-376;S16;MSK1 - 2023-06-12 14.10.18.ndpi,Peripheral Blood Smear,2023-06-12,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Lymphoma\par Clinical Hx/Op Findings: pt with R/R CLL, screening for protocol 21-375\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: \~\~\par      - Chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), 10% involvement with PAX5/CD20 immunohistochemistry. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy and aspirate specimens show mildly hypercellular bone marrow for age (60-70% cellularity). There is\~trilineage maturing hematopoiesis with atypical lymphocytic infiltrate showing nodular and interstitial distribution. \par\~\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 Bone Marrow Aspirate Smear Quality:  Adequate \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Blasts \tab\tab\tab 3%\par Promyelocytes \tab\tab 2%\par Myelocytes \tab\tab 15%\par Metamyelocytes \tab\tab 7%\par Neutrophils/Bands \tab 35%\par Monocytes \tab\tab 3%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 24%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 9%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 2.6\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par PAX5, CD20 (dim) and CD23 (dim) show involvement by CLL/SLL, comprising approximately 10% of marrow cellularity, showing nodular and interstitial distribution. \par These CLL/SLL cells co-express CD5, LEF1, and P53.\par Cyclin D1 is negative.\par CD3 highlights background T-cells.  \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-536)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par Abnormal B cell population detected. \par The findings are consistent with previously diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)\par Abnormal B cell population represents 7.2% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD20 (variable - negative to dim), CD23 (partial - dim), CD43 (positive), CD79b (partial - dim), CD81 (dim), CD200 (bright), ROR1 (positive), CD19 (dim), CD45 (dim)\par Normal: CD40\par Negative: CD38, CD10, CD3\par\par Number of cells acquired 416 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (1/13/2023):\par\par WBC 20.1 H [4.0-11.0 K/mcL] \par RBC 5.24 [3.95-5.54 M/mcL] \par HGB 15.2 [12.5-16.2 g/dL] \par HCT 45.1 [37.5-49.3 %] \par MCV 86 [80-98 fL] \par MCH 29.0 [27.0-33.0 pg] \par MCHC 33.7 [31.0-36.5 g/dL] \par RDW 13.3 [12.2-15.1 %] \par Platelets 163 [160-400 K/mcL] \par\par Neutrophil 64.0 [32.5-74.8 %] \par Mono 9.0 [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Metamyelocyte 3.0 H [0.0-0.0 %] \par Lymph 23.0 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 12.9 H [1.5-7.5 K/mcL] \par Abs Mono 1.8 H [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Meta 0.6 H [0.0-0.0 K/mcL] \par Abs Lymph 4.6 H [0.9-3.2 K/mcL] \par\par Morphology: Circulating atypical lymphocytes with high N/C ratio, clumped chromatin and occasional distinct nucleoli are present. \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-303. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M23-2219. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-82;S2;MSKQ - 2023-06-15 09.05.37.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Acute Lymphoid Leukemia\par  \par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-2.  Bone marrow, right posterior iliac crest, \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2  aspirate and peripheral blood smears:\plain\rtlch\af1\afs18\alang1033\ltrch\f1\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2   \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033    - Involvement by B-lymphoblastic leukemia/lymphoma (blasts 75% by aspirate smear differential). See comment.\par\par COMMENT:\par Correlation of these findings with cytogenetic and molecular studies is recommended. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate\par\par Blasts \tab\tab\tab 75%\par Promyelocytes \tab\tab 2%\par Myelocytes \tab\tab 4%\par Metamyelocytes \tab\tab 2%\par Neutrophils/Bands \tab 2%\par Monocytes \tab\tab 1%\par Eosinophils \tab\tab 2%\par Erythroid Precursors \tab 10%\par Lymphocytes \tab\tab 2%\par Number of Cells Counted 500\par M:E Ratio \tab\tab N/A\par\par Morphology:\par Spicular and cellular aspirate smears show an expanded population of blasts (small to intermediate cells with scant amphophilic cytoplasm, round to oval nuclei, fine chromatin and distinct nucleoli). Myeloid elements show maturation without significant dysplasia. Erythroid elements show maturation with occasional binucleation, nuclear membrane irregularities, and late stage mitosis. Megakaryocytes are present and display occasional hypolobated forms. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (01/04/2023):\par WBC 243.8 H [7.1-15.9 K/mcL] \par RBC 2.33 L [2.93-4.75 M/mcL] \par HGB 6.2 L [9.2-12.7 g/dL] \par HCT 19.3 L [27.7-37.9 %] \par MCV 83 [70-85 fL] \par MCH 26.6 [22.7-29.5 pg] \par MCHC 32.1 [31.0-36.5 g/dL] \par RDW 19.2 H [12.2-15.1 %] \par Platelets 61 L [160-400 K/mcL] \par\par Neutrophil 1.0 L [16.9-74.5 %] \par Mono 0.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Blast 89.0 H [0.0-0.0 %] \par Lymph 10.0 L [18.1-79.9 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 2.4 [1.5-8.5 K/mcL] \par Abs Mono 0.0 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Blasts 217.0 H [0.0-0.0 K/mcL] \par Abs Lymph 24.4 H [1.1-8.1 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] \par\par Morphology:\par WBC: Increased circulating blasts present (89%).\par RBC: Moderate normocytic  anemia. \par PLT: Moderate thrombocytopenia. \plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-112)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Abnormal immature B cell population represents 81.2% of WBC.\par Abnormal immature B cell population represents 84.8% of the mononuclear cells..\par\par Immunophenotype:\par Abnormal: CD20 (partial), CD24 (bimodal - dim to intermediate), CD34 (negative), CD45 (variable - negative to intermediate), CD66c/CD123 (partial), CD86 (partial), CD123 (positive)\par Normal: CD10, CD19, CD22, CD36, CD38, CD45RA, CD71, CD81, CD105, CD371 (clec12a), HLA-DR, cytoplasmic CD79a\par Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD25, CD26, CD33, CD56, CD64, CD66b, CD73/CD304, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par Number of cells acquired 4.25 million \par\par 2. No abnormal myeloid blast, mature B or mature T cell populations identified.                               \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par Myeloid blast population with an unremarkable phenotype represents 0.24% of WBC.\par\par Number of cells acquired: 761 thousand \par\par  Also see F23-111 submitted on the same day.\~\~\~\~\~\~\~\~\par\par\par\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 CG?23-64, CG23-465.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par  \plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par MOLECULAR STUDIES \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Molecular analysis will be reported separately. See separate report\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 ,M23-465, M22-464\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-889;S12;MSK6 - 2023-06-15 16.25.05.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Hairy cell leukemia\par Requested Studies: Gross/Micro\par Clinical Hx/Op Findings: 47 yo man with hairy cell leukemia, treated in past with cladribine, now with decreasing counts\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\par      - Extensive involvement by hairy cell leukemia (50-80% with CD20 immunohistochemistry).  \par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy and aspirate specimens show cellular bone marrow (50-60% cellularity). There is\~trilineage maturing hematopoiesis with an extensive interstitial infiltrate of hairy cells with clear cytoplasm.\par\~\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The immunostains for CD20, BRAF (weak) and CD103 highlight the hairy cell infiltrate taking up 50-80% of the cellularity.  CD3 highlights the small background T-cells.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-1248)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par 1. Abnormal B cell population detected.\par The immunophenotype of the abnormal B-cell is consistent with involvement by hairy cell leukemia (HCL).\par Abnormal B cell population represents 6.5% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (bright), CD20 (bright), CD22 (bright), CD25 (positive), CD11c (positive), CD103 (positive), CD200 (bright), CD45 (variable - intermediate to bright), surface Lambda (restriction), Forward Scatter (increased), Side Scatter (increased)\par Normal: CD38\par Negative: CD5, CD10, CD279 (PD1), CD3, CD14, surface Kappa\par\par 2. No abnormal mature T cell population detected. \par No immunophenotypic evidence of T-cell lymphoma is identified.  \par\par Number of cells acquired: 190 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Morphology:  Circulating hairy cells are seen\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-795.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M23-5109, M23-5110.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-165;S16;MSKX - 2023-06-15 09.28.41.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Lymphoma\par Clinical Hx/Op Findings: d+28 s/p car t\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears:   \par      - Involvement by previously diagnosed CD30+ large B-celll lymphoma. See comment. \par      - Limited marrow biopsy with trilineage maturing hematopoiesis.\par\par COMMENT: The core biopsy is limited and markedly fragmented; and the level of disease involvement can not be accurately assessed.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Suboptimal small and fragmented core biopsy shows variably cellular marrow (10% to ~70%cellularity) with focal interstitial and paratrabecular atypical lymphohistiocytic infiltrate, composed of medium to occasional large-sized atypical cells intermixed with histiocytes and frequent small lymphocytes. Background trilineage maturing hematopoiesis is present with no increase in blasts. Touch imprints are markedly hypocellular and show scattered maturing myeloid and erythroid elements and lymphoid cells. Aspirate smears are not available. \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The atypical lymphoid cells are positive for CD30, PAX5 (dim), MUM1, OCT-2 (dim), CD79a (subset, dim) and EBV-LMP1; and are negative for CD15. EBER-ISH is negative. \par CD3 and CD7 (dim) highlight numerous background small T-cells. \par CD20 immunostain is negative. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-222)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par No abnormal mature B cell population detected. Virtually no B cells seen.\par No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.\par\par Number of cells acquired: 31 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (01/06/2023 ):\par WBC 4.4 [4.0-11.0 K/mcL] \par RBC 2.31 L [3.80-5.00 M/mcL] \par HGB 8.3 L [11.2-15.4 g/dL] \par HCT 23.8 L [34.3-46.0 %] \par MCV103 H [80-98 fL] \par MCH 35.9 H [27.0-33.0 pg] \par MCHC 34.9 [31.0-36.5 g/dL] \par RDW 21.9 H [12.2-15.1 %] \par Platelets 36 L [160-400 K/mcL] \par\par Neutrophil 3.0 L [32.5-74.8 %] \par Mono 1.0 [0.0-12.3 %] \par Eos 5.0 H [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Lymph 91.0 H [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 0.1 L [1.5-7.5 K/mcL] \par Abs Mono 0.0 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Lymph 4.0 H [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] \par\par Morphology:\par WBC: No circulating blasts; few atypical lymphoid cells and large granular lymphocytes present \par RBC: Anisocytosis \par PLT: Marked thrombocytopenia \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Not requested. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Not requested. \plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-306;S14;MSK2 - 2023-06-15 19.11.48.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Leukemia, CMML\par Clinical Hx/Op Findings: 63 yo man w/ suspected CMML vs other MDS/MPN or AML\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: \par      - Involvement by Mantle cell lymphoma (approximately 80-90% by CD20 immunostain), see comment.\par      - Background trilineage hematopoiesis is reduced.\par   \par COMMENT:  The biopsy shows an extensive involvement by mantle cell lymphoma, focally revealing blastoid morphology.  Correlation with cytogenetic and molecular studies is recommended.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adeqaute\par Cellularity:  Hypercellular, approximately 90%\par M:E ratio: NA\par Blasts:  Not increased\par Myeloid lineage:  Reduced\par Erythroid lineage:  Reduced\par Megakaryocytes:  Present with few forms with hyperchromatic nuclei\par Lymphocytes:  Extensive involvement by an atypical lymphoid infiltrate composed of medium sized cells with ovoid to slightly irregular nuclei, coarse chromatin and inconspicuous nucleoli. In focal areas the infiltarte is composed of larger lymphoid cells with finer chromatin and consipicous nucleoli.\par Plasma cells:  Scattered\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules\par\par Blasts \tab\tab\tab 3%\par Myelocytes \tab\tab 4%\par Metamyelocytes \tab\tab 1%\par Neutrophils/Bands \tab 3%\par Eosinophils \tab\tab 3%\par Erythroid Precursors \tab 11%\par Lymphocytes \tab\tab 75%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 1\par\par Special stain \par Iron: Present\par Ring sideroblasts: Absent \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -The aspirate smears are aspicular and hemodilute.  The touch imprints are cellular and show an atypical lymphoid infiltrate composed of medium size cells with with ovoid to slightly irregular nuclei, coarse chromatin and inconspicuous nucleoli and admixed larger cells with conspicuous nucleoli.  The myeloid and erythroid elements are reduced.  Few scattered megakaryocytes are noted.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (01/11/2023):\par WBC 12.6 H [4.0-11.0 K/mcL] \par RBC 4.02 [3.95-5.54 M/mcL] \par HGB 12.1 L [12.5-16.2 g/dL] \par HCT 35.1 L [37.5-49.3 %] \par MCV 87 [80-98 fL] \par MCH 30.1 [27.0-33.0 pg] \par MCHC 34.5 [31.0-36.5 g/dL] \par RDW 13.8 [12.2-15.1 %] \par Platelets 33 L [160-400 K/mcL] \par\par Neutrophil 33.0 [32.5-74.8 %] \par Mono 9.0 [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Blast 2.0 H [0.0-0.0 %] \par Myelocyte 5.0 H [0.0-0.0 %] \par Metamyelocyte 3.0 H [0.0-0.0 %] \par Lymph 14.0 [12.2-47.4 %] \par Other 33.0 H [0.0-0.0 %] \par Mononuclear cells with prominent nucleoli, some with irregular nuclear contours.\par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 4.2 [1.5-7.5 K/mcL] \par Abs Mono 1.1 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Blasts 0.3 H [0.0-0.0 K/mcL] \par Abs Myelocytes 0.6 H [0.0-0.0 K/mcL] \par Abs Meta 0.4 H [0.0-0.0 K/mcL] \par Abs Lymph 1.8 [0.9-3.2 K/mcL] \par Abs Others 4.2 H [0.0-0.0 K/mcL] \par\par Morphology:  Frequent atypical lymphoid cells noted.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The atypical lymphoid cells\par Express:  CD20, CD5, cyclin D1, Sox 11\par Do not express:  CD3, CD23, LEF1\par Others:  P53 strongly stains few scattered cells on this decalcified material\par CD138 and BCMA stain plasma cells, less than 5% of cellularity.  The plasma cells are polytypic by kappa and lambda immunostains\par\par CD34 stains few scattered blasts, less than 1%\par CD 71 and MPO stain reduced erythroid and myeloid elements, respectively\par CD61 stains scattered megakaryocytes\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-447)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal B cell population detected.\par The immunophenotype of this abnormal B cell population is not entirely specific and does not allow for full classification by flow cytometry.\par Correlation with immunohistochemical or cytogenetic studies for Cyclin D1 is recommended to rule out mantle cell lymphoma (MCL).\par\par Abnormal B cell population represents 70.7% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD43 (positive), ROR1 (positive), CD19 (positive -dim), surface Kappa (restriction)\par Normal: CD20, CD22, CD79b, CD81, CD40, CD45, CD38\par Negative: CD23, CD200, CD10, CD3, surface Lambda, CD14, CD25, CD279 (PD1)\par\par Number of cells acquired 596 thousand\par\par 2. No abnormal myeloid blast, monocyte or maturing myeloid population identified.\par Flow cytometry is generally not a sensitive methodology in the context of myeloproliferative disorders, correlation with molecular studies for JAK2, CALR, MPL mutation status and/or BCR-ABL and morphology is advised if clinically indicated.\par\par Myeloid blast population with an unremarkable phenotype represents 0.91% of WBC.\par\par Number of cells acquired: 275 thousand\par\par 3. No abnormal mature T cell population detected.\par No immunophenotypic evidence of T-cell lymphoma is identified.\par\par Number of cells acquired: 301 thousand\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-389;S10;MSK9 - 2023-06-15 16.07.49.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: ALL\par Clinical Hx/Op Findings: new dx ALL\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b 1-3. Bone marrow, left posterior iliac crest; biopsy, \plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears: \plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\~\~\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par      - B-lymphoblastic leukemia/lymphoma, 45% blasts by aspirate differential count.\par    \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Correlation with forthcoming cytogenetic and molecular studies is advised.\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Multiple core biopsy fragments with significant aspiration and partial crush artifact, limiting evaluation\par Cellularity: Cannot be accurately assessed; the intact residual areas appear approximately 60% cellular\par M:E ratio: Cannot be assessed\par Blasts: Markedly increased in number and comprise most of the assessable cellularity (predominantly intermediate-sized) with rounded nuclei, fine chromatin, indistinct nucleoli and scant amount of cytoplasm\par Myeloid lineage: Markedly reduced\par Erythroid lineage: Reduced\par Megakaryocytes: Present; include forms with hyperchromatic nuclei\par Lymphocytes: Interstitially scattered\tab\par Plasma cells: Not increased\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate \par Blasts \tab\tab\tab 45%\par Neutrophils/Bands \tab 1%\par Eosinophils \tab\tab 2%\par Erythroid Precursors \tab 17%\par Lymphocytes \tab\tab 35%\par Number of Cells Counted  500\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par The aspirate smears are spicular and hypercellular with an expanded population of blasts that are variably-sized, predominantly intermediate, with rounded to slightly irregular nuclei, fine to mildly condensed chromatin, occasionally prominent nucleoli, and scant amount of cytoplasm, frequently with azurophilic granules. Maturing myeloid elements are markedly reduced. Erythroid precursors exhibit megaloblastoid maturation. Megakaryocytes are present and show unremarkable morphology. Small mature lymphocytes and a few plasma cells are also present.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (1/13/2023):\par WBC 2.0 L [4.0-11.0 K/mcL] \par RBC 2.29 L [3.80-5.00 M/mcL] \par HGB 7.2 L [11.2-15.4 g/dL] \par HCT 22.1 L [34.3-46.0 %] \par MCV 97 [80-98 fL]\par MCH 31.4 [27.0-33.0 pg] \par MCHC 32.6 [31.0-36.5 g/dL] \par RDW 16.9 H [12.2-15.1 %] \par Platelets 82 L [160-400 K/mcL] \par\par Neutrophil 32.2 L [32.5-74.8 %] \par Mono 2.1 [0.0-12.3 %] \par Eos 2.6 [0.0-4.9 %] \par Baso 0.5 [0.0-1.5 %] \par Immature Granulocyte 0.0 [0.0-0.6 %] \par Lymph 62.6 H [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 0.6 L [1.5-7.5 K/mcL] \par Abs Mono 0.0 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 1.2 [0.9-3.2 K/mcL] \par\par Morphology:\par RBC: Normocytic to borderline macrocytic anemia; anisocytosis with increase in polychromasia; rare nRBCs.\par WBC: Leukopenia with neutropenia; only rare circulating blasts noted.\par PLT: Moderate thrombocytopenia; unremarkable morphology.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and TdT highlight markedly increased number of blasts (approximately 70% of cellularity in the intact areas).\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-555)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal immature B-cell population detected.\par The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.\par\par Abnormal immature B-cell population represents 28.0% of WBC.\par Abnormal immature B-cell population represents 27.4% of the mononuclear cells.\par\par Immunophenotype:\par Abnormal: CD10 (positive - bright), CD24 (bimodal - negative to intermediate), CD25 (positive), CD33 (intermediate), CD38 (dim), CD45 (variable - dim to negative), CD45RA (variable - negative to intermediate), CD66c/CD123 (positive), CD81 (variable - intermediate to dim)\par Normal: CD19, CD22, CD34, CD36, CD71, CD105, HLA-DR, cytoplasmic CD79a\par Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD20 (no definite), CD26, CD56, CD64, CD66b, CD73/CD304, CD86, CD117, CD123, CD279 (PD1), CD371 (clec12a), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par Number of cells acquired: 1.32 million \par\par 2. No abnormal mature B- or T-cell populations detected. \par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par Number of cells acquired: 467 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-310.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M23-2125, M23-2128, M23-2129, M23-2130.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-164;S11;MSKR - 2023-06-15 09.22.57.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: ALL\par Clinical Hx/Op Findings: New Dx\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears:   \~\par      - B lymphoblastic leukemia/lymphoma, not further classifed (89% blasts by aspirate differential count). \par      - Hypercellular marrow with markedly reduced trilineage maturing hematopoiesis.\par   \par See comment\par\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  Correlation with concurrent cytogenetic and molecular genetic/genomic studies is required for further classification.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Hypercellular (80%)\par M:E ratio: N/A\par Blasts: Increased\par Myeloid lineage: N/A\par Erythroid lineage: N/A\par Megakaryocytes: Present, forms with hyperchromatic nuclei are seen\par Lymphocytes: Scattered\par Plasma cells: Scattered\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules\par Differential performed on touch imprint \par\par Blasts \tab\tab\tab 89%\par Myelocytes \tab\tab 1%\par Neutrophils/Bands \tab 1%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 3%\par Lymphocytes \tab\tab 5%\par Number of Cells Counted   500\par M:E Ratio \tab\tab 1\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -Aspicular and hypocellular aspirate smears and cellular tough imprint showing increased blasts with fine chromatin, prominent nucleoli and scant cytoplasm with vacuoles. Myeloid and erythroid elements are rare. Megakaryocytes are not seen.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (01/06/2023 ):\par\par WBC 2.4 L [4.0-11.0 K/mcL] \par RBC 2.69 L [3.80-5.00 M/mcL] \par HGB 7.7 L [11.2-15.4 g/dL] \par HCT 22.7 L [34.3-46.0 %] \par MCV 84 [80-98 fL] \par MCH 28.6 [27.0-33.0 pg] \par MCHC 33.9 [31.0-36.5 g/dL] \par RDW 14.3 [12.2-15.1 %] \par Platelets. 32 L [160-400 K/mcL] \par\par Neutrophil 27.0 L [32.5-74.8 %] \par Mono 2.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Blast 4.0 H [0.0-0.0 %] \par Myelocyte 1.0 H [0.0-0.0 %] \par Lymph 66.0 H [12.2-47.4 %] \par Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 0.6 L [1.5-7.5 K/mcL] \par Abs Mono 0.0 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Blasts 0.1 H [0.0-0.0 K/mcL] \par Abs Myelocytes 0.0 [0.0-0.0 K/mcL] \par Abs Lymph 1.6 [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] \par\par\par Morphology: WBC: Circulating blasts are increased; Neutropenia\par RBC: Normocytic normochromic anemia, polychromasia and rare nucleated red blood cells are present\par Platelets: Thrombocytopenia\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The blasts are predominantly negative for CD34 and TdT with occasional cells showing weak expression. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-217)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal immature B cell population detected.\par The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.\par\par Abnormal immature B cell population represents 86.9% of WBC.\par Abnormal immature B cell population represents 91.7% of the mononuclear cells..\par\par Immunophenotype:\par Abnormal: CD10 (dim), CD20 (partial), CD34 (variable - negative to dim), CD45 (variable - negative to intermediate), CD66c/CD123 (partial), CD73/CD304 (positive), CD86 (partial)\par Normal: CD19, CD22, CD24, CD36, CD38, CD45RA, CD71, CD81, CD105, CD123, CD371 (clec12a), HLA-DR, cytoplasmic CD79a\par Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD25, CD26, CD33, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par 2. No abnormal myeloid blast, mature B or mature T cell populations identified.                               \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par Myeloid blast population with an unremarkable phenotype represents 0.042% of WBC.\par\par Number of cells acquired: 900 thousand \par\par  Also see F23-188 submitted on the same day.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-128.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M23-862, M23-867, M23-871.\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-614;S3;MSKS - 2023-04-14 14.27.33.ndpi,Peripheral Blood Smear,2023-04-14,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\*\cs10\additive Default Paragraph Font;}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon0 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 MDS \par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\*\cs10\additive Default Paragraph Font;}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon0 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears: \plain\rtlch\af1\afs18\alang1033\ltrch\f1\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033      - Cellular bone marrow aspirate with maturing trilineage hematopoiesis.\par      - No morphologic or immunophenotypic evidence of myeloid neoplasm.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate \par\par Blasts \tab\tab\tab 2%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 9%\par Metamyelocytes \tab\tab 5%\par Neutrophils/Bands \tab 35%\par Monocytes \tab\tab 4%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 35%\par Lymphocytes \tab\tab 8%\par Number of Cells Counted \tab 500\par M:E Ratio \tab\tab 1.6\par\par Special stain\par Iron: Present\par Ring sideroblasts: Absent \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Morphology:\par The aspirate smears are spicular, cellular, and show maturing trilineage hematopoiesis. There is no increase in blasts. Erythroid and myeloid elements are adequate in proportion with progressive maturation and no overt atypia. Megakaryocytes are present with overall unremarkable morphology. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (1/23/2023):\par\par WBC 5.0 [4.0-11.0 K/mcL] \par RBC 3.43 L [3.95-5.54 M/mcL] \par HGB 12.1 L [12.5-16.2 g/dL] \par HCT 35.7 L [37.5-49.3 %] \par MCV 104 H [80-98 fL] \par MCH 35.3 H [27.0-33.0 pg] \par MCHC 33.9 [31.0-36.5 g/dL] \par RDW 13.2 [12.2-15.1 %] \par Platelets 292 [160-400 K/mcL] \par\par Neutrophil 57.7 [32.5-74.8 %] \par Mono 13.7 H [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 0.4 [0.0-1.5 %] \par Immature Granulocyte 0.2 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 27.0 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 2.9 [1.5-7.5 K/mcL] \par Abs Mono 0.7 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL]\par Abs Lymph 1.3 [0.9-3.2 K/mcL] \par\par Morphology: No circulating blasts identified. WBCs, RBCs and platelets are morphologically unremarkable. \par\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-861)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par Myeloid blast population with an unremarkable phenotype represents 0.48% of WBC.\par\par Number of cells acquired: 519 thousand \par\par\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis not requested.\par  \plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par MOLECULAR STUDIES \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Molecular analysis will be reported separately. See separate report, M22-3430.\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-852;S12;MSKW - 2023-06-15 16.36.52.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Lymphoma, Mantle Cell\par Clinical Hx/Op Findings: pre-treatment\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\par      - Involvement by mantle cell lymphoma (approximately 10% with CD20 immunohistochemistry)\par      - Hypercellular marrow with trilineage maturing hematopoiesis.\par\par See comment.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT:\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b  \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  The intrasinusoidal infiltrative pattern of the lymphoma is unusual but is reported in mantle cell lymphoma.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy shows hypercellular bone marrow (60% cellularity). There is\~trilineage maturing hematopoiesis and interstitial small lymphocytes.  The aspirate smears are hypercellular and show increased small lymphocytes.  \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Immunostain for CD20 highlights an interstitial and predominantly intrasinusoidal lymphoid infiltrate taking up 10% of the cellularity.  The lymphoid infiltrate shows CD5 and weak CyclinD1 expression.  CD3 highlights the T-cells.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-1200)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Abnormal B cell population detected. \par The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)\par Abnormal B cell population represents 19.7% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD43 (positive), CD79b (dim), ROR1 (positive), CD19 (dim)\par Normal: CD20, CD81, CD40, CD45, CD38\par Negative: CD23, CD200, CD10, CD3\par\par Number of cells acquired: 552 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (01/31/2023):\par WBC 13.6 H [4.0-11.0 K/mcL] \par RBC 4.96 [3.80-5.00 M/mcL] \par HGB 14.5 [11.2-15.4 g/dL] \par HCT 43.7 [34.3-46.0 %] \par MCV 88 [80-98 fL] \par MCH 29.2 [27.0-33.0 pg] \par MCHC 33.2 [31.0-36.5 g/dL] \par RDW 12.7 [12.2-15.1 %] \par Platelets 269 [160-400 K/mcL] \par\par Neutrophil 19.0 L [32.5-74.8 %] \par Mono 4.0 [0.0-12.3 %] \par Eos 8.0 H [0.0-4.9 %] \par Baso 2.0 H [0.0-1.5 %] \par Lymph 22.0 [12.2-47.4 %] \par Abnormal Lymphoid Cells 45.0 H [0.0-0.0 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 2.6 [1.5-7.5 K/mcL] \par Abs Mono 0.5 [0.0-1.3 K/mcL] \par Absolute Eosinophil 1.1 H [0.0-0.7 K/mcL] \par Absolute Basophil 0.3 H [0.0-0.2 K/mcL] \par Abs Lymph 9.1 H [0.9-3.2 K/mcL] \par\par Morphology:  Lymphocytosis of predominantly small lymphocytes\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Not available\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Not available\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-532;S15;MSKU - 2023-06-15 15.56.14.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: MDS\par Clinical Hx/Op Findings: MDS + T-LGL - evaluate for relative contribution to cytopenias\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, right posterior iliac crest, biopsy, clot, \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\~\par      - Limited biopsy showing myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD), see comment (1).\par      - Flow cytometry detected TCR gamma/delta positive large granular lymphocyte population (5.6% of WBC), see comment (2). \par      - Small abnormal B-cell population detected by flow cytometry (1.2% of WBC). \par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par (1) \par This biopsy shows increase in ring sideroblasts and dysmegakaryopoiesis and is best classified as MDS-RS-MLD by WHO 2016 classification. However, core biopsy and aspirate smears are very limited for morphological evaluation.  Please correlate with the results of ancillary studies. \par\par (2) Morphological evaluation of peripheral blood smear shows large granular lymphocytes (LGL), comprising approximately 10% of WBC. LGL population is estimated 5.6% by flow cytometry with bone marrow aspirate sample (F23-457).\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Limited. Mostly bone and soft tissue and small marrow particle present to show maturing trilineage hematopoiesis. \par Cellularity: Unable to accurately estimate\par M:E ratio: Inverted\par Blasts: Not overtly increased\par Myeloid lineage: Relative decrease. Orderly maturation.  \par Erythroid lineage: Relatively increased. Left shifted maturation \par Megakaryocytes: Few present.\par Lymphocytes: Scattered, without lymphoid aggregates seen.\par Plasma cells: Scattered\par Special stains: Reticulin stain shows no increase in reticulin fibrosis.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules \par Blasts \tab\tab\tab 1%\par Myelocytes \tab\tab 6%\par Metamyelocytes \tab\tab 3%\par Neutrophils/Bands \tab 45%\par Monocytes \tab\tab 4%\par Eosinophils \tab\tab 3%\par Erythroid Precursors \tab 22%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 15%\par Number of Cells Counted \tab 500\par M:E Ratio \tab\tab 2.8\par\par Special stain\par Iron: Inadequate for evaluation; devoid of spicules\par Ring sideroblasts: Present. Appear >15% however, slide is limited for evaluation.  \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Aspirate smears are aspicular, paucicellular, and markedly  hemodiluted.\par Erythroid elements show progressive maturation with mild megaloblastoid changes. Myeloid elements show complete maturation with rare hypogranular forms seen (<10%). Megakaryocytes are not well represented. Rare possible large granular lymphocyte seen. Lymphocytes do not show appreciable atypia. \par\par The differential may not be representative of marrow composition.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (1/19/23):\par WBC 3.1 L [4.0-11.0 K/mcL] \par RBC 2.66 L [3.80-5.00 M/mcL] \par HGB 9.7 L [11.2-15.4 g/dL] \par HCT 28.9 L [34.3-46.0 %] \par MCV 109 H [80-98 fL] \par MCH 36.5 H [27.0-33.0 pg] \par MCHC 33.6 [31.0-36.5 g/dL] \par RDW 24.4 H [12.2-15.1 %] \par Platelets. 141 L [160-400 K/mcL] \par\par Neutrophil 63.4 [32.5-74.8 %] \par Mono 10.5 [0.0-12.3 %] \par Eos 3.2 [0.0-4.9 %] \par Baso 0.3 [0.0-1.5 %] \par Immature Granulocyte 0.3 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 22.3 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 2.0 [1.5-7.5 K/mcL] \par Abs Mono 0.3 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 0.7 L [0.9-3.2 K/mcL]\par\par Morphology:\par WBC: Neutrophils with rare hypogranular forms (<10%). No circulating blasts.  Large granular lymphocytes are not markedly increased (approximately 10%) \par RBC: Anemia with mild anisopoikilocytosis\par PLT: Mild thrombocytopenia with no significant morphologic findings\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 highlight no increase in blasts, accounting for <5% of cellularity. \par CD117 also highlight scattered mast cells.\par CD61 highlights small dysplastic megakaryocytes in this limited biopsy. \par MPO and CD71 highlight myeloid and erythroid elements with an inverted M:E. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-752)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par\par 1. Highly atypical myeloid blast population detected.          \par In light of the atypical expression of the following markers listed below on a subset of myeloid blasts, a low-grade myeloid stem cell neoplasm cannot be entirely excluded by these studies. Normal myelomonocytic maturation is present. Morphologic, cytogenetic, and molecular genetic assessment is suggested to exclude myeloid stem cell neoplasm. Clinical correlation is advised. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment.\par\par Highly atypical myeloid blast population represents 0.04% of WBC.\par\par Immunophenotype:\par Atypical: CD7 (partial), CD13 (dim to negative), CD34 (bright), HLA-DR (uniform - bright)\par Normal: CD4, CD33, CD34, CD36, CD38, CD45, CD45RA, CD71, CD105, CD117, CD123, CD371 (clec12a)\par Negative: CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda, CD42b, CD90\par\par Number of cells acquired: 236 thousand \par\par 2. No abnormal mature T-cell population detected. An expanded population of large granular lymphocytes is not seen. \par TCR gamma/delta positive large granular lymphocyte population represents 5.6% of WBC.\par No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.\par\par Number of cells acquired: 363 thousand \par\par 3. Abnormal B-cell population detected.\par\par Abnormal B-cell population represents 1.2% of WBC.\par\par Immunophenotype:\par Abnormal: CD10 (possible dim), CD20 (bright), CD22 (bright), CD45 (bright), surface Kappa (restriction)\par Normal: CD19\par Negative: CD5, CD38, CD25, CD279 (PD1), CD3, CD14, surface Lambda\par\par Number of cells acquired: 285 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-457.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M23-3165, M23-3166, M23-3167, M23-3168, M23-3197. \plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-41;S17;MSKR - 2023-06-15 10.09.25.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Lymphoma\par Requested Studies: Gross/Micro\par Clinical Hx/Op Findings: MCL  pre treatment disease assessment per protocol\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: \~\~\par      - Extensive involvement by mantle cell lymphoma (90% of cellularity by CD20 immunostain).\par\par See comment.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  Suggest correlation with genetic findings for further characterization.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Fragmented biopsy shows focally preserved marrow spaces almost entirely replaced by a lymphoid infiltrate of small lymphocytes with slightly irregular nuclei and clumped chromatin.  Occasional hematopoietic elements are seen in the background.  The aspirate smears are aspicular and hypocellular but shows increased numbers of small to medium lymphoid cells.  \par\~\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The lymphoid infiltrate is positive for CD20, PAX5, CD5 and CyclinD1 and negative for Sox11. P53 shows weak expression in a large subset of the lymphoid cells. CD3 highlights small background T-cells.  Ki67 highlights occasional nuclei.  \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-65)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Abnormal B cell population detected. \par The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)\par\par Abnormal B cell population represents 69.5% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (bimodal - negative to bright), CD43 (positive), CD81 (dim), ROR1 (positive)\par Normal: CD20, CD79b, CD19, CD40, CD45, CD38\par Negative: CD23, CD200, CD10, CD3\par\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (01/03/2022):\par WBC 167.0 H [4.0-11.0 K/mcL] \par RBC 3.73 L [3.95-5.54 M/mcL] \par HGB 10.4 L [12.5-16.2 g/dL] \par HCT 33.2 L [37.5-49.3 %] \par MCV 89 [80-98 fL] \par MCH 27.9 [27.0-33.0 pg] \par MCHC 31.3 [31.0-36.5 g/dL] \par RDW 15.6 H [12.2-15.1 %] \par Platelets 124 L [160-400 K/mcL] \par\par Neutrophil 0.0 L [32.5-74.8 %] \par Mono 1.0 [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Lymph 5.0 L [12.2-47.4 %] \par Abnormal Lymphoid Cells 93.0 H [0.0-0.0 %] \par\par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par Abs Neut 0.0 L [1.5-7.5 K/mcL] \par Abs Mono 1.7 H [0.0-1.3 K/mcL] \par Absolute Eosinophil 1.7 H [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Lymph 163.6 H [0.9-3.2 K/mcL] \par\par Morphology:  Marked lymphocytosis of small to medium lymphoid cells and occasional large atypical lymphoid cells.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-36\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Not available\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-114;S2;MSKM - 2023-06-15 09.17.21.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par ALL \par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-2.  Bone marrow, right posterior iliac crest, \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2  aspirate and peripheral blood smears:\plain\rtlch\af1\afs18\alang1033\ltrch\f1\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033      - Involvement by B-lymphoblastic leukemia/lymphoma (blasts 70% by aspirate smear differential). See comment. \par\par  COMMENT:\par Correlation of these findings with cytogenetic and molecular studies is recommended. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules \par\par Blasts \tab\tab\tab 70%\par Myelocytes \tab\tab 3%\par Neutrophils/Bands \tab 12%\par Monocytes \tab\tab 1%\par Basophils \tab\tab 2%\par Erythroid Precursors \tab 3%\par Lymphocytes \tab\tab 9%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 6\par\par Morphology:\par Aspicular and hypocellular aspirate smears show bone marrow with increased population of blasts (large cells with high N:C ratios, round nuclei, fine chromatin, and prominent nucleoli). Background scattered myeloid and erythroid precursors are seen. Rare megakaryocytes are identified. Scattered lymphocytes and plasma cells are present.\par\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (1/4/2023):\par WBC 4.2 L [7.1-15.9 K/mcL] \par RBC 2.50 L [2.93-4.75 M/mcL] \par HGB 7.2 L [8.9-12.7 g/dL] \par HCT 20.3 L [26.8-37.8 %] \par MCV 81 [70-85 fL] \par MCH 28.8 [22.7-29.5 pg] \par MCHC 35.5 [31.0-36.5 g/dL] \par RDW 12.9 [12.2-15.1 %] \par Platelets. 59 L [160-400 K/mcL] \par\par\par Morphology:Pancytopenia with many circulating blasts.\par\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-147)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal immature B cell population detected.\par\par Abnormal immature B cell population represents 16.3% of WBC.\par Abnormal immature B cell population represents 21.8% of the mononuclear cells..\par\par Immunophenotype:\par Abnormal: CD10 (bright), CD13 (partial - dim), CD20 (positive), CD34 (negative), CD45 (negative), CD66c/CD123 (positive), CD73/CD304 (positive), CD123 (positive)\par Normal: CD19, CD22, CD24, CD36, CD38, CD45RA, CD71, CD81, CD105, CD371 (clec12a), HLA-DR, cytoplasmic CD79a\par Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD25, CD26, CD33, CD56, CD64, CD66b, CD86, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par Number of cells acquired 200 thousand \par\par 2. No abnormal myeloid blast, mature B or mature T cell populations identified.                               \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par\par Myeloid blast population with an unremarkable phenotype represents 0.56% of WBC.\par\par Number of cells acquired: 220 thousand \par\par\par\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-89.\par  \plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par MOLECULAR STUDIES \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Molecular analysis will be reported separately. See separate report\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-867;S13;MSK3 - 2023-06-15 16.31.02.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Lymphoma, Mantle Cell\par Requested Studies: Gross/Micro\par Clinical Hx/Op Findings: EOD\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: \~\~\par      - Involvement by mantle cell lymphoma (80% with CD20 immunohistochemistry)\par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par See comment.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Increased number of large atypical lymphoid cells is seen in peripheral blood and marrow, suggesting a blastoid variant of mantle cell lymphoma.  Suggest correlation with cytogenetic and molecular genetic studies for further characterization.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Small biopsy, adequate clot sections and aspirate specimens show hypercellular bone marrow (50-60%cellularity). There is\~trilineage maturing hematopoiesis with increased numbers of lymphocytes of variable size ranging from small to large with irregular nuclei and condensed chromatin.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The lymphoid infiltrate is positive for CD20 and CD5 and weakly express CyclinD1.  CD3 highlights scattered small T-cells in the background.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-1227)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Abnormal B cell population detected. \par The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)\par Abnormal B cell population represents 51.4% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD43 (positive), ROR1 (positive), CD19 (negative), CD45 (dim)\par Normal: CD20, CD79b, CD81, CD40, CD38\par Negative: CD23, CD200, CD10, CD3\par\par Number of cells acquired: 301 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (01/31/2023):\par WBC 14.0 H [4.0-11.0 K/mcL] \par RBC 3.27 L [3.95-5.54 M/mcL] \par HGB 10.9 L [12.5-16.2 g/dL] \par HCT 33.0 L [37.5-49.3 %] \par MCV 101 H [80-98 fL] \par MCH 33.3 H [27.0-33.0 pg] \par MCHC 33.0 [31.0-36.5 g/dL] \par RDW 16.3 H [12.2-15.1 %] \par Platelets 75 L [160-400 K/mcL] \par\par Neutrophil 30.0 L [32.5-74.8 %] \par Mono 4.0 [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Lymph 18.0 [12.2-47.4 %] \par Abnormal Lymphoid Cells 46.0 H [0.0-0.0 %] \par\par Abs Neut 4.2 [1.5-7.5 K/mcL] \par Abs Mono 0.6 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.1 [0.0-0.2 K/mcL] \par Abs Lymph 9.0 H [0.9-3.2 K/mcL] \par\par Morphology:  Lymphocytosis composed predominantly of medium to large lymphoid cells with round to irregular nuclei and distinct single to multiple nucleoli.  Numerous smudge cells are seen.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-786.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M23-4989.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-196;S15;MSK- - 2023-06-15 09.34.30.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: MDS\par Clinical Hx/Op Findings: pre BMT\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, left posterior iliac crest, biopsy; \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears: \~\~\par  \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033        - Hypercellular marrow with marked erythroid predominance, increased megakaryocytes, multilineage dysplasia predominantly involving megakaryocytic and erythroid lineages, increased ring sideroblasts and no increase in blasts consistent with myelodysplastic syndrome (MDS). \par   \par See comment\par\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:  \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Per clinical note, the patient has a history of intermediate risk myelodysplastic syndrome (MDS) with trisomy 8 and SF3B1 and DNMT3A mutations (both over 40% VAF). \plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b  \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The morphologic findings of the current marrow specimen support a diagnosis of MDS that could be best classified as MDS with mutated SF3B1 based on reported prior genetic profiling.  No increase in blasts seen.  Correlation with the concurrent cytogenetic and molecular genetic findings is recommended for definitive classification.\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate, fragmented\par Cellularity: Hypercellular (90%)\par M:E ratio: Inverted\par Blasts: Not increased\par Myeloid lineage: Relatively decreased, progressive maturation\par Erythroid lineage: Increased, left shifted maturation\par Megakaryocytes: Increased, small hypolobated dysplastic forms are frequent\par Lymphocytes: Scattered\par Plasma cells: Scattered\par\par Special stains: Reticulin stain shows focal mild increase in reticulin fibrosis up to MF1/3. \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate \par\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 3%\par Metamyelocytes \tab\tab 2%\par Neutrophils/Bands \tab 15%\par Monocytes \tab\tab 2%\par Eosinophils \tab\tab 3%\par Erythroid Precursors \tab 68%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 4%\par Number of Cells Counted   500\par M:E Ratio \tab\tab 0.4\par\par Special stain\par Iron: Present\par Ring sideroblasts: Present, >15% \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -Spicular and cellular smears show erythroid predominant marrow with no increase in blasts. Myeloid elements show progressive maturation with occasional forms with hypergranulation. Erythroid elements show left shifted maturation, megaloblastoid changes and forms with nuclear irregularities. Megakaryocytes are increased and show many small hypolobated forms.  Mast cells are increased and show frequent spindle cell forms.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (1/9/2023):\par\par WBC 4.3 [4.0-11.0 K/mcL] \par RBC 1.90 L [3.95-5.54 M/mcL] \par HGB 6.1 L [12.5-16.2 g/dL] \par HCT 18.7 L [37.5-49.3 %] \par MCV 98 [80-98 fL]\par MCH 32.1 [27.0-33.0 pg] \par MCHC 32.6 [31.0-36.5 g/dL] \par RDW 27.0 H [12.2-15.1 %] \par Platelets 246 [160-400 K/mcL] \par\par Neutrophil 62.2 [32.5-74.8 %] \par Mono 10.3 [0.0-12.3 %] \par Eos 7.7 H [0.0-4.9 %] \par Baso 0.9 [0.0-1.5 %] \par Immature Granulocyte 0.9 H [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 18.0 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 2.6 [1.5-7.5 K/mcL] \par Abs Mono 0.4 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL]\par Abs Lymph 0.8 L [0.9-3.2 K/mcL] \par\par Morphology: \par WBC: No circulating blasts are seen\par RBC: Normochromic normocytic anemia, anisopoikilocytosis\par Platelets:  A subset shows hypogranulation\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 positive blasts are not increased (<5% of bone marrow cellularity). CD34 also highlights dysplastic megakaryocytes.  CD117 highlights increased mast cells without forming large aggregates and showing predominantly atypical spindled morphology.  The mast cells are negative for CD2, CD25, and CD30.\par CD3 and CD2 highlight scattered T-cells.\par CD61 highlights megakaryocytes including many small hypolobated forms.\par CD71 highlights markedly increased erythroid precursors.\par MPO highlights myeloid elements.\par\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-270)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Abnormal myeloid blast population detected.          \par Myeloid blast population represents 1.7% of WBC.\par\par Mastocytosis is seen, 0.76% of WBC.\par\par Immunophenotype:\par Abnormal: CD7 (partial), CD34 (bright)\par Normal: CD4, CD13, CD33, CD36, CD38, CD45, CD45RA, CD71, CD105, CD117, CD123, CD371 (clec12a), HLA-DR, CD90\par Negative: CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda, CD42b\par\par Number of cells acquired 292 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-154.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M23-1135.\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-618;S15;MSKZ - 2023-06-12 13.51.39.ndpi,Peripheral Blood Smear,2023-06-12,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: AML\par Clinical Hx/Op Findings: relapsed aml\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: \~\par      - Acute myeloid leukemia, 48% blasts by aspirate differential count. \par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  Per clinical notes, the patient has a history of AML, diagnosed 3 years ago. Please correlate with clinical history and the results of concurrent cytogenetic and molecular analysis for further characterization.  \plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate; partially aspirated and hemorrhagic.\par Cellularity: Patchy, overall ~30%\par M:E ratio: Decreased\par Blasts: Increased interstitially\par Myeloid lineage: Decreased, left-shifted with full spectrum of maturation seen.\par Erythroid lineage: Decreased\par Megakaryocytes: Markedly decreased\par Lymphocytes: Scattered without defined aggregates seen\par Plasma cells: Scattered\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate \par\par Blasts \tab\tab\tab 48%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 2%\par Metamyelocytes \tab\tab 1%\par Neutrophils/Bands \tab 4%\par Monocytes \tab\tab 2%\par Eosinophils \tab\tab 4%\par Erythroid Precursors \tab 10%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 27%\par Number of Cells Counted \tab 500\par M:E Ratio \tab\tab 1.4\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Aspirate smears are spicular and cellular, however show suboptimal smear preparation with numerous stripped cells. The blast population is expanded and are composed of predominantly intermediate-sized cells with ovoid or indented nuclear contours, fine chromatin, distinct nucleoli, and azurophilic, agranular cytoplasm with occasional vacuoles. Residual myeloid and erythroid elements are decreased. Lymphocytes and mast cells appear relatively increased without atypia. Few megakaryocytes are seen.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (1/23/2023):\par\par WBC 1.2 L [4.0-11.0 K/mcL] \par RBC 2.97 L [3.95-5.54 M/mcL] \par HGB 8.9 L [12.5-16.2 g/dL] \par HCT 26.2 L [37.5-49.3 %] \par MCV 88 [80-98 fL]\par MCH 30.0 [27.0-33.0 pg]\par MCHC 34.0 [31.0-36.5 g/dL]\par RDW 13.0 [12.2-15.1 %] \par Platelets 10 L [160-400 K/mcL] \par\par Neutrophil 24.0 L [32.5-74.8 %] \par Mono 0.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Blast 3.0 H [0.0-0.0 %] \par Lymph 73.0 H [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 0.3 L [1.5-7.5 K/mcL] \par Abs Mono 0.0 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Blasts 0.0 [0.0-0.0 K/mcL] \par Abs Lymph 0.9 [0.9-3.2 K/mcL] \par\par Morphology: Pancytopenia. Circulating blasts seen.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 highlight increased blasts, with interstitial and paratrabecular distribution, accounting for 30-40% of cellularity.\par The blasts are positive for muramidase and MPO; a small subset of blasts are positive for TdT. \par CD117 also highlights increased mast cells, scattered, without clusters or significant spindling\par CD61 highlights decreased megakaryocytes, small forms present.\par CD71 highlights erythroid elements.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-870)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par\par 1. Expanded abnormal myeloid blast population detected.\par\par Abnormal myeloid blast population represents 33.5% of WBC.\par\par Immunophenotype:\par Abnormal: CD2 (partial - dim), CD7 (partial - dim), CD13 (variable - bright to negative), CD25 (partial - dim), CD33 (variable - bright to negative), CD34 (bright), CD38 (variable - dim to negative), CD117 (variable - bright to negative), CD371 (clec12a) (negative), MPO (variable - negative to intermediate), CD90 (increased)\par Normal: CD4, CD36, CD45, CD45RA, CD71, CD105, CD123, HLA-DR\par Negative: CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD26, CD56, CD64, cytoplasmic CD3, cytoplasmic CD79a, surface Kappa, surface Lambda, CD42b, CD61\par\par Number of cells acquired: 381 thousand \par\par 2. No abnormal mature B- or T-cell populations detected. \par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par Number of cells acquired 296 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-545.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M23-3652, M23-3658, M23-3663, M23-3665.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-386;S16;MSK2 - 2023-06-15 18.49.02.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: DLBCL\par Clinical Hx/Op Findings: concern for relapse on imaging\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: \~\~\par      - Large B-cell lymphoma, 15-20% involvement with CD20/PAX5 immunohistochemistry. \par\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b Comment: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Preliminary findings were communicated with Dr. William Johnson by Dr. Shenon Sethi via e-mail on 1/17/2023. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy and aspirate specimens show mildly hypocellular bone marrow for age (10-20% cellularity). There is\~trilineage maturing hematopoiesis with atypical lymphocytic infiltrate composed of large cells with irregular nuclear contours and prominent nucleoli. \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 CD20 and PAX5 show involvement by large B-cell lymphoma, comprising approximately 15-20% of marrow cellularity, showing nodular and interstitial distribution. \par CD3 highlights background reactive T-cells. \par Immunohistochemistry for CD138, Kappa light chain and lambda light chain will be reported as an addendum. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-548)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par 1. Abnormal B-cell population detected.\par\par Abnormal B-cell population represents 6.7% of WBC.\par\par Immunophenotype:\par Abnormal: CD22 (dim), CD45 (dim)\par Normal: CD19, CD20, CD38\par Negative: CD5, CD10, CD25, CD279 (PD1), CD3, CD14\par Other: No definite surface light chain expression\par\par Number of cells acquired: 391 thousand \par\par 2. Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par\par Abnormal plasma cell population comprises 54.5% of total plasma cells.\par Abnormal plasma cell population represents 0.095% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (negative), CD27 (dim), CD45 (negative), CD81 (bright), cytoplasmic Lambda (restriction)\par Normal: CD138, CD38, CD229\par Negative: CD56, CD117, cytoplasmic Kappa\par\par Number of cells acquired: 927 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (1/13/2023):\par\par WBC 3.8 L [4.0-11.0 K/mcL] \par RBC 2.95 L [3.80-5.00 M/mcL] \par HGB 9.4 L [11.2-15.4 g/dL] \par HCT 28.8 L [34.3-46.0 %] \par MCV 98 [80-98 fL]\par MCH 31.9 [27.0-33.0 pg] \par MCHC 32.6 [31.0-36.5 g/dL] \par RDW 19.3 H [12.2-15.1 %] \par Platelets 27 L [160-400 K/mcL] \par\par Neutrophil 59.0 [32.5-74.8 %] \par Mono 11.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Promyelocyte 1.0 H [0.0-0.0 %] \par Metamyelocyte 4.0 H [0.0-0.0 %] \par Lymph 14.0 [12.2-47.4 %] \par Abnormal Lymphoid Cells 5.0 H [0.0-0.0 %] \par Variant Lymph 5.0 H [0.0-2.0 %] \par Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 2.2 [1.5-7.5 K/mcL] \par Abs Mono 0.4 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] \par Abs Meta 0.2 H [0.0-0.0 K/mcL] \par Abs Lymph 0.9 [0.9-3.2 K/mcL] \par\par Morphology:  Will be reported as an addendum. \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-307.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M23-2223.\par\plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-602;S10;MSK7 - 2023-06-15 18.54.36.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: B-ALL\par Clinical Hx/Op Findings: relapsed dx\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\par     - B-lymphoblastic leukemia/lymphoma (B-ALL) (86% blasts by aspirate differential count). See comment.\par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  Per clinical notes, the patient has a history of B-ALL with t(v;11q23.3); \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i KMT2A\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  rearrangement diagnosed in 3/2022 and the current findings represent relapsed disease. The blast immunophenotype is compatible with this cytogenetic abnormality, however correlation with results of the forthcoming cytogenetic studies is needed to confirm the final classification. Results of the forthcoming molecular studies will also be helpful for further characterization. \plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Preliminary findings were reported to Dr. Eytan Stein, Department of Medicine, via email on 1/25/2023.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Marked hypercellular for age (>95% cellularity)\par M:E ratio: NA \par Blasts: Markedly increased replacing nearly all of the marrow cellularity and present in sheets. Blasts range in size, intermediate to large, with round to elongated nuclei, fine chromatin, prominent eosinophilic nucleoli, and scant amount of cytoplasm. Frequent apoptotic bodies and mitotic figures are seen. \par Myeloid lineage: Markedly reduced\par Erythroid lineage: Markedly reduced\par Megakaryocytes: Rare\par Lymphocytes: Few, scattered\par Plasma cells: Rare\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate\par\par Blasts \tab\tab\tab 86%\par Myelocytes \tab\tab 1%\par Metamyelocytes \tab\tab 1%\par Neutrophils/Bands \tab 2%\par Erythroid Precursors \tab 7%\par Lymphocytes \tab\tab 3%\par Number of Cells Counted \tab 500\par M:E Ratio \tab\tab 0.6\par\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Spicular and hypercellular aspirate smears show reduced background trilineage hematopoiesis and a markedly expanded blast population. Blasts range in size from intermediate to large cells, with predominantly round to slightly irregular nuclei, fine chromatin, large prominent nucleoli, and scant amount of basophilic cytoplasm, occasionally with vacuoles. Auer rods are not seen. Scattered erythroid and myeloid precursors present in various stages of maturation. Erythroid cells show occasional budding and nuclear irregularities. Megakaryocytes are rare. Scattered small mature appearing lymphocytes are present.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (01/23/2023):\par WBC 1.3 L [4.0-11.0 K/mcL] \par RBC 2.61 L [3.80-5.00 M/mcL] \par HGB 7.8 L [11.2-15.4 g/dL] \par HCT 23.2 L [34.3-46.0 %] \par MCV89 [80-98 fL] \par MCH 29.9 [27.0-33.0 pg] \par MCHC 33.6 [31.0-36.5 g/dL] \par RDW 14.3 [12.2-15.1 %] \par Platelets. 27 L [160-400 K/mcL] \par\par Neutrophil 52.0 [32.5-74.8 %] \par Mono 0.0 [0.0-12.3 %] \par Eos 2.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Blast 14.0 H [0.0-0.0 %] \par Lymph 32.0 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 0.7 L [1.5-7.5 K/mcL] \par Abs Mono 0.0 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Blasts 0.2 H [0.0-0.0 K/mcL] \par Abs Lymph 0.4 L [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] \par\par Morphology:\par WBC: Leukopenia with marked neutropenia and lymphopenia and frequent circulating blasts with similar morphology as on the aspirate smears. \par RBC: Normocytic, normochromic anemia\par PLT: Marked thrombocytopenia. \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Blasts are negative for TdT and CD34.\par Additional immunohistology is in progress and will be reported in an addendum.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-851)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal immature B cell population detected.\par The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.\par\par Abnormal immature B cell population represents 86.33% of WBC.\par\par Immunophenotype:\par Abnormal: CD15 (variable - negative to dim), CD19 (variable - dim to intermediate), CD34 (negative), CD38 (bright), CD45 (variable - bright to dim), CD66b (dim), CD81 (dim), CD86 (variable - negative to bright), HLA-DR (variable - negative to bright), cytoplasmic CD79a (positive), CD90 (increased)\par Normal: CD22, CD24, CD36, CD45RA, CD71, CD105, CD371 (clec12a)\par Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD13, CD14, CD16, CD20, CD25, CD26, CD33, CD56, CD64, CD66c/CD123, CD73/CD304, CD117, CD123, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61\par\par Number of cells acquired 1.32 million \par\par 2. No abnormal mature B- or T-cell populations detected. \par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par\par Number of cells acquired 482 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-530.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate reports, M23-3845, M23-3846, and M23-3847.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-203;S14;MSKY - 2023-06-15 09.40.16.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: MDS\par Clinical Hx/Op Findings: pt with isolated macrocytic anemia c/f MDS\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, right posterior iliac crest, biopsy; \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\~\par        - Hypercellular marrow showing trilineage maturing hematopoiesis, increased erythroid precursors, mild dyserythropoiesis and dysmegakaryopoiesis, increased ring sideroblasts (more than 15%) and no increase in blasts (2%).\par        - Small abnormal blast population (1.1% of WBC) is detected by flow cytometric studies.\par\par See comment\par\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  Per limited clinical information available, the patient is identified to have anemia in September 2022. The tandem CBC shows low hemoglobin (8.7 g/dL), high MCV and unremarkable white blood cell and platelet counts. \plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b  \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The overall morphologic findings in light of the flow cytometric analysis showing small abnormal myeloid blast population are suggestive of myelodysplastic syndrome (MDS) with increased ring sideroblasts and no increase in blasts.  Suggest correlation with clinical history, laboratory studies, cytogenetic and molecular genomic studies (including evaluation for SF3B1 mutation) for definitive diagnosis and further classification.\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Although the WBC is within normal limits, mild neutrophilia is noted; the significance unclear.  Suggest clinical follow-up and CBC surveillance.\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Hypercellular (60%)\par M:E ratio: Normal\par Blasts: Not increased\par Myeloid lineage: Progressive maturation\par Erythroid lineage:  Increased and show mildly left-shifted maturation\par Megakaryocytes: Present and show occasional small and hypolobated forms\par Lymphocytes: Scattered\par Plasma cells: Scattered\par\par Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0/3). \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate\par\par Blasts \tab\tab\tab 2%\par Promyelocytes \tab\tab 3%\par Myelocytes \tab\tab 15%\par Metamyelocytes \tab\tab 9%\par Neutrophils/Bands \tab 24%\par Monocytes \tab\tab 3%\par Eosinophils \tab\tab 4%\par Basophils \tab\tab 1%\par Erythroid Precursors \tab 26%\par Plasma Cells \tab\tab 3%\par Lymphocytes \tab\tab 10%\par Number of Cells Counted   500\par M:E Ratio \tab\tab 2.3\par\par Special stain \par Iron: Absent\par Ring sideroblasts: Present, >15%\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -Spicular and cellular aspirate smears showing maturing trilineage hematopoiesis. Blasts are not increased. Myeloid elements show progressive maturation and overall unremarkable morphology. Erythroid elements show increased early precursors, megaloblastoid changes and occasional dyspoietic forms with nuclear irregularities and budding. Megakaryocytes are present and show unremarkable morphology and occasional forms with small and hypolobated morphology.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (01/09/2023):\par WBC 10.2 4.0-11.0 K/mcL \par RBC 2.66 L 3.95-5.54 M/mcL \par HGB 8.7 L 12.5-16.2 g/dL \par HCT 26.4 L 37.5-49.3 % \par MCV 99 H 80-98 fL \par MCH 32.7 27.0-33.0 pg \par MCHC 33.0 31.0-36.5 g/dL \par RDW 19.8 H 12.2-15.1 % \par Platelets 256 160-400 K/mcL \par\par Neutrophil 81.0 H 32.5-74.8 % \par Mono 6.0 0.0-12.3 % \par Eos 2.0 0.0-4.9 % \par Baso 1.0 0.0-1.5 % \par Lymph 10.0 L 12.2-47.4 % \par Nucleated RBC 0.0 0.0-0.0 /100(WBCs) \par\par Abs Neut 8.3 H 1.5-7.5 K/mcL \par Abs Mono 0.6 0.0-1.3 K/mcL \par Absolute Eosinophil 0.2 0.0-0.7 K/mcL \par Absolute Basophil 0.1 0.0-0.2 K/mcL \par Abs Lymph 1.0 0.9-3.2 K/mcL \par\par Morphology:\par WBC: No circulating blasts seen \par RBC: Macrocytic anemia, anisocytosis\par Platelets: Rare large platelets are seen\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 positive blasts are not increased (<5% of bone marrow cellularity)\par CD61 highlights megakaryocytes\par CD71 highlights increased erythroid precursors\par MPO highlights myeloid elements\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-276)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal myeloid blast population detected.\par Abnormal myeloid blast population represents 1.1% of WBC.\par\par Immunophenotype:\par Abnormal: CD7 (partial), CD13 (retention), CD38 (dim), CD117 (bright), CD371 (clec12a) (partial - dim), CD90 (increased)\par Normal: CD4, CD33, CD34, CD36, CD45, CD45RA, CD71, CD105, CD123, HLA-DR\par Negative: CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda, CD42b\par\par 2. No abnormal mature B- or T-cell populations detected. \par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par Number of cells acquired 466 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-162.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M23-1088, M23-1170, M23-1171, M23-1173.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-894;S17;MSK7 - 2023-06-15 19.18.03.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Lymphoma\par Clinical Hx/Op Findings: pre-tx\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:  \~\~\par      - Involvement by mantle cell lymphoma (50-60% with CD20 immunohistochemistry)\par      - Hypercellular marrow with trilineage maturing hematopoiesis.\par\par See comment.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  Cytogenetic studies using a peripheral blood sample (CG23-511;1/23/2023) show CCND1 rearrangements in 45% of cells. \par\par CylcinD1 and SOX11 immunostains are pending and will be reported in an addendum.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/TOUCH IMPRINT MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Fragmented biopsy shows hypercellular marrow (80% cellularity) with maturing trilineage hematopoiesis and an extensive lymphoid infiltrate of small lymphocytes.  The touch imprints are markedly hypocellular.\par\~\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The lymphoid infiltrate is positive for CD20 and PAX5.  CD3 highlights background small T-cells.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-1287)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Abnormal B cell population detected. \par The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)\par Abnormal B cell population represents 62.3% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD20 (dim), CD43 (partial), CD79b (dim), CD81 (dim), ROR1 (positive)\par Normal: CD19, CD40, CD45, CD38\par Negative: CD23, CD200, CD10, CD3\par\par Number of cells acquired: 445 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (2/1/23)\par WBC 19.3 H [4.0-11.0 K/mcL] \par RBC 3.62 L [3.95-5.54 M/mcL] \par HGB 10.1 L [12.5-16.2 g/dL] \par HCT 31.5 L [37.5-49.3 %] \par MCV 87 [80-98 fL] \par MCH 27.9 [27.0-33.0 pg] \par MCHC 32.1 [31.0-36.5 g/dL] \par RDW15.1 [12.2-15.1 %] \par Platelets 122 L [160-400 K/mcL]\par\par Morphology:  Lymphocytosis of small to medium lymphoid cells.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-818, 820.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Not available\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-336;S16;MSKX - 2023-06-12 14.22.19.ndpi,Peripheral Blood Smear,2023-06-12,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: HTLV 1 ATLL\par Clinical Hx/Op Findings: complete staging\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: \~\~\par      - T-cell lymphoma, 30% involvement with CD3 immunohistochemistry, see comment. \par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Findings are consistent with involvement by the patient's previously diagnosed adult T-cell leukemia/lymphoma. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy specimen shows mildly hypercellular bone marrow for age (60-70% cellularity). There is\~trilineage maturing hematopoiesis with increased atypical lymphocytes showing interstitial distribution with scattered aggregates. Spicular aspirate smear shows many atypical lymphocytes, small sized, high N/C ratio and occasional markedly irregular nuclear contours. Dysplasia is not seen in background trilineage hematopoiesis. Smudge cells are present. \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD3 highlights increase in T-cells, comprising approximately 30% of marrow cellularity, showing interstitial distribution with occasional clustering. \par CD20 and PAX5 show B-cells, comprising approximately 5% of marrow cellularity. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-477)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par\par Abnormal T cell population detected.\par Abnormal T cell population represents 30.2% of WBC.\par\par Immunophenotype:\par Abnormal: CD3 (dim), CD7 (negative), CD25 (partial), CD26 (negative), CD45 (dim), TCRCbeta1 (restriction - monotypic positive)\par Normal: CD2, CD4, CD5, CD38\par Negative: CD8, CD10, CD14, CD56, CD279 (PD1), TCR gamma/delta\par\par Number of cells acquired 377 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (1/12/2023):\par WBC 26.0 H [4.0-11.0 K/mcL] \par RBC 4.38 [3.80-5.00 M/mcL] \par HGB 12.7 [11.2-15.4 g/dL] \par HCT 39.1 [34.3-46.0 %] \par MCV 89 [80-98 fL] \par MCH 29.0 [27.0-33.0 pg] \par MCHC 32.5 [31.0-36.5 g/dL] \par RDW 13.7 [12.2-15.1 %] \par Platelets 233 [160-400 K/mcL] \par\par Neutrophil 15.0 L [32.5-74.8 %] \par Mono 3.0 [0.0-12.3 %] \par Eos 2.0 [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Lymph 12.0 L [12.2-47.4 %] \par Abnormal Lymphoid Cells 67.0 H [0.0-0.0 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 3.9 [1.5-7.5 K/mcL] \par Abs Mono 0.8 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.5 [0.0-0.7 K/mcL] \par Absolute Basophil 0.3 H [0.0-0.2 K/mcL] \par Abs Lymph 20.6 H [0.9-3.2 K/mcL] \par\par Morphology: Markedly increased atypical lymphocytes with clumped chromatin, high N/C ratio and folded nuclei. \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-275. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M23-1958, M23-1959, M23-1960. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-817;S16;MSK1 - 2023-06-15 16.48.57.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: CLL\par Requested Studies: Gross/Micro\par Clinical Hx/Op Findings: history of CLL with malignant pleural effusions s/p CVP chemo here for a second opinion with a minimal response\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: \~\~\par      - Involvement by mantle cell lymphoma (80-90% with CD20 immunohistochemistry).\par      - Cellular marrow with background trilineage maturing hematopoiesis.\par\par See comment.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT:\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b  \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  P53 expression is identified by immunohistochemical studies.  Suggest correlation with cytogenetic and molecular genetic/genomic studies for further characterization.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy shows hypercellular bone marrow (60-70%cellularity). There is\~limited trilineage maturing hematopoiesis and a dense lymphoid infiltrate of small lymphocytes with irregular nuclei and condensed chromatin in aggregates and interstitial distribution.  Background hematopoiesis shows mildly left-shifted myeloid maturation, erythroid elements with maturation, megakaryocytes with predominantly unremarkable morphology and occasional with small and hypolobated forms.  The aspirate smears are aspicular and show focal cellularity represented predominantly by lymphoid cells of small to medium-sized with round to slightly irregular nuclei.  Occasional large lymphoid cells are seen.\par\~\par\par Myelocytes \tab\tab 2%\par Metamyelocytes \tab\tab 1%\par Neutrophils/Bands \tab 8%\par Monocytes \tab\tab 1%\par Erythroid Precursors \tab 1%\par Lymphocytes \tab\tab 87%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 12\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The lymphoid infiltrate is positive for CD20, PAX5, CyclinD1, CD23 (weak subset) and P53 and takes up to 80-90% of the cellularity.  The infiltrate is negative for CD5 and LEF1. CD3 and CD5 highlight the small T-cells.  \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-1148)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par 1. Abnormal B cell population detected.\par The immunophenotype of this abnormal B cell population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.\par\par Abnormal B cell population represents 73.8% of WBC.\par\par Immunophenotype:\par Abnormal: CD20 (dim), CD79b (variable - negative to intermediate), CD81 (dim), surface Lambda (restriction - dim)\par Normal: CD22, CD23, CD19, CD40, CD45\par Negative: CD5, CD43, CD200, ROR1, CD38, CD10, CD3, surface Kappa, CD25, CD14, CD279 (PD1)\par\par\par 2. No abnormal mature T cell population detected. \par No immunophenotypic evidence of T-cell lymphoma is identified.  \par\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (1/30/2023):\par\par WBC 25.2 H 4.0-11.0 K/mcL \par RBC 2.78 L 3.80-5.00 M/mcL \par HGB 9.1 L 11.2-15.4 g/dL \par HCT 27.1 L 34.3-46.0 % \par MCV 98 80-98 fL \par MCH 32.7 27.0-33.0 pg \par MCHC 33.6 31.0-36.5 g/dL \par RDW 21.7 H 12.2-15.1 % \par Platelets 73 L 160-400 K/mcL \par\par Neutrophil 6.0 L 32.5-74.8 % \par Mono 3.0 0.0-12.3 % \par Eos 0.0 0.0-4.9 % \par Baso 0.0 0.0-1.5 % \par Lymph 3.0 L 12.2-47.4 % \par Abnormal Lymphoid Cells 88.0 H 0.0-0.0 % \par Nucleated RBC 0.0 0.0-0.0 /100(WBCs) \par\par Abs Neut 1.5 1.5-7.5 K/mcL \par Abs Mono 0.8 0.0-1.3 K/mcL \par Absolute Eosinophil 0.0 0.0-0.7 K/mcL \par Absolute Basophil 0.0 0.0-0.2 K/mcL \par Abs Lymph 22.9 H 0.9-3.2 K/mcL \par\par Morphology:  Lymphocytosis with variable morphology ranging from small lymphoid cells with irregular nuclei to medium lymphoid cells and occasional larger forms.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-731, CG23-732.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M23-4814, 4815, 4817.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-513;S14;MSKS - 2023-06-15 16.02.12.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Myelodysplastic Syndrome\par Requested Studies: Gross/Micro\par Clinical Hx/Op Findings: MDS on azacitidine\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:   \~\~\par      - Persistent involvement by myelodysplastic syndrome (MDS) with \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i SF3B1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  and \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i RUNX1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  mutations,  in course of therapy. See comment.\par      - Hypercellular marrow with maturing trilineage hematopoiesis, mild erythroid hyperplasia, multilineage dysplasia, increased ring sideroblasts, and no increase in blasts.\par       - Minute abnormal B-cell population detected by flow cytometry only (0.056% of WBC). See comment.\par  \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  Per clinical notes, the patient has been treated with azacitidine. Recent in-house molecular studies (M23-19) revealed a number of somatic mutations including in \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i SF3B1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 , \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i TET2\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 ,\plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i  and ASXL1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  with >35% variant allele frequency (VAF), \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i RUNX1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  p.S410Afs*173  at 16% VAF, in addition to other subclonal \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i RUNX1 \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 variants. Of note, mutated \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i RUNX1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  in this context may be associated with a less favorable prognosis (PMID: 25957392, 34161603). Based on ICC 2022, this MDS is best classified as MDS, NOS with multilineage dysplasia (due to exclusion from MDS with mutated \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i SF3B1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  by presence of the \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i RUNX1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  mutation). WHO 2022 classifies these findings as MDS with low blasts and \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i SF3B1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  mutation (MDS-\plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i SF3B1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 ). \par\tab In addition, preliminary karyotype results (CG23-465, communicated by Dr. Y. Zhang, Cytogenetics lab) detected a single metaphase cell with a deletion of the long arm of chromosome 7, which does not meet the criteria for a clonal cytogenetic abnormality at this time. Close clinical follow-up and repeat karyotype analysis in a clinically appropriate time interval is needed to monitor this finding. Correlation with results of the forthcoming molecular studies is also advised.\par\tab In addition, a minute abnormal B-cell population was detected by flow cytometry with a nonspecific immunophenotype. There is no morphologic correlate of this population and likely this represents minimal involvement by a B-cell lymphoproliferative disorder, and monoclonal B-cell lymphocytosis with a non-CLL immunophenotype is favored, however correlation with imaging studies is needed to exclude the possibility of extramedullary tissue involvement. \par\par Preliminary findings were provided to Dr. Tamanna Haque, Department of Medicine, via email on 1/25/23.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Hypercellular for age normocellular for age (50-60% cellularity)\par M:E ratio: Mildly decreased. \par Blasts: Not overtly increased.\par Myeloid lineage: Actively maturing. \par Erythroid lineage: Actively maturing\par Megakaryocytes: Increased for the cellularity with frequent small and hypolobated forms. \par Lymphocytes: Few, scattered. \par Plasma cells: Rare, scattered. \par Clot section: Adequate for evaluation and shows similar morphology as the core biopsy.\par\par Special stains: Reticulin stain shows no significant increase in reticulin fibrosis (MF-0). \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate\par\par Blasts \tab\tab\tab 2%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 20%\par Metamyelocytes \tab\tab 6%\par Neutrophils/Bands \tab 23%\par Monocytes \tab\tab 5%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 33%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 8%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 1.7\par\par Special stain\par Iron: Present\par Ring sideroblasts: Present >15%\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Spicular and cellular aspirate smears show maturing trilineage hematopoiesis with no increase in blasts. The M:E ratio is slightly decreased due mild erythroid hyperplasia. Myeloid elements show full maturation with occasional dyspoiesis (hypogranular and hyposegmented forms, ~10%). Erythroid elements are relatively increased and show progressive maturation with dyspoiesis (nuclear irregularity, budding, nuclear-cytoplasmic dyssynchrony, megaloblastoid changes >10%). Megakaryocytes are present associated with spicules, some with dysplasia (> 10%) including small hypolobated forms and those with widely separated nuclear lobes. Few scattered mature appearing mast cells are present. Scattered small and mature-appearing lymphocytes are present. Scattered plasma cells with unremarkable morphology are seen. \par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (01/19/2023):\par WBC 2.1 L [4.0-11.0 K/mcL] \par RBC 2.61 L [3.95-5.54 M/mcL] \par HGB 9.5 L [12.5-16.2 g/dL] \par HCT 28.8 L [37.5-49.3 %] \par MCV 110 H [80-98 fL] \par MCH 36.4 H [27.0-33.0 pg] \par MCHC 33.0 [31.0-36.5 g/dL] \par RDW 18.7 H [12.2-15.1 %] \par Platelets 369 [160-400 K/mcL] \par\par Neutrophil 52.6 [32.5-74.8 %] \par Mono 13.6 H [0.0-12.3 %] \par Eos 1.9 [0.0-4.9 %] \par Baso 0.9 [0.0-1.5 %] \par Immature Granulocyte 2.8 H [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 28.2 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 1.1 L [1.5-7.5 K/mcL] \par Abs Mono 0.3 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature 0.1 [0.0-0.1 K/mcL] \par Granulocyte\par Abs Lymph 0.6 L [0.9-3.2 K/mcL] \par\par Morphology:\par WBC: No definitive circulating blasts present. Leukopenia with neutropenia and dysplasia (Pseudo Pelger\loch\af0\dbch\af0\hich\f0\'96\hich\af0\dbch\af0\loch\f0 Hu\loch\af0\dbch\af0\hich\f0\'eb\hich\af0\dbch\af0\loch\f0 t forms, abnormal nuclear segmentation, and hypogranular forms). Relative monocytosis. Rare mature granulocytes seen (metamyelocytes myelocytes).\par RBC: Macrocytic anemia with anisocytosis\par PLT: Adequate in number with frequent large forms  \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 show no increase in blasts, <5% of cellularity. \par CD117 also highlights early myeloid and erythroid cells and few scattered mast cells without cluster formation or significant spindled morphology. \par CD61 is positive in the megakaryocytes which are increased in number for the cellularity with frequent (> 10%) small forms. \par MPO highlights myeloid cells, while CD71 highlights mildly increased erythroid cells, with an overall mildly decreased M:E ratio.\par CD20 (performed on the core biopsy and clot section) highlights rare scattered B-cells, without lymphoid aggregates.\par CD3 (performed on the core biopsy and clot section) highlights few scattered T-cells.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-770)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par\par 1. Abnormal myeloid blast population detected.          \par\par Abnormal myeloid blast population represents 0.95% of WBC.\par Atypical monocyte population with partial expression of CD56 detected.\par\par Immunophenotype:\par Abnormal: CD5 (partial), CD7 (partial), CD13 (uniform bright), CD33 (uniform intermediate), CD45RA (negative)\par Normal: CD4, CD34, CD36, CD38, CD45, CD71, CD105, CD117, CD123, CD371 (clec12a), HLA-DR\par Negative: CD2, CD3, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda, CD42b, CD90\par\par Number of cells acquired 637 thousand\par\par 2. Minute abnormal B cell population detected. \par Flow cytometry reveals a minute abnormal B cell population with a similar immunophenotype as seen in prior (F22-14142).\par\par Abnormal B cell population represents 0.056% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD22 (slightly dim), CD38 (negative), surface Kappa (restriction - dim)\par Normal: CD19, CD20, CD45\par Negative: CD10, CD25, CD279 (PD1), CD3, CD14, surface Lambda\par\par Number of cells acquired 433 thousand \par\par 3. No abnormal mature T cell population detected. \par No immunophenotypic evidence of T-cell lymphoma is identified.  \par\par\par Number of cells acquired: 433 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG23-465.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate reports, M23-3200, M23-3203. M23-3205, & M23-3206.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H23-84;S12;MSKT - 2023-06-15 09.11.44.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par T-ALL\par Newly diagnosed T-ALL \par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, right posterior iliac crest, biopsy; \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\~\par      - Lymphoblastic leukemia predominantly with early T precursor lymphoblastic leukemia/lymphoma phenotype (blasts 92% by aspirate smear differential). See comment. \par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The dominant population shows an immature T cell phenotype consistent with early T cell precursor leukemia. A small subset of the blasts shows features compatible with additional B cell lineage (CD19 bright, CD79a bright, CD22 dim) which warrants assignment of mixed phenotype T/B leukemia which is the favored diagnosis, however >95% of the blasts show purely T cell phenotype. Follow up will include both T and B lineages.\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Correlation of these findings with cytogenetic and molecular studies is recommended. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Hypercellular (>95%)\par M:E ratio: N/A\par Blasts: Marked expansion with effacement of marrow spaces by immature cells, consistent with blasts\par Myeloid lineage: Reduced\par Erythroid lineage: Reduced\par Megakaryocytes: Present with occasional hyperchromatic and hyperlobated nuclei.\par Lymphocytes: Rare \par Plasma cells: Rare \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules \par Naked nuclei noted on scan of aspirate slide. Differential performed on touch imprints.\par\par Blasts \tab\tab\tab 92%\par Myelocytes \tab\tab 1%\par Erythroid Precursors \tab 4%\par Lymphocytes \tab\tab 3%\par Number of Cells Counted   500\par M:E Ratio \tab\tab 0.2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Aspicular and hypocellular aspirate are suboptimal for evaluation but show a expanded population of blasts (small to intermediate size cells with scant amphophilic cytoplasm,  round nuclei, fine chromatin, and distinct nucleoli). Background myeloid and erythroid elements are reduced. Rare megakaryocytes are present.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (1/4/2023):\par\par WBC 3.2 L [4.0-11.0 K/mcL] \par RBC 2.66 L [3.95-5.54 M/mcL] \par HGB 8.0 L [12.5-16.2 g/dL] \par HCT 23.3 L [37.5-49.3 %] \par MCV 88 [80-98 fL]\par MCH 30.1 [27.0-33.0 pg] \par MCHC 34.3 [31.0-36.5 g/dL] \par RDW 14.2 [12.2-15.1 %] \par Platelets 29 L [160-400 K/mcL] \par\par\par Morphology:\par\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 WBC: Increased circulating blasts present.\par RBC: Mild normocytic anemia.\par PLT: Moderate thrombocytopenia. \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 highlights increased blasts comprising greater than 90% of the total cellularity. Blasts are positive for CD3 and CD7.\par Blasts are negative for TDT.\par Additional stains will be reported when available, but will not change the diagnosis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F23-114)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal lymphoblast population detected.\par\par The dominant population shows an immature T cell phenotype consistent with early T cell precursor leukemia. A small subset of the blasts shows features compatible with additional B cell lineage (CD19 bright, CD79a bright, CD22 dim) which warrants assignment of mixed phenotype T/B, however >95% of the blasts show purely T cell phenotype. Follow up will include both T and B lineages.\par\par Abnormal blast population represents 74.3% of WBC .\par\par Immunophenotype:\par Abnormal: CD5 (variable - negative to dim), CD7 (bright), CD11b (partial), CD13 (partial), CD19 (partial), CD22 (partial - dim), CD33 (partial), CD34 (positive), CD38 (dim), CD48 (negative), CD117 (partial), CD123 (positive), cytoplasmic CD3 (variable - negative to bright), cytoplasmic CD79a (partial)\par Normal: CD2, CD36, CD45, CD45RA, CD71, CD105\par Negative: CD3, CD4, CD8, CD10, CD14, CD15, CD16, CD20, CD25, CD26, CD56, CD64, CD279 (PD1), CD371 (clec12a), HLA-DR, TCR gamma/delta, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par Number of cells acquired: 192 thousand \par\par 2. No abnormal myeloid blast, mature B or mature T cell populations identified. Few myeloid blasts seen.                              \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par\par\par Number of cells acquired: 263 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M23-352\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-391;S10;MSK1 - 2023-05-31 21.16.06.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: ALL
Clinical Hx/Op Findings: New ALL
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate, and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma, 83% blasts by aspirate differential count.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular (>95%)
M:E ratio: N/A
Blasts: Markedly increased, present in sheets nearly entirely replacing the marrow
Myeloid lineage: Markedly reduced 
Erythroid lineage: Markedly reduced
Megakaryocytes: Reduced
Lymphocytes: Rare 
Plasma cells: Rare 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                83%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      1%
Erythroid Precursors      12%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
-Spicular and cellular aspirate smears show a markedly expanded population of blasts, which are mostly intermediate in size with rounded to irregular nuclei, fine chromatin, occasional distinct nucleoli and scant cytoplasm. Myeloid and erythroid elements are markedly reduced. Scattered megakaryocytes are present without overt atypia. 

PERIPHERAL BLOOD
CBC (01/14/2022):
WBC 22.4 H [4.0-11.0 K/mcL] 
RBC 4.44 [3.95-5.54 M/mcL] 
HGB 14.1 [12.5-16.2 g/dL] 
HCT 42.1 [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 31.8 [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 15.2 H [12.2-15.1 %] 
Platelets 72 L [160-400 K/mcL] 

Neutrophil 5.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 63.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 29.0 [12.2-47.4 %] 
Variant Lymph 1.0 [0.0-2.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 14.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 6.7 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Leukocytosis with frequent circulating blasts morphologically similar to those in the aspirate smears. Absolute neutropenia with few myelocytes and metamyelocytes.
RBC: Normochromic, normocytic RBCs with rare nucleated RBCs.
PLT: Thrombocytopenia.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
TdT highlights markedly increased blasts comprising >90% of the marrow cellularity. The blasts show variable expression of CD34.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-492)
Interpretation: 
1. Abnormal immature B cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 96.5% of the mononuclear cells.
Abnormal immature B cell population represents 96.0% of WBC.

Immunophenotype:
Abnormal: CD10 (positive - bright), CD20 (partial), CD34 (variable - negative to intermediate), CD45 (dim), CD66c/CD123 (positive), CD73/CD304 (partial), CD81 (positive - dim), CD86 (partial), CD123 (positive)
Normal: CD19, CD22, CD24, CD38, CD71, HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD25, CD26, CD33, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, cytoplasmic MPO, surface Kappa, surface Lambda

Number of cells acquired 814 thousand 

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 475 thousand 

4. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                                                                                
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.092% of WBC.

Number of cells acquired: 331 thousand 

Also see F22-454 (PB) submitted on the same day.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-454)
Interpretation: 
1. Abnormal immature B cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 72.9% of the mononuclear cells..
Abnormal immature B cell population represents 68.7% of WBC.

Immunophenotype:
Abnormal: CD10 (positive - bright), CD20 (variable - negative to bright), CD22 (dim), CD45 (dim), CD66c/CD123 (positive), CD73/CD304 (positive), CD81 (positive - dim), CD86 (positive), CD123 (positive)
Normal: CD19, CD24, CD34, CD38, CD71, HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD25, CD26, CD33, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, cytoplasmic MPO, surface Kappa, surface Lambda

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

4. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.54% of WBC.

Number of cells acquired: 466 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-320.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-2184, M21-2188, M21-2194, M21-2197, M21-2198.
"
H22-7529;S14;MSK5 - 2023-04-14 15.44.07.ndpi,Peripheral Blood Smear,2023-04-14,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: CML\par Clinical Hx/Op Findings: assess response to aza/ven\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, right posterior iliac crest, biopsy; \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \~\~\par      - Blast phase of chronic myeloid leukemia, presenting as acute myeloid leukemia.      \par   \plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: adequate \par Cellularity:100%\par The marrow is effaced by many blasts with fibrosis. Normal hematopoietic elements are reduced.\par\par Special stains: Reticulin stain shows moderate/ marked increase in reticulin fibrosis (MF-2-3/3). \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules\par Few mast cells are noted.\par\par Blasts \tab\tab\tab 23%\par Promyelocytes \tab\tab 2%\par Myelocytes \tab\tab 2%\par Metamyelocytes \tab\tab 4%\par Neutrophils/Bands \tab 42%\par Monocytes \tab\tab 2%\par Eosinophils \tab\tab 4%\par Basophils \tab\tab 3%\par Erythroid Precursors \tab 5%\par Lymphocytes \tab\tab 13%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 11.8\par\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -The aspirate is aspicular and represents blood. \par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (09/12/2022):\par WBC 68.0 H [4.0-11.0 K/mcL] \par RBC 2.44 L [3.80-5.00 M/mcL] \par HGB 8.0 L [11.2-15.4 g/dL] \par HCT 23.0 L [34.3-46.0 %] \par MCV 94 [80-98 fL] \par MCH 32.8 [27.0-33.0 pg] \par MCHC 34.8 [31.0-36.5 g/dL] \par RDW 21.3 H [12.2-15.1 %] \par Platelets 30 L [160-400 K/mcL] \par\par Neutrophil 31.0 L [32.5-74.8 %] \par Mono 2.0 [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 4.0 H [0.0-1.5 %] \par Blast 31.0 H [0.0-0.0 %] \par Myelocyte 3.0 H [0.0-0.0 %] \par Promyelocyte 1.0 H [0.0-0.0 %] \par Metamyelocyte 2.0 H [0.0-0.0 %] \par Lymph 21.0 [12.2-47.4 %] \par Variant Lymph 4.0 H [0.0-2.0 %] \par Nucleated RBC 7.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 21.1 H [1.5-7.5 K/mcL] \par Abs Mono 1.4 H [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.7 [0.0-0.7 K/mcL] \par Absolute Basophil 2.7 H [0.0-0.2 K/mcL] \par Absolute Blasts 21.1 H [0.0-0.0 K/mcL] \par Abs Myelocytes 2.0 H [0.0-0.0 K/mcL] \par Abs Promyelocytes 0.7 H [0.0-0.0 K/mcL] \par Abs Meta 1.4 H [0.0-0.0 K/mcL] \par Abs Lymph 17.0 H [0.9-3.2 K/mcL] \par\par Morphology: Leukoerythroblastic smear. Marked leukocytosis with left shift and increased blasts. \par\plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The blasts are positive for CD34 and CD117. MPO and CD71 show increased M:E ratio. CD61 stains clusters of megakaryocytes. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9858)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal myeloid blast population detected. The immunophenotype of this population is similar to that seen in prior sample [F22-6277] \par\par Abnormal myeloid blast population represents 36.6% of WBC.\par Basophilia is seen, 5.6% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (partial), CD7 (variable - negative to intermediate), CD13 (variable - intermediate to negative), CD25 (partial), CD33 (variable - intermediate to negative), CD34 (variable - bright to dim), CD38 (dim), CD45RA (negative), CD117 (variable - dim to bright), CD123 (variable - negative to intermediate), CD371 (clec12a) (negative), HLA-DR (bimodal - negative to intermediate), CD90 (increased)\par Normal: CD4, CD36, CD45, CD71\par Negative: CD2, CD10, CD11b, CD14, CD15, CD16, CD19, CD56, CD64, CD105, CD42b\par\par Number of cells acquired: 784 thousand \par\par 2. Abnormal B cell population detected.\par The immunophenotype of this abnormal B cell population is not entirely specific and does not allow for full classification by flow cytometry. \par\par Abnormal B cell population represents 0.006% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD20 (dim), CD43 (positive), CD79b (dim), CD81 (dim), ROR1 (positive)\par Normal: CD23, CD19, CD40, CD45, CD38\par Negative: CD200, CD10, CD3\par\par Number of cells acquired 781 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG?22-6792..\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-38641, 38642 and 38643.\par\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-7576;S2;MSK4 - 2023-06-15 16.54.33.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 ALL \par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-2.  Bone marrow, right posterior iliac crest,  \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 :\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080      - B-lymphoblastic leukemia/lymphoma (80% blasts on aspirate).      \par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080 Bone Marrow Aspirate Smear Quality:  Adequate \par\par Blasts \tab\tab\tab 80%\par Myelocytes \tab\tab 1%\par Erythroid Precursors \tab 1%\par Lymphocytes \tab\tab 18%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 1\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -The smear is cellular and show numerous blasts. \par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (9/12/2022):\par\par WBC 3.4 L [7.1-15.9 K/mcL] \par RBC 3.78 [2.93-4.75 M/mcL] \par HGB 10.0 [9.2-12.7 g/dL] \par HCT 29.6 [27.7-37.9 %] \par MCV 78 [70-85 fL] \par MCH 26.5 [22.7-29.5 pg] \par MCHC 33.8 [31.0-36.5 g/dL] \par RDW 12.9 [12.2-15.6 %] \par Platelets 58 L [160-400 K/mcL] \par\par Neutrophil 0.0 L [16.9-74.5 %] \par Mono 1.0 L [3.8-15.5 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Blast 9.0 H [0.0-0.0 %] \par Lymph 90.0 H [18.1-79.9 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 0.0 L [1.5-8.5 K/mcL] \par Abs Mono 0.0 L [0.2-1.2 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Blasts 0.3 H [0.0-0.0 K/mcL] \par Abs Lymph 3.1 [1.1-8.1 K/mcL] \par\par Morphology: Agranulocytosis. Circulating blasts seen. \par\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9914)\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Abnormal immature B cell population detected.\par An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously [F22-9782].                         \par\par Abnormal immature B cell population represents 84.4% of WBC.\par Abnormal immature B cell population represents 84.6% of the mononuclear cells.\par\par Immunophenotype:\par Abnormal: CD10 (positive - bright), CD20 (partial), CD34 (uniform - intermediate), CD38 (uniform - dim), CD45 (negative), CD81 (dim), CD73/CD304 (positive), CD66c/CD123 (positive), CD86 (positive)\par Normal: CD19, CD22, CD24\par Negative: CD66b\par\par Number of cells acquired 797 thousand \par\par\par Also see F22-9913 (CSF) submitted on the same day.\par\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s18\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-6825 and 6849\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-38592 and 38794\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-5721;S12;MSKV - 2023-04-14 16.13.00.ndpi,Peripheral Blood Smear,2023-04-14,"Clinical Diagnosis: Mult Myeloma
Clinical Hx/Op Findings: Per Protocol
Protocol # 19-392
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
Overall, 20-30% involvement by CD138 immunohistochemistry with patchy distribution
65% involvement by aspirate differential
10.2% involvement by flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality:  Adequate 
Cellularity: Overall 40%
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes:  Adequate   
Plasma cells: Increased    

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Paucispicular, limited

Promyelocytes           2%
Myelocytes           2%
Metamyelocytes           1%
Neutrophils/Bands      10%
Monocytes           6%
Eosinophils           1%
Erythroid Precursors      9%
Plasma Cells           65%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           2.4 

Morphology: 
Marrow spicules: Paucispicular 
Cellularity: Cellular 
Plasma cell morphology: Intermediate to large, bi/multinucleated.
Myeloid lineage: Orderly maturation 
Erythroid Lineage: Orderly maturation 
Megakaryocytes:  Present 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells with patchy distribution, ranging from 10-70% of cellularity, the overall cellularity is approximately 20-30%.  
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.
BCMA highlights 80-90% of plasma cells, (2-3+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-7504) 
Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.

Abnormal plasma cell population comprises 96.8% of total plasma cells.
Abnormal plasma cell population represents 10.2% of WBC.

Immunophenotype:
Abnormal: CD19 (negative), CD27 (negative), CD45 (bimodal negative, intermediate), CD56 (positive), CD81 (negative), CD117 (partial dim), cytoplasmic Kappa (restriction)
Normal: CD138, CD38, CD229, CD319
Negative: cytoplasmic Lambda

Number of cells acquired: 1.8 million

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (07/14/2022):
WBC 1.2 L [4.0-11.0 K/mcL] 
RBC 3.45 L [3.95-5.54 M/mcL] 
HGB 10.5 L [12.5-16.2 g/dL] 
HCT 32.2 L [37.5-49.3 %] 
MCV 93 [80-98 fL] 
MCH 30.4 [27.0-33.0 pg] 
MCHC 32.6 [31.0-36.5 g/dL] 
RDW 17.0 H [12.2-15.1 %] 
Platelets 157 L [160-400 K/mcL] 

Neutrophil 37.0 [32.5-74.8 %] 
Mono 50.0 H [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Lymph 9.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.1 L [0.9-3.2 K/mcL] 

Morphology: 
Leukopenia. No circulating plasma cell seen from scanning.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Not submitted.

MOLECULAR STUDIES 
Not submitted.
"
H22-6605;S14;MSK9 - 2023-04-14 15.55.39.ndpi,Peripheral Blood Smear,2023-04-14,"Clinical Diagnosis: Leukemia, Chronic Myeloid
Clinical Hx/Op Findings: newly dx- evaluate disease- confirm dx
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia, BCR-ABL1-positive, chronic phase (3% blasts by aspirate differential count and ~5% blasts by CD34 immunohistochemistry).
  
BONE MARROW BIOPSY
Quality: Subcortical biopsy with partial aspiration artifact
Cellularity: Markedly hypercellular for age (approximately 90% cellularity) in the limited biopsy
M:E ratio: Appears normal
Blasts: Not overtly increased
Myeloid lineage: Shows full maturation with a mild left-shift     
Erythroid lineage: Shows full maturation with a mild left-shift   
Megakaryocytes: Increased and include many atypical forms (small, hypolobated and hyperchromatic) as well as occasional clusters
Lymphocytes: Interstitially scattered     
Plasma cells: Not overtly increased
Special stain: Reticulin stain shows focal mild increase in reticulin fibrosis (0-1+/3)          

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate 
Blasts                3%
Promyelocytes           1%
Myelocytes           5%
Metamyelocytes           13%
Neutrophils/Bands      45%
Monocytes           1%
Eosinophils           3%
Erythroid Precursors      24%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           2.8

Morphology:
The aspirate smears are spicular and hypercellular demonstrating trilineage hematopoiesis. Myeloid elements show complete maturation with mild increase in left-shifted forms. Patchy increase in eosinophils and their precursors is present. An expanded population of blasts is not seen. Erythroid elements show mildly left-shifted progressive maturation with occasional dyspoiesis (nuclear irregularity/budding, binucleation, megaloblastoid change). Megakaryocytes appear increased in number and include some atypical small forms with hypolobated nuclei. Lymphoid cells are scattered and show mature features. Touch imprints are also hypercellular and show findings concordant with the aspirate smear.

PERIPHERAL BLOOD
CBC (8/11/2022):
WBC 13.4 H [4.0-11.0 K/mcL] 
RBC 5.23 H [3.80-5.00 M/mcL] 
HGB 14.6 [11.2-15.4 g/dL] 
HCT 47.7 H [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 27.9 [27.0-33.0 pg] 
MCHC 30.6 L [31.0-36.5 g/dL] 
RDW 13.3 [12.2-15.1 %] 
Platelets 292 [160-400 K/mcL] 

Neutrophil 78.5 H [32.5-74.8 %] 
Mono 3.3 [0.0-12.3 %] 
Eos 2.7 [0.0-4.9 %] 
Baso 4.5 H [0.0-1.5 %] 
Immature Granulocyte 0.6 [0.0-0.6 %] 
Lymph 10.4 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 10.5 H [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.6 H [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL] 

Morphology:
WBC: Leukocytosis with neutrophilia, and basophilia; no increase in circulating blasts (<2%) seen.
RBCs: Normocytic normochromic RBCs. 
Platelets: Unremarkable morphology.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
CD34 immunostain shows aberrant expression in a subset of megakaryocytes and highlights approximately 5% blasts in the limited evaluable areas.
CD117 highlights immature cells (blasts, early erythroid and myeloid progenitors) and rare mast cells. 
CD61 highlights the increased number of megakaryocytes that form occasional clusters and include rare micromegakaryocytes. 
MPO labels myeloid elements while CD71 labels erythroid elements.     

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-8678)
Abnormal myeloid blast population detected. 
The immunophenotype of this population is similar to that seen in prior sample [F22-7025]. 
Abnormal myeloid blast population represents 1.3% of WBC.
Basophilia is seen, 1.6% of WBC.

Immunophenotype:
Abnormal: CD7 (positive), CD13 (dim), CD33 (dim), CD38 (uniform - dim), CD45RA (negative), CD117 (bright), CD371 (clec12a) (negative), HLA-DR (bright)
Normal: CD4, CD34, CD36, CD45, CD71, CD123
Negative: CD2, CD5, CD10, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64, CD105, CD42b, CD90

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES (CG22-5975)
FISH ANALYSIS:
BCR-ABL1 fusion/t(9;22) detected in 64.7% of cells, with a signal pattern of one fusion signal, one signal of ABL1 (9q34.1) and two signals of BCR (22q11.2).

KARYOTYPE ANALYSIS:
Chromosome analysis detected t(X;2) and t(9;22), which results in BCR-ABL1 fusion, in seventeen out of twenty metaphases. This finding is consistent with this patient's clinical diagnosis of CML. The remaining three metaphase cells were of normal female karyotype.

MOLECULAR STUDIES (M22-34276, M22-34278, M22-34282) 
M22-34278:
POSITIVE FOR THE FOLLOWING GENE FUSIONS IN THE CLINICALLY VALIDATED PANEL: BCR::ABL1 fusion.
Note: The rearrangement is an in-frame fusion (e14a2, p210) between genes BCR Exon14 (NM_004327) and ABL1 Exon2 (NM_005157). 

M22-34282:
BCR-ABL1 p210 fusion gene transcript is DETECTED

After normalization and standardization to the international scale (IS), the level of positivity for the BCR-ABL1 transcript (p210) is approximately 75% (IS). 

See separate report for M22-34276.

Note: Relevant portions of the case were also reviewed with Dr. Pallavi K. Galera, Hematopathology Service, with agreement on the diagnosis.





"
H22-9281;S17;MSK5 - 2023-04-14 14.58.30.ndpi,Peripheral Blood Smear,2023-04-14,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0  Clinical Diagnosis: Multiple Myeloma\par Clinical Hx/Op Findings: pre-transplant\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\par      - Plasma cell neoplasm, \~\par\~\~\~\~\~\~\~\~\~\~60% involvement by CD138 immunohistochemistry.\par\~\~\~\~\~\~\~\~\~\~15% involvement by aspirate differential\par\~\~\~\~\~\~\~\~\~\~3.7% involvement by flow cytometry\par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate, hemorrhage  \par Cellularity: Variable, Overall 60-70% at the preserved areas\par Myeloid lineage: Orderly maturation    \par Erythroid lineage: Orderly maturation   \par Megakaryocytes: Present\par Plasma cells: Increased    \par Clot section: Similar to biopsy\par\par Special stain: Congo Red stain is negative for amyloid deposition.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate\par Patchy aspirate\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Differential count performed on touch imprints\par\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 2%\par Myelocytes \tab\tab 6%\par Metamyelocytes \tab\tab 3%\par Neutrophils/Bands \tab 35%\par Monocytes \tab\tab 2%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 28%\par Plasma Cells \tab\tab 15% (2% - up to 25%, patchy distribution)\par Lymphocytes \tab\tab 7%\par Number of Cells Counted \tab 500\par M:E Ratio \tab\tab 1.8\par\par Morphology: \par Marrow spicules: Spicular \par Cellularity: Hypercellular\par Plasma cell morphology:  Small to large, Bi/multi nucleated, nucleolated\par Myeloid lineage: Orderly maturation \par Erythroid Lineage: Orderly maturation \par Megakaryocytes:  Present\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD138 immunostain highlights increased plasma cells with patchy distribution, overall 60% of cellularity. \par Kappa and lambda immunostains show the plasma cells are lambda light chain restricted.\par BCMA highlights 80-90% of plasma cells, (2+) intensity, membranous/ Golgi pattern. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-12058)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par\par 1. Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par\par Abnormal plasma cell population comprises 99% of total plasma cells.\par Abnormal plasma cell population represents 3.7% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (negative), CD27 (negative), CD45 (negative), CD56 (positive), CD81 (negative), CD117 (positive), no definite light chain expression\par Normal: CD138, CD38, CD229, CD319\par\par Number of cells acquired: 5.8 million \par\par 2. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par\par Myeloid blast population with an unremarkable phenotype represents 0.42% of WBC.\par\par Number of cells acquired: 695 thousand \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/03/2022):\par WBC 3.7 L [4.0-11.0 K/mcL] \par RBC 2.44 L [3.95-5.54 M/mcL] \par HGB 8.2 L [12.5-16.2 g/dL] \par HCT 24.3 L [37.5-49.3 %] \par MCV 100 H [80-98 fL] \par MCH 33.6 H [27.0-33.0 pg] \par MCHC 33.7 [31.0-36.5 g/dL] \par RDW 19.0 H [12.2-15.1 %] \par Platelets. 104 L [160-400 K/mcL] \par\par Neutrophil 84.0 H [32.5-74.8 %] \par Mono 7.0 [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Lymph 7.0 L [12.2-47.4 %] \par Variant Lymph 1.0 [0.0-2.0 %] \par Nucleated RBC 2.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 3.1 [1.5-7.5 K/mcL] \par Abs Mono 0.3 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Lymph 0.3 L [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]\par\par Morphology: \par WBC: Lymphopenia. No circulating plasma cells seen on scanning\par RBC: Macrocytic anemia with poikilocytosis. Tear drop cells seen. \par PLT: Thrombocytopenia\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8302, CG22-8303.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-47159.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-226;S13;MSKR - 2023-05-31 21.10.27.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: cytopenia
Clinical Hx/Op Findings: cytopenai breast cancer
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Metastatic adenocarcinoma involving bone (see comment)
  
COMMENT: The metastatic adenocarcinoma involving the bone marrow is morphologically nonspecific, but similar to the previous liver metastasis (S21-80110), compatible with breast primary. Further immunohistochemistry study and tumor markers are pending and an addendum report will follow.


In addition, this case was also reviewed by Dr. Ying Liu in Hematopathology Service. 

BONE MARROW BIOPSY
Hypercellular marrow shows extensive involvement by metastatic carcinoma (?). 
Special stains: Reticulin stain shows extensive fibrosis.  
Clot section: Shows predominantly blood with no marrow particles. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules
Positive for extrinsic cells

Special stain
Iron: Suboptimal for evaluation due to poor quality of slide
Ring sideroblasts: Suboptimal for evaluation due to poor quality of slide

PERIPHERAL BLOOD
CBC (01/10/2022):
WBC 9.0 [4.0-11.0 K/mcL] 
RBC 2.45 L [3.80-5.00 M/mcL] 
HGB 8.5 L [11.2-15.4 g/dL] 
HCT 26.6 L [34.3-46.0 %] 
MCV 109 H [80-98 fL] 
MCH 34.7 H [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 19.1 H [12.2-15.1 %] 
Platelets 257 [160-400 K/mcL] 

Neutrophil 72.0 [32.5-74.8 %] 
Mono 10.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 14.0 [12.2-47.4 %] 
Nucleated RBC 2.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 6.4 [1.5-7.5 K/mcL] 
Abs Mono 0.9 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
WBC: No circulating blasts.
RBC: Macrocytic anemia with anisocytosis and polychromasia. 
PLT: Unremarkable. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 highlights vasculature with no increase in blasts. 
CD117 highlights few scattered mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-278)
1. No abnormal myeloid blast, mature B or mature T cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.12% of WBC.

Number of cells acquired: 427 thousand  

Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-182.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-1356.
"
H22-9632;S14;MSK2 - 2023-06-15 19.06.08.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Leukemia\par Requested Studies: Gross/Micro\par Clinical Hx/Op Findings: neutropenia and thrombocytopenia\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, \plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b (RPIC)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 , biopsy, aspirate and peripheral blood smears: \~\~\par      - Involvement by hairy cell leukemia (at least 80% cellularity).\par       -Small abnormal plasma cell population detected by flow cytometry only. \par      - Cellular marrow with residual  trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Morphologic and phenotypic findings are consistent with hairy cell leukemia. Small plasma cell population is a polyclonal background by flow cytometry may represent MGUS, however clinical correlation is advised. Morphologic or phenotypic criteria for MDS or other myeloid neoplasm are not met.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy and aspirate specimens show hypercellular bone marrow (70%cellularity). There is\~trilineage maturing hematopoiesis with increased numbers of lymphocytes in interstitial pattern.\par\~\par Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules \par\par Myelocytes \tab\tab 4%\par Metamyelocytes \tab\tab 1%\par Neutrophils/Bands \tab 16%\par Monocytes \tab\tab 1%\par Erythroid Precursors \tab 24%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 36%\par Hairy cells \tab\tab 17%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 0.9\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\par CD20 highlights markedly increased atypical B cells (at least 80% cellularity). CD3 highlights T cells. \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 CD34,  and CD117 show no increase in blasts. CD61 highlights megakaryocytes, CD71 highlights erythroid forms (relatively increased compared to myeloid forms). MPO highlights few myeloid forms.\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-12513)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par 1. Abnormal B cell population detected.\par The immunophenotype of the abnormal B-cell is consistent with involvement by hairy cell leukemia (HCL).\par\par Abnormal B cell population represents 41.5% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (bright), CD20 (bright), CD22 (bright), CD25 (positive), CD11c (positive), CD103 (positive), CD200 (bright), surface Kappa (restriction), Forward Scatter (increased), Side Scatter (increased)\par Normal: CD38, CD45\par Negative: CD5, CD10, CD279 (PD1), CD3, CD14, surface Lambda\par\par Number of cells acquired: 288 thousand \par\par 2. No definite abnormal myeloid blast, monocyte and maturing granulocyte populations detected.                                                  \par There is no definite immunophenotypic evidence of a myeloid stem cell neoplasm by flow cytometry. \par\par Myeloid blast population represents 0.60% of WBC.\par\par Immunophenotype:\par Atypical: CD38 (bimodal - negative to intermediate), CD71 (negative), CD117 (dim)\par Normal: CD4, CD13, CD33, CD34, CD36, CD45, CD105, CD123, HLA-DR\par Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD45RA, CD56, CD64, CD371 (clec12a), cytoplasmic CD3, cytoplasmic CD79a, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par Number of cells acquired 587 thousand \par\par 3. No abnormal mature T cell population detected. \par No immunophenotypic evidence of T-cell lymphoma is identified.  \par\par Number of cells acquired: 316 thousand \par\par 4. Small abnormal plasma cell population detected (see report)\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/15/2022):\par WBC 1.8 L [4.0-11.0 K/mcL] \par RBC 3.46 L [3.95-5.54 M/mcL] \par HGB 12.4 L [12.5-16.2 g/dL] \par HCT 35.3 L [37.5-49.3 %] \par MCV 102 H [80-98 fL] \par MCH 35.8 H [27.0-33.0 pg] \par MCHC 35.1 [31.0-36.5 g/dL] \par RDW 12.9 [12.2-15.1 %] \par Platelets 102 L [160-400 K/mcL] \par\par Neutrophil 23.0 L [32.5-74.8 %] \par Mono 0.0 [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Lymph 72.0 H [12.2-47.4 %] \par Abnormal Lymphoid Cells 4.0 H [0.0-0.0 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 0.4 L [1.5-7.5 K/mcL] \par Abs Mono 0.0 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Lymph 1.4 [0.9-3.2 K/mcL] \par\par Morphology: Pancytopenia with circulating hairy cells\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-1881;S11;MSKX - 2023-05-26 12.47.39.ndpi,Peripheral Blood Smear,2023-05-26,"Clinical Diagnosis: CML
Clinical Hx/Op Findings: recent diagnosis; treatment planning
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate, and peripheral blood smears: 
     - Chronic Myeloid Leukemia (CML), (BCR-ABL-positive), consistent with chronic phase (see comment)

COMMENT:
The findings of hypercellular bone marrow with marked myeloid hyperplasia, megakaryocyte atypia (small hypolobated forms) without additional dysplasia along with peripheral blood granulocytosis and basophilia without significant increase in blasts (<10%) in either bone marrow or peripheral blood in the setting of documented t(9;22)(q34.1;q11.2) BCR-ABL translocation demonstrated by FISH and molecular genetic analysis as per clinical note are consistent with diagnosis above. 
Please note that confirmation of the diagnosis requires exclusion of additional cytogenetic abnormalities developing while on therapy and exclusion of trisomy 8, isochromosome 17q, trisomy 19, complex karyotype and abnormalities of 3q26.2. In addition, exclusion of lack of clinical response to TKI including persistent elevation of WBC (>10X109/L), persistent splenomegaly, thromobocytosis (>1000X109/L) or thrombocytopenia (<100X109/L) is required. Presence of any of the factors listed or of hematological, cytogenetic or molecular resistance to two sequential TKI would be diagnostic for accelerated phase CML.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Increased for age (90%)
M:E ratio: Increased
Blasts: Not overtly increased 
Myeloid lineage: Full maturation with myeloid hyperplasia and expansion of early maturing forms in paratrabecular areas
Erythroid lineage: Full maturation, hypoplastic 
Megakaryocytes: Normal in number with some small hypolobated (dwarf) forms present
Lymphocytes: Scattered, lymphoid aggregates are not seen
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate 
Blasts                1%
Promyelocytes           8%
Myelocytes           6%
Metamyelocytes           3%
Neutrophils/Bands      64%
Monocytes           4%
Eosinophils           2%
Erythroid Precursors      8%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           10.9

Morphology:
- Myeloid hyperplasia with left shift and full maturation. Erythroid lineage is relatively reduced and shows orderly maturation. Megakaryocytes are normal in number and show occasional small and hypolobated forms, blasts are not increased 

PERIPHERAL BLOOD
CBC (3/7/2022):
WBC 21.6 H [4.0-11.0 K/mcL] 
RBC 4.07 [3.95-5.54 M/mcL] 
HGB 11.3 L [12.5-16.2 g/dL] 
HCT 35.7 L [37.5-49.3 %] 
MCV 88 [80-98 fL] 
MCH 27.8 [27.0-33.0 pg] 
MCHC 31.7 [31.0-36.5 g/dL] 
RDW 15.6 H [12.2-15.1 %] 
Platelets. 329 [160-400 K/mcL] 

Neutrophil 55.0 [32.5-74.8 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 
Myelocyte 4.0 H [0.0-0.0 %] 
Promyelocyte 4.0 H [0.0-0.0 %] 
Metamyelocyte 5.0 H [0.0-0.0 %] 
Lymph 18.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 11.9 H [1.5-7.5 K/mcL] 
Abs Mono 1.5 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.6 [0.0-0.7 K/mcL] 
Absolute Basophil 0.9 H [0.0-0.2 K/mcL] 
Abs Myelocytes 0.9 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.9 H [0.0-0.0 K/mcL] 
Abs Meta 1.1 H [0.0-0.0 K/mcL] 
Abs Lymph 3.9 H [0.9-3.2 K/mcL]

Morphology: Granulocytosis with left shift, basophilia, few blasts seen 



Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight blasts, <5% 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-2457)
1. Abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 0.28% of WBC.

Immunophenotype:
Abnormal: CD7 (positive), CD13 (dim), CD117 (bright)
Normal: CD4, CD33, CD34, CD36, CD38, CD45, CD45RA, CD71, CD105, CD123, CD371 (clec12a), HLA-DR
Negative: CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda


2. No abnormal mature B- or T-cell populations detected. 
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

Number of cells acquired: 404 thousand 

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.


Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-1662.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-10366.
"
H22-7760;S3;MSK0 - 2023-06-15 17.06.07.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Myelodysplastic Syndrome (MDS) \par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-2.  Bone marrow, right posterior iliac crest,  \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 :\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080      - Cellular marrow aspirate with erythroid predominant trilineage hematopoiesis, multilineage dyspoiesis, ring sideroblasts, and 2% blasts, consistent with patient's known myelodysplastic syndrome. See comment. \par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par COMMENT: The patient's reported history of MDS with ring sideroblasts and multilineage dysplasia, s/p chemotherapy is noted. The current biopsy findings are consistent with persistent disease involvement. Correlation with the pending cytogenetic and molecular studies is suggested for further characterization. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080 Bone Marrow Aspirate Smear Quality:  Adequate\par Blasts \tab\tab\tab 2%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 3%\par Metamyelocytes \tab\tab 2%\par Neutrophils/Bands \tab 7%\par Eosinophils \tab\tab 1%\par Basophils \tab\tab 1%\par Erythroid Precursors \tab 62%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 20%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 0.2\par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080 Special stain \par Iron: Present\par Ring sideroblasts: Present, >15%\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Spicular and cellular aspirate smears show erythroid predominant trilineage hematopoiesis with no overt increase in blasts. Erythroid elements are predominant and show dysplasia (nuclear irregularity and budding, binucleation, karyorrhexis, and ring sideroblasts). Maturing myeloid elements are few. Megakaryocytes are present and show dysplasia (hypolobated or widely-separated nuclei). \par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (09/19/2022):\par WBC 1.0 L [4.0-11.0 K/mcL] \par RBC 2.70 L [3.80-5.00 M/mcL] \par HGB 7.9 L [11.2-15.4 g/dL] \par HCT 25.2 L [34.3-46.0 %] \par MCV 93 [80-98 fL] \par MCH 29.3 [27.0-33.0 pg] \par MCHC 31.3 [31.0-36.5 g/dL] \par RDW 19.7 H [12.2-15.1 %] \par Platelets 94 L [160-400 K/mcL] \par\par Neutrophil 25.0 L [32.5-74.8 %] \par Mono 0.0 [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 5.0 H [0.0-1.5 %] \par Lymph 69.0 H [12.2-47.4 %] \par Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 0.3 L [1.5-7.5 K/mcL] \par Abs Mono 0.0 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.1 [0.0-0.2 K/mcL] \par Abs Lymph 0.7 L [0.9-3.2 K/mcL] \par\par Morphology:\par WBC: No circulating blasts; neutropenia with hypogranular and hyposegmented forms \par RBC: Anisopoikilocytosis\par PLT: Some large and hypogranular forms \par\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10142)\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1. Abnormal myeloid blast population detected.\par\par Abnormal myeloid blast population represents 3.4% of WBC.\par Basophilia is seen, 2.4% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (partial), CD13 (bimodal - dim to intermediate), CD15 (partial), CD25 (partial), CD33 (dim), CD38 (negative), CD45RA (negative), CD117 (bright), CD123 (bright), CD371 (clec12a) (negative), HLA-DR (bright)\par Normal: CD4, CD34, CD36, CD45, CD71, CD105\par Negative: CD2, CD3, CD7, CD8, CD10, CD11b, CD14, CD16, CD19, CD20, CD22, CD26, CD56, CD64, surface Kappa, surface Lambda, CD42b, CD90\par\par Number of cells acquired: 326 thousand \par\par 2. No abnormal mature B- or T-cell populations detected. \par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par\par Number of cells acquired 193 thousand \par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s18\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-6954. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-39624.\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-6606;S15;MSKA - 2023-06-15 12.07.38.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: mastocytosis
Clinical Hx/Op Findings: diagnostic
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
     - Systemic mastocytosis, approximately 5-10% by CD117/tryptase immunohistochemistry.
     - Hypocellular marrow with maturing trilineage hematopoiesis and no increase in blasts.
  
COMMENT: The presence of elevated serum tryptase (37.8 ng/mL) and reported cutaneous, GI, and cardiovascular symptoms of mast cell activation responsive to antihistamines as well as the findings of a prior skin biopsy (S22-51456) are noted. The bone marrow is notable for presence of multifocal dense aggregates of cytologically atypical mast cells with CD25 and partial CD2 expression. Taken together, these findings fulfill diagnostic criteria for systemic mastocytosis. 

The case was also reviewed with Dr. Mariko Yabe, Hematopathology Service, with agreement on the diagnosis.     
 
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypocellular for age (30-40% cellularity)
M:E ratio: Appears normal
Blasts: Not overtly increased     
Myeloid lineage: Exhibits full maturation
Erythroid lineage: Exhibits full maturation
Megakaryocytes: Adequate in number; include occasional small, hypolobated and/or hyperchromatic forms
Lymphocytes: Interstitially scattered     
Plasma cells: Not increased
Others: Rare clusters of spindled mast cells (atypical mast cell aggregates are better seen with CD117/tryptase immunostains)
Special stain: Reticulin stain shows no significant increase in reticulin fibrosis (MF-0). 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate 
Blasts                2%
Promyelocytes           1%
Myelocytes           6%
Metamyelocytes           9%
Neutrophils/Bands      21%
Monocytes           3%
Eosinophils           4%
Erythroid Precursors      31%
Plasma Cells           1%
Lymphocytes           22%
Number of Cells Counted  500
M:E Ratio           1.4

Morphology:
Spicular and cellular aspirate smears show partial crush artifact. There is trilineage hematopoiesis and scattered degranulated atypical spindle shaped mast cells. Blasts are not increased, and Auer rods are not identified. Myeloid lineage shows progressive maturation with a mild left-shift. A few granulocytes show dyspoietic features in the form of abnormal chromatin clumping or abnormal nuclear lobation (<10% of lineage). Erythroid elements show orderly maturation without prominent dyspoiesis. Megakaryocytes are present and show include occasional hypolobated forms. Lymphocytes are small sized and mature appearing; no prominent aggregates are seen.     

PERIPHERAL BLOOD
CBC (8/11/2022):
WBC 7.2 [4.0-11.0 K/mcL] 
RBC 4.71 [3.95-5.54 M/mcL] 
HGB 14.4 [12.5-16.2 g/dL] 
HCT 40.6 [37.5-49.3 %] 
MCV 86 [80-98 fL] 
MCH 30.6 [27.0-33.0 pg] 
MCHC 35.5 [31.0-36.5 g/dL] 
RDW 12.0 L [12.2-15.1 %] 
Platelets 258 [160-400 K/mcL] 

Neutrophil 62.4 [32.5-74.8 %] 
Mono 6.1 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 1.2 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Lymph 29.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 4.5 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 2.1 [0.9-3.2 K/mcL] 

Morphology:
WBCs: Neutrophils show increased granularity and occasional vacuoles; rare possible mast cells; rare left-shifted granulocytes; no circulating blasts.
RBCs: Normocytic normochromic RBCs. 
Platelets: Unremarkable morphology.     

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
CD117 and tryptase highlight increased number of mast cells (approximately 5-10%) that show atypical, spindled morphology, form occasional dense aggregates and show aberrant expression of CD25 and CD2 (partial, weak).
CD34 immunostain shows no increase in blasts (<5% of cellularity).
Aberrant CD34 expression is present in a subset of megakaryocytes. 
CD61 highlights megakaryocytes.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-8677)
1. Atypical mast cells present.
Mast cell population represents 0.30% of WBC.

Immunophenotype:
Abnormal: CD2 (positive), CD25 (positive)
Normal: CD117
Negative: CD5, HLA-DR, CD42b, CD90

2. No abnormal mature B-cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.
Number of cells acquired: 466 thousand

3. No abnormal myeloid blast or mature T-cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.
Myeloid blast population with an unremarkable phenotype represents 1.3% of WBC.
Number of cells acquired: 892 thousand 

4. No abnormal plasma cell population detected. 
No evidence of an abnormal plasma cell population is identified by flow cytometry.
Normal plasma cell population represents 0.32% of WBC.
Number of cells acquired: 922 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES (CG22-5972)
KARYOTYPE ANALYSIS:
Normal male karyotype. No evidence of clonal chromosome abnormality was observed.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-34268.




"
H22-8123;S15;MSKX - 2023-06-15 10.27.04.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Myelodysplastic Syndrome\par Clinical Hx/Op Findings: MDS was on Enasednib complicated by aplasia\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\par      - Persistent myelodysplastic syndrome without increased blasts (with ring sideroblasts, but without SF3B1 mutation)\par      - Cellular marrow with trilineage maturing hematopoiesis.\par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 While ring sideroblasts are seen, prognostic significance is unlcear in the absence of the documented SF3B1 mutation. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Increased (70-80%)\par M:E ratio: Decreased \par Blasts:\par Myeloid lineage: Maturation seen\par Erythroid lineage: Left shifted with maturation\par Megakaryocytes: Present in adequate numbers\par Lymphocytes: Scattered\par Plasma cells: Scattered\par Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW TOUCH PREPARATION\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Only touch imprints available for differential.\par\par Blasts \tab\tab\tab 2%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 11%\par Metamyelocytes \tab\tab 5%\par Neutrophils/Bands \tab 21%\par Monocytes \tab\tab 3%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 46%\par Lymphocytes \tab\tab 10%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 0.9\par\par Special stain\par Iron: Present on touch imprint\par Ring sideroblasts: Present, >15%\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -Trilineage maturing hematopoiesis with no increased blasts\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (9/29/2022):\par\par WBC 6.3 [4.0-11.0 K/mcL] \par RBC 3.12 L [3.80-5.00 M/mcL] \par HGB 8.6 L [11.2-15.4 g/dL] \par HCT 27.6 L [34.3-46.0 %] \par MCV 89 [80-98 fL] \par MCH 27.6 [27.0-33.0 pg] \par MCHC 31.2 [31.0-36.5 g/dL] \par RDW 21.0 H [12.2-15.1 %] \par Platelets 196 [160-400 K/mcL] \par\par Neutrophil 76.0 H [32.5-74.8 %] \par Mono 4.0 [0.0-12.3 %] \par Eos 4.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Lymph 16.0 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 4.8 [1.5-7.5 K/mcL] \par Abs Mono 0.3 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Lymph 1.0 [0.9-3.2 K/mcL] \par\par Morphology: anemia, with occasional NRBC, anisopoikilocytosis, occasional hypogranular neutrophils, no increased blasts\par\plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080 CD34 and CD117 show no increase (<5%) in blasts. CD61 highlights megakaryocytes (with few small forms seen), CD71 highlights erythroid forms (hyperplastic), MPO highlights myeloid forms.\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10572)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Abnormal myeloid blast population detected. \par\par Abnormal myeloid blast population represents 1.5% of WBC.\par\par Immunophenotype:\par Abnormal: CD13 (negative), CD117 (bright)\par Normal: CD4, CD33, CD34, CD36, CD38, CD45, CD45RA, CD71, CD123, CD371 (clec12a), HLA-DR\par Negative: CD2, CD5, CD7, CD10, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64, CD105, CD42b, CD90\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-7277.\par\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-5219;S13;MSKY - 2023-04-14 16.25.09.ndpi,Peripheral Blood Smear,2023-04-14,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: diagnostic
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Plasma cell neoplasm, 
  10-15% involvement by CD138 immunohistochemistry.
2% involvement by aspirate differential
0.047% (50.2% of plasma cells) involvement by flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.
     - A minute abnormal B cell population with CLL/SLL-like immunophenotype detected by flow cytometry, see note 

Note: The minute abnormal B-cell population may represent a monoclonal B-cell lymphocytosis (MBL) with CLL-like immunophenotype. Peripheral blood flow cytometric analysis can be considered for further evaluation, if clinically indicated.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Variable, ranging 5-20%, overall approximately 10-20%,
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes: Adequate   
Plasma cells: Mildly Increased 

Special stain: Congo Red stain is negative for amyloid deposition 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules 
Performed on touch imprint
Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           8%
Neutrophils/Bands      38%
Monocytes           1%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      24%
Plasma Cells           2%
Lymphocytes           15%
Number of Cells Counted 500
M:E Ratio           2.5

Morphology: 
Marrow spicules: aspicular.
Cellularity: Hypocellular on touch imprint
Plasma cell morphology: Small
Myeloid lineage: Orderly maturation 
Erythroid Lineage: Orderly maturation 
Megakaryocytes: Present 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 10-15% of cellularity. 
Kappa and lambda immunostains show the plasma cells are lambda light chain predominant.
BCMA highlights 80% of plasma cells, (2-3+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-6822) 
Abnormal B cell and plasma cell populations identified.
1. Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.

Abnormal plasma cell population comprises 50.2% of total plasma cells.
Abnormal plasma cell population represents 0.047% of WBC.
Immunophenotype:
Abnormal: CD19 (negative), CD27 (negative), CD45 (negative), CD56 (positive), CD81 (dim), CD117 (positive), cytoplasmic Lambda (restriction)
Normal: CD138, CD38, CD229, CD319
Negative: CD20, cytoplasmic Kappa

Number of cells acquired: 2.2 million 

2. Abnormal B cell population detected.
The immunophenotype of this abnormal B cell population is consistent with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or CLL-like monoclonal B-cell lymphocytosis. 

Abnormal B cell population represents 0.067% of WBC.
Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (positive), CD43 (positive), CD79b (dim), CD81 (dim), ROR1 (positive), surface Kappa (restriction - dim), CD25 (positive)
Normal: CD200, CD19, CD40, CD45, CD38
Negative: CD10, CD3, surface Lambda, CD14, CD279 (PD1)

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (06/24/2022):
WBC 5.9 [4.0-11.0 K/mcL] 
RBC 4.39 [3.80-5.00 M/mcL] 
HGB 13.3 [11.2-15.4 g/dL] 
HCT 40.4 [34.3-46.0 %] 
MCV 92 [80-98 fL] 
MCH 30.3 [27.0-33.0 pg] 
MCHC 32.9 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets. 160 [160-400 K/mcL] 

Neutrophil 58.1 [32.5-74.8 %] 
Mono 5.4 [0.0-12.3 %] 
Eos 0.7 [0.0-4.9 %] 
Baso 0.7 [0.0-1.5 %] 
Immature Granulocyte 0.2 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 34.9 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 3.4 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 2.1 [0.9-3.2 K/mcL]

Morphology:  No circulating plasma cells seen on scanning

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-4713, CG22-4714.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-27102. 
"
H22-1367;S10;MSK5 - 2023-05-26 16.46.29.ndpi,Peripheral Blood Smear,2023-05-31,"Lymphoma
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - CD5-/CD10- low grade B-cell lymphoma, suggestive of splenic marginal zone lymphoma, 30% involvement with CD20 immunohistochemistry, see comment. 

COMMENT: Lymphoma cells show intra-sinusoidal distribution in the bone marrow, and villous projection is seen in atypical lymphocytes in peripheral blood smear. Overall findings are highly suggestive of splenic marginal zone lymphoma (SMZL). Per clinical notes, BCL6 rearrangement was detected elsewhere. BCL6 rearrangement could be seen in SMZL. Immunophenotypically, other low-grade B-cell lymphomas, including CLL/SLL, mantle cell lymphoma or follicular lymphoma, are unlikely. Please correlate with radiological findings. Corresponding cytogenetic and molecular analysis are in progress. Please also correlate with these findings. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show mildly hypercellular bone marrow for age (approximately 40% cellularity). There istrilineage maturing hematopoiesis with increased atypical lymphocytes, showing intra-sinusoidal and interstitial distribution. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight increased atypical lymphocytes, showing intra-sinusoidal and interstitial distribution, comprising approximately 30% of cellularity. 
These B-cells do not express CD5, CD23, LEF1 or Cyclin D1. 
CD3 highlights reactive T-cells, 10-15% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1788) 
Interpretation: 
Abnormal B cell population detected.
The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.

Abnormal B cell population represents 29.8% of WBC.

Immunophenotype:
Abnormal: CD5 (partial), CD23 (partial), ROR1 (partial), surface Lambda (restriction)
Normal: CD20, CD22, CD43, CD79b, CD81, CD200, CD19, CD40, CD45
Negative: CD38, CD10, CD3, surface Kappa

Number of cells acquired: 307 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (2/11/2022):

WBC 9.2 [4.0-11.0 K/mcL] 
RBC 3.39 L [3.80-5.00 M/mcL] 
HGB 9.7 L [11.2-15.4 g/dL] 
HCT 29.6 L [34.3-46.0 %] 
MCV 87 [80-98 fL] 
MCH 28.6 [27.0-33.0 pg] 
MCHC 32.8 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 216 [160-400 K/mcL] 

Neutrophil 35.0 [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 26.0 [12.2-47.4 %] 
Other 33.0 H [0.0-0.0 %] (Atypical lymphoid cells)
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 3.2 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Lymph 2.4 [0.9-3.2 K/mcL] 
Abs Others 3.0 H [0.0-0.0 K/mcL] 

Morphology: 
Circulating atypical lymphocytes present. A subset of atypical lymphocytes has villous projection; however, overall, villous projection is not prominent. Occasional nucleoli are also seen.  

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-1168. 

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-7364, M22-7365, M22-7366, M22-7368. 
"
H22-9495;S15;MSK0 - 2023-06-15 14.00.05.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Leukemia\par Clinical Hx/Op Findings: High peripheral blast count and worsening thrombocytopenia>anemia\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-2. Bone marrow, left posterior iliac crest, biopsy and aspirate smears: \~\~\par      - Therapy related acute myeloid leukemia, 85% blasts by aspirate differential, see comment..\par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  The patient's history of recurrent, metastatic serous carcinoma of the ovary with previous cytotoxic therapy is noted. The findings are consistent with the diagnosis of therapy-related acute myeloid leukemia. Correlation with forthcoming cytogenetic and molecular studies is suggested.\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Fragmented but adequate.\par Cellularity: 70-80%\par M:E ratio: N/A\par Blasts: Markedly increased and present in sheets.\par Myeloid lineage: Rare scattered elements.\par Erythroid lineage: Rare scattered elements.\par Megakaryocytes:  Markedly decreased; without overt atypia.\par Lymphocytes: Scattered.\par Plasma cells: Scattered.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par Special stains: Reticulin stain shows no increase in reticulin fibrosis.\par\par Clot section: Not submitted.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate\par\par Blasts \tab\tab\tab 85%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 1%\par Neutrophils/Bands \tab 1%\par Monocytes \tab\tab 10%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 1%\par Number of Cells Counted \tab 500\par M:E Ratio \tab\tab N/A\par\par Special stain\par Iron: Present\par Ring sideroblasts: Unable to assess due to limited erythroids\par\par Morphology:\par Spicular and hypercellular bone marrow aspirate smears show a marked increase in blasts which appear small to medium-sized with round or indented nuclei, fine chromatin, mostly inconspicuous nucleoli, and moderate cytoplasm. Rare myeloid, erythroid and megakaryocytic elements are present in the background.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/10/2022):\par WBC 82.5 H [4.0-11.0 K/mcL] \par RBC 2.57 L [3.80-5.00 M/mcL] \par HGB 7.3 L [11.2-15.4 g/dL] \par HCT 23.9 L [34.3-46.0 %] \par MCV 93 [80-98 fL] \par MCH 28.4 [27.0-33.0 pg] \par MCHC 30.5 L [31.0-36.5 g/dL] \par RDW 21.5 H [12.2-15.1 %] \par Platelets. 21 L [160-400 K/mcL] \par\par Neutrophil 3.0 L [32.5-74.8 %] \par Mono 47.0 H [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Blast 45.0 H [0.0-0.0 %] \par Lymph 5.0 L [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 2.5 [1.5-7.5 K/mcL] \par Abs Mono 38.8 H [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Blasts 37.1 H [0.0-0.0 K/mcL] \par Abs Lymph 4.1 H [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]\par\par Morphology: Not submitted.\plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 is negative in blasts and CD117 weakly highlights a small subset of blasts (<5% of cellularity); MPO shows partial, variable expression (~60%).\par CD71 highlights rare erythroid elements.\par CD61 highlights decreased megakaryocytes.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-12327)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Expanded abnormal blast/immature blast equivalent population detected, represents 84% of WBC.\par\par Immunophenotype:\par Abnormal: CD13 (variable - negative to intermediate), CD33 (variable - negative to bright), CD34 (negative), CD64 (partial), CD117 (variable - dim to intermediate), HLA-DR (negative), MPO (variable)\par Normal: CD4, CD36, CD38, CD45, CD45RA, CD71, CD123, CD371 (clec12a)\par Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD105, cytoplasmic CD3, cytoplasmic CD79a, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par Number of cells acquired: 956 thousand \par\par 2. Abnormal myeloid blast population detected.\par\par Abnormal myeloid blast population represents 0.18% of WBC.\par\par Immunophenotype:\par Abnormal: CD13 (negative), CD34 (positive), HLA-DR (negative)\par Normal: CD4, CD33, CD36, CD38, CD45, CD45RA, CD71, CD105, CD117, CD123, CD371 (clec12a)\par Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, cytoplasmic CD3, cytoplasmic CD79a, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par 3. No abnormal mature B- or T-cell populations detected. \par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par Number of cells acquired 487 thousand \par\par The case was also reviewed by Dr. Mikhail Roshal (Hematopathology Service) who agrees with the diagnosis.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-12294)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Acute myeloid leukemia, expanded abnormal blast/immature blast equivalent population detected.\par\par Expanded abnormal blast/immature blast equivalent population is seen, represents 66.7% of WBC.\par\par Immunophenotype:\par Abnormal: CD13 (variable - negative to intermediate), CD33 (variable - negative to bright), CD34 (negative), CD64 (partial), CD117 (variable - dim to intermediate), HLA-DR (negative), MPO (variable)\par Normal: CD4, CD36, CD38, CD45, CD45RA, CD71, CD105, CD123, CD371 (clec12a)\par Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, cytoplasmic CD3, cytoplasmic CD79a, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par Number of cells acquired: 778 thousand \par\par 2. Abnormal myeloid blast population detected.\par\par Abnormal myeloid blast population represents 0.49% of WBC.\par\par Immunophenotype:\par Abnormal: CD13 (negative), CD34 (positive), HLA-DR (negative)\par Normal: CD4, CD33, CD36, CD38, CD45, CD45RA, CD71, CD105, CD117, CD123, CD371 (clec12a)\par Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, cytoplasmic CD3, cytoplasmic CD79a, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par 3. No abnormal mature B- or T-cell populations detected. \par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par Number of cells acquired 421 thousand\par\par The case was also reviewed by Dr. Mikhail Roshal (Hematopathology Service) who agrees with the diagnosis.\par\par\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8491.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate reports, M22-48502, M22-48503, M22-48504, M22-48505.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-6364;S14;MSK1 - 2023-06-15 12.56.17.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: Restaging - r/o SMM -> MM
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
~20-30% involvement by CD138 immunohistochemistry.
17% involvement by aspirate differential
0.81% involvement by flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality: Limited, fragmented
Cellularity: Overall 30%
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes: Present  
Plasma cells: Increased    
Clot section: Similar to biopsy

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                2%
Promyelocytes           2%
Myelocytes           11%
Metamyelocytes           10%
Neutrophils/Bands      27%
Monocytes           3%
Eosinophils           4%
Erythroid Precursors      15%
Plasma Cells           17%
Lymphocytes           9%
Number of Cells Counted      500
M:E Ratio           3.8 

Morphology: 
Marrow spicules: Spicular 
Cellularity: Cellular 
Plasma cell morphology: Small to intermediate, binucleated
Myeloid lineage: Orderly maturation 
Erythroid Lineage: Orderly maturation with rare forms showing nuclear membrane irregularities
Megakaryocytes: Present with rare forms showing separated nuclear lobes
Other findings: Rare Dutcher bodies noted.  

IMMUNOHISTOCHEMISTRY
IHC was performed on parts 1-1 and 1-2
CD138 immunostain highlights plasma cells, 20-30% of cellularity. 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.
BCMA highlights >90% of plasma cells, (1-2) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW F22-8365 
1. Abnormal plasma cell population detected.
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.

Abnormal plasma cell population comprises 99% of total plasma cells.
Abnormal plasma cell population represents 0.81% of WBC.

Immunophenotype:
Abnormal: CD19 (negative), CD27 (variable - negative to dim), CD45 (bimodal - dim to negative), CD56 (positive), CD81 (negative), cytoplasmic Kappa (restriction)
Normal: CD138, CD38, CD229, CD319
Negative: CD117, cytoplasmic Lambda

Number of cells acquired: 176 thousand

2. No abnormal myeloid blast, monocyte or maturing myeloid population identified.
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.07% of WBC.
Monocytosis is seen, 10.0% of WBC.
Basophilia is seen, 1.1% of WBC.
Eosinophilia is seen, 10.6% of WBC.

Number of cells acquired: 226 thousand
Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition.

3. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

Number of cells acquired: 280 thousand
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (08/04/2022):
WBC 6.5 [4.0-11.0 K/mcL] 
RBC 2.63 L [3.95-5.54 M/mcL] 
HGB 8.6 L [12.5-16.2 g/dL] 
HCT 25.8 L [37.5-49.3 %] 
MCV 98 [80-98 fL] 
MCH 32.7 [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 15.3 H [12.2-15.1 %] 
Platelets 221 [160-400 K/mcL] 

Neutrophil 46.6 [32.5-74.8 %] 
Mono 11.0 [0.0-12.3 %] 
Eos 9.5 H [0.0-4.9 %] 
Baso 0.8 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 31.6 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 3.0 [1.5-7.5 K/mcL] 
Abs Mono 0.7 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.6 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 2.1 [0.9-3.2 K/mcL] 

Morphology: 
No circulating plasma cell seen from scanning.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-5730, CG22-5731.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-32726.
"
H22-2829;S10;MSK9 - 2023-05-26 16.01.03.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Burkitt lymphoma
Clinical Hx/Op Findings: Assess Burkitt lymphoma
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Cellular marrow with erythroid predominant trilineage maturing hematopoiesis.
     - No morphologic or immunophenotypic evidence of involvement by lymphoma. See comment.

Comment: Immunohistochemistry for CD20 is essentially negative. PAX5 highlights relatively numerous small cells scattered in the interstitium, accounting for ~10% of cellularity. Correlation with the flow cytometric analysis results suggest that these represents hematogones.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show mildly hypocellular bone marrow for age (30-35% cellularity). There istrilineage maturing hematopoiesis. Lymphocytes do not appear increased in number. Myeloid lineage is relatively decreased and shows left-shifted maturation. Erythroid lineage shows complete maturation. Megakaryocytes display overall normal morphology with occasional small forms. Peripheral blood smears show presence of scattered small immature cells morphologically consistent with hematogones.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 is essentially negative. PAX5 highlights scattered small cells in the interstitium accounting for 5-10% of total cellularity. CD3 highlights scattered T cells, accounting for ~5% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-3693) 
No abnormal mature B-cell population detected. Virtually no mature B cells seen.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

Number of cells acquired: 325 thousand 

Also see F22-3681 submitted on the same day.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS,      PERIPHERAL BLOOD (F22-3681) 
No abnormal mature B- or T-cell populations detected. Virtually no B cells seen.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

Number of cells acquired: 433 thousand 

Also see F22-3693 submitted on the same day.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (04/06/2022):
WBC 4.6 [4.0-11.0 K/mcL] 
RBC 3.97 [3.95-5.54 M/mcL] 
HGB 11.8 L [12.5-16.2 g/dL] 
HCT 37.0 L [37.5-49.3 %] 
MCV 93 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 15.5 H [12.2-15.1 %] 
Platelets 218 [160-400 K/mcL] 

Neutrophil 21.0 L [32.5-74.8 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 65.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 3.0 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: No atypical lymphocytes seen.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Not requested. 

MOLECULAR STUDIES 
Not requested.  
"
H22-9087;S17;MSKI - 2023-06-15 10.50.29.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Lymphoma\par Requested Studies: Gross/Micro\par Clinical Hx/Op Findings: anemia and lymphoma\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:  \~\~\par      - Involvement by CD5 positive B-cell lymphoproliferative disorder (30% with CD20 immunohistochemistry)\par      - Hypercellular marrow with trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  The overall morphologic and immunophenotypic findings are consistent with involvement by a CD5 positive B-cell lymphoproliferative disorder, and favored to represent mantle cell lymphoma with \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i CCND1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  and \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i BCL6\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  gene rearrangements based on the prior cytogenetic studies (CG22-7754). Correlation with the pending cytogenetic and molecular studies is recommended. The case was also reviewed by Dr. Ahmet Dogan (Hematopathology Service) who agrees with the diagnosis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy and aspirate specimens show hypercellular bone marrow (40%cellularity). There is\~trilineage maturing hematopoiesis with increased numbers of atypical lymphocytes. Blasts are not increased. Overt dysplasia is not appreciated.\par\par Bone Marrow Aspirate Smear Quality: Adequate\par\par Blasts \tab\tab\tab 2%\par Promyelocytes \tab\tab 4%\par Myelocytes \tab\tab 14%\par Metamyelocytes \tab\tab 10%\par Neutrophils/Bands \tab 30%\par Monocytes \tab\tab 4%\par Eosinophils \tab\tab 5%\par Erythroid Precursors \tab 18%\par Plasma Cells \tab\tab 5%\par Lymphocytes \tab\tab 8%\par Number of Cells Counted\tab 500\par M:E Ratio \tab\tab 3.7\par\par Special stain\par Iron: Absent\par Ring sideroblasts: Absent \par\~\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 CD3 and CD5 highlight small T-cells.\par CD20 and PAX5 highlight an increase in B-cells, comprising approximately 30% of marrow cellularity.\par The atypical B-cells appear positive for cyclin D1 (subset) and CD10 (minor subset).\par They are negative for LEF1, SOX11, BCL6, HGAL, LMO2, ATM, and P53.\par Co-expression of CD5 on the B-cells is difficult to evaluate but favored to be negative.\par The Ki67 proliferation index is approximately 5%.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-11819)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par Two abnormal B cell populations detected.\par 1. The 1st major abnormal B cell population detected.\par The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.\par Abnormal B cell population represents 32.2% of WBC.\par Immunophenotype:\par Abnormal: CD5 (partial), CD20 (dim), CD22 (dim), CD19 (dim), CD38 (variable - intermediate to negative), CD10 (partial - dim), surface Kappa (restriction)\par Normal: CD79b, CD81, ROR1, CD40, CD45\par Negative: CD23, CD43, CD200, CD3, surface Lambda, CD25, CD14, CD279 (PD1)\par\par Number of cells acquired 527 thousand \par\par 2. The 2nd minute abnormal B cell population detected. \par Flow cytometry reveals an abnormal B cell population with CLL/SLL-like immunophenotype (see below).\par Abnormal B cell population represents 0.11% of WBC.\par Immunophenotype:\par Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (positive), CD43 (positive), CD79b (dim), CD81 (dim), CD200 (bright), ROR1 (positive), surface Kappa (restriction - dim), surface Lambda (restriction - dim)\par Normal: CD19, CD40, CD45\par Negative: CD38, CD10, CD3, CD14, CD25, CD279 (PD1)\par\par Number of cells acquired 527 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (10/28/2022)\par WBC 10.8 [4.0-11.0 K/mcL] \par RBC 3.50 L [3.95-5.54 M/mcL] \par HGB 9.2 L [12.5-16.2 g/dL] \par HCT 28.7 L [37.5-49.3 %] \par MCV 82 [80-98 fL] \par MCH 26.3 L [27.0-33.0 pg] \par MCHC 32.1 [31.0-36.5 g/dL] \par RDW 16.7 H [12.2-15.1 %] \par Platelets. 183 [160-400 K/mcL] \par\par Neutrophil 62.0 [32.5-74.8 %]  \par Mono 7.0 [0.0-12.3 %]  \par Eos 2.0 [0.0-4.9 %]  \par Baso 0.0 [0.0-1.5 %]  \par Immature Granulocyte [0.0-0.6] \par Lymph 20.0 [12.2-47.4 %]  \par Abnormal Lymphoid Cells 9.0 H [0.0-0.0 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)]  \par\par Abs Neut 6.7 [1.5-7.5 K/mcL]  \par Abs Mono 0.8 [0.0-1.3 K/mcL]  \par Absolute Eosinophil 0.2 [0.0-0.7 K/mcL]  \par Absolute Basophil 0.0 [0.0-0.2 K/mcL]  \par Absolute Immature Granulocyte [0.0-0.1] \par Abs Lymph 3.1 [0.9-3.2 K/mcL]  \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]\par\par Morphology:\par WBC: unremarkable, no definitive circulating atypical lymphocytes seen\par RBC: anemia\par PLT: unremarkable\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8144, CG22-8229.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-46440.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-1124;S10;MSKW - 2023-05-31 22.18.39.ndpi,Peripheral Blood Smear,2023-05-31,"{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch31505\stshfloch31506\stshfhich31506\stshfbi0\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}
{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;
\red0\green0\blue0;}{\*\defchp \fs22\loch\af31506\hich\af31506\dbch\af31505 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*
\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\trcbpat1\trcfpat1\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused 
Normal Table;}{\s15\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\f1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext15 \spriority0 Arial;}}
{\*\rsidtbl \rsid1736676\rsid1926613\rsid6949486\rsid8271858\rsid12137372}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\operator Chan, Alexander Y./Pathology}
{\creatim\yr2022\mo2\dy14\hr11\min50}{\revtim\yr2022\mo2\dy14\hr11\min50}{\version2}{\edmins0}{\nofpages1}{\nofwords17}{\nofchars99}{\nofcharsws115}{\vern21}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}
\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata1\grfdocevents0\validatexml0\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors0\horzdoc\dghspace120\dgvspace120\dghorigin1701
\dgvorigin1984\dghshow0\dgvshow3\jcompress\viewkind1\viewscale130\rsidroot8271858 \fet0{\*\wgrffmtfilter 2450}\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2
\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}\pard\plain \ltrpar\s15\ql \li0\ri0\nowidctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\af1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \fs18\insrsid12137372 \hich\af1\dbch\af31505\loch\f1 Clinical Diagnosis: Lymphoma, Mantle Cell\par \hich\af1\dbch\af31505\loch\f1 Clinical Hx/Op Findings: recurrent disease\par \hich\af1\dbch\af31505\loch\f1 Requested Studies: Gross/Micro\par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Involved by previously diagnosed mantle cell lymphoma, ~10-20% of total cellularity by CD20 immunohistochemistry.
    - Hypercellular bone marrow with maturing trilineage hematopoiesis 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy specimen shows a hypercellular (~70%) bone marrow with maturing trilineage hematopoiesis and an atypical lymphoid infiltrate with interstitial and intrasinusoidal distribution composed of small to medium sized atypical lymphoid cells with moderate amounts of cytoplasm, irregular nuclei, and condensed chromatin. Aspirate smears are spicular, cellular, and show maturing trilineage hematopoiesis without expanded blast population, with frequent atypical lymphoid cells.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight the atypical lymphoid infiltrate, ~10-20% of total cellularity. 
B-cells co-express CD5 and CyclinD1, while negative for CD3, CD23, and P53.
SOX11 is technically suboptimal.
BCL2 and BCL6 appear mostly negative in the B-cells.
CD3 highlights scattered T-cells, <5% of total cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1438) 
Abnormal B cell population detected.
The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.
Abnormal B cell population represents 21.0% of WBC.

Immunophenotype:
Abnormal: CD5 (partial), CD20 (bright), CD79b (bright), CD200 (negative), CD19 (bright), CD45 (bright), CD10 (partial), surface Kappa (restriction)
Normal: CD22, CD23, CD43, CD81, CD40
Negative: ROR1, CD38, CD3, surface Lambda

Also see F21-1439 (PB) submitted on the same day.
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (2/08/2022):
WBC 5.8 [4.0-11.0 K/mcL] 
RBC 4.37 [3.95-5.54 M/mcL] 
HGB 13.0 [12.5-16.2 g/dL] 
HCT 38.8 [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 108 L [160-400 K/mcL] 

Neutrophil 47.0 [32.5-74.8 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 17.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 28.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 2.7 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 2.6 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Frequent circulating atypical lymphoid cells seen.
RBC: Normocytic, normochromic RBCs.
PLT: Mild thrombocytopenia. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-928.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-5779, M22-5782, M22-5783.

"
H22-1814;S12;MSKU - 2023-05-26 12.41.47.ndpi,Peripheral Blood Smear,2023-05-26,"Aplastic Anemia

","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     
-Variably cellular marrow with a mild erythroid hyperplasia, megakaryocytic dyspoiesis, mild erythroid dyspoiesis and no increased blasts
-Low level involvement by B cell lymphoproliferative neoplasm with marginal zone lymphoma-like phenotype
-A small LGL like population with TRBC1 restriction seen by flow cytometry 
 
COMMENT:
This is a complicated case. Peripheral blood shows anemia and thrombocytopenia. No clinical history record was found in the medical chart. The marrow evaluation shows a regenerative/insult pattern with areas of hypocellularity alternating with nearly empty hypocellular bone marrow. Such pattern may be seen in bone marrow failure syndromes. Dyspoiesis is seen and is exceeding 10% at least in megakaryocytic lineage. Flow cytometry shows abnormal blast maturation. Such findings raise a possibility of a myeloid stem cell disorder such as MDS. Cytogenetic evaluation was unrevealing.
Conversely the finding of at least a low-level monoclonal B cell lymphocytosis with marginal zone lymphoma like phenotype and morphologically atypical B cell distribution in the bone marrow along with a likely clonal small LGL-like proliferation raise a possibility of a reactive change. Small LGL expansions are of unclear significance, even if clonal. 
It will be critical to correlate these findings with the tandem molecular genetic evaluation. Should such evaluation reveal myeloid related mutations, a primary myeloid cause (MDS) would be favored. If alternatively, the evaluation fails to reveal the myeloid-related changes and/or shows T-LGL related mutations such as STAT3 or STAT5 a reactive/LGL/immune mediated cause would become a primary consideration.  Nutritional/metabolic causes should also be considered due to significant megaloblastic changes.  

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Variable 0-60%. Overall 30%
M:E ratio: Slightly reduced 
Blasts: No increase
Myeloid lineage: Full maturation 
Erythroid lineage: Full maturation
Megakaryocytes: Present, hypolobated forms seen 
Lymphocytes: Small aggregates and scattered
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 


The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                1%
Promyelocytes           2%
Myelocytes           15%
Metamyelocytes           10%
Neutrophils/Bands      20%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      30%
Plasma Cells           1%
Lymphocytes           17%
Number of Cells Counted      500
M:E Ratio           1.7

Special stain 
Iron: Absent
Ring sideroblasts: Absent 

Morphology:
-Spicular and cellular with maturing trilineage hematopoiesis, mild erythroid hyperplasia with mild dyspoiesis (megaloblastic, late mitosis, occasional nuclear budding), megakaryocytes are adequate in number, however small hypolobated forms are seen (>10%). Granulocytes show occasional hypersegmented forms

PERIPHERAL BLOOD
CBC (03/04/2022):
WBC 5.8 [4.0-11.0 K/mcL] 
RBC 2.53 L [3.95-5.54 M/mcL] 
HGB 10.0 L [12.5-16.2 g/dL] 
HCT 30.7 L [37.5-49.3 %] 
MCV 121 H [80-98 fL] 
MCH 39.5 H [27.0-33.0 pg] 
MCHC 32.6 [31.0-36.5 g/dL] 
RDW 17.7 H [12.2-15.1 %] 
Platelets 34 L [160-400 K/mcL] 

Neutrophil 62.7 [32.5-74.8 %] 
Mono 13.8 H [0.0-12.3 %] 
Eos 0.7 [0.0-4.9 %] 
Baso 0.2 [0.0-1.5 %] 
Immature Granulocyte 2.1 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 20.5 [12.2-47.4 %] 
Nucleated RBC 0.5 H [0.0-0.0 %] 

Abs Neut 3.6 [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.1 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.2 [0.9-3.2 K/mcL] 

Morphology:
Granulocytes show occasional hypersegmented forms, macrocytic anemia, thrombocytopenia, no increase in blasts or large granular lymphocytes.
Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight blasts, <5%

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-2359)
1. Abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 0.59% of WBC.

Immunophenotype:
Abnormal: CD7, CD117 (bright), HLA-DR (bright)
Normal: CD4, CD13, CD33, CD34, CD36, CD38, CD45, CD45RA, CD71, CD105, CD123, CD371 (clec12a)
Negative: CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda


2. Atypical T cell population detected with the phenotype as follows. The population is of unclear pathologic significance and may represent an LGL-like clone. 

Immunophenotype:
Abnormal: CD5 (bright), CD7 (dim), TCRCbeta1 (restriction - monotypic positive)
Normal: CD2, CD3, CD4, CD26, CD38, CD45
Negative: CD8, CD10, CD14, CD25, CD279 (PD1), TCR gamma/delta
Atypical: CD56 (partial)

TCR Vbeta Repertoire: deficient - deficient reactivity with anti-Vbeta fragment antibodies covering 70-80% of Vbeta repertoire, suggestive but not definitive for clonality
Number of cells acquired: 264 thousand 

3. Abnormal B cell population detected.
The population is 1.4% WBC

The immunophenotype of this abnormal B cell population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

Abnormal: CD19 (bright), CD20 (bright), CD22 (bright), surface Kappa (restriction)
Normal: CD45
Negative: CD5, CD10, CD38, CD25, CD279 (PD1), CD3, CD14, surface Lambda
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-1589.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-9650, 9655, 9688, 9627
"
H22-2466;S12;MSKY - 2023-05-26 12.13.08.ndpi,Peripheral Blood Smear,2023-05-26,"Clinical Diagnosis: MDS
Clinical Hx/Op Findings: MDS
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Myelodysplastic syndrome with ring sideroblasts (MDS-RS). 
     - Hypercellular marrow with erythroid hyperplasia and granulocytic aplasia.
  
BONE MARROW BIOPSY
Quality: adequate 
Cellularity: 100% 
M:E ratio: markedly reduced 
Blasts: not increased 
Myeloid lineage: rare 
Erythroid lineage: markedly increased
Megakaryocytes: many, often forming loose clusters
Lymphocytes: rare 
Plasma cells: rare 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1/3). 

Clot section: not submitted 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate

Blasts                1%
Promyelocytes           2%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      2%
Eosinophils           3%
Erythroid Precursors      83%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           0.1

Special stain
Iron: Present
Ring sideroblasts: >15%

Morphology:
Spicular and very cellular bone marrow aspirate shows marked erythroid hyperplasia with mild dyserythropoiesis. Blasts are not increased. Myeloid precursors are rare. Megakaryocytes are present with unremarkable morphology.

PERIPHERAL BLOOD
CBC (03/25/2022):
WBC 1.2 L [4.0-11.0 K/mcL] 
RBC 2.97 L [3.95-5.54 M/mcL] 
HGB 9.9 L [12.5-16.2 g/dL] 
HCT 30.9 L [37.5-49.3 %] 
MCV 104 H [80-98 fL] 
MCH 33.3 H [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 27.2 H [12.2-15.1 %] 
Platelets. 215 [160-400 K/mcL] 

Neutrophil 13.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 6.0 H [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 79.0 H [12.2-47.4 %] 
Nucleated RBC 2.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 0.2 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 
Ovalocytes

Morphology: nRBC and target RBCs, neutropenia 


Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight blasts, <5% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-3181)
Interpretation: 
Abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 3.8% of WBC.

Eosinophilia is seen, 17% of WBC.
Basophilia is seen, 1.6% of WBC.

Immunophenotype:
Abnormal: CD5 (partial), CD7 (partial), CD13 (dim)
Normal: CD4, CD33, CD34, CD36, CD38, CD45, CD45RA, CD71, CD117, CD123, CD371 (clec12a), HLA-DR
Negative: CD2, CD10, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64, CD105

Number of cells acquired: 612 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Not performed 

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-13263, M22-13265. 
"
H22-1185;S47;MSK3 - 2023-05-31 22.30.27.ndpi,Peripheral Blood Smear,2023-05-31,"MCL
Protocol#: 18-427     
Newly diagnosed
","1-4. Bone marrow, right posterior iliac crest, biopsy, clot, aspirate, and peripheral blood smears: 
     - CD5-positive B-cell lymphoma, consistent with mantle cell lymphoma, 30-40% involvement with CD20 immunohistochemistry. 

BONE MARROW BIOPSY/CLOT/ASPIRATE MORPHOLOGY
Adequate biopsy, clot and aspirate specimens show normocellular bone marrow (overall 30% cellularity). There istrilineage maturing hematopoiesis with increased atypical lymphocytes, showing interstitial and diffuse distribution. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
Performed with block 1_1
CD20 highlights increase in B-cells, comprising 30-40% of marrow cellularity.
These B-cells co-express CD5, cyclin D1 (dim) and SOX11 (very dim).  
CD3 highlights T-cells, 10-15% of cellularity. 

Performed with block 2_14
CD20 highlights atypical B-cell aggregates, comprising overall 30-40% of marrow cellularity in this clot section.
These B-cells co-express CD5, cyclin D1 and SOX11.
CD23 is expressed in a subset of B-cells. 
P53 is expressed in 10-15% of B-cells.    
CD3 highlights T-cells, 10-15% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1500) 
Interpretation: 
Abnormal B cell population detected. 
The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.
Abnormal B cell population represents 47.5% of WBC.

Immunophenotype:
Abnormal: CD5 (positive), CD23 (partial), CD43 (positive), CD79b (variable - dim to intermediate), ROR1 (positive)
Normal: CD20, CD81, CD19, CD40, CD45, CD38
Negative: CD200, CD10, CD3

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (02/08/2022):
WBC 17.2 H [4.0-11.0 K/mcL] 
RBC 4.66 [3.95-5.54 M/mcL] 
HGB 12.8 [12.5-16.2 g/dL] 
HCT 39.7 [37.5-49.3 %] 
MCV 85 [80-98 fL] 
MCH 27.5 [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 13.1 [12.2-15.1 %] 
Platelets 139 L [160-400 K/mcL] 

Neutrophil 22.0 L [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 19.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 55.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 3.8 [1.5-7.5 K/mcL] 
Abs Mono 0.7 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 12.8 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: Numerous circulating atypical lymphocytes present, showing irregular nuclear contours and prominent nucleoli. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-981, CG22-1046.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-6206.

"
H22-9252;S12;MSKY - 2023-06-15 13.24.53.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Multiple Myeloma\par Clinical Hx/Op Findings: pre-transplant\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate, and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : \~\~\par      - Plasma cell neoplasm, \~\par\~\~\~\~\~\~\~\~\~\~~15-20% involvement by CD138 immunohistochemistry.\par\~\~\~\~\~\~\~\~\~\~4% involvement by aspirate differential\par\~\~\~\~\~\~\~\~\~\~1.9% involvement by flow cytometry\par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate \par Cellularity: ~20%\par Myeloid lineage: Orderly maturation    \par Erythroid lineage: Orderly maturation   \par Megakaryocytes: Adequate   \par Plasma cells: Increased; occasional Dutcher bodies present  \par Clot section: Predominantly blood with no marrow particles \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 2%\par Metamyelocytes \tab\tab 1%\par Neutrophils/Bands \tab 47%\par Monocytes \tab\tab 7%\par Eosinophils \tab\tab 3%\par Erythroid Precursors \tab 14%\par Plasma Cells \tab\tab 4%\par Lymphocytes \tab\tab 21%\par Number of Cells Counted  200\par M:E Ratio \tab\tab 4.4\par\par Morphology: \par Marrow spicules:  Aspicular\par Cellularity: N/A\par Plasma cell morphology: Rare seen\par Myeloid lineage: Mainly nerutrophils\par Erythroid Lineage: Present\par Megakaryocytes: Present \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD138 immunostain highlights plasma cells, ~15-20% of cellularity. \par Kappa and lambda immunostains show the plasma cells are kappa light chain restricted. \par BCMA highlights 90% of plasma cells, (1-2+) intensity, membranous/ Golgi pattern. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-12025)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par 1. Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par\par Abnormal plasma cell population comprises 99.5% of total plasma cells.\par Abnormal plasma cell population represents 1.9% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (negative), CD27 (negative), CD45 (negative), CD56 (partial), CD81 (negative), cytoplasmic Kappa (restriction)\par Normal: CD138, CD229, CD319\par Negative: CD38 (consistent with anti-CD38 therapy effect), CD20, CD117, cytoplasmic Lambda\par\par Number of cells acquired: 5.6 million \par\par\par 2. No abnormal mature B cell population detected.\par No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.\par\par Number of cells acquired: 405 thousand \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/02/2022 ):\par WBC 3.3 L [4.0-11.0 K/mcL] \par RBC 3.63 L [3.95-5.54 M/mcL] \par HGB 12.4 L [12.5-16.2 g/dL] \par HCT 36.8 L [37.5-49.3 %] \par MCV101 H [80-98 fL] \par MCH34.2 H [27.0-33.0 pg] \par MCHC 33.7 [31.0-36.5 g/dL] \par RDW14.6 [12.2-15.1 %] f\par Platelets 146 L [160-400 K/mcL] \par\par Neutrophil 62.4 [32.5-74.8 %] \par Mono 14.1 H [0.0-12.3 %] \par Eos 1.8 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Immature Granulocyte 0.3 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 21.4 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 2.0 [1.5-7.5 K/mcL] \par Abs Mono 0.5 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 0.7 L [0.9-3.2 K/mcL] \par\par Morphology: \par WBC: No circulating plasma cells seen\par RBC: Macrocytic RBCs\par PLT: Unremarkable morphology \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8280, CG22-8281.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-47148. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-1861;S15;MSKZ - 2023-05-22 08.01.16.ndpi,Peripheral Blood Smear,2023-05-22,"CLL

","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Focal involvement by classic Hodgkin lymphoma, EBV positive (5% with CD30 immunohistochemistry)
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show mildly hypocellular bone marrow (10-20% cellularity). There istrilineage maturing hematopoiesis with focal atypical lymphoid proliferation composed of inflammatory cells including small lymphocytes, plasma cells, histiocytes, and occasional eosinophils admixed with aggregates of large atypical cells with monolobed and multilobed nuclei, and prominent nucleoli.
 
The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD30, PAX5 (dim), MUM1, LMP1, LEF1
Do not express: CD20, CD45, CD15, CD3, CD5, CD23, CyclinD1

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-2422) 
No abnormal mature B cell population detected. Virtually no B cells seen.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.
Number of cells acquired: 704 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (03/07/2022):
WBC 2.4 L [4.0-11.0 K/mcL] 
RBC 2.62 L [3.95-5.54 M/mcL] 
HGB 7.6 L [12.5-16.2 g/dL] 
HCT 22.7 L [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 29.0 [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 17.1 H [12.2-15.1 %] 
Platelets 285 [160-400 K/mcL] 

Neutrophil 77.0 H [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 17.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.8 [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Leukopenia with left shift. 
RBC: Normocytic anemia with anisopoikilocytosis
PLT: Unremarkable.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-1641. 

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-9992.
"
H22-7466;S16;MSK7 - 2023-06-15 14.52.23.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\fswiss\fcharset0\fprq2{\*\panose 020F0502020204030204}Calibri;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\sa160\sl259\slmult1\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon0 Arial;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s17\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Clinical Diagnosis: AML\par Clinical Hx/Op Findings: newly diagnosed\par Requested Studies: Gross/Micro\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par }","{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\fswiss\fcharset0\fprq2{\*\panose 020F0502020204030204}Calibri;}
{\f2\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f3\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red192\green0\blue0;\red0\green255\blue0;\red255\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\sa160\sl259\slmult1\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon0 Arial;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs20\alang1033\ab\aul\ltrch\f0\fs20\lang1033\langnp1033\langfe1033\langfenp1033\b\ul AMENDMENT DETAIL:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b Reason for Amendment:\~\tab\tab SUPPLEMENTAL DIAGNOSIS PROVIDED DUE TO ADDITIONAL MATERIAL NOT \tab\tab\tab\tab\tab\tab PREVIOUSLY RECEIVED. \plain\rtlch\af2\afs20\alang1033\ab\ltrch\f2\fs20\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b Report Section Changed:\tab Specimen Description\par\par Description of Change: \tab\tab\plain\rtlch\af0\afs18\alang1033\ab\aul\acf2\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\cf2 Part 3. Peripheral Blood Smear\plain\rtlch\af0\afs18\alang1033\acf3\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf3\par\pard\ltrpar\s18\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\sa160\sl259\slmult1\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b Note: This document represents an amended version of the Hematopathology report originally issued on 9/13/2022. Dr. Kamal Menghrajani has been notified via e-mail on 9/14/2022\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 . \par\par 1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: \~\par      - Acute myeloid leukemia, see comment.\par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  According to Dr. Yanming Zhang, director of CG lab, the preliminary study showed normal karyotype. Final classification is pending final cytogenetic and molecular studies.\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: 70-80%\par M:E ratio: Unable to assess\par Blasts: Increased\par Myeloid lineage: Markedly reduced\par Erythroid lineage: Reduced with full maturation spectrum seen.\par Megakaryocytes: Reduced, without atypia\par Lymphocytes: Scattered\par Plasma cells: Scattered\par\par Clot section: Adequate; similar to core biopsy.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate \par\par Blasts \tab\tab\tab 70%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 2%\par Metamyelocytes \tab\tab 2%\par Neutrophils/Bands \tab 2%\par Monocytes \tab\tab 1%\par Erythroid Precursors \tab 18%\par Lymphocytes \tab\tab 4%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 0.4\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb4\chshdng0\chcfpat0\chcbpat4\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -Spicular and cellular aspirate smears show an expanded blast population. The blasts are intermediate sized, with round to indented nuclei, fine chromatin, conspicuous nucleoli, and moderate cytoplasm. Some blasts contain cytoplasmic granules with rare Auer rods noted. Background myeloid and erythroid elements are present, without atypia. Few megakaryocytes are seen.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (9/9/2022):\par WBC 6.4 [4.0-11.0 K/mcL] \par RBC 3.03 L [3.80-5.00 M/mcL] \par HGB 8.7 L [11.2-15.4 g/dL] \par HCT 26.6 L [34.3-46.0 %] \par MCV 88 [80-98 fL] \par MCH 28.7 [27.0-33.0 pg] \par MCHC 32.7 [31.0-36.5 g/dL] \par RDW 14.6 [12.2-15.1 %] \par Platelets 34 L [160-400 K/mcL] \par\par Neutrophil 7.0 L [32.5-74.8 %] \par Mono 0.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Blast 61.0 H [0.0-0.0 %] \par Lymph 31.0 [12.2-47.4 %] \par Variant Lymph 1.0 [0.0-2.0 %] \par Nucleated RBC 4.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 0.4 L [1.5-7.5 K/mcL] \par Abs Mono 0.0 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Blasts 3.9 H [0.0-0.0 K/mcL] \par Abs Lymph 2.0 [0.9-3.2 K/mcL] \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb5\chshdng0\chcfpat0\chcbpat5\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology: numerous blasts with rare Auer rods. \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs22\alang1033\ltrch\f1\fs22\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and MPO highlight blasts, accounting for ~70-80% of cellularity. The blasts show partial expression of muramidase and CD117 (weak) and are negative for TdT\par CD61 highlights reduced background megakaryocytes.\par CD71 highlights erythroid elements\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9765)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Expanded abnormal myeloid blast population detected.\par\par Abnormal myeloid blast population represents 81.5% of WBC. The immunophenotype although not entirely specific, is often seen in AML with t(8;21). Correlation with CG studies is suggested. \par\par Immunophenotype:\par Abnormal: CD7 (partial), CD11b (partial), CD13 (bright), CD15 (partial), CD19 (bimodal - negative to dim), CD34 (uniform - intermediate), CD38 (uniform - intermediate), CD56 (partial), CD64 (partial), HLA-DR (uniform - intermediate), cytoplasmic CD79a (bimodal - negative to intermediate), MPO (uniform - intermediate)\par Normal: CD4, CD33, CD36, CD45, CD45RA, CD71, CD105, CD117, CD123, CD371 (clec12a)\par Negative: CD2, CD3, CD5, CD8, CD10, CD14, CD16, CD20, CD22, CD25, CD26, cytoplasmic CD3, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par Number of cells acquired: 398 thousand \par\par 2. No abnormal mature B- or T-cell populations detected. \par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par Number of cells acquired 232 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-9747)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Expanded abnormal myeloid blast population detected.\par\par Abnormal myeloid blast population represents 75.0% of WBC.\par\par Immunophenotype:\par Abnormal: CD7 (partial), CD13 (variable - dim to bright), CD15 (partial), CD19 (bimodal - negative to dim), CD33 (variable - negative to intermediate), CD34 (variable - dim to intermediate), CD56 (partial), cytoplasmic CD79a (partial), MPO (uniform - intermediate)\par Normal: CD4, CD36, CD38, CD45, CD45RA, CD71, CD105, CD117, CD123, CD371 (clec12a), HLA-DR\par Negative: CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD16, CD20, CD22, CD25, CD26, CD64, cytoplasmic CD3, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par Number of cells acquired: 900 thousand \par\par\par 2. Atypical/No definite abnormal T cell population detected. \par There is no definite immunophenotypic evidence of abnormal T cell population detected by flow cytometry. However, there is a T cell population with mild abnormalities seen (see below). The clinical significance of this population is not entirely clear. Correlation with additional studies (morphologic, cytogenetic, and molecular) is advised.\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\par\par Atypical T cell population represents 0.01% of WBC.\par Concentration of Abnormal population in peripheral blood is 0.00064 thousand/microliter.\par\par Immunophenotype:\par Atypical: CD3 (negative), CD7 (bimodal - negative to intermediate), CD38 (negative)\par Normal: CD2, CD4, CD5, CD26, CD45\par Negative: CD8, CD10, CD14, CD25, CD56, CD279 (PD1), TCR gamma/delta\par\par\par 3. No abnormal mature B cell population detected.\par No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-6733\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-38118, M22-38119, M22-38120, M22-38121\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par }"
H22-10113;S15;MSKZ - 2023-06-15 15.33.37.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Myelodysplastic Syndrome\par Clinical Hx/Op Findings: determine response\par Requested Studies: Intraoperative Consultation\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\par      - Hypercellular marrow with erythroid hyperplasia and dysplasia, myeloid dysplasia, marked megakaryocytic hyperplasia with atypia, marked myelofibrosis and no increase in blasts, consistent with persistent myeloid neoplasm, previously characterized as MDS/MPN with ring sideroblasts see comment\par\par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The patient's history of a myeloid neoplasm with reported JAK2 and SF3B1 mutations currently treated with ruxolitinib and decitabine is noted. Since the initiation of the dual therapy the patient's thrombocytosis has normalized, though developed anemia and neutropenia, with circulating blasts at 4%. The current marrow specimen is markedly hypercellular with an expansion of atypical megakaryocytes, erythroid forms and marked myelofibrosis, in the absence of increased blasts. While there is no evidence of transformation to acute myeloid leukemia, morphologic comparison to prior specimen from 2020 (H20-6852, 10/21/2020) show an overall increase in atypical megakaryocytes and increase in reticulin fiber deposition, most consistent with disease progression. In the absence of increased blasts in the marrow by CD34 immunostain, the increase in peripheral blood blasts could be derived from the spleen given the degree of myelofibrosis. It is also noteworthy that the blast percentage discordance between bone marrow flow cytometry and immunohistochemistry is primarily due to the erythroid bias seen in the specimen.\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Hypercellular (Nearly 100%)\par M:E ratio: Erythroid predominant\par Blasts: Not increased\par Myeloid lineage: Markedly reduced \par Erythroid lineage: Present with maturation\par Megakaryocytes: Markedly expanded, comprising more than 50% of the total cellularity, showing atypical cytology (bulbous nuclei) and tight cluster formation\par Lymphocytes: Scattered\par Plasma cells: Scattered\par Special stains: Reticulin stain shows marked increase in reticulin fibrosis (MF-2 to 3 out of 3). \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:   Adequate \par\par Blasts \tab\tab\tab 2%\par Myelocytes \tab\tab 1%\par Metamyelocytes \tab\tab 1%\par Neutrophils/Bands \tab 22%\par Monocytes \tab\tab 1%\par Erythroid Precursors \tab 57%\par Lymphocytes \tab\tab 16%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 0.4\par\par Special stain\par Iron: Present on touch imprints\par Ring sideroblasts: Absent, but limited by the quality of the aspirate\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Aspicular and hypocellular aspirate smears show scattered marrow elements with significant crush artifact t. Myeloid elements predominate and show maturation with occasional hypogranular forms. Erythroid elements show occasional dyspoietic forms, including karyorrhexis, nuclear blebbing and megaloblastoid features. Megakaryocytes are not cytologically preserved, though there are abundant megakaryocytic nuclear remnants. Blasts are not increased. Scattered lymphocytes and plasma cells are present.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (12/1/2022):\par\par WBC 2.2 L [4.0-11.0 K/mcL] \par Adjusted for NRBC's and Megakaryocyte Fragments.\par RBC 3.20 L [3.95-5.54 M/mcL] \par HGB 9.0 L [12.5-16.2 g/dL] \par HCT 28.4 L [37.5-49.3 %] \par MCV 89 [80-98 fL]\par MCH 28.1 [27.0-33.0 pg] \par MCHC 31.7 [31.0-36.5 g/dL] \par RDW 20.1 H [12.2-15.1 %] \par Platelets 240 [160-400 K/mcL] \par\par Neutrophil 63.0 [32.5-74.8 %] \par Mono 3.0 [0.0-12.3 %] \par Eos 3.0 [0.0-4.9 %] \par Baso 2.0 H [0.0-1.5 %] \par Blast 7.0 H [0.0-0.0 %] \par Metamyelocyte 2.0 H [0.0-0.0 %] \par Lymph 20.0 [12.2-47.4 %] \par Nucleated RBC 27.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 1.4 L [1.5-7.5 K/mcL] \par Abs Mono 0.1 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Blasts 0.2 H [0.0-0.0 K/mcL] \par Abs Meta 0.0 [0.0-0.0 K/mcL] \par Abs Lymph 0.4 L [0.9-3.2 K/mcL] \par\par Morphology: \par RBC: Marked anisopoikilocytosis. Polychromasia. Occasional dacrocytes. Markedly increased circulating nucleated  RBCs.\par WBC: Neutropenia. Pseudo-Pelger-Huet forms with hypogranular cytoplasm and hypolobation. Occasional circulating blasts noted.\par PLT: Marked pleomorphism with large platelet forms and megakaryocyte fragments\plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD61 labels markedly increased atypical megakaryocytes. CD71 labels residual erythroid islands. MPO labels residual foci of myelopoiesis.\par CD34 and CD117 show no increase (<5%) in blasts. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-13138)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal myeloid blast population detected.\par Abnormal myeloid blast population represents 11.6% of WBC.\par Immunophenotype:\par Abnormal: CD7 (partial), CD13 (dim), CD33 (variable - negative to dim), CD34 (bright), CD38 (partial - dim), CD45RA (negative), CD117 (bright), CD371 (clec12a) (negative), HLA-DR (bright)\par Normal: CD4, CD36, CD45, CD71, CD105, CD123\par Negative: CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda, CD42b, CD90\par\par Number of cells acquired: 198 thousand \par\par 2. No abnormal mature B- or T-cell populations detected. \par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par Number of cells acquired 196 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Not submitted\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Not submitted\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-10676;S31;MSKA - 2023-06-15 09.51.51.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: MDS vs Infiltrative Solid Tumor\par Clinical Hx/Op Findings: metastatic breast cancer with circulating blasts. r/o MDS.\par Requested Studies: Gross/Micro\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b 1-4. Bone marrow, right post iliac crest, biopsy, clot, aspirate and peripheral blood smears: \~\~\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par      - Extensive involvement by metastatic tumor. See comment.\par      - Cellular marrow with maturing trilineage hematopoiesis, left-shifted myelopoiesis and no increase in blasts.\par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  The metastatic tumor occupies ~60-70% of the marrow spaces in this sample. The morphologic findings are suggestive of metastatic carcinoma, however, immunostains are in progress for confirmation and establishment of the site of origin, which will be reported in an addendum. While evaluation of the background bone marrow is limited by little residual marrow on the core biopsy and aspicular and markedly hemodilute aspirate smears, features of a myeloid neoplasm are not seen. The left-shifted myelopoiesis is consistent with the patient's recent G-CSF therapy.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate core biopsy with some aspiration/crush artifact shows cellular marrow (~80% cellularity overall) with extensive involvement by metastatic tumor with associated fibrosis (occupies ~60-70% of the marrow spaces). The remaining marrow shows maturing trilineage hematopoiesis with no increase in blasts. The M:E ratio appears within normal limits. Myeloid elements show left-shifted maturation. Erythroid precursors show progressive maturation. Megakaryocytes are present and show no overt atypia. Clot sections are non-contributory due to a lack of marrow particles.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules\par\par Myelocytes \tab\tab 1%\par Metamyelocytes \tab\tab 1%\par Neutrophils/Bands \tab 34%\par Monocytes \tab\tab 10%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 33%\par Lymphocytes \tab\tab 20%\par Number of Cells Counted \tab 200\par M:E Ratio \tab\tab 1.4\par\par Special stain\par Iron: Suboptimal for evaluation, devoid of spicules\par Ring sideroblasts: Absent \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par The aspirate smears are aspicular, markedly hypocellular, hemodilute and suboptimal for evaluation. They show predominantly peripheral blood elements, which is reflected in the differential count. Scattered predominantly mature myeloid elements are present with occasional hyposegmented forms but without significant dysplasia. Scattered nucleated red cells are present with rare nuclear irregularities. Megakaryocytes are not well represented. No expanded blast population is seen.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (12/19/2022):\par\par WBC 3.8 L [4.0-11.0 K/mcL] \par Adjusted for NRBC.\par RBC 3.43 L [3.80-5.00 M/mcL] \par HGB 9.7 L [11.2-15.4 g/dL] \par HCT 31.8 L [34.3-46.0 %] \par MCV 93 [80-98 fL]\par MCH 28.3 [27.0-33.0 pg] \par MCHC 30.5 L [31.0-36.5 g/dL] \par RDW 21.8 H [12.2-15.1 %]\par Platelets 214 [160-400 K/mcL] \par\par Neutrophil 47.0 [32.5-74.8 %] \par Mono 23.0 H [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Myelocyte 1.0 H [0.0-0.0 %] \par Metamyelocyte 2.0 H [0.0-0.0 %] \par Lymph 27.0 [12.2-47.4 %] \par Nucleated RBC 30.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 1.8 [1.5-7.5 K/mcL] \par Abs Mono 0.9 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Myelocytes 0.0 [0.0-0.0 K/mcL] \par Abs Meta 0.1 H [0.0-0.0 K/mcL] \par Abs Lymph 1.0 [0.9-3.2 K/mcL] \par\par Morphology:\par WBC: Rare myeloid precursors, including rare blasts. Relative monocytosis.\par RBC: Anemia with anisocytosis and frequent nucleated red cells.\par PLT: Adequate with occasional large platelets.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34, CD117 and TdT show no increase in blasts. MPO and lysozyme highlight myelomonocytic elements. CD71 labels erythroid precursors. CD61 labels megakaryocytes without significant atypia.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-13840)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par 1. No definite abnormal myeloid blast population detected.                                                  \par There is no definite immunophenotypic evidence of a myeloid stem cell neoplasm by flow cytometry. While some atypia is seen (see below), its significance is uncertain and reactive change is not excluded. Correlation with morphologic and genomic evaluation is suggested. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment.\par\par Myeloid blast population represents 0.56% of WBC.\par Monocytosis with partial CD56 expression is seen, 17.0% of WBC.\par\par Immunophenotype:\par Atypical: CD13 (bright), CD33 (bright), CD56 (partial), CD123 (bright), CD90 (increased)\par Normal: CD4, CD36, CD34, CD38, CD45, CD45RA, CD71, CD117, HLA-DR\par Negative: CD2, CD3, CD5, CD7, CD10, CD11b, CD14, CD15, CD16, CD19, CD25, CD64, CD105, CD371 (clec12a), cytoplasmic CD3, cytoplasmic CD79a, MPO, CD42b, CD61\par\par In addition, a small population with bright CD90 and CD56 expression without expression of other B, T, or myeloid markers is seen, suggestive of a non-hematopoietic cell population. Morphologic correlation is advised to rule out other non-hematologic neoplasms.\par\par Number of cells acquired 259 thousand \par\par 2. No abnormal mature B- or T-cell populations detected. \par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par Number of cells acquired 228 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-13792)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par 1. No definite abnormal myeloid blast population detected.     \par There is no definite immunophenotypic evidence of a myeloid stem cell neoplasm by flow cytometry. While some atypia is seen (see below), its significance is uncertain and reactive change is not excluded. Correlation with morphologic and genomic evaluation is suggested. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment.\par\par Myeloid blast population represents 0.53% of WBC.\par Monocytosis with partial CD56 expression is seen, 27.2% of WBC.\par\par Immunophenotype:\par Atypical: CD13 (bright), CD25 (partial), CD33 (bright), CD34 (bright), CD56 (partial), CD90 (increased)\par Normal: CD4, CD36, CD38, CD45, CD45RA, CD71, CD105, CD117, CD123, CD371 (clec12a), HLA-DR\par Negative: CD2, CD3, CD5, CD7, CD10, CD11b, CD14, CD15, CD16, CD19, CD64, cytoplasmic CD3, cytoplasmic CD79a, MPO, CD42b, CD61\par\par Number of cells acquired 536 thousand \par\par 2. No abnormal mature B- or T-cell populations detected. \par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par Number of cells acquired 405 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-9580.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-54595, M22-54597.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-1367;S10;MSK5 - 2023-05-31 22.41.38.ndpi,Peripheral Blood Smear,2023-05-31,"Lymphoma
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - CD5-/CD10- low grade B-cell lymphoma, suggestive of splenic marginal zone lymphoma, 30% involvement with CD20 immunohistochemistry, see comment. 

COMMENT: Lymphoma cells show intra-sinusoidal distribution in the bone marrow, and villous projection is seen in atypical lymphocytes in peripheral blood smear. Overall findings are highly suggestive of splenic marginal zone lymphoma (SMZL). Per clinical notes, BCL6 rearrangement was detected elsewhere. BCL6 rearrangement could be seen in SMZL. Immunophenotypically, other low-grade B-cell lymphomas, including CLL/SLL, mantle cell lymphoma or follicular lymphoma, are unlikely. Please correlate with radiological findings. Corresponding cytogenetic and molecular analysis are in progress. Please also correlate with these findings. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show mildly hypercellular bone marrow for age (approximately 40% cellularity). There istrilineage maturing hematopoiesis with increased atypical lymphocytes, showing intra-sinusoidal and interstitial distribution. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight increased atypical lymphocytes, showing intra-sinusoidal and interstitial distribution, comprising approximately 30% of cellularity. 
These B-cells do not express CD5, CD23, LEF1 or Cyclin D1. 
CD3 highlights reactive T-cells, 10-15% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1788) 
Interpretation: 
Abnormal B cell population detected.
The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.

Abnormal B cell population represents 29.8% of WBC.

Immunophenotype:
Abnormal: CD5 (partial), CD23 (partial), ROR1 (partial), surface Lambda (restriction)
Normal: CD20, CD22, CD43, CD79b, CD81, CD200, CD19, CD40, CD45
Negative: CD38, CD10, CD3, surface Kappa

Number of cells acquired: 307 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (2/11/2022):

WBC 9.2 [4.0-11.0 K/mcL] 
RBC 3.39 L [3.80-5.00 M/mcL] 
HGB 9.7 L [11.2-15.4 g/dL] 
HCT 29.6 L [34.3-46.0 %] 
MCV 87 [80-98 fL] 
MCH 28.6 [27.0-33.0 pg] 
MCHC 32.8 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 216 [160-400 K/mcL] 

Neutrophil 35.0 [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 26.0 [12.2-47.4 %] 
Other 33.0 H [0.0-0.0 %] (Atypical lymphoid cells)
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 3.2 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Lymph 2.4 [0.9-3.2 K/mcL] 
Abs Others 3.0 H [0.0-0.0 K/mcL] 

Morphology: 
Circulating atypical lymphocytes present. A subset of atypical lymphocytes has villous projection; however, overall, villous projection is not prominent. Occasional nucleoli are also seen.  

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-1168. 

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-7364, M22-7365, M22-7366, M22-7368. 
"
H22-10119;S23;MSK4 - 2023-06-15 15.39.19.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Lymphoma, Diffuse Large Cell\par Clinical Hx/Op Findings: h/o DLBCL, s/p CD19 CAR, pancytopenia\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: \par      - Involvement by diffuse large B-cell lymphoma, 30-40% by PAX5 immunostain. \par      - Cellular marrow with erythroid predominant trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate \par Cellularity: Approximately 60% \par M:E ratio: decreased \par Blasts: Not increased  \par Myeloid lineage: Orderly maturation  \par Erythroid lineage: Orderly maturation \par Megakaryocytes: Present with unremarkable morphology\par Lymphocytes: large clusters composed by large atypical cells with small amounts of cytoplasm, irregular nuclear contours, vesicular chromatin and distinct nucleoli.\par Plasma cells: Not increased  \par Special stains: Reticulin stain shows  focal increase in reticulin fibrosis in the lymphoid aggregates. \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate\par\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 4%\par Metamyelocytes \tab\tab 4%\par Neutrophils/Bands \tab 23%\par Monocytes \tab\tab 1%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 60%\par Lymphocytes \tab\tab 5%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 0.6\par\par Special stain\par Iron: Present\par Ring sideroblasts: Rare <5% \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -Spicular and cellular bone marrow aspirate shows progressive erythroid predominant trilineage hematopoiesis. Blasts are not increased. Myeloid precursors are orderly maturing. Erythroid precursors are orderly maturing with occasional dyspoietic forms (irregular nuclei contour, nuclear budding, <5%). Megakaryocytes are present with unremarkable morphology. A few large typical lymphoid cells are seen with irregular nuclei, vesicular chromatin and small amount of cytoplasm. \par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (12/02/2022):\par WBC 4.0 [4.0-11.0 K/mcL] \par RBC 2.73 L [3.80-5.00 M/mcL] \par HGB 8.0 L [11.2-15.4 g/dL] \par HCT 23.5 L [34.3-46.0 %] \par MCV 86 [80-98 fL] \par MCH 29.3 [27.0-33.0 pg] \par MCHC 34.0 [31.0-36.5 g/dL] \par RDW 15.9 H [12.2-15.1 %] \par Platelets. 9 LL [160-400 K/mcL] \par\par Neutrophil 94.0 H [32.5-74.8 %] \par Mono 4.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Myelocyte 2.0 H [0.0-0.0 %] \par Lymph 0.0 L [12.2-47.4 %] \par Nucleated RBC 7.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 3.7 [1.5-7.5 K/mcL] \par Abs Mono 0.2 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] \par Abs Lymph 0.0 L [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]\par\par Morphology:\par WBC: Lymphopenia. No circulating blasts.\par RBC: Normocytic anemia.\par PLT: Marked thrombocytopenia. \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par PAX5 stains large clusters of atypical B lymphoid cells (30-40% of total cellularity). CD20 is negative.  CD3 highlights scattered T cells. CD34 and CD117 immunohistochemical stains show no increase in blasts.\~MPO highlights myeloid components. CD71 highlights erythroid components. CD61 highlights megakaryocytes\par\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-13147)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Abnormal B cell population with larger size detected.\par Abnormal B cell population represents 2.1% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (partial), CD19 (dim), CD20 (negative), CD22 (variable - negative to intermediate), surface Kappa (restriction), Forward Scatter (increased), Side Scatter (increased)\par Normal: CD45\par Negative: CD10, CD38, CD25, CD279 (PD1), CD3, CD14, surface Lambda\par\par Number of cells acquired: 188 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-9101.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-51863, M22-51864 and M22-51866. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-7742;S11;MSKZ - 2023-06-15 17.00.19.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: ALL\par Clinical Hx/Op Findings: relapsed ALL\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;\red255\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, touch imprint, aspirate and peripheral blood smears: \~\par      - B-lymphoblastic leukemia/lymphoma, 90% blasts by CD34 immunostain.\par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  Correlation with forthcoming cytogenetic and molecular genetic studies is recommended.\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate; significant aspiration artifact and hemorrhage present\par Cellularity: Virtually 100%\par M:E ratio: N/A\par Blasts: Markedly increased\par Myeloid lineage: Rare scattered elements\par Erythroid lineage: Rare scattered elements\par Megakaryocytes: Decreased, present. Few small, hpolobated forms show hyperchromatic nuclei. Few are enlarged. \par Lymphocytes: Scattered\par Plasma cells: Present\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate \par\par Blasts \tab\tab\tab 79%\par Neutrophils/Bands \tab 1%\par Lymphocytes \tab\tab 20%\par Number of Cells Counted \tab 500\par M:E Ratio \tab\tab N/A\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -Hypercellular aspirate smears, along with touch imprints, show an expanded blast population. The blasts are small to intermediate with round nuclei, fine chromatin, inconspicuous nucleoli, and scant, agranular cytoplasm. Few mature lymphocytes are seen. Rare myeloid and erythroid elements are present. Few megakaryocytes are present.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (9/19/2022):\par WBC 8.9 [4.0-11.0 K/mcL] \par RBC 2.95 L [3.80-5.00 M/mcL] \par HGB 9.5 L [11.2-15.4 g/dL] \par HCT 27.5 L [34.3-46.0 %] \par MCV 93 [80-98 fL] \par MCH 32.2 [27.0-33.0 pg] \par MCHC 34.5 [31.0-36.5 g/dL] \par RDW 13.5 [12.2-15.1 %] \par Platelets 37 L [160-400 K/mcL] \par\par Neutrophil 12.0 L [32.5-74.8 %] \par Mono 0.0 [0.0-12.3 %] \par Eos 2.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Blast 63.0 H [0.0-0.0 %] \par Lymph 22.0 [12.2-47.4 %] \par Variant Lymph 1.0 [0.0-2.0 %] \par Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 1.1 L [1.5-7.5 K/mcL] \par Abs Mono 0.0 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Blasts 5.6 H [0.0-0.0 K/mcL] \par Abs Lymph 2.0 [0.9-3.2 K/mcL] \par\par Morphology: Numerous blasts present.\plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and TdT highlight sheets of blasts, accounting for ~90% of cellularity.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10134)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Abnormal immature B cell population detected.\par The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.\par\par Abnormal immature B cell population represents 92.1% of WBC.\par Abnormal immature B cell population represents 97.6% of the mononuclear cells..\par\par Immunophenotype:\par Abnormal: CD10 (variable - negative to bright), CD13 (variable - negative to dim), CD20 (partial - dim), CD24 (bright), CD34 (bright), CD38 (dim), CD45 (bimodal - negative to dim), CD66c/CD123 (positive), CD73/CD304 (positive), CD81 (dim), CD86 (positive), CD123 (positive)\par Normal: CD19, CD22, CD36, CD45RA, CD71, CD371 (clec12a), HLA-DR, cytoplasmic CD79a\par Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD25, CD26, CD33, CD56, CD64, CD66b, CD105, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-6938\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-39447, M22-39449, M22-39450.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-2733;S11;MSKU - 2023-05-26 15.55.02.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: HCL
Clinical Hx/Op Findings: staging
","{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch31506\stshfhich31506\stshfbi31506\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}
{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}
{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}










{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}
{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}
{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}
{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}
{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}
{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;
\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;
\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;\red0\green0\blue0;}{\*\defchp \f31506\fs22 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 
\f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31506\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused Normal Table;}}
{\*\rsidtbl \rsid1405724\rsid2915398\rsid3219057\rsid3476385\rsid5117709\rsid6176304\rsid10381454\rsid10551340\rsid10843648\rsid11209980\rsid13769909\rsid13961447\rsid14026760\rsid14177482}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1
\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\author Tejada, Aries Mae/Pathology}{\operator Boiocchi, Leonardo/Pathology}{\creatim\yr2022\mo4\dy6\hr16\min5}{\revtim\yr2022\mo4\dy6\hr16\min5}{\version2}{\edmins0}{\nofpages3}
{\nofwords586}{\nofchars3558}{\nofcharsws4033}{\vern21}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont1\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1440\dgvorigin1440\dghshow1\dgvshow1
\jexpand\viewkind1\viewscale130\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\rsidroot10551340\newtblstyruls\nogrowautofit\usenormstyforlist\noindnmbrts\felnbrelev\nocxsptable\indrlsweleven\noafcnsttbl\afelev\utinl\hwelev\spltpgpar\notcvasp\notbrkcnstfrctbl\notvatxbx\krnprsnet\cachedcolbal \nouicompat \fet0
{\*\wgrffmtfilter 2450}\nofeaturethrottle1\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang 
{\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}
\pard\plain \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid1405724 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057\charrsid3476385 1-3. Bone marrow,}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057  right posterior iliac crest, }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057\charrsid3476385 biopsy, aspirate and peripheral blood smears: \~\~}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par      - Involvement by }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 hairy cell leukemia }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 (}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 80}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 % with CD20 immunohistochemistry)\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\insrsid3219057\charrsid14177482 COMMENT:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 Patient's reported previous diagnosis of hairy cell leukemia is noted. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 The overall morphologic features seen in the }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 current }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 marrow }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 sample, }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 together with the immunophenotype identified by flow cytometry}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 ,}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 appear}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482  consistent with }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 involvement }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 by }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 the same process}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 .}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057  Correlation with the results of the concurrent molecular genetic studies is recommended.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid3219057\charrsid3476385 BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 Small }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 biopsy}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057  including only limited hematopoietic marrow, but overall adequate. Marrow cellularity is 50-60% and appears to be represented predominantly by small to medium-sized lymphocytes with round nuclei, condensed chromatin and moderately abundant cytoplasm. Only rare scattered hematopoietic precursors are seen in the background, including occasional megakaryocytes with overall normal features.\par Bone marrow aspirate smear are aspicular, hypocellular and hemodilute. Scattered erythroid and myeloid precursors at various stages of maturation and without obvious dysplasia are present. Megakaryocytes are not seen. Occasional medium-sized lymphocytes with round to mildly irregular nuclei, condensed chromatin, inconspicuous nucleoli and moderately abundant cytoplasm with occasional cytoplasmic projections are noted. Differential count cannot be performed.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \~\par }{\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\cf1\insrsid3219057\charrsid3476385 \par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.}{\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid3219057\charrsid3476385 IMMUNOHISTOCHEMISTRY}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid14177482 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 CD20 immunostain highlights }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 the markedly increased number of B-cells accounting for >80% of cellularity in the limited marrow included in the sample. Staining for BRAF is noncontributory. CD3 is positive in scattered T-cells (<5% of cellularity). }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid1405724 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \~\par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid3219057\charrsid14177482 FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-3573)}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385  \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid14177482 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 1. Abnormal B-cell population detected.\par The immunophenotype of the abnormal B-cell is consistent with involvement by hairy cell leukemia (HCL).\par \par Abnormal B cell population represents 11.4% of WBC.\par Immunophenotype:\par Abnormal: CD19 (bright), CD20 (bright), CD22 (bright), CD25 (positive), CD11c (positive), CD103 (positive), CD200 (bright), surface Lambda (restriction), Forward Scatter (increased), Side Scatter (increased)\par Normal: CD38, CD45\par Negative: CD5, CD10, CD279 (PD1), CD3, CD14, surface Kappa\par \par 2. No abnormal mature T-cell population detected. \par No immunophenotypic evidence of T-cell lymphoma is identified.  \par \par Number of cells acquired: 355 thousand}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid1405724 {\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\cf1\insrsid3219057\charrsid3476385 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid1405724 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid3219057\charrsid3476385 PERIPHERAL BLOOD}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid2915398 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 CBC (}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 4/4/2022)\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398 WBC 2.9 L [4.0-11.0 K/mcL] \par RBC 4.09 [3.95-5.54 M/mcL] \par HGB 13.4 [12.5-16.2 g/dL] \par HCT 36.7 L [37.5-49.3 %] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 MCV}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398  90 [80-98 fL] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 MCH}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398  32.8 [27.0-33.0 pg] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 MCHC}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398  36.5 [31.0-36.5 g/dL] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 RDW}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398  14.9 [12.2-15.1 %] \par Platelets. 133 L [160-400 K/mcL] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398 Neutrophil 47.5 [32.5-74.8 %] \par Mono 2.8 [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Immature Granulocyte 0.3 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 48.4 H [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398 Abs Neut 1.4 L [1.5-7.5 K/mcL] \par Abs Mono 0.1 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature 0.0 [0.0-0.1 K/mcL] \par Granulocyte\par Abs Lymph 1.4 [0.9-3.2 K/mcL]}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid1405724 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\tx1428\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid14177482 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 Morphology}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 : Mild leukopenia with relative lymphocytosis. Lymphocytes include occasional elements with round to mildly irregular nuclei, relatively condensed chromatin, and moderately abundant cytoplasm with subset of cells showing irregular cytoplasmic projections.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid1405724 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid6176304 {\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\cf1\insrsid3219057 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid3219057 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid1405724 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid3219057\charrsid3476385 CYTOGENETIC STUDIES}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par Cytogenetic analysis will be reported separately. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057\charrsid3476385 See separate report, CG}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057 22-2421.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par \~\par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid3219057\charrsid3476385 MOLECULAR STUDIES}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385  \par Molecular analysis will be reported separately. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057\charrsid3476385 See separate report, M}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057 22-14782, M 22-14784.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid3219057\charrsid3476385 \par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}"
H22-8974;S15;MSKA - 2023-06-15 13.02.05.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Myelodysplastic Syndrome\par Clinical Hx/Op Findings: MDS/MPN-RS-T\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\par      -  Myeloid neoplasm with ring sideroblasts and no increased blasts. See comment.  \par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The bone marrow biopsy and aspirate smears are remarkable for hypercellularity for age, erythroid dysplasia, presence of >15% ring sideroblasts and striking megakaryocytic hyperplasia and atypia. Per report, recent outside molecular studies showed presence of \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i SF3B1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 , \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i JAK2 \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 and the \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i DNMT3A \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 mutations. At the time of the current biopsy CBC shows macrocytic anemia and normal levels of platelets. However, per report markedly increased platelets were detected on multiple occasions in the past, as high as ~800 K/mL. The overall findings appear consistent with a diagnosis of myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Correlation with molecular genetic studies initiated at MSKCC is recommended. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Hypercellular (70-80%)\par M:E ratio: Inverted\par Blasts: Not increased\par Myeloid lineage: Relatively reduced\par Erythroid lineage:  Relatively increased, with left-shifted but complete maturation\par Megakaryocytes:  Increased in number, heterogeneous, ranging from giant to small in size, with frequent elements showing nuclear hyperlobation but also less numerous elements with hypolobated nuclei\par Lymphocytes: Scattered\par Plasma cells: Scattered \par Reticulin stain shows mild increase in reticulin fibrosis (MF-0)\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate \par Differential count:\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 1%\par Metamyelocytes \tab\tab 1%\par Neutrophils/Bands \tab 4%\par Monocytes \tab\tab 1%\par Eosinophils \tab\tab 7%\par Erythroid Precursors \tab 78%\par Lymphocytes \tab\tab 8%\par Number of Cells Counted \tab 500\par M:E Ratio \tab\tab 0.2\par\par Special stain\par Iron: Present\par Ring sideroblasts: Present, >15% \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Spicular and hypercellular aspirate smears show erythroid elements with dysplastic changes including nuclear lobation, binucleation, megaloblastoid change, and late stage mitosis. Megakaryocytes are present, include atypical giant forms with nuclear hyper lobation as well as rarer forms with widely separated nuclei. Myeloid elements are reduced and show occasional hypogranular forms. Blasts are not increased. Scattered lymphocytes and plasma cells are present. \par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (10/25/2022):\par WBC 3.8 L [4.0-11.0 K/mcL] \par RBC 2.41 L [3.95-5.54 M/mcL] \par HGB 8.2 L [12.5-16.2 g/dL] \par HCT 25.3 L [37.5-49.3 %] \par MCV 105 H [80-98 fL] \par MCH 34.0 H [27.0-33.0 pg] \par MCHC 32.4 [31.0-36.5 g/dL] \par RDW 22.7 H [12.2-15.1 %]\par Platelets 248 [160-400 K/mcL] \par\par Neutrophil 68.4 [32.5-74.8 %] \par Mono 6.6 [0.0-12.3 %] \par Eos 1.3 [0.0-4.9 %] \par Baso 0.5 [0.0-1.5 %] \par Immature Granulocyte 1.3 H [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 21.9 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 2.6 [1.5-7.5 K/mcL] \par Abs Mono 0.2 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 0.8 L [0.9-3.2 K/mcL] \par\par Morphology:\par\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 WBC: Leukopenia and lymphopenia. No circulating blasts seen.\par RBC: Mild macrocytic anemia. Marked anisopoikilocytosis. Polychromasia. \par PLT: Unremarkable morphology. \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 highlight rare blasts comprising less than 5% of the total cellularity.\par CD61 highlights variably sized megakaryocytes. CD71 highlights increased left-shifted erythroid precursors. MPO highlights reduced myeloid precursors.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-11679)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal myeloid blast population detected.\par\par Abnormal myeloid blast population represents 4.3% of WBC.\par\par Basophilia is seen, 1.8% of WBC.\par Eosinophilia is seen, 10.6% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (partial), CD7 (partial), CD13 (dim), CD33 (uniform - intermediate), CD34 (bright), CD117 (dim), CD123 (uniform -\par intermediate), HLA-DR (dim)\par Normal: CD4, CD36, CD38, CD45, CD45RA, CD71, CD105, CD371 (clec12a)\par Negative: CD2, CD3, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa,\par surface Lambda, CD42b, CD90\par\par 2. No abnormal mature B- or T-cell populations detected.\par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par Number of cells acquired 353 thousand\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8028.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-45643.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-3461;S11;MSKT - 2023-04-17 07.39.53.ndpi,Peripheral Blood Smear,2023-04-17,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: 3 months post BMT
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Plasma cell neoplasm, 
10-15% involvement by CD138 immunohistochemistry.
15% involvement by aspirate differential
6.5% of total WBC involvement by flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: approximately 20%
Myeloid lineage: Orderly maturation  
Erythroid lineage: Orderly maturation   
Megakaryocytes: Adequate 
Plasma cells: Increased     

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                1%
Promyelocytes           2%
Myelocytes           12%
Metamyelocytes           10%
Neutrophils/Bands      26%
Monocytes           4%
Eosinophils           3%
Erythroid Precursors      18%
Plasma Cells           15%
Lymphocytes           9%
Number of Cells Counted 500
M:E Ratio           3.2

Morphology: 
Marrow spicules: Spicular 
Cellularity: Hypocellular
Plasma cell morphology: Large to small sized with prominent nucleoli and occasional multinucleation
Myeloid lineage: Orderly maturation 
Erythroid Lineage: Orderly maturation  
Megakaryocytes: Present 
Other findings: Numerous naked nuclei noted  

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, ~10-15% of marrow cellularity 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted
BCMA highlights 90% of plasma cells, (2+) intensity, membranous / Golgi pattern 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-4475)
Interpretation: 
Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.
Abnormal plasma cell population comprises 91.6% of total plasma cells.
Abnormal plasma cell population represents 6.5% of WBC.

Immunophenotype:
Abnormal: CD38 (dim), CD19 (negative), CD27 (negative), CD45 (negative), CD56 (positive), CD117 (positive), cytoplasmic Kappa (restriction)
Normal: CD138, CD229, CD319, CD81
Negative: cytoplasmic Lambda

Number of cells acquired: 5.8 million

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (04/27/2022):
WBC 3.6 L [4.0-11.0 K/mcL] 
RBC 3.98 [3.95-5.54 M/mcL] 
HGB 12.5 [12.5-16.2 g/dL] 
HCT 38.4 [37.5-49.3 %] 
MCV 97 [80-98 fL] 
MCH 31.4 [27.0-33.0 pg] 
MCHC 32.6 [31.0-36.5 g/dL] 
RDW 15.3 H [12.2-15.1 %] 
Platelets 166 [160-400 K/mcL] 

Neutrophil 49.9 [32.5-74.8 %] 
Mono 9.6 [0.0-12.3 %] 
Eos 1.4 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 38.5 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 1.8 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL] 

Morphology: No circulating plasma cell on scanning. 

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-3068, CG22-3069

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-18338. 
"
H22-76;S10;MSK1 - 2023-05-26 13.57.21.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Lymphoma, Multiple Myeloma
Clinical Hx/Op Findings: hx of MCL, pre-treatment, in screening for 18-427
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Morphologic findings consistent with involvement by the patient's previously diagnosed mantle cell lymphoma (50% by CD20 immunohistochemistry)
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show hypercellular bone marrow (50 %cellularity). There istrilineage maturing hematopoiesis with increased numbers of lymphocytes scattered in the interstitium and forming occasional small aggregates.

The bone marrow aspirate smear are spicular and cellular. In the background of maturing trilineage hematopoiesis there is an increased number of medium-sized atypical lymphoid elements, with round to slightly irregular nuclei, variably condensed chromatin, occasionally prominent nucleoli and scant cytoplasm.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight increased number of B-cells, accounting for approximately 50% of total cellularity. CD3 is positive in scattered T-cells in the background.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-97) 
1. Abnormal B cell population detected. 
The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)

Abnormal B cell population represents 50.6% of WBC.
Immunophenotype:
Abnormal: CD5 (variable - dim to intermediate), CD23 (variable - negative to intermediate), CD43 (partial), ROR1 (positive), CD19 (dim), CD40 (dim)
Normal: CD20, CD79b, CD81, CD200, CD45, CD38
Negative: CD10, CD3

Number of cells acquired: 535 thousand  

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-85) 
1. Abnormal B cell population detected. 
The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)

Abnormal B cell population represents 39.8% of WBC.
Immunophenotype:
Abnormal: CD5 (variable - negative to intermediate), CD23 (variable - dim to intermediate), CD43 (partial), ROR1 (positive), CD19 (dim), CD40 (dim)
Normal: CD20, CD79b, CD81, CD200, CD45
Negative: CD38, CD10, CD3

Number of cells acquired: 859 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (01/04/2022):
WBC 18.0 H [4.0-11.0 K/mcL] 
RBC 4.59 [3.80-5.00 M/mcL] 
HGB 12.5 [11.2-15.4 g/dL] 
HCT 38.8 [34.3-46.0 %] 
MCV 85 [80-98 fL] 
MCH 27.2 [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 14.6 [12.2-15.1 %] 
Platelets 138 L [160-400 K/mcL] 

Neutrophil 17.0 L [32.5-74.8 %] 
Mono 6.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 76.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 3.1 [1.5-7.5 K/mcL] 
Abs Mono 1.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 13.6 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: Numerous medium-sized atypical lymphocytes with round to slightly irregular nuclei, variably condensed chromatin, occasionally prominent nucleoli and scant cytoplasm are present.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-50, CG22-51.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-462.
"
H22-9252;S12;MSKY - 2023-06-15 13.30.32.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Multiple Myeloma\par Clinical Hx/Op Findings: pre-transplant\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate, and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : \~\~\par      - Plasma cell neoplasm, \~\par\~\~\~\~\~\~\~\~\~\~~15-20% involvement by CD138 immunohistochemistry.\par\~\~\~\~\~\~\~\~\~\~4% involvement by aspirate differential\par\~\~\~\~\~\~\~\~\~\~1.9% involvement by flow cytometry\par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate \par Cellularity: ~20%\par Myeloid lineage: Orderly maturation    \par Erythroid lineage: Orderly maturation   \par Megakaryocytes: Adequate   \par Plasma cells: Increased; occasional Dutcher bodies present  \par Clot section: Predominantly blood with no marrow particles \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 2%\par Metamyelocytes \tab\tab 1%\par Neutrophils/Bands \tab 47%\par Monocytes \tab\tab 7%\par Eosinophils \tab\tab 3%\par Erythroid Precursors \tab 14%\par Plasma Cells \tab\tab 4%\par Lymphocytes \tab\tab 21%\par Number of Cells Counted  200\par M:E Ratio \tab\tab 4.4\par\par Morphology: \par Marrow spicules:  Aspicular\par Cellularity: N/A\par Plasma cell morphology: Rare seen\par Myeloid lineage: Mainly nerutrophils\par Erythroid Lineage: Present\par Megakaryocytes: Present \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD138 immunostain highlights plasma cells, ~15-20% of cellularity. \par Kappa and lambda immunostains show the plasma cells are kappa light chain restricted. \par BCMA highlights 90% of plasma cells, (1-2+) intensity, membranous/ Golgi pattern. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-12025)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par 1. Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par\par Abnormal plasma cell population comprises 99.5% of total plasma cells.\par Abnormal plasma cell population represents 1.9% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (negative), CD27 (negative), CD45 (negative), CD56 (partial), CD81 (negative), cytoplasmic Kappa (restriction)\par Normal: CD138, CD229, CD319\par Negative: CD38 (consistent with anti-CD38 therapy effect), CD20, CD117, cytoplasmic Lambda\par\par Number of cells acquired: 5.6 million \par\par\par 2. No abnormal mature B cell population detected.\par No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.\par\par Number of cells acquired: 405 thousand \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/02/2022 ):\par WBC 3.3 L [4.0-11.0 K/mcL] \par RBC 3.63 L [3.95-5.54 M/mcL] \par HGB 12.4 L [12.5-16.2 g/dL] \par HCT 36.8 L [37.5-49.3 %] \par MCV101 H [80-98 fL] \par MCH34.2 H [27.0-33.0 pg] \par MCHC 33.7 [31.0-36.5 g/dL] \par RDW14.6 [12.2-15.1 %] f\par Platelets 146 L [160-400 K/mcL] \par\par Neutrophil 62.4 [32.5-74.8 %] \par Mono 14.1 H [0.0-12.3 %] \par Eos 1.8 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Immature Granulocyte 0.3 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 21.4 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 2.0 [1.5-7.5 K/mcL] \par Abs Mono 0.5 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 0.7 L [0.9-3.2 K/mcL] \par\par Morphology: \par WBC: No circulating plasma cells seen\par RBC: Macrocytic RBCs\par PLT: Unremarkable morphology \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8280, CG22-8281.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-47148. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-10024;S15;MSK0 - 2023-06-15 15.21.38.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: MPN\par Clinical Hx/Op Findings: 66y w/ h/o ET, want to determine whether she has post-ET MF or MDS/MPN\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\par      - Hypercellular marrow with trilineage hematopoiesis with erythroid hyperplasia and dysplasia, myeloid dysplasia, megakaryocytic atypia, ring sideroblasts (>15%), mild myelofibrosis (MF-1/3) and no increase in blasts, see comment.\par   \par COMMENT:  Patient's history of essential thrombocythemia (thrombocytosis 1st noted in 2001 with a reported CAL-R mutation) on hydroxyurea now with worsening cytopenias is noted. In light of the presence of ring sideroblasts the differential includes ET with progression and clonal evolution vs Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). Currently marrow shows no increase in blasts. Correlation with forthcoming molecular and cytogenetic studies is recommended.\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: >90%\par M:E ratio: Reduced\par Blasts: Not overtly increased\par Myeloid lineage: Left shifted maturation\par Erythroid lineage: Increased with full range of maturation\par Megakaryocytes: Present with variable morphology with a subset of small hypolobated forms, form with hyperchromatic nuclei and forms with hypersegmentation\par Lymphocytes:\par Plasma cells:\par Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1/3). \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate \par Blasts \tab\tab\tab 2%\par Promyelocytes \tab\tab 3%\par Myelocytes \tab\tab 2%\par Metamyelocytes \tab\tab 2%\par Neutrophils/Bands \tab 11%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 74%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 4%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 0.3\par\par Special stain\par Iron: Present\par Ring sideroblasts: Present; >15%\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -Spicular and cellular smears show trilineage hematopoiesis with no increase in blasts.  The myeloid lineage is reduced and shows mildly left-shifted maturation along with dysplasia with a subset of hypogranular forms and forms with abnormal lobation.  The erythroid lineage is increased and  shows moderate to marked dysplasia including of elements showing nuclear membrane irregularities, budding, binucleation and late form mitosis.  Megakaryocytes are present with open variable morphology with a subset of small hypo lobated forms and rare forms showing nuclear lobes separation.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/28/2022):\par WBC 2.5 L [4.0-11.0 K/mcL] \par RBC 2.42 L [3.80-5.00 M/mcL] \par HGB 8.3 L [11.2-15.4 g/dL] \par HCT 25.1 L [34.3-46.0 %] \par MCV 104 H [80-98 fL] \par MCH 34.3 H [27.0-33.0 pg] \par MCHC 33.1 [31.0-36.5 g/dL] \par RDW 20.2 H [12.2-15.1 %] \par Platelets. 751 H [160-400 K/mcL] \par\par Neutrophil 49.0 [32.5-74.8 %] \par Mono 5.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Myelocyte 3.0 H [0.0-0.0 %] \par Lymph 42.0 [12.2-47.4 %] \par Nucleated RBC 9.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 1.2 L [1.5-7.5 K/mcL] \par Abs Mono 0.1 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] \par Abs Lymph 1.1 [0.9-3.2 K/mcL]\par\par Morphology:\par\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 WBC: Leukopenia with neutropenia. Rare hypogranular and hypolobated granulocytes noted\par RBC: Anisopoikilocytosis with few nucleated RBCs\par Platelet: Thrombocytosis with few giant platelets\plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 stains scattered blasts, less than 5% of cellularity.  CD34 also stains a subset of megakaryocytes.\par CD61 stains the megakaryocytes with a subset of small forms.  \par CD 71 and MPO stain the erythroid and myeloid series, respectively with a reduced M: E ratio.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-13038)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal myeloid blast population detected.\par Abnormal myeloid blast population represents 14.0% of WBC.\par\par Immunophenotype:\par Abnormal: CD7 (bimodal - negative to intermediate), CD13 (bimodal - negative to dim), CD38 (dim), CD45RA (negative), CD64 (partial), CD117 (bimodal - dim to intermediate), HLA-DR (variable - negative to dim)\par Normal: CD4, CD33, CD34, CD36, CD45, CD71, CD105, CD123, CD371 (clec12a)\par Negative: CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, surface Kappa, surface Lambda, CD42b, CD90\par\par Number of cells acquired: 384 thousand\par\par 2. No abnormal mature B- or T-cell populations detected.\par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par Number of cells acquired 116 thousand\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-9002;S16;MSKE - 2023-06-15 10.56.05.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Pancytopenia\par Clinical Hx/Op Findings: Pancytopenia\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\par      - Therapy related acute myeloid leukemia (40-50% blasts by immunohistochemistry). See comment. \par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The patient's history of left lung adenocarcinoma in 2020 treated with carboplatin, paclitaxel, and radiation therapy in addition to a history of melanoma, ovarian cancer, and left breast cancer (treatment history is not known) are noted. The patient's history of chemotherapy and radiation therapy and subsequent acute myeloid leukemia are consistent with a therapy related acute myeloid leukemia. Correlation of these findings with cytogenetic and molecular studies is recommended. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Normocellular (30%)\par M:E ratio: Reduced\par Blasts: Increased interstitially and in small aggregates\par Myeloid lineage: Relatively reduced with progressive maturation\par Erythroid lineage: Present with progressive maturation\par Megakaryocytes: Present with occasional hyperchromatic nuclei\par Lymphocytes: Scattered\par Plasma cells: Scattered \par Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0)\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Suboptimal \par Differential count:\par Blasts \tab\tab\tab 27%\par Myelocytes \tab\tab 3%\par Metamyelocytes \tab\tab 1%\par Neutrophils/Bands \tab 15%\par Eosinophils \tab\tab 3%\par Erythroid Precursors \tab 36%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 14%\par Number of Cells Counted \tab 500\par M:E Ratio \tab\tab 0.6\par\par Special stain\par Iron: Present on touch imprint\par Ring sideroblasts: Absent\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Aspicular, hypocellular, and hemodilute smears are suboptimal for accurate blast enumeration but show a increased population of blasts (large cells with round nuclei, scant cytoplasm, fine chromatin with prominent nucleoli). Scattered myeloid and erythroid elements are present. Megakaryocytes are not readily identified. Scattered lymphocytes and plasma cells are present. \par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (10/26/2022):\par\par WBC 1.6 L [4.0-11.0 K/mcL] \par RBC 3.92 [3.80-5.00 M/mcL] \par HGB 9.8 L [11.2-15.4 g/dL] \par HCT 32.0 L [34.3-46.0 %] \par MCV 82 [80-98 fL] \par MCH 25.0 L [27.0-33.0 pg] \par MCHC 30.6 L [31.0-36.5 g/dL]\par RDW 16.9 H [12.2-15.1 %] \par Platelets 151 L [160-400 K/mcL] \par\par Neutrophil 61.0 [32.5-74.8 %] \par Mono 1.0 [0.0-12.3 %] \par Eos 5.0 H [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Blast 12.0 H [0.0-0.0 %] \par Lymph 21.0 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 1.0 L [1.5-7.5 K/mcL] \par Abs Mono 0.0 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Blasts 0.2 H [0.0-0.0 K/mcL] \par Abs Lymph 0.3 L [0.9-3.2 K/mcL] \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 highlight increased blasts comprising 40-50% of the total cellularity.\par CD61 highlights megakaryocytes. CD71 highlights erythroid precursors and MPO is positive in the blasts and myeloid precursors.\par TP53 stain is negative.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-11745)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Abnormal myeloid blast population detected. \par\par Abnormal myeloid blast population represents 68.5% of WBC.\par\par Immunophenotype:\par Abnormal: CD7 (partial), CD13 (negative), CD15 (partial), CD25 (partial), CD33 (variable - negative to intermediate), CD38 (uniform - intermediate), CD45RA (variable - negative to dim), CD117 (variable - negative to intermediate), CD371 (clec12a) (variable - negative to dim), HLA-DR (variable - negative to dim)\par Normal: CD4, CD34, CD36, CD45, CD71, CD123\par Negative: CD2, CD5, CD10, CD11b, CD14, CD16, CD19, CD56, CD64, CD105, CD42b, CD90\par\par Number of cells acquired: 624 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8082\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-45934, M22-45935 and M22-45936.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-7033;S13;MSK4 - 2023-06-15 12.19.17.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: FLC disease
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
   40% involvement by CD138 immunohistochemistry.
   28% involvement by aspirate differential
   12.6% involvement by flow cytometry
     - Mildly hypercellular marrow for age with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: 50-60%
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes: Adequate   
Plasma cells: Increased with frequent Dutcher bodies  

Special stain: Congo Red stain is negative for amyloid deposition.  

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality:  Adequate

Blasts                1%
Promyelocytes           1%
Myelocytes           12%
Metamyelocytes           9%
Neutrophils/Bands      25%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      18%
Plasma Cells           28%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           2.7

Morphology: 
Marrow spicules: Spicular 
Cellularity: Normocellular 
Plasma cell morphology: Small to intermediate with Dutcher bodies noted
Myeloid lineage: Orderly maturation 
Erythroid Lineage: Orderly maturation 
Megakaryocytes: Present 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, overall 40% of cellularity. 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted
BCMA highlights >90% of plasma cells, (3+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9210) 
Interpretation:
1. Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.
Abnormal plasma cell population comprises 99.4% of total plasma cells.
Abnormal plasma cell population represents 12.6% of WBC.

Immunophenotype:
Abnormal: CD38 (dim), CD19 (negative), CD27 (variable - negative to intermediate), CD45 (variable - negative to dim), CD56 (partial), CD81 (variable - negative to dim), CD117 (partial), cytoplasmic Kappa (restriction)
Normal: CD138, CD229, CD319
Negative: CD20, cytoplasmic Lambda

Number of cells acquired: 6.9 million 

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

Number of cells acquired: 312 thousand 


Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (08/25/2022):
WBC 6.9 [4.0-11.0 K/mcL] 
RBC 4.12 [3.80-5.00 M/mcL] 
HGB 12.4 [11.2-15.4 g/dL] 
HCT 36.2 [34.3-46.0 %] 
MCV 88 [80-98 fL] 
MCH 30.1 [27.0-33.0 pg] 
MCHC 34.3 [31.0-36.5 g/dL] 
RDW 11.9 L [12.2-15.1 %] 
Platelets. 349 [160-400 K/mcL] 

Neutrophil 57.8 [32.5-74.8 %] 
Mono 6.9 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Immature Granulocyte 0.7 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 30.6 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 4.0 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 2.1 [0.9-3.2 K/mcL] 

Morphology: No circulating plasma cells seen. WBCs, RBCs and platelets are morphologically unremarkable. 

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-6374, CG22-6375. 

MOLECULAR STUDIES 
Not submitted. 
"
H22-138;S11;MSKR - 2023-05-31 21.04.46.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: Per MD
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Plasma cell neoplasm, 
     15-20% involvement by CD138 immunohistochemistry.
     1% involvement by aspirate differential
     0.0076% of total WBC involvement by 12 color flow cytometry
    - Hypocellular marrow with eosinophilia and non-necrotizing granulomata; see comment.

COMMENT: The reason for the discrepancy between plasma cell count by aspirate differential and immunohistochemistry is not entirely clear and was also seen in the prior specimen (H21-6760). Non-necrotizing granulomata are seen; special stains for infectious organisms will be reported in an addendum.

BONE MARROW BIOPSY
Quality: Inadequate with limited material present / aspiration artifact / hemorrhage seen
Cellularity: Appears hypocellular
Myeloid lineage: Progressive maturation with eosinophilia.
Erythroid lineage: Progressive maturation  
Megakaryocytes: Scattered forms noted 
Plasma cells: Increased    
Other: Non-necrotizing granulomata seen 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                1%
Promyelocytes           3%
Myelocytes           13%
Metamyelocytes           10%
Neutrophils/Bands      24%
Monocytes           1%
Eosinophils           21%
Erythroid Precursors      18%
Plasma Cells           1%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           4

Morphology: 
Marrow spicules: Spicular    
Cellularity: Cellular   
Plasma cell morphology: Rare small forms noted without cytologic atypia
Myeloid lineage: Orderly maturation   
Erythroid Lineage: Orderly maturation
Megakaryocytes: Present but appear decreased in number     
Other findings: Numerous naked nuclei are noted. 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 10-15% of marrow cellularity. 
Kappa and lambda immunostains show no definitive light chain restriction of plasma cells.
BCMA highlights 80% of plasma cells, (1-2+) intensity, membranous / Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-160)
Interpretation: 
1. Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.

Abnormal plasma cell population comprises 77.0% of total plasma cells.
Abnormal plasma cell population represents 0.0076% of WBC.
Immunophenotype:
Abnormal: CD19 (negative), CD27 (bright), CD45 (negative), CD56 (positive), with no definite light chain expression
Normal: CD138, CD38, CD229, CD319, CD81
Negative: CD117, cytoplasmic Kappa, cytoplasmic Lambda

Number of cells acquired: 5.2 million  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (01/06/2022):
WBC 3.3 L [4.0-11.0 K/mcL] 
RBC 3.42 L [3.95-5.54 M/mcL] 
HGB 12.6 [12.5-16.2 g/dL] 
HCT 36.8 L [37.5-49.3 %] 
MCV 108 H [80-98 fL] 
MCH 36.8 H [27.0-33.0 pg] 
MCHC 34.2 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 115 L [160-400 K/mcL] 

Neutrophil 29.0 L [32.5-74.8 %] 
Mono 15.0 H [0.0-12.3 %] 
Eos 45.0 H [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 10.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.5 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Mild leukopenia with neutropenia and marked eosinophilia; no circulating plasma cells seen.  
RBC: Macrocytosis.
PLT: Mild thrombocytopenia. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Not submitted

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-889.
"
H22-1103;S12;MSKV - 2023-04-19 16.25.56.ndpi,Peripheral Blood Smear,2023-04-19,"Clinical Diagnosis: CML
Clinical Hx/Op Findings: newly diagnosed
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate, and peripheral blood smears: 
     - Chronic myeloid leukemia (CML), BCR-ABL1-positive, see comment. 

COMMENT: Morphologic findings of this biopsy are consistent with chronic phase (CP); however, please correlate with the clinical and laboratory findings at the time of initial presentation to confirm CML-CP (per clinical notes, patient had already been exposed to imatinib for a week).

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: 50-60%
M:E ratio: Increased
Blasts: Not increased
Myeloid lineage: Increased with left-shifted maturation
Erythroid lineage: Reduced with maturation
Megakaryocytes: Increased with small atypical, monolobated forms
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0 out of 3). 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate 

Blasts                1%
Promyelocytes           2%
Myelocytes           21%
Metamyelocytes           3%
Neutrophils/Bands      52%
Monocytes           5%
Eosinophils           2%
Erythroid Precursors      10%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           8.5

Morphology:
Spicular and cellular aspirate smears show marrow with increased M:E ratio. Myeloid elements show progressive, left shifted maturation without significant dysplasia. Erythroid elements are decreased and show no overt dysplasia. Many small monolobated megakaryocytes are present. Blasts are not increased. Scattered lymphocytes and plasma cells are present.

PERIPHERAL BLOOD
CBC (2/8/2022):
WBC 11.4 H [4.0-11.0 K/mcL] 
RBC 5.54 [3.95-5.54 M/mcL] 
HGB 14.1 [12.5-16.2 g/dL] 
HCT 46.6 [37.5-49.3 %] 
MCV 84 [80-98 fL] 
MCH 25.5 L [27.0-33.0 pg] 
MCH 30.3 L [31.0-36.5 g/dL] 
RDW 16.5 H [12.2-15.1 %] 
Platelets. 227 [160-400 K/mcL] 

Neutrophil 72.5 [32.5-74.8 %] 
Mono 7.9 [0.0-12.3 %] 
Eos 1.8 [0.0-4.9 %] 
Baso 2.5 H [0.0-1.5 %] 
Immature Granulocyte 1.0 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 14.3 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 8.3 H [1.5-7.5 K/mcL] 
Abs Mono 0.9 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.3 H [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] 
Abs Lymph 1.6 [0.9-3.2 K/mcL]

Morphology:
RBC: Ansiopoikilocytosis.
WBC: Neutrophilia. Basophilia. Increased immature myeloid cells. No circulating blasts.
PLT: Unremarkable morphology.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight no increase in blasts, <5% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1408)
Interpretation: 
1. No definite abnormal myeloid blast population detected.          
There is no definite immunophenotypic evidence of a myeloid stem cell neoplasm by flow cytometry. 
However, in light of the atypical expression of the following markers listed below, a low-grade myeloid stem cell neoplasm cannot be entirely excluded by these studies. 
Normal myelomonocytic maturation is present. Morphologic, cytogenetic, and molecular genetic assessment is suggested to exclude myeloid stem cell neoplasm. Clinical correlation is advised.
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment.

Myeloid blast population represents 0.56% of WBC.

Immunophenotype:
Abnormal: CD7 (partial), CD38 (variable - negative to dim)
Normal: CD4, CD13, CD33, CD34, CD36, CD45, CD45RA, CD71, CD105, CD117, CD123, CD371 (clec12a), HLA-DR
Negative: CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda

Number of cells acquired 825 thousand 

2. No abnormal mature B- or T-cell populations detected. 
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

Number of cells acquired: 347 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.


CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-899.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-5710, M22-5711, M22-5712, M22-5713, M22-5714. 
"
H22-6487;S15;MSK8 - 2023-06-15 15.15.58.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: Myelodysplastic Syndrome
Clinical Hx/Op Findings: + 6 months post allo BMT with MRD
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
     - Persistent flow cytometric evidence of abnormal myeloid blast population (0.03% of WBC).
     - Mildly hypercellular marrow with maturing trilineage hematopoiesis, left-shifted myeloid maturation and no increase in blasts. See comment.

COMMENT: The bone marrow is mildly hypercellular and shows a normal M:E ratio, left-shifted myeloid maturation, and mild morphologic atypia in the erythroid and megakaryocytic lineages. The significance of these morphologic findings is not certain as these may represent reactive changes in the post-transplant setting and in the context of recent G-CSF administration (8/2/2022). However, flow cytometric analysis detected a persistent small abnormal myeloid blast population, similar to that described in the prior sample (H22-4811), raising concern for relapse of the patient's previously diagnosed myeloid neoplasm. The corresponding engraftment analysis shows similar results as the prior with a minor host component (3%). Although IMPACT-heme on the prior marrow sample (M22-25377) did not detect any alterations, the possibility of low-level recurrent disease cannot be entirely ruled out as it may be below the technical sensitivity of the assay. Correlation with concurrent molecular genetic results and close clinical follow-up is advised.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Variable cellularity, ranging from 20% to 70% and overall, approximately 30-40%
M:E: Appears normal 
Blasts: Not overtly increased 
Myeloid lineage: Exhibits left-shifted but full maturation
Erythroid lineage: Exhibits full maturation 
Megakaryocytes: Adequate in number; include a few hypolobated forms and rare hyperchromatic bare nuclei
Lymphocytes: Interstitially scattered 
Plasma cells: Not increased 

Special stain: Reticulin stain shows patchy mild increase in reticulin fibrosis (0-1+/3).     

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                1%
Promyelocytes           3%
Myelocytes           18%
Metamyelocytes           10%
Neutrophils/Bands      34%
Monocytes           5%
Eosinophils           1%
Erythroid Precursors      23% (patchy distribution)
Plasma Cells           1%
Lymphocytes           5%
Number of Cells Counted      500
M:E Ratio           3.1

Special stain 
Iron: Storage iron is present
Ring sideroblasts: Absent 

Morphology:
The aspirate smears are spicular and cellular demonstrating trilineage hematopoiesis. Blasts are not overtly increased. The M:E ratio appears normal. Myeloid elements show left-shifted progressive maturation with prominent granulation and perinuclear Golgi zones in the earlier forms. A few neutrophils show pseudo Pelger-Huet morphology and hypogranular cytoplasm. Erythroid elements show progressive maturation with occasional dyspoiesis (nuclear irregularity/budding, binucleation, megaloblastoid changes). Megakaryocytes are present and include a few hypolobated forms. Lymphocytes show mature features and do not form any prominent aggregates.

PERIPHERAL BLOOD
CBC (08/09/2022):
WBC 9.2 [4.0-11.0 K/mcL] 
RBC 3.23 L [3.95-5.54 M/mcL] 
HGB 11.2 L [12.5-16.2 g/dL] 
HCT 33.9 L [37.5-49.3 %] 
MCV 105 H [80-98 fL] 
MCH 34.7 H [27.0-33.0 pg] 
MCHC 33.0 [31.0-36.5 g/dL] 
RDW 14.3 [12.2-15.1 %] 
Platelets 84 L [160-400 K/mcL] 

Neutrophil 83.0 H [32.5-74.8 %] 
Mono 10.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 7.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 7.7 H [1.5-7.5 K/mcL] 
Abs Mono 0.9 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Neutrophils show prominent toxic granulation, Dohle bodies, occasional cytoplasmic vacuolation, and include rare forms with nuclear hypersegmentation or cytoplasmic hypogranularity; no increase in circulating blasts.
RBC: Macrocytic anemia. 
PLT. Thrombocytopenia; unremarkable morphology. 

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
CD34 and CD117 immunostains show no increase in blasts (<5% of cellularity). 
CD117 highlights scattered mast cells as well as early erythroid and myeloid precursors. 
CD61 highlights megakaryocytes. 
MPO labels myeloid elements while CD71 labels erythroid elements.     

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-8540)
1. Abnormal myeloid blast population detected. The immunophenotype of this population is similar to that seen in prior sample [F22-6299]. 

Abnormal myeloid blast population represents at least 0.03% of WBC.

Immunophenotype:
Abnormal: CD5 (positive), CD13 (bright), CD33 (bright), CD34 (bright), CD38 (dim), HLA-DR (bright), CD90 (increased)
Normal: CD4, CD36, CD45, CD71, CD117, CD123
Negative: CD2, CD7, CD10, CD11b, CD14, CD15, CD16, CD19, CD25, CD45RA, CD56, CD64, CD105, CD371 (clec12a), CD42b

Number of cells acquired: 668 thousand 

2. No abnormal mature B-cell population detected. Virtually no mature B-cell seen.       
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

Number of cells acquired: 460 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES (CG22-5861)
KARYOTYPE ANALYSIS:
Normal male karyotype; no evidence of clonal chromosomal abnormalities was observed.

MOLECULAR STUDIES (M22-33801, M22-33821) 
M22-33801
ENGRAFTMENT STATUS: CHIMERIC, MOSTLY DONOR

Note: Calculated host and donor DNA percentages are as follows:

Host: 3%
Donor: 97% (M21-50946)

See separate report for M22-33821.
"
H22-2286;S12;MSKY - 2023-06-15 23.40.06.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: pancytopenia
Clinical Hx/Op Findings: agranulocytosis, low platelets, PARP-inhibitor therapy for ovarian cancer r/o AML
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute promyelocytic leukemia with PML-RARA (49% blasts/abnormal promyelocytes).

BONE MARROW BIOPSY
Quality: Small, but adequate
Cellularity: 25-30%
M:E ratio: N/a
Blasts: Most of the cellularity is represented by small blasts, scattered in the interstitium, and forming small aggregates
Myeloid lineage: Decreased, with left-shifted maturation
Erythroid lineage: Decreased, with complete maturation
Megakaryocytes: Rare
Lymphocytes: Not increased
Plasma cells: Not increased
Special stains: Reticulin stain shows no significant increase in reticulin fibrosis (MF-0). 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Extrinsic cells are not seen.

Blasts/ abnormal promyelocytes 49% (multiple Auer rod seen)
Myelocytes           1%
Neutrophils/Bands      1%
Erythroid Precursors      29%
Plasma Cells           2%
Lymphocytes           18%
Number of Cells Counted      200
M:E Ratio           0.1

Special stain
Iron: Present
Ring sideroblasts: Absent

Morphology:
Spicular and cellular bone marrow aspirate smears. Numerous blasts with round to for the nuclei, variably granular cytoplasm and frequent Auer rods are seen. Residual myeloid and erythroid precursors at various stages of maturation are also present in the background. Megakaryocytes are present with overall normal morphology.

PERIPHERAL BLOOD
CBC (03/21/2022):
WBC 0.8 L [4.0-11.0 K/mcL] 
RBC 3.85 [3.80-5.00 M/mcL] 
HGB 12.5 [11.2-15.4 g/dL] 
HCT 36.1 [34.3-46.0 %] 
MCV 94 [80-98 fL] 
MCH 32.5 [27.0-33.0 pg] 
MCHC 34.6 [31.0-36.5 g/dL] 
RDW 15.9 H [12.2-15.1 %] 
Platelets 109 L [160-400 K/mcL] 

Neutrophil 19.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 79.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: Leukopenia and thrombocytopenia. No definite blasts seen.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
Numerous small blasts show weak positivity for CD117. The blasts account for >70% of total cellularity and are largely negative for CD34 (only minor subset positive, 3-5% of total cellularity). CD117 is also positive in scattered mast cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-2977)
1. Expanded abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 53.4% of WBC.

Immunophenotype:
Abnormal: CD13 (uniform - bright), CD33 (uniform - bright), CD34 (variable - negative to intermediate), CD38 (negative), CD45RA (uniform - bright), CD117 (uniform - intermediate), CD371 (clec12a) (uniform - intermediate), HLA-DR (dim)
Normal: CD4, CD36, CD45, CD71, CD105, CD123, MPO
Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, cytoplasmic CD3, cytoplasmic CD79a, surface Kappa, surface Lambda, CD42b, CD61

Number of cells acquired: 304 thousand 

2. Minute abnormal B cell population detected. 
Flow cytometry reveals an abnormal B cell population with CLL/SLL-like immunophenotype (see below).

Abnormal B cell population represents 0.057% of WBC.

Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (positive), CD43 (positive), CD79b (negative), CD81 (dim), CD200 (positive), ROR1 (positive), no definite light chain expression
Normal: CD19, CD40, CD45
Negative: CD38, CD10, CD3


3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 278 thousand 

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Concurrent cytogenetic analysis showed: 
-          PML-RARA fusion/t(15;17) detected in 28.7% of cells
-     Rearrangement of RARA (17q21.2) detected in 33.3% of cells.
-     
See separate report, CG22-2022, for the complete report.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-12404.
"
H22-3454;S11;MSKV - 2023-04-17 07.23.16.ndpi,Peripheral Blood Smear,2023-04-17,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: Newly diagnosed plasma cell disorder vs lymphoma
Requested Studies: Gross/Micro
Special Requests: Rush
","1-2. Bone marrow, right posterior iliac crest, biopsy, and aspirate smears: 
     - Plasma cell neoplasm, 
70-80% involvement by CD138 immunohistochemistry.
46% involvement by aspirate differential
15% involvement by flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality: Adequate  
Cellularity: 30-40%
Myeloid lineage: Reduced, with maturation    
Erythroid lineage: Reduced, with maturation    
Megakaryocytes: Present
Plasma cells: Increased   

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules
Performed on touch smear

Blasts                1%
Myelocytes           6%
Metamyelocytes           5%
Neutrophils/Bands      18%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      14%
Plasma Cells           46%
Lymphocytes           6%
Number of Cells Counted 500
M:E Ratio           2.4

Morphology: 
Marrow spicules: Aspicular.
Cellularity: N/A
Plasma cell morphology: Small to large, few with binucleated noted.
Myeloid lineage: Orderly maturation 
Erythroid Lineage: Orderly maturation 
Megakaryocytes: Present 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 70-80% of cellularity. 
Kappa and lambda appear negative on plasma cells.   
BCMA highlights >90% of plasma cells, (1-2+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW F22-4466 
1. Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.

Abnormal plasma cell population comprises 99.3% of total plasma cells.
Abnormal plasma cell population represents 15.0% of WBC.

Immunophenotype:
Abnormal: CD138 (dim), CD38 (dim), CD19 (negative), CD20 (positive), CD27 (negative), CD45 (negative), CD81 (negative), CD117 (positive), no definite cytoplasmic light chain expression
Normal: CD229, CD319
Negative: CD56

Number of cells acquired: 2.9 million 

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.


Number of cells acquired: 117 thousand
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (04/27/2022):
WBC 3.0 L [4.0-11.0 K/mcL] 
RBC 2.66 L [3.80-5.00 M/mcL] 
HGB 8.0 L [11.2-15.4 g/dL] 
HCT 26.5 L [34.3-46.0 %] 
MCV 100 H [80-98 fL] 
MCH 30.1 [27.0-33.0 pg] 
MCHC 30.2 L [31.0-36.5 g/dL] 
RDW 17.6 H [12.2-15.1 %] 
Platelets 84 L [160-400 K/mcL] 

Neutrophil 55.0 [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Promyelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 29.0 [12.2-47.4 %] 
Plasma Cell 2.0 H [0.0-0.0 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.6 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL] 
Abs Plasma Cells 0.1 H [0.0-0.0 K/mcL] 


Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-3061, CG22-3062.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-18336 and M22-18337. 
"
H22-550;S12;MSK- - 2023-05-26 11.01.55.ndpi,Peripheral Blood Smear,2023-05-26,"Clinical Diagnosis: Lymphoma, Mantle Cell
Clinical Hx/Op Findings: newly dx, pre-treatment baseline
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Involvement by mantle cell lymphoma (~10% with CD20 immunohistochemistry). See Comment.
     - Cellular marrow with trilineage maturing hematopoiesis.

COMMENT:
The patient's history of mantle cell lymphoma is noted (H22-456).

A P53 immunostain has been ordered, and the findings will be reported in an addendum.

Correlation with pending cytogenetic and molecular studies is recommended.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show mildly hypercellular bone marrow (40-50% cellularity). There are scattered prominent lymphoid nodules. The lymphocytes are small with a scant to moderate amount of cytoplasm, irregular nuclear borders and mature chromatin. There is backgroundtrilineage maturing hematopoiesis. The myeloid and erythroid lineages show progressive maturation with no overt dysplasia. There are scattered morphologically unremarkable megakaryocytes.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
A CD20 immunostain highlights the vast majority of the lymphocytes in the nodules (overall ~10% of cellularity). The atypical B-cells coexpress CD5 (dim), Cyclin D1 (dim) and Sox-11. CD3 labels scattered T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-689) 
Abnormal B cell population detected.
The immunophenotype of this abnormal B cell population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with immunohistochemical or cytogenetic studies for Cyclin D1 is recommended to rule out mantle cell lymphoma (MCL).

Abnormal B cell population represents 4.4% of WBC.

Immunophenotype:
Abnormal: CD5 (positive), CD23 (partial), CD43 (partial), ROR1 (positive), CD19 (dim)
Normal: CD20, CD79b, CD81, CD40, CD45, CD38
Negative: CD200, CD10, CD3

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (01/20/2022):
WBC 6.6 [4.0-11.0 K/mcL] 
RBC 4.76 [3.80-5.00 M/mcL] 
HGB 12.9 [11.2-15.4 g/dL] 
HCT 38.6 [34.3-46.0 %] 
MCV 81 [80-98 fL] 
MCH 27.1 [27.0-33.0 pg] 
MCHC 33.4 [31.0-36.5 g/dL] 
RDW 14.6 [12.2-15.1 %] 
Platelets 226 [160-400 K/mcL] 

Neutrophil 69.8 [32.5-74.8 %] 
Mono 8.4 [0.0-12.3 %] 
Eos 1.8 [0.0-4.9 %] 
Baso 0.5 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 19.2 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 4.6 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 

Morphology:
WBC: Atypical lymphocytes are not increased.
RBC: Normochromic, normocytic
Platelets: Morphologically unremarkable

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate reports, CG22-433 and CD22-434.

MOLECULAR STUDIES 
Molecular analysis not requested.

"
H22-6602;S13;MSK5 - 2023-06-15 12.01.56.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: Leukemia
Clinical Hx/Op Findings: work up of relapsed disease
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Involvement by large B-cell lymphoma (20-30% by CD20 immunohistochemistry).
    - Hypercellular marrow with erythroid-predominant maturing trilineage hematopoiesis.

COMMENT: The bone marrow and the peripheral blood also show a minor component of small to intermediate sized neoplastic lymphoid cells that would be compatible with the patient's previously reported chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

BONE MARROW BIOPSY AND ASPIRATE SMEAR
Differential count:
Blasts                1%
Promyelocytes           1%
Myelocytes           4%
Metamyelocytes           3%
Neutrophils/Bands      9%
Monocytes           2%
Eosinophils           3%
Erythroid Precursors      24%
Plasma Cells           1%
Lymphocytes           10%
Atypical lymphoid cells      42% 
Number of Cells Counted 500
M:E Ratio           0.9

Morphology:
The core biopsy is adequate for assessment and shows a hypercellular marrow (90% cellularity) with an atypical nodular and interstitial infiltrate of predominantly large sized lymphoid cells with irregular nuclei, vesicular chromatin, distinct nucleoli and moderate amount of cytoplasm. In addition, there are a few admixed small to intermediate sized lymphoid cells. The background marrow shows trilineage hematopoiesis with erythroid predominance and left-shifted maturation. Megakaryocytes are adequate in number in proportion to cellularity and show mild morphologic atypia.

The aspirate smears are spicular and show partial crush artifact. There are numerous intermediate to large sized atypical lymphoid cells, some of which show plasmacytoid morphology. A small subset of cells is smaller in size. Background marrow elements show progressive maturation without significant dyspoiesis. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

PERIPHERAL BLOOD
CBC (8/11/2022):
WBC 37.2 H [4.0-11.0 K/mcL] 
RBC 2.03 L [3.80-5.00 M/mcL] 
HGB 6.9 L [11.2-15.4 g/dL] 
HCT 21.2 L [34.3-46.0 %] 
MCV 104 H [80-98 fL] 
MCH 34.0 H [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 16.8 H [12.2-15.1 %] 
Platelets 34 L [160-400 K/mcL] 

Neutrophil 21.0 L [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 18.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 55.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 7.8 H [1.5-7.5 K/mcL] 
Abs Mono 1.9 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 27.1 H [0.9-3.2 K/mcL] 

Morphology:
WBC: Leukocytosis with marked lymphocytosis including numerous large markedly atypical lymphoid cells with variably convoluted nuclei and some small to intermediate sized lymphoid cells.
RBC: Macrocytic anemia with mild anisopoikilocytosis.
PLT: Thrombocytopenia.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD20 (20-30% of cellularity), PAX5, CD5, CD23 (weak)
Others: CD3 highlights admixed T-cells.
Additional immunostains are in progress and will be reported in an addendum.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-8666)
Abnormal B-cell population with larger size detected.
The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.

Abnormal B cell population represents 63.1% of WBC.
Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (partial), CD43 (positive), CD79b (dim), CD200 (bright), ROR1 (positive), CD19 (dim), CD38 (variable - negative to intermediate), surface Kappa (restriction), CD25 (partial), Forward Scatter (increased), Side Scatter (increased)
Normal: CD81, CD40, CD45
Negative: CD10, CD3, surface Lambda, CD14, CD279 (PD1)

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-8606)
Abnormal B-cell population detected. 
A portion of the population shows increased forward and side scatter suggestive of larger size.
Flow cytometry reveals an abnormal B-cell population with CLL/SLL-like immunophenotype (see below).
Abnormal B cell population represents 69.4% of WBC.
Concentration of Abnormal population in peripheral blood is 21.44 thousand/microliter.

Immunophenotype:
Abnormal: CD5 (positive), CD20 (variable - negative to intermediate), CD23 (variable - negative to bright), CD79b (variable - dim to negative), CD81 (dim), CD200 (bright), ROR1 (variable - bright to negative), CD38 (bright), Forward Scatter (increased), Side Scatter (increased)
Normal: CD19, CD40, CD45
Negative: CD43, CD10, CD3
Number of cells acquired 950 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-5967.
"
H22-10246;S15;MSK6 - 2023-06-15 12.37.37.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Lymphoma, Waldenstrom's\par Clinical Hx/Op Findings: for diagnosis\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: \~\~\par      - Extensive involvement by low grade B-cell lymphoma with plasmacytic differentiation (80% with CD20 immunohistochemistry), see note. \par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par Note: The overall findings favor Lymphoplasmacytic lymphoma (LPL) over marginal zone lymphoma and other low grade B-cell lymphoma entities. Correlation with molecular testing for the status of MYD88 and CXCR4 mutations is recommended.  \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy and aspicular/hemodiluted aspirate specimens show hypercellular bone marrow (80% cellularity). There is reduced\~trilineage maturing hematopoiesis with markedly increased interstitial lymphoplasmacytic proliferation.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD20 (80% of total cellularity) and PAX5 highlight markedly increased interstitial tumor cells. CD138 stains markedly increased plasmacytoid cells (60-70% of total cellularity). The tumor cells are kappa light chains restricted by kappa/lambda light chain stains. CD3 highlights scattered and small clusters of T cells.\par\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-13338)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal B- and plasma cell populations detected.\par The abnormal B cell population has the same light chain restriction as the abnormal plasma cell population mentioned below. Given the similar light chain restriction, these two populations likely represent manifestations of the same neoplasm, but the immunophenotypic profiles do not allow specific classification.  Clinical and morphologic correlation is advised.\par\par\par Abnormal B cell population represents 11.7% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (dim), CD20 (dim), CD22 (dim), surface Kappa (restriction)\par Normal: CD38, CD45\par Negative: CD5, CD10, CD25, CD279 (PD1), CD3, CD14, surface Lambda\par\par Number of cells acquired: 484 thousand \par\par 2. Abnormal plasma cell population detected.\par The abnormal plasma cell population has the same light chain restriction (see immunophenotype below) as the abnormal B cell population mentioned above. \par\par Abnormal plasma cell population represents 0.16% of WBC.\par Abnormal plasma cell population comprises 94.7% of total plasma cells.\par\par Immunophenotype:\par Abnormal: CD19 (partial - dim), CD27 (negative), cytoplasmic Kappa (restriction)\par Normal: CD138, CD38, CD229, CD319, CD45, CD81\par Negative: CD20, CD56, CD117, cytoplasmic Lambda\par\par Number of cells acquired 23.7 thousand \par\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (12/06/2022):\par WBC 5.1 [4.0-11.0 K/mcL] \par RBC 2.66 L [3.80-5.00 M/mcL] \par HGB 8.6 L [11.2-15.4 g/dL] \par HCT 27.8 L [34.3-46.0 %] \par MCV 105 H [80-98 fL] \par MCH 32.3 [27.0-33.0 pg] \par MCHC 30.9 L [31.0-36.5 g/dL] \par RDW 14.6 [12.2-15.1 %] \par Platelets 232 [160-400 K/mcL] \par\par Neutrophil 59.3 [32.5-74.8 %] \par Mono 8.8 [0.0-12.3 %] \par Eos 0.6 [0.0-4.9 %] \par Baso 0.4 [0.0-1.5 %] \par Immature Granulocyte 0.4 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 30.5 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 3.0 [1.5-7.5 K/mcL] \par Abs Mono 0.4 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 1.6 [0.9-3.2 K/mcL] \par\par Morphology:\par WBC: Unremarkable.\par RBC: Macrocytic anemia. Rouleaux is seen. \par PLT: Unremarkable.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-9225.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-1124;S10;MSKW - 2023-05-26 16.29.19.ndpi,Peripheral Blood Smear,2023-05-31,"{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch31505\stshfloch31506\stshfhich31506\stshfbi0\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}
{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;
\red0\green0\blue0;}{\*\defchp \fs22\loch\af31506\hich\af31506\dbch\af31505 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*
\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\trcbpat1\trcfpat1\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused 
Normal Table;}{\s15\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\f1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext15 \spriority0 Arial;}}
{\*\rsidtbl \rsid1736676\rsid1926613\rsid6949486\rsid8271858\rsid12137372}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\operator Chan, Alexander Y./Pathology}
{\creatim\yr2022\mo2\dy14\hr11\min50}{\revtim\yr2022\mo2\dy14\hr11\min50}{\version2}{\edmins0}{\nofpages1}{\nofwords17}{\nofchars99}{\nofcharsws115}{\vern21}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}
\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata1\grfdocevents0\validatexml0\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors0\horzdoc\dghspace120\dgvspace120\dghorigin1701
\dgvorigin1984\dghshow0\dgvshow3\jcompress\viewkind1\viewscale130\rsidroot8271858 \fet0{\*\wgrffmtfilter 2450}\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2
\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}\pard\plain \ltrpar\s15\ql \li0\ri0\nowidctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\af1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \fs18\insrsid12137372 \hich\af1\dbch\af31505\loch\f1 Clinical Diagnosis: Lymphoma, Mantle Cell\par \hich\af1\dbch\af31505\loch\f1 Clinical Hx/Op Findings: recurrent disease\par \hich\af1\dbch\af31505\loch\f1 Requested Studies: Gross/Micro\par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Involved by previously diagnosed mantle cell lymphoma, ~10-20% of total cellularity by CD20 immunohistochemistry.
    - Hypercellular bone marrow with maturing trilineage hematopoiesis 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy specimen shows a hypercellular (~70%) bone marrow with maturing trilineage hematopoiesis and an atypical lymphoid infiltrate with interstitial and intrasinusoidal distribution composed of small to medium sized atypical lymphoid cells with moderate amounts of cytoplasm, irregular nuclei, and condensed chromatin. Aspirate smears are spicular, cellular, and show maturing trilineage hematopoiesis without expanded blast population, with frequent atypical lymphoid cells.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight the atypical lymphoid infiltrate, ~10-20% of total cellularity. 
B-cells co-express CD5 and CyclinD1, while negative for CD3, CD23, and P53.
SOX11 is technically suboptimal.
BCL2 and BCL6 appear mostly negative in the B-cells.
CD3 highlights scattered T-cells, <5% of total cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1438) 
Abnormal B cell population detected.
The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.
Abnormal B cell population represents 21.0% of WBC.

Immunophenotype:
Abnormal: CD5 (partial), CD20 (bright), CD79b (bright), CD200 (negative), CD19 (bright), CD45 (bright), CD10 (partial), surface Kappa (restriction)
Normal: CD22, CD23, CD43, CD81, CD40
Negative: ROR1, CD38, CD3, surface Lambda

Also see F21-1439 (PB) submitted on the same day.
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (2/08/2022):
WBC 5.8 [4.0-11.0 K/mcL] 
RBC 4.37 [3.95-5.54 M/mcL] 
HGB 13.0 [12.5-16.2 g/dL] 
HCT 38.8 [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 108 L [160-400 K/mcL] 

Neutrophil 47.0 [32.5-74.8 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 17.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 28.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 2.7 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 2.6 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Frequent circulating atypical lymphoid cells seen.
RBC: Normocytic, normochromic RBCs.
PLT: Mild thrombocytopenia. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-928.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-5779, M22-5782, M22-5783.

"
H22-9425;S13;MSK1 - 2023-04-14 14.33.35.ndpi,Peripheral Blood Smear,2023-04-14,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Multiple Myeloma\par Clinical Hx/Op Findings: monoclonal protein\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, left posterior iliac crest,  biopsy, \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate, and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : \~\~\par      - Plasma cell neoplasm, \~\par\~\~\~\~\~\~\~\~\~\~10-20% involvement by CD138 immunohistochemistry.\par\~\~\~\~\~\~\~\~\~\~8% involvement by aspirate differential\par\~\~\~\~\~\~\~\~\~\~0.2% involvement by flow cytometry\par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate \par Cellularity: 60-70%\par Myeloid lineage: Orderly maturation    \par Erythroid lineage: Orderly maturation  \par Megakaryocytes: Adequate   \par Plasma cells: Increased  \par\par Special stain: Congo Red stain is negative for amyloid deposition.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate \par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 8%\par Metamyelocytes \tab\tab 4%\par Neutrophils/Bands \tab 40%\par Monocytes \tab\tab 2%\par Eosinophils \tab\tab 4%\par Erythroid Precursors \tab 23%\par Plasma Cells \tab\tab 8%\par Lymphocytes \tab\tab 9%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 2.6\par\par Morphology: \par Marrow spicules: Spicular \par Cellularity: Cellular \par Plasma cell morphology: Small to intermediate in size\par Myeloid lineage: Orderly maturation \par Erythroid Lineage: Orderly maturation \par Megakaryocytes: Present \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD138 immunostain highlights plasma cells, 10-20% of cellularity. \par Kappa and lambda immunostains show the plasma cells are lambda light chain restricted.\par BCMA highlights >90% of plasma cells, (1-2+) intensity, membranous/ Golgi pattern. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-12239)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par\par Abnormal plasma cell population comprises 93% of total plasma cells.\par Abnormal plasma cell population represents 0.20% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (negative), CD20 (positive, partial), CD27 (negative), CD45 (negative), CD56 (bimodal - negative to intermediate), CD81 (negative), CD117 (positive), cytoplasmic Lambda (restriction)\par Normal: CD138, CD38, CD229, CD319\par Negative: cytoplasmic Kappa\par\par Number of cells acquired: 5.6 million \par\par\par 2. No abnormal mature B cell population detected.\par No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.\par\par Number of cells acquired: 395 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/8/2022):\par WBC 7.4 [4.0-11.0 K/mcL] \par RBC 3.96 [3.95-5.54 M/mcL] \par HGB 12.1 L [12.5-16.2 g/dL] \par HCT 35.1 L [37.5-49.3 %] \par MCV 89 [80-98 fL] \par MCH 30.6 [27.0-33.0 pg] \par MCHC 34.5 [31.0-36.5 g/dL] \par RDW 12.1 L [12.2-15.1 %] \par Platelets. 212 [160-400 K/mcL] \par\par Neutrophil 57.4 [32.5-74.8 %] \par Mono 8.0 [0.0-12.3 %] \par Eos 2.3 [0.0-4.9 %] \par Baso 0.8 [0.0-1.5 %] \par Immature Granulocyte 0.3 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 31.2 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 4.2 [1.5-7.5 K/mcL] \par Abs Mono 0.6 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] \par Absolute Basophil 0.1 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 2.3 [0.9-3.2 K/mcL]\par\par Morphology: \par No circulating plasma cells\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8437 and CG22-8438. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-48050. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-7092;S23;MSK0 - 2023-06-15 17.11.38.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Hx/Op Findings: suspected new diagnosis of leukemia
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma with t(9;22); BCR-ABL1, 88% blasts by aspirate differential count. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular (90%)
M:E ratio: N/A
Blasts: Markedly increased 
Myeloid lineage: Markedly decreased
Erythroid lineage: Markedly decreased
Megakaryocytes: Decreased
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows no significant increase in reticulin fibrosis 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate 

Blasts                88%
Neutrophils/Bands      1%
Eosinophils           1%
Erythroid Precursors      1%
Plasma Cells           2%
Lymphocytes           9%
Number of Cells Counted  500
M:E Ratio           2

Morphology:
Spicular and cellular aspirate smears show a markedly expanded population of blasts, which are mostly small to medium in size with rounded to irregular nuclei, moderately dispersed chromatin, occasional distinct nucleoli, and scant cytoplasm. Background trilineage hematopoiesis is reduced. 

PERIPHERAL BLOOD
CBC (8/26/2022):
WBC 59.5 H [4.0-11.0 K/mcL] 
RBC 4.87 [3.95-5.54 M/mcL] 
HGB 14.2 [12.5-16.2 g/dL] 
HCT 42.2 [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 29.2 [27.0-33.0 pg] 
MCHC 33.6 [31.0-36.5 g/dL] 
RDW 14.2 [12.2-15.1 %] 
Platelets 27 L [160-400 K/mcL] 

Neutrophil 6.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 86.0 H [0.0-0.0 %] 
Lymph 6.0 L [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 3.6 [1.5-7.5 K/mcL] 
Abs Mono 1.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 51.2 H [0.0-0.0 K/mcL] 
Abs Lymph 3.6 H [0.9-3.2 K/mcL] 

Morphology: 
WBC: Frequent circulating blasts.
RBC: Normochromic, normocytic RBCs with occasional nucleated RBCs.
Platelets: Marked thrombocytopenia.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
The blasts, comprising ~80-90% of the cellularity, express CD34, TdT, and CD19, while are negative for CD117, MPO, lysozyme, CD3, CD71 and CD61. CD71 shows markedly reduced erythroid precursors. MPO and lysozyme demonstrate markedly reduced myelomonocytic elements. CD61 highlights reduced megakaryocytes. CD3 labels scattered T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9287)
Interpretation:
1. Abnormal immature B cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 93.5% of WBC.
Abnormal immature B cell population represents 93.5% of the mononuclear cells.

Immunophenotype:
Abnormal: CD10 (bright), CD20 (partial), CD33 (partial), CD34 (variable - negative to bright), CD38 (variable - negative to intermediate), CD45 (variable - negative to intermediate), CD66c/CD123 (positive), CD73/CD304 (positive), CD81 (dim), CD86 (positive), CD123 (positive)
Normal: CD19, CD22, CD24, CD36, CD45RA, CD71, CD105, CD371 (clec12a), HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD25, CD26, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90

Number of cells acquired 319 thousand 

2. No abnormal myeloid blast, mature B or mature T cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.074% of WBC.

Number of cells acquired: 921 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-9255)
Interpretation:
1. Abnormal immature B-cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 81.5% of WBC.
Abnormal immature B cell population represents 86.5% of the mononuclear cells.

Immunophenotype:
Abnormal: CD10 (bright), CD20 (partial), CD33 (partial), CD34 (variable - negative to bright), CD38 (variable - negative to intermediate), CD45 (variable - negative to intermediate), CD66c/CD123 (partial), CD73/CD304 (positive), CD81 (positive - dim), CD86 (partial), CD123 (positive)
Normal: CD19, CD22, CD24, CD36, CD45RA, CD71, CD105, HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD25, CD26, CD56, CD64, CD66b, CD117, CD279 (PD1), CD371 (clec12a), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90

Number of cells acquired 819 thousand 

2. No abnormal myeloid blast, mature B or mature T-cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.24% of WBC.

Number of cells acquired: 725 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-6420.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports.

"
H22-8545;S21;MSK2 - 2023-06-15 10.21.01.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0  \par Prostate, Malignant Neoplasm.  Thrombocytopenia rule out MDS.\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red255\green255\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, right posterior iliac crest,  biopsy; \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : \~\~\par      - Plasma cell neoplasm, see comment 1.\par           10% involvement by CD138 immunohistochemistry.\par           9% involvement by aspirate differential\par           1.9% involvement by flow cytometry\par      - Normocellular marrow with maturing trilineage hematopoiesis, mildly left-shifted myeloid and erythroid maturation, and no increase in blasts. See comment 3.  \par      - Minute abnormal B cell population with CLL-like immunophenotype detected by flow cytometry only (0.0095% of WBC). See comment 2. \par      - No morphologic or immunophenotypic evidence of involvement by metastatic carcinoma.\par\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENTS: \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1. Correlation with clinical findings including metabolic and CBC parameters, serum/ urine protein electrophoresis and immunofixation, and imaging studies is needed to further classify this plasma cell neoplasm.\par 2. A morphologic correlate of the minute abnormal B-cell population with a CLL-like immunophenotype is not seen and it is favored to represent CLL-like monoclonal B-cell lymphocytosis, however clinical correlation is needed to exclude the possibility of tissue involvement. \par 3. Mild thrombocytopenia is noted (137 K/cmL).  Mild atypia is present in the erythroid and megakaryocytic lineages (<10%), however diagnostic criteria for myelodysplastic syndrome are not fulfilled at this time based on the 2017 WHO and other etiologies such as medications, nutritional deficiencies, and autoimmune causes should be evaluated. However, prior peripheral blood molecular testing (M22-19199, 5/4/2022) revealed the presence of a TP53 mutation at low allele frequency (2.9%), which is consistent with at least clonal hematopoiesis. Correlation with results of the forthcoming molecular studies is recommended to evaluate for an expansion of this clone or presence of any additional mutations. Submission of a nail matched normal and obtaining a patient consent for a more comprehensive IMPACT heme matched analysis with future samples is recommended. Close clinical follow-up is advised given the high risk of progression to an overt myeloid neoplasm and the patient's history of radiation therapy for prostate cancer. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Marginally adequate, small, fragmented, and with intramedullary hemorrhage\par Cellularity: Variable, ranging from < 5% to approximately 30%, overall approximately normocellular (20%)\par M:E ratio: Normal\par Blasts: Not increased\par Myeloid lineage: Present with progressive maturation\par Erythroid lineage: Present with progressive maturation\par Megakaryocytes: Mildly decreased for the cellularity, with occasional forms showing nuclear hyperchromasia\par Lymphocytes: Few, scattered\par Plasma cells: Mildly increased, best appreciated by immunohistology (see below), with occasional Dutcher bodies \par Special stains:\par Reticulin stain shows focal mild increase in reticulin fibrosis (focal MF-1). \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Clot section: The clot section contains no marrow particles and is inadequate for evaluation. \plain\rtlch\af0\afs17\alang1033\ltrch\f0\fs17\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1  \plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate\par Numerous naked nuclei noted\par\par Blasts \tab\tab\tab 3%\par Promyelocytes \tab\tab 3%\par Myelocytes \tab\tab 12%\par Metamyelocytes \tab\tab 10%\par Neutrophils/Bands \tab 23%\par Monocytes \tab\tab 4%\par Eosinophils \tab\tab 3%\par Erythroid Precursors \tab 25%\par Plasma Cells \tab\tab 9% \par Lymphocytes \tab\tab 8%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 2.2\par\par Special stain\par Iron: Present\par Ring sideroblasts: Absent \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb4\chshdng0\chcfpat0\chcbpat4\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology\par Adequate, spicular and cellular aspirate smears with maturing trilineage hematopoiesis and no expanded blast population. The M:E ratio is normal. Myeloid elements show mildly left-shifted maturation no significant dysplasia. Erythroid cells are mildly left-shifted and show occasional (< 10%) megaloblastoid features, binucleation, and karyorrhexis. Megakaryocytes are seen with occasional (< 10%) small forms. Few small mature-appearing lymphocytes are seen. Few scattered plasma cells are seen, which show occasional atypia such as nuclear inclusions (Dutcher bodies) and binucleation.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (10/13/2022):\par WBC 6.0 [4.0-11.0 K/mcL] \par RBC 3.93 L [3.95-5.54 M/mcL] \par HGB 13.1 [12.5-16.2 g/dL] \par HCT 38.8 [37.5-49.3 %] \par MCV 99 H [80-98 fL] \par MCH 33.3 H [27.0-33.0 pg] \par MCHC 33.8 [31.0-36.5 g/dL] \par RDW 12.5 [12.2-15.1 %] \par Platelets 137 L [160-400 K/mcL] \par\par Neutrophil 45.2 [32.5-74.8 %] \par Mono 13.1 H [0.0-12.3 %] \par Eos 3.2 [0.0-4.9 %] \par Baso 0.8 [0.0-1.5 %] \par Immature Granulocyte 0.2 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 37.5 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 2.7 [1.5-7.5 K/mcL] \par Abs Mono 0.8 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 2.2 [0.9-3.2 K/mcL] \par\par Morphology:\line WBC: Relative monocytosis and occasional (< 10%) hypersegmented neutrophils. No circulating blasts seen.\par RBC: Normocytic, normochromic RBCs.\par PLT: Mild thrombocytopenia. \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080 CD34 and CD117 show no increase in blasts (<5%).\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 CD117 also highlights early myeloid and erythroid cells, as well as shows bright expression in rare scattered mast cells.\par MPO highlights myeloid cells, and CD71 highlights erythroid cells, with an overall normal M:E ratio.\par CD61 is positive in megakaryocytes, which are mildly decreased for the cellularity.\par OSCAR (pan-cytokeratin stain) is negative \par CD138 immunostain highlights increased plasma cells, scattered singly and in small clusters, overall accounting for ~10% of cellularity.\par Kappa and lambda immunostains show the plasma cells are lambda light chain restricted.\par BCMA highlights 95% of plasma cells, (2-3) intensity, membranous/ Golgi/ cytoplasmic pattern. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-11199)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par 1. Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par\par Abnormal plasma cell population comprises 95.6% of total plasma cells.\par Abnormal plasma cell population represents 2.1% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (negative), CD27 (variable - negative to dim), CD45 (bimodal - negative, intermediate), CD81 (bimodal - major subset negative, minor subset intermediate), CD117 (partial dim), cytoplasmic Lambda (restriction)\par Normal: CD138, CD38, CD229, CD319\par Negative: CD56, cytoplasmic Kappa\par\par Number of cells acquired: 436 thousand \par\par 2. Minute abnormal B cell population detected. \par Flow cytometry reveals a minute abnormal B cell population with CLL/SLL-like immunophenotype (see below).\par\par Abnormal B cell population represents 0.0095% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD20 (dim), CD23 (positive), CD43 (positive), CD79b (negative), CD81 (dim), CD200 (bright), ROR1 (positive)\par Normal: CD19, CD40, CD45\par Negative: CD38, CD10, CD3\par\par Number of cells acquired 401 thousand \par\par 3. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par\par Myeloid blast population with an unremarkable phenotype represents 0.78% of WBC.\par\par Number of cells acquired: 583 thousand \par\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-7718.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate reports, M22-43722 & M22-43722\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-741;S10;MSK- - 2023-05-31 21.33.03.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Lymphoma, Follicular
Requested Studies: Gross/Micro
Clinical Hx/Op Findings: FL, c/f POD
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Extensive involvement by the patient's previously diagnosed follicular lymphoma (~90% with CD20 immunohistochemistry).
     - Hypercellular marrow with focal maturing trilineage hematopoiesis. See comment.

COMMENT:
There is no definitive morphologic evidence of involvement by metastatic carcinoma; however, additional immunostains (pancytokeratin and Cam5.2) have been requested, and the findings will be reported in an addendum.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
An adequate biopsy specimen and cellular touch preparations show hypercellular bone marrow (~95% cellularity). The marrow is largely replaced by small to medium sized atypical lymphocytes that have mildly irregular nuclear contours and mature chromatin. A few vaguely nodular areas contain scattered large lymphocytes, but sheets of large lymphocytes are not seen. There are scattered foci of trilineage hematopoiesis, which show progressive maturation of the myeloid and erythroid lineages as well as scattered morphologically unremarkable megakaryocytes.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 and Pax-5 highlight the atypical lymphocytes (~90% of the cellularity).
CD3 marks scattered background T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW CORE TISSUE (F22-931) 
1. Abnormal B cell population detected.

Abnormal B cell population represents 88.0% of WBC.

Immunophenotype:
Abnormal: CD10 (partial), CD19 (dim), CD20 (dim), surface Lambda (restriction), Forward Scatter (partially increased), Side Scatter (partially increased)
Normal: CD22, CD45
Negative: CD5, CD38, CD25, CD279 (PD1), CD3, CD14, surface Kappa


2. No abnormal mature T cell population detected.
No immunophenotypic evidence of T-cell lymphoma is identified.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-898) 
Abnormal B cell population detected.

Abnormal B cell population represents 21.9% of WBC.

Immunophenotype:
Abnormal: CD10 (partial - dim), CD19 (dim), CD22 (variable - dim to intermediate), surface Lambda (restriction)
Normal: CD20, CD45
Negative: CD5, CD38, CD25, CD279 (PD1), CD3, CD14, surface Kappa

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (01/26/2022):
WBC 3.1 L [4.0-11.0 K/mcL] 
RBC 3.35 L [3.80-5.00 M/mcL] 
HGB 9.7 L [11.2-15.4 g/dL] 
HCT 30.3 L [34.3-46.0 %] 
MCV 90 [80-98 fL] 
MCH 29.0 [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 17.3 H [12.2-15.1 %] 
Platelets 16 L [160-400 K/mcL] 

Neutrophil 28.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 53.0 H [12.2-47.4 %] 
Abnormal Lymphoid Cells 17.0 H [0.0-0.0 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 2.1 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Leukopenia. Occasional atypical lymphocytes are seen, some of which are relatively large.
RBC: Normochromic anemia with anisocytosis.
Platelets: Thrombocytopenia

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis not requested.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-3652.

"
H22-10033;S17;MSKB - 2023-06-15 15.27.45.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: mantle cell lymphoma\par Clinical Hx/Op Findings: recent POD via stomach biopsy\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\par        - Involvement by Mantle cell lymphoma (<5% with CD20/ Cyclin D1 immunohistochemistry).\par        - Low level involvement by CLL/SLL like population (0.084% of WBC) by flow cytometry only.\par        - Hypercellular marrow with trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy, clot and aspirate specimens show mildly hypercellular bone marrow (~30-40%cellularity). There is\~trilineage maturing hematopoiesis with scattered atypical lymphoid aggregates composed of small atypical lymphocytes (predominantly in the clot section). Rare small hypolobated megakaryocytes are noted. Mild eosinophilia is noted.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Immunostains are performed on blocks 1-1 and 1-2 show \par The atypical B cells are positive for CD20, PAX5, CD5 and, CyclinD1 (<5% of cellularity), mostly in aggregates.\par CD3 highlights T-cells, 5% of cellularity.\par CD23 stains rare cells.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-13045)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par 1. Abnormal B cell population detected.\par The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)\par\par Abnormal B cell population represents 3.2% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD43 (positive), CD81 (dim), ROR1 (positive), CD19 (dim)\par Normal: CD20, CD79b, CD40, CD45, CD38\par Negative: CD23, CD200, CD10, CD3\par\par 2. Abnormal B cell population detected.\par The findings are consistent with previously diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)\par\par Abnormal B cell population represents 0.084% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD20 (dim), CD23 (positive), CD43 (positive), CD79b (negative), CD81 (variable - negative to dim), CD200 (bright), ROR1 (positive)\par Normal: CD19, CD40, CD45\par Negative: CD38, CD10, CD3\par\par Number of cells acquired 291 thousand\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/30/2022):\par\par WBC 5.2 [4.0-11.0 K/mcL] \par RBC 4.41 [3.95-5.54 M/mcL] \par HGB 11.5 L [12.5-16.2 g/dL] \par HCT 36.5 L [37.5-49.3 %] \par MCV 83 [80-98 fL] \par MCH 26.1 L [27.0-33.0 pg] \par MCHC 31.5 [31.0-36.5 g/dL] \par RDW 14.3 [12.2-15.1 %] \par Platelets 155 L [160-400 K/mcL] \par\par Neutrophil 70.9 [32.5-74.8 %] \par Mono 9.2 [0.0-12.3 %] \par Eos 6.6 H [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Immature Granulocyte 0.2 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 12.1 L [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 3.7 [1.5-7.5 K/mcL] \par Abs Mono 0.5 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL]\par Abs Lymph 0.6 L [0.9-3.2 K/mcL] \par\par Morphology:\par WBC: Lymphopenia\par RBC: Mild anisocytosis\par Platelets: Unremarkable\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8999, CG22-9000.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-2829;S10;MSK9 - 2023-05-31 21.56.13.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Burkitt lymphoma
Clinical Hx/Op Findings: Assess Burkitt lymphoma
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Cellular marrow with erythroid predominant trilineage maturing hematopoiesis.
     - No morphologic or immunophenotypic evidence of involvement by lymphoma. See comment.

Comment: Immunohistochemistry for CD20 is essentially negative. PAX5 highlights relatively numerous small cells scattered in the interstitium, accounting for ~10% of cellularity. Correlation with the flow cytometric analysis results suggest that these represents hematogones.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show mildly hypocellular bone marrow for age (30-35% cellularity). There istrilineage maturing hematopoiesis. Lymphocytes do not appear increased in number. Myeloid lineage is relatively decreased and shows left-shifted maturation. Erythroid lineage shows complete maturation. Megakaryocytes display overall normal morphology with occasional small forms. Peripheral blood smears show presence of scattered small immature cells morphologically consistent with hematogones.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 is essentially negative. PAX5 highlights scattered small cells in the interstitium accounting for 5-10% of total cellularity. CD3 highlights scattered T cells, accounting for ~5% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-3693) 
No abnormal mature B-cell population detected. Virtually no mature B cells seen.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

Number of cells acquired: 325 thousand 

Also see F22-3681 submitted on the same day.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS,      PERIPHERAL BLOOD (F22-3681) 
No abnormal mature B- or T-cell populations detected. Virtually no B cells seen.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

Number of cells acquired: 433 thousand 

Also see F22-3693 submitted on the same day.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (04/06/2022):
WBC 4.6 [4.0-11.0 K/mcL] 
RBC 3.97 [3.95-5.54 M/mcL] 
HGB 11.8 L [12.5-16.2 g/dL] 
HCT 37.0 L [37.5-49.3 %] 
MCV 93 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 15.5 H [12.2-15.1 %] 
Platelets 218 [160-400 K/mcL] 

Neutrophil 21.0 L [32.5-74.8 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 65.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 3.0 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: No atypical lymphocytes seen.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Not requested. 

MOLECULAR STUDIES 
Not requested.  
"
H22-76;S10;MSK1 - 2023-05-31 19.53.45.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Lymphoma, Multiple Myeloma
Clinical Hx/Op Findings: hx of MCL, pre-treatment, in screening for 18-427
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Morphologic findings consistent with involvement by the patient's previously diagnosed mantle cell lymphoma (50% by CD20 immunohistochemistry)
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show hypercellular bone marrow (50 %cellularity). There istrilineage maturing hematopoiesis with increased numbers of lymphocytes scattered in the interstitium and forming occasional small aggregates.

The bone marrow aspirate smear are spicular and cellular. In the background of maturing trilineage hematopoiesis there is an increased number of medium-sized atypical lymphoid elements, with round to slightly irregular nuclei, variably condensed chromatin, occasionally prominent nucleoli and scant cytoplasm.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight increased number of B-cells, accounting for approximately 50% of total cellularity. CD3 is positive in scattered T-cells in the background.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-97) 
1. Abnormal B cell population detected. 
The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)

Abnormal B cell population represents 50.6% of WBC.
Immunophenotype:
Abnormal: CD5 (variable - dim to intermediate), CD23 (variable - negative to intermediate), CD43 (partial), ROR1 (positive), CD19 (dim), CD40 (dim)
Normal: CD20, CD79b, CD81, CD200, CD45, CD38
Negative: CD10, CD3

Number of cells acquired: 535 thousand  

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-85) 
1. Abnormal B cell population detected. 
The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)

Abnormal B cell population represents 39.8% of WBC.
Immunophenotype:
Abnormal: CD5 (variable - negative to intermediate), CD23 (variable - dim to intermediate), CD43 (partial), ROR1 (positive), CD19 (dim), CD40 (dim)
Normal: CD20, CD79b, CD81, CD200, CD45
Negative: CD38, CD10, CD3

Number of cells acquired: 859 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (01/04/2022):
WBC 18.0 H [4.0-11.0 K/mcL] 
RBC 4.59 [3.80-5.00 M/mcL] 
HGB 12.5 [11.2-15.4 g/dL] 
HCT 38.8 [34.3-46.0 %] 
MCV 85 [80-98 fL] 
MCH 27.2 [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 14.6 [12.2-15.1 %] 
Platelets 138 L [160-400 K/mcL] 

Neutrophil 17.0 L [32.5-74.8 %] 
Mono 6.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 76.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 3.1 [1.5-7.5 K/mcL] 
Abs Mono 1.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 13.6 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: Numerous medium-sized atypical lymphocytes with round to slightly irregular nuclei, variably condensed chromatin, occasionally prominent nucleoli and scant cytoplasm are present.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-50, CG22-51.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-462.
"
H22-7755;S14;MSK6 - 2023-04-14 15.32.37.ndpi,Peripheral Blood Smear,2023-04-14,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: myeloproliferative neoplasm\par Clinical Hx/Op Findings: Suspected PV/MPN, newly diagnosed\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, right posterior iliac crest,  biopsy; \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : \~\~\par      - Markedly hypercellular marrow with trilineage maturing hematopoiesis, megakaryocytic hyperplasia with atypia and dysplasia, monocytosis and 6% blasts by aspirate differential. See comment. \par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The patient's initial presentation of microcytic erythrocytosis (Hgb: 18.5g/dL; MCV: 71fL, 8/26/2022) with suboptimal EPO level (<1.0IU/L) and normal iron study; thrombocytopenia, and monocytosis is noted. NGS analysis on prior blood sample (M22-35206) identified multiple mutations including \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i TET2, RUNX1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  and \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i SH2B3\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 ; without any \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i JAK2\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  (V617F or exon12) mutations. Corresponding cytogenetic studies show normal karyotype with no evidence of \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i BCR-ABL1\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  fusion. The overall findings are consistent with a myeloid neoplasm; however further classification is challenging.  Marked erythrocytosis with low EPO and monocytosis raise the possibility of PV with monocytosis; however, concurrent initial presentation of monocytosis and morphologic dysplasia without a prior history of PV or \plain\rtlch\af0\afs18\alang1033\ai\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\i JAK2\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  mutation do not support it. Chronic myelomonocytic leukemia (CMML) is also a diagnostic consideration given the presentation of monocytosis and mutational profile; however, concurrent erythrocytosis with low EPO would be highly unusual. Therefore, the overall findings are most compatible with a myelodysplastic/myeloproliferative neoplasm, NOS (MDS/MPN-NOS). Correlation with clinical findings and molecular studies, including ARCHER analysis for any fusion-driven process, are suggested. MATCHED IMPACT-HEME analysis may be of help for further characterization as well. \plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Small subcortical biopsy \par Cellularity: Markedly hypercellular (>90%)\par M:E ratio: Mildly decreased \par Blasts: Mildly increased \par Myeloid lineage: Shows full maturation \par Erythroid lineage: Shows full maturation \par Megakaryocytes: Increased and show atypia and dysplasia (small hypolobated or widely-separated nuclei)\par Lymphocytes: Scattered \par Plasma cells: Scattered\par\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate \par Blasts \tab\tab\tab 6%\par Promyelocytes \tab\tab 3%\par Myelocytes \tab\tab 13%\par Metamyelocytes \tab\tab 9%\par Neutrophils/Bands \tab 22%\par Monocytes \tab\tab 10%\par Erythroid Precursors \tab 33%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 3%\par Number of Cells Counted  500\par M:E Ratio \tab\tab 1.7\par\par Morphology:\par Spicular and cellular aspirate smears show maturing trilineage hematopoiesis with mild increase in blasts. Myeloid elements show full maturation with mild dyspoiesis (hyposegmented and hypogranular forms). Monocytosis is seen. Erythroid elements show full maturation with mild dyspoiesis (nuclear-cytoplasmic dyssnychrony and karyorrhexis). Megakaryocytes are present and show hypolobated forms. \plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (09/19/2022):\par WBC 10.6 [4.0-11.0 K/mcL] \par RBC 7.93 H [3.95-5.54 M/mcL] \par HGB 16.1 [12.5-16.2 g/dL] \par HCT 56.2 H [37.5-49.3 %] \par MCV 71 L [80-98 fL] \par MCH 20.3 L [27.0-33.0 pg] \par MCHC 28.6 L [31.0-36.5 g/dL] \par RDW 20.7 H [12.2-15.1 %] \par Platelets 76 L [160-400 K/mcL] \par\par Neutrophil 59.0 [32.5-74.8 %] \par Mono 19.0 H [0.0-12.3 %] \par Eos 2.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Myelocyte 1.0 H [0.0-0.0 %] \par Metamyelocyte 1.0 H [0.0-0.0 %] \par Lymph 18.0 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 6.2 [1.5-7.5 K/mcL] \par Abs Mono 2.0 H [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] \par Abs Meta 0.1 H [0.0-0.0 K/mcL] \par Abs Lymph 1.9 [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] \par\par Morphology:\par WBC: No circulating blasts; few hyposegmented neutrophils; relative and absolute monocytosis; large granular lymphocytes present \par RBC: Anisocytosis and polychromasia \par PLT: Some large and hypogranular forms \par\plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 highlight scattered blasts (~3-5% of cellularity).\par CD117 also highlights myeloid and erythroid precursors.\par CD61 highlights increased megakaryocytes including dysplastic forms. \par MPO highlights myeloid elements. \par CD71 highlights mildly increased erythroid elements. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10138)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Abnormal myeloid blast population detected. The immunophenotype of this population is similar to that seen in prior sample [case F22-8975] \par\par Abnormal myeloid blast population represents 1.4% of WBC.\par Expanded immature monocyte population is seen, represents 4.1% of WBC.\par Total myeloid blast/blast equivalents represent 5.5% of WBC.\par Monocytosis is seen, 11.9% of WBC.\par\par Immunophenotype:\par Abnormal: CD7 (partial), CD11b (positive), CD25 (partial), CD45RA (bimodal - negative to dim), CD117 (uniform - bright), HLA-DR (uniform - bright)\par Normal: CD4, CD13, CD33, CD34, CD36, CD38, CD45, CD71, CD123, CD371 (clec12a)\par Negative: CD2, CD5, CD10, CD14, CD15, CD16, CD19, CD56, CD64, CD105, CD42b, CD90\par\par Number of cells acquired: 889 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-6951. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-39751, M22-39752. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-7475;S21;MSK3 - 2023-06-15 14.46.41.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\fswiss\fcharset0\fprq2{\*\panose 020F0502020204030204}Calibri;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\sa160\sl259\slmult1\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon0 Arial;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s17\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Clinical Diagnosis: Lymphoma, Diffuse Large Cell\par Clinical Hx/Op Findings: \plain\rtlch\af0\afs24\alang1033\ltrch\f0\fs24\lang1033\langnp1033\langfe1033\langfenp1033 N\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 ewly diagnosed DLBCL, workup\par Requested Studies: Gross/Micro\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par }","{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\fswiss\fcharset0\fprq2{\*\panose 020F0502020204030204}Calibri;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\sa160\sl259\slmult1\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon0 Arial;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\sa160\sl259\slmult1\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-4. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: \~\~\par      - Extensive involvement by previously diagnosed large B-cell lymphoma, see comment. \par      - Hypercellular marrow with residual trilineage hematopoiesis.\par\par COMMENT: The patient's recently diagnosed DLBCL, non-GCB is noted. Current biopsy shows involvement by large B-cell lymphoma with similar immunophenotype (BCL6+/MUM1+) and T-cell/histiocyte-rich background to those seen in the prior diagnostic biopsy (H22-7198). The overall findings support the invovlement by the same neoplastic process.\par This case was also reviewed by Dr. Natasha Lewis, Hematopathology Service.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy shows hypercellular bone marrow (>90% cellularity) with marrow spaces nearly replaced by a diffuse lymphohistiocytic infiltrate with extensive crush artifact. The atypical infiltrate is composed predominantly of small lymphoid cells, frequent histiocytes admixed with few large atypical cells with nuclear irregularity and abundant cytoplasm, some with prominent nuclei. No increased eosinophils are seen. Trilineage maturing hematopoiesis is markedly reduced to absent. Blasts are not increased. Touch imprints show similar morphology to the core biopsy. \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The large atypical cells are highlighted by CD20, PAX5, BCL6, MUM1 and are negative for CD3, CD5, CD10, CD15, CD30, c-MYC and EMA.\par CD3 and CD5 highlight background numerous T-cells.\par Ki-67 highlights mostly the large atypical cells.\par BCl2 appears to be positive in a small subset of T-cells. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9778)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par 1. Minute suspicious B cell population detected.\par\par There is no definite immunophenotypic evidence of abnormal B cell population identified. However, there is a minute B cell population with mild abnormalities seen (see below). Light chains cannot be confidently established. The clinical significance of this population is not entirely clear. Correlation with additional studies (morphologic, cytogenetic, and molecular) is advised.\par\par Suspicious B cell population represents 0.33% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD19 (dim), CD22 (dim), CD38 (intermediate), no definite light chain expression\par Normal: CD20, CD45, CD40\par Negative: CD10, CD25, CD79b, CD279 (PD1), CD3, CD14\par\par\par 2. No abnormal mature T cell population detected. \par No immunophenotypic evidence of T-cell lymphoma is identified.  \par\par Number of cells acquired: 40 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (09/09/2022):\par WBC 2.1 L [4.0-11.0 K/mcL] \par RBC 2.74 L [3.95-5.54 M/mcL] \par HGB 7.4 L [12.5-16.2 g/dL] \par HCT 23.7 L [37.5-49.3 %] \par MCV 87 [80-98 fL] \par MCH 27.0 [27.0-33.0 pg] \par MCHC 31.2 [31.0-36.5 g/dL] \par RDW 17.7 H [12.2-15.1 %] \par Platelets 90 L [160-400 K/mcL] \par\par Neutrophil 47.6 [32.5-74.8 %] \par Mono 13.3 H [0.0-12.3 %] \par Eos 0.5 [0.0-4.9 %] \par Baso 0.5 [0.0-1.5 %] \par Immature Granulocyte 0.5 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 37.6 [12.2-47.4 %] \par Nucleated RBC 1.4 H [0.0-0.0 %] \par\par Abs Neut 1.0 L [1.5-7.5 K/mcL] \par Abs Mono 0.3 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature\plain\rtlch\af1\afs22\alang1033\ltrch\f1\fs22\lang1033\langnp1033\langfe1033\langfenp1033  \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 0.8 L [0.9-3.2 K/mcL] \par\par Morphology:\par WBC: No circulating blasts or atypical lymphoid cells\par RBC: Anisocytosis \par PLT: Few large and giant forms\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs22\alang1033\ltrch\f1\fs22\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Not requested \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately.\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par }"
H22-1038;S11;MSK1 - 2023-05-26 16.17.56.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Leukemia
Clinical Hx/Op Findings: New Dx
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     -  B-lymphoblastic leukemia/lymphoma, 82% blast by aspirate differential count, see comment.
  
COMMENT: Cases of B-ALL developing after cytotoxic therapy for a prior malignancy are reported (PMID: 31869410). Please correlate with the results of corresponding cytogenetic and molecular analysis. 
CD19, PAX5, TdT and pan-cytokeratin immunohistochemistry are in progress, and the results will be reported as an addendum.  

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: 80-90%
M:E ratio: N/A 
Blasts: Markedly increased, replacing marrow spaces. 
Myeloid lineage: Rare
Erythroid lineage: Present, decreased. 
Megakaryocytes: Few present 
Lymphocytes: Rare 
Plasma cells: Rare
Reticulin stain shows no increase in reticulin fibrosis. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate 
Blasts 82%
Promyelocytes 1%
Neutrophils/Bands 3%
Monocytes 1%
Erythroid Precursors 10%
Plasma Cells 2%
Lymphocytes 1%
Number of Cells Counted 500
M:E Ratio 0.5

Morphology:
Spicular and cellular aspirate smears show an expanded population of intermediate sized cells with scant amphophilic cytoplasm, bearing coarse vacuoles, with round to oval nuclei, fine chromatin and distinct nucleoli, accounting for 82% of cells. Background hematopoietic elements are limited. Myeloid and erythroid elements show maturation without significant dysplasia. Megakaryocytes are present and display unremarkable morphology.

PERIPHERAL BLOOD
CBC (2/4/2022):
WBC 2.9 L [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 2.72 L [3.95-5.54 M/mcL] 
HGB 8.1 L [12.5-16.2 g/dL] 
HCT 24.4 L [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 29.8 [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 24.4 H [12.2-15.1 %] 
Platelets. 24 L [160-400 K/mcL] 

Neutrophil 29.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 19.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 47.0 [12.2-47.4 %] 
Nucleated RBC 16.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 0.8 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.5 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL]

Morphology:
RBC: Anisopoikilocytosis. Increased nucleated RBC present. Normochromic, normocytic anemia.
WBC: Increased circulating blasts. Neutropenia.
PLT: Thrombocytopenia.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
Blasts are negative for CD34 and CD117 (<1% of cells are highlighted with CD34 and CD117).
CD19, PAX5, TdT and pan-cytokeratin are in progress, and the results will be reported as an addendum.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1317)
Interpretation: 
1. Abnormal immature B cell population detected.                      
Abnormal immature B cell population represents 57.7% of the mononuclear cells.
Abnormal immature B cell population represents 57.7% of WBC.

Immunophenotype:
Abnormal: CD20 (partial), CD34 (negative), CD38 (dim), CD81 (dim), CD73/CD304 (uniform - intermediate), CD66c/CD123 (positive)
Normal: CD10, CD19, CD22, CD24, CD45
Negative: CD86, CD66b

Number of cells acquired 540 thousand 

2. No abnormal myeloid blast, mature B or mature T cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.
Myeloid blast population with an unremarkable phenotype represents 0.97% of WBC.

Number of cells acquired: 676 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-837.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-5351, M22-5352, M22-5353, M22-5354.
"
H22-9925;S17;MSK0 - 2023-06-15 19.00.17.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Lymphoma\par Clinical Hx/Op Findings: fevers/ pancytopneia\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, left posterior iliac crest, biopsy; \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : \~\~\par      - Extensive involvement by previously diagnosed Angioimmunoblastic T-cell lymphoma (~50% by PD1 stain) and associated EBV positive Large B cell proliferation, see comment.  \par   \par COMMENT: The biopsy shows EBV positive Large B cell proliferation, which can be seen in cases of Angioimmunoblastic T-cell lymphoma. However, in focal areas this proliferation morphologically fulfils criteria for EBV positive Diffuse large B cell lymhpoma.\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The case was also reviewed by Dr. Ahmet Dogan (Hematopathology Service) who agrees with the diagnosis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy and aspirate specimens show hypercellular bone marrow (variably cellular; <5 to 90%, overall 70% cellularity). There are numerous large lymphohistiocytic aggregatescontaining predominantly intermediate sized lymphoid cells with admixed large cells with prominent nucleoli and histiocytes. Few foci of  background trilineage hematopoiesis are noted.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate\par\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 2%\par Myelocytes \tab\tab 6%\par Metamyelocytes \tab\tab 2%\par Neutrophils/Bands \tab 16%\par Monocytes \tab\tab 2%\par Eosinophils \tab\tab 6%\par Erythroid Precursors \tab 34%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 30%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 1\par\par Special stain\par Iron: Suboptimal for evaluation\par Ring sideroblasts: Suboptimal for evaluation\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/25/2022)):\par WBC 1.9 L [4.0-11.0 K/mcL] \par RBC 2.72 L [3.95-5.54 M/mcL] \par HGB 7.2 L [12.5-16.2 g/dL] \par HCT 23.4 L [37.5-49.3 %] \par MCV 86 [80-98 fL] \par MCH 26.5 L [27.0-33.0 pg] \par MCHC 30.8 L [31.0-36.5 g/dL] \par RDW 17.4 H [12.2-15.1 %] \par Platelets. 27 L [160-400 K/mcL] \par\par Neutrophil 75.0 H [32.5-74.8 %] \par Mono 8.0 [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Lymph 15.0 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 1.4 L [1.5-7.5 K/mcL] \par Abs Mono 0.2 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Lymph 0.3 L [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]\par\par Morphology: Pancytopenia\par\plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The atypical T cell proliferation\par Express: CD3, CD4, CD7 (partial), PD1\par Do not express: CD8\par\par The atypical B cell proliferation\par Express: CD20, PAX5, CD30, MUM1, EBER ISH, EBV/LMP1\par Do not express: CD15\par\par CD34 stains scattered blasts, <5%\par CD61 stains the megakaryocytes\par CD71 and MPO stain the erythroid and myeloid lineages.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-12904)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal T cell population detected.\par The immunophenotype of the abnormal T cell population is similar to that identified previously, and is consistent with previous case [F22-12590].\par Abnormal T cell population represents 18.8% of WBC.\par\par Immunophenotype:\par Abnormal: CD3 (dim), CD4 (dim), CD5 (bright), CD7 (variable - negative to intermediate), CD279 (PD1) (uniform - intermediate), TCRCbeta1 (restriction - monotypic positive)\par Normal: CD2, CD26, CD38, CD45\par Negative: CD8, CD10, CD14, CD25, CD56, TCR gamma/delta\par\par Number of cells acquired 246 thousand\par\par 2. No abnormal mature B cell population detected.\par No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8882.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report.\par\plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-8699;S13;MSKC - 2023-06-15 13.13.26.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Multiple Myeloma\par Clinical Hx/Op Findings: MM\par Requested Studies: Gross/Micro\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par      - Plasma cell neoplasm, \~\par\~\~\~\~\~\~\~\~\~\~Approximately 10-15% involvement by CD138 immunohistochemistry overall with a patchy distribution. See comment.\par\~\~\~\~\~\~\~\~\~\~2% involvement by aspirate differential\par\~\~\~\~\~\~\~\~\~\~0.92% involvement by flow cytometry\par      - Minute abnormal B cell population with a chronic lymphocytic leukemia/small lymphocytic lymphoma-like phenotype detected by flow cytometry only (0.0086% of WBC), favor monoclonal B cell lymphocytosis.\par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : The plasma cells show a patchy distribution by CD138 immunohistochemistry, comprising <5% of the marrow cellularity in the majority of the core biopsy with a focal area containing increased plasma cells with aggregate formation, comprising ~50-60% of the cellularity in that area.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate  \par Cellularity: 30-40%\par Myeloid lineage: Orderly maturation    \par Erythroid lineage: Orderly maturation  \par Megakaryocytes: Adequate  \par Plasma cells: Patchy distribution (see immunohistochemistry section below)\par\par Special stain: Congo Red stain is negative for amyloid deposition \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate\par\par Blasts \tab\tab\tab 2%\par Promyelocytes \tab\tab 2% \par Myelocytes \tab\tab 15% \par Metamyelocytes \tab\tab 9%\par Neutrophils/Bands \tab 37% \par Monocytes \tab\tab 2% \par Eosinophils \tab\tab 2%\par Erythroid Precursors \tab 19% \par Plasma Cells \tab\tab 2%\par Lymphocytes \tab\tab 11%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 3.5\par\par Morphology: \par Marrow spicules: Spicular \par Cellularity: Cellular\par Plasma cell morphology: Intermediate to large with nucleolated and bi/multinucleated forms and occasional Dutcher bodies\par Myeloid lineage: Orderly maturation  \par Erythroid Lineage: Orderly maturation \par Megakaryocytes: Present\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD138 immunostain highlights plasma cells in a patchy distribution, overall approximately 10-15%. The majority of the core shows singly scattered and small clusters of plasma cells (comprising <5% of the cellularity) while a focal area shows increased plasma cells with aggregates (comprising ~50-60% of the cellularity in that area).\par Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.\par BCMA highlights 90% of plasma cells, (2-3+) intensity, membranous/ Golgi pattern. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW F22-11345\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par 1. Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par\par Abnormal plasma cell population comprises 97.2% of total plasma cells.\par Abnormal plasma cell population represents 0.92% of WBC.\par\par Immunophenotype:\par Abnormal: CD38 (dim, consistent with anti-CD38 therapy), CD19 (negative), CD27 (negative), CD45 (negative), CD81 (negative), cytoplasmic Kappa (restriction)\par Normal: CD138, CD229, CD319\par Negative: CD56, CD117, cytoplasmic Lambda\par\par Number of cells acquired: 5.7 million \par\par 2. Minute abnormal B cell population detected. \par Flow cytometry reveals an abnormal B cell population with CLL/SLL-like immunophenotype (see below).\par\par Abnormal B cell population represents 0.0086% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (positive), CD43 (positive), CD79b (dim), CD81 (dim), CD200 (bright), ROR1 (positive), surface Lambda (restriction - dim)\par Normal: CD19, CD40, CD45\par Negative: CD38, CD10, CD3, surface Kappa, CD25, CD14, CD279 (PD1)\par\par Number of cells acquired 443 thousand \par\par 3. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par\par Myeloid blast population with an unremarkable phenotype represents 0.59% of WBC.\par\par Number of cells acquired: 853 thousand \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (10/18/2022):\par WBC 4.2 [4.0-11.0 K/mcL] \par RBC 2.89 L [3.95-5.54 M/mcL] \par HGB 9.7 L [12.5-16.2 g/dL] \par HCT 29.2 L [37.5-49.3 %] \par MCV 101 H [80-98 fL] \par MCH 33.6 H [27.0-33.0 pg] \par MCHC 33.2 [31.0-36.5 g/dL] \par RDW 19.1 H [12.2-15.1 %] \par Platelets 168 [160-400 K/mcL] \par\par Neutrophil 66.0 [32.5-74.8 %] \par Mono 4.1 [0.0-12.3 %] \par Eos 1.2 [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Immature Granulocyte 0.5 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 27.2 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 2.8 [1.5-7.5 K/mcL] \par Abs Mono 0.2 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature 0.0 [0.0-0.1 K/mcL] \par Granulocyte\par Abs Lymph 1.1 [0.9-3.2 K/mcL] \par\par Morphology: \par WBC: No circulating plasma cells seen on scanning.\par RBC: Anemia with anisopoikilocytosis.\par Platelets: Adequate with occasional large platelets.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-7808, CG22-7810.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-44531.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-8955;S17;MSKB - 2023-06-15 13.07.37.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Lymphoma, Diffuse Large Cell\par Clinical Hx/Op Findings: hlh?\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\fswiss\fcharset0\fprq2{\*\panose 020B0502040204020203}Segoe UI;}
{\f3\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\par      - No diagnostic morphologic or immunophenotypic evidence of involvement by previously diagnosed B-cell lymphoma. \par      - Hypocellular marrow with maturing trilineage hematopoiesis and myeloid hypoplasia with left-shifted maturation. See comment.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  Clinical concern for hemophagocytic lymphohistiocytosis (HLH) is noted. Hemophagocytosis is not prominent on the aspirate smears. Correlation with clinical and laboratory studies is needed to further evaluate for the possibility of HLH. \par\tab Of note, the patient's prior molecular studies revealed presence of a low allele frequency TET2 alteration (M22-7478). Morphologic findings are not diagnostic of an overt myeloid neoplasm at this time. However in light of the persistent cytopenias and mutated TET2, the features represent at least clonal cytopenia of undetermined significance (CCUS). Correlation with results of molecular studies is recommended to assess for clone expansion/ or evolution and close clinical follow-up is advised.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy and aspirate specimens show variably cellular, ranging 10-50%, overall hypocellular for age bone marrow (30% cellularity). There is maturing trilineage hematopoiesis and the M:E ratio appears decreased due to myeloid hypoplasia. Blasts are not overtly increased. Myeloid cells are relatively decreased with left-shifted maturation, and erythroid elements appear relatively increased and present in various stages of maturation. Megakaryocytes are adequate in number for the cellularity without overt atypia. Rare scattered, small, loose lymphoid aggregates are seen, favor reactive (see immunohistology below). On the aspirate smears, myeloid cells show left-shifted maturation and no significant dysplasia, while erythroid cells are present in various stages of maturation and show occasional (< 10%) karyorrhexis. Few scattered mast cells are noted. Hemophagocytic histiocytes are not prominent on the aspirate smears.\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080 The clot section contains no marrow particles and is inadequate for evaluation. \par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\~\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD3 highlights many T-cells, which are scattered and in small lymphoid aggregates.\par PAX5 highlights rare scattered B-lineage cells.\par CD20 is negative.\par Additional immunohistology to evaluate the mast cells will be reported in an addendum.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-11652)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par\par 1. No abnormal mature B cell population detected.\par No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.\par\par Number of cells acquired: 240 thousand \par\par 2. No large granular lymphocyte population detected.\par\par Number of cells acquired 253 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (10/25/2022)\par WBC 2.2 L [4.0-11.0 K/mcL] \par RBC 3.89 L [3.95-5.54 M/mcL] \par HGB 13.5 [12.5-16.2 g/dL] \par HCT 39.4 [37.5-49.3 %] \par MCV 101 H [80-98 fL] \par MCH 34.7 H [27.0-33.0 pg] \par MCHC 34.3 [31.0-36.5 g/dL] \par RDW 13.8 [12.2-15.1 %] \par Platelets. 106 L [160-400 K/mcL] \par\par Neutrophil 57.0 [32.5-74.8 %] \par Mono 15.0 H [0.0-12.3 %] \par Eos 2.0 [0.0-4.9 %] \par Baso 2.0 H [0.0-1.5 %] \par Lymph 23.0 [12.2-47.4 %] \par Variant Lymph 1.0 [0.0-2.0 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 1.3 L [1.5-7.5 K/mcL] \par Abs Mono 0.3 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Lymph 0.5 L [0.9-3.2 K/mcL]\par\par Morphology:\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 WBC: No circulating blasts seen. Leukopenia with absolute neutropenia, lymphopenia, and relative monocytosis.\par RBC: Macrocytic RBCs.\par Platelets: Thrombocytopenia, mild\plain\rtlch\af2\afs24\alang0\ltrch\f2\fs24\lang0\langnp0\langfe0\langfenp0\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Not submitted.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800 Molecular analysis will be reported separately. See separate reports, M22-45586 and M22-45587.\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-5729;S13;MSK4 - 2023-04-14 16.07.09.ndpi,Peripheral Blood Smear,2023-04-14,"Clinical Diagnosis: Mult Myeloma
Clinical Hx/Op Findings: day 100 post allo
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
70% involvement by CD138 immunohistochemistry.
24% involvement by aspirate differential
5.9% involvement by flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality:  Adequate 
Cellularity: Overall 60-70%
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation  
Megakaryocytes:  Adequate  
Plasma cells: Increased 

Special stain: Congo Red stain is negative for amyloid deposition. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality:  Adequate 
Blasts                1%
Myelocytes           9%
Metamyelocytes           6%
Neutrophils/Bands      33%
Monocytes           3%
Eosinophils           1%
Erythroid Precursors      13%
Plasma Cells           24%
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           4
Morphology: 
Marrow spicules: Spicular 
Cellularity: Cellular 
Plasma cell morphology: Small to large in size, bi/multinucleated, occasional prominent nucleoli
Myeloid lineage: Orderly maturation 
Erythroid Lineage: Orderly maturation 
Megakaryocytes:  Present 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 70% of cellularity. 
Kappa and lambda immunostains show the plasma cells are lambda light chain restricted.
BCMA highlights 90% of plasma cells, (2-3+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-7508)
Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.
Abnormal plasma cell population comprises 99.5% of total plasma cells.
Abnormal plasma cell population represents 5.9% of WBC.

Immunophenotype:
Abnormal: CD19 (variable - negative to intermediate), CD27 (variable - negative to intermediate), CD45 (variable - negative to intermediate), CD81 (variable - negative to intermediate), cytoplasmic Lambda (restriction)
Normal: CD138, CD38, CD229, CD319
Negative: CD56, CD117, cytoplasmic Kappa

Number of cells acquired: 5.3 million

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (7/14/2022):
WBC 3.4 L [4.0-11.0 K/mcL] 
RBC 3.77 L [3.80-5.00 M/mcL] 
HGB 11.9 [11.2-15.4 g/dL] 
HCT 35.7 [34.3-46.0 %] 
MCV 95 [80-98 fL] 
MCH 31.6 [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 12.8 [12.2-15.1 %] 
Platelets. 230 [160-400 K/mcL] 

Neutrophil 66.1 [32.5-74.8 %] 
Mono 14.0 H [0.0-12.3 %] 
Eos 0.6 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 1.2 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 17.5 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.3 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL]

Morphology: No circulating plasma cells on scanning. 

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-5162, CG22-5163.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-29719, M22-29720.
"
H22-418;S12;MSKT - 2023-05-26 15.26.30.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: MDS
Clinical Hx/Op Findings: Hx lymphoma, now with MDS and anemia
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia (MDS-RS-SLD).
     - Minute abnormal B-cell population with a chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)-like immunophenotype detected by flow cytometry only (0.011%)
     - No diagnostic morphologic or immunophenotypic evidence of follicular lymphoma.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular (90%)
M:E ratio: Reduced
Blasts: Not increased
Myeloid lineage: Relatively reduced with full maturation
Erythroid lineage: Increased with left-shifted maturation
Megakaryocytes: Adequate to focally increased, variable in size with some large forms and without overt dysplasia
Lymphocytes: Scattered, no aggregates seen
Plasma cells: Scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0/3) 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                1%
Promyelocytes           3%
Myelocytes           9%
Metamyelocytes           5%
Neutrophils/Bands      26%
Monocytes           2%
Eosinophils           3%
Erythroid Precursors      37%
Plasma Cells           2%
Lymphocytes           12%
Number of Cells Counted 500
M:E Ratio           1.3 

Special stain
Iron: Present
Ring sideroblasts: Present, >15%

Morphology:
- Spicular and cellular aspirate smears show erythroid-predominant maturing trilineage hematopoiesis with no increase in blasts. Myeloid elements show full maturation without significant dysplasia. Erythroid precursors show left-shifted maturation with dyserythropoiesis (ring sideroblasts, megaloblastoid changes, nuclear irregularity/budding, cytoplasmic vacuolization). Megakaryocytes are present and are variable in size with some large forms and without significant dysplasia.

PERIPHERAL BLOOD
CBC (01/18/2022):
WBC 4.1 [4.0-11.0 K/mcL] 
RBC 2.74 L [3.95-5.54 M/mcL] 
HGB 8.7 L [12.5-16.2 g/dL] 
HCT 26.9 L [37.5-49.3 %] 
MCV 98 [80-98 fL] 
MCH 31.8 [27.0-33.0 pg] 
MCHC 32.3 [31.0-36.5 g/dL] 
RDW 20.5 H [12.2-15.1 %] 
Platelets 183 [160-400 K/mcL] 

Neutrophil 57.7 [32.5-74.8 %] 
Mono 10.8 [0.0-12.3 %] 
Eos 10.1 H [0.0-4.9 %] 
Baso 1.5 [0.0-1.5 %] 
Immature Granulocyte 1.5 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 18.4 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.4 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Unremarkable morphology. No circulating blasts seen on scanning.
RBC: Normochromic, normocytic anemia with mild anisopoikilocytosis.
PLT: Adequate with unremarkable morphology.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 highlights scattered blasts comprising <5% of overall cellularity. CD34 also labels a subset of megakaryocytes. CD117 highlights blasts and early myeloid/erythroid progenitors as well as scattered mast cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-531)
Interpretation: 
1. Abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 2.5% of WBC.
Eosinophilia is seen, 6.9% of WBC.

Immunophenotype:
Abnormal: CD7 (partial - dim), CD13 (dim on CD34 bright subset), CD33 (dim), CD34 (bright), CD117 (bright)
Normal: CD4, CD15, CD38, CD45, CD71, CD123, HLA-DR
Negative: CD2, CD5, CD11b, CD14, CD16, CD19, CD25, CD56, CD64


2. Minute abnormal B cell population detected. 
Flow cytometry reveals an abnormal B cell population with a CLL/SLL-like immunophenotype (see below).

Abnormal B cell population represents 0.011% of WBC.

Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (positive), CD43 (positive), CD79b (dim), CD81 (dim), ROR1 (positive)
Normal: CD200, CD19, CD40, CD45
Negative: CD38, CD10, CD3

Number of cells acquired: 346 thousand 


3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-338.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-2359, M22-2368, M22-2369.


"
H22-2565;S12;MSKY - 2023-05-26 12.30.23.ndpi,Peripheral Blood Smear,2023-05-26,"Requested Studies: Gross/Micro
Clinical Diagnosis: Myelodysplastic Syndrome
Clinical Hx/Op Findings: hx AML 1999 now tMDS
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent therapy related myelodysplastic syndrome with ring sideroblasts and excess blasts 2 (10% blasts on aspirate). 

BONE MARROW BIOPSY
Quality: adequate 
Cellularity: 100% 
M:E ratio: markedly reduced 
Blasts: mildly increased 
Myeloid lineage: reduced 
Erythroid lineage: markedly increased with left shifted maturation 
Megakaryocytes: scattered, small monolobated 
Lymphocytes: rare 
Plasma cells: rare 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0/3). 

Clot section: not submitted 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                10%
Promyelocytes           2%
Myelocytes           4%
Metamyelocytes           2%
Neutrophils/Bands      10%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      58%
Plasma Cells           2%
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           0.3

Special stain
Iron: Present
Ring sideroblasts: Present; >15% 

Morphology:
Spicular and very cellular bone marrow aspirate shows markedly erythroid hyperplasia with left shifted maturation and dyserythropoiesis. Blasts are mildly increased. Myeloid precursors are rare. Megakaryocytes are present with small monolobated morphology. 

PERIPHERAL BLOOD
CBC (3/29/2022):
WBC 3.7 L [4.0-11.0 K/mcL] 
RBC 2.61 L [3.95-5.54 M/mcL] 
HGB 7.3 L [12.5-16.2 g/dL] 
HCT 23.0 L [37.5-49.3 %] 
MCV 88 [80-98 fL] 
MCH 28.0 [27.0-33.0 pg] 
MCHC 31.7 [31.0-36.5 g/dL] 
RDW 30.3 H [12.2-15.1 %] 
Platelets. 69 L [160-400 K/mcL] 

Neutrophil 32.0 L [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 3.0 H [0.0-0.0 %] 
Lymph 58.0 H [12.2-47.4 %] 
Nucleated RBC 8.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.2 L [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 2.2 [0.9-3.2 K/mcL]

Morphology: marked anisopoikilocytosis, nRBCs, circulating blasts, pancytopenia. 


Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight blasts, 10% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-3316)
Abnormal myeloid blast population detected. The immunophenotype of this population is similar to that seen in prior sample [case F22-1410] 

Abnormal myeloid blast population represents 14.6% of WBC.

Immunophenotype:
Abnormal: CD5 (partial), CD7 (partial), CD11b (partial), CD13 (uniform - bright), CD15 (partial), CD33 (bright), CD34 (uniform - intermediate), CD38 (variable - negative to dim), CD117 (bright), CD371 (clec12a) (uniform - intermediate)
Normal: CD4, CD36, CD45, CD45RA, CD71, CD123, HLA-DR
Negative: CD2, CD10, CD14, CD16, CD19, CD25, CD56, CD64, CD105

Number of cells acquired: 369 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Not performed 

MOLECULAR STUDIES 
Not performed 
"
H22-7118;S11;MSKW - 2023-06-15 17.23.30.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: ALL
Clinical Hx/Op Findings: new diagnosis of leukemia
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1, 88% blasts by aspirate differential count. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular (nearly 100%)
M:E ratio: N/A
Blasts: Markedly increased, present in sheets nearly entirely replacing the marrow
Myeloid lineage: Markedly decreased
Erythroid lineage: Markedly decreased
Megakaryocytes: Decreased
Lymphocytes: Scattered
Plasma cells: Scattered

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate

Blasts                88%
Myelocytes           1%
Neutrophils/Bands      1%
Erythroid Precursors      5%
Lymphocytes           5%
Number of Cells Counted      500
M:E Ratio           0.4

Morphology:
-Hypercellular smears show markedly increased mostly intermediate sized blasts with rounded to irregular nuclei, dispersed chromatin, mostly distinct nucleoli and scant basophilic cytoplasm. Myeloid and erythroid elements are markedly reduced. Megakaryocytes are present and show no overt atypia. 

PERIPHERAL BLOOD
CBC (08/29/2022):
WBC 17.9 H [4.0-11.0 K/mcL] 
RBC 2.66 L [3.80-5.00 M/mcL] 
HGB 7.5 L [11.2-15.4 g/dL] 
HCT 22.2 L [34.3-46.0 %] 
MCV 84 [80-98 fL] 
MCH 28.2 [27.0-33.0 pg] 
MCHC 33.8 [31.0-36.5 g/dL] 
RDW 17.8 H [12.2-15.1 %] 
Platelets. 57 L [160-400 K/mcL] 

Neutrophil 10.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 65.0 H [0.0-0.0 %] 
Lymph 24.0 [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.8 [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.2 [0.0-0.2 K/mcL] 
Absolute Blasts 11.6 H [0.0-0.0 K/mcL] 
Abs Lymph 4.3 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology: Frequent circulating blasts.
RBC: Normochromic anemia with occasional nucleated RBCs.
Platelets: Thrombocytopenia.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
Blasts are positive for CD34 and TdT (comprise >90% of marrow cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9321)
Interpretation:
1. Abnormal immature B cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 88.4% of WBC.
Abnormal immature B cell population represents 90.4% of the mononuclear cells.

Immunophenotype:
Abnormal: CD10 (bright), CD13 (positive), CD25 (partial), CD34 (bright), CD38 (dim), CD45 (variable - negative to dim), CD66c/CD123 (positive), CD73/CD304 (partial), CD81 (dim), CD86 (positive), CD123 (positive)
Normal: CD19, CD22, CD24, CD36, CD45RA, CD71, CD105, CD371 (clec12a), HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD20, CD26, CD33, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90

Number of cells acquired 415 thousand 


2. No abnormal myeloid blast, mature B or mature T cell populations identified. Virtually no myeloid blasts seen.                            
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.


Number of cells acquired: 439 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES (CG22-6437)
KARYOTYPE ANALYSIS:
Chromosome analysis detected loss of chromosome 7 and t(9;22), which results in BCR::ABL1 fusion, in eighteen out of twenty metaphases, consistent with this patient's B-ALL (H22-7118). The remaining two metaphase cells were of normal female karyotype.

TEST RESULTS:
KARYOTYPE ANALYSIS
Number of cells counted:20
Number of cells analyzed:20 
Number of cells karyotyped: 4
Modal chromosome number(s):45,46
Modal karyotype(s):45,XX,-7,t(9;22)(q34.1;q11.2)[18]/46,XX[2]

FISH ANALYSIS:
BCR-ABL1 fusion/t(9;22) detected in 91% of cells, with a signal pattern of one fusion signal, one signal of ABL1 (9q34.1) and two signals of BCR (22q11.2).

Rearrangement of ABL1 (9q34.1) detected in 93% of cells, of which 88% of cells showed the signal pattern of one fusion and one isolated 3' ABL1 locus, indicative of deletion of the 5' ABL1 region of one ABL1 locus.

Interphase/Nuclear In Situ Hybridization [ISCN 2016]: nuc ish(ABL1x2,BCRx3)(ABL1 con BCRx1)[273/300],
(5'ABL1x1,3'ABL1x2)(5'ABL1 con 3'ABL1x1)[264/300]/(ABL1x2)(5'ABL1 sep 3'ABL1x1)[15/300]

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-36623, M22-36625, M22-36628, M22-36629, M22-36632.
"
H22-10427;S15;MSK7 - 2023-06-15 10.38.50.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Myelodysplastic Syndrome\par Clinical Hx/Op Findings: History of MDS, persistent cytopenias on EPO\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;\red255\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\par      - Mildly hypercellular marrow with multilineage dysplasia, increased ring sideroblasts, increased singly scattered mast cells and no increase in blasts consistent with myeloid neoplasm with SF3B1 mutation. See comment. \par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The patient's history of myelodysplastic syndrome (MDS) with ring sideroblasts and an SF3B1 alteration identified in 2017 is noted. The current marrow biopsy and aspirate smears show a hypercellular marrow with multilineage dysplasia, increased ring sideroblasts, increased singly scattered mast cells and no increase in blasts.  The overall findings likely represent an MDS with mutated SF3B1.  However, we also noted the patient's borderline high platelet count (399) which is not common in the setting of MDS.  Therefore, the possibility of an evolving overlap MDS/MPN with SF3B1 mutation and thrombocytosis cannot be ruled out.  Suggest correlation with patient's historic CBCs and close CBC surveillance for the possibility of evolving thrombocytosis and a myeloproliferative component. Correlation with pending cytogenetic and molecular genetic studies may also help further characterize this myeloid neoplasm by way of identifying possible genetic alterations associated with a myeloproliferative process.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Mildly hypercellular for age (50-60%)\par M:E ratio: Mildly reduced to normal\par Blasts: Not increased\par Myeloid lineage: Present with progressive maturation\par Erythroid lineage:  Increased and show left-shifted maturation\par Megakaryocytes: Present with scattered small and hypolobated dysplastic forms and few enlarged forms with hyperlobulated nuclei\par Lymphocytes: Scattered, small interstitial lymphoid aggregate of small lymphocytes is seen.\par Plasma cells: Scattered \par Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF 0 out of 3)\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate\par\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 12%\par Metamyelocytes \tab\tab 10%\par Neutrophils/Bands \tab 33%\par Eosinophils \tab\tab 3%\par Erythroid Precursors \tab 27%\par Lymphocytes \tab\tab 13%\par Number of Cells Counted \tab 500\par M:E Ratio \tab\tab 2.2\par\par Special stain\par Iron: Present\par Ring sideroblasts: Present, >15%\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Spicular and cellular aspirate smears show bone marrow with a normal M:E ratio. Myeloid elements show maturation with frequent granulocytes with abnormal nuclear lobation and cytoplasmic hypogranularity.  Erythroid elements are increased and show left-shifted maturation with increased early precursors, dysplastic features such as binucleation, nuclear budding and irregularities, nuclear cytoplasmic asynchrony and cytoplasmic vacuolization. Megakaryocytes are present and show frequent small and hypolobated forms.  Blasts are not increased. Scattered lymphocytes and plasma cells are present. \par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (12/13/2022):\par WBC 7.3 [4.0-11.0 K/mcL] \par RBC 2.83 L [3.80-5.00 M/mcL] \par HGB 9.6 L [11.2-15.4 g/dL] \par HCT 29.9 L [34.3-46.0 %] \par MCV 106 H [80-98 fL] \par MCH 33.9 H [27.0-33.0 pg] \par MCHC 32.1 [31.0-36.5 g/dL] \par RDW 16.9 H [12.2-15.1 %] \par Platelets 399 [160-400 K/mcL] \par\par Neutrophil 60.7 [32.5-74.8 %] \par Mono 4.8 [0.0-12.3 %] \par Eos 2.7 [0.0-4.9 %] \par Baso 0.4 [0.0-1.5 %] \par Immature Granulocyte 0.3 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 31.1 [12.2-47.4 %] \par Nucleated RBC 0.3 H [0.0-0.0 %] \par\par Abs Neut 4.4 [1.5-7.5 K/mcL] \par Abs Mono 0.4 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature 0.0 [0.0-0.1 K/mcL] \par Granulocyte\par Abs Lymph 2.3 [0.9-3.2 K/mcL] \par\par Morphology:\par\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 WBC:  Granulocytes with abnormal nuclear lobation and hypogranular cytoplasm are seen. No circulating blasts seen.\par RBC: Mild macrocytic anemia. Anisopoikilocytosis.\par PLT:  Mildly increased platelets, subset showing enlarged and hypogranular forms. \plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 highlight rare blasts comprising less than 5% of the total cellularity.\par CD117 highlights mildly increased mast cells which are scattered spindle cells not forming aggregates.  Additional immunohistochemical studies will be performed and reported in an addendum.\par CD61 highlights megakaryocytes.\par CD71 highlights increased and left-shifted erythroid precursors. \par MPO highlights myeloid precursors.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\cb3\chshdng0\chcfpat0\chcbpat3 FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-13524)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par\par Myeloid blast population with an unremarkable phenotype represents 0.82% of WBC.\par\par Number of cells acquired: 371 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-9369\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-53476.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-9370;S27;MSKE - 2023-06-15 13.48.32.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: CLL\par Clinical Hx/Op Findings: Neutropenia workup\par Requested Studies: Gross/Micro\par Secondary diagnosis as per FLOW [Secondary Diagnosis (Confirmed or Rule Out): MGUS].\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest,  biopsy, aspirate, and peripheral blood smears: \~\~\par      - Low grade B-cell lymphoma with plasmacytic differentiation, kappa light chain restricted, 20-25% involvement with CD138/CD20 immunohistochemistry, see comment. \par      - Chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), lambda light chain restricted, 5% involvement with CD20/CD5/CD23 immunohistochemistry. \par\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Differential diagnosis includes marginal zone lymphoma and lymphoplasmacytic lymphoma. We will perform MYD88 mutational analysis for further evaluation. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy and aspirate smears show hypercellular bone marrow (80-85% cellularity) with markedly increased atypical lymphoid infiltrate demonstrating diffuse, nodular and interstitial pattern. Scattered Dutcher bodies are also noted. Megakaryocytes are adequate in number, morphologically unremarkable. Myeloid and erythroid precursors are suppressed, and show orderly maturation. Dyspoietic features are not evident. \par\~\par Bone Marrow Aspirate Smear Quality:  Adequate \par\par Blasts \tab\tab\tab 1%\par Myelocytes \tab\tab 6%\par Metamyelocytes \tab\tab 3%\par Neutrophils/Bands \tab 19%\par Monocytes \tab\tab 2%\par Eosinophils \tab\tab 3%\par Erythroid Precursors \tab 20%\par Plasma Cells \tab\tab 3%\par Lymphocytes \tab\tab 43%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 1.6\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY/ SPECIAL STAIN\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD20 and PAX5 highlight markedly increased B-cells, comprising approximately 25-30% of total cellularity.\par CD5 and CD23 is expressed in a subset of B-cells, approximately 5% of cellularity. \par Expression of LEF1 in B-cells is not clear.\par CD138 and BCMA highlight increase in plasma cells/plasmacytoid cells, 5-10% of marrow cellularity. \par These plasma cells show kappa light chain predominance by kappa and lambda light chain stain.\par Cyclin D1 is negative. \par CD34 and CD117 show no increase in blasts.\par CD3 highlights background T-cells. \par CD61 highlights megakaryocytes, adequate in number, morphologically unremarkable. \par MPO and CD71 highlight myeloid cells and erythroid precursors, respectively, showing mildly decreased M/E ratio. \par P53 is negative.\par\par Reticulin stain shows mildly increased reticulin fibrosis associated with lymphoid infiltrate.\par Congo red stain is negative. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-12155)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par\par CLL/SLL-like population and abnormal B cells with plasmacytic differentiation detected.\par\par 1. Abnormal B cell population detected. \par Flow cytometry reveals an abnormal B cell population with CLL/SLL-like immunophenotype (see below).\par\par Abnormal B cell population represents 2.1% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (partial), CD79b (dim), CD81 (dim), CD200 (bright), ROR1 (positive), surface Lambda (restriction - dim)\par Normal: CD19, CD40, CD45\par Negative: CD43, CD38, CD10, CD3, surface Kappa, CD14, CD25, CD279 (PD1)\par\par Number of cells acquired 549 thousand \par\par 2. Abnormal B- and plasma cell populations detected.\par The abnormal B cell population has the same light chain restriction as the abnormal plasma cell population mentioned below. Given the similar light chain restriction, these two populations likely represent manifestations of the same neoplasm, but the immunophenotypic profiles do not allow specific classification.  Clinical and morphologic correlation is advised.\par\par Abnormal B cell population represents 15.0% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (partial - dim), CD10 (partial), CD20 (dim), CD22 (dim), CD38 (variable - negative to bright), surface Kappa (restriction)\par Normal: CD19, CD45\par Negative: CD25, CD279 (PD1), CD3, CD14, surface Lambda\par\par Number of cells acquired: 158 thousand \par\par Abnormal plasma cell population detected.\par The abnormal plasma cell population has the same light chain restriction (see immunophenotype below) as the abnormal B cell population mentioned above. \par\par Abnormal plasma cell population represents 0.37% of WBC.\par Abnormal plasma cell population comprises 55.5% of total plasma cells.\par\par Immunophenotype:\par Abnormal: CD229 (dim), CD319 (bimodal - dim to bright), CD19 (variable - negative to bright), CD27 (bimodal - bright to dim), CD45 (bimodal - dim to intermediate), cytoplasmic Kappa (restriction)\par Normal: CD138, CD38, CD81\par Negative: CD20, CD56, CD117, cytoplasmic Lambda\par\par Number of cells acquired 5.4 million \par\par 3. No abnormal mature T cell population detected. \par No immunophenotypic evidence of T-cell lymphoma is identified.  \par\par Number of cells acquired: 158 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/7/2022):\par\par WBC 3.9 L [4.0-11.0 K/mcL] \par RBC 3.69 L [3.80-5.00 M/mcL] \par HGB 11.5 [11.2-15.4 g/dL] \par HCT 34.7 [34.3-46.0 %] \par MCV 94 [80-98 fL] \par MCH 31.2 [27.0-33.0 pg]\par MCHC 33.1 [31.0-36.5 g/dL] \par RDW 17.1 H [12.2-15.1 %] \par Platelets 295 [160-400 K/mcL] \par\par Neutrophil 23.8 L [32.5-74.8 %] \par Mono 12.7 H [0.0-12.3 %] \par Eos 1.5 [0.0-4.9 %] \par Baso 1.3 [0.0-1.5 %] \par Immature Granulocyte 0.0 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 60.7 H [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 0.9 L [1.5-7.5 K/mcL] \par Abs Mono 0.5 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 2.4 [0.9-3.2 K/mcL] \par\par Morphology:\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8375. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-47681.  \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-6410;S15;MSK4 - 2023-06-15 15.04.31.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: AML
Clinical Hx/Op Findings: new Dx
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
    - Acute myeloid leukemia, 93% blasts on aspirate differential count. See comment.
  
COMMENT: FISH analysis on a peripheral blood sample (CG22-5764) did not detect PML-RARA fusion/t(15;17) or RARA (17q21.2) rearrangement. Further classification of this acute myeloid leukemia requires correlation with forthcoming additional cytogenetic and molecular genetic studies, and clinical history. Per clinical notes, the patient has a history of prostate cancer treated with radiation therapy in 2016. Correlation with the extent of the field of radiation is recommended and if significant, it would be most consistent with a therapy-related myeloid neoplasm (t-MN).

BONE MARROW BIOPSY
The core biopsy is limited for evaluation due to fragmentation and significant aspiration artifact. The cellularity of the residual marrow spaces and in the surrounding blood clot is almost entirely comprised of blasts that are variably sized and show slightly indented nuclei and dispersed chromatin. Residual maturing trilineage hematopoiesis is markedly reduced to absent.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Paucispicular

Blasts                93% 
Neutrophils/Bands      3%
Erythroid Precursors      2%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
The aspirate smears are hypercellular. The cellularity is comprised predominantly of intermediate to large sized blasts with round to slightly indented and occasionally bilobed nuclei, fine chromatin, conspicuous nucleoli and scant to moderate amount of cytoplasm, including some forms with granules and/or single thin Auer rods. Background hematopoietic elements are markedly reduced.

PERIPHERAL BLOOD
CBC (08/05/2022):
WBC 174.7 H [4.0-11.0 K/mcL] 
RBC 3.22 L [3.95-5.54 M/mcL] 
HGB 9.5 L [12.5-16.2 g/dL] 
HCT 28.7 L [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 29.5 [27.0-33.0 pg] 
MCHC 33.1 [31.0-36.5 g/dL] 
RDW 18.3 H [12.2-15.1 %] 
Platelets 25 L [160-400 K/mcL] 

Neutrophil 3.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 91.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 3.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 5.2 [1.5-7.5 K/mcL] 
Abs Mono 3.5 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 159.0 H [0.0-0.0 K/mcL] 
Abs Meta 1.7 H [0.0-0.0 K/mcL] 
Abs Lymph 5.2 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: 
WBC: Numerous circulating blasts, morphologically similar to the aspirate smears.
RBC: Normocytic normochromic anemia. 
PLT: Marked thrombocytopenia.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
The expanded myeloid blast population is positive for CD34, CD117, MPO and Lysozyme (subset), while TdT and CD61 are negative. CD71 highlights rare erythroid precursors as well as rare blasts. No definite megakaryocytes are seen with CD61.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-8429)
1. Expanded abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 93.7% of WBC.

Immunophenotype:
Abnormal: CD11b (partial), CD13 (variable - negative to intermediate), CD33 (bright), CD34 (dim), CD56 (partial), CD64 (partial), CD117 (bright), CD371 (clec12a) (dim), HLA-DR (uniform - intermediate)
Normal: CD4, CD36, CD38, CD45, CD45RA, CD71, CD105, CD123, MPO
Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, cytoplasmic CD3, cytoplasmic CD79a, surface Kappa, surface Lambda, CD42b, CD61, CD90

Number of cells acquired: 979 thousand 

2. No abnormal mature B- or T-cell populations detected. 
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

Number of cells acquired 493 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.
CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-5789

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-32947, M22-32948, M22-32949, M22-32950.
"
H22-10019;S2;MSK0 - 2023-06-15 16.19.11.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Leukemia, Acute Lymphoid (ALL)  \par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-2.  Bone marrow, left posterior iliac crest, aspirate and peripheral blood smears:\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080      - B-lymphoblastic leukemia/lymphoma (B-ALL), see comment.\par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par COMMENT:  Correlation with forthcoming cytogenetic and molecular studies is recommended for further subclassification of the process. \plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b  \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080 Bone Marrow Aspirate Smear Quality:  Adequate\par  \par Blasts \tab\tab\tab 95%\par Neutrophils/Bands \tab 1%\par Erythroid Precursors \tab 2%\par Lymphocytes \tab\tab 2%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 0.5\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -Aspicular but cellular aspirate smears show an expanded blast population.  The blasts are intermediate to large in size with ovoid to slightly irregular nuclei, fine chromatin, conspicuous nucleoli and scant basophilic agranular cytoplasm.  Rare myeloid and erythroid elements are noted.  Megakaryocytes are not well represented on the smears.\par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/29/2022):\par WBC 2.2 L [7.1-15.9 K/mcL] \par RBC 3.73 L [3.89-5.03 M/mcL] \par HGB 9.7 L [10.7-14.5 g/dL] \par HCT 28.8 L [32.2-43.5 %] \par MCV 77 [74-91 fL] \par MCH 26.0 [24.8-30.2 pg] \par MCHC 33.7 [31.0-36.5 g/dL] \par RDW 16.5 H [12.2-15.1 %] \par Platelets. 30 L [160-400 K/mcL] \par\par Neutrophil 19.0 L [32.5-74.8 %] \par Mono 2.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Blast 4.0 H [0.0-0.0 %] \par Myelocyte 3.0 H [0.0-0.0 %] \par Lymph 72.0 H [12.2-47.4 %] \par Nucleated RBC 3.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 0.4 L [1.5-7.5 K/mcL] \par Abs Mono 0.0 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Blasts 0.1 H [0.0-0.0 K/mcL] \par Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] \par Abs Lymph 1.6 [0.9-3.2 K/mcL]\par\par Morphology:  Occasional circulating blasts noted.\par\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-13026)\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Abnormal immature B cell population detected.\par\par Abnormal immature B cell population represents 92.1% of WBC.\par Abnormal immature B cell population represents 90.9% of the mononuclear\par cells..\par\par Immunophenotype:\par Abnormal: CD10 (bright), CD20 (partial), CD38 (dim), CD45 (variable -negative to bright), CD81 (dim), CD73/CD304 (positive), CD66c/CD123 (positive - bright), CD86 (partial)\par Normal: CD19, CD22, CD24, CD34\par Negative: CD66b\par\par Number of cells acquired 432 thousand\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s18\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report.\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-10935;S16;MSKB - 2023-06-15 10.44.43.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Lymphoma\par Clinical Hx/Op Findings: increased uptake on PET\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\par      - Involvement by patient's known large B-cell lymphoma of germinal center B cell phenotype (up to 20% with CD20 immunohistochemistry)\par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par See comment.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Additional immunohistochemical studies are pending and will be reported in an addendum. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy and aspirate specimens show hypercellular bone marrow (60-70%cellularity). There is\~trilineage maturing hematopoiesis with increased numbers of large lymphocytes with irregular nuclei.  Plasma cells appear to be increased focally.  Occasional Dutcher bodies are seen.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Immunostains for CD20 and PAX5 highlights the atypical large lymphocytic infiltrate distributed in a paratrabecular and interstitial pattern and focal aggregates.  CD3 highlights the background small T-cells.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-14120)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par\par 1. Abnormal B cell population detected.\par\par Abnormal B cell population represents 21.2% of WBC.\par\par Immunophenotype:\par Abnormal: CD10 (positive - dim), CD19 (dim), CD20 (bright), CD22 (dim), CD38 (intermediate), surface Kappa (restriction)\par Normal: CD45\par Negative: CD5, CD25, CD279 (PD1), CD3, CD14, surface Lambda\par\par Number of cells acquired 336 thousand \par\par 2. No abnormal mature T cell population detected. \par No immunophenotypic evidence of T-cell lymphoma is identified.  \par\par Atypical NK cell population without expression of CD7 and CD56 detected, representing 2.5% of WBC.\par\par Number of cells acquired: 336 thousand \par\par Also see F22-14099 and F22-14100 submitted on the same day.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (12/30/2022):\par WBC 4.2 [4.0-11.0 K/mcL] \par RBC 3.96 [3.95-5.54 M/mcL] \par HGB 12.0 L [12.5-16.2 g/dL] \par HCT 36.5 L [37.5-49.3 %] \par MCV 92 [80-98 fL] \par MCH 30.3 [27.0-33.0 pg] \par MCHC 32.9 [31.0-36.5 g/dL] \par RDW 14.8 [12.2-15.1 %] \par Platelets 123 L [160-400 K/mcL] \par\par Neutrophil 48.0 [32.5-74.8 %] \par Mono 5.5 [0.0-12.3 %] \par Eos 1.7 [0.0-4.9 %] \par Baso 0.5 [0.0-1.5 %] \par Immature Granulocyte 1.0 H [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 43.3 [12.2-47.4 %] \par Nucleated RBC 0.5 H [0.0-0.0 %] \par\par Abs Neut 2.0 [1.5-7.5 K/mcL] \par Abs Mono 0.2 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature 0.0 [0.0-0.1 K/mcL] \par Granulocyte\par Abs Lymph 1.8 [0.9-3.2 K/mcL] \par\par Morphology:  Circulating atypical lymphoid cells are seen.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-9790.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-56152.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-8032;S16;MSK7 - 2023-06-15 14.23.23.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Lymphoma\par Clinical Hx/Op Findings: newly diagnosed\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\fswiss\fcharset0\fprq2{\*\panose 020B0502040204020203}Segoe UI;}
{\f3\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b ,\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  biopsy, aspirate smears: \~\~\par      - Atypical mast cell aggregates (5-10% of the cellularity by CD117 immunohistology), consistent with systemic mastocytosis. See comment 1.\par      - Approximately normocellular marrow with maturing trilineage hematopoiesis and mild megakaryocytic atypia. See comment 2.\par      - Minute abnormal B-cell population with kappa light chain restriction (0.41% of WBC) detected by flow cytometry only. See comment 3.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT:\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1. Multifocal dense aggregates of mast cells are present, which show spindled morphology and aberrantly express CD2 and CD25. Correlation with molecular studies and assessment for serum total tryptase levels is also advised.\par 2. While CBC parameters are within normal limits at this time, mild megakaryocytic atypia is noted, and the possibility of an early / evolving myeloid stem cell disorder cannot be entirely excluded. Correlation with results of the forthcoming molecular and cytogenetic studies is needed to complete the diagnostic evaluation. Close clinical follow-up is advised.\par 3. A morphologic correlate of the minute abnormal B-cell population detected by flow cytometry is not detected. The light chain restriction of this abnormal population (kappa) is different from the patient's DLBCL (F22-10606, lambda), compatible with involvement by an unrelated B-cell lymphoproliferative disorder. The differential diagnosis includes monoclonal B-cell lymphocytosis with a non-CLL immunophenotype, which is favored, while minimal involvement by a separate extramedullary B-cell process cannot be entirely excluded. Clinical correlation is advised.\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Reviewed at Hematopathology service consensus conference on 10/5/2022 with all in agreement.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy (although fragmented and partially aspirated) and aspirate specimens show approximately normocellular for age bone marrow (50% cellularity). There is\~trilineage maturing hematopoiesis without lymphoid aggregates. Myeloid and erythroid elements are actively maturing. Megakaryocytes are adequate to mildly increased in number with atypical forms (~10%) showing nuclear hyperchromasia, small size, and hypolobation. Several small, perivascular and interstitial aggregates of spindled cells are with small nuclei, condensed chromatin, inconspicuous nucleoli, and abundant granular cytoplasm are seen, which are consistent with mast cells (see immunohistology below). These aggregates show admixed eosinophils\par On the aspirate smears, myeloid and erythroid cells are seen in various stages of maturation without significant dysplasia. Many megakaryocytes are noted with a subset (~10%) showing small size and hypolobation. Few scattered mast cells are seen which show spindled morphology and are mature appearing.\par\par Special stains for AFB and GMS are negative for acid-fast bacilli and microorganisms, respectively.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD20 and PAX5 highlight few scattered B-cells.\par CD3 highlights few scattered T-cells.\par CD117 highlights a few dense aggregates of mast cells with spindled morphology, accounting for approximately 5-10% of the marrow cellularity, which are also positive for mast cell tryptase, with aberrant expression of CD25 and CD2.\par CD30 appears negative in the mast cells.\par CD68(KP1) is positive in the mast cell aggregates and also highlights scattered monocytic cells.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10489)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par 1. Minute abnormal B cell population detected.\par The immunophenotype of this abnormal B-cell population is similar to that in prior (F22-10185) and is not entirely specific and does not allow for full classification by flow cytometry. \par\par Abnormal B cell population represents 0.41% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (dim), CD38 (negative), surface Kappa (restriction)\par Normal: CD20, CD22, CD45\par Negative: CD5, CD10, CD25, CD279 (PD1), CD3, CD14, surface Lambda\par\par Number of cells acquired: 402 thousand\par\par 2. Atypical mast cells present.\par Mast cell population represents 0.087% of WBC.\par Immunophenotype:\par Atypical: CD2 (positive), CD25 (positive)\par Normal: CD117\par Negative: HLA-DR\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (09/27/2022):\par WBC 9.8 [4.0-11.0 K/mcL] \par RBC 4.56 [3.95-5.54 M/mcL] \par HGB 14.0 [12.5-16.2 g/dL] \par HCT 40.7 [37.5-49.3 %] \par MCV 89 [80-98 fL] \par MCH 30.7 [27.0-33.0 pg] \par MCHC 34.4 [31.0-36.5 g/dL] \par RDW 11.4 L [12.2-15.1 %] \par Platelets 270 [160-400 K/mcL] \par\par Neutrophil 59.6 [32.5-74.8 %] \par Mono 6.7 [0.0-12.3 %] \par Eos 1.4 [0.0-4.9 %] \par Baso 0.2 [0.0-1.5 %] \par Immature Granulocyte 0.7 H [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 31.4 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 5.8 [1.5-7.5 K/mcL] \par Abs Mono 0.6 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] \par Abs Lymph 3.1 [0.9-3.2 K/mcL] \par\par Morphology:\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 WBC: Overall unremarkable morphology. No definitive atypical lymphocytosis seen.\par RBC: Normocytic, normochromic RBCs.\par Platelets: Adequate in number with unremarkable morphology\plain\rtlch\af2\afs24\alang0\ltrch\f2\fs24\lang0\langnp0\langfe0\langfenp0\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate reports, CG22-7212 & CG22-7213\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate reports, M22-40941& M22-40943\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-6514;S10;MSK4 - 2023-06-15 12.24.56.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Hx/Op Findings: diagnostic
Clinical Diagnosis: B-ALL
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, touch imprints, and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma, 50% blasts by touch imprint differential, see comment.
  
COMMENT: Correlation with forthcoming cytogenetic and molecular studies is recommended.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Variable (<10-90%), overall ~60-70%
M:E ratio: Appears normal
Blasts: Increased with foci containing sheets of blasts
Myeloid lineage: Full spectrum of maturation
Erythroid lineage: Full spectrum of maturation
Megakaryocytes: Present
Lymphocytes: Scattered
Plasma cells: Scattered

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: N/A
Aspirate smears are not submitted
Performed on touch smear

Blasts                50%
Myelocytes           8%
Metamyelocytes           7%
Neutrophils/Bands      19%
Eosinophils           2%
Erythroid Precursors      11%
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           3.3 

Morphology: Touch imprints are cellular and adequate for evaluation. Increased blasts predominate the cellularity and are small-to-medium size, round nuclei, 1-2 small nucleoli, and scant, agranular cytoplasm. Erythroid and myeloid elements in the background are present in adequate proportion and show the full spectrum of maturation. Megakaryocytes show no significant dysplasia.

PERIPHERAL BLOOD
CBC (08/09/2022):
WBC 8.6 [4.0-11.0 K/mcL] 
RBC 5.31 H [3.80-5.00 M/mcL] 
HGB 15.5 H [11.2-15.4 g/dL] 
HCT 46.6 H [34.3-46.0 %] 
MCV 88 [80-98 fL] 
MCH 29.2 [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 12.2 [12.2-15.1 %] 
Platelets 309 [160-400 K/mcL] 

Neutrophil 41.0 [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 7.0 H [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Blast 30.0 H [0.0-0.0 %] 
Lymph 15.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 3.5 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.6 [0.0-0.7 K/mcL] 
Absolute Basophil 0.2 [0.0-0.2 K/mcL] 
Absolute Blasts 2.6 H [0.0-0.0 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 

Morphology: 
WBC: Many circulating blasts present 
RBC: Unremarkable
PLT: Unremarkable

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
CD34 and TDT highlight blasts, focally sheets up to 70%, overall ~50-60% of cellularity

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-8586)
1. Abnormal immature B-cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B-cell population represents 45.9% of WBC.
Abnormal immature B-cell population represents 44.4% of the mononuclear cells.

Immunophenotype:
Abnormal: CD10 (bright), CD13 (partial), CD38 (dim), CD45 (variable - negative to intermediate), CD66c/CD123 (positive), CD73/CD304 (positive), CD81 (dim), CD86 (partial), CD123 (positive)
Normal: CD19, CD22, CD24, CD34, CD36, CD45RA, CD71, CD105, CD371 (clec12a), HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD20, CD25, CD26, CD33, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90

Number of cells acquired: 0.87 million

2. No definite abnormal myeloid blast or mature B- and T-cell populations identified. Very few myeloid blasts seen.                              
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Number of cells acquired: 615 thousand
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-5915

MOLECULAR STUDIES 
Molecular analysis will be reported separately. 
"
H22-4743;S14;MSK- - 2023-04-19 15.26.39.ndpi,Peripheral Blood Smear,2023-04-19,"Special Requests: Rush
Clinical Diagnosis: CML
Clinical Hx/Op Findings: New dx CML
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Chronic myeloid leukemia, BCR-ABL1 positive, <5% blasts; see comment.

COMMENT: The specimen does not meet criteria for accelerated phase in the criteria that can be assessed in the peripheral blood and marrow by morphology and immunohistochemistry. Other criteria require clinical correlation as well as correlation with cytogenetic and molecular studies. Overall findings are consistent with chronic phase of CML, but correlation with additional studies is required for full exclusion of accelerated phase.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypercellular (>90%)
M:E ratio: Increased
Blasts: Not overtly increased
Myeloid lineage: Markedly increased, with left shifted but complete maturation
Erythroid lineage: Reduced 
Megakaryocytes: Increased, including occasional forms with small size and monolobation
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows a mild increase in reticulin fibers (1+/3). 
The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate

Blasts                1%
Promyelocytes           2%
Myelocytes           9%
Metamyelocytes           6%
Neutrophils/Bands      52%
Monocytes           1%
Eosinophils           15%
Basophils           5%
Erythroid Precursors      7%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           12.9

Morphology: The aspirate smears are spicular and hypercellular and show myeloid predominant maturing trilineage hematopoiesis, no increase in blasts is seen. Myeloid elements show complete maturation and are markedly increased, with eosinophilia and basophilia. Erythroid elements are reduced but show full maturation. Megakaryocytes are increased and show monolobated smaller forms consistent with so-called ""dwarf"" megakaryocytes. 

PERIPHERAL BLOOD
CBC (06/10/2022):
WBC 152.2 H [4.0-11.0 K/mcL] 
RBC 3.09 L [3.80-5.00 M/mcL] 
HGB 9.2 L [11.2-15.4 g/dL] 
HCT 28.9 L [34.3-46.0 %] 
MCV 94 [80-98 fL] 
MCH 29.8 [27.0-33.0 pg] 
MCHC 31.8 [31.0-36.5 g/dL] 
RDW 17.5 H [12.2-15.1 %] 
Platelets. 693 H [160-400 K/mcL] 

Neutrophil 63.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 15.0 H [0.0-1.5 %] 
Blast 1.0 H [0.0-0.0 %] 
Myelocyte 8.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 7.0 H [0.0-0.0 %] 
Lymph 0.0 L [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 95.9 H [1.5-7.5 K/mcL] 
Abs Mono 3.0 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 4.6 H [0.0-0.7 K/mcL] 
Absolute Basophil 22.8 H [0.0-0.2 K/mcL] 
Absolute Blasts 1.5 H [0.0-0.0 K/mcL] 
Abs Myelocytes 12.2 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 1.5 H [0.0-0.0 K/mcL] 
Abs Meta 10.7 H [0.0-0.0 K/mcL] 
Abs Lymph 0.0 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
WBC: Marked leukocytosis with basophilia, left shifted granulocytes seen; occasional circulating blasts seen.
RBC: Normocytic, normochromic anemia with anisocytosis. 
PLT: Thrombocytosis.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no definite increase in blasts, slightly less than but approaching 5% of total cellularity. 
CD117 also highlights early myeloid and erythroid elements.
CD61 highlights increased megakaryocytes as well as platelet clumps.
CD71 highlights erythroid elements, which are relatively decreased. 
MPO highlights increased myeloid elements.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-6194)
Flow cytometry assessment will be reported separately. Please see separate report.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-6108)
1. Abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 4.2% of WBC.
Basophilia is seen, 8.3% of WBC.

Immunophenotype:
Abnormal: CD7 (partial), CD13 (bright), CD25 (partial), CD33 (bright), CD117 (variable - negative to intermediate), HLA-DR (uniform - bright)
Normal: CD4, CD34, CD36, CD38, CD45, CD45RA, CD71, CD105, CD123, CD371 (clec12a)
Negative: CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD26, CD56, CD64, cytoplasmic CD3, cytoplasmic CD79a, MPO, surface Kappa, surface Lambda, CD61

Number of cells acquired: 951 thousand 

2. No abnormal mature B- or T-cell populations detected. 
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

Number of cells acquired 475 thousand
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-4309.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-24997, M22-24998.
"
H22-7092;S23;MSK0 - 2023-06-15 17.17.39.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Hx/Op Findings: suspected new diagnosis of leukemia
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma with t(9;22); BCR-ABL1, 88% blasts by aspirate differential count. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular (90%)
M:E ratio: N/A
Blasts: Markedly increased 
Myeloid lineage: Markedly decreased
Erythroid lineage: Markedly decreased
Megakaryocytes: Decreased
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows no significant increase in reticulin fibrosis 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate 

Blasts                88%
Neutrophils/Bands      1%
Eosinophils           1%
Erythroid Precursors      1%
Plasma Cells           2%
Lymphocytes           9%
Number of Cells Counted  500
M:E Ratio           2

Morphology:
Spicular and cellular aspirate smears show a markedly expanded population of blasts, which are mostly small to medium in size with rounded to irregular nuclei, moderately dispersed chromatin, occasional distinct nucleoli, and scant cytoplasm. Background trilineage hematopoiesis is reduced. 

PERIPHERAL BLOOD
CBC (8/26/2022):
WBC 59.5 H [4.0-11.0 K/mcL] 
RBC 4.87 [3.95-5.54 M/mcL] 
HGB 14.2 [12.5-16.2 g/dL] 
HCT 42.2 [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 29.2 [27.0-33.0 pg] 
MCHC 33.6 [31.0-36.5 g/dL] 
RDW 14.2 [12.2-15.1 %] 
Platelets 27 L [160-400 K/mcL] 

Neutrophil 6.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 86.0 H [0.0-0.0 %] 
Lymph 6.0 L [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 3.6 [1.5-7.5 K/mcL] 
Abs Mono 1.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 51.2 H [0.0-0.0 K/mcL] 
Abs Lymph 3.6 H [0.9-3.2 K/mcL] 

Morphology: 
WBC: Frequent circulating blasts.
RBC: Normochromic, normocytic RBCs with occasional nucleated RBCs.
Platelets: Marked thrombocytopenia.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
The blasts, comprising ~80-90% of the cellularity, express CD34, TdT, and CD19, while are negative for CD117, MPO, lysozyme, CD3, CD71 and CD61. CD71 shows markedly reduced erythroid precursors. MPO and lysozyme demonstrate markedly reduced myelomonocytic elements. CD61 highlights reduced megakaryocytes. CD3 labels scattered T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9287)
Interpretation:
1. Abnormal immature B cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 93.5% of WBC.
Abnormal immature B cell population represents 93.5% of the mononuclear cells.

Immunophenotype:
Abnormal: CD10 (bright), CD20 (partial), CD33 (partial), CD34 (variable - negative to bright), CD38 (variable - negative to intermediate), CD45 (variable - negative to intermediate), CD66c/CD123 (positive), CD73/CD304 (positive), CD81 (dim), CD86 (positive), CD123 (positive)
Normal: CD19, CD22, CD24, CD36, CD45RA, CD71, CD105, CD371 (clec12a), HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD25, CD26, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90

Number of cells acquired 319 thousand 

2. No abnormal myeloid blast, mature B or mature T cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.074% of WBC.

Number of cells acquired: 921 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-9255)
Interpretation:
1. Abnormal immature B-cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 81.5% of WBC.
Abnormal immature B cell population represents 86.5% of the mononuclear cells.

Immunophenotype:
Abnormal: CD10 (bright), CD20 (partial), CD33 (partial), CD34 (variable - negative to bright), CD38 (variable - negative to intermediate), CD45 (variable - negative to intermediate), CD66c/CD123 (partial), CD73/CD304 (positive), CD81 (positive - dim), CD86 (partial), CD123 (positive)
Normal: CD19, CD22, CD24, CD36, CD45RA, CD71, CD105, HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD25, CD26, CD56, CD64, CD66b, CD117, CD279 (PD1), CD371 (clec12a), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90

Number of cells acquired 819 thousand 

2. No abnormal myeloid blast, mature B or mature T-cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.24% of WBC.

Number of cells acquired: 725 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-6420.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports.

"
H22-7237;S18;MSK5 - 2023-06-15 17.29.19.ndpi,Peripheral Blood Smear,2023-06-15,"Myelofibrosis. Myelofibrosis to begin protocol.
","{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch31506\stshfhich31506\stshfbi31506\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}
{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri{\*\falt Calibri};}
{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}










{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE{\*\falt Calibri};}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr{\*\falt Calibri};}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek{\*\falt Calibri};}
{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur{\*\falt Calibri};}{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew){\*\falt Calibri};}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic){\*\falt Calibri};}
{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic{\*\falt Calibri};}{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese){\*\falt Calibri};}
{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;
\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;
\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;\red0\green0\blue0;\red192\green0\blue0;}{\*\defchp \f31506\fs22 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 
\f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31506\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused Normal Table;}{
\s15\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 
\f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext15 \spriority0 \styrsid15625276 CoPath Text;}}{\*\rsidtbl \rsid205014\rsid1577361\rsid2052756\rsid2244535\rsid2384879\rsid2631653\rsid3605695\rsid4728884\rsid4730581\rsid5596652\rsid6769662
\rsid8413119\rsid8921095\rsid8992042\rsid9517721\rsid10554078\rsid10556834\rsid10819200\rsid11010281\rsid11208252\rsid11556405\rsid12129899\rsid13045495\rsid13516055\rsid13638062\rsid14121195\rsid14495549\rsid15414626\rsid15625276\rsid16218054
\rsid16331704\rsid16449873}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\author Melo, Heydi L./Pathology}{\operator Roshal, Mikhail/Pathology}
{\creatim\yr2022\mo9\dy9\hr22\min35}{\revtim\yr2022\mo9\dy9\hr22\min35}{\version2}{\edmins0}{\nofpages4}{\nofwords799}{\nofchars4995}{\nofcharsws5676}{\vern111}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}
\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont1\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1440\dgvorigin1440\dghshow1\dgvshow1
\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\rsidroot16331704\newtblstyruls\nogrowautofit\usenormstyforlist\noindnmbrts\felnbrelev\nocxsptable\indrlsweleven\noafcnsttbl\afelev\utinl\hwelev\spltpgpar\notcvasp\notbrkcnstfrctbl\notvatxbx\krnprsnet\cachedcolbal \nouicompat \fet0
{\*\wgrffmtfilter 2450}\nofeaturethrottle1\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang 
{\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}
\pard\plain \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid2631653 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\ul\insrsid13516055\charrsid2631653 AMENDMENT DETAIL:}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid2631653 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid13516055\charrsid2631653 Reason for Amendment:\~}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid13516055 \tab \tab }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\caps\f1\fs18\insrsid13516055\charrsid5596652 Clerical Error}{\rtlch\fcs1 \ab\af0 \ltrch\fcs0 \b\insrsid13516055 \par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid2244535 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid13516055\charrsid2244535 R}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid13516055 eport Section Changed:\tab }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid13516055\charrsid5596652 Diagnosis/ Interpretation}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid13516055\charrsid2244535 \par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid2244535 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid13516055\charrsid2244535 Original Text:}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid13516055 \tab \tab \tab }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid5596652 Involvement by myeloid neoplasm most consistent with ring sideroblasts,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid2244535 \par }\pard \ltrpar\ql \fi720\li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid2631653 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid13516055\charrsid2244535 \par }\pard \ltrpar\ql \fi-2880\li2880\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin2880\itap0\pararsid5596652 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid13516055 Revised Text: \tab }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\ul\cf2\insrsid13516055\charrsid5596652 Involvement by myeloid neoplasm most consistent with MDS/MPN with ring sideraoblasts,}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\ul\cf2\insrsid13516055  or MPN progression}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\fs18\cf19\insrsid13516055\charrsid2244535 \par }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid2384879 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 \f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid13516055 \par }\pard \ltrpar\s15\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid5596652 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid13516055 Note: This document represents an amended version of the Hematopathology report originally issued on 9/7/2022. }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid13516055\charrsid5596652 Kimberly Rajmohan}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid13516055  has been notified via e-mail on 9/9/2022. \par \par }\pard\plain \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid14121195 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 \par 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate smears and peripheral blood smear: \par      - Involvement by myeloid neoplasm most consistent with MDS/MPN ring sideroblasts or MPN progression, myelofibrosis and granulocytic dysplasia, no increase in blasts \par   \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\insrsid13516055 COMMENT:\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 Per medical records, the patient has a history of essential }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid8921095 thrombocythemia}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055  (ET)}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid8921095  (diagnosed in 2013) with recent outside bone marrow biopsy (6/08/22) showing increased myelofibrosis and atypical megakaryocytes. The patient has a peripheral blood IMPACT-Heme panel showing CALR, IDH2, SF3B1, and KIT alterations. The current bone marrow biopsy and aspirate smears show a hyper}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 cellular marrow with atypical megakaryocytes and increased fibrosis with mild }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid8921095 dysgranulopoiesis }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 and }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid8921095 dyserythropoiesis}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 , and ring sideroblasts. These findings combined with the patient\rquote s history of ET and CALR alteration, anemia, leukoerythroblastosis, splenomegaly, and increased lactate dehydrogenase may represent post-essential thrombocythemia myelofibrosis. However, given that the original diagnosis was NOT reviewed at MSKCC AND the presence of SF3B1 mutation and ring sideroblasts, the original diagnosis of MDS/MPN with ring sideroblasts and thromobocytosis is not excluded. In that case the findings would represent an advanced stage of the MDS/MPN.  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid8921095 Clinical correlation of these findings with cytogenetic and molecular studies is recommended.\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid13516055 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid13516055\charrsid8921095 BONE MARROW BIOPSY}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid8921095 \par Quality: Adequate\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 Cellularity: Hypercellular (80-90%)\par M:E ratio: Within normal limits\par Blasts: Not increased\par Myeloid lineage: Present with progressive maturation\par Erythroid lineage: Present with left shifted maturation \par Megakaryocytes: Many atypical forms present including large hyperlobated megakaryocytes \par Lymphocytes: Scattered\par Plasma cells: Scattered\par \par Special stains: \par Reticulin stain shows moderate increase in reticulin fibrosis (MF 2-3 (overall 3 out of 3), osteosclerosis is seen.\par \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid12129899 Clot section:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055  Predominantly blood with scattered hypercellular marrow elements\par }{\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\cf1\insrsid13516055 \par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.}{\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\insrsid13516055 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid13516055 BONE MARROW ASPIRATE SMEAR}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid2052756 Bone Marrow Aspirate Smear Quality: Adequate}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 \par Numerous naked nuclei noted\par \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid11208252 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid11208252 Blasts \tab \tab \tab 3%\par Promyelocytes \tab \tab }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 4}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid11208252 %\par Myelocytes \tab \tab 1}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 6}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid11208252 %\par Metamyelocytes \tab \tab 13%\par Neutrophils/Bands \tab 29%\par Monocytes \tab \tab 1%\par Eosinophils \tab \tab 1%\par Erythroid Precursors \tab 29%\par Lymphocytes \tab \tab 4%\par Number of Cells Counted 500\par M:E Ratio \tab \tab 2.2}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 \par \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid10556834 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid10556834 Special stain\par Iron: Present}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055  to abundant}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid10556834 \par Ring sideroblasts: }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 Present, >15%\par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid14121195 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\highlight4\insrsid13516055 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 Morphology:\par Spicular and cellular aspirate smears show marrow with normal M:E ratio. Myeloid elements show maturation with occasional }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid11556405 nuclear hyposegmentation and cytoplasmic hypogranularity}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 . Erythroid elements show maturation with slightly increase in immature forms and}{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid11556405  nuclear irregularity/budding}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 . Megakaryocytes are present with many large hyperlobated forms present. Blasts are not increased. Scattered lymphocytes and plasma cells are present.\par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid13516055 PERIPHERAL BLOOD}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 \par No CBC available within 7 days\par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid8413119 {\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\cf1\insrsid13516055 Morpholgoy:\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cf1\insrsid13516055\charrsid11556405 WBC: }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cf1\insrsid13516055 Leukocytosis with left shift and occasional hyposegmented and hypogranular leukocytes}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cf1\insrsid13516055\charrsid11556405 . }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cf1\insrsid13516055 Rare c}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cf1\insrsid13516055\charrsid11556405 irculating blasts seen.\par RBC: Mild }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cf1\insrsid13516055 normocytic}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cf1\insrsid13516055\charrsid11556405  anemia. Anisopoikilocytosis. Increased nucleated RBC.\par PLT: }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cf1\insrsid13516055 Unremarkable morphology}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cf1\insrsid13516055\charrsid11556405 .\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cf1\insrsid13516055 Findings are consistent with leukoerythroblastosis.\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cf1\insrsid13516055\charrsid11556405 \par }{\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\cf1\insrsid13516055 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid13516055 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid14121195 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid13516055 IMMUNOHISTOCHEMISTRY}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 \par CD34 highlights rare blasts comprising less than 5% of the total cellularity.\par CD117 highlights erythroid and myeloid precursors\par TDT highlights rare lymphoid precursors less than 5% of the total cellularity\par CD61 highlights variably sized megakaryocytes.\par CD71 highlights erythroid precursors. \par MPO highlights myeloid precursors.\par Lysozyme highlights scattered monocytes and neutrophils\par \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid13516055\charrsid8921095 FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9507)}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid8921095 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid11556405 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055\charrsid11556405 Interpretation:\par 1. Abnormal myeloid blast population detected. The immunophenotype of this population is similar to that seen in prior sample [F22-9043] \par Abnormal myeloid blast population represents 0.86% of WBC.\par Immunophenotype:\par Abnormal: CD7 (partial), CD13 (variable - dim to intermediate), CD33 (dim), CD34 (bright), CD117 (bright), CD123 (uniform - intermediate), HLA-DR (dim)\par Normal: CD4, CD36, CD38, CD45, CD45RA, CD71, CD105, CD371 (clec12a), CD90\par Negative: CD2, CD5, CD10, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64, CD42b\par \par \par 2. Abnormal B cell population detected. \par The findings are consistent with previously identified chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or CLL-like monoclonal B-cell lymphocytosis.\par Abnormal B cell population represents 0.0072% of WBC.\par Immunophenotype:\par Abnormal: CD5 (positive), CD20 (dim), CD23 (partial), CD43 (positive), CD79b (negative), CD81 (dim), ROR1 (positive)\par Normal: CD200, CD19, CD40, CD45\par Negative: CD38, CD10, CD3}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid14121195 {\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\cf1\insrsid13516055 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.}{\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\insrsid13516055 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid14121195 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid13516055 CYTOGENETIC STUDIES}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 \par Cytogenetic analysis will be reported separately. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid13516055 See separate report CG22-6575}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 \par \~\par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid13516055 MOLECULAR STUDIES}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055  \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid10819200 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid13516055 Molecular analysis will be reported separately. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid13516055 See separate report M22-37226\par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}"
H22-3444;S11;MSKU - 2023-04-17 07.29.00.ndpi,Peripheral Blood Smear,2023-04-17,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: SMM
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Plasma cell neoplasm, 
20-30% involvement by CD138 immunohistochemistry.
10% involvement by aspirate differential
4.1% involvement by flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.


BONE MARROW BIOPSY
Quality: Adequate  
Cellularity: Variable, overall 50%
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes: Adequate   
Plasma cells: Increased    

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                1%
Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           4%
Neutrophils/Bands      32%
Monocytes           2%
Eosinophils           2%
Basophils           1%
Erythroid Precursors      30%
Plasma Cells           10%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           1.7

Morphology: 
Marrow spicules: Spicular 
Cellularity: Cellular 
Plasma cell morphology: Small to intermediate
Myeloid lineage: Orderly maturation 
Erythroid Lineage: Orderly maturation 
Megakaryocytes:  Present 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 20-30% of cellularity. 
Kappa and lambda immunostains show the plasma cells are lambda light chain restricted.
BCMA highlights 70% of plasma cells, (1-2+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-4459) 
1. Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.

Abnormal plasma cell population comprises 99.3% of total plasma cells.
Abnormal plasma cell population represents 4.1% of WBC.

Immunophenotype:
Abnormal: CD19 (negative), CD20 (partial), CD27 (bimodal - negative to intermediate), CD45 (variable - negative to intermediate), CD38(dim), CD56 (partial), CD81 (variable - negative to dim), cytoplasmic Lambda (restriction)
Normal: CD138, CD229, CD319
Negative: CD117, cytoplasmic Kappa

Number of cells acquired: 5.6 million 

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

Number of cells acquired: 259 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (04/27/2022)
WBC 4.7 [4.0-11.0 K/mcL] 
RBC 4.82 [3.95-5.54 M/mcL] 
HGB 13.9 [12.5-16.2 g/dL] 
HCT 42.4 [37.5-49.3 %] 
MCV 88 [80-98 fL] 
MCH 28.8 [27.0-33.0 pg] 
MCHC 32.8 [31.0-36.5 g/dL] 
RDW 14.0 [12.2-15.1 %] 
Platelets. 222 [160-400 K/mcL] 

Neutrophil 62.7 [32.5-74.8 %] 
Mono 10.8 [0.0-12.3 %] 
Eos 2.8 [0.0-4.9 %] 
Baso 1.3 [0.0-1.5 %] 
Immature Granulocyte 0.2 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 22.2 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 3.0 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL]

Morphology: 
No circulating plasma cells seen on scanning

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-3057, CG22-3058.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-18141.
"
H22-1731;S11;MSKR - 2023-04-19 16.20.06.ndpi,Peripheral Blood Smear,2023-04-19,"Clinical Diagnosis: AML
Clinical Hx/Op Findings: AML
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate, and peripheral blood smears: 
     - Acute myeloid leukemia with monocytic differentiation, 44% blasts by aspirate differential count.
     - Flow cytometry studies detect two separate abnormal B-cell populations (0.061% of WBC and 0.0054% of WBC); one of which with CLL/SLL like immunophenotype.

See comment.
  
COMMENT:  Background hematopoiesis shows dysplasia.  Correlation with molecular genetic, genomic, and cytogenetic studies is required for further classification of the acute myeloid leukemia.

A morphologic correlate of the abnormal B-cell populations detected by flow cytometry studies is not seen.  The findings likely represent monoclonal B-cell lymphocytosis.  Suggest correlation with clinical findings and imaging studies.  

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular 
M:E ratio: Normal in the limited background hematopoiesis. 
Blasts: Increased, medium to large blasts with oval to irregular/folded nuclei, fine chromatin, occasional distinct nucleoli and small to moderate cytoplasm.
Myeloid lineage: Reduced. Shows progressive maturation. 
Erythroid lineage: Reduced and shows progressive maturation
Megakaryocytes: Present, with small hypolobated forms and enlarged forms with hyperlobulated nuclei and few forms with widely separated nuclear lobes
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate

Blasts                44%
Promyelocytes           2%
Myelocytes           5%
Metamyelocytes           6%
Neutrophils/Bands      25%
Monocytes           4%
Eosinophils           1%
Erythroid Precursors      7%
Lymphocytes           6%
Number of Cells Counted 500
M:E Ratio           6.1

Morphology:
- Spicular and cellular aspirate smears show expanded population of medium to large blasts with oval to irregular/folded nuclei, fine chromatin, distinct nucleoli and scant to moderate cytoplasm. Maturing myeloid and erythroid elements are reduced and show dysplastic changes. Megakaryocytes are present with occasional hypolobated forms.  

PERIPHERAL BLOOD
CBC (03/01/2022):
WBC 32.7 H [4.0-11.0 K/mcL] 
RBC 2.84 L [3.95-5.54 M/mcL] 
HGB 8.9 L [12.5-16.2 g/dL] 
HCT 26.8 L [37.5-49.3 %] 
MCV 94 [80-98 fL] 
MCH 31.3 [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 14.4 [12.2-15.1 %] 
Platelets 115 L [160-400 K/mcL] 

Neutrophil 61.0 [32.5-74.8 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 6.0 H [0.0-0.0 %] 
Myelocyte 4.0 H [0.0-0.0 %] 
Promyelocyte 3.0 H [0.0-0.0 %] 
Metamyelocyte 3.0 H [0.0-0.0 %] 
Lymph 16.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 20.0 H [1.5-7.5 K/mcL] 
Abs Mono 2.3 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 2.0 H [0.0-0.0 K/mcL] 
Abs Myelocytes 1.3 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 1.0 H [0.0-0.0 K/mcL] 
Abs Meta 1.0 H [0.0-0.0 K/mcL] 
Abs Lymph 5.2 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
WBC: Circulating blast/blast equivalents are seen.
RBC: Normocytic anemia, mild anisocytosis
PLT: Mild thrombocytopenia. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
The blasts are mostly negative for CD34. Rare CD34 positive blasts are seen. CD117 highlights a subset of the blasts (weak).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-2263)
1. Expanded abnormal myeloid blast population detected.

Total myeloid blast/blast equivalents represent 27% of WBC.
Abnormal myeloid blast population represents 7.3% of WBC.
Expanded immature monocyte population is seen, represents 19.7% of WBC.
Monocytosis is seen, 35.4% of WBC.

Immunophenotype:
Abnormal: CD11b (partial), CD13 (uniform - bright), CD33 (uniform - bright), CD34 (bimodal - negative to dim), CD38 (dim), CD117 (uniform - intermediate), CD371 (clec12a) (bright), HLA-DR (variable - negative to intermediate)
Normal: CD4, CD36, CD45, CD45RA, CD71, CD105, CD123
Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, cytoplasmic CD3, cytoplasmic CD79a, cytoplasmic MPO, surface Kappa, surface Lambda

Number of cells acquired: 915 thousand 

2. Abnormal immature monocyte population detected.

Immunophenotype:
Abnormal: CD11b (positive), CD13 (negative), CD14 (negative), CD56 (partial), CD117 (positive), HLA-DR (bright)
Normal: CD4, CD10, CD15, CD33, CD36, CD38, CD45, CD45RA, CD64, CD105, CD123, CD371 (clec12a)
Negative: CD2, CD19, CD25

Two abnormal B cell populations detected.
3. The first abnormal B cell population represents 0.061% of WBC.

The immunophenotype of this abnormal B cell population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.


Immunophenotype:
Abnormal: CD20 (bright), surface Kappa (restriction)
Normal: CD19, CD22, CD45
Negative: CD5, CD10, CD38, CD25, CD279 (PD1), CD3, CD14, surface Lambda


4. The second abnormal B cell population represents 0.0054% of WBC.
Flow cytometry reveals an abnormal B cell population with CLL/SLL-like immunophenotype (see below).


Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (positive), CD43 (positive), CD79b (negative), CD81 (dim), CD200 (positive), ROR1 (positive), CD19 (dim), surface Kappa (restriction - dim)
Normal: CD40, CD45
Negative: CD38, CD10, CD3, surface Lambda


5. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 466 thousand 

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-2243)
1. Abnormal myeloid blast population detected.
Abnormal myeloid blast population represents 10.8% of WBC.
Monocytosis is seen, 10.9% of WBC.

Immunophenotype:
Abnormal: CD13 (uniform - bright), CD33 (uniform - bright), CD34 (bimodal - negative to dim), CD38 (variable - negative to dim), CD117 (uniform - intermediate), HLA-DR (dim)
Normal: CD4, CD36, CD45, CD45RA, CD71, CD105, CD123, CD371 (clec12a)
Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, cytoplasmic CD3, cytoplasmic CD79a, cytoplasmic MPO, surface Kappa, surface Lambda

Number of cells acquired: 897 thousand 

Two abnormal B cell populations detected.
2. The first abnormal B cell population represents 0.97% of WBC.

The immunophenotype of this abnormal B cell population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

Immunophenotype:
Abnormal: CD19 (slightly bright), CD20 (slightly bright), CD22 (slightly dim), surface Kappa (restriction)
Normal: CD45
Negative: CD5, CD10, CD38, CD25, CD279 (PD1), CD3, CD14, surface Lambda


3. The second abnormal B cell population represents 0.061% of WBC.

Flow cytometry reveals an abnormal B cell population with CLL/SLL-like immunophenotype (see below).

Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (positive), CD43 (positive), CD79b (dim), CD81 (dim), CD200 (bright), ROR1 (positive), CD19 (dim), surface Kappa (restriction - dim)
Normal: CD40, CD45
Negative: CD38, CD10, CD3, surface Lambda


4. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 487 thousand
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-1502.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-8886 and M22-8887.
"
H22-3104;S10;MSK6 - 2023-05-31 19.47.40.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Lymphoma
Clinical Hx/Op Findings: staging
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Mantle cell lymphoma, blastoid variant, with focal necrosis, involving 40% of marrow space and 90% of marrow cellularity with PAX5 immunohistochemistry.
    - Bone marrow with patchy cellularity, reduced trilineage hematopoiesis and focal stromal injury/therapy-effect.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
The core biopsy is adequate and shows bone marrow with patchy areas of cellularity (comprising 40% of marrow space) with partial crush artifact that are nearly entirely replaced by sheets of intermediate sized atypical lymphoid cells with blastoid morphology. There is an intervening patch of nearly acellular area consistent with stromal injury/therapy-effect as well as an area of tumor necrosis. Background trilineage hematopoiesis is markedly reduced. 

The aspirate smears are aspicular, hemodiluted and paucicellular. There are many intermediate sized atypical lymphoid cells with slightly irregular nuclear contours, dispersed chromatin, variably conspicuous nucleoli and scant to moderate amount of cytoplasm. The remainder of the cellularity is comprised of mostly mature granulocytes and monocytes, a few myeloid and erythroid precursors, and rare megakaryocytes. The touch imprints are non-contributory.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
Immunostains are interpreted in the non-crushed areas. 
The neoplastic cells
Express: PAX5 (40% of marrow space and 90% of marrow cellularity), cyclin D1 and SOX11
Do not express: CD20
Others: CD3 highlights T-cells, <5% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-4012) 
Abnormal B cell population detected. 
The immunophenotype of this abnormal B cell population is similar to that seen previously (F22-2893) and is compatible with previously diagnosed mantle cell lymphoma (MCL).

Abnormal B cell population represents 26.8% of WBC.

Immunophenotype:
Abnormal: CD5 (positive - partial), CD20 (negative), CD79b (dim), ROR1 (positive), CD19 (variable - negative to dim), CD38 (uniform - bright)
Normal: CD81, CD40, CD45
Negative: CD23, CD43, CD200, CD10, CD3

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (4/15/2022)
WBC 10.6 [4.0-11.0 K/mcL] 
RBC 3.05 L [3.95-5.54 M/mcL] 
HGB 8.8 L [12.5-16.2 g/dL] 
HCT 25.9 L [37.5-49.3 %] 
MCV 85 [80-98 fL] 
MCH 28.9 [27.0-33.0 pg] 
MCHC 34.0 [31.0-36.5 g/dL] 
RDW 13.8 [12.2-15.1 %] 
Platelets 74 L [160-400 K/mcL] 

Neutrophil 78.0 H [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 4.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 9.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 8.2 H [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.4 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL]

Morphology:
WBCs: Many atypical intermediate sized cells with blastoid morphology; Neutrophilia and occasional left-shifted granulocytes; rare pseudo Pelger-Huet forms. 
RBCs: Normocytic normochromic anemia with increase in polychromasia. 
Platelets: Thrombocytopenia; unremarkable morphology.     

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES (CG22-2714)
FISH ANALYSIS:
Translocation of CCND1 (11q13.3) detected in 4% of cells.

No evidence of MYC (8q24.1) rearrangement.
No evidence of TP53 (17p13.1) deletion or loss of chromosome 17.

Please refer to CG22-2820 for SNP-array.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-16618.
"
H22-9215;S16;MSK1 - 2023-06-15 13.42.22.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Lymphoma\par Clinical Hx/Op Findings: for diagnosis - MZL vs MCL vs CLL\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, left posterior iliac crest,  biopsy, aspirate, and peripheral blood smears: \~\~\par      - Involvement by B-cell lymphoma (20% by CD20 immunohistochemistry)\par      - Hypercellular marrow with trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  The overall morphologic and immunophenotypic findings are consistent with involvement by a B-cell lymphoma with an intrasinusoidal infiltration pattern. The findings likely represent B-cell lymphoma of splenic origin and these changes may be seen in splenic red pulp lymphoma/hairy cell leukemia variant versus progression of splenic marginal zone lymphoma. Correlation with pending molecular and cytogenetic studies is recommended for definitive classification. The case was also reviewed by Dr. Ahmet Dogan (Hematopathology Service) who agrees with the diagnosis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy specimen shows hypercellular bone marrow (50% cellularity) with increased atypical lymphocytes scattered and in aggregates. The atypical lymphocytes are mostly small in size with irregular nuclear contours, condensed chromatin, and mild to moderate amounts of pale cytoplasm. There is trilineage maturing hematopoiesis. Blasts are not increased. Overt dysplasia is not appreciated.\par\par Aspirate smears are aspicular, hypocellular and mostly demonstrate peripheral blood elements.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD3 highlights scattered small T-cells. \par CD20 highlights atypical B lymphocytes present throughout the marrow in an intrasinusoidal pattern. \par The atypical lymphocytes are positive for PAX5, CD11c, CD103 (weak),  \par They are negative for CD25, LEF1, CD23, cyclin D1, CMYC (<10%), MUM1, BCL6.\par CD10 is difficult to interpret given the staining on granulocytes, but favored to be negative in the atypical lymphocytes.\par The Ki67 is difficult to interpret due to staining of background hematopoiesis but favored to be less than 10%.\par Staining for P53 and BRAF V600E is negative.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-11987)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par 1. Abnormal B cell population detected.\par Abnormal B cell population represents 21.1% of WBC.\par Immunophenotype:\par Abnormal: CD19 (bright), CD20 (bright), CD22 (bright), CD11c (positive), CD103 (bimodal - negative to intermediate), surface Kappa (restriction), Forward Scatter (increased), Side Scatter (increased)\par Normal: CD38, CD200, CD45\par Negative: CD5, CD10, CD25, CD279 (PD1), CD3, CD14, surface Lambda\par\par Number of cells acquired: 397 thousand \par\par 2. Abnormal B cell population detected. \par Flow cytometry reveals an abnormal B cell population with CLL/SLL-like immunophenotype (see below).\par Abnormal B cell population represents 0.062% of WBC.\par Immunophenotype:\par Abnormal: CD5 (positive), CD20 (dim), CD23 (positive), CD43 (positive), CD79b (dim), CD81 (dim), CD200 (bright), ROR1 (positive)\par Normal: CD19, CD40, CD45\par Negative: CD38, CD10, CD3\par\par Number of cells acquired 544 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/01/2022 ):\par WBC 6.7 [4.0-11.0 K/mcL] \par RBC 4.88 [3.95-5.54 M/mcL] \par HGB 13.3 [12.5-16.2 g/dL] \par HCT 42.1 [37.5-49.3 %] \par MCV 86 [80-98 fL] \par MCH 27.3 [27.0-33.0 pg] \par MCHC 31.6 [31.0-36.5 g/dL] \par RDW 16.3 H [12.2-15.1 %] \par Platelets. 103 L [160-400 K/mcL] \par\par Neutrophil 44.0 [32.5-74.8 %] \par Mono 9.0 [0.0-12.3 %] \par Eos 2.0 [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Lymph 22.0 [12.2-47.4 %] \par Abnormal Lymphoid Cells 22.0 H [0.0-0.0 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 2.9 [1.5-7.5 K/mcL] \par Abs Mono 0.6 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.1 [0.0-0.2 K/mcL] \par Abs Lymph 2.9 [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] \par\par Morphology:\par WBC: circulating atypical lymphocytes with prominent nucleoli, condensed chromatin, and moderate amounts of basophilic cytoplasm\par RBC: Unremarkable\par PLT: Thrombocytopenia\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8244, CG22-8245. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-47095, M22-47339, M22-47340, M22-47343.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-6428;S16;MSK4 - 2023-06-15 15.10.18.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch31505\stshfloch31506\stshfhich31506\stshfbi0\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri{\*\falt Calibri};}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}
{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}
{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE{\*\falt Calibri};}
{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr{\*\falt Calibri};}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek{\*\falt Calibri};}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur{\*\falt Calibri};}
{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew){\*\falt Calibri};}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic){\*\falt Calibri};}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic{\*\falt Calibri};}
{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese){\*\falt Calibri};}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;
\red0\green0\blue0;}{\*\defchp \fs22\loch\af31506\hich\af31506\dbch\af31505 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*
\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused 
Normal Table;}{\s15\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\f1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext15 \spriority0 Arial;}}
{\*\rsidtbl \rsid7672030\rsid9721198\rsid9902195\rsid12144888\rsid12403534\rsid14899757}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info
{\operator Chan, Alexander Y./Pathology}{\creatim\yr2022\mo8\dy10\hr11\min38}{\revtim\yr2022\mo8\dy10\hr11\min38}{\version2}{\edmins0}{\nofpages1}{\nofwords14}{\nofchars87}{\nofcharsws99}{\vern31}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/
word/2003/wordml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata1\grfdocevents0\validatexml0\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors0\horzdoc\dghspace120\dgvspace120\dghorigin1701
\dgvorigin1984\dghshow0\dgvshow3\jcompress\viewkind1\viewscale130\rsidroot9721198 \fet0{\*\wgrffmtfilter 2450}\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2
\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}\pard\plain \ltrpar\s15\ql \li0\ri0\nowidctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\af1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \fs18\insrsid9902195 \hich\af1\dbch\af31505\loch\f1 Clinical Diagnosis: Lymphoma\par \hich\af1\dbch\af31505\loch\f1 Clinical Hx/Op Findings: bone met}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \insrsid9902195 \hich\af1\dbch\af31505\loch\f1 astasis}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \fs18\insrsid9902195 \par \hich\af1\dbch\af31505\loch\f1 Requested Studies: Gross/Micro\par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Involved by large B-cell lymphoma with germinal center phenotype and aggressive features, 60-70% involvement by immunohistochemistry; see comment.
    - Hypercellular bone marrow with reduced maturing trilineage hematopoiesis.

COMMENT: Findings of dual expression of BCL2 and MYC, P53 expression, and extensive necrosis may be associated with aggressive behavior. Correlation with cytogenetic studies is required to assess for rearrangements of MYC, BCL2, and/or BCL6 genes. Close clinical follow-up is advised. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
The adequate biopsy specimen shows a hypercellular (~60-70%) bone marrow with extensive marrow replacement by an atypical lymphoid proliferation composed of large atypical lymphoid cells with variable amounts of cytoplasm, irregular nuclei, vesicular chromatin, and distinct nucleoli. Apoptotic and mitotic activity is seen. Areas of the marrow show geographic necrosis. Reduced background maturing trilineage hematopoiesis is seen. Aspirate smears are suboptimal (aspicular, hemodilute, hypocellular), but show extensive replacement of the marrow by atypical lymphoid cells.
The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
The neoplastic cells (~60-70% involvement by immunohistochemistry)
Express: PAX5, CD10, BCL6, BCL2, MYC (appears >40%), P53 (>50%)
Do not express: CD3, CD20, CD23, CD30, CD34, TdT, MUM1, EBER (in situ hybridization stain)
Other: CD23 shows no follicular dendritic cell meshworks.
The Ki-67 stain is difficult to interpret due to technical artifacts but proliferative index appears to be at least 70%.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-8452) 
1. Abnormal B cell population with larger size detected. Per clinical notes and outside reports, the patient has a history of a diffuse large B-cell lymphoma with germinal center phenotype, findings are compatible with peripheral blood involvement by a large B-cell lymphoma of germinal center phenotype.

Immunophenotype:
Abnormal: CD10 (positive), CD20 (negative), CD22 (bright), CD38 (uniform - intermediate), Forward Scatter (increased), Side Scatter (increased), no definite light chain expression
Normal: CD19, CD45
Negative: CD5, CD25, CD279 (PD1), CD3, CD14, surface Kappa, surface Lambda, Tdt

2. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  
Number of cells acquired: 429 thousand 

3. No abnormal immature B cell population detected. Virtually no immature B cells seen.                   
Number of cells acquired 301 thousand
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (08/05/2022):
WBC 3.0 L [4.0-11.0 K/mcL] 
RBC 3.87 L [3.95-5.54 M/mcL] 
HGB 10.3 L [12.5-16.2 g/dL] 
HCT 30.5 L [37.5-49.3 %] 
MCV 79 L [80-98 fL] 
MCH 26.6 L [27.0-33.0 pg] 
MCHC 33.8 [31.0-36.5 g/dL] 
RDW 13.7 [12.2-15.1 %] 
Platelets 75 L [160-400 K/mcL] 

Neutrophil 49.0 [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 4.0 H [0.0-0.0 %] 
Promyelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 3.0 H [0.0-0.0 %] 
Lymph 35.0 [12.2-47.4 %] 
Variant Lymph 1.0 [0.0-2.0 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Circulating atypical lymphoid cells seen.
RBC: Normocytic, normochromic anemia.
PLT: Moderate thrombocytopenia. 

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-5801, CG22-5802, CG22-5902.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-33204.
"
H22-10246;S15;MSK6 - 2023-06-15 12.31.04.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Lymphoma, Waldenstrom's\par Clinical Hx/Op Findings: for diagnosis\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: \~\~\par      - Extensive involvement by low grade B-cell lymphoma with plasmacytic differentiation (80% with CD20 immunohistochemistry), see note. \par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par Note: The overall findings favor Lymphoplasmacytic lymphoma (LPL) over marginal zone lymphoma and other low grade B-cell lymphoma entities. Correlation with molecular testing for the status of MYD88 and CXCR4 mutations is recommended.  \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy and aspicular/hemodiluted aspirate specimens show hypercellular bone marrow (80% cellularity). There is reduced\~trilineage maturing hematopoiesis with markedly increased interstitial lymphoplasmacytic proliferation.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD20 (80% of total cellularity) and PAX5 highlight markedly increased interstitial tumor cells. CD138 stains markedly increased plasmacytoid cells (60-70% of total cellularity). The tumor cells are kappa light chains restricted by kappa/lambda light chain stains. CD3 highlights scattered and small clusters of T cells.\par\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-13338)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal B- and plasma cell populations detected.\par The abnormal B cell population has the same light chain restriction as the abnormal plasma cell population mentioned below. Given the similar light chain restriction, these two populations likely represent manifestations of the same neoplasm, but the immunophenotypic profiles do not allow specific classification.  Clinical and morphologic correlation is advised.\par\par\par Abnormal B cell population represents 11.7% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (dim), CD20 (dim), CD22 (dim), surface Kappa (restriction)\par Normal: CD38, CD45\par Negative: CD5, CD10, CD25, CD279 (PD1), CD3, CD14, surface Lambda\par\par Number of cells acquired: 484 thousand \par\par 2. Abnormal plasma cell population detected.\par The abnormal plasma cell population has the same light chain restriction (see immunophenotype below) as the abnormal B cell population mentioned above. \par\par Abnormal plasma cell population represents 0.16% of WBC.\par Abnormal plasma cell population comprises 94.7% of total plasma cells.\par\par Immunophenotype:\par Abnormal: CD19 (partial - dim), CD27 (negative), cytoplasmic Kappa (restriction)\par Normal: CD138, CD38, CD229, CD319, CD45, CD81\par Negative: CD20, CD56, CD117, cytoplasmic Lambda\par\par Number of cells acquired 23.7 thousand \par\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (12/06/2022):\par WBC 5.1 [4.0-11.0 K/mcL] \par RBC 2.66 L [3.80-5.00 M/mcL] \par HGB 8.6 L [11.2-15.4 g/dL] \par HCT 27.8 L [34.3-46.0 %] \par MCV 105 H [80-98 fL] \par MCH 32.3 [27.0-33.0 pg] \par MCHC 30.9 L [31.0-36.5 g/dL] \par RDW 14.6 [12.2-15.1 %] \par Platelets 232 [160-400 K/mcL] \par\par Neutrophil 59.3 [32.5-74.8 %] \par Mono 8.8 [0.0-12.3 %] \par Eos 0.6 [0.0-4.9 %] \par Baso 0.4 [0.0-1.5 %] \par Immature Granulocyte 0.4 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 30.5 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 3.0 [1.5-7.5 K/mcL] \par Abs Mono 0.4 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 1.6 [0.9-3.2 K/mcL] \par\par Morphology:\par WBC: Unremarkable.\par RBC: Macrocytic anemia. Rouleaux is seen. \par PLT: Unremarkable.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-9225.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-1072;S11;MSKZ - 2023-05-27 01.06.01.ndpi,Peripheral Blood Smear,2023-05-27,"Clinical Diagnosis: AML
Clinical Hx/Op Findings: relapsed AML associated with a t(16;16) after an allo transplant. Confirm relapsed disease
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia with t(16;16)(p13.1;q22), 65% blast by aspirate differential count, see comment. 
       
COMMENT: Per communication with Dr. Yanming Zhang, cytogenetic lab, preliminary cytogenetic findings show t(16;16). Findings are consistent with relapsed acute myeloid leukemia with t(16;16)(p13.1;q22). Please see CG22-862 for complete results of cytogenetic work up. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: >90%
M:E ratio: N/A
Blasts: Markedly increased 
Myeloid lineage: Present with left shifted maturation and expansion of eosinophil precursors and mature eosinophils.
Erythroid lineage: Reduced
Megakaryocytes: Reduced with occasional hypolobated forms
Lymphocytes: Rare 
Plasma cells: Rare
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0 out of 3). 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts 65%
Promyelocytes 2%
Myelocytes 1%
Neutrophils/Bands 8%
Monocytes 2%
Eosinophils 5%
Basophils 2%
Erythroid Precursors 9%
Lymphocytes 6%
Number of Cells Counted 500
M:E Ratio 2.2

Morphology:
Spicular and cellular aspirate smears show an expanded population of intermediate to large cells with scant amphophilic cytoplasm, with round to oval nuclei, fine chromatin and distinct nucleoli, accounting for 65% of the total cellularity. Eosinophil precursors and mature forms account for 5% of the total cellularity. Promyelocytes and myelocytes show coarse, violet cytoplasmic vacuoles. Erythroid elements are reduced and show maturation without significant dysplasia. Megakaryocytes are reduced and have mostly unremarkable morphology.

PERIPHERAL BLOOD
CBC (02/07/2022):
WBC 3.8 L [4.0-11.0 K/mcL] 
RBC 3.31 L [3.80-5.00 M/mcL] 
HGB 11.4 [11.2-15.4 g/dL] 
HCT 33.3 L [34.3-46.0 %] 
MCV 101 H [80-98 fL] 
MCH 34.4 H [27.0-33.0 pg] 
MCHC 34.2 [31.0-36.5 g/dL] 
RDW 17.1 H [12.2-15.1 %] 
Platelets. 64 L [160-400 K/mcL] 

Neutrophil 9.0 L [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 42.0 H [0.0-0.0 %] 
Lymph 37.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.3 L [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 1.6 H [0.0-0.0 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
RBC: Anisopoikilocytosis.
WBC: Increased circulating blasts (42%). Neutropenia.
PLT: Moderate thrombocytopenia.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight expanded blasts, 60-70% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1356)
1. Expanded abnormal myeloid blast population detected.

Total myeloid blast/blast equivalents represent 72.6% of WBC.
Abnormal myeloid blast population represents 69.7% of WBC.
Expanded immature monocyte population is seen, represents 2.9% of WBC.
Monocytosis is seen, 11.6% of WBC.

Immunophenotype:
Abnormal: CD2 (partial), CD13 (variable - negative to bright), CD15 (variable - negative to bright), CD33 (bright), CD34 (variable - negative to bright), CD38 (dim), CD45RA (bright), CD117 (dim), CD371 (clec12a) (partial), HLA-DR (dim)
Normal: CD4, CD36, CD45, CD71, CD105, CD123, cytoplasmic MPO
Negative: CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, cytoplasmic CD3, cytoplasmic CD79a, surface Kappa, surface Lambda

Number of cells acquired: 778 thousand 

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 460 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-862.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-5515, M22-5516, M22-5517, M22-5518, M22-5519. 
"
H22-1072;S11;MSKZ - 2023-04-19 16.31.59.ndpi,Peripheral Blood Smear,2023-05-27,"Clinical Diagnosis: AML
Clinical Hx/Op Findings: relapsed AML associated with a t(16;16) after an allo transplant. Confirm relapsed disease
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia with t(16;16)(p13.1;q22), 65% blast by aspirate differential count, see comment. 
       
COMMENT: Per communication with Dr. Yanming Zhang, cytogenetic lab, preliminary cytogenetic findings show t(16;16). Findings are consistent with relapsed acute myeloid leukemia with t(16;16)(p13.1;q22). Please see CG22-862 for complete results of cytogenetic work up. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: >90%
M:E ratio: N/A
Blasts: Markedly increased 
Myeloid lineage: Present with left shifted maturation and expansion of eosinophil precursors and mature eosinophils.
Erythroid lineage: Reduced
Megakaryocytes: Reduced with occasional hypolobated forms
Lymphocytes: Rare 
Plasma cells: Rare
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0 out of 3). 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts 65%
Promyelocytes 2%
Myelocytes 1%
Neutrophils/Bands 8%
Monocytes 2%
Eosinophils 5%
Basophils 2%
Erythroid Precursors 9%
Lymphocytes 6%
Number of Cells Counted 500
M:E Ratio 2.2

Morphology:
Spicular and cellular aspirate smears show an expanded population of intermediate to large cells with scant amphophilic cytoplasm, with round to oval nuclei, fine chromatin and distinct nucleoli, accounting for 65% of the total cellularity. Eosinophil precursors and mature forms account for 5% of the total cellularity. Promyelocytes and myelocytes show coarse, violet cytoplasmic vacuoles. Erythroid elements are reduced and show maturation without significant dysplasia. Megakaryocytes are reduced and have mostly unremarkable morphology.

PERIPHERAL BLOOD
CBC (02/07/2022):
WBC 3.8 L [4.0-11.0 K/mcL] 
RBC 3.31 L [3.80-5.00 M/mcL] 
HGB 11.4 [11.2-15.4 g/dL] 
HCT 33.3 L [34.3-46.0 %] 
MCV 101 H [80-98 fL] 
MCH 34.4 H [27.0-33.0 pg] 
MCHC 34.2 [31.0-36.5 g/dL] 
RDW 17.1 H [12.2-15.1 %] 
Platelets. 64 L [160-400 K/mcL] 

Neutrophil 9.0 L [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 42.0 H [0.0-0.0 %] 
Lymph 37.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.3 L [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 1.6 H [0.0-0.0 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
RBC: Anisopoikilocytosis.
WBC: Increased circulating blasts (42%). Neutropenia.
PLT: Moderate thrombocytopenia.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight expanded blasts, 60-70% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1356)
1. Expanded abnormal myeloid blast population detected.

Total myeloid blast/blast equivalents represent 72.6% of WBC.
Abnormal myeloid blast population represents 69.7% of WBC.
Expanded immature monocyte population is seen, represents 2.9% of WBC.
Monocytosis is seen, 11.6% of WBC.

Immunophenotype:
Abnormal: CD2 (partial), CD13 (variable - negative to bright), CD15 (variable - negative to bright), CD33 (bright), CD34 (variable - negative to bright), CD38 (dim), CD45RA (bright), CD117 (dim), CD371 (clec12a) (partial), HLA-DR (dim)
Normal: CD4, CD36, CD45, CD71, CD105, CD123, cytoplasmic MPO
Negative: CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, cytoplasmic CD3, cytoplasmic CD79a, surface Kappa, surface Lambda

Number of cells acquired: 778 thousand 

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 460 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-862.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-5515, M22-5516, M22-5517, M22-5518, M22-5519. 
"
H22-1038;S11;MSK1 - 2023-05-31 22.13.07.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Leukemia
Clinical Hx/Op Findings: New Dx
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     -  B-lymphoblastic leukemia/lymphoma, 82% blast by aspirate differential count, see comment.
  
COMMENT: Cases of B-ALL developing after cytotoxic therapy for a prior malignancy are reported (PMID: 31869410). Please correlate with the results of corresponding cytogenetic and molecular analysis. 
CD19, PAX5, TdT and pan-cytokeratin immunohistochemistry are in progress, and the results will be reported as an addendum.  

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: 80-90%
M:E ratio: N/A 
Blasts: Markedly increased, replacing marrow spaces. 
Myeloid lineage: Rare
Erythroid lineage: Present, decreased. 
Megakaryocytes: Few present 
Lymphocytes: Rare 
Plasma cells: Rare
Reticulin stain shows no increase in reticulin fibrosis. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate 
Blasts 82%
Promyelocytes 1%
Neutrophils/Bands 3%
Monocytes 1%
Erythroid Precursors 10%
Plasma Cells 2%
Lymphocytes 1%
Number of Cells Counted 500
M:E Ratio 0.5

Morphology:
Spicular and cellular aspirate smears show an expanded population of intermediate sized cells with scant amphophilic cytoplasm, bearing coarse vacuoles, with round to oval nuclei, fine chromatin and distinct nucleoli, accounting for 82% of cells. Background hematopoietic elements are limited. Myeloid and erythroid elements show maturation without significant dysplasia. Megakaryocytes are present and display unremarkable morphology.

PERIPHERAL BLOOD
CBC (2/4/2022):
WBC 2.9 L [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 2.72 L [3.95-5.54 M/mcL] 
HGB 8.1 L [12.5-16.2 g/dL] 
HCT 24.4 L [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 29.8 [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 24.4 H [12.2-15.1 %] 
Platelets. 24 L [160-400 K/mcL] 

Neutrophil 29.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 19.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 47.0 [12.2-47.4 %] 
Nucleated RBC 16.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 0.8 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.5 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL]

Morphology:
RBC: Anisopoikilocytosis. Increased nucleated RBC present. Normochromic, normocytic anemia.
WBC: Increased circulating blasts. Neutropenia.
PLT: Thrombocytopenia.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
Blasts are negative for CD34 and CD117 (<1% of cells are highlighted with CD34 and CD117).
CD19, PAX5, TdT and pan-cytokeratin are in progress, and the results will be reported as an addendum.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1317)
Interpretation: 
1. Abnormal immature B cell population detected.                      
Abnormal immature B cell population represents 57.7% of the mononuclear cells.
Abnormal immature B cell population represents 57.7% of WBC.

Immunophenotype:
Abnormal: CD20 (partial), CD34 (negative), CD38 (dim), CD81 (dim), CD73/CD304 (uniform - intermediate), CD66c/CD123 (positive)
Normal: CD10, CD19, CD22, CD24, CD45
Negative: CD86, CD66b

Number of cells acquired 540 thousand 

2. No abnormal myeloid blast, mature B or mature T cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.
Myeloid blast population with an unremarkable phenotype represents 0.97% of WBC.

Number of cells acquired: 676 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-837.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-5351, M22-5352, M22-5353, M22-5354.
"
H22-501;S11;MSKV - 2023-04-19 16.37.45.ndpi,Peripheral Blood Smear,2023-04-19,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: MM
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Plasma cell neoplasm, 
20-30% involvement by CD138 immunohistochemistry.
33% involvement by aspirate differential
9.7% involvement by 12 color flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality: Limited, small
Cellularity: Could not be precisely assessed
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes: Present 
Plasma cells: Increased    

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality:  Adequate

Blasts                1%
Promyelocytes           1%
Myelocytes           8%
Metamyelocytes           5%
Neutrophils/Bands      21%
Monocytes           2%
Eosinophils           1%
Erythroid Precursors      25%
Plasma Cells           33% (5% to 60%)
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           1.5

Morphology: 
Marrow spicules: Spicular    
Cellularity: Cellular  
Plasma cell morphology: Small to large in size with occasional nucleolated forms
Myeloid lineage: Orderly maturation   
Erythroid Lineage: Orderly maturation   
Megakaryocytes: Present    

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, overall 20-30% of cellularity in the limited biopsy. 
Kappa and lambda immunostains show the plasma cells are lambda light chain restricted
BCMA highlights >90% of plasma cells, (3+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-634) 
Interpretation: 
1. Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.

Abnormal plasma cell population comprises 99.8% of total plasma cells.
Abnormal plasma cell population represents 9.7% of WBC.

Immunophenotype:
Abnormal: CD19 (negative), CD27 (negative), CD45 (negative), CD56 (partial), CD81 (negative), cytoplasmic Lambda (restriction)
Normal: CD138, CD38, CD229, CD319
Negative: CD20, CD117, cytoplasmic Kappa

Number of cells acquired: 5.3 million 

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (01/19/2022):
WBC 5.0 [4.0-11.0 K/mcL] 
RBC 3.86 [3.80-5.00 M/mcL] 
HGB 11.1 L [11.2-15.4 g/dL] 
HCT 34.2 L [34.3-46.0 %] 
MCV 89 [80-98 fL] 
MCH 28.8 [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 14.6 [12.2-15.1 %] 
Platelets. 126 L [160-400 K/mcL] 

Neutrophil 65.2 [32.5-74.8 %] 
Mono 8.9 [0.0-12.3 %] 
Eos 0.8 [0.0-4.9 %] 
Baso 0.2 [0.0-1.5 %] 
Immature Granulocyte 0.4 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 24.5 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 3.2 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.2 [0.9-3.2 K/mcL] 

Morphology: No circulating plasma cells seen


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-407, CG22-408

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-2601. 
"
H22-7280;S12;MSK7 - 2023-06-15 17.34.58.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: Lymphoma, Mantle Cell
Clinical Hx/Op Findings: Left Neck Lymphadenopathy
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Involvement by patient's known mantle cell lymphoma. See comment.
     - Cellular marrow with maturing trilineage hematopoiesis.

COMMENT: The core biopsy is limited, precluding accurate assessment of the extent of bone marrow involvement by lymphoma. The pleomorphic cytologic features reported in the patient's recently diagnosed mantle cell lymphoma (left base of tongue biopsy, H22-7200) is noted. Similarly, the atypical lymphoid cells in the current blood and marrow aspirates range from small to large in size, suggestive of the pleomorphic variant.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Limited core biopsy (predominantly bone, cartilage and soft tissue with scant subcortical marrow showing aspiration artifact) shows cellular bone marrow. The marrow cellularity cannot be accurately assessed. There istrilineage hematopoiesis with an infiltrate of variably sized atypical lymphoid cells scattered singly and in focal apparent small aggregates (best seen with CD20 immunohistochemistry described below).

Spicular and cellular aspirate smears show orderly maturing trilineage hematopoiesis. Atypical lymphoid cells are seen, which range from small to large in size with irregular/cleaved nuclei, mostly dense chromatin, occasional distinct nucleoli and scant cytoplasm.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 highlights scattered and focal apparent small aggregates of variably sized B cells, which show co-expression of CD5 and cyclin D1. CD3 labels background T cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9517) 
Interpretation:
Abnormal B cell population detected. 
The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)

Abnormal B cell population represents 27.9% of WBC.

Immunophenotype:
Abnormal: CD5 (positive), CD20 (bimodal - intermediate to bright), CD43 (positive), ROR1 (positive)
Normal: CD79b, CD81, CD19, CD40, CD45, CD38
Negative: CD23, CD200, CD10, CD3

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (08/30/2022):
WBC 6.8 [4.0-11.0 K/mcL] 
RBC 4.70 [3.95-5.54 M/mcL] 
HGB 13.6 [12.5-16.2 g/dL] 
HCT 40.1 [37.5-49.3 %] 
MCV 85 [80-98 fL] 
MCH 28.9 [27.0-33.0 pg] 
MCHC 33.9 [31.0-36.5 g/dL] 
RDW 13.3 [12.2-15.1 %] 
Platelets 50 L [160-400 K/mcL] 

Neutrophil 42.0 [32.5-74.8 %] 
Mono 17.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 17.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 24.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 2.9 [1.5-7.5 K/mcL] 
Abs Mono 1.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 2.8 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Circulating atypical lymphoid cells seen, which range from small to large in size with irregular/cleaved nuclei. 
RBC: Normochromic, normocytic RBCs.
Platelets: Thrombocytopenia.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-6569, CG22-6570. 

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-37230, M22-37234.
"
H22-7825;S14;MSK4 - 2023-04-14 15.27.02.ndpi,Peripheral Blood Smear,2023-04-14,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Multiple Myeloma\par Clinical Hx/Op Findings: pre Car T cell\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\par      - Plasma cell neoplasm, \~\par\~\~\~\~\~\~\~\~\~\~70% involvement by CD138 immunohistochemistry.\par\~\~\~\~\~\~\~\~\~\~28% involvement by aspirate differential\par\~\~\~\~\~\~\~\~\~\~7.4%  involvement by flow cytometry\par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Fragmented\par Cellularity: Could not be precisely assessed\par Myeloid lineage: Few seen\par Erythroid lineage: Few seen\par Megakaryocytes: Present\par Plasma cells: Markedly Increased    \par Clot section: Similar to biopsy\par\par Special stain: Congo Red stain is negative for amyloid deposition \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate\par\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 5%\par Metamyelocytes \tab\tab 4%\par Neutrophils/Bands \tab 18%\par Monocytes \tab\tab 1%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 39%\par Plasma Cells \tab\tab 28% (patchy distribution)\par Lymphocytes \tab\tab 2%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 0.8\par\par Morphology: \par Marrow spicules: Spicular \par Cellularity:  Hypercellular \par Plasma cell morphology: Intermediate to large in size nucleolated\par Myeloid lineage: Orderly maturation \par Erythroid Lineage: Orderly maturation \par Megakaryocytes: Present \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD138 immunostain highlights plasma cells, overall 70% of cellularity. \par Kappa and lambda immunostains show the plasma cells are lambda light chain restricted\par BCMA highlights >90% of plasma cells, (1-3+) intensity, membranous/ Golgi pattern. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10237)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par 1. Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par\par Abnormal plasma cell population comprises 98.3% of total plasma cells.\par Abnormal plasma cell population represents 7.4% of WBC.\par\par Immunophenotype:\par Abnormal: CD38 (dim), CD19 (negative), CD27 (negative), CD45 (negative), CD56 (positive), CD81 (negative), CD117 (positive), cytoplasmic Lambda (restriction)\par Normal: CD138, CD229, CD319\par Negative: cytoplasmic Kappa\par\par Number of cells acquired: 5.5 million \par\par\par 2. No abnormal mature B cell population detected. Virtually no B cells seen.\par No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.\par\par Number of cells acquired: 151 thousand \par\par\par 3. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par\par Myeloid blast population with an unremarkable phenotype represents 1.3% of WBC.\par\par Number of cells acquired: 291 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (  09/21/2022 ):\par WBC 3.8 L [4.0-11.0 K/mcL] \par RBC 2.83 L [3.95-5.54 M/mcL] \par HGB 8.8 L [12.5-16.2 g/dL] \par HCT 27.2 L [37.5-49.3 %] \par MCV 96 [80-98 fL] \par MCH31.1 [27.0-33.0 pg] \par MCHC 32.4 [31.0-36.5 g/dL] \par RDW 18.3 H [12.2-15.1 %] \par Platelets. 237 [160-400 K/mcL] \par\par Neutrophil 83.0 H [32.5-74.8 %] \par Mono 4.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 2.0 H [0.0-1.5 %] \par Myelocyte 1.0 H [0.0-0.0 %] \par Lymph 10.0 L [12.2-47.4 %] \par Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 3.2 [1.5-7.5 K/mcL] \par Abs Mono 0.2 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.1 [0.0-0.2 K/mcL] \par Abs Myelocytes 0.0 [0.0-0.0 K/mcL] \par Abs Lymph 0.4 L [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] \par\par Morphology: No circulating plasma cells seen. \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-7026, CG22-7027.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-39932.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-1124;S10;MSKW - 2023-05-31 22.24.37.ndpi,Peripheral Blood Smear,2023-05-31,"{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch31505\stshfloch31506\stshfhich31506\stshfbi0\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}
{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;
\red0\green0\blue0;}{\*\defchp \fs22\loch\af31506\hich\af31506\dbch\af31505 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*
\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\trcbpat1\trcfpat1\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused 
Normal Table;}{\s15\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\f1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext15 \spriority0 Arial;}}
{\*\rsidtbl \rsid1736676\rsid1926613\rsid6949486\rsid8271858\rsid12137372}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\operator Chan, Alexander Y./Pathology}
{\creatim\yr2022\mo2\dy14\hr11\min50}{\revtim\yr2022\mo2\dy14\hr11\min50}{\version2}{\edmins0}{\nofpages1}{\nofwords17}{\nofchars99}{\nofcharsws115}{\vern21}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}
\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata1\grfdocevents0\validatexml0\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors0\horzdoc\dghspace120\dgvspace120\dghorigin1701
\dgvorigin1984\dghshow0\dgvshow3\jcompress\viewkind1\viewscale130\rsidroot8271858 \fet0{\*\wgrffmtfilter 2450}\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2
\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}\pard\plain \ltrpar\s15\ql \li0\ri0\nowidctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\af1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \fs18\insrsid12137372 \hich\af1\dbch\af31505\loch\f1 Clinical Diagnosis: Lymphoma, Mantle Cell\par \hich\af1\dbch\af31505\loch\f1 Clinical Hx/Op Findings: recurrent disease\par \hich\af1\dbch\af31505\loch\f1 Requested Studies: Gross/Micro\par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Involved by previously diagnosed mantle cell lymphoma, ~10-20% of total cellularity by CD20 immunohistochemistry.
    - Hypercellular bone marrow with maturing trilineage hematopoiesis 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy specimen shows a hypercellular (~70%) bone marrow with maturing trilineage hematopoiesis and an atypical lymphoid infiltrate with interstitial and intrasinusoidal distribution composed of small to medium sized atypical lymphoid cells with moderate amounts of cytoplasm, irregular nuclei, and condensed chromatin. Aspirate smears are spicular, cellular, and show maturing trilineage hematopoiesis without expanded blast population, with frequent atypical lymphoid cells.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight the atypical lymphoid infiltrate, ~10-20% of total cellularity. 
B-cells co-express CD5 and CyclinD1, while negative for CD3, CD23, and P53.
SOX11 is technically suboptimal.
BCL2 and BCL6 appear mostly negative in the B-cells.
CD3 highlights scattered T-cells, <5% of total cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1438) 
Abnormal B cell population detected.
The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.
Abnormal B cell population represents 21.0% of WBC.

Immunophenotype:
Abnormal: CD5 (partial), CD20 (bright), CD79b (bright), CD200 (negative), CD19 (bright), CD45 (bright), CD10 (partial), surface Kappa (restriction)
Normal: CD22, CD23, CD43, CD81, CD40
Negative: ROR1, CD38, CD3, surface Lambda

Also see F21-1439 (PB) submitted on the same day.
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (2/08/2022):
WBC 5.8 [4.0-11.0 K/mcL] 
RBC 4.37 [3.95-5.54 M/mcL] 
HGB 13.0 [12.5-16.2 g/dL] 
HCT 38.8 [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 108 L [160-400 K/mcL] 

Neutrophil 47.0 [32.5-74.8 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 17.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 28.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 2.7 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 2.6 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Frequent circulating atypical lymphoid cells seen.
RBC: Normocytic, normochromic RBCs.
PLT: Mild thrombocytopenia. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-928.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-5779, M22-5782, M22-5783.

"
H22-138;S11;MSKR - 2023-05-26 15.09.39.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: Per MD
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Plasma cell neoplasm, 
     15-20% involvement by CD138 immunohistochemistry.
     1% involvement by aspirate differential
     0.0076% of total WBC involvement by 12 color flow cytometry
    - Hypocellular marrow with eosinophilia and non-necrotizing granulomata; see comment.

COMMENT: The reason for the discrepancy between plasma cell count by aspirate differential and immunohistochemistry is not entirely clear and was also seen in the prior specimen (H21-6760). Non-necrotizing granulomata are seen; special stains for infectious organisms will be reported in an addendum.

BONE MARROW BIOPSY
Quality: Inadequate with limited material present / aspiration artifact / hemorrhage seen
Cellularity: Appears hypocellular
Myeloid lineage: Progressive maturation with eosinophilia.
Erythroid lineage: Progressive maturation  
Megakaryocytes: Scattered forms noted 
Plasma cells: Increased    
Other: Non-necrotizing granulomata seen 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                1%
Promyelocytes           3%
Myelocytes           13%
Metamyelocytes           10%
Neutrophils/Bands      24%
Monocytes           1%
Eosinophils           21%
Erythroid Precursors      18%
Plasma Cells           1%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           4

Morphology: 
Marrow spicules: Spicular    
Cellularity: Cellular   
Plasma cell morphology: Rare small forms noted without cytologic atypia
Myeloid lineage: Orderly maturation   
Erythroid Lineage: Orderly maturation
Megakaryocytes: Present but appear decreased in number     
Other findings: Numerous naked nuclei are noted. 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 10-15% of marrow cellularity. 
Kappa and lambda immunostains show no definitive light chain restriction of plasma cells.
BCMA highlights 80% of plasma cells, (1-2+) intensity, membranous / Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-160)
Interpretation: 
1. Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.

Abnormal plasma cell population comprises 77.0% of total plasma cells.
Abnormal plasma cell population represents 0.0076% of WBC.
Immunophenotype:
Abnormal: CD19 (negative), CD27 (bright), CD45 (negative), CD56 (positive), with no definite light chain expression
Normal: CD138, CD38, CD229, CD319, CD81
Negative: CD117, cytoplasmic Kappa, cytoplasmic Lambda

Number of cells acquired: 5.2 million  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (01/06/2022):
WBC 3.3 L [4.0-11.0 K/mcL] 
RBC 3.42 L [3.95-5.54 M/mcL] 
HGB 12.6 [12.5-16.2 g/dL] 
HCT 36.8 L [37.5-49.3 %] 
MCV 108 H [80-98 fL] 
MCH 36.8 H [27.0-33.0 pg] 
MCHC 34.2 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 115 L [160-400 K/mcL] 

Neutrophil 29.0 L [32.5-74.8 %] 
Mono 15.0 H [0.0-12.3 %] 
Eos 45.0 H [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 10.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.5 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Mild leukopenia with neutropenia and marked eosinophilia; no circulating plasma cells seen.  
RBC: Macrocytosis.
PLT: Mild thrombocytopenia. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Not submitted

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-889.
"
H22-7924;S15;MSK5 - 2023-06-15 14.06.16.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Breast, Malignant Neoplasm\par Clinical Hx/Op Findings: Persistent hypoproductive anemia\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, right posterior iliac crest\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b ,\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  biops\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 y; aspirate and peripheral blood smears: \~\~\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par     \par      -Normocellular marrow with trilineage maturing hematopoiesis, ring sideroblasts and reduced erythropoiesis. See comment. \par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The patient's history of breast cancer and persistent anemia are noted. The bone marrow biopsy and aspirate smears show a cellular marrow with reduced erythropoiesis and ring sideroblasts.  While this finding is associated with myelodysplastic syndrome with ring sideroblasts (or SF3B1 mutation in the new ICC classification) reactive etiology of ring sideroblast finding such as toxic marrow insults or inflammation should be excluded. The presentation is also unusual with marked anemia, absence of dysplasia and normal flow cytometry. The molecular genetic evaluation will be critical to establish the diagnosis. If no molecular alterations associated with ring sideroblasts are found, reactive etiology should be strongly considered. Clinical correlation is also advised \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Patchy but normocellular (40%)\par M:E ratio: Increased \par Blasts: Not increased\par Myeloid lineage: Present with progressive maturation\par Erythroid lineage: Decreased with progressive maturation\par Megakaryocytes: Present with occasional hypolobated forms and small loose clusters \par Lymphocytes: Scattered\par Plasma cells: Scattered \par Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF 0 out of 3)\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 EXTRINSIC CELLS: None seen\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\par Blasts \tab\tab\tab 2%\par Promyelocytes \tab\tab 7%\par Myelocytes \tab\tab 19%\par Metamyelocytes \tab\tab 15%\par Neutrophils/Bands \tab 34%\par Monocytes \tab\tab 3%\par Eosinophils \tab\tab 3%\par Erythroid Precursors \tab 10%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 6%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 8.1\par\par Special stain\par Iron: Increased\par Ring sideroblasts: Present, >15%\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -Spicular and cellular aspirate smears show marrow with an increased M:E ratio. Myeloid elements show left shifted maturation without significant dysplasia. Erythroid elements are reduced but show maturation. Megakaryocytes are present and display occasional hyperlobated and unilobated forms. Blasts are not increased. Scattered lymphocytes and plasma cells are present. \par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (09/23/2022):\par WBC 13.7 H [4.0-11.0 K/mcL] \par RBC 2.50 L [3.80-5.00 M/mcL] \par HGB 7.6 L [11.2-15.4 g/dL] \par HCT 23.1 L [34.3-46.0 %] \par MCV 92 [80-98 fL] \par MCH 30.4 [27.0-33.0 pg] \par MCHC 32.9 [31.0-36.5 g/dL] \par RDW 17.3 H [12.2-15.1 %] \par Platelets 280 [160-400 K/mcL] \par\par Neutrophil 86.0 H [32.5-74.8 %] \par Mono 4.7 [0.0-12.3 %] \par Eos 0.7 [0.0-4.9 %] \par Baso 0.1 [0.0-1.5 %] \par Immature Granulocyte 2.3 H [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 6.2 L [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 11.7 H [1.5-7.5 K/mcL] \par Abs Mono 0.6 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.3 H [0.0-0.1 K/mcL] \par Abs Lymph 0.8 L [0.9-3.2 K/mcL] \par\par Morphology:\par\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 WBC: Unremarkable morphology. No circulating blasts seen.\par RBC: Moderate normocytic anemia. Anisopoikilocytosis. Polychromasia. Increased nucleated RBC.\par PLT: Unremarkable morphology. \plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 highlight rare blasts comprising less than 5% of the total cellularity.\par CD61 highlights variably sized megakaryocytes.\par CD71 highlights erythroid precursors. \par MPO highlights myeloid precursors.\par OSCAR (pan-cytokeratin stain) is negative\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10358)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par\par No abnormal myeloid blast, mature B or mature T cell populations identified.                               \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par\par Number of cells acquired: 748 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-7104.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-580;S13;MSK4 - 2023-05-31 21.44.22.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Breast, Malignant Neoplasm
Clinical Hx/Op Findings: worsening pancytopenia requiring prbc transfusion
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate, and peripheral blood smears: 
     - Extensive marrow involvement by GATA3-positive metastatic carcinoma, consistent with mammary origin
     - No hematolymphoid neoplasm observed.  
 Dr. Yabe from Hematopathology service has also reviewed the case.

Immunohistochemical stains were performed on formalin-fixed tissue with the following results for metastatic carcinoma (block 1-1):
ESTROGEN RECEPTOR (clone 6F11, Leica): 10% nuclear staining with weak intensity
PROGESTERONE RECEPTOR (clone 16; Leica): 5% nuclear staining with moderate intensity
HER2 (4B5, Ventana): Negative (0) 
Note: The interpretation of these results is based in part on the decalcification procedure performed. 


BONE MARROW BIOPSY
Quality: Adequate

Marrow spaces are effaced by metastatic carcinoma, associated with significant desmoplasia. No hematopoietic elements are readily recognized.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules 
Positive for extrinsic cells.

Special stain unable to performed due lack of marrow elements.

Morphology:
-Aspicular and paucicellular smears show malignant cells arranged singly and in clusters, most consistent with epithelial neoplasm. Hematopoietic elements are rare, predominantly lymphocytes.

PERIPHERAL BLOOD
CBC (1/21/2022):
WBC 4.0 [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 2.24 L [3.80-5.00 M/mcL] 
HGB 6.9 L [11.2-15.4 g/dL] 
HCT 22.4 L [34.3-46.0 %] 
MCV 100 H [80-98 fL] 
MCH 30.8 [27.0-33.0 pg] 
MCHC 30.8 L [31.0-36.5 g/dL] 
RDW 29.3 H [12.2-15.1 %] 
Platelets. 44 L [160-400 K/mcL] 

Neutrophil 44.0 [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 40.0 [12.2-47.4 %] 
Nucleated RBC 12.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.8 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.6 [0.9-3.2 K/mcL]

Morphology:
RBC: Anisopoikilocytosis. Macrocytic anemia. Increased nucleated red blood cells.
WBC: Rare myeloid progenitors noted. No increase in circulating blasts.
PLT: Marked thrombocytopenia. Larger platelet forms noted.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
Immunostain for CD34 highlights endothelial cells. CD117 highlights rare mast cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-723)
No abnormal myeloid blast, mature B or mature T cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.39% of WBC.

Number of cells acquired: 25 thousand 
Less than target number of cells acquired for myeloid analysis. Target sensitivity is not achieved.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-464.

MOLECULAR STUDIES 
Not submitted


"
H22-4792;S14;MSK4 - 2023-04-14 16.30.46.ndpi,Peripheral Blood Smear,2023-04-14,"Clinical Diagnosis: CML
Clinical Hx/Op Findings: POD
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
    - Chronic myeloid leukemia, BCR-ABL1 positive, accelerated phase, ~5-9% blasts by immunohistochemistry; see comment.
  
COMMENT: Findings of persistent peripheral leukocytosis, basophilia > 20%, and ABL mutations, with clinical resistance to TKI therapy are consistent with accelerated phase of CML. Close clinical follow-up is advised. Correlation with cytogenetic and molecular studies is recommended. 

Trichrome stain will be reported in an addendum.

BONE MARROW BIOPSY
Quality: Suboptimal (fragmented biopsy), limited evaluable marrow 
Cellularity: Markedly hypercellular (>90%)
M:E ratio: Increased / marked myeloid hyperplasia
Blasts: Increased scattered blasts seen
Myeloid lineage: Exhibits full maturation 
Erythroid lineage: Markedly reduced 
Megakaryocytes: Present with small forms with monolobation
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows a moderate to marked increase in reticulin fibers (2-3+/3). 
The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: N/A
Blasts                8%
Promyelocytes           1%
Myelocytes           10%
Metamyelocytes           8%
Neutrophils/Bands      35%
Monocytes           2%
Eosinophils           2%
Basophils           13%
Erythroid Precursors      12%
Lymphocytes           9%
Number of Cells Counted      200
M:E Ratio           5.9

Morphology: The touch imprint smears are suboptimal for review but show maturing myeloid and erythroid elements with myeloid hyperplasia and a mild increase in blasts with medium to large sized blasts with small amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli. Myeloid elements show full maturation and are markedly increased. Erythroid elements are markedly reduced. Megakaryocytes are not well represented on the suboptimal imprints.

PERIPHERAL BLOOD
CBC (06/13/2022):
WBC 36.5 H [4.0-11.0 K/mcL] 
RBC 3.08 L [3.80-5.00 M/mcL] 
HGB 9.5 L [11.2-15.4 g/dL] 
HCT 27.6 L [34.3-46.0 %] 
MCV 90 [80-98 fL] 
MCH 30.8 [27.0-33.0 pg] 
MCH 34.4 [31.0-36.5 g/dL] 
RDW 17.7 H [12.2-15.1 %] 
Platelets. 155 L [160-400 K/mcL] 

Neutrophil 35.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 42.0 H [0.0-1.5 %] 
Blast 4.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Promyelocyte 3.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 11.0 L [12.2-47.4 %] 
Nucleated RBC 2.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 12.8 H [1.5-7.5 K/mcL] 
Abs Mono 0.7 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 15.3 H [0.0-0.2 K/mcL] 
Absolute Blasts 1.5 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.4 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 1.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.4 H [0.0-0.0 K/mcL] 
Abs Lymph 4.0 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 3.0 H [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Leukocytosis with marked basophilia, few circulating blasts seen, left shifted granulocytes seen. 
RBC: Normocytic, normochromic anemia with anisocytosis. 
PLT: Unremarkable morphology. 

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight increased blasts, overall ~5-9% of total cellularity. 
CD117 also highlights early myeloid and erythroid elements.
CD61 highlights megakaryocytes including forms with monolobation.
MPO highlights myeloid elements with marked myeloid hyperplasia.
CD71 highlights markedly reduced erythroid elements.
M:E ratio by immunohistochemistry is increased.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW
Not submitted. 

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-6277)
Interpretation:
1. Abnormal myeloid blast population detected.
Abnormal myeloid blast population represents 8.0% of WBC.
Basophilia is seen, 33.9% of WBC.

Immunophenotype:
Abnormal: CD5 (bimodal - negative to dim), CD7 (partial), CD11b (partial), CD13 (variable - negative to intermediate), CD34 (uniform - bright), CD38 (variable - negative to intermediate), CD117 (variable - negative to bright), HLA-DR (variable - negative to intermediate)
Normal: CD4, CD33, CD36, CD45, CD45RA, CD71, CD105 (partial), CD123, CD371 (clec12a)
Negative: CD2, CD3, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda, CD42b, CD90
Number of cells acquired: 898 thousand 

2. Abnormal B cell population detected. 
The immunophenotype of this abnormal B cell population is not entirely specific and does not allow for full classification by flow cytometry. 
Concentration of the abnormal population in peripheral blood is 0.07 thousand/microliter.
Abnormal B cell population represents 0.19% of WBC.

Immunophenotype:
Abnormal: CD5 (partial), CD22 (dim), CD43 (positive), CD81 (dim), ROR1 (positive), surface Kappa (restriction)
Normal: CD20, CD79b, CD19, CD40, CD45, CD38
Negative: CD23, CD200, CD10, CD3, surface Lambda, CD14, CD25, CD279(PD1)

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.


"
H22-6251;S15;MSKX - 2023-06-15 12.44.35.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: Myelodysplastic Syndrome
Clinical Hx/Op Findings: evaluate disease
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Variably cellular bone marrow with erythroid predominant trilineage hematopoiesis, borderline dyspoiesis in the erythroid and megakaryocytic lineages, 5-15% ring sideroblasts and no increase in blasts, see comment.
  
COMMENT: Per clinical notes patient's history of Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia (MDS-RS-SLD) on EPO is noted. The diagnostic material has not been reviewed at MSKCC but reportedly showed trisomy 8 and SF3B1 mutation. The core biopsy shows variable cellularity; however, is predominantly subcortical sampling. There is borderline dyspoiesis involving both megakaryocytic (~10-15%) and erythroid lineages (~10-15%) including ringed sideroblasts (5-15%). If the forthcoming in-house cytogenetic and molecular studies show clonality and confirm trisomy 8 and SF3B1 mutation the findings of the case will be consistent with MDS-RS-MLD. Review of the diagnostic material at MSKCC as well as correlation with clinical history and forthcoming cytogenetic and molecular studies is recommended.

BONE MARROW BIOPSY
Quality: Subcortical sampling but limited for evaluation
Cellularity: Variable (0-50%)
M:E ratio: Slightly decreased
Blasts: Not increased
Myeloid lineage: Full spectrum of maturation
Erythroid lineage: Full spectrum of maturation
Megakaryocytes: Present; rare small, hypolobated forms
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate 

Blasts                1%
Promyelocytes           2%
Myelocytes           6%
Metamyelocytes           7%
Neutrophils/Bands      30%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      44%
Plasma Cells           2%
Lymphocytes           5%
Number of Cells Counted      500
M:E Ratio           1.1

Special stain
Iron: Trace
Ring sideroblasts: Present, 5-15%

Morphology: Spicular and cellular aspirate smears show trilineage hematopoiesis. There is no increase in blasts. The myeloid elements show progressive maturation with rare elements showing abnormal lobation (<10%). The erythroid lineage is relatively increased in proportion and shows borderline dyspoiesis with elements showing nuclear contour irregularities and nuclear budding (~10-15%). Megakaryocytes are present and show a subset of small, hypolobated forms (~10-15%). 

PERIPHERAL BLOOD
CBC (8/1/2022):
WBC 5.7 [4.0-11.0 K/mcL] 
RBC 3.18 L [3.80-5.00 M/mcL] 
HGB 9.6 L [11.2-15.4 g/dL] 
HCT 29.5 L [34.3-46.0 %] 
MCV 93 [80-98 fL] 
MCH 30.2 [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 25.4 H [12.2-15.1 %] 
Platelets 329 [160-400 K/mcL] 

Neutrophil 43.0 [32.5-74.8 %] 
Mono 8.2 [0.0-12.3 %] 
Eos 13.8 H [0.0-4.9 %] 
Baso 0.9 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 33.6 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.5 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.8 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.9 [0.9-3.2 K/mcL] 

Morphology:
WBC: Mild eosinophilia; no atypia or circulating blasts seen.
RBC: Anemia with anisopoikilocytosis, including scattered target cells.
PLT: No significant morphologic findings.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight blasts, accounting for <5% of cellularity 
MPO and CD71 highlight myeloid and erythroid elements, with a reduced M:E 
CD61 highlights megakaryocytes, including few small forms

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-8200)
1.  No definite abnormal myeloid blast population detected. 
There is no definite immunophenotypic evidence of a myeloid stem cell neoplasm by flow cytometry. However, in light of the atypical expression of the following markers listed below, a low-grade myeloid stem cell neoplasm cannot be entirely excluded by these studies. Morphologic, cytogenetic, and molecular genetic assessment is suggested to exclude myeloid stem cell neoplasm. Clinical correlation is advised. 

Myeloid blast population represents 0.93% of WBC.


Normal: CD4, CD33, CD36, CD38, CD45, CD45RA, CD71, CD105, CD117, CD123, CD371 (clec12a) 
Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda, CD42b, CD90 
Atypical: CD13 (dim), CD34 (retention), HLA-DR (retention) on CD71 positive subset

Number of cells acquired 585 thousand

2.  No abnormal mature B- or T-cell populations detected. 
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-5619

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-32169, M22-32170.
"
H22-226;S13;MSKR - 2023-05-26 15.15.19.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: cytopenia
Clinical Hx/Op Findings: cytopenai breast cancer
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Metastatic adenocarcinoma involving bone (see comment)
  
COMMENT: The metastatic adenocarcinoma involving the bone marrow is morphologically nonspecific, but similar to the previous liver metastasis (S21-80110), compatible with breast primary. Further immunohistochemistry study and tumor markers are pending and an addendum report will follow.


In addition, this case was also reviewed by Dr. Ying Liu in Hematopathology Service. 

BONE MARROW BIOPSY
Hypercellular marrow shows extensive involvement by metastatic carcinoma (?). 
Special stains: Reticulin stain shows extensive fibrosis.  
Clot section: Shows predominantly blood with no marrow particles. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules
Positive for extrinsic cells

Special stain
Iron: Suboptimal for evaluation due to poor quality of slide
Ring sideroblasts: Suboptimal for evaluation due to poor quality of slide

PERIPHERAL BLOOD
CBC (01/10/2022):
WBC 9.0 [4.0-11.0 K/mcL] 
RBC 2.45 L [3.80-5.00 M/mcL] 
HGB 8.5 L [11.2-15.4 g/dL] 
HCT 26.6 L [34.3-46.0 %] 
MCV 109 H [80-98 fL] 
MCH 34.7 H [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 19.1 H [12.2-15.1 %] 
Platelets 257 [160-400 K/mcL] 

Neutrophil 72.0 [32.5-74.8 %] 
Mono 10.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 14.0 [12.2-47.4 %] 
Nucleated RBC 2.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 6.4 [1.5-7.5 K/mcL] 
Abs Mono 0.9 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
WBC: No circulating blasts.
RBC: Macrocytic anemia with anisocytosis and polychromasia. 
PLT: Unremarkable. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 highlights vasculature with no increase in blasts. 
CD117 highlights few scattered mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-278)
1. No abnormal myeloid blast, mature B or mature T cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.12% of WBC.

Number of cells acquired: 427 thousand  

Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-182.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-1356.
"
H22-6495;S21;MSK4 - 2023-06-15 15.50.37.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: Lymphoma, Diffuse Large Cell
Clinical Hx/Op Findings: CLL/SLL with Richter's transformation s/p RCHOP now D+28 s/p CART
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
    - Involvement by large B-cell lymphoma, consistent with previously diagnosed Richter's transformation, ~70-80% of cellularity by immunohistochemistry; see comment.
    - Smaller CLL/SLL-like abnormal B-cell population detected by flow cytometry only (1.4% of WBC).

COMMENT: Most of the bone marrow is occupied by large atypical lymphoid cells consistent with involvement by the patient's known transformed CLL/SLL (Richter's transformation). A small subset of the atypical lymphoid proliferation is composed of smaller cells and is compatible with the underlying CLL/SLL.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
The suboptimal biopsy section (small subcortical biopsy) shows a hypercellular bone marrow (~90% cellularity) replaced by a diffuse atypical lymphoid proliferation of large cells with variable amounts of cytoplasm, irregular nuclei, vesicular chromatin, and distinct nucleoli, in a background of markedly reduced hematopoiesis. Occasional apoptotic bodies and mitoses are seen. Occasional smaller atypical lymphoid cells are seen with more condensed chromatin, but the vast majority of the population is large cells. Aspirate smears are spicular and cellular and show replacement of the hematopoietic elements with large atypical lymphoid cells.
 
The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
The neoplastic cells (~70-80% of cellularity by immunohistochemistry)
Express: CD20, PAX5, CD5 (subset, mostly smaller cells), CD23 (subset, mostly smaller cells)
Do not express: CD3

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-8553) 
Two abnormal B cell populations identified.

1. Abnormal B cell population with larger size detected.
The immunophenotype is similar to previous specimen (F22-5285).
Abnormal B cell population represents 31.1% of WBC.

Immunophenotype:
Abnormal: CD5 (partial), CD19 (dim), CD20 (bright), CD22 (bimodal - dim to bright), CD38 (uniform - intermediate), CD45 (dim), surface Kappa (restriction), Forward Scatter (increased), Side Scatter (increased), CD23 (positive), CD40 (variable - negative to intermediate), CD43 (positive), CD79b (variable - negative to dim)
Normal: CD200
Negative: CD10, CD25, CD279 (PD1), CD3, CD14, surface Lambda, CD81, ROR1

2. Abnormal B cell population detected. 
Flow cytometry reveals an abnormal B cell population with CLL/SLL-like immunophenotype (see below).
Abnormal B cell population represents 1.4% of WBC.
Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (partial), CD43 (positive), CD79b (negative), CD81 (dim), CD200 (bright), ROR1 (positive), CD38 (variable - negative to intermediate), surface Kappa (restriction - dim)
Normal: CD19, CD40, CD45
Negative: CD10, CD3, surface Lambda, CD14, CD25, CD279 (PD1)

Number of cells acquired 726 thousand
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (08/09/2022):
WBC 1.1 L [4.0-11.0 K/mcL] 
RBC 3.47 L [3.95-5.54 M/mcL] 
HGB 10.4 L [12.5-16.2 g/dL] 
HCT 30.2 L [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 30.0 [27.0-33.0 pg] 
MCHC 34.4 [31.0-36.5 g/dL] 
RDW 17.9 H [12.2-15.1 %] 
Platelets. 21 L [160-400 K/mcL] 

Neutrophil 11.0 L [32.5-74.8 %] 
Mono 13.0 H [0.0-12.3 %] 
Eos 6.0 H [0.0-4.9 %] 
Baso 5.0 H [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 64.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Marked leukopenia with absolute/relative lymphopenia; occasional large atypical lymphoid cells seen 
RBC: Normocytic, normochromic anemia with anisopoikilocytosis 
PLT: Marked thrombocytopenia 

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-5885.


"
H22-7716;S13;MSK2 - 2023-04-14 15.38.18.ndpi,Peripheral Blood Smear,2023-04-14,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: MGUS\par Clinical Hx/Op Findings: MGUS\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: \~\~\par      - Plasma cell neoplasm, \~\par\~\~\~\~\~\~\~\~\~\~10-20% involvement by CD138 immunohistochemistry.\par\~\~\~\~\~\~\~\~\~\~12% involvement by aspirate differential\par\~\~\~\~\~\~\~\~\~\~2.9% involvement by flow cytometry\par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate \par Cellularity: 50-60%\par Myeloid lineage: Orderly maturation   \par Erythroid lineage: Orderly maturation   \par Megakaryocytes: Adequate   \par Plasma cells: Increased    \par\par Special stain: Congo Red stain is negative for amyloid deposition \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate\par Blasts \tab\tab\tab 2%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 12%\par Metamyelocytes \tab\tab 4%\par Neutrophils/Bands \tab 18%\par Monocytes \tab\tab 2%\par Eosinophils \tab\tab 2%\par Basophils \tab\tab 1%\par Erythroid Precursors \tab 38%\par Plasma Cells \tab\tab 12%\par Lymphocytes \tab\tab 8%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 1.1\par\par Morphology: \par Marrow spicules: Spicular \par Cellularity: Cellular \par Plasma cell morphology: Small in size, bi/ multi-nucleated \par Myeloid lineage: Orderly maturation\par Erythroid Lineage: Orderly maturation \par Megakaryocytes: Present \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD138 immunostain highlights plasma cells, 10-20% of cellularity. \par Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.\par BCMA highlights >90% of plasma cells, (3+) intensity, membranous/ Golgi pattern. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10093)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1. Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par Abnormal plasma cell population comprises 90.0% of total plasma cells.\par Abnormal plasma cell population represents 2.9% of WBC.\par Immunophenotype:\par Abnormal: CD38 (dim), CD19 (negative), CD27 (dim), CD45 (variable - negative to intermediate), CD56 (positive), CD81 (negative), CD117 (partial - dim), cytoplasmic Kappa (restriction)\par Normal: CD138, CD229, CD319\par Negative: CD20, cytoplasmic Lambda\par Number of cells acquired: 4.6 million \par\par 2. No abnormal mature B cell population detected.\par No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.\par\par Number of cells acquired: 403 thousand \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (9/16/2022):\par WBC 4.2 [4.0-11.0 K/mcL] \par RBC 3.93 L [3.95-5.54 M/mcL] \par HGB 12.8 [12.5-16.2 g/dL] \par HCT 38.4 [37.5-49.3 %] \par MCV 98 [80-98 fL] \par MCH 32.6 [27.0-33.0 pg] \par MCHC 33.3 [31.0-36.5 g/dL] \par RDW 11.9 L [12.2-15.1 %] \par Platelets. 172 [160-400 K/mcL] \par\par Neutrophil 46.8 [32.5-74.8 %] \par Mono 10.9 [0.0-12.3 %] \par Eos 4.0 [0.0-4.9 %] \par Baso 0.2 [0.0-1.5 %] \par Immature Granulocyte 0.2 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 37.9 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 2.0 [1.5-7.5 K/mcL] \par Abs Mono 0.5 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 1.6 [0.9-3.2 K/mcL]\par\par Morphology: No circulating plasma cells on scanning. \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-6919, CG22-6920.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-39308. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-2888;S10;MSKD - 2023-05-31 19.41.51.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: ALL
Clinical Hx/Op Findings: pretreatment
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Extensive involvement by Hairy cell leukemia (~70% with CD20 immunohistochemistry)
     - Variably cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy specimen shows variably cellular bone marrow (ranging from 10-80%cellularity). There isan extensive interstitial atypical lymphoid infiltrate composed of medium sized cells with ovoid nuclei and ample amount of pale eosinophilic cytoplasm. Background trilineage maturing hematopoiesis is noted.

Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules
The differential cell count was performed on touch imprints only

Blasts                2%
Promyelocytes           2%
Myelocytes           10%
Metamyelocytes           8%
Neutrophils/Bands      18%
Monocytes           4%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      23%
Plasma Cells           1%
Lymphocytes           30%
Number of Cells Counted 500
M:E Ratio           1.9

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
The atypical lymphoid infiltrate is positive for CD20 (~70% of cellularity) and CD103. 
CD3 highlights T-cells, 5-10% of cellularity. 
CD34 stains few blasts, <5%
CD61 stains megakaryocytes
CD71 stains erythroid elements

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-3769) 
1. Abnormal B cell population detected.
The immunophenotype of the abnormal B-cell is consistent with involvement by hairy cell leukemia (HCL).

Abnormal B cell population represents 4.0% of WBC.
Immunophenotype:
Abnormal: CD19 (bright), CD20 (bright), CD22 (bright), CD25 (positive), CD11c (positive), CD103 (positive), CD200 (bright), surface Kappa (restriction), Forward Scatter (increased), Side Scatter (increased)
Normal: CD38, CD45
Negative: CD5 (no convincing), CD10, CD279 (PD1), CD3, CD14, surface Lambda

2. No abnormal mature T cell population detected.
No immunophenotypic evidence of T-cell lymphoma is identified.

Number of cells acquired: 358 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (04/08/2022):
WBC 2.0 L [4.0-11.0 K/mcL] 
RBC 3.22 L [3.95-5.54 M/mcL] 
HGB 11.2 L [12.5-16.2 g/dL] 
HCT 33.4 L [37.5-49.3 %] 
MCV 104 H [80-98 fL] 
MCH 34.8 H [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 14.8 [12.2-15.1 %] 
Platelets 104 L [160-400 K/mcL] 

Neutrophil 42.0 [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 55.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: 
WBC: Absolute neutropenia. Few atypical lymphocytes with cytoplasmic projections noted
RBC: Mild anisocytosis
Platelet: Mild thrombocytopenia

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-2546

MOLECULAR STUDIES 
Molecular analysis will be reported separately. 
"
H22-1283;S11;MSKT - 2023-05-26 16.40.50.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Multiple Myeloma
Requested Studies: Gross/Micro
Clinical Hx/Op Findings: Hx of Prostate CA in BM and MM
","
1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Metastatic adenocarcinoma, consistent with prostate primary, see note
    - Cellular marrow with residual hematopoiesis.
    - No morphologic or immunophenotypic evidence of plasma cell neoplasm.

Note: Immunohistochemical stains reveal that the tumor cells are positive CK-PAN, CAM5.2, NKX3.1, and PSA, supporting the above diagnosis.  

This hematological portion of the case was reviewed by Dr. Ying Liu of Hematopathology Service.

BONE MARROW BIOPSY
Quality: Inadequate, small subcortical biopsy with rare marrow space
Cellularity: N/A
Myeloid lineage: Rare
Erythroid lineage: Rare
Megakaryocytes: None seen
Plasma cells: Rare 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules

The differential cell count was not performed. Touch imprints contain too few cells for evaluation. The cellular elements present are composed primarily of peripheral blood elements.

Morphology: 
Marrow spicules: Aspicular.
Cellularity: Hypocellular
Plasma cell morphology: None seen
Myeloid lineage: Neutrophils / lymphocytes / monocytes noted  
Erythroid Lineage: None seen
Megakaryocytes:  None seen

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights rare plasma cells. 
Kappa and lambda highlight rare cells with no evidence of light chain restriction  
BCMA stain is non-contributory due the rarity of plasma cells

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1662)
Interpretation: 
No abnormal plasma cell population detected. 
No evidence of an abnormal plasma cell population is identified by flow cytometry.
Normal plasma cell population represents 0.44% of WBC.

Number of cells acquired: 1.3 million

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (02/14/2022):
WBC 3.4 L [4.0-11.0 K/mcL] 
RBC 2.35 L [3.95-5.54 M/mcL] 
HGB 7.3 L [12.5-16.2 g/dL] 
HCT 21.5 L [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 31.1 [27.0-33.0 pg] 
MCHC 34.0 [31.0-36.5 g/dL] 
RDW 17.2 H [12.2-15.1 %] 
Platelets 35 L [160-400 K/mcL] 

Neutrophil 47.0 [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 44.0 [12.2-47.4 %] 
Variant Lymph 1.0 [0.0-2.0 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.6 [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.5 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: No circulating plasma cells
RBC: Anisocytosis (1+) / Poikilocytosis (1+); Rouleaux formation is not seen
Platelets: Markedly thrombocytopenia 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-1095, CG22-1096.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-6770, M22-6771.
"
H22-8032;S16;MSK7 - 2023-06-15 14.29.04.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Lymphoma\par Clinical Hx/Op Findings: newly diagnosed\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\fswiss\fcharset0\fprq2{\*\panose 020B0502040204020203}Segoe UI;}
{\f3\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b ,\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  biopsy, aspirate smears: \~\~\par      - Atypical mast cell aggregates (5-10% of the cellularity by CD117 immunohistology), consistent with systemic mastocytosis. See comment 1.\par      - Approximately normocellular marrow with maturing trilineage hematopoiesis and mild megakaryocytic atypia. See comment 2.\par      - Minute abnormal B-cell population with kappa light chain restriction (0.41% of WBC) detected by flow cytometry only. See comment 3.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT:\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1. Multifocal dense aggregates of mast cells are present, which show spindled morphology and aberrantly express CD2 and CD25. Correlation with molecular studies and assessment for serum total tryptase levels is also advised.\par 2. While CBC parameters are within normal limits at this time, mild megakaryocytic atypia is noted, and the possibility of an early / evolving myeloid stem cell disorder cannot be entirely excluded. Correlation with results of the forthcoming molecular and cytogenetic studies is needed to complete the diagnostic evaluation. Close clinical follow-up is advised.\par 3. A morphologic correlate of the minute abnormal B-cell population detected by flow cytometry is not detected. The light chain restriction of this abnormal population (kappa) is different from the patient's DLBCL (F22-10606, lambda), compatible with involvement by an unrelated B-cell lymphoproliferative disorder. The differential diagnosis includes monoclonal B-cell lymphocytosis with a non-CLL immunophenotype, which is favored, while minimal involvement by a separate extramedullary B-cell process cannot be entirely excluded. Clinical correlation is advised.\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Reviewed at Hematopathology service consensus conference on 10/5/2022 with all in agreement.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy (although fragmented and partially aspirated) and aspirate specimens show approximately normocellular for age bone marrow (50% cellularity). There is\~trilineage maturing hematopoiesis without lymphoid aggregates. Myeloid and erythroid elements are actively maturing. Megakaryocytes are adequate to mildly increased in number with atypical forms (~10%) showing nuclear hyperchromasia, small size, and hypolobation. Several small, perivascular and interstitial aggregates of spindled cells are with small nuclei, condensed chromatin, inconspicuous nucleoli, and abundant granular cytoplasm are seen, which are consistent with mast cells (see immunohistology below). These aggregates show admixed eosinophils\par On the aspirate smears, myeloid and erythroid cells are seen in various stages of maturation without significant dysplasia. Many megakaryocytes are noted with a subset (~10%) showing small size and hypolobation. Few scattered mast cells are seen which show spindled morphology and are mature appearing.\par\par Special stains for AFB and GMS are negative for acid-fast bacilli and microorganisms, respectively.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD20 and PAX5 highlight few scattered B-cells.\par CD3 highlights few scattered T-cells.\par CD117 highlights a few dense aggregates of mast cells with spindled morphology, accounting for approximately 5-10% of the marrow cellularity, which are also positive for mast cell tryptase, with aberrant expression of CD25 and CD2.\par CD30 appears negative in the mast cells.\par CD68(KP1) is positive in the mast cell aggregates and also highlights scattered monocytic cells.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10489)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par 1. Minute abnormal B cell population detected.\par The immunophenotype of this abnormal B-cell population is similar to that in prior (F22-10185) and is not entirely specific and does not allow for full classification by flow cytometry. \par\par Abnormal B cell population represents 0.41% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (dim), CD38 (negative), surface Kappa (restriction)\par Normal: CD20, CD22, CD45\par Negative: CD5, CD10, CD25, CD279 (PD1), CD3, CD14, surface Lambda\par\par Number of cells acquired: 402 thousand\par\par 2. Atypical mast cells present.\par Mast cell population represents 0.087% of WBC.\par Immunophenotype:\par Atypical: CD2 (positive), CD25 (positive)\par Normal: CD117\par Negative: HLA-DR\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (09/27/2022):\par WBC 9.8 [4.0-11.0 K/mcL] \par RBC 4.56 [3.95-5.54 M/mcL] \par HGB 14.0 [12.5-16.2 g/dL] \par HCT 40.7 [37.5-49.3 %] \par MCV 89 [80-98 fL] \par MCH 30.7 [27.0-33.0 pg] \par MCHC 34.4 [31.0-36.5 g/dL] \par RDW 11.4 L [12.2-15.1 %] \par Platelets 270 [160-400 K/mcL] \par\par Neutrophil 59.6 [32.5-74.8 %] \par Mono 6.7 [0.0-12.3 %] \par Eos 1.4 [0.0-4.9 %] \par Baso 0.2 [0.0-1.5 %] \par Immature Granulocyte 0.7 H [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 31.4 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 5.8 [1.5-7.5 K/mcL] \par Abs Mono 0.6 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] \par Abs Lymph 3.1 [0.9-3.2 K/mcL] \par\par Morphology:\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 WBC: Overall unremarkable morphology. No definitive atypical lymphocytosis seen.\par RBC: Normocytic, normochromic RBCs.\par Platelets: Adequate in number with unremarkable morphology\plain\rtlch\af2\afs24\alang0\ltrch\f2\fs24\lang0\langnp0\langfe0\langfenp0\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate reports, CG22-7212 & CG22-7213\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate reports, M22-40941& M22-40943\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-3309;S11;MSK4 - 2023-04-17 07.45.21.ndpi,Peripheral Blood Smear,2023-04-17,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: M
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
60-70% involvement by CD138 immunohistochemistry.
70% involvement by aspirate differential
29.1% involvement by flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality: Limited, fragmented 
Cellularity: Cannot be accurately evaluated 
Myeloid lineage: Decreased
Erythroid lineage: Decreased
Megakaryocytes: Present 
Plasma cells: Increased 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Adequate 

Blasts                1%
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      10%
Eosinophils           1%
Erythroid Precursors      9%
Plasma Cells           70%
Lymphocytes           4%
Number of Cells Counted      500
M:E Ratio           1.8

Morphology: 
Marrow spicules: Spicular 
Cellularity: Cellular 
Plasma cell morphology: Small to large sized, occasionally bi-nucleated
Myeloid lineage: Orderly maturation 
Erythroid Lineage: Orderly maturation 
Megakaryocytes: Present 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 60-70% of cellularity. 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.
BCMA highlights 80% of plasma cells, (2-3) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-4277) 
1. Abnormal plasma cell population detected.
Abnormal plasma cell population comprises 99.4% of total plasma cells.
Abnormal plasma cell population represents 29.1% of WBC.

Immunophenotype:
Abnormal: CD38 (dim), CD19 (negative), CD27 (negative), CD45 (bimodal - negative to intermediate), CD56 (positive), CD81 (negative), CD117 (positive), cytoplasmic Kappa (restriction)
Normal: CD138, CD229, CD319, CD20
Negative: cytoplasmic Lambda
Number of cells acquired: 5.7 million 

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.
Number of cells acquired: 102 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (4/22/2022):
WBC 3.7 L [4.0-11.0 K/mcL] 
RBC 2.67 L [3.80-5.00 M/mcL] 
HGB 8.5 L [11.2-15.4 g/dL] 
HCT 24.7 L [34.3-46.0 %] 
MCV 93 [80-98 fL] 
MCH 31.8 [27.0-33.0 pg] 
MCHC 34.4 [31.0-36.5 g/dL] 
RDW 15.2 H [12.2-15.1 %] 
Platelets. 212 [160-400 K/mcL] 

Neutrophil 54.1 [32.5-74.8 %] 
Mono 4.6 [0.0-12.3 %] 
Eos 2.1 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.8 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 38.1 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.0 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL]

Morphology: No circulating plasma cells on scanning. 

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-2917, CG22-2918.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-17495, M22-17496.
"
H22-7854;S12;MSK4 - 2023-04-14 15.15.41.ndpi,Peripheral Blood Smear,2023-04-14,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: MM/amyloid\par Clinical Hx/Op Findings: newly diagnosed\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue0;\red0\green255\blue255;\red255\green255\blue255;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: \~\~\par      - Plasma cell neoplasm, \~\par\~\~\~\~\~\~\~\~\~\~10-20% involvement by CD138 immunohistochemistry.\par\~\~\~\~\~\~\~\~\~\~15% involvement by aspirate differential\par\~\~\~\~\~\~\~\~\~\~2.7% involvement by flow cytometry\par      - Cellular marrow with trilineage maturing hematopoiesis.\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate  \par Cellularity: 40-50%\par Myeloid lineage: Orderly maturation    \par Erythroid lineage: Orderly maturation   \par Megakaryocytes: Adequate   \par Plasma cells: Increased   \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 2%\par Myelocytes \tab\tab 13%\par Metamyelocytes \tab\tab 8%\par Neutrophils/Bands \tab 28%\par Monocytes \tab\tab 5%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 23%\par Plasma Cells \tab\tab 15%\par Lymphocytes \tab\tab 4%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 2.5\par\par\par Morphology: \par Marrow spicules: Spicular \par Cellularity: Cellular \par Plasma cell morphology: Small to large in size with rare bi/multi-nucleated forms \par Myeloid lineage: Orderly maturation \par Erythroid Lineage: Orderly maturation \par Megakaryocytes: Present \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD138 immunostain highlights plasma cells, 10-20% of cellularity. \par Kappa and lambda immunostains show the plasma cells are  lambda light chain restricted\par BCMA highlights >90% of plasma cells, (1-2+) intensity, membranous/ Golgi pattern. \par\~\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10269)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par 1. Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par\par Abnormal plasma cell population comprises 99.6% of total plasma cells.\par Abnormal plasma cell population represents 2.7% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (negative), CD27 (negative), CD45 (negative), CD56 (positive), CD81 (variable - dim to intermediate), CD117 (positive), cytoplasmic Lambda (restriction)\par Normal: CD138, CD229, CD319\par Negative: CD38 (consistent with anti-CD38 therapy effect), CD20, cytoplasmic Kappa\par\par Number of cells acquired: 5.8 million \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC ( 09/21/2022  ):\par\par WBC 6.5 [4.0-11.0 K/mcL] \par RBC 4.23 [3.95-5.54 M/mcL] \par HGB 12.4 L [12.5-16.2 g/dL] \par HCT 36.8 L [37.5-49.3 %] \par MCV 87 [80-98 fL] \par MCH29.3 [27.0-33.0 pg] \par MCHC 33.7 [31.0-36.5 g/dL] \par RDW 12.4 [12.2-15.1 %] \par Platelets. 279 [160-400 K/mcL] \par\par Neutrophil 75.6 H [32.5-74.8 %] \par Mono 11.5 [0.0-12.3 %] \par Eos 0.3 [0.0-4.9 %] \par Baso 0.5 [0.0-1.5 %] \par Immature Granulocyte 1.1 H [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 11.0 L [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 4.9 [1.5-7.5 K/mcL] \par Abs Mono 0.7 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] \par Abs Lymph 0.7 L [0.9-3.2 K/mcL] \par\par Morphology: No circulating plasma cells seen\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb4\chshdng0\chcfpat0\chcbpat4 CG22-7048, CG22-7049\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-40087 and M22-40088. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-1185;S47;MSK3 - 2023-05-26 16.35.13.ndpi,Peripheral Blood Smear,2023-05-31,"MCL
Protocol#: 18-427     
Newly diagnosed
","1-4. Bone marrow, right posterior iliac crest, biopsy, clot, aspirate, and peripheral blood smears: 
     - CD5-positive B-cell lymphoma, consistent with mantle cell lymphoma, 30-40% involvement with CD20 immunohistochemistry. 

BONE MARROW BIOPSY/CLOT/ASPIRATE MORPHOLOGY
Adequate biopsy, clot and aspirate specimens show normocellular bone marrow (overall 30% cellularity). There istrilineage maturing hematopoiesis with increased atypical lymphocytes, showing interstitial and diffuse distribution. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
Performed with block 1_1
CD20 highlights increase in B-cells, comprising 30-40% of marrow cellularity.
These B-cells co-express CD5, cyclin D1 (dim) and SOX11 (very dim).  
CD3 highlights T-cells, 10-15% of cellularity. 

Performed with block 2_14
CD20 highlights atypical B-cell aggregates, comprising overall 30-40% of marrow cellularity in this clot section.
These B-cells co-express CD5, cyclin D1 and SOX11.
CD23 is expressed in a subset of B-cells. 
P53 is expressed in 10-15% of B-cells.    
CD3 highlights T-cells, 10-15% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1500) 
Interpretation: 
Abnormal B cell population detected. 
The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.
Abnormal B cell population represents 47.5% of WBC.

Immunophenotype:
Abnormal: CD5 (positive), CD23 (partial), CD43 (positive), CD79b (variable - dim to intermediate), ROR1 (positive)
Normal: CD20, CD81, CD19, CD40, CD45, CD38
Negative: CD200, CD10, CD3

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (02/08/2022):
WBC 17.2 H [4.0-11.0 K/mcL] 
RBC 4.66 [3.95-5.54 M/mcL] 
HGB 12.8 [12.5-16.2 g/dL] 
HCT 39.7 [37.5-49.3 %] 
MCV 85 [80-98 fL] 
MCH 27.5 [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 13.1 [12.2-15.1 %] 
Platelets 139 L [160-400 K/mcL] 

Neutrophil 22.0 L [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 19.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 55.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 3.8 [1.5-7.5 K/mcL] 
Abs Mono 0.7 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 12.8 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: Numerous circulating atypical lymphocytes present, showing irregular nuclear contours and prominent nucleoli. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-981, CG22-1046.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-6206.

"
H22-9290;S13;MSKA - 2023-06-15 13.19.10.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Multiple Myeloma\par Clinical Hx/Op Findings: Newly dx MM\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: \~\par      - Extensive involvement by lymphoplasmacytic lymphoma (60-70% by CD20 immunohistochemical stain), see note 1.\par      - Hypercellular marrow with reduced trilineage maturing hematopoiesis.\par      - A small abnormal B cell population detected by flow cytometry study only (1.9% of WBC), see note 2. \par\par Note: \par 1. The MYD88 L265P and CXCR4 variant detected by IMPACT-Heme (M22-40944) in recent peripheral blood specimen support the diagnosis of lymphoplasmacytic lymphoma. This case is unusual that the patient presents with IgA/IgM biclonal gammopathy. IgA lymphoplasmacytic lymphoma has been described in literatures, some of them may also carry concurrent smaller IgM spike (PMID:31107988, 36244464). \par 2. Flow cytometry detected a second abnormal CD5+ lambda restricted population that likely represents either non-CLL/SLL monoclonal B-cell lymphocytosis (MBL) or low level involvement by a second B-cell lymphoproliferative disorder. Correlation with clinical findings is recommended. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate  \par Cellularity: 90-100%\par Myeloid lineage: Reduced with orderly maturation    \par Erythroid lineage: Reduced with orderly maturation   \par Megakaryocytes: Present\par Plasma cells: Slightly increased \par\par Special stain: Congo Red stain is negative for amyloid deposition \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate\par\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 7%\par Metamyelocytes \tab\tab 5%\par Neutrophils/Bands \tab 21%\par Monocytes \tab\tab 2%\par Eosinophils \tab\tab 2%\par Erythroid Precursors \tab 6%\par Plasma Cells \tab\tab 5%\par Lymphocytes \tab\tab 50%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 6.3\par\par Morphology: \par Marrow spicules: Spicular\par Cellularity: Cellular \par Plasma cell morphology: Small to intermediate \par Myeloid lineage: Orderly maturation \par Erythroid Lineage: Orderly maturation \par Megakaryocytes: Present \par Lymphocytes: Markedly increased, small to intermediate in size with irregular nuclei, dense/clumped chromatin, inconspicuous nucleoli, scant to intermediate amount of cytoplasm (many plasmacytoid forms). \par Other findings: Few mast cells are noted.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD20 and PAX5 stains extensive involvement of neoplastic cells (60-70% of total cellularity). The neoplastic cells are dim positive for IgA and kappa light chain. CD138 and BCMA highlight scattered plasma cells with kappa light chain restriction by kappa/lambda light chain stains. IgM and IgG stains a few scattered plasma cells. CD3 and CD5 highlight scattered T lymphocytes. CyclinD1 stains rare positive cells.  \par\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-12070)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Two abnormal B- cell and plasma cell populations detected.\par\par 1. The first abnormal B cell population has the same light chain restriction as the abnormal plasma cell population mentioned below. Given the similar light chain restriction, these two populations likely represent manifestations of the same neoplasm, but the immunophenotypic profiles do not allow specific classification.  Clinical and morphologic correlation is advised.\par\par Abnormal B cell population represents 16.6% of WBC.\par Immunophenotype:\par Abnormal: CD19 (dim), CD22 (dim), CD25 (partial), surface Kappa (restriction)\par Normal: CD20, CD38, CD45\par Negative: CD5, CD10, CD279 (PD1), CD3, CD14, surface Lambda\par\par Abnormal plasma cell population detected.\par The abnormal plasma cell population has the same light chain restriction (see immunophenotype below) as the abnormal B cell population mentioned above. \par Abnormal plasma cell population represents 1.2% of WBC.\par Abnormal plasma cell population comprises 95.9% of total plasma cells.\par Immunophenotype:\par Abnormal: CD229 (dim), CD27 (variable - negative to intermediate), cytoplasmic Kappa (restriction)\par Normal: CD138, CD38, CD319, CD19, CD45, CD81\par Negative: CD20, CD56, CD117, cytoplasmic Lambda\par\par Number of cells acquired 5.7 million \par\par 2. A second abnormal B cell population detected. \par The immunophenotype of this abnormal B cell population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with immunohistochemical or cytogenetic studies for Cyclin D1 is recommended to rule out mantle cell lymphoma (MCL). The abnormal B cell population show Kappa (subset) and Lambda (subset) expression with the immunophenotype similar to that of the two CD5+ B cell populations seen previously (F22-11528). \par\par Abnormal B cell population represents 1.9% of WBC.\par Immunophenotype:\par Abnormal: CD5 (positive), CD22 (dim), CD43 (partial), CD81 (dim), CD19 (dim), surface Kappa (subset- restriction), surface Lambda (subset- restriction)\par Normal: CD20, CD79b, CD40, CD45, CD38\par Negative: CD23, CD200, ROR1, CD10, CD3, CD14, CD25, CD279 (PD1)\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/03/2022):\par WBC 4.4 [4.0-11.0 K/mcL] \par RBC 2.88 L [3.95-5.54 M/mcL] \par HGB 8.6 L [12.5-16.2 g/dL] \par HCT 27.6 L [37.5-49.3 %] \par MCV 96 [80-98 fL] \par MCH 29.9 [27.0-33.0 pg] \par MCHC 31.2 [31.0-36.5 g/dL] \par RDW 15.9 H [12.2-15.1 %] \par Platelets 128 L [160-400 K/mcL] \par\par Neutrophil 48.0 [32.5-74.8 %] \par Mono 18.0 H [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Myelocyte 1.0 H [0.0-0.0 %] \par Metamyelocyte 2.0 H [0.0-0.0 %] \par Lymph 31.0 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 2.1 [1.5-7.5 K/mcL] \par Abs Mono 0.8 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Myelocytes 0.0 [0.0-0.0 K/mcL] \par Abs Meta 0.1 H [0.0-0.0 K/mcL] \par Abs Lymph 1.4 [0.9-3.2 K/mcL] \par\par Morphology: \par WBC: No circulating plasma cells by scanning. \par RBC: Normocytic anemia. Mild rouleaux formation. \par PLT: Mild thrombocytopenia. \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8307, CG22-8308.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-47182. \plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-2888;S10;MSKD - 2023-05-26 13.45.24.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: ALL
Clinical Hx/Op Findings: pretreatment
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Extensive involvement by Hairy cell leukemia (~70% with CD20 immunohistochemistry)
     - Variably cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy specimen shows variably cellular bone marrow (ranging from 10-80%cellularity). There isan extensive interstitial atypical lymphoid infiltrate composed of medium sized cells with ovoid nuclei and ample amount of pale eosinophilic cytoplasm. Background trilineage maturing hematopoiesis is noted.

Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules
The differential cell count was performed on touch imprints only

Blasts                2%
Promyelocytes           2%
Myelocytes           10%
Metamyelocytes           8%
Neutrophils/Bands      18%
Monocytes           4%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      23%
Plasma Cells           1%
Lymphocytes           30%
Number of Cells Counted 500
M:E Ratio           1.9

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
The atypical lymphoid infiltrate is positive for CD20 (~70% of cellularity) and CD103. 
CD3 highlights T-cells, 5-10% of cellularity. 
CD34 stains few blasts, <5%
CD61 stains megakaryocytes
CD71 stains erythroid elements

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-3769) 
1. Abnormal B cell population detected.
The immunophenotype of the abnormal B-cell is consistent with involvement by hairy cell leukemia (HCL).

Abnormal B cell population represents 4.0% of WBC.
Immunophenotype:
Abnormal: CD19 (bright), CD20 (bright), CD22 (bright), CD25 (positive), CD11c (positive), CD103 (positive), CD200 (bright), surface Kappa (restriction), Forward Scatter (increased), Side Scatter (increased)
Normal: CD38, CD45
Negative: CD5 (no convincing), CD10, CD279 (PD1), CD3, CD14, surface Lambda

2. No abnormal mature T cell population detected.
No immunophenotypic evidence of T-cell lymphoma is identified.

Number of cells acquired: 358 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (04/08/2022):
WBC 2.0 L [4.0-11.0 K/mcL] 
RBC 3.22 L [3.95-5.54 M/mcL] 
HGB 11.2 L [12.5-16.2 g/dL] 
HCT 33.4 L [37.5-49.3 %] 
MCV 104 H [80-98 fL] 
MCH 34.8 H [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 14.8 [12.2-15.1 %] 
Platelets 104 L [160-400 K/mcL] 

Neutrophil 42.0 [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 55.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: 
WBC: Absolute neutropenia. Few atypical lymphocytes with cytoplasmic projections noted
RBC: Mild anisocytosis
Platelet: Mild thrombocytopenia

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-2546

MOLECULAR STUDIES 
Molecular analysis will be reported separately. 
"
H22-9425;S13;MSK1 - 2023-04-14 14.40.23.ndpi,Peripheral Blood Smear,2023-04-14,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Multiple Myeloma\par Clinical Hx/Op Findings: monoclonal protein\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, left posterior iliac crest,  biopsy, \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate, and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : \~\~\par      - Plasma cell neoplasm, \~\par\~\~\~\~\~\~\~\~\~\~10-20% involvement by CD138 immunohistochemistry.\par\~\~\~\~\~\~\~\~\~\~8% involvement by aspirate differential\par\~\~\~\~\~\~\~\~\~\~0.2% involvement by flow cytometry\par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate \par Cellularity: 60-70%\par Myeloid lineage: Orderly maturation    \par Erythroid lineage: Orderly maturation  \par Megakaryocytes: Adequate   \par Plasma cells: Increased  \par\par Special stain: Congo Red stain is negative for amyloid deposition.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate \par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 8%\par Metamyelocytes \tab\tab 4%\par Neutrophils/Bands \tab 40%\par Monocytes \tab\tab 2%\par Eosinophils \tab\tab 4%\par Erythroid Precursors \tab 23%\par Plasma Cells \tab\tab 8%\par Lymphocytes \tab\tab 9%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 2.6\par\par Morphology: \par Marrow spicules: Spicular \par Cellularity: Cellular \par Plasma cell morphology: Small to intermediate in size\par Myeloid lineage: Orderly maturation \par Erythroid Lineage: Orderly maturation \par Megakaryocytes: Present \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD138 immunostain highlights plasma cells, 10-20% of cellularity. \par Kappa and lambda immunostains show the plasma cells are lambda light chain restricted.\par BCMA highlights >90% of plasma cells, (1-2+) intensity, membranous/ Golgi pattern. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-12239)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par\par Abnormal plasma cell population comprises 93% of total plasma cells.\par Abnormal plasma cell population represents 0.20% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (negative), CD20 (positive, partial), CD27 (negative), CD45 (negative), CD56 (bimodal - negative to intermediate), CD81 (negative), CD117 (positive), cytoplasmic Lambda (restriction)\par Normal: CD138, CD38, CD229, CD319\par Negative: cytoplasmic Kappa\par\par Number of cells acquired: 5.6 million \par\par\par 2. No abnormal mature B cell population detected.\par No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.\par\par Number of cells acquired: 395 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/8/2022):\par WBC 7.4 [4.0-11.0 K/mcL] \par RBC 3.96 [3.95-5.54 M/mcL] \par HGB 12.1 L [12.5-16.2 g/dL] \par HCT 35.1 L [37.5-49.3 %] \par MCV 89 [80-98 fL] \par MCH 30.6 [27.0-33.0 pg] \par MCHC 34.5 [31.0-36.5 g/dL] \par RDW 12.1 L [12.2-15.1 %] \par Platelets. 212 [160-400 K/mcL] \par\par Neutrophil 57.4 [32.5-74.8 %] \par Mono 8.0 [0.0-12.3 %] \par Eos 2.3 [0.0-4.9 %] \par Baso 0.8 [0.0-1.5 %] \par Immature Granulocyte 0.3 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 31.2 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 4.2 [1.5-7.5 K/mcL] \par Abs Mono 0.6 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] \par Absolute Basophil 0.1 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 2.3 [0.9-3.2 K/mcL]\par\par Morphology: \par No circulating plasma cells\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8437 and CG22-8438. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-48050. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-8337;S15;MSK4 - 2023-04-14 15.04.16.ndpi,Peripheral Blood Smear,2023-04-14,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Leukemia\par Clinical Hx/Op Findings: Hx of CMML-MDS with progressive pancytopenia\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b 1-3. Bone marrow, right posterior iliac crest; biopsy, \plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b : \~\~\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par      - Persistent involvement by myeloid neoplasm, most consistent with chronic myelomonocytic leukemia (CMML). See comment.\par      - Hypercellular marrow with myeloid hyperplasia, multilineage dysplasia and no increase in blasts/blast equivalents (3% blasts/blast equivalents by aspirate differential count).\par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The findings of bone marrow hypercellularity with myeloid hyperplasia, multilineage morphologic dysplasia and phenotypically abnormal myeloid blast population by flow cytometry in the context of peripheral cytopenias, and absolute and relative monocytosis support a diagnosis of persistent involvement by myeloid neoplasm, most consistent with chronic myelomonocytic leukemia (CMML) with previously reported TET2 and SRSF2 mutations (H22-7265). Correlation with forthcoming molecular genetic studies (M22-41062 and M22-42415) and cytogenetic studies (CG22-7506) at MSKCC is recommended. \plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Hypercellular for age (90% cellularity)\par M:E ratio: Increased\par Blasts: Not overtly increased\par Myeloid lineage: Increased in number; exhibits complete maturation\par Erythroid lineage: Relatively decreased in number; exhibits complete maturation\par Megakaryocytes: Mildly increased in number; include some small and/or mono/hypolobated and occasional hyperchromatic forms, and rare forms with disjointed nuclear lobes\par Lymphocytes: Scattered\par Plasma cells: Not increased\par\par Special stains: Reticulin stain shows no significant increase in reticulin fibrosis (MF-0 out of 3). \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate\par Blasts//blast equivalents \tab 3%\par Promyelocytes \tab\tab 2%\par Myelocytes \tab\tab 12%\par Metamyelocytes \tab\tab 12%\par Neutrophils/Bands \tab 43%\par Monocytes \tab\tab 10%\par Erythroid Precursors \tab 10%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 7%\par Number of Cells Counted   500\par M:E Ratio \tab\tab 8\par\par Special stain:\par Ir\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 on: Storage iron is present \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Ring sideroblasts: Absent \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par The bone marrow aspirate smears are spicular and hypercellular showing maturing trilineage hematopoiesis. Blasts/blast equivalents are not increased, and Auer rods are not identified. Myeloid elements are increased and display full maturation with dysplastic changes (abnormal nuclear lobation, abnormal chromatin clumping and cytoplasmic hypogranularity). Monocytes appear increased and predominantly show mature features. Erythroid elements are relatively decreased and show progressive maturation with mild dyspoiesis (nuclear-cytoplasmic dyssynchrony, nuclear irregularity, binucleation). Megakaryocytes are present and include small mono/hypolobated forms and rare forms with disjointed nuclear lobes.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (10/06/2022):\par WBC 4.7 [4.0-11.0 K/mcL] \par RBC 3.96 [3.80-5.00 M/mcL] \par HGB 10.9 L [11.2-15.4 g/dL] \par HCT 33.1 L [34.3-46.0 %] \par MCV 84 [80-98 fL] \par MCH 27.5 [27.0-33.0 pg] \par MCHC 32.9 [31.0-36.5 g/dL] \par RDW 15.5 H [12.2-15.1 %] \par Platelets 62 L [160-400 K/mcL] \par\par Neutrophil 32.0 L [32.5-74.8 %] \par Mono 49.0 H [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Myelocyte 2.0 H [0.0-0.0 %] \par Lymph 17.0 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 1.5 [1.5-7.5 K/mcL] \par Abs Mono 2.3 H [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] \par Abs Lymph 0.8 L [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]\par\par Morphology:\par WBC: Monocytosis; neutrophils with dysplastic features (abnormal nuclear lobation and hypogranular cytoplasm); no increase in circulating blasts.\par RBC: Normochromic normocytic anemia with mild anisopoikilocytosis.\par Platelets: Thrombocytopenia; occasional large/giant forms.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 immunostains show no increase in blasts (<5% of cellularity). \par CD61 highlights megakaryocytes which appear increased in number and include a few micromegakaryocytes.\par Aberrant CD34 expression is seen in a subset of megakaryocytes.\par MPO labels myeloid elements while CD71 labels erythroid elements, highlighting the increased M:E ratio.\tab\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10878)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Abnormal myeloid blast population detected. The immunophenotype of this population is similar to that seen in prior sample [case F22-10518]. \par\par Abnormal myeloid blast population represents 0.15% of WBC.\par Expanded immature monocyte population is seen, represents 2.6% of WBC.\par Total myeloid blast/blast equivalents represent 2.75% of WBC.\par Monocytosis is seen, 25.8% of WBC.\par\par Immunophenotype:\par Abnormal: CD13 (dim), CD45RA (negative), CD117 (bright), CD371 (clec12a) (variable - negative to dim)\par Normal: CD4, CD33, CD34, CD36, CD38, CD45, CD71, CD123, HLA-DR\par Negative: CD2, CD5, CD7, CD10, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64, CD105, CD42b, CD90\par\par Number of cells acquired: 572 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-7506.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-42414, M22-42415. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-1550;S11;MSK- - 2023-04-19 16.14.21.ndpi,Peripheral Blood Smear,2023-04-19,"Clinical Diagnosis: AML
Clinical Hx/Op Findings: restaging bone marrow
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Relapsed acute leukemia, 18% blasts by touch imprint differential count. See comment.
  
COMMENT: The blasts show a myeloid phenotype and are immunophenotypically similar to those seen previously (H19-9413/F19-8340), consistent with recurrent disease.  

BONE MARROW BIOPSY
Quality: Adequate with fragmentation
Cellularity: Hypercellular, ~70% overall
M:E ratio: Mildly reduced
Blasts: Increased
Myeloid lineage: Exhibits left shifted maturation
Erythroid lineage: Exhibits progressive maturation
Megakaryocytes: Adequate in number with occasional small, hypolobated forms and forms with disjointed nuclear lobes and focal clustering
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows no significant increase in reticulin fibrosis 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules
Differential performed on touch imprint smear

Blasts                18%
Promyelocytes           4%
Myelocytes           10%
Metamyelocytes           7%
Neutrophils/Bands      14%
Eosinophils           2%
Erythroid Precursors      30%
Lymphocytes           15%
Number of Cells Counted 500
M:E Ratio           1.2 

Morphology:
- Moderately cellular touch imprint and aspicular, hypocellular and hemodilute aspirate smears show an expanded population of mostly intermediate to large sized blasts with rounded to irregular nuclei, dispersed chromatin, distinct nuclei, and scant to moderate amounts of cytoplasm with occasional cytoplasmic vacuoles. Myeloid elements show left-shifted maturation without significant dysplasia. Erythroid precursors show progressive maturation with occasional nuclear irregularities or binucleation. Megakaryocytes are present with occasional small, hypolobated forms and few forms with apparent disjointed nuclear lobes.

PERIPHERAL BLOOD
CBC (02/23/2022):
WBC 2.4 L [4.0-11.0 K/mcL] 
RBC 3.00 L [3.80-5.00 M/mcL] 
HGB 9.5 L [11.2-15.4 g/dL] 
HCT 31.9 L [34.3-46.0 %] 
MCV 106 H [80-98 fL] 
MCH 31.7 [27.0-33.0 pg] 
MCHC 29.8 L [31.0-36.5 g/dL] 
RDW 19.9 H [12.2-15.1 %] 
Platelets 152 L [160-400 K/mcL] 

Neutrophil 75.8 H [32.5-74.8 %] 
Mono 3.7 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Immature Granulocyte 0.4 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 20.1 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 1.8 [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 0.5 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Rare circulating blasts seen.
RBC: Macrocytic anemia.
PLT: Unremarkable morphology. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD117 highlights increased interstitial blasts, ~20% of cellularity. The blasts are largely negative for CD34.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-2023)
Interpretation: 
Abnormal myeloid blast population detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample [F19-11188] having abnormal expression of CD7, CD11b (partial), CD13 (bright), CD33 (bright), CD34 (negative), CD38 (bright), CD45RA (bright), CD117 (bright), CD123 (bright) and HLA-DR (negative); with normal expression of CD4, CD36, CD45, CD71, CD105 and CD371; without CD2, sCD3, cyCD3, CD5, CD10, CD14, CD15, CD16, CD19, CD25, CD56, cyCD79a, or CD64. MPO is expressed on a small subset of blasts. The abnormal myeloid blasts represent 16.5% of WBC. 

No abnormal immature B cell population is detected. Virtually no immature B cell seen. 
4.8 million cells acquired.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Not requested. 

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-8218. 
"
H22-1124;S10;MSKW - 2023-05-26 16.23.30.ndpi,Peripheral Blood Smear,2023-05-31,"{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch31505\stshfloch31506\stshfhich31506\stshfbi0\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}
{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;
\red0\green0\blue0;}{\*\defchp \fs22\loch\af31506\hich\af31506\dbch\af31505 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*
\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\trcbpat1\trcfpat1\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused 
Normal Table;}{\s15\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\f1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext15 \spriority0 Arial;}}
{\*\rsidtbl \rsid1736676\rsid1926613\rsid6949486\rsid8271858\rsid12137372}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\operator Chan, Alexander Y./Pathology}
{\creatim\yr2022\mo2\dy14\hr11\min50}{\revtim\yr2022\mo2\dy14\hr11\min50}{\version2}{\edmins0}{\nofpages1}{\nofwords17}{\nofchars99}{\nofcharsws115}{\vern21}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}
\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata1\grfdocevents0\validatexml0\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors0\horzdoc\dghspace120\dgvspace120\dghorigin1701
\dgvorigin1984\dghshow0\dgvshow3\jcompress\viewkind1\viewscale130\rsidroot8271858 \fet0{\*\wgrffmtfilter 2450}\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2
\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}\pard\plain \ltrpar\s15\ql \li0\ri0\nowidctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\af1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \fs18\insrsid12137372 \hich\af1\dbch\af31505\loch\f1 Clinical Diagnosis: Lymphoma, Mantle Cell\par \hich\af1\dbch\af31505\loch\f1 Clinical Hx/Op Findings: recurrent disease\par \hich\af1\dbch\af31505\loch\f1 Requested Studies: Gross/Micro\par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Involved by previously diagnosed mantle cell lymphoma, ~10-20% of total cellularity by CD20 immunohistochemistry.
    - Hypercellular bone marrow with maturing trilineage hematopoiesis 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy specimen shows a hypercellular (~70%) bone marrow with maturing trilineage hematopoiesis and an atypical lymphoid infiltrate with interstitial and intrasinusoidal distribution composed of small to medium sized atypical lymphoid cells with moderate amounts of cytoplasm, irregular nuclei, and condensed chromatin. Aspirate smears are spicular, cellular, and show maturing trilineage hematopoiesis without expanded blast population, with frequent atypical lymphoid cells.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight the atypical lymphoid infiltrate, ~10-20% of total cellularity. 
B-cells co-express CD5 and CyclinD1, while negative for CD3, CD23, and P53.
SOX11 is technically suboptimal.
BCL2 and BCL6 appear mostly negative in the B-cells.
CD3 highlights scattered T-cells, <5% of total cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1438) 
Abnormal B cell population detected.
The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.
Abnormal B cell population represents 21.0% of WBC.

Immunophenotype:
Abnormal: CD5 (partial), CD20 (bright), CD79b (bright), CD200 (negative), CD19 (bright), CD45 (bright), CD10 (partial), surface Kappa (restriction)
Normal: CD22, CD23, CD43, CD81, CD40
Negative: ROR1, CD38, CD3, surface Lambda

Also see F21-1439 (PB) submitted on the same day.
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (2/08/2022):
WBC 5.8 [4.0-11.0 K/mcL] 
RBC 4.37 [3.95-5.54 M/mcL] 
HGB 13.0 [12.5-16.2 g/dL] 
HCT 38.8 [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 108 L [160-400 K/mcL] 

Neutrophil 47.0 [32.5-74.8 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 17.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 28.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 2.7 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 2.6 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Frequent circulating atypical lymphoid cells seen.
RBC: Normocytic, normochromic RBCs.
PLT: Mild thrombocytopenia. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-928.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-5779, M22-5782, M22-5783.

"
H22-8201;S15;MSK4 - 2023-04-14 15.09.58.ndpi,Peripheral Blood Smear,2023-05-04,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: AML\par Clinical Hx/Op Findings: new diagnosis\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\par      - Acute myeloid leukemia, 65% blasts by aspirate differential count. See comment.\par  \par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT: \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Eosinophiia is noted, exclusion of progression from myeloid neoplasm with eosinphilia via gene fusion testing is advised. Further classification of this acute myeloid leukemia requires correlation with molecular genetic and cytogenetic studies. \plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Hypercellular (>90%)\par M:E ratio: N/A\par Blasts: Increased\par Myeloid lineage: Overall decreased, relatively increased eosinophils\par Erythroid lineage: Markedly decreased\par Megakaryocytes: Markedly decreased, only rare forms present\par Lymphocytes: Decreased\par Plasma cells: Decreased\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate\par\par Blasts \tab\tab\tab 65%\par Promyelocytes \tab\tab 2%\par Myelocytes \tab\tab 2%\par Metamyelocytes \tab\tab 2%\par Neutrophils/Bands \tab 2%\par Monocytes \tab\tab 10%\par Eosinophils \tab\tab 5%\par Basophils \tab\tab 1%\par Plasma Cells \tab\tab 2%\par Lymphocytes \tab\tab 9%\par Number of Cells Counted   500\par M:E Ratio \tab\tab 0\par\par Morphology:\par -The bone marrow aspirate smears are spicular and hypercellular showing increased medium to large blasts with fine chromatin, distinct nucleoli and scant basophilic cytoplasm. Occasional binucleated blasts are present. Eosinophils are relatively increased. Rare plasma cell, erythroid elements, and megakaryocytes are present. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (10/04/2022):\par WBC 5.9 [4.0-11.0 K/mcL] \par RBC 2.44 L [3.95-5.54 M/mcL] \par HGB 7.6 L [12.5-16.2 g/dL] \par HCT 22.8 L [37.5-49.3 %] \par MCV 93 [80-98 fL] \par MCH31.1 [27.0-33.0 pg] \par MCHC 33.3 [31.0-36.5 g/dL] \par RDW18.6 H [12.2-15.1 %] \par Platelets. 18 L [160-400 K/mcL] \par\par Morphology:\par WBC: Monocytosis, with many blasts are seen\par RBC: Normochromic normocytic anemia, anisopoikilocytosis\par Platelets: Thrombocytopenia\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Blasts are positive CD117, MPO and muramidase, while negative for TdT. CD34 stains a minority of the blasts\par CD61 highlights rare megakaryocytes\par CD71 highlights rare erythroid progenitors.\par\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10682)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Expanded abnormal myeloid blast population detected.\par Abnormal myeloid blast population represents 36.36% of WBC.\par Expanded immature monocyte population is seen, represents 21.5% of WBC.\par Total myeloid blast/blast equivalents represent 57.86% of WBC.\par\par Monocytosis is seen, 39.0% of WBC.\par\par Immunophenotype:\par Abnormal: CD13 (bright), CD15 (partial), CD33 (bright), CD34 (variable - negative to bright), CD38 (uniform - intermediate), CD45RA (uniform - dim), CD64 (partial), CD117 (variable - intermediate to bright), CD123 (bright), CD371 (clec12a) (uniform - dim), HLA-DR (variable - negative to intermediate)\par Normal: CD4, CD36, CD45, CD71, MPO\par Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD105, cytoplasmic CD3, cytoplasmic CD79a, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-7352.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-41700, M22-41701, M22-41702, M22-41704, M22-41737 \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par\par }"
H22-786;S11;MSK- - 2023-05-26 15.43.21.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: myelofibrosis
Clinical Hx/Op Findings: Leukocytosis / Thrombocytosis
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate, and peripheral blood smears: 
     - Persistent MDS/MPN with ring sideroblasts and thrombocytosis, now with marked fibrosis   

COMMENT:
Stain for ring sideroblasts will be reported in addendum, however, it would not change the diagnosis 
BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Increased (80-90%)
M:E ratio: Appears mildly increased
Blasts: No increase
Myeloid lineage: Full maturation 
Erythroid lineage: Full maturation 
Megakaryocytes: Increased in number, with many atypical, mostly larger forms, forming loose clustres 
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows marked increase in reticulin fibrosis (MF-3). 


The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules

Blasts                1%
Myelocytes           2%
Metamyelocytes           5%
Neutrophils/Bands      61%
Monocytes           2%
Eosinophils           1%
Basophils           2%
Erythroid Precursors      22%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           3.3

Morphology:
-Spicular and cellular with trilineage hematopoiesis, erythroid dysplasia (nuclear budding) and no increase in blasts. Increased atypical megakaryocytes are noted

PERIPHERAL BLOOD
CBC (1/27/2022):

WBC 24.8 H [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 2.90 L [3.80-5.00 M/mcL] 
HGB 7.9 L [11.2-15.4 g/dL] 
HCT 26.2 L [34.3-46.0 %] 
MCV 90 [80-98 fL] 
MCH 27.2 [27.0-33.0 pg] 
MCHC 30.2 L [31.0-36.5 g/dL] 
RDW 25.2 H [12.2-15.1 %] 
Platelets 1031 H [160-400 K/mcL] 

Neutrophil 80.0 H [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 
Metamyelocyte 7.0 H [0.0-0.0 %] 
Lymph 2.0 L [12.2-47.4 %] 
Nucleated RBC 31.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 19.9 H [1.5-7.5 K/mcL] 
Abs Mono 0.7 [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.0 H [0.0-0.7 K/mcL] 
Absolute Basophil 1.0 H [0.0-0.2 K/mcL] 
Abs Meta 1.7 H [0.0-0.0 K/mcL] 
Abs Lymph 0.5 L [0.9-3.2 K/mcL] 

Morphology: Leukoerythroblastosis with thrombocytosis. No increased blasts noted.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 do not show an increase in blasts 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-974)
1. Abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 1.8% of WBC.

Immunophenotype:
Abnormal: CD7 (partial), CD13 (variable - negative to dim), CD34 (uniform - bright), CD38 (variable - negative to intermediate), HLA-DR (uniform - intermediate)
Normal: CD4, CD33, CD36, CD45, CD45RA, CD71, CD105, CD117, CD123, CD371 (clec12a)
Negative: CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda

Number of cells acquired: 568 thousand 

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-613.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-3959.
"
H22-9232;S14;MSKY - 2023-06-15 13.36.19.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: CLL\par Requested Studies: Gross/Micro\par Clinical Hx/Op Findings: Flow with abnormal B cell population represents 29.3% of WBC.\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\par      - Involvement by CD5 positive B-cell lymphoma (30% by CD20 immunohistochemistry); See Comment\par      - Hypercellular marrow with trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  The differential diagnosis for a CD5 positive, CD10 negative B-cell lymphoma includes chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma, versus marginal zone lymphoma. We note the prior cytogenetic studies that were negative for CCND1 rearrangement (CG22-6923), which makes mantle cell lymphoma unlikely. Given that the flow immunophenotype is not typical for CLL/SLL, an atypical CLL/SLL and marginal zone lymphoma remain in the differential. If clinically indicated, sampling of secondary lymphoid tissue may be considered for further classification. Correlation with the pending cytogenetic and molecular studies is recommended. The case was also reviewed by Dr. Mariko Yabe (Hematopathology Service) who agrees with the diagnosis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy and aspirate specimens show hypercellular bone marrow (50%cellularity). There is\~trilineage maturing hematopoiesis with increased numbers of atypical lymphocytes that are small in size with coarse chromatin and scant cytoplasm. Blasts are not increased. Overt dysplasia is not appreciated. The clot section shows mostly blood without marrow elements.\par\~\par Bone Marrow Aspirate Smear Quality: Adequate\par Patchy cellular distribution noted. Naked nuclei noted\par\par Blasts \tab\tab\tab 2%\par Promyelocytes \tab\tab 2%\par Myelocytes \tab\tab 7%\par Metamyelocytes \tab\tab 7%\par Neutrophils/Bands \tab 15%\par Monocytes \tab\tab 2%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 13%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 50% (occasional lymphoid aggregates noted)\par Number of Cells Counted \tab 500\par M:E Ratio \tab\tab 2.6\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD3 highlights scattered T-cells throughout the specimen, comprising 5-10% of marrow cellularity.\par CD20 and PAX5 highlight atypical B-cells showing mostly interstitial aggregates, accounting for 30% of marrow cellularity.\par These B-cells appear to co-express CD23 in a subset. CD5 is difficult to interpret and appears to highlight mostly T-cells.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-12033)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par Abnormal B cell population detected.\par The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.\par\par Abnormal B cell population represents 29.2% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (partial), CD20 (dim), CD23 (partial), CD79b (dim), CD81 (dim), surface Kappa (restriction)\par Normal: CD22, CD200, CD19, CD40, CD45, CD38\par Negative: CD43, ROR1, CD10, CD3, surface Lambda, CD25, CD14, CD279 (PD1)\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/02/2022):\par WBC 14.6 H [4.0-11.0 K/mcL] \par RBC 5.26 [3.95-5.54 M/mcL] \par HGB 14.5 [12.5-16.2 g/dL] \par HCT 44.5 [37.5-49.3 %] \par MCV 85 [80-98 fL] \par MCH 27.6 [27.0-33.0 pg] \par MCHC 32.6 [31.0-36.5 g/dL] \par RDW 13.2 [12.2-15.1 %] \par Platelets 283 [160-400 K/mcL] \par\par Neutrophil 56.0 [32.5-74.8 %] \par Mono 9.0 [0.0-12.3 %] \par Eos 3.0 [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Lymph 31.0 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 8.2 H [1.5-7.5 K/mcL] \par Abs Mono 1.3 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] \par Absolute Basophil 0.1 [0.0-0.2 K/mcL] \par Abs Lymph 4.5 H [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] \par\tab\par Morphology:\par WBC: Scattered atypical lymphocyte with coarse chromatin and scant cytoplasm\par RBC: Unremarkable\par PLT: Unremarkable\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8287.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-47230.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-580;S13;MSK4 - 2023-05-26 15.49.03.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Breast, Malignant Neoplasm
Clinical Hx/Op Findings: worsening pancytopenia requiring prbc transfusion
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate, and peripheral blood smears: 
     - Extensive marrow involvement by GATA3-positive metastatic carcinoma, consistent with mammary origin
     - No hematolymphoid neoplasm observed.  
 Dr. Yabe from Hematopathology service has also reviewed the case.

Immunohistochemical stains were performed on formalin-fixed tissue with the following results for metastatic carcinoma (block 1-1):
ESTROGEN RECEPTOR (clone 6F11, Leica): 10% nuclear staining with weak intensity
PROGESTERONE RECEPTOR (clone 16; Leica): 5% nuclear staining with moderate intensity
HER2 (4B5, Ventana): Negative (0) 
Note: The interpretation of these results is based in part on the decalcification procedure performed. 


BONE MARROW BIOPSY
Quality: Adequate

Marrow spaces are effaced by metastatic carcinoma, associated with significant desmoplasia. No hematopoietic elements are readily recognized.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules 
Positive for extrinsic cells.

Special stain unable to performed due lack of marrow elements.

Morphology:
-Aspicular and paucicellular smears show malignant cells arranged singly and in clusters, most consistent with epithelial neoplasm. Hematopoietic elements are rare, predominantly lymphocytes.

PERIPHERAL BLOOD
CBC (1/21/2022):
WBC 4.0 [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 2.24 L [3.80-5.00 M/mcL] 
HGB 6.9 L [11.2-15.4 g/dL] 
HCT 22.4 L [34.3-46.0 %] 
MCV 100 H [80-98 fL] 
MCH 30.8 [27.0-33.0 pg] 
MCHC 30.8 L [31.0-36.5 g/dL] 
RDW 29.3 H [12.2-15.1 %] 
Platelets. 44 L [160-400 K/mcL] 

Neutrophil 44.0 [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 40.0 [12.2-47.4 %] 
Nucleated RBC 12.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.8 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.6 [0.9-3.2 K/mcL]

Morphology:
RBC: Anisopoikilocytosis. Macrocytic anemia. Increased nucleated red blood cells.
WBC: Rare myeloid progenitors noted. No increase in circulating blasts.
PLT: Marked thrombocytopenia. Larger platelet forms noted.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
Immunostain for CD34 highlights endothelial cells. CD117 highlights rare mast cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-723)
No abnormal myeloid blast, mature B or mature T cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.39% of WBC.

Number of cells acquired: 25 thousand 
Less than target number of cells acquired for myeloid analysis. Target sensitivity is not achieved.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-464.

MOLECULAR STUDIES 
Not submitted


"
H22-7317;S10;MSK6 - 2023-06-15 14.40.55.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: Ph + ALL
Clinical Hx/Op Findings: newly diagnosed; untreated
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B lymphoblastic leukemia/lymphoma, Ph+

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Increased, largely replaced by blasts

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate 

Blasts                52% (patchy distribution)
Myelocytes           1%
Neutrophils/Bands      5%
Eosinophils           1%
Erythroid Precursors      20%
Lymphocytes           21%
Number of Cells Counted 500
M:E Ratio           0.4

Morphology:
-Spicular and cellular showing numerous blasts. Erythroid predominant trilineage is present, but reduced. Overt dysplasia is not seen.

PERIPHERAL BLOOD
CBC (9/2/2022):
WBC 5.8 [4.0-11.0 K/mcL] 
RBC 3.41 L [3.80-5.00 M/mcL] 
HGB 8.8 L [11.2-15.4 g/dL] 
HCT 28.5 L [34.3-46.0 %] 
MCV 84 [80-98 fL] 
MCH 25.8 L [27.0-33.0 pg] 
MCHC 30.9 L [31.0-36.5 g/dL] 
RDW 16.1 H [12.2-15.1 %] 
Platelets 416 H [160-400 K/mcL] 

Neutrophil 43.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 9.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 41.0 [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 2.5 [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.5 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 2.4 [0.9-3.2 K/mcL] 

Morphology: no smear provided


Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY

TdT and CD34 stain blasts
FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9560)
bnormal immature B cell population detected.
An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously [F22-9412].                         

Abnormal immature B cell population represents 81.0% of WBC.
Abnormal immature B cell population represents 83.1% of the mononuclear cells.

Immunophenotype:
Abnormal: CD10 (variable - bright to negative), CD34 (variable - dim to intermediate), CD38 (variable - negative to bright), CD81 (variable - dim to negative), CD66c/CD123 (positive), CD86 (partial)
Normal: CD19, CD22, CD24, CD45
Negative: CD20, CD73/CD304, CD66b

Number of cells acquired 553 thousand
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
1. Abnormal immature B cell population detected.

Abnormal immature B cell population represents 18.4% of WBC.
Abnormal immature B cell population represents 32.4% of the mononuclear cells.

Immunophenotype:
Abnormal: CD10 (variable - negative to bright), CD13 (dim), CD34 (uniform - intermediate), CD38 (dim), CD45 (dim), CD66c/CD123 (positive), CD73/CD304 (partial), CD81 (positive - dim), CD86 (partial), CD123 (positive)
Normal: CD19, CD22, CD24, CD36, CD45RA, CD71, CD105, CD371 (clec12a), HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD20, CD25, CD26, CD33, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61, CD90

Number of cells acquired 923 thousand 

2. No abnormal myeloid blast, mature B or mature T cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.16% of WBC.

Number of cells acquired: 592 thousand
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-6591.

"
H22-7024;S14;MSK5 - 2023-06-15 12.13.34.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: Lymphoma, Mantle Cell
Clinical Hx/Op Findings: Newly diagnosed
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by Mantle cell lymphoma (~5-10% with CD20 and Cyclin D1 immunohistochemistry), see comment.
     - Involvement by CD5 positive B cell lymphoproliferative disorder with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) like immunophenotype (~5-10% with CD20 and LEF1 immunohistochemistry), see comment.
     - Normocellular marrow with trilineage maturing hematopoiesis.

COMMENT: Cytogenetic studies performed on the prior peripheral blood specimen (CG22-5248) showed translocation of CCND1 (11q13.3) supporting the diagnosis. The prior PB flow (F22-7045) revealed a similar abnormal B cell population with CLL/SLL like immunophenotype at a concentration of 0.76 thousand/microliter, which did not meet quantitative criterion for CLL. Clinical and radiological correlation to evaluate for lymphadenopathy, organomegaly and other extramedullary involvement is recommended.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show normocellular bone marrow (~30%cellularity). There istrilineage maturing hematopoiesis with an atypical interstitial lymphoid infiltrate composed of small to medium sized cells with ovoid nuclei and condensed chromatin.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
Immunostains show 2 distinct atypical lymphoid populations
The First population 
Express: PAX5, CD20, CD5, Cyclin D1, SOX11 (subset)
Do not express: LEF1, CD3
Other: p53 stains few scattered cells

The second population
Express: PAX5, CD20, CD5, CD23, LEF1
Do not express: Cyclin D1, SOX11, CD3

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9200) 
1. Abnormal B cell population detected.
The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)

Abnormal B cell population represents 25.6% of WBC.

Immunophenotype:
Abnormal: CD5 (positive), CD43 (positive), CD81 (dim), ROR1 (positive)
Normal: CD20, CD79b, CD19, CD40, CD45, CD38
Negative: CD23, CD200, CD10, CD3


2. Abnormal B cell population detected.
Flow cytometry reveals an abnormal B cell population with CLL/SLL-like immunophenotype (see below).

Abnormal B cell population represents 5.6% of WBC.

Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD23 (positive), CD43 (positive), CD79b (dim), CD81 (dim), CD200 (bright), ROR1 (positive)
Normal: CD19, CD40, CD45
Negative: CD38, CD10, CD3

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (08/25/2022)
WBC 7.7 [4.0-11.0 K/mcL] 
RBC 4.09 [3.80-5.00 M/mcL] 
HGB 12.8 [11.2-15.4 g/dL] 
HCV CT 37.8 [34.3-46.0 %] 
MCV Volume 92 [80-98 fL] 
MCH 31.3 [27.0-33.0 pg] 
MCHC 33.9 [31.0-36.5 g/dL] 
RDW 11.9 L [12.2-15.1 %] 
Platelets. 261 [160-400 K/mcL] 

Neutrophil 43.1 [32.5-74.8 %] 
Mono 5.9 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.7 [0.0-1.5 %] 
Immature Granulocyte 0.1 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 49.2 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 3.3 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 3.8 H [0.9-3.2 K/mcL]

Morphology:
WBC: Mild absolute lymphocytosis
RBC: Normocytic normochromic
Platelets: Unremarkable

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-6371, CG22-6372.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. 
"
H22-8545;S21;MSK2 - 2023-06-15 10.15.19.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0  \par Prostate, Malignant Neoplasm.  Thrombocytopenia rule out MDS.\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red255\green255\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, right posterior iliac crest,  biopsy; \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : \~\~\par      - Plasma cell neoplasm, see comment 1.\par           10% involvement by CD138 immunohistochemistry.\par           9% involvement by aspirate differential\par           1.9% involvement by flow cytometry\par      - Normocellular marrow with maturing trilineage hematopoiesis, mildly left-shifted myeloid and erythroid maturation, and no increase in blasts. See comment 3.  \par      - Minute abnormal B cell population with CLL-like immunophenotype detected by flow cytometry only (0.0095% of WBC). See comment 2. \par      - No morphologic or immunophenotypic evidence of involvement by metastatic carcinoma.\par\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENTS: \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1. Correlation with clinical findings including metabolic and CBC parameters, serum/ urine protein electrophoresis and immunofixation, and imaging studies is needed to further classify this plasma cell neoplasm.\par 2. A morphologic correlate of the minute abnormal B-cell population with a CLL-like immunophenotype is not seen and it is favored to represent CLL-like monoclonal B-cell lymphocytosis, however clinical correlation is needed to exclude the possibility of tissue involvement. \par 3. Mild thrombocytopenia is noted (137 K/cmL).  Mild atypia is present in the erythroid and megakaryocytic lineages (<10%), however diagnostic criteria for myelodysplastic syndrome are not fulfilled at this time based on the 2017 WHO and other etiologies such as medications, nutritional deficiencies, and autoimmune causes should be evaluated. However, prior peripheral blood molecular testing (M22-19199, 5/4/2022) revealed the presence of a TP53 mutation at low allele frequency (2.9%), which is consistent with at least clonal hematopoiesis. Correlation with results of the forthcoming molecular studies is recommended to evaluate for an expansion of this clone or presence of any additional mutations. Submission of a nail matched normal and obtaining a patient consent for a more comprehensive IMPACT heme matched analysis with future samples is recommended. Close clinical follow-up is advised given the high risk of progression to an overt myeloid neoplasm and the patient's history of radiation therapy for prostate cancer. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Marginally adequate, small, fragmented, and with intramedullary hemorrhage\par Cellularity: Variable, ranging from < 5% to approximately 30%, overall approximately normocellular (20%)\par M:E ratio: Normal\par Blasts: Not increased\par Myeloid lineage: Present with progressive maturation\par Erythroid lineage: Present with progressive maturation\par Megakaryocytes: Mildly decreased for the cellularity, with occasional forms showing nuclear hyperchromasia\par Lymphocytes: Few, scattered\par Plasma cells: Mildly increased, best appreciated by immunohistology (see below), with occasional Dutcher bodies \par Special stains:\par Reticulin stain shows focal mild increase in reticulin fibrosis (focal MF-1). \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Clot section: The clot section contains no marrow particles and is inadequate for evaluation. \plain\rtlch\af0\afs17\alang1033\ltrch\f0\fs17\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1  \plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Adequate\par Numerous naked nuclei noted\par\par Blasts \tab\tab\tab 3%\par Promyelocytes \tab\tab 3%\par Myelocytes \tab\tab 12%\par Metamyelocytes \tab\tab 10%\par Neutrophils/Bands \tab 23%\par Monocytes \tab\tab 4%\par Eosinophils \tab\tab 3%\par Erythroid Precursors \tab 25%\par Plasma Cells \tab\tab 9% \par Lymphocytes \tab\tab 8%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 2.2\par\par Special stain\par Iron: Present\par Ring sideroblasts: Absent \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb4\chshdng0\chcfpat0\chcbpat4\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology\par Adequate, spicular and cellular aspirate smears with maturing trilineage hematopoiesis and no expanded blast population. The M:E ratio is normal. Myeloid elements show mildly left-shifted maturation no significant dysplasia. Erythroid cells are mildly left-shifted and show occasional (< 10%) megaloblastoid features, binucleation, and karyorrhexis. Megakaryocytes are seen with occasional (< 10%) small forms. Few small mature-appearing lymphocytes are seen. Few scattered plasma cells are seen, which show occasional atypia such as nuclear inclusions (Dutcher bodies) and binucleation.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (10/13/2022):\par WBC 6.0 [4.0-11.0 K/mcL] \par RBC 3.93 L [3.95-5.54 M/mcL] \par HGB 13.1 [12.5-16.2 g/dL] \par HCT 38.8 [37.5-49.3 %] \par MCV 99 H [80-98 fL] \par MCH 33.3 H [27.0-33.0 pg] \par MCHC 33.8 [31.0-36.5 g/dL] \par RDW 12.5 [12.2-15.1 %] \par Platelets 137 L [160-400 K/mcL] \par\par Neutrophil 45.2 [32.5-74.8 %] \par Mono 13.1 H [0.0-12.3 %] \par Eos 3.2 [0.0-4.9 %] \par Baso 0.8 [0.0-1.5 %] \par Immature Granulocyte 0.2 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 37.5 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 2.7 [1.5-7.5 K/mcL] \par Abs Mono 0.8 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 2.2 [0.9-3.2 K/mcL] \par\par Morphology:\line WBC: Relative monocytosis and occasional (< 10%) hypersegmented neutrophils. No circulating blasts seen.\par RBC: Normocytic, normochromic RBCs.\par PLT: Mild thrombocytopenia. \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080 CD34 and CD117 show no increase in blasts (<5%).\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 CD117 also highlights early myeloid and erythroid cells, as well as shows bright expression in rare scattered mast cells.\par MPO highlights myeloid cells, and CD71 highlights erythroid cells, with an overall normal M:E ratio.\par CD61 is positive in megakaryocytes, which are mildly decreased for the cellularity.\par OSCAR (pan-cytokeratin stain) is negative \par CD138 immunostain highlights increased plasma cells, scattered singly and in small clusters, overall accounting for ~10% of cellularity.\par Kappa and lambda immunostains show the plasma cells are lambda light chain restricted.\par BCMA highlights 95% of plasma cells, (2-3) intensity, membranous/ Golgi/ cytoplasmic pattern. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-11199)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par 1. Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par\par Abnormal plasma cell population comprises 95.6% of total plasma cells.\par Abnormal plasma cell population represents 2.1% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (negative), CD27 (variable - negative to dim), CD45 (bimodal - negative, intermediate), CD81 (bimodal - major subset negative, minor subset intermediate), CD117 (partial dim), cytoplasmic Lambda (restriction)\par Normal: CD138, CD38, CD229, CD319\par Negative: CD56, cytoplasmic Kappa\par\par Number of cells acquired: 436 thousand \par\par 2. Minute abnormal B cell population detected. \par Flow cytometry reveals a minute abnormal B cell population with CLL/SLL-like immunophenotype (see below).\par\par Abnormal B cell population represents 0.0095% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD20 (dim), CD23 (positive), CD43 (positive), CD79b (negative), CD81 (dim), CD200 (bright), ROR1 (positive)\par Normal: CD19, CD40, CD45\par Negative: CD38, CD10, CD3\par\par Number of cells acquired 401 thousand \par\par 3. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par\par Myeloid blast population with an unremarkable phenotype represents 0.78% of WBC.\par\par Number of cells acquired: 583 thousand \par\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-7718.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate reports, M22-43722 & M22-43722\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-1283;S11;MSKT - 2023-05-31 22.36.04.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Multiple Myeloma
Requested Studies: Gross/Micro
Clinical Hx/Op Findings: Hx of Prostate CA in BM and MM
","
1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Metastatic adenocarcinoma, consistent with prostate primary, see note
    - Cellular marrow with residual hematopoiesis.
    - No morphologic or immunophenotypic evidence of plasma cell neoplasm.

Note: Immunohistochemical stains reveal that the tumor cells are positive CK-PAN, CAM5.2, NKX3.1, and PSA, supporting the above diagnosis.  

This hematological portion of the case was reviewed by Dr. Ying Liu of Hematopathology Service.

BONE MARROW BIOPSY
Quality: Inadequate, small subcortical biopsy with rare marrow space
Cellularity: N/A
Myeloid lineage: Rare
Erythroid lineage: Rare
Megakaryocytes: None seen
Plasma cells: Rare 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules

The differential cell count was not performed. Touch imprints contain too few cells for evaluation. The cellular elements present are composed primarily of peripheral blood elements.

Morphology: 
Marrow spicules: Aspicular.
Cellularity: Hypocellular
Plasma cell morphology: None seen
Myeloid lineage: Neutrophils / lymphocytes / monocytes noted  
Erythroid Lineage: None seen
Megakaryocytes:  None seen

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights rare plasma cells. 
Kappa and lambda highlight rare cells with no evidence of light chain restriction  
BCMA stain is non-contributory due the rarity of plasma cells

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-1662)
Interpretation: 
No abnormal plasma cell population detected. 
No evidence of an abnormal plasma cell population is identified by flow cytometry.
Normal plasma cell population represents 0.44% of WBC.

Number of cells acquired: 1.3 million

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (02/14/2022):
WBC 3.4 L [4.0-11.0 K/mcL] 
RBC 2.35 L [3.95-5.54 M/mcL] 
HGB 7.3 L [12.5-16.2 g/dL] 
HCT 21.5 L [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 31.1 [27.0-33.0 pg] 
MCHC 34.0 [31.0-36.5 g/dL] 
RDW 17.2 H [12.2-15.1 %] 
Platelets 35 L [160-400 K/mcL] 

Neutrophil 47.0 [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 44.0 [12.2-47.4 %] 
Variant Lymph 1.0 [0.0-2.0 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.6 [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.5 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: No circulating plasma cells
RBC: Anisocytosis (1+) / Poikilocytosis (1+); Rouleaux formation is not seen
Platelets: Markedly thrombocytopenia 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-1095, CG22-1096.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-6770, M22-6771.
"
H22-418;S12;MSKT - 2023-05-31 21.21.39.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: MDS
Clinical Hx/Op Findings: Hx lymphoma, now with MDS and anemia
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia (MDS-RS-SLD).
     - Minute abnormal B-cell population with a chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)-like immunophenotype detected by flow cytometry only (0.011%)
     - No diagnostic morphologic or immunophenotypic evidence of follicular lymphoma.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular (90%)
M:E ratio: Reduced
Blasts: Not increased
Myeloid lineage: Relatively reduced with full maturation
Erythroid lineage: Increased with left-shifted maturation
Megakaryocytes: Adequate to focally increased, variable in size with some large forms and without overt dysplasia
Lymphocytes: Scattered, no aggregates seen
Plasma cells: Scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0/3) 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                1%
Promyelocytes           3%
Myelocytes           9%
Metamyelocytes           5%
Neutrophils/Bands      26%
Monocytes           2%
Eosinophils           3%
Erythroid Precursors      37%
Plasma Cells           2%
Lymphocytes           12%
Number of Cells Counted 500
M:E Ratio           1.3 

Special stain
Iron: Present
Ring sideroblasts: Present, >15%

Morphology:
- Spicular and cellular aspirate smears show erythroid-predominant maturing trilineage hematopoiesis with no increase in blasts. Myeloid elements show full maturation without significant dysplasia. Erythroid precursors show left-shifted maturation with dyserythropoiesis (ring sideroblasts, megaloblastoid changes, nuclear irregularity/budding, cytoplasmic vacuolization). Megakaryocytes are present and are variable in size with some large forms and without significant dysplasia.

PERIPHERAL BLOOD
CBC (01/18/2022):
WBC 4.1 [4.0-11.0 K/mcL] 
RBC 2.74 L [3.95-5.54 M/mcL] 
HGB 8.7 L [12.5-16.2 g/dL] 
HCT 26.9 L [37.5-49.3 %] 
MCV 98 [80-98 fL] 
MCH 31.8 [27.0-33.0 pg] 
MCHC 32.3 [31.0-36.5 g/dL] 
RDW 20.5 H [12.2-15.1 %] 
Platelets 183 [160-400 K/mcL] 

Neutrophil 57.7 [32.5-74.8 %] 
Mono 10.8 [0.0-12.3 %] 
Eos 10.1 H [0.0-4.9 %] 
Baso 1.5 [0.0-1.5 %] 
Immature Granulocyte 1.5 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 18.4 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.4 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Unremarkable morphology. No circulating blasts seen on scanning.
RBC: Normochromic, normocytic anemia with mild anisopoikilocytosis.
PLT: Adequate with unremarkable morphology.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 highlights scattered blasts comprising <5% of overall cellularity. CD34 also labels a subset of megakaryocytes. CD117 highlights blasts and early myeloid/erythroid progenitors as well as scattered mast cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-531)
Interpretation: 
1. Abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 2.5% of WBC.
Eosinophilia is seen, 6.9% of WBC.

Immunophenotype:
Abnormal: CD7 (partial - dim), CD13 (dim on CD34 bright subset), CD33 (dim), CD34 (bright), CD117 (bright)
Normal: CD4, CD15, CD38, CD45, CD71, CD123, HLA-DR
Negative: CD2, CD5, CD11b, CD14, CD16, CD19, CD25, CD56, CD64


2. Minute abnormal B cell population detected. 
Flow cytometry reveals an abnormal B cell population with a CLL/SLL-like immunophenotype (see below).

Abnormal B cell population represents 0.011% of WBC.

Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (positive), CD43 (positive), CD79b (dim), CD81 (dim), ROR1 (positive)
Normal: CD200, CD19, CD40, CD45
Negative: CD38, CD10, CD3

Number of cells acquired: 346 thousand 


3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-338.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-2359, M22-2368, M22-2369.


"
H22-431;S12;MSKO - 2023-05-31 21.27.19.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Myelodysplastic Syndrome
Clinical Hx/Op Findings: Cytopenias
","1-3. Bone marrow, right posterior iliac crest, biopsy; and aspirate smears: 
     - Involvement by Burkitt lymphoma (involvement 90% of cellularity by CD20 immunostain) 
     - Normocellular marrow with trilineage maturing hematopoiesis.
  
Comment: Dr. Johnson notified on 01/25/2022 at 10: 58 AM

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Normocellular for age (30% cellularity)
M:E ratio: difficult to assess on the limited background hematopoiesis. 
Blasts: Not increased.
Myeloid lineage: Reduced
Erythroid lineage: Reduced
Megakaryocytes: Reduced
Lymphocytes: Diffuse sheets of intermediate sized lymphoid cells with round nuclei, condensed but evenly distributed chromatin, and occasional nucleoli. 
Plasma cells: Not increased. 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis. 


The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules
The differential cell count was performed on touch imprints and aspirate smear.

Promyelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      11%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      7%
Lymphocytes           1%
Abnormal Lymphoid Cells      77%
Number of Cells Counted      500
M:E Ratio           N/A

Special stain
Iron: suboptimal for evaluation, devoid of spicules
Ring sideroblasts: Absent 

Morphology:
-Touch imprints show scattered erythroid precursors and rare myeloid precursors. Megakaryocytes are not readily seen. A predominant lymphoid population of intermediate to large-sized lymphoid cells with round nuclei, condensed but evenly distributed chromatin, occasional nucleoli is seen, basophilic chromatin and cytoplasmic vacuoles.


PERIPHERAL BLOOD
CBC (01/18/2022):
WBC 15.9 H [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 3.01 L [3.80-5.00 M/mcL] 
HGB 8.9 L [11.2-15.4 g/dL] 
HCT 26.4 L [34.3-46.0 %] 
MCV 88 [80-98 fL] 
MCH 29.6 [27.0-33.0 pg] 
MCHC 33.7 [31.0-36.5 g/dL] 
RDW 16.9 H [12.2-15.1 %] 
Platelets 72 L [160-400 K/mcL] 

Neutrophil 59.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 14.0 H [0.0-0.0 %] 
Myelocyte 3.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 3.0 H [0.0-0.0 %] 
Lymph 17.0 [12.2-47.4 %] 
Nucleated RBC 27.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 9.4 H [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abnormal lymphocytes 2.2 H [0.0-0.0 K/mcL]  
Abs Myelocytes 0.5 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.5 H [0.0-0.0 K/mcL] 
Abs Lymph 2.7 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: lymphoid population of intermediate to large-sized lymphoid cells with round nuclei, condensed but evenly distributed chromatin, and occasional nucleoli is seen.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
The neoplastic  cells
Express: CD20, MUM1, CD10, CD23 (subset), CD38, LEF1,
Don't express: CD3, CD5, BCL2, BCL6, CD21, IgD, LMO2, CyclinD1, TdT, CD34, CD117
Ki-67 proliferation index is >90%. 
CD34, CD117, and TdT highlights only rare immature precursors.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-544)
1. Abnormal B cell population detected.

Abnormal B cell population represents 52.7% of WBC.

Immunophenotype:
Abnormal: CD10 (positive - dim), CD19 (slightly dim), CD20 (bright), CD22 (dim), CD38 (bright), surface Kappa (restriction), Forward Scatter (increased), Side Scatter (increased)
Normal: CD45
Negative: CD5, CD25, CD279 (PD1), CD3, CD14, surface Lambda

In addition, the abnormal B cell population expresses:

Abnormal: CD86
Normal: CD81, CD24
Negative: CD34, CD66b, CD66c/CD123, CD73/CD304

2. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                                                                                
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.31% of WBC.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.
 
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-347.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-2385.
"
H22-5756;S12;MSK3 - 2023-04-14 16.01.19.ndpi,Peripheral Blood Smear,2023-04-14,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: per protocol
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
>90% involvement by CD138 immunohistochemistry.
93% involvement by aspirate differential
8.4% involvement by flow cytometry

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: 90-100%
Myeloid lineage: Nearly absent
Erythroid lineage: Nearly absent
Megakaryocytes: Nearly absent 
Plasma cells: Markedly increased 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules 
Differential count performed on touch smear

Blasts               0%
Myelocytes           2%
Neutrophils/Bands      1%
Eosinophils           1%
Erythroid Precursors      3%
Plasma Cells           93% (with blastic features)
Number of Cells Counted      500
M:E Ratio           1.3

Morphology: 
Marrow spicules: Aspicular.
Cellularity: Hypocellular
Plasma cell morphology: Small to large in size with prominent nucleoli with blastic features
Myeloid lineage: Orderly maturation 
Erythroid Lineage: Orderly maturation 
Megakaryocytes: Present  

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 90% of cellularity. 
Plasma cells do not display definite light chain restriction by immunohistochemistry
BCMA highlights >90% of plasma cells, (3+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-7570)
Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.
Abnormal plasma cell population comprises 99.9% of total plasma cells.
Abnormal plasma cell population represents 8.4% of WBC.

Immunophenotype:
Abnormal: CD38 (dim, consistent with anti-CD38 therapy), CD19 (negative), CD27 (negative), CD45 (variable - negative to bright), CD56 (partial), CD81 (bimodal - negative to intermediate), no definite light chain
Normal: CD138, CD229, CD319
Negative: CD117, cytoplasmic Kappa, cytoplasmic Lambda
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (7/14/2022):
WBC 4.8 L [7.1-15.9 K/mcL] 
RBC 3.11 [2.93-4.75 M/mcL] 
HGB 10.2 [9.2-12.7 g/dL] 
HCT 29.4 [27.7-37.9 %] 
MCV 95 H [70-85 fL] 
MCH 32.8 H [22.7-29.5 pg] 
MCHC 34.7 [31.0-36.5 g/dL] 
RDW 13.1 [12.2-15.1 %] 
Platelets. 111 L [160-400 K/mcL] 

Neutrophil 61.3 [16.9-74.5 %] 
Mono 7.4 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.2 [0.0-1.5 %] 
Immature Granulocyte 0.2 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 29.9 [18.1-79.9 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 3.0 [1.5-8.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.4 [1.1-8.1 K/mcL]

Morphology: 
WBC: Mild left shift. A few circulating atypical plasma cells seen.  
RBC: Rare nucleated RBC seen. 
PLT: Mild thrombocytopenia. 

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Not submitted.

MOLECULAR STUDIES 
Not submitted.
"
H22-7405;S15;MSK9 - 2023-04-14 15.49.57.ndpi,Peripheral Blood Smear,2023-04-14,"{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\fswiss\fcharset0\fprq2{\*\panose 020F0502020204030204}Calibri;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\sa160\sl259\slmult1\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon0 Arial;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s17\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Clinical Diagnosis: AML\par Clinical Hx/Op Findings: AML\par Requested Studies: Gross/Micro\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par }","{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\fswiss\fcharset0\fprq2{\*\panose 020F0502020204030204}Calibri;}
{\f2\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f3\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red192\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\sa160\sl259\slmult1\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon0 Arial;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs20\alang1033\ab\aul\ltrch\f0\fs20\lang1033\langnp1033\langfe1033\langfenp1033\b\ul AMENDMENT DETAIL:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b Reason for Amendment:\~\tab\tab SUPPLEMENTAL DIAGNOSIS PROVIDED DUE TO ADDITIONAL MATERIAL NOT \tab\tab\tab\tab\tab\tab PREVIOULSY RECEIVED.  \plain\rtlch\af2\afs20\alang1033\ab\ltrch\f2\fs20\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b Report Section Changed:\tab Specimen Description \par\par Description of Change: \tab\tab\plain\rtlch\af0\afs18\alang1033\ab\aul\acf2\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\cf2 Part 3. Peripheral Blood Smear\plain\rtlch\af0\afs18\alang1033\acf3\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf3\par\pard\ltrpar\s18\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\sa160\sl259\slmult1\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080 Note: This document represents an amended version of the Hematopathology report originally issued on 9/9/2022. Dr. Brian Schaffer has been notified via e-mail on 9/14/2022. \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\par 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\par      - Relapsed/persistent acute myeloid leukemia with inv16 (per report) (20% blasts by aspirate differential).\par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT:\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 A small abnormal immature B cell population was also noted. The population is almost certainly clonally related to the underlying AML and is of unclear significance. It DOES NOT change the diagnosis, but will be monitored as a part of residual disease evaluation. Clinical correlation of these findings with cytogenetic and molecular studies is recommended.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Hypercellular (70-80%)\par M:E ratio: Within normal limits\par Blasts: Increased\par Myeloid lineage: Reduced with progressive maturation\par Erythroid lineage: Present with progressive maturation\par Megakaryocytes: Present with occasional hypolobated forms \par Lymphocytes: Scattered\par Plasma cells: Scattered\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate\par\par Blasts \tab\tab\tab 20%\par Promyelocytes \tab\tab 2%\par Myelocytes \tab\tab 4%\par Metamyelocytes \tab\tab 2%\par Neutrophils/Bands \tab 22%\par Monocytes \tab\tab 1%\par Eosinophils \tab\tab 2%\par Erythroid Precursors \tab 32%\par Plasma Cells \tab\tab 2%\par Lymphocytes \tab\tab 13%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 1\par\par Morphology:\par -Spicular and hypercellular aspirate smears show an expanded population of intermediate to large cells with scant cytoplasm, round to oval nuclei, fine chromatin and distinct nuceoli (blasts), accounting for 20% of the total cellularity. Myeloid elements are reduced but show maturation. Erythroid elements show occasional binuclear/nuclear lobation with maturation. Megakaryocytes are present and display occasional hypolobated forms.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (09/07/2022):\par WBC 5.6 [4.0-11.0 K/mcL] \par RBC 3.54 L [3.80-5.00 M/mcL] \par HGB 9.9 L [11.2-15.4 g/dL] \par HCT 30.1 L [34.3-46.0 %] \par MCV 85 [80-98 fL] \par MCH 28.0 [27.0-33.0 pg] \par MCHC 32.9 [31.0-36.5 g/dL] \par RDW 16.8 H [12.2-15.1 %] \par Platelets. 116 L [160-400 K/mcL] \par\par Neutrophil 78.0 H [32.5-74.8 %] \par Mono 3.0 [0.0-12.3 %] \par Eos 3.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Blast 4.0 H [0.0-0.0 %] \par Lymph 12.0 L [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 4.3 [1.5-7.5 K/mcL] \par Abs Mono 0.2 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Blasts 0.2 H [0.0-0.0 K/mcL] \par Abs Lymph 0.7 L [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs22\alang1033\ltrch\f1\fs22\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34, CD117, MPO, and lysozyme highlight blasts comprising 20% of the total cellularity.\par TDT highlights lymphoid precursors less than 5% of the total cellularity (likely mostly normal based on flow cytometry)\par CD61 highlights variably sized megakaryocytes.\par CD71 highlights erythroid precursors. \par\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9683)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par 1. Expanded abnormal myeloid blast population detected (see phenotype below).\par The CD19 positive population (<1% of the total blasts) shows similar phenotype, but also shows expression of CD10, and cyCD79a consistent with additional B cell lineage. The significance of the finding in the setting of inv16 (per report) AML is uncertain and does not affect the diagnosis. The population will be monitored in subsequent MRD evaluations\par\par Abnormal myeloid blast population represents 21.2% of WBC.\par\par Immunophenotype:\par Abnormal: CD2 (positive), CD13 (bright), CD15 (partial), CD19 (bimodal - negative to intermediate), CD33 (increased), CD45RA (positive), CD117 (bright), CD123 (uniform - intermediate), HLA-DR (uniform - intermediate), cytoplasmic CD3 (partial), cytoplasmic CD79a (bimodal - negative to intermediate), MPO (uniform - intermediate)\par Normal: CD4, CD34, CD36, CD38, CD45, CD71, CD371 (clec12a)\par Negative: CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD16, CD20, CD22, CD25, CD26, CD56, CD64, CD105, surface Kappa, surface Lambda, CD42b, CD61, CD90\par\par Number of cells acquired: 827 thousand \par 2. No abnormal mature B- or T-cell populations detected. \par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par\par Number of cells acquired 300 thousand \par\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-6685. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-37902, M22-37899, M22-37896\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par }"
H22-10459;S15;MSKB - 2023-06-15 16.13.33.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Lung, Malignant Neoplasm\par Requested Studies: Gross/Micro\par Clinical Hx/Op Findings: Anemia and Thrombocytopenia, multiple alterations on HEME-IMPACT.\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22\sbasedon16 No Spacing;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, right posterior iliac crest, biopsy; \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : \~\~\par      - Hypercellular marrow with erythroid predominance, multilineage dysplasia, no increase in blasts, no ring sideroblasts and reported SF3B1 mutation consistent with myelodysplastic syndrome (MDS). See comment. \par      -Information from pending cytogenetic and molecular genetic studies is required for further subclassification of the MDS.\par  \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The marrow biopsy and aspirate smears show a hypercellular marrow with erythroid predominance, multilineage dysplasia, no increase in blasts and no ring sideroblasts.  The patient is noted to have multiple genetic mutations including SF3B1 (VAF 44%), DNMT3A and MPL on a previous HEME IMPACT study using a peripheral blood sample (M21-40331; 10/01/2021).  The overall findings would be consistent with a myelodysplastic syndrome with mutated SF3B1 if the pending cytogenetic and molecular genetic studies are supportive.  \par\par The patient is noted to have a remote history of follicular lymphoma and diffuse large B-cell lymphoma and has been treated with R-CHOP and radiation therapy in 2004-2005.  Although, the latency period between the therapy history and the cytopenias/MDS is not typical for a therapy related myeloid neoplasm, the possibility of  this myeloid neoplasm being therapy related cannot be entirely ruled out.  In addition, we noted that the patient is diagnosed with lung adenocarcinoma recently and a radiation therapy has been planned in 09/2022.  It is not clear if this therapy has occurred.\par\par The presence of MPL mutation (VAF 14%) in prior NGS studies, raises the possibility of an overlap MDS/MPN with mutated SF3B1 and thrombocytosis.  However, the patient does not have thrombocytosis.  Suggest close patient follow-up with CBC surveillance. \par\par Another remarkable finding is the presence of numerous elliptocytes in the peripheral blood smears and the clinical history of hemolytic anemia.  The findings may represent an inherited red blood cell membrane disorder.  However, the possibility of  elliptocytes being due to MDS cannot be ruled out.  Correlation with review of historic peripheral blood smears and additional laboratory studies may help in further characterization if clinically indicated.\par\par A morphologic correlate of the abnormal B-cell population detected by flow cytometric studies is not seen.  The findings may represent monoclonal B-cell lymphocytosis.  However, the possibility of low-level involvement by a B-cell lymphoproliferative disorder cannot be entirely ruled out.  Suggest correlation with clinical findings and imaging studies.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Hypercellular for age (50-60%)\par M:E ratio: Reduced \par Blasts: Not increased\par Myeloid lineage: Relatively reduced with progressive maturation\par Erythroid lineage:  Predominant with left-shifted maturation\par Megakaryocytes: Present, adequate to mildly increased numbers with hypolobated and hyperchromatic nuclei.\par Lymphocytes: Scattered\par Plasma cells: Scattered \par Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF 0 out of 3)\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate \par\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 10%\par Metamyelocytes \tab\tab 5%\par Neutrophils/Bands \tab 17%\par Monocytes \tab\tab 2%\par Eosinophils \tab\tab 2%\par Erythroid Precursors \tab 58%\par Lymphocytes \tab\tab 4%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 0.6\par\par Special stain\par Iron: Trace present, granular\par Ring sideroblasts: Absent \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Spicular and hypercellular cellular aspirate smears show marrow with a reduced M:E ratio. Myeloid elements show maturation with frequent granulocytes with abnormal nuclear lobation and cytoplasmic hypogranularity.  Erythroid elements are predominant and show dysplastic changes such as irregular nuclei and nuclear cytoplasmic asynchrony. Megakaryocytes are present and display hypolobated forms. Blasts are not increased. Scattered lymphocytes and plasma cells are present. \par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (12/13/2022):\par\par WBC 3.3 L [4.0-11.0 K/mcL] \par RBC 2.26 L [3.95-5.54 M/mcL] \par HGB 8.1 L [12.5-16.2 g/dL] \par HCT 23.5 L [37.5-49.3 %] \par MCV 104 H [80-98 fL] \par MCH 35.8 H [27.0-33.0 pg] \par MCHC 34.5 [31.0-36.5 g/dL] \par RDW 17.2 H [12.2-15.1 %] \par Platelets 101 L [160-400 K/mcL] \par\par Neutrophil 53.0 [32.5-74.8 %] \par Mono 6.0 [0.0-12.3 %] \par Eos 5.0 H [0.0-4.9 %] \par Baso 3.0 H [0.0-1.5 %] \par Myelocyte 5.0 H [0.0-0.0 %] \par Metamyelocyte 2.0 H [0.0-0.0 %] \par Lymph 26.0 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 1.8 [1.5-7.5 K/mcL] \par Abs Mono 0.2 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] \par Absolute Basophil 0.1 [0.0-0.2 K/mcL] \par Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] \par Abs Meta 0.1 H [0.0-0.0 K/mcL] \par Abs Lymph 0.9 [0.9-3.2 K/mcL] \par\par Morphology:\par\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 WBC: Myeloid precursors are seen. No circulating blasts seen.\par RBC: Moderate macrocytic anemia. Marked anisopoikilocytosis. Numerous elliptocytes. \par PLT: Mild thrombocytopenia. Abnormal enlarged platelets and hypogranular platelets are seen. \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 highlight rare blasts comprising less than 5% of the total cellularity.\par CD61 highlights mildly increased megakaryocytes including hypolobated forms.\par CD71 highlights predominant erythropoiesis and left-shifted erythroid precursors. \par MPO highlights myeloid precursors.\par CD20 and CD3 highlights singly scattered small B and T-cells.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-13566)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par 1. Abnormal myeloid blast population detected.\par In addition, monocytic and granulocytic populations show abnormal retention of CD13 and expression of CD56.\par Abnormal myeloid blast population represents 1.4% of WBC.\par\par Immunophenotype:\par Abnormal: CD13 (increased), CD33 (variable - negative to dim), CD34 (increased), CD56 (partial), CD117 (increased), HLA-DR (uniform - intermediate)\par Normal: CD4, CD36, CD38, CD45, CD45RA, CD71, CD105, CD123, CD371 (clec12a)\par Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD64, surface Kappa, surface Lambda, CD42b, CD90\par\par 2. Abnormal B cell population detected.\par The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.\par Abnormal B cell population represents 0.019% of WBC.\par Immunophenotype:\par Abnormal: CD5 (positive - dim), CD79b (dim), surface Lambda (restriction)\par Normal: CD20, CD22, CD23, CD81, CD200, CD19, CD40, CD45, CD38\par Negative: CD43, ROR1, CD10, CD3, surface Kappa, CD25, CD14, CD279 (PD1)\par\par 3. No abnormal mature T cell population detected. \par No immunophenotypic evidence of T-cell lymphoma is identified.  \par\par Number of cells acquired: 398 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-9389.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-53543\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-7403;S17;MSK9 - 2023-06-15 17.40.43.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\fswiss\fcharset0\fprq2{\*\panose 020F0502020204030204}Calibri;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\sa160\sl259\slmult1\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon0 Arial;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s17\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Clinical Diagnosis: Lymphoma\par Clinical Hx/Op Findings: progressive anemia\par Requested Studies: Gross/Micro\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par }","{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\fswiss\fcharset0\fprq2{\*\panose 020F0502020204030204}Calibri;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\sa160\sl259\slmult1\cbpat0\rtlch\af1\afs22\ltrch\f1\fs22 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon0 Arial;}{\s18\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\sa160\sl259\slmult1\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\~\par      - Low-grade B cell lymphoma with plasmacytic differentiation (~40-50% involvement with CD20/CD138 immunohistochemistry). See comment.    \par\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : The patient's long history of untreated CD10+ low-grade B cell lymphoma with trisomies of chromosomes 4 and 18 and without a t(14;18) or deletion 7q31 is noted (S10-32218, CG10-3190). Also noted is the patient's serum IgM kappa monoclonal gammopathy and elevated serum IgM level. Recent imaging shows thoracic and abdominopelvic lymphadenopathy and splenomegaly while CBCs show anemia and mild lymphocytosis. \par\par Based on the morphologic and immunophenotypic features in conjunction with the clinical findings, lymphoplasmacytic lymphoma is favored over other considerations such as follicular lymphoma or marginal zone lymphoma. Correlation with the forthcoming genomic studies (e.g. MYD88 mutation) is suggested. \par\par Case reviewed with Dr. A. Dogan, Chief, Hematopathology service, who concurs.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate but fragmented core biopsy, limited aspirate smears (hypocellular, paucispicular) and cellular touch imprint show markedly hypercellular bone marrow (nearly 100% cellularity) with an atypical lymphoid infiltrate with interstitial, paratrabecular and possible intrasinusoidal growth patterns composed predominantly of small to intermediate sized cells with rounded to irregular nuclei, condensed chromatin, inconspicuous nucleoli and scant cytoplasm with rare larger cells with distinct nucleoli. Scattered and small clusters of plasma cells are present with rare Dutcher bodies noted. Scattered hemosiderin-laden macrophages are seen. Myeloid and erythroid elements appear relatively reduced and are present at various stages of maturation. Occasional erythroid precursors showing nuclear irregularity are noted. Megakaryocytes are adequate to mildly increased in number without overt dysplasia.\par\~\par Bone Marrow Aspirate Smear Quality: Limited, hypocellular, paucispicular\par\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 5%\par Metamyelocytes \tab\tab 8%\par Neutrophils/Bands \tab 15%\par Monocytes \tab\tab 1%\par Eosinophils \tab\tab 1%\par Erythroid Precursors \tab 16%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 51%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 1.9 \par\par Special stain \par Iron: Suboptimal for evaluation; devoid of spicules\par Ring sideroblasts: Absent \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The atypical lymphoid cells\par Express: CD20, PAX5, CD10, BCL2\par Do not express: CD3, BCL6, cyclin D1 (B cells and plasma cells)\par Other: CD138 highlights plasma cells, which show a kappa light chain predominance with kappa and lambda immunostains. IgM labels the majority of the plasma cells with fewer IgG+ and IgA+ plasma cells seen. CD34 shows no increase in blasts (<5% of cellularity). CD34 also weakly labels occasional megakaryocytes. CD61 shows an adequate to mildly increased number of megakaryocytes with few small forms.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-9682)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par 1. Abnormal B- and plasma cell populations detected.\par The abnormal B cell population has the same light chain restriction as the abnormal plasma cell population mentioned below. Given the similar light chain restriction, these two populations likely represent manifestations of the same neoplasm, but the immunophenotypic profiles do not allow specific classification. Clinical and morphologic correlation is advised.\par\par Abnormal B cell population represents 22.9% of WBC.\par\par Immunophenotype:\par Abnormal: CD10 (partial), CD19 (dim), CD20 (dim), CD22 (dim), CD38 (variable - negative to intermediate), surface Kappa (restriction)\par Normal: CD45\par Negative: CD5, CD25, CD279 (PD1), CD3, CD14, surface Lambda\par\par Number of cells acquired: 244 thousand \par\par 2. Abnormal plasma cell population detected.\par The abnormal plasma cell population has the same light chain restriction (see immunophenotype below) as the abnormal B cell population mentioned above. \par\par Abnormal plasma cell population represents 0.027% of WBC.\par Abnormal plasma cell population comprises 33.8% of total plasma cells.\par\par Immunophenotype:\par Abnormal: CD319 (negative), CD45 (bright), CD81 (dim), cytoplasmic Kappa (restriction)\par Normal: CD138, CD38, CD229, CD19, CD27\par Negative: CD20, CD56, CD117, cytoplasmic Lambda\par\par Number of cells acquired 973 thousand \par\par 3. No abnormal mature T cell population detected. \par No immunophenotypic evidence of T-cell lymphoma is identified.  \par\par Number of cells acquired: 244 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-9661) \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par 1. Abnormal B cell population detected.\par The immunophenotype of this abnormal B cell population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.\par\par Abnormal B cell population represents 19.3% of WBC.\par\par Immunophenotype:\par Abnormal: CD10 (partial), CD19 (dim), CD20 (dim), CD22 (dim), surface Kappa (restriction)\par Normal: CD38, CD45\par Negative: CD5, CD25, CD279 (PD1), CD3, CD14, surface Lambda\par\par 2. No abnormal mature T cell population detected. \par No immunophenotypic evidence of T-cell lymphoma is identified.  \par\par Number of cells acquired: 454 thousand \par\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (09/07/2022):\par WBC 8.3 [4.0-11.0 K/mcL] \par RBC 3.73 L [3.80-5.00 M/mcL] \par HGB 10.1 L [11.2-15.4 g/dL] \par HCT 31.7 L [34.3-46.0 %] \par MCV 85 [80-98 fL] \par MCH 27.1 [27.0-33.0 pg] \par MCHC 31.9 [31.0-36.5 g/dL] \par RDW 17.1 H [12.2-15.1 %] \par Platelets 162 [160-400 K/mcL] \par\par Neutrophil 31.0 L [32.5-74.8 %] \par Mono 4.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Lymph 46.0 [12.2-47.4 %] \par Abnormal Lymphoid Cells 19.0 H [0.0-0.0 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 2.6 [1.5-7.5 K/mcL] \par Abs Mono 0.3 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Lymph 5.4 H [0.9-3.2 K/mcL] \par\par Morphology:\par WBC: Mild lymphocytosis with circulating atypical lymphoid cells, which are mostly small in size with round to irregular nuclei and condensed chromatin with rare intermediate sized cells with distinct nucleoli.  \par RBC: Normochromic, normocytic anemia.\par Platelets: Adequate with unremarkable morphology.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs22\alang1033\ltrch\f1\fs22\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-6683, CG22-6684. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-37894.\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par }"
H22-4743;S14;MSK- - 2023-04-14 16.36.26.ndpi,Peripheral Blood Smear,2023-04-19,"Special Requests: Rush
Clinical Diagnosis: CML
Clinical Hx/Op Findings: New dx CML
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Chronic myeloid leukemia, BCR-ABL1 positive, <5% blasts; see comment.

COMMENT: The specimen does not meet criteria for accelerated phase in the criteria that can be assessed in the peripheral blood and marrow by morphology and immunohistochemistry. Other criteria require clinical correlation as well as correlation with cytogenetic and molecular studies. Overall findings are consistent with chronic phase of CML, but correlation with additional studies is required for full exclusion of accelerated phase.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypercellular (>90%)
M:E ratio: Increased
Blasts: Not overtly increased
Myeloid lineage: Markedly increased, with left shifted but complete maturation
Erythroid lineage: Reduced 
Megakaryocytes: Increased, including occasional forms with small size and monolobation
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows a mild increase in reticulin fibers (1+/3). 
The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate

Blasts                1%
Promyelocytes           2%
Myelocytes           9%
Metamyelocytes           6%
Neutrophils/Bands      52%
Monocytes           1%
Eosinophils           15%
Basophils           5%
Erythroid Precursors      7%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           12.9

Morphology: The aspirate smears are spicular and hypercellular and show myeloid predominant maturing trilineage hematopoiesis, no increase in blasts is seen. Myeloid elements show complete maturation and are markedly increased, with eosinophilia and basophilia. Erythroid elements are reduced but show full maturation. Megakaryocytes are increased and show monolobated smaller forms consistent with so-called ""dwarf"" megakaryocytes. 

PERIPHERAL BLOOD
CBC (06/10/2022):
WBC 152.2 H [4.0-11.0 K/mcL] 
RBC 3.09 L [3.80-5.00 M/mcL] 
HGB 9.2 L [11.2-15.4 g/dL] 
HCT 28.9 L [34.3-46.0 %] 
MCV 94 [80-98 fL] 
MCH 29.8 [27.0-33.0 pg] 
MCHC 31.8 [31.0-36.5 g/dL] 
RDW 17.5 H [12.2-15.1 %] 
Platelets. 693 H [160-400 K/mcL] 

Neutrophil 63.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 15.0 H [0.0-1.5 %] 
Blast 1.0 H [0.0-0.0 %] 
Myelocyte 8.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 7.0 H [0.0-0.0 %] 
Lymph 0.0 L [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 95.9 H [1.5-7.5 K/mcL] 
Abs Mono 3.0 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 4.6 H [0.0-0.7 K/mcL] 
Absolute Basophil 22.8 H [0.0-0.2 K/mcL] 
Absolute Blasts 1.5 H [0.0-0.0 K/mcL] 
Abs Myelocytes 12.2 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 1.5 H [0.0-0.0 K/mcL] 
Abs Meta 10.7 H [0.0-0.0 K/mcL] 
Abs Lymph 0.0 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
WBC: Marked leukocytosis with basophilia, left shifted granulocytes seen; occasional circulating blasts seen.
RBC: Normocytic, normochromic anemia with anisocytosis. 
PLT: Thrombocytosis.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no definite increase in blasts, slightly less than but approaching 5% of total cellularity. 
CD117 also highlights early myeloid and erythroid elements.
CD61 highlights increased megakaryocytes as well as platelet clumps.
CD71 highlights erythroid elements, which are relatively decreased. 
MPO highlights increased myeloid elements.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-6194)
Flow cytometry assessment will be reported separately. Please see separate report.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-6108)
1. Abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 4.2% of WBC.
Basophilia is seen, 8.3% of WBC.

Immunophenotype:
Abnormal: CD7 (partial), CD13 (bright), CD25 (partial), CD33 (bright), CD117 (variable - negative to intermediate), HLA-DR (uniform - bright)
Normal: CD4, CD34, CD36, CD38, CD45, CD45RA, CD71, CD105, CD123, CD371 (clec12a)
Negative: CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD26, CD56, CD64, cytoplasmic CD3, cytoplasmic CD79a, MPO, surface Kappa, surface Lambda, CD61

Number of cells acquired: 951 thousand 

2. No abnormal mature B- or T-cell populations detected. 
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

Number of cells acquired 475 thousand
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-4309.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-24997, M22-24998.
"
H22-9578;S15;MSKB - 2023-06-15 13.54.24.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Myelodysplastic Syndrome\par Clinical Hx/Op Findings: evaluate disease\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red255\green255\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow,  right posterior iliac crest, biopsy, touch imprint, \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate, and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : \~\~\par      - Myelodysplastic syndrome with multilineage dysplasia, ring sideroblasts, mild myelofibrosis and 1% blasts on aspirate. see comment.\par\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b Comment:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The patient's CBC showed monocytosis (highest absolute monocyte count 1.4k/uL, 33% on 10/23/2022) in 10/2022. He has multiple complications including adrenal infarct and ileus therefore a reactive monocytosis is favored. His recent monocyte count was trending down, <0.5k/uL (11/14/2022) further supporting a reactive monocytosis. \par   \par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate; partially crushed\par Cellularity: Variable 5-90%; average ~50%\par M:E ratio: Inverted\par Blasts: Not overtly increased\par Myeloid lineage: Relative decrease, left-shifted with complete maturation\par Erythroid lineage: Full spectrum of maturation \par Megakaryocytes: Mildly increased, mostly dysplastic including small, hypolobated forms and/or forms with discrete, separate, nuclear lobes.\par Lymphocytes: Scattered.\par Plasma cells: Scattered.\par Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1+/3).\par\par Stromal changes with fat depletion and foci of cellular streaming present.\par\par Clot section: Not submitted\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules\par\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 5%\par Metamyelocytes \tab\tab 4%\par Neutrophils/Bands \tab 13%\par Monocytes \tab\tab 12%\par Erythroid Precursors \tab 55%\par Lymphocytes \tab\tab 9%\par Number of Cells Counted \tab 500\par M:E Ratio \tab\tab 0.6\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Special stain \par Iron: Suboptimal for evaluation, devoid of spciules\par Ring sideroblasts: >15%\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb4\chshdng0\chcfpat0\chcbpat4\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Aspirate smears are aspicular, hypocellular, and hemodilute, and along with touch imprints, touch maturing hematopoiesis. Blasts are not increased. Erythroid elements predominate and show occasional elements with maturation dyssynchrony, nuclear irregularities, or binucleation (~10%). Scattered granulocytic elements are identified without overt atypia. Megakaryocytes are not well represented. Frequent mature monocytes are seen.\par\par Differential may not be representative of marrow composition.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/14/2022):\par WBC 2.6 L [4.0-11.0 K/mcL] \par RBC 3.05 L [3.95-5.54 M/mcL] \par HGB 8.0 L [12.5-16.2 g/dL] \par HCT 25.4 L [37.5-49.3 %] \par MCV 83 [80-98 fL] \par MCH26.2 L [27.0-33.0 pg] \par MCHC31.5 [31.0-36.5 g/dL] \par RDW26.2 H [12.2-15.1 %] \par Platelets. 99 L [160-400 K/mcL] \par\par Morphology:\par WBC: Mild neutropenia with left-shifted myeloid elements and relative monocytosis; rare suspicious circulating blasts identified. \par RBC: Anemia with anisopoikilocytosis and increased polychromasia; occasional nucleated red cells seen.\par PLT: Thrombocytopenia with frequent hypogranular platelets.\plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 highlight blasts, focally approaching 5%, and overall accounting for <5% of cellularity. CD34 is also expressed in a subset of megakaryocytes. CD117 highlights mild increase in scattered mast cells.\par CD61 highlights increased megakaryocytes with frequent small, hypolobated forms.\par MPO and CD71 highlight myeloid and erythroid elements with an inverted M:E. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-12433)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par 1. Abnormal myeloid blast population detected. The immunophenotype of this population is similar to that seen in prior sample [case F22-10345] \par\par Abnormal myeloid blast population represents 2.3% of WBC.\par Monocytosis is seen, 18.5% of WBC.\par\par Immunophenotype:\par Abnormal: CD7 (partial), CD13 (variable - dim to intermediate), CD33 (variable - negative to dim), CD45RA (variable - negative to dim), CD56 (partial), HLA-DR (uniform - intermediate)\par Normal: CD4, CD34, CD36, CD38, CD45, CD71, CD117, CD123, CD371 (clec12a)\par Negative: CD2, CD5, CD10, CD11b, CD14, CD15, CD16, CD19, CD25, CD64, CD105, CD42b, CD90\par\par Number of cells acquired: 320 thousand \par\par 2. No abnormal mature B cell population detected.         \par No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.\par\par Number of cells acquired: 261 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8557.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-48729, M22-48732. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-3104;S10;MSK6 - 2023-05-26 13.51.15.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Lymphoma
Clinical Hx/Op Findings: staging
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Mantle cell lymphoma, blastoid variant, with focal necrosis, involving 40% of marrow space and 90% of marrow cellularity with PAX5 immunohistochemistry.
    - Bone marrow with patchy cellularity, reduced trilineage hematopoiesis and focal stromal injury/therapy-effect.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
The core biopsy is adequate and shows bone marrow with patchy areas of cellularity (comprising 40% of marrow space) with partial crush artifact that are nearly entirely replaced by sheets of intermediate sized atypical lymphoid cells with blastoid morphology. There is an intervening patch of nearly acellular area consistent with stromal injury/therapy-effect as well as an area of tumor necrosis. Background trilineage hematopoiesis is markedly reduced. 

The aspirate smears are aspicular, hemodiluted and paucicellular. There are many intermediate sized atypical lymphoid cells with slightly irregular nuclear contours, dispersed chromatin, variably conspicuous nucleoli and scant to moderate amount of cytoplasm. The remainder of the cellularity is comprised of mostly mature granulocytes and monocytes, a few myeloid and erythroid precursors, and rare megakaryocytes. The touch imprints are non-contributory.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
Immunostains are interpreted in the non-crushed areas. 
The neoplastic cells
Express: PAX5 (40% of marrow space and 90% of marrow cellularity), cyclin D1 and SOX11
Do not express: CD20
Others: CD3 highlights T-cells, <5% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-4012) 
Abnormal B cell population detected. 
The immunophenotype of this abnormal B cell population is similar to that seen previously (F22-2893) and is compatible with previously diagnosed mantle cell lymphoma (MCL).

Abnormal B cell population represents 26.8% of WBC.

Immunophenotype:
Abnormal: CD5 (positive - partial), CD20 (negative), CD79b (dim), ROR1 (positive), CD19 (variable - negative to dim), CD38 (uniform - bright)
Normal: CD81, CD40, CD45
Negative: CD23, CD43, CD200, CD10, CD3

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (4/15/2022)
WBC 10.6 [4.0-11.0 K/mcL] 
RBC 3.05 L [3.95-5.54 M/mcL] 
HGB 8.8 L [12.5-16.2 g/dL] 
HCT 25.9 L [37.5-49.3 %] 
MCV 85 [80-98 fL] 
MCH 28.9 [27.0-33.0 pg] 
MCHC 34.0 [31.0-36.5 g/dL] 
RDW 13.8 [12.2-15.1 %] 
Platelets 74 L [160-400 K/mcL] 

Neutrophil 78.0 H [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 4.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 9.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 8.2 H [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.4 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL]

Morphology:
WBCs: Many atypical intermediate sized cells with blastoid morphology; Neutrophilia and occasional left-shifted granulocytes; rare pseudo Pelger-Huet forms. 
RBCs: Normocytic normochromic anemia with increase in polychromasia. 
Platelets: Thrombocytopenia; unremarkable morphology.     

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES (CG22-2714)
FISH ANALYSIS:
Translocation of CCND1 (11q13.3) detected in 4% of cells.

No evidence of MYC (8q24.1) rearrangement.
No evidence of TP53 (17p13.1) deletion or loss of chromosome 17.

Please refer to CG22-2820 for SNP-array.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-16618.
"
H22-5715;S12;MSKY - 2023-04-14 16.19.03.ndpi,Peripheral Blood Smear,2023-04-14,"Clinical Diagnosis: Mult Myeloma
Clinical Hx/Op Findings: s/p induction, eval residual dz prior to ASCT
Requested Studies: Gross/Micro
","AMENDMENT DETAIL:
Reason for Amendment:          correction to specimen description 

Report Section Changed:     Specimen Description- Part 3  

Description of Change:           Part 3  Peripheral Blood Smear


Note: This document represents an amended version of the Hematopathology report originally issued on 7/18/2022. Dr. Oscar Lahoud has been notified via e-mail on 7/19/2022. 


1-3. Bone marrow, right posterior iliac crest, biopsy; touch imprint and peripheral blood smears: 
     - Plasma cell neoplasm, 
80-90% involvement by CD138 immunohistochemistry.
70% involvement by touch imprint differential
59.4% involvement by flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality:  Adequate, short
Cellularity: 90-100%
Myeloid lineage: Orderly maturation, decreased  
Erythroid lineage: Orderly maturation, decreased
Megakaryocytes:  Present  
Plasma cells: Increased  

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

TOUCH SMEAR MORPHOLOGY
Bone Marrow Touch Smear Quality:  Inadequate, hypocellular, devoid of spicules 
Blasts                1%
Promyelocytes           1%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      5%
Monocytes           2%
Eosinophils           6%
Erythroid Precursors      10%
Plasma Cells           70%
Lymphocytes           3%
Number of Cells Counted      500
M:E Ratio           1.6

Morphology: 
Marrow spicules: aspicular.
Cellularity: Hypocellular
Plasma cell morphology: Small to large in size; prominent nucleoli  
Myeloid lineage: Decreased
Erythroid Lineage: Decreased
Megakaryocytes: Present 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 80-90% of cellularity. 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted
BCMA highlights 90% of plasma cells, (3+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-7491) 
1. Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.

Abnormal plasma cell population comprises 100% of total plasma cells.
Abnormal plasma cell population represents 59.4% of WBC.

Immunophenotype:
Abnormal: CD19 (negative), CD27 (negative), CD45 (negative), CD81 (negative), cytoplasmic Kappa (restriction)
Normal: CD138, CD229, CD319
Negative: CD38, CD56, CD117, CD20, cytoplasmic Lambda

Number of cells acquired: 522  

2. No abnormal mature B cell population detected. Virtually no B cells seen.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

Number of cells acquired: 753  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (7/14/2022):
WBC 3.6 L [4.0-11.0 K/mcL] 
RBC 3.66 L [3.80-5.00 M/mcL] 
HGB 10.1 L [11.2-15.4 g/dL] 
HCT 31.3 L [34.3-46.0 %] 
MCV 86 [80-98 fL] 
MCH 27.6 [27.0-33.0 pg] 
MCHC 32.3 [31.0-36.5 g/dL] 
RDW 19.0 H [12.2-15.1 %] 
Platelets. 161 [160-400 K/mcL] 

Neutrophil 62.5 [32.5-74.8 %] 
Mono 17.6 H [0.0-12.3 %] 
Eos 0.3 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 18.7 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.2 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL]

Morphology: No circulating plasma cell on scanning. 
 
Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Not submitted.

MOLECULAR STUDIES 
Not submitted.
"
H22-9411;S13;MSKW - 2023-04-14 14.46.28.ndpi,Peripheral Blood Smear,2023-04-14,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Amyloid\par Clinical Hx/Op Findings: serological POD\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red255\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate, and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : \~\~\par      - Plasma cell neoplasm, \~\par\~\~\~\~\~\~\~\~\~\~15-20% involvement by CD138 immunohistochemistry.\par\~\~\~\~\~\~\~\~\~\~3% involvement by aspirate differential\par\~\~\~\~\~\~\~\~\~\~0.87% involvement by flow cytometry\par      - Cellular marrow with trilineage maturing hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Limited, fragmented\par Cellularity: Could not be precisely assessed\par Myeloid lineage: Orderly maturation    \par Erythroid lineage: Orderly maturation   \par Megakaryocytes: Present\par Plasma cells: Increased    \par\par Special stain: Congo Red stain is negative for amyloid deposition \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate\par\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 1%\par Myelocytes \tab\tab 7%\par Metamyelocytes \tab\tab 5%\par Neutrophils/Bands \tab 39%\par Monocytes \tab\tab 7%\par Eosinophils \tab\tab 2%\par Erythroid Precursors \tab 25%\par Plasma Cells \tab\tab 3%\par Lymphocytes \tab\tab 10%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 2.4\par\par\par Morphology: \par Marrow spicules: Paucispicular \par Cellularity: Mildly hypocellular\par Plasma cell morphology: Small to intermediate \par Myeloid lineage: Orderly maturation \par Erythroid Lineage: Orderly maturation \par Megakaryocytes: Present \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD138 immunostain highlights plasma cells, 15-20% of cellularity. \par Kappa and lambda immunostains show the plasma cells are lambda light chain restricted\par BCMA highlights >90% of plasma cells, (2+) intensity, membranous/ Golgi pattern. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-12225)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par\par Abnormal plasma cell population comprises 65.5% of total plasma cells.\par Abnormal plasma cell population represents 0.87% of WBC.\par\par Immunophenotype:\par Abnormal: CD38 (dim), CD19 (negative), CD27 (dim), CD45 (negative), CD81 (negative), CD117 (partial - dim), cytoplasmic Lambda (restriction)\par Normal: CD138, CD229, CD319\par Negative: CD56, cytoplasmic Kappa\par\par Number of cells acquired: 4.6 million \par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (11/07/2022):\par WBC 5.1 [4.0-11.0 K/mcL] \par RBC 4.48 [3.95-5.54 M/mcL] \par HGB 12.8 [12.5-16.2 g/dL] \par HCT 40.1 [37.5-49.3 %] \par MCV 90 [80-98 fL] \par MCH 28.6 [27.0-33.0 pg] \par MCHC 31.9 [31.0-36.5 g/dL] \par RDW16.1 H [12.2-15.1 %] \par Platelets. 216 [160-400 K/mcL] \par\par Neutrophil 56.5 [32.5-74.8 %] \par Mono 18.3 H [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.4 [0.0-1.5 %] \par Immature Granulocyte 0.2 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 24.6 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 2.9 [1.5-7.5 K/mcL] \par Abs Mono 0.9 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] \par Abs Lymph 1.2 [0.9-3.2 K/mcL] \par\par Morphology: No circulating plasma cells seen\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-8428.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Not submitted.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-1758;S10;MSK9 - 2023-05-26 12.36.01.ndpi,Peripheral Blood Smear,2023-05-26,"Clinical Diagnosis: ALL
Clinical Hx/Op Findings: 53 yo F with suspicion of B-ALL
Requested Studies: Gross/Micro
Special Requests: Rush
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B lymphoblastic leukemia/lymphoma, BCR-ABL1-positive, (84% blasts by touch imprint differential count). See comment.   
  
COMMENT:  Correlation with clinical history and historic CBC parameters as well as the BCR-ABL1 fusion transcript (p190 vs p210) is recommended. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular (80-95%)
M:E ratio: NA 
Blasts: Expanded blast population of predominantly intermediate size cells, with high nuclear/cytoplasmic ratio, round to irregular nucleus, fine chromatin, distinct nucleoli, and scant cytoplasm. 
Myeloid lineage: Markedly reduced.
Erythroid lineage: Markedly reduced.
Megakaryocytes: Reduced to absent
Lymphocytes: Scattered
Plasma cells: Scattered
The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules
Only touch imprints available

Blasts                84%
Lymphocytes           16%
Number of Cells Counted 500
M:E Ratio           0

Morphology:
-Touch imprints are cellular and show expanded blast population of predominantly intermediate size cells, with high nuclear/cytoplasmic ratio, large irregular/folded nucleus, fine chromatin, distinct nucleoli, and scant cytoplasm. Background hematopoiesis is markedly reduced to absent. 

PERIPHERAL BLOOD
CBC (3/2/2022):

WBC 1.3 L [4.0-11.0 K/mcL] 
RBC 2.43 L [3.80-5.00 M/mcL] 
HGB 6.7 L [11.2-15.4 g/dL] 
HCT 19.9 L [34.3-46.0 %] 
MCV 82 [80-98 fL] 
MCH 27.6 [27.0-33.0 pg] 
MCHC 33.7 [31.0-36.5 g/dL] 
RDW 15.2 H [12.2-15.1 %] 
Platelets 10 L [160-400 K/mcL] 

Neutrophil 4.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 26.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Lymph 68.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.3 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL] 

Morphology:
WBC:  Numerous circulating blasts 
RBC: Marked normocytic anemia
Platelets: Markedly decreased in number with unremarkable morphology. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 and TdT highlight expanded blast population, ~90% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW
Not available.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD, 03/01/2022 (F22-2204)
1. Abnormal immature B cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 43.1% of the mononuclear cells.
Abnormal immature B cell population represents 41.4% of WBC.

Immunophenotype:
Abnormal: CD10 (variable - dim to bright), CD13 (partial - dim), CD33 (partial dim), CD20 (partial), CD24 (dim), CD25 (partial - dim), CD34 (bright), CD38 (dim to negative), CD66c/CD123 (positive), CD73/CD304 (positive), CD81 (dim), CD86 (positive), CD123 (positive)
Normal: CD19, CD22, CD36, CD45, CD45RA, CD71, CD105, CD371 (clec12a), HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD26, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, cytoplasmic MPO, surface Kappa, surface Lambda

Number of cells acquired 329 thousand 

2. No abnormal myeloid blast, mature B or mature T cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.
Myeloid blast population with an unremarkable phenotype represents 0.64% of WBC.

Number of cells acquired: 290 thousand

CYTOGENETIC STUDIES
Cytogenetic analysis is requested on peripheral blood specimen, see reports CG1490 and CG22-1501

MOLECULAR STUDIES 
Molecular analysis is requested on peripheral blood specimen, see reports M22-9297, M22-9300, M22-9301, and M22-9302




"
H22-3460;S11;MSK2 - 2023-04-17 07.17.46.ndpi,Peripheral Blood Smear,2023-04-17,"
Multiple Myeloma

","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
20-30% involvement by CD138 immunohistochemistry.
5% involvement by aspirate differential
0.68% involvement by flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: 10-20%
Myeloid lineage: Orderly maturation  
Erythroid lineage: Orderly maturation   
Megakaryocytes:  Adequate   
Plasma cells: Increased

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY

Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, hemodiluted, devoid of spicules 
Differential performed on touch smear

Blasts                2%
Promyelocytes           1%
Myelocytes           5%
Metamyelocytes           2%
Neutrophils/Bands      42%
Monocytes           3%
Eosinophils           4%
Erythroid Precursors      28%
Plasma Cells           5%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           2

Morphology: 
Marrow spicules: Aspicular.
Cellularity: Hypocellular
Plasma cell morphology: small to intermediate 
Myeloid lineage: Orderly maturation 
Erythroid Lineage: Orderly maturation 
Megakaryocytes:  Not seen

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, overall, 20-30% of total cellularity. 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.
BCMA highlights 90% of plasma cells, (2-3) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW F22-4473 
1. Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.

Abnormal plasma cell population comprises 83.3% of total plasma cells.
Abnormal plasma cell population represents 0.68% of WBC.

Immunophenotype:
Abnormal: CD38 (dim), CD19 (negative), CD27 (negative), CD45 (bright), CD56 (positive), CD81 (negative), cytoplasmic Kappa (restriction)
Normal: CD138, CD229, CD319
Negative: CD20, CD117, cytoplasmic Lambda

Number of cells acquired: 951 thousand 

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (4/27/2022):
WBC 4.6 [4.0-11.0 K/mcL] 
RBC 3.71 L [3.95-5.54 M/mcL] 
HGB 11.1 L [12.5-16.2 g/dL] 
HCT 30.5 L [37.5-49.3 %] 
MCV 82 [80-98 fL] 
MCH 29.9 [27.0-33.0 pg] 
MCHC 36.4 [31.0-36.5 g/dL] 
RDW 15.2 H [12.2-15.1 %] 
Platelets. 212 [160-400 K/mcL] 

Neutrophil 64.7 [32.5-74.8 %] 
Mono 9.3 [0.0-12.3 %] 
Eos 5.2 H [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 1.1 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 19.3 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 3.0 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL]

Morphology: 
No circulating plasma cells on scanning.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-3070, CG22-3071.
MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-18339 and M22-18340. 




     
"
H22-1634;S12;MSKU - 2023-06-12 15.40.23.ndpi,Peripheral Blood Smear,2023-06-12,"Clinical Diagnosis: Breast, Malignant Neoplasm
Clinical Hx/Op Findings: h/o recurrent BC x 4 s/p lumpectomy, RT, AC-T. Lung Cancer s/p carbotaxol with progressive pancytopenia
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Therapy-related myeloid neoplasm, 13% blasts by aspirate differential count.
     - No diagnostic morphologic or immunophenotypic evidence of metastatic carcinoma.
  
COMMENT: The patient's reported history of breast and lung cancers previously treated with chemotherapy (including cyclophosphamide, carboplatin, doxorubicin and paclitaxel) and radiation is noted. In light of this history, the current findings are best classified as a therapy-related myeloid presenting as myelodysplastic syndrome with excess blasts 2 (MDS-EB-2).

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular (80-90% cellularity)
M:E ratio: Reduced
Blasts: Increased
Myeloid lineage: Exhibits left-shifted maturation
Erythroid lineage: Exhibits full maturation
Megakaryocytes: Present with small, hypolobated forms
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows no significant increase in reticulin fibrosis  

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate
Extrinsic cells are not seen

Blasts                13%
Promyelocytes           2%
Myelocytes           8%
Metamyelocytes           4%
Neutrophils/Bands      14%
Monocytes           1%
Eosinophils           3%
Basophils           1%
Erythroid Precursors      41%
Plasma Cells           1%
Lymphocytes           12%
Number of Cells Counted 500
M:E Ratio           0.8

Special stain
Iron: Present
Ring sideroblasts: Present, >15%

Morphology:
Spicular and cellular aspirate smears with crush artifact and bare nuclei and cellular touch imprint show an expanded population of mostly intermediate to large sized blasts with rounded to irregular nuclei, fine chromatin, distinct nucleoli and scant to moderate amounts of cytoplasm. Myeloid elements show left-shifted maturation with dysplastic forms (hypogranulation, atypical nuclear segmentation). Erythroid precursors show progressive maturation with dysplastic forms (nuclear irregularity/budding, binucleation, karyorrhexis). Megakaryocytes are present with some small, hypolobated forms and rare forms with disjointed nuclear lobes.

PERIPHERAL BLOOD
CBC (2/25/2022):
WBC 5.0 [4.0-11.0 K/mcL] 
RBC 2.26 L [3.80-5.00 M/mcL] 
HGB 7.0 L [11.2-15.4 g/dL] 
HCT 21.2 L [34.3-46.0 %] 
MCV 94 [80-98 fL] 
MCH 31.0 [27.0-33.0 pg] 
MCHC 33.0 [31.0-36.5 g/dL] 
RDW 19.6 H [12.2-15.1 %] 
Platelets 59 L [160-400 K/mcL] 

Neutrophil 49.0 [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 5.0 H [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 5.0 H [0.0-0.0 %] 
Myelocyte 3.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 34.0 [12.2-47.4 %] 
Nucleated RBC 5.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 2.5 [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Blasts 0.3 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.7 [0.9-3.2 K/mcL] 

Morphology:
WBC: Circulating blasts and myeloid precursors seen. A subset of neutrophils shows hypogranulation and/or atypical nuclear segmentation.
RBC: Normocytic anemia with anisopoikilocytosis and occasional nucleated RBCs.
PLT: Thrombocytopenia.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight increased interstitial blasts, ~10-15% of cellularity. CD33 and CD71 highlight myeloid and erythroid elements, respectively. CD61 highlights megakaryocytes with small forms. CD61 also labels scattered very small cells, possibly representing micromegakaryocytes or some blasts. OSCAR and AE1/AE3 pancytokeratin stains show no evidence of metastatic carcinoma.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-2119)
Interpretation: 
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.
Basophilia is seen, 2.0% of WBC.

The blasts have abnormal expression of CD5 (partial), CD7 (partial), CD13 (bimodal- dim to bright), CD33 (uniform-bright), CD34 (intermediate to bright), CD38 (dim to negative), CD45RA (negative), CD56 (partial), CD117 (bimodal- negative to bright), CD123 (uniform-bright), CD371 (partial-dim), HLA-DR (bright), with normal expression of CD4, CD36, CD45, CD71, CD105 and without CD2, surface CD3, cytoplasmic CD3, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD64, cytoplasmic CD79a, or surface light chains. MPO expression is present on a subset of blasts. CD34 positive myeloid blasts represent 26.7% of WBC.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES (CG22-1411)
KARYOTYPE ANALYSIS:
Chromosome analysis detected a complex karyotype with deletion of 5q, loss of chromosome 7, loss of chromosome 18, t(5;6), and add(16q) in all twenty metaphases, of which three metaphases had additional abnormalities such as gain of chromosome 8 and t(7;20). This finding likely represents a myeloid neoplasm and correlation with the pending hematopathology studies is recommended (H22-1634).

FISH ANALYSIS:
No evidence of EVI1(3q26.2) rearrangement.
No evidence of MLL (11q23) rearrangement.
No evidence of TP53 (17p13.1) deletion or loss of chromosome 17.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-8517.
"
H22-1984;S10;MSK0 - 2023-05-26 12.53.26.ndpi,Peripheral Blood Smear,2023-05-26,"Clinical Diagnosis: ALL
Clinical Hx/Op Findings: PRE-TREATMENT
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma, with t(9;22)(q34.1;q11.2); BCR-ABL1, 75% blast by aspirate differential count. 
  
BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: ~100%
M:E ratio: N/A
Blasts: Markedly increased, replacing marrow cellularity. 
Myeloid lineage: Decreased. 
Erythroid lineage: Maturing erythroid precursors present. 
Megakaryocytes: Present, mildly decreased, morphologically unremarkable. 
Lymphocytes: Not increased 
Plasma cells: Not increased
Additional finding: Geographic necrosis present   

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                75%
Promyelocytes           1%
Neutrophils/Bands      5%
Monocytes           1%
Erythroid Precursors      10%
Lymphocytes           8%
Number of Cells Counted      500
M:E Ratio           0.7

Morphology:
Spicular and cellular smears show expanded blast population. Background residual trilineage hematopoiesis is still present. 

PERIPHERAL BLOOD
CBC (03/10/2022):
WBC 5.5 [4.0-11.0 K/mcL] 
RBC 3.59 L [3.95-5.54 M/mcL] 
HGB 10.1 L [12.5-16.2 g/dL] 
HCT 29.5 L [37.5-49.3 %] 
MCV 82 [80-98 fL] 
MCH 28.1 [27.0-33.0 pg] 
MCHC 34.2 [31.0-36.5 g/dL] 
RDW 12.1 L [12.2-15.1 %] 
Platelets. 88 L [160-400 K/mcL] 

Neutrophil 60.0 [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 8.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Lymph 30.0 [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 3.3 [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.4 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.7 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology: Circulating blast present. Few circulating immature myeloid cells are also appreciated.  

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
CD34 and TdT highlight blasts, 80-90% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-2591)
Interpretation: 
1. Abnormal immature B cell population detected.

Abnormal immature B cell population represents 55.8% of WBC.
Abnormal immature B cell population represents 57.8% of the mononuclear cells..

Immunophenotype:
Abnormal: CD10 (variable - dim to bright), CD13 (partial), CD19 (bright), CD20 (partial), CD25 (partial), CD33 (partial), CD34 (bright), CD38 (dim), CD45 (variable - negative to dim), CD66c/CD123 (positive), CD73/CD304 (positive), CD81 (dim), CD86 (partial), CD123 (positive)
Normal: CD22, CD24, CD36, CD45RA, CD71, CD105, CD371 (clec12a), HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD26, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, cytoplasmic MPO, surface Kappa, surface Lambda

Number of cells acquired 630 thousand 

2. No abnormal myeloid blast, mature B or mature T cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.47% of WBC.

Number of cells acquired: 713 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-1752.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-10850, M22-10871, M22-10872, M22-10873, M22-10874, M22-10875, M22-10876.
"
H22-2733;S11;MSKU - 2023-05-31 21.50.21.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: HCL
Clinical Hx/Op Findings: staging
","{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch31506\stshfhich31506\stshfbi31506\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}
{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}
{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}










{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}
{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}
{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}
{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}
{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}
{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;
\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;
\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;\red0\green0\blue0;}{\*\defchp \f31506\fs22 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 
\f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31506\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused Normal Table;}}
{\*\rsidtbl \rsid1405724\rsid2915398\rsid3219057\rsid3476385\rsid5117709\rsid6176304\rsid10381454\rsid10551340\rsid10843648\rsid11209980\rsid13769909\rsid13961447\rsid14026760\rsid14177482}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1
\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\author Tejada, Aries Mae/Pathology}{\operator Boiocchi, Leonardo/Pathology}{\creatim\yr2022\mo4\dy6\hr16\min5}{\revtim\yr2022\mo4\dy6\hr16\min5}{\version2}{\edmins0}{\nofpages3}
{\nofwords586}{\nofchars3558}{\nofcharsws4033}{\vern21}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont1\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1440\dgvorigin1440\dghshow1\dgvshow1
\jexpand\viewkind1\viewscale130\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\rsidroot10551340\newtblstyruls\nogrowautofit\usenormstyforlist\noindnmbrts\felnbrelev\nocxsptable\indrlsweleven\noafcnsttbl\afelev\utinl\hwelev\spltpgpar\notcvasp\notbrkcnstfrctbl\notvatxbx\krnprsnet\cachedcolbal \nouicompat \fet0
{\*\wgrffmtfilter 2450}\nofeaturethrottle1\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang 
{\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}
\pard\plain \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid1405724 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057\charrsid3476385 1-3. Bone marrow,}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057  right posterior iliac crest, }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057\charrsid3476385 biopsy, aspirate and peripheral blood smears: \~\~}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par      - Involvement by }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 hairy cell leukemia }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 (}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 80}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 % with CD20 immunohistochemistry)\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\insrsid3219057\charrsid14177482 COMMENT:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 Patient's reported previous diagnosis of hairy cell leukemia is noted. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 The overall morphologic features seen in the }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 current }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 marrow }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 sample, }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 together with the immunophenotype identified by flow cytometry}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 ,}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 appear}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482  consistent with }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 involvement }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 by }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 the same process}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 .}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057  Correlation with the results of the concurrent molecular genetic studies is recommended.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid3219057\charrsid3476385 BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 Small }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 biopsy}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057  including only limited hematopoietic marrow, but overall adequate. Marrow cellularity is 50-60% and appears to be represented predominantly by small to medium-sized lymphocytes with round nuclei, condensed chromatin and moderately abundant cytoplasm. Only rare scattered hematopoietic precursors are seen in the background, including occasional megakaryocytes with overall normal features.\par Bone marrow aspirate smear are aspicular, hypocellular and hemodilute. Scattered erythroid and myeloid precursors at various stages of maturation and without obvious dysplasia are present. Megakaryocytes are not seen. Occasional medium-sized lymphocytes with round to mildly irregular nuclei, condensed chromatin, inconspicuous nucleoli and moderately abundant cytoplasm with occasional cytoplasmic projections are noted. Differential count cannot be performed.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \~\par }{\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\cf1\insrsid3219057\charrsid3476385 \par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.}{\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid3219057\charrsid3476385 IMMUNOHISTOCHEMISTRY}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid14177482 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 CD20 immunostain highlights }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 the markedly increased number of B-cells accounting for >80% of cellularity in the limited marrow included in the sample. Staining for BRAF is noncontributory. CD3 is positive in scattered T-cells (<5% of cellularity). }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid1405724 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \~\par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid3219057\charrsid14177482 FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-3573)}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385  \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid14177482 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid14177482 1. Abnormal B-cell population detected.\par The immunophenotype of the abnormal B-cell is consistent with involvement by hairy cell leukemia (HCL).\par \par Abnormal B cell population represents 11.4% of WBC.\par Immunophenotype:\par Abnormal: CD19 (bright), CD20 (bright), CD22 (bright), CD25 (positive), CD11c (positive), CD103 (positive), CD200 (bright), surface Lambda (restriction), Forward Scatter (increased), Side Scatter (increased)\par Normal: CD38, CD45\par Negative: CD5, CD10, CD279 (PD1), CD3, CD14, surface Kappa\par \par 2. No abnormal mature T-cell population detected. \par No immunophenotypic evidence of T-cell lymphoma is identified.  \par \par Number of cells acquired: 355 thousand}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid1405724 {\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\cf1\insrsid3219057\charrsid3476385 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid1405724 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid3219057\charrsid3476385 PERIPHERAL BLOOD}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid2915398 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 CBC (}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 4/4/2022)\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398 WBC 2.9 L [4.0-11.0 K/mcL] \par RBC 4.09 [3.95-5.54 M/mcL] \par HGB 13.4 [12.5-16.2 g/dL] \par HCT 36.7 L [37.5-49.3 %] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 MCV}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398  90 [80-98 fL] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 MCH}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398  32.8 [27.0-33.0 pg] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 MCHC}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398  36.5 [31.0-36.5 g/dL] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 RDW}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398  14.9 [12.2-15.1 %] \par Platelets. 133 L [160-400 K/mcL] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398 Neutrophil 47.5 [32.5-74.8 %] \par Mono 2.8 [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Immature Granulocyte 0.3 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 48.4 H [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid2915398 Abs Neut 1.4 L [1.5-7.5 K/mcL] \par Abs Mono 0.1 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature 0.0 [0.0-0.1 K/mcL] \par Granulocyte\par Abs Lymph 1.4 [0.9-3.2 K/mcL]}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid1405724 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\tx1428\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid14177482 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 Morphology}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057 : Mild leukopenia with relative lymphocytosis. Lymphocytes include occasional elements with round to mildly irregular nuclei, relatively condensed chromatin, and moderately abundant cytoplasm with subset of cells showing irregular cytoplasmic projections.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid1405724 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid6176304 {\rtlch\fcs1 \af1\afs16 \ltrch\fcs0 \f1\fs16\cf1\insrsid3219057 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid3219057 \par }\pard \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid1405724 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid3219057\charrsid3476385 CYTOGENETIC STUDIES}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par Cytogenetic analysis will be reported separately. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057\charrsid3476385 See separate report, CG}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057 22-2421.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par \~\par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid3219057\charrsid3476385 MOLECULAR STUDIES}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385  \par Molecular analysis will be reported separately. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057\charrsid3476385 See separate report, M}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid3219057 22-14782, M 22-14784.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid3219057\charrsid3476385 \par }{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid3219057\charrsid3476385 \par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}"
H22-391;S10;MSK1 - 2023-05-26 15.20.58.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: ALL
Clinical Hx/Op Findings: New ALL
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate, and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma, 83% blasts by aspirate differential count.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular (>95%)
M:E ratio: N/A
Blasts: Markedly increased, present in sheets nearly entirely replacing the marrow
Myeloid lineage: Markedly reduced 
Erythroid lineage: Markedly reduced
Megakaryocytes: Reduced
Lymphocytes: Rare 
Plasma cells: Rare 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                83%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      1%
Erythroid Precursors      12%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
-Spicular and cellular aspirate smears show a markedly expanded population of blasts, which are mostly intermediate in size with rounded to irregular nuclei, fine chromatin, occasional distinct nucleoli and scant cytoplasm. Myeloid and erythroid elements are markedly reduced. Scattered megakaryocytes are present without overt atypia. 

PERIPHERAL BLOOD
CBC (01/14/2022):
WBC 22.4 H [4.0-11.0 K/mcL] 
RBC 4.44 [3.95-5.54 M/mcL] 
HGB 14.1 [12.5-16.2 g/dL] 
HCT 42.1 [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 31.8 [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 15.2 H [12.2-15.1 %] 
Platelets 72 L [160-400 K/mcL] 

Neutrophil 5.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 63.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 29.0 [12.2-47.4 %] 
Variant Lymph 1.0 [0.0-2.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 14.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 6.7 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Leukocytosis with frequent circulating blasts morphologically similar to those in the aspirate smears. Absolute neutropenia with few myelocytes and metamyelocytes.
RBC: Normochromic, normocytic RBCs with rare nucleated RBCs.
PLT: Thrombocytopenia.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
TdT highlights markedly increased blasts comprising >90% of the marrow cellularity. The blasts show variable expression of CD34.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-492)
Interpretation: 
1. Abnormal immature B cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 96.5% of the mononuclear cells.
Abnormal immature B cell population represents 96.0% of WBC.

Immunophenotype:
Abnormal: CD10 (positive - bright), CD20 (partial), CD34 (variable - negative to intermediate), CD45 (dim), CD66c/CD123 (positive), CD73/CD304 (partial), CD81 (positive - dim), CD86 (partial), CD123 (positive)
Normal: CD19, CD22, CD24, CD38, CD71, HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD25, CD26, CD33, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, cytoplasmic MPO, surface Kappa, surface Lambda

Number of cells acquired 814 thousand 

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 475 thousand 

4. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                                                                                
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.092% of WBC.

Number of cells acquired: 331 thousand 

Also see F22-454 (PB) submitted on the same day.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-454)
Interpretation: 
1. Abnormal immature B cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 72.9% of the mononuclear cells..
Abnormal immature B cell population represents 68.7% of WBC.

Immunophenotype:
Abnormal: CD10 (positive - bright), CD20 (variable - negative to bright), CD22 (dim), CD45 (dim), CD66c/CD123 (positive), CD73/CD304 (positive), CD81 (positive - dim), CD86 (positive), CD123 (positive)
Normal: CD19, CD24, CD34, CD38, CD71, HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD25, CD26, CD33, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, cytoplasmic MPO, surface Kappa, surface Lambda

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

4. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.54% of WBC.

Number of cells acquired: 466 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-320.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-2184, M21-2188, M21-2194, M21-2197, M21-2198.
"
H22-10150;S16;MSKA - 2023-06-15 15.44.53.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: Cytopenias\par Clinical Hx/Op Findings: Metastatic urothelial cancer, new thrombocytopenia and leukocytosis\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b . \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Bone marrow, left posterior iliac crest, biopsy; \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 aspirate and peripheral blood smears\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 : \~\~\par      - Involvement by metastatic urothelial carcinoma, see note\par      - Hypercellular marrow with trilineage maturing hematopoiesis and myeloid hyperplasia.\par   \par Note: The tumor shows focal plasmacytoid features and is positive for pan-cytokeratin, GATA3, and CK7 (focal) while negative for PAX8. The morphologic features and immunoprofile support the diagnosis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The patient's history of metastatic urothelial carcinoma presenting with anemia, thrombocytopenia and leukocytosis is noted. The current marrow specimen shows involvement by metastatic carcinoma, which could be the etiology behind the patient's cytopenias. Additionally, the patient's ongoing infection could be a contributing factor to the myeloid hyperplasia seen in the marrow. Overall, there is no morphologic or immunophenotypic evidence of involvement by a hematolymphoid neoplasm. Correlation with cytogenetic and molecular studies is recommended.\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Dr. Roshal (Hematopathology service) has reviewed the case.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Quality: Adequate\par Cellularity: Hypercellular (80%\par M:E ratio: Increased\par Blasts: Not increased\par Myeloid lineage: Predominant with maturation\par Erythroid lineage: Present with maturaiton\par Megakaryocytes: Present with unremarkable morphology\par Lymphocytes: Scattered\par Plasma cells: Scattered\par\par Special stains: Reticulin stain shows focal, mild increase in reticulin fibrosis (MF-0 to 1 out of 3). \par\par Clot section: Predominantly blood with scattered marrow elements\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Adequate\par Numerous primitive cells seen singly and/or in clumps which appear to be extrinsic in origin\par\par Blasts \tab\tab\tab 1%\par Promyelocytes \tab\tab 4%\par Myelocytes \tab\tab 16%\par Metamyelocytes \tab\tab 4%\par Neutrophils/Bands \tab 48%\par Monocytes \tab\tab 3%\par Eosinophils \tab\tab 2%\par Erythroid Precursors \tab 17%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 4%\par Number of Cells Counted 500\par M:E Ratio \tab\tab 4.5\par\par Special stain\par Iron: Present\par Ring sideroblasts: Absent \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Spicular and cellular aspirate smears show marrow with an expansion non-hematopoietic, neoplastic cells, which arranged in aggregates resembling papillary structures. The neoplastic cells have a high nuclear:cytoplasmic ratio, ample basophilic cytoplasm fine to reticular chromatin and occasionally distinct nucleoli. Background marrow shows increased myeloid elements with mildly left shifted maturation without significant dysplasia. Erythroid elements show maturation without significant dysplasia. Megakaryocytes are present and display unremarkable morphology. Blasts are not increased. Scattered lymphocytes and plasma cells are present.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (12/02/2022):\par WBC 57.0 H [4.0-11.0 K/mcL] \par RBC 2.98 L [3.95-5.54 M/mcL] \par HGB 7.6 L [12.5-16.2 g/dL] \par HCT 24.6 L [37.5-49.3 %] \par MCV 83 [80-98 fL] \par MCH25.5 L [27.0-33.0 pg] \par MCHC 30.9 L [31.0-36.5 g/dL] \par RDW18.9 H [12.2-15.1 %] \par Platelets. 39 L [160-400 K/mcL] \par\par Neutrophil 91.0 H [32.5-74.8 %] \par Mono 3.0 [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Promyelocyte 2.0 H [0.0-0.0 %] \par Metamyelocyte 1.0 H [0.0-0.0 %] \par Lymph 2.0 L [12.2-47.4 %] \par Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 51.9 H [1.5-7.5 K/mcL] \par Abs Mono 1.7 H [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.6 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Promyelocytes 1.1 H [0.0-0.0 K/mcL] \par Abs Meta 0.6 H [0.0-0.0 K/mcL] \par Abs Lymph 1.1 [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]\par\par Morphology: \par RBC: Normochromic, normocytic anemia. Anisopoikilocytosis. Polychromasia. Increased circulating nRBCs.\par WBC: Leukocytosis, with neutrophilia and circulating immature myeloid cells. Monocytosis. No increase in circulating blasts.\par PLT: Marked thrombocytopenia\plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 show no increase (<5%) in blasts. CD61 highlights megakaryocytes, CD71 highlights erythroid forms, MPO highlights myeloid forms\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-13176)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par No abnormal myeloid blast, mature B or mature T cell populations identified.                               \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par Myeloid blast population with an unremarkable phenotype represents 0.12% of WBC.\par\par Number of cells acquired: 511 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-9118, CG22-9119. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-51888, M22-51891, M22-52410.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-10585;S14;MSKA - 2023-06-15 09.45.51.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: carcinoma of unknown primary\par Clinical Hx/Op Findings: thrombocytopenia, bone mets, abnormal blood smear\par Requested Studies: Gross/Micro\par }","{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par      - Involvement by metastatic adenocarcinoma. See comment.\par      - Cellular marrow with maturing trilineage hematopoiesis.\par   \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b COMMENT: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The bone marrow is involved by adenocarcinoma, which is negative for TTF-1, NapsinA and NKX3.1. Mucicarmine highlights focal mucin in the tumor cells. Although overall findings are not specific for site of origin, this may be compatible with a lung primary given the presence of a dominant lung mass. Recommend clinical and radiologic correlation to exclude other primary sites. IMPACT may also be helpful to more definitely determine the site of origin. The result of PD-L1 immunohistochemistry is reported below under ""Immunohistochemistry."" This case was reviewed by Dr. Jason Chang and Dr. Marina Baine (Thoracic Pathology).\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate core biopsy with aspiration artifact shows cellular marrow (cellularity is difficult to accurately assess but appears ~50%) with extensive involvement by metastatic carcinoma with fibrosis and focal necrosis. The relatively scant residual bone marrow shows maturing trilineage hematopoiesis with a normal M:E ratio and no increase in blasts. Myeloid and erythroid elements show full maturation. Megakaryocytes are present and show no overt atypia. Boney trabeculae show reactive remodeling changes.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW ASPIRATE SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules \par Differential performed on touch imprints. \par\par Blasts \tab\tab\tab 1%\par Myelocytes \tab\tab 11%\par Metamyelocytes \tab\tab 3%\par Neutrophils/Bands \tab 38%\par Monocytes \tab\tab 1%\par Eosinophils \tab\tab 3%\par Erythroid Precursors \tab 23%\par Plasma Cells \tab\tab 1%\par Lymphocytes \tab\tab 19%\par Number of Cells Counted 200\par M:E Ratio \tab\tab 2.4\par\par Special stain\par Iron: Suboptimal for evaluation, devoid of spicules\par Ring sideroblasts: Absent \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par Aspicular, hypocellular, and hemodilute aspirate smears and paucicellular touch imprint show the presence of extrinsic cells. Scattered myeloid elements at various stages of maturation are present without overt dysplasia. Rare erythroid precursors and megakaryocytes are seen. No expanded blast population is identified.\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (12/16/2022):\par WBC 5.0 [4.0-11.0 K/mcL] \par RBC 4.74 [3.95-5.54 M/mcL] \par HGB 12.6 [12.5-16.2 g/dL] \par HCT 39.8 [37.5-49.3 %] \par MCV 84 [80-98 fL]\par MCH 26.6 L [27.0-33.0 pg]\par MCHC 31.7 [31.0-36.5 g/dL] \par RDW 13.4 [12.2-15.1 %]\par Platelets 13 L [160-400 K/mcL] \par\par Neutrophil 67.0 [32.5-74.8 %] \par Mono 4.0 [0.0-12.3 %] \par Eos 5.0 H [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Myelocyte 2.0 H [0.0-0.0 %] \par Metamyelocyte 2.0 H [0.0-0.0 %] \par Lymph 19.0 [12.2-47.4 %] \par Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 3.4 [1.5-7.5 K/mcL] \par Abs Mono 0.2 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] \par Absolute Basophil 0.1 [0.0-0.2 K/mcL] \par Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] \par Abs Meta 0.1 H [0.0-0.0 K/mcL] \par Abs Lymph 1.0 [0.9-3.2 K/mcL] \par\par Morphology:\par WBC: Circulating myeloid precursors, including rare possible blasts.\par RBC: Normocytic RBCs with occasional nucleated RBCs.\par Platelets: Platelet clumps are noted.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY/SPECIAL STAINS\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 shows no increase in blasts. CD117 highlights occasional early myeloid/erythroid precursors and scattered mast cells. MPO and CD71 highlight myeloid and erythroid elements, respectively, with a normal M:E ratio. CD61 highlights scattered megakaryocytes.\par\par The metastatic carcinoma is negative for TTF-1, NapsinA and NKX3.1. Mucicarmine highlights focal mucin in the tumor cells.\par\par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b PD-L1 \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 (clone SP263, Ventana):\par Positive (membranous labeling of tumor cells is approximately 20%)\par  \par Comment: Scant tumor cells are represented in this material. Therefore, negative result for PD-L1 should be interpreted with caution and re-testing should be performed if a more cellular sample becomes available.\par  \par Reporting of PD-L1 immunohistochemistry is according to tumor proportion score (TPS) that was developed to assess PD-L1 expression in thoracic tumors. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-13710)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par 1. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                                                                                \par Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.\par\par Myeloid blast population with an unremarkable phenotype represents 0.47% of WBC.\par\par Number of cells acquired 807 thousand \par\par 2. No abnormal mature B- or T-cell populations detected. \par No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.\par\par Number of cells acquired 476 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-9479.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Not submitted.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-6271;S11;MSKV - 2023-06-15 12.50.19.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: ALL
Clinical Hx/Op Findings: h/o ALL at 8 years old
Requested Studies: Gross/Micro
","1-2. Bone marrow, right posterior iliac crest, biopsy, aspirate clot, and aspirate smear: 
     - B-lymphoblastic leukemia/lymphoma (B-ALL).
  
COMMENT: Correlation with molecular and cytogenetic studies is suggested.

BONE MARROW BIOPSY
Quality: Adequate with aspiration artifact
Cellularity: >95%
M:E ratio: Unable to estimate
Blasts: Markedly increased
Myeloid lineage: Markedly reduced
Erythroid lineage: Markedly reduced
Megakaryocytes: Few present
Lymphocytes: Scattered
Plasma cells: Scattered

Clot section: Paucispicular; similar to core biopsy

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate 

Blasts                92%
Metamyelocytes           1%
Neutrophils/Bands      2%
Erythroid Precursors      3%
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           1

Morphology: Spicular and hypercellular smears show that the marrow elements are extensively replaced by sheets of blasts. The blasts are medium-sized with fine chromatin, prominent nucleoli, and scant agranular cytoplasm; a subset show irregular nuclear contours. Erythroid and myeloid precursors are decreased and show the full spectrum of maturation. Megakaryocytes are present and appear unremarkable.

PERIPHERAL BLOOD
CBC (8/1/2022):

WBC 8.2 [4.0-11.0 K/mcL] 
RBC 4.38 [3.80-5.00 M/mcL] 
HGB 12.6 [11.2-15.4 g/dL] 
HCT 38.0 [34.3-46.0 %] 
MCV 87 [80-98 fL] 
MCH 28.8 [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 13.6 [12.2-15.1 %] 
Platelets 60 L [160-400 K/mcL] 

Neutrophil 39.0 [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 28.0 H [0.0-0.0 %] 
Myelocyte 3.0 H [0.0-0.0 %] 
Metamyelocyte 3.0 H [0.0-0.0 %] 
Lymph 22.0 [12.2-47.4 %] 
Variant Lymph 1.0 [0.0-2.0 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 3.2 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 2.3 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 1.9 [0.9-3.2 K/mcL] 

Peripheral blood not submitted for review.


Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
CD34 and TDT show expanded blast population, >90% of cellularity

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-8226)
1. Abnormal immature B cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 91.6% of WBC.
Abnormal immature B cell population represents 91.2% of the mononuclear cells.
Immunophenotype: 
Abnormal: CD10 (bimodal - intermediate to bright), CD13 (partial), CD24 (bright), CD34 (uniform - dim), CD38 (dim), CD45 (variable - negative to dim), CD66c/CD123 (positive), CD73/CD304 (positive), CD81 (positive - dim), CD86 (partial), CD90 (positive) 
Normal: CD19, CD22, CD36, CD45RA, CD71, CD105, CD371 (clec12a), HLA-DR, cytoplasmic CD79a 
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD20, CD25, CD26, CD33, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, MPO, surface Kappa, surface Lambda, CD42b, CD61 

Number of cells acquired 6.5 million

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-5632.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M22-3274, M22-32275, M22-32278.
"
H22-8079;S16;MSKH - 2023-06-15 14.34.55.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Lymphoma\par Clinical Hx/Op Findings: MCL\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\fswiss\fcharset0\fprq2{\*\panose 020B0502040204020203}Segoe UI;}
{\f3\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: \~\~\par      - Involvement by mantle cell lymphoma (20-30% with CD20 immunohistochemistry)\par      - Hypercellular marrow with maturing trilineage hematopoiesis.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul COMMENT:\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  The immunophenotype of the neoplastic B-cell population is similar to that seen in prior samples and is consistent with involvement by previously diagnosed mantle cell lymphoma. Additional immunohistology to characterize the neoplastic cells is in progress and will be reported in an addendum.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy (although partially fragmented) and aspirate specimens show hypercellular for age bone marrow (~70% cellularity). There is\~trilineage maturing hematopoiesis with an atypical lymphoid infiltrate composed of interstitial aggregates of small in predominantly intermediate size atypical lymphoid cells with irregular nuclei, condensed chromatin, variably conspicuous small nucleoli, and moderate amount of pale cytoplasm. Sheets or aggregates of large cells are not seen. In the uninvolved marrow areas there is actively maturing myeloid and erythroid cells. Megakaryocytes are adequate in number with occasional forms showing nuclear hyperchromasia.\~The aspirate smears show an expanded population of atypical lymphocytes which are intermediate in size, with round to irregular nuclei, coarse chromatin, variably conspicuous small nucleoli, and moderate amount of cytoplasm. Myeloid and erythroid cells are present in various stages of maturation. The myeloid lineage shows occasional forms with nuclear hypo segmentation. Erythroid cells show occasional forms with karyorrhexis, and late stage mitoses. Megakaryocytes are seen without overt atypia.\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD20 and PAX5 show that the lymphoid aggregates are composed predominantly of the neoplastic B-cells, which account for 20-30% of the cellularity.\par CD3 highlights few T-cells admixed in the lymphoid aggregates and scattered singly interstitially.\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10536)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Interpretation:\par\par Abnormal B cell population detected. \par The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)\par\par Abnormal B cell population represents 34.6% of WBC.\par\par Immunophenotype:\par Abnormal: CD5 (positive), CD19 (dim), CD43 (partial), CD81 (dim), ROR1 (positive)\par Normal: CD20, CD38, CD40, CD45, CD79b\par Negative: CD3, CD10, CD23, CD200\par\par Number of cells acquired 792 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (09/28/2022):\par WBC 7.5 [4.0-11.0 K/mcL] \par RBC 4.39 [3.80-5.00 M/mcL] \par HGB 12.4 [11.2-15.4 g/dL] \par HCT 36.8 [34.3-46.0 %] \par MCV 84 [80-98 fL] \par MCH 28.2 [27.0-33.0 pg] \par MCHC 33.7 [31.0-36.5 g/dL] \par RDW 13.6 [12.2-15.1 %] \par Platelets 140 L [160-400 K/mcL] \par\par Neutrophil 42.7 [32.5-74.8 %] \par Mono 5.5 [0.0-12.3 %] \par Eos 1.1 [0.0-4.9 %] \par Baso 0.4 [0.0-1.5 %] \par Immature Granulocyte 0.4 [0.0-0.6 %] \par Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.\par Lymph 49.9 H [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 %] \par\par Abs Neut 3.2 [1.5-7.5 K/mcL] \par Abs Mono 0.4 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Absolute Immature 0.0 [0.0-0.1 K/mcL] \par Granulocyte\par Abs Lymph 3.7 H [0.9-3.2 K/mcL] \par\par Morphology:\par\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 WBC: Frequent atypical lymphocytes seen, which are intermediate in size, with slightly irregular and elongated nuclei, variably clumped chromatin, occasional small nucleoli, and moderate amount of pale cytoplasm.\par RBC: Normocytic, normochromic RBCs.\par Platelets: Mild thrombocytopenia with unremarkable morphology\plain\rtlch\af2\afs24\alang0\ltrch\f2\fs24\lang0\langnp0\langfe0\langfenp0\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate reports, CG22-7248, CG22-7249\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate reports, M22-41222 & M22-41223.\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-3398;S10;MSKA - 2023-04-17 07.34.38.ndpi,Peripheral Blood Smear,2023-04-17,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: per protocol
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Plasma cell neoplasm, 
10% involvement by CD138 immunohistochemistry.
3% involvement by aspirate differential
3.1% involvement by flow cytometry
     - Cellular marrow with trilineage erythroid predominant maturing hematopoiesis.


BONE MARROW BIOPSY
Quality: Adequate, hemorrhage  
Cellularity: Variable, overall 40-50%
Myeloid lineage: Left shifted maturation
Erythroid lineage: Orderly maturation   
Megakaryocytes: Adequate   
Plasma cells: Not increased 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                1%
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      5%
Monocytes           5%
Eosinophils           2%
Basophils           1%
Erythroid Precursors      50%
Plasma Cells           3%
Lymphocytes           28%
Number of Cells Counted 500
M:E Ratio           0.4

Morphology: 
Marrow spicules: Spicular 
Cellularity: Hypercellular 
Plasma cell morphology: Small to intermediate 
Myeloid lineage: Left shifted maturation   
Erythroid Lineage: Orderly maturation   
Megakaryocytes: Present 
Other findings: Mast cells

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, approximately 10% of cellularity. 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.
BCMA highlights 90% of plasma cells, (2-3+) intensity, membranous/ Golgi pattern. 
CD3 highlights scattered T cells. CD20 and PAX5 stain scattered and small clusters of B lymphoid cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-4410) 
1. Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.
Abnormal plasma cell population comprises 99.9% of total plasma cells.
Abnormal plasma cell population represents 3.1% of WBC.

Immunophenotype:
Abnormal: CD38 (dim-consistent with anti-CD38 therapy), CD19 (bimodal - negative to intermediate), CD45 (bimodal - negative to intermediate), CD56 (partial), cytoplasmic Kappa (restriction)
Normal: CD138, CD229, CD319, CD27, CD81
Negative: CD117, cytoplasmic Lambda

Number of cells acquired: 5.6 million 

2. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.
Monocytosis is seen, 11.3% of WBC.
Myeloid blast population with an unremarkable phenotype represents 0.83% of WBC.

Number of cells acquired: 448 thousand 

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (04/26/2022):
WBC 3.3 L [4.0-11.0 K/mcL] 
RBC 3.74 L [3.95-5.54 M/mcL] 
HGB 12.8 [12.5-16.2 g/dL] 
HCT 37.4 L [37.5-49.3 %] 
MCV 100 H [80-98 fL] 
MCH 34.2 H [27.0-33.0 pg] 
MCHC 34.2 [31.0-36.5 g/dL] 
RDW 14.6 [12.2-15.1 %] 
Platelets. 50 L [160-400 K/mcL] 

Neutrophil 64.2 [32.5-74.8 %] 
Mono 10.0 [0.0-12.3 %] 
Eos 6.4 H [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 10.0 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 8.8 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.1 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.3 H [0.0-0.1 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL]

Morphology: No circulating plasma cell on scanning. Thrombocytopenia. 

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-3004, CG22-3005.

MOLECULAR STUDIES 
Not submitted. 
"
H22-6602;S13;MSK5 - 2023-06-15 17.46.30.ndpi,Peripheral Blood Smear,2023-06-15,"Clinical Diagnosis: Leukemia
Clinical Hx/Op Findings: work up of relapsed disease
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Involvement by large B-cell lymphoma (20-30% by CD20 immunohistochemistry).
    - Hypercellular marrow with erythroid-predominant maturing trilineage hematopoiesis.

COMMENT: The bone marrow and the peripheral blood also show a minor component of small to intermediate sized neoplastic lymphoid cells that would be compatible with the patient's previously reported chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

BONE MARROW BIOPSY AND ASPIRATE SMEAR
Differential count:
Blasts                1%
Promyelocytes           1%
Myelocytes           4%
Metamyelocytes           3%
Neutrophils/Bands      9%
Monocytes           2%
Eosinophils           3%
Erythroid Precursors      24%
Plasma Cells           1%
Lymphocytes           10%
Atypical lymphoid cells      42% 
Number of Cells Counted 500
M:E Ratio           0.9

Morphology:
The core biopsy is adequate for assessment and shows a hypercellular marrow (90% cellularity) with an atypical nodular and interstitial infiltrate of predominantly large sized lymphoid cells with irregular nuclei, vesicular chromatin, distinct nucleoli and moderate amount of cytoplasm. In addition, there are a few admixed small to intermediate sized lymphoid cells. The background marrow shows trilineage hematopoiesis with erythroid predominance and left-shifted maturation. Megakaryocytes are adequate in number in proportion to cellularity and show mild morphologic atypia.

The aspirate smears are spicular and show partial crush artifact. There are numerous intermediate to large sized atypical lymphoid cells, some of which show plasmacytoid morphology. A small subset of cells is smaller in size. Background marrow elements show progressive maturation without significant dyspoiesis. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

PERIPHERAL BLOOD
CBC (8/11/2022):
WBC 37.2 H [4.0-11.0 K/mcL] 
RBC 2.03 L [3.80-5.00 M/mcL] 
HGB 6.9 L [11.2-15.4 g/dL] 
HCT 21.2 L [34.3-46.0 %] 
MCV 104 H [80-98 fL] 
MCH 34.0 H [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 16.8 H [12.2-15.1 %] 
Platelets 34 L [160-400 K/mcL] 

Neutrophil 21.0 L [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 18.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 55.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 7.8 H [1.5-7.5 K/mcL] 
Abs Mono 1.9 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 27.1 H [0.9-3.2 K/mcL] 

Morphology:
WBC: Leukocytosis with marked lymphocytosis including numerous large markedly atypical lymphoid cells with variably convoluted nuclei and some small to intermediate sized lymphoid cells.
RBC: Macrocytic anemia with mild anisopoikilocytosis.
PLT: Thrombocytopenia.

Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD20 (20-30% of cellularity), PAX5, CD5, CD23 (weak)
Others: CD3 highlights admixed T-cells.
Additional immunostains are in progress and will be reported in an addendum.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-8666)
Abnormal B-cell population with larger size detected.
The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.

Abnormal B cell population represents 63.1% of WBC.
Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (partial), CD43 (positive), CD79b (dim), CD200 (bright), ROR1 (positive), CD19 (dim), CD38 (variable - negative to intermediate), surface Kappa (restriction), CD25 (partial), Forward Scatter (increased), Side Scatter (increased)
Normal: CD81, CD40, CD45
Negative: CD10, CD3, surface Lambda, CD14, CD279 (PD1)

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-8606)
Abnormal B-cell population detected. 
A portion of the population shows increased forward and side scatter suggestive of larger size.
Flow cytometry reveals an abnormal B-cell population with CLL/SLL-like immunophenotype (see below).
Abnormal B cell population represents 69.4% of WBC.
Concentration of Abnormal population in peripheral blood is 21.44 thousand/microliter.

Immunophenotype:
Abnormal: CD5 (positive), CD20 (variable - negative to intermediate), CD23 (variable - negative to bright), CD79b (variable - dim to negative), CD81 (dim), CD200 (bright), ROR1 (variable - bright to negative), CD38 (bright), Forward Scatter (increased), Side Scatter (increased)
Normal: CD19, CD40, CD45
Negative: CD43, CD10, CD3
Number of cells acquired 950 thousand

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-5967.
"
H22-7985;S16;MSKC - 2023-06-15 14.17.40.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\par Clinical Diagnosis: Breast, Malignant Neoplasm\par Clinical Hx/Op Findings: widely metastatic breast cancer to the bones with progressive pancytopenia on Abemaciclib. On G-CSF bi weekly.\par Requested Studies: Gross/Micro\par Additional Studies: Immunostains for Breast Cancer\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff0\adeff0\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;\red255\green255\blue255;\red255\green255\blue0;\red0\green255\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}{\s17\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\cbpat0\rtlch\af0\afs18\ltrch\f0\fs18\sbasedon16 CoPath Text;}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b 1-3. Bone marrow\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\cb2\chshdng0\chcfpat0\chcbpat2 , right post iliac crest, biopsy; aspirate and peripheral blood smears: \~\~\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033     - Metastatic adenocarcinoma, morphologically compatible with mammary origin, see comment\par     - Scant background hematopoiesis, no definitive evidence of a myeloid neoplasms.\par\par Comment: The tumor is morphologically similar to the prior bone metastasis (S20-72240). The patient's history of treated breast adenocarcinoma and subsequent cytopenias is noted. Flow cytometry has detected a small abnormal myeloid blast population, however, the current bone marrow biopsy  and touch imprints are extremely limited for morphologic assessment of bone marrow elements. While the patient's cytopenias are likely due to the patient's metastatic carcinoma, the presence of the abnormal myeloid blast population by flow cytometry raises the possibility of a myeloid neoplasm or clonal hematopoiesis. Full assessment is not possible due to the lack of evaluable bone marrow elements. Correlation of these findings with concurrent molecular studies is recommended. Dr. Hanna (Breast pathologist) has reviewed this case and agrees with the above findings.      \par\pard\ltrpar\s17\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\par Immunohistochemical stains were performed on formalin-fixed tissue with the following results:\par\par GATA-3: Positive\par CK7: Negative\par ESTROGEN RECEPTOR (clone 6F11, Leica): Negative (0% nuclear staining)\par PROGESTERONE RECEPTOR (clone 16; Leica): Negative (0% nuclear staining)\par HER2 (4B5, Ventana): Negative (1+)  \par\plain\rtlch\af0\afs18\alang1033\ab\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\par\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 The decalcification procedure may affect the antigenicity of the tissue. Reduced or negative immunohistochemical results may be artifactual. Clinical correlation is recommended. \par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone marrow biopsy is diffusely involved by malignant cells with associated peritumoral fibrosis with little background hematopoietic elements. \par\par Special stains: \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 Reticulin stain is not interpreted due the presence of malignant cells and associated peritumoral fibrosis \plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW TOUCH SMEAR\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Bone Marrow Touch Smear Quality:  Inadequate, hypocellular, devoid of spicules \par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb2\chshdng0\chcfpat0\chcbpat2 Differential count and Iron stain not performed, touch imprints are acellular.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Extrinsic cells: present singly / clusters\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb3\chshdng0\chcfpat0\chcbpat3\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cb4\chshdng0\chcfpat0\chcbpat4\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 Morphology:\par -Aspicular and hypocellular touch imprints show clusters of malignant cells with scant background hematopoietic elements present. \par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul\par PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (9/26/2022):\par WBC 2.8 L [4.0-11.0 K/mcL] \par RBC 3.22 L [3.80-5.00 M/mcL] \par HGB 9.8 L [11.2-15.4 g/dL] \par HCT 29.7 L [34.3-46.0 %] \par MCV 92 [80-98 fL] \par MCH 30.4 [27.0-33.0 pg] \par MCHC 33.0 [31.0-36.5 g/dL] \par RDW 16.9 H [12.2-15.1 %] \par Platelets. 33 L [160-400 K/mcL] \par\par Neutrophil 61.0 [32.5-74.8 %] \par Mono 6.0 [0.0-12.3 %] \par Eos 1.0 [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Myelocyte 3.0 H [0.0-0.0 %] \par Promyelocyte 1.0 H [0.0-0.0 %] \par Metamyelocyte 2.0 H [0.0-0.0 %] \par Lymph 25.0 [12.2-47.4 %] \par Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] \par\par Abs Neut 1.7 [1.5-7.5 K/mcL] \par Abs Mono 0.2 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] \par Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] \par Abs Meta 0.1 H [0.0-0.0 K/mcL] \par Abs Lymph 0.7 L [0.9-3.2 K/mcL]\par\par Morphology:\par\plain\rtlch\af0\afs18\alang1033\acf1\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\cf1 WBC: Leukopenia with lymphopenia. No circulating blasts seen.\par RBC: Mild normocytic anemia. \par PLT: Moderate thrombocytopenia. \plain\rtlch\af0\afs14\alang1033\acf1\ltrch\f0\fs14\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1\par Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CD34 and CD117 highlight rare blasts comprising less than 5% of the total cellularity.\par CD61 demonstrates absence of megakaryocytes \par CD71 demonstrates absence of erythroid precursors. \par MPO demonstrates absence of myeloid precursors.\par\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-10432)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Interpretation:\par\par Abnormal myeloid blast population detected.\par\par Abnormal myeloid blast population represents 0.22% of WBC.\par\par Immunophenotype:\par Abnormal: CD13 (bright), CD33 (dim), CD38 (dim), HLA-DR (bright)\par Normal: CD4, CD34, CD36, CD45, CD45RA, CD71, CD105, CD117, CD123, CD371 (clec12a)\par Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda, CD42b, CD90\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-7153\par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-40709\plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H22-431;S12;MSKO - 2023-05-26 15.32.09.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Myelodysplastic Syndrome
Clinical Hx/Op Findings: Cytopenias
","1-3. Bone marrow, right posterior iliac crest, biopsy; and aspirate smears: 
     - Involvement by Burkitt lymphoma (involvement 90% of cellularity by CD20 immunostain) 
     - Normocellular marrow with trilineage maturing hematopoiesis.
  
Comment: Dr. Johnson notified on 01/25/2022 at 10: 58 AM

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Normocellular for age (30% cellularity)
M:E ratio: difficult to assess on the limited background hematopoiesis. 
Blasts: Not increased.
Myeloid lineage: Reduced
Erythroid lineage: Reduced
Megakaryocytes: Reduced
Lymphocytes: Diffuse sheets of intermediate sized lymphoid cells with round nuclei, condensed but evenly distributed chromatin, and occasional nucleoli. 
Plasma cells: Not increased. 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis. 


The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules
The differential cell count was performed on touch imprints and aspirate smear.

Promyelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      11%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      7%
Lymphocytes           1%
Abnormal Lymphoid Cells      77%
Number of Cells Counted      500
M:E Ratio           N/A

Special stain
Iron: suboptimal for evaluation, devoid of spicules
Ring sideroblasts: Absent 

Morphology:
-Touch imprints show scattered erythroid precursors and rare myeloid precursors. Megakaryocytes are not readily seen. A predominant lymphoid population of intermediate to large-sized lymphoid cells with round nuclei, condensed but evenly distributed chromatin, occasional nucleoli is seen, basophilic chromatin and cytoplasmic vacuoles.


PERIPHERAL BLOOD
CBC (01/18/2022):
WBC 15.9 H [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 3.01 L [3.80-5.00 M/mcL] 
HGB 8.9 L [11.2-15.4 g/dL] 
HCT 26.4 L [34.3-46.0 %] 
MCV 88 [80-98 fL] 
MCH 29.6 [27.0-33.0 pg] 
MCHC 33.7 [31.0-36.5 g/dL] 
RDW 16.9 H [12.2-15.1 %] 
Platelets 72 L [160-400 K/mcL] 

Neutrophil 59.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 14.0 H [0.0-0.0 %] 
Myelocyte 3.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 3.0 H [0.0-0.0 %] 
Lymph 17.0 [12.2-47.4 %] 
Nucleated RBC 27.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 9.4 H [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abnormal lymphocytes 2.2 H [0.0-0.0 K/mcL]  
Abs Myelocytes 0.5 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.5 H [0.0-0.0 K/mcL] 
Abs Lymph 2.7 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: lymphoid population of intermediate to large-sized lymphoid cells with round nuclei, condensed but evenly distributed chromatin, and occasional nucleoli is seen.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
The neoplastic  cells
Express: CD20, MUM1, CD10, CD23 (subset), CD38, LEF1,
Don't express: CD3, CD5, BCL2, BCL6, CD21, IgD, LMO2, CyclinD1, TdT, CD34, CD117
Ki-67 proliferation index is >90%. 
CD34, CD117, and TdT highlights only rare immature precursors.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-544)
1. Abnormal B cell population detected.

Abnormal B cell population represents 52.7% of WBC.

Immunophenotype:
Abnormal: CD10 (positive - dim), CD19 (slightly dim), CD20 (bright), CD22 (dim), CD38 (bright), surface Kappa (restriction), Forward Scatter (increased), Side Scatter (increased)
Normal: CD45
Negative: CD5, CD25, CD279 (PD1), CD3, CD14, surface Lambda

In addition, the abnormal B cell population expresses:

Abnormal: CD86
Normal: CD81, CD24
Negative: CD34, CD66b, CD66c/CD123, CD73/CD304

2. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                                                                                
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.31% of WBC.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.
 
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-347.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-2385.
"
H22-786;S11;MSK- - 2023-05-31 21.38.34.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: myelofibrosis
Clinical Hx/Op Findings: Leukocytosis / Thrombocytosis
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate, and peripheral blood smears: 
     - Persistent MDS/MPN with ring sideroblasts and thrombocytosis, now with marked fibrosis   

COMMENT:
Stain for ring sideroblasts will be reported in addendum, however, it would not change the diagnosis 
BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Increased (80-90%)
M:E ratio: Appears mildly increased
Blasts: No increase
Myeloid lineage: Full maturation 
Erythroid lineage: Full maturation 
Megakaryocytes: Increased in number, with many atypical, mostly larger forms, forming loose clustres 
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows marked increase in reticulin fibrosis (MF-3). 


The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules

Blasts                1%
Myelocytes           2%
Metamyelocytes           5%
Neutrophils/Bands      61%
Monocytes           2%
Eosinophils           1%
Basophils           2%
Erythroid Precursors      22%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           3.3

Morphology:
-Spicular and cellular with trilineage hematopoiesis, erythroid dysplasia (nuclear budding) and no increase in blasts. Increased atypical megakaryocytes are noted

PERIPHERAL BLOOD
CBC (1/27/2022):

WBC 24.8 H [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 2.90 L [3.80-5.00 M/mcL] 
HGB 7.9 L [11.2-15.4 g/dL] 
HCT 26.2 L [34.3-46.0 %] 
MCV 90 [80-98 fL] 
MCH 27.2 [27.0-33.0 pg] 
MCHC 30.2 L [31.0-36.5 g/dL] 
RDW 25.2 H [12.2-15.1 %] 
Platelets 1031 H [160-400 K/mcL] 

Neutrophil 80.0 H [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 
Metamyelocyte 7.0 H [0.0-0.0 %] 
Lymph 2.0 L [12.2-47.4 %] 
Nucleated RBC 31.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 19.9 H [1.5-7.5 K/mcL] 
Abs Mono 0.7 [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.0 H [0.0-0.7 K/mcL] 
Absolute Basophil 1.0 H [0.0-0.2 K/mcL] 
Abs Meta 1.7 H [0.0-0.0 K/mcL] 
Abs Lymph 0.5 L [0.9-3.2 K/mcL] 

Morphology: Leukoerythroblastosis with thrombocytosis. No increased blasts noted.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 do not show an increase in blasts 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-974)
1. Abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 1.8% of WBC.

Immunophenotype:
Abnormal: CD7 (partial), CD13 (variable - negative to dim), CD34 (uniform - bright), CD38 (variable - negative to intermediate), HLA-DR (uniform - intermediate)
Normal: CD4, CD33, CD36, CD45, CD45RA, CD71, CD105, CD117, CD123, CD371 (clec12a)
Negative: CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda

Number of cells acquired: 568 thousand 

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG22-613.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-3959.
"
H22-741;S10;MSK- - 2023-05-26 15.37.48.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: Lymphoma, Follicular
Requested Studies: Gross/Micro
Clinical Hx/Op Findings: FL, c/f POD
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Extensive involvement by the patient's previously diagnosed follicular lymphoma (~90% with CD20 immunohistochemistry).
     - Hypercellular marrow with focal maturing trilineage hematopoiesis. See comment.

COMMENT:
There is no definitive morphologic evidence of involvement by metastatic carcinoma; however, additional immunostains (pancytokeratin and Cam5.2) have been requested, and the findings will be reported in an addendum.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
An adequate biopsy specimen and cellular touch preparations show hypercellular bone marrow (~95% cellularity). The marrow is largely replaced by small to medium sized atypical lymphocytes that have mildly irregular nuclear contours and mature chromatin. A few vaguely nodular areas contain scattered large lymphocytes, but sheets of large lymphocytes are not seen. There are scattered foci of trilineage hematopoiesis, which show progressive maturation of the myeloid and erythroid lineages as well as scattered morphologically unremarkable megakaryocytes.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 and Pax-5 highlight the atypical lymphocytes (~90% of the cellularity).
CD3 marks scattered background T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW CORE TISSUE (F22-931) 
1. Abnormal B cell population detected.

Abnormal B cell population represents 88.0% of WBC.

Immunophenotype:
Abnormal: CD10 (partial), CD19 (dim), CD20 (dim), surface Lambda (restriction), Forward Scatter (partially increased), Side Scatter (partially increased)
Normal: CD22, CD45
Negative: CD5, CD38, CD25, CD279 (PD1), CD3, CD14, surface Kappa


2. No abnormal mature T cell population detected.
No immunophenotypic evidence of T-cell lymphoma is identified.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F22-898) 
Abnormal B cell population detected.

Abnormal B cell population represents 21.9% of WBC.

Immunophenotype:
Abnormal: CD10 (partial - dim), CD19 (dim), CD22 (variable - dim to intermediate), surface Lambda (restriction)
Normal: CD20, CD45
Negative: CD5, CD38, CD25, CD279 (PD1), CD3, CD14, surface Kappa

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (01/26/2022):
WBC 3.1 L [4.0-11.0 K/mcL] 
RBC 3.35 L [3.80-5.00 M/mcL] 
HGB 9.7 L [11.2-15.4 g/dL] 
HCT 30.3 L [34.3-46.0 %] 
MCV 90 [80-98 fL] 
MCH 29.0 [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 17.3 H [12.2-15.1 %] 
Platelets 16 L [160-400 K/mcL] 

Neutrophil 28.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 53.0 H [12.2-47.4 %] 
Abnormal Lymphoid Cells 17.0 H [0.0-0.0 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 2.1 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Leukopenia. Occasional atypical lymphocytes are seen, some of which are relatively large.
RBC: Normochromic anemia with anisocytosis.
Platelets: Thrombocytopenia

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis not requested.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-3652.

"
H22-10251;S13;MSK- - 2023-06-15 10.32.43.ndpi,Peripheral Blood Smear,2023-06-15,"{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0 Clinical Diagnosis: hairy cell leukemia\par Clinical Hx/Op Findings: HCL + MGUS\par Requested Studies: Gross/Micro\par\par }","{\rtf1\ansi\ansicpg1252\uc1\deff1\adeff1\deflang0\deflangfe0\adeflang0{\fonttbl
{\f0\fswiss\fcharset0\fprq2{\*\panose 020B0604020202020204}Arial;}
{\f1\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\f2\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}}
{\colortbl;\red0\green0\blue0;}
{\stylesheet{\s0\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af1\afs20\ltrch\f1\fs20 Normal;}{\*\cs10\additive Default Paragraph Font;}{\s16\ltrpar\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\cbpat0\rtlch\af0\afs24\ltrch\f0\fs24 [Normal];}}
{\info
{\*\txInfo{\txVer 25.0.720.500}}}
\paperw12240\paperh15840\margl1080\margt1440\margr720\margb1440\deftab1134\widowctrl\lytexcttp\formshade\sectd
\headery567\footery567\pgwsxn12240\pghsxn16838\marglsxn1080\margtsxn1134\margrsxn720\margbsxn1134\pgbrdropt32\pard\ltrpar\itap0\widctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033 1-3. Bone marrow, right posterior iliac crest,  biopsy, aspirate and peripheral blood smears: \~\~\par      - Involvement by hairy cell leukemia (10-20% with CD20 immunohistochemistry)\par      - Minimal involvement by plasma cell neoplasm (<5% by CD138 immunohistochemistry stain, 0.15% of WBC by flow cytometry study)  \par      - Hypocellular marrow with trilineage maturing hematopoiesis, see note. \par\par Note: The patient's history of persistent neutropenia and anemia is noted. The bone marrow biopsy appears hypocellular, and reduced hematopoiesis is observed, although the sampling bias cannot be entirely ruled out. The inadequate aspirate specimen limits morphologic evaluation for dysplasia.  The etiology of cytopenia is not clear. Reactive causes including but not limited to infections, medication, toxicity, nutrition deficiencies, autoimmune etiologies, peripheral consumption should be excluded. Evolving hypocellular myelodysplastic syndromes and aplastic anemia are also on the differential diagnosis list. Correlation with forthcoming cytogenetic and molecular studies is recommended.\par\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Adequate biopsy specimen shows hypocellular bone marrow (variable 5-20%, overall 10% cellularity). There is\~trilineage maturing hematopoiesis with mildly increased numbers of interstitial infiltrating lymphocytes with small to intermediate size, irregular nuclei and intermediate amount of cytoplasm. There is no overt increase of plasma cells. The aspirate smear is inadequate/aspicular. \par\~\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.\plain\rtlch\af0\afs16\alang1033\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul IMMUNOHISTOCHEMISTRY\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par The neoplastic cells of hairy cell leukemia \par Express: CD20, BRAF, CD103\par Do not express: CD3\par Other: CD3 highlights scattered T cells. CD138 and BCMA highlights scattered plasma cells (<5% of total cellularity) with no definitive light chain restriction by kappa/lambda light chain stains.  \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F22-13323)\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par 1. Abnormal B cell population detected.\par The immunophenotype of the abnormal B-cell is consistent with involvement by hairy cell leukemia (HCL).\par\par Abnormal B cell population represents 3.1% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (bright), CD20 (bright), CD22 (bright), CD25 (positive), CD11c (positive), CD103 (positive), CD200 (bright), surface Lambda (restriction), Forward Scatter (increased), Side Scatter (increased)\par Normal: CD45\par Negative: CD5, CD10, CD38, CD279 (PD1), CD3, CD14, surface Kappa\par\par Number of cells acquired: 182 thousand \par\par 2. Abnormal plasma cell population detected.  \par Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.\par\par Abnormal plasma cell population comprises 81.9% of total plasma cells.\par Abnormal plasma cell population represents 0.15% of WBC.\par\par Immunophenotype:\par Abnormal: CD19 (negative), CD27 (dim), CD45 (negative), CD81 (bimodal - negative to intermediate), CD117 (positive), cytoplasmic Kappa (restriction)\par Normal: CD138, CD38, CD229, CD319\par Negative: CD56, cytoplasmic Lambda\par\par Number of cells acquired: 1.6 million \par\par 3. Atypical T cell population detected. \par There is no definite immunophenotypic evidence of abnormal T cell population detected by flow cytometry. However, there is a T cell population with mild abnormalities seen (see below). The clinical significance of this population is not entirely clear. Correlation with additional studies (morphologic, cytogenetic, and molecular) is advised.\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\par\par Atypical T cell population represents 0.59% of WBC.\par\par Immunophenotype:\par Atypical: CD5 (dim), CD7 (negative), CD26 (uniform - bright), CD56 (bimodal - dim to intermediate), TCRCbeta1 (restriction - monotypic negative)\par Normal: CD2, CD3, CD4, CD45\par Negative: CD8, CD10, CD14, CD25, CD38, CD279 (PD1), TCR gamma/delta\par\par Number of cells acquired 198 thousand \par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul PERIPHERAL BLOOD\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par CBC (12/06/2022):\par WBC 1.6 L [4.0-11.0 K/mcL] \par RBC 3.98 [3.95-5.54 M/mcL] \par HGB 10.8 L [12.5-16.2 g/dL] \par HCT 34.0 L [37.5-49.3 %] \par MCV 85 [80-98 fL] \par MCH 27.1 [27.0-33.0 pg] \par MCHC 31.8 [31.0-36.5 g/dL] \par RDW 14.9 [12.2-15.1 %] \par Platelets 177 [160-400 K/mcL] \par\par Neutrophil 67.0 [32.5-74.8 %] \par Mono 4.0 [0.0-12.3 %] \par Eos 5.0 H [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Lymph 23.0 [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par\par Abs Neut 1.1 L [1.5-7.5 K/mcL] \par Abs Mono 0.1 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Lymph 0.4 L [0.9-3.2 K/mcL] \par\par Morphology:\par WBC: Mild leukopenia\par RBC: Normocytic anemia.\par PLT: Unremarkable.\par\par\plain\rtlch\af0\afs16\alang1033\acf1\ltrch\f0\fs16\lang1033\langnp1033\langfe1033\langfenp1033\cf1 Peripheral Blood Analysis performed at the MSKCC Main Hospital Rapid Results Laboratory, 1275 York Ave. New York, NY 10065; Dr. Lauren McVoy, MD PhD, Director CLIA: 33D2127929\plain\rtlch\af1\afs20\alang1033\ltrch\f1\fs20\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul CYTOGENETIC STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\par Cytogenetic analysis will be reported separately. See separate report, CG22-9215, CG22-9216 and CG22-9302. \par\~\par\plain\rtlch\af0\afs18\alang1033\ab\aul\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033\b\ul MOLECULAR STUDIES\plain\rtlch\af0\afs18\alang1033\ltrch\f0\fs18\lang1033\langnp1033\langfe1033\langfenp1033  \par Molecular analysis will be reported separately. See separate report, M22-52874 and M22-52876. \plain\rtlch\af1\afs18\alang0\ltrch\f1\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\sl180\slmult0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7938\tx9072\tx10080\tx10800\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0{\txfielddef{\*\txfieldstart\txfieldtype0\txfieldflags3}{\*\txfieldtext \par {\*\txfieldend}}\par }\pard\ltrpar\s16\itap0\nowidctlpar\ql\li0\ri0\lin0\rin0\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\plain\rtlch\af0\afs18\alang0\ltrch\f0\fs18\lang0\langnp0\langfe0\langfenp0\loch\af0\dbch\af0\hich\f0\u8204 ?\par\par }"
H21-6822;S12;MSKX - 2023-05-19 18.44.43.ndpi,Peripheral Blood Smear,2023-05-19,"Lymphoma, Mantle Cell 
Relapsed Disease
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by mantle cell lymphoma (30% with CD20 immunohistochemistry)
     - Hypercellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show hypercellular bone marrow (~80% cellularity). There istrilineage maturing hematopoiesis with increased numbers of small lymphocytes with round to slightly irregular nuclei, condensed chromatin and inconspicuous nuclei forming sheets. No increase in large cells noted.

Bone Marrow Aspirate Smear Quality: Adequate
Blasts                1%
Promyelocytes           1%
Myelocytes           12%
Metamyelocytes           2%
Neutrophils/Bands      30%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      29%
Plasma Cells           1%
Lymphocytes           20%
Number of Cells Counted      500
M:E Ratio           1.7

IMMUNOHISTOCHEMISTRY
CD20 immunostain demonstrate that the large lymphoid aggregates are composed of small B-cells (30% of cellularity) with coexpression of CD5 and cyclin D1 (weak). SOX11 is essentially negative. CD3 highlights small T-cells in the background.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-9016) 
Abnormal B cell population detected. 
The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)

Abnormal B cell population represents 21.1% of WBC

Immunophenotype:
Abnormal: CD5 (variable - negative, bright), CD23 (partial), CD200 (negative), ROR1 (partial)
Normal: CD20, CD79b, CD81, CD19, CD40, CD45, CD38
Negative: CD43, CD10, CD3

Number of cells acquired: 477 thousand  

PERIPHERAL BLOOD
CBC (9/16/2021)
WBC 6.1 [4.0-11.0 K/mcL] 
RBC 4.45 [3.95-5.54 M/mcL] 
HGB 12.8 [12.5-16.2 g/dL] 
HCT 38.6 [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 28.8 [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 12.9 [12.2-15.1 %] 
Platelets 192 [160-400 K/mcL] 

Neutrophil 71.6 [32.5-74.8 %] 
Mono 9.2 [0.0-12.3 %] 
Eos 0.7 [0.0-4.9 %] 
Baso 0.5 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 17.5 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 4.4 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.1 [0.9-3.2 K/mcL]

Morphology:
WBC: No atypical cells identified.
RBC: Normochromic normocytic
Platelets: Morphologically unremarkable

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5927, CG21-5928.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-358167, M21-38177.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-9398;S10;MSKF - 2023-06-01 06.28.01.ndpi,Peripheral Blood Smear,2023-06-01,"Clinical Diagnosis: Lymphoma
Clinical Hx/Op Findings: pt with MZL, progression
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Extensive involvement by low grade B-cell lymphoma, consistent with the patient's known marginal zone lymphoma, 85-90% involvement with CD20/PAX5 immunohistochemistry.      

COMMENT: Aspirate smears are hemodiluted; therefore, flow cytometry is likely underestimating the abnormal B-cell population. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Small and focally fragmented biopsy shows hypercellular bone marrow for age (60-70% cellularity) with expanded atypical lymphoid population, replacing marrow cellularity. Backgroundtrilineage maturing hematopoiesis is markedly suppressed. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight marked increase in B-cells, comprising 85-90% of marrow cellularity, replacing marrow elements.  
CD3 highlights scattered reactive T-cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-12483) 
Interpretation: 
1. Abnormal B cell population detected.

Abnormal B cell population represents 13.2% of WBC.
Immunophenotype:
Abnormal: CD19 (slightly dim), CD20 (dim), CD22 (dim), surface Lambda (restriction)
Normal: CD38, CD45
Negative: CD5, CD10, CD25, CD279 (PD1), CD3, CD14, surface Kappa

Number of cells acquired: 434 thousand  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (12/15/2021):
WBC 5.7 [4.0-11.0 K/mcL] 
RBC 2.82 L [3.95-5.54 M/mcL] 
HGB 8.7 L [12.5-16.2 g/dL] 
HCT 27.2 L [37.5-49.3 %] 
MCV 97 [80-98 fL] 
MCH 30.9 [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 14.3 [12.2-15.1 %] 
Platelets 137 L [160-400 K/mcL] 

Neutrophil 72.5 [32.5-74.8 %] 
Mono 10.2 [0.0-12.3 %] 
Eos 1.1 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 1.2 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 14.6 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 4.1 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 

Morphology: WBCs, RBCs and platelets are morphologically unremarkable. Lymphocytes are not increased. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

CYTOGENETIC STUDIES
Not submitted. 

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-52134.

"
H21-3682;S12;MSKY - 2023-05-27 02.34.35.ndpi,Peripheral Blood Smear,2023-05-27,"MDS.  Paraspinal masses. 
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Myeloid neoplasm, consistent with myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD), 3% blast, see comment. 
  
COMMENT: Although thrombocytopenia is not seen, dysmegakaryopoiesis is more prominent in this biopsy than that seen in the patient's previous bone marrow biopsy (MSK Path ID: H21-2005). Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is still considered as differential diagnosis, reported CBC and morphologic findings support the diagnosis of MDS-RS-MLD (MDS/MPN-RS-T requires persistent thrombocytosis =450k/ul) . 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: 90-95% 
M:E ratio: Normal 
Blasts: not increased 
Myeloid lineage: Left-shifted maturation 
Erythroid lineage: Left-shifted maturation 
Megakaryocytes: Increased. Many small monolobated forms present. 
Lymphocytes: Not increased 
Plasma cells: Not increased 
Special stains: Reticulin stain shows no increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate.

Blasts                3%
Promyelocytes           6%
Myelocytes           16%
Metamyelocytes           9%
Neutrophils/Bands      20%
Monocytes           1%
Eosinophils           5%
Basophils           1%
Erythroid Precursors      35%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           1.7

Special stain 
Iron: Increased
Ring sideroblasts: Present >15% 

Morphology:
Spicular and hypercellular smears show trilineage hematopoiesis with no increase in blasts. Myeloid and erythroid maturation is left-shifted. Many dysplastic megakaryocytes with separated nuclear lobation and small forms with nuclear monolobation are present. 

PERIPHERAL BLOOD
CBC (05/24/2021):
WBC 8.1 [4.0-11.0 K/mcL] 
RBC 2.94 L [3.95-5.54 M/mcL] 
HGB 9.1 L [12.5-16.2 g/dL] 
HCT 29.2 L [37.5-49.3 %] 
MCV 99 H [80-98 fL] 
MCH 31.0 [27.0-33.0 pg] 
MCHC 31.2 [31.0-36.5 g/dL] 
RDW 25.2 H [12.2-15.1 %] 
Platelets 215 [160-400 K/mcL] 

Neutrophil 89.0 H [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 4.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 7.2 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: Circulating immature myeloid cells and few nucleated RBC are present. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts.
CD71 highlights erythroid precursors.
CD61 and FVIII are in progress and the results will be reported as an addendum.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-4935)
Interpretation: 
Abnormal myeloid blast population detected.
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.
No abnormal plasma cell population detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD5 (subset), CD7 (partial), CD13 (absent to intermediate), CD34 (dim to bright), CD38 (dim to intermediate), CD117 (bright) with normal expression of CD4, CD33, CD45, CD71, CD123 and HLA-DR without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 2.3% of WBC.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD20 (slightly dim), CD22 (dim), CD38 (absent), kappa light chain restriction, and normal expression of CD19, and CD45; and without CD3, CD5, CD10, CD14, CD25, or CD279 (PD1). The abnormal B-cell population represents 0.029% of the total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

No evidence of an abnormal plasma cell population is identified by flow cytometry. Plasma cells comprise 0.041% of the viable cells, following erythroid lysis.
5.4 million cells acquired.  Please note that flow cytometry studies generally underestimate the number of plasma cells, as compared to morphologic assessment.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3228.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-21015, M21-21016, M21-21017.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-8227;S11;MSKX - 2023-04-19 17.07.01.ndpi,Peripheral Blood Smear,2023-04-19,"Clinical Diagnosis: CML
Clinical Hx/Op Findings: CML untreated
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Chronic myeloid leukemia (CML); see comment.             

COMMENT: The overall morphologic findings of the biopsy (markedly hypercellular marrow with left shifted myeloid hyperplasia and atypical megakaryocytic hyperplasia without additional dysplasia) and peripheral blood granulocytosis, basophilia (<20% of WBC), and without significant increase in blasts (<10%) in either bone marrow or peripheral blood in the setting of documented t(9;22)(q34.1;q11.2) and BCR-ABL fusion demonstrated by (FISH; CG21-7022 and molecular genetic analysis; M21-44987) are consistent with diagnosis above.

Please note that the diagnosis of Chronic phase requires exclusion of trisomy 8, isochromosome 17q, trisomy 19, complex karyotype and abnormalities of 3q26.2. Presence of any of the factors listed would be diagnostic for accelerated phase CML. Correlation with forthcoming molecular and cytogenetic results is recommeded.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular (>95% cellularity)
M:E ratio: Increased
Blasts: Not increased
Myeloid lineage: Full maturation with myeloid hyperplasia and expansion of early maturing forms in paratrabecular areas
Erythroid lineage: Full maturation, hypoplastic
Megakaryocytes: Increased, with frequent small hypolobated (dwarf) forms 
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows mild focal increase in reticulin fibrosis (MF0-1+/3). 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                1%
Promyelocytes           2%
Myelocytes           17%
Metamyelocytes           15%
Neutrophils/Bands      41%
Monocytes           1%
Eosinophils           4%
Basophils           1%
Erythroid Precursors      14%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           5.8 

Morphology:
- Spicular and hypercellular smears show trilineage hematopoiesis with increased M:E ratio, mildly left shifted myeloid maturation, reduced erythroid elements, no increase in blasts, mildly increased basophils and eosinophils and mildly increased megakaryocytes with small and hypolobated forms.

PERIPHERAL BLOOD
CBC (11/05/2021):
WBC 57.3 H [4.0-11.0 K/mcL] 
RBC 4.42 [3.95-5.54 M/mcL] 
HGB 13.9 [12.5-16.2 g/dL] 
HCT 44.6 [37.5-49.3 %] 
MCV 101 H [80-98 fL] 
MCH 31.4 [27.0-33.0 pg] 
MCHC 31.2 [31.0-36.5 g/dL] 
RDW 15.6 H [12.2-15.1 %] 
Platelets 307 [160-400 K/mcL] 

Neutrophil 62.0 [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 7.0 H [0.0-1.5 %] 
Myelocyte 7.0 H [0.0-0.0 %] 
Metamyelocyte 6.0 H [0.0-0.0 %] 
Lymph 12.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 35.5 H [1.5-7.5 K/mcL] 
Abs Mono 1.7 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.7 H [0.0-0.7 K/mcL] 
Absolute Basophil 4.0 H [0.0-0.2 K/mcL] 
Abs Myelocytes 4.0 H [0.0-0.0 K/mcL] 
Abs Meta 3.4 H [0.0-0.0 K/mcL] 
Abs Lymph 6.9 H [0.9-3.2 K/mcL] 

Morphology:
WBC: Leukocytosis, left shifted myeloid elements, basophilia, and no increase in circulating blasts
RBC: Macrocytic RBC, polychromasia is seen
PLT: Occasional large forms are seen.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts (<5% of cellularity)
CD117 highlights left shifted early myeloid/erythroid elements and rare scattered mast cells. 
CD61 highlights increased megakaryocytes with frequent small hypolobated forms 
CD71 and MPO highlight erythroid and myeloid elements respectively. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-10947)
1. Abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 1.6% of WBC.
Basophilia is seen, 1.9% of WBC.

Immunophenotype:
Abnormal: CD7 (bimodal - negative, dim), CD11b (bimodal - negative, dim), CD34 (uniform - dim), CD56 (bimodal - negative, intermediate), CD123 (dim), HLA-DR (uniform - intermediate)
Normal: CD4, CD13, CD33, CD38, CD45, CD71, CD117
Negative: CD2, CD3, CD5, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD64, surface Kappa, surface Lambda

Number of cells acquired: 369 thousand  

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 397 thousand  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-7183.

MOLECULAR STUDIES 
Molecular analysis, peripheral blood specimen. See separate report, M21-44987
"
H21-4102;S11;MSKV - 2023-05-19 22.19.12.ndpi,Peripheral Blood Smear,2023-05-19,"ALL, no remission
New dx of B-ALL 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma (91% blasts by touch imprint)

BONE MARROW BIOPSY
Quality: adequate 
Cellularity: >90% 
The marrow is entirely replaced by sheets of leukemic blasts. Normal hematopoietic elements are markedly reduced. 
Clot section: blood clot only 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Devoid of spicules

Blasts                91%
Myelocytes           1%
Neutrophils/Bands      1%
Erythroid Precursors      3%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           0.7

Morphology:
Touch imprint shows numerous blasts that are medium in size and have high N:C ratio, and pale chromatin. 

PERIPHERAL BLOOD
CBC (06/08/2021):

WBC 32.7 H [4.0-11.0 K/mcL] 
RBC 3.32 L [3.95-5.54 M/mcL] 
HGB 9.7 L [12.5-16.2 g/dL] 
HCT 29.7 L [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 29.2 [27.0-33.0 pg] 
MCHC 32.7 [31.0-36.5 g/dL] 
RDW 17.8 H [12.2-15.1 %] 
Platelets. 91 L [160-400 K/mcL] 

Neutrophil 3.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 85.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 8.0 L [12.2-47.4 %] 
Nucleated RBC 2.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.7 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 27.8 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.3 H [0.0-0.0 K/mcL] 
Abs Meta 0.3 H [0.0-0.0 K/mcL] 
Abs Lymph 2.6 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: numerous blasts. 


IMMUNOHISTOCHEMISTRY
CD34 and TdT stain many blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5458)
Abnormal immature B-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature B- or T-cell populations detected.

The presence of greater than 20% abnormal immature B-cells in the bone marrow (92.7% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD2, CD10 (variable, absent to bright), CD11b (partial), CD13 (partial), CD19 (dim to bright), CD22 (dim to normal), CD24 (variable, absent to bright), CD25 (partial), CD34, CD38 (dim), CD45 (dim), CD56 (partial, bright), CD66c/CD123, CD81 (absent to dim),; with normal expression of CD71, cytoplasmic CD79a, and HLA-DR; and without cytoplasmic CD3, surface CD3, CD4, CD5, CD7, CD8, CD14, CD15, CD16, CD20, CD33, CD64, CD66b, CD86, CD117, CD73/CD304, MPO, or surface light chains.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.11% of WBC.
272,190 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-5457)
Abnormal immature B-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature B- or T-cell populations detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood (78.3% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD2, CD10 (variable, absent to bright), CD13 (partial), CD22 (dim), CD24 (bright), CD25 (partial), CD34 (bright), CD45 (dim), CD56 (partial), CD66c/CD123, CD81 (dim), with normal expression of CD19, CD71, and HLA-DR; and without CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD20, CD33, CD64, CD66b, CD86, CD117, CD73/CD304 or surface kappa or lambda light chains.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.28% of WBC.
388,612 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3559, CG21-3560.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-23323, 23324, 23325, 23326, 23328 and 23330

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H21-4280;S10;MSKA - 2023-05-27 01.47.29.ndpi,Peripheral Blood Smear,2023-05-27,"Lymphoma
Newly dx MZL
Protocol#: 19-243 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - B-cell lymphoma, consistent with marginal zone lymphoma, 60-70% involvement with CD20 immunohistochemistry. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate smear show hypercellular bone marrow (70-80% cellularity) with prominent atypical lymphoid infiltrate. These lymphoid cells are small and have irregular nuclei, condensed chromatin, and inconspicuous nucleoli. Foci suggestive of intra-sinusoidal distribution present. Sheets of large cells are not present. There istrilineage maturing hematopoiesis in a background. Myeloid and erythroid elements show progressive maturation. Megakaryocytes appear adequate in number and morphology. 

Bone Marrow Aspirate Smear Quality:  Adequate

Blasts                1%
Myelocytes           4%
Metamyelocytes           2%
Neutrophils/Bands      6%
Eosinophils           1%
Erythroid Precursors      16%
Lymphocytes           70%
Number of Cells Counted 500
M:E Ratio           0.8

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight increased abnormal B-cell population, comprising 60-70% of marrow cellularity. 
CD3 highlights scattered and focal aggregates of T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5674) 
Interpretation: 
Abnormal B-cell population identified.

Flow cytometry reveals an abnormal mature B-cell population similar to that seen previously in [F21-4670] with abnormal expression of CD19 (slightly bright), CD20 (slightly bright), CD22 (slightly bright), CD45 (bright), kappa light chain restriction; and without CD3, CD5, CD10, CD14, CD25, CD38 or CD279 (PD1). The abnormal B-cell population represents 27.8% of the total white cells.

PERIPHERAL BLOOD
CBC (06/15/2021):
WBC 33.5 H [4.0-11.0 K/mcL] 
RBC 4.38 [3.95-5.54 M/mcL] 
HGB 11.1 L [12.5-16.2 g/dL] 
HCT 35.8 L [37.5-49.3 %] 
MCV 82 [80-98 fL] 
MCH 25.3 L [27.0-33.0 pg] 
MCHC 31.0 [31.0-36.5 g/dL] 
RDW 15.6 H [12.2-15.1 %] 
Platelets. 179 [160-400 K/mcL] 

Neutrophil 11.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 32.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 55.0 H [0.0-0.0 %] 

Abs Neut 3.7 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 29.2 H [0.9-3.2 K/mcL] 

Morphology: Many circulating atypical lymphocytes and smudge cells are present. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3730, CG21-3770.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-24670. 



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-4685;S10;MSK0 - 2023-04-25 17.14.32.ndpi,Peripheral Blood Smear,2023-04-25,"Follicular lymphoma. Rule out transformation 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by low-grade B-cell lymphoma (~5% by CD20 immunohistochemistry).
     - Cellular marrow with trilineage maturing hematopoiesis.

The case was also reviewed by Dr. Ahmet Dogan (Hematopathology Service) who agrees with the diagnosis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Suboptimal biopsy specimen shows cellular bone marrow (overall 30%, ranging between 15 and 70%), with partial crush and aspiration artifact limiting morphologic evaluation. There istrilineage maturing hematopoiesis. Myeloid and erythroid elements show progressive maturation. Megakaryocytes appear adequate in morphology. Focal paratrabecular aggregates composed of small lymphoid cells with condensed chromatin and inconspicuous nucleoli are present; no significant increase in the number of large cells is noted. The aspirate smears are hemodiluted.

Bone Marrow Aspirate Smear Quality: Adequate; devoid of spicules.

Blasts                1%
Promyelocytes           1%
Myelocytes           7%
Metamyelocytes           3%
Neutrophils/Bands      55%
Monocytes           8%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      13%
Lymphocytes           10%
Number of Cells Counted      500
M:E Ratio           5.8

IMMUNOHISTOCHEMISTRY
Immunostains performed at MSKCC showed that CD20 appears to highlight numerous cells in the para trabecular lymphoid aggregate. PAX5, BCL2, BCL6, CD10, LMO2, MUM1 highlights scattered cells in the aggregate. CD3 and CD5 are positive in scattered T cells in the para trabecular aggregates and in the remaining marrow. Cyclin D1 is positive only in scattered rare cells. Ki-67 proliferation index is <5% in the focal lymphoid aggregates but highlights numerous proliferating hematopoietic precursors in the background.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-6179) 
No abnormal mature B-cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

PERIPHERAL BLOOD
CBC (6/28/2021)
WBC 5.8 [4.0-11.0 K/mcL] 
RBC 4.06 [3.80-5.00 M/mcL] 
HGB 13.1 [11.2-15.4 g/dL] 
HCT 39.3 [34.3-46.0 %] 
MCV 97 [80-98 fL] 
MCH 32.3 [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 12.6 [12.2-15.1 %] 
Platelets. 224 [160-400 K/mcL] 

Neutrophil 65.6 [32.5-74.8 %] 
Mono 13.0 H [0.0-12.3 %] 
Eos 2.8 [0.0-4.9 %] 
Baso 1.2 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 16.9 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 3.8 [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.0 [0.9-3.2 K/mcL]

Morphology: No circulating atypical lymphoid cells seen.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-4083.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-26432.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-5358;S12;MSK- - 2023-06-06 03.14.48.ndpi,Peripheral Blood Smear,2023-06-06,"66 M MDS, pre-BMT
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Persistent involvement by myelodysplastic syndrome with increased ring sideroblasts (blasts 3%) 
     - Involvement by B-cell lymphoproliferative disorder with flow cytometric detection of CLL/SLL like immunophenotype.
  
COMMENT:  The extent of involvement by lymphoproliferative disorder appears to be increased in comparison to the prior bone marrow biopsy (H20-7960; 12/02/2020).  Even though a lymphocytic infiltrate of small lymphocytes is detected, the extent of involvement cannot be determined with certainty on histologic sections due to limited marrow core biopsy with crush artifact. The aspirate smears show patchy areas of sheets of small lymphocytes with round nuclei and clumped chromatin and some of which showing plasmacytoid morphology.  Immunohistochemical studies will be performed on the biopsy sections and the findings will be reported in an addendum.

BONE MARROW BIOPSY
Fragmented biopsy with marked aspiration artifact shows only limited marrow spaces with hematopoietic marrow with crush artifact.  The marrow appears hypercellular for age (possibly 70-80%), with markedly increased dysplastic megakaryocytes, scattered erythroid and myeloid elements and numerous small lymphocytes. 

Special stains: Reticulin stain shows increased reticulin fibrosis.  However, there is marked crush artifact which may be significantly contributing to the increased fibrosis by reticulin stain.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate.
Blasts                3%
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      6%
Monocytes           2%
Eosinophils           4%
Erythroid Precursors      52% 
Plasma Cells           7%
Lymphocytes           21%
Number of Cells Counted 500
M:E Ratio           0.3

Special stain
Iron: Trace
Ring sideroblasts: Present 5-15% 

Morphology:
-Spicular and hypercellular smears show patchy areas of marked increase in small lymphocytes with round nuclei and clumped chromatin and subset showing plasmacytoid morphology, overall markedly increased erythroid precursors with dysplastic changes, reduced myeloid elements, dysplastic megakaryocytes, and markedly increased mast cells with round cytoplasmic borders.  No increase in blasts is seen.

PERIPHERAL BLOOD
CBC (07/22/2021):
WBC 3.0 L [4.0-11.0 K/mcL] 
RBC 1.98 L [3.95-5.54 M/mcL] 
HGB 7.5 L [12.5-16.2 g/dL] 
HCT 23.7 L [37.5-49.3 %] 
MCV 120 H [80-98 fL] 
MCH 37.9 H [27.0-33.0 pg] 
MCHC 31.6 [31.0-36.5 g/dL] 
RDW 24.4 H [12.2-15.1 %] 
Platelets 291 [160-400 K/mcL]
 
Neutrophil 43.1 [32.5-74.8 %] 
Mono 8.1 [0.0-12.3 %] 
Eos 4.1 [0.0-4.9 %] 
Baso 1.7 H [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 42.7 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 1.3 L [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 

Morphology:  Moderate anisopoikilocytosis, teardrop forms, neutrophils with dysplastic abnormal nuclear lobation, platelets with enlarged forms, and no circulating blasts.

IMMUNOHISTOCHEMISTRY
Immunostain for CD34 and CD117 show no increase in blasts.  CD117 highlights increased mast cells with no clustering.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7070)
Abnormal myeloid blast population detected.
Abnormal B-cell population identified.

Flow cytometry identifies a small abnormal myeloid blast population having abnormal expression of CD13 (absent to dim), CD33 (dim), CD34 (slightly dim), CD38 (absent to dim); with normal expression of CD4, CD45, CD71, CD117, CD123 and HLADR; without CD2, convincing CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, or CD64. The definite abnormal myeloid blast population represents 0.95% of WBC while total CD34 positive myeloid blasts represent 2.8% of the WBC.

Flow cytometry identified an abnormal B-cell population with CLL/SLL-like immunophenotype having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23, CD43, CD79b (dim), CD81 (dim), CD200 (bright), ROR1 and no definite surface light chain expression; normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The abnormal B-cell population comprises 2.8% of the white cells.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-4654.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-29929.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-7919;S10;MSKC - 2023-04-19 17.12.57.ndpi,Peripheral Blood Smear,2023-04-19,"Clinical Diagnosis: Lymphoma vs HLH
Clinical Hx/Op Findings: Concern for HLH
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by large B cell lymphoma (<5% with PAX5 immunohistochemistry).
     - Hypocellular marrow with trilineage maturing hematopoiesis. See comment.

COMMENT: No definite morphologic evidence of hemophagocytosis is noted. The case was also reviewed by Dr. Mariko Yabe (Hematopathology Service) who agrees with the diagnosis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show hypocellular bone marrow (~30% cellularity, ranging between 5% and 50%). There istrilineage maturing hematopoiesis. Myeloid and erythroid lineage show complete maturation. Megakaryocytes are present with overall normal morphology. There is a focal area showing increased fibrosis with presence of scattered large atypical cells.

The bone marrow aspirate smears are spicular and cellular. Myeloid and erythroid lineages show complete maturation. A subset of erythroid precursors displays nuclear irregularities, occasional blebbing and cytoplasmic vacuolization. Megakaryocytes display overall normal morphology with only rare small forms. Lymphocytes do not appear significantly increased. Differential count was not performed.

Bone Marrow Aspirate Smear Quality: Adequate.

IMMUNOHISTOCHEMISTRY
PAX5 and BCL6 highlight scattered large atypical B-cells associated with the focal area of fibrosis. CD20 and CD19 immunostains are virtually negative. CD3 labels reactive T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-10545)
1. No abnormal B cell population detected. Virtually no B cells seen.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

Number of cells acquired: 253 thousand  

2. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.23% of WBC

Number of cells acquired: 265 thousand

Also see F21-10498 submitted on the same day.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-10498)
1. No abnormal B cell population detected. Virtually no B cells seen.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

Number of cells acquired: 335 thousand  

Also see F21-10545 submitted on the same day.

PERIPHERAL BLOOD
CBC (10/26/2021):
WBC 6.4 [4.0-11.0 K/mcL] 
RBC 3.11 L [3.80-5.00 M/mcL] 
HGB 10.9 L [11.2-15.4 g/dL] 
HCT 33.5 L [34.3-46.0 %] 
MCV 108 H [80-98 fL] 
MCH 35.0 H [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 16.9 H [12.2-15.1 %] 
Platelets 31 L [160-400 K/mcL] 

Neutrophil 88.7 H [32.5-74.8 %] 
Mono 6.4 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 3.5 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 1.1 L [12.2-47.4 %] 
Nucleated RBC 3.5 H [0.0-0.0 %] 

Abs Neut 5.6 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.2 H [0.0-0.1 K/mcL] 
Abs Lymph 0.1 L [0.9-3.2 K/mcL] 

Morphology: No atypical lymphoid elements are seen. Rare nucleated red blood cells are present.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-6926.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-44382, M21-44383.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-7901;S11;MSK5 - 2023-05-31 15.48.23.ndpi,Peripheral Blood Smear,2023-05-31,"{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch31505\stshfloch31506\stshfhich31506\stshfbi0\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}
{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;
\red0\green0\blue0;}{\*\defchp \fs22\loch\af31506\hich\af31506\dbch\af31505 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*
\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\trcbpat1\trcfpat1\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused 
Normal Table;}{\s15\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\f1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext15 \spriority0 Arial;}}
{\*\rsidtbl \rsid2769078\rsid3427305\rsid4089081\rsid4393964\rsid4723562\rsid7481005\rsid8477061\rsid10051108\rsid11680817\rsid12467123\rsid15683945\rsid16017239}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1
\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\operator Colon Cartagena, Lorraine/Graduate Medical Education}{\creatim\yr2021\mo10\dy29\hr8\min35}{\revtim\yr2021\mo10\dy29\hr8\min35}{\version2}{\edmins0}{\nofpages1}{\nofwords23}{\nofchars132}{\nofcharsws154}
{\vern7}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata1\grfdocevents0\validatexml0\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors0\horzdoc\dghspace120\dgvspace120\dghorigin1701
\dgvorigin1984\dghshow0\dgvshow3\jcompress\viewkind1\viewscale100\rsidroot3427305 \fet0{\*\wgrffmtfilter 2450}\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2
\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}\pard\plain \ltrpar\s15\ql \li0\ri0\nowidctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\af1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \insrsid7481005 \hich\af1\dbch\af31505\loch\f1 Clinical Diagnosis: Prostate, Malignant Neoplasm\par \hich\af1\dbch\af31505\loch\f1 Clinical Hx/Op Findings: persistent thrombocytopenia, evaluate for ITP/MDS\par \hich\af1\dbch\af31505\loch\f1 Requested Studies: Gross/Micro\par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Consistent with metastatic prostatic adenocarcinoma; see comment.

Comment: The tumor in these specimens is morphologically similar to the patient's prior prostate cancer (S21-10243), which was reviewed. Hematopathology findings will be reported in an addendum. 
"
H21-7067;S13;MSK0 - 2023-05-31 16.11.47.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Hx/Op Findings: 81M w new anemia, thrombocytopenia
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
     - Involvement by diffuse large B-cell lymphoma (15-20% by CD20 immunohistochemistry). 
     - Hypercellular marrow with left-shifted erythroid maturation, mild megakaryocytic hyperplasia and increased histiocytes.
      See comment.

COMMENT: The accurate subclassification of the diffuse large B-cell lymphoma (DLBCL) based on cell of origin is not feasible on the current specimen due to limitations of immunohistochemical studies as a consequence of the decalcification process as well as due to patchy distribution of the lymphoma. Given the lack of CD10 expression (by flow cytometry as well as immunohistochemistry) and presence of MUM1 expression at least in a subset, the DLBCL is favored to be of non-germinal center origin (Hans' algorithm).

There are increased number of histiocytes some of which show features suggestive of hemophagocytosis. These findings are in keeping with macrophage activation syndrome and would meet one criterion for Hemophagocytic lymphohistiocytosis (HLH) that was suspected on the clinical and laboratory grounds. There is no diagnostic morphologic or immunophenotypic evidence of involvement by myeloid neoplasm.

There are a few small loose aggregates of CD23+ small-sized lymphoid cells (<1% of cellularity) that may represent correlate of the CLL/SLL-like abnormal B-cell population (0.36% of WBC) identified by flow cytometry. The clonal relationship of this aberrant population with the diffuse large B-cell lymphoma is not clear.

The case was also reviewed with Dr. Filiz Sen, Division of Hematopathology, with agreement on the diagnosis. 

BONE MARROW BIOPSY/CLOT SECTION
Quality: Fragmented biopsy admixed with clot, adequate for assessment
Cellularity: Hypercellular for age (60-70%)
M:E ratio: Within normal limits
Blasts: Not increased
Myeloid lineage: Shows progressive maturation
Erythroid lineage: Shows left-shifted progressive maturation
Megakaryocytes: Mildly increased in number and include a few hypolobated and hyperchromatic forms
Lymphocytes: An interstitial infiltrate of many large-sized atypical lymphoid cells (best seen by CD20 immunohistochemistry) admixed with some small lymphoid cells 
Plasma cells: Not increased
Other: Increased number of histiocytes in the background

Special stain: Reticulin stain shows minimal increase in reticulin fibrosis. 

Clot section: Predominantly blood with some marrow elements including occasional large atypical lymphoid cells similar to the core biopsy.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                2%
Promyelocytes           2%
Myelocytes           10%
Metamyelocytes           7%
Neutrophils/Bands      38%
Monocytes           4%
Eosinophils           2%
Erythroid Precursors      17%
Lymphocytes           18%
Number of Cells Counted 500
M:E Ratio           3.7

Special stain
Iron: Cannot evaluate for storage iron as the smears are devoid of spicules     
Ring sideroblasts: Suboptimal for evaluation due to poor quality of slides

Morphology:
The aspirate smears are paucispicular and show significant crush artifact. There is maturing trilineage hematopoiesis with normal M:E ratio. There are occasional large and rare giant atypical lymphoid cells with irregular nuclei, fine chromatin, conspicuous nucleoli, moderate to large amount of basophilic cytoplasm with occasional vacuoles. An expanded population of blasts is not seen. Myeloid elements show maturation without significant dysplasia. Erythroid elements show left-shifted progressive maturation with a few binucleated and karyorrhectic forms. Megakaryocytes are present and display a few small and hypolobated forms. A few histiocytes with intracytoplasmic erythrocytes/leukocytes, suggestive of hemophagocytosis are noted.

PERIPHERAL BLOOD
CBC (09/24/2021):
WBC 11.2 H [4.0-11.0 K/mcL] 
RBC 2.79 L [3.95-5.54 M/mcL] 
HGB 7.5 L [12.5-16.2 g/dL] 
HCT 23.5 L [37.5-49.3 %] 
MCV 84 [80-98 fL] 
MCH 26.9 L [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 16.6 H [12.2-15.1 %] 
Platelets. 77 L [160-400 K/mcL] 

Neutrophil 66.0 [32.5-74.8 %] 
Mono 19.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 15.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 7.4 [1.5-7.5 K/mcL] 
Abs Mono 2.1 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.7 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
WBC: Leukocytosis with absolute and relative monocytosis. Rare large/giant atypical lymphoid cells (similar to aspirate smear) are seen. 
RBC: Normochromic, normocytic anemia with mild anisopoikilocytosis.
PLT: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
The large atypical lymphoid cells show patchy distribution and-
Express: CD20 (15-20% of cellularity), CD5 (weak, minor subset), PAX5 (variable intensity), MUM1 (subset), BCL2, c-MYC (subset, weak)
Do not express: CD3, CD10, CD30, P53, CD23, cyclin D1
Others:
CD20 also highlights a few small-sized lymphoid cells.
CD23 highlights a few small and loose aggregates of small-sized lymphoid cells (<1% of cellularity).
CD3 and CD5 highlight singly scattered and occasional aggregates of small T-cells. A predominance of CD5+ small lymphoid cells is seen focally. 
CD138 highlights scattered and small clusters of plasma cells (<5% of cellularity).
Cyclin D1 labels scattered cells that likely represent histiocytes and endothelial cells.
In situ hybridization for EBV-encoded small RNAs (EBER) is negative. EBV (LMP1) immunohistochemistry is also negative.
CD163 highlights the histiocytes that appear increased in number. A few histiocytes show features suggestive of hemophagocytosis.
CD34 and CD117 highlight rare blasts comprising less than 5% of the total cellularity. 
CD117 also highlights early myeloid progenitors, erythroid progenitors and mast cells.
MPO and CD71 highlight the myeloid and erythroid elements, respectively that appear adequate in proportion.
CD61 highlights megakaryocytes that appear mildly increased in number and include a few small forms.
Cytokeratin 5/6 and calretinin immunostains are negative.
BCL6 immunostain is technically suboptimal for evaluation likely due to decalcification.
CD3, CD20, CD5, CD138, CD30 and EBER were also performed on the clot section with similar findings.
Results of Ki-67 and SOX11 immunostains will be reported in an addendum.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-9369)
1. Abnormal B cell population with larger size detected.

Abnormal B cell population represents 0.56% of WBC

Immunophenotype:
Abnormal: CD5 (positive), CD20 (bright), CD22 (dim), CD38 (uniform - bright), surface Kappa (restriction), Forward Scatter (increased), Side Scatter (increased)
Normal: CD19, CD45
Negative: CD10, CD25, CD279 (PD1), CD3, CD14, surface Lambda

2. Abnormal B cell population detected. 
Flow cytometry reveals an abnormal B cell population with CLL/SLL-like immunophenotype (see below).

Abnormal B cell population represents 0.36% of WBC
The rest of B cells shows kappa light chain predominance (kappa to lambda ratio 5:1) but otherwise unremarkable immunophenotype. 

Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (positive), CD43 (positive), CD79b (dim), CD81 (dim), CD200 (bright), ROR1 (positive), surface Kappa (restriction - dim)
Normal: CD19, CD40, CD45
Negative: CD38, CD10, CD3, surface Lambda

3. No abnormal T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

4. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.15% of WBC
Monocytosis is seen, 26.9% of WBC
Number of cells acquired: 372 thousand  

CYTOGENETIC STUDIES
Cytogenetic studies will be attempted, and the results will be reported separately.

MOLECULAR STUDIES 
Not requested/performed.     

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

"
H21-1320;S11;MSKU - 2023-05-22 12.16.54.ndpi,Peripheral Blood Smear,2023-05-22,"Hairy Cell Leukemia (HCL)
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Extensive involvement by hairy cell leukemia (80-90% by CD20 immunohistochemistry).
      -Atypical myeloid blast population seen by flow cytometry, dyserythropoiesis and no increase in blasts (see comment).
  
COMMENT: The marrow shows extensive involvement by hairy cell leukemia with some residual background trilineage hematopoiesis showing dyserythropoiesis. No significant dysplasia is noted in the granulocytes or megakaryocytes in this sample. The dyserythropoiesis could just be a reactive process secondary to marrow involvement by hairy cell leukemia. However, a recent IMPACT hotspot (M20-43581) detected IDH2 and TP53 mutations in the peripheral blood at low variant allele frequency, indicating a clonal process that may be unrelated to the hairy cell leukemia. In addition, the concurrent bone marrow flow cytometry identified a highly atypical myeloid blast population. In this context, the possibility of a myeloid neoplasm is not excluded. Close clinical follow-up and correlation with forthcoming cytogenetic and molecular studies is advised. A sample negatively selected for abnormal B cells was sent for molecular genetic evaluation to evaluate for presence of IDH2 and TP53 mutations. If these are found to be in the myeloid compartment, at least high risk clonal hematopoiesis would be suspected.

The flow cytometry also identified a mildly expanded LGL population (9.5% of the leukocytes) with restricted expression of Vbeta chains on the large granular lymphocyte population. Though this is consistent with clonality, small LGL clones can be seen in reactive conditions as well and the significance of this population is not entirely clear. 

BONE MARROW BIOPSY
Quality: Adequate with focal aspiration artifact
Cellularity: Variable cellularity, ranging from 30% to 100%, overall mildly hypercellular for age (~50% cellularity)
M:E ratio: Decreased
Blasts: Not increased
Myeloid lineage: Decreased
Erythroid lineage: Shows progressive maturation          
Megakaryocytes: Show patchy distribution, overall mildly decreased in number and morphologically predominantly unremarkable
Lymphocytes: An infiltrate of small to medium-sized atypical lymphoid cells with round to oval nuclei, and moderate clear cytoplasm is present in an interstitial and diffuse pattern.
Plasma cells: Interstitially scattered     

Reticulin stain: There is marked increase in reticulin fibrosis mostly in association with hairy cell leukemia

BONE MARROW ASPIRATE SMEAR
Differential: (Performed on touch imprints by HM)
Blasts                3%
Promyelocytes           4%
Myelocytes           9%
Metamyelocytes           9%
Neutrophils/Bands      18%
Monocytes           4%
Eosinophils           3%
Erythroid Precursors      40%
Plasma Cells           3%
Lymphocytes           7%
Number of Cells Counted 500
M:E Ratio           1.2

Morphology:
Touch imprints show erythroid predominance with orderly erythroid maturation and dyserythropoiesis (nuclear irregularity/budding, late stage mitosis, >10% of lineage). Myeloid elements show mildly left shifted progressive maturation with no dysplasia apparent in this limited cellularity. Megakaryocytes are not well represented, and only rare forms are seen. An expanded blast population is not seen. There are occasional atypical lymphoid cells that are small to medium sized with oval nucleus with occasional indentations, homogeneous chromatin, inconspicuous nucleoli and moderate amount of pale blue cytoplasm. A few large granular lymphocytes and rare binucleate plasma cells are also seen. 

Aspirate smears are aspicular and markedly hemodiluted and hypocellular with many atypical lymphoid cells as the touch imprint. 

PERIPHERAL BLOOD
CBC (02/23/2021):
WBC 2.1 L [4.0-11.0 K/mcL] 
RBC 3.02 L [3.95-5.54 M/mcL] 
HGB 9.0 L [12.5-16.2 g/dL] 
HCT 28.8 L [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 29.8 [27.0-33.0 pg] 
MCHC 31.3 [31.0-36.5 g/dL] 
RDW 17.2 H [12.2-15.1 %] 
Platelets 82 L [160-400 K/mcL] 

Neutrophil 48.0 [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 51.0 H [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBCs: Relative lymphocytosis. Hairy cells as well as few LGLs are seen.
RBCs: Normocytic normochromic RBCs anemia with mild to moderate anisopoikilocytosis (target cells, elliptocytes) and mild increase in polychromasia. 
Platelets: Thrombocytopenia, unremarkable morphology

IMMUNOHISTOCHEMISTRY
CD20 immunostain highlights the diffuse and interstitial atypical lymphoid infiltrate (overall 80-90% of the cellularity). This infiltrate is positive for BRAF V600E immunostain. CD3 immunostain highlights predominantly scattered and rare aggregate of small T-cells.
CD34 immunostain shows no increase in blasts (<5% of cellularity). 
CD117 highlights mildly increased number of scattered mast cells.     
CD61 highlights megakaryocytes with patchy distribution that appear to be overall mildly decreased in number.
MPO and CD71 highlight the myeloid and erythroid elements, respectively with low M:E ratio.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-1767)
Abnormal B-cell population identified.
Mildly expanded large granular lymphocyte population detected.
Highly atypical myeloid blast population detected. 

Flow cytometry reveals an abnormal mature B-cell population having abnormal expression of CD19 (slightly bright), CD20 (bright), CD11c, CD22 (bright), CD25, CD103, CD200 (bright), and with slightly increased forward and side scatter and lambda light chain restriction (bright); with normal expression of CD45 and without CD3, CD5, CD10, CD14, CD38 or CD279 (PD1).  The immunophenotype of the abnormal B-cell population is consistent with involvement by hairy cell leukemia. The abnormal B cell population represents 2.5% of the total white cells.

In addition, a mildly expanded population of large granular lymphocytes with expression of CD8, CD5 (dim to absent), CD7 (slightly dim), CD56 and CD57, without CD4. CD2, CD3, and CD45 are expressed at the normal level. The population represents 9.5% of the leukocytes.TCR Vbeta repertoire analysis demonstrates restricted expression of Vbeta chains on the large granular lymphocyte population. Though this is consistent with clonality, small LGL clones can be seen in reactive conditions as well.

Very few myeloid blasts are seen precluding detailed evaluation. However, in light of the myeloid blasts with expression of CD7 (minute subset) and CD117 (negative to dim), a low-grade myeloid stem cell neoplasm cannot be entirely excluded by these studies. CD34 positive myeloid blasts represent 0.19% of the white blood cells.  
26211 cells acquired. Morphologic, cytogenetic, and molecular genetic assessment is suggested to exclude myeloid stem cell neoplasm. Clinical correlation is also advised. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-1167.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-7176, M21-7177, M21-7178, M21-7179.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-1196;S2;MSKV - 2023-05-19 21.29.17.ndpi,Peripheral Blood Smear,2023-05-19,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma, 13% blasts on aspirate differential count, see comment.     

COMMENT: The concurrent flow cytometry (F21-1632) shows an abnormal immature B-cell population. The diagnosis is challenging as the immunophenotype of the immature B-cell population is unusual and shows only subtle immunophenotypic abnormalities. Baseline molecular genetic evaluation (Lymphotrak) is advised for more sensitive residual disease follow-up.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Blasts                13%
Promyelocytes           1%
Myelocytes           6%
Metamyelocytes           5%
Neutrophils/Bands      39%
Monocytes           1%
Eosinophils           3%
Erythroid Precursors      14%
Lymphocytes           18%
Number of Cells Counted 500
M:E Ratio           3.9

Morphology:
Spicular and cellular aspirate smears demonstrate maturing trilineage hematopoiesis with an expanded population of small and intermediate-sized blasts with round to slightly irregular nuclei, fine chromatin, prominent nucleoli and small amount of cytoplasm without granules. Myeloid elements show progressive maturation with unremarkable morphology. Erythroid elements show progressive maturation with occasional dyspoiesis (nuclear irregularity). Megakaryocytes are present and show a few hypolobated forms.     

PERIPHERAL BLOOD
CBC (02/18/2021):
WBC 4.9 L [7.1-15.9 K/mcL] 
RBC 3.36 [2.93-4.75 M/mcL] 
HGB 8.8 L [9.2-12.7 g/dL] 
HCT 26.6 L [27.7-37.9 %] 
MCV 79 [70-85 fL] 
MCH 26.2 [22.7-29.5 pg] 
MCHC 33.1 [31.0-36.5 g/dL] 
RDW 12.8 [12.2-15.1 %] 
Platelets 335 [160-400 K/mcL] 

Neutrophil 37.2 [16.9-74.5 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 1.8 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 0.2 [0.0-0.6 %] 
Lymph 53.4 [18.1-79.9 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 1.8 [1.5-8.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 2.6 [1.1-8.1 K/mcL] 

Morphology:
WBCs: No definite circulating blasts seen. 
RBCs: Normocytic normochromic anemia. 
Platelets: Unremarkable morphology.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-1632)
Abnormal immature B-cell population detected.

An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously [F21-1436]. The abnormal immature B-cells represent 12.0% of the white cells and 19.2% of the mononuclear cells in the sample and abnormally express CD10 (slightly bright), CD19 (slightly bright), CD20 (partial), CD34 (absent), CD38 (dim), CD81 (dim); with normal expression of CD22, CD24, CD45; and without CD66b, CD66c/CD123 or CD73/CD304.  This finding is consistent with persistent/recurrent B-lymphoblastic leukemia/lymphoma, depending on the clinical context.  Clinical and morphologic correlation is recommended.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-1072, CG21-1073.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-6449, M21-6450, M21-6452.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. PessinMD., PhD., Director.
"
H21-4165;S12;MSKV - 2023-05-19 22.02.42.ndpi,Peripheral Blood Smear,2023-05-19,"Myelodysplastic syndrome. Status post allo-HCT for FA. Now with donor derived MDS. 
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD), 2% blasts by aspirate differential count. See comment. 
  
COMMENT: Patient's history of Fanconi anemia with trisomy 8, status post allogeneic stem cell transplant with recent presentation of pancytopenia is noted. The current biopsy shows dysplasia in megakaryocytic and erythroid lineages with increased ring sideroblasts (>15%) and no increase in blasts. The overall morphologic findings are consistent with MDS-RS-MLD; however, correlation with cytogenetic findings is required for further classification and to fully exclude MDS with isolated del(5q). The findings on in-house cytogenetic analysis of peripheral blood (CG21-2549, 4/23/21) showing 96.6% donor cells with no evidence of gain of chromosome 8 raise the possibility of a donor-derived MDS.

This case was also reviewed by Dr. Mariko Yabe in Hematopathology Service.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular (>90%) for age
M:E ratio: Mildly decreased 
Blasts: Not increased 
Myeloid lineage: Exhibits left-shifted maturation 
Erythroid lineage: Exhibits left-shifted maturation
Megakaryocytes: Mildly increased and show dysplastic changes (hypo/monolobated and hyperchromatic, >10%)
Lymphocytes: Scattered 
Plasma cells: Scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1+/3). 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                2%
Promyelocytes           2%
Myelocytes           14%
Metamyelocytes           6%
Neutrophils/Bands      20%
Eosinophils           3%
Erythroid Precursors      41%
Lymphocytes           12%
Number of Cells Counted  500
M:E Ratio           1.1 

Special stain 
Iron: Present
Ring sideroblasts: Present >15%

Morphology:
Spicular and hypercellular smears show trilineage maturing hematopoiesis with no increase in blasts. Myeloid elements are relatively decreased and show left-shifted maturation with dysplastic change (hypogranularity and hyposegmentation, ~10%). Erythroid elements are increased and show left-shifted maturation with dysplastic changes (nuclear irregularity and budding, karyorrhexis, nuclear-cytoplasmic dysynchrony and ring-sideroblasts, >10%). Megakaryocytes are present with frequent dysplastic hypo/monolobated forms. Scattered small and mature-appearing lymphocytes are also present. 

PERIPHERAL BLOOD
CBC (06/10/2021):
WBC 2.3 L [4.0-11.0 K/mcL] 
RBC 3.88 L [3.95-5.54 M/mcL] 
HGB 8.7 L [12.5-16.2 g/dL] 
HCT 29.7 L [37.5-49.3 %] 
MCV 77 L [80-98 fL] 
MCH 22.4 L [27.0-33.0 pg] 
MCHC 29.3 L [31.0-36.5 g/dL] 
RDW 23.0 H [12.2-15.1 %] 
Platelets 30 L [160-400 K/mcL] 

Neutrophil 44.0 [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 5.0 H [0.0-4.9 %] 
Baso 6.0 H [0.0-1.5 %] 
Myelocyte 4.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 4.0 H [0.0-0.0 %] 
Lymph 32.0 [12.2-47.4 %] 
Nucleated RBC 3.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 

Morphology:
WBC: No circulating blasts; left shifted granulocytes (myelocytes, metamyelocytes) are present. 
RBC: Anisopoikilocytosis with rare nucleated RBCs.
PLT: Few large and hypogranular forms. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts (<5% marrow cellularity).
CD117 also highlights erythroid and myeloid precursors and scattered mast cells. 
Aberrant CD34 staining is present in some dysplastic megakaryocytes. 
CD61 highlights mildly increased megakaryocytes including frequent dysplastic forms. 
CD71 highlights increased erythroid elements.
MPO highlights relatively decreased myeloid elements. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5531)
Abnormal myeloid blast population detected.
No abnormal mature B- or T-cell populations detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD5 (dim, partial), CD7 (partial), CD13 (subset bright, including the CD38 dim population and subset dim), CD117 (uniform, bright), and HLA-DR (uniform, bright); with normal expression of CD4, CD33, CD34, CD38, CD45, CD71 and CD123; without CD2, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 4.1% of WBC. In addition, an expanded and atypical (CD14-, CD11b, largely positive) immature monocyte population is seen (8.3%). Together blasts/equivalents are 12.4% WBC, although given a large number of erythroid precursors excluded from the count, this may represent an overestimate of the overall morphologic blast count 
The findings are consistent with a myeloid neoplasm; however, correlation with additional studies (morphologic, cytogenetic, and molecular) is required for further characterization.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3599.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-23672, M21-23673, M21-23674.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-4022;S13;MSKY - 2023-05-19 22.42.18.ndpi,Peripheral Blood Smear,2023-05-22,"Myelodysplastic Syndrome.  Suspect myelofibrosis or atypical infection.  Evaluate for bacterial, fungal and mycobacterial pathogens, stain for iron. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Hypercellular marrow with granulocytic hyperplasia and increased ring sideroblasts. See comment.
     - Minute CLL-like population detected by flow cytometry only. 
  
COMMENT:
The differential diagnosis includes a myeloid neoplasm with ring sideroblasts vs reactive process. The presence of >15% ring sideroblasts is highly suspicious for a diagnosis of myeloid neoplasm such as MDS/MPN with ring sideroblasts or MDS with ring sideroblasts. On the other hand, ring sideroblasts can be seen in non-neoplastic process such as excessive alcohol use, pyridoxine deficiency, lead poisoning and copper deficiency. There is no morphologic evidence of microorganisms. Correlation with clinical history, pending cytogenetic and molecular studies is recommended. 

BONE MARROW BIOPSY
Quality: adequate  
Cellularity: 80%
M:E ratio: increased 
Blasts: no increase
Myeloid lineage: increased with maturation
Erythroid lineage: relatively decreased 
Megakaryocytes: adequate, unremarkable 
Lymphocytes: rare 
Plasma cells: rare 
Granulomas are not seen. 
Special stains: Reticulin stain shows no to mild increase in reticulin fibrosis (MF-0-1/3). 
Clot section: blood clot only 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                2%
Promyelocytes           1%
Myelocytes           12%
Metamyelocytes           3%
Neutrophils/Bands      54%
Monocytes           4%
Basophils           1%
Erythroid Precursors      15%
Plasma Cells           3%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           5

Special stain
Iron: Present
Ring sideroblasts: Present >15%

Morphology:
Spicular and very cellular bone marrow aspirate shows progressive trilineage hematopoiesis. Blasts are not increased. Myeloid precursors are orderly maturing with mild left shift and occasional hypogranuloarity (<10%). Erythroid precursors are orderly maturing but show dysplasia (~10%). Megakaryocytes are present with unremarkable morphology. 

PERIPHERAL BLOOD
CBC (6/4/2021):
WBC 15.3 H [4.0-11.0 K/mcL] 
RBC 2.71 L [3.95-5.54 M/mcL] 
HGB 8.4 L [12.5-16.2 g/dL] 
HCT 27.0 L [37.5-49.3 %] 
MCV 100 H [80-98 fL] 
MCH 31.0 [27.0-33.0 pg] 
MCHC 31.1 [31.0-36.5 g/dL] 
RDW 26.1 H [12.2-15.1 %] 
Platelets. 330 [160-400 K/mcL] 

Neutrophil 77.0 H [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 3.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 11.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 11.8 H [1.5-7.5 K/mcL] 
Abs Mono 1.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.5 H [0.0-0.0 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 1.7 [0.9-3.2 K/mcL]

Morphology: anemia with elliptocytes, target cells and some fragments. Increased polychromasia. Neutrophilia with left shift. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts.
Immunostains for Parvovirus, CMV, adenovirus are negative.
E-cadherin shows reduced erythroid progenitors. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5352)
No definite abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
There is no definite immunophenotypic evidence of a myeloid stem cell neoplasm by flow cytometry. However, in light of the CD7 (small subset), CD13 (bright), CD34 (bright), and CD117 (bright), a low-grade myeloid stem cell neoplasm or underlying abnormal clonal hematopoiesis cannot be entirely excluded by these studies. CD34 positive myeloid blasts represent 0.38% of the white blood cells with expression of CD33, CD38, CD45, CD71 and low CD123. Normal myelomonocytic maturation is present. 450 thousand cells acquired. Morphologic, cytogenetic, and molecular genetic assessment is suggested to exclude myeloid stem cell neoplasm. Clinical correlation is also advised. 
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment.

Atypical TCR gamma/delta T-cell population detected.
Flow cytometry reveals a relatively increased TCR gamma/delta T-cell population with a subset having atypical expression of CD3 (dim), CD5 (absent), CD7 (bright), CD56 (uniformly bright); with normal expression of CD2, CD45; and without CD8, CD10, CD14, CD25, CD38 or CD279 (PD1). The clinical significance of this finding is not entirely clear and may represent either reactive or neoplastic process. The total TCR gamma/delta population represents 1.0% of the total white cells. 

No abnormal plasma cell population detected.
No evidence of an abnormal plasma cell population is identified by flow cytometry. 393 thousand cells acquired.

Abnormal B-cell population identified.
Flow cytometry identified an abnormal B-cell population with CLL/SLL-like immunophenotype having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD79b (dim), CD81 (dim), CD200 (bright), with small subsets expressing kappa and lambda light chains; normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The abnormal B-cell population comprises 0.008% of the white cells.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3480.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-22827 to M21-22829.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H21-4914;S11;MSKW - 2023-04-19 18.00.08.ndpi,Peripheral Blood Smear,2023-04-19,"AML
Assess response to protocol
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Acute myeloid leukemia, persistent disease, 77% by aspirate differential count.
    - Abnormal B-cell population with CLL/SLL-like immunophenotype detected by flow cytometry, 0.46% of WBC.
  
COMMENT: Additional immunohistochemistry to assess lymphoid aggregates will be reported in an addendum.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Normocellular (~40-50%)
M:E ratio: N/A
Blasts: Markedly expanded interstitial population of variably sized blasts with small amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli 
Myeloid lineage: Markedly reduced, with left shifted maturation
Erythroid lineage: Reduced
Megakaryocytes: Present, with unremarkable morphology 
Lymphocytes: Focal interstitial lymphoid aggregates seen 
Plasma cells: Scattered 
Special stains: A reticulin stain shows no significant increase in reticulin fibers (0/3). 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate 
Blasts                77%
Myelocytes           3%
Neutrophils/Bands      5%
Eosinophils           1%
Erythroid Precursors      12%
Lymphocytes           2%
Number of Cells Counted      500
M:E Ratio           0.8

Morphology: The aspirate smears are spicular and cellular and show a markedly expanded population of variably sized blasts with small amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli, in a background of markedly decreased, erythroid predominant trilineage hematopoiesis. 

PERIPHERAL BLOOD
CBC (7/8/2021):
WBC 2.1 L [4.0-11.0 K/mcL] 
RBC 3.46 L [3.80-5.00 M/mcL] 
HGB 11.7 [11.2-15.4 g/dL] 
HCT 35.4 [34.3-46.0 %] 
MCV 102 H [80-98 fL] 
MCH 33.8 H [27.0-33.0 pg] 
MCHC 33.1 [31.0-36.5 g/dL] 
RDW 12.8 [12.2-15.1 %] 
Platelets. 138 L [160-400 K/mcL] 

Neutrophil 50.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 6.0 H [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Lymph 40.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL]

Morphology:
WBC: Leukopenia with absolute neutropenia; rare cells suspicious for blasts seen. 
RBC: Mild macrocytosis.
PLT: Mild thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains for CD34 and CD117 show increased blasts, approximately ~50-60% of the bone marrow cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-6487)
Expanded abnormal myeloid blast population detected.
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD13 (absent to dim), CD34 (absent to dim), CD38 (dim), CD117 (absent to bright), and HLA-DR (absent); with normal expression of CD4, CD33, CD45, CD71, CD123 without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. The abnormal myeloid blasts represent 74.4% of WBC.

Flow cytometry also identified an abnormal B-cell population having abnormal expression of CD5, CD20 (dim), CD23, CD43, CD79b (dim to absent), CD81 (dim), CD200 (bright), and ROR1; normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The findings are consistent with previously diagnosed chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL) or CLL-like monoclonal B-cell lymphocytosis. The abnormal B-cell population comprises 0.46% of the white cells.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-4273.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-27792.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-8255;S11;MSKY - 2023-05-19 16.06.29.ndpi,Peripheral Blood Smear,2023-05-19,"Clinical Diagnosis: Leukemia, Hairy Cell
Clinical Hx/Op Findings: outside dx of HCL
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Extensive involvement by hairy cell leukemia (HCL) (~95% with CD20 immunohistochemistry).
     - Mildly hypercellular marrow with markedly reduced maturing trilineage hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate (although small) biopsy and aspicular/hypocellular aspirate and touch imprint specimens show approximately normocellular to mildly hypercellular for age marrow (70-80% cellularity). There is an atypical lymphoid infiltrate replacing the majority of the marrow cellularity present in show allele singly and in clusters, composed of small to intermediate size atypical lymphoid cells with round to angulated nuclei, condensed chromatin, inconspicuous nucleoli, and abundant pale cytoplasm. Background maturing trilineage hematopoiesis is decreased. Myeloid and erythroid cells are new actively maturing. Few megakaryocytes are seen.
The clot section shows few small marrow particles and is morphologically similar to the core biopsy.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD20 (95% of the marrow cellularity), BRAF VE, CD25, CD103, CD11c, cyclin D1, annexin A1
Do not express: CD3, CD123
Other:
CD3 highlights few scattered T-cells.
MPO highlights markedly reduced myeloid cells, while CD71 highlights few erythroid islands.
CD61 is positive in rare megakaryocytes appear

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-10978) 
Interpretation: 
1. Expanded abnormal B cell population detected.
The immunophenotype of the abnormal B-cell is consistent with involvement by hairy cell leukemia (HCL).

Abnormal B cell population represents 52.4% of WBC.

Immunophenotype:
Abnormal: CD5 (variable), CD19 (bright), CD20 (bright), CD22 (bright), CD25 (positive), CD11c (positive), CD103 (positive), CD200 (bright), surface Kappa (restriction - bright), Forward Scatter (slightly increased), Side Scatter (increased)
Normal: CD38, CD45
Negative: CD10, CD279 (PD1), CD3, CD14, surface Lambda

2. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 276 thousand  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (11/05/2021):
WBC 3.1 L [4.0-11.0 K/mcL] 
RBC 3.64 L [3.95-5.54 M/mcL] 
HGB 11.3 L [12.5-16.2 g/dL] 
HCT 34.8 L [37.5-49.3 %] 
MCV 96 [80-98 fL] 
MCH 31.0 [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 15.9 H [12.2-15.1 %] 
Platelets 42 L [160-400 K/mcL] 

Neutrophil 16.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 37.0 [12.2-47.4 %] 
Other 45.0 H [0.0-0.0 %] 
Abnormal lymphoid cells with villous cytoplasmic projections.
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.5 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Abs Others 1.4 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Leukopenia with an expanded population of atypical lymphocytes, which are small to intermediate in size with round to slightly irregular nuclei, clumped chromatin, generally inconspicuous nucleoli, and moderate amount of cytoplasm with cytoplasmic projections. Neutropenia and marked monocytopenia are present. Occasional large granular lymphocytes are seen.
RBC: Normocytic, normochromic anemia, mild, with polychromasia
Platelets: Thrombocytopenia

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate reports, CG21-7197 & CG21-7323.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M21-46146, M21-46148. M21-46149, & M21-46157.
"
H21-5039;S12;MSK6 - 2023-05-27 01.23.47.ndpi,Peripheral Blood Smear,2023-05-27,"Breast, Malignant Neoplasm
Widely metastatic breast cancer including bone involvement on 10-line Doxil with pancytopenia, n.b thrombocytopenia 1.5mo from last chemo
Special requests: Rush
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Involved by metastatic carcinoma, consistent with mammary origin; see comment.
    - Cellular bone marrow with maturing trilineage hematopoiesis.

COMMENT: The metastatic carcinoma is positive for GATA3, consistent with mammary origin; the carcinoma is morphologically similar to prior specimen at the same site (S14-45423, digital slides reviewed).

No diagnostic morphologic or immunophenotypic evidence of a myeloid stem cell neoplasm is seen. Peripheral cytopenias are likely related to metastatic carcinoma. However, correlation with concurrent cytogenetic and molecular studies is recommended to fully exclude a myeloid stem cell neoplasm.  

Additional immunohistochemistry and breast pathology evaluation will be reported in an addendum.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: N/A
M:E ratio: N/A
Blasts: Not increased (<5%) 
Myeloid lineage: Reduced, with full maturation  
Erythroid lineage: Exhibits full maturation 
Megakaryocytes: Present
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows a moderate increase in reticulin fibers (2+/3) associated with metastatic carcinoma.
Other: Extensive metastatic carcinoma seen.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules.

Scattered mast cells are seen.
Numerous naked nuclei are noted.
Blasts                3%
Promyelocytes           4%
Myelocytes           8%
Metamyelocytes           6%
Neutrophils/Bands      20%
Monocytes           6%
Eosinophils           5%
Erythroid Precursors      31%
Plasma Cells           5%
Lymphocytes           12%
Number of Cells Counted 500
M:E Ratio           1.6

Special stain
Iron: Suboptimal for evaluation; devoid of spicules.
Ring sideroblasts: Absent but sensitivity is reduced by lack of spicular marrow.

Morphology: The aspirate smears are spicular, cellular and show maturing trilineage hematopoiesis; no expanded blast population is seen. Mast cells are mildly increased. Erythroid and myeloid elements show progressive maturation. Megakaryocytes are present and unremarkable.

PERIPHERAL BLOOD
CBC (07/13/2021):
WBC 4.1 [4.0-11.0 K/mcL] 
RBC 2.51 L [3.80-5.00 M/mcL] 
HGB 9.2 L [11.2-15.4 g/dL] 
HCT 27.6 L [34.3-46.0 %] 
MCV 110 H [80-98 fL] 
MCH 36.7 H [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 17.6 H [12.2-15.1 %]
Platelets 69 L [160-400 K/mcL] 

Neutrophil 79.7 H [32.5-74.8 %] 
Mono 8.2 [0.0-12.3 %] 
Eos 0.7 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 9.9 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 3.3 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Absolute/relative lymphopenia; no circulating blasts seen. 
RBC: Macrocytic anemia with anisopoikilocytosis.
PLT: Moderate thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
Pan-cytokeratin AE1/AE3 highlights the metastatic carcinoma, which is also positive for GATA-3. A subset of metastatic carcinoma is positive for CD117. Immunohistochemical stains show no increases in CD34 and/or CD117 positive blasts (<5%). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-6675)
No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.58% of WBC.
387 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-4372.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-28470.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-2771;S13;MSKX - 2023-04-19 12.42.19.ndpi,Peripheral Blood Smear,2023-04-19,"Myelodysplastic Syndrome
Pancytopenia 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by large B cell lymphoma, non germinal center cell phenotype (10-15% involvement with CD20 immunostain)
     - Minute small abnormal B cell population with CLL/SLL phenotype also identified by flow cytometry studies.
     - Cellular marrow with trilineage maturing hematopoiesis.
  
     COMMENT: Clinico-radiological correlation to evaluate for systemic lymphadenopathy is recommended. The marrow also shows increase in reticulin fibers. Correlation with cytogenetic and molecular studies is suggested.

BONE MARROW BIOPSY
Quality:Good
Cellularity: Hypercellular     
M:E ratio:  Decreased
Blasts: Not increased
Myeloid lineage: Adequate maturation
Erythroid lineage: Left shifted
Megakaryocytes: Adequate
Lymphocytes: Increased with interstitial and paratrabecular aggregates composed of large cells
Plasma cells: not increased
Special stains: Reticulin stain shows moderate increase in reticulin fibrosis (MF-2+). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)
Numerous smudge cells/naked nuclei are noted

Blasts                2%
Promyelocytes           1%
Myelocytes           7%
Metamyelocytes           5%
Neutrophils/Bands      25%
Monocytes           7%
Eosinophils           1%
Erythroid Precursors      46%
Lymphocytes           6%
Number of Cells Counted 500
M:E Ratio           1

Special stain 
Iron:Trace
Ring sideroblasts: Absent 

Morphology:
-Paucispicular and cellular

PERIPHERAL BLOOD
CBC (04/19/2021):
WBC 2.6 L [4.0-11.0 K/mcL] 
RBC 2.90 L [3.95-5.54 M/mcL] 
HGB 8.3 L [12.5-16.2 g/dL] 
HCT 25.9 L [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 28.6 [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 15.7 H [12.2-15.1 %] 
Platelets. 70 L [160-400 K/mcL] 

Neutrophil 45.0 [32.5-74.8 %] 
Mono 43.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 11.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.2 L [1.5-7.5 K/mcL] 
Abs Mono 1.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 
Morphology:

IMMUNOHISTOCHEMISTRY
Immunostains show the large lymphoid cells to 
    Express: CD20, PAX5, MUM1, bcl2, CD71 (weak), 
    Do not express:  CD10, bcl6, CD30, cMYC, CD23, E-cadherin, MPO, SOX11, LEF1, Cyclin D1
    Other: CD3 highlights T lymphocytes, CD61 is noted in megakaryocytes, MPO highlights myeloid cells, CD71 also highlights erythroid cells. CD34 immunostain is negative, CD117 highlights few scattered cells. Ki-67 (30-9) highlights approximately 60-70% of the neoplastic cells.



FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-3695)
Two abnormal B-cell populations identified.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature T-cell population detected.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD5 (partial dim), CD22 (subset bright), kappa light chain restriction, and normal expression of CD20, CD38 and CD45; and without CD3, CD10, CD14, CD25, or CD279 (PD1). The abnormal B-cell population represents 4.7% of the total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

Flow cytometry identified an abnormal B-cell population with CLL/SLL-like immunophenotype having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23, CD43, CD79b (dim), CD81 (dim), CD200 (bright), ROR1 and lambda surface light chain restriction (dim); normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The abnormal B-cell population comprises 0.017% of the white cells.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.18% of WBC.
336 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.


CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-2417.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-15580.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-4209;S12;MSK4 - 2023-05-19 21.56.55.ndpi,Peripheral Blood Smear,2023-05-19,"Myelodysplastic Syndrome
Suspect BOTH MDS and B Cell Lymphoma

","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by low grade B-cell lymphoma, favor marginal zone lymphoma, (~40% by CD20/PAX5 immunohistochemistry), 
     - No definitive morphologic, immunophenotypic and cytogenetic support for myelodysplastic syndrome.  
     - Hypercellular marrow with trilineage maturing hematopoiesis.

See comment. 
  
COMMENT: Comprehensive genomic analysis was performed with this patient's peripheral blood and bone marrow aspirate sample (MSK-IMPACT is in progress). Based on morphologic and immunophenotypic findings along with the presence of TP53 mutation (M21-22897), marginal zone lymphoma is favored over CD5-negative chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Mild dysmegakaryopoiesis is present, and this could raise the possibility of underlying myelodysplastic syndrome (MDS); however, the origin of the complex clone with del(7q) and +15 was confirmed to be lymphoid cells, not myeloid cells, by FISH with cell sorting. Myeloid cells do not have these cytogenetic abnormalities. Therefore, the diagnosis of MDS cannot be rendered without thrombocytopenia or MDS-defining cytogenetic abnormality. 

This case was also reviewed by Dr. Mariko Yabe in Hematopathology Service. 
Cytogenetic findings were discussed with Dr. Yanming Zhang, Cytogenetic laboratory.
Dr. Martin Tallman was notified via e-mail on 6/22/2021.  

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular (~70-80%) for age 
M:E ratio: Normal 
Blasts: Not increased 
Myeloid lineage: Exhibits full maturation 
Erythroid lineage: Exhibits full maturation
Megakaryocytes: Adequate in number with some small and hypolobated forms (<10%)
Lymphocytes: Increased and form interstitial large aggregates, composed predominantly of small to medium-sized lymphoid cells with round to irregular nuclei, condensed chromatin, occasional distinct nucleoli and scant to moderate cytoplasm
Plasma cells: Scattered 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1+/3). 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:   Adequate
Blasts                1%
Promyelocytes           1%
Myelocytes           4%
Metamyelocytes           1%
Neutrophils/Bands      16%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      9%
Plasma Cells           1%
Lymphocytes           64%
Number of Cells Counted      500
M:E Ratio           2.8

Special stain 
Iron: Absent
Ring sideroblasts: Absent 

Morphology:
Aspicular and cellular aspirate smears showing markedly expanded monotonous lymphoid population, composed predominantly of small to medium sized cells with round nuclei, clumped to condensed chromatin, occasional distinct nucleoli and scant to moderate clear cytoplasm. Maturing myeloid and erythroid elements are reduced with no significant dysplasia. Megakaryocytes are present with mostly unremarkable morphology. Blasts are not increased.  

PERIPHERAL BLOOD
CBC (06/11/2021):
WBC 33.7 H [4.0-11.0 K/mcL] 
RBC 3.07 L [3.80-5.00 M/mcL] 
HGB 8.6 L [11.2-15.4 g/dL] 
HCT 28.5 L [34.3-46.0 %] 
MCV 93 [80-98 fL] 
MCH 28.0 [27.0-33.0 pg] 
MCHC 30.2 L [31.0-36.5 g/dL] 
RDW 16.2 H [12.2-15.1 %] 
Platelets 208 [160-400 K/mcL] 

Neutrophil 14.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 82.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 4.7 [1.5-7.5 K/mcL] 
Abs Mono 1.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.3 H [0.0-0.2 K/mcL] 
Abs Lymph 27.6 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
WBC: Expanded population of atypical lymphoid cells with similar morphology to those on the core biopsy present; no circulating blasts. 
RBC: Mild anisopoikilocytosis and polychromasia. 
PLT: Unremarkable morphology. 

IMMUNOHISTOCHEMISTRY
The neoplastic lymphoid cells (comprising ~40% marrow cellularity):
Express: CD20, PAX5, CD23 (subset) and BCL2
Do not express: CD5, LEF1, CyclinD1, BCL6, MUM1 and BRAF
Others:
CD3 and CD5 highlight intermixed small T-cells.
CD138 highlights scattered polytypic plasma cells (by kappa and lambda immunostains).
CD34 and CD117 show no increased blasts (<5% marrow cellularity).
CD117 also highlights scattered mast cells.
CD61 highlights megakaryocytes including few small and hypolobated forms.
CD71 and MPO highlight erythroid and myeloid precursors, respectively, with adequate proportion.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5574)
Interpretation: 
Two abnormal B-cell populations identified.
No abnormal mature T-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5 (partial), CD23 (partial), ROR1 and lambda surface light chain restriction (bright); normal expression of CD19, CD20, CD22, CD38, CD40, CD79b, CD81, CD200 and CD45; and without CD3, CD10, CD14, CD25, convincing CD43 or CD279. The abnormal B cell population represents 35.7% of total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. 

Flow cytometry identifies a second abnormal B-cell population having abnormal expression of CD19 (dim), CD20 (dim), CD45 (dim), CD79b (dim) and lambda surface light chain restriction (dim); normal expression of CD22, CD40, CD81, CD200 and CD45; and without CD3, CD5, CD10, CD14, CD23, CD25, CD38, ROR1, convincing CD43 or CD279.  The abnormal B cell population represents 0.51% of total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

Relationship between the two populations is not fully clear, but they are somewhat favored to represent immunophenotypically divergent, but likely related populations given same light chain restriction and shared key phenotypic features.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.63% of WBC.
333 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES 
Cytogenetic analysis will be reported separately. See separate report, CG21-3652.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-23996, M21-23997, M21-23998.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-2525;S2;MSKS - 2023-06-01 06.16.48.ndpi,Peripheral Blood Smear,2023-06-01,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate, and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma.

 COMMENT:
Correlation with pending cytogenetic and molecular studies is recommended.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                85%
Promyelocytes           1%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      3%
Erythroid Precursors      7%
Plasma Cells           1%
Lymphocytes           1%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
-Spiculate and hypercellular smears contain sheets of blasts. The blasts are small with scant cytoplasm, irregular nuclear borders, and fine chromatin. There are a few scattered background myeloid and erythroid elements, which are too infrequent to adequately assess for dysplasia in either of these lineages. Megakaryocytes are rare.

PERIPHERAL BLOOD
CBC (04/07/2021):
WBC 2.4 L [7.1-15.9 K/mcL] 
RBC 2.70 L [2.93-4.75 M/mcL] 
HGB 7.2 L [8.9-12.7 g/dL] 
HCT 23.5 L [26.8-37.8 %] 
MCV 87 H [70-85 fL] 
MCH 26.7 [22.7-29.5 pg] 
MCHC 30.6 L [31.0-36.5 g/dL] 
RDW 17.3 H [12.2-15.1 %] 
Platelets 223 [160-400 K/mcL] 

Neutrophil 15.0 L [16.9-74.5 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 15.0 H [0.0-0.0 %] 
Lymph 69.0 [18.1-79.9 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.4 L [1.5-8.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.4 H [0.0-0.0 K/mcL] 
Abs Lymph 1.6 [1.1-8.1 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Leukopenia. Occasional circulating blasts are present.
RBC: Normochromic anemia with mild anisocytosis.
Platelets: Morphologically unremarkable

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-3312)
Abnormal immature B-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified.
No abnormal mature B- or T-cell populations detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow (69.9% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression CD10 (dim to bright), CD13 (partial), CD24 (dim), CD33 (partial), CD34 (mostly absent), CD38 (dim), CD45 (absent to dim), CD66c/CD123, CD81 (absent to dim) with normal expression of CD19, CD22, CD71 and HLA-DR; and without CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD20, CD56, CD64, CD66b, CD86, CD117, CD73/CD304 or surface light chains.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.19% of WBC. 236 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-2194.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-13815.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. Pessin MD., PhD., Director.
"
H21-5452;S11;MSKU - 2023-06-06 03.20.41.ndpi,Peripheral Blood Smear,2023-06-06,"Lymphoma
Screening for 19-203 hx MZL
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Low grade B-cell lymphoma (80% with CD20 immunohistochemistry). See comment. 
     - Cellular marrow with trilineage maturing hematopoiesis.

COMMENT:
The patient's previous molecular studies detected a BRAF V600E mutation and some additional mutations. Although BRAF V600E mutation is characteristic for Hairy cell leukemia, the immunophenotype and morphology do not support it. The immunophenotype rather supports a diagnosis of splenic marginal zone lymphoma. Clinical correlation is suggested. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy specimen and clot section show hypercellular bone marrow (90-100% cellularity) with an extensive infiltrate by an atypical lymphoid infiltrate composed of small lymphoid cells with slightly irregular nuclei, condensed chromatin and inconspicuous nucleoli. There isreduction of normal maturing hematopoiesis. Megakaryocytes appear decreased in number. The aspirate smears are suboptimal

Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules.

Promyelocytes           1%
Myelocytes           1%
Neutrophils/Bands      7%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      1%
Lymphocytes           88% 
Number of Cells Counted 500
M:E Ratio           N/A 

IMMUNOHISTOCHEMISTRY
The lymphoid cells
Express: CD20, PAX5, TRAP (minor subset), IGD (dim)
Do not express: CD11c, CD25, CD103, CD123, Annexin, 
IGM, IGG and IGA stain rare plasma cells. 
Other: Ki-67 proliferative index is approximately <5% in lymphoid cells.
CD3 highlights background T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7202) 
Interpretation: 
Abnormal B-cell population identified.
No abnormal plasma cell population detected.

Flow cytometry reveals an abnormal mature B-cell population with an immunophenotype similar to that seen previously (F21-4982) showing abnormal expression of CD19 (slightly bright), CD38 (absent), and lambda light chain restriction, and normal expression of CD20, CD22, and CD45; and without CD3, CD5, CD10, CD14, significant CD25, or CD279 (PD1). The abnormal B-cell population represents 50.9% of the total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

No evidence of an abnormal plasma cell population is identified by flow cytometry. 736 thousand cells acquired.

PERIPHERAL BLOOD
CBC (07/27/2021):
WBC 51.9 H [4.0-11.0 K/mcL] 
RBC 3.04 L [3.95-5.54 M/mcL] 
HGB 9.6 L [12.5-16.2 g/dL] 
HCT 29.3 L [37.5-49.3 %] 
MCV 96 [80-98 fL] 
MCH 31.6 [27.0-33.0 pg] 
MCHC 32.8 [31.0-36.5 g/dL] 
RDW 18.7 H [12.2-15.1 %] 
Platelets 111 L [160-400 K/mcL] 

Neutrophil 10.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 14.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 73.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 5.2 [1.5-7.5 K/mcL] 
Abs Mono 1.6 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 45.2 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: marked lymphocytosis. The lymphoid cells are medium in size and have abundant cytoplasm, round to oval nuclei and conspicuous nucleoli. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-4755.

MOLECULAR STUDIES 
Not performed.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-8229;S25;MSK4 - 2023-05-19 16.57.20.ndpi,Peripheral Blood Smear,2023-05-19,"Clinical Diagnosis: Leukemia, Hairy Cell
Clinical Hx/Op Findings: 67 y/o man w/ multilineage cytopenias and concern for hairy cell leukemia
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Extensive involvement by hairy cell leukemia (60-70% with CD20 immunohistochemistry).
     - Hypercellular marrow with reduced maturing trilineage hematopoiesis and erythroid hyperplasia.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate (although paucity spicular and hypocellular with numerous naked nuclei) specimens show hypercellular for age bone marrow (60%cellularity). There istrilineage maturing hematopoiesis with an atypical lymphoid infiltrate present singly and in clusters interstitially, composed of small to intermediate size atypical lymphoid cells, with round to irregular nuclei, clumped chromatin, generally inconspicuous nucleoli, and abundant pale cytoplasm. Background maturing trilineage hematopoiesis is reduced. The M:E ratio appears decreased. Myeloid elements are relatively decreased and present in various stages of maturation without overt dysplasia. Erythroid cells are relatively increased without overt dysplasia. Megakaryocytes are adequate in number without overt atypia. Few scattered mast cells are noted on the aspirate smears.

Bone Marrow Aspirate Smear Quality: Adequate
Blasts               0%
Myelocytes           4%
Metamyelocytes           1%
Neutrophils/Bands      22%
Eosinophils           1%
Erythroid Precursors      43%
Plasma Cells           2%
Lymphocytes           15%
Hairy cells           12%
Number of Cells Counted     500
M:E Ratio           0.7

Special Stain:
Iron stain cannot be performed due to lack of available unstained aspirate smears.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD20 (account for 62 70% of the marrow cellularity, present interstitially singly and in clusters), PAX5, BRAF VE, Annexin A1, CD25 (weak, partial), CD103, CD11c, cyclin D1 (small subset, weak),
Do not express: CD3, CD123, CD5, CD23, LEF1
Other:
CD3 highlights few scattered admixed T-cells.
CD34 and CD117 show no increase in blasts (< 5%).
CD117 also highlights few scattered mast cells, without forming clusters or aggregates.
MPO highlights myeloid cells, which are decreased; while CD71 highlights erythroid cells which appear increased, with an overall decreased M:E ratio.
CD61 is positive and megakaryocytes which are adequate in number.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW
Not submitted

PERIPHERAL BLOOD
CBC (11/5/2021)
WBC 3.3 L [4.0-11.0 K/mcL] 
RBC 4.30 [3.95-5.54 M/mcL] 
HGB 13.7 [12.5-16.2 g/dL] 
HCT 40.5 [37.5-49.3 %] 
MCV 94 [80-98 fL] 
MCH 31.9 [27.0-33.0 pg] 
MCHC 33.8 [31.0-36.5 g/dL] 
RDW 12.8 [12.2-15.1 %] 
Platelets. 117 L [160-400 K/mcL] 

Neutrophil 51.7 [32.5-74.8 %] 
Mono 4.2 [0.0-12.3 %] 
Eos 2.7 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.0 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 40.8 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 1.7 [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.4 [0.9-3.2 K/mcL]

Morphology:
WBC: Leukopenia with monocytopenia and mild neutropenia. Rare atypical lymphoid cells are seen, with round clear elements chromatin, inconspicuous nucleoli, and moderate amount of cytoplasm with occasional projections.
RBC: Normocytic, normochromic RBCs
Platelets: Thrombocytopenia, mild

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Not submitted

MOLECULAR STUDIES 
Not submitted 
"
H21-142;S11;MSKL - 2023-04-19 12.55.05.ndpi,Peripheral Blood Smear,2023-04-19,"Multiple Myeloma 
Calvarial lesions r/o myeloma 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by mantle cell lymphoma, 20-30% by CD20 immunohistology. See comment.
     - Minimal involvement by mature B-cell lymphoma with increased large cells, ~5% by CD20/MUM1 immunohistology. See comment.
     - Hypercellular marrow with maturing trilineage hematopoiesis and erythroid hyperplasia.
     - No morphologic or immunophenotypic evidence of plasma cell neoplasm.

COMMENT: There is involvement by a kappa light chain restricted B-cell lymphoma with a mantle cell lymphoma (MCL) immunophenotype, which is present in large nodules and scattered interstitially. The corresponding FISH analysis (CG21-121) revealed a CCND1-IGH fusion diagnostic for MCL. Peripheral blood flow cytometric analysis (F21-509) also showed predominant involvement by the same MCL population. The leukemic involvement and lack of SOX11 expression raise the possibility that the MCL may represent a leukemic variant. Clinical correlation is needed. 
     In addition, by flow cytometry there is a second abnormal B-cell population (lambda light chain restricted) with a nonspecific immunophenotype accounting for 4.8% of the WBC. By morphologic assessment this population appears to correspond to intermediate to large neoplastic B-cells intimately admixed and scattered interstitially with the MCL nodules. This may represent a composite B-cell lymphoma in the form of minimal bone marrow involvement by a second mature B-cell lymphoma which shares the same immunophenotype as the patient's right frontal skull mass (F21-489). Due to the limited involvement, further characterization is not possible in this sample and correlation with the forthcoming report of the right frontal skull mass (S21-2989) is required. 

Reviewed with Dr. Ahmet Dogan, Chief of Hematopathology service, who agrees.

BONE MARROW BIOPSY
Marginally adequate, fragmented, and partially aspirated with intramedullary hemorrhage core biopsy shows approximately hypercellular for age (60-70%) marrow. There are several small and large interstitial atypical lymphoid aggregates composed of small atypical lymphoid cells, with round to elongated nuclei, condensed chromatin, inconspicuous nucleoli, and scant cytoplasm. Few admixed scattered intermediate to large atypical lymphoid cells with more prominent nucleoli and more abundant pale cytoplasm are also identified within the atypical lymphoid nodules. In uninvolved areas there is maturing trilineage hematopoiesis. Myeloid and erythroid cells are actively maturing. Megakaryocytes appear adequate in number with occasional forms showing nuclear hyperchromasia. Plasma cells are not increased.

ASPIRATE MORPHOLOGY
Aspirate differential: (Performed by HM)


Blasts                1%
Promyelocytes           2%
Myelocytes           5%
Metamyelocytes           3%
Neutrophils/Bands      10%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      14%
Plasma Cells           1%
Lymphocytes           62%
Number of Cells Counted 500
M:E Ratio           1.6

Morphology: 
Adequate, spicular and cellular aspirate smears with maturing trilineage hematopoiesis and no expanded blast population. Many large lymphoid aggregates are noted, with patchy involvement focally reaching 90%, which are composed of atypical lymphoid cells which are small in size, with round to irregular nuclei, variably condensed chromatin, occasionally prominent nucleoli and scant to moderate amount of cytoplasm. Occasionally large atypical lymphoid cells are seen with more open chromatin and prominent nucleoli. Myeloid elements are present at various stages of maturation and show no significant dysplasia. Erythroid cells are present at various stages of maturation and show occasional megaloblastoid features. Megakaryocytes are seen without overt atypia. Rare plasma cells with mature appearance are seen.

IMMUNOHISTOCHEMISTRY
The small neoplastic cells
Express:CD20, PAX5 (present in nodular lymphoid aggregates and scattered interstitially singly and in clusters, occupying approximately 20-30% of the marrow), CD5, Cyclin D1 (variable, weak), BCL2, IgD
Do not express: CD3, LEF1, SOX11, CD10, BCL6, LMO2, p53, cMYC, CD23.
Other:
The Ki-67 proliferation rate is low in the small neoplastic B-cells (< 10%).
CD3 highlights many admixed T-cells, with a subset of these positive for PD-1.
BCL2 is also positive in the admixed T-cells.

The few admixed intermediate to large neoplastic cells:
Express: CD20, PAX5, BCL6, BCL2 (weak), OCT2, MUM1, p53 (weak, subset), CD23 (subset) 
Do not express:CD3, LEF1, cyclin D1, CD5, SOX11, CD10, BCL6, LMO2, CD15, cMYC, IgD  
CD23 and CD21 highlights the follicular dendritic cell meshworks associated with the lymphoid nodules.
Other: 
Ki-67 highlights the majority of the larger neoplastic cells, which appear to be actively proliferating.
EBER in situ hybridization for EBV RNA is negative.
CD30 appears to be positive in rare scattered cells.

CD138 immunostain highlights rare scattered plasma cells, <5% of marrow cellularity. 
Kappa and lambda immunostains show that the plasma cells are polytypic.  
BCMA highlights 90% of plasma cells, (1-2+) intensity, membranous / Golgi pattern. 
CD117 highlights the early myeloid and erythroid cells as well as shows bright expression in the few scattered mast cells.
CD15 is positive in the granulocytic cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-182) 
Interpretation: 

Two abnormal B-cell populations identified.
No abnormal plasma cell population detected.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD19 (slightly bright), CD20 (slightly dim), ROR1 and kappa surface light chain restriction (bright); normal expression of CD22, CD38, CD40, CD79b, CD81, and CD45; and without CD3, CD10, CD23, CD25, CD43, PD1 (CD279), CD14 or CD200. The abnormal B cell population represents 10.9% of total white cells.

This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with immunohistochemical or cytogenetic studies for Cyclin D1 is recommended to rule out mantle cell lymphoma.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD19 (slightly bright), CD23 (subset), CD79b (absent), lambda light chain restriction, and normal expression of CD20, CD22, CD38 and CD45; and without CD3, CD5, CD10, CD14, CD25, or CD279 (PD1). The abnormal B-cell population represents 4.8% of the total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

No evidence of an abnormal plasma cell population is identified by flow cytometry.  Plasma cells comprise 0.055% of the viable cells, following erythroid lysis.
4.4 million cells acquired.  Please note that flow cytometry studies generally underestimate the number of plasma cells, as compared to morphologic assessment.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-509; 1/15/21)
Interpretation: 
Two abnormal B-cell populations identified.
No abnormal plasma cell population detected.
No evidence of an abnormal plasma cell population is identified by flow cytometry. Virtually no plasma cells seen.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD19 (dim), CD22 (dim), CD43 (partial, dim), ROR1, and kappa surface light chain restriction (bright); normal expression of CD20, CD40, CD79b, CD81, and CD45; and without CD3, CD10, CD23, CD25, CD38, PD1 (CD279), CD14 or CD200.  The abnormal B cell population represents 30.4% of total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with immunohistochemical or cytogenetic studies for Cyclin D1 is recommended to rule out mantle cell lymphoma.

Flow cytometry reveals a mature B-cell population having abnormal expression of CD20 (dim), CD23 (partial), CD79b (absent), and lambda light chain restriction; with normal expression of CD19, CD22, CD38 and CD45; and without CD5, CD10, CD43, or ROR1. The immunophenotype of the abnormal B cell population is similar to that identified previously F21-182. The abnormal B-cell population represents 1.1% of the total white cells. 

5,463,338 cells acquired for plasma cell assessment. Please note that flow cytometry studies generally underestimate the number of plasma cells, as compared to morphologic assessment.

PERIPHERAL BLOOD
CBC (01/07/2021):
WBC 6.6 [4.0-11.0 K/mcL] 
RBC 4.58 [3.95-5.54 M/mcL] 
HGB 13.6 [12.5-16.2 g/dL] 
HCT 41.3 [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 32.9 [31.0-36.5 g/dL] 
RDW 13.0 [12.2-15.1 %] 
Platelets 150 L [160-400 K/mcL] 

Neutrophil 33.0 [32.5-74.8 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 57.0 H [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 2.2 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 3.8 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBC: An atypical lymphocytosis is noted, with intermediate to occasionally large size lymphocytes with round to angulated nuclei, variably condensed chromatin occasionally prominent nucleoli, and moderate amount of cytoplasm. 
RBC: Normochromic, normocytic RBCs.
Platelets: Adequate in number with unremarkable morphology.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate reports, CG21-122 & CG21-122.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M21-1888 & M21-1891.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-6761;S11;MSKY - 2023-05-19 18.38.57.ndpi,Peripheral Blood Smear,2023-05-19,"Multiple Myeloma     
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
    - Low-grade B-cell lymphoma with plasmacytic differentiation, 20-30% involvement by CD20/CD138 immunohistochemistry. 

Comment: Differential diagnosis includes marginal zone lymphoma and lymphoplasmacytic lymphoma. Please correlate with clinical and radiological findings. Corresponding molecular evaluation is in progress.  

BONE MARROW BIOPSY AND ASPIRATE SMEAR MORPHOLOGY
Quality: Adequate  
Cellularity: 90-95%
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes: Adequate   
Plasma cells: Increased    
Other findings: Lymphocytic infiltrate present. 

Bone Marrow Aspirate Smear Quality: Hypo/hemodiluted
Performed on touch imprints
Blasts                2%
Promyelocytes           2%
Myelocytes           4%
Metamyelocytes           3%
Neutrophils/Bands      21%
Monocytes           2%
Eosinophils           1%
Erythroid Precursors      38%
Plasma Cells           3%
Lymphocytes           24%
Number of Cells Counted      500
M:E Ratio           0.9

Morphology: 
Marrow spicules: Aspicular.
Cellularity: Cellular on touch imprints
Plasma cell morphology: Small to intermediate   
Myeloid lineage: Orderly maturation   
Erythroid Lineage: Orderly maturation   
Megakaryocytes: Present    

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight increased B-cell population, comprising 15-20% of marrow cellularity, mostly showing nodular distribution with few foci suggestive of intra-sinusoidal distribution.  
CD138 highlights increase in plasma cells, 5-10% of cellularity. 
Kappa and lambda immunostains show the plasma cells are kappa light chain predominant. 
BCMA highlights >80% of plasma cells, (1-2+) intensity, membranous/ Golgi pattern. 
CD3 highlights background reactive T-cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-8946) 
Interpretation: 
1. Abnormal B- and plasma cell populations detected.
The abnormal B cell population has the same light chain restriction as the abnormal plasma cell population mentioned below. Given the similar light chain restriction, these two populations likely represent manifestations of the same neoplasm, but the immunophenotypic profiles do not allow specific classification. Clinical and morphologic correlation is advised.

Abnormal B cell population represents 23.3% of WBC

Immunophenotype:
Abnormal: CD5 (partial), CD20 (bright), CD22 (dim), surface Kappa (restriction), CD13 (positive), CD79b (variable - negative, intermediate)
Normal: CD19, CD38, CD45, CD40, CD81, CD200
Negative: CD10, CD25, CD279 (PD1), CD3, CD14, surface Lambda, CD23, CD43, ROR1

Number of cells acquired: 299 thousand  

2. Abnormal plasma cell population detected.
The abnormal plasma cell population has the same light chain restriction (see immunophenotype below) as the abnormal B cell population mentioned above. 

Abnormal plasma cell population represents 0.015% of WBC

Immunophenotype:
Abnormal: CD38 (dim), CD27 (bright), cytoplasmic Kappa (restriction)
Normal: CD138, CD229, CD319, CD19, CD45, CD81
Negative: CD20, CD56, CD117, cytoplasmic Lambda

Number of cells acquired: 5.7 million  

3. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.14% of WBC
Monocytosis is seen, 14.1% of WBC
Number of cells acquired: 301 thousand  

PERIPHERAL BLOOD
CBC (09/14/2021):
WBC 10.4 [4.0-11.0 K/mcL] 
RBC 2.49 L [3.95-5.54 M/mcL] 
HGB 8.3 L [12.5-16.2 g/dL] 
HCT 24.6 L [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 29.6 [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL]
RDW 17.5 H [12.2-15.1 %] 
Platelets. 224 [160-400 K/mcL] 

Neutrophil 23.0 L [32.5-74.8 %] 
Mono 12.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 1.0 H [0.0-0.0 %] 
Lymph 42.0 [12.2-47.4 %] 
Plasma Cell 20.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 
Abs Neut 2.4 [1.5-7.5 K/mcL] 
Abs Mono 1.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 4.4 H [0.9-3.2 K/mcL] 
Abs Plasma Cells 2.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
Circulating plasma cells/plasmacytoid cells seen. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5883, CG21-5884.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-37815, M21-37824.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

     
"
H21-6220;S11;MSKY - 2023-06-06 02.05.30.ndpi,Peripheral Blood Smear,2023-06-06,"ALL. 6 months status post allo SCT. 
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Extensive involvement by T-lymphoblastic leukemia (93% blasts by differential count).

COMMENT: The morphologic findings are consistent with involvement by the previously diagnosed T lymphoblastic leukemia.  Correlation with the concurrent molecular genetic results is suggested.
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Overall 60%
Blasts: Most of the cellularity (~ 90%) is represented by blasts forming sheets
Scattered clusters of myeloid precursors displaying left-shifted maturation are presents with only rare maturing erythroid elements and megakaryocytes seen.
Lymphocytes: Not increased
Plasma cells: Not increased
Clot section: Mostly blood, with scant fragments of marrow with features overlapping those seen in the core biopsy.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate 
Blasts                93%
Neutrophils/Bands      1%
Eosinophils           1%
Erythroid Precursors      2%
Plasma Cells           2%
Lymphocytes           1%
Number of Cells Counted      500
M:E Ratio           1

Morphology:
-Spicular and cellular bone marrow aspirate smears. Blasts are markedly increased. They have round nuclei, dispersed chromatin, prominent nucleoli and very scant cytoplasm. Rare myeloid and erythroid maturing elements are seen. Megakaryocytes are virtually absent.

PERIPHERAL BLOOD
CBC (8/24/2021):
WBC 4.8 [4.0-11.0 K/mcL] 
RBC 3.16 L [3.95-5.54 M/mcL] 
HGB 10.7 L [12.5-16.2 g/dL] 
HCT 32.5 L [37.5-49.3 %] 
MCV 103 H [80-98 fL] 
MCH 33.9 H [27.0-33.0 pg] 
MCHC 32.9 [31.0-36.5 g/dL] 
RDW 16.1 H [12.2-15.1 %] 
Platelets. 27 L [160-400 K/mcL] 

Neutrophil 29.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 30.0 H [0.0-0.0 %] 
Lymph 35.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 1.4 H [0.0-0.0 K/mcL] 
Abs Lymph 1.7 [0.9-3.2 K/mcL]

Morphology: Numerous circulating blasts seen.

IMMUNOHISTOCHEMISTRY
Immunostains show markedly increased number of CD34+, TdT+ blasts accounting for 90-95% of the cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-8251)
Abnormal immature T cell population detected.
Abnormal immature T cell population of WBC: 85.8 %  

Abnormal: CD2 (negative), CD7 (positive - bright), CD34 (positive), CD45 (dim), cytoplasmic CD3 (bimodal - negative, dim), CD10 (partial), CD48 (negative), CD38 (uniform - bright), CD16/CD56 (positive)
Normal: CD5
Negative: CD3, CD4, CD8

Number of Cells Acquired: 356 thousand.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-8220)
Abnormal immature T cell population detected. 
Abnormal immature T cell population of WBC: 33.3 %

The phenotype may represent ""near"" early T cell precursor ALL, given expression of CD5, but otherwise early T cell phenotype.
Abnormal: CD7 (bright), CD10 (partial), CD11b (partial), CD13 (positive), CD19 (partial), CD33 (variable - negative, intermediate), CD34 (positive), CD38 (positive - bright), CD45 (dim), CD48 (negative), CD56 (partial), CD123 (partial), cytoplasmic CD3 (variable - negative, dim), cytoplasmic CD79a (partial) 
Normal: CD2, CD5, CD71 
Negative: CD3, CD4, CD8, CD14, CD15, CD16, CD25, CD26, CD64, CD117, CD279 (PD1), HLA-DR, TCR gamma/delta, cytoplasmic MPO
Number of Cells Acquired: 529 thousand

No abnormal myeloid blast, monocyte or maturing myeloid population identified. Few myeloid blasts seen. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5430.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-34979, 35015, M21-35016, M21-35045.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-1172;S11;MSKP - 2023-04-19 15.38.20.ndpi,Peripheral Blood Smear,2023-04-19,"AML. Newly diagnosed. 
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate and peripheral blood smears:   
     - Acute myeloid leukemia (AML) with monocytic differentiation (65% blasts on aspirate differential count), see comment #1.
     - Minute abnormal B-cell population (0.044% of white cells) detected by flow cytometry, see comment #2.  

COMMENT #1: Correlation with the clinical history, cytogenetic and molecular genetic studies is required for complete subclassification.

COMMENT #2: In addition to the abnormal myeloid blast population, flow cytometric analysis detected an abnormal B-cell population (0.044% of white cells) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)-like immunophenotype. A morphologic correlate of this population is not identified, and it likely represents monoclonal B-cell lymphocytosis. 

BONE MARROW BIOPSY
Quality: Adequate biopsy with fragmentation
Cellularity: Hypercellular for age (~70% cellularity)
M:E ratio: N/A
Blasts: Sheets of intermediate-sized blasts/blast equivalents with round or folded/irregular nuclei, fine to dispersed chromatin, conspicuous nucleoli and scant to moderate amount of cytoplasm     
Myeloid lineage: Markedly reduced 
Erythroid lineage: Markedly reduced 
Megakaryocytes: Markedly reduced 
Lymphocytes: Interstitially scattered     
Plasma cells: Interstitially scattered     

Special stains: Reticulin stain shows no significant increase in reticulin fibrosis (0/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Blasts/ Blast equivalents     65% 
Promyelocytes           1%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      10%
Monocytes           8%
Eosinophils           1%
Erythroid Precursors      10%
Lymphocytes           3%
Number of Cells Counted      500
M:E Ratio           N/A

Morphology:
The aspirate smears are spicular and hypercellular demonstrating markedly increased number of blasts/blast equivalents that are predominantly intermediate-sized with round to irregular/folded nuclei, fine chromatin, conspicuous nucleoli and scant to moderate amount of cytoplasm with granules. Myeloid and erythroid elements are decreased and show progressive maturation with some dysgranulopoiesis (hypogranular cytoplasm, abnormal lobation, pseudo Pelger-Huet forms) and some dyserythropoiesis (binucleation, nuclear irregularity/budding, N/C dyssynchrony). Megakaryocytes are markedly reduced. 

PERIPHERAL BLOOD
CBC (02/17/2021):
WBC 7.5 [4.0-11.0 K/mcL] 
RBC 2.49 L [3.95-5.54 M/mcL] 
HGB 7.7 L [12.5-16.2 g/dL] 
HCT 24.3 L [37.5-49.3 %] 
MCV 98 [80-98 fL] 
MCH 30.9 [27.0-33.0 pg] 
MCHC 31.7 [31.0-36.5 g/dL] 
RDW 20.4 H [12.2-15.1 %] 
Platelets 11 L [160-400 K/mcL] 

Neutrophil 25.0 L [32.5-74.8 %] 
Mono 54.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 11.0 H [0.0-0.0 %] 
Lymph 10.0 L [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 1.9 [1.5-7.5 K/mcL] 
Abs Mono 4.0 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.8 H [0.0-0.0 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBCs: Many blasts/blast equivalents (immature monocytes) with folded nuclei, fine chromatin, conspicuous nucleoli and moderate amount of cytoplasm are present. Borderline lymphopenia. 
RBCs: Normocytic normochromic anemia with moderate anisopoikilocytosis (target cells, echinocytes). 
Platelets: Marked thrombocytopenia.     

IMMUNOHISTOCHEMISTRY
CD117 highlights sheets of blasts (~70% of cellularity).
CD34 highlights a major subset of blasts with variable intensity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-1590)
Expanded abnormal myeloid blast population detected.
Monocytosis seen (34.0% of WBC).
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD7 (partial), CD13 (dim), CD33 (uniform intermediate), CD38 (uniform intermediate), CD117 (uniform bright), CD123 (uniform intermediate), HLADR (uniform intermediate) with normal expression of CD4, CD34, CD45 and CD71; without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 31.1% of WBC. In addition, immature monocytes with loss of CD14 expression are approximately 13% of WBC. Therefore, the total blasts/blast equivalent are 44.1%. 

Flow cytometry identified an abnormal B-cell population having abnormal expression of CD5, CD20 (dim), CD23, CD43, CD79b (absent), CD81 (dim), CD200 (bright), and ROR1; normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The findings are consistent with previously diagnosed chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL). The abnormal B-cell population comprises 0.020% of the white cells.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-1267; 2/9/2021)
Abnormal myeloid blast population detected. 
Abnormal B-cell population identified.
Marked relative monocytosis seen, 63.2% of WBC.
No abnormal mature T-cell population detected.

The blasts have abnormal expression of CD5 (partial), CD7, CD11b (subset), CD13 (dim), CD33 (bright), CD34 (variable, dim to bright), CD117 (dim), and HLA-DR (variable, absent to bright); with normal expression of CD4, CD38, CD45, CD71, and CD123; without CD2, surface CD3, cytoplasmic CD3, CD8, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cytoplasmic CD79a, or surface light chains. MPO expression is present on a subset of blasts. Marked relative monocytosis is also seen, 63.2% of WBC, with blast equivalent immature monocytes (with dim CD14, and abnormally dim HLA-DR) present as well, 3.4% of WBC. CD34 positive myeloid blasts represent 7.8% of WBC.

Overall blasts and blast equivalent immature monocytes are 11.2% of WBC. Findings are consistent with a myeloid neoplasm. However, morphologic correlation is required, as is correlation with cytogenetic and molecular studies. Bone marrow sampling is also recommended. 

The immunophenotypic identification of an abnormal B-cell population having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23 (partial), CD43, CD79b (absent), CD81 (absent to dim), CD200 (bright), ROR1, and no definite surface light chain; normal expression of CD19, CD40 and CD45; and without CD3, CD25, CD38, CD10, PD1 (CD279), or CD14 expression is consistent with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or CLL-like monoclonal B-cell lymphocytosis. Quantitative criterion for CLL (>5000 cells/microliter) abnormal CLL clone is not met in the current sample.  The abnormal B-cell population comprises 0.044% of the white cells representing absolute count of 0.005 thousand/microliter of blood.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-1045.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-6358, M21-6361, M21-6360, M21-6363.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-9611;S12;MSKW - 2023-04-19 17.01.12.ndpi,Peripheral Blood Smear,2023-04-19,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: Per protocol
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Plasma cell neoplasm, 
20-30% involvement by CD138 immunohistochemistry.
20% involvement by aspirate differential
8.7% of the total WBC involvement by 12 color flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/CLOT
Quality: Limited
Cellularity: Approximately 50-60% in limited evaluable area
Myeloid lineage: Orderly maturation  
Erythroid lineage: Orderly maturation
Megakaryocytes: Adequate    
Plasma cells: Increase of interstitial plasma cells.  
Clot section: Adequate with similar morphologic findings to the core biopsy.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                2%
Promyelocytes           4%
Myelocytes           13%
Metamyelocytes           9%
Neutrophils/Bands      18%
Monocytes           1%
Eosinophils           5%
Erythroid Precursors      25%
Plasma Cells           20%
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           2

Morphology: 
Marrow spicules: Paucispicular   
Cellularity: Cellular   
Plasma cell morphology: Large to small sized with prominent nucleoli and occasional binucleation. 
Myeloid lineage: Orderly maturation  
Erythroid Lineage: Orderly maturation    
Megakaryocytes: Present     

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 20-30% of marrow cellularity. 
Kappa and lambda immunostains show the plasma cells are lambda light chain restricted.  
BCMA highlights 90% of plasma cells, (1-2+) intensity, membranous / Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-12773) 
Interpretation: 
1. Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.

Abnormal plasma cell population comprises 99.0% of total plasma cells.
Abnormal plasma cell population represents 8.7% of WBC.

Immunophenotype:
Abnormal: CD38 (dim; consistent with anti-CD38 therapy), CD19 (negative), CD27 (variable - negative to intermediate), CD45 (negative), CD56 (positive), CD81 (variable - negative to intermediate), CD117 (partial), cytoplasmic Lambda (restriction)
Normal: CD138, CD229, CD319
Negative: cytoplasmic Kappa

Number of cells acquired: 4.8 million  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (12/22/2021):
WBC 3.5 L [4.0-11.0 K/mcL] 
RBC 3.50 L [3.95-5.54 M/mcL] 
HGB 10.8 L [12.5-16.2 g/dL] 
HCT 32.5 L [37.5-49.3 %] 
MCV 93 [80-98 fL] 
MCH 30.9 [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 18.9 H [12.2-15.1 %] 
Platelets 119 L [160-400 K/mcL] 

Neutrophil 57.0 [32.5-74.8 %] 
Mono 17.0 H [0.0-12.3 %]  
Eos 5.0 H [0.0-4.9 %]  
Baso 0.0 [0.0-1.5 %]  
Immature Granulocyte [0.0-0.6] 
Lymph 21.0 [12.2-47.4 %]  
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)]  

Abs Neut 2.0 [1.5-7.5 K/mcL]  
Abs Mono 0.6 [0.0-1.3 K/mcL]  
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL]  
Absolute Basophil 0.0 [0.0-0.2 K/mcL]  
Absolute Immature Granulocyte [0.0-0.1] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL]  
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: 
WBC: No circulating plasma cell on scanning. 
RBC: Mild normocytic anemia, 
PLT: Morphologic unremarkable. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-8411, CG21-8412.

MOLECULAR STUDIES 
Not submitted.
"
H21-3976;S11;MSK3 - 2023-05-19 22.53.11.ndpi,Peripheral Blood Smear,2023-05-19,"ALL
B-ALL, being considered for CD19 CAR therapy
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma (49% blasts on aspirate). 

BONE MARROW BIOPSY
Quality: adequate 
Cellularity: 40-50% 
M:E ratio: not applicable 
Blasts: markedly increased 
Myeloid lineage: reduced 
Erythroid lineage: reduced 
Megakaryocytes: reduced 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0/3). 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                49%
Myelocytes           3%
Metamyelocytes           4%
Neutrophils/Bands      16%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      17%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
Spicular and very cellular bone marrow aspirate shows markedly increased blasts. Normal trilineage hematopoiesis is suppressed. 

PERIPHERAL BLOOD
CBC (06/03/2021):
WBC 5.8 [4.0-11.0 K/mcL] 
RBC 3.58 L [3.80-5.00 M/mcL] 
HGB 12.7 [11.2-15.4 g/dL] 
HCT 37.6 [34.3-46.0 %] 
MCV 105 H [80-98 fL] 
MCH 35.5 H [27.0-33.0 pg] 
MCHC 33.8 [31.0-36.5 g/dL] 
RDW 16.1 H [12.2-15.1 %] 
Platelets 99 L [160-400 K/mcL] 

Neutrophil 47.0 [32.5-74.8 %] 
Mono 7.9 [0.0-12.3 %] 
Eos 1.4 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 42.9 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.7 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 2.5 [0.9-3.2 K/mcL] 

Morphology: no obviously increased blasts 

IMMUNOHISTOCHEMISTRY
CD34 shows increased blasts, ~50%.
CD117 is negative in blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5290)
Abnormal immature B-cell population detected.
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow (31.5% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD5 (partial), CD10 (bright), CD20 (partial dim), CD33 (partial dim), CD13 (partial dim), CD25 (partial), CD34 (absent to bright), CD38 (absent to intermediate), CD45 (subset absent, subset dim), CD66c/CD123, CD73/CD304, and CD81 (dim); with normal expression of CD19, CD22, CD24, cytoplasmic CD79a, and HLA-DR; and without CD2, CD3, CD4, CD7, CD8, CD11b, CD14, CD15, CD16, CD56, CD64, CD66b, CD86, CD117, MPO or surface light chains.

No immunophenotypic evidence of involvement by mature B- or T-cell lymphoma or leukemia is identified.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.27% of WBC.
200,000 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3450.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-22659, 22660.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H21-6564;S12;MSK- - 2023-05-19 18.22.19.ndpi,Peripheral Blood Smear,2023-05-19,"Leukemia, Hairy Cell. Worsening cytopenias evaluate MDS. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Extensive involvement by hairy cell leukemia (70% by CD20 immunohistochemistry)
     - Background hypocellular marrow with maturing trilineage hematopoiesis 

Comment: Additional stains are stains are pending and will be reported in addendum. Evaluation for myeloid component by flow cytometry will be likewise reported in addendum to the flow case.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypocellular (30-40%)
M:E ratio: Within normal limits
Blasts: Not increased
Myeloid lineage: Present with maturation
Erythroid lineage: Present with maturation
Megakaryocytes: Slightly increased with atypical cells, exhibiting small hypolobated or hyperchromatic nuclei
Lymphocytes: Increased small interstitial lymphocytes with scant to moderate cytoplasm, round nuclei and condensed chromatin
Plasma cells: Scattered


BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: hypocellular, devoid of spicules

Myelocytes           6%
Metamyelocytes           2%
Neutrophils/Bands      30%
Erythroid Precursors      21%
Plasma Cells           1%
Lymphocytes           16%
Hairy cells           24%
Number of Cells Counted 500
M:E Ratio           1.8 


Morphology:
- Aspicular and hypocellular marrow shows an expanded population of atypical, intermediate-sized lymphoid cells with moderate amount of clear to amphophilic cytoplasm, round to oval nuclei and condensed chromatin, which comprise 24% of the total cellularity. Background marrow shows trilineage hematopoiesis. Overt dysplasia is not seen.

PERIPHERAL BLOOD
CBC (09/08/2021):
WBC 5.4 [4.0-11.0 K/mcL] 
RBC 5.87 H [3.95-5.54 M/mcL] 
HGB 15.7 [12.5-16.2 g/dL] 
HCT 49.6 H [37.5-49.3 %] 
MCV 85 [80-98 fL] 
MCH 26.7 L [27.0-33.0 pg] 
MCHC 31.7 [31.0-36.5 g/dL] 
RDW 13.9 [12.2-15.1 %] 
Platelets 71 L [160-400 K/mcL] 

Neutrophil 42.0 [32.5-74.8 %]  
Mono 4.0 [0.0-12.3 %]  
Eos 2.0 [0.0-4.9 %]  
Baso 0.0 [0.0-1.5 %]  
Lymph 48.0 H [12.2-47.4 %]  
Hairy Cell 4.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)]
  
Abs Neut 2.3 [1.5-7.5 K/mcL]  
Abs Mono 0.2 [0.0-1.3 K/mcL]  
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL]  
Absolute Basophil 0.0 [0.0-0.2 K/mcL]  
Abs Lymph 2.6 [0.9-3.2 K/mcL]  
Abs Hairy Cells 0.2 H [0.0-0.0 K/mcL] 


Morphology:
WBC: Circulating hairy cells. No circulating blasts.
RBC: Unremarkable morphology.
PLT: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunostain for CD20 highlights neoplastic B-cells, involving 70% of the bone marrow. 
BRAF V600E immunostain is negative (unclear if for technical reasons, on slide control is adequate)
CD3 highlights background T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-8681)
Abnormal B cell population detected.
The immunophenotype of the abnormal B-cell is consistent with involvement by previously diagnosed hairy cell leukemia (HCL).

Abnormal B cell population of WBC: 15.1 %  

Immunophenotype:
Abnormal: CD10 (positive - dim), CD19 (positive - bright), CD20 (positive - bright), CD22 (positive - bright), CD25 (positive), CD11c (positive), CD103 (positive), CD200 (positive), CD45 (bright), surface Kappa (restriction), Side Scatter (increased)
Normal: CD38, Forward Scatter
Negative: CD5, CD279 (PD1), CD3, CD14, surface Lambda

Number of Cells Acquired: 396 thousand  

No abnormal T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of Cells Acquired: 410 thousand  

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5709 & CG21-5710.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-36927 & M21-36946.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-9414;S10;MSK5 - 2023-06-01 06.39.22.ndpi,Peripheral Blood Smear,2023-06-01,"Clinical Diagnosis: Ph+ ALL
Clinical Hx/Op Findings: Ph+ ALL untreated
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Extensive involvement by B-lymphoblastic leukemia/lymphoma.
  
BONE MARROW BIOPSY
Quality: adequate 
Cellularity: 80-90%
The marrow is entirely replaced by sheets of blasts. Normal hematopoiesis is markedly reduced.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate

Blasts                75%
Promyelocytes           1%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      8%
Erythroid Precursors      10%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           1.1

Morphology:
Spicular and very cellular bone marrow aspirate shows numerous blasts. Normal trilineage hematopoietic elements are still present but markedly reduced.


PERIPHERAL BLOOD
CBC (12/15/2021):
WBC 6.5 [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 3.72 L [3.80-5.00 M/mcL] 
HGB 11.5 [11.2-15.4 g/dL] 
HCT 38.1 [34.3-46.0 %] 
MCV 102 H [80-98 fL] 
MCH 30.9 [27.0-33.0 pg] 
MCHC 30.2 L [31.0-36.5 g/dL] 
RDW 19.3 H [12.2-15.1 %] 
Platelets. 68 L [160-400 K/mcL] 

Neutrophil 70.0 [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 2.0 H [0.0-0.0 %] 
Myelocyte 7.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 15.0 [12.2-47.4 %] 
Nucleated RBC 22.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 4.6 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.5 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology: left shifted granulopoiesis, nRBCs and occasional blasts. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 and TdT show numerous blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-12501)
See separate report. 

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-12484)
1. Abnormal immature B cell population detected.

Abnormal immature B cell population represents 7.0% of the mononuclear cells.
Abnormal immature B cell population represents 1.9% of WBC.

Immunophenotype:
Abnormal: CD10 (positive - bright), CD11b (partial), CD13 (positive), CD20 (dim), CD24 (bright), CD25 (partial), CD33 (positive), CD34 (uniform - bright), CD38 (dim), CD45 (dim), CD66c/CD123 (positive), CD73/CD304 (positive), CD81 (dim), CD86 (positive), CD123 (positive), HLA-DR (bright)
Normal: CD19, CD22, CD71, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD14, CD15, CD16, CD26, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, cytoplasmic MPO, surface Kappa, surface Lambda


2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.


3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 458 thousand  


4. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.67% of WBC.

Number of cells acquired: 448 thousand  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-8244.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-52108, M21-52122, M21-52123, M21-52124, M21-52126, M21-52127.

"
H21-5825;S11;MSKY - 2023-05-27 02.57.17.ndpi,Peripheral Blood Smear,2023-05-27,"Multiple Myeloma
D81 post auto SCT
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by metastatic prostatic adenocarcinoma. See Comment.
     - No morphologic or immunophenotypic evidence of plasma cell neoplasm.

Note: The interpretation of these results is based in part on the decalcification procedure performed. 

COMMENT:
The patient's history of IgG kappa multiple myeloma status post stem cell transplant, as well as metastatic prostate cancer is noted. There is no evidence of residual myeloma; however, the marrow space is largely replaced by metastatic carcinoma, most compatible with involvement by the patient's known prostate cancer.

This case was also reviewed by Dr. Duffield (Hematopathology).

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: N/A; the marrow space is essentially replaced by carcinoma.
Myeloid lineage: Markedly reduced
Erythroid lineage: Markedly reduced
Megakaryocytes: Not seen
Plasma cells: Not increased
Other: Osteosclerosis

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Not available for evaluation
Dry tap aspiration
The differential cell count was not performed

Scattered atypical cells that are present singly and in a small cluster are seen on the touch preparation.

Morphology: 
Marrow spicules: N/A
Cellularity: Hypocellular
Plasma cell morphology: Not seen
Myeloid lineage: Rare mature elements noted 
Erythroid Lineage: Rare mature elements noted
Megakaryocytes:  Not seen 
Other findings: Many naked nuclei noted  

IMMUNOHISTOCHEMISTRY
The abnormal cells 
Express: NKX3.1 (diffuse strong), Cam5.2 (focal), PAS (focal), AE1 (focal weak)
Other: Immunostains for BCMA, kappa and lambda do not reveal background plasma cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7710)
Interpretation: 
No abnormal plasma cell population detected. Virtually no plasma cells seen.
No evidence of an abnormal plasma cell population is identified by flow cytometry. 200 thousand cells acquired.

PERIPHERAL BLOOD
CBC (08/10/2021):
WBC 3.9 L [4.0-11.0 K/mcL] 
RBC 3.13 L [3.95-5.54 M/mcL] 
HGB 9.8 L [12.5-16.2 g/dL] 
HCT 29.1 L [37.5-49.3 %] 
MCV 93 [80-98 fL] 
MCH 31.3 [27.0-33.0 pg] 
MCHC 33.7 [31.0-36.5 g/dL] 
RDW 13.9 [12.2-15.1 %] 
Platelets 197 [160-400 K/mcL] 

Neutrophil 45.8 [32.5-74.8 %] 
Mono 9.3 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 43.3 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 1.8 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.7 [0.9-3.2 K/mcL] 

Morphology:
WBC: Mild leukopenia. Circulating plasma cells are not seen
RBC: Normocytic / Normochromic RBC's. Rouleaux formation is not seen
Platelets: Adequate with unremarkable morphology

CYTOGENETIC STUDIES
Not submitted

MOLECULAR STUDIES 
Not submitted

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-8956;S10;MSKE - 2023-05-19 15.44.23.ndpi,Peripheral Blood Smear,2023-05-19,"{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch31505\stshfloch31506\stshfhich31506\stshfbi0\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}
{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;
\red0\green0\blue0;}{\*\defchp \fs22\loch\af31506\hich\af31506\dbch\af31505 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*
\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused 
Normal Table;}{\s15\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\f1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext15 \spriority0 Arial;}}
{\*\rsidtbl \rsid3943166\rsid5510331\rsid5862190\rsid5926296\rsid7150442\rsid8475256\rsid8720981\rsid8783482\rsid10898621\rsid14294674}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0
\mnaryLim1}{\info{\operator Chan, Alexander Y./Pathology}{\creatim\yr2021\mo12\dy7\hr15\min25}{\revtim\yr2021\mo12\dy7\hr15\min25}{\version2}{\edmins0}{\nofpages1}{\nofwords15}{\nofchars96}{\nofcharsws105}{\vern7}}{\*\xmlnstbl {\xmlns1 http://schemas.micr
osoft.com/office/word/2003/wordml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata1\grfdocevents0\validatexml0\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors0\horzdoc\dghspace120\dgvspace120\dghorigin1701
\dgvorigin1984\dghshow0\dgvshow3\jcompress\viewkind1\viewscale130\rsidroot8475256 \fet0{\*\wgrffmtfilter 2450}\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2
\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}\pard\plain \ltrpar\s15\ql \li0\ri0\nowidctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\af1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \insrsid5926296 \hich\af1\dbch\af31505\loch\f1 Clinical Diagnosis: Lymphoma, Mantle Cell\par \hich\af1\dbch\af31505\loch\f1 Clinical Hx/Op Findings: splenomegaly\par \hich\af1\dbch\af31505\loch\f1 Requested Studies: Gross/Micro\par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Involved by CD5 positive B-cell lymphoma most consistent with previously diagnosed mantle cell lymphoma, ~60% of total cellularity by immunohistochemistry; see comment.

COMMENT: Correlation with concurrent cytogenetic studies is recommended to confirm diagnosis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy sections show a hypercellular bone marrow (~80% cellularity) with an atypical lymphoid proliferation composed of small atypical cells with small amounts of cytoplasm, irregular nuclei, and condensed chromatin, in a background of maturing trilineage hematopoiesis. Aspirate smears are spicular and cellular and show atypical lymphoid cells in a background of maturing trilineage hematopoiesis without increased blasts. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight the atypical lymphoid proliferation, B-cells are approximately 60% of total cellularity by immunohistochemistry.
The B-cells co-express CD5.
SOX11 and CyclinD1 appear positive in a subset of neoplastic cells though staining quality is suboptimal.
Ki67 appears to highlight <10% of neoplastic cells.

B-cells are negative for CD23, LEF1, and P53. 
CD3 and CD5 highlight T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-11907) 
1. Abnormal B cell population detected (32.3% of WBC)
The immunophenotype of this abnormal B cell population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with immunohistochemical or cytogenetic studies for Cyclin D1 is recommended to rule out mantle cell lymphoma (MCL).

Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD79b (variable - dim to intermediate), ROR1 (positive), CD19 (positive - dim), surface Kappa (restriction)
Normal: CD22, CD81, CD40, CD45, CD38
Negative: CD23, CD43, CD200, CD10, CD3, surface Lambda

2. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  
Number of cells acquired: 321 thousand  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (11/30/2021)
WBC 4.0 [4.0-11.0 K/mcL] 
RBC 3.79 L [3.95-5.54 M/mcL] 
HGB 11.9 L [12.5-16.2 g/dL] 
HCT 36.4 L [37.5-49.3 %] 
MCV 96 [80-98 fL] 
MCH 31.4 [27.0-33.0 pg] 
MCHC 32.7 [31.0-36.5 g/dL] 
RDW 16.1 H [12.2-15.1 %] 
Platelets. 105 L [160-400 K/mcL] 

Neutrophil 41.0 [32.5-74.8 %] 
Mono 5.8 [0.0-12.3 %] 
Eos 1.8 [0.0-4.9 %] 
Baso 0.8 [0.0-1.5 %] 
Immature Granulocyte 1.0 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 49.6 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 1.6 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 2.0 [0.9-3.2 K/mcL]

Morphology:
WBC: Occasional atypical lymphoid cells seen.
RBC: Normocytic, normochromic anemia with anisocytosis.
PLT: Mild thrombocytopenia. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-7834, CG21-7835.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-49642.

"
H21-1313;S12;MSKN - 2023-05-22 11.26.33.ndpi,Peripheral Blood Smear,2023-05-22,"Mantle Cell Lymphoma
POD on acalabrutinib. Screening for 19-077
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by mantle cell lymphoma (10% with CD20 immunohistochemistry)
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy specimen shows hypercellular bone marrow (30% cellularity) with focal interstitial aggregates of small lymphocytes with irregular nuclei, condensed chromatin and inconspicuous nucleoli. There istrilineage maturing hematopoiesis. Myeloid and erythroid elements show progressive maturation. Megakaryocytes appear adequate in number and morphology. The aspirate smears are aspicular but cellular and show trilineage maturing hematopoiesis.

Aspirate differential: (Performed by HM) 

Blasts                2%
Promyelocytes           6%
Myelocytes           18%
Metamyelocytes           12%
Neutrophils/Bands      25%
Monocytes           2%
Eosinophils           5%
Erythroid Precursors      18%
Plasma Cells           2%
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           3.8

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD20, CD5, Cyclin D1
Do not express: CD3, SOX11
Other:
CD3 highlights background T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-1762) 
Interpretation: 
Abnormal B-cell population identified.
Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD20 (dim to intermediate), CD43, CD81 (dim), and ROR1; normal expression of CD19, CD38, CD40, CD79b, and CD45; and without CD3, CD10, CD23, or CD200.  The abnormal B cell population represents 13.7% of total white cells.
This immunophenotype is consistent with previously diagnosed mantle cell lymphoma (MCL).

PERIPHERAL BLOOD
CBC (02/23/2021):
WBC 7.6 [4.0-11.0 K/mcL] 
RBC 3.19 L [3.95-5.54 M/mcL] 
HGB 10.2 L [12.5-16.2 g/dL] 
HCT 30.9 L [37.5-49.3 %] 
MCV 97 [80-98 fL] 
MCH 32.0 [27.0-33.0 pg] 
MCHC 33.0 [31.0-36.5 g/dL] 
RDW 13.9 [12.2-15.1 %] 
Platelets 101 L [160-400 K/mcL] 

Neutrophil 76.6 H [32.5-74.8 %] 
Mono 7.2 [0.0-12.3 %] 
Eos 3.3 [0.0-4.9 %] 
Baso 0.8 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 11.6 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 5.9 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte0.0 [0.0-0.1 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL] 

Morphology:
WBC: Mild lymphopenia. Occasionally atypical lymphocytes.
RBC: Normocytic anemia. 
PLT: Unremarkable.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-1182, CG21-1183

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-7172, 7173, 7214.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-4054;S11;MSK1 - 2023-04-19 12.36.03.ndpi,Peripheral Blood Smear,2023-04-19,"AML
protocol
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     -Persistent acute myeloid leukemia (50% blasts by aspirate count).
     -Small abnormal CLL population only seen by flow cytometry.

BONE MARROW BIOPSY
Quality: adequate 
Cellularity: 30% 
M:E ratio: not applicable 
Blasts: increased 
Myeloid lineage: reduced 
Erythroid lineage: present 
Megakaryocytes: scattered 
Lymphocytes: rare 
Plasma cells: rare 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0/3). 
Clot section: not submitted 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules
Performed on touch imprint smear.

Blasts                50%
Promyelocytes           1%
Myelocytes           5%
Metamyelocytes           2%
Neutrophils/Bands      9%
Eosinophils           1%
Erythroid Precursors      29%
Plasma Cells           1%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           0.6

Morphology:
The aspirate smear is aspicular and hemodiluted. Touch imprint is cellular and shows numerous blasts. 

PERIPHERAL BLOOD
CBC (06/07/2021):
WBC 2.8 L [4.0-11.0 K/mcL] 
RBC 3.60 L [3.80-5.00 M/mcL] 
HGB 12.2 [11.2-15.4 g/dL] 
HCT 36.5 [34.3-46.0 %] 
MCV 101 H [80-98 fL] 
MCH 33.9 H [27.0-33.0 pg] 
MCHC 33.4 [31.0-36.5 g/dL] 
RDW 12.7 [12.2-15.1 %] 
Platelets 206 [160-400 K/mcL] 

Neutrophil 60.0 [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 
Blast 1.0 H [0.0-0.0 %] 
Lymph 27.0 [12.2-47.4 %] 
Variant Lymph 1.0 [0.0-2.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.7 [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Blasts 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 

Morphology: occasional circulating blasts. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show markedly increased blasts, 40-50%. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5392)
Expanded abnormal myeloid blast population detected.
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample F21-3671 having abnormal expression of CD13 (absent to dim), CD34 (absent to dim), CD38 (uniform, intermediate), CD117 (absent to intermediate), and HLA-DR (absent); with normal expression of CD4, CD33, CD45, CD71, CD123 without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. The abnormal myeloid blasts represent 21.2% of WBC.

Flow cytometry also identified an abnormal B-cell population having abnormal expression of CD5, CD20 (dim), CD23, CD43, CD79b (dim to absent), CD81 (dim), CD200 (bright), and ROR1; normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The findings are consistent with previously diagnosed chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL) or CLL-like monoclonal B-cell lymphocytosis. The abnormal B-cell population comprises 0.55% of the white cells.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3534.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-23119.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-6123;S21;MSKR - 2023-06-06 02.16.59.ndpi,Peripheral Blood Smear,2023-06-06,"Lymphoma, Diffuse Large Cell.   Pancytopenia.  Restaging. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Involvement by large B-cell lymphoma (20% including granulomatous background)
     - Normocellular marrow with trilineage maturing hematopoiesis and left shifted myeloid maturation.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show normocellular bone marrow (20-30% cellularity). There is myeloid predominanttrilineage maturing hematopoiesis with left shifted myeloid maturation. Granulomatous areas composed of histiocytes and rare, large atypical lymphoid cells are noted, comprising 20% of the total cellularity. 

Bone Marrow Aspirate Smear Quality: Adequate

Blasts                3%
Promyelocytes           9%
Myelocytes           26%
Metamyelocytes           9%
Neutrophils/Bands      19%
Monocytes           5%
Eosinophils           5%
Erythroid Precursors      18%
Plasma Cells           1%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           4.1

Special stain
Iron: Present but appear decreased
Ring sideroblasts: Absent

IMMUNOHISTOCHEMISTRY
The neoplastic cells 
Express: CD20 (weak), CD79a (weak), PAX5, MUM1, BCL2 (partial, weak)
Do not express: CD19, OCT2, CMYC
Other:
CD3 highlights scattered background T-cells.
CD34 and CD117 highlight rare blasts, comprising less than 1% of the total cellularity. CD117 also highlights early myeloid precursors, erythroid precursors, and mast cells. CD33 and MPO highlight myeloid cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-8114) 
No abnormal B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

No abnormal T cell population detected.
No immunophenotypic evidence of T-cell lymphoma is identified.  

PERIPHERAL BLOOD
CBC (08/20/2021):
WBC 2.4 L [4.0-11.0 K/mcL] 
RBC 2.95 L [3.95-5.54 M/mcL] 
HGB 9.2 L [12.5-16.2 g/dL] 
HCT 27.2 L [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 31.2 [27.0-33.0 pg] 
MCHC 33.8 [31.0-36.5 g/dL] 
RDW 13.3 [12.2-15.1 %] 
Platelets 39 L [160-400 K/mcL] 

Neutrophil 35.0 [32.5-74.8 %] 
Mono 20.0 H [0.0-12.3 %] 
Eos 7.0 H [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 36.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Neutropenia. Relative monocytosis. No circulating atypical lymphoid cells.
RBC: Normocytic, normochromic anemia.
PLT: Marked thrombocytopenia.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5326.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-34222, M21-34223.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-1666;S11;MSKX - 2023-05-22 09.40.30.ndpi,Peripheral Blood Smear,2023-05-22,"New acute leukemia, p/w WBC 41, blast 60%.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 (91% blasts by aspirate differential count).

COMMENT: The specific BCR-ABL1 fusion product (p190 vs p210) is not yet known at this time. While the overall findings are most consistent with a B-lymphoblastic leukemia/lymphoma, a B-lymphoid blast phase of chronic myeloid leukemia cannot be entirely excluded. Correlation with clinical history and the pending molecular studies is suggested.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular (>95% cellularity)
M:E ratio: N/A
Blasts: Markedly increased, forming sheets that nearly entirely replace the marrow
Myeloid lineage: Markedly reduced
Erythroid lineage: Markedly reduced
Megakaryocytes: Reduced 
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows a mild increase in reticulin fibrosis (MF-1+/3) 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                91%
Neutrophils & Precursors     2%
Erythroid Precursors      3%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           0.7

Morphology:
Spicular and cellular smears show a markedly expanded population of blasts, which range from small to large in size with rounded to irregular nuclei, moderately dispersed chromatin, variably distinct nucleoli and scant cytoplasm. Background trilineage hematopoiesis is markedly reduced.

PERIPHERAL BLOOD
CBC (3/5/2021):
WBC 41.8 H [4.0-11.0 K/mcL] 
RBC 3.93 [3.80-5.00 M/mcL] 
HGB 11.8 [11.2-15.4 g/dL] 
HCT 35.9 [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 30.0 [27.0-33.0 pg] 
MCHC 32.9 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 31 L [160-400 K/mcL] 

Neutrophil 8.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 59.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 23.0 [12.2-47.4 %]

Abs Neut 3.3 [1.5-7.5 K/mcL] 
Abs Mono 1.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.3 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 24.7 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.4 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.4 H [0.0-0.0 K/mcL] 
Abs Meta 0.8 H [0.0-0.0 K/mcL] 
Abs Lymph 9.6 H [0.9-3.2 K/mcL]

Morphology:
WBC: Frequent circulating blasts morphologically similar to those in the aspirate smears. Occasional myeloid precursors.
RBC: Normocytic, normochromic RBCs with occasional nucleated RBCs.
PLT: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
CD34 and TdT highlight markedly increased blasts comprising >90% of the marrow cellularity. The blasts are negative for CD117.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-2226)
Interpretation: 
Abnormal immature B-cell population detected.
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow (89.5% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD2 (partial), CD10 (variable, absent to bright), CD11b (partial), CD13 (partial), CD20 (partial) ,CD24 (variable, absent to bright), CD25 (partial), CD38 (dim), CD45 (absent to dim), CD66c/CD123, CD73/CD304 (partial), CD81 (absent to dim), with normal expression of CD19, CD22, CD34, CD71, and HLA-DR; and without CD3, CD4, CD5, CD7, CD8, CD14, CD15, CD16, CD33, CD56, CD64, CD66b, CD86, CD117, or surface light chains.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.12% of WBC.
253,834 of cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-2190)
Interpretation: 
Abnormal immature B-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature B- or T-cell populations detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow (72.8 % of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD2 (dim, minor subset), CD11b (partial), CD13 (partial dim), CD15 (partial dim), CD16 (partial), CD20 (variable, intermediate to absent), CD25 (partial dim), CD34 (variable, absent to bright), CD38 (dim), CD45 (absent to intermediate), CD123 (dim to intermediate), HLA-DR (bright), with normal expression of CD4, CD19, CD22, CD24, CD71, and CD81, and without CD3, CD5, CD7, CD8, CD14, CD33, CD56, CD64, CD66b, CD86, CD117, CD66c, CD73/CD304 or surface light chains. Blasts show partial dim expression of MPO, and in an otherwise typical immature B-lineage immunophenotype this is consistent with B-ALL with isolated MPO expression (PMID: 28340210). Correlation with morphologic and cytogenetic studies is also advised.  

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.53% of WBC.
458 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

Preliminary results provided to Dr. Jae Park, Department of Medicine on 3/5/21.
Reviewed with Dr. Mikhail Roshal, division of Hematopathology, who agrees.

CYTOGENETIC STUDIES (CG21-1471)
FISH ANALYSIS:
BCR-ABL1 fusion/t(9;22) detected in 95.3% of cells.

No evidence of MLL (11q23) rearrangement.

Chromosome analysis is in progress and will be reported as an addendum to case CG21-1471 (see separate report).

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M21-9060, M21-9062, M21-9063, M21-9064.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-2362;S11;MSKR - 2023-05-22 12.00.08.ndpi,Peripheral Blood Smear,2023-05-22,"T-ALL
Bone Marrow
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by T-lymphoblastic leukemia/lymphoma (50-60% by TdT immunostain).

COMMENT:
The results of a prior mediastinal biopsy (S21-20298; 03/29/2021) demonstrating ""Involvement by T-lymphoblastic lymphoma/leukemia"" are noted. The findings in the current biopsy are compatible with marrow involvement by the same process.

Correlation with pending molecular and cytogenetic studies is recommended.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Normocellular (60-70%)
M:E ratio: N/A
Blasts: Increased to 50-60% of the cellularity
Myeloid lineage: Decreased; progressive maturation
Erythroid lineage: Decreased; progressive maturation
Megakaryocytes: Normal in number and morphology
Lymphocytes: Mature lymphocytes are not increased
Plasma cells: Not increased
Clot section: Findings similar to the biopsy section

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)

Blasts                54%
Myelocytes           5%
Metamyelocytes           5%
Neutrophils/Bands      14%
Monocytes           1%
Eosinophils           3%
Erythroid Precursors      13%
Plasma Cells           1%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           2.2

Morphology:
Spiculate and cellular smears show that blasts are increased to 50-60% of the cellularity. The blasts are small-to-medium in size with scant cytoplasm, fine chromatin and inconspicuous nucleoli. There is background trilineage hematopoiesis. The myeloid and erythroid lineages show a full range of maturation with no overt dysplasia. Scattered morphologically unremarkable megakaryocytes are present.

PERIPHERAL BLOOD
CBC (04/01/2021):
WBC 9.8 [4.0-11.0 K/mcL] 
RBC 4.88 [3.80-5.00 M/mcL] 
HGB 14.7 [11.2-15.4 g/dL] 
HCT 44.4 [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 30.1 [27.0-33.0 pg] 
MCHC 33.1 [31.0-36.5 g/dL] 
RDW 12.9 [12.2-15.1 %] 
Platelets 255 [160-400 K/mcL] 

Neutrophil 61.0 [32.5-74.8 %] 
Mono 5.7 [0.0-12.3 %] 
Eos 0.8 [0.0-4.9 %] 
Baso 0.7 [0.0-1.5 %] 
Immature Granulocyte 0.8 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 31.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 6.0 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] 
Abs Lymph 3.0 [0.9-3.2 K/mcL] 

Morphology:
WBC: Circulating blasts are not markedly increased. Granulocytes are morphologically unremarkable.
RBC: Morphologically unremarkable.
Platelets: Morphologically unremarkable.

IMMUNOHISTOCHEMISTRY
Immunostains show that TdT+ blasts are increased to 50-60% of the cellularity. CD34+ blasts are not increased. There is dim cytoplasmic expression of CD34 on a subset of the megakaryocytes.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-3128)
Interpretation:
Abnormal immature T-cell population identified.

An abnormal immature T-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously F21-2995. The abnormal blasts represent 46.4% of the white cells and abnormally express surface CD3 (negative to dim), cytoplasmic CD3, CD4 (dim), CD5 (dim), CD7 (bright), CD10 (partial), CD38 (bright), CD45 (dim), CD48 (dim); with normal expression of CD2; and without CD8, CD34 or significant CD16/CD56.
Additional phenotyping will be reported in addendum.

Addendum Diagnosis
The abnormal immature T-cell population also shows expression of CD71 and cytoplasmic CD79a, without CD11b, CD13, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD33, CD64, CD117, CD123, CD279 (PD1), MPO, T-cell receptor gamma/delta, or surface light chains.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.81% of WBC.
199 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No abnormal mature B-cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-3128, 04/01/2021)
Interpretation:
Abnormal immature T-cell population identified.

An abnormal immature T-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously F21-2995. The abnormal blasts represent 0.21% of the white cells and abnormally express surface CD3 (negative to dim), cytoplasmic CD3, CD4 (dim), CD5 (dim), CD7, CD10, CD38 (bright), CD45 (dim), CD48 (negative); with normal expression of CD2; and without CD8, CD16, CD34 or CD56.

FLOW CYTOMETRIC ANALYSIS, MEDIASTINAL TISSUE (F21-2995, 03/29/2021)
Interpretation:

Immature T cell population identified (see comment)
No abnormal mature B cell populations detected.
Abnormal CD30 positive population is NOT detected.

Immature T cell population with expression of cytoplasmic CD3, but not surface CD3, and expresses CD7(variable), CD5, CD4, CD2, CD10, CD38(bright), CD48(dim), CD79a(dim), without CD8, CD13, CD19, CD20, CD22, CD33, CD34, MPO, CD64, CD14 is seen. The population shows virtually no maturational progression. Differential diagnosis includes T lymphoblastic leukemia/lymphoma vs. highly unusual thymic tissue. Morphologic correlation will be critical for precise diagnosis.

No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

No immunophenotypic evidence of an abnormal population with Classic Hodgkin Lymphoma phenotype detected. Morphologic correlation is advised.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-2066.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M21-13123, M21-13127 and M21-13128.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-9771;S11;MSK2 - 2023-04-19 16.49.30.ndpi,Peripheral Blood Smear,2023-04-19,"{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch31505\stshfloch31506\stshfhich31506\stshfbi0\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri{\*\falt Calibri};}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE{\*\falt Calibri};}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr{\*\falt Calibri};}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek{\*\falt Calibri};}
{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur{\*\falt Calibri};}{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew){\*\falt Calibri};}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic){\*\falt Calibri};}
{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic{\*\falt Calibri};}{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese){\*\falt Calibri};}
{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;
\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;
\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;\red0\green0\blue0;}{\*\defchp \fs22\loch\af31506\hich\af31506\dbch\af31505 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 
\fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused 
Normal Table;}{\s15\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\f1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext15 \spriority0 Arial;}}
{\*\rsidtbl \rsid4929306\rsid6701427\rsid9830527\rsid12593211\rsid14768385\rsid15091934\rsid15992937\rsid16059532}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info
{\operator Chan, Alexander Y./Pathology}{\creatim\yr2022\mo1\dy5\hr15\min57}{\revtim\yr2022\mo1\dy5\hr15\min57}{\version2}{\edmins0}{\nofpages1}{\nofwords16}{\nofchars92}{\nofcharsws106}{\vern21}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/w
ord/2003/wordml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata1\grfdocevents0\validatexml0\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors0\horzdoc\dghspace120\dgvspace120\dghorigin1701
\dgvorigin1984\dghshow0\dgvshow3\jcompress\viewkind1\viewscale130\rsidroot12593211 \fet0{\*\wgrffmtfilter 2450}\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2
\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}\pard\plain \ltrpar\s15\ql \li0\ri0\nowidctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\af1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \fs18\insrsid15992937 \hich\af1\dbch\af31505\loch\f1 Clinical Diagnosis: CML\par \hich\af1\dbch\af31505\loch\f1 Clinical Hx/Op Findings: pt progressing on Bosutinib\par \hich\af1\dbch\af31505\loch\f1 Requested Studies: Gross/Micro\par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Consistent with chronic myeloid leukemia in chronic phase (CML, CP), undergoing therapy; see comment.

COMMENT: Overall the findings are consistent with chronic phase CML undergoing tyrosine kinase therapy. While thrombocytopenia is listed by the WHO as a criterion for accelerated phase of CML, thrombocytopenia must specifically be unrelated to therapy. Thus, clinical correlation is required to make this distinction. Correlation with concurrent molecular and cytogenetic studies is also recommended.

Relevant portions of this case were also reviewed on 1/5/2022 with Dr. Filiz Sen, who agrees with the interpretation. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Mildly hypocellular (~40%)
M:E ratio: Normal
Blasts: Not increased (<5%) 
Myeloid lineage: Exhibits full maturation 
Erythroid lineage: Exhibits full maturation 
Megakaryocytes: Present with occasional small hypolobated forms 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows no significant increase in reticulin fibers (0/3). 
The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules
Performed on touch imprint smear.
      
Blasts                3%
Promyelocytes           1%
Myelocytes           10%
Metamyelocytes           6%
Neutrophils/Bands      28%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      32%
Lymphocytes           16%
Number of Cells Counted 500
M:E Ratio           1.5

Morphology: Aspirate smears are suboptimal (aspicular, hypocellular), but touch imprints are cellular and show maturing myeloid and erythroid elements with no increase in blasts. Myeloid elements show full maturation. Basophils are not overtly increased. Erythroid elements show full maturation. Megakaryocytes are not well represented on the suboptimal aspirates and touch imprints. 

PERIPHERAL BLOOD
CBC (12/30/2021):
WBC 7.6 [4.0-11.0 K/mcL] 
RBC 4.76 [3.95-5.54 M/mcL] 
HGB 14.6 [12.5-16.2 g/dL] 
HCT 43.8 [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 30.7 [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 13.6 [12.2-15.1 %] 
Platelets 76 L [160-400 K/mcL] 

Neutrophil 72.0 [32.5-74.8 %] 
Mono 5.8 [0.0-12.3 %] 
Eos 0.3 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 21.2 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 5.5 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.6 [0.9-3.2 K/mcL] 

Morphology:
WBC: Unremarkable morphology; no leukocytosis, basophilia, or blasts seen. 
RBC: Normocytic, normochromic RBCs.
PLT: Moderate thrombocytopenia. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains show no increases in CD34 and/or CD117 positive blasts (<5%). 
CD61 highlights megakaryocytes with mostly unremarkable morphology.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-12963)
1. No abnormal myeloid blast, monocyte, maturing myeloid, B-cell or T-cell populations identified.                    
Flow cytometry is generally not a sensitive methodology in the context of myeloproliferative disorders, correlation with molecular studies for JAK2, CALR, MPL mutation status and/or BCR-ABL and morphology is advised if clinically indicated.
Myeloid blast population with an unremarkable phenotype represents 0.57% of WBC.
Number of cells acquired: 375 thousand  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-8555.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M22-17, M22-18.
"
H21-6371;S12;MSKW - 2023-05-19 15.21.47.ndpi,Peripheral Blood Smear,2023-05-19,"Breast Cancer
DdCAT 5 yrs ago, Mbc to bone+. Acute anemia on Abemeciclib.> 3 mon off no increase. Little response to ESA last dose 7/21. r/o MDS
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Metastatic carcinoma, see note
     - Inadequate biopsy and aspirate for marrow evaluation

Note: Sections reveal an infiltrative carcinoma within the bone marrow. Tumor cell stain positive for AE1/AE3, GATA3, and ER (weak). The patient's prior bone biopsy (S21-34884) shows tumor with similar morphology and immunophenotype. In the proper clinical context, this metastatic tumor is likely breast in origin. The biopsy does not contain marrow elements. This case was also reviewed by Dr. Edelweiss, breast pathology service. 

BONE MARROW BIOPSY
Inadequate bone marrow biopsy showing cortical bone with minute marrow spaces. There is metastatic carcinoma within the bone fragments.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Inadequate touch imprint smears. Few peripheral blood cells are noted on scanning

Special stain
Iron: Suboptimal for evaluation
Ring sideroblasts: Suboptimal for evaluation

PERIPHERAL BLOOD
CBC (08/31/2021):
WBC 5.4 [4.0-11.0 K/mcL] 
RBC 2.95 L [3.80-5.00 M/mcL] 
HGB 8.6 L [11.2-15.4 g/dL] 
HCT 29.1 L [34.3-46.0 %] 
MCV 99 H [80-98 fL] 
MCH 29.2 [27.0-33.0 pg] 
MCHC 29.6 L [31.0-36.5 g/dL] 
RDW 18.3 H [12.2-15.1 %] 
Platelets. 250 [160-400 K/mcL] 

Neutrophil 66.9 [32.5-74.8 %] 
Mono 6.6 [0.0-12.3 %] 
Eos 2.6 [0.0-4.9 %] 
Baso 0.2 [0.0-1.5 %] 
Immature Granulocyte 0.4 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 23.3 [12.2-47.4 %] 
Nucleated RBC 1.3 H [0.0-0.0 %] 

Abs Neut 3.6 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 

Morphology:
WBC: Unremarkable morphology
RBC: Anisopoikilocytosis. Circulated nucleated RBC noted
PLT: Unremarkable morphology

IMMUNOHISTOCHEMISTRY
Immunostains for CD34 and CD117 are non-contributory.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW 
Not submitted 

CYTOGENETIC STUDIES
Not submitted 

MOLECULAR STUDIES 
Not submitted 



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H21-7400;S10;MSKH - 2023-05-27 02.11.28.ndpi,Peripheral Blood Smear,2023-05-27,"Lymphoma
Untreated lymphoma 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Mantle cell lymphoma, 30-40% involvement with CD20 immunohistochemistry. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy shows hypercellular bone marrow for age (approximately 60% cellularity). There istrilineage maturing hematopoiesis with increased numbers of atypical lymphocytes with crush artifact, showing nodular and interstitial distribution. Aspirate smear shows numerous smudge cells. 

Bone Marrow Aspirate Smear Quality: Adequate
Aspirate differential count: Not performed

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlights the increased number of lymphoid cells, showing nodular and interstitial distribution, comprising 30-40% of marrow cellularity.  
These B-cells co-express CD5, Cyclin D1 (dim, nuclear and cytoplasmic blush staining. Could be due to crush artifact), and SOX11.
These B-cells are negative for CD23 and LEF1. 
CD3 labels reactive T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-9813) 
Interpretation: 
Abnormal B cell population detected. 

Abnormal B cell population represents 3.9% of WBC

Immunophenotype:
Abnormal: CD5 (positive), CD22 (dim), CD43 (partial), CD79b (negative), ROR1 (positive), CD19 (positive - dim), surface Lambda (restriction)
Normal: CD20, CD81, CD40, CD45, CD38
Negative: CD23, CD200, CD10, CD3, surface Kappa

Number of cells acquired: 253 thousand  

PERIPHERAL BLOOD
CBC (10/07/2021):
WBC 6.9 [4.0-11.0 K/mcL] 
RBC 5.00 [3.80-5.00 M/mcL] 
HGB 13.3 [11.2-15.4 g/dL] 
HCT 42.7 [34.3-46.0 %] 
MCV 85 [80-98 fL] 
MCH 26.6 L [27.0-33.0 pg] 
MCHC 31.1 [31.0-36.5 g/dL] 
RDW 14.7 [12.2-15.1 %] 
Platelets 153 L [160-400 K/mcL] 

Neutrophil 41.4 [32.5-74.8 %] 
Mono 8.3 [0.0-12.3 %] 
Eos 5.1 H [0.0-4.9 %] 
Baso 0.9 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 44.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.8 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 3.0 [0.9-3.2 K/mcL] 

Morphology: Circulating atypical lymphocytes present, small in size with irregular nuclear contours, clumped chromatin and high N/C ratio.  

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-6436.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-41525, M21-41526.




Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-5738;S11;MSK1 - 2023-04-19 17.30.16.ndpi,Peripheral Blood Smear,2023-04-19,"CML and CLL
67 yo man with s,ultaneous dx of CLL and CML 12/20 (Slides reviewed here by Dr. Petrova), had=s persistent low plts since dx, please comment re: megas.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Persistent involvement by the previously diagnosed chronic myeloid leukemia (CML) (<5% blasts)
     - Persistent involvement by previously diagnosed chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL) like immunophenotype (10-20% of overall cellularity by CD20 and PAX-5 immunohistochemistry) 
  
COMMENT: Patient's history of persistent thrombocytopenia is noted. Clinical correlation is needed to exclude causes of thrombocytopenia including but not limited to autoimmune, medication, peripheral destruction. Correlation with radiological findings (splenomegaly) is recommended.  The presence of persistent thrombocytopenia raises a concern for accelerated phase (AP) of CML; however, it is unclear if confounding factors may explain this.

The case was discussed with Dr. Ellin Berman on 8/12/2021.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular for age (~50-60% cellularity)
M:E ratio: Normal
Blasts: Not increased
Myeloid lineage: Full range of maturation
Erythroid lineage: Full range of maturation
Megakaryocytes: Mildly increased with few atypical small/hypolobated forms.
Lymphocytes: Increased, interstitially scattered and small aggregates of atypical lymphoid cells, small to medium in size with ovoid nuclei and condensed chromatin.
Plasma cells: Scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF1+/3). 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                1%
Promyelocytes           2%
Myelocytes           10%
Metamyelocytes           6%
Neutrophils/Bands      26%
Monocytes           1%
Eosinophils           3%
Erythroid Precursors      18%
Plasma Cells           1%
Lymphocytes           32%
Number of Cells Counted 500
M:E Ratio           2.7

Morphology:
Spicular and cellular aspirate smears show maturing trilineage hematopoiesis, normal myeloid/erythroid ratio, and no expanded blast population. Myeloid lineage shows full range of maturation with no significant dyspoiesis.  Erythroid lineage shows full range of maturation with occasional megaloblastoid features and nuclear irregularity. Megakaryocytes are seen with occasional small and hypolobated forms. Lymphocytes are increased with small -intermediate size, round nuclei, variably clumped chromatin, inconspicuous nucleoli, and scant amount of cytoplasm.

PERIPHERAL BLOOD
CBC (08/04/2021):
WBC 33.5 H [4.0-11.0 K/mcL] 
RBC 4.61 [3.95-5.54 M/mcL] 
HGB 13.7 [12.5-16.2 g/dL] 
HCT 40.5 [37.5-49.3 %] 
MCV 88 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 33.8 [31.0-36.5 g/dL] 
RDW 12.3 [12.2-15.1 %] 
Platelets 46 L [160-400 K/mcL] 

Neutrophil 18.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 77.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 6.0 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.3 H [0.0-0.2 K/mcL] 
Abs Myelocytes 0.3 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.3 H [0.0-0.0 K/mcL] 
Abs Meta 0.3 H [0.0-0.0 K/mcL] 
Abs Lymph 25.8 H [0.9-3.2 K/mcL] 

Morphology:
WBC: Lymphocytosis, Lymphocytes are small -intermediate size, round nuclei, variably clumped chromatin, inconspicuous nucleoli, and scant amount of cytoplasm. 
RBC: Normocytic RBC's
Platelets: Thrombocytopenia with few large forms.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight no increase in blasts (<5% of cellularity)
CD117 also highlights immature myeloid/erythroid precursors as well as scattered mast cells. 
CD61 stains mildly increased megakaryocytes
CD71 stains the erythroid lineage

The atypical lymphoid cells are positive for CD20, PAX5, CD5, LEF1, CD23 and negative for CD3, Cyclin D1. KI67 is low in the lymphoid infiltrate. P53 stains rare cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7581)
Interpretation: 

Abnormal myeloid blast population detected. 
Basophilia is seen (1.1% of WBC).
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD7 (partial), CD56 (partial), CD38 (subset absent to dim) with normal expression of CD4, CD13, CD33, CD34, CD45, CD71, CD117, CD123 and HLA-DR without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, CD64. The findings are consistent with previously diagnosed myeloproliferative neoplasm. CD34 positive myeloid blasts represent 1.2% of WBC. 

Flow cytometry identified an abnormal B-cell population having abnormal expression of CD5, CD20 (dim), CD23, CD43, CD79b (dim), CD81 (dim), CD200 (bright), and ROR1; normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The findings are consistent with previously diagnosed chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL). The abnormal B-cell population comprises 50.1% of the white cells.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-4993.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-32222, M21-32262, M21-32263, M21-32264, M21-32265.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-5243;S10;MSK1 - 2023-06-06 03.09.05.ndpi,Peripheral Blood Smear,2023-06-06,"ALL.
Newly diagnosed T-ALL.

","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - T-lymphoblastic leukemia (T-ALL), see comment.
 
COMMENT: Correlation with cytogenetic and molecular findings is recommended for further subclassification and for excluding near-early T-cell precursor-ALL (near-ETP-ALL). 

The case was also reviewed by Dr. Mikhail Roshal, division of Hematopathology, who agrees.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular, 70-80%
M:E ratio: Reduced
Blasts: Increased, present in sheets. Blasts are medium to large in size with high N:C ratio, slightly irregular nuclei and smudged chromatin.
Myeloid lineage: Reduced
Erythroid lineage: Full range of maturation
Megakaryocytes: Present with few small hypolobated forms and forms with hyperchromatic nuclei
Lymphocytes: Loose aggregates of small mature appearing lymphocytes noted
Plasma cells: Scattered

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Hypocellular, devoid of spicules

Differential performed on touch imprint smear

Blasts                55%
Myelocytes           2%
Neutrophils/Bands      2%
Eosinophils           1%
Erythroid Precursors      33%
Lymphocytes           7%
Number of Cells Counted 500
M:E Ratio           0.2

Morphology:
The touch imprint smears show an expanded blast population. Blasts are medium to large in size with high N:C ratio, slightly irregular nuclei, fine chromatin and conspicuous nucleoli. The myeloid lineage is hypoplastic with very few maturing forms noted. The erythroid lineage shows full range of maturation. Rare megakaryocytes are present.

PERIPHERAL BLOOD
CBC (07/18/2021):
WBC 0.6 L [4.0-11.0 K/mcL] 
RBC 2.75 L [3.95-5.54 M/mcL] 
HGB 8.7 L [12.5-16.2 g/dL] 
HCT 25.0 L [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 31.6 [27.0-33.0 pg] 
MCHC 34.8 [31.0-36.5 g/dL] 
RDW 17.1 H [12.2-15.1 %] 
Platelets. 93 L [160-400 K/mcL] 

Neutrophil 18.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 8.0 H [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 18.0 H [0.0-0.0 %] 
Lymph 55.0 H [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 0.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: Frequent circulating blasts noted.

IMMUNOHISTOCHEMISTRY
Immunostain for TdT shows increased blasts, focally forming sheets (~50% of cellularity). The blasts are positive for CD34 (subset), CD3 (dim), CD5 (slightly dim), CD33 and negative for CD1a, MPO, PAX5
CD61 stains megakaryocytes
CD71 stains erythroid islands
CD117 stains erythroid precursors and scattered mast cells
CD3 and CD20/PAX5 stain the small mature appearing B and T cells in the loose aggregates.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-6909)
Abnormal immature T-cell population identified. 

An abnormal immature T-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously (F21-6875). The abnormal blasts represent 45.5% of the white cells and abnormally express CD2 (absent), surface CD3 (negative), CD7 (bright), CD34 (partial), CD38 (bright), CD45 (dim), CD48 (negative); with normal expression of cytoplasmic CD3, CD4, and CD5; and without CD8, CD10, CD16 or CD56. This finding is consistent with persistent/recurrent precursor T-cell lymphoblastic leukemia/lymphoma depending on the clinical context.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. 

MOLECULAR STUDIES 
Molecular analysis will be reported separately.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-8318;S12;MSKZ - 2023-05-19 16.11.52.ndpi,Peripheral Blood Smear,2023-05-19,"Clinical Diagnosis: Prostate, Malignant Neoplasm
Clinical Hx/Op Findings: Fevers of unknown origin and pancytopenia history of prostate CA and Colon CA
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Consistent with metastatic prostatic adenocarcinoma
     - See comment

COMMENT: Though there is extensive crush artifact, the tumor morphology is not in keeping with a moderately differentiated enteric type adenocarcinoma. Immunohistochemistry shows positive staining for NKX3.1 (strong diffuse) and pancytokeratin, though the latter is not strong and diffuse. AR shows strikingly cytoplasmic tumoral staining. Synaptophysin shows focal staining in only a few tumor cells. RB shows either faint retained staining or loss in tumoral cells. Moreover, PSA shows a rare positive cell while chromogranin and INSM1 are negative. Overall, the findings are consistent with a metastatic prostatic adenocarcinoma that has undergone abiraterone treatment and does not express abundant PSA. Likewise, the tumor does not demonstrate yet a strong neuroendocrine phenotype.

BONE MARROW BIOPSY
Additional stains: Reticulin stain shows no/mild/moderate/ marked increase in reticulin fibrosis. CD34 and CD117 stains were also performed


The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules 
Differential not performed. Aspirate is replaced with primitive cells which appears to be an extrinsic in origin.


PERIPHERAL BLOOD
CBC (11/8/2021):
WBC 1.8 L [4.0-11.0 K/mcL] 
RBC 2.79 L [3.95-5.54 M/mcL] 
HGB 7.7 L [12.5-16.2 g/dL] 
HCT 24.8 L [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 27.6 [27.0-33.0 pg] 
MCHC 31.0 [31.0-36.5 g/dL] 
RDW 17.1 H [12.2-15.1 %] 
Platelets. 101 L [160-400 K/mcL] 

Neutrophil 51.0 [32.5-74.8 %] 
Mono 6.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 35.0 [12.2-47.4 %] 
Nucleated RBC 2.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL]

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-11060)
1. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                                                                                
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.17% of WBC.
Monocytosis is seen, 10.6% of WBC.

Number of cells acquired: 131 thousand  

Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition.

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-7241.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-46445, 46455.

"
H21-3800;S10;MSKH - 2023-05-22 10.02.17.ndpi,Peripheral Blood Smear,2023-05-22,"""DLBCL. Newly diagnosed DLBCL""
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Extensive involvement by mantle cell lymphoma with high proliferation index (80% with CD20 immunohistochemistry)

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy specimen shows hypercellular bone marrow (80% cellularity) with an atypical lymphoid infiltrate composed of intermediate sized lymphocytes with irregular nuclei, condensed chromatin and inconspicuous nucleoli. Trilineage hematopoiesis is virtually absent. 

Bone Marrow Aspirate Smear Quality: Adequate.

Neutrophils/Bands      1%
Eosinophils           1%
Lymphocytes           98%
Number of Cells Counted 500
M:E Ratio           N/A

IMMUNOHISTOCHEMISTRY
The atypical cells
Express: CD20 (stains 80% of total cells), PAX5, CD5 (dim), Cyclin D1, SOX11     
Do not express: CD3, LEF1, P53
Other: Ki-67 proliferative index is approximately 80%.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5066) 
Interpretation: 
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5 (partial), CD19 (dim), CD43 (partial), ROR1, and lambda light chain restricted; normal expression of CD20, CD22, CD38, CD40, CD79b, CD81, and CD45; and without CD3, CD10, CD23, or CD200. The abnormal B cell population represents 72.0% of total white cells.
This immunophenotype is consistent with previously diagnosed mantle cell lymphoma (MCL).

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

PERIPHERAL BLOOD
CBC (05/27/2021):
WBC 8.2 [4.0-11.0 K/mcL] 
RBC 4.40 [3.95-5.54 M/mcL] 
HGB 13.6 [12.5-16.2 g/dL] 
HCT 42.0 [37.5-49.3 %] 
MCV 96 [80-98 fL] 
MCH 30.9 [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL] 
RDW 14.2 [12.2-15.1 %] 
Platelets 29 L [160-400 K/mcL] 

Neutrophil 31.0 L [32.5-74.8 %] 
Mono 11.0 [0.0-12.3 %] 
Eos 5.0 H [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 10.0 L [12.2-47.4 %] 
Abnormal Lymphoid Cells 39.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 2.6 [1.5-7.5 K/mcL] 
Abs Mono 0.9 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 4.0 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: lymphocytosis with many atypical lymphoid cells. 


CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3320.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-21667, M21-21668.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-3566;S10;MSK7 - 2023-05-27 02.40.20.ndpi,Peripheral Blood Smear,2023-05-27,"Lymphoma
Pt with MCL, screening for protocol 19-007     
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by mantle cell lymphoma (~30% with CD20/PAX-5 immunohistochemistry). See comment.
     - Mildly hypercellular marrow with maturing trilineage hematopoiesis.

COMMENT: Numerous intermediate and large size atypical lymphoid cells with prominent nucleoli are noted on the peripheral blood smear, which are reminiscent of prolymphocyte morphology. This may be related to ibrutinib therapy, which can induce egression of large atypical neoplastic cells into the periphery. Clinical correlation is advised.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate bone marrow biopsy shows mildly hypercellular for age (~50-60% cellularity) marrow with an interstitial atypical lymphoid infiltrate composed of small clusters of intermediate size atypical lymphoid cells with elongated to irregular nuclei, variably clumped chromatin, occasionally prominent nucleoli, and scant to moderate amount of cytoplasm. There is also maturing trilineage hematopoiesis with no overt increase in blasts.  Myeloid and erythroid elements are actively maturing.  Megakaryocytes are adequate in number with occasional nuclear hyperchromasia, loose clusters, and hypolobation.

The aspirate smears are adequate, spicular, and cellular. They show increased number of intermediate and large size atypical lymphoid cells, with round to slightly irregular nuclei, variably condensed chromatin, occasionally with prominent nucleoli, and small to moderate amount of cytoplasm. The lymphoid infiltrate shows a patchy distribution. Blasts are not increased. Myeloid and erythroid elements show progressive maturation with no significant dyspoiesis. Megakaryocytes are present, associated with spicules, show occasional hypolobated forms.     

Bone Marrow Aspirate Smear Quality:  Adequate

Blasts                1%
Promyelocytes           1%
Myelocytes           8%
Metamyelocytes           5%
Neutrophils/Bands      20%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      19%
Lymphocytes           43% (patchy distribution)
Number of Cells Counted 500
M:E Ratio           1.9

IMMUNOHISTOCHEMISTRY
The neoplastic cells are scattered interstitially and in small clusters, occupying approximately 30% of the cellularity by CD20:
Express: CD5, CD20, PAX-5, cyclin D1 
Do not express: CD3, SOX-11
Other: 
CD3 highlights few scattered T-cells in the background.
No convincing CD23 expression is seen in the neoplastic cells.
P53 shows strong expression in a subset of the neoplastic B-cells (~10%). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-4761) 
Abnormal B-cell population identified.

Flow cytometry identified an abnormal B-cell population having abnormal expression of CD5, CD19 (dim to intermediate), CD20 (variable, dim to bright), CD79b (mostly bright), and ROR1 (partial); normal expression of CD40, CD81 and CD45; and without CD3, CD10, CD23, CD38, CD43 or CD200 expression. The abnormal B-cell population comprises 54.1% of the white cells. The phenotype is consistent with mantle cell lymphoma.

PERIPHERAL BLOOD
CBC (5/19/2021)
WBC 32.4 H [4.0-11.0 K/mcL] 
RBC 5.06 [3.95-5.54 M/mcL] 
HGB 14.0 [12.5-16.2 g/dL] 
HCT 42.7 [37.5-49.3 %] 
MCV 84 [80-98 fL] 
MCH 27.7 [27.0-33.0 pg] 
MCHC 32.8 [31.0-36.5 g/dL] 
RDW 13.3 [12.2-15.1 %] 
Platelets. 143 L [160-400 K/mcL] 

Neutrophil 18.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 8.0 L [12.2-47.4 %] 
Abnormal Lymphoid Cells 71.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 5.8 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.3 H [0.0-0.2 K/mcL] 
Abs Lymph 25.6 H [0.9-3.2 K/mcL]

Morphology:
WBCs: Leukocytosis with absolute lymphocytosis. Frequent intermediate and occasionally large atypical lymphoid cells, with irregular nuclei, variably dispersed chromatin, prominent central nucleoli, and scant to moderate amount of cytoplasm. Frequent smudge cells are noted.
RBCs: Normocytic normochromic RBCs. 
Platelets: Adequate in number, with occasional large platelets seen.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate reports, CG21-3130, CG21-3131. 

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M21-20362, M21-20364.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-5600;S11;MSK9 - 2023-04-19 17.42.13.ndpi,Peripheral Blood Smear,2023-04-19,"AML
Assess response to protocol 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
    - Persistent involvement by Acute Myeloid Leukemia (85% blasts by aspirate differential count).
    - Flow Cytometric evidence of Small Abnormal CLL/SLL-like B cell population (0.48% of WBC), likely representing Monoclonal B-cell Lymphocytosis (MBL)

BONE MARROW BIOPSY
Quality: Suboptimal fragmented and hemorrhagic biopsy
Cellularity: Hypercellular for age (40-50% cellularity)
M:E ratio: Cannot accurately assess
Blasts: Expanded blast population with intermediate-sized nuclei, high nuclear cytoplasmic ratio, fine to smudged chromatin, occasional visible nucleoli, and scant cytoplasm.
Myeloid lineage: Markedly decreased in number with limited maturation
Erythroid lineage: Markedly decreased in number with some maturation
Megakaryocytes: Adequate to mildly decreased in number with atypical hyperchromatic and hypolobated forms. 
Lymphocytes: Scattered. No aggregates or abnormal forms of mature lymphocytes are seen.
Plasma cells: Scattered.

Special stains:
Reticulin stain shows no significant increase in reticulin fibrosis (0/3). 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                85%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      2%
Erythroid Precursors      5%
Plasma Cells           1%
Lymphocytes           5%
Number of Cells Counted      500
M:E Ratio           0.8

Morphology:
Spicular and cellular marrow aspirate smears a markedly expanded blast population of variably sized blasts (mainly intermediate to large in size) with slightly irregular nuclei, high nuclear cytoplasmic ratio, fine/dispersed chromatin, prominent nucleoli and small amount of pale blue cytoplasm. The background maturing hematopoiesis is markedly decreased, with left-shifted maturation, and erythroid predominance. Megakaryocytes are seen with frequent dysplastic forms (small hypolobated forms mostly). Few scattered small mature-appearing lymphoid cells are seen.
Cellular touch imprint preparations show similar morphology.  

PERIPHERAL BLOOD
CBC (8/2/2021):
WBC 1.9 L [4.0-11.0 K/mcL] 
RBC 3.55 L [3.80-5.00 M/mcL] 
HGB 12.2 [11.2-15.4 g/dL] 
HCT 35.8 [34.3-46.0 %] 
MCV 101 H [80-98 fL] 
MCH 34.4 H [27.0-33.0 pg] 
MCHC 34.1 [31.0-36.5 g/dL] 
RDW 13.4 [12.2-15.1 %] 
Platelets. 128 L [160-400 K/mcL] 

Neutrophil 48.9 [32.5-74.8 %] 
Mono 2.7 [0.0-12.3 %] 
Eos 2.7 [0.0-4.9 %] 
Baso 0.5 [0.0-1.5 %] 
Immature Granulocyte 0.0 [0.0-0.6 %] 
Lymph 45.2 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL]
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 0.8 L [0.9-3.2 K/mcL]

Morphology:
WBC: No circulating blasts are seen. Leukopenia and absolute neutropenia with some pseudo Pelger-Huët forms and abnormally segmented neutrophils are present.
RBC: Normocytic normochromic RBC's. Mild anisopoikilocytosis is seen.
Platelets: Mildly decreased. No significant platelets aggregates are seen.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains for CD34 and CD117 show increased blasts (~70% of the bone marrow cellularity)

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7395)
Abnormal myeloid blast population detected.
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD13 (absent to dim), CD33 (dim to normal), CD34 (absent to intermediate), CD38 (absent to dim), CD117 (variable absent to bright), and HLA-DR (absent); with normal expression of CD4, CD45, CD71, and CD123; without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. Myeloid blasts represent 80.2% of WBC.

Flow cytometry identified an abnormal B-cell population having abnormal expression of CD5, CD20 (dim), CD23, CD43, CD79b (absent), CD81 (dim), CD200 (bright), and ROR1; normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The findings are consistent with previously diagnosed chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL). The abnormal B-cell population comprises 0.48% of the white cells.


CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-4880.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-31486

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-8492;S12;MSK2 - 2023-05-27 02.28.59.ndpi,Peripheral Blood Smear,2023-05-27,"Clinical Diagnosis: MDS
Clinical Hx/Op Findings: protocol 19-219 with vidaza+APR-246
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
     - Persistent myeloid neoplasm with ring sideroblasts, 3% blasts by aspirate differential count.
  
BONE MARROW BIOPSY
Quality: Marginally adequate; small and subcortical biopsy
Cellularity: Hypercellular for age (approximately 70% cellularity)
M:E ratio: Inverted
Blasts: Not overtly increased     
Myeloid lineage: Markedly decreased overall; however, eosinophils appear increased
Erythroid lineage: Increased and shows left-shifted progressive maturation     
Megakaryocytes: Increased in number with focal loose clustering and include small, hypolobated and/or hyperchromatic dysplastic forms
Lymphocytes: Interstitially scattered
Plasma cells: Not increased
Others: Hemosiderin deposition
Special stain: Reticulin stain shows mild increase in reticulin fibrosis (MF-1). 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Mast cells noted
Blasts                3%
Promyelocytes           1%
Myelocytes           4%
Metamyelocytes           1%
Neutrophils/Bands      7%
Eosinophils           12%
Basophils           3%
Erythroid Precursors      44% (patchy distribution with some early ones and/or dysplastic changes)
Lymphocytes           25%
Number of Cells Counted      500
M:E Ratio           0.6

Special stain
Iron: Present
Ring sideroblasts: >15% 

Morphology:
The aspirate smears are spicular and hypercellular demonstrating erythroid predominant maturing trilineage hematopoiesis. Erythroid elements show complete maturation with prominent left-shift and dyspoiesis (megaloblastoid changes, nuclear irregularity/budding, binucleation, basophilic stippling). Blasts are not increased, and Auer rods are not identified. Myeloid elements are reduced; however, show complete maturation. Eosinophils and their precursors are increased. Increased number of basophils with hypogranular cytoplasm are noted. Megakaryocytes appear increased in number and show frequent dysplastic mono/hypolobated forms. Lymphocytes are small-sized and mature appearing. Mast cells are increased but lack clustering and show unremarkable morphology.     

PERIPHERAL BLOOD
CBC (11/15/2021):
WBC 1.4 L [4.0-11.0 K/mcL] 
RBC 3.27 L [3.95-5.54 M/mcL] 
HGB 9.4 L [12.5-16.2 g/dL] 
HCT 29.2 L [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 28.7 [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 14.1 [12.2-15.1 %] 
Platelets 420 H [160-400 K/mcL] 

Neutrophil 40.0 [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 10.0 H [0.0-4.9 %] 
Baso 9.0 H [0.0-1.5 %] 
Lymph 40.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.6 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
WBCs: Leukopenia with absolute neutropenia and lymphopenia. Rare pseudo Pelger-Huet forms seen. Relative eosinophilia and basophilia. No circulating blasts seen. 
RBCs: Normocytic normochromic anemia. 
Platelets: Thrombocytosis, unremarkable morphology.     

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 immunostain shows no increase in blasts (<5% of cellularity). 
CD117 highlights mildly increased but scattered mast cells as well as increased early erythroid and some myeloid precursors.     

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-11287)
1. Abnormal myeloid blast population detected. 
The immunophenotype of this population is similar to that seen in prior sample [F21-7637] 

Abnormal myeloid blast population represents 3.3% of WBC.
Basophilia is seen, 4.5% of WBC.
Eosinophilia is seen, 13.3% of WBC.
Mastocytosis is seen, 1.3% of WBC.

Immunophenotype:
Abnormal: CD5 (bimodal, mostly negative, subset dim), CD7 (partial), CD11b (partial), CD13 (dim), CD33 (variable, dim to bright), CD34 (uniform - intermediate), CD38 (uniform - dim), HLA-DR (bright)
Normal: CD4, CD45, CD71, CD117, CD123
Negative: CD2, CD14, CD15, CD16, CD19, CD25, CD56, CD64

Number of cells acquired: 223 thousand  

2. No abnormal mast cells present.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-7426.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-47351.

NOTE: Preliminary results were conveyed to Dr. A. Goldberg on 11/19/2021 via email.     
"
H21-9139;S10;MSK9 - 2023-05-19 15.49.57.ndpi,Peripheral Blood Smear,2023-05-19,"Clinical Diagnosis: ALL
Clinical Hx/Op Findings: pre car T cells
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma (70% blasts on aspirate). 

BONE MARROW BIOPSY
Quality: adequate 
Cellularity: 20-30% 
M:E ratio: reduced 
Blasts: increased 
Myeloid lineage: reduced 
Erythroid lineage: present 
Megakaryocytes: present but overall reduced 
Lymphocytes: rare 
Plasma cells: rare 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                70%
Myelocytes           2%
Metamyelocytes           1%
Neutrophils/Bands      5%
Basophils           1%
Erythroid Precursors      20%
Lymphocytes           1%
Number of Cells Counted      500
M:E Ratio           0.4

Morphology:
Spicular and very cellular bone marrow aspirate shows markedly increased blasts with frequent cytoplasmic vacuoles. Normal hematopoietic elements are markedly reduced.


PERIPHERAL BLOOD
CBC (12/7/2021):
WBC 1.4 L [4.0-11.0 K/mcL] 
RBC 2.12 L [3.80-5.00 M/mcL] 
HGB 7.3 L [11.2-15.4 g/dL] 
HCT 22.5 L [34.3-46.0 %] 
MCV 106 H [80-98 fL] 
MCH 34.4 H [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL] 
RDW 20.5 H [12.2-15.1 %] 
Platelets. 16 L [160-400 K/mcL] 

Neutrophil 75.0 H [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 18.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL]

Morphology: pancytopenia, rare blasts. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 and TdT show increased blasts, 40-50%. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-12140)
Interpretation: 
Abnormal immature B cell population detected.
An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously [F21-6554].                         

Abnormal immature B cell population represents 44.1% of the mononuclear cells..
Abnormal immature B cell population represents 43.6% of WBC.

Immunophenotype:
Abnormal: CD10 (bimodal - dim to bright), CD20 (variable - negative to bright), CD34 (bright), CD38 (dim), CD81 (dim), CD66c/CD123 (bright), CD86 (partial), CD73/CD304 (bright)
Normal: CD19, CD22, CD24, CD45
Negative: CD66b

Number of cells acquired 4.5 million  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-8003.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-50644, M21-50646, M21-50647.
"
H21-1656;S12;MSKX - 2023-04-19 13.13.01.ndpi,Peripheral Blood Smear,2023-04-19,"Leukemia, acute promyelocytic. 62 year old suspicion of new diagnosis of APL.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
     - Acute promyelocytic leukemia with PML-RARA (77% involvement by differential count). 
     - Hypercellular marrow with reduced trilineage hematopoiesis.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular (~90%)
M:E ratio: NA
Blasts: Markedly increased promyelocytes 
Myeloid lineage: Markedly reduced 
Erythroid lineage: Markedly reduced 
Megakaryocytes: Scattered 
Lymphocytes: Scattered 
Plasma cells: Scattered 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts/Promyelocytes      77% (Several with folded nucleoli)
Myelocytes           2%
Neutrophils/Bands      2%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      6%
Plasma Cells           1%
Lymphocytes           10%
Number of Cells Counted  500
M:E Ratio           13.2

Morphology:
Spicular and hypercellular aspirate smears show markedly expanded population of atypical promyelocytes with oval to irregular/folded nuclei, abundant cytoplasm frequently filled with dense purple granules or Auer rods. Scattered maturing myeloid and erythroid elements are present in the background. Few megakaryocytes are present. 

PERIPHERAL BLOOD
CBC (3/5/2021):
WBC 2.9 L [4.0-11.0 K/mcL] 
RBC 2.81 L [3.80-5.00 M/mcL] 
HGB 9.0 L [11.2-15.4 g/dL] 
HCT 26.0 L [34.3-46.0 %] 
MCV 93 [80-98 fL] 
MCH 32.0 [27.0-33.0 pg] 
MCHC 34.6 [31.0-36.5 g/dL] 
RDW 15.6 H [12.2-15.1 %] 
Platelets 11 L [160-400 K/mcL] 

Neutrophil 27.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Promyelocyte 52.0 H [0.0-0.0 %] 
Lymph 19.0 [12.2-47.4 %] 
Nucleated RBC 3.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 0.8 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Promyelocytes 1.5 H [0.0-0.0 K/mcL] 
Abs Lymph 0.5 L [0.9-3.2 K/mcL]

Morphology:
WBC: Atypical promyelocytes with morphology similar to those on the core biopsy are present 
RBC: Mild anisocytosis; few nucleated RBCs. 
PLT: Marked thrombocytopenia with few large and hypogranular forms. 

IMMUNOHISTOCHEMISTRY
CD117 shows expanded population of promyelocytes and blasts (~80% marrow cellularity), which are negative for CD34.
CD3 and CD20 highlights scattered T- and B-cells, respectively. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-2204)
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD19 (partial), CD22 (partial), CD56 (subset), CD11b (partial dim), CD13 (bright), CD15 (partial dim), CD25 (partial dim), CD33 (uniform bright), CD34 (predominantly absent, small subset bright), CD38 (uniform dim), CD64, CD117 (uniform intermediate), CD123 (bright). HLA-DR (negative), cyCD79a (dimmer than B cells); with normal expression of CD4, CD45, CD71; without CD2, CD5, CD7, surface CD3, cytoplasmic CD3, CD8, CD14, CD16, CD20 or surface light chains. MPO is uniformly expressed by the blasts. CD117 positive myeloid blasts represent 92.7% of WBC. This immunophenotype is highly suggestive of acute promyelocytic leukemia (APL), which is confirmed by peripheral blood FISH analysis (CG21-1439). Correlation with the morphologic findings is also advised.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-1455.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-9122, M2109124, M21-9125.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H21-4138;S11;MSKU - 2023-04-19 12.29.49.ndpi,Peripheral Blood Smear,2023-04-19,"Lymphoma, Diffuse Large Cell
Bone Disease
Protocol#: 17-421 
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate, and peripheral blood smears: 
    - Minimal involvement by B-cell lymphoma, <5% by PAX5 immunohistochemistry; see comment.
    - Hypocellular bone marrow with maturing trilineage hematopoiesis 

COMMENT: The findings are most consistent with minimal involvement by the patient's previously diagnosed diffuse large B-cell lymphoma. This case was also reviewed at the Hematopathology Consensus Conference on 6/14/2021, with agreement on the interpretation between the present hematopathology attending staff. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Suboptimal biopsy and clot specimens show hypocellular bone marrow (20-30% cellularity) with trilineage maturing hematopoiesis. Focal atypical lymphoid aggregates are seen, composed of large atypical lymphoid cells with small amounts of cytoplasm, irregular enlarged nuclei, open chromatin, and distinct, central nucleoli. Background myeloid and erythroid elements show progressive maturation. Megakaryocytes appear adequate in morphology. Aspirate smears are spicular and cellular and also show atypical lymphoid cells with large size, small amounts of cytoplasm with cytoplasmic vacuoles, enlarged nuclei, and distinct nucleoli. 

Bone Marrow Aspirate Smear Quality:  Adequate
Blasts                1%
Promyelocytes           1%
Myelocytes           16%
Metamyelocytes           12%
Neutrophils/Bands      24%
Monocytes           2%
Eosinophils           3%
Erythroid Precursors      24%
Lymphocytes           12%
Others                  5% (appear to be abnormal lymphoid elements with few clusters)
Number of Cells Counted      500
M:E Ratio           2.5

IMMUNOHISTOCHEMISTRY
The neoplastic cells (<5% of total cellularity by PAX5 immunohistochemistry).
Express: PAX5, MUM1, BCL2, P53
Do not express: CD3, CD5, CD10, CD20, CD138, BCL6
Other: CD23 shows no residual follicular dendritic meshwork. 
The Ki-67 proliferative index is increased in the atypical cells. 

In situ hybridization stain for EBER is negative. 
CD138 highlights rare plasma cells. Kappa/lambda in situ hybridization stains highlight rare plasma cells.
CMYC is non-contributory due to loss of lymphoid aggregates on the immunohistochemical stained level though rare atypical cells are positive.
CD19 is technically suboptimal and cannot be interpreted. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5506) 
No abnormal mature B-cell population detected. Virtually no B-cells seen.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

PERIPHERAL BLOOD
CBC (06/09/2021)
WBC 4.1 [4.0-11.0 K/mcL] 
RBC 2.90 L [3.95-5.54 M/mcL] 
HGB 8.3 L [12.5-16.2 g/dL] 
HCT 25.5 L [37.5-49.3 %] 
MCV 88 [80-98 fL] 
MCH 28.6 [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 20.3 H [12.2-15.1 %] 
Platelets. 28 L [160-400 K/mcL] 

Neutrophil 77.6 H [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Immature Granulocyte 10.0 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 4.4 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 3.2 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.4 H [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 0.2 L [0.9-3.2 K/mcL]

Morphology:
WBC: Left shifted granulocytes seen; no definite atypical lymphoid cells are seen.
RBC: Normocytic, normochromic anemia with anisocytosis.
PLT: Marked thrombocytopenia. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3594.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-23617, M21-23619, and M21-23620.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-1951;S11;MSKU - 2023-05-17 13.07.55.ndpi,Peripheral Blood Smear,2023-05-17,"Leukemia, hairy cell. Evaluate for progression.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Hairy cell leukemia, involving 30-40% of marrow cellularity by CD20 immunohistochemistry. 
     - Small abnormal B-cell population with CLL/SLL-like immunophenotype detected by flow cytometry (0.14% of WBC).


BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Approximately 40%
M:E ratio: Decreased. Erythroid-predominant. 
Blasts: Not increased 
Myeloid lineage: Orderly maturation 
Erythroid lineage: Orderly maturation
Megakaryocytes: Adequate in number, morphologically unremarkable. 
Lymphocytes: Increased, interstitially scattered, as well as forming sheets and focally replacing marrow
Plasma cells: Not increased. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                1%
Myelocytes           4%
Metamyelocytes           3%
Neutrophils/Bands      12%
Monocytes           1%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      56%
Lymphocytes           16%
Hairy cells           5%
Number of Cells Counted 500
M:E Ratio           0.4

Morphology:
Spicular and cellular smears show orderly trilineage maturing hematopoiesis. Large atypical lymphocytes with cytoplasmic projection, consistent with hairy cells, are present. 

PERIPHERAL BLOOD
CBC (03/16/2021):
WBC 1.8 L [4.0-11.0 K/mcL] 
RBC 3.81 L [3.95-5.54 M/mcL] 
HGB 11.5 L [12.5-16.2 g/dL] 
HCT 34.6 L [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 30.2 [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 15.1 [12.2-15.1 %] 
Platelets. 63 L [160-400 K/mcL] 

Neutrophil 59.9 [32.5-74.8 %] 
Mono 2.2 [0.0-12.3 %] 
Eos 3.9 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.6 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 32.8 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 1.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL]

Morphology: Thrombocytopenia and neutropenia. Few circulating atypical lymphocytes noted. 

IMMUNOHISTOCHEMISTRY
CD20 highlights increase in atypical B-cells, focally replacing marrow, comprising overall 30-40% of marrow cellularity.
BRAF immunohistochemistry shows cytoplasmic brush expression in these atypical B-cells.
CD3 highlights reactive T-cells.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-2593)
Interpretation: 
Two abnormal B-cell populations identified.

Flow cytometry reveals the first abnormal mature B-cell population having abnormal expression of CD10(partial), CD11c, CD19 (bright), CD20 (bright), CD22 (bright), CD25, CD45 (bright), CD103, CD200 (bright), and with slightly increased forward and side scatter and kappa light chain restriction; with normal expression of; and without CD3, CD14, CD38 or convincing CD5 and CD279 (PD1). The immunophenotype of the abnormal B-cell population is consistent with involvement by hairy cell leukemia. The abnormal B cell population represents 17.6% of the total white cells.

In addition, flow cytometry also identified a second abnormal B-cell population with CLL/SLL-like immunophenotype having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23, CD43, CD79b (absent), CD81 (dim), CD200, ROR1 and lambda surface light chain restriction (dim); normal expression of CD19, CD38, CD40 and CD45; and without CD3, or CD10 expression. The abnormal B-cell population comprises 0.14% of the white cells. These findings are similar to that seen previously in F19-9186.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-1711, CG21-1713.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-10597. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-7705;S13;MSK9 - 2023-05-31 15.37.06.ndpi,Peripheral Blood Smear,2023-05-31,"Small Cell Lung Cancer
Pancytopenia, unclear if metastatic marrow involvement or other process 
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Metastatic small cell carcinoma, see comment.  

COMMENT: The patient's history of small cell lung carcinoma with extensive metastasis is noted. The bone marrow specimen is nearly replaced by metastatic small cell carcinoma. Background hematopoiesis is markedly reduced to absent. 

The diagnosis was rendered in consultation with Dr. W. Travis of thoracic pathology.

Additional stains will be ordered and reported as an addendum; material will be sent for molecular studies that will be reported separately.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Nearly replaced by metastatic small cell carcinoma with small foci of necrosis. Background hematopoiesis is markedly reduced to absent. 
Clot section: Findings similar to biopsy

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Numerous naked nuclei noted

The differential cells count was not performed.

Hypercellular bone marrow aspirate replaced by extrinsic cells (clusters / singly). Maturing trilineage hematopoiesis is markedly diminished. Touch imprints show small clusters of extrinsic cells. 

PERIPHERAL BLOOD
CBC (10/19/2021):
WBC 3.0 L [4.0-11.0 K/mcL] 
RBC 2.33 L [3.95-5.54 M/mcL] 
HGB 6.9 L [12.5-16.2 g/dL] 
HCT 21.3 L [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 29.6 [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL] 
RDW 16.6 H [12.2-15.1 %] 
Platelets 20 L [160-400 K/mcL] 

Neutrophil 73.7 [32.5-74.8 %] 
Mono 8.1 [0.0-12.3 %] 
Eos 0.3 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 6.8 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 10.8 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.2 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.2 H [0.0-0.1 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Leukopenia
RBC: Mild anisopoikilocytosis with mild polychromasia
Platelets: Thrombocytopenia

IMMUNOHISTOCHEMISTRY
Immunostains show the malignant cells are positive for synaptophysin and CD117 with a high KI67 proliferation index (80-90%). Additionally, chromogranin is focally positive. Segments of the tumor are not well fixed and appear artefactually negative by immunohistochemistry.

TTF-1 and CD34 are negative in the neoplastic cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW
Not submitted

CYTOGENETIC STUDIES
Not submitted

MOLECULAR STUDIES 
Additional material will be sent for molecular studies.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-8723;S14;MSK1 - 2023-05-19 16.23.18.ndpi,Peripheral Blood Smear,2023-05-19,"Clinical Diagnosis: Breast, Malignant Neoplasm
Clinical Hx/Op Findings: Anemia and metastatic LOBULAR breast cancer
Specific Comments/Questions: R/O breast cancer infiltrating the marrow
Previous Path Accessions #: S21-74869
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears:     
     - Involvement by metastatic mammary carcinoma (~40% of marrow space).
     - Variably cellular marrow with trilineage maturing hematopoiesis, see comment.
  
COMMENT: The patient's history of metastatic lobular carcinoma is noted. The current bone marrow is shows 40% involvement by GATA3 positive metastatic carcinoma most consistent with marrow involvement by the same process.

The case was also reviewed by Dr. Grabenstetter (Breast Pathology) who agrees with the diagnosis.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Variable cellular (50 up to focally 90%)
M:E ratio: Increased
Blasts: Not increased
Myeloid lineage: Shows progressive maturation
Erythroid lineage: Shows progressive maturation
Megakaryocytes: Increased in number, including occasional hypolobated and hyperlobated forms
Lymphocytes: Scattered
Plasma cells: Scattered
Other: Involvement by metastatic breast carcinoma

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Primitive cells occurring singly and/or in clumps are present which appear to be extrinsic origin.
Differential count: 

Blasts                3%
Promyelocytes           3%
Myelocytes           10%
Metamyelocytes           6%
Neutrophils/Bands      24%
Monocytes           4%
Eosinophils           5%
Erythroid Precursors      21%
Plasma Cells           1%
Lymphocytes           23%
Number of Cells Counted      500
M:E Ratio           2.5 

Special stain
Iron: Suboptimal for evaluation devoid of spicules.
Ring sideroblasts: Absent 

Morphology:
The aspirate smears contain adequately cellular spicules for evaluation. There are frequent clusters of epithelioid cells representing metastatic carcinoma. Erythroid and myeloid elements are adequate in number and show normal maturation without overt dysplasia. Megakaryocytes are adequate in number. There is no increased blast population identified. 

PERIPHERAL BLOOD
CBC (11/22/2021):
WBC 3.4 L [4.0-11.0 K/mcL] 
RBC 3.41 L [3.80-5.00 M/mcL] 
HGB 9.0 L [11.2-15.4 g/dL] 
HCT 29.3 L [34.3-46.0 %] 
MCV 86 [80-98 fL] 
MCH 26.4 L [27.0-33.0 pg] 
MCHC 30.7 L [31.0-36.5 g/dL] 
RDW 16.9 H [12.2-15.1 %] 
Platelets 265 [160-400 K/mcL] 

Neutrophil 60.6 [32.5-74.8 %] 
Mono 7.9 [0.0-12.3 %] 
Eos 0.9 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.6 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 29.4 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.1 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.0 [0.9-3.2 K/mcL] 

Morphology: No circulating blasts identified.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
Immunostains show an increase in interstitially scattered CD3+ T cells and few interstitial CD20/PAX5+ B cells.

AE1/3 and CK7 highlight involvement by metastatic carcinoma that is also GATA3.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-11575)
1. No abnormal myeloid blast, mature B or mature T cell populations identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.85% of WBC.

Number of cells acquired: 386 thousand  

The case was also reviewed by Dr. Mikhail Roshal, who concurs.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Not requested.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-48720.
"
H21-5776;S12;MSK4 - 2023-06-06 02.11.14.ndpi,Peripheral Blood Smear,2023-06-06,"Myelodysplastic Syndrome
MDS s/p azacytidine + APR-246

","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Persistent involvement by myeloid neoplasm with ring sideroblasts (3% blasts by aspirate smear differential count)

BONE MARROW BIOPSY
Quality: Small fragmented biopsy
Cellularity: Hypercellular (~80-90% cellularity)
M:E ratio: Decreased
Blasts: Not overtly increased
Myeloid lineage: Reduced 
Erythroid lineage: Increased with left-shifted maturation. 
Megakaryocytes: Present with frequent dysplastic forms including small hypolobated forms, forms with hyperchromatic nuclei.
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF1/3).

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                3%
Promyelocytes           2%
Myelocytes           4%
Metamyelocytes           2%
Neutrophils/Bands      5%
Monocytes           1%
Eosinophils           8%
Erythroid Precursors      54%
Lymphocytes           21%
Number of Cells Counted 500
M:E Ratio           0.4 

Special stain 
Iron: Present
Ring sideroblasts: Present >15%

Morphology:
-Spicular and cellular aspirate smears show trilineage hematopoiesis inverted myeloid/erythroid ratio, and no increase in blasts. Myeloid elements are decreased. Eosinophilia is noted. Erythroid elements are relatively increased and show left shifted maturation with dyspoiesis (nuclear irregularity and budding, nuclear-cytoplasmic dysynchrony, and megaloblastoid forms). Megakaryocytes are present and show dysplastic small and hypo/monolobated forms. Scattered small and mature-appearing lymphocytes are present.

PERIPHERAL BLOOD
CBC (08/09/2021):
WBC 1.6 L [4.0-11.0 K/mcL] 
RBC 2.14 L [3.95-5.54 M/mcL] 
HGB 6.6 L [12.5-16.2 g/dL] 
HCT 20.2 L [37.5-49.3 %] 
MCV 94 [80-98 fL] 
MCH 30.8 [27.0-33.0 pg] 
MCHC 32.7 [31.0-36.5 g/dL] 
RDW 19.1 H [12.2-15.1 %] 
Platelets 441 H [160-400 K/mcL] 

Neutrophil 37.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 7.0 H [0.0-4.9 %] 
Baso 11.0 H [0.0-1.5 %] 
Lymph 43.0 [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 0.6 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.2 [0.0-0.2 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 

Morphology:
WBC: No circulating blasts are seen. Leukopenia with absolute neutropenia. Relative eosinophilia and basophilia.
RBC: Normocytic anemia. Moderate anisopoikilocytosis and rare nucleated RBC's are seen. 
Platelets: Few large forms are seen.

IMMUNOHISTOCHEMISTRY
CD34 highlight no increase in blasts (<5% of cellularity)CD117 highlight left shifted myeloid/erythroid precursors as well as mildly increased but scattered mast cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7637)
Interpretation: 
Abnormal myeloid blast population detected.
Eosinophilia and basophilia seen (10.5% and 3.2% of the WBC respectively). 

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample [F21-3688] having abnormal expression of CD5 (minute subset), CD7 (partial), CD13 (dim), CD33 (variable, absent to bright), CD38 (dim), and HLA-DR (bright); with normal expression of CD4, CD34 CD45, CD71, CD117and CD123; without CD2, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 10.8% of WBC. Please note that significant erythroid hyperplasia as suspected in this case may increase blasts proportion as measured by flow cytometry. Please note that significant erythroid hyperplasia as suspected in this case may increase blasts proportion as measured by flow cytometry (as % of WBC) vs morphologic count (as % of nucleated cells).

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5026.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-32507.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-2110;S11;MSKS - 2023-04-19 12.48.21.ndpi,Peripheral Blood Smear,2023-04-19,"AML.  On Enasidenib. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Relapsed acute myeloid leukemia (37% blasts on aspirate).
     - Minute clonal B-cell populations of unknown significance, incidentally identified by flow cytometry 
  
BONE MARROW BIOPSY
Quality: adequate 
Cellularity: variable, 5-50%, overall 20% 
M:E ratio: reduced 
Blasts: increased 
Myeloid lineage: left shifted 
Erythroid lineage: increased 
Megakaryocytes: reduced 
Lymphocytes: scattered 
Plasma cells: rare 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0/3). 
Clot section: not submitted 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Blasts                37%
Promyelocytes           2%
Myelocytes           5%
Metamyelocytes           4%
Neutrophils/Bands      18%
Eosinophils           3%
Erythroid Precursors      21%
Plasma Cells           1%
Lymphocytes           9%
Number of Cells Counted 500
M:E Ratio           1.5

Morphology:
Spicular and paucicellular bone marrow aspirate shows increased blasts. Both myeloid and erythroid precursors are reduced. Megakaryocytes are present with unremarkable morphology.

PERIPHERAL BLOOD
CBC (03/22/2021):
WBC 3.4 L [4.0-11.0 K/mcL] 
RBC 3.57 L [3.80-5.00 M/mcL] 
HGB 12.1 [11.2-15.4 g/dL] 
HCT 36.3 [34.3-46.0 %] 
MCV 102 H [80-98 fL] 
MCH 33.9 H [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 13.7 [12.2-15.1 %] 
Platelets 128 L [160-400 K/mcL] 

Neutrophil 65.8 [32.5-74.8 %] 
Mono 3.3 [0.0-12.3 %] 
Eos 2.1 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 27.9 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.2 [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 0.9 [0.9-3.2 K/mcL] 

Morphology: unremarkable 


IMMUNOHISTOCHEMISTRY
CD34 and CD117 show increased blasts, 40-50%. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-2772)
Expanded abnormal myeloid blast population detected. 
Two abnormal B-cell populations identified.
No abnormal T cell populations detected.

The blasts have abnormal expression of CD13 (absent to dim), CD33 (dim to intermediate), CD34 (absent to dim), CD38 (dim to intermediate), CD117 (absent to intermediate), HLADR (mostly absent) with normal expression of CD4, CD45, CD71, and CD123; without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cytoplasmic CD79a, or surface light chains. The blasts show dim MPO expression. Abnormal myeloid blasts represent 62.0% of WBC.

The larger abnormal chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)-like B cell population shows abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23, CD43, CD79b (dim), CD81 (dim), CD200 (bright), ROR1 and lambda surface light chain restriction (dim); normal expression of CD19, CD40 and CD45; and without CD3, CD25, CD38, CD10, PD1 (CD279), or CD14. This population represents 0.39% of WBC. The smaller abnormal CLL/SLL-like B cell population shows abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23, CD43, CD79b (dim), CD81 (dim), CD200 (bright), ROR1 and kappa surface light chain restriction (dim); normal expression of CD19, CD40 and CD45; and without CD3, CD25, CD38, CD10, PD1 (CD279), or CD14. This population represents 0.02% of WBC. Together the populations represent 0.41% of WBC. The populations are consistent with at least bi-clonal CLL/SLL or a CLL-like proliferation.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-1837.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-11421 and 11422.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-7322;S10;MSK1 - 2023-05-31 15.54.06.ndpi,Peripheral Blood Smear,2023-05-31,"Lymphoma, Mantle Cell (MCL)
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by mantle cell lymphoma (~60% with CD20 immunohistochemistry). 
     - Hypercellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show hypercellular marrow (50-90% cellularity) with extensive involvement by an atypical interstitial and nodular lymphoid proliferation. The atypical infiltrate is composed of small to medium-sized lymphoid cells with slightly irregular nuclei, dispersed to granular chromatin, variably distinct nuclei and small amount of cytoplasm. The background trilineage hematopoiesis is reduced. Myeloid and erythroid elements show orderly maturation with mostly unremarkable morphology. Megakaryocytes are present with occasional hyperchromatic forms. Blasts are not increased.

Bone Marrow Aspirate Smear Quality:  Adequate
Promyelocytes           1%
Myelocytes           2%
Metamyelocytes           1%
Neutrophils/Bands      14%
Monocytes           2%
Eosinophils           1%
Erythroid Precursors      11%
Plasma Cells           1%
Lymphocytes           67%
Number of Cells Counted     500
M:E Ratio           1.9

IMMUNOHISTOCHEMISTRY
The neoplastic cells (comprising ~60% marrow cellularity)
Express: CD20, CD5, Cyclin D1, SOX11
Do not express: CD3, CD23
Others:
CD3 highlights background T cells. 
P53 highlights few scattered cells.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-9733) 
Abnormal B cell population detected. 
The immunophenotype of this abnormal B cell population is consistent with previously diagnosed mantle cell lymphoma (MCL)

Abnormal B cell population represents 60.8% of WBC

Immunophenotype:
Abnormal: CD5 (positive), CD43 (positive), ROR1 (positive), CD19 (dim)
Normal: CD20, CD23, CD79b, CD81, CD40, CD45, CD38
Negative: CD200, CD10, CD3

PERIPHERAL BLOOD
CBC (10/05/2021):
WBC 15.4 H [4.0-11.0 K/mcL] 
RBC 3.44 L [3.95-5.54 M/mcL] 
HGB 10.7 L [12.5-16.2 g/dL] 
HCT 32.5 L [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 31.1 [27.0-33.0 pg] 
MCHC 32.9 [31.0-36.5 g/dL] 
RDW 13.7 [12.2-15.1 %] 
Platelets 137 L [160-400 K/mcL] 

Neutrophil 26.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 3.0 L [12.2-47.4 %] 
Abnormal Lymphoid Cells 65.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 4.0 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.2 [0.0-0.2 K/mcL] 
Abs Lymph 10.5 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Circulating atypical lymphoid cells with similar morphology to those on aspirate smears present
RBC: Normocytic and normochromic anemia
PLT: Some hypogranular forms

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-6364, CG21-6365.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-40929.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-4022;S13;MSKY - 2023-05-22 09.56.48.ndpi,Peripheral Blood Smear,2023-05-22,"Myelodysplastic Syndrome.  Suspect myelofibrosis or atypical infection.  Evaluate for bacterial, fungal and mycobacterial pathogens, stain for iron. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Hypercellular marrow with granulocytic hyperplasia and increased ring sideroblasts. See comment.
     - Minute CLL-like population detected by flow cytometry only. 
  
COMMENT:
The differential diagnosis includes a myeloid neoplasm with ring sideroblasts vs reactive process. The presence of >15% ring sideroblasts is highly suspicious for a diagnosis of myeloid neoplasm such as MDS/MPN with ring sideroblasts or MDS with ring sideroblasts. On the other hand, ring sideroblasts can be seen in non-neoplastic process such as excessive alcohol use, pyridoxine deficiency, lead poisoning and copper deficiency. There is no morphologic evidence of microorganisms. Correlation with clinical history, pending cytogenetic and molecular studies is recommended. 

BONE MARROW BIOPSY
Quality: adequate  
Cellularity: 80%
M:E ratio: increased 
Blasts: no increase
Myeloid lineage: increased with maturation
Erythroid lineage: relatively decreased 
Megakaryocytes: adequate, unremarkable 
Lymphocytes: rare 
Plasma cells: rare 
Granulomas are not seen. 
Special stains: Reticulin stain shows no to mild increase in reticulin fibrosis (MF-0-1/3). 
Clot section: blood clot only 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                2%
Promyelocytes           1%
Myelocytes           12%
Metamyelocytes           3%
Neutrophils/Bands      54%
Monocytes           4%
Basophils           1%
Erythroid Precursors      15%
Plasma Cells           3%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           5

Special stain
Iron: Present
Ring sideroblasts: Present >15%

Morphology:
Spicular and very cellular bone marrow aspirate shows progressive trilineage hematopoiesis. Blasts are not increased. Myeloid precursors are orderly maturing with mild left shift and occasional hypogranuloarity (<10%). Erythroid precursors are orderly maturing but show dysplasia (~10%). Megakaryocytes are present with unremarkable morphology. 

PERIPHERAL BLOOD
CBC (6/4/2021):
WBC 15.3 H [4.0-11.0 K/mcL] 
RBC 2.71 L [3.95-5.54 M/mcL] 
HGB 8.4 L [12.5-16.2 g/dL] 
HCT 27.0 L [37.5-49.3 %] 
MCV 100 H [80-98 fL] 
MCH 31.0 [27.0-33.0 pg] 
MCHC 31.1 [31.0-36.5 g/dL] 
RDW 26.1 H [12.2-15.1 %] 
Platelets. 330 [160-400 K/mcL] 

Neutrophil 77.0 H [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 3.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 11.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 11.8 H [1.5-7.5 K/mcL] 
Abs Mono 1.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.5 H [0.0-0.0 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 1.7 [0.9-3.2 K/mcL]

Morphology: anemia with elliptocytes, target cells and some fragments. Increased polychromasia. Neutrophilia with left shift. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts.
Immunostains for Parvovirus, CMV, adenovirus are negative.
E-cadherin shows reduced erythroid progenitors. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5352)
No definite abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
There is no definite immunophenotypic evidence of a myeloid stem cell neoplasm by flow cytometry. However, in light of the CD7 (small subset), CD13 (bright), CD34 (bright), and CD117 (bright), a low-grade myeloid stem cell neoplasm or underlying abnormal clonal hematopoiesis cannot be entirely excluded by these studies. CD34 positive myeloid blasts represent 0.38% of the white blood cells with expression of CD33, CD38, CD45, CD71 and low CD123. Normal myelomonocytic maturation is present. 450 thousand cells acquired. Morphologic, cytogenetic, and molecular genetic assessment is suggested to exclude myeloid stem cell neoplasm. Clinical correlation is also advised. 
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment.

Atypical TCR gamma/delta T-cell population detected.
Flow cytometry reveals a relatively increased TCR gamma/delta T-cell population with a subset having atypical expression of CD3 (dim), CD5 (absent), CD7 (bright), CD56 (uniformly bright); with normal expression of CD2, CD45; and without CD8, CD10, CD14, CD25, CD38 or CD279 (PD1). The clinical significance of this finding is not entirely clear and may represent either reactive or neoplastic process. The total TCR gamma/delta population represents 1.0% of the total white cells. 

No abnormal plasma cell population detected.
No evidence of an abnormal plasma cell population is identified by flow cytometry. 393 thousand cells acquired.

Abnormal B-cell population identified.
Flow cytometry identified an abnormal B-cell population with CLL/SLL-like immunophenotype having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD79b (dim), CD81 (dim), CD200 (bright), with small subsets expressing kappa and lambda light chains; normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The abnormal B-cell population comprises 0.008% of the white cells.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3480.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-22827 to M21-22829.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H21-4806;S12;MSK7 - 2023-05-27 01.35.24.ndpi,Peripheral Blood Smear,2023-05-27,"Leukemia, Hairy Cell
Relapsed HCL 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Extensive involvement by hairy cell leukemia (HCL), 90% by CD20 immunohistochemistry. 
     - Background cellular marrow with trilineage maturing hematopoiesis, reduced myeloid elements and mildly reduced megakaryocytes.
  

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Normocellular (40-50%)
M:E ratio: Reduced.
Blasts: Not increased.
Myeloid lineage: Reduced and shows progressive maturation.
Erythroid lineage: Predominant and shows progressive maturation.
Megakaryocytes: Low-normal in number and a subset shows small and hyperchromatic nuclei.
Lymphocytes: Small to medium lymphoid cells with oval to irregular nuclei and abundant clear cytoplasm are increased diffusely in an interstitial distribution.  
Plasma cells: Not increased.
Special stains: Reticulin stain is pending
Clot section: Few tiny marrow particles identified with hematopoietic elements. 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Hypocellular, devoid of spicules.
Blasts                1%
Myelocytes           9%
Metamyelocytes           6%
Neutrophils/Bands      32%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      29%
Lymphocytes           14%
Hairy cells           6%
Number of Cells Counted      500
M:E Ratio           1.7

Morphology:
- Aspicular, paucicellular, and hemodilute aspirates. Touch imprints are evaluated and show scattered maturing myeloid and erythroid precursors and rare hairy cells.

PERIPHERAL BLOOD
CBC (7/2/2021):
WBC 1.7 L [4.0-11.0 K/mcL] 
RBC 3.49 L [3.80-5.00 M/mcL] 
HGB 11.8 [11.2-15.4 g/dL] 
HCT 35.0 [34.3-46.0 %] 
MCV 100 H [80-98 fL] 
MCH 33.8 H [27.0-33.0 pg] 
MCHC 33.7 [31.0-36.5 g/dL] 
RDW 12.6 [12.2-15.1 %] 
Platelets 109 L [160-400 K/mcL] 

Neutrophil 68.7 [32.5-74.8 %] 
Mono 1.8 [0.0-12.3 %] 
Eos 2.4 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.0 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 26.5 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 1.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 0.4 L [0.9-3.2 K/mcL]

Morphology: Leukopenia, monocytopenia and thrombocytopenia noted. Small lymphocytes with occasional cytoplasmic projections (hairy cells) are seen.

IMMUNOHISTOCHEMISTRY
Immunohistochemical staining for CD20 shows positive diffuse involvement of marrow by hairy cell leukemia (approximately 90%). BRAF shows similar staining to CD20(~80%). CD3 highlights scattered T-cells and rare small aggregates.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-6331)
Interpretation: 
Abnormal B-cell population identified.
Flow cytometry reveals an abnormal mature B-cell population having abnormal expression of CD19 (bright), CD20 (bright), CD11c, CD22 (bright), CD25, CD45 (bright), CD103, CD200 (bright), with slightly increased forward and side scatter and lambda light chain restriction (bright); with normal expression of CD38 and without CD3, CD5, CD10, CD14 or CD279 (PD1).  The immunophenotype of the abnormal B-cell population is consistent with involvement by the patient's previously diagnosed hairy cell leukemia. The abnormal B cell population represents 11.1% of the total white cells.

No abnormal mature T-cell population detected.
No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate reports, CG21-4180 and CG21-4226.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M21-27037, M21-27038, M21-27039, M21-27042, M21-27044, M21-27045, and M21-27124.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-6594;S12;MSK3 - 2023-04-19 17.18.36.ndpi,Peripheral Blood Smear,2023-04-19,"33 M CML chronic phase, off therapy, persistent pancytopenia, peripheral blasts
Pre-BMT
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia, BCR-ABL1-positive, blast phase with a B/myeloid phenotype (65% blasts by aspirate differential count). See comment

COMMENT: The patient's reported history of CML in conjunction with the detection of a BCR-ABL1/t(9;22) fusion in 73% of cells by concurrent FISH analysis (CG21-5744) support the diagnosis. By flow cytometry, both a large abnormal myeloid blast population (69% of WBC) and a small abnormal immature B-cell population (2.9% of WBC) were detected (F21-8721), consistent with a B/myeloid blast phenotype. Case reviewed at the Hematopathology Consensus Conference on 9/15/2021.
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Mildly hypercellular for age (80%)
M:E ratio: N/A
Blasts: Markedly increased
Myeloid lineage: Reduced
Erythroid lineage: Reduced
Megakaryocytes: Increased in number with numerous small, hypo/monolobated forms and micromegakaryocytes
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1+/3) 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate with frequent bare nuclei noted

Blasts                65%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      5%
Eosinophils           1%
Basophils           2%
Erythroid Precursors      23% 
Plasma Cells           1%
Lymphocytes           1%
Number of Cells Counted 500
M:E Ratio           0.4

Special stain
Iron: Present
Ring sideroblasts: Absent

Morphology:
-Spicular and cellular aspirate smears show an expanded population of intermediate to large sized blasts with rounded, irregular or folded/lobulated nuclei, fine chromatin, distinct nucleoli and scant to moderate amounts of cytoplasm with occasional cytoplasmic vacuoles and/or granules. Auer rods are not seen. Background marrow shows erythroid predominant trilineage hematopoiesis. Myeloid elements are reduced and are seen at various stages of maturation without significant dysplasia. A mild relative increase in basophils is noted. Erythroid precursors show progressive maturation with dyserythropoiesis (megaloblastoid changes, nuclear irregularity/budding). Megakaryocytes are present with small, hypolobated forms, micromegakaryocytes, and forms with disjointed nuclear lobes seen. 

PERIPHERAL BLOOD
CBC (09/09/2021):
WBC 2.6 L [4.0-11.0 K/mcL] 
RBC 3.19 L [3.95-5.54 M/mcL] 
HGB 9.8 L [12.5-16.2 g/dL] 
HCT 29.0 L [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 30.7 [27.0-33.0 pg] 
MCHC 33.8 [31.0-36.5 g/dL] 
RDW 17.2 H [12.2-15.1 %] 
Platelets 10 L [160-400 K/mcL] 

Neutrophil 44.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 3.0 H [0.0-1.5 %] 
Blast 5.0 H [0.0-0.0 %] 
Lymph 46.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.2 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Circulating blasts seen (5%). Leukopenia with absolute neutropenia and mild relative basophilia. 
RBC: Normochromic, normocytic anemia. 
PLT: Marked thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunostains show markedly increased CD34+, CD117+ blasts comprising ~60% of the marrow cellularity. TdT and PAX5 highlights scattered cells comprising <5% of overall cellularity. CD61 highlights increased megakaryocytes with numerous small, hypo/monolobated forms and micromegakaryocytes. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-8721)
Interpretation: 
Expanded abnormal myeloid blast population detected.
Abnormal immature B-cell population detected.
The findings are consistent with chronic myeloid leukemia, blast phase. 

Myeloid blast population of WBC: 69.0 %  
Expanded Basophils Population of WBC: 4.6 %  

Immunophenotype:
Abnormal: CD7 (positive), CD11b (partial), CD13 (variable - negative, intermediate), CD15 (partial), CD25 (bimodal - negative, intermediate), CD33 (variable - negative, intermediate), CD34 (variable - negative, bright), CD56 (variable - negative, intermediate), CD117 (variable - negative, bright)
Normal: CD4, CD38, CD45, CD71, CD123, HLA-DR, cytoplasmic MPO
Negative: CD2, CD3, CD5, CD14, CD16, CD19, CD64, cytoplasmic CD3, cytoplasmic CD79a


Abnormal immature B cell population detected.
                      
The abnormal immature B-cells represent 2.9% of the white cells and 2.8% of the mononuclear cells.

Immunophenotype:
Abnormal: CD10 (variable - dim, bright), CD19 (dim), CD24 (bright), CD34 (uniform - dim), CD81 (positive - dim), CD73/CD304 (partial - dim), CD66c/CD123 (partial), CD86 (partial), CD33 (partial)
Normal: CD22, CD38, CD45, cytoplasmic CD79a (positive), HLA-DR
Negative: CD20, CD66b, surface CD3, cytoplasmic CD3, cytoplasmic MPO, CD13, CD117

This case was also reviewed by Dr. Mikhail Roshal of Hematopathology Service.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5744.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-36993, M21-37236, M21-37250.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-2063;S10;MSK8 - 2023-05-17 13.13.32.ndpi,Peripheral Blood Smear,2023-05-17,"ALL. Newly diagnosed ALL.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
     - B-lymphoblastic leukemia/lymphoma. See comment
  
COMMENT:
The biopsy is inadequate for evaluation but the touch imprint and flow cytometric findings support the above diagnosis.

BONE MARROW BIOPSY
Quality: Cortical bone with a minute clusters of crushed blue cells. 

BONE MARROW TOUCH SMEAR
Differential: (Performed by MT)
Blasts                90%
Erythroid Precursors      2%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           0

Morphology:
The touch imprint is cellular with sheets of medium sized agranular blasts. 

PERIPHERAL BLOOD
CBC (3/19/2021):
WBC 2.8 L [4.0-11.0 K/mcL] 
RBC 4.03 [3.95-5.54 M/mcL] 
HGB 11.4 L [12.5-16.2 g/dL] 
HCT 33.5 L [37.5-49.3 %] 
MCV 83 [80-98 fL] 
MCH 28.3 [27.0-33.0 pg] 
MCHC 34.0 [31.0-36.5 g/dL] 
RDW 12.6 [12.2-15.1 %] 
Platelets. 40 L [160-400 K/mcL] 

Neutrophil 20.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 12.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 62.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.6 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.3 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 1.7 [0.9-3.2 K/mcL]

Morphology: pancytopenia with occasional circulating blasts. 


IMMUNOHISTOCHEMISTRY
CD34 stains the crushed cells. TdT is negative. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-2734)
Expanded abnormal immature B-cell population detected.
No abnormal myeloid blast population detected.
No abnormal mature B or T cell populations detected. 

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (88.9 % of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD45 (dim to negative), CD25 (partial), CD33 (partial), CD38 (dim), CD66c/CD123, CD81 (dim) with normal expression of CD10, CD19, CD22, CD24, CD34, CD71, cytoCD79, and HLA-DR; and without MPO, CD2, cytoCD3, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD20, CD56, CD64, CD117, CD73/CD304 or surface light chains.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-1798.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-11170, 11171, 11172, 11174, 11175, 11176.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-7213;S12;MSKS - 2023-05-31 16.05.54.ndpi,Peripheral Blood Smear,2023-05-31,"Multiple Myeloma
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
80-90% involvement by CD138 immunohistochemistry.
86% involvement by aspirate differential
53.7% involvement by 12 color flow cytometry
     - Hypercellular marrow with reduced background trilineage hematopoiesis.

BONE MARROW BIOPSY
Quality:  Adequate, hemorrhage  
Cellularity: > 90 %
Myeloid lineage: Few
Erythroid lineage: Few
Megakaryocytes: Present
Plasma cells: Increased    
Clot section: Focal clusters of plasma cells seen

ASPIRATE MORPHOLOGY

Bone Marrow Aspirate Smear Quality:  Adequate

Myeloid elements      6%
Eosinophils           2%
Erythroid Precursors      3%
Plasma Cells           86%
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           2.7

Morphology: 
Marrow spicules: Spicular    
Cellularity: Hypercellular  
Plasma cell morphology: Small to large, bi-nucleated, nucleolated, Dutcher bodies (nuclear pseudo-inclusion)   
Myeloid lineage: Few
Erythroid Lineage: Few
Megakaryocytes:  Present    

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 80-90% of cellularity. 
Kappa and lambda immunostains show the plasma cells are lambda light chain restricted.
BCMA highlights >90% of plasma cells, with variable (1-3+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-9584) 
1. Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.

Abnormal plasma cell population comprises 99.6% of total plasma cells
Abnormal plasma cell population represents 53.7% of WBC
Immunophenotype:
Abnormal: CD138 (variable - dim, intermediate), CD19 (negative), CD27 (variable - negative, intermediate), CD45 (variable - negative, dim), CD56 (partial), CD81 (variable - negative, dim), CD117 (positive), cytoplasmic Lambda (restriction)
Normal: CD38, CD229, CD319
Negative: CD20, cytoplasmic Kappa

Number of cells acquired: 5.6 million  

2. No abnormal B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

Number of cells acquired: 232 thousand  

PERIPHERAL BLOOD
CBC (09/30/2021):
WBC 4.9 [4.0-11.0 K/mcL] 
RBC 4.06 [3.95-5.54 M/mcL] 
HGB 12.6 [12.5-16.2 g/dL] 
HCT 38.3 [37.5-49.3 %] 
MCV 94 [80-98 fL] 
MCH 31.0 [27.0-33.0 pg] 
MCHC 32.9 [31.0-36.5 g/dL] 
RDW 15.9 H [12.2-15.1 %] 
Platelets. 184 [160-400 K/mcL] 

Neutrophil 44.0 [32.5-74.8 %] 
Mono 9.0 [0.0-12.3 %] 
Eos 18.0 H [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 
Lymph 23.0 [12.2-47.4 %] 
Plasma Cell 2.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 2.2 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.9 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.2 [0.0-0.2 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Abs Plasma Cells 0.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
Rare plasma cells seen on scanning

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-6269, CG21-6270.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-40378



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

     
"
H21-1528;S12;MSKV - 2023-04-19 15.32.36.ndpi,Peripheral Blood Smear,2023-04-19,"MDS and CLL
60 years old woman with both CLL and MDS off therapy 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent chronic lymphocytic leukemia/ small lymphocytic lymphoma (20% involvement by CD20/ PAX5 immunohistology).
     - Hypocellular marrow with maturing trilineage hematopoiesis, mildly left-shifted myelopoiesis, and no increase in blasts. See comment.
  
COMMENT: Corresponding cytogenetic studies including FISH (CG21-1339) did not detect clonal chromosomal abnormalities including deletion or loss of chromosome 5 as was seen in prior studies. In addition, corresponding flow cytometric analysis did not detect an abnormal myeloid blast population. Overall, there is no diagnostic morphologic or immunophenotypic evidence of involvement by previously diagnosed myeloid neoplasm, which is also supported by the cytogenetic results.

BONE MARROW BIOPSY
Quality: Adequate, partially fragmented with intramedullary hemorrhage
Cellularity: Variable ranging from 10-40%, overall hypocellular for age (20%)
M:E ratio: N/A
Blasts: Not increased
Myeloid lineage: Adequate, actively maturing
Erythroid lineage: Adequate, actively maturing
Megakaryocytes: Patchy distribution, overall approximately adequate in number for the cellularity, with occasional hypolobated forms
Lymphocytes: Increased; present scattered singly interstitially and in clusters. Lymphoid aggregates are not well represented on the H&E section, however they are appreciated on the immunohistology (see below). The atypical lymphoid cells are small in size, with round to slightly irregular nuclei, condensed chromatin, inconspicuous nucleoli, and scant amount of cytoplasm. Sheets or areas of large cells are not seen.
Plasma cells: Rare, scattered
Special stains: Reticulin special stain shows no increase in reticulin fibrosis (MF-0).

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                2%
Promyelocytes           4%
Myelocytes           14%
Metamyelocytes           10%
Neutrophils/Bands      25%
Monocytes           4%
Eosinophils           3%
Erythroid Precursors      24%
Plasma Cells           2%
Lymphocytes           12%
Number of Cells Counted 500
M:E Ratio           2.5

Special stain
Iron: Increased
Ring sideroblasts: Absent 

Morphology:
Adequate, paucispicular and cellular aspirate smears with maturing trilineage hematopoiesis and no expanded blast population. There is an expanded population of small to intermediate size atypical lymphocytes, with round to irregular nuclei, condensed chromatin, inconspicuous nucleoli, and scant to occasionally moderate amount of cytoplasm. They are present in a patchy distribution ranging from 10% to focally 90% involvement where lymphoid aggregates are present. The M:E ratio is normal. Myeloid elements show mildly left-shifted progressive maturation and no significant dysplasia. Erythroid cells are present at various stages of maturation and show occasional karyorrhexis. Few megakaryocytes are seen without overt atypia. Rare mast cells are also noted without overt atypia.

PERIPHERAL BLOOD
CBC (03/02/2021):
WBC 9.9 [4.0-11.0 K/mcL] 
RBC 4.48 [3.80-5.00 M/mcL] 
HGB 14.5 [11.2-15.4 g/dL] 
HCT 43.7 [34.3-46.0 %] 
MCV 98 [80-98 fL] 
MCH 32.4 [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 13.6 [12.2-15.1 %] 
Platelets 185 [160-400 K/mcL] 

Neutrophil 34.3 [32.5-74.8 %] 
Mono 5.7 [0.0-12.3 %] 
Eos 2.3 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 57.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 3.4 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 5.7 H [0.9-3.2 K/mcL] 

Morphology:
WBC: No circulating blasts seen. Lymphocytosis with predominantly atypical small to intermediate size lymphocytes, with round to irregular nuclei, clumped chromatin, inconspicuous nucleoli, and scant to occasionally moderate amount of cytoplasm. Frequent smudge cells are noted.
RBC: Normocytic, normochromic RBCs. 
Platelets: Adequate in number with unremarkable morphology.

IMMUNOHISTOCHEMISTRY
CD34 shows no increase in blasts (< 5%).
CD117 highlights early myeloid and erythroid cells and shows few scattered mast cells.
CD20 and PAX5 highlight increased atypical B-cells scattered singly interstitially and in small clusters accounting for 20% of the cellularity. In interstitial small lymphoid aggregate is best appreciated by CD20 which shows relatively dim expression.
The neoplastic B-cells also coexpress CD5, CD23, and LEF1.
CD3 highlights few scattered and admixed T-cells. 
CD61 is positive in megakaryocytes which are decreased.
MPO highlights the myeloid cells, and CD71 highlights the erythroid cells, which show an overall slightly decreased to normal M:E ratio.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-2023)
Interpretation: 
Abnormal B-cell population identified.
No abnormal myeloid blast, monocyte or maturing myeloid population identified.

Flow cytometry identified an abnormal B-cell population having abnormal expression of CD5, CD20 (absent to dim), CD23 (partial), CD43 (partial), CD79b (absent to dim), CD81 (absent to dim), CD200 (bright), and ROR1; normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The findings are consistent with previously diagnosed chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL). The abnormal B-cell population comprises 26.8% of the white cells.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.25% of WBC.
433113 of cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis reported separately. See separate report, CG21-1339.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-8304.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-4460;S12;MSK3 - 2023-05-27 01.29.41.ndpi,Peripheral Blood Smear,2023-05-27,"Anemia
Isolated Anemia, c/f MDS
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Hypercellular marrow with trilineage maturing hematopoiesis, Ring Sideroblasts (5-14% of erythroid elements), increased megakaryocytes with dysmegakaryopoiesis, no increase in blasts or reticulin fibrosis, Highly suspicious for Myeloid Neoplasm (See Comment 1)
     - Involvement by Plasma Cell Proliferative Disorder, lambda-restricted (See Comment 2)
     <5% involvement by CD138 immunostain
     <5% involvement by aspirate differential count
     0.061% of total WBC (38.5% of total plasma cells) by 12-color Flow cytometric 
  
COMMENT 1: Overall, the dyspoiesis seen in predominantly in the megakaryocytes, and to a lesser degree in the erythroid elements. Ring sideroblasts comprise 5-15% of erythroid elements (=15% is considered increased in cases without molecular studies, =5% is considered increased if SF3B1 mutation is detected).

Together with the abnormal flow cytometric findings, and history of otherwise unexplained macrocytic anemia, the findings are highly suspicious for a myeloid neoplasm, particularly Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia (MDS-RS-MLD). Noted is made of the patient's borderline relative monocytosis in peripheral blood (11%), without absolute monocytosis (<1.0K/uL) in a single CBC measurement at MSK. If the monocytosis is sustained and worsened over time without therapy, then a diagnosis of Chronic Myelomonocytic Leukemia-0 (CMML-0) may be more appropriate.

Regardless, pending cytogenetics and molecular studies, including mutational profiling, will be helpful in confirming a myeloid neoplasm diagnosis, and may aid in classification. In particular, the detection of SF3B1 mutation in this case will be highly supportive of MDS with ring sideroblasts.

COMMENT 2: Overall, plasma cells comprise <10% of marrow cellularity. A review of recent labs at MSK shows elevated free lambda protein, but no evidence of detectable serum monoclonal gammopathy by immunofixation. This is likely an incidental finding of uncertain clinical significance at the moment.

BONE MARROW BIOPSY
Quality: Fragmented
Cellularity: Hypercellular for age (~60% cellularity)
M:E ratio: Normal
Blasts: Not increased
Myeloid lineage: Progressive maturation
Erythroid lineage: Left-shifted, progressive maturation
Megakaryocytes: Mildly increased in number with frequent atypical hypolobated or hyperchromatic forms, as well as nuclear lobe separation
Lymphocytes: Scattered
Plasma cells: Scattered

Special stains: 
Reticulin stain shows no significant increase in reticulin fibrosis (0/3). 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                4%
Promyelocytes           3%
Myelocytes           15%
Metamyelocytes           6%
Neutrophils/Bands      30%
Monocytes           4%
Eosinophils           3%
Erythroid Precursors      21%
Plasma Cells           1%
Lymphocytes           13%
Number of Cells Counted 500
M:E Ratio           2.9

Special stain 
Iron: Trace/decreased storage iron.
Ring sideroblasts: Present (5% to 14% of erythroid elements).

Morphology:
Cellular, spicular smears showing maturing trilineage hematopoiesis, with no increase in blasts. Myeloid elements exhibit progressive maturation with occasional hypogranular forms (<10% of lineage). Scattered mature monocytes are seen. Erythroid elements show left-shifted, progressive maturation with some dyspoietic forms (nuclear-cytoplasmic dyssynchrony, karyorrhexis, cytoplasmic vacuoles, <10% of lineage). Megakaryocytes are present, appears increased in number, with frequent atypical forms (small lobation, nuclear lobe separation). The lymphoid cells present are mostly small and maturing-appearing. Scattered plasma cells are seen.

PERIPHERAL BLOOD
CBC (6/21/2021):
WBC 7.0 [4.0-11.0 K/mcL] 
RBC 2.73 L [3.95-5.54 M/mcL] 
HGB 9.8 L [12.5-16.2 g/dL] 
HCT 29.9 L [37.5-49.3 %] 
MCV 110 H [80-98 fL] 
MCH 35.9 H [27.0-33.0 pg] 
MCHC 32.8 [31.0-36.5 g/dL] 
RDW 14.8 [12.2-15.1 %] 
Platelets. 333 [160-400 K/mcL] 

Neutrophil 70.0 [32.5-74.8 %] 
Mono 11.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 3.0 H [0.0-1.5 %] 
Lymph 15.0 [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 4.9 [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.2 [0.0-0.2 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL]

Morphology:
WBC: Relative basophilia. Some pseudo-Pelger Huet forms and left-shifted band forms seen. No circulating blasts
RBC: Macrocytic anemia. No Rouleaux formation.
Platelets: Some large and occasional giant platelets seen.

IMMUNOHISTOCHEMISTRY
CD34 shows no increase in blasts (<5% cellularity). It also highlights a subset of dysplastic hypolobated megakaryocytes.
CD117 highlights the blasts, as well as increased early myeloid and erythroid elements.
CD61 highlights increased atypical megakaryocytes.

CD3 highlights scattered small T cells.
CD20 highlights rare scattered small B cells.
CD138 highlights plasma cells scattered interstitially and forming some aggregates (<5% of cellularity).
BCMA highlights 100% of plasma cells (3+ intensity), membranous and Golgi pattern.
Kappa and lambda immunostains show no definitive light chain restriction.
Cyclin D1 appears positive in a small subset of plasma cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5898)
Interpretation: 
Abnormal myeloid blast population detected.
Monocytosis seen (10.7% of WBC).
Abnormal plasma cell population detected.
No abnormal mature B- or T-cell populations detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD5 (subset), CD7 (partial), CD38 (dim), CD117 (bright), and HLA-DR (bright); with normal expression of CD4, CD13, CD33, CD34, CD45, CD71, and CD123; without CD2, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 2.1% of WBC. 
Monocytes are mildly expanded (10.7% of WBC) with patrial CD56 expression. 

Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (absent), CD20, CD27 (absent), CD45 (absent), CD56, CD81 (dim), CD117 (partial, dim), and monoclonal lambda cytoplasmic light chain restriction; with normal expression of CD38, CD138, CD229, and CD319. The abnormal population represents 0.061% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 38.5% of total plasma cells in the sample.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3896.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-25357 to M21-25359 and M21-25361.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-5995;S10;MSKE - 2023-05-27 03.02.58.ndpi,Peripheral Blood Smear,2023-05-27,"Lymphoma. Eval for MCL. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Involvement by mantle cell lymphoma; see comment.
     - Markedly hypocellular marrow with trilineage maturing hematopoiesis.

COMMENT: While the findings are compatible with involvement by mantle cell lymphoma, the degree of involvement is not entirely clear due to markedly hypocellular biopsy specimen. Given that the aspirate smears show normal to high cellularity, the proportion of involvement on the biopsy may not be truly representative of the marrow composition. Circulating atypical lymphoid cells are seen in the peripheral blood as well, which suggests significant levels of marrow involvement.
The etiology of the patient's thrombocytopenia is not entirely clear. While no overt evidence of myeloid neoplasia is seen, correlation with cytogenetic and molecular studies is recommended. Thrombocytopenia may also be related to peripheral destruction and/or splenic sequestration. Clinical, laboratory, and radiology correlation is advised. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy shows markedly hypocellular bone marrow (5-10% cellularity). There istrilineage maturing hematopoiesis with increased numbers of small, atypical lymphocytes with an interstitial distribution. Aspirate smears are spicular, hypercellular, and show occasional atypical lymphoid cells in a background of maturing trilineage hematopoiesis. No overt dyspoiesis or increase in blasts is seen.

Bone Marrow Aspirate Smear Quality: Adequate
Blasts                1%
Promyelocytes           2%
Myelocytes           14%
Metamyelocytes           6%
Neutrophils/Bands      19%
Monocytes           4%
Eosinophils           2%
Erythroid Precursors      27%
Lymphocytes           25% (few atypical/ immature lymphoid cells noted)
Number of Cells Counted 500
M:E Ratio           1.7 

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 immunostains highlight an increased number of lymphoid cells (~10% of cellularity), which are cyclin-D1 positive. CD3 labels background T-cells. SOX11, P53 and Ki-67 are non-contributory due to loss of tissue upon sectioning.
CD34 and CD117 highlight blasts comprising less than 5% of the total cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7942) 
Abnormal B-cell population identified.
Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5 and ROR1; normal expression of CD19, CD20, CD22, CD38, CD40, CD43, CD79b, CD81, and CD45; and without CD3, CD10, CD23, or CD200.  The abnormal B cell population represents 25.6% of total white cells.
This immunophenotype is consistent with previously diagnosed mantle cell lymphoma (MCL).

ADDENDUM:
No definite abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
There is no definite immunophenotypic evidence of a myeloid stem cell neoplasm by flow cytometry. However, in light of the blast population having expression of CD5 (small subset), a low-grade myeloid stem cell neoplasm or underlying abnormal clonal hematopoiesis cannot be entirely excluded by these studies. CD34 positive myeloid blasts represent 0.92% of the white blood cells with expression of CD13, CD33, CD34, CD38, CD45, CD71, CD117 and low CD123.  Normal myelomonocytic maturation is present. 217 thousand cells acquired. Morphologic, cytogenetic, and molecular genetic assessment is suggested to exclude myeloid stem cell neoplasm. Clinical correlation is also advised. 
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment.

PERIPHERAL BLOOD
CBC (08/16/2021):
WBC 4.9 [4.0-11.0 K/mcL] 
RBC 4.54 [3.95-5.54 M/mcL] 
HGB 14.1 [12.5-16.2 g/dL] 
HCT 40.5 [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 31.1 [27.0-33.0 pg] 
MCHC 34.8 [31.0-36.5 g/dL] 
RDW 12.9 [12.2-15.1 %] 
Platelets 65 L [160-400 K/mcL] 

Neutrophil 49.0 [32.5-74.8 %] 
Mono 9.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 27.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 10.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 2.4 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.8 [0.9-3.2 K/mcL] 

Morphology:
WBC: Circulating atypical lymphoid cells present.
RBC: Unremarkable morphology.
PLT: Moderate to severe thrombocytopenia.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5215, CG21-5216.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-33356 & M21-33570.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-7705;S13;MSK9 - 2023-05-27 02.23.06.ndpi,Peripheral Blood Smear,2023-05-31,"Small Cell Lung Cancer
Pancytopenia, unclear if metastatic marrow involvement or other process 
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Metastatic small cell carcinoma, see comment.  

COMMENT: The patient's history of small cell lung carcinoma with extensive metastasis is noted. The bone marrow specimen is nearly replaced by metastatic small cell carcinoma. Background hematopoiesis is markedly reduced to absent. 

The diagnosis was rendered in consultation with Dr. W. Travis of thoracic pathology.

Additional stains will be ordered and reported as an addendum; material will be sent for molecular studies that will be reported separately.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Nearly replaced by metastatic small cell carcinoma with small foci of necrosis. Background hematopoiesis is markedly reduced to absent. 
Clot section: Findings similar to biopsy

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Numerous naked nuclei noted

The differential cells count was not performed.

Hypercellular bone marrow aspirate replaced by extrinsic cells (clusters / singly). Maturing trilineage hematopoiesis is markedly diminished. Touch imprints show small clusters of extrinsic cells. 

PERIPHERAL BLOOD
CBC (10/19/2021):
WBC 3.0 L [4.0-11.0 K/mcL] 
RBC 2.33 L [3.95-5.54 M/mcL] 
HGB 6.9 L [12.5-16.2 g/dL] 
HCT 21.3 L [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 29.6 [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL] 
RDW 16.6 H [12.2-15.1 %] 
Platelets 20 L [160-400 K/mcL] 

Neutrophil 73.7 [32.5-74.8 %] 
Mono 8.1 [0.0-12.3 %] 
Eos 0.3 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 6.8 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 10.8 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.2 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.2 H [0.0-0.1 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Leukopenia
RBC: Mild anisopoikilocytosis with mild polychromasia
Platelets: Thrombocytopenia

IMMUNOHISTOCHEMISTRY
Immunostains show the malignant cells are positive for synaptophysin and CD117 with a high KI67 proliferation index (80-90%). Additionally, chromogranin is focally positive. Segments of the tumor are not well fixed and appear artefactually negative by immunohistochemistry.

TTF-1 and CD34 are negative in the neoplastic cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW
Not submitted

CYTOGENETIC STUDIES
Not submitted

MOLECULAR STUDIES 
Additional material will be sent for molecular studies.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-5762;S10;MSK7 - 2023-06-06 01.29.48.ndpi,Peripheral Blood Smear,2023-06-06,"New diagnosed of ALL. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
    - B-lymphoblastic leukemia/lymphoma (B-ALL) with t(9;22) BCR-ABL1; see comment.

COMMENT: Correlation with concurrent molecular and cytogenetic studies is recommended.
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular >95%
M:E ratio: N/A
Blasts: Markedly expanded population of blasts forming sheets, the cells are large in size with variable shape, the nuclei have open chromatin with distinct nucleoli, and minimal cytoplasm.
Myeloid lineage: Markedly reduced 
Erythroid lineage: Markedly reduced 
Megakaryocytes: Markedly reduced 
Lymphocytes: Rare
Plasma cells: Rare

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                91%
Neutrophils/Bands      1%
Erythroid Precursors      2%
Lymphocytes           6%
Number of Cells Counted      500
M:E Ratio           0.5

Morphology: The aspirate smears are spicular and cellular and show a markedly expanded population of medium to large sized blasts with small amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli, in a background of markedly decreased trilineage hematopoiesis. Marked crush artifact is noted. 

PERIPHERAL BLOOD
CBC (8/6/2021):
WBC 35.8 H [4.0-11.0 K/mcL] 
RBC 2.29 L [3.95-5.54 M/mcL] 
HGB 6.9 L [12.5-16.2 g/dL] 
HCT 20.7 L [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 30.1 [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 17.4 H [12.2-15.1 %] 
Platelets. 19 L [160-400 K/mcL] 

Neutrophil 2.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 87.0 H [0.0-0.0 %] 
Lymph 11.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.7 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 31.2 H [0.0-0.0 K/mcL] 
Abs Lymph 3.9 H [0.9-3.2 K/mcL]

Morphology:
WBC: Leukocytosis with markedly expanded blast population  
RBC: Normocytic, normochromic anemia with anisocytosis 
PLT: Marked thrombocytopenia 

IMMUNOHISTOCHEMISTRY
TdT and CD34 highlight sheets of blasts occupying the bone marrow, >90% of total cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7615)
Abnormal immature B-cell population detected.

The presence of greater than 20% abnormal immature B-cells in the marrow (92.7% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD10 (bright), CD13 (partial), CD24 (bright), CD25 (partial), CD33 (partial), CD34 (dim), CD38 (variable, absent to dim), CD45 (absent), CD81 (dim), CD86 (minute subset), CD66c/CD123, with normal expression of CD19, CD22, CD71, cytoplasmic CD79a and HLA-DR; and without CD2, sCD3, cyCD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD20, CD56, CD64, CD66b, CD117, MPO, surface light chains or convincing CD73/CD304.

No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.077% of WBC.
303 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-7600)
Abnormal immature B-cell population detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood (77.7% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD10 (bright), CD11b (partial), CD13 (partial), CD24 (bright), CD25 (partial), CD33 (partial), CD34 (dim), CD38 (mostly absent), CD45 (variable, absent to dim), CD81 (dim), CD86 (minute subset) andCD66c/CD123 (partial); with normal expression of CD19, CD22, CD71, cytoplasmic CD79a and HLA-DR ; and without CD2, sCD3, cyCD3, CD4, CD5, CD7, CD8, CD14, CD15, CD16, CD20, CD56, CD64, CD66b, CD117, CD73/CD304 or surface light chains.

No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.19% of WBC.
471 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5002.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-32268, M21-32270, M21-32271
.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-4506;S10;MSKB - 2023-05-27 02.05.15.ndpi,Peripheral Blood Smear,2023-05-27,"Lymphoma
Newly diagnosed MCL 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Involvement by mantle cell lymphoma (less than 10% with CD20 immunohistochemistry)
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy specimen shows normocellular bone marrow (30% cellularity) with focal interstitial aggregates composed of small lymphoid cells with condensed chromatin and inconspicuous nucleoli. There istrilineage maturing hematopoiesis. Myeloid and erythroid elements show progressive maturation. Megakaryocytes appear adequate in number and morphology. The aspirate smears are paucispicular and cellular and show trilineage maturing hematopoiesis.

Bone Marrow Aspirate Smear Quality: Adequate.

Blasts                2%
Promyelocytes           3%
Myelocytes           13%
Metamyelocytes           10%
Neutrophils/Bands      21%
Monocytes           2%
Eosinophils           3%
Erythroid Precursors      24%
Plasma Cells           7%
Lymphocytes           15%
Number of Cells Counted      500
M:E Ratio           2.2

IMMUNOHISTOCHEMISTRY
The lymphoid cells
Express: CD20, PAX5, Cyclin D1 (weak), SOX11
Other:
CD3 highlights background T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5957) 
Interpretation: 
Abnormal B-cell population identified.
Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD19 (dim), CD43, and ROR1; normal expression of CD20, CD38, CD40, CD79b, CD81, and CD45; and without CD3, CD10, CD23, or CD200.  The abnormal B cell population represents 5.6% of total white cells.
This immunophenotype is consistent with previously diagnosed mantle cell lymphoma (MCL).

PERIPHERAL BLOOD
CBC (06/22/2021):
WBC 3.4 L [4.0-11.0 K/mcL] 
RBC 4.48 [3.95-5.54 M/mcL] 
HGB 11.9 L [12.5-16.2 g/dL] 
HCT 37.3 L [37.5-49.3 %] 
MCV 83 [80-98 fL] 
MCH 26.6 L [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 15.5 H [12.2-15.1 %] 
Platelets 109 L [160-400 K/mcL] 

Neutrophil 62.9 [32.5-74.8 %] 
Mono 11.4 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.9 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 22.2 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.2 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL]
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 

Morphology: Few atypical small lymphoid cells are seen


CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3939, CG21-3940.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-25502, M21-25503.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-5800;S10;MSKJ - 2023-05-27 02.51.42.ndpi,Peripheral Blood Smear,2023-05-27,"Leukemia, Acute Lymphoid

66 yo woman w/ new diagnosis of Leukemia , unclear subtype, performing initial evaluation 
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma (B-ALL) (95% blast by touch imprint preparation differential counts, >90% by CD34 and TdT immunohistochemistry)   

COMMENT: For further classification, correlate with the forthcoming molecular and cytogenetic results.

BONE MARROW BIOPSY
Quality: Small fragmented
Cellularity: Hypercellular (>90% cellularity)
M:E ratio: n/a
Blasts: : Expanded blast population of predominantly intermediate size cells, with high nuclear/cytoplasmic ratio, large irregular/folded nucleus, fine chromatin, distinct nucleoli, and scant cytoplasm.
Myeloid lineage: Markedly reduced
Erythroid lineage: Markedly reduced
Megakaryocytes: Reduced
Lymphocytes: Scattered
Plasma cells: Scattered

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules
The differential cell count was performed on touch imprints 

Blasts                95%
Myeloid precursors     1%
Erythroid Precursors      3%
Lymphocytes          1%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
-Touch imprint preparation is cellular and show reduced background trilineage hematopoiesis and expanded blast population. Blasts are predominantly intermediate size cells, with high nuclear/cytoplasmic ratio, large irregular/folded nucleus, fine chromatin, distinct nucleoli, and scant cytoplasm. Scattered erythroid and myeloid precursors present. Rare megakaryocyte is seen. 
PERIPHERAL BLOOD
CBC (08/09/2021):
WBC 4.6 [4.0-11.0 K/mcL] 
RBC 4.59 [3.80-5.00 M/mcL] 
HGB 13.1 [11.2-15.4 g/dL] 
HCT 39.1 [34.3-46.0 %] 
MCV 85 [80-98 fL] 
MCH 28.5 [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 13.9 [12.2-15.1 %] 
Platelets 16 L [160-400 K/mcL] 

Neutrophil 15.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 43.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 38.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.7 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 3.8 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Frequent circulating blasts are seen.
RBC: Normocytic normochromic
Platelets: Decreased in number with unremarkable morphology. 

IMMUNOHISTOCHEMISTRY
Immunostains for CD34 and TdT show >90% blasts

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7665)
Abnormal immature B-cell population detected.
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.12% of WBC.

The presence of greater than 20% abnormal immature B-cells in the marrow (93.8 % of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD10 (slightly bright), CD11b, CD13 (partial), CD33 (partial), CD20 (partial), CD24 (bright), CD25 (partial), CD34 (dim), CD38 (dim), CD45 (dim), CD81 (dim), CD86 (partial) and CD66c/CD123; with normal expression of CD19, CD22, CD71, cytoplasmic CD79a and HLA-DR; and without CD2, sCD3, cyCD3, CD4, CD5, CD7, CD8, CD14, CD15, CD16, CD56, CD64, CD66b, CD117, CD73/CD304, MPO or surface light chains.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-7638)
Abnormal immature B-cell population detected.
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 1.4% of WBC.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood (27.5% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD10 (bright), CD11b, CD13 (partial), CD20 (dim), CD22 (bright), CD24 (bright), CD25 (partial), CD33 (partial), CD34 (dim), CD38 (dim), CD45 (dim), CD81 (dim), CD86 (partial) andCD66c/CD123; with normal expression of, CD19, CD71, cytoplasmic CD79a and HLA-DR; and without CD2, sCD3, cyCD3, CD4, CD5, CD7, CD8, CD14, CD15, CD16, CD56, CD64, CD66b, CD117, CD73/CD304, MPO or surface light chains.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5042.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M21-32540, M21-32541, M21-32542, M21-32543, and M21-32550.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-6912;S11;MSKW - 2023-05-19 18.50.35.ndpi,Peripheral Blood Smear,2023-05-19,"Clinical Diagnosis: ALL
Clinical Hx/Op Findings: New Dx ALL
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma. 
  
BONE MARROW BIOPSY
Quality: adequate 
Cellularity: 100%
The marrow is entirely replaced by leukemic blasts. 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                75%
Myelocytes           3%
Metamyelocytes           2%
Neutrophils/Bands      7%
Eosinophils           1%
Erythroid Precursors      10%
Plasma Cells           1%
Lymphocytes           1%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
The aspirate smear shows sheets of leukemic blasts. Normal trilineage hematopoiesis is markedly reduced. 

PERIPHERAL BLOOD
CBC (09/20/2021):
WBC 57.1 H [4.0-11.0 K/mcL] 
RBC 3.22 L [3.80-5.00 M/mcL] 
HGB 9.0 L [11.2-15.4 g/dL] 
HCT 28.9 L [34.3-46.0 %] 
MCV 90 [80-98 fL] 
MCH 28.0 [27.0-33.0 pg] 
MCHC 31.1 [31.0-36.5 g/dL] 
RDW 19.1 H [12.2-15.1 %] 
Platelets 94 L [160-400 K/mcL] 

Neutrophil 4.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 86.0 H [0.0-0.0 %] 
Lymph 9.0 L [12.2-47.4 %] 
Nucleated RBC 2.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 2.3 [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.6 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 49.1 H [0.0-0.0 K/mcL] 
Abs Lymph 5.1 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
Numerous leukemic blasts. 

IMMUNOHISTOCHEMISTRY
CD34 and TdT stain numerous blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-9135)
1. Abnormal immature B cell population detected. 
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  

Abnormal immature B cell population of the mononuclear cells: 90.0%
Abnormal immature B cell population represents 90.3% of WBC

Immunophenotype:
Abnormal: CD10 (positive - bright), CD11b (partial), CD13 (negative to intermediate), CD19 (slightly dim), CD20 (partial), CD24 (variable - negative, bright), CD25 (positive), CD33 (negative to intermediate), CD34 (uniform - bright), CD38 (variable - dim, intermediate), CD45 (variable - negative, dim), CD66c/CD123 (positive), CD73/CD304 (positive), CD81 (dim), CD86 (partial), CD123 (positive)
Normal: CD22, CD71, HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD14, CD15, CD16, CD26, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, cytoplasmic MPO, Surface Kappa, Surface Lambda

Number of cells acquired: 822 thousand  

2. No abnormal B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.


3. No abnormal T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 432 thousand  

4. No abnormal myeloid blast population identified. Very few myeloid blasts noted.                             
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.056% of WBC

Number of cells acquired: 470 thousand  

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5988.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-38538, M21-38545, M21-38546.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H21-1882;S11;MSKX - 2023-05-22 09.51.11.ndpi,Peripheral Blood Smear,2023-05-22,"CML
Newly diagnosed CML
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia, BCR-ABL1-positive, chronic phase. See comment.
  
COMMENT:
The patient's history of germline BRCA2 mutation and recent diagnosis of breast cancer treated with tamoxifen is noted, as is his recently noted leukocytosis. Molecular studies on the peripheral blood [M21-8023 (03/02/2021) and M21-9118 (03/08/2021)] demonstrated BCR-ABL1 fusion (e14a2; p210). Correlation with pending cytogenetic studies is recommended to evaluate for the presence of any additional clonal chromosomal abnormalities.

BONE MARROW BIOPSY
Quality: Fragmented but adequate
Cellularity: Appears hypercellular (~80%) in a fragmented specimen; however, the precise cellularity is difficult to determine
M:E ratio: Increased
Blasts: Not increased
Myeloid lineage: Progressive maturation
Erythroid lineage: Relatively decreased; progressive maturation
Megakaryocytes: Sightly increased in number. Frequent small forms with hypolobated nuclei.
Lymphocytes: Scattered
Plasma cells: Not increased
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 
Other: No morphologic evidence of metastatic carcinoma.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                2%
Promyelocytes           1%
Myelocytes           20%
Metamyelocytes           13%
Neutrophils/Bands      37%
Monocytes           2%
Eosinophils           5%
Basophils           2%
Erythroid Precursors      15%
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           5.3

Morphology:
-Spiculate and cellular smears show trilineage hematopoiesis with a myeloid predominance. Blasts are not increased. Both the myeloid and erythroid lineages show a full range of maturation with no overt dysplasia. Scattered basophils are identified, but they are not markedly increased. There are scattered megakaryocytes, many of which are small with hypolobated nuclei.

PERIPHERAL BLOOD
CBC (03/15/2021):
WBC 40.1 H [4.0-11.0 K/mcL] 
RBC 7.15 H [3.95-5.54 M/mcL] 
HGB 14.1 [12.5-16.2 g/dL] 
HCT 47.1 [37.5-49.3 %] 
MCV 66 L [80-98 fL] 
MCH 19.7 L [27.0-33.0 pg] 
MCHC 29.9 L [31.0-36.5 g/dL] 
RDW 22.5 H [12.2-15.1 %] 
Platelets. 517 H [160-400 K/mcL] 

Neutrophil 68.0 [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 6.0 H [0.0-1.5 %] 
Myelocyte 3.0 H [0.0-0.0 %] 
Metamyelocyte 3.0 H [0.0-0.0 %] 
Lymph 13.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 27.3 H [1.5-7.5 K/mcL] 
Abs Mono 2.0 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.8 H [0.0-0.7 K/mcL] 
Absolute Basophil 2.4 H [0.0-0.2 K/mcL] 
Abs Myelocytes 1.2 H [0.0-0.0 K/mcL] 
Abs Meta 1.2 H [0.0-0.0 K/mcL] 
Abs Lymph 5.2 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Leukocytosis with increased neutrophils in various stages of maturation. Occasional circulating blasts and basophils are seen.
RBC: Normochromic, microcytic
Platelets: Increased with occasional large forms.

IMMUNOHISTOCHEMISTRY
Immunostains show focal increases in CD34+ blasts, but CD34+ blasts comprise <5% of the overall cellularity. CD117 marks mildly increased immature cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-2498)
Abnormal myeloid blast population detected.
No abnormal mature T-cell population detected.
Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD7 (partial), CD11b (partial), CD13 (absent to dim), CD33 (variable, absent to bright), CD34 (dim), and HLA-DR (bright); with normal expression of CD4, CD38, CD45, CD71, CD117, CD123 without CD2, CD5, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 1.9% of WBC.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-1654.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-10155.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-1768;S11;MSK- - 2023-04-19 13.01.05.ndpi,Peripheral Blood Smear,2023-04-19,"CML
62 yo man with newly diagnosed CML
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia, BCR-ABL1-positive
     - Hypercellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality: Fragmented with aspiration artifact 
Cellularity: Hypercellular (~70% in better preserved areas)
M:E ratio: Increased 
Blasts: Not increased 
Myeloid lineage: Exhibits progressive maturation 
Erythroid lineage: Exhibits progressive maturation
Megakaryocytes: Adequate in number with small mono/hypolobated forms
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no significant increase in reticulin fibrosis (0/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)
Blasts                1%
Promyelocytes           2%
Myelocytes           14%
Metamyelocytes           10%
Neutrophils/Bands      46%
Monocytes           2%
Eosinophils           2%
Basophils           2%
Erythroid Precursors      17%
Plasma Cells           1%
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           4.6

Morphology:
Spicular and hypercellular aspirate smears show trilineage maturing hematopoiesis with no increased blasts. Myeloid elements show full maturation with no significant dysplasia. Scattered eosinophiles and basophiles are present. Erythroid elements show full maturation with no significant dysplasia. Megakaryocytes are present with some small mono/hypolobated forms. 

PERIPHERAL BLOOD
CBC (03/10/2021):
WBC 18.5 H [4.0-11.0 K/mcL] 
RBC 4.34 [3.95-5.54 M/mcL] 
HGB 12.2 L [12.5-16.2 g/dL] 
HCT 39.1 [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 28.1 [27.0-33.0 pg] 
MCHC 31.2 [31.0-36.5 g/dL] 
RDW 15.3 H [12.2-15.1 %] 
Platelets 394 [160-400 K/mcL] 

Neutrophil 60.0 [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 3.0 H [0.0-1.5 %] 
Blast 1.0 H [0.0-0.0 %] 
Myelocyte 5.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 3.0 H [0.0-0.0 %] 
Lymph 20.0 [12.2-47.4 %] 
Variant Lymph 1.0 [0.0-2.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 11.1 H [1.5-7.5 K/mcL] 
Abs Mono 0.9 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.6 H [0.0-0.2 K/mcL] 
Absolute Blasts 0.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.9 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.6 H [0.0-0.0 K/mcL] 
Abs Lymph 3.9 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Rare circulating blasts and few left-shifted granulocytes present; absolute neutrophilia and basophilia. 
RBC: Mild anisocytosis and polychromasia; rare nucleated RBCs. 
PLT: Few large forms. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increased blasts (<5% marrow cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-2354)
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature B- or T-cell populations detected.

CD34 positive myeloid blast population with apparent normal immunophenotype is 1.3% of WBC.
455 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.
Flow cytometry is generally not a sensitive methodology in the context of myeloproliferative disorders, correlation with molecular studies for JAK2, CALR, MPL mutation status and/or BCR-ABL and morphology is advised if clinically indicated.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-1547.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-9618, M21-9619, M21-9620, M21-9621.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-1724;S16;MSKX - 2023-04-19 13.07.06.ndpi,Peripheral Blood Smear,2023-04-19,"CLL
CLL on ibrutinib w/ POD
","{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch31506\stshfhich31506\stshfbi31506\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri{\*\falt Calibri};}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE{\*\falt Calibri};}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr{\*\falt Calibri};}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek{\*\falt Calibri};}
{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur{\*\falt Calibri};}{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew){\*\falt Calibri};}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic){\*\falt Calibri};}
{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic{\*\falt Calibri};}{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese){\*\falt Calibri};}
{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;
\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;
\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;\red0\green0\blue0;}{\*\defchp \f31506\fs22 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 
\f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31506\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused Normal Table;}{
\s15\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 
\snext15 \slink16 \sqformat \spriority1 \styrsid3015850 No Spacing;}{\*\cs16 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \dbch\af31505 \sbasedon10 \slink15 \slocked \spriority1 \styrsid3015850 No Spacing Char;}{\s17\ql \li0\ri0\widctlpar
\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 
\f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext17 \styrsid1922531 CoPath Text;}}{\*\rsidtbl \rsid1922531\rsid2180332\rsid3015850\rsid3610987\rsid4349262\rsid4352493\rsid4851710\rsid5131266\rsid5393065\rsid5471874\rsid6039124\rsid6440376
\rsid7345479\rsid8012503\rsid8093638\rsid8407712\rsid8791250\rsid11476474\rsid11553398\rsid12216991\rsid12610225\rsid13046825\rsid13784635\rsid13842715\rsid14096415\rsid14889983\rsid16476786\rsid16542634}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0
\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\author Tam, Chiu Shek/Pathology}{\operator Liu, Ying(Emily)/Pathology}{\creatim\yr2021\mo3\dy12\hr18\min5}{\revtim\yr2021\mo3\dy12\hr18\min5}{\version2}
{\edmins0}{\nofpages2}{\nofwords535}{\nofchars3279}{\nofcharsws3717}{\vern7}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont1\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1440\dgvorigin1440\dghshow1\dgvshow1
\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\rsidroot13784635\newtblstyruls\nogrowautofit\usenormstyforlist\noindnmbrts\felnbrelev\nocxsptable\indrlsweleven\noafcnsttbl\afelev\utinl\hwelev\spltpgpar\notcvasp\notbrkcnstfrctbl\notvatxbx\krnprsnet\cachedcolbal \nouicompat \fet0
{\*\wgrffmtfilter 2450}\nofeaturethrottle1\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang 
{\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}
\pard\plain \ltrpar\s17\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid4611213 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 \f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531      }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 - }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 Chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid8791250 ) (~30% involvement by}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  CD20/PAX5 immunohistochemistry)}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 .}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 \par      }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 - }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 Hyperc}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 ellular marrow with trilineage maturing hematopoiesis.\par   \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\ul\insrsid1922531\charrsid7345479 BONE MARROW BIOPSY}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par Quality:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  Adequate }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par Cellularity:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  Hypercellular (~50-60%)}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par M:E ratio:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  Normal }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par Blasts:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  Not increased }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par Myeloid lineage:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  Exhibits full maturation }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par Erythroid lineage:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  Exhibits full maturation }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par Megakaryocytes:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  Adequate in number with occasional hyperchromatic/hypolobated forms}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par Lymphocytes:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493  }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 I}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 ncreased and form }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 interstitial aggregates}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 , composed predominantly }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 of }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 small cells with round to irregular nuclei, clumped chromatin, inconspicuous nucleoli and scant cytoplasm}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par Plasma cells:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  Scattered }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par Clot section:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  Contains many marrow particles showing nodular lymphoid proliferation with similar morphology to the core biopsy }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\ul\insrsid1922531\charrsid7345479 BONE MARROW ASPIRATE SMEAR}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par Differential:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  (Performed by HM) }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid5393065 Blasts \tab \tab \tab 1%\par Promyelocytes \tab \tab 2%\par Myelocytes \tab \tab 8%\par Metamyelocytes \tab \tab 6%\par Neutrophils/Bands \tab 11%\par Monocytes \tab \tab 1%\par Eosinophils \tab \tab 2%\par Erythroid Precursors \tab 18%\par Plasma Cells \tab \tab 1%\par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 Lymphocytes \tab \tab 50%}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid5393065 \par Number of Cells Counted 500\par M:E Ratio \tab \tab 1.7}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \highlight4\insrsid1922531\charrsid7345479 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 Morphology:\par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 S}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 picular and cellular aspirate smears show expanded monotonous lymphoid population, composed predominantly of small}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 -}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 sized cells with round }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 to irregular }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 nuclei, clumped to condensed chromatin, inconspicuous nucleoli and scant cytoplasm. Maturing myeloid and erythroid elements are }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 present and show full maturation with no overt dysplasia}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 . Megakaryocytes are }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 present with mostly unremarkable morphology}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 . Blasts are not increased.  }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\ul\insrsid1922531\charrsid7345479 \par PERIPHERAL BLOOD}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par CBC (}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 03/09/2021}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 ):}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid16542634 WBC 40.0 H [4.0-11.0 K/mcL] \par RBC 4.55 [3.95-5.54 M/mcL] \par HGB 15.1 [12.5-16.2 g/dL] \par HCT 44.5 [37.5-49.3 %] \par M}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 CV}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid16542634  98 [80-98 fL] \par M}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 CH}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid16542634  33.2 H [27.0-33.0 pg] \par M}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 CHC}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid16542634  33.9 [31.0-36.5 g/dL] \par R}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 DW}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid16542634  13.3 [12.2-15.1 %]\par Platelets 120 L [160-400 K/mcL] }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid16542634 \par Neutrophil 10.0 L [32.5-74.8 %] \par Mono 1.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 0.0 [0.0-1.5 %] \par Lymph 89.0 H [12.2-47.4 %] \par Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid16542634 Abs Neut 4.0 [1.5-7.5 K/mcL] \par Abs Mono 0.4 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.0 [0.0-0.2 K/mcL] \par Abs Lymph 35.6 H [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par \par Morphology:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 \par WBC: Circulating atypical lymphoid cells and smudge cells. \par RBC: {\*\bkmkstart _Hlk66386832}Unremarkable morphology. \par {\*\bkmkend _Hlk66386832}PLT:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid12610225  Unremarkable morphology.}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\ul\insrsid1922531\charrsid7345479 IMMUNOHISTOCHEMISTRY}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 Immunohistochemical studies show}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  (performed on both core biopsy and clot section)}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 :}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 The neoplastic cells}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  (~30% marrow cellularity)}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 \par Express: CD20}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  (dim)}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 , }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 PAX5, }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 CD5}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 ,}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493  CD23}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531  and LEF1}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 \par Do not express: }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 C}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 yclin D1\par Other: \par CD3 highlights scattered small T-lymphocytes. \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\ul\insrsid1922531\charrsid4352493 FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-2305)}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid4352493 \par Abnormal B-cell population identified.\par Flow cytometry identified an abnormal B-cell population with CLL/SLL-like immunophenotype having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23, CD43, CD79b (absent), CD81 (dim), CD200 (bright), ROR1 and lambda surface light chain restriction (dim); normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The abnormal B-cell population comprises 61.6% of the white cells.\~\~\~\~\~}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par }{\rtlch\fcs1 \ab\af0 \ltrch\fcs0 \b\ul\insrsid1922531\charrsid7345479 CYTOGENETIC STUDIES}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par Cytogenetic analysis will be reported separately. }{\rtlch\fcs1 \af0 \ltrch\fcs0 \cgrid0\insrsid1922531\charrsid7345479 See separate report, CG}{\rtlch\fcs1 \af0 \ltrch\fcs0 \cgrid0\insrsid1922531 21-1521, CG21-1522.}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par \~\par }{\rtlch\fcs1 \ab\af0 \ltrch\fcs0 \b\ul\insrsid1922531\charrsid7345479 MOLECULAR STUDIES}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479  \par Molecular analysis will be reported separately. }{\rtlch\fcs1 \af0 \ltrch\fcs0 \cgrid0\insrsid1922531\charrsid7345479 See separate report, M}{\rtlch\fcs1 \af0 \ltrch\fcs0 \cgrid0\insrsid1922531 21-9440}{\rtlch\fcs1 \af0 \ltrch\fcs0 \cgrid0\insrsid1922531\charrsid7345479 .}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid7345479 \par }{\rtlch\fcs1 \af0\afs14 \ltrch\fcs0 \fs14\cf1\insrsid1922531 \par }{\rtlch\fcs1 \af0\afs14 \ltrch\fcs0 \fs14\cf1\insrsid1922531\charrsid4349262 Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin}{\rtlch\fcs1 \af0\afs14 \ltrch\fcs0 \fs14\cf1\insrsid1922531  }{\rtlch\fcs1 \af0\afs14 \ltrch\fcs0 \fs14\cf1\insrsid1922531\charrsid4349262 MD.,}{\rtlch\fcs1 \af0\afs14 \ltrch\fcs0 \fs14\cf1\insrsid1922531  }{\rtlch\fcs1 \af0\afs14 \ltrch\fcs0 \fs14\cf1\insrsid1922531\charrsid4349262 PhD., Director.\par \par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid8093638 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid1922531\charrsid13842715 \par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}"
H21-2362;S11;MSKR - 2023-05-22 11.54.07.ndpi,Peripheral Blood Smear,2023-05-22,"T-ALL
Bone Marrow
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by T-lymphoblastic leukemia/lymphoma (50-60% by TdT immunostain).

COMMENT:
The results of a prior mediastinal biopsy (S21-20298; 03/29/2021) demonstrating ""Involvement by T-lymphoblastic lymphoma/leukemia"" are noted. The findings in the current biopsy are compatible with marrow involvement by the same process.

Correlation with pending molecular and cytogenetic studies is recommended.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Normocellular (60-70%)
M:E ratio: N/A
Blasts: Increased to 50-60% of the cellularity
Myeloid lineage: Decreased; progressive maturation
Erythroid lineage: Decreased; progressive maturation
Megakaryocytes: Normal in number and morphology
Lymphocytes: Mature lymphocytes are not increased
Plasma cells: Not increased
Clot section: Findings similar to the biopsy section

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)

Blasts                54%
Myelocytes           5%
Metamyelocytes           5%
Neutrophils/Bands      14%
Monocytes           1%
Eosinophils           3%
Erythroid Precursors      13%
Plasma Cells           1%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           2.2

Morphology:
Spiculate and cellular smears show that blasts are increased to 50-60% of the cellularity. The blasts are small-to-medium in size with scant cytoplasm, fine chromatin and inconspicuous nucleoli. There is background trilineage hematopoiesis. The myeloid and erythroid lineages show a full range of maturation with no overt dysplasia. Scattered morphologically unremarkable megakaryocytes are present.

PERIPHERAL BLOOD
CBC (04/01/2021):
WBC 9.8 [4.0-11.0 K/mcL] 
RBC 4.88 [3.80-5.00 M/mcL] 
HGB 14.7 [11.2-15.4 g/dL] 
HCT 44.4 [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 30.1 [27.0-33.0 pg] 
MCHC 33.1 [31.0-36.5 g/dL] 
RDW 12.9 [12.2-15.1 %] 
Platelets 255 [160-400 K/mcL] 

Neutrophil 61.0 [32.5-74.8 %] 
Mono 5.7 [0.0-12.3 %] 
Eos 0.8 [0.0-4.9 %] 
Baso 0.7 [0.0-1.5 %] 
Immature Granulocyte 0.8 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 31.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 6.0 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] 
Abs Lymph 3.0 [0.9-3.2 K/mcL] 

Morphology:
WBC: Circulating blasts are not markedly increased. Granulocytes are morphologically unremarkable.
RBC: Morphologically unremarkable.
Platelets: Morphologically unremarkable.

IMMUNOHISTOCHEMISTRY
Immunostains show that TdT+ blasts are increased to 50-60% of the cellularity. CD34+ blasts are not increased. There is dim cytoplasmic expression of CD34 on a subset of the megakaryocytes.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-3128)
Interpretation:
Abnormal immature T-cell population identified.

An abnormal immature T-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously F21-2995. The abnormal blasts represent 46.4% of the white cells and abnormally express surface CD3 (negative to dim), cytoplasmic CD3, CD4 (dim), CD5 (dim), CD7 (bright), CD10 (partial), CD38 (bright), CD45 (dim), CD48 (dim); with normal expression of CD2; and without CD8, CD34 or significant CD16/CD56.
Additional phenotyping will be reported in addendum.

Addendum Diagnosis
The abnormal immature T-cell population also shows expression of CD71 and cytoplasmic CD79a, without CD11b, CD13, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD33, CD64, CD117, CD123, CD279 (PD1), MPO, T-cell receptor gamma/delta, or surface light chains.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.81% of WBC.
199 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No abnormal mature B-cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-3128, 04/01/2021)
Interpretation:
Abnormal immature T-cell population identified.

An abnormal immature T-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously F21-2995. The abnormal blasts represent 0.21% of the white cells and abnormally express surface CD3 (negative to dim), cytoplasmic CD3, CD4 (dim), CD5 (dim), CD7, CD10, CD38 (bright), CD45 (dim), CD48 (negative); with normal expression of CD2; and without CD8, CD16, CD34 or CD56.

FLOW CYTOMETRIC ANALYSIS, MEDIASTINAL TISSUE (F21-2995, 03/29/2021)
Interpretation:

Immature T cell population identified (see comment)
No abnormal mature B cell populations detected.
Abnormal CD30 positive population is NOT detected.

Immature T cell population with expression of cytoplasmic CD3, but not surface CD3, and expresses CD7(variable), CD5, CD4, CD2, CD10, CD38(bright), CD48(dim), CD79a(dim), without CD8, CD13, CD19, CD20, CD22, CD33, CD34, MPO, CD64, CD14 is seen. The population shows virtually no maturational progression. Differential diagnosis includes T lymphoblastic leukemia/lymphoma vs. highly unusual thymic tissue. Morphologic correlation will be critical for precise diagnosis.

No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

No immunophenotypic evidence of an abnormal population with Classic Hodgkin Lymphoma phenotype detected. Morphologic correlation is advised.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-2066.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M21-13123, M21-13127 and M21-13128.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-9708;S12;MSKC - 2023-05-19 16.51.44.ndpi,Peripheral Blood Smear,2023-05-19,"{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch31505\stshfloch31506\stshfhich31506\stshfbi0\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}
{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;
\red0\green0\blue0;}{\*\defchp \fs22\loch\af31506\hich\af31506\dbch\af31505 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*
\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused 
Normal Table;}{\s15\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\f1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 \snext15 \spriority0 Arial;}}
{\*\rsidtbl \rsid134628\rsid5325239\rsid8089369\rsid8196303\rsid8597326\rsid8872640\rsid11098535\rsid11497168\rsid12395733\rsid12936092}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0
\mnaryLim1}{\info{\operator Chan, Alexander Y./Pathology}{\creatim\yr2022\mo1\dy3\hr16}{\revtim\yr2022\mo1\dy3\hr16}{\version2}{\edmins0}{\nofpages1}{\nofwords20}{\nofchars115}{\nofcharsws132}{\vern21}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/of
fice/word/2003/wordml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata1\grfdocevents0\validatexml0\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors0\horzdoc\dghspace120\dgvspace120\dghorigin1701
\dgvorigin1984\dghshow0\dgvshow3\jcompress\viewkind1\viewscale130\rsidroot5325239 \fet0{\*\wgrffmtfilter 2450}\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2
\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}\pard\plain \ltrpar\s15\ql \li0\ri0\nowidctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af1\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\loch\af1\hich\af1\dbch\af31505\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \insrsid12936092 \hich\af1\dbch\af31505\loch\f1 Clinical Diagnosis: MDS\par \hich\af1\dbch\af31505\loch\f1 Clinical Hx/Op Findings: hx bladder cancer treated with chemotherapy, now ? MDS\par \hich\af1\dbch\af31505\loch\f1 Requested Studies: Gross/Micro\par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
    - Hypercellular bone marrow with dyserythropoiesis and ring sideroblasts, with <5% blasts by aspirate differential; see comment.

COMMENT: In the context of a patient with history of urothelial carcinoma status post chemotherapy, findings raise the possibility of a therapy related myeloid neoplasm (t-MN). Increased ring sideroblasts and dyserythropoiesis in this patient with macrocytic anemia are compatible with a t-MN presenting as myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia (t-MDS-RS-SLD). However, alterative etiologies for sideroblastic anemias must be excluded clinically, including drug/alcohol effects, toxin exposures (lead/benzene), and nutritional deficiencies. 

Clinical correlation as well as correlation with concurrent cytogenetic and molecular studies is recommended, particularly molecular assessment for SF3B1 or other spliceosome mutations.  

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular (~60-70%)
M:E ratio: Reduced 
Blasts: Not increased (<5%) 
Myeloid lineage: Exhibits full maturation 
Erythroid lineage: Exhibits left-shifted maturation 
Megakaryocytes: Present with hypolobation 
Lymphocytes: Focal small lymphoid aggregates seen
Plasma cells: Scattered 
Special stains: A reticulin stain shows no significant increase in reticulin fibers (0/3). 
The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                1%
Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           5%
Neutrophils/Bands      28%
Monocytes           1%
Eosinophils           3%
Erythroid Precursors      45%
Plasma Cells           1%
Lymphocytes           6%
Number of Cells Counted      500
M:E Ratio           1

Special stain:
Iron- Present
Ring sideroblasts- Present, >15%

Morphology: The aspirate smears are spicular, cellular and show maturing trilineage hematopoiesis; no expanded blast population is seen. Erythroid elements show marked dyserythropoiesis (binucleation, megaloblastic changes, ring sideroblasts, total dysplasia >10%). Myeloid elements show mild dysgranulopoiesis (hypogranularity, <10%). Megakaryocytes show occasional hypolobation.

PERIPHERAL BLOOD
CBC (12/29/2021):
WBC 6.4 [4.0-11.0 K/mcL] 
RBC 2.55 L [3.95-5.54 M/mcL] 
HGB 8.9 L [12.5-16.2 g/dL] 
HCT 27.3 L [37.5-49.3 %] 
MCV 107 H [80-98 fL] 
MCH 34.9 H [27.0-33.0 pg] 
MCHC 32.6 [31.0-36.5 g/dL] 
RDW 18.6 H [12.2-15.1 %] 
Platelets 225 [160-400 K/mcL] 

Neutrophil 52.0 [32.5-74.8 %] 
Mono 10.3 [0.0-12.3 %] 
Eos 4.4 [0.0-4.9 %] 
Baso 2.3 H [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 30.5 [12.2-47.4 %] 
Nucleated RBC 0.3 H [0.0-0.0 %] 

Abs Neut 3.3 [1.5-7.5 K/mcL] 
Abs Mono 0.7 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.2 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 2.0 [0.9-3.2 K/mcL] 

Morphology:
WBC: Mild basophilia noted; no circulating blasts seen.  
RBC: Macrocytic anemia with anisopoikilocytosis.
PLT: Unremarkable morphology. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains show no increases in CD34 and/or CD117 positive blasts (<5%). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-12896)
1. Abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 1.8% of WBC.

Immunophenotype:
Abnormal: CD5 (partial), CD13 (bimodal  negative, intermediate), CD117 (bright), HLA-DR (bright)
Normal: CD4, CD33, CD34, CD38, CD45, CD71, CD123
Negative: CD2, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified. 
 
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-8509.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-53839.
"
H21-2533;S12;MSKS - 2023-06-01 06.33.46.ndpi,Peripheral Blood Smear,2023-06-01,"Myelodysplastic Syndrome
Macrocytic anemia, one alteration on HEME-IMPACT 
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Variably cellular marrow with trilineage maturing hematopoiesis and serous fat atrophy.
  
COMMENT:
The patient's history of invasive urothelial carcinoma treated with cystoprostatectomy and chemotherapy, as well as prostate cancer (organ confined, Gleason score 3+4=7) is noted. Molecular studies on the peripheral blood from September 2020 demonstrated a missense mutation in ATM (VAF: 11.8%). Currently, the patient has pancytopenia.

The findings in this biopsy are unusual but non-specific and are not, by themselves, diagnostic for a myeloid neoplasm; however, correlation with pending cytogenetic studies is needed. It should also be noted that ATM mutations are seen on peripheral blood studies in both clonal cytopenia of undetermined significance (CCUS) and in patients with prostate cancer, and correlation with PSA may be of value if clinically indicated.

The etiology of the serous fat atrophy seen in the marrow is also unclear, but these stromal changes can be associated with malnutrition/cachexia; clinical correlation is recommended.

BONE MARROW BIOPSY
Quality: Fragmented.
Cellularity: Hypocellular in the biopsy section (~10%); however, one of the aspirates is normo/hypercellular, suggestive of patchy marrow cellularity
M:E ratio: Appears slightly decreased
Blasts: Not increased
Myeloid lineage: Progressive maturation
Erythroid lineage: Progressive maturation
Megakaryocytes: Rare megakaryocytes seen are morphologically unremarkable
Lymphocytes: Scattered
Plasma cells: Mildly increased
Other: The adipose tissue in the marrow shows morphologic changes compatible with serous fat atrophy. There is no morphologic evidence of metastatic carcinoma.
Special stains: Reticulin stain shows no increase in reticulin fibrosis. A Congo red stain is negative for amyloid deposition.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                1%
Promyelocytes           1%
Myelocytes           10%
Metamyelocytes           4%
Neutrophils/Bands      25%
Monocytes           3%
Eosinophils           2%
Erythroid Precursors      38%
Plasma Cells           7%
Lymphocytes           9%
Number of Cells Counted 500
M:E Ratio           1.2

Special stain 
Iron: Absent in a paucicellular specimen
Ring sideroblasts: Absent 

Morphology:
One of the aspirates is spiculate and hypocellular; however, the other aspirate is spiculate with cellular areas. The cellular smear shows progressive trilineage hematopoiesis. Blasts are not increased. The myeloid and erythroid lineages show a full range of maturation with no significant dysplasia. Scattered megakaryocytes are seen. There are frequent morphologically unremarkable plasma cells.

PERIPHERAL BLOOD
CBC (4/7/2021):
WBC 2.8 L [4.0-11.0 K/mcL] 
RBC 3.04 L [3.95-5.54 M/mcL] 
HGB 10.1 L [12.5-16.2 g/dL] 
HCT 31.2 L [37.5-49.3 %] 
MCV 103 H [80-98 fL] 
MCH 33.2 H [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL] 
RDW 12.8 [12.2-15.1 %] 
Platelets. 146 L [160-400 K/mcL] 

Neutrophil 46.8 [32.5-74.8 %] 
Mono 12.0 [0.0-12.3 %] 
Eos 0.7 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 0.0 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 40.1 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 1.3 L [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.1 [0.9-3.2 K/mcL]

Morphology:
WBC: Leukopenia. No circulating blasts seen.
RBC: Macrocytic
Platelets: Morphologically unremarkable

IMMUNOHISTOCHEMISTRY
Immunostains show no increase in CD34+ blasts or CD117+ immature cells. CD138 marks the plasma cells, which are relatively increased. An immunostain for pancytokeratin is negative. In situ hybridization for kappa and lambda are non-contributory.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-3326)
No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.41% of WBC.
241 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No abnormal mature B- or T-cell populations detected. No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

Addendum Diagnosis
No abnormal plasma cell population detected.

No evidence of an abnormal plasma cell population is identified by flow cytometry. 421,936 cells acquired.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-2195.

MOLECULAR STUDIES 
Molecular analysis not requested.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H21-8636;S10;MSK0 - 2023-05-19 16.17.26.ndpi,Peripheral Blood Smear,2023-05-19,"Clinical Diagnosis: Lymphoma
Clinical Hx/Op Findings: post-treatment assessment
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - B-cell lymphoma, consistent with marginal zone lymphoma, 70-80% involvement with CD20/PAX5 stain. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show hypercellular bone marrow (approximately 80% cellularity). There istrilineage maturing hematopoiesis with markedly increased atypical lymphoid cells focally replacing marrow cellularity. Sheets of large cells are not present. 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight marked increase in atypical lymphoid cells, comprising 70-80% of marrow cellularity). 
CD3 labels few background T-cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-11453) 
Interpretation: 
1. Abnormal B cell population detected.
The immunophenotype of this abnormal population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphology, immunohistochemistry, and molecular studies is advised.

Abnormal B cell population represents 87.3% of WBC.

Immunophenotype:
Abnormal: CD5 (partial - dim), CD20 (variable - negative, dim), CD81 (dim), CD200 (negative), ROR1 (positive), surface Kappa (restriction)
Normal: CD22, CD79b, CD19, CD40, CD45
Negative: CD38, CD10, CD3, CD23, CD43, surface Lambda

Number of cells acquired: 123 thousand  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (11/18/2021):
WBC 227.8 H [4.0-11.0 K/mcL] 
RBC 2.26 L [3.95-5.54 M/mcL] 
HGB 7.6 L [12.5-16.2 g/dL] 
HCT 25.1 L [37.5-49.3 %] 
MCV 111 H [80-98 fL] 
MCH 33.6 H [27.0-33.0 pg] 
MCHC 30.3 L [31.0-36.5 g/dL] 
RDW 19.6 H [12.2-15.1 %] 
Platelets 104 L [160-400 K/mcL] 

Neutrophil 3.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 86.0 H [12.2-47.4 %] 
Abnormal Lymphoid Cells 11.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 6.8 [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 220.9 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: Numerous circulating atypical lymphocytes present. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Not submitted. 

MOLECULAR STUDIES 
Not submitted. 

"
H21-1662;S13;MSKV - 2023-05-19 22.13.41.ndpi,Peripheral Blood Smear,2023-05-19,"MDS. MDS-RARS (+8, possible SF3B1 per outside documentation)
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Hypercellular marrow with left-shifted erythroid hyperplasia, multilineage dysplasia, ring sideroblasts and no increase in blasts, consistent with myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia. See comment.
  
COMMENT: The patient's reported history of macrocytic anemia without significant thrombocytosis since 2018 is noted. Also noted is the reported detection of ring sideroblasts and a trisomy 8 in multiple prior bone marrow biopsies since 8/2019. Per scanned reports in the medical record, trisomy 8 was detected in 18/18 metaphases by karyotype and 78% of cells by FISH in a prior bone marrow biopsy obtained 11/2019. Concurrent karyotype (CG21-2218) similarly demonstrates trisomy 8 in 19/20 metaphases (per Dr. U. Aypar, MSK Cytogenetics Laboratory). The persistence of the patient's anemia, ring sideroblasts and high level trisomy 8 over multiple years in conjunction with the remaining morphologic findings support a diagnosis of a myelodysplastic syndrome. Correlation with clinical findings and the pending in-house molecular studies (particularly for the presence of a SF3B1 mutation) is suggested. Case reviewed with Dr. F. Sen, Hematopathology service, who agrees.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular (nearly 100% cellularity)
M:E ratio: Markedly reduced
Blasts: Not increased
Myeloid lineage: Relatively reduced with left-shifted maturation
Erythroid lineage: Increased with left-shifted maturation
Megakaryocytes: Adequate in number, variable in size with few forms showing hyper- or hyposegmentation or hyperchromasia
Lymphocytes: Scattered
Plasma cells: Scattered
Clot section: Contains rare minute marrow particles morphologically similar to the core biopsy
Special stains: Reticulin stain shows minimal reticulin fibrosis (MF-0-1+/3) 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                1%
Promyelocytes           1%
Myelocytes           7%
Metamyelocytes           2%
Neutrophils/Bands      11%
Monocytes           1%
Eosinophils           3%
Erythroid Precursors      64%
Plasma Cells           1%
Lymphocytes           9%
Number of Cells Counted 500
M:E Ratio           0.4

Special stain
Iron: Present
Ring sideroblasts: Present, >15% 

Morphology:
Spicular and cellular smears show erythroid-predominant maturing trilineage hematopoiesis with no increase in blasts. Myeloid elements are relatively reduced and show left-shifted maturation with forms showing atypical nuclear segmentation seen (~10%). Erythroid precursors are relatively increased and show left-shifted maturation with marked dyserythropoiesis (nuclear irregularity/budding, bi/multinucleation, karyorrhexis, nuclear-cytoplasmic dyssynchrony, megaloblastoid change; >10%). Megakaryocytes are present with some large, hypersegmented forms, hypolobated forms and forms with disjointed nuclear lobes.

PERIPHERAL BLOOD
CBC (3/5/2021):
WBC 7.4 [4.0-11.0 K/mcL] 
RBC 2.55 L [3.95-5.54 M/mcL] 
HGB 8.5 L [12.5-16.2 g/dL] 
HCT 26.3 L [37.5-49.3 %] 
MCV 103 H [80-98 fL] 
MCH 33.3 H [27.0-33.0 pg] 
MCHC 32.3 [31.0-36.5 g/dL] 
RDW 33.7 H [12.2-15.1 %] 
Platelets 365 [160-400 K/mcL] 

Neutrophil 40.0 [32.5-74.8 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 5.0 H [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 48.0 H [12.2-47.4 %] 
Nucleated RBC 4.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 3.0 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 3.6 H [0.9-3.2 K/mcL]

Morphology:
WBC: Occasional myelocytes and metamyelocytes. No circulating blasts seen.
RBC: Macrocytic anemia with marked anisopoikilocytosis and occasional nucleated RBCs.
PLT: Adequate with unremarkable morphology.

IMMUNOHISTOCHEMISTRY
CD34 shows no increase in blasts (<5% of marrow cellularity).
CD117 highlights relatively increased early erythroid precursors and scattered mast cells.
Myeloperoxidase and CD71 highlight myeloid and erythroid elements, respectively, with a markedly reduced M:E ratio.
E-cadherin highlights relatively increased early erythroid precursors
CD61 highlights an adequate number of megakaryocytes that range from small to large in size. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-2218)
Interpretation: 
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CD34 positive myeloid blast population with apparent normal immunophenotype is 2.7% of WBC.
116,885 of cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-1469, CG21-1470.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-9058.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-7705;S13;MSK9 - 2023-05-31 15.31.31.ndpi,Peripheral Blood Smear,2023-05-31,"Small Cell Lung Cancer
Pancytopenia, unclear if metastatic marrow involvement or other process 
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Metastatic small cell carcinoma, see comment.  

COMMENT: The patient's history of small cell lung carcinoma with extensive metastasis is noted. The bone marrow specimen is nearly replaced by metastatic small cell carcinoma. Background hematopoiesis is markedly reduced to absent. 

The diagnosis was rendered in consultation with Dr. W. Travis of thoracic pathology.

Additional stains will be ordered and reported as an addendum; material will be sent for molecular studies that will be reported separately.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Nearly replaced by metastatic small cell carcinoma with small foci of necrosis. Background hematopoiesis is markedly reduced to absent. 
Clot section: Findings similar to biopsy

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Numerous naked nuclei noted

The differential cells count was not performed.

Hypercellular bone marrow aspirate replaced by extrinsic cells (clusters / singly). Maturing trilineage hematopoiesis is markedly diminished. Touch imprints show small clusters of extrinsic cells. 

PERIPHERAL BLOOD
CBC (10/19/2021):
WBC 3.0 L [4.0-11.0 K/mcL] 
RBC 2.33 L [3.95-5.54 M/mcL] 
HGB 6.9 L [12.5-16.2 g/dL] 
HCT 21.3 L [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 29.6 [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL] 
RDW 16.6 H [12.2-15.1 %] 
Platelets 20 L [160-400 K/mcL] 

Neutrophil 73.7 [32.5-74.8 %] 
Mono 8.1 [0.0-12.3 %] 
Eos 0.3 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 6.8 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 10.8 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 2.2 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.2 H [0.0-0.1 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Leukopenia
RBC: Mild anisopoikilocytosis with mild polychromasia
Platelets: Thrombocytopenia

IMMUNOHISTOCHEMISTRY
Immunostains show the malignant cells are positive for synaptophysin and CD117 with a high KI67 proliferation index (80-90%). Additionally, chromogranin is focally positive. Segments of the tumor are not well fixed and appear artefactually negative by immunohistochemistry.

TTF-1 and CD34 are negative in the neoplastic cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW
Not submitted

CYTOGENETIC STUDIES
Not submitted

MOLECULAR STUDIES 
Additional material will be sent for molecular studies.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-7033;S12;MSK2 - 2023-05-19 17.59.13.ndpi,Peripheral Blood Smear,2023-05-19,"Myelodysplastic syndrome.  Relapsed MDS post DLI and decitabine. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent myelodysplastic syndrome (3% blasts by aspirate differential, with ring sideroblasts). See Comment.
     - Mildly hypocellular marrow with maturing trilineage hematopoiesis.

COMMENT:
The dysplastic changes in the marrow are subtle, but the presence of ring sideroblasts and the abnormal myeloid blast population seen on flow cytometric analysis are compatible with persistence of the patient's previously diagnosed myeloid neoplasm. Correlation with pending cytogenetic and molecular studies is recommended.
  
BONE MARROW BIOPSY
Quality: Suboptimal, aspiration artifact
Cellularity: Somewhat hypocellular (10-20%)
M:E ratio: Appears normal
Blasts: Not increased
Myeloid lineage: Full maturation
Erythroid lineage: Full maturation
Megakaryocytes: Present. Variable morphology with occasional small forms with hypolobated nuclei.
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0/3). 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                3%
Promyelocytes           6%
Myelocytes           17%
Metamyelocytes           10%
Neutrophils/Bands      26%
Monocytes           8%
Eosinophils           4%
Basophils           1%
Erythroid Precursors      16%
Plasma Cells           2%
Lymphocytes           7%
Number of Cells Counted 500
M:E Ratio           4.5

Special stain
Iron: Markedly Increased
Ring sideroblasts: Present, >15% 

Morphology:
Spiculate and cellular bone marrow aspirate smears show maturing trilineage hematopoiesis with no increase in blasts. Myeloid and erythroid precursors show progressive maturation. Erythroid precursors show only mild dysplastic features including occasional nuclear irregularities, and megaloblastic changes. Megakaryocytes are present and include scattered small forms with hypolobated nuclei.

PERIPHERAL BLOOD
CBC (09/20/2021):
WBC 2.5 L [4.0-11.0 K/mcL] 
RBC 2.97 L [3.80-5.00 M/mcL] 
HGB 10.6 L [11.2-15.4 g/dL] 
HCT 32.3 L [34.3-46.0 %] 
MCV 109 H [80-98 fL] 
MCH 35.7 H [27.0-33.0 pg] 
MCHC 32.8 [31.0-36.5 g/dL] 
RDW 16.2 H [12.2-15.1 %] 
Platelets 291 [160-400 K/mcL] 

Neutrophil 46.0 [32.5-74.8 %] 
Mono 13.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 41.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Leukopenia. No increase in circulating blasts. Neutrophils do not exhibit overt dysplasia.
RBC: Macrocytic anemia with mild anisopoikilocytosis.
PLT: Morphologically unremarkable.

IMMUNOHISTOCHEMISTRY
Immunostains show no increase in CD34+ blasts or CD117+ immature cells (<5%).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-9367)
1. Abnormal myeloid blast population detected. The immunophenotype of this population is similar to that seen in prior sample [case F21-2960] 

Total myeloid blast/blast equivalent represents 7.3% of WBC
Abnormal myeloid blast population represents 1.7% of WBC
Expanded immature monocyte population is seen, represents 5.6% of WBC
Monocytosis is seen, 16.7% of WBC

Immunophenotype:
Abnormal: CD11b (partial), CD38 (uniform - intermediate), CD117 (uniform - bright)
Normal: CD4, CD13, CD33, CD34, CD45, CD71, CD123, HLA-DR
Negative: CD2, CD5, CD7, CD14, CD15, CD16, CD19, CD25, CD56, CD64

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-6122.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M21-39484 and M21-39509.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-7497;S12;MSK6 - 2023-05-31 15.25.41.ndpi,Peripheral Blood Smear,2023-05-31,"CCUS
Pretreatment; clinical trial (protocol 21-268)
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Normocellular marrow with trilineage maturing hematopoiesis, mildly increased erythroid elements and dyspoietic megakaryopoiesis.
     - Abnormal myeloblast population detected by flow cytometry (0.11% of WBC).
     - Flow cytometry detects a minute abnormal B-cell population with CLL/SLL-like immunophenotype (0.034% of WBC)

COMMENT: The patient is reported to have persistent neutropenia and harbor mutations in IDH2 and SRSF2 (VAF 38.6% and 43.6%). Evaluation of the marrow shows a small subset of the megakaryocytes with small and hypolobated dysplastic morphology.  In addition, occasional neutrophils with hypergranulation and abnormal nuclear lobation are seen in the aspirate smear.  Overall, in the setting of high-risk mutations for myeloid malignancy, and a morphologic dysplasia that is sub diagnostic for MDS this case is best classified as clonal cytopenia of undetermined significance (CCUS). 

In addition, increased monocytes are detected by flow cytometric and immunohistochemical analysis of the marrow.  However, no absolute monocytosis is identified in the peripheral blood.  The etiology of the marrow monocytosis is unclear and may represent a reactive proliferation versus a clonal population that belongs to the myeloid clone.  Suggest close patient follow-up with CBC surveillance and interval marrow evaluation for further characterization.

BONE MARROW BIOPSY
Quality: Suboptimal due to prominent aspiration artifact
Cellularity: Normocellular (40%)
M:E ratio: Normal
Blasts: Not increased
Myeloid lineage: Shows progressive maturation
Erythroid lineage: Shows progressive maturation
Megakaryocytes: Mildly increased and show small and hypolobated dysplastic forms
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate

Blasts                1%
Promyelocytes           1%
Myelocytes           6%
Metamyelocytes           5%
Neutrophils/Bands      35%
Monocytes           4%
Basophils           1%
Erythroid Precursors      30%
Plasma Cells           2%
Lymphocytes           15%
Number of Cells Counted 500
M:E Ratio           1.7

Special stain
Iron: Present
Ring sideroblasts: Absent

Morphology:
The aspirate smear is paucispicular and cellular. Occasional neutrophils show abnormal nuclear morphology and hypogranulation. The erythroid elements show progressive maturation.  Megakaryocytes are mildly increased and show pleomorphic morphology. No increase in blasts is seen. 

PERIPHERAL BLOOD
CBC (10/11/2021):
WBC 2.7 L [4.0-11.0 K/mcL] 
RBC 4.75 [3.95-5.54 M/mcL] 
HGB 14.7 [12.5-16.2 g/dL] 
HCT 43.3 [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 30.9 [27.0-33.0 pg] 
MCHC 33.9 [31.0-36.5 g/dL] 
RDW 12.3 [12.2-15.1 %] 
Platelets 141 L [160-400 K/mcL] 

Neutrophil 43.0 [32.5-74.8 %] 
Mono 14.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 42.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.2 L [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
WBC: Leukopenia and neutropenia. No circulating blasts identified
RBC: Normochromic and normocytic
PLT: Mild thrombocytopenia

IMMUNOHISTOCHEMISTRY
Immunostains for CD34 and CD117 show no increase in blasts (<5%). A subset of the megakaryocytes express CD34.
CD61 highlights mildly increased megakaryocytes with a subset showing small and hypolobated morphology. 
CD14 highlights an increase in monocytes.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-9938)
1. Abnormal B cell population detected. 
Flow cytometry reveals an abnormal B cell population with CLL/SLL-like immunophenotype (see below).

Abnormal B cell population represents 0.034% of WBC

Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD23 (positive), CD43 (positive), CD79b (negative), CD81 (dim), CD200 (positive), ROR1 (positive), no definite light chain expression
Normal: CD19, CD40, CD45
Negative: CD38, CD10, CD3, surface Kappa, surface Lambda


2. No abnormal T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 293 thousand  

3. Abnormal myeloid blast population detected.
Abnormal myeloid blast population represents .11% of WBC.
Monocytosis is seen, 14.6% of WBC

Blasts comprise 0.99% of the WBC. Most of the blasts have an unremarkable phenotype; however, a small subset (0.11% of WBC) has the abnormal immunophenotype described below.

Abnormal: CD33 (variable - dim), CD34, CD38 (variable - dim) Normal: CD4, CD13, CD45, CD71, CD117, CD123, HLA-DR Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, Surface Kappa, Surface Lambda

Number of cells acquired: 265 thousand
CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-6517.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-41928.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-8900;S10;MSKN - 2023-05-19 15.38.53.ndpi,Peripheral Blood Smear,2023-05-19,"Clinical Diagnosis: Leukemia, Acute Lymphoid
Clinical Hx/Op Findings: MM on Lenalidomide maintenance, c/f ALL
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma (90% blasts by aspirate differential count).
     - No diagnostic morphologic or immunophenotypic evidence of plasma cell neoplasm.
  
COMMENT: Karyotype performed on peripheral blood demonstrated a low hypodiploid clone in 16 of 20 metaphases (CG21-7764; 11/26/21), which is associated with a poor prognosis in B-lymphoblastic leukemia/lymphoma.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular (>90%)
M:E ratio: N/A
Blasts: Markedly increased, present in sheets 
Myeloid lineage: Markedly reduced
Erythroid lineage: Markedly reduced
Megakaryocytes: Markedly reduced
Lymphocytes: Scattered
Plasma cells: Not overtly increased

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate

Blasts                90%
Myelocytes           1%
Neutrophils/Bands      1%
Erythroid Precursors      1%
Lymphocytes           7%
Number of Cells Counted 500
M:E Ratio           2

Morphology:
Paucispicular and cellular aspirate smears show an expanded population of intermediate to large sized blasts with rounded to irregular nuclei, fine chromatin, distinct nucleoli and scant to moderate amounts of cytoplasm with occasional cytoplasmic vacuoles. Background trilineage hematopoiesis appears markedly reduced.

PERIPHERAL BLOOD
CBC (11/29/2021):
WBC 4.2 [4.0-11.0 K/mcL] 
RBC 2.27 L [3.80-5.00 M/mcL] 
HGB 6.9 L [11.2-15.4 g/dL] 
HCT 20.3 L [34.3-46.0 %] 
MCV 89 [80-98 fL] 
MCH 30.4 [27.0-33.0 pg] 
MCHC 34.0 [31.0-36.5 g/dL] 
RDW 15.0 [12.2-15.1 %] 
Platelets 14 L [160-400 K/mcL] 

Neutrophil 3.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 72.0 H [0.0-0.0 %] 
Lymph 25.0 [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 0.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 3.0 H [0.0-0.0 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
WBC: Frequent circulating blasts morphologically similar to those in the aspirate smears. Marked absolute neutropenia.
RBC: Marked normocytic anemia with occasional nucleated RBCs. 
PLT: Marked thrombocytopenia. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
TdT highlights markedly increased blasts comprising >90% of the cellularity. CD34 labels a subset of the blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-11817)
Interpretation: 
1. Abnormal immature B cell population detected.
                  
Abnormal immature B cell population represents 98.2% of the mononuclear cells.
Abnormal immature B cell population represents 96.5% of WBC.

Immunophenotype:
Abnormal: CD10 (positive - bright), CD20 (positive), CD34 (variable - negative, bright), CD66c/CD123 (positive), CD86 (partial), CD73/CD304 (positive)
Normal: CD19, CD22, CD24, CD38, CD45, CD81
Negative: CD66b

Number of cells acquired 75 thousand  


2. No abnormal plasma cell population detected. Very few plasma cells seen.
No evidence of an abnormal plasma cell population is identified by flow cytometry.

Number of cells acquired: 79 thousand  

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-11738; 11/26/2021)
Interpretation: 
1. Abnormal immature B cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 86.3% of the mononuclear cells.
Abnormal immature B cell population represents 85.8% of WBC.

Immunophenotype:
Abnormal: CD10 (dim to intermediate), CD19 (slightly dim), CD20 (positive), CD34 (variable - negative, intermediate), CD38 (dim), CD45 (negative to dim), CD66c/CD123 (positive - dim), CD73/CD304 (positive), CD86 (partial), CD123 (partial)
Normal: CD22, CD24, CD71, CD81, HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD25, CD26, CD33, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, cytoplasmic MPO, surface Kappa, surface Lambda

In addition, the abnormal immature B cell population has TdT expression.

Number of cells acquired 956 thousand  

2. MRD analysis was attempted, however insufficient number of myeloid blast cells seen. 
While no abnormal blast, granulocytes or monocytes were detected, the study is insufficient to exclude residual disease at detection limit. MRD status is best considered indeterminate.


3. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.


4. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  


5. No abnormal plasma cell population detected. 
No evidence of an abnormal plasma cell population is identified by flow cytometry.

Normal plasma cell population represents 0.21% of WBC.

Number of cells acquired: 850 thousand  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES, PERIPHERAL BLOOD (CG21-7764; 11/26/2021)
KARYOTYPE ANALYSIS:
Chromosome analysis of this peripheral blood sample detected a low hypodiploid clone in sixteen of twenty metaphase cells with loss of chromosomes X, 2, 3, 4, 7, 9, 12, 13, 15, 16, 18, and 20, which is a recurring chromosome abnormality in B cell ALL, and is often associated with TP53 mutations and a poor prognosis. The remaining four metaphase cells were of normal female karyotype.

A correlation with other studies is recommended for a precise diagnosis.

TEST PERFORMED:
CHROMOSOME ANALYSIS.

PREPARATION INFORMATION:
KARYOTYPE ANALYSIS
Preparation information:48HRS
Sample Preparation: POOR (APPROXIMATELY 300-400 BANDS; G-BANDING)

TEST RESULTS:
KARYOTYPE ANALYSIS
Number of cells counted:20
Number of cells analyzed:20
Number of cells karyotyped: 4
Modal chromosome number(s):33,46
Modal karyotype(s):33,X,-X,-2,-3,-4,-7,-9,-12,-13,-15,-16,-17,-18,-20[16]/46,XX[4]

FISH ANALYSIS:
No evidence of BCR-ABL1 fusion/t(9;22), however deletion of ABL1 (9q34.1) detected in 90% of cells.

No evidence of MLL (11q23) rearrangement.

"
H21-7250;S14;MSK5 - 2023-05-27 02.17.27.ndpi,Peripheral Blood Smear,2023-05-27,"Clinical Diagnosis: Lymphoma, Diffuse Large Cell
Clinical Hx/Op Findings: Ongoing thrombocytopenia and anemia
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by previously diagnosed large B-cell lymphoma with intra-sinusoid pattern (~5-10% with PAX5 immunohistochemistry).
     - Normocellular marrow with trilineage maturing hematopoiesis. See comment. 

COMMENT: Patient's history of intravascular large B-cell lymphoma (H18-6343), status post chemotherapy and stem cell transplant with persistent anemia and thrombocytopenia is noted. Although megakaryocytes appear to be mildly decreased; diagnostic morphologic evidence of a myelodysplastic syndrome is not seen. Correlation with the forthcoming cytogenetic and molecular studies is suggested.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Small subcortical biopsy and adequate aspirate specimens show normocellular marrow (30-40% cellularity) withtrilineage maturing hematopoiesis and no increase in blasts. There are atypical lymphoid infiltrates with predominant intrasinusoidal distribution, composed mostly of medium to large-sized cells with oval to irregular nuclei, dispersed chromatin and variably distinct nucleoli. Myeloid elements show full maturation with few hypogranular and hyposegmented forms. Erythroid elements show full maturation with occasional atypical forms (<10%, nuclear irregularity and budding, karyorrhexis). Megakaryocytes are mildly decreased in number with occasional hypolobated forms.

Bone Marrow Aspirate Smear Quality: Adequate
Blasts               0%
Myelocytes           2%
Metamyelocytes           2%
Neutrophils/Bands      50%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      22%
Lymphocytes           6%
Atypical lymphoid cells     16%
Number of Cells Counted 500
M:E Ratio           2.5

Special stain
Iron: Trace
Ring sideroblasts: Absent

IMMUNOHISTOCHEMISTRY
The neoplastic cells (~5-10% marrow cellularity) are positive for PAX5, CD79a and CD5; and are negative for CD20. 
CD3 highlights background scattered small T-cells. 
CD61 highlights mildly decreased megakaryocytes. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-9628) 
Abnormal B cell population detected.
The immunophenotype of the abnormal B cell population is similar to that seen previously (F21-9381).

Abnormal B cell population represents 18.5% of WBC

Immunophenotype:
Abnormal: CD5 (positive), CD10 (positive - dim), CD19 (negative), CD20 (negative), surface Kappa (restriction), Forward Scatter (increased), Side Scatter (slightly increased)
Normal: CD22, CD38, CD45
Negative: CD25, CD279 (PD1), CD3, CD14, surface Lambda

Number of cells acquired: 308 thousand  

No definite abnormal myeloid blast, monocyte or maturing myeloid population identified.
Overall, too few blasts seen to fully characterize for possible myeloid neoplasm, sensitivity is reduced. 

Myeloid blast population represents 0.055% of WBC
137 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

PERIPHERAL BLOOD
CBC (10/1/2021)
WBC 9.8 [4.0-11.0 K/mcL] 
RBC 2.82 L [3.95-5.54 M/mcL] 
HGB 9.4 L [12.5-16.2 g/dL] 
HCT 30.2 L [37.5-49.3 %] 
MCV 107 H [80-98 fL] 
MCH 33.3 H [27.0-33.0 pg] 
MCHC 31.1 [31.0-36.5 g/dL] 
RDW 24.4 H [12.2-15.1 %] 
Platelets 11 L [160-400 K/mcL] 

Neutrophil 13.0 L [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 0.0 [0.0-0.0 %] Updated
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 21.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 57.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.3 L [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.0 [0.0-0.0 K/mcL]
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL]
Abs Lymph 7.7 H [0.9-3.2 K/mcL]

Morphology:
WBC: Circulating atypical lymphoid cells with similar morphology to those on aspirate smears; few large granular lymphocytes. 
RBC: Macrocytic anemia with anisocytosis and few nucleated RBCs. 
PLT: Marked thrombocytopenia with few large and hypogranular forms. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-6287.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-40590, M21-40636.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-444;S10;MSKZ - 2023-05-17 11.22.46.ndpi,Peripheral Blood Smear,2023-05-19,"Lymphoma. Relapsed refractory lymphoma last tx ibrutinib. Within 7 days prior to Chemo. Protocol #: 15-295. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by B cell lymphoma consistent with mantle cell lymphoma (~40% with CD20 immunohistochemistry).
     - Mildly hypercellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate core biopsy and aspirate specimens show mildly hypercellular bone marrow for age (approximately 30-40% cellularity) with maturing trilineage hematopoiesis and interstitially scattered and aggregates of atypical lymphocytes that are predominantly small to intermediate sized with irregular nuclei, moderately clumped chromatin, occasionally visible nucleolus and small amount of cytoplasm. Myeloid elements show left-shifted progressive maturation with no significant dyspoiesis. Erythroid elements are relatively increased and show progressive maturation with occasional dyspoiesis (<10% of lineage; nuclear irregularity, binucleation). Megakaryocytes are adequate in number and show mostly unremarkable morphology.

Aspirate differential: (Performed by HM)

Promyelocytes           3%
Myelocytes           6%
Metamyelocytes           5%
Neutrophils/Bands      7%
Eosinophils           3%
Erythroid Precursors      18%
Plasma Cells           1%
Abnormal Lymphoid Cells      57%
Number of Cells Counted 500
M:E Ratio           1.3

IMMUNOHISTOCHEMISTRY
The atypical lymphoid cells are positive for CD20 and PAX-5 (~40% cellularity).
CD3 highlights scattered and rare clusters of small T-cells.
P53 and Ki-67 immunostains are in progress and the results will be reported in an addendum.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-596) 
Abnormal B-cell population identified.
Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD19(dim), CD43, and ROR1; normal expression of CD20, CD22, CD38, CD40, CD79b, CD81, and CD45; and without CD3, CD10, CD23, or CD200.  The abnormal B cell population represents 75.7% of total white cells.
This immunophenotype is consistent with previously diagnosed mantle cell lymphoma (MCL).

PERIPHERAL BLOOD
WBC 22.6 H [4.0-11.0 K/mcL] 
RBC 3.81 L [3.95-5.54 M/mcL] 
HGB 12.9 [12.5-16.2 g/dL] 
HCT 40.5 [37.5-49.3 %] 
MCV 106 H [80-98 fL] 
MCH 33.9 H [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 14.1 [12.2-15.1 %] 
Platelets 84 L [160-400 K/mcL] 

Neutrophil 7.0 L [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 10.0 L [12.2-47.4 %] 
Abnormal Lymphoid Cells 78.0 H [0.0-0.0 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 1.6 [1.5-7.5 K/mcL] 
Abs Mono 1.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 19.9 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] CBC (01/09/2021):

Morphology:
WBCs: Absolute lymphocytosis comprised of intermediate sized atypical lymphocytes with irregular nuclei and conspicuous nucleoli. 
RBCs: Macrocytic RBCs. 
Platelets: Thrombocytopenia; unremarkable morphology.     

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-394.

MOLECULAR STUDIES 
Not requested/performed.     

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-5054;S12;MSK3 - 2023-04-19 17.54.01.ndpi,Peripheral Blood Smear,2023-04-19,"CML.  Newly diagnosed CML, rule out fibrosis / accelerated disease. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia, BCR-ABL1 positive, chronic phase.
  
COMMENT: Blasts comprise 1% of the total marrow cellularity. FISH studies (CG21-4381; 7/13/2021) in the bone marrow, as well as FISH (CG21-3949, 6/23/2021) and molecular genetic studies (M21-25529, 6/23/2021) in the peripheral blood, have detected a BCR-ABL1 fusion/ t(9;22). The overall findings are consistent with chronic myeloid leukemia (CML) in chronic phase. Due to the nature of the biopsy specimen the presence/degree of fibrosis cannot be accurately evaluated. Nonetheless the hypercellularity of the aspirate favors against a significant amount of fibrosis in the marrow. Moreover, although subtle dyspoietic changes are seen in a subset of myeloid cells in the marrow and peripheral blood, their significance in the context of CML is unclear. Suggest correlation with comprehensive genomic studies.

BONE MARROW BIOPSY
Quality: Suboptimal sample that shows small fragments of cortical bone associated with clotted blood and detached myeloid predominant marrow spicules
Cellularity: Available marrow fragments appear hypercellular 
M:E ratio: Appears increased
Blasts: Not increased
Myeloid lineage: Predominant
Erythroid lineage: Present
Megakaryocytes: Increased small forms
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain cannot be interpreted due to nature of the specimen
Clot section: Blood clot with small bone marrow spicules, showing myeloid predominant hematopoiesis.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate

Blasts                1%
Promyelocytes           2%
Myelocytes           21%
Metamyelocytes           10%
Neutrophils/Bands      40%
Monocytes           2%
Eosinophils           3%
Basophils           2%
Erythroid Precursors      18%
Lymphocytes           1%
Number of Cells Counted 500
M:E Ratio           4.4

Morphology:
-Spicular and hypercellular aspirate smears show myeloid predominant trilineage hematopoiesis. Myeloid elements show left shifted, yet complete maturation. Subset of granulocytes shows hypogranular cytoplasm and subtle abnormal nuclear lobation. No increase in blasts is seen. Eosinophils and basophils (atypical features) are increased. Erythroid precursors show progressive maturation. Young megakaryocyte forms are present, while occasional mature megakaryocytes display hyperlobated nuclear forms. No overt dysplastic features are seen.

PERIPHERAL BLOOD
CBC (07/13/2021):
WBC 51.6 H [4.0-11.0 K/mcL] 
RBC 4.28 [3.95-5.54 M/mcL] 
HGB 11.7 L [12.5-16.2 g/dL] 
HCT 38.2 [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 27.3 [27.0-33.0 pg] 
MCHC 30.6 L [31.0-36.5 g/dL] 
RDW 14.5 [12.2-15.1 %] 
Platelets. 158 L [160-400 K/mcL] 

Neutrophil 64.0 [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 3.0 H [0.0-1.5 %] 
Myelocyte 9.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 8.0 H [0.0-0.0 %] 
Lymph 11.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 33.0 H [1.5-7.5 K/mcL] 
Abs Mono 1.5 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.5 [0.0-0.7 K/mcL] 
Absolute Basophil 1.5 H [0.0-0.2 K/mcL] 
Abs Myelocytes 4.6 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.5 H [0.0-0.0 K/mcL] 
Abs Meta 4.1 H [0.0-0.0 K/mcL] 
Abs Lymph 5.7 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
RBC: Unremarkable morphology
WBC: Marked leukocytosis, neutrophilia, mild monocytosis, basophilia, increased circulating myelocytes, metamyelocytes and promyelocytes. No circulating blasts seen.
PLT: Mild thrombocytopenia, occasional large platelets noted

IMMUNOHISTOCHEMISTRY
CD34 and CD117 do not highlight an increase in blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-6702)
Interpretation: 
Abnormal myeloid blast population detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample [F21-6002] having abnormal expression of CD7 (partial), CD11b (partial), and HLA-DR (bright); with normal expression of CD4, CD13, CD33, CD34, CD38, CD45, CD71, CD117, and CD123; and without CD2, CD5, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 0.35% of the white blood cells.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-4381.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-28475, M21-28476.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H21-5494;S12;MSK1 - 2023-06-06 03.32.23.ndpi,Peripheral Blood Smear,2023-06-06,"Leukemia, Hairy Cell
67 yo man with history of hairy cell leukemia, prior splenectomy, pentostatin, most recently treated with cladribine 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Extensive involvement by hairy cell leukemia (90% of the cellularity).  
     

BONE MARROW BIOPSY
Hypocellular marrow (20%) with extensive involvement by medium-sized lymphoid cells with abundant clear cytoplasm.  Markedly reduced hematopoietic elements are seen in the background.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Inadequate, hypocellular, devoid of spicules

Neutrophils/Bands      46%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      5%
Plasma Cells           1%
Lymphocytes           26%
Hairy cells           20%
Number of Cells Counted 100
M:E Ratio           9.6

Morphology:
-Inadequate, aspicular and hypocellular smears and touch imprints are evaluated.  Medium-sized lymphoid cells with oval nuclei, moderately abundant cytoplasm, and cytoplasmic projections consistent with hairy cells are seen.

PERIPHERAL BLOOD
CBC (07/28/2021):
WBC 1.2 L [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 2.51 L [3.95-5.54 M/mcL] 
HGB 7.5 L [12.5-16.2 g/dL] 
HCT 22.4 L [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 29.9 [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 19.2 H [12.2-15.1 %] 
Platelets. 29 L [160-400 K/mcL] 

Neutrophil 62.0 [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 37.0 [12.2-47.4 %] 
Nucleated RBC 11.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 0.7 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:  Circulating hairy cells are seen.  

IMMUNOHISTOCHEMISTRY
Immunostains show the hairy cell infiltrate is positive for CD20 and BRAF.  CD3 highlights small background T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7262)
Abnormal B-cell population identified.

Flow cytometry reveals an abnormal mature B-cell population similar to prior specimen (F21-6734) having abnormal expression of CD11c, CD19 (bright), CD20 (bright), CD25, CD45 (bright), CD103 (partial), and CD200 (bright); with normal expression of CD22 and CD38; and without CD3, CD5, CD10 or CD14. The immunophenotype of the abnormal B-cell population is consistent with involvement by previously diagnosed hairy cell leukemia. The abnormal B cell population represents 3.9% of the total white cells.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-4791.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-30881, M21-30882. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-2678;S13;MSK3 - 2023-05-19 22.30.58.ndpi,Peripheral Blood Smear,2023-06-01,"MCL
Neutropenia, ANC 0.0
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Extensive involvement by mantle cell lymphoma (~80-90% with CD20 immunohistochemistry).
     - Background marrow with megakaryocytic hyperplasia, and myeloid and erythroid hypoplasia and a rare granuloma. See comment.

COMMENT: The etiology of myeloid and erythroid hypoplasia and peripheral blood cytopenias is not entirely clear. The peripheral blood shows an absolute neutrophil count (ANC) of 0, which is highly unusual. This finding at least in part may be due to the extensive marrow replacement by mantle cell lymphoma. However, as the pre-treatment marrow (H21-2409; 4/2/2021) also showed a similar level of involvement but with a normal ANC and hemoglobin, the cytopenias at this time point are likely related to recent ibrutinib/venetoclax chemotherapy. Other etiologies, such autoimmune processes cannot entirely be excluded. Overall, these findings are favored to be reactive and there is no overt evidence of a myeloid neoplasm. Close clinical follow-up is advised.

The lymphoid work-up was performed and reviewed by Dr. Ahmet Dogan (Chief, Hematopathology service).


BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
The bone marrow biopsy and aspirate smears are hypercellular for age (~80% cellularity) and show a diffuse interstitial infiltrate of atypical small to intermediate sized lymphoid cells with slightly irregular nuclei, clumped chromatin, occasional inconspicuous nucleolus and small amount of cytoplasm. Myeloid and erythroid elements are markedly decreased to absent. Megakaryocytes appear increased in number forming occasional loose clusters and show occasional atypical forms with widely separated nuclear lobes. A rare focus shows clusters of epithelioid histiocytes with admixed small lymphocytes and are eosinophils. Touch imprints are cellular and show similar findings.

Aspirate differential: (Performed by HM)

Blasts                1%
Monocytes           1%
Eosinophils           1%
Lymphocytes           97%
Number of Cells Counted 500
M:E Ratio           N/A

Special stain:
Iron: Absent
Ring sideroblasts: Suboptimal for evaluation due to absent of erythroid elements.

IMMUNOHISTOCHEMISTRY
The neoplastic cells 
Express: CD20, CD5 (few cells), cyclin D1
Do not express: CD3, SOX-11
Other: CD3 highlights small T-cells in the background. 
CD61 highlights increased number of megakaryocytes.
CD117 highlights scattered mast cells and rare early erythroid and myeloid precursors.
CD34 immunostain shows no increase in blasts (<5% of cellularity).
MPO and CD71 highlight rare myeloid and erythroid elements, respectively.
GMS and AFB stains do not highlight any fungal organisms or acid-fast bacilli, respectively.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-3558) 
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5 (partial), CD20 (dim to intermediate), CD23 (partial dim), CD79b (negative to intermediate), CD81 (dim), CD200 (subset), ROR1 (partial), and lambda light chain restriction (dim to intermediate); normal expression of CD19, CD22, CD38, CD40, CD81, and CD45; and without CD3, CD10, CD25, CD43 or CD279 (PD1). The abnormal B cell population represents 81.0% of total white cells.

PERIPHERAL BLOOD
CBC (04/14/2021):
WBC 1.2 L [4.0-11.0 K/mcL] 
RBC 2.85 L [3.95-5.54 M/mcL] 
HGB 8.7 L [12.5-16.2 g/dL] 
HCT 27.7 L [37.5-49.3 %] 
MCV 97 [80-98 fL] 
MCH 30.5 [27.0-33.0 pg] 
MCHC 31.4 [31.0-36.5 g/dL] 
RDW 12.5 [12.2-15.1 %] 
Platelets 63 L [160-400 K/mcL] 

Neutrophil 0.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 
Lymph 91.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBCs: Neutrophils are virtually absent. Relative lymphocytosis comprised of mostly small and intermediate sized atypical lymphoid cells with clumped chromatin. 
RBCs: Normocytic normochromic anemia. 
Platelets: Thrombocytopenia; unremarkable morphology.     

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-2344.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-14951, M21-14954, M21-14958.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-156;S12;MSKR - 2023-04-19 15.56.22.ndpi,Peripheral Blood Smear,2023-04-19,"CML
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia, BCR-ABL1-positive, see comment.
     - Small abnormal B-cell population with CLL/SLL-like immunophenotype detected by flow cytometry (0.15% of WBC).
  
COMMENT: Morphologic findings are consistent with chronic phase. Please correlate with cytogenetic results. 

BONE MARROW BIOPSY/CLOT SECTION
Quality: Adequate but small with focal crush artifact
Cellularity: Hypercellular for age (~80% cellularity)
M:E ratio: Increased
Blasts: Not overtly increased     
Myeloid lineage: Increased; shows left-shifted progressive maturation     
Erythroid lineage: Decreased; shows left-shifted progressive maturation     
Megakaryocytes: Markedly increased atypical forms (small hypolobated and hyperchromatic) forming loose clusters
Lymphocytes: Interstitially scattered, small and mature appearing
Plasma cells: Not increased

Special stains: 
Reticulin stain shows mild increase in reticulin fibrosis (1+/3). 

Clot section: Shows a few marrow particles with similar findings as the core biopsy

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by AS)

Blasts                3%
Promyelocytes           2%
Myelocytes           15%
Metamyelocytes           7%
Neutrophils/Bands      46%
Monocytes           1%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      12%
Lymphocytes           12%
Number of Cells Counted 500
M:E Ratio           6.1

Morphology:
The aspirate smears are cellular demonstrating myeloid hyperplasia. Myeloid elements show left-shifted progressive maturation, increased basophils and no significant dyspoiesis. Blasts are not increased. Erythroid elements are decreased and show left-shifted progressive maturation with no significant dyspoiesis. Small hypolobated atypical megakaryocytes are frequent. Lymphocytes are small and mature appearing.  

PERIPHERAL BLOOD
CBC (01/07/2021):
WBC 23.5 H [4.0-11.0 K/mcL] 
RBC 2.77 L [3.80-5.00 M/mcL] 
HGB 8.6 L [11.2-15.4 g/dL] 
HCT 25.6 L [34.3-46.0 %] 
MCV 92 [80-98 fL] 
MCH 31.0 [27.0-33.0 pg] 
MCHC 33.6 [31.0-36.5 g/dL] 
RDW 16.7 H [12.2-15.1 %] 
Platelets 537 H [160-400 K/mcL] 

Neutrophil 77.0 H [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 3.0 H [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 3.0 H [0.0-0.0 %] 
Lymph 14.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 18.1 H [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.5 [0.0-0.7 K/mcL] 
Absolute Basophil 0.7 H [0.0-0.2 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.7 H [0.0-0.0 K/mcL] 
Abs Lymph 3.3 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBCs: Absolute basophilia. Absolute neutrophilia with many immature myeloid precursors (myelocytes, metamyelocytes). No circulating blasts are seen.
RBCs: Normocytic normochromic anemia with mild anisopoikilocytosis, mild increase in polychromasia and rare nucleated RBCs. 
Platelets: Thrombocytosis; occasional large forms.     

IMMUNOHISTOCHEMISTRY
CD34 immunostain shows no increase in blasts (<5% of cellularity).
CD117 highlights a few scattered mast cells as well as scattered early erythroid and myeloid precursors.     

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-199)
Abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
Basophilia (1.4% of WBC) is seen.
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD7 (major subset), CD11b (small subset), CD13 (dim). CD56 (subset), CD123 (absent) and HLA-DR (bright) with normal expression of CD4, CD33, CD34, CD38, CD45, CD71, CD117 without CD2, CD5, CD14, CD15, CD16, CD19, CD25, CD64. Granulocytes show abnormal expression of CD56, monocytes show expression of CD56. CD34 positive myeloid blasts represent 0.72% of WBC. 

In addition, flow cytometry identified an abnormal B-cell population with CLL/SLL-like immunophenotype having abnormal expression of CD5, CD20 (negative), CD22 (negative), CD23, CD43, CD79b (negative), CD81 (negative), CD200 (bright), ROR1 and no definite surface light chain expression; normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The abnormal B-cell population comprises 0.15% of the white cells.

No abnormal mature T-cell population detected.
No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-127.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-851, M21-852, M21-853, M21-854.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-9405;S10;MSKE - 2023-05-19 16.01.05.ndpi,Peripheral Blood Smear,2023-05-19,"Clinical Diagnosis: ALL
Requested Studies: Gross/Micro
Clinical Hx/Op Findings: new possible ALL
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma (B-ALL), 85% blasts by aspirate differential count.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular (~95-100%)
M:E ratio: NA
Blasts: Markedly increased; present in sheets nearly replacing the marrow cellularity
Myeloid lineage: Rare 
Erythroid lineage: Few 
Megakaryocytes: Few
Lymphocytes: Scattered 
Plasma cells: Rare 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                85%
Neutrophils/Bands      1%
Erythroid Precursors      5%
Lymphocytes           9%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
Spicular and hypercellular aspirate smears show a markedly expanded population of blasts, which are mostly small to medium in size, with oval to slightly irregular nuclei, dispersed chromatin, mostly indistinct nucleoli, and scant basophilic cytoplasm. Rare scatted maturing myeloid and some erythroid elements are present. Megakaryocytes are present. Few mature appearing lymphocytes are seen.

PERIPHERAL BLOOD
CBC (12/15/2021):
WBC 63.3 H [4.0-11.0 K/mcL] 
RBC 1.91 L [3.95-5.54 M/mcL] 
HGB 6.0 LL [12.5-16.2 g/dL] 
HCT 19.8 L [37.5-49.3 %] 
MCV 104 H [80-98 fL]
MCH 31.4 [27.0-33.0 pg] 
MCHC 30.3 L [31.0-36.5 g/dL] 
RDW 21.4 H [12.2-15.1 %] 
Platelets 75 L [160-400 K/mcL] 

Neutrophil 2.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 75.0 H [0.0-0.0 %] 
Lymph 21.0 [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.3 L [1.5-7.5 K/mcL] 
Abs Mono 1.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 47.5 H [0.0-0.0 K/mcL] 
Abs Lymph 13.3 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Markedly expanded blast population with similar morphology to those of the aspirate smear
RBC: Macrocytic anemia with few nucleated RBCs
PLT: Thrombocytopenia

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 and TdT show markedly expanded blast population (~95% marrow cellularity). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-12495)
1. Abnormal immature B cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 96.5% of the mononuclear cells.
Abnormal immature B cell population represents 97.6% of WBC.

Immunophenotype:
Abnormal: CD10 (positive - bright), CD19 (dim), CD20 (partial), CD24 (bright), CD25 (partial), CD33 (partial-dim), CD34 (uniform - bright), CD38 (negative), CD45 (dim), CD66c/CD123 (positive), CD73/CD304 (positive), CD81 (positive - dim), CD86 (partial), CD123 (positive), HLA-DR (dim)
Normal: CD22, CD71, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD26, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, cytoplasmic MPO, surface Kappa, surface Lambda

Number of cells acquired 7.7 million  


2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.


3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 329 thousand  


4. Analysis was attempted, however insufficient number of cells and/or blast cells seen. 
While no abnormal blast, granulocytes, or monocytes were detected, the study is insufficient to exclude an involvement of myeloid neoplasm at the detection limit. 

Number of cells acquired 489 thousand  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-8231.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-52091, M21-52092, M21-52094.
"
H21-2300;S10;MSKB - 2023-05-22 11.48.36.ndpi,Peripheral Blood Smear,2023-05-22,"ALL, no remission. Ph+ B-ALL, pre-treatment before CAR T cells.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Extensive involvement by relapsed/persistent B-lymphoblastic leukemia (B-ALL; 84% blasts by differential count).
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: ~50%
M:E ratio: N/A
Blasts:  Markedly increased
Myeloid lineage: Markedly decreased
Erythroid lineage: Residual maturing elements seen
Megakaryocytes: Decreased in number, with overall normal morphology
Lymphocytes: Scattered
Plasma cells: Scattered

BONE MARROW ASPIRATE SMEAR
Differential (performed on aspirate smears and touch imprints by HM):
Blasts                84%
Neutrophils/Bands      1%
Erythroid Precursors      5%
Lymphocytes           10%
Number of Cells Counted      500
M:E Ratio           N/A

Morphology:
Spicular and cellular bone marrow aspirate smears. Numerous medium-sized blasts with round nuclei, dispersed chromatin, conspicuous nucleoli and scant pleural basophilic cytoplasm with occasional vacuolization are seen. Residual maturing erythroid elements are also present, together with rare megakaryocytes with overall normal morphology. Myeloid precursors are markedly decreased.

PERIPHERAL BLOOD
CBC (03/30/2021):
WBC 0.4 LL [4.0-11.0 K/mcL] 
RBC 3.37 L [3.80-5.00 M/mcL] 
HGB 9.7 L [11.2-15.4 g/dL] 
HCT 28.3 L [34.3-46.0 %] 
MCV 84 [80-98 fL] 
MCH 28.8 [27.0-33.0 pg] 
MCHC 34.3 [31.0-36.5 g/dL] 
RDW 15.1 [12.2-15.1 %] 
Platelets 38 L [160-400 K/mcL] 

Morphology: Pancytopenia. No definite circulating blasts are noted.

IMMUNOHISTOCHEMISTRY
Immunostains show markedly increased number of CD34+, TdT+ blasts, accounting for 80-90% of total cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-3032)
Abnormal immature B-cell population detected.

An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously [F21-1021]. The abnormal immature B-cells represent 82.1% of the white cells and 82.1% of the mononuclear cells in the sample and abnormally express CD10 (absent to dim), CD19 (bright), CD22 (absent to intermediate), CD24 (absent to intermediate), CD34 (bright), CD38 (dim to intermediate), CD81 (dim), CD73/CD304; with normal expression of CD10, CD19, CD22, CD24, CD34, CD38, CD45 and CD81; and without CD20, CD66b, CD86, CD66c/CD123. This finding is consistent with persistent/recurrent B-lymphoblastic leukemia/lymphoma, depending on the clinical context. Clinical and morphologic correlation is recommended.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-2003.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-12628, M21-12630, M21-12633.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H21-985;S12;MSK1 - 2023-04-19 15.44.01.ndpi,Peripheral Blood Smear,2023-04-19,"MDS
71yo with MDS diagnosed elsewhere 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Cellular marrow with trilineage hematopoiesis, erythroid predominance and dysplasia and increased blasts (11% by aspirate differential), see comment.
  
COMMENT: Patient's CBC findings of macrocytosis, borderline neutropenia, and thrombocytopenia are noted. The biopsy specimen is limited by small size. Immunostain for CD34 shows increased blasts, focally approaching ~20%, overall 10-15% of cellularity in this limited specimen. The aspirate smears are spicular and show dyserythropoiesis and increased blasts (11% by aspirate differential). The concurrent flow cytometric evaluation reveals an abnormal myeloid blast population (13.8% of WBC). Per clinical notes work up revealed normal folate and Vitamin B12 levels. These findings along with peripheral cytopenias are consistent with the diagnosis of myelodysplastic syndrome with excess blasts-2 (MDS-EB2). Correlation with forthcoming cytogenetic and molecular studies is recommended.

The case was also reviewed by Dr. Amy Duffield, Hematopathology Service, who concurs with the interpretation and diagnosis.

BONE MARROW BIOPSY
Quality: Small
Cellularity: 20-30% in this limited specimen.
M:E ratio: Decreased
Blasts: Increased interstitial
Myeloid lineage: Left shifted maturation
Erythroid lineage: Relatively increased with left shifted maturation
Megakaryocytes: Few megakaryocytes noted
Lymphocytes: Scattered interstitial
Plasma cells: Scattered interstitial
Special stain: Reticulin stain shows no significant increase in reticulin fibrosis.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                11% 
Promyelocytes           1%
Myelocytes           8%
Metamyelocytes           3%
Neutrophils/Bands      14%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      44%
Plasma Cells           3%
Lymphocytes           14%
Number of Cells Counted 500
M:E Ratio           0.6

Special stain 
Iron: Present
Ring sideroblasts: Absent 

Morphology:
Spicular and cellular aspirate smears show increased blasts accounting for 11% of total cells. The erythroid elements show megaloblastic maturation along with nuclear membrane irregularities and budding. Myeloid elements show left shifted maturation. Megakaryocytes are decreased in number and include rare hypolobated forms. Scattered round and rare spindled mast cells are noted in the background without clustering.

PERIPHERAL BLOOD
CBC (2/10/2021):
WBC 3.2 L [4.0-11.0 K/mcL] 
RBC 3.97 [3.95-5.54 M/mcL] 
HGB 14.0 [12.5-16.2 g/dL] 
HCT 40.6 [37.5-49.3 %] 
MCV 102 H [80-98 fL] 
MCH 35.3 H [27.0-33.0 pg] 
MCHC 34.5 [31.0-36.5 g/dL] 
RDW 12.8 [12.2-15.1 %] 
Platelets. 89 L [160-400 K/mcL] 

Neutrophil 50.5 [32.5-74.8 %] 
Mono 6.2 [0.0-12.3 %] 
Eos 2.2 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.0 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 40.5 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 1.6 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.3 [0.9-3.2 K/mcL]

Morphology:
WBC: Mild leukopenia with occasional pelgeroid granulocytes noted.
RBC: Macrocytosis.
Platelet: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunostain for CD34 shows increased blasts, focally approaching ~20%, overall 10-15% of cellularity in this limited specimen.
CD117 stains early erythroid precursors, myeloid precursors and scattered mast cells.
CD61 stains scattered megakaryocytes.
CD138 stains scattered and small clusters of plasma cells, <5% of cellularity and show no definite light chain restriction by kappa and lambda immunostains.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-1343)
Interpretation:
Abnormal myeloid blast population detected.
No abnormal mature B- or T-cell populations detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD13 (uniform dim), CD34 (uniform bright), CD38 (absent to dim), CD56 (small subset), CD117 (slightly bright), CD123 (uniform), HLADR (uniform); with normal expression of CD4, CD33, CD45, CD71; without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25 or CD64. CD34 positive myeloid blasts represent 13.8% of WBC.

Findings are compatible with a myeloid neoplasm, but correlation with morphology is required for accurate blast enumeration, and complete evaluation requires correlation with morphology, cytogenetic, and molecular studies.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

No abnormal plasma cell population detected.

No evidence of an abnormal plasma cell population is identified by flow cytometry. Plasma cells comprise 1.2% of the white cells, following erythroid lysis.
5.0 million cells acquired. Please note that flow cytometry studies generally underestimate the number of plasma cells, as compared to morphologic assessment.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-882.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-5406, M21-5410, M21-5413, M21-5414.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H21-5013;S18;MSK4 - 2023-04-19 17.48.19.ndpi,Peripheral Blood Smear,2023-04-19,"Lymphoma.  History of TCL now with follicular lymphoma. 
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by diffuse large B-cell lymphoma, germinal B-cell immunophenotype (Hans' algorithm) (50-60% with CD20 immunohistochemistry). See comment.
     - Persistent involvement by previously diagnosed CD8-positive T-cell lymphoproliferative disorder (5-10% with CD8 immunohistochemistry). 
     - Hypercellular marrow with maturing trilineage hematopoiesis.

COMMENT: The immunophenotypic features of the B-cell lymphoma are similar to that seen in the prior inguinal lymph node sample (H21-4721). 
Unstained material will be submitted to diagnostic molecular pathology for IMPACT heme testing and these results will be reported separately. Correlation with cytogenetic studies is also advised.
Reviewed with Dr. Ahmet Dogan, Chief of Hematopathology service, who agrees.
Preliminary findings were provided to Dr. William T.Johnson, Department of Medicine, on 7/14/21 and 7/16/21 via email. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy showing hypercellular for age bone marrow (90%cellularity). There isatypical nodular, interstitial, lymphoid infiltrate composed predominantly of intermediate and large size atypical lymphoid cells with irregular nuclei, clumped to variably dispersed chromatin, variably conspicuous multiple nucleoli, and scant to moderate amount of cytoplasm. Frequent mitotic figures and apoptotic bodies are seen with the in the lymphoid nodules. In areas outside the lymphoid nodules there is maturing trilineage hematopoiesis. The myeloid and erythroid elements are actively maturing. Megakaryocytes appear mildly increased for the cellularity with occasional atypical forms including those showing nuclear hyperchromasia and ""bare nuclei"" morphology.

Bone Marrow Touch Imprint Smear Quality: Adequate
Blasts                3%
Promyelocytes           4%
Myelocytes           20%
Metamyelocytes           13%
Neutrophils/Bands      20%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      16%
Lymphocytes           22%
Number of Cells Counted 500
M:E Ratio           3.7 

Morphology:
Hypocellular and hemodiluted touch imprints show scattered hematopoietic elements and no expanded blast population. Myeloid and erythroid precursors show progressive maturation and no significant dysplastic features. Megakaryocytes are not definitively identified. An atypical lymphoid proliferation is not well represented.

IMMUNOHISTOCHEMISTRY
CD20 highlights the nodular atypical lymphoid infiltrates, which are composed of B-cells, accounting for approximately 60-70% of the marrow cellularity.
These large B-cells also
Express PAX5, BCL2, CD10 (weak, subset >40%), FoxP1(50%), MUM1
Do not express: CD3, LMO2, cMYC, CD23, CD30. 
Other:
BCL6 is expressed in a small subset of the neoplastic large cells (<30%). 
CD21 and CD23 show no evidence of follicular dendritic cell meshworks associated with the nodules.
The Ki-67 proliferative index is appropriately high in the hematopoietic marrow and appears approximately 30-40% in the lymphoid nodules.
EBER in situ hybridization for EBV RNA is negative. 
LMP1 (EBV) is negative.
CD30 is positive in few scattered cells. 

CD3 highlights numerous admixed T-cells, a small subset of which show atypical reduction of CD8 expression, accounting for 5-10% of the marrow cellularity. These also show reduced expression of CD5 and absent CD7, while CD2 expression is normal.
CD4 is positive in T-cells and myelomonocytic/ histiocytic cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-6659) 
Interpretation: 
Abnormal B-cell population identified.
Abnormal T-cell population detected.
No abnormal plasma cell population detected.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD20 (bright), CD45 (slightly bright), lambda light chain restriction, and normal expression of CD19, CD22 and CD38; and without CD3, CD5, CD10, CD14, CD25, or CD279 (PD1). The abnormal B-cell population represents 18.7% of the total white cells. 

In addition, flow cytometry also reveals an abnormal T-cell population having abnormal expression of CD5 (subset dim, subset absent), CD7 (absent), CD8 (dim), CD279 (PD1) (uniform, dim); with normal expression of CD2, CD3, CD38 and CD45; without CD4, CD10, CD14, CD25, CD56 or T-cell receptor gamma/delta. The abnormal population represents 17.5% of the total white cells.

No evidence of an abnormal plasma cell population is identified by flow cytometry. 109 thousand cells acquired.

PERIPHERAL BLOOD
CBC (07/12/2021):
WBC 8.4 [4.0-11.0 K/mcL] 
RBC 2.56 L [3.80-5.00 M/mcL] 
HGB 8.3 L [11.2-15.4 g/dL] 
HCT 24.6 L [34.3-46.0 %] 
MCV 96 [80-98 fL] 
MCH 32.4 [27.0-33.0 pg] 
MCHC 33.7 [31.0-36.5 g/dL] 
RDW 15.3 H [12.2-15.1 %] 
Platelets 203 [160-400 K/mcL] 

Neutrophil 69.0 [32.5-74.8 %] 
Mono 10.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 3.0 H [0.0-0.0 %] 
Lymph 16.0 [12.2-47.4 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 5.8 [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.3 H [0.0-0.0 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 

Morphology:
WBC: No circulating blasts seen. Unremarkable morphology.
RBC: Normocytic, normochromic RBCs.
Platelets: Adequate in number, occasional large platelets are seen.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-4346.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-9632;S10;MSK7 - 2023-05-19 16.39.53.ndpi,Peripheral Blood Smear,2023-05-19,"Clinical Diagnosis: Leukemia, Acute Lymphoid
Clinical Hx/Op Findings: 57 y/o man w/ new B-ALL
Requested Studies: Gross/Micro
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - B lymphoblastic leukemia/lymphoma  

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Increased (90%)
M:E ratio: N/A
Blasts: Markedly increased
Myeloid lineage: Few seen 
Erythroid lineage: Few seen 
Megakaryocytes: Adequate with no dysmorphology
Lymphocytes: Scattered
Plasma cells: Scattered

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW TOUCH PREAPARATIONS
Bone Marrow Aspirate Smear Quality: N/A
The bone marrow aspiration yields a dry tap.

Blasts                89%
Eosinophils           1%
Erythroid Precursors      10%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
-Cellularity nearly replaced by small blasts 

PERIPHERAL BLOOD
CBC (12/23/2021):
WBC 1.7 L [4.0-11.0 K/mcL] 
RBC 3.46 L [3.95-5.54 M/mcL] 
HGB 10.4 L [12.5-16.2 g/dL] 
HCT 31.8 L [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 30.1 [27.0-33.0 pg] 
MCHC 32.7 [31.0-36.5 g/dL] 
RDW 14.5 [12.2-15.1 %] 
Platelets 156 L [160-400 K/mcL] 


Morphology: Marked neutropenia, many small blasts seen.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 is largely negative on blasts, TdT highlights a major subset of blasts

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-12800)
1. Abnormal immature B cell population detected.
The presence of greater than 20% abnormal immature B-cells in the bone marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 57.7% of the mononuclear cells.
Abnormal immature B cell population represents 58.1% of WBC.

Immunophenotype:
Abnormal: CD10 (positive - bright), CD13 (partial), CD22 (variable - dim to bright), CD24 (bright), CD33 (partial), CD38 (dim), CD66c/CD123 (positive), CD73/CD304 (positive), CD81 (dim), CD86 (positive), CD123 (positive), HLA-DR (positive), cytoplasmic CD79a (variable - negative to intermediate)
Normal: CD19, CD34, CD45, CD71
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD20, CD25, CD26, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, cytoplasmic MPO, surface Kappa, surface Lambda

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

4. No abnormal myeloid blast, monocyte or maturing myeloid population identified.                               
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Myeloid blast population with an unremarkable phenotype represents 0.26% of WBC.

Number of cells acquired: 60 thousand  

Less than target number of cells acquired for AML. Number of cells acquired 60 thousand. Target sensitivity is not achieved.
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.


CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-8427.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-53342, 53343, 53348.
"
H21-8526;S10;MSK8 - 2023-05-19 18.10.06.ndpi,Peripheral Blood Smear,2023-05-19,"Clinical Diagnosis: DLBCL
Clinical Hx/Op Findings: Assess DLBCL
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by patient's previously diagnosed Diffuse large B-cell lymphoma (10-15% with CD20 immunohistochemistry)
     - Cellular marrow with trilineage maturing hematopoiesis.

COMMENT: Patient's recent diagnosis of Diffuse large B-cell lymphoma, non-germinal center phenotype (Hans algorithm) made on left inguinal lymph node biopsy is noted (H21-8329) is noted.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and paucispicular aspirate specimens show normocellular bone marrow (~40-50%cellularity). There istrilineage maturing hematopoiesis with scattered small aggregates of large atypical lymphoid cells with variable amount of cytoplasm, ovoid/ slightly irregular nuclei, vesicular chromatin, and distinct nucleoli.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD20, PAX5, MUM1, BCL2
Do not express: CD3, CD10
Other: The Ki-67 weakly stains the atypical cells.
CD23 stains rare cells.
BCL6 and CMYC are suboptimal for evaluationdue to decalcification.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-11326) 
1. Abnormal B cell population with larger size detected.

Abnormal B cell population represents 4.6% of WBC.

Immunophenotype:
Abnormal: CD19 (dim), CD20 (bimodal - negative, dim), CD22 (bimodal - dim, intermediate), CD45 (dim), surface Kappa (restriction), Forward Scatter (increased), Side Scatter (increased)
Normal: CD38
Negative: CD5, CD10, CD25, CD279 (PD1), CD3, CD14, surface Lambda

2. No abnormal mature T cell population detected.
No immunophenotypic evidence of T-cell lymphoma is identified.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (11/15/2021):
WBC 9.0 [4.0-11.0 K/mcL] 
RBC 3.56 L [3.80-5.00 M/mcL] 
HGB 8.9 L [11.2-15.4 g/dL] 
HCT 28.8 L [34.3-46.0 %] 
MCV 81 [80-98 fL] 
MCH 25.0 L [27.0-33.0 pg] 
MCHC 30.9 L [31.0-36.5 g/dL] 
RDW 14.0 [12.2-15.1 %] 
Platelets 308 [160-400 K/mcL] 

Neutrophil 65.0 [32.5-74.8 %] 
Mono 16.1 H [0.0-12.3 %] 
Eos 0.9 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 0.2 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 17.4 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 5.9 [1.5-7.5 K/mcL] 
Abs Mono 1.4 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.6 [0.9-3.2 K/mcL] 

Morphology: Smear shows marked cytologic artifact, suboptimal for evaluation

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Not submitted

MOLECULAR STUDIES 
Not submitted
"
H21-5777;S10;MSKC - 2023-05-27 02.45.57.ndpi,Peripheral Blood Smear,2023-05-27,"Mantle Cell Lymphoma
Assess Mantle Cell Lymphoma
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
    - Extensive involvement by mantle cell lymphoma (~90% with CD20 immunohistochemistry).

BONE MARROW BIOPSY/ASPIRATE/TOUCH IMPRINT MORPHOLOGY
Adequate core biopsy shows hypercellular bone marrow (90% cellularity) with extensive involvement by a diffuse atypical lymphocytic infiltrate composed predominantly of small to intermediate sized cells. Background trilineage hematopoiesis appears markedly reduced. Aspirate smears and touch imprint are aspicular, hypocellular and hemodilute. They show predominantly scattered small to intermediate sized atypical lymphoid cells with irregular nuclear contours, condensed chromatin, occasional small nucleoli and scant cytoplasm with rare myeloid and erythroid elements.

Bone Marrow Aspirate Smear Quality: Suboptimal

Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      5%
Promonocytes           1%
Erythroid Precursors      2%
Lymphocytes           90% 
Number of Cells Counted 500
M:E Ratio           4 

IMMUNOHISTOCHEMISTRY
The neoplastic lymphoid cells 
Express: CD20, PAX5, CD5, Cyclin D1, SOX 11 (partial, may be due to decalcification)
Do not express: CD3, CD23, p53 
Other: CD3 highlights scattered background T-cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7639) 
Interpretation: 
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD20 (dim), CD43, CD79b (absent to dim), CD200 (partial), and ROR1; normal expression of CD19, CD38, CD40, CD81, and CD45; and without CD3, CD10, or CD23.  The abnormal B cell population represents 81.1% of total white cells.
This immunophenotype is consistent with previously diagnosed mantle cell lymphoma (MCL).

PERIPHERAL BLOOD
CBC (08/09/2021):
WBC 6.6 [4.0-11.0 K/mcL] 
RBC 3.10 L [3.95-5.54 M/mcL] 
HGB 9.1 L [12.5-16.2 g/dL] 
HCT 28.2 L [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 29.4 [27.0-33.0 pg] 
MCHC 32.3 [31.0-36.5 g/dL] 
RDW 15.8 H [12.2-15.1 %] 
Platelets 50 L [160-400 K/mcL] 

Neutrophil 41.0 [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Lymph 8.0 L [12.2-47.4 %] 
Abnormal Lymphoid Cells 39.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 2.7 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Lymph 3.1 [0.9-3.2 K/mcL] 

Morphology:
WBC: Circulating atypical lymphoid cells morphologically similar to those in the aspirate smears/touch imprint. Occasional myelocytes and metamyelocytes.
RBC: Normochromic, normocytic anemia.
Platelets: Thrombocytopenia.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5027.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-32531.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-4685;S10;MSK0 - 2023-04-19 18.11.58.ndpi,Peripheral Blood Smear,2023-04-25,"Follicular lymphoma. Rule out transformation 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by low-grade B-cell lymphoma (~5% by CD20 immunohistochemistry).
     - Cellular marrow with trilineage maturing hematopoiesis.

The case was also reviewed by Dr. Ahmet Dogan (Hematopathology Service) who agrees with the diagnosis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Suboptimal biopsy specimen shows cellular bone marrow (overall 30%, ranging between 15 and 70%), with partial crush and aspiration artifact limiting morphologic evaluation. There istrilineage maturing hematopoiesis. Myeloid and erythroid elements show progressive maturation. Megakaryocytes appear adequate in morphology. Focal paratrabecular aggregates composed of small lymphoid cells with condensed chromatin and inconspicuous nucleoli are present; no significant increase in the number of large cells is noted. The aspirate smears are hemodiluted.

Bone Marrow Aspirate Smear Quality: Adequate; devoid of spicules.

Blasts                1%
Promyelocytes           1%
Myelocytes           7%
Metamyelocytes           3%
Neutrophils/Bands      55%
Monocytes           8%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      13%
Lymphocytes           10%
Number of Cells Counted      500
M:E Ratio           5.8

IMMUNOHISTOCHEMISTRY
Immunostains performed at MSKCC showed that CD20 appears to highlight numerous cells in the para trabecular lymphoid aggregate. PAX5, BCL2, BCL6, CD10, LMO2, MUM1 highlights scattered cells in the aggregate. CD3 and CD5 are positive in scattered T cells in the para trabecular aggregates and in the remaining marrow. Cyclin D1 is positive only in scattered rare cells. Ki-67 proliferation index is <5% in the focal lymphoid aggregates but highlights numerous proliferating hematopoietic precursors in the background.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-6179) 
No abnormal mature B-cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

PERIPHERAL BLOOD
CBC (6/28/2021)
WBC 5.8 [4.0-11.0 K/mcL] 
RBC 4.06 [3.80-5.00 M/mcL] 
HGB 13.1 [11.2-15.4 g/dL] 
HCT 39.3 [34.3-46.0 %] 
MCV 97 [80-98 fL] 
MCH 32.3 [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 12.6 [12.2-15.1 %] 
Platelets. 224 [160-400 K/mcL] 

Neutrophil 65.6 [32.5-74.8 %] 
Mono 13.0 H [0.0-12.3 %] 
Eos 2.8 [0.0-4.9 %] 
Baso 1.2 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 16.9 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 3.8 [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.0 [0.9-3.2 K/mcL]

Morphology: No circulating atypical lymphoid cells seen.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-4083.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-26432.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-7770;S10;MSKH - 2023-05-31 15.42.42.ndpi,Peripheral Blood Smear,2023-05-31,"Clinical Diagnosis: ALL
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Extensive involvement by B-lymphoblastic leukemia/lymphoma (98% blasts by differential count). See comment.

COMMENT: Correlation with the concurrent molecular and cytogenetic results is recommended.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: >90%
M:E ratio: N/A
Blasts: Markedly increased, forming sheets. Blasts account for >95% of total cellularity. Only very rare residual myeloid and erythroid precursors are seen in the background together with scattered megakaryocytes with normal morphology.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Aspicular but cellular

Differential count:
Blasts                98%
Myelocytes           1%
Neutrophils/Bands      1%
Number of Cells Counted      500
M:E Ratio           0

Morphology:
Most of the cellularity is represented by medium-sized blasts, with round to slightly irregular nuclei, dispersed chromatin, prominent nucleoli and scant basophilic cytoplasm.

PERIPHERAL BLOOD
CBC (10/20/2021):
WBC 2.2 L [7.1-15.9 K/mcL] 
RBC 2.79 L [2.93-4.75 M/mcL] 
HGB 8.1 L [8.9-12.7 g/dL] 
HCT 24.3 L [26.8-37.8 %] 
MCV 87 H [70-85 fL] 
MCH 29.0 [22.7-29.5 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 13.1 [12.2-15.1 %] 
Platelets 86 L [160-400 K/mcL] 

Neutrophil 8.0 L [16.9-74.5 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 9.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 80.0 H [18.1-79.9 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.2 L [1.5-8.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 1.8 [1.1-8.1 K/mcL] 

Morphology: Circulating blasts are seen.

IMMUNOHISTOCHEMISTRY
Stains for TdT and CD34 highlights sheets of blasts accounting for >95% of total cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-10307)
1. Abnormal immature B cell population detected.
An abnormal immature B-cell population is identified by flow cytometry.

Immunophenotype from B-ALL tube:
Abnormal: CD10 (variable - dim, bright), CD19 (variable - intermediate, bright), CD20 (partial), CD38 (dim), CD45 (negative), CD81 (dim), CD66c/CD123 (positive), CD86 (positive)
Normal: CD22, CD24, CD34, CD73/CD304
Negative: CD66b

COG comment:
Abnormal immature B-cell population detected.
An abnormal immature B-cell population is identified by flow. The abnormal immature B-cells represent 89.3% of the white cells and 92.1% of the mononuclear cells in the sample and abnormally express CD9 (uniform bright), CD10 (dim to bright), CD19 (intermediate to bright), CD20 (partial), CD38 (dim), CD45 (negative to dim), CD58 (uniform bright); with normal expression of CD34; and without CD13/CD33. This finding is consistent with persistent/recurrent B-lymphoblastic leukemia/lymphoma, depending on the clinical context. Determination of proportion of abnormal cells is performed according to COG protocol. Clinical and morphologic correlation is recommended.
Testing performed as per Children's Oncology Group (COG) protocol.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-10261)
Flow cytometric analysis performed on the peripheral blood will be reported separately.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-6787, CG21-6788. 

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-43545, M21-43579, M21-43588.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-8049;S2;MSK9 - 2023-05-27 01.41.31.ndpi,Peripheral Blood Smear,2023-05-27,[NULL],"1. Bone marrow, right posterior iliac crest; aspirate and peripheral blood smears:
    - B-lymphoblastic leukemia/lymphoma, 72% blasts by aspirate differential; see comment.

COMMENT: Correlation with cytogenetic and molecular studies is required for full subclassification.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                72%
Promyelocytes           1%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      9%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      2%
Plasma Cells           1%
Lymphocytes           10%
Number of Cells Counted      500
M:E Ratio           N/A

Morphology: Adequate spicular and cellular aspirate smears show a markedly expanded blast population comprised of small to medium sized blasts with scant cytoplasm, round to irregular nuclei, fine chromatin, and indistinct nucleoli, in a background of markedly reduced trilineage hematopoiesis. Occasional hand-mirror forms are seen. 

PERIPHERAL BLOOD
CBC (10/28/2021):
WBC 6.5 L [7.1-15.9 K/mcL] 
RBC 4.77 H [2.93-4.75 M/mcL] 
HGB 13.2 H [9.2-12.7 g/dL] 
HCT 38.2 H [27.7-37.9 %] 
MCV 80 [70-85 fL] 
MCH 27.7 [22.7-29.5 pg] 
MCHC 34.6 [31.0-36.5 g/dL] 
RDW 11.9 L [12.2-15.1 %] 
Platelets 391 [160-400 K/mcL] 

Neutrophil 18.0 [16.9-74.5 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 73.0 [18.1-79.9 %] 
Variant Lymph 2.0 [0.0-2.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.2 L [1.5-8.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Lymph 4.8 [1.1-8.1 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Mild neutropenia; occasional circulating blasts seen.
RBC: Normocytic, normochromic RBCs.
PLT: Unremarkable morphology. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. Pessin MD., PhD., Director.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-10712)
1. Abnormal immature B cell population detected. 
Abnormal immature B-cells represent 42.8% of WBC and 50.8% of mononuclear cells.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.
2.17 million cells acquired.

Abnormal: CD10 (positive - bright), CD19 (variable - partially dim), CD24 (bright), CD38 (dim), CD45 (negative), CD66c/CD123 (positive), CD86 (partial), CD123 (positive)
Normal: CD22, CD34, CD71, CD81, HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD20, CD25, CD26, CD33, CD56, CD64, CD66b, CD73/CD304, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, cytoplasmic MPO, Surface Kappa, Surface Lambda

2. No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
CD34 positive myeloid blasts represent 0.25% of WBC.                                                                         
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.
387 thousand cells acquired.

3. No abnormal B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.
394 thousand cells acquired.

4. No abnormal T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  
394 thousand cells acquired.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-7017, CG21-7018.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-45027. 

"
H21-9688;S11;MSK9 - 2023-04-19 16.55.24.ndpi,Peripheral Blood Smear,2023-04-19,"Clinical Diagnosis: Multiple Myeloma
Clinical Hx/Op Findings: ND MM
Requested Studies: Gross/Micro
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Plasma cell neoplasm, 
80% involvement by CD138 immunohistochemistry (patchy distribution, up to ~100% focally)
65% involvement by aspirate differential
27.5% of the total WBC involvement by 12 color flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY with Large Clots
Quality: Adequate / fragmented
Cellularity: Hypercellular, overall >90% 
Myeloid lineage: Progressive maturation   
Erythroid lineage: Progressive maturation  
Megakaryocytes: Present with occasional hypolobated forms 
Plasma cells: Markedly Increased 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

ASPIRATE MORPHOLOGY
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                2%
Promyelocytes           2%
Myelocytes           5%
Metamyelocytes           4%
Neutrophils/Bands      11%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      9%
Plasma Cells           65% 
Number of Cells Counted 500
M:E Ratio           N/A

Morphology: 
Marrow spicules: Spicular    
Cellularity: Markedly hypercellular  
Plasma cell morphology: Intermediate to small sized 
Myeloid lineage: Progressive maturation   
Erythroid Lineage: Progressive maturation
Megakaryocytes: Present 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, overall ~80% of marrow cellularity (up to ~100% focally). 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.
BCMA highlights >90% of plasma cells, (1+) intensity, membranous / Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-12875) 
1. Abnormal plasma cell population detected.  
Note that the percentage of abnormal plasma cell population will certainly be an underestimate in comparison with morphology.
Abnormal plasma cell population comprises 99.8% of total plasma cells.
Abnormal plasma cell population represents 27.5% of WBC.

Immunophenotype:
Abnormal: CD19 (negative), CD20 (positive), CD27 (variable - dim to negative), CD45 (negative), CD56 (positive), CD81 (negative), cytoplasmic Kappa (restriction)
Normal: CD138, CD38, CD229, CD319
Negative: CD117, cytoplasmic Lambda

Number of cells acquired: 5.3 million  

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.
Number of cells acquired: 291 thousand  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (12/28/2021):
WBC 9.4 [4.0-11.0 K/mcL] 
RBC 3.19 L [3.80-5.00 M/mcL] 
HGB 10.2 L [11.2-15.4 g/dL] 
HCT 31.4 L [34.3-46.0 %] 
MCV 98 [80-98 fL] 
MCH 32.0 [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 14.4 [12.2-15.1 %] 
Platelets 300 [160-400 K/mcL] 

Neutrophil 53.0 [32.5-74.8 %]  
Mono 12.0 [0.0-12.3 %]  
Eos 2.0 [0.0-4.9 %]  
Baso 0.0 [0.0-1.5 %]  
Lymph 30.0 [12.2-47.4 %]  
Variant Lymph (Plasmacytoid lymphocytes) 3.0 H [0.0-2.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)]  

Abs Neut 5.0 [1.5-7.5 K/mcL]  
Abs Mono 1.1 [0.0-1.3 K/mcL]  
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL]  
Absolute Basophil 0.0 [0.0-0.2 K/mcL]   
Abs Lymph 3.1 [0.9-3.2 K/mcL]  
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: No circulating plasma cells on scanning. 
RBC: Rouleaux formation is noted.
Platelets: Unremarkable
 
Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-8485, CG21-8486.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-53758. 
"
H21-4038;S12;MSK4 - 2023-05-19 22.58.57.ndpi,Peripheral Blood Smear,2023-05-19,"Leukemia, Hairy Cell
Relapsed Hairy Cell Leukemia
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Extensive involvement by Hairy cell leukemia (80% by CD20 immunostain)

BONE MARROW BIOPSY
Quality: adequate 
Cellularity: 70% 
M:E ratio: not applicable 
The marrow is largely replaced by interstitial lymphoid infiltrate composed of small lymphoid cells that have fried egg morphology. Normal trilineage hematopoiesis is largely suppressed. 
Clot section: blood clot only 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Inadequate, hypocellular, devoid of spicules

Differential cell count was performed on aspirate smears and touch imprints.

Blasts                1%
Promyelocytes           3%
Myelocytes           10%
Metamyelocytes           11%
Neutrophils/Bands      29%
Monocytes           3%
Eosinophils           3%
Erythroid Precursors      15%
Plasma Cells           1%
Lymphocytes           6%
Hairy cells           18%
Number of Cells Counted 500
M:E Ratio           3.9

Morphology:
The aspirate smear is aspicular and hemodiluted. Touch imprint is cellular with distorted morphology. However, increased atypical lymphoid cells that are medium in size and have abundant cytoplasm with projections are seen, compatible with Hairy cells. Normal hematopoietic elements are also seen. 

PERIPHERAL BLOOD
CBC (06/07/2021):
WBC 4.0 [4.0-11.0 K/mcL] 
RBC 5.23 [3.95-5.54 M/mcL] 
HGB 14.9 [12.5-16.2 g/dL] 
HCT 46.1 [37.5-49.3 %] 
MCV 88 [80-98 fL] 
MCH 28.5 [27.0-33.0 pg] 
MCHC 32.3 [31.0-36.5 g/dL] 
RDW 14.9 [12.2-15.1 %] 
Platelets 39 L [160-400 K/mcL] 

Neutrophil 36.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 33.0 [12.2-47.4 %] 
Hairy Cell 28.0 H [0.0-0.0 %] 
Variant Lymph 1.0 [0.0-2.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 
Abs Hairy Cells 1.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology: Circulating Hairy cells. 


IMMUNOHISTOCHEMISTRY
CD20 shows markedly increased B cells, >80%. The B cells are positive for BRAF V600E. CD3 stains scattered T cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5378)
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.

Flow cytometry reveals an abnormal mature B-cell population having abnormal expression of CD19 (bright), CD20 (slightly bright), CD11c, CD22 (bright), CD25, CD45 (bright), CD103, and CD200 (bright), with slightly increased forward and side scatter and lambda light chain restriction (bright); with normal expression of CD38 and without CD3, CD5, CD10 or CD14. The immunophenotype of the abnormal B-cell population is consistent with involvement by hairy cell leukemia. The abnormal B cell population represents 8.1% of the total white cells.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3510.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-23061, 23063.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-213;S11;MSKK - 2023-04-19 15.50.10.ndpi,Peripheral Blood Smear,2023-04-19,"ET
Pretreatment 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Myeloproliferative neoplasm, most consistent with essential thrombocythemia (ET), see comment.

COMMENT: Per clinical notes, the patient shows persistent thrombocytosis, and JAK2 p.V617F mutation was detected elsewhere. Although Hgb level shows mild increase, morphologic findings of this biopsy (normocelluar marrow, no evidence of panmyelosis, no fibrosis, no leukoerythroblastosis) do not support the diagnosis of polycythemia vera (PV) or primary myelofibrosis at the moment. Please correlate with upcoming cytogenetic/molecular results, clinical and radiological finding.  

BONE MARROW BIOPSY/CLOT SECTION
Quality: Adequate
Cellularity: 40-50% 
M:E ratio: Normal
Blasts: Not overtly increased
Myeloid lineage: Shows mildly left-shifted progressive maturation
Erythroid lineage: Shows mildly left-shifted progressive maturation
Megakaryocytes: Increased in number and show atypical features (occasional loose clusters and pleomorphic morphology including enlarged forms with bulbous nuclei and small forms with hypolobated and/or hyperchromatic nuclei) 
Lymphocytes: Interstitially scattered
Plasma cells: Interstitially scattered

Special stain:
Reticulin: A reticulin stain does not show significant increase in reticulin fibrosis (0/3).

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                1%
Promyelocytes           1%
Myelocytes           22%
Metamyelocytes           4%
Neutrophils/Bands      33%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      24%
Plasma Cells           1%
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           2.7

Morphology:
The aspirate smears are spicular and cellular demonstrating maturing trilineage hematopoiesis and normal M:E ratio. Blasts are not increased. Myeloid and erythroid elements show mildly left-shifted progressive maturation with unremarkable morphology. Many megakaryocytes are present and show atypical features similar to the core biopsy.     

PERIPHERAL BLOOD
CBC (1/11/2021):
WBC 9.8 [4.0-11.0 K/mcL] 
RBC 5.96 H [3.95-5.54 M/mcL] 
HGB 17.0 H [12.5-16.2 g/dL] 
HCT 50.9 H [37.5-49.3 %] 
MCV 85 [80-98 fL] 
MCH 28.5 [27.0-33.0 pg] 
MCHC 33.4 [31.0-36.5 g/dL] 
RDW 13.0 [12.2-15.1 %] 
Platelets. 564 H [160-400 K/mcL] 

Neutrophil 68.1 [32.5-74.8 %] 
Mono 6.4 [0.0-12.3 %] 
Eos 2.7 [0.0-4.9 %] 
Baso 1.4 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 20.9 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 6.7 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 2.0 [0.9-3.2 K/mcL]

Morphology:
WBCs: Scattered basophils present. No circulating immature cells are seen.
RBCs: Unremarkable morphology. No circulating nucleated RBC. 
Platelets: Thrombocytosis with unremarkable morphology.

IMMUNOHISTOCHEMISTRY
CD34 immunostain shows no increase in blasts (<5% of cellularity). 
CD117 highlights scattered mast cells as well as mildly increased early erythroid and myeloid precursors.     

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-291)
No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 1.4% of WBC.

299 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required. Flow cytometry is generally not a sensitive methodology in the context of myeloproliferative disorders, correlation with molecular studies for JAK2, CALR, MPL mutation status and/or BCR-ABL and morphology is advised if clinically indicated.

No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-191.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-1216, M21-1217.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-40;S12;MSKT - 2023-04-19 16.02.49.ndpi,Peripheral Blood Smear,2023-04-19,"Leukemia. Hyperleukocytosis.
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
     - Involvement by acute myeloid leukemia. See comment.
  
COMMENT:
The mild reticulin fibrosis seen in the core biopsy is somewhat unusual; however, morphologic assessment for an antecedent myeloid disorder is limited by the fact that the marrow space is essentially entirely replaced by blasts. Correlation with clinical history as well as pending cytogenetic and molecular studies is needed for definitive subclassification.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: ~95%
M:E ratio: N/A
Blasts: Essentially replace the marrow
Myeloid lineage: N/A
Erythroid lineage: N/A
Megakaryocytes: Virtually absent
Lymphocytes: No prominent lymphoid aggregates seen
Plasma cells: Not increased
Special stains: Reticulin stain shows a mild increase in reticulin fibrosis (MF-1). 
Clot section: Concordant with the biopsy

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Few mast cells noted
Blasts                97%
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           0

Morphology:
-Spiculate and hypercellular smears show sheets of blasts. The blasts are medium to large in size with a moderate amount of lightly basophilic cytoplasm, and occasional blasts have fine eosinophilic granules. The nuclear borders are irregular or folded, and the nuclei contain occasional small but conspicuous nucleoli. Background hematopoiesis is virtually absent.

PERIPHERAL BLOOD
CBC (01/04/2021):
WBC 9.0 [4.0-11.0 K/mcL] 
RBC 3.51 L [3.95-5.54 M/mcL] 
HGB 9.2 L [12.5-16.2 g/dL] 
HCT 28.9 L [37.5-49.3 %] 
MCV 82 [80-98 fL] 
MCH 26.2 L [27.0-33.0 pg] 
MCHC 31.8 [31.0-36.5 g/dL] 
RDW 15.6 H [12.2-15.1 %] 
Platelets. 10 L [160-400 K/mcL] 

Neutrophil 0.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 37.0 H [0.0-0.0 %] 
Lymph 63.0 H [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 0.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL]
Absolute Blasts 3.3 H [0.0-0.0 K/mcL] 
Abs Lymph 5.6 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology:
WBC: Circulating blasts are readily identified. The remaining WBCs are predominantly mature lymphocytes.
RBC: Normochromic anemia with mild anisocytosis
Platelets: Thrombocytopenia

IMMUNOHISTOCHEMISTRY
Immunostains show that the marrow is largely replaced by sheets of blasts that co-express CD34 and CD117 (variable).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-50)
Interpretation:
Expanded blast population detected, favor myeloid
No abnormal mature B or T cell population detected.

The blasts have abnormal expression of CD4(partial), CD7(bright), CD11b, CD13(bright to negative), CD25, CD34, CD45(dim), CD117(dim), CD123(bright) with normal expression of CD38, CD71, and HLA-DR without CD2, surface CD3, cytoplasmic CD3, CD5, CD8, CD14, CD15, CD16, CD19, CD20, CD33, CD56, CD64, cytoplasmic CD79a, or surface light chains. MPO expression is present on a small subset of blasts. CD34 positive blasts represent 42.2% of WBC. Bright and uniform CD7 is somewhat unusual in AML, however no additional compelling evidence of T or B cell maturation is seen. Myeloid lineage is therefore favored.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-29.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M21-187 to M21-190.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-5663;S16;MSK3 - 2023-04-19 17.36.14.ndpi,Peripheral Blood Smear,2023-04-19,"CML and CLL history, worsening anemia. 
","1-3. Bone marrow, left posterior iliac crest; biopsy aspirate and peripheral blood smears: 
     - Persistent involvement by B-cell Lymphoproliferative Disorder, previously diagnosed as Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (~30% involvement by PAX-5 immunostain)
     - Mildly Hypercellular bone marrow with decreased trilineage hematopoiesis, dysmegakaryopoiesis, and no increase in blasts (See Comment)
  
COMMENT: Due to the extent of involvement by abnormal B cells in the marrow, and the small fragmented nature of the biopsy, it is difficult to evaluate for involvement by the patient's reported history chronic myeloid leukemia (CML). Hypolobated megakaryocytes are seen, but may be attributed to reactive changes secondary to therapy for the patient's B cell lymphoma, rather than CML. Correlation with pending qRT-PCR for BCR-ABL1 fusion transcript (M21-31764) is recommended for assessment of CML involvement.

BONE MARROW BIOPSY
Quality: Suboptimal small, fragmented, and hemorrhagic biopsy.
Cellularity: Mildly hypercellular for age (~30% cellularity)
M:E ratio: Appears normal.
Blasts: Not increased
Myeloid lineage: Decreased in number with Left shifted progressive maturation
Erythroid lineage: Decreased in number with Left shifted progressive maturation
Megakaryocytes: Adequate in numbers, with frequent atypical hypolobated and occasional hyperchromatic forms.
Lymphocytes: Increased in number, with aggregate formation.
Plasma cells: Scattered.

Clot section: Predominantly blood with scattered marrow elements.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Hypocellular, devoid of spicules

Promyelocytes           1%
Myelocytes           6%
Metamyelocytes           4%
Neutrophils/Bands      21%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      14%
Plasma Cells           1%
Lymphocytes           51%
Number of Cells Counted 500
M:E Ratio           2.4

Morphology:
Aspicular, hypocellular and hemodiluted bone marrow aspirates show no increase in blasts. The myeloid lineage appears mildly left shifted with progressive maturation and no significant dysplasia. The erythroid lineage is mildly left shifted with progressive maturation and few dyspoietic forms with nuclear irregularity, budding and nuclear/cytoplasmic dyssynchrony (<10% of lineage). Megakaryocytes are not readily identifiable. Lymphoid population is expanded, and are small in size, mature appearing with condensed-clumped chromatin, inconspicuous nucleoli, and scant cytoplasm. There is no increase in large-size lymphoid cells or prolymphocytes. Scattered plasma cells with unremarkable morphology are seen.

PERIPHERAL BLOOD
CBC (08/03/2021):
WBC 3.7 L [4.0-11.0 K/mcL] 
RBC 2.38 L [3.80-5.00 M/mcL] 
HGB 8.3 L [11.2-15.4 g/dL] 
HCT 25.8 L [34.3-46.0 %] 
MCV 108 H [80-98 fL] 
MCH 34.9 H [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 15.7 H [12.2-15.1 %] 
Platelets. 165 [160-400 K/mcL] 
Neutrophil 82.7 H [32.5-74.8 %] 

Mono 3.8 [0.0-12.3 %] 
Eos 0.5 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 12.4 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 3.1 [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 0.5 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Mild leukopenia with rare/occasional pseudo-Pelger-Huet forms. The lymphoid cells present are mostly small-sized and mature-appearing. No circulating blasts are seen.
RBC: Macrocytic anemia.
Platelets: Some large platelets are seen.

IMMUNOHISTOCHEMISTRY
Neoplastic B-cell population (30% of cellularity)
Express: CD20 (subset weak), PAX-5, CD23, CD5, and LEF-1 (small subset)
Don't express: CD3 and Cyclin D1
CD3 and CD5 also highlight interstitial T-cells singly and in small aggregates. 

Immunohistochemistry for CD34 and CD117 are pending and will be reported an addendum. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7483)
Abnormal B-cell population identified.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.25% of WBC.

Flow cytometry identified an abnormal B-cell population similar to that seen previously in [F21-6742] having abnormal expression of CD5, CD20 (dim), CD23, CD40 (dim), CD43, CD79b (absent), CD81 (absent), CD200 (bright) and ROR1; normal expression of CD19 and CD45; and without CD3, CD38, or CD10 expression. The findings are consistent with previously diagnosed chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL). The abnormal B-cell population comprises 48.4% of the white cells.

341 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-4939.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-31763, M21-31764, and M21-31765.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H21-4375;S11;MSKX - 2023-05-27 01.59.26.ndpi,Peripheral Blood Smear,2023-05-27,"B-ALL
Assess response to Blina 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - No diagnostic morphologic or immunophenotypic evidence of previously diagnosed B-lymphoblastic leukemia/lymphoma.
     - Hypercellular marrow with maturing trilineage hematopoiesis and marked hematogone (normal B-lymphoid precursor) hyperplasia. See comment.
  
COMMENT: Although the degree of hematogone hyperplasia seen in this case is unusual, hematogone hyperplasia has been described following therapy for acute leukemias (Ref PMID 11588048). Based on the morphology and flow cytometric findings, definitive evidence of B-lymphoblastic leukemia/lymphoma is not seen. Correlation with the pending cytogenetic and molecular studies is also advised. Case reviewed with Dr. F. Sen, Hematopathology service, who agrees.

BONE MARROW BIOPSY
Quality: Adequate with some fragmentation and crush artifact
Cellularity: Hypercellular for age (~80% overall)
M:E ratio: Approximately normal
Blasts: Not overtly increased
Myeloid lineage: Exhibits progressive maturation
Erythroid lineage: Exhibits progressive maturation
Megakaryocytes: Adequate in number without significant atypia
Lymphocytes: Increased, composed predominantly of lymphoid precursors (see immunohistochemistry section below)
Plasma cells: Not increased
Clot section: Predominantly blood with few marrow elements

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Suboptimal, paucicellular, devoid of spicules

Blasts                2%
Promyelocytes           1%
Myelocytes           2%
Metamyelocytes           2%
Neutrophils/Bands      22%
Monocytes           3%
Eosinophils           2%
Erythroid Precursors      12%
Lymphocytes           54% 
Number of Cells Counted 500
M:E Ratio           2.5

Morphology:
Aspirate smears and touch imprint are aspicular, paucicellular, and hemodilute. The differential count may not fully reflect the marrow composition. Scattered myeloid and erythroid elements are seen at various stages of maturation without significant dysplasia. Rare megakaryocytes are identified. Lymphoid cells are relatively increased, many of which show morphology consistent with lymphoid precursors (hematogones).

PERIPHERAL BLOOD
CBC (06/17/2021):
WBC 4.6 [4.0-11.0 K/mcL] 
RBC 4.63 [3.95-5.54 M/mcL] 
HGB 13.7 [12.5-16.2 g/dL] 
HCT 42.0 [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 29.6 [27.0-33.0 pg] 
MCHC 32.6 [31.0-36.5 g/dL] 
RDW 14.0 [12.2-15.1 %] 
Platelets 26 L [160-400 K/mcL] 

Neutrophil 28.0 L [32.5-74.8 %] 
Mono 24.0 H [0.0-12.3 %] 
Eos 5.0 H [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 42.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.3 L [1.5-7.5 K/mcL] 
Abs Mono 1.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.9 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
WBC: Mild absolute neutropenia and monocytosis. No definitive circulating blasts are seen, however, rare possible circulating hematogones cannot be excluded.
RBC: Normochromic, normocytic RBCs.
Platelets: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
PAX5 highlights frequent interstitially scattered cells of variable size (comprising ~40% of marrow cellularity), which express CD10, partial CD20, partial TdT (small subset) and partial CD34 (small subset), consistent with predominantly B-cell precursors (hematogones).
CD117 highlights scattered early myeloid/erythroid precursors.
CD71 highlights erythroid precursors. 
Myeloperoxidase highlights a subset of myeloid elements (appears technically suboptimal).
CD61 highlights an adequate number of megakaryocytes without significant atypia.
CD3 highlights scattered T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5793)
Interpretation: 
No abnormal immature B cell population is detected. 
Immature B cells with normal immunophenotype by this method account for 36.6% of WBC following erythroid lysis. While the proportion of immature B-cells is increased, the immunophenotype shows normal maturation pattern. Increased hematogones can be seen in various reactive conditions. 
5.7 million cells acquired.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 1.5% of WBC.
334 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

This case was also reviewed by Dr. Mikhail Roshal, hematopathology service.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3813

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-24855, M21-24856.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-7044;S11;MSK3 - 2023-05-19 18.04.40.ndpi,Peripheral Blood Smear,2023-05-19,"Lymphoma, Follicular.  Thrombocytopenia.

","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Hypercellular marrow with erythroid predominant trilineage hematopoiesis, dyserythropoiesis with ring sideroblasts (>15%), dysmegakaryopoiesis, and no increase in blasts, see comment 1. 
     - No diagnostic morphologic or immunophenotypic evidence of involvement by B-cell lymphoma, see comment 2. 

COMMENT 1: Patient's history of relapsed/refractory Follicular lymphoma treated with multiple lines of therapy is noted. The concurrent flow cytometric analysis reveals an abnormal myeloid blast population. The overall findings of the case are highly concerning for a Therapy related myeloid neoplasm. If a clonal process is proven by cytogenetic or molecular studies, the diagnosis of Therapy related myeloid neoplasm best classified as Myelodysplastic syndrome with ring sideroblasts and
multilineage dysplasia (MDS-RS-MLD) will be confirmed.

COMMENT 2: Though no diagnostic morphologic or immunophenotypic evidence of involvement by patient's known Follicular lymphoma is seen, focal markedly crushed lymphoid aggregates are noted. CD3 stains numerous T cells in these lymphoid aggregates and CD20 stains fewer cells where as PAX5 is negative. The significance of these aggregates is not known. 

The case was reviewed by Dr. Mikhail Roshal, who concurs with the interpretation.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular (70-80%)
M:E ratio: Inverted
Blasts: Not overtly increased
Myeloid lineage: Reduced with left shifted maturation
Erythroid lineage: Increased with left shifted maturation 
Megakaryocytes: Adequate to mildly increased with subset of small hypolobated atypical forms
Lymphocytes: Scattered with focal markedly crushed lymphoid aggregate noted
Plasma cells: Scattered
Special stain: Reticulin stain shows no significant increase in reticulin fibrosis

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate / hypercellular

Blasts                4%
Promyelocytes           2%
Myelocytes           2%
Metamyelocytes           1%
Neutrophils/Bands      6%
Eosinophils           7%
Basophils           1%
Erythroid Precursors      72%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           0.3

Special stain 
Iron: Markedly Increased
Ring sideroblasts: Present >15% 

Morphology: Spicular aspirate specimens show trilineage hematopoiesis with no increase in blasts. The myeloid lineage is decreased and shows left shifted maturation with increase in eosinophilic forms. The erythroid lineage shows marked dyspoiesis (nuclear irregularity and budding, bi/multinucleation, karyorrhexis). Megakaryocytes show a subset of dyspoietic forms (small hypolobated forms).

IMMUNOHISTOCHEMISTRY
CD3 stains numerous T cells in the markedly crushed lymphoid aggregate and CD20 stains fewer cells where as PAX5 was negative in the crushed lymphoid aggregate.
In other areas, CD20 and PAX5 highlight few scattered B cells. CD3 labels scattered T-cells.
CD61 stains megakaryocytes with a subset of small hypolobated forms.
CD34 shows no increase in blasts, <5% of cellularity
CD117 stains blasts, early erythroid and myeloid precursors and few scattered mast cells.
CD71 stains increased erythroid lineage

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-9365) 
1. No abnormal B cell population detected. Few Mature B cells seen. 
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified

2. Abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 6.0% of WBC
Basophilia is seen, 1.9% of WBC

Immunophenotype:
Abnormal: CD11b (bimodal - negative, intermediate), CD13 (dim), CD25
(partial), CD38 (dim), CD56 (partial), CD117 (uniform - intermediate)
Normal: CD4, CD33, CD34, CD45, CD71, CD123, HLA-DR
Negative: CD2, CD5, CD7, CD14, CD15, CD16, CD19, CD64

Number of cells acquired: 187 thousand

PERIPHERAL BLOOD
CBC (09/21/2021):
WBC 7.6 [4.0-11.0 K/mcL] 
RBC 3.50 L [3.80-5.00 M/mcL] 
HGB 9.9 L [11.2-15.4 g/dL] 
HCT 32.2 L [34.3-46.0 %] 
MCV 92 [80-98 fL] 
MCH28.3 [27.0-33.0 pg] 
MCHC 30.7 L [31.0-36.5 g/dL] 
RDW 27.9 H [12.2-15.1 %] 
Platelets 74 L [160-400 K/mcL] 

Neutrophil 64.0 [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 7.0 H [0.0-4.9 %] 
Baso 5.0 H [0.0-1.5 %] 
Myelocyte 3.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 14.0 [12.2-47.4 %] 
Nucleated RBC 9.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 4.9 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.5 [0.0-0.7 K/mcL] 
Absolute Basophil 0.4 H [0.0-0.2 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Basophilia, increased in left shifted forms with occasional hypogranular forms.
RBC: Moderate anisopoikilocytosis, moderate increase in polychromatic forms with few nucleated RBCs.
PLT: Thrombocytopenia with occasional large forms. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-6123.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-39507.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-6260;S11;MSK2 - 2023-06-06 01.59.34.ndpi,Peripheral Blood Smear,2023-06-06,"HCL
Treated in 2013; blood counts decreasing; assess for released HCL
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Hairy cell leukemia, 90% involvement by CD20 immunohistochemistry. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Variably cellular, up to 70-80%
M:E ratio: Within normal limits
Blasts: No blasts are seen
Myeloid lineage: Rare myeloid cells noted.
Erythroid lineage: Rare erythroid progenitors noted.
Megakaryocytes: Present with unremarkable morphology
Lymphocytes: Atypical lymphocytes with abundant cytoplasm, replacing marrow cellularity. 
Plasma cells: Scattered

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Neutrophils/Bands      15%
Monocytes           1%
Erythroid Precursors      3%
Plasma Cells           1%
Lymphocytes           20%
Hairy cells           60%
Number of Cells Counted 500
M:E Ratio           5.3 

Morphology:
Paucispicular and cellular smears show abundant atypical lymphoid cells with ample, delicate cytoplasm, round to slightly irregular centrally placed nuclei, condensed chromatin and small nucleoli. Rare myeloid and erythroid progenitors, as well as megakaryoctes are seen. No overt dyspoietic features are seen.

PERIPHERAL BLOOD
CBC (08/26/2021):
WBC 1.4 L [4.0-11.0 K/mcL] 
RBC 2.79 L [3.80-5.00 M/mcL] 
HGB 9.9 L [11.2-15.4 g/dL] 
HCT 29.7 L [34.3-46.0 %] 
MCV 107 H [80-98 fL] 
MCH 35.5 H [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 13.8 [12.2-15.1 %] 
Platelets 99 L [160-400 K/mcL] 

Neutrophil 61.1 [32.5-74.8 %] 
Mono 7.6 [0.0-12.3 %] 
Eos 2.8 [0.0-4.9 %] 
Baso 0.7 [0.0-1.5 %] 
Immature Granulocyte 0.7 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 27.1 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Neutropenia. Lymphopenia. Rare atypical lymphoid cells present.
RBC: Macrocytic anemia.
PLT: Moderate thrombocytopenia.

IMMUNOHISTOCHEMISTRY
CD20 highlights the aypical lymphoid cells, comprising approximately 90% of marrow cellularity. 
BRAF V600E shows weak cytoplasmic staining in neoplastic cells. 
CD3 highlights background T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-8296)
Abnormal B cell population with larger size detected.
Abnormal B cell population of WBC: 22.7 %  

Abnormal: CD10 (positive), CD19 (bright), CD20 (bright), CD22 (bright), CD25 (positive), surface Lambda (restriction), Forward Scatter (increased), Side Scatter (increased), CD11c (bright), CD103 (bimodal - negative, intermediate), CD200 (bright)
Normal: CD45
Negatives: CD5, CD38, CD279 (PD1), CD3, CD14, surface Kappa

No abnormal T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5480.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-35173, M21-35174, M21-35175, M21-35194.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-9206;S10;MSKD - 2023-05-19 15.55.42.ndpi,Peripheral Blood Smear,2023-05-19," Clinical Diagnosis: Lymphoma
Clinical Hx/Op Findings: concern for POD/transformation
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by large B-cell lymphoma (~30% with CD20/PAX5 immunohistochemistry).

COMMENT: The immunophenotype is similar to that of the large B-cell lymphoma demonstrated in a recent left retroperitoneal biopsy (H21-9192), including a non-germinal center B-cell like phenotype (Hans algorithm). A definitive low-grade B-cell lymphoma component is not identified in this sample.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate but fragmented core biopsy and adequate, spicular and cellular aspirate smears show cellular bone marrow (~80-90% cellularity within the fragmented marrow spaces present). There ismaturing trilineage hematopoiesis with an atypical lymphoid infiltrate in a nodular to diffuse growth pattern composed predominantly of intermediate to large sized lymphoid cells with rounded to irregular nuclei, dispersed chromatin and small nucleoli.Admixed mitotic figures and apoptotic debris are noted. Myeloid and erythroid elements show progressive maturation. Occasional erythroid precursors showing nuclear irregularity/budding are noted. Megakaryocytes are adequate to mildly increased number.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

IMMUNOHISTOCHEMISTRY
The neoplastic lymphoid cells
Express: CD20, PAX5, BCL6 (partial, weak, likely due to decalcification), MUM1, BCL2, LEF1
Do not express: CD3, CD10, CD5, CD23, cyclin D1
Other: Ki-67 proliferation index is ~80-90% within the atypical lymphoid infiltrate. CD23 shows focal follicular dendritic cell meshworks associated with the lymphoid infiltrate. No p53 overexpression is seen in the decalcified sample. CD138 highlights scattered plasma cells, which show a mild lambda predominance with kappa and lambda immunostains. CD34 shows no increase in blasts (<5% of cellularity). CD71 and myeloperoxidase highlight erythroid and myeloid elements, respectively. CD61 highlights an adequate to mildly increased number of megakaryocytes of variable size. CD3 highlights background small T cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-12228) 
Interpretation: 
1. Abnormal B cell population detected.
The immunophenotype of this abnormal B cell population is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

Abnormal B cell population represents 21.9% of WBC.

Immunophenotype:
Abnormal: CD5 (partial - dim), CD19 (dim), CD22 (variable  dim to bright), surface Lambda (restriction)
Normal: CD20, CD38, CD45
Negative: CD10, CD25, CD279 (PD1), CD3, CD14, surface Kappa

2. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 384 thousand  

Also see F21-12210 submitted on the same day.

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

PERIPHERAL BLOOD
CBC (12/08/2021):
WBC 4.6 [4.0-11.0 K/mcL] 
RBC 2.97 L [3.80-5.00 M/mcL] 
HGB 7.0 L [11.2-15.4 g/dL] 
HCT 24.6 L [34.3-46.0 %] 
MCV 83 [80-98 fL] 
MCH 23.6 L [27.0-33.0 pg] 
MCHC 28.5 L [31.0-36.5 g/dL] 
RDW 17.8 H [12.2-15.1 %] 
Platelets 166 [160-400 K/mcL] 

Neutrophil 41.0 [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Lymph 16.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 34.0 H [0.0-0.0 %] 
Nucleated RBC 1.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.9 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Lymph 2.3 [0.9-3.2 K/mcL] 

Morphology:
WBC: Occasional myelocytes and metamyelocytes. The lymphoid cells are mostly small to intermediate in size with condensed chromatin and inconspicuous nucleoli.
RBC: Normocytic anemia.
Platelets: Adequate with unremarkable morphology.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-8048.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-50965.

"
H21-2525;S2;MSKS - 2023-05-22 12.06.12.ndpi,Peripheral Blood Smear,2023-06-01,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate, and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma.

 COMMENT:
Correlation with pending cytogenetic and molecular studies is recommended.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                85%
Promyelocytes           1%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      3%
Erythroid Precursors      7%
Plasma Cells           1%
Lymphocytes           1%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
-Spiculate and hypercellular smears contain sheets of blasts. The blasts are small with scant cytoplasm, irregular nuclear borders, and fine chromatin. There are a few scattered background myeloid and erythroid elements, which are too infrequent to adequately assess for dysplasia in either of these lineages. Megakaryocytes are rare.

PERIPHERAL BLOOD
CBC (04/07/2021):
WBC 2.4 L [7.1-15.9 K/mcL] 
RBC 2.70 L [2.93-4.75 M/mcL] 
HGB 7.2 L [8.9-12.7 g/dL] 
HCT 23.5 L [26.8-37.8 %] 
MCV 87 H [70-85 fL] 
MCH 26.7 [22.7-29.5 pg] 
MCHC 30.6 L [31.0-36.5 g/dL] 
RDW 17.3 H [12.2-15.1 %] 
Platelets 223 [160-400 K/mcL] 

Neutrophil 15.0 L [16.9-74.5 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 15.0 H [0.0-0.0 %] 
Lymph 69.0 [18.1-79.9 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.4 L [1.5-8.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.4 H [0.0-0.0 K/mcL] 
Abs Lymph 1.6 [1.1-8.1 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBC: Leukopenia. Occasional circulating blasts are present.
RBC: Normochromic anemia with mild anisocytosis.
Platelets: Morphologically unremarkable

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-3312)
Abnormal immature B-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified.
No abnormal mature B- or T-cell populations detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow (69.9% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression CD10 (dim to bright), CD13 (partial), CD24 (dim), CD33 (partial), CD34 (mostly absent), CD38 (dim), CD45 (absent to dim), CD66c/CD123, CD81 (absent to dim) with normal expression of CD19, CD22, CD71 and HLA-DR; and without CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD20, CD56, CD64, CD66b, CD86, CD117, CD73/CD304 or surface light chains.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.19% of WBC. 236 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-2194.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-13815.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. Pessin MD., PhD., Director.
"
H21-6237;S11;MSKW - 2023-06-06 01.53.36.ndpi,Peripheral Blood Smear,2023-06-06,"Leukemia Work-up. Blasts in peripheral blood. 
","1-3. Bone marrow, right posterior iliac crest,biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 (35% blasts by differential count).

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: 70%
M:E ratio: Slightly increased
Blasts: Increased in number, scattered in the interstitium and forming small to medium-sized aggregates
Myeloid lineage: Left-shifted but complete maturation
Erythroid lineage: Complete maturation
Megakaryocytes: Decreased in number, including small forms with hypolobated nuclei
Lymphocytes: Not increased
Plasma cells: Not increased
Special stains: Reticulin stain shows no significant increase in reticulin fibrosis (MF-0). 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate

Blasts                35%
Promyelocytes           3%
Myelocytes           10%
Metamyelocytes           6%
Neutrophils/Bands      20%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      14%
Plasma Cells           1%
Lymphocytes           7%
Number of Cells Counted      500
M:E Ratio           3.1

Morphology:
Spicular and hypercellular bone marrow aspirate smears. Blasts are markedly increased in number, with round nuclei, dispersed chromatin, prominent nucleoli, scant to moderately abundant cytoplasm with frequent perinuclear clearing. Erythroid precursors show left-shifted but complete maturation. Megakaryocytes are present with overall normal morphology and rare small forms.

PERIPHERAL BLOOD
CBC (08/25/2021):
WBC 3.8 L [4.0-11.0 K/mcL] 
RBC 3.09 L [3.80-5.00 M/mcL] 
HGB 9.9 L [11.2-15.4 g/dL] 
HCT 28.8 L [34.3-46.0 %] 
MCV 93 [80-98 fL] 
MCH 32.0 [27.0-33.0 pg] 
MCHC 34.4 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 34 L [160-400 K/mcL] 

Neutrophil 25.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 42.0 H [0.0-0.0 %] 
Myelocyte 4.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 25.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 1.6 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology: Pancytopenia. Occasional circulating blasts are seen. A subset of granulocytes shows hypogranular cytoplasm.

IMMUNOHISTOCHEMISTRY
Immunostains show markedly increased number of CD34+, CD117+ blasts scattered in the interstitium and forming small to medium-sized aggregates. Blasts account for 30-40% of total cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-8268)
Expanded abnormal myeloid blast population detected.
Myeloid blast population of WBC: 34.8 %  

Abnormal: CD13 (variable - negative, dim), CD15 (bimodal - negative, dim), CD19 (partial - dim), CD33 (variable - negative, bright), CD34 (bright), CD38 (intermediate), CD56 (uniform - bright), CD117 (variable - negative, bright), CD123 (bright), HLA-DR (variable - dim, bright), cytoplasmic CD79a (partial), cytoplasmic MPO (uniform - bright)
Normal: CD4, CD45, CD71
Negative: CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD16, CD20, CD22, CD25, CD26, CD64, cytoplasmic CD3, Surface Kappa, Surface Lambda

Abnormal maturing granulocyte population detected. Very few monocytes seen.
Abnormal: CD56 (uniform - bright)
Normal: CD13, CD15, CD16, CD33, CD38, CD64
Negative: CD14

No abnormal B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

No abnormal T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of Cells Acquired: 448 thousand.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-8238)
Expanded abnormal myeloid blast population detected. 
Myeloid blast population of WBC: 43.1 %, diagnostic for AML

Abnormal: CD7 (partial - dim), CD11b (partial - dim), CD13 (variable - dim, intermediate), CD19 (partial), CD33 (variable - negative, dim), CD34 (bright), CD56 (positive), CD117 (variable - dim, bright), cytoplasmic CD79a (partial) Normal: CD4, CD38, CD45, CD71, CD123, HLA-DR, cytoplasmic MPO (uniform)
Negative: CD2, CD3, CD5, CD8, CD10, CD14, CD15, CD16, CD20, CD22, CD25, CD26, CD64, cytoplasmic CD3, Surface Kappa, Surface Lambda

No abnormal B cell population detected. No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

No abnormal T cell population detected. No immunophenotypic evidence of T-cell lymphoma is identified.

CYTOGENETIC STUDIES
Concurrent cytogenetic analysis showed presence of with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 rearrangement.. See separate report, CG21-5442.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-35002, M21-35003, M21-35004, M21-35005, M21-35006, M21-35039, M21-35040.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-182;S10;MSKY - 2023-05-19 23.04.30.ndpi,Peripheral Blood Smear,2023-05-19,"ALL
T-ALL, untreated, newly diagnosed 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - T-lymphoblastic leukemia/lymphoma (T-ALL), 50% blasts by aspirate differential count. 
  
BONE MARROW BIOPSY
Quality: Adequate but shows partial aspiration artifact
Cellularity: Hypercellular for age (~90% cellularity)
M:E ratio: N/A
Blasts: Increased interstitial clusters of intermediate-sized blasts
Myeloid lineage: Shows left-shifted progressive maturation     
Erythroid lineage: Shows progressive maturation     
Megakaryocytes: Adequate in number and show predominantly unremarkable morphology     
Lymphocytes: Not increased
Plasma cells: Not increased

BONE MARROW ASPIRATE SMEAR/ TOUCH IMPRINTS
Differential: (Performed by HM)

Blasts                50%
Promyelocytes           2%
Myelocytes           8%
Metamyelocytes           5%
Neutrophils/Bands      16%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      12%
Plasma Cells           1%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
The aspirate smears are spicular and cellular demonstrating increased number of variably sized (predominantly small to intermediate-sized and occasionally large) blasts with round to oval nuclei, dense chromatin, conspicuous single or multiple nucleoli and small to moderate amount of lightly basophilic agranular cytoplasm with occasional vacuoles. The myeloid elements show left-shifted progressive maturation with no significant dyspoiesis. Erythroid elements show progressive maturation with no significant dyspoiesis. Megakaryocytes are present and show mostly unremarkable morphology. Touch imprints are also cellular and show similar findings as the aspirate smears.

PERIPHERAL BLOOD
CBC (01/08/2021):
WBC 9.2 [4.0-11.0 K/mcL] 
RBC 4.69 [3.95-5.54 M/mcL] 
HGB 14.3 [12.5-16.2 g/dL] 
HCT 41.9 [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 30.5 [27.0-33.0 pg] 
MCHC 34.1 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 288 [160-400 K/mcL] 

Neutrophil 60.0 [32.5-74.8 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 18.0 H [0.0-0.0 %] 
Lymph 15.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 5.5 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 1.7 H [0.0-0.0 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 2 [/100(WBCs)] 

Morphology:
WBCs: Many blasts (predominantly intermediate-sized) are seen that are morphologically similar to the aspirate smears. 
RBCs: Normocytic normochromic RBCs. 
Platelets: Unremarkable morphology.     

IMMUNOHISTOCHEMISTRY
CD34 and TdT highlight increased interstitial clusters of blasts (~40% of cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-242)
T-lymphoblastic leukemia/lymphoma.

The presence of greater than 20% abnormal immature T-cells in the peripheral blood and/or marrow (41.3% of the total white cells) is diagnostic for T-lymphoblastic leukemia/lymphoma (T-ALL) by WHO criteria. The blasts have abnormal expression of surface CD3 (negative), cytoplasmic CD3, CD7 (bright), CD11b (partial), CD19 (small subset dim), CD34 (dim), CD38 (bright), CD45 (dim), CD48 (negative), CD56, CD71, cytoplasmic CD79a (subset dim), CD117 (subset dim), CD123 (subset dim); with normal expression of CD2, CD5; and without CD4, CD8, CD10, CD13, CD14, CD15, CD16, CD20, CD25, CD26, CD33, CD64, CD279 (PD1), T-cell receptor gamma/delta, HLA-DR or MPO.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-153.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-1078, M21-1079, M21-1080.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-2678;S13;MSK3 - 2023-06-01 06.22.19.ndpi,Peripheral Blood Smear,2023-06-01,"MCL
Neutropenia, ANC 0.0
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Extensive involvement by mantle cell lymphoma (~80-90% with CD20 immunohistochemistry).
     - Background marrow with megakaryocytic hyperplasia, and myeloid and erythroid hypoplasia and a rare granuloma. See comment.

COMMENT: The etiology of myeloid and erythroid hypoplasia and peripheral blood cytopenias is not entirely clear. The peripheral blood shows an absolute neutrophil count (ANC) of 0, which is highly unusual. This finding at least in part may be due to the extensive marrow replacement by mantle cell lymphoma. However, as the pre-treatment marrow (H21-2409; 4/2/2021) also showed a similar level of involvement but with a normal ANC and hemoglobin, the cytopenias at this time point are likely related to recent ibrutinib/venetoclax chemotherapy. Other etiologies, such autoimmune processes cannot entirely be excluded. Overall, these findings are favored to be reactive and there is no overt evidence of a myeloid neoplasm. Close clinical follow-up is advised.

The lymphoid work-up was performed and reviewed by Dr. Ahmet Dogan (Chief, Hematopathology service).


BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
The bone marrow biopsy and aspirate smears are hypercellular for age (~80% cellularity) and show a diffuse interstitial infiltrate of atypical small to intermediate sized lymphoid cells with slightly irregular nuclei, clumped chromatin, occasional inconspicuous nucleolus and small amount of cytoplasm. Myeloid and erythroid elements are markedly decreased to absent. Megakaryocytes appear increased in number forming occasional loose clusters and show occasional atypical forms with widely separated nuclear lobes. A rare focus shows clusters of epithelioid histiocytes with admixed small lymphocytes and are eosinophils. Touch imprints are cellular and show similar findings.

Aspirate differential: (Performed by HM)

Blasts                1%
Monocytes           1%
Eosinophils           1%
Lymphocytes           97%
Number of Cells Counted 500
M:E Ratio           N/A

Special stain:
Iron: Absent
Ring sideroblasts: Suboptimal for evaluation due to absent of erythroid elements.

IMMUNOHISTOCHEMISTRY
The neoplastic cells 
Express: CD20, CD5 (few cells), cyclin D1
Do not express: CD3, SOX-11
Other: CD3 highlights small T-cells in the background. 
CD61 highlights increased number of megakaryocytes.
CD117 highlights scattered mast cells and rare early erythroid and myeloid precursors.
CD34 immunostain shows no increase in blasts (<5% of cellularity).
MPO and CD71 highlight rare myeloid and erythroid elements, respectively.
GMS and AFB stains do not highlight any fungal organisms or acid-fast bacilli, respectively.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-3558) 
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5 (partial), CD20 (dim to intermediate), CD23 (partial dim), CD79b (negative to intermediate), CD81 (dim), CD200 (subset), ROR1 (partial), and lambda light chain restriction (dim to intermediate); normal expression of CD19, CD22, CD38, CD40, CD81, and CD45; and without CD3, CD10, CD25, CD43 or CD279 (PD1). The abnormal B cell population represents 81.0% of total white cells.

PERIPHERAL BLOOD
CBC (04/14/2021):
WBC 1.2 L [4.0-11.0 K/mcL] 
RBC 2.85 L [3.95-5.54 M/mcL] 
HGB 8.7 L [12.5-16.2 g/dL] 
HCT 27.7 L [37.5-49.3 %] 
MCV 97 [80-98 fL] 
MCH 30.5 [27.0-33.0 pg] 
MCHC 31.4 [31.0-36.5 g/dL] 
RDW 12.5 [12.2-15.1 %] 
Platelets 63 L [160-400 K/mcL] 

Neutrophil 0.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 
Lymph 91.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 

Morphology:
WBCs: Neutrophils are virtually absent. Relative lymphocytosis comprised of mostly small and intermediate sized atypical lymphoid cells with clumped chromatin. 
RBCs: Normocytic normochromic anemia. 
Platelets: Thrombocytopenia; unremarkable morphology.     

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-2344.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-14951, M21-14954, M21-14958.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-8887;S12;MSK0 - 2023-05-19 16.28.55.ndpi,Peripheral Blood Smear,2023-05-19,"Clinical Diagnosis: Myelodysplastic Syndrome
Clinical Hx/Op Findings: MDS
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Myelodysplastic syndrome with multilineage dysplasia (MDS-MLD), 4% blasts by aspirate differential count. 
     - Minute abnormal B-cell population with a chronic lymphocytic leukemia/small lymphocytic lymphoma-like phenotype detected by flow cytometry only (0.012% of WBC).

BONE MARROW BIOPSY
Quality: Adequate with some fragmentation and aspiration artifact
Cellularity: Hypercellular for age (~60-70%) 
M:E ratio: Increased
Blasts: Not overtly increased
Myeloid lineage: Increased with left-shifted maturation 
Erythroid lineage: Relatively reduced with full maturation
Megakaryocytes: Present with dysplastic morphology (small, hypolobated forms, micromegakaryocytes, separated nuclear lobes; >10%; best seen with CD61 immunohistochemistry described below)
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows no significant increase in reticulin fibrosis 

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality:  Adequate
Blasts                4%
Promyelocytes           2%
Myelocytes           18%
Metamyelocytes           16%
Neutrophils/Bands      33%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      15%
Plasma Cells           1%
Lymphocytes           8%
Number of Cells Counted      500
M:E Ratio           5.1

Special stain
Iron: Present
Ring sideroblasts: Absent 

Morphology:
Spicular and cellular aspirate smears show myeloid-predominant maturing trilineage hematopoiesis with no increase in blasts. Myeloid elements are increased and show left-shifted maturation with frequent atypical/dysplastic forms (hyposegmentation, atypical chromatin pattern, hypogranulation, cytoplasmic vacuolization, Dohle bodies; >10%). Erythroid precursors are relatively reduced and are seen at various stages of maturation with occasional dysplastic forms (nuclear irregularity/budding, binucleation, megaloblastoid change; ~10%). Megakaryocytes are present and show dysplastic morphology (small, hypolobated forms, micromegakaryocytes, separated nuclear lobes; >10%). 

PERIPHERAL BLOOD
CBC (11/29/.2021):
WBC 3.4 L [4.0-11.0 K/mcL] 
RBC 2.78 L [3.80-5.00 M/mcL] 
HGB 9.9 L [11.2-15.4 g/dL] 
HCT 29.7 L [34.3-46.0 %] 
MCV 107 H [80-98 fL] 
MCH 35.6 H [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 16.4 H [12.2-15.1 %] 
Platelets 87 L [160-400 K/mcL] 

Neutrophil 32.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 17.0 H [0.0-0.0 %] 
Lymph 50.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 1.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.6 H [0.0-0.0 K/mcL] 
Abs Lymph 1.7 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)]

Morphology:
WBC: Absolute neutropenia with occasional myelocytes. Frequent myeloid elements with atypical/dysplastic morphology similar to that in the aspirate smears seen. No definitive circulating blasts identified.
RBC: Macrocytic anemia.
PLT: Thrombocytopenia.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
CD34 highlights blasts scattered singly and in rare minute clusters, comprising <5% of marrow cellularity. CD117 highlights blasts and early myeloid/erythroid precursors as well as rare mast cells. Myeloperoxidase and CD71 highlight myeloid and erythroid elements, respectively, with an increased M:E ratio. CD61 highlights megakaryocytes with frequent small forms and micromegakaryocytes.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-11786)
Interpretation: 
1. Abnormal myeloid blast population detected.

Abnormal myeloid blast population represents 2.7% of WBC.

Immunophenotype:
Abnormal: CD5 (partial), CD11b (partial), CD13 (uniform - bright), CD33 (variable - negative, dim), CD34 (uniform - intermediate), CD38 (variable - negative, dim), CD45 (dim), CD117 (uniform - bright)
Normal: CD4, CD71, CD123, HLA-DR
Negative: CD2, CD3, CD7, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD26, CD56, CD64, surface Kappa, surface Lambda

Number of cells acquired: 436 thousand  

2. Small abnormal B cell population detected. 
Flow cytometry reveals an abnormal B cell population with CLL/SLL-like immunophenotype (see below).

Abnormal B cell population represents 0.012% of WBC.

Immunophenotype:
Abnormal: CD5 (positive), CD20 (dim), CD22 (dim), CD43 (positive), CD79b (dim), CD81 (dim), CD200 (negative), ROR1 (positive), surface Kappa (restriction - dim)
Normal: CD19, CD40, CD45
Negative: CD23, CD38, CD10, CD3, surface Lambda

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-7779.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-49255, M21-49257, M21-49258, M21-49259.
"
H21-5644;S12;MSKY - 2023-06-06 01.35.54.ndpi,Peripheral Blood Smear,2023-06-06,"MDS with dendritic cell component
MDS s/p 2 cycles of azacytidine
Assess status of disease
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistence involvement by Myelodysplastic Syndrome (<5% Blasts by aspirate differential counts)
     - Markedly Hypercellular marrow with maturing trilineage hematopoiesis, multilineage dysplasia, increased ring sideroblasts, and no increase in blasts

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly Hypercellular (>90% cellularity)
M:E ratio: Decreased/inverted
Blasts: Not increased
Myeloid lineage: Relatively decreased with marked left shifted progressive maturation. 
Erythroid lineage: Relatively increased, with Marked left shifted progressive maturation
Megakaryocytes: Adequate in numbers with frequent dysplastic small hypolobated forms and some nuclear lobe separation.
Lymphocytes: Scattered
Plasma cells: Scattered

Special stains: 
Reticulin stain shows no significant increase in reticulin fibrosis (0/3). 

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate
Blasts                1%
Myelocytes           3%
Metamyelocytes           2%
Neutrophils/Bands      11%
Monocytes           2%
Eosinophils           1%
Erythroid Precursors      73%
Plasma Cells           1%
Lymphocytes           6%
Number of Cells Counted 500
M:E Ratio           0.3

Special stain
Iron: Present
Ring sideroblasts: Present (>15% of erythroid elements)

Morphology:
Spicular and cellular smears showing trilineage maturing hematopoiesis with markedly decreased myeloid/erythroid ratio, and no increase in blasts. Myeloid elements are relatively decreased and show mildly left shifted progressive maturation with frequent dysplastic forms (hypogranular and pseudo Pelger-Huet forms). No Auer rods are seen. Erythroid elements are increased, and show marked left shifted maturation with frequent dysplastic forms (nuclear irregularity and budding, nuclear-cytoplasmic dyssynchrony, ring sideroblasts, megaloblastoid changes, binucleation). Megakaryocytes are present and show frequent dysplastic small and hypo/monolobated forms. Scattered small and mature-appearing lymphocytes are present. 

PERIPHERAL BLOOD
CBC (8/3/2021):
WBC 3.0 L [4.0-11.0 K/mcL] 
RBC 2.59 L [3.95-5.54 M/mcL] 
HGB 7.7 L [12.5-16.2 g/dL] 
HCT 23.4 L [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 32.9 [31.0-36.5 g/dL] 
RDW 22.0 H [12.2-15.1 %] 
Platelets. 98 L [160-400 K/mcL] 

Neutrophil 33.0 [32.5-74.8 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 57.0 H [12.2-47.4 %] 
Nucleated RBC 6.0 H [0.0-0.0 /100(WBCs)] 

Abs Neut 1.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.7 [0.9-3.2 K/mcL]

Morphology:
WBC: No circulating blasts. Mild leukopenia and absolute neutropenia with left-shifted granulocytes, showing some dysplastic forms (hypogranular and occasional pseudo-Pelger Huet forms present).
RBC: Normocytic, normochromic anemia with moderate anisopoikilocytosis. Scattered nucleated RBCs seen.
PLT: Thrombocytopenia. Few large hypogranular forms. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts (<5% marrow cellularity).
CD117 also highlights mildly increased left shifted myeloid/erythroid precursors, as well as scattered mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7646)
Interpretation: 
Abnormal myeloid blast population detected. 
Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD13(dim), HLA-DR(bright) with normal expression of CD4, CD33, CD34, CD38, CD45, CD71, CD117, CD123 without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64. CD34 positive myeloid blasts represent 1.3% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-4928.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-31757.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H21-1611;S12;MSKO - 2023-05-19 22.08.08.ndpi,Peripheral Blood Smear,2023-05-19,"MDS
Patient with MDS on observation 
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears:  
     - Hypercellular marrow with erythroid predominant trilineage hematopoiesis, multilineage dysplasia, increased ring-sideroblasts and thrombocytosis, consistent with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
  
COMMENT: Patient's persistent anemia (since 2018) and thrombocytosis (since 2019) are noted. Mutations of SF3B1, DNMT3A and TET2 were detected on prior peripheral blood (01/2019, M19-834) and JAK2 V617F mutation was reported on peripheral blood from 04/08/2020 by outside molecular study. Current biopsy shows hypercellular marrow with trilineage dysplasia and increased ring-sideroblasts (>15%). The overall findings are most consistent with a diagnosis of MDS/MPN-RS-T. Please also correlate with forthcoming molecular and cytogenetic studies for the further characterization.  

This case was also reviewed by Dr. Filiz Sen in Hematopathology Service.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Overall hypercellular (~80%) with focal hypocellular areas (~10%)
M:E ratio: Decreased 
Blasts: Not increased 
Myeloid lineage: Exhibit left shifted maturation 
Erythroid lineage: Exhibit left shifted maturation
Megakaryocytes: Increased and focally clustered; with frequent dysplastic forms (>10%, small mono/hypolobated or abnormal nuclear lobation)
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Blasts                2%
Promyelocytes           3%
Myelocytes           10%
Metamyelocytes           7%
Neutrophils/Bands      15%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      51%
Plasma Cells           2%
Lymphocytes           7%
Number of Cells Counted 500
M:E Ratio           0.7

Special stain
Iron: Present.
Ring sideroblasts: Increased, >15% 

Morphology:
Spicular and hypercellular aspirate smears show erythroid predominant trilineage hematopoiesis with no increased blasts. Myeloid elements are relatively decreased and show left shifted maturation with dyspoiesis (>10%, hyposegmentation and hypogranularity). Erythroid elements are increased and show left shifted maturation with dyspoiesis (>10%, nuclear-cytoplasmatic dyssynchrony, ring-sideroblasts and megaloblastoid change). Megakaryocytes are increased and show dyspoiesis (small hypolobated or widely separated nuclei). Scattered mast cells are present in the background. 

PERIPHERAL BLOOD
CBC (03/04/2021):
WBC 7.3 [4.0-11.0 K/mcL]
RBC 2.79 L [3.80-5.00 M/mcL]
HGB 9.0 L [11.2-15.4 g/dL]
HCT 28.4 L [34.3-46.0 %]
MCV 102 H [80-98 fL]
MCH 32.3 [27.0-33.0 pg]
MCHC 31.7 [31.0-36.5 g/dL]
RDW 27.4 H [12.2-15.1 %]
Platelets 706 H [160-400 K/mcL]

Neutrophil 53.6 [32.5-74.8 %]
Mono 12.3 [0.0-12.3 %]
Eos 2.3 [0.0-4.9 %]
Baso 1.6 H [0.0-1.5 %]
Immature Granulocyte 0.3 [0.0-0.6 %]
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 29.9 [12.2-47.4 %]
Nucleated RBC 0.0 [0.0-0.0 %]

Abs Neut 3.9 [1.5-7.5 K/mcL]
Abs Mono 0.9 [0.0-1.3 K/mcL]
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL]
Absolute Basophil 0.1 [0.0-0.2 K/mcL]
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL]
Abs Lymph 2.2 [0.9-3.2 K/mcL]

Morphology:
WBC: No circulating blasts; few hyposegmented neutrophils seen. 
RBC: Marked anisopoikilocytosis. 
PLT: Thrombocytosis with some large and hypogranular forms. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increased blasts (<5% marrow cellularity).
CD117 also highlights increased mast cells (~5-10% marrow cellularity), mostly interstitially scattered or focally aggregated (<15 cells/aggregate) without atypical morphology.
CD117 also highlights erythroid precursors. 
MPO highlights decreased myeloid elements.
CD71 highlights increased erythroid elements. 
CD61 highlights increased megakaryocytes including dysplastic forms.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-2152)
Abnormal myeloid blast population detected. 
Basophilia noted (1.1% of WBC).
Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD5 (subset), CD7 (partial), CD34 (bright), CD117 (bright), with normal expression of CD4, CD13, CD33, CD38, CD45, CD71, CD123 and HLA-DR without CD2, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64. CD34 positive myeloid blasts represent 1.1% of WBC. 

No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-1424.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-8839, M21-8843, M21-8845. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-1589;S11;MSK1 - 2023-05-22 08.07.13.ndpi,Peripheral Blood Smear,2023-05-22,"AML. Newly diagnosed AML. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
     - Acute leukemia, most consistent with acute myeloid leukemia (AML), 70% blasts by aspirate differential count and 70-80% blasts by CD34 immunohistology. See comment.
     - Hypercellular marrow with decreased maturing trilineage hematopoiesis.
  
COMMENT: Per clinical information the patient has no history of prior chemo-radiation therapy. The abnormal blasts show predominantly myeloid maturation most consistent with AML, however additional B-lineage maturation (dim partial CD19, CD22, and dim partial CD79a) is noted and will be monitored in future samples. Correlation with cytogenetic analysis is required for final classification of this acute leukemia. Correlation with the forthcoming molecular studies is also advised.

Reviewed at Hematopathology service consensus conference on 3/5/21 with all in agreement.
Discussed and microscopy reviewed remotely with Dr. Jae Park, Department of Medicine on 3/5/2021.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Mildly hypercellular for age (90%)
M:E ratio: N/A
Blasts: Markedly increased occupying most of the marrow cellularity, present in sheets and large clusters. Blasts are large in size with irregular nuclei, fine chromatin, prominent central nucleoli, and scant to moderate amount of cytoplasm.
Myeloid lineage: Decreased
Erythroid lineage: Decreased
Megakaryocytes: Decreased with dysplastic forms (~50%) showing nuclear hyperchromasia, small size, and hyposegmented nuclei
Lymphocytes: Few, scattered
Plasma cells: Rare, scattered
Special stains: Reticulin special stain shows no increase in reticulin fibrosis (MF-0).

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Blasts                70%
Metamyelocytes           1%
Neutrophils/Bands      4%
Monocytes           1%
Erythroid Precursors      5%
Plasma Cells           1%
Lymphocytes           18%
Number of Cells Counted 500
M:E Ratio           1.2

Morphology:
Paucispicular and cellular aspirate smears with decreased maturing trilineage hematopoiesis and an expanded blast population. Blasts are intermediate to large in size, with round to irregular nuclei, fine chromatin, large central nucleoli, and scant to moderate amount of cytoplasm. Auer rods are not seen. Myeloid precursors are decreased. Granulocytic forms show dysplastic features including hypogranularity and pseudo-Pelger-Huet morphology. Erythroid precursors are decreased, show progressive maturation, with few megaloblastoid features and karyorrhexis. Rare megakaryocytes are seen.  Few small mature-appearing lymphocytes are seen.

PERIPHERAL BLOOD
CBC (03/03/2021):
WBC 1.9 L [4.0-11.0 K/mcL] 
RBC 2.49 L [3.95-5.54 M/mcL] 
HGB 8.7 L [12.5-16.2 g/dL] 
HCT 25.9 L [37.5-49.3 %] 
MCV 104 H [80-98 fL] 
MCH 34.9 H [27.0-33.0 pg] 
MCHC 33.6 [31.0-36.5 g/dL] 
RDW 17.3 H [12.2-15.1 %] 
Platelets 57 L [160-400 K/mcL] 

Neutrophil 9.0 L [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 3.0 H [0.0-1.5 %] 
Blast 59.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 23.0 [12.2-47.4 %] 
Variant Lymph 1.0 [0.0-2.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.2 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Blasts 1.1 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.5 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Frequent circulating blasts seen, which are large in size with round to elongated nuclei fine chromatin, large nucleoli, and scant to moderate amount of cytoplasm. Marked lymphopenia and neutropenia with hypogranularity and pseudo-Pelger-Huet forms. 
RBC: Macrocytic anemia with anisocytosis.
Platelets: Thrombocytopenia

IMMUNOHISTOCHEMISTRY
CD34 and CD117 are positive in blasts which account for 70-80% of the cellularity, present in large clusters interstitially.
A subset of the blasts also show weak expression of CD79a, and the blasts are overall negative for PAX5, CD19, and CD3.
There is no definite MPO expression in the majority of blasts.
PAX5 highlights rare scattered B-cells.
CD19 and CD79a highlight few scattered B-cells and plasma cells.
CD3 highlights few scattered T-cells.
Lysozyme highlights few scattered myelomonocytic cells, and expression in a small subset of the blasts cannot be excluded, although the majority are negative.
CD61 is positive in the megakaryocytes, which are decreased with small monolobated forms seen.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-2110)
Interpretation: 
Expanded abnormal myeloid blast population detected. 
Basophilia seen (1.5% of WBC).
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD7 (partial dim), CD19 (partial), CD25 (partial dim), CD56 (subset), cytoplasmic CD79a (partial), CD13 (uniform bright), CD33 (uniform dim), CD34 (uniform intermediate), CD117 (uniform slightly bright), CD123 (uniform intermediate), HLADR (bright) with normal expression of CD4, CD38, CD45, CD71; without CD2, surface CD3, cytoplasmic CD3, CD5, CD8, CD11b, CD14, CD15, CD16, CD20, CD64, or surface light chains. MPO expression is present on a subset of blasts. CD34 positive myeloid blasts represent 76.0% of WBC. The findings are similar to those seen in the peripheral blood sample F21-2078.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F21-2078)
Interpretation: 
Expanded abnormal myeloid blast population detected. 
Basophilia seen (4.2% of WBC).
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD7 (dim partial), CD19 (partial), CD25 (partial), CD56 (major subset), cytoplasmic CD79a (partial), CD13 (uniform bright), CD33 (uniform dim), CD34 (uniform intermediate), CD117 (dim to intermediate), CD123 (uniform intermediate), and HLA-DR (bright), with normal expression of CD4, CD38, CD45, CD71; without CD2, surface CD3, cytoplasmic CD3, CD5, CD8, CD11b, CD14, CD15, CD16, CD20, CD64, or surface light chains. MPO expression is present on a subset of blasts. CD34 positive myeloid blasts represent 45.8% of WBC. Although formally partial B-cell maturation is present (with expression of CD19 and cCD79a), overall these findings are diagnostic for acute myeloid leukemia (AML). Correlation with cytogenetic studies is advised to evaluate for the possibility of t(8;21) based on the immunophenotypic features.

No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.
132,297 cells acquired for B- and T-cell analysis.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-1397.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M21-8542, M21-8543, M21-8550-53.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

"
H21-444;S10;MSKZ - 2023-05-19 22.25.12.ndpi,Peripheral Blood Smear,2023-05-19,"Lymphoma. Relapsed refractory lymphoma last tx ibrutinib. Within 7 days prior to Chemo. Protocol #: 15-295. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by B cell lymphoma consistent with mantle cell lymphoma (~40% with CD20 immunohistochemistry).
     - Mildly hypercellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate core biopsy and aspirate specimens show mildly hypercellular bone marrow for age (approximately 30-40% cellularity) with maturing trilineage hematopoiesis and interstitially scattered and aggregates of atypical lymphocytes that are predominantly small to intermediate sized with irregular nuclei, moderately clumped chromatin, occasionally visible nucleolus and small amount of cytoplasm. Myeloid elements show left-shifted progressive maturation with no significant dyspoiesis. Erythroid elements are relatively increased and show progressive maturation with occasional dyspoiesis (<10% of lineage; nuclear irregularity, binucleation). Megakaryocytes are adequate in number and show mostly unremarkable morphology.

Aspirate differential: (Performed by HM)

Promyelocytes           3%
Myelocytes           6%
Metamyelocytes           5%
Neutrophils/Bands      7%
Eosinophils           3%
Erythroid Precursors      18%
Plasma Cells           1%
Abnormal Lymphoid Cells      57%
Number of Cells Counted 500
M:E Ratio           1.3

IMMUNOHISTOCHEMISTRY
The atypical lymphoid cells are positive for CD20 and PAX-5 (~40% cellularity).
CD3 highlights scattered and rare clusters of small T-cells.
P53 and Ki-67 immunostains are in progress and the results will be reported in an addendum.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-596) 
Abnormal B-cell population identified.
Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD19(dim), CD43, and ROR1; normal expression of CD20, CD22, CD38, CD40, CD79b, CD81, and CD45; and without CD3, CD10, CD23, or CD200.  The abnormal B cell population represents 75.7% of total white cells.
This immunophenotype is consistent with previously diagnosed mantle cell lymphoma (MCL).

PERIPHERAL BLOOD
WBC 22.6 H [4.0-11.0 K/mcL] 
RBC 3.81 L [3.95-5.54 M/mcL] 
HGB 12.9 [12.5-16.2 g/dL] 
HCT 40.5 [37.5-49.3 %] 
MCV 106 H [80-98 fL] 
MCH 33.9 H [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 14.1 [12.2-15.1 %] 
Platelets 84 L [160-400 K/mcL] 

Neutrophil 7.0 L [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 10.0 L [12.2-47.4 %] 
Abnormal Lymphoid Cells 78.0 H [0.0-0.0 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 1.6 [1.5-7.5 K/mcL] 
Abs Mono 1.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 19.9 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] CBC (01/09/2021):

Morphology:
WBCs: Absolute lymphocytosis comprised of intermediate sized atypical lymphocytes with irregular nuclei and conspicuous nucleoli. 
RBCs: Macrocytic RBCs. 
Platelets: Thrombocytopenia; unremarkable morphology.     

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-394.

MOLECULAR STUDIES 
Not requested/performed.     

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-9651;S2;MSKZ - 2023-05-19 16.45.46.ndpi,Peripheral Blood Smear,2023-05-19,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears:
     - Involvement by B-lymphoblastic leukemia/lymphoma.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate 
Blasts                85%
Myelocytes           3%
Neutrophils/Bands      2%
Erythroid Precursors      7%
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           0.7

Morphology:
-Spiculate and hypercellular smears show sheets of blasts. The blasts range in size from small to large, and have a scant-to-moderate amount of basophilic agranular cytoplasm, clefted nuclear borders, and fine chromatin. There are infrequent myeloid cells and occasional maturing erythroid precursors. Scattered morphologically unremarkable megakaryocytes are seen.

PERIPHERAL BLOOD
CBC (12/27/2021):
WBC 12.2 H [4.0-11.0 K/mcL] 
RBC 3.10 L [3.95-5.54 M/mcL] 
HGB 9.5 L [12.5-16.2 g/dL] 
HCT 29.8 L [37.5-49.3 %] 
MCV 96 [80-98 fL] 
MCH 30.6 [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 13.9 [12.2-15.1 %] 
Platelets. 174 [160-400 K/mcL] 

Neutrophil 9.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 52.0 H [0.0-0.0 %] 
Lymph 34.0 [12.2-47.4 %] 

Abs Neut 1.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.5 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 6.3 H [0.0-0.0 K/mcL] 
Abs Lymph 4.1 H [0.9-3.2 K/mcL]

Morphology:
WBC: Numerous circulating blasts. Scattered smudged cells. Occasional morphologically unremarkable granulocytes.
RBC: Normochromic, normocytic anemia. Infrequent circulating nucleated red cell precursors.
Platelets: Morphologically unremarkable.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. Pessin MD., PhD., Director.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-12834)
1. Abnormal immature B cell population detected.
An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously [F21-12703].

Abnormal immature B cell population represents 89.3% of the mononuclear cells.
Abnormal immature B cell population represents 88.3% of WBC.

Immunophenotype:
Abnormal: CD10 (bright), CD34 (variable - negative to bright), CD38 (dim), CD45 (variable - negative to intermediate), CD81 (dim), CD22 (dim), CD73/CD304 (positive), CD66c/CD123 (uniform - intermediate)
Normal: CD19, CD24
Negative: CD20, CD86, CD66b

Number of cells acquired 1.2 million

Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate reports, CG21-8450 and CG21-8460.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M21-53583, M21-53589, and M21-53673.


"
H21-5876;S10;MSKC - 2023-04-19 17.24.24.ndpi,Peripheral Blood Smear,2023-04-19,"DLBCL
Relapsed DLBCL; need good core
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
     - Extensive involvement by large B-cell lymphoma (~60-70% with PAX5 immunohistochemistry). See comment.

COMMENT: The findings most likely represent involvement by the patient's previously diagnosed high-grade B-cell lymphoma. Additional immunohistochemical studies will be performed for full immunophenotyping, which will be reported in an addendum. Correlation with the forthcoming cytogenetic and molecular studies is also suggested. 

BONE MARROW BIOPSY/ASPIRATE/TOUCH IMPRINT MORPHOLOGY
Adequate core biopsy with some crush artifact and cellular touch imprints show hypercellular bone marrow (~50-60% cellularity overall) with a diffuse atypical lymphoid infiltrate composed of intermediate to large sized cells with irregular nuclei, vesicular chromatin and distinct nucleoli. Scattered apoptotic bodies and mitotic figures are noted. Some background histiocytes and small lymphocytes are seen. Background trilineage hematopoiesis appears markedly reduced. Aspirate smears are aspicular, hypocellular and hemodilute and show predominantly peripheral blood elements with rare myeloid precursors and rare large atypical cells.

Bone Marrow Aspirate Smear Quality: Hemodiluted; devoid of spicules
Differential performed on Touch Prep Smear

Blasts               0%
Neutrophils/Bands      3%
Monocytes           1%
Erythroid Precursors      3%
Lymphocytes           93% (Many large atypical lymphoid cells with prominent nucleoli)
Number of Cells Counted  500
M:E Ratio           1.3

IMMUNOHISTOCHEMISTRY
The atypical lymphoid cells express PAX5 and CD20 (partial). CD3 highlights background T-cells.

Additional immunohistochemical studies are in progress and will be reported in an addendum.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-7789) 
Interpretation: 
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD10, CD19 (dim), CD20 (dim to negative), CD22 (bright), CD38 (uniform, intermediate), increased forward and side scatter suggestive of larger size, kappa light chain restriction, and normal expression of CD45; and without CD3, CD5, CD14, CD25, or CD279 (PD1). The abnormal B-cell population represents 8.8% of the total white cells. Morphologic correlation will be required to rule out large B-cell Lymphoma.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

PERIPHERAL BLOOD
CBC (8/11/2021)
WBC 4.9 [4.0-11.0 K/mcL] 
RBC 4.51 [3.95-5.54 M/mcL] 
HGB 12.3 L [12.5-16.2 g/dL] 
HCT 38.7 [37.5-49.3 %] 
MCV 86 [80-98 fL] 
MCH 27.3 [27.0-33.0 pg] 
MCHC 31.8 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 288 [160-400 K/mcL] 

Neutrophil 80.0 H [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 3.0 H [0.0-0.0 %] 
Lymph 7.0 L [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 3.9 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL]

Morphology: 
WBC: Occasional myelocytes and metamyelocytes. No definitive atypical lymphoid cells seen on scanning.
RBC: Normochromic, normocytic RBCs.
PLT: Rare small platelet clumps noted.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5116.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-32919.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-9456;S10;MSKA - 2023-05-19 15.27.27.ndpi,Peripheral Blood Smear,2023-05-19,"Requested Studies: Gross/Micro
Clinical Diagnosis: ALL, No Remission
Clinical Hx/Op Findings: 6 y/o with fatigue, newly diagnosed B-ALL
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B lymphoblastic leuekemia/lymphoma

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Largely replaced by blasts (normocellular for age, 90% cellular)
Megakaryocytes: Present


The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Cellular with only stromal elements

Blasts                85%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      1%
Eosinophils           1%
Erythroid Precursors      3%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           1.3

Morphology:
-Spicular and cellular, cellularity composed predominantly of small blasts. Very scant residual hematopoiesis present  


PERIPHERAL BLOOD
CBC (12/17/2021):
WBC 6.2 L [7.1-15.9 K/mcL] 
RBC 2.95 L [3.70-4.90 M/mcL] 
HGB 8.6 L [10.6-13.3 g/dL] 
HCT 27.3 L [32.4-40.4 %] 
MCV 93 H [74-91 fL] 
MCH 29.2 [22.7-29.5 pg] 
MCHC 31.5 [31.0-36.5 g/dL] 
RDW 21.6 H [12.2-15.1 %] 
Platelets. 252 [160-400 K/mcL] 


Morphology: Circulating blasts noted. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

IMMUNOHISTOCHEMISTRY
TdT highlights blasts, which are negative for CD34.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-12560)
1. Abnormal immature B cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.

Abnormal immature B cell population represents 47.1% of the mononuclear cells.
Abnormal immature B cell population represents 37.8% of WBC.

Immunophenotype:
Abnormal: CD10 (positive - bright), CD19 (dim), CD20 (partial), CD24 (bright), CD34 (partial) CD38 (uniform - dim), CD45 (dim), CD66c/CD123 (positive), CD73/CD304 (dim), CD81 (positive - dim), CD86 (partial), CD123 (positive)
Normal: CD22, CD71, HLA-DR, cytoplasmic CD79a
Negative: CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD25, CD26, CD33, CD56, CD64, CD66b, CD117, CD279 (PD1), TCR gamma/delta, cytoplasmic CD3, cytoplasmic MPO, surface Kappa, surface Lambda

Number of cells acquired 326 thousand  

2. No abnormal mature B cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

3. No abnormal mature T cell population detected. 
No immunophenotypic evidence of T-cell lymphoma is identified.  

Number of cells acquired: 141 thousand  
Flow Cytometry test processing performed by: Cell Marker Laboratory, Hematopathology Service, Center for Laboratory Medicine, 327 East 64th Street, C1, New York, NY 10065, 212-639-7474.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-8264, CG21-8265.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-(52418, 52424, 52425, 52598)

"
H21-6586;S11;MSK3 - 2023-05-19 18.27.53.ndpi,Peripheral Blood Smear,2023-05-19,"Lymphoma, Mantle Cell
Pancytopenia
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Mantle cell lymphoma, approximately 10% involvement with CD20 and Cyclin D1 immunohistochemistry. 
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show normocellular bone marrow (30% cellularity). There istrilineage maturing hematopoiesis with occasional lymphoid aggregates composed of small lymphocytes with irregular nuclei, high N/C ratio and prominent nucleoli (best seen on aspirate smear). Dysplasia is not seen in background hematopoiesis. 

Bone Marrow Aspirate Smear Quality: Adequate
Promyelocytes           1%
Myelocytes           12%
Metamyelocytes           2%
Neutrophils/Bands      15%
Monocytes           6%
Eosinophils           2%
Erythroid Precursors      22%
Lymphocytes           20%
Other                20% (Atypical lymphoid cells)
Number of Cells Counted 500
M:E Ratio           1.7

Special stain
Iron: Present
Ring sideroblasts: Absent

IMMUNOHISTOCHEMISTRY
CD20 and Pax-5 immunostains highlights the increased number of lymphoid cells (5-10% of cellularity); these cells are also positive for Cyclin D1 and Sox11. 
CD3 labels reactive T-cells

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-8711) 
Interpretation: 
Abnormal B cell population detected. 
The immunophenotype of this abnormal B cell population is similar to that seen previously (F21-8095). 

Abnormal B cell population of WBC: 7.7 %  
Immunophenotype:
Abnormal: CD5 (positive), CD43 (positive), CD79b (dim), CD200 (dim), ROR1 (positive)
Normal: CD20, CD81, CD19, CD40, CD45, CD38
Negative: CD23, CD10, CD3

Number of Cells Acquired: 302 thousand  

PERIPHERAL BLOOD
CBC (9/9/2021)
WBC 0.9 L [4.0-11.0 K/mcL] 
RBC 2.51 L [3.95-5.54 M/mcL] 
HGB 9.0 L [12.5-16.2 g/dL] 
HCT 25.7 L [37.5-49.3 %] 
MCV 102 H [80-98 fL] 
MCH 35.9 H [27.0-33.0 pg] 
MCHC 35.0 [31.0-36.5 g/dL] 
RDW 13.9 [12.2-15.1 %] 
Platelets. 139 L [160-400 K/mcL] 

Neutrophil 47.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 51.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 0.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.5 L [0.9-3.2 K/mcL]

Morphology:
WBC: Leukopenia, absolute neutropenia
RBC: Macrocytic anemia
PLT: Mild thrombocytopenia

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5738.

MOLECULAR STUDIES 
Not submitted.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-4041;S12;MSKY - 2023-05-19 23.10.15.ndpi,Peripheral Blood Smear,2023-05-19,"Myelodysplastic Syndrome 
Chronic Neutropenia r/o MDS 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Persistent myelodysplastic syndrome with ring sideroblasts with multilineage dysplasia (2% blasts on aspirate)
  
BONE MARROW BIOPSY
Quality: adequate  
Cellularity: 60% 
M:E ratio: normal  
Blasts: no increase
Myeloid lineage: orderly maturing 
Erythroid lineage: orderly maturing 
Megakaryocytes: adequate, subset being monolobated  
Lymphocytes: rare 
Plasma cells:rare 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0/3). 
Clot section:

BONE MARROW ASPIRATE SMEAR
Bone Marrow Aspirate Smear Quality: Adequate.

Numerous naked nuclei noted.

Blasts                2%
Promyelocytes           5%
Myelocytes           15%
Metamyelocytes           10%
Neutrophils/Bands      30%
Monocytes           5%
Eosinophils           2%
Basophils           1%
Erythroid Precursors      20%
Plasma Cells           4%
Lymphocytes           6%
Number of Cells Counted 500
M:E Ratio           3.4

Special stain 
Iron: Absent
Ring sideroblasts: Present 5%-15% 

Morphology:
Spicular and cellular bone marrow aspirate shows progressive trilineage hematopoiesis. Blasts are not increased. Myeloid precursors are orderly maturing with left shift. A subset shows cytoplasmic vacuoles. Erythroid precursors are orderly maturing with occasional dysplasia. Megakaryocytes are present with often monolobated forms.


PERIPHERAL BLOOD
CBC (06/07/2021):
WBC 1.9 L [4.0-11.0 K/mcL] 
RBC 3.30 L [3.80-5.00 M/mcL] 
HGB 10.3 L [11.2-15.4 g/dL] 
HCT 31.7 L [34.3-46.0 %] 
MCV 96 [80-98 fL] 
MCH 31.2 [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 20.4 H [12.2-15.1 %] 
Platelets 265 [160-400 K/mcL] 

Neutrophil 19.3 L [32.5-74.8 %] 
Mono 18.2 H [0.0-12.3 %] 
Eos 1.6 [0.0-4.9 %] 
Baso 0.5 [0.0-1.5 %] 
Immature Granulocyte 4.3 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 56.1 H [12.2-47.4 %] 
Nucleated RBC 0.0 [0.0-0.0 %] 

Abs Neut 0.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL] 

Morphology: marked neutropenia. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts. CD34 stains megakaryocytes. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5380)
Abnormal myeloid blast population detected.
No abnormal mature B- or T-cell populations detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample [F17-1709] having abnormal expression of CD7 (partial), CD13(dim on a subset blasts with bright CD34), CD117 (bright) and HLA-DR (uniform, bright); with normal expression of CD4, CD33, CD38, CD45, CD71 and CD123; and without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. Maturing granulocytes show retention of CD64. CD34 positive myeloid blasts represent 3.1% of WBC.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-3513.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-23047.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H21-6521;S10;MSK1 - 2023-05-19 15.32.50.ndpi,Peripheral Blood Smear,2023-05-19,"Lymphoma, Diffuse Large Cell
90 days post Car T cell infusion with relapsed disease as evidence by MRI and PET imaging. R/O BMA involvement
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate, and peripheral blood smears: 
     - Extensive involvement by patient's known large B-cell lymphoma (60% with PAX5 immunohistochemistry).

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy shows hypercellular bone marrow (100% cellularity) with an extensive lymphoid infiltrate of medium to large cells with irregular nuclei. Background hematopoiesis is greatly reduced. 

Bone Marrow Aspirate Smear Quality: Paucispicular and shows predominantly naked nuclei.
The differential cell count was performed on touch imprints

Promyelocytes           1%
Myelocytes           2%
Metamyelocytes           2%
Neutrophils/Bands      8%
Monocytes           2%
Eosinophils           1%
Erythroid Precursors      1%
Lymphocytes           6%
Abnormal lymphoid Cells 77%
Number of Cells Counted 500
M:E Ratio           N/A

IMMUNOHISTOCHEMISTRY
PAX5 immunostain highlights the increased number of large lymphoid cells (60% of cellularity). CD3 labels reactive T-cells and CD20 is negative in the large B-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F21-5628) 
Interpretation: 
Abnormal B- and plasma cell populations detected.
The abnormal B cell population has the same light chain restriction as the abnormal plasma cell population mentioned below. Given the similar light chain restriction, these two populations likely represent manifestations of the same neoplasm, but the immunophenotypic profiles do not allow specific classification.  Clinical and morphologic correlation is advised.

1. Abnormal B cell population of WBC: 12.0 %  

Immunophenotype:
Abnormal: CD5 (bimodal - negative, intermediate), surface Kappa (restriction)
Normal: CD19, CD22, CD38, CD45
Negative: CD10, CD20, CD25, CD279 (PD1), CD3, CD14, surface Lambda

Number of Cells Acquired: 371 thousand  

2. Abnormal plasma cell population detected.
The abnormal plasma cell population has the same light chain restriction (see immunophenotype below) as the abnormal B cell population mentioned above. 

Abnormal plasma cell population of WBC: 0.18 %  

Immunophenotype:
Abnormal: CD19 (bimodal - negative, intermediate), CD45 (slightly bright), cytoplasmic Kappa (restriction)
Normal: CD138, CD38, CD229, CD319, CD27, CD81
Negative: CD20, CD56, CD117, cytoplasmic Lambda

Number of Cells Acquired: 4.9 million  

PERIPHERAL BLOOD
CBC (09/07/2021):
WBC 11.4 H [4.0-11.0 K/mcL] 
RBC 3.66 L [3.80-5.00 M/mcL] 
HGB 11.3 [11.2-15.4 g/dL] 
HCT 35.2 [34.3-46.0 %] 
MCV 96 [80-98 fL] 
MCH 30.9 [27.0-33.0 pg] 
MCHC 32.1 [31.0-36.5 g/dL] 
RDW 19.6 H [12.2-15.1 %] 
Platelets. Unable to report accurate count due to clumps, platelet estimate
appears decreased on smear. 

Neutrophil 38.0 [32.5-74.8 %] 
Mono 12.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 4.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 32.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 11.0 H [0.0-0.0 %] 
Nucleated RBC 0.0 [0.0-0.0 /100(WBCs)] 

Abs Neut 4.3 [1.5-7.5 K/mcL] 
Abs Mono 1.4 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.5 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 4.9 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0.0 [0.0-0.0 /100(WBCs)] 


Morphology: Not available

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG21-5677.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M21-36758.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-2113;S11;MSKU - 2023-03-24 07.31.18.ndpi,Peripheral Blood Smear,2023-04-25,"AML
Disease Status 
","1-3. Bone marrow, left posterior iliac crest; biopsy, touch imprints and peripheral blood smear: 
     - Persistent acute myeloid leukemia (56% blasts by differential count on paucicellular/hemodilute touch imprints and 51% in peripheral blood).
  
BONE MARROW BIOPSY
Quality: Suboptimal (subcortical with crush artifact)
Cellularity: Markedly hypercellular (>90%)
M:E ratio: Appears increased 
Blasts: Increased 
Myeloid lineage: Left-shifted maturation 
Erythroid lineage: Reduced 
Megakaryocytes: Appear markedly reduced to absent
Lymphocytes: Rare 
Plasma cells: Rare 
Other: Small foci of necrosis are seen
Special stains: Reticulin stain shows a mild to moderate increase in reticulin fibrosis (MF-1-2)

BONE MARROW TOUCH IMPRINTS
Differential: (Performed touch imprint smear by CB)
Blasts                56%
Myelocytes           3%
Metamyelocytes           3%
Neutrophils/Bands      17%
Monocytes           2%
Erythroid Precursors      2%
Lymphocytes           17%
Number of Cells Counted 100
M:E Ratio           12.5

Morphology:
Touch imprints are paucicellular and hemodilute. The show an expanded population of intermediate to large sized blasts with rounded to irregular nuclei, fine chromatin, distinct nucleoli and scant cytoplasm. Few scattered myeloid elements and rare nucleated red blood cells are seen. Megakaryocytes are not readily identified. 

PERIPHERAL BLOOD
CBC (03/11/2020):
WBC 17.8 H [4.0-11.0 K/mcL] 
RBC 2.73 L [3.95-5.54 M/mcL] 
HGB 8.0 L [12.5-16.2 g/dL] 
HCT 25.0 L [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 29.3 [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 16.2 H [12.2-15.1 %] 
Platelets 22 L [160-400 K/mcL] 

Neutrophil 20.0 L [32.5-74.8 %] 
Mono 10.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 51.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Promyelocyte 2.0 H [0.0-0.0 %] 
Lymph 15.0 [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 3.6 [1.5-7.5 K/mcL] 
Abs Mono 1.8 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 9.1 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.4 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.4 H [0.0-0.0 K/mcL] 
Abs Lymph 2.7 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBCs: Leukocytosis with numerous circulating blasts and frequent neutrophils showing hypogranulation and/or abnormal nuclear segmentation. 
RBCs: Normocytic, normochromic anemia with rare nucleated RBCs. 
Platelets: Marked thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight an increase in blasts, which are difficult to definitively enumerate due to the crush artifact and high background staining but are estimated to comprise ~20% of the cellularity overall, focally reaching ~50%. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW
Not performed 

CYTOGENETIC STUDIES
Not requested 

MOLECULAR STUDIES 
Not requested 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-715;S11;MSK- - 2023-06-27 22.37.55.ndpi,Peripheral Blood Smear,2023-06-27,"ALL. Newly diagnosed early T-precursor ALL. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by T-lymphoblastic lymphoma/ leukemia (T-ALL)

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular for age (>95%)
M:E ratio: N/A
Blasts: Markedly increased, present in sheets, replacing the bone marrow.
Myeloid lineage: Markedly decreased
Erythroid lineage: Markedly decreased
Megakaryocytes: Present, predominantly unremarkable in morphology
Lymphocytes: Not increased
Plasma cells: Not increased
CLOT: Rare marrow particle with similar findings as the biopsy

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                83%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      2%
Erythroid Precursors      3%
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           1.3

Morphology:
-Spicular and cellular smears show marked increase in blasts with an ovoid to irregular nuclei, fine chromatin, variably conspicuous nucleoli and scant cytoplasm. Rare maturing myeloid and erythroid elements seen, Rare megakaryocytes noted.

PERIPHERAL BLOOD
CBC (1/23/2020):
WBC 45.9 H [4.0-11.0 K/mcL] 
RBC 3.70 L [3.95-5.54 M/mcL] 
HGB 11.9 L [12.5-16.2 g/dL] 
HCT 37.1 L [37.5-49.3 %] 
MCV 100 H [80-98 fL] 
MCH 32.2 [27.0-33.0 pg] 
MCHC 32.1 [31.0-36.5 g/dL] 
RDW 15.6 H [12.2-15.1 %] 
Platelets. 92 L [160-400 K/mcL] 

Neutrophil 4.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 83.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 10.0 L [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 1.8 [1.5-7.5 K/mcL] 
Abs Mono 0.9 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 38.1 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.5 H [0.0-0.0 K/mcL] 
Abs Lymph 4.6 H [0.9-3.2 K/mcL]

Morphology: 
WBC: Numerous blasts with similar morphology seen
RBC: Mild anisocytosis, rare nucleated RBCs seen.
Platelets: Thrombocytopenia

IMMUNOHISTOCHEMISTRY
Immunostains for CD34 and TDT show sheets of blasts, comprising >90% of cellularity

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-863)
Abnormal immature T-cell population identified. 
No abnormal mature B-cell population detected. 

An abnormal immature T-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously F20-767. The abnormal blasts represent 96.1% of the white cells and abnormally express surface CD2 (negative to dim), surface CD3 (negative), CD7 (bright), CD10 (negative), CD16/CD56 (small subset), CD34 (negative to dim), CD38 (absent to bright), CD45 (dim), CD48 (negative to dim); with normal expression of CD5, cytoplasmic CD3 (bright); and without CD4, CD8 or CD10. This finding is consistent with precursor T-cell lymphoblastic leukemia 

No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-519.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-3291 to M20-3293.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-6057;S13;MSKG - 2023-06-07 00.47.45.ndpi,Peripheral Blood Smear,2023-06-07,"MDS
Progressive anemia 
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Persistent myelodysplastic syndrome, ~2% blasts by aspirate differential.
    - Hypercellular bone marrow with trilineage dysplasia and increased ring sideroblasts.

BONE MARROW BIOPSY
Quality: Suboptimal (fragmented biopsy) 
Cellularity: Hypercellular (~80%)
M:E ratio: Normal
Blasts: Not overtly increased, scattered immature cells noted
Myeloid lineage: Exhibits full maturation 
Erythroid lineage: Exhibits left-shifted maturation 
Megakaryocytes: Present with dysplastic changes (hypolobation, micromegakaryocytes, hyperchromasia)
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows a mild increase in reticulin fibers (1+/3). 
Clot section: Clot section shows scattered minute hematopoietic marrow fragments with findings similar to biopsy 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                2%
Promyelocytes           2%
Myelocytes           14%
Metamyelocytes           9%
Neutrophils/Bands      35%
Monocytes           3%
Eosinophils           1%
Erythroid Precursors      21%
Plasma Cells           1%
Lymphocytes           12%
Number of Cells Counted      500
M:E Ratio           3

Special stain
Iron: Present
Ring sideroblasts: Present; 5% to 15% 

Morphology: The aspirate smears are spicular, cellular and show maturing trilineage hematopoiesis; no expanded blast population is seen. Myeloid elements show dysgranulopoiesis (hypogranularity, lobation abnormalities, ~10%) while erythroid elements show marked dysplasia (nuclear irregularities, polylobation, binucleation, karyorrhexis, >10%). Megakaryocytes are present with dysplastic changes (hypolobation, micromegakaryocytes). 

PERIPHERAL BLOOD
CBC (09/22/2020):
WBC 2.8 L [4.0-11.0 K/mcL] 
RBC 3.32 L [3.95-5.54 M/mcL] 
HGB 9.8 L [12.5-16.2 g/dL] 
HCT 31.5 L [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 29.5 [27.0-33.0 pg] 
MCHC 31.1 [31.0-36.5 g/dL] 
RDW 27.2 H [12.2-15.1 %] 
Platelets. 53 L [160-400 K/mcL] 

Neutrophil 16.0 L [32.5-74.8 %] 
Mono 37.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 44.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 0.4 L [1.5-7.5 K/mcL] 
Abs Mono 1.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.2 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology:
WBC: Leukopenia with absolute/relative neutropenia and monocytosis. No circulating blasts seen.
RBC: Normocytic, normochromic anemia with anisopoikilocytosis; occasional elliptocytes seen; dimorphic RBC population suggestive of recent transfusion.
PLT: Moderate thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains show no increases in CD34 and/or CD117 positive blasts (<5%). CD117 also highlights mildly increased mast cells, which are scattered singly without clustering or atypia.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-7631)
Abnormal myeloid blast population detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD34 (dim), CD71 (bright), CD117 (bright), CD123 (bright), and HLA-DR (bright); with normal expression of CD4, CD13, CD33, CD38, CD45, without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 0.43% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-4780.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-29933.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-8479;S10;MSKN - 2023-06-15 20.18.16.ndpi,Peripheral Blood Smear,2023-06-15,"Lymphoma. Restaging baseline to enroll to protocol. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Extensive involvement by previously diagnosed mantle cell lymphoma (~80% with CD20 immunohistochemistry). 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
The bone marrow biopsy is suboptimal, small and subcortical with aspiration artifact and fragmentation, but marginally adequate for analysis. The assessable areas appear hypercellular (~50-60% cellularity) and show an interstitial infiltrate of mostly small sized lymphoid cells with irregular nuclei, clumped chromatin, inconspicuous nucleoli and small amount of cytoplasm. Background trilineage hematopoiesis is present. 

The touch imprints are cellular and show numerous atypical intermediate-sized sized lymphocytes with only occasional larger lymphoid cells. Only a few maturing myeloid elements and rare erythroid precursors are seen. Megakaryocytes are not readily identified.

Aspirate differential (performed by KT):
Myelocytes           4%
Neutrophils/Bands      15%
Eosinophils           2%
Erythroid Precursors      5%
Lymphocytes           74%  
Number of Cells Counted      500
M:E Ratio           4.2

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 immunostains highlight the atypical lymphoid infiltrate (~80% of cellularity). 
CD3 labels a few scattered small T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-10849) 
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5 (subset), CD43, ROR1 and lambda surface light chain restriction (bright); normal expression of CD19, CD20, CD22, CD40, CD79b, CD81, and CD45; and without CD3, CD10, CD23, CD25, CD38, PD1 (CD279), CD14 or CD200. The abnormal B cell population represents 74.2% of total white cells. This immunophenotype is consistent with previously diagnosed mantle cell lymphoma (MCL). 

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

PERIPHERAL BLOOD
CBC (12/24/2020):
WBC 261.2 H [4.0-11.0 K/mcL] 
RBC 4.06 [3.95-5.54 M/mcL] 
HGB 11.0 L [12.5-16.2 g/dL] 
HCT 36.0 L [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 27.1 [27.0-33.0 pg] 
MCHC 30.6 L [31.0-36.5 g/dL] 
RDW 15.9 H [12.2-15.1 %] 
Platelets 163 [160-400 K/mcL] 

Neutrophil 7.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 19.0 [12.2-47.4 %] 
Abnormal Lymphoid Cells 71.0 H [0.0-0.0 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 18.3 H [1.5-7.5 K/mcL] 
Abs Mono 7.8 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 235.1 H [0.9-3.2 K/mcL] 

Morphology:
WBCs: Absolute lymphocytosis with many intermediate-sized atypical lymphoid cells with variably conspicuous nucleoli. 
RBCs: Rare nucleated RBCs. 
Platelets: Unremarkable morphology.     

CYTOGENETIC STUDIES
Not requested/performed.     

MOLECULAR STUDIES 
Not requested/performed.     


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-5431;S10;MSK9 - 2023-04-19 09.56.27.ndpi,Peripheral Blood Smear,2023-04-19,"Lymphoma, Diffuse Large Cell
DLBCL with a leukemic relapse currently 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:
     - B-cell lymphoma, approximately 30% involvement by CD20 immunohistochemistry 
     - Cellular marrow with trilineage maturing hematopoiesis.

COMMENT: Bone marrow is involved by B-cell lymphoma of germinal center origin (CD10-positive). Corresponding cytogenetic and molecular tests are in progress. These results will be reported separately.  

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show normocellular bone marrow (40% cellularity) with lymphoid aggregates composed of cells with condensed chromatin. There istrilineage maturing hematopoiesis. Myeloid and erythroid elements show progressive maturation. There are large atypical lymphocytes with prominent nucleoli present on aspirate smear. 

Aspirate differential: (Performed by SS)
Blasts                1%
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           2%
Neutrophils/Bands      20%
Monocytes           2%
Eosinophils           1%
Erythroid Precursors      14%
Plasma Cells           2%
Lymphocytes           54%
Number of Cells Counted 500
M:E Ratio           2.1

IMMUNOHISTOCHEMISTRY
The neoplastic cells 
Express: CD20 (approximately 30% of marrow cellularity), PAX5
Do not express: CD3
Other: 
cMYC highlights a few lymphoma cells. 
BCL6 stain is technically suboptimal. 
Interpretation of BCL2 is difficult due to the background T-cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6835) 
Interpretation: 
Abnormal B-cell population identified.

Flow cytometry reveals an abnormal mature B-cell population with similar immunophenotype as seen previously (F20-5810) having abnormal expression of CD10, CD19 (dim), CD22 (dim to negative), CD38 (bright), increased forward and side scatter, suggestive of large cell size; and kappa light chain restriction, and normal expression of CD20 and CD45, and without convincing CD5 expression. The abnormal B-cell population represents 32.4% of the total white cells. 

PERIPHERAL BLOOD
CBC (08/27/2020)
WBC 28.5 H [4.0-11.0 K/mcL] 
RBC 4.68 [3.95-5.54 M/mcL] 
HGB 15.5 [12.5-16.2 g/dL] 
HCT 45.5 [37.5-49.3 %] 
MCV 97 [80-98 fL] 
MCH 33.1 H [27.0-33.0 pg] 
MCHC 34.1 [31.0-36.5 g/dL] 
RDW 12.3 [12.2-15.1 %] 
Platelets. 208 [160-400 K/mcL] 

Neutrophil 27.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 12.0 L [12.2-47.4 %] 
Other 57.0 H [0.0-0.0 %] 
Abnormal lymphoid cells with clefted-grooved-convoluted nuclear contours, visible nucleoli
and coarse chromatin.
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 7.7 H [1.5-7.5 K/mcL] 
Abs Mono 0.9 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 3.4 H [0.9-3.2 K/mcL] 
Abs Others 16.2 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology:
WBC: Mild lymphopenia. No circulating blasts.
RBC: Normocytic anemia. 
PLT: Unremarkable.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-4225.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-26606.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-6150;S12;MSK0 - 2023-06-07 00.13.39.ndpi,Peripheral Blood Smear,2023-06-07,"Myelodysplastic Syndrome 
MDS, transfusion dependent 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent myelodysplastic syndrome with multilineage dysplasia, increased ring sideroblasts and 7% blasts.

BONE MARROW BIOPSY
Quality: Adequate but fragmented
Cellularity: Hypercellular for age (~40% cellularity)
M:E ratio: Decreased
Blasts: Mild increase in interstitially scattered blasts
Myeloid lineage: Relatively decreased in number and shows left-shifted progressive maturation
Erythroid lineage: Relatively increased in number and shows left-shifted progressive maturation
Megakaryocytes: scattered dysplastic small hypolobated forms
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered
Others: Scattered hemosiderin-laden macrophages.

Special stains: Reticulin stain shows focal mild increase in reticulin fibrosis (0-1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by AS)

Blasts                7%
Promyelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      9%
Monocytes           9%
Eosinophils           1%
Erythroid Precursors      58%
Plasma Cells           1%
Lymphocytes           11%
Number of Cells Counted 500
M:E Ratio           0.4

Special stain
Iron: Present
Ring sideroblasts: Present: >15% 

Morphology:
The aspirate smears are spicular and hypercellular demonstrating maturing trilineage hematopoiesis with mildly increased intermediate sized blasts with round nuclei, fine chromatin, conspicuous nucleoli and scant to moderate amount of cytoplasm with granules. Myeloid elements are relatively decreased and show left shifted progressive maturation. Scattered hypogranular myeloid elements are seen. Erythroid elements are relatively increased and show left-shifted progressive maturation with significant dysplasia (>10%; megaloblastoid changes, nuclear irregularity, cytoplasmic vacuolization). Megakaryocytes are present and show frequent small dysplastic forms with nuclear hypolobation (>10% of lineage).     

PERIPHERAL BLOOD
CBC (09/24/2020):
WBC 2.7 L [4.0-11.0 K/mcL] 
RBC 2.62 L [3.95-5.54 M/mcL] 
HGB 7.6 L [12.5-16.2 g/dL] 
HCT 23.8 L [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 29.0 [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 19.0 H [12.2-15.1 %] 
Platelets 26 L [160-400 K/mcL] 

Neutrophil 13.0 L [32.5-74.8 %] 
Mono 28.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 58.0 H [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 0.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.6 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBCs: Absolute and relative neutropenia including forms with nuclear hyposegmentation, relative monocytosis and lymphocytosis. No circulating blasts seen.
RBCs: Normocytic normochromic anemia with anisopoikilocytosis (elliptocytes and dacrocytes) and rare nucleated red blood cells.
Platelets: Thrombocytopenia with occasional hypogranular forms.

IMMUNOHISTOCHEMISTRY
CD34 highlights mildly increased interstitial blasts (~5% of cellularity).
CD117 shows increased myeloid and erythroid precursors.
CD61 highlights small and hypolobated megakaryocytes. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-7760)
Abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
No abnormal mature B- or T-cell populations detected.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD13(bright) CD25, CD33(dim), CD34(dim), CD117(bright) with normal expression of CD4, CD38, CD45, CD71, CD123 and HLA-DR without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD56, CD64. Granulocytes show discontinuous maturation pattern, monocytes show abnormal increase in CD15.The findings are consistent with myeloid neoplasm with myeloid dysplasia. CD117 positive myeloid blasts represent 7.6% of WBC. 

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-4862.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-30412, M20-30413.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H20-2562;S3;MSK3 - 2023-06-27 02.48.25.ndpi,Peripheral Blood Smear,2023-06-27,[NULL],"1-3. Bone marrow, right posterior, right anterior iliac crest, aspirates and peripheral blood smears:   
-          Numerous extrinsic cells seen on aspirate smears from both anterior and posterior sites, consistent with metastatic retinoblastoma. 
-     Maturing trilineage hematopoiesis. 

PERIPHERAL BLOOD
CBC (4/7/2020):
WBC 4.8 L [7.1-15.9 K/mcL] 
RBC 3.10 [2.93-4.75 M/mcL] 
HGB 7.8 L [9.2-12.7 g/dL] 
HCT 24.4 L [27.7-37.9 %] 
MCV 79 [70-85 fL] 
MCH 25.2 [22.7-29.5 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 13.1 [12.2-15.1 %] 
Platelets. 79 L [160-400 K/mcL] 

Neutrophil 40.0 [16.9-74.5 %] 
Mono 11.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 46.0 [18.1-79.9 %] 
Nucleated RBC 2 [/100(WBCs)] 

Abs Neut 1.9 [1.5-8.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 2.2 [1.1-8.1 K/mcL]

Morphology: thrombocytopenia. No circulating tumor cells. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

"
H20-3051;S12;MSK7 - 2023-06-27 02.31.27.ndpi,Peripheral Blood Smear,2023-06-27,"Mantle cell lymphoma. 
","1-3. Bone marrow, right anterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Mantle cell lymphoma, see comment. 
    
Comment: Core biopsy is inadequate for evaluation. Aspirate smears show many atypical lymphocyte (67% by aspirate differential) and flow cytometry detected abnormal B-cell population (64.9% of total WBC). Overall findings are consistent with bone marrow involvement by mantle cell lymphoma.  

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Core biopsy is inadequate for evaluation (cortical bone, blood clot, soft tissue, and very minute crushed marrow).  
Aspirate smears show reduced trilineage hematopoiesis and numerous atypical lymphocytes with distinct nucleoli.  

Aspirate differential: (Performed by AS)

Blasts                1%
Neutrophils/Bands      4%
Erythroid Precursors      18%
Lymphocytes           10%
Other                    67% (abnormal lymphoid cells, many with irregular nuclei and prominent nucleoli).
Number of Cells Counted 500
M:E Ratio           0.2

IMMUNOHISTOCHEMISTRY
Crushed cells are highlighted with CD20. 
There are scattered CD20+/cyclin D1 dim+/SOX11 dim+ cells within blood clot. 
CD3 and CD5 are non-contributory.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-3700) 
Abnormal B-cell population identified.
No abnormal T cell population detected.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD43, ROR1 and kappa surface light chain restriction (bright); normal expression of CD19, CD20, CD22, CD38, CD40, CD79b, CD81, and CD45; and without CD3, CD10, CD23, or CD200.  The abnormal B cell population represents 64.9% of total white cells.
This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with immunohistochemical or cytogenetic studies for Cyclin D1 is recommended to rule out mantle cell lymphoma.

PERIPHERAL BLOOD
CBC (05/19/2020):
WBC 13.6 H [4.0-11.0 K/mcL] 
RBC 4.65 [3.95-5.54 M/mcL] 
HGB 14.5 [12.5-16.2 g/dL] 
HCT 45.7 [37.5-49.3 %] 
MCV 98 [80-98 fL] 
MCH 31.2 [27.0-33.0 pg] 
MCHC 31.7 [31.0-36.5 g/dL] 
RDW 19.9 H [12.2-15.1 %] 
Platelets 60 L [160-400 K/mcL] 

Neutrophil 47.0 [32.5-74.8 %] 
Mono 9.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 9.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 4.0 H [0.0-0.0 %] 
Lymph 23.0 [12.2-47.4 %] 
Other 5.0 H [0.0-0.0 %] 
Abnormal lymphoid cells with prominent nucleoli.
Nucleated RBC 3 [/100(WBCs)] 

Abs Neut 6.4 [1.5-7.5 K/mcL] 
Abs Mono 1.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 1.2 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.5 H [0.0-0.0 K/mcL] 
Abs Lymph 3.1 [0.9-3.2 K/mcL] 
Abs Others 0.7 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 


Morphology:
WBC: lymphocytosis. Atypical lymphoid cells present.   
RBC: Unremarkable
PLT: Thrombocytopenia

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-2262.

MOLECULAR STUDIES 
Not submitted.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-6318;S12;MSK6 - 2023-06-07 00.59.34.ndpi,Peripheral Blood Smear,2023-06-07,"Multiple Myeloma 
MGUS vs MM
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
10% involvement by CD138 immunohistochemistry.
4% involvement by aspirate differential.
3.6% (98.4% of plasma cells) involvement by 10-color flow cytometry.
     - Cellular marrow with trilineage maturing hematopoiesis. See comment.

Comment:
Per Dr. Flombaum's clinical note, the patient is reported to have an elevated free serum kappa light chains with an elevated kappa:lambda light chain ratio, though immuofixation studies reportedly showed an IgG lambda monoclonal gammopathy. The atypical plasma cell seen in this biopsy and identified on flow cytometric analysis express kappa light chain. The etiology of the reported IgG lambda monoclonal gammopathy is unclear, and correlation with repeat laboratory studies may be of value if clinically indicated.

A morphologic correlate of the minute population of clonal B-cells identified on flow cytometry analysis is not seen in the biopsy. The immunophenotype of the clonal B-cells is non-specific. This population may represent a non-CLL monoclonal B-lymphocytosis or peripheral blood involvement by a B-cell lymphoma (i.e. splenic marginal zone lymphoma). Clinical correlation, including evaluation for lymphadenopathy and splenomegaly, is recommended.

The patient's history of urothelial carcinoma with mixed histologic features, including: NOS, small cell carcinoma/high grade neuroendocrine carcinoma, micropapillary carcinoma, and adenocarcinoma is noted. There is nothing to suggest bone marrow involvement by metastatic carcinoma.

BONE MARROW BIOPSY
Quality: Limited, hemorrhage seen
Cellularity: Overall ~20% in evaluable areas
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes: Present
Plasma cells: Increased
Lymphocytes: Scattered. No prominent lymphoid aggregates noted
Clot section: Mainly blood

ASPIRATE MORPHOLOGY

Aspirate differential: (Performed by: CB )

Blasts                1%
Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           8%
Neutrophils/Bands      47%
Monocytes           3%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      13%
Plasma Cells           4%
Lymphocytes           12%
Number of Cells Counted 500
M:E Ratio           5.4

Morphology: 
Marrow spicules: Aspicular.
Cellularity: Hypocellular/hemodilute
Plasma cell morphology: Small to intermediate in size 
Myeloid lineage: Orderly maturation   
Erythroid Lineage: Orderly maturation   
Megakaryocytes: Rare 

IMMUNOHISTOCHEMISTRY
Immunostains for CD138 and Cyclin D1 highlight plasma cells, which overall comprise approximately 10% of the cellularity. 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.
BCMA highlights>90% of plasma cells, (1-2+) intensity, membranous/ Golgi pattern.
CD3 and CD20 highlight scattered T and B-cells, respectively, with T-cells predominating. The B-cells are relatively rare, and are singly-scattered.
AE1/AE3 is negative.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-7961) 
Abnormal plasma cell population detected.
Abnormal B-cell population identified.

Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (absent), CD27 (absent), CD38 (dim), CD45 (absent), CD81 (absent) and monoclonal kappa cytoplasmic light chain restriction; with normal expression of CD138; and without CD20, CD56, or CD117 expression.  The abnormal population represents 3.6% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 98.4% of total plasma cells in the sample.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD20 (bright), CD22 (bright), CD38 (absent), kappa light chain restriction, and normal expression of CD19 and CD45; and without CD5 or CD10. The abnormal B-cell population represents 0.74% of the total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

PERIPHERAL BLOOD
CBC (10/01/2020):
WBC 7.4 [4.0-11.0 K/mcL] 
RBC 3.58 L [3.95-5.54 M/mcL] 
HGB 11.5 L [12.5-16.2 g/dL] 
HCT 34.5 L [37.5-49.3 %] 
MCV 96 [80-98 fL] 
MCH 32.1 [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 13.6 [12.2-15.1 %] 
Platelets. 263 [160-400 K/mcL] 

Neutrophil 53.0 [32.5-74.8 %] 
Mono 13.2 H [0.0-12.3 %] 
Eos 5.4 H [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Immature Granulocyte 0.7 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 26.7 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 3.9 [1.5-7.5 K/mcL] 
Abs Mono 1.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 2.0 [0.9-3.2 K/mcL] 

Morphology:
WBC: Unremarkable granulocytes with rare circulating plasmacytoid lymphocytes seen.
RBC: Normochromic, normocytic
Platelets: Unremarkable.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-5007, CG20-5008.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-31326



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-1623;S11;MSKZ - 2023-06-27 23.37.00.ndpi,Peripheral Blood Smear,2023-06-27,"B-Cell LPD
Patient with chronic renal failure and B-Cell lymphoproliferative disorder (CD5+, CD23-, CCND1-, CD200-) with progressive anemia 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:
     - CD5 positive low-grade B cell lymphoproliferative disorder consistent with marginal zone lymphoma (20% with CD20 immunohistochemistry). 
     - Mildly hypercellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Limited bone marrow biopsy with fragmentation and aspiration artifact shows slightly hypercellular marrow (~50% cellularity) with trilineage maturing hematopoiesis. There is no increase in blasts. Myeloid lineage is predominant and shows full maturation. Erythroid lineage is reduced. Megakaryocytes are present and show unremarkable morphology. There is mild increase in lymphocytes scattered interstitially and as focal aggregates. Rare scattered plasma cells are seen. Aspirate specimen and touch preps are aspicular and hemodiluted. 

Aspirate differential: (Performed by KT)
Blasts                1%
Promyelocytes           1%
Myelocytes           6%
Metamyelocytes           2%
Neutrophils/Bands      20%
Monocytes           1%
Eosinophils           5%
Erythroid Precursors      4%
Lymphocytes           60% (several lymphocytes with folded nuclei noted)
Number of Cells Counted 500
M:E Ratio           8.8

IMMUNOHISTOCHEMISTRY
CD20/PAX5 immunostains highlight the increased number of B cells (~10% of cellularity) with intrasinusoidal distribution. CD3 labels reactive T-cells. CD5 is positive. CD23, LEF1, CyclinD1 and SOX11 are negative.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-1968) 
Abnormal B-cell population identified.
Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD5, CD23 (partial), CD40 (bright), and normal expression of CD19, CD20, CD38, CD79b, CD81, CD200, and CD45; and without CD3, CD10, CD43 or ROR1. The abnormal B-cell population represents 38.5% of the total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

PERIPHERAL BLOOD
CBC (02/24/2020):
WBC 13.2 H [4.0-11.0 K/mcL] 
RBC 3.20 L [3.95-5.54 M/mcL] 
HGB 9.1 L [12.5-16.2 g/dL] 
HCT 28.9 L [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 28.4 [27.0-33.0 pg] 
MCHC 31.5 [31.0-36.5 g/dL] 
RDW 14.8 [12.2-15.1 %] 
Platelets 201 [160-400 K/mcL] 

Neutrophil 45.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 52.0 H [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 6.0 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 6.9 H [0.9-3.2 K/mcL] 

Morphology:
WBC: Many atypical lymphoid cells with small nuclei and abundant cytoplasm are seen. No circulating blasts.
RBC: Normocytic anemia.
Platelets: Unremarkable morphology.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-1211.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-8048.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-3051;S12;MSK7 - 2023-06-27 02.37.04.ndpi,Peripheral Blood Smear,2023-06-27,"Mantle cell lymphoma. 
","1-3. Bone marrow, right anterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Mantle cell lymphoma, see comment. 
    
Comment: Core biopsy is inadequate for evaluation. Aspirate smears show many atypical lymphocyte (67% by aspirate differential) and flow cytometry detected abnormal B-cell population (64.9% of total WBC). Overall findings are consistent with bone marrow involvement by mantle cell lymphoma.  

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Core biopsy is inadequate for evaluation (cortical bone, blood clot, soft tissue, and very minute crushed marrow).  
Aspirate smears show reduced trilineage hematopoiesis and numerous atypical lymphocytes with distinct nucleoli.  

Aspirate differential: (Performed by AS)

Blasts                1%
Neutrophils/Bands      4%
Erythroid Precursors      18%
Lymphocytes           10%
Other                    67% (abnormal lymphoid cells, many with irregular nuclei and prominent nucleoli).
Number of Cells Counted 500
M:E Ratio           0.2

IMMUNOHISTOCHEMISTRY
Crushed cells are highlighted with CD20. 
There are scattered CD20+/cyclin D1 dim+/SOX11 dim+ cells within blood clot. 
CD3 and CD5 are non-contributory.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-3700) 
Abnormal B-cell population identified.
No abnormal T cell population detected.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD43, ROR1 and kappa surface light chain restriction (bright); normal expression of CD19, CD20, CD22, CD38, CD40, CD79b, CD81, and CD45; and without CD3, CD10, CD23, or CD200.  The abnormal B cell population represents 64.9% of total white cells.
This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with immunohistochemical or cytogenetic studies for Cyclin D1 is recommended to rule out mantle cell lymphoma.

PERIPHERAL BLOOD
CBC (05/19/2020):
WBC 13.6 H [4.0-11.0 K/mcL] 
RBC 4.65 [3.95-5.54 M/mcL] 
HGB 14.5 [12.5-16.2 g/dL] 
HCT 45.7 [37.5-49.3 %] 
MCV 98 [80-98 fL] 
MCH 31.2 [27.0-33.0 pg] 
MCHC 31.7 [31.0-36.5 g/dL] 
RDW 19.9 H [12.2-15.1 %] 
Platelets 60 L [160-400 K/mcL] 

Neutrophil 47.0 [32.5-74.8 %] 
Mono 9.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 9.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 4.0 H [0.0-0.0 %] 
Lymph 23.0 [12.2-47.4 %] 
Other 5.0 H [0.0-0.0 %] 
Abnormal lymphoid cells with prominent nucleoli.
Nucleated RBC 3 [/100(WBCs)] 

Abs Neut 6.4 [1.5-7.5 K/mcL] 
Abs Mono 1.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 1.2 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.5 H [0.0-0.0 K/mcL] 
Abs Lymph 3.1 [0.9-3.2 K/mcL] 
Abs Others 0.7 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 


Morphology:
WBC: lymphocytosis. Atypical lymphoid cells present.   
RBC: Unremarkable
PLT: Thrombocytopenia

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-2262.

MOLECULAR STUDIES 
Not submitted.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-5390;S12;MSKE - 2023-06-07 00.02.14.ndpi,Peripheral Blood Smear,2023-06-07,"Leukemia, Hairy Cell
Reassess progression HCL r/o MDS  please RUSH
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Extensive involvement by hairy cell leukemia (90-95% by CD20 immunohistochemistry).
     - Reduced background trilineage maturing hematopoiesis. See comment.
  
COMMENT:
The patient's history of hairy cell leukemia is noted, as are his decreasing peripheral blood counts, the atypical megakaryocytes reported on a previous biopsy, and the clinical concern for an underlying myelodysplastic syndrome. There is persistent atypia in the megakaryocytic lineage; however, there are very few maturing hematopoietic elements present due to extensive involvement of the marrow by hairy cell leukemia, which limits morphologic evaluation for an underlying myeloid neoplasm. Correlation with pending cytogenetic and molecular analysis is recommended.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular for age (70-80% cellular)
M:E ratio: Decreased
Blasts: Not increased
Myeloid lineage: Markedly reduced, appears mildly left-shifted
Erythroid lineage: Reduced with progressive maturation
Megakaryocytes: Moderately reduced; some forms show atypical/dysplastic features such as widely separated nuclear lobes or hypolobated and hyperchromatic nuclei
Lymphocytes: Small-to-medium sized lymphocytes with mature chromatin, mild nuclear irregularities, and a moderate amount of clear cytoplasm largely replaced the marrow
Plasma cells: Not increased
Special stains: A reticulin stain has been ordered, and the findings will be reported in an addendum.

BONE MARROW ASPIRATE SMEAR/TOUCH IMPRINTS
Differential: (Performed on touch imprints by HM)

Aspicular / hemodiluted aspirate smears

Myelocytes           2%
Metamyelocytes           2%
Neutrophils/Bands      5%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      18%
Plasma Cells           1%
Lymphocytes           70% 
Number of Cells Counted 500
M:E Ratio           0.6

Special stain
Iron: Suboptimal for evaluation; devoid of spicules
Ring sideroblasts: Absent in a limited specimen

Morphology: Aspirate smears are aspiculate and hemodilute, and are suboptimal for evaluation. There are very few maturing myeloid and erythroid precursors present. Blasts do not appear increased. Rare, if any, megakaryocytes are seen. There are occasional atypical lymphocytes that are small to medium sized with oval nucleus with occasional indentations, homogeneous chromatin and moderate amount of pale blue cytoplasm. 

PERIPHERAL BLOOD
CBC (8/26/2020):
WBC 3.2 L [4.0-11.0 K/mcL] 
RBC 2.68 L [3.95-5.54 M/mcL] 
HGB 8.7 L [12.5-16.2 g/dL] 
HCT 27.8 L [37.5-49.3 %] 
MCV 104 H [80-98 fL] 
MCH 32.5 [27.0-33.0 pg] 
MCHC 31.3 [31.0-36.5 g/dL] 
RDW 18.4 H [12.2-15.1 %] 
Platelets 30 L [160-400 K/mcL] 

Neutrophil 83.0 H [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 13.0 [12.2-47.4 %] 
Hairy Cell 2.0 H [0.0-0.0 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 2.7 [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 
Abs Hairy Cells 0.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBCs: Leukopenia. Granulocytes are unremarkable. Scattered large granular lymphocytes. Rare atypical lymphocytes that are small to medium sized with oval nucleus with slight indentations, homogeneous chromatin, and moderate amount of pale blue cytoplasm with occasional cytoplasmic extensions.
RBCs: Macrocytic normochromic with mild anisocytosis. Occasional nucleated red blood cells are seen.
Platelets: Markedly reduced; occasional giant platelets.

IMMUNOHISTOCHEMISTRY
CD20 immunostain highlights the diffuse atypical lymphoid infiltrate (overall 90-95% of the marrow cellularity). This infiltrate is positive for BRAF V600E immunostain. A CD3 immunostain highlights infrequent scattered small T-cells.
CD34 and CD117 blasts are increased. CD117 highlights scattered mast cells and a few erythroid and myeloid precursors. CD61 labels megakaryocytes that are mildly decreased in number. CD71 and MPO highlight the erythroid and myeloid precursors, respectively.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6772)
Interpretation: 
Abnormal B-cell population identified.
Flow cytometry reveals an abnormal mature B-cell population having abnormal expression of CD10 (subset), CD19 (bright), CD20 (bright), CD11c, CD22 (bright), CD25, CD38 (absent), CD45 (bright), CD103 and CD200 (bright), and lambda light chain restriction; and without CD5. The immunophenotype of the abnormal B-cell population is consistent with involvement by hairy cell leukemia. The abnormal B cell population represents 12.4% of the total white cells.

No abnormal mature T-cell population detected.
The hairy cells are PD-1 positive. 
No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. Few CD34 positive blasts seen.

369,041 of cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-4208, CG20-4209.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-26462, M20-26463.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-5104;S10;MSKF - 2023-04-17 16.39.46.ndpi,Peripheral Blood Smear,2023-04-17,"ALL. New B-ALL. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears:   
     - Chronic myeloid leukemia, BCR-ABL1 positive, B-lymphoblastic blast phase, 25% blasts by aspirate differential count. See comment.
     - Hypercellular marrow with myeloid-predominant maturing trilineage hematopoiesis.
  
COMMENT: Recent cytogenetic studies (CG20-3864) detected the BCR-ABL1 fusion by FISH. Corresponding flow cytometric analysis detected an expanded abnormal B-lymphoblast and a small abnormal myeloblast population suggestive of the above interpretation. Preliminary findings of BCR-ABL1 FISH studies on flow sorted populations from the peripheral blood (F20-6330) (communicated by Dr. Umut Aypar, division of Cytogenetics) indicate that the fusion is present in B-lymphoblasts as well as myeloid lineage derived cells, and confirm the above interpretation (see forthcoming results of CG20-3920, CG20-3921, CG20-3922, and CG20-3923).

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular for age (> 95%)
M:E ratio: N/A
Blasts: Increased, scattered singly interstitially and in small clusters blasts are intermediate to large in size, within irregular nuclei, fine chromatin, single to multiple conspicuous nucleoli, and scant to moderate amount of cytoplasm.
Myeloid lineage: Appears increased, with left-shifted maturation 
Erythroid lineage: Present, actively maturing
Megakaryocytes: Adequate to mildly increased in number, with atypical forms including small size, nuclear hypolobation, loose clusters, nuclear hyperchromasia, and ""bare nuclei"" morphology
Lymphocytes: Few, scattered
Plasma cells: Rare, scattered

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                25% 
Promyelocytes           1%
Myelocytes           15%
Metamyelocytes           10%
Neutrophils/Bands      26%
Eosinophils           3%
Basophils           1%
Erythroid Precursors      10%
Lymphocytes           9%
Number of Cells Counted 500
M:E Ratio           5.6

Morphology:
Spicular and hypercellular aspirate smears with granulocytic-predominant maturing trilineage hematopoiesis and an expanded blast population. Blasts show a patchy distribution ranging 13-35%. Blasts are intermediate to large in size, with round to irregular nuclei, fine chromatin, variably prominent nucleoli (some single and large, others multiple small), and scant cytoplasm. Auer rods are not seen. Myeloid elements of multiple increased, with left maturation, and atypical/dysplastic forms including toxic granulation/ hypergranularity (reminiscent of basophil precursors), pseudo-Pelger-Huet morphology, and hyposegmentation. Erythroid precursors appear relatively decreased, show progressive maturation and occasional megaloblastoid features. Megakaryocytes are seen with subset showing atypical ""dwarf""-like morphology.  Few small mature-appearing lymphocytes are seen.

PERIPHERAL BLOOD
CBC (08/14/2020):
WBC 12.0 H [4.0-11.0 K/mcL] 
RBC 4.40 [3.95-5.54 M/mcL] 
HGB 11.8 L [12.5-16.2 g/dL] 
HCT 36.4 L [37.5-49.3 %] 
MCV 83 [80-98 fL] 
MCH 26.8 L [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL] 
RDW 14.7 [12.2-15.1 %] 
Platelets. 296 [160-400 K/mcL] 

Neutrophil 84.0 H [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 4.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 8.0 L [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 10.1 H [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.5 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBC: Rare circulating blasts seen (~2%). Leukocytosis with neutrophilia and immature granulocytes. Neutrophils show toxic granulation. Mild basophilia is noted with atypical morphology. 
RBC: Mild normocytic, normochromic anemia.
Platelets: Adequate in number with occasional giant forms.

IMMUNOHISTOCHEMISTRY
TdT highlights increased blasts, which are scattered singly and in small clusters interstitially, accounting for 20-25% of the marrow cellularity.
Rare scattered blasts are positive for CD34 (< 5% of the cellularity), while the majority of blasts are negative. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6423)
Interpretation: 
Abnormal immature B-cell population detected.
Abnormal myeloid blast and maturing granulocyte populations detected. 

An abnormal immature B-cell population is identified by flow cytometry.  The abnormal immature B-cells represent 14.2% of the white cells and 36.0% of the mononuclear cells in the sample and abnormally express CD10 (bright), CD20 (partial), CD33 (partial), CD34 (absent to intermediate), CD38 (bright), CD45 (dim), CD66c/CD123, CD73/CD304; with normal expression of CD19, CD22, CD24, and CD81; and without CD66b.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD7 (partial), CD11b (subset), CD33 (uniform bright), HLADR (uniform intermediate) with normal expression of CD4, CD13, CD34, CD38, CD45, CD71, CD117 and CD123; without CD2, CD5, CD14, CD15, CD16, CD19, CD25, CD56, CD64. CD34 positive myeloid blasts represent 0.29% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F20-6330)
Interpretation: 
Abnormal immature B-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature T-cell population detected.

The blasts have abnormal expression of CD19 (dim), CD20 (partial), CD22 (dim), CD24 (dim), CD38(dim), CD33 (partial), CD66c/CD123, and CD73/CD304; with normal expression of CD10, CD34, CD45, CD71, CD81 and HLA-DR; and without CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD56, CD64, CD66b, CD86, or CD117. The abnormal blasts represent 3.8% of WBC and 8.5% mononuclear cells. The findings may represent either B-ALL or CML in lymphoid blast phase. Analysis of sorted cells may be helpful in defining the diagnosis. Correlation with clinical history is also required.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.14% of WBC.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-3931.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M20-24923, M20-24925, M20-24926, M20-24929, & M20-24930.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     
"
H20-22;S12;MSKS - 2023-06-20 12.51.18.ndpi,Peripheral Blood Smear,2023-06-20,"Hairy cell leukemia. Status post 5 cycles antibody with persistent pancytopenia: questionable hypocellular versus persistent hairy cell. 
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
     - Hairy cell leukemia (~95% involvement by CD20 immunohistochemistry).

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Patchy (some areas demonstrate ~95% cellularity while other areas show <5% cellularity; overall average ~60%) 
M:E ratio: N/A
Blasts: Not increased
Myeloid lineage: Markedly reduced
Erythroid lineage: Markedly reduced
Megakaryocytes: Not definitively identified
Lymphocytes: Markedly increased, present in sheets within the cellular areas and scattered singly within the hypocellular areas; predominantly small to intermediate in size with ovoid to irregular nuclei, condensed to dispersed chromatin, inconspicuous nucleoli and abundant pale to clear cytoplasm 
Plasma cells: Virtually absent

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Neutrophils/Bands      7%
Eosinophils           1%
Erythroid Precursors      5%
Lymphocytes           25%
Hairy cells           62%
Number of Cells Counted  500
M:E Ratio           1.6

Special stain
Iron: Inadequate for evaluation due to a lack of spicules
Ring sideroblasts: Not identified, however, evaluation is suboptimal due to limited erythroid precursors

Morphology:
Aspirate smears and touch imprint are aspicular, hypocellular, and hemodilute. The cellular elements are composed predominantly of small to intermediate sized atypical lymphoid cells with ovoid to irregular nuclei, moderately dispersed chromatin, occasional small nucleoli and mostly moderate amounts of cytoplasm with occasional cells showing cytoplasmic projections. Occasional scattered myeloid elements and nucleated red blood cells are seen. Megakaryocytes are not well represented and not readily identified. No expanded blast population is seen.

PERIPHERAL BLOOD
CBC (01/02/2020):
WBC 4.0 [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 2.31 L [3.95-5.54 M/mcL] 
HGB 8.5 L [12.5-16.2 g/dL] 
HCT 25.5 L [37.5-49.3 %] 
MCV 110 H [80-98 fL] 
MCH 36.8 H [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 20.4 H [12.2-15.1 %] 
Platelets 81 L [160-400 K/mcL] 

Neutrophil 35.0 [32.5-74.8 %] 
Mono 6.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 53.0 H [12.2-47.4 %] 
Nucleated RBC 11 [/100(WBCs)] 

Abs Neut 1.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 2.1 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology:
WBC: Neutropenia with few myelocytes and metamyelocytes. Atypical lymphoid cells morphologically similar to those in the aspirate smears are seen.
RBC: Macrocytic anemia with anisopoikilocytosis and occasional nucleated RBCs.
Platelets: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
CD20 highlights markedly increased B-cells, which are present in sheets within the cellular areas and scattered singly within the hypocellular areas, comprise ~95% of the marrow cellularity overall and co-express BRAF V600E.
CD3 highlights occasional scattered T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-35)
Interpretation: 
Abnormal B-cell population identified.

Flow cytometry reveals an abnormal mature B-cell population having abnormal expression of CD19 (bright), CD20 (bright), CD11c, CD22 (bright), CD25, CD45 (bright), CD103, and CD200 (bright), with slightly increased forward and side scatter, and kappa light chain restriction (bright); and without CD5, CD10, or CD38.  The immunophenotype of the abnormal B-cell population is consistent with involvement by hairy cell leukemia. The abnormal B cell population represents 27.5% of the total white cells.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-31.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-190.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H20-394;S10;MSKB - 2023-04-20 09.25.31.ndpi,Peripheral Blood Smear,2023-04-20,"Lymphoma, Follicular. 58 years old M with relapsed follicular lymphoma. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by follicular lymphoma (20% with CD20 immunohistochemistry)
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show hypercellular bone marrow (50% cellularity). There istrilineage maturing hematopoiesis with increased numbers of lymphocytes with small size, irregular nuclei, dense chromatin and patchy paratrabecular distribution.  

Aspirate differential: (Performed by SS)
Patchy aspirate
Blasts                1%
Promyelocytes           1%
Myelocytes           5%
Metamyelocytes           5%
Neutrophils/Bands      15%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      15%
Plasma Cells           1%
Lymphocytes           55% (15-95%)
Number of Cells Counted 500
M:E Ratio           1.9

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 show increased number of lymphoid cells in a patchy paratrabecular pattern (10-20% of cellularity). CD3 labels reactive T-cells

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-507) 
Abnormal B-cell population identified.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD10, CD19 (dim to normal), CD20 (bright), CD22 (dim to normal), CD38 (variable, absent to bright), and lambda light chain restriction; and normal expression of CD45; and without CD5. The abnormal B-cell population represents 9.3% of the total white cells.

PERIPHERAL BLOOD
CBC (01/14/2020)
WBC 5.0 [4.0-11.0 K/mcL] 
RBC 4.86 [3.95-5.54 M/mcL] 
HGB 14.9 [12.5-16.2 g/dL] 
HCT 43.3 [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 30.7 [27.0-33.0 pg] 
MCHC 34.4 [31.0-36.5 g/dL] 
RDW 13.1 [12.2-15.1 %] 
Platelets. 78 L [160-400 K/mcL] 

Neutrophil 78.3 H [32.5-74.8 %] 
Mono 5.1 [0.0-12.3 %] 
Eos 0.4 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 0.4 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 15.4 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 4.0 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL]

Morphology:
WBC: Mild lymphopenia. No circulating blasts.
RBC: Unremarkable.
PLT: Thrombocytopenia.  

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-303.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-1903.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-2814;S11;MSK2 - 2023-06-27 23.24.38.ndpi,Peripheral Blood Smear,2023-06-27,"Concern for relapse of HCL
Concern for progression of HCL
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by hairy cell leukemia (50-60% cellularity)
     - Cellular marrow with residual trilineage maturing hematopoiesis with myeloid hypoplasia.
  
COMMENT:

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Normal for age (40%)
M:E ratio: Reduced
Blasts: No increase
Myeloid lineage: Relatively reduced
Erythroid lineage: Maturation seen
Megakaryocytes: Present, adequate in number 
Lymphocytes: Markedly increased mature forms with abundant cytoplasm, mostly interstitial 
Plasma cells: Scattered

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)

Blasts                1%
Myelocytes           9%
Metamyelocytes           3%
Neutrophils/Bands      14%
Monocytes           1%
Eosinophils           3%
Erythroid Precursors      44%
Plasma Cells           4%
Lymphocytes           17%
Hairy cells           4%
Number of Cells Counted 500
M:E Ratio           0.7

Morphology:
-Spicular and cellular with trilineage maturing hematopoiesis with myeloid hypoplasia, increased atypical lymphocytes
-Hypercellular smears show......

PERIPHERAL BLOOD
CBC (5/4/2020):
WBC 2.0 L [4.0-11.0 K/mcL] 
RBC 4.38 [3.95-5.54 M/mcL] 
HGB 14.2 [12.5-16.2 g/dL] 
HCT 41.6 [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 32.4 [27.0-33.0 pg] 
MCHC 34.1 [31.0-36.5 g/dL] 
RDW 13.5 [12.2-15.1 %] 
Platelets. 81 L [160-400 K/mcL] 

Neutrophil 50.7 [32.5-74.8 %] 
Mono 2.1 [0.0-12.3 %] 
Eos 3.1 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Immature Granulocyte 0.0 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 43.1 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 1.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 0.8 L [0.9-3.2 K/mcL]

Morphology: Neutropenia, rare hairy cells seen 

IMMUNOHISTOCHEMISTRY
CD20 and BRAF show an expanded abnormal B cell population (50-60% of cellularity), CD3 stains scattered T cells 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-3361)
Abnormal B-cell population identified.
Flow cytometry reveals an abnormal mature B-cell population having abnormal expression of CD19 (bright), CD20 (bright), CD11c, CD22 (bright), CD25, CD45 (bright), CD103 and CD200 (bright) with slightly increased forward and side scatter and lambda light chain restriction (bright); with normal expression of CD38 and without CD5 or CD10.  The immunophenotype of the abnormal B-cell population is consistent with involvement by hairy cell leukemia. The abnormal B cell population represents 15.1% of the total white cells

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-2081.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-7660;S11;MSKF - 2023-06-15 19.29.54.ndpi,Peripheral Blood Smear,2023-06-15,"
Leukemia, Acute Myeloid
Determined response to Gilteritinib
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Residual acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214 (7% blasts by aspirate differential count). See comment.
     - Hypercellular marrow with trilineage dysplasia.
  
COMMENT:
Correlation with pending molecular and cytogenetic studies is recommended.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular (~95%)
M:E ratio: Normal
Blasts: Mildly increased
Myeloid lineage: Progressive maturation; mildly left-shifted
Erythroid lineage: Progressive maturation
Megakaryocytes: Decreased. Frequent small forms with hypolobated and hyperchromatic nuclei.
Lymphocytes: No prominent lymphoid aggregates.
Plasma cells: Not increased.
Special stains: A reticulin stain shows a mild increase in reticulin fibrosis.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Blasts                8%
Promyelocytes           2%
Myelocytes           16%
Metamyelocytes           10%
Neutrophils/Bands      38%
Monocytes           3%
Eosinophils           1%
Erythroid Precursors      19%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           3.6

Morphology:
Spiculate and hypercellular aspirate smears show mildly increased blasts. They have a patchy distribution, and overall comprise approximately 7% of the cellularity (34 blasts/518 cells). The myeloid lineage shows progressive maturation with dysplastic changes (abnormal patterns of cytoplasmic granularity and nuclear segmentation). The erythroid lineage also shows a full range of maturation with dysplastic changes, including irregular nuclear borders, nuclear fragmentation, and megaloblastoid maturation. Occasional megakaryocytes are seen, some of which are relatively small.

PERIPHERAL BLOOD
CBC (11/19/2020):
WBC 5.3 [4.0-11.0 K/mcL] 
RBC 3.12 L [3.80-5.00 M/mcL] 
HGB 8.5 L [11.2-15.4 g/dL] 
HCT 25.4 L [34.3-46.0 %] 
MCV 81 [80-98 fL] 
MCH 27.2 [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 12.9 [12.2-15.1 %] 
Platelets 12 L [160-400 K/mcL] 

Neutrophil 95.0 H [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 3.0 L [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 5.1 [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.2 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Dysplastic granulocytes. Circulating blasts are not increased.
RBC: Normochromic, normocytic anemia.
Platelets: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunostains show that CD34+ blasts are not increased. CD117+ immature cells are mildly increased (10-20% of the cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-7659)
Interpretation: 
Abnormal myeloid blast population detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD33 (bright), CD34 (absent), CD38 (dim), CD45 (dim), CD123 (uniform intermediate), HLA-DR (dim) with normal expression of CD4, CD13, CD71, CD117; without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD117 positive myeloid blasts represent 4.7% of WBC

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-6175.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-38399, M20-38400.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-528;S13;MSK4 - 2023-06-27 02.54.20.ndpi,Peripheral Blood Smear,2023-06-27,"MF. Anemia. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent JAK2 mutated myeloproliferative neoplasm with myelofibrosis (MPN) in a limited sample. See comment.
     - Persistent B lymphoproliferative neoplasm (1.4% by flow cytometry) with marginal zone phenotype, as previously described.

COMMENT: The bone marrow biopsy specimen is inadequate for morphologic evaluation, displaying only a small marrow space with marked fibrosis. Flow cytometry identified and abnormal myeloid blast phenotype and basophilia, which in conjunction with peripheral leukoerythroblastosis, are consistent with persistence of the patient's previously diagnosed MPN.

BONE MARROW BIOPSY
Quality: Inadequate, small biopsy with focal marrow space showing fibrosis and extensive crush artifact 
Cellularity: Cannot be assessed due to nature of the biopsy 
Hematopoiesis: Cannot be assessed due to nature of the biopsy
Special stains: Reticulin stain shows focal marked increase in reticulin fibrosis in a preserved small marrow space (MF-3+/3). 
Clot section: Paucicellular and predominantly blood 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                3% 
Promyelocytes           1%
Neutrophils/Bands      56%
Monocytes           6%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      14%
Lymphocytes           18%
Number of Cells Counted 500
M:E Ratio           4.6

Special stain
Iron: Suboptimal for evaluation due to lack of spicules
Ring sideroblasts: Absent 

Morphology:
Aspicular and hypocellular aspirate smears are suboptimal for morphologic assessment and demonstrate maturing hematopoiesis. Blasts are not increased. Myeloid elements show progressive maturation without significant atypia. Erythroid elements are actively maturing with rare late-stage mitoses. Megakaryocytes are not readily appreciated. 

PERIPHERAL BLOOD
CBC (01/17/2020):
WBC 3.7 L [4.0-11.0 K/mcL] 
RBC 2.63 L [3.80-5.00 M/mcL] 
HGB 9.0 L [11.2-15.4 g/dL] 
HCT 27.2 L [34.3-46.0 %] 
MCV 103 H [80-98 fL] 
MCH 34.2 H [27.0-33.0 pg] 
MCHC 33.1 [31.0-36.5 g/dL] 
RDW 17.5 H [12.2-15.1 %] 
Platelets 127 L [160-400 K/mcL] 

Neutrophil 64.0 [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 3.0 H [0.0-0.0 %] 
Lymph 28.0 [12.2-47.4 %] 
Variant Lymph 1.0 [%] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 2.4 [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 1 [/100(WBCs)]

Morphology:
WBC: Leukoerythroblastosis with few circulating blasts. Basophilia, eosinophilia
RBC: Macrocytic anemia. Few nucleated RBCs. 
Platelets: Mild thrombocytopenia with giant platelets and megakaryocyte fragments

IMMUNOHISTOCHEMISTRY
CD34 and CD117 are non-contributory due to nature of the biopsy.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-663)
Abnormal myeloid blast population detected. 
Basophilia detected, representing 2.3% of WBC. 
Abnormal B-cell population identified. 

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD2 (partial), CD25, CD13 (dim), CD33 (uniform intermediate), CD34 (uniform), CD38 (absent to dim), CD117 (uniform, intermediate); with normal expression of CD4, CD45, CD71, CD123 and HLA-DR; without CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD56 or CD64. CD34 positive myeloid blasts represent 2.4% of WBC. Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition. 

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD20 (bright), CD22 (bright), CD38 (absent), and lambda light chain restriction; with normal expression of CD19 and CD45; and without CD5 or CD10. The abnormal B-cell population represents 1.4% of the total white cells. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-396.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-2521

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-5173;S15;MSK7 - 2023-04-19 11.40.03.ndpi,Peripheral Blood Smear,2023-04-19,"CLL
New onset of leukocytosis. Assess for myeloproliferative neoplasm. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia, BCR-ABL 1 positive, chronic phase.
     - Markedly hypercellular marrow with myeloid predominant maturing trilineage hematopoiesis, with myeloid left-shifted maturation, megakaryocytic atypia, and no increase in blasts.
  
COMMENT: Corresponding karyotype revealed t(9;22) in all 20 metaphases cells and FISH analysis also identified the BCR-ABL fusion in 99.7% of cells, diagnostic for the above entity. The current findings are consistent with chronic phase. No abnormal B-cell populations were identified by flow cytometry and lymphoid aggregates are absent by CD20/PAX5 immunohistology.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular for age (100%)
M:E ratio: Increased
Blasts: Not increased
Myeloid lineage: Increased, with left-shifted maturation
Erythroid lineage: Relatively decreased, actively maturing
Megakaryocytes: Decreased for the cellularity, with atypical forms (""dwarf""-like morphology and nuclear hyperchromasia)
Lymphocytes: Few, scattered
Plasma cells: Rare, scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Blasts                1%
Promyelocytes           7%
Myelocytes           22%
Metamyelocytes           12%
Neutrophils/Bands      32%
Monocytes           1%
Eosinophils           8%
Erythroid Precursors      15%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           5.5

Morphology:
Adequate, spicular and hypercellular aspirate smears with maturing trilineage hematopoiesis and no expanded blast population. The M:E ratio is increased. Myeloid elements are increased, with left-shifted maturation showing an expansion of myelocytes, and no significant dysplasia. Erythroid cells are relatively decreased, present at various stages of maturation and show occasional megaloblastoid features and karyorrhexis. Megakaryocytes are seen associated with spicules with occasional forms showing small size and monolobation. Rare small mature-appearing lymphocytes are seen. Few mast cells are noted.


PERIPHERAL BLOOD
CBC (08/18/2020):
WBC 65.9 H [4.0-11.0 K/mcL] 
RBC 4.42 [3.95-5.54 M/mcL] 
HGB 14.0 [12.5-16.2 g/dL] 
HCT 43.8 [37.5-49.3 %] 
MCV 99 H [80-98 fL] 
MCH 31.7 [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 14.4 [12.2-15.1 %] 
Platelets 157 L [160-400 K/mcL] 

Neutrophil 67.0 [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 6.0 H [0.0-1.5 %] 
Blast 1.0 H [0.0-0.0 %] 
Myelocyte 4.0 H [0.0-0.0 %] 
Promyelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 9.0 H [0.0-0.0 %] 
Lymph 3.0 L [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 44.1 H [1.5-7.5 K/mcL] 
Abs Mono 2.6 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 2.6 H [0.0-0.7 K/mcL] 
Absolute Basophil 4.0 H [0.0-0.2 K/mcL] 
Absolute Blasts 0.7 H [0.0-0.0 K/mcL] 
Abs Myelocytes 2.6 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 1.3 H [0.0-0.0 K/mcL] 
Abs Meta 5.9 H [0.0-0.0 K/mcL] 
Abs Lymph 2.0 [0.9-3.2 K/mcL] 

Morphology:
WBC: No definitive circulating blasts seen. Leukocytosis with neutrophilia and immature granulocytes, including myelocytes and metamyelocytes. Relative and absolute basophilia is also noted. Absolute eosinophilia and monocytosis.
RBC: Normocytic, normochromic RBCs. Rare nucleated RBCs seen.
Platelets: Adequate in number.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts (<5%).
CD117 also highlights early myeloid and erythroid cells.
MPO and CD33 highlight markedly increased myeloid cells, while CD71 highlights decreased erythroid cells, consistent with an increased M:E ratio.
CD61 highlights megakaryocytes, which are decreased for the cellularity, with some small forms identified.
CD3 highlights few, scattered T-cells.
PAX5 and CD20 highlight rare scattered B-cells.
CD5 shows a similar distribution as the is CD3, highlighting scattered T-cells.
LEF1 is positive in a subset of the T-cells.
Cyclin D1 and CD23 are negative in B-cells and

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6505)
Interpretation: 
Abnormal myeloid blast population detected.
No abnormal mature B- or T-cell populations detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD13 (negative), CD33 (uniform), CD34 (dim), HLA-DR (bright); with normal expression of CD4, CD38, CD45, CD71, CD117, CD123, and without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 0.33% of WBC. 

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis reported separately. See separate report, CG20-3995.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M20-25287, M20-25288, M20-26022.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-934;S12;MSK4 - 2023-06-27 23.54.13.ndpi,Peripheral Blood Smear,2023-06-27,"Multiple Myeloma
Pre-transplant on RVD
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
~5% involvement by CD138 immunohistochemistry. See comment.
4% involvement by aspirate differential
1.6% involvement by 10-color flow cytometry
     - Approximately normocellular marrow with maturing trilineage hematopoiesis.

COMMENT: The core biopsy is small, markedly fragmented, with rare intact marrow areas and is limited for evaluation. The clot section is marginally adequate for evaluation, and the quantification of involvement is based on review of CD138 immunohistology on the clot and core sections.
Of note, peripheral thrombocytosis is noted, of unclear etiology. Correlation with molecular studies is advised.
Preliminary findings reported to Dr. Sergio Giralt via email on 2/3/20.

BONE MARROW BIOPSY
Quality: Suboptimal, small, markedly crushed, composed predominantly of bony fragments, bone dust, and rare marrow areas.  
Cellularity: Difficult to assess due to the quality of the biopsy, appears approximately 30% in rare intact marrow areas, and is approximately normocellular (40%) based on the clot section
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes:  Adequate in number without overt atypia  
Plasma cells: Appear mildly increased, however difficult to assess accurately based on the core biopsy. On the clot section, plasma cells appear mildly increased and show atypical morphology, including occasional intermediate to large size, Dutcher bodies, and prominent nucleoli.
Clot section: Contains several small marrow particles and is marginally adequate for evaluation. The description above is largely based on evaluation of the clot section.

ASPIRATE MORPHOLOGY
Aspirate differential: (Performed by: SS)
Blasts                1%
Promyelocytes           2%
Myelocytes           7%
Metamyelocytes           5%
Neutrophils/Bands      44%
Monocytes           4%
Eosinophils           4%
Erythroid Precursors      22%
Plasma Cells           4%
Lymphocytes           7%
Number of Cells Counted 500
M:E Ratio           3

Morphology: 
Marrow spicules: paucispicular    
Cellularity: cellular   
Plasma cell morphology: Small to intermediate, occasionally large in size, with prominent nucleoli and rare bi-nucleated forms seen. 
Myeloid lineage: Orderly maturation   
Erythroid Lineage: Orderly maturation, with occasional forms showing karyorrhexis and late stage mitoses  
Megakaryocytes: Present, with occasional forms showing nuclear hypolobation

IMMUNOHISTOCHEMISTRY
Immunohistology performed on the limited core biopsy shows:
In focal areas of intact marrow particles on the core and clot sections, CD138 immunostain highlights mildly increased plasma cells, ~5% of the cellularity, present scattered singly and in small clusters. 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.  
BCMA highlights 80% of plasma cells, (3+) intensity, predominantly Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-1156) 
Interpretation: 
Small abnormal plasma cell population detected.

Flow cytometry reveals an abnormal plasma cell population with a similar immunophenotype as seen in prior (F19-4386) having abnormal expression of CD19 (absent), CD27 (variable, absent to normal), CD38 (dim), CD45 (major subset absent), CD56 (partial, subset bright), CD81 (absent), and monoclonal kappa cytoplasmic light chain restriction; with normal expression of CD138; and without convincing CD117 expression.  The abnormal population represents 1.6% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 98.2% of total plasma cells in the sample.

PERIPHERAL BLOOD
CBC (01/30/2020):
WBC 8.0 [4.0-11.0 K/mcL] 
RBC 4.48 [3.95-5.54 M/mcL] 
HGB 13.2 [12.5-16.2 g/dL] 
HCT 41.0 [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 29.5 [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 17.4 H [12.2-15.1 %] 
Platelets. 648 H [160-400 K/mcL] 

Neutrophil 74.6 [32.5-74.8 %] 
Mono 12.3 [0.0-12.3 %] 
Eos 3.3 [0.0-4.9 %] 
Baso 0.8 [0.0-1.5 %] 
Immature Granulocyte 0.4 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 8.6 L [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 6.0 [1.5-7.5 K/mcL] 
Abs Mono 1.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 0.7 L [0.9-3.2 K/mcL]

Morphology:
WBC: Lymphopenia. No circulating plasma cells seen on scanning.
RBC: Normocytic, normochromic RBCs with anisocytosis.
Platelets: Thrombocytosis with occasional giant forms seen.


CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate reports, CG20-679, CG20-680.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-4413.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-1675;S12;MSK7 - 2023-06-27 23.48.27.ndpi,Peripheral Blood Smear,2023-06-27,"Plasmacytoid dendritic cell neoplasm status post ASCT and multiple lines of therapy c/b worsening pancytopenia.  
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
     - Extensive involvement by Necrotic Blastic Neoplasm, compatible with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (Close to 100% involvement by CD56 immunostain) (See Comment)
     - Markedly Hypercellular marrow with virtual absence of maturing hematopoiesis

COMMENT: Based on the patient's history, and recent peripheral blood flow cytometry findings (F20-1772; 2/18/20), the findings are compatible with extensive involvement by BPDCN. An unusual finding is the apparent negativity of the tumor cells for CD123 immunostains (stain repeated to confirm), which differed from prior specimens. The significance of this finding is unclear and could be related to the necrotic/poor viability nature of the tumor cells.

Case reviewed at the hematopathology consensus conference on 3/2/20 with concurrence.
The preliminary findings were communicated to Melanie Douglas via email on 2/27/20 11:13am.
  
BONE MARROW BIOPSY
Quality: Small but adequate
Cellularity: Markedly hypercellular (>90% cellularity)
M:E ratio: N/A
Blasts: Extensive marrow replacement by poorly-viable intermediate-sized immature mononuclear cells, with irregular nuclei, fine to dispersed chromatin, and small amount of cytoplasm, associated with patchy areas of necrosis (close to 100% of cellularity)
Myeloid lineage: Markedly reduced
Erythroid lineage: Markedly reduced
Megakaryocytes: Not identified
Lymphocytes: Scattered and small interstitial aggregates.
Plasma cells: Rare

Special stains: 
Reticulin stain shows moderate to marked diffuse reticulin fibrosis (2-3+/3). 

BONE MARROW TOUCH PREPARATION
Differential not performed by MT
Quality of the slides precludes interpretation.

Special stain
Iron: Cannot assess storage iron due to quality of smears
Ring sideroblasts: Suboptimal for evaluation due to paucity of erythroid elements.

Morphology:
Markedly hypocellular touch preparation showing a population of intermediate-sized immature mononuclear cells with round to slightly indented/irregular nuclei, dispersed chromatin, prominent nucleoli, and small amount of cytoplasm. Maturing myeloid and erythroid elements are very rare. Megakaryocytes are not seen.

PERIPHERAL BLOOD
CBC (2/25/2020):
WBC 3.4 L [4.0-11.0 K/mcL] 
RBC 2.67 L [3.80-5.00 M/mcL] 
HGB 7.8 L [11.2-15.4 g/dL] 
HCT 22.7 L [34.3-46.0 %] 
MCV 85 [80-98 fL] 
MCH 29.2 [27.0-33.0 pg] 
MCHC 34.4 [31.0-36.5 g/dL] 
RDW 15.3 H [12.2-15.1 %] 
Platelets. 5 LL [160-400 K/mcL] 

Neutrophil 2.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 72.0 H [0.0-0.0 %] 
Lymph 24.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 0.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 2.4 H [0.0-0.0 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL]

Morphology:
WBC: Leukopenia with marked absolute neutropenia. Frequent circulating intermediate- to large-sized blastic mononuclear cells with irregular/folded nuclei are seen.
RBC: Normocytic, normochromic anemia
Platelets: Marked thrombocytopenia

IMMUNOHISTOCHEMISTRY
The blastic mononuclear cells:
Express: CD4 (weak, subset), CD33 (weak, subset), CD56 (diffuse, strong), TdT (small subset)
Do Not express: CD34, CD117, CD123 (stain repeated), TCL-1A, CD14, CD68, lysozyme, MPO, CD3, CD19

FLOW CYTOMETRIC ANALYSIS, BONE MARROW
Not performed.

CYTOGENETIC STUDIES
Not requested.

MOLECULAR STUDIES 
Not requested.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H20-5314;S11;MSK- - 2023-04-19 10.46.07.ndpi,Peripheral Blood Smear,2023-04-19,"AML. Newly diagnosed. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia with t(8;21). See comment.

COMMENT:
Cytogenetic studies are positive for the presence of t(8;21) (see CG40-4122), and the morphologic and immunophenotypic findings are in keeping with AML with t(8;21).

Clinical correlation is needed to rule out the possibility of a therapy-related myeloid neoplasm.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Normocellular (~30%)
M:E ratio: Not applicable
Blasts: Increased
Myeloid lineage: Limited maturation
Erythroid lineage: Decreased with progressive maturation
Megakaryocytes: Decreased. The few seen are morphologically unremarkable
Lymphocytes: Scattered. One small and benign-appearing lymphoid aggregate that is composed of small, mature lymphocytes is seen in the biopsy.
Plasma cells: Not increased.
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                33%
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           2%
Neutrophils/Bands      30%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      3%
Plasma Cells           1%
Lymphocytes           25%
Number of Cells Counted 500
M:E Ratio           12.7

Morphology:
The aspirates are aspiculate and paucicellular, and are suboptimal for evaluation. Relatively cellular areas show a mixture of blasts and atypical immature myeloid cells with abundant small eosinophilic granules. Rare cells contain Auer rods. Background neutrophils have dysplastic features, including Pelgeroid nuclei and abnormal patterns of cytoplasmic granularity. There are too few erythroid precursors present on this paucicellular aspirate to assess for dysplasia in the erythroid lineage. Rare, if any, megakaryocytes are seen in this limited specimen.

PERIPHERAL BLOOD
CBC (8/24/2020):
WBC 4.1 [4.0-11.0 K/mcL] 
RBC 2.18 L [3.95-5.54 M/mcL] 
HGB 7.3 L [12.5-16.2 g/dL] 
HCT 21.9 L [37.5-49.3 %] 
MCV 101 H [80-98 fL] 
MCH 33.5 H [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 20.0 H [12.2-15.1 %] 
Platelets. 14 LL [160-400 K/mcL] 

Neutrophil 64.0 [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 9.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 21.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 2.6 [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.4 H [0.0-0.0 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL]

Morphology:
WBC: Occasional circulating blasts. Frequent dysplastic neutrophils. Monocytopenia.
RBC: Normochromic RBCs with anisocytosis
Platelets: Marked thrombocytopenia

IMMUNOHISTOCHEMISTRY
Immunostains show that CD34 and CD117+ blast comprise approximately 50% of the marrow cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6680)
Interpretation: 
Expanded abnormal myeloid blast population with partial B-lineage differentiation detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD4 (mostly negative), CD13 (dim), CD19 (dim to normal), CD22 (partial), CD33 (dim), CD34 (bright), CD56 (subset), cCD79a (partial), CD117 (uniform intermediate), HLA-DR (bright) and MPO, with normal expression of CD38, CD45, CD71 and CD123, without CD2, surface CD3, cytoplasmic CD3, CD8, CD10, CD11b, CD14, CD15, CD16, CD25, CD64, or surface light chains.  CD34 positive myeloid blasts represent 32.7% of WBC. Despite a B-lineage differentiation is observed, the expression of CD19 and CD56 is often seen in acute myeloid leukemia with t(8;21). Other possibilities such as mixed phenotype acute leukemia or CML with blast crisis is not favored. Clinical history is required to rule out therapy related myeloid neoplasm. Correlation with morphology and cytogenetic results is required to further classify this leukemia.

CYTOGENETIC STUDIES
RUNX1T1-RUNX1 fusion/t(8;21) detected in 86% of cells.
Full cytogenetic analysis will be reported separately. See separate report, CG20-4122.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-25986, M20-25987, M20-25988, M20-25989.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-550;S12;MSK8 - 2023-04-20 08.56.52.ndpi,Peripheral Blood Smear,2023-04-20,"Leukemia
Acute Leukemia, ?promyelocytic leukemia 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute promyelocytic leukemia; with PML-RARA fusion t(15;17).
  

BONE MARROW BIOPSY
Quality: Adequate. 
Cellularity: Hypercellular for age (>90% cellularity overall).
M:E ratio: NA.
Blasts and blast equivalents: Markedly increased, in sheets.
Myeloid lineage: Decreased, left shifted maturation.
Erythroid lineage: Decreased, progressive maturation.
Megakaryocytes: Decreased, unremarkable morphology
Lymphocytes: Interstitially scattered. 
Plasma cells: Interstitially scattered. 
Special stains: Reticulin stain shows mild to moderate increase in reticulin fibrosis (1-2/3).
Clot: Cellular and similar to biopsy

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Auer Rods noted
Blasts                12%
Promyelocytes           48%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      2%
Erythroid Precursors      22%
Lymphocytes           12%
Number of Cells Counted 500
M:E Ratio           2.5

Morphology:
- Spicular and cellular smears show increased blasts (12% by 500 cell aspirates differential count) and blast equivalents (promyelocytes  48%). The blasts are intermediate sized with round to slightly irregular indented nuclei, fine chromatin, variably prominent nucleoli and scant, occasionally vacuolated cytoplasm. Auer rods are noted. In addition, there are increased promyelocytes. There is decreased background trilineage hematopoiesis. Myeloid elements show left shifted maturation with no overt dysplasia. Erythroid elements are normal in proportion with progressive maturation and no overt dysplasia. Megakaryocytes are markedly decreased.

PERIPHERAL BLOOD
CBC (01/20/2020):
WBC 3.6 L [4.0-11.0 K/mcL] 
RBC 2.74 L [3.80-5.00 M/mcL] 
HGB 8.7 L [11.2-15.4 g/dL] 
HCT 25.9 L [34.3-46.0 %] 
MCV 95 [80-98 fL] 
MCH 31.8 [27.0-33.0 pg] 
MCHC 33.6 [31.0-36.5 g/dL] 
RDW 16.8 H [12.2-15.1 %] 
Platelets 48 L [160-400 K/mcL] 

Neutrophil 31.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 3.0 H [0.0-0.0 %] 
Promyelocyte 10.0 H [0.0-0.0 %] Auer rods noted.
Lymph 54.0 H [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 1.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.4 H [0.0-0.0 K/mcL] 
Abs Lymph 1.9 [0.9-3.2 K/mcL]

Attending Review 
Manual differential is confirmed, including presence of circulating blasts and promyelocytes. Auer rods confirmed. Suggest correlation with flow cytometry and cytogenetic studies for further evaluation. Clinical correlation is recommended. I attest that the above interpretation/recommendation is based upon my personal examination of the source material and patient clinical history, if indicated, and that I have reviewed this report. Amanda Blouin MD, PhD Prov ID: 021121 01/20/2020 1:36 PM EST

Morphology: 
WBC: Absolute neutropenia, with circulating blasts having auer rods. Increase in promyelocytes.
RBC: Normocytic anemia.
Platelets: Thrombocytopenia with unremarkable morphology.

IMMUNOHISTOCHEMISTRY
Immunostains for CD117 show sheets of blasts (~80% cellularity). CD34 stains a minor subset of blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-675)
Expanded abnormal myeloid blast/atypical promyelocyte population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD2 (mostly positive), CD7 (partial dim), CD11b (partial), CD13 (uniform, intermediate), CD15 (partial), CD19 (partial, dim), CD33 (uniform, intermediate), CD34 (absent to intermediate), CD38 (absent to dim), CD64, cytoplasmic CD79a (partial, dim), CD117 (absent to intermediate), CD123 (uniform bright), HLADR (mostly absent) with normal expression of CD4, CD45, CD71; without surface CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD16, CD20, CD25, CD56 or surface light chains. MPO expression is present. CD117 positive myeloid blasts/promyelocytes represent 88.0% of WBC. The findings raise a possibility of microgranular APL correlation with cytogenetic study is advised.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F20-671)
Expanded abnormal myeloid blast/atypical promyelocyte population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD2 (mostly positive), CD7 (partial dim), CD11b (partial), CD13 (dim to intermediate), CD19 (partial, dim), CD33 (uniform, intermediate), CD34 (absent to intermediate), CD38 (absent to dim), cytoplasmic CD79a (partial, dim), CD117 (absent to dim), CD123 (uniform bright), HLADR (mostly absent) with normal expression of CD4, CD45, CD71; without surface CD3, significant cytoplasmic CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD20, CD25, CD56, CD64 or surface light chains. MPO expression is present. CD117 positive myeloid blasts represent 47.4% of WBC. The findings raise a possibility of microgranular variant of APL, correlation with cytogenetic studies is required.

CYTOGENETIC STUDIES
CG20-406. FISH ANALYSIS:
PML-RARA fusion/t(15;17) detected in 79.3% of cells.
Translocation of RARA (17q21.2) detected in 73% of cells.
Chromosome analysis is in progress and will be reported as an addendum.
A correlation with other studies is recommended for a precise diagnosis.
Note: Cytogenetics Laboratory Interim Report electronically mailed to referring clinician on 1/20/2020.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-2594, M20-2595, M20-2596, M20-2597, M20-2598.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     
"
H20-767;S11;MSK7 - 2023-06-27 02.20.02.ndpi,Peripheral Blood Smear,2023-06-27,"Chronic neutropenia and low-grade lymphoma 
h/o chronic neutropenia since birth, new abnormal lymphoid population
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by CD5 positive B cell lymphoproliferative disorder (10-15% by CD20 immunostain), see comment 1.
     - Mildly hypercellular marrow with trilineage maturing hematopoiesis and mildly left shifted myeloid maturation, see comment 2.
  
COMMENT: 1) The immunophenotype of this B-LPD is non-specific. The differential diagnosis includes marginal zone lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma, less likely, follicular lymphoma and mantle cell lymphoma. Clinical correlation with cytogenetic and molecular findings is suggested.

2) Per clinical notes patient has a history of congenital neutropenia and has been on Neupogen (G-CSF) therapy. Current specimen reveals mild degree of dyspoiesis in the myeloid lineage; however, this is likely related to G-CSF therapy. The concurrent cytogenetic studies (CG20-557) reveal a normal female karyotype. Correlation with molecular studies is recommended. 

The case was reviewed with Dr. Wenbin Xiao, Hematopathology service, who agrees.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Mildly hypercellular for age (60-70%)
M:E ratio: Normal 
Blasts: Not overtly increased
Myeloid lineage: Shows mildly left shifted maturation 
Erythroid lineage: Shows progressive maturation
Megakaryocytes: Adequate in number with occasional small hypolobated forms
Lymphocytes: Scattered non-paratrabecular lymphoid aggregates composed of small to medium sized lymphoid cells with ovoid nuclei and clumped chromatin are noted.
Plasma cells: Interstitially scattered 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Patchy Aspirates
Blasts                2%
Promyelocytes           5%
Myelocytes           8%
Metamyelocytes           4%
Neutrophils/Bands      13%
Monocytes           1%
Eosinophils           12%
Erythroid Precursors      24%
Plasma Cells           1%
Lymphocytes           30% 
Number of Cells Counted 500
M:E Ratio           1.9

Special Stain
Iron: Suboptimal for evaluation, devoid of spicules
Ring sideroblasts: Absent

Morphology:
- Spicular and cellular smears showing trilineage hematopoiesis, with no overt increase in blasts. There are numerous lymphoid cells small to medium in size with ovoid nuclei and clumped chromatin. Myeloid elements show left shifted maturation with a subset of elements showing cytoplasmic vacuolation and hypogranularity. Mild eosinophilia is noted. Erythroid elements exhibit progressive maturation with no overt dysplasia. Megakaryocytes are adequate in number with rare small hypolobated forms noted. Scattered plasma cells are seen. Touch imprints have similar findings as aspirates.

PERIPHERAL BLOOD
CBC (01/27/2020):
WBC 5.4 [4.0-11.0 K/mcL] 
RBC 4.53 [3.80-5.00 M/mcL] 
HGB 13.0 [11.2-15.4 g/dL] 
HCT 40.0 [34.3-46.0 %] 
MCV 88 [80-98 fL] 
MCH 28.7 [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 13.0 [12.2-15.1 %] 
Platelets 179 [160-400 K/mcL] 

Neutrophil 26.5 L [32.5-74.8 %] 
Mono 23.6 H [0.0-12.3 %] 
Eos 10.9 H [0.0-4.9 %] 
Baso 2.6 H [0.0-1.5 %] 
Immature Granulocyte 1.8 H [0.0-0.6 %] 
Lymph 34.6 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 1.4 L [1.5-7.5 K/mcL] 
Abs Mono 1.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.6 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] 
Abs Lymph 1.9 [0.9-3.2 K/mcL] 

Morphology:
WBC: Immature granulocytes. A subset of hypogranular granulocytes noted
RBC: Unremarkable
PLT: Unremarkable

IMMUNOHISTOCHEMISTRY
CD20 and PAX 5 show increased B cells in aggregates (10-15% cellularity). The atypical B cells are positive for CD5 and negative for LEF1, SOX11 and Cyclin D1.
CD138 shows scattered and small clusters of plasma cells, <5% of total cellularity. Kappa and Lambda immunostains do not show a definite light chain restriction. 
CD3 labels scattered T cells
CD61 labels megakaryocytes, few small hypolobated forms noted.
CD34 and CD117 do not show an increase in blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-950)
Abnormal B-cell population identified.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
Eosinophilia and basophilia seen, representing 9.9% and 1.9% of WBC respectively.

Flow cytometry identified an abnormal B-cell population having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23 (partial), CD200 (dim to absent) and lambda surface light chain restriction (dim); normal expression of CD19 and CD45; and without FMC7, CD38, or CD10 expression. The abnormal B-cell population comprises 2.4% of the white cells.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.63% of WBC.
355,596 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F20-951)
Abnormal B-cell population identified.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
Eosinophilia and basophilia seen, representing 11.6% and 2.5% of WBC, respectively.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23 (partial), CD45 (slightly dim), and lambda surface light chain restriction (dim); normal expression of CD19 and CD38; and without CD10, CD200 or FMC7. The abnormal B-cell population comprises 0.13% of the white cells representing absolute count of 0.007 thousand/microliter of blood. 

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.063% of WBC.
198,400 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Also see F20-950 submitted on the same day.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-557.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-3690, M20-3691.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-8242;S12;MSK4 - 2023-06-15 20.29.43.ndpi,Peripheral Blood Smear,2023-06-15,"Thrombocytopenia.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Extensive involvement by hairy cell leukemia.
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular for age, ~90%
M:E ratio: N/A
Lymphocytes: Diffuse infiltrate of atypical lymphoid elements ranging in size between small and intermediate, with round nuclei, clumped chromatin, and abundant clear cytoplasm. The atypical lymphocytes represent >95% of total cellularity
Only scattered residual myeloid and erythroid precursors at body stages of maturation are seen in the background. Rare megakaryocytes with overall normal morphology are present.
Plasma cells: Not increased
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1). 
Clot: Blood

BONE MARROW ASPIRATE SMEAR
Differential (performed by CB):
Myelocytes           1%
Neutrophils/Bands      1%
Erythroid Precursors      10%
Plasma Cells           1%
Lymphocytes           3%
Hairy cells           84%  
Number of Cells Counted     500
M:E Ratio           0.2

Morphology:
Spicular and cellular bone marrow aspirate smears showing marked increased number of atypical lymphoid elements ranging in size between small and intermediate, with round nuclei, clumped chromatin, and abundant clear cytoplasm. A subset of lymphocytes shows villous cytoplasmic projections.

PERIPHERAL BLOOD
CBC (12/14/2020):
WBC 25.6 H [4.0-11.0 K/mcL] 
RBC 3.62 L [3.95-5.54 M/mcL] 
HGB 12.8 [12.5-16.2 g/dL] 
HCT 37.8 [37.5-49.3 %] 
MCV 104 H [80-98 fL] 
MCH 35.4 H [27.0-33.0 pg] 
MCHC 33.9 [31.0-36.5 g/dL] 
RDW 14.6 [12.2-15.1 %] 
Platelets. 98 L [160-400 K/mcL] 

Neutrophil 8.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 22.0 [12.2-47.4 %] 
Hairy Cell 67.0 H [0.0-0.0 %] 
Nucleated RBC 2 [/100(WBCs)] 

Abs Neut 2.0 [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.3 H [0.0-0.0 K/mcL] 
Abs Meta 0.3 H [0.0-0.0 K/mcL] 
Abs Lymph 5.6 H [0.9-3.2 K/mcL] 
Abs Hairy Cells 17.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology: Presence of atypical lymphocytes with features consistent with hairy cells, including medium size, round nuclei with variably condensed chromatin, moderate to abundant cytoplasm and occasional villous cytoplasmic projections.

IMMUNOHISTOCHEMISTRY
Immunostains show that the atypical lymphoid elements are diffusely positive for CD20, display weak staining for BRAF and cyclin D1 (subset). CD123 highlights scattered positive cells. CD3 is positive in small T-cells in the background.  Additional stains have been ordered and results will be reported in an addendum.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-10528)
Abnormal B-cell population identified.
Atypical myeloid blast population detected. 
No abnormal mature T-cell population detected.

Flow cytometry reveals an abnormal mature B-cell population having abnormal expression of CD10, CD19 (dim to bright), CD20 (bright), CD11c, CD22 (bright), CD25, CD45 (bright), CD103 (partial), CD200 (bright), and CD279 (PD1) with slightly increased forward and side scatter and kappa light chain restriction (bright); and without CD3, CD5, CD14 or CD38. The immunophenotype of the abnormal B-cell population is compatible with involvement by hairy cell leukemia. The abnormal B cell population represents 76.6% of the total white cells.

Flow cytometry identifies an atypical myeloid blast population having atypical expression of CD33 (dim/absent), CD38 (dim/absent), CD117 (dim) and HLA-DR (subset dim), with normal expression of CD4, CD13, CD34, CD45, CD71, and CD123 without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64. CD34 positive myeloid blasts represent 0.16% of WBC. In the context of involvement by hairy cell leukemia, the clinical significance of this finding is not entirely clear, but a low-grade myeloid stem cell disorder cannot be entirely excluded. Sorted populations will be forwarded to diagnostic molecular pathology laboratories for additional testing. Please see separate reports.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-6702.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-41930 and M20-41958.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-5125;S12;MSK1 - 2023-04-17 16.45.07.ndpi,Peripheral Blood Smear,2023-04-17,"AML with t(6;9), also FLT3-ITD. D+49 from induction, persistent transfusion dependence 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Relapsed/ persistent acute myeloid leukemia with t(6;9)(p23:q34); DEK-NUP214, 45% blasts by aspirate differential count. 
     - Hypercellular marrow with maturing trilineage hematopoiesis, decreased erythropoiesis and megakaryopoiesis, and multilineage dysplasia.
  
COMMENT: Preliminary findings provided to Dr. Martin Tallman, Department of Medicine, via email on 8/20/2020.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular for age (95%)
M:E ratio: N/A
Blasts: Increased, distributed singly and in small clusters interstitially and in periosteal cuffs. Blasts are large in size, with round to slightly irregular nuclei, fine chromatin, conspicuous single to multiple nucleoli, and moderate amount of pale to eosinophilic cytoplasm.
Myeloid lineage: Shows maturation to the neutrophil stage
Erythroid lineage: Appears relatively decreased
Megakaryocytes: Decreased for the cellularity with dysplastic forms (small, hypolobated, and forms with ""bare nuclei"" morphology)
Lymphocytes: Few, scattered
Plasma cells: Rare, scattered
Special stains: Reticulin stain shows mild to moderate increase in reticulin fibrosis (MF-1 to MF-2). 
Clot section: Contains rare marrow particles with similar morphology as the core biopsy.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                45% 
Promyelocytes           1%
Myelocytes           4%
Metamyelocytes           3%
Neutrophils/Bands      22%
Monocytes           7%
Basophils           1%
Erythroid Precursors      12%
Plasma Cells           1%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           3.2

Morphology:
Spicular and cellular aspirate smears with maturing trilineage hematopoiesis and an expanded blast population. Blasts show a patchy distribution and focally up to 70% involvement is seen. Blasts are large in size, with round to slightly irregular nuclei, fine chromatin, inconspicuous nucleoli, and scant to moderate amount of cytoplasm. Auer rods are not seen. Myeloid cells show progressive maturation with dysplasia (hypogranulation and pseudo-Pelger-Huet forms). Erythroid precursors show progressive maturation with occasional karyorrhexis. Few megakaryocytes are seen with occasional monolobated small forms. Rare small mature-appearing lymphocytes are present.

PERIPHERAL BLOOD
CBC (8/17/2020):
WBC 1.9 L [4.0-11.0 K/mcL] 
RBC 2.77 L [3.80-5.00 M/mcL] 
HGB 8.5 L [11.2-15.4 g/dL] 
HCT 24.6 L [34.3-46.0 %] 
MCV 89 [80-98 fL] 
MCH 30.7 [27.0-33.0 pg] 
MCHC 34.6 [31.0-36.5 g/dL] 
RDW 12.0 L [12.2-15.1 %] 
Platelets 28 L [160-400 K/mcL] 

Neutrophil 74.0 [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Lymph 24.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 1.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBC: Rare circulating blasts (~1%), morphologically similar to those on the aspirate smears. Leukopenia neutropenia and lymphopenia. Mild basophilia is noted. Neutrophils are hypogranular.
RBC: Normocytic, hypochromic anemia with mild anisocytosis.
Platelets: Thrombocytopenia

IMMUNOHISTOCHEMISTRY
CD117 shows increased scattered singly interstitially, in small clusters, and in a periosteal distribution, occupying approximately 30% of the marrow cellularity.
A small subset blasts are positive for CD34.
CD34 also highlights the vasculature.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6445)
Interpretation: 
Abnormal myeloid blast and maturing granulocyte populations detected. 

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD7 (partial), CD11b (partial), CD13 (bright), CD33 (bright), CD34 (subset dim/absent), CD117 (uniform bright), CD123 (uniform intermediate) with normal expression of CD4, CD38, CD45, CD71, and HLA-DR without CD2, CD5, CD14, CD15, CD16, CD19, CD25, CD56, CD64. CD117 positive myeloid blasts represent 17.0% of WBC. 

Granulocytic population shows retention of CD13 and CD64 as well as reduced side scatter suggestive of hypogranularity.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-3961.

MOLECULAR STUDIES 
Not submitted.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-8248;S2;MSK9 - 2023-06-15 20.23.55.ndpi,Peripheral Blood Smear,2023-06-15,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears:
     - B-lymphoblastic acute leukemia/lymphoma (B-ALL; 50% involvement by differential count).

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Blasts                50%
Myelocytes           8%
Metamyelocytes           4%
Neutrophils/Bands      10%
Eosinophils           2%
Erythroid Precursors      22%
Lymphocytes           4%
Number of Cells Counted      500
M:E Ratio           1.1

Morphology:
Spicular and cellular bone marrow aspirate smears. There is a markedly increased in number of blasts, showing round to slightly irregular nuclei, dispersed chromatin, conspicuous nucleoli and scant basophilic cytoplasm. Only occasional myeloid and erythroid elements at various stages of maturation are seen in the background, together with the scattered megakaryocytes with overall normal morphology.

PERIPHERAL BLOOD
CBC (12/14/2020):
WBC 4.2 L [7.1-15.9 K/mcL] 
RBC 3.74 [3.70-4.90 M/mcL] 
HGB 11.1 [10.6-13.3 g/dL] 
HCT 32.7 [32.4-40.4 %] 
MCV 87 [74-91 fL] 
MCH 29.7 H [22.7-29.5 pg] 
MCHC 33.9 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 261 [160-400 K/mcL] 

Neutrophil 19.0 [16.9-74.5 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 17.0 H [0.0-0.0 %] 
Lymph 63.0 H [15.5-57.8 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 0.8 L [1.5-8.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.7 H [0.0-0.0 K/mcL] 
Abs Lymph 2.7 [1.0-4.3 K/mcL] 

Morphology: Reviewed peripheral blood smear shows occasional circulating blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-10544)
Abnormal immature B-cell population detected.
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow (89.7% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD10 (dim to bright), CD33 (partial), CD38 (absent to intermediate), CD45 (absent to dim), CD66c/CD123 (bright), CD81 (dim), CD86 with normal expression of CD10, CD19, CD22, CD24, CD34, CD71, cytoplasmic CD79a, and HLA-DR; and without CD2, surface/cytoplasmic CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD20, CD56, CD64, CD66b, CD86, CD117, CD73/CD304, MPO, or surface light chains.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.17% of WBC.
401 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-6679 and CG20-6680.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-41909, M20-41910 and M20-41911.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. PessinMD., PhD., Director.

"
H20-8390;S12;MSKH - 2023-04-17 16.11.44.ndpi,Peripheral Blood Smear,2023-04-17,"Leukemia
Leukocytosis 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
    - Chronic myelomonocytic leukemia 0 (CMML-0), 1% blasts by aspirate differential. See comment.

COMMENT: In the context of thrombocytopenia and anemia, with peripheral absolute and relative monocytosis, the bone marrow findings of granulocytic hyperplasia, dysmegakaryopoiesis and reported mutational profile (ASXL1, CBL, TET2, KRAS) are consistent with a myelodysplastic/myeloproliferative syndrome overlap and is best subclassified as chronic myelomonocytic leukemia 0 (CMML-0). Correlation with forthcoming in-house cytogenetic and molecular studies is recommended.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular for age (~95% cellularity)
M:E ratio: Increased
Blasts: Not overtly increased     
Myeloid lineage: Increased in number, shows left-shifted progressive maturation     
Erythroid lineage: Relatively decreased in number, shows progressive maturation     
Megakaryocytes: Adequate in number and show atypical/dysplastic forms (small and hypolobated and/or hyperchromatic)
Lymphocytes: A few crushed possible lymphoid aggregates are seen
Plasma cells: Interstitially scattered     
Clot section: Shows blood clot admixed with marrow elements and minute marrow particles with similar findings

Special stains: 
Reticulin stain shows focal mild increase in reticulin fibrosis (0-1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                1%
Promyelocytes           2%
Myelocytes           18%
Metamyelocytes           11%
Neutrophils/Bands      38%
Monocytes           17%
Eosinophils           1%
Erythroid Precursors      10%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           8.7

Morphology:
Spicular and cellular aspirate smears demonstrate maturing trilineage hematopoiesis and increased M:E ratio. No increase in blasts/blasts equivalents is seen. No definite Auer rods are seen. Myeloid elements show left-shifted maturation with mild dyspoiesis (<10% of lineage; Pseudo Pelger-Huet forms). Erythroid elements show progressive maturation with mild dyspoiesis (<10% of lineage; binucleation, late stage mitosis). Megakaryocytes are present and show a few hypolobated forms.     

PERIPHERAL BLOOD
CBC (12/21/2020):
WBC 45.5 H [4.0-11.0 K/mcL] 
RBC 4.28 [3.95-5.54 M/mcL] 
HGB 10.9 L [12.5-16.2 g/dL] 
HCT 35.3 L [37.5-49.3 %] 
MCV 83 [80-98 fL] 
MCH 25.5 L [27.0-33.0 pg] 
MCHC 30.9 L [31.0-36.5 g/dL] 
RDW 15.0 [12.2-15.1 %] 
Platelets. 83 L [160-400 K/mcL] 

Neutrophil 58.0 [32.5-74.8 %] 
Mono 19.0 H [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 3.0 H [0.0-0.0 %] 
Promyelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 5.0 H [0.0-0.0 %] 
Lymph 12.0 L [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 26.4 H [1.5-7.5 K/mcL] 
Abs Mono 8.7 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.5 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 1.4 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.9 H [0.0-0.0 K/mcL] 
Abs Meta 2.3 H [0.0-0.0 K/mcL] 
Abs Lymph 5.5 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBCs: Absolute neutrophilia with marked left shift (band forms, myelocytes, metamyelocytes). Absolute monocytosis with occasional atypical monocytes. Blasts are not increased.
RBCs: Normocytic normochromic anemia. 
Platelets: Thrombocytopenia with occasional giant forms.     

IMMUNOHISTOCHEMISTRY
CD34 immunostain shows no increase in blasts (<5% of cellularity). Aberrant CD34 expression is seen in rare megakaryocytes. 
CD117 highlights scattered mast cells as well as scattered early erythroid and myeloid precursors, and occasional megakaryocytes.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-10721)
Abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD5 (subset), CD7 (partial), CD13 (subset dim), CD33 (absent to dim), CD38 (slightly dim), CD117 (uniform bright), HLADR (uniform bright) with normal expression of CD4, CD34, CD45, CD71, CD123; without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cytoplasmic CD79a, or surface light chains. MPO expression is present on a subset of blasts. CD34 positive myeloid blasts represent 0.79% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-6840.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-42727, M20-42728.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-1055;S12;MSK9 - 2023-06-27 01.23.08.ndpi,Peripheral Blood Smear,2023-06-27,"Multiple Myeloma. 
Rule out systemic disease.

","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
20-25% involvement by CD138 immunohistochemistry.
23% involvement by aspirate differential
6% involvement by 10-color flow cytometry
     - Approximately normocellular marrow with erythroid predominant maturing trilineage hematopoiesis. See comment.
     - No diagnostic morphologic evidence of metastatic carcinoma.

Comment: Correlation with clinical findings including metabolic and CBC parameters, serum/ urine protein electrophoresis and immunofixation, and imaging studies is needed to further classify this plasma cell neoplasm.


BONE MARROW BIOPSY
Quality: Adequate, although fragmented, partially aspirated, and with intramedullary hemorrhage
Cellularity: Difficult to assess accurately due to the quality of the biopsy, appears approximately normocellular for age (30%)
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes: Adequate in number, with occasional forms showing nuclear hyperchromasia and hypolobation  
Plasma cells: Increased, scattered singly interstitially and in small clusters, with mature morphology, best appreciated by immunohistology (see below)    
Clot section: Adequate for evaluation with similar morphology as the core biopsy

ASPIRATE MORPHOLOGY
Aspirate differential: (Performed by CB)

Blasts                1%
Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           7%
Neutrophils/Bands      23%
Monocytes           2%
Eosinophils           1%
Erythroid Precursors      26%
Plasma Cells           23%
Lymphocytes           7%
Number of Cells Counted 500
M:E Ratio           1.7

Morphology: 
Marrow spicules: Spicular    
Cellularity: Cellular   
Plasma cell morphology: Patchy distribution. Intermediate in size with few binucleate forms seen, and rare forms showing prominent nucleoli
Myeloid lineage: Orderly maturation   
Erythroid Lineage: Orderly maturation with occasional megaloblastoid features, late stage mitoses, and karyorrhexis   
Megakaryocytes: Present associated with spicules, without overt atypia    

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights increased plasma cells, and a patchy distribution, scattered singly interstitially and in focal large clusters, overall accounting for ~20-25% of the marrow cellularity. 
Kappa and lambda immunostains show that the plasma cells are lambda light chain restricted.  
BCMA highlights >90% of plasma cells, (2+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-1321)
Interpretation: 
Abnormal plasma cell population detected.
No abnormal mature B-cell population detected.

Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (absent), CD20 (partial), CD27 (variable, normal to absent), CD45 (major subset absent), CD81 (absent) and monoclonal lambda cytoplasmic light chain restriction; with normal expression of CD38 and CD138; and without convincing CD56 or CD117 expression. The abnormal population represents 6.0% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 82.3% of total plasma cells in the sample.

No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

PERIPHERAL BLOOD
CBC (2/05/2020):
WBC 6.9 [4.0-11.0 K/mcL] 
RBC 3.75 L [3.80-5.00 M/mcL] 
HGB 12.2 [11.2-15.4 g/dL] 
HCT 38.1 [34.3-46.0 %] 
MCV 102 H [80-98 fL] 
MCH 32.5 [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 13.4 [12.2-15.1 %] 
Platelets 191 [160-400 K/mcL]
 
Neutrophil 65.4 [32.5-74.8 %] 
Mono 7.1 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.1 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 25.8 [12.2-47.4 %] 

Abs Neut 4.5 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.8 [0.9-3.2 K/mcL] 

Morphology: No circulating plasma cells seen

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate reports, CG20-780, CG20-781.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-5118.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.
 
The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

     
"
H20-4917;S2;MSK8 - 2023-06-07 02.42.18.ndpi,Peripheral Blood Smear,2023-06-07,[NULL],"1-2.  Bone marrow, left posterior iliac crest, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 (96% blasts by aspirate differential count).

COMMENT: Cytogenetic analysis performed on the peripheral blood demonstrated a t(12;21) ETV6-RUNX1 fusion (CG20-3710), supporting the above classification.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                96%
Neutrophils/Bands      1%
Erythroid Precursors      2%
Lymphocytes           1%
Number of Cells Counted 500
M:E Ratio           0.5

Morphology:
Aspicular but cellular smears show a markedly expanded population of blasts, which range from small to large in size with rounded to irregular/convoluted nuclei, fine chromatin, occasional distinct nucleoli and scant cytoplasm. Rare myeloid and erythroid elements and megakaryocytes are seen. 

PERIPHERAL BLOOD
CBC (8/7/2020):
WBC 34.6 H [7.1-15.9 K/mcL] 
RBC 1.99 L [2.93-4.75 M/mcL] 
HGB 6.1 L [9.2-12.7 g/dL] 
HCT 17.3 L [27.7-37.9 %] 
MCV 87 H [70-85 fL] 
MCH 30.5 H [22.7-29.5 pg] 
MCHC 34.9 [31.0-36.5 g/dL] 
RDW 15.7 H [12.2-15.1 %] 
Platelets 51 L [160-400 K/mcL] 

Neutrophil 1.0 L [16.9-74.5 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 88.0 H [0.0-0.0 %] 
Smudge cells noted.
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 10.0 L [18.1-79.9 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 0.3 L [1.5-8.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 30.4 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.3 H [0.0-0.0 K/mcL] 
Abs Lymph 3.5 [1.1-8.1 K/mcL]

Morphology:
WBC: Frequent circulating blasts morphologically similar to those in the aspirate smears. Absolute neutropenia.
RBC: Macrocytic anemia. 
Platelets: Thrombocytopenia.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6186)
Interpretation: 
Abnormal immature B-cell population detected.
An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously [F20-6103].  The abnormal immature B-cells represent 96.6% of the white cells and 97.0% of the mononuclear cells in the sample and abnormally express CD10 (bright), CD19 (bright), CD20 (absent to dim), CD34 (absent to intermediate), CD45 (absent to dim), CD73/CD304 (uniform); with normal expression of CD22, CD24, CD38 and CD81; and without CD66b, CD66c/CD123 or CD86.  This finding is consistent with persistent/recurrent B-lymphoblastic leukemia/lymphoma, depending on the clinical context.  Clinical and morphologic correlation is recommended.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F20-6103)
Interpretation: 
Abnormal immature B-cell population detected.
No abnormal mature B- or T-cell populations detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood (76.1% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD10 (bright), CD20 (negative to dim), CD38 (slightly dim), CD66c/CD123 (negative to dim), CD73/CD304, with normal expression of CD19, CD22, CD24, CD34, CD71, cytoplasmic CD79a, CD81, and HLA-DR; and without CD2, surface CD3, cytoplasmic CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD25, CD33, CD56, CD64, CD66b, CD86, CD117, MPO or surface light chains. 

No abnormal myeloid blast, monocyte or maturing myeloid population identified. Few CD34 positive myeloid blasts are seen.
162932 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Not submitted.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-24118, M20-24119, M20-24122.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. Pessin MD., PhD., Director.
  
"
H20-2113;S11;MSKU - 2023-04-25 22.14.51.ndpi,Peripheral Blood Smear,2023-04-25,"AML
Disease Status 
","1-3. Bone marrow, left posterior iliac crest; biopsy, touch imprints and peripheral blood smear: 
     - Persistent acute myeloid leukemia (56% blasts by differential count on paucicellular/hemodilute touch imprints and 51% in peripheral blood).
  
BONE MARROW BIOPSY
Quality: Suboptimal (subcortical with crush artifact)
Cellularity: Markedly hypercellular (>90%)
M:E ratio: Appears increased 
Blasts: Increased 
Myeloid lineage: Left-shifted maturation 
Erythroid lineage: Reduced 
Megakaryocytes: Appear markedly reduced to absent
Lymphocytes: Rare 
Plasma cells: Rare 
Other: Small foci of necrosis are seen
Special stains: Reticulin stain shows a mild to moderate increase in reticulin fibrosis (MF-1-2)

BONE MARROW TOUCH IMPRINTS
Differential: (Performed touch imprint smear by CB)
Blasts                56%
Myelocytes           3%
Metamyelocytes           3%
Neutrophils/Bands      17%
Monocytes           2%
Erythroid Precursors      2%
Lymphocytes           17%
Number of Cells Counted 100
M:E Ratio           12.5

Morphology:
Touch imprints are paucicellular and hemodilute. The show an expanded population of intermediate to large sized blasts with rounded to irregular nuclei, fine chromatin, distinct nucleoli and scant cytoplasm. Few scattered myeloid elements and rare nucleated red blood cells are seen. Megakaryocytes are not readily identified. 

PERIPHERAL BLOOD
CBC (03/11/2020):
WBC 17.8 H [4.0-11.0 K/mcL] 
RBC 2.73 L [3.95-5.54 M/mcL] 
HGB 8.0 L [12.5-16.2 g/dL] 
HCT 25.0 L [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 29.3 [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 16.2 H [12.2-15.1 %] 
Platelets 22 L [160-400 K/mcL] 

Neutrophil 20.0 L [32.5-74.8 %] 
Mono 10.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 51.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Promyelocyte 2.0 H [0.0-0.0 %] 
Lymph 15.0 [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 3.6 [1.5-7.5 K/mcL] 
Abs Mono 1.8 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 9.1 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.4 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.4 H [0.0-0.0 K/mcL] 
Abs Lymph 2.7 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBCs: Leukocytosis with numerous circulating blasts and frequent neutrophils showing hypogranulation and/or abnormal nuclear segmentation. 
RBCs: Normocytic, normochromic anemia with rare nucleated RBCs. 
Platelets: Marked thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight an increase in blasts, which are difficult to definitively enumerate due to the crush artifact and high background staining but are estimated to comprise ~20% of the cellularity overall, focally reaching ~50%. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW
Not performed 

CYTOGENETIC STUDIES
Not requested 

MOLECULAR STUDIES 
Not requested 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-488;S12;MSK8 - 2023-06-27 03.00.06.ndpi,Peripheral Blood Smear,2023-06-27,"Myelodysplastic syndrome.  Post dli.

","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
    - Highly suspicious for persistent MDS with ring sideroblasts and no increase in blasts 
    - Mildly hypocellular marrow with maturing trilineage hematopoiesis, mild erythroid and granulocytic dyspoiesis, including rare ring sideroblasts and no increase in blasts.
  
COMMENT: While definitive criteria for morphologic diagnosis of MDS are not fully met in the current sample, presence of ring sideroblasts (slightly below 5%) and hypolobated granulocytes in the setting of relapsed MDS-RS with SF3B1 mutation is highly concerning for the persistence of the underlying clone at least at low levels. While flow cytometry failed to identify a definitive abnormal blast population, the finding doe s NOT rule out a low level MDS clone. Correlation with molecular genetic and cytogenetic studies is advised, 

BONE MARROW BIOPSY
Quality: Adequate, partially subcortical 
Cellularity: Mildly hypocellular for age (20-30%) with evidence of stromal damage 
M:E ratio: Increased 
Blasts: Not increased
Myeloid lineage: Relatively increased, with left-shifted maturation 
Erythroid lineage: Relatively decreased, with progressive maturation 
Megakaryocytes: Adequate in number with atypical forms showing nuclear hyperchromasia and hypo-/monolobation
Lymphocytes: Few, scattered 
Plasma cells: Few, scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 
Other: Hemosiderin deposition 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Blasts                2%
Promyelocytes           6%
Myelocytes           17%
Metamyelocytes           13%
Neutrophils/Bands      26%
Monocytes           6%
Eosinophils           3%
Erythroid Precursors      12%
Plasma Cells           1%
Lymphocytes           14%
Number of Cells Counted      500
M:E Ratio           5.9

Special stain
Iron: Present.
Ring sideroblasts: Rare <5%.

Morphology:
The aspirate smears are spicular, cellular and show maturing trilineage hematopoiesis; no expanded blast population is seen. Myeloid elements are show left shifted maturation with few hypolobated/hypogranular forms . Erythroid elements are relatively reduced with full maturation with few atypical forms (karyorrhexis, late stage mitoses). Megakaryocytes are mostly unremarkable with few hypolobated forms. Mast cells noted. 

PERIPHERAL BLOOD
CBC (1/16/2020):
WBC 6.3 [4.0-11.0 K/mcL] 
RBC 3.04 L [3.80-5.00 M/mcL] 
HGB 10.3 L [11.2-15.4 g/dL] 
HCT 32.0 L [34.3-46.0 %] 
MCV 105 H [80-98 fL] 
MCH 33.9 H [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 17.6 H [12.2-15.1 %] 
Platelets 218 [160-400 K/mcL]
 
Neutrophil 53.9 [32.5-74.8 %] 
Mono 16.9 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.8 H [0.0-0.6 %] 
Lymph 28.1 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 3.4 [1.5-7.5 K/mcL] 
Abs Mono 1.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.8 [0.9-3.2 K/mcL] 

Morphology:
WBCs: Unremarkable morphology. Relative monocytosis. No circulating blasts seen. 
RBCs: Macrocytic anemia with anisocytosis. 
Platelets: Unremarkable morphology. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts (<5% total cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-646)
No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.74% of WBC.
424,526 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-385.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-2527-2528.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-4733;S13;MSK6 - 2023-04-17 17.29.44.ndpi,Peripheral Blood Smear,2023-04-17,"Myelodysplastic syndrome. Newly diagnosed AML. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
     - Therapy-related myeloid neoplasm (17% blasts by aspirate differential count)
  
COMMENT: In the context of the patient's history of endometrioid adenocarcinoma status post adjuvant cisplatin and radiation therapy in 2015, the marrow findings are consistent with a diagnosis of therapy-related myeloid neoplasm, best classified as therapy-related myelodysplastic syndrome with excess blasts-2 (MDS-EB-2). 

This case was also been reviewed by Dr. Mariko Yabe in Hematopathology Service. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (50-60% cellularity)
M:E ratio: Decreased 
Blasts: Increased, scattered or form small clusters
Myeloid lineage: Left shifted maturation 
Erythroid lineage: Full maturation 
Megakaryocytes: Increased in number with frequent dyspoietic forms (small monolobated forms, abnormal nuclear lobe separation) 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1) 
Clot section: Predominantly blood with a few marrow particles showing similar morphology to the biopsy

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                17%
Promyelocytes           3%
Myelocytes           4%
Metamyelocytes           3%
Neutrophils/Bands      17%
Monocytes           5%
Eosinophils           2%
Basophils           1%
Erythroid Precursors      32%
Plasma Cells           1%
Lymphocytes           15%
Number of Cells Counted  500
M:E Ratio           1

Special stain
Iron: Present
Ring sideroblasts: Present, >15% 

Morphology:
Paucispicular and cellular aspirate smears showing trilineage hematopoiesis with an expanded blast population, composed of medium to large-sized blasts with scant to abundant cytoplasm and occasional cytoplasmic vacuoles, oval to slightly irregular nuclei, fine chromatin and prominent nucleoli. The myeloid elements show left shifted maturation with occasional hypogranular forms. The erythroid elements show full maturation with dyspoietic forms (nuclear irregularity, nuclear-cytoplasmic dyssynchrony and ring-sideroblasts). Megakaryocytes are present with dyspoietic forms. Small mature-appearing lymphoid cells are present.


PERIPHERAL BLOOD
CBC (07/31/2020):
WBC 1.4 L [4.0-11.0 K/mcL] 
RBC 2.35 L [3.80-5.00 M/mcL] 
HGB 7.1 L [11.2-15.4 g/dL] 
HCT 22.6 L [34.3-46.0 %] 
MCV 96 [80-98 fL] 
MCH 30.2 [27.0-33.0 pg] 
MCHC 31.4 [31.0-36.5 g/dL] 
RDW 22.1 H [12.2-15.1 %] 
Platelets. 57 L [160-400 K/mcL] 

Neutrophil 48.0 [32.5-74.8 %] 
Mono 10.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Blast 7.0 H [0.0-0.0 %] 
Lymph 32.0 [12.2-47.4 %] 
Nucleated RBC 2 [/100(WBCs)] 

Abs Neut 0.7 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology:
WBC: Leukocytopenia with occasional hypogranular forms; few circulating blasts present.
RBC: Anisopoikilocytosis and rare nucleated RBCs. 
PLT: Unremarkable morphology.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight increased blasts (~15% cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-5957)
Abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
Flow cytometry identifies an abnormal myeloid blast population having abnormal expression ofCD7, CD56, CD34(bright), CD38(dim) with normal expression of CD4, CD13, CD33, CD45, CD71, CD117, CD123 and HLA-DR without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, CD64. Granulocytes show abnormal retention of CD13. The findings are consistent with high grade myeloid neoplasm with myeloid dysplasia. CD34 positive myeloid blasts represent 14% of WBC. In addition, a CD34 population that may represent either erythroid or megakaryocytic precursors is seen. Morphologic correlation is advised

No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-3638.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-23281 to M20=23284.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H20-2731;S12;MSK1 - 2023-06-28 00.11.24.ndpi,Peripheral Blood Smear,2023-06-28,"MDS
R/O POD 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:      
     - Persistent myelodysplastic syndrome with multilineage dysplasia and ring sideroblasts (MDS-MLD-RS), 1% blasts by aspirate differential count
     - Hypercellular marrow with markedly erythroid predominant maturing trilineage hematopoiesis and multilineage dysplasia.

COMMENT: The blast percentage detected by flow cytometry is 6.4%, likely due to marked erythroid predominance seen in the marrow. Morphologic review of the aspirate smear and the immunostains on the core biopsy reveal no increase in blasts. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: 80-90%
M:E ratio: Normal
Blasts: Not increased
Myeloid lineage: Orderly maturation
Erythroid lineage: Markedly increased and show left shifted maturation
Megakaryocytes: Increased and show dysplastic forms (abnormal lobation, hyperchromatic)
Lymphocytes: Scattered
Plasma cells: Not increased
Special stains: Reticulin stain shows mild increase in reticulin fibrosis.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)

Blasts                1%
Myelocytes           2%
Metamyelocytes           1%
Neutrophils/Bands      6%
Eosinophils           3%
Erythroid Precursors      81%
Plasma Cells           1%
Lymphocytes           5%
Number of Cells Counted      500
M:E Ratio           0.1

Special stain
Iron: Present
Ring sideroblasts: Present; >15% 

Morphology:
-Aspicular and hypocellular bone marrow aspirate shows erythroid predominant trilineage hematopoiesis. Blasts are not increased. Myeloid precursors are maturing with occasional hypogranular forms. Erythroid precursors are maturing with marked dyserythropoiesis (megaloblastic changes, irregular nuclear contours, nuclear budding, binucleation). Megakaryocytes rarely seen. 

PERIPHERAL BLOOD
CBC (4/28/2020):
WBC 3.6 L [4.0-11.0 K/mcL] 
RBC 2.16 L [3.95-5.54 M/mcL] 
HGB 7.5 L [12.5-16.2 g/dL] 
HCT 22.6 L [37.5-49.3 %] 
MCV 105 H [80-98 fL] 
MCH 34.7 H [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 22.1 H [12.2-15.1 %] 
Platelets 261 [160-400 K/mcL] 

Neutrophil 59.0 [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 5.0 H [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 30.0 [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 2.1 [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL]

Morphology:
WBC: No circulating blasts.
RBC: Macrocytic anemia with anisopoikilocytosis.
PLT: Unremarkable.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 immunohistochemical stains show no increase in blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-3279)
Interpretation: 
Abnormal myeloid blast population detected. 
Basophilia is seen, representing 1.2% of WBC.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD4 (bright), CD5 (subset), CD7 (partial), CD13 (dim), CD34 (dim), CD38 (uniform), CD117 (bright), CD123 (absent to dim) and HLA-DR (bright); with normal expression of CD33, CD45, and CD71, without CD2, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, or CD64. CD34 positive myeloid blasts represent 6.4% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-2038.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-14288.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-3599;S13;MSKE - 2023-04-25 17.08.37.ndpi,Peripheral Blood Smear,2023-04-25,"MDS on darbe 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
     - Chronic myelomonocytic leukemia-0 (CMML-0). 

Comment: History of persistent monocytosis in this patient is noted. RUNX1, SF3B1 and TET2 mutations were identified in previous specimen (M19-41730). These findings together with morphologic features are consistent with a diagnosis of CMML-0. 
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Approximately 90%, hypercellular for age 
M:E ratio: Normal
Blasts: Not increased
Myeloid lineage: Orderly maturation and increased 
Erythroid lineage: Orderly maturation
Megakaryocytes: Increased in number with dysplastic forms (hyperchromatic, hypolobated, forming small clusters) 
Lymphocytes: Scattered
Plasma cells: Not increased
Special stains: Reticulin stain shows focal increase in reticulin fibrosis (1+/3)
Clot section: Similar to biopsy

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Blasts/blast equivalent      3%
Promyelocytes           3%
Myelocytes           12%
Metamyelocytes           11%
Neutrophils/Bands      34%
Monocytes           8%
Eosinophils           4%
Erythroid Precursors      19%
Plasma Cells           1%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           3.9

Special stain
Iron: Present
Ring sideroblasts: Few present, <5% 

Morphology:
-Spicular and hypercellular bone marrow aspirate shows progressive trilineage hematopoiesis. Blasts are not increased. Myeloid precursors are maturing with many dysplastic forms (hypogranular and abnormally segmented neutrophils, >10%). Erythroid precursors are maturing with occasional dyserythropoiesis (irregular nuclear contour, megalobastic changes, <10%). Megakaryocytes are present with many dysplastic forms (hypogranular and abnormally segmented neutrophils, >10%)

PERIPHERAL BLOOD
CBC (06/15/2020):
WBC 13.5 H [4.0-11.0 K/mcL] 
RBC 2.85 L [3.95-5.54 M/mcL] 
HGB 9.4 L [12.5-16.2 g/dL] 
HCT 29.7 L [37.5-49.3 %] 
MCV 104 H [80-98 fL] 
MCH 33.0 [27.0-33.0 pg] 
MCHC 31.6 [31.0-36.5 g/dL] 
RDW 23.9 H [12.2-15.1 %] 
Platelets 57 L [160-400 K/mcL] 

Neutrophil 42.0 [32.5-74.8 %] 
Mono 31.0 H [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 3.0 H [0.0-0.0 %] 
Promyelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 10.0 H [0.0-0.0 %] 
Lymph 10.0 L [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 5.7 [1.5-7.5 K/mcL] 
Abs Mono 4.2 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.4 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.3 H [0.0-0.0 K/mcL] 
Abs Meta 1.4 H [0.0-0.0 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL] 

Morphology:
WBC: Granulocytic left shift with many dysplastic forms including hypogranular neutrophils. No circulating blasts. Monocytosis
RBC: Macrocytic anemia with anisopoikilocytosis
PLT: Thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 immunohistochemical stains show focally borderline increased blasts, but overall <5%.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-4450)
Abnormal myeloid blast population detected.

Flow cytometry identified an abnormal myeloid blast population that has abnormal expression of CD117 (bright), CD123 (uniform) and CD38 (bright), and normal expression of CD4, CD13, CD33, CD45, while negative for CD14, CD15, CD64, CD19, CD2, 5, CD7, CD25, CD56. CD34 positive myeloid blast population is 2.0% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-2682.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-17975.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-5214;S11;MSKZ - 2023-04-17 16.50.29.ndpi,Peripheral Blood Smear,2023-04-17,"CMMOL
64 yo man with newly diagnosed CMMOL, please confirm
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Most consistent with myelodysplastic/myeloproliferative neoplasm (MDS/MPN), favor chronic myelomonocytic leukemia (CMML-2).
     - Markedly hypercellular marrow with maturing trilineage hematopoiesis, relatively decreased erythropoiesis, increased monocytes, eosinophilia, dysgranulopoiesis, and increase in blasts/ blast equivalents (12% by aspirate differential count). See comment.
  
COMMENT: Per clinical notes, the patient had leukocytosis elevated to WBC of 38 K/mcL dating back to 07/2019. Bone marrow biopsy performed outside on 7/23/20 (pending review at MSKCC) was reportedly markedly hypercellular, and corresponding cytogenetics showed a normal karyotype, FISH was reportedly negative for BCR-ABL1, which is also supported by in-house cytogenetic studies (CG20-4043). Imaging studies revealed significant hepatomegaly and splenomegaly (15.9 cm). Current marrow findings are consistent with a myelodysplastic/myeloproliferative neoplasm (MDS/MPN, and chronic myelomonocytic leukemia (CMML-2) is favored. Presence of significant eosinophilia raise the possibility of a myeloid/lymphoid neoplasm with eosinophilia and gene rearrangements, and exclusion of rearrangements involving PDGFRA, PDGFRB, FGFR1, or PCM1-JAK2 is needed to complete the work up as these can be cryptic by routine karyotype analysis. Correlation with the forthcoming cytogenetic and molecular genetic studies is needed.   

Preliminary findings reported to Dr. Benjamin Schrank, Department of Medicine, via phone on 8/24/2020.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypercellular for age (~100%)
M:E ratio: Appears approximately normal
Blasts: Not overtly increased
Myeloid lineage: Markedly increased, actively maturing, with left-shifted maturation, increased monocytic forms, and increased eosinophils
Erythroid lineage: Decreased, actively maturing
Megakaryocytes: Relatively decreased for the cellularity, with occasional forms showing nuclear hyperchromasia and small size (<10%)
Lymphocytes: Few, scattered
Plasma cells: Rare, scattered
Special stains: Reticulin stain shows focal mild increase in reticulin fibrosis (focal MF-1). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                12% (Blasts/blast equivalents)
Promyelocytes           2%
Myelocytes           4%
Metamyelocytes           2%
Neutrophils/Bands      24%
Monocytes           23%
Eosinophils           10%
Erythroid Precursors      20%
Plasma Cells           1%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           3.2

Special stain:
Iron: Present 
Ring sideroblasts: Absent

Morphology:
Adequate, spicular and hypercellular aspirate smears with maturing trilineage hematopoiesis. Blasts and promonocytes (blast equivalents) account for 12%. They are large in size, with round to irregular nuclei, fine chromatin, inconspicuous nucleoli, and scant to moderate amount of cytoplasm. Monocytes are markedly increased, with frequent atypical forms. Myeloid elements are present at various stages of maturation and show dysplasia (> 10%; including hypo granulation in hyposegmented forms). Eosinophils and precursors are increased, showing a spectrum of morphologies. Erythroid cells are present at various stages of maturation and show some (~10%) with megaloblastoid features. Megakaryocytes are seen with occasional forms showing pleomorphism of size (large forms). Few small mature-appearing lymphocytes are seen.

PERIPHERAL BLOOD
CBC (8//2020):
WBC 280.4 H [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 3.01 L [3.95-5.54 M/mcL] 
HGB 7.7 L [12.5-16.2 g/dL] 
HCT 26.0 L [37.5-49.3 %] 
MCV 86 [80-98 fL] 
MCH 25.6 L [27.0-33.0 pg] 
MCHC 29.6 L [31.0-36.5 g/dL] 
RDW 21.0 H [12.2-15.1 %] 
Platelets. 151 L [160-400 K/mcL] 

Neutrophil 41.0 [32.5-74.8 %] 
Mono 35.0 H [0.0-12.3 %] 
Eos 9.0 H [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 1.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Promyelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 7.0 L [12.2-47.4 %] 
Nucleated RBC 11 [/100(WBCs)] 

Abs Neut 115.0 H [1.5-7.5 K/mcL] 
Abs Mono 98.2 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 25.2 H [0.0-0.7 K/mcL] 
Absolute Basophil 2.8 H [0.0-0.2 K/mcL] 
Absolute Blasts 2.8 H [0.0-0.0 K/mcL] 
Abs Myelocytes 5.6 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 5.6 H [0.0-0.0 K/mcL] 
Abs Meta 5.6 H [0.0-0.0 K/mcL] 
Abs Lymph 19.6 H [0.9-3.2 K/mcL]

Morphology:
WBC: No definitive circulating blasts seen. Marked leukocytosis with absolute neutrophilia with dysgranulopoiesis (>10%; pseudo-Pelger-Huet, hypogranular, and hyposegemented forms) and left-shifted forms (promyelocytes, myelocyte, metamyelocytes). Absolute and relative monocytosis with atypical monocytes (large size and lack of nuclear folding). Absolute and relative eosinophilia with atypical morphology (giant forms, those with abnormal nuclear segmentation, and occasional forms with basophilic granules). Absolute basophilia. 
RBC: Normochromic, normocytic anemia with anisocytosis. Numerous nucleated RBCs seen.
Platelets: Adequate in number

IMMUNOHISTOCHEMISTRY
CD34-positive blasts account for < 5% of the marrow cellularity.
CD117 also highlights few, scattered blasts, and early erythroid and rare early myeloid cells.
CD33 and lysozyme highlight markedly increased myelomonocytic cells.
Myeloperoxidase highlights increased myeloid cells.
CD71 highlights erythroid cells, which appear decreased.
CD61 highlights megakaryocytes which appear decreased for the cellularity.
CD68 (PGM1) highlights increased monocytic forms; megakaryocytes also show weak cytoplasmic staining.
CD14 highlights increased immature monocytes.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6562)
Interpretation: 
Monocytosis seen, 37.3% of WBC with left shift and 7.6% blast equivalent immature monocytes.

No abnormal myeloid blast population detected. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.94% of WBC. However, there is monocytosis noted, 37.3% of WBC, including blast equivalent immature monocytes with dim CD11b, dim CD14, and bright HLA-DR, 7.6% of WBC. A subset of monocytes shows partial CD56 expression. Overall blasts and blast equivalent immature monocytes are 8.5% of WBC.

No abnormal mature B- or T-cell populations detected. No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

427206 cells acquired. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-4043.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M20-25511, M20-25512, M20-25514, M20-25516, & M20-25517.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-8559;S16;MSKI - 2023-06-15 19.41.35.ndpi,Peripheral Blood Smear,2023-06-15,"Leukemia, chronic lymphoid. 77 years old woman with prior history of stage III breast cancer, now with suspected bone mets. Also has CLL. Rush. Concern for breast cancer in marrow along with CLL.  
","{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch31506\stshfhich31506\stshfbi31506\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}
{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;
\red0\green0\blue0;}{\*\defchp \f31506\fs22 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive 
\ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv 
\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31506\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused 
Normal Table;}{\s15\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 
\snext15 \slink16 \sqformat \spriority1 \styrsid15884028 No Spacing;}{\*\cs16 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \dbch\af31505 \sbasedon10 \slink15 \slocked \spriority1 \styrsid15884028 No Spacing Char;}}{\*\rsidtbl \rsid83877\rsid133096\rsid1076998
\rsid1389231\rsid1458436\rsid2495667\rsid2632648\rsid2646266\rsid4349262\rsid4534212\rsid7345479\rsid8093638\rsid8145187\rsid9970583\rsid11357336\rsid13046825\rsid13842715\rsid14162451\rsid14643237\rsid15088393\rsid15686258\rsid15884028\rsid16476786}
{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\author Tam, Chiu Shek/Pathology}{\operator Ewalt, Mark D./Pathology}{\creatim\yr2021\mo1\dy4\hr10\min50}
{\revtim\yr2021\mo1\dy4\hr10\min50}{\version2}{\edmins0}{\nofpages4}{\nofwords812}{\nofchars4865}{\*\company MSKCC}{\nofcharsws5566}{\vern111}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}
\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont1\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1440\dgvorigin1440\dghshow1\dgvshow1
\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\rsidroot2632648\newtblstyruls\nogrowautofit\usenormstyforlist\noindnmbrts\felnbrelev\nocxsptable\indrlsweleven\noafcnsttbl\afelev\utinl\hwelev\spltpgpar\notcvasp\notbrkcnstfrctbl\notvatxbx\krnprsnet\cachedcolbal \nouicompat \fet0
{\*\wgrffmtfilter 2450}\nofeaturethrottle1\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang 
{\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}
\pard\plain \ltrpar\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid15088393 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096      }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 - }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393 Metastatic adenocarcinoma, compatible with }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 mammary origin.\par      }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 - }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 Hemodiluted aspirate smears and peripheral blood smears with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).\par \par See comment.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393 \par COMMENT: }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 The bone marrow core biopsy shows a markedly fibrotic marrow with infiltrating atypical glands and singly scattered epithelioid cells. These are also identified on the aspirate smears. Per clinical notes, the patient has a history of invasive ductal carcinoma with lobular features, moderately to poorly differentiated of the right breast, status post mastectomy (2005), chemotherapy and radiation. The overall immunoprofile of the metastatic carcinoma is compatible with breast origin.\par \par In addition, there are a few loosely clustered and scattered small lymphoid cells in the marrow space and the accompanying clotted blood comprised of an admixture of B- and T-cells. The aspirate smears on the other hand show many atypical lymphocytes that are predominantly small-sized. However, the aspirate smears are aspicular and hemodiluted so the accurate estimation of marrow involvement by CLL/SLL is not possible. \par \par The preliminary results were communicated with Dr. Mark Geyer by Dr. Mariko Yabe via email on 12/31/2020 at 2:45 pm.\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid133096\charrsid7345479 BONE MARROW BIOPSY}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par Quality:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  Adequate}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par Cellularity:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  N/A}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par M:E ratio:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  N/A}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par Blasts:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  Not increased}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par Myeloid lineage:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  Present}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par Erythroid lineage:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  Present}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par Megakaryocytes:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  Present}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par Lymphocytes:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  Loosely clustered and scattered small lymphoid cells}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par Plasma cells:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  Interstitially scattered\tab \par The marrow is fibrotic with infiltrating atypical glands and single cells.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid133096\charrsid7345479 BONE MARROW ASPIRATE SMEAR}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid133096 /TOUCH IMPRINTS}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par Differential:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  (Performed by KT)\par Hemodiluted aspirate devoid of spicules.\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393 Extrinsic cells are present}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid1389231 Myelocytes \tab \tab 1%\par Neutrophils/Bands \tab 6%\par Erythroid Precursors \tab 25%\par Lymphocytes \tab \tab 68%\par Number of Cells Counted 500\par M:E Ratio \tab \tab 0.3}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\highlight4\insrsid133096\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 Morphology:\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393 The aspirate smears are aspicular, hemodiluted and demonstrat}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 e}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393  predominantly peripheral blood elements. Occasional }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 singly scattered and }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393 cohesive clusters of large epithelioid cells with high N:C ratio, irregular nuclear contours, coarse chromatin, conspicuous nucleoli and scant cytoplasm are seen.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  There are many atypical lymphocytes that are predominantly small-sized with round nuclei, clumped chromatin, occasionally visible nucleolus and small amount of cytoplasm. Only a few larger cells with round to oval nuclei, vesicular chromatin, prominent nucleoli and moderate amount of cytoplasm, consistent with prolymphocytes and paraimmunoblasts, are present. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393 Occasional maturing myeloid}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  elements are present. There are many maturing }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393 erythroid elements with }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 occasional dyspoiesis (nuclear irregularity/budding).}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393  Megakaryocytes are }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 not readily seen}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393 . }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 Touch imprints show similar findings.\tab \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid133096\charrsid7345479 \par PERIPHERAL BLOOD}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par CBC (}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 12}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 /}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 30}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 /}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 2020}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 ):\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15686258 WBC 32.0 H [4.0-11.0 K/mcL] \par RBC 1.96 L [3.80-5.00 M/mcL] \par HGB 7.4 L [11.2-15.4 g/dL] \par HCT 22.8 L [34.3-46.0 %] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 MCV}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15686258  116 H [80-98 fL] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 MCH}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15686258  37.8 H [27.0-33.0 pg] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 MCHC}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15686258  32.5 [31.0-36.5 g/dL] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 RDW}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15686258  23.7 H [12.2-15.1 %] \par Platelets 41 L [160-400 K/mcL] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15686258 Neutrophil 4.0 L [32.5-74.8 %] \par Mono 2.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Lymph 93.0 H [12.2-47.4 %] \par Nucleated RBC 10 [/100(WBCs)] }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15686258 \par Abs Neut 1.3 L [1.5-7.5 K/mcL] \par Abs Mono 0.6 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolute Basophil 0.3 H [0.0-0.2 K/mcL] \par Abs Lymph 29.8 H [0.9-3.2 K/mcL] }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par Morphology:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 \par WBCs: Absolute lymphocytosis. Many atypical lymphocytes with round to slightly irregular nuclei, predominantly small-sized similar to the aspirate smears, are seen. Occasional smudge cells are present. Occasional immature granulocytes are seen. \par RBCs: Macrocytic anemia with moderate anisopoikilocytosis and increase in polychromasia. Many nucleated RBCs are seen \par Platelets: Marked thrombocytopenia.\tab }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid133096\charrsid7345479 IMMUNOHISTOCHEMISTRY}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393 Immunohistochemical stain shows that the }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 atypical epithelial}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393  cells are positive for }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 pan-cytokeratin, cytokeratin 7 (patchy) and }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393 GATA-3}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  while they are negative for cytokeratin 20}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393 .}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096  This immunoprofile is compatible with mammary origin.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393  The results of ER, PR, HER2/neu immunostains will be reported in addendum.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 \par \par CD3/CD5 and CD20/PAX5 show an admixture of small T- and small B-cells, respectively. CD23 labels a subset of the lymphoid cells. Expression of LEF1 in the B-cells is difficult to interpret due to the admixed T-cells. Cyclin D1 immunostain is negative in the lymphoid cells.\par \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid11357336 The interpretation of these results is based in part on the decalcification procedure performed.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid133096\charrsid15088393 FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-10965)}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid15088393 Abnormal B-cell population identified.\par Flow cytometry identified an abnormal B-cell population having abnormal expression of CD5 (variable negative to bright), CD20 (dim), CD23, CD43, CD79b (dim), CD81 (dim), CD200 (bright; normal expression of CD19, CD38, CD40 and CD45; and without CD3, CD38, or CD10 expression. The abnormal B-cell population comprises 78.5% of the white cells. The findings are consistent with previously diagnosed CLL/SLL.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid133096\charrsid7345479 CYTOGENETIC STUDIES}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par Cytogenetic analysis will be reported separately. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid133096\charrsid7345479 See separate report, CG}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid133096 20-6982}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid133096\charrsid7345479 .}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par \~\par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid133096\charrsid7345479 MOLECULAR STUDIES}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479  \par Molecular analysis will be reported separately. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid133096\charrsid7345479 See separate report, M}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid133096 20-43637, M20-43638}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid133096\charrsid7345479 .}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid133096\charrsid7345479 \par \par \par }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid15088393 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\af31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid133096 \par }{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid133096\charrsid4349262 \hich\af1\dbch\af31505\loch\f1 Peripheral Blood Analysis Performed By: Hematology Laborato\hich\af1\dbch\af31505\loch\f1 ry, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin}{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid133096 \hich\af1\dbch\af31505\loch\f1  }{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid133096\charrsid4349262 \hich\af1\dbch\af31505\loch\f1 MD.,}{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid133096 \hich\af1\dbch\af31505\loch\f1  }{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid133096\charrsid4349262 \hich\af1\dbch\af31505\loch\f1 PhD., Director.\par \par \hich\af1\dbch\af31505\loch\f1 The in\hich\af1\dbch\af31505\loch\f1 terpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.}{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid133096 \par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}"
H20-748;S12;MSK7 - 2023-06-27 22.49.20.ndpi,Peripheral Blood Smear,2023-06-27,"Multiple Myeloma.  Plasmacytoma; rule out MM; initial staging. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
     - Plasma Cell Neoplasm, Kappa-restricted
60-70% involvement by CD138 immunohistochemistry
45% involvement by aspirate differential
7.2% involvement by 10-color flow cytometry
     - Small Abnormal B-cell population detected by Flow Cytometry (0.56% of WBC) (See Comment)
     - Mildly Hypercellular marrow with trilineage maturing hematopoiesis

COMMENT: In the proper clinical context, the small abnormal B-cell population may represent incidental Monoclonal B-cell Lymphocytosis (MBL), provided that the patient doesn't have evidence of involvement by B-cell lymphoma in other anatomic locations. Additional immunostains will be reported in an addendum.

BONE MARROW BIOPSY
Quality: Subcortical, slightly fragmented
Cellularity: Mildly hypercellular for age (~30-40% cellularity)
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes: Adequate in number with some atypical hyperchromatic forms
Plasma cells: Small- to intermediate-sized, forming large aggregates. Frequent Dutch bodies are seen.
 
Clot section: Shows similar findings as the core biopsy

ASPIRATE MORPHOLOGY

Aspirate differential: (Performed by CB )

Blasts                1%
Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           5%
Neutrophils/Bands      18%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      14%
Plasma Cells           45%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           2.5

Morphology: 
Marrow spicules: Spicular    
Cellularity: Cellular  
Plasma cell morphology: Small to intermediate in size with rare bi/multi-nucleated forms, and some nucleolated forms. Frequent Dutcher bodies are seen.
Myeloid lineage: Orderly maturation   
Erythroid Lineage: Orderly maturation   
Megakaryocytes: Present with unremarkable morphology   
Lymphoid cells: Small-sized and mature-appearing 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights marked increase in plasma cells (60-70% of cellularity). 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.
BCMA highlights >50% of plasma cells, (1+) intensity, membranous/ Golgi pattern. 

Additional immunostains will be reported in an addendum.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-925) 
Small Abnormal B-cell population identified.
Abnormal plasma cell population detected.

The immunophenotypic identification of a small abnormal B-cell population with having abnormal expression of CD5 (partial), CD22 (slightly dim), CD23 (partial), CD200 (bright) and lambda surface light chain restriction (dim); normal expression of CD19, CD20, CD38, and CD45; and without FMC7 or CD10 expression. The abnormal B-cell population comprises 0.56% of the white cells.

In addition, flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (absent), CD27 (absent), CD38 (dim), CD45 (major subset absent), CD81 (absent), CD138 (dim), and monoclonal kappa cytoplasmic light chain restriction; and without CD20, CD56, or CD117 expression. The abnormal population represents 7.2% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 99.8% of total plasma cells in the sample.

Considering the difference in light chain expression by the small abnormal B cell population and the abnormal plasma cell population, they are favored to be separate, unrelated processes. In the proper clinical context, the small abnormal B cell population may represent Monoclonal B-cell Lymphocytosis (MBL).

2,863,793 cells acquired for plasma cell analysis.

PERIPHERAL BLOOD
CBC (01/24/2020):
WBC 7.6 [4.0-11.0 K/mcL] 
RBC 3.20 L [3.95-5.54 M/mcL] 
HGB 10.8 L [12.5-16.2 g/dL] 
HCT 32.0 L [37.5-49.3 %] 
MCV 100 H [80-98 fL] 
MCH 33.8 H [27.0-33.0 pg] 
MCHC 33.8 [31.0-36.5 g/dL] 
RDW 11.7 L [12.2-15.1 %] 
Platelets. 309 [160-400 K/mcL] 

Neutrophil 64.4 [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 1.8 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 28.2 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 4.9 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 2.1 [0.9-3.2 K/mcL] 

Morphology:
WBC: No circulating plasma cell seen.
RBC: Macrocytic anemia. No Rouleaux formation
Platelets: Unremarkable in morphology

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-543, CG20-544.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-3475, M20-3476.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-7178;S12;MSKA - 2023-06-07 01.16.59.ndpi,Peripheral Blood Smear,2023-06-07,"MDS
r/o POD
Protocol#: 19-219
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent involvement by myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD) (3% blasts on aspirate)

BONE MARROW BIOPSY
Quality: adequate 
Cellularity: 80% 
M:E ratio: markedly reduced 
Blasts: not increased 
Myeloid lineage: markedly reduced 
Erythroid lineage: markedly increased, left shifted
Megakaryocytes: increased, dysplastic, monolobated 
Lymphocytes: rare 
Plasma cells: rare
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1/3). 
Clot section:

BONE MARROW ASPIRATE SMEAR
Differential: (Performed on aspirate smears and touch imprints by HM)

Mast cells (with cytologic atypia) are increased.

Blasts                3%
Promyelocytes           3%
Myelocytes           4%
Neutrophils/Bands      5%
Eosinophils           8%
Erythroid Precursors      74% (left-shift maturation)
Plasma Cells           1%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           0.3

Special stain
Iron: Increased.
Ring sideroblasts: Present 15%. 

Morphology:
Spicular and very cellular bone marrow aspirate shows markedly erythroid hyperplasia with left shifted maturation. Blasts are not increased. Myeloid precursors are few. Megakaryocytes are monolobated.

PERIPHERAL BLOOD
CBC (11/03/2020):
WBC 2.4 L [4.0-11.0 K/mcL] 
RBC 2.46 L [3.95-5.54 M/mcL] 
HGB 7.5 L [12.5-16.2 g/dL] 
HCT 23.3 L [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 30.5 [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 20.4 H [12.2-15.1 %] 
Platelets 544 H [160-400 K/mcL]
 
Neutrophil 47.8 [32.5-74.8 %] 
Mono 3.7 [0.0-12.3 %] 
Eos 6.6 H [0.0-4.9 %] 
Baso 5.3 H [0.0-1.5 %] 
Immature Granulocyte 0.8 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 35.8 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 1.2 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL] 

Morphology: thrombocytosis. Anemia. No circulating blasts. Basophilia. 


IMMUNOHISTOCHEMISTRY
CD34 shows no increase in blasts. CD117 stains mildly increased mast cells and many progenitors. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-9126)
Interpretation: 
Abnormal myeloid blast population detected.
Basophilia and eosinophilia are seen (2.6% and 11.1% respectively)

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD5 (subset), CD7 (partial), CD34 (dim), CD117 (slightly bright), and HLA-DR (bright); with normal expression of CD4, CD13, CD33, CD38, CD45, and CD71; without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 9.0% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-5748.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-35956.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-49;S17;MSK6 - 2023-06-28 00.05.33.ndpi,Peripheral Blood Smear,2023-06-28,"Myelodysplastic Syndrome. Pancytopenia.  

","1-2. Bone marrow, right posterior iliac crest, biopsy and aspirate: 
     - Metastatic carcinoma involving marrow. 
     - Markedly hypocellular marrow (<5%) with sparse maturing hematopoiesis and no definitive evidence of a myeloid neoplasm.
  
BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypocellular (<5%)
M:E ratio: N/A
Blasts: Not increased 
Myeloid lineage: Scattered precursors 
Erythroid lineage: Scattered
Megakaryocytes: None readily identified 
Lymphocytes: Few and scattered 
Plasma cells: Rare 
Special stains: Reticulin stain shows no increase in reticulin fibrosis 
Other: Singly scattered and small clusters of large atypical cells are seen associated with fibrosis.
Clot section: Single small cluster of cohesive atypical cells.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed on touch imprints by HM)
Blasts                2%
Promyelocytes           2%
Myelocytes           4%
Metamyelocytes           7%
Neutrophils/Bands      43%
Monocytes           12%
Eosinophils           3%
Erythroid Precursors      7%
Lymphocytes           20%
Number of Cells Counted 500
M:E Ratio           10.1

Special stain
Iron: Suboptimal for evaluation; devoid of spicules.
Ring sideroblasts: Absent 

Morphology:
Hemodiluted aspicular and hypocellular aspirate smears, along with touch imprints, are suboptimal for morphologic assessment. Blasts are not obviously increased. Focal cohesive clusters of foreign cells are noted. Myeloid elements show progressive maturation without significant atypia. Rare erythroid elements are actively maturing without atypia. Megakaryocytes are not readily appreciated. Platelet clumps noted. 

PERIPHERAL BLOOD
CBC (12/30/2019):
WBC 5.0 [4.0-11.0 K/mcL] 
RBC 3.07 L [3.80-5.00 M/mcL] 
HGB 9.9 L [11.2-15.4 g/dL] 
HCT 31.0 L [34.3-46.0 %] 
MCV 101 H [80-98 fL] 
MCH 32.2 [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 19.6 H [12.2-15.1 %] 
Platelets 130 L [160-400 K/mcL]
 
Neutrophil 71.0 [32.5-74.8 %] 
Mono 9.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 3.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 13.0 [12.2-47.4 %] 
Nucleated RBC 7 [/100(WBCs)] 

Abs Neut 3.6 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBCs: Unremarkable morphology; no circulating blasts seen. 
RBCs: Macrocytic anemia with anisocytosis. 
Platelets: Mild thrombocytopenia with unremarkable morphology. 

IMMUNOHISTOCHEMISTRY
Pancytokeratin (AE1/AE3) staining on the biopsy specimen demonstrates positivity of the atypical cohesive clusters. The clot section is exhausted, and the foci of cluster is lost. CAM5.2 also highlights the atypical cells on the biopsy. 
CD61 stains platelet clumps.
CD34 and CD117 show no increase in blasts (<5% total cellularity). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-83)
No definite abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
No abnormal mature B- or T-cell populations detected.

There is no definite immunophenotypic evidence of a myeloid stem cell neoplasm by flow cytometry. However, in light of CD33 (dim), CD38 (dim), CD117 (dim), and CD123 (uniform); a low-grade myeloid stem cell neoplasm cannot be entirely excluded by these studies.  CD34 positive myeloid blasts represent 0.24% of the white blood cells with expression of CD13, CD33, CD34, CD38, CD45, CD71, CD117 and low CD123.  Normal myelomonocytic maturation is present. 

345,633 cells acquired. Morphologic, cytogenetic, and molecular genetic assessment is suggested to exclude myeloid stem cell neoplasm. Clinical correlation is also advised. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-58.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-362.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-6310;S11;MSK7 - 2023-04-17 17.13.08.ndpi,Peripheral Blood Smear,2023-04-17,"Leukemia, Chronic Myeloid 
On Nilotinib for CML, Jak2 +, evaluate MPN erythrocytosis and thrombocytosis
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
    - Normocellular marrow with atypical megakaryocytic hyperplasia, consistent with a myeloproliferative neoplasm (MPN), morphologically best classified as essential thrombocythemia (ET), see comment.
  
COMMENT: Marrow biopsy is normocellular and shows increased large atypical megakaryocytes without fibrosis. Findings are consistent with MPN, morphologically best classified as ET. Background hematopoiesis shows preserved erythroid maturation. Therefore, Polycythemia vera (PV) could be differential diagnosis; however, panmyelosis is not prominent. Morphological findings suggestive of Chronic myeloid leukemia (CML) are not evident. Please correlate with pending molecular results for BCL-ABL1 transcript level and JAK2 p.V617F VAF.   

Co-occurrence of JAK2 p.V617F and BCRABL1 is uncommon but has been previously reported.    

Reference:
Soderquist, C., Ewalt, M., Czuchlewski, D. et al. Myeloproliferative neoplasms with concurrent BCRABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol 31, 690704 (2018).

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Normocellular for age (~50% cellularity)
M:E ratio: Normal
Blasts: Not overtly increased
Myeloid lineage: Shows progressive maturation
Erythroid lineage: Shows progressive maturation
Megakaryocytes: Increased in number and predominantly show atypical features (loose clustering, variable size ranging from small to large with hypolobated and bulbous nuclei and/or hyperchromatic nuclei)
Lymphocytes: Interstitially scattered
Plasma cells: Interstitially scattered

Special stains: 
Reticulin stain shows no significant increase in reticulin fibrosis (0/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                1%
Promyelocytes           1%
Myelocytes           12%
Metamyelocytes           10%
Neutrophils/Bands      33%
Monocytes           2%
Eosinophils           3%
Erythroid Precursors      29%
Plasma Cells           1%
Lymphocytes           8%
Number of Cells Counted      500
M:E Ratio           2.1

Morphology:
The aspirate smears are spicular and cellular and demonstrate maturing trilineage hematopoiesis with normal M:E ratio. Markedly atypical megakaryocytes of variable sizes (including forms with hypolobated and bulbous nuclei) are present. Myeloid elements show mildly left-shifted progressive maturation with unremarkable morphology. Erythroid elements are actively maturing with no overt dyspoiesis. Blasts are not increased.     

PERIPHERAL BLOOD
CBC (10/01/2020):
WBC 7.6 [4.0-11.0 K/mcL] 
RBC 5.18 [3.95-5.54 M/mcL] 
HGB 14.9 [12.5-16.2 g/dL] 
HCT 45.0 [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 28.8 [27.0-33.0 pg] 
MCHC 33.1 [31.0-36.5 g/dL] 
RDW 12.9 [12.2-15.1 %] 
Platelets. 529 H [160-400 K/mcL] 

Neutrophil 72.5 [32.5-74.8 %] 
Mono 4.9 [0.0-12.3 %] 
Eos 2.5 [0.0-4.9 %] 
Baso 0.7 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 18.9 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 5.5 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL] 

Morphology:
WBCs: Unremarkable morphology. No circulating blasts seen.
RBCs: Normocytic normochromic RBCs.
Platelets: Thrombocytosis with occasional large and giant forms.

IMMUNOHISTOCHEMISTRY
Rare atypical megakaryocyte shows aberrant weak CD34 expression. 
No increase in CD34-positive blasts is seen (<5% of cellularity).
CD117 labels myeloid and erythroid precursors and a few scattered mast cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-7951)
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature B- or T-cell populations detected.

CD34 positive myeloid blast population with apparent normal immunophenotype is 1.1% of WBC.
358,000 of cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.
Flow cytometry is generally not a sensitive methodology in the context of myeloproliferative disorders, correlation with molecular studies for JAK2, CALR, MPL mutation status and/or BCR-ABL and morphology is advised if clinically indicated.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-5000.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-31198, M20-31204, M20-21206.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-1065;S11;MSK9 - 2023-04-20 08.13.27.ndpi,Peripheral Blood Smear,2023-04-20,"CML. 54 years old woman, with newly diagnosed CML.  
","1-3. Bone marrow, right posterior iliac crest, biopsy, touch imprints, aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia, BCR-ABL1 positive, chronic phase. 

COMMENT: Corresponding fluorescence in situ hybridization (FISH) analysis (CG20-786) detected BCR-ABL1 fusion/t(9;22) in 97.7% of cells. Correlation with pending molecular studies (including BCR-ABL1 quantitative PCR) will be helpful for additional evaluation.

BONE MARROW BIOPSY
Quality: Adequate.
Cellularity: Markedly hypercellular for age, (>95% cellularity).
M:E ratio: Markedly increased.
Blasts: Not increased.
Myeloid lineage: Markedly increased with left shifted maturation.
Erythroid lineage: Decreased.
Megakaryocytes: Present with occasional small mono/hypolobated forms.
Lymphocytes: Scattered.
Plasma cells: Scattered.
Special stains: Reticulin stain shows mild to focally moderate increase in reticulin fibrosis (MF-1). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                1%
Promyelocytes           2%
Myelocytes           21%
Metamyelocytes           15%
Neutrophils/Bands      50%
Monocytes           1%
Eosinophils           4%
Basophils           1%
Erythroid Precursors      3%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           31.3

Morphology:
The aspirate smears and touch imprints are paucispicular and cellular. The myeloid lineage is markedly increased in proportion with left shifted by complete maturation and no significant dysplasia. There is expansion of myelocytes, metamyelocytes and mature neutrophils. There is no increase in blasts. The erythroid lineage is decreased in proportion. Few megakaryocytes are present with rare small, hypolobated forms. 

PERIPHERAL BLOOD
CBC (02/05/2020):
WBC 181.8 H [4.0-11.0 K/mcL] 
RBC 3.17 L [3.80-5.00 M/mcL] 
HGB 10.1 L [11.2-15.4 g/dL] 
HCT 31.8 L [34.3-46.0 %] 
MCV 100 H [80-98 fL] 
MCH 31.9 [27.0-33.0 pg] 
MCHC 31.8 [31.0-36.5 g/dL] 
RDW 17.0 H [12.2-15.1 %] 
Platelets 163 [160-400 K/mcL] 

Neutrophil 62.0 [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 
Myelocyte 20.0 H [0.0-0.0 %] 
Metamyelocyte 7.0 H [0.0-0.0 %] 
Lymph 4.0 L [12.2-47.4 %] 
Nucleated RBC 3 [/100(WBCs)] 

Abs Neut 112.7 H [1.5-7.5 K/mcL] 
Abs Mono 5.5 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 7.3 H [0.0-0.2 K/mcL] 
Abs Myelocytes 36.4 H [0.0-0.0 K/mcL] 
Abs Meta 12.7 H [0.0-0.0 K/mcL] 
Abs Lymph 7.3 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology:
WBC: Marked leukocytosis and neutrophilia with prominent left shift showing full developmental stages (including many myelocytes, metamyelocytes, and mature neutrophils); absolute basophilia is present; no dysplasia and no circulating blasts seen.
RBC: Normocytic, normochromic anemia with frequent nucleated red blood cells. 
Platelets: Unremarkable morphology.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 stains show no increase in blasts (<5% of total cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-1331)
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature B- or T-cell populations detected.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.34% of WBC.
473,450 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Flow cytometry is generally not a sensitive methodology in the context of myeloproliferative disorders, correlation with molecular studies for BCR-ABL and/or JAK2, CALR, MPL mutation status and morphology is advised if clinically indicated.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES (CG20-786)
FISH ANALYSIS:
BCR-ABL1 fusion/t(9;22) detected in 97.7% of cells.

Chromosome analysis is in progress and will be reported separately as an addendum to CG20-786.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-5224, M20-5226, M20-5227, M20-5228.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-3467;S10;MSKF - 2023-06-07 02.31.08.ndpi,Peripheral Blood Smear,2023-06-07,"B-ALL
Assess Response to Blina. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by B-lymphoblastic lymphoma/leukemia (10-15% blasts)
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Approximately 20-30%, hypocellular for age 
M:E ratio: Normal
Blasts: Increased, best seen by IHC stains
Myeloid lineage: Reduced with maturation
Erythroid lineage: Reduced with maturation
Megakaryocytes: Present with unremarkable morphology
Lymphocytes: Scattered
Plasma cells: Not increased

BONE MARROW ASPIRATE SMEAR
Differential: (Performed on aspirates and touch imprints by MT)

Blasts                13%
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           2%
Neutrophils/Bands      64%
Monocytes           3%
Eosinophils           2%
Erythroid Precursors      10%
Plasma Cells           1%
Lymphocytes           1%
Number of Cells Counted      500
M:E Ratio           7.6

Morphology:
-Aspicular, hypocellular and hemodiluted aspirate and touch imprint show trilineage hematopoiesis.  The myeloid elements consist predominantly of mature neutrophils, reflecting hemodilution. Blasts are increased (small with scant cytoplasm). Erythroid elements show orderly maturation. Megakaryocytes are present with unremarkable morphology.

PERIPHERAL BLOOD
CBC (6/10/2020):
WBC 8.5 [4.0-11.0 K/mcL] 
RBC 4.07 [3.80-5.00 M/mcL] 
HGB 9.7 L [11.2-15.4 g/dL] 
HCT 32.2 L [34.3-46.0 %] 
MCV 79 L [80-98 fL] 
MCH 23.8 L [27.0-33.0 pg] 
MCHC 30.1 L [31.0-36.5 g/dL] 
RDW 19.6 H [12.2-15.1 %] 
Platelets. 257 [160-400 K/mcL] 

Morphology:
WBC: Mild lymphopenia. Few blasts noted.
RBC: Normocytic anemia.
PLT: Unremarkable.

IMMUNOHISTOCHEMISTRY
CD34 and TdT immunohistochemical stains show patchy increase in blasts (up to 30% focally, 10-15% overall).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-4268)
Abnormal immature B-cell population detected.
An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously [F20-3957]. The abnormal immature B-cells represent 10.1% of the white cells and 49.9% of the mononuclear cells in the sample and abnormally express CD10 (bright), CD20 (negative to dim), CD34 (negative to intermediate), CD38 (negative to dim), CD81 (slightly dim), CD66c/CD123 (negative to dim), CD73/CD304 (uniform dim); with normal expression of CD19, CD22, CD24, CD45; and without CD66b or CD86.  This finding is consistent with persistent/recurrent B-lymphoblastic leukemia/lymphoma, depending on the clinical context.  Clinical and morphologic correlation is recommended.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-2594.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-17402.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-6778;S12;MSKF - 2023-06-07 00.53.39.ndpi,Peripheral Blood Smear,2023-06-07,"Myelofibrosis
POD, evaluate baseline for protocol 
","1-3. Bone marrow, RPIC biopsy; aspirate and peripheral blood smears: 
     - Persistent JAK2-mutated myeloproliferative neoplasm (MPN) with myelofibrosis.
     - Peripheral blood with 8% circulating blasts.
     - Persistent B-lymphoproliferative neoplasm (1.8% by flow cytometry) with marginal zone phenotype.

This case was also reviewed by Dr. Mariko Yabe in Hematopathology Service.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (~50-60% cellularity) 
M:E ratio: Decreased 
Blasts: Not overtly increased  
Myeloid lineage: Shows maturation 
Erythroid lineage: Shows maturation 
Megakaryocytes: Markedly increased with loose clustering and atypical forms (hyperlobated/bulbous and hyperchromatic forms)
Lymphocytes: Scattered 
Plasma cells: Scattered
Others: Osteosclerosis and sinusoidal dilation present  

Special stains: 
Reticulin stain shows marked increase in reticulin fibrosis (MF-3+/3). 
Trichrome stain shows paratrabecular and central collagen deposition. 

Clot section: Predominantly blood with no marrow particles 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                5%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      38%
Monocytes           8%
Eosinophils           1%
Erythroid Precursors      29%
Lymphocytes           15%
Number of Cells Counted  200
M:E Ratio           1.8

Morphology:
Aspirate smears and touch imprint are aspicular, hemodilute and markedly hypocellular, with scattered blasts seen. Maturing myeloid and erythroid elements are present. Megakaryocytes are not identified. 

PERIPHERAL BLOOD
CBC (10/16/2020):
WBC 4.8 [4.0-11.0 K/mcL] 
RBC 2.69 L [3.80-5.00 M/mcL] 
HGB 8.6 L [11.2-15.4 g/dL] 
HCT 25.8 L [34.3-46.0 %] 
MCV 96 [80-98 fL] 
MCH 32.0 [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 22.3 H [12.2-15.1 %] 
Platelets 55 L [160-400 K/mcL] 

Neutrophil 53.0 [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 
Blast 8.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 6.0 H [0.0-0.0 %] 
Lymph 20.0 [12.2-47.4 %] 
Nucleated RBC 14 [/100(WBCs)] 

Abs Neut 2.5 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.2 [0.0-0.2 K/mcL] 
Absolute Blasts 0.4 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.3 H [0.0-0.0 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL]

Morphology:
WBC: Circulating blasts present, relative basophilia. 
RBC: Anisopoikilocytosis with few tear-drop cells; polychromasia and frequent nucleated RBCs. 
Platelets: Thrombocytopenia with few large and hypogranular forms. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts (<2% marrow cellularity).
CD117 also highlights erythroid precursors.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-8580)
Abnormal myeloid blast population detected. 
Basophilia seen, representing 3.4% of WBC.
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD25 (partial), CD13 (absent to intermediate), CD33 (intermediate), CD38 (absent to intermediate), CD71 (mostly absent), HLADR (uniform bright) with normal expression of CD4, CD34, CD45, CD71, CD117, CD123; without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD56, CD64. The findings are consistent with myeloid neoplasm with myeloid dysplasia. CD34 positive myeloid blasts represent 5.0% of WBC.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD20 (bright), CD22 (bright), and lambda light chain restriction; with normal expression of CD19 and CD45; and without CD38, CD5 or CD10. The abnormal B-cell population represents 1.8% of the total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-5394

MOLECULAR STUDIES 
Not submitted. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H20-6107;S11;MSKA - 2023-04-17 17.07.15.ndpi,Peripheral Blood Smear,2023-04-17,"Myelofibrosis 
History of post-ET now with increased blasts and splenomegaly. Please assess disease status.
","{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch31506\stshfhich31506\stshfbi31506\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \froman\fcharset0\fprq2{\*\panose 00000000000000000000}Cambria;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \froman\fcharset238\fprq2 Cambria CE;}{\fhimajor\f31529\fbidi \froman\fcharset204\fprq2 Cambria Cyr;}
{\fhimajor\f31531\fbidi \froman\fcharset161\fprq2 Cambria Greek;}{\fhimajor\f31532\fbidi \froman\fcharset162\fprq2 Cambria Tur;}{\fhimajor\f31535\fbidi \froman\fcharset186\fprq2 Cambria Baltic;}
{\fhimajor\f31536\fbidi \froman\fcharset163\fprq2 Cambria (Vietnamese);}{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}
{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}
{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}
{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;
\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;
\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;\red0\green0\blue0;}{\*\defchp \f31506\fs22 }{\*\defpap \ql \li0\ri0\sa200\sl276\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 
\f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa200\sl276\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31506\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused Normal Table;}{
\s15\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 
\snext15 \slink16 \sqformat \spriority1 \styrsid3487421 No Spacing;}{\*\cs16 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \dbch\af31505 \sbasedon10 \slink15 \slocked \spriority1 \styrsid3487421 No Spacing Char;}{\s17\ql \li0\ri0\widctlpar
\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 
\f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext17 \spriority0 \styrsid5599393 CoPath Text;}}{\*\rsidtbl \rsid791700\rsid3487421\rsid4135798\rsid4349262\rsid5570980\rsid5599393\rsid6244929\rsid6895582\rsid7345479\rsid7805912\rsid8093638
\rsid9664368\rsid10713710\rsid11362323\rsid11674807\rsid12131741\rsid12790803\rsid13046825\rsid13566751\rsid13842715\rsid14296801\rsid15009505\rsid15756443\rsid16087030\rsid16387280\rsid16476786}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0
\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\author Melo, Heydi L./Pathology}{\operator Chan, Alexander Y./Pathology}{\creatim\yr2020\mo9\dy25\hr17\min2}{\revtim\yr2020\mo9\dy25\hr17\min2}{\version2}{\edmins0}
{\nofpages2}{\nofwords708}{\nofchars4328}{\nofcharsws4922}{\vern111}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont1\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1440\dgvorigin1440\dghshow1\dgvshow1
\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\rsidroot11362323\newtblstyruls\nogrowautofit\usenormstyforlist\noindnmbrts\felnbrelev\nocxsptable\indrlsweleven\noafcnsttbl\afelev\utinl\hwelev\spltpgpar\notcvasp\notbrkcnstfrctbl\notvatxbx\krnprsnet\cachedcolbal \nouicompat \fet0
{\*\wgrffmtfilter 2450}\nofeaturethrottle1\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang 
{\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}
\pard\plain \ltrpar\s17\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid8677547 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 \f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid16087030 1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: }{\rtlch\fcs1 \af0 \ltrch\fcs0 \cgrid0\insrsid5599393\charrsid16087030  \~\~}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid16087030 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393     - Myeloproliferative neoplasm with marked myelofibrosis consistent with post-essential thrombocytosis (post-ET) myelofibrosis, with increased blasts (10% by aspirate differential count, 5-10% by CD34 immunohistochemistry); see comment.\par \par COMMENT: The finding of increased blasts (10% by aspirate differential, ~5-10% by CD34 immunohistochemistry) in a patient with history of post-ET myelofibrosis with }{\rtlch\fcs1 \ai\af0 \ltrch\fcs0 \i\insrsid5599393\charrsid12131741 CALR}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393  mutation is suggestive of disease progression. Close clinical follow-up is advised. Correlation with cytogenetic and molecular studies is recommended to assess for clonal evolution. \par \par This case was also reviewed at the Hematopathology Consensus Conference on 9/25/2020, with agreement on the interpretation between the present hematopathology attending staff. Preliminary findings were discussed with Dr. Raajit Rampal via email on 9/25/2020.}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \ul\insrsid5599393\charrsid7345479 BONE MARROW BIOPSY}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par Quality:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393  Adequate }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par Cellularity:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393  Difficult to accurately enumerate due to marked fibrosis}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par M:E ratio:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393  Increased}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par Blasts:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393  Mildly increased scattered and clustered immature cells}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par Myeloid lineage:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393  Exhibits left-shifted maturation }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par Erythroid lineage:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393  Markedly reduced}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par Megakaryocytes:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393  Increased, with atypical features (hyperchromasia, lobation abnormalities)}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par Lymphocytes:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393  Scattered }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par Plasma cells:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393  Scattered }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par Special stains:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393  A reticulin stain shows a marked increase in reticulin fibers (3+/3). \par Trichrome stain shows patchy collagen fibrosis, with foci of interconnected meshwork (2+/3)\par Other: Marked osteosclerosis seen}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \ul\insrsid5599393\charrsid7345479 BONE MARROW ASPIRATE SMEAR}{\rtlch\fcs1 \af0 \ltrch\fcs0 \ul\insrsid5599393  / TOUCH IMPRINTS}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par Differential:}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393  (Performed by HM)\par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid16387280 Blasts \tab \tab \tab 10%}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid6244929 \par Promyelocytes \tab \tab 16%\par Myelocytes \tab \tab 13%\par Metamyelocytes \tab \tab 9%\par Neutrophils/Bands \tab 28%\par Monocytes \tab \tab 1%\par Eosinophils \tab \tab 1%\par Basophils \tab \tab 5%\par Erythroid Precursors \tab 2%\par Lymphocytes \tab \tab 15%\par Number of Cells Counted 500\par M:E Ratio \tab \tab }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393 N/A\par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \highlight4\insrsid5599393\charrsid7345479 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393 Morphology: The aspirate smears and touch imprints are aspicular and hemodilute, but show a mildly expanded blast population of medium to large sized blasts with small amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli, in a background of myeloid predominant hematopoiesis. Myeloid elements show left shifted maturation. Erythroid elements are reduced to absent. Megakaryocytes are not well represented in this material.}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \ul\insrsid5599393\charrsid7345479 \par PERIPHERAL BLOOD}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par CBC (}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393 9/23/2020}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 ):}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid10713710 WBC 21.0 H [4.0-11.0 K/mcL] \par RBC 3.63 L [3.80-5.00 M/mcL] \par HGB 9.5 L [11.2-15.4 g/dL] \par HCT 30.7 L [34.3-46.0 %] \par M}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393 CV}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid10713710  85 [80-98 fL] \par M}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393 CH}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid10713710  26.2 L [27.0-33.0 pg] \par M}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393 CHC}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid10713710  30.9 L [31.0-36.5 g/dL] \par R}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393 DW}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid10713710  18.6 H [12.2-15.1 %] \par Platelets 190 [160-400 K/mcL] }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid10713710 \par Neutrophil 55.0 [32.5-74.8 %] \par Mono 1.0 [0.0-12.3 %] \par Eos 2.0 [0.0-4.9 %] \par Baso 17.0 H [0.0-1.5 %] \par Blast 3.0 H [0.0-0.0 %] \par Myelocyte 7.0 H [0.0-0.0 %] \par Promyelocyte 4.0 H [0.0-0.0 %] \par Metamyelocyte 4.0 H [0.0-0.0 %] \par Lymph 7.0 L [12.2-47.4 %] \par Nucleated RBC 0 [/100(WBCs)] \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid10713710 Abs Neut 11.5 H [1.5-7.5 K/mcL] \par Abs Mono 0.2 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] \par Absolute Basophil 3.6 H [0.0-0.2 K/mcL] \par Absolute Blasts 0.6 H [0.0-0.0 K/mcL] \par Abs Myelocytes 1.5 H [0.0-0.0 K/mcL] \par Abs Promyelocytes 0.8 H [0.0-0.0 K/mcL] \par Abs Meta 0.8 H [0.0-0.0 K/mcL] \par Abs Lymph 1.5 [0.9-3.2 K/mcL] \par Megakaryocyte Fragment 5 [/100(WBCs)] }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393 Morphology:\par WBC: Leukocytosis with left shifted granulocytes and occasional circulating blasts.\par RBC: Normocytic, normochromic anemia with anisopoikilocytosis. Nucleated RBCs noted.\par PLT: Unremarkable morphology.}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \ul\insrsid5599393\charrsid7345479 IMMUNOHISTOCHEMISTRY}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393 Immunohistochemical stain for CD34 highlights mildly increased blast, 5-10% of total cellularity, with patchy distribution. CD117 highlights a subset of blasts. CD71 highlights markedly reduced erythroid elements. E-cadherin shows very rare early erythroid elements. }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \ul\insrsid5599393\charrsid16387280 FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-7701)}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid16387280 Abnormal myeloid blast population detected.\par Basophilia detected, representing 8.6% of WBC.\par \par Flow cytometry identifies an abnormal myeloid blast population similar to prior specimen (F20-982), with abnormal expression of CD7 (partial), CD13 (dim to absent), CD25 (partial), CD34 (uniform, slightly bright), CD38 (dim), CD56 (partial), CD117 (subset absent, subset bright), CD123 (uniform), and HLA-DR (subset absent); with normal expression of CD4, CD33, CD45, and CD71; without CD5, CD2, CD11b, CD14, CD15, CD16, CD19, or CD64. CD34 positive myeloid blasts represent 11.7% of WBC. Findings are consistent with a persistent myeloid neoplasm.}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \ul\insrsid5599393\charrsid7345479 CYTOGENETIC STUDIES}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par Cytogenetic analysis will be reported separately. }{\rtlch\fcs1 \af0 \ltrch\fcs0 \cgrid0\insrsid5599393\charrsid7345479 See separate report, CG}{\rtlch\fcs1 \af0 \ltrch\fcs0 \cgrid0\insrsid5599393 20-4833.}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par \~\par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \ul\insrsid5599393\charrsid7345479 MOLECULAR STUDIES}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479  \par Molecular analysis will be reported separately. }{\rtlch\fcs1 \af0 \ltrch\fcs0 \cgrid0\insrsid5599393\charrsid7345479 See separate report, M}{\rtlch\fcs1 \af0 \ltrch\fcs0 \cgrid0\insrsid5599393 20-30196, M20-30197.}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid7345479 \par \par }{\rtlch\fcs1 \af0\afs14 \ltrch\fcs0 \fs14\cf1\insrsid5599393 \par }{\rtlch\fcs1 \af0\afs14 \ltrch\fcs0 \fs14\cf1\insrsid5599393\charrsid4349262 Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin}{\rtlch\fcs1 \af0\afs14 \ltrch\fcs0 \fs14\cf1\insrsid5599393  }{\rtlch\fcs1 \af0\afs14 \ltrch\fcs0 \fs14\cf1\insrsid5599393\charrsid4349262 MD.,}{\rtlch\fcs1 \af0\afs14 \ltrch\fcs0 \fs14\cf1\insrsid5599393  }{\rtlch\fcs1 \af0\afs14 \ltrch\fcs0 \fs14\cf1\insrsid5599393\charrsid4349262 PhD., Director.\par \par The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid5599393\charrsid8093638 \par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}"
H20-8054;S11;MSKD - 2023-04-17 16.06.17.ndpi,Peripheral Blood Smear,2023-04-17,"CML
Leukocytosis. Marked thrombocytosis. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
    - Chronic myeloid leukemia, BCR-ABL1 positive (chronic phase).

See comment.

COMMENT: BCR-ABL1 p210 fusion gene transcript detected using a peripheral blood sample (M20-39266;11/25/2020). 
  
BONE MARROW BIOPSY&ASPIRATE SMEAR
Core biopsy shows hypercellular marrow (80-90%) with myeloid hyperplasia with left shifted maturation, reduced erythroid elements, markedly increased megakaryocytes with small and ""dwarf"" forms. 

Aspirate Smear Morphology:
-Spicular and hypercellular smears show myeloid hyperplasia with left shifted maturation, mild basophilia and eosinophilia, erythroid elements adequate and increased megakaryocytes. Erythroid elements show mild dyspoietic changes such as nuclear irregularities. 

Special stains: Reticulin stain shows mild focal increase in reticulin fibrosis (0-1/3). 

Differential: (Performed by CB)
Blasts                1%
Promyelocytes           1%
Myelocytes           13%
Metamyelocytes           9%
Neutrophils/Bands      39%
Monocytes           2%
Eosinophils           5%
Basophils           2%
Erythroid Precursors      23%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           3.1



PERIPHERAL BLOOD
CBC (12/07/2020):
WBC 13.8 H [4.0-11.0 K/mcL] 
RBC 4.65 [3.80-5.00 M/mcL] 
HGB 13.4 [11.2-15.4 g/dL] 
HCT 40.8 [34.3-46.0 %] 
MCV 88 [80-98 fL] 
MCH 28.8 [27.0-33.0 pg] 
MCHC 32.8 [31.0-36.5 g/dL] 
RDW 15.7 H [12.2-15.1 %] 
Platelets 1171 H [160-400 K/mcL] 

Neutrophil 78.2 H [32.5-74.8 %] 
Mono 4.8 [0.0-12.3 %] 
Eos 0.9 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Immature Granulocyte 1.4 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 12.7 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 10.8 H [1.5-7.5 K/mcL] 
Abs Mono 0.7 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.3 H [0.0-0.2 K/mcL] 
Absolute Immature 0.2 H [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.8 [0.9-3.2 K/mcL] 

Morphology: Leukocytosis with circulating myeloid precursors, increased basophils and markedly increased platelets

IMMUNOHISTOCHEMISTRY
Immunostains for CD34 and CD117 show mildly increased immature cells 5-6% of cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-10282)
Abnormal myeloid blast population detected.
Flow cytometry identifies an abnormal myeloid blast population abnormal expression of CD7, CD11b, CD13(dim), CD33(dim), CD34(bright). HLA-DR (bright) with normal expression of CD4, CD38, CD45, CD71, CD117, CD123 without CD2, CD5, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 2.2% of WBC.
429 thousand cells acquired.

No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.       

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-6521.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-40776, 40777, 40778.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-3065;S11;MSKA - 2023-06-27 23.30.42.ndpi,Peripheral Blood Smear,2023-06-27,"Leukemia, Hairy Cell
Evaluate disease pre protocol
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Hairy cell leukemia (~70% by CD20 immunohistochemistry).
  
BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Normocellular for age (50%)
M:E ratio: Reduced 
Blasts: Not increased 
Myeloid lineage: Relatively reduced with few maturing forms
Erythroid lineage: Relatively increased with full maturation 
Megakaryocytes: Adequate in number with mostly unremarkable morphology. 
Lymphocytes: Diffuse interstitial increase in small lymphocytes with ample clear cytoplasm and dense chromatin.
Plasma cells: Few, scattered 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                1%
Myelocytes           1%
Neutrophils/Bands      24%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      25%
Plasma Cells           2%
Lymphocytes           45% (major subset 25% with vague cytoplasmic projections)
Number of Cells Counted 500
M:E Ratio           1.1

Morphology:
Aspicular and hypocellular aspirate smears demonstrate maturing hematopoiesis. Blasts are not increased. Myeloid elements show progressive maturation without significant atypia. Erythroid elements are actively maturing without significant atypia. Megakaryocytes are rare. Small to medium sized lymphoid cells with clumped chromatin and vague cytoplasmic projections are increased.  

PERIPHERAL BLOOD
CBC (5/20/2020):
WBC 2.2 L [4.0-11.0 K/mcL] 
RBC 3.06 L [3.80-5.00 M/mcL] 
HGB 11.2 [11.2-15.4 g/dL] 
HCT 31.7 L [34.3-46.0 %] 
MCV 104 H [80-98 fL] 
MCH 36.6 H [27.0-33.0 pg] 
MCHC 35.3 [31.0-36.5 g/dL] 
RDW 14.3 [12.2-15.1 %] 
Platelets 115 L [160-400 K/mcL] 

Neutrophil 31.9 L [32.5-74.8 %] 
Mono 0.9 [0.0-12.3 %] 
Eos 1.4 [0.0-4.9 %] 
Baso 0.5 [0.0-1.5 %] 
Immature Granulocyte 0.0 [0.0-0.6 %] 
Lymph 65.3 H [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 0.7 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.4 [0.9-3.2 K/mcL]

Morphology:
WBCs: Relative lymphocytosis. Occasional circulating Hairy cells seen. 
RBCs: Normocytic, normochromic anemia with anisocytosis. 
Platelets: Thrombocytopenia with unremarkable morphology. 

IMMUNOHISTOCHEMISTRY
CD20 stains a diffuse interstitial infiltrate of small B cells which co-express BRAF V600E and comprise ~60% of marrow cellularity. 
CD3 stains background T cells

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-3709)
Abnormal B-cell population identified.
No abnormal T cell population detected. 

Flow cytometry reveals an abnormal mature B-cell population having abnormal expression of CD19 (bright), CD20 (bright), CD11c, CD22 (bright), CD25, CD45 (bright), CD103 and CD200 (bright) with slightly increased forward and side scatter and kappa light chain restriction (bright); with normal expression of CD38 and without CD5 or CD10. The immunophenotype of the abnormal B-cell population is consistent with involvement by hairy cell leukemia. The abnormal B cell population represents 24.5% of the total white cells.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-2271, 2296

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-15721


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-4473;S11;MSK5 - 2023-04-25 20.58.14.ndpi,Peripheral Blood Smear,2023-04-25,"MPN
H/o erythrocytosis 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by JAK2 V617+ myeloproliferative neoplasm, favor polycythemia vera.
  
COMMENT:
The patient's current thrombocytosis without erythrocytosis or leukocytosis is noted. Per report, the patient has a history of erythrocytosis with presumed polycythemia vera (PV). While the marrow cellularity is lower than typically seen in PV, the morphology of the megakaryocytes is in keeping with PV. Correlation with molecular and cytogenetic studies is recommended.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Normocellular (approximately 50%)
M:E ratio: Normal
Blasts: Not increased
Myeloid lineage: Progressive maturation
Erythroid lineage: Progressive maturation
Megakaryocytes: Mildly increased with rare clusters. Variable morphology, including large forms with abnormal ""cloud-like"" nuclear lobation and small forms with hypolobated and hyperchromatic nuclei
Lymphocytes: Scattered
Plasma cells: Scattered
Trabecular bone: No significant osteosclerosis
Stroma: No significant fibrosis
Special stains: Reticulin stain shows focal mild reticulin fibrosis (MF-0-1+). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed on aspirates and touch imprints by MT)
Blasts                2%
Myelocytes           11%
Metamyelocytes           5%
Neutrophils/Bands      38%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      25%
Plasma Cells           2%
Lymphocytes           13%
Number of Cells Counted 500
M:E Ratio           2.3

Morphology:
Spicular and cellular aspirates show progressive maturation of the myeloid and erythroid lineages with no significant dysplasia. Blasts are not increased. Few megakaryocytes are present for evaluation, including rare large forms with complex nuclei. There are prominent platelet clumps.

PERIPHERAL BLOOD
CBC (7/22/2020):
WBC 5.0 [4.0-11.0 K/mcL] 
RBC 5.40 H [3.80-5.00 M/mcL] 
HGB 12.0 [11.2-15.4 g/dL] 
HCT 40.9 [34.3-46.0 %] 
MCV 76 L [80-98 fL] 
MCH 22.2 L [27.0-33.0 pg] 
MCHC 29.3 L [31.0-36.5 g/dL] 
RDW 14.8 [12.2-15.1 %] 
Platelets. 688 H [160-400 K/mcL] 

Neutrophil 64.3 [32.5-74.8 %] 
Mono 4.6 [0.0-12.3 %] 
Eos 2.6 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Immature Granulocyte 0.2 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 26.3 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 3.2 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.3 [0.9-3.2 K/mcL]

Morphology:
WBC: Unremarkable
RBC: Unremarkable
Platelets: Thrombocytosis

IMMUNOHISTOCHEMISTRY
Immunostains show no increase in CD34+ blasts or CD117+ immature cells. Occasional megakaryocytes show aberrant expression of CD34.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-5599)
Interpretation: 
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature B- or T-cell populations detected.

CD34 positive myeloid blast population with apparent normal immunophenotype is 1.1% of WBC.
Mild basophilia seen, representing 1.1% of WBC.
395,603 of cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.
Flow cytometry is generally not a sensitive methodology in the context of myeloproliferative disorders, correlation with molecular studies for JAK2, CALR, MPL mutation status and/or BCR-ABL and morphology is advised if clinically indicated.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-3401.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M20-22003, M20-22002.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-4878;S11;MSKD - 2023-04-17 16.34.24.ndpi,Peripheral Blood Smear,2023-04-17,"Leukemia, Chronic Myeloid 
~5 mos post allo HCT w/ decline in plts  concerned for relapse 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Relapsed chronic myelomonocytic leukemia 2 (CMML-2) (12% blasts by aspirate differential count).

BONE MARROW BIOPSY
Quality: Suboptimal (small, fragmented)
Cellularity: Difficult to accurately assess due to limited intact marrow spaces, appears ~50-60% overall
M:E ratio: Increased
Blasts: Increased (best seen with CD34 immunohistochemistry described below)
Myeloid lineage: Increased with left-shifted maturation
Erythroid lineage: Relatively reduced with progressive maturation
Megakaryocytes: Reduced in number with rare hypolobated and hyperchromatic forms
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows patchy mild reticulin fibrosis (MF-0-1/3) 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                12%
Promyelocytes           2%
Myelocytes           31%
Metamyelocytes           15%
Neutrophils/Bands      14%
Monocytes           1%
Eosinophils           3%
Erythroid Precursors      10%
Plasma Cells           2%
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           6.6

Morphology:
Spicular and cellular smears show an expanded population of blasts, which range from small to large in size with rounded to irregular nuclei, fine chromatin, distinct nucleoli and scant cytoplasm. Myeloid elements are relatively increased and show left-shifted maturation with hyposegmented forms seen. Erythroid precursors are relatively reduced and are present at various stages of maturation with occasional forms showing nuclear irregularity/budding, binucleation or nuclear-cytoplasmic dyssynchrony. Megakaryocytes appear reduced without overt atypia identified.

PERIPHERAL BLOOD
CBC (8/6/2020):
WBC 3.3 L [4.0-11.0 K/mcL] 
RBC 2.86 L [3.80-5.00 M/mcL] 
HGB 10.1 L [11.2-15.4 g/dL] 
HCT 29.2 L [34.3-46.0 %] 
MCV 102 H [80-98 fL] 
MCH 35.3 H [27.0-33.0 pg] 
MCHC 34.6 [31.0-36.5 g/dL] 
RDW 13.3 [12.2-15.1 %] 
Platelets 50 L [160-400 K/mcL] 

Neutrophil 41.5 [32.5-74.8 %] 
Mono 11.1 [0.0-12.3 %] 
Eos 5.4 H [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 2.1 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 39.6 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 1.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL]

Morphology:
WBC: Absolute neutropenia with occasional myelocytes and metamyelocytes and a rare possible blast.
RBC: Macrocytic anemia.
Platelets: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
CD34 highlights blasts present in a patchy distribution, comprising ~5-10% of the marrow cellularity.
CD117 highlights relatively increased early myeloid/erythroid precursors as well as relatively increased mast cells, which are mostly singly distributed and rounded in shape.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6141)
Interpretation: 
Abnormal myeloid blast and granulocyte populations detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD7 (partial), CD25 (partial), CD56 (partial), CD11b (partial), CD13 (uniform intermediate), CD33 (uniform intermediate), CD34 (uniform bright), CD38 (uniform, slightly dim), CD117 (uniform intermediate), CD123 (absent), HLADR (uniform intermediate), with normal expression of CD4, CD45, CD71; without CD2, CD5, CD14, CD15, CD16, CD19, or CD64. CD34 positive myeloid blasts represent 6.6% of WBC. In addition, a subset of granulocytes shows abnormal retention of CD13 and CD38.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-3751.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-23949, M20-23951.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H20-1564;S10;MSKB - 2023-06-27 23.42.36.ndpi,Peripheral Blood Smear,2023-06-27,"ALL. New diagnosis
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B acute lymphoblastic leukemia/lymphoma (B-ALL) (87% blasts by aspirate differential count). 
     - Hypercellular marrow with markedly reduced trilineage hematopoiesis.
  
BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypercellular for age (~90%)
M:E ratio: Cannot be assessed 
Blasts: Diffuse interstitial sheets of blasts
Myeloid lineage: Markedly reduced 
Erythroid lineage: Markedly reduced
Megakaryocytes: Decreased showing hyperchromatic to hypolobated morphology 
Lymphocytes: Rare
Plasma cells: Rare

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                87%
Neutrophils/Bands      4%
Erythroid Precursors      1%
Lymphocytes           8%
Number of Cells Counted     500
M:E Ratio           4

Morphology:
The aspirate smears are spicular, cellular and demonstrate a prominent expanded population of blasts which vary in size from intermediate to large, show scant cytoplasm with subset showing small vacuoles, fine nuclear chromatin and distinct nucleolus. Erythroid and myeloid elements markedly recued. Few megakaryocytes are present.

PERIPHERAL BLOOD
CBC (02/21/2020):
WBC 12.4 H [4.0-11.0 K/mcL] 
RBC 3.68 L [3.95-5.54 M/mcL] 
HGB 10.6 L [12.5-16.2 g/dL] 
HCT 31.9 L [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 28.8 [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 14.4 [12.2-15.1 %] 
Platelets 160 [160-400 K/mcL] 

Neutrophil 16.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 52.0 H [0.0-0.0 %] 
Myelocyte 3.0 H [0.0-0.0 %] 
Lymph 27.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 2.0 [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Blasts 6.5 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.4 H [0.0-0.0 K/mcL] 
Abs Lymph 3.4 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology:
WBCs: Numerous circulating blasts seen. 
RBCs: Normocytic, normochromic anemia.
Platelets: Unremarkable.  

IMMUNOHISTOCHEMISTRY
CD34 and TdT highlights an extensive interstitial infiltrate of blasts comprising 85-90% of total cellularity. 
MPO shows weak subset staining in the blasts. 
Lysozyme highlights myeloid cells and monocytes; blasts are negative. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-1895)
Abnormal immature B-cell population detected.
No abnormal mature T-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (77.1% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD13 (partial), CD20 (partial), CD24 (dim), CD25 (partial), CD33 (partial), CD38 (dim to intermediate), CD45 (absent to intermediate), CD66c/CD123, CD73/CD304 (partial dim), CD81 (dim), MPO (partial dim); with normal expression of CD10, CD19, CD22, CD34, CD71 and HLA-DR; and without CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD56, CD64, CD66b, CD86 or CD117.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.33% of WBC.
296,084 of cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotyped with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-1150.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-7690, M20-7691, M20-7692.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-1805;S30;MSKL - 2023-06-27 23.18.52.ndpi,Peripheral Blood Smear,2023-06-27,"Lymphoma. MCL vs CLL
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
     - B-cell lymphoproliferative disorder most consistent with marginal zone lymphoma (~50% involvement with CD20 immunohistochemistry) (see comment).

COMMENT: Although a subset of the atypical lymphocytes in the peripheral blood (~10%) appear larger in size with distinct nucleoli, the majority of the lymphocytes in the blood and bone marrow are small to intermediate in size. However, the presence of a TP53 mutation and loss of chromosome 17p (as detected by recent peripheral blood molecular and cytogenetic studies [M20-6660, CG20-980]) in marginal zone lymphomas has been associated with more adverse clinical outcomes. Of note, a definitive morphologic correlate to the second, minute abnormal B-cell population detected by flow cytometry is not apparent. The case was reviewed with Dr. Ahmet Dogan, Chief, Hematopathology service, who agrees.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate but partially fragmented core biopsy and suboptimal aspirate smears (due to suboptimal cellular preservation/morphology) show hypercellular bone marrow for age (~60% cellularity overall) with a predominantly interstitial atypical lymphoid infiltrate composed predominantly of small to intermediate sized cells with rounded to irregular nuclei, condensed chromatin, mostly inconspicuous nucleoli and scant to moderate amounts of cytoplasm. Few scattered larger cells with distinct nucleoli are seen. Background maturing trilineage hematopoiesis appears relatively reduced.

Aspirate differential: (Performed by CB)

Myelocytes           3%
Metamyelocytes           2%
Neutrophils/Bands      4%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      4%
Lymphocytes           85%
Number of Cells Counted 500
M:E Ratio           2.8

IMMUNOHISTOCHEMISTRY
The neoplastic B-cells (comprising ~50% of the cellularity by CD20 immunohistochemistry)
Express: CD20, PAX5, CD5 (small subset weak), p53 (~80%, strong), IgM, IgD
Do not express: CD3, CD10, BCL6, LMO2, CD23, LEF1, cyclin D1, cyclin D2, SOX11, IgG, CD43, CD11c
Other: CD138 highlights few scattered plasma cells (<5% of cellularity), which are too few to evaluate for light chain restriction with kappa and lambda immunostains. CD117 highlights rare mast cells. Ki-67 proliferation index appears <10% within the lymphoid infiltrate, however, the stain may be technically suboptimal. CD3 and CD5 highlight background T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-2156) 
Interpretation: 
Two abnormal B-cell populations identified.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5 (partial dim), CD19 (dim), CD20 (dim to normal), CD23 (partial), CD81 (dim), and ROR1; normal expression of CD38, CD40, CD79b, and CD45; and without CD3, CD10, CD43, or CD200. The abnormal B-cell population represents 89.4% of total white cells. 

In addition, flow cytometry identifies another small abnormal B-cell population with a CLL/SLL-like immunophenotype having abnormal expression of CD5, CD20 (dim), CD23 (partial), CD79b (dim), CD81 (dim), CD200 (bright), and ROR1; normal expression of CD19, CD40 and CD45; and without CD3, CD38, CD43 or CD10 expression. The abnormal B-cell population comprises 0.08% of the white cells.

PERIPHERAL BLOOD
CBC (02/27/2020):
WBC 138.9 H [4.0-11.0 K/mcL] 
RBC 3.95 [3.95-5.54 M/mcL] 
HGB 12.2 L [12.5-16.2 g/dL] 
HCT 38.1 [37.5-49.3 %] 
MCV 97 [80-98 fL] 
MCH 30.9 [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 14.4 [12.2-15.1 %] 
Platelets 117 L [160-400 K/mcL] 

Neutrophil 8.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 87.0 H [12.2-47.4 %] 
Variant Lymph 2.0 [%] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 11.1 H [1.5-7.5 K/mcL] 
Abs Mono 4.2 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 123.6 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBC: Marked lymphocytosis with frequent atypical lymphoid cells morphologically similar to those in the aspirate smears. Occasional larger cells with distinct nucleoli are seen (comprise ~10% of the lymphocytes). Neutrophilia and monocytosis are also present.
RBC: Normochromic, normocytic anemia.
Platelets: Mild thrombocytopenia.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-1345, CG20-1346.

MOLECULAR STUDIES 
Not submitted.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.
  
The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-5846;S11;MSK0 - 2023-06-16 00.20.56.ndpi,Peripheral Blood Smear,2023-06-16,"ALL. Relapsed T-ALL
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
     - T-lymphoblastic leukemia/lymphoma (~40-50% blasts by TdT immunohistochemistry). See comment.
     - Normocellular marrow with reduced erythroid-predominant maturing trilineage hematopoiesis, left-shifted myelopoiesis, multilineage dyspoiesis and a t(10;11)(q22;p15); NUP98-KAT6B fusion, consistent with myeloid neoplasm. See comment.
  
COMMENT: This is a highly unusual case. The patient's reported history of T-lymphoblastic leukemia/lymphoma (T-ALL) status post chemotherapy is noted. Concurrent in-house cytogenetics analysis on bulk and flow sorted populations demonstrates two clonal populations. First, an expanded T-lymphoblast population harboring an isochromosome 17q (i(17q)) is present, consistent with T-ALL with i(17q). 

Second, a myeloid population (myeloid blasts and maturing myelomonocytic cells) harboring a t(10;11)(q22;p15); NUP98-KAT6B fusion is also identified. In addition, limited molecular analysis on peripheral blood demonstrates an IDH2 p.R140Q with a VAF of 23.3% (M20-27922; 9/4/20), higher than the percentage of circulating immature T-cells detected by flow cytometry (1%, F20-7091; 9/4/20), consistent with its presence in the myeloid compartment. These findings in conjunction with the relatively increased, atypical myeloid blasts (3.5% of WBC) and immature monocytes (5.8%) detected by concurrent flow cytometry (F20-7334) are consistent with the presence of a myeloid neoplasm. Further characterization of this myeloid neoplasm is very difficult due to patient's recent chemotherapy, extensive marrow involvement by T-ALL and lack of available pre-treatment CBC values. While multilineage dyspoiesis is seen in this sample, the significance of it is unclear in the setting of recent chemotherapy. Of note, accurate quantitation of myeloid blasts by morphology/IHC is limited by extensive involvement by CD34+ T-ALL.

The relationship between these two populations is also uncertain. Based on the work up to date, definitive evidence of a clonal link between the T-ALL and myeloid populations is not apparent, making a mixed phenotype acute leukemia less likely and suggesting the populations may represent two separate processes. While a therapy-related myeloid neoplasm (T-MN) secondary to the patient's T-ALL directed chemotherapy is another possibility, the reported presence of the IDH2 p.R140Q mutation at initial diagnosis (see H20-5753) suggests both populations may have been present at presentation and, in addition to the short time course, somewhat argues against a T-MN. Lastly, in-house unmatched molecular analysis on blood detected a TP53 p.P47S variant with a VAF that raises the possibility of germline origin (M20-27922; 9/4/20), which could predispose to two hematologic malignancies. Unstained material has been requested from the patient's initial diagnostic lymph node biopsy. If received, additional studies (FISH, IMPACT, Archer) will be attempted to help confirm the genomic alterations present at initial presentation and for comparison to the current results. Matched MSK-IMPACT on the current sample is also in progress. Results of these additional studies may help in further characterization. 

Case reviewed at the Hematopathology Consensus Conference on 9/18/2020 and 9/25/2020 with agreement. Preliminary findings were communicated to Dr. M. Geyer via email on 9/18/2020.

BONE MARROW BIOPSY
Quality: Adequate but small
Cellularity: ~40-50% 
M:E ratio: Reduced
Blasts: Increased
Myeloid lineage: Relatively reduced with left-shifted maturation
Erythroid lineage: Relatively reduced with progressive maturation
Megakaryocytes: Reduced in number with occasional small, hypolobated forms
Lymphocytes: Scattered
Plasma cells: Scattered
Clot section: Contains few marrow particles morphologically similar to the core biopsy

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                55%
Promyelocytes           1%
Myelocytes           2%
Metamyelocytes           1%
Neutrophils/Bands      5%
Monocytes           1%
Erythroid Precursors      27%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           0.4

Morphology:
Spicular and cellular smears show an expanded population of intermediate to large sized blasts with rounded to irregular nuclei, fine chromatin, distinct nucleoli and scant cytoplasm. Myeloid elements are relatively reduced and show left-shifted maturation with some dyspoietic forms (hypogranulation, abnormal nuclear segmentation). Erythroid precursors are relatively reduced and show progressive maturation with some dyspoietic forms (nuclear irregularity/budding, binucleation, nuclear-cytoplasmic dyssynchrony). Megakaryocytes are present with some small, hypolobated forms, micromegakaryocytes, and forms with disjointed nuclear lobes seen. 

PERIPHERAL BLOOD
CBC (09/14/2020):
WBC 3.0 L [4.0-11.0 K/mcL] 
RBC 3.10 L [3.95-5.54 M/mcL] 
HGB 10.0 L [12.5-16.2 g/dL] 
HCT 32.7 L [37.5-49.3 %] 
MCV 106 H [80-98 fL] 
MCH 32.3 [27.0-33.0 pg] 
MCHC 30.6 L [31.0-36.5 g/dL] 
RDW 23.0 H [12.2-15.1 %] 
Platelets 21 L [160-400 K/mcL]
 
Neutrophil 23.0 L [32.5-74.8 %] 
Mono 21.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 3.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Lymph 52.0 H [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 0.7 L [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 1.6 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology:
WBC: Leukopenia with absolute neutropenia, relative monocytosis, occasional myelocytes and metamyelocytes and rare circulating blasts.
RBC: Macrocytic anemia with anisopoikilocytosis and occasional nucleated RBCs.
Platelets: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
CD34 and TdT highlight increased interstitial blasts comprising ~40-50% of the marrow cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-7334)
Interpretation: 
Abnormal immature T-cell population identified.
An abnormal immature T-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously (F20-7091). The abnormal blasts represent 41.6% of the white cells and abnormally express CD2 (minimal, dim), surface CD3 (absent), cytoplasmic CD3 (slightly dim to intermediate), CD4 (largely negative, partial intermediate), CD7 (bright), CD10 (subset dim), CD34 (absent to dim), CD38 (bright), CD45 (dim), and CD48 (negative to dim); but without CD8, CD16 or CD56. In the appropriate clinical context, this finding is consistent with persistent/recurrent precursor T-cell lymphoblastic leukemia/lymphoma.In addition, the abnormal immature T cell population expresses CD13 (dim) and CD33 (partial); and without CD14, CD15, CD19, CD25, CD64, CD117, CD123 or HLA-DR.

Atypical myeloid blasts and immature monocytes detected.
The atypical myeloid blast show dim to negative expression of CD34, bright CD38 without CD15 or CD64. The myeloid blasts are 3.5% WBC. Immature monocyte population is expanded (5.8% WBC) and expresses CD56. The findings do not exclude an additional myeloid neoplasm.

CYTOGENETIC STUDIES:
CG20-4569 (BULK BONE MARROW):
KARYOTYPE ANALYSIS:
Chromosome analysis of this sample detected two unrelated clones including t(10;11) with NUP98 translocation in fourteen cells, and an isolated chromosome 17q in the remaining six cells. The t(10;11) was observed in a previous peripheral blood sample (9/8/0202, CG20-4405).  

TEST RESULTS:
KARYOTYPE ANALYSIS
Number of cells counted:          20
Number of cells analyzed:          20
Number of cells karyotyped:      4
Modal chromosome number(s):     46
Modal karyotype(s):          46,XY,t(10;11)(q22;p15)[14]/46,XY,i(17)(q10)[6]

FISH ANALYSIS:
Translocation of NUP98 (11p15.4), i.e., t(10;11), detected in 40% of cells.
Deletion of TP53 (17p13.1) detected in 30% of cells, consistent with the i(17q) noted by chromosome analysis.

CG20-4713 (FLOW SORTED T-LYMPHOBLASTS):
FISH ANALYSIS:
Deletion of TP53 (17p13.1) detected in 91% of cells.
No evidence of NUP98 (11p15.4) translocation.

CG20-4616 and CG20-4712 (FLOW SORTED MONOCYTES):
FISH ANALYSIS:
Rearrangement of NUP98 (11p15.4) detected in 93% of cells.
No evidence of TP53 (17p13.1) deletion, i.e., i(17q).

CG20-4619 (FLOW SORTED MYELOID BLASTS):
FISH ANALYSIS:
Translocation of NUP98 (11p15.4) detected in 100% of cells. 
No evidence of TP53 (17p13.1) deletion or loss of chromosome 17.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-28842, M20-28843, M20-28844, M20-30256.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     
"
H20-4615;S11;MSK3 - 2023-06-07 00.30.55.ndpi,Peripheral Blood Smear,2023-06-07,"Multiple Myeloma 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Metastatic Adenocarcinoma with mucinous features. (see Note)
     - Background hypercellular marrow with trilineage maturing hematopoiesis.
     - No morphologic or immunophenotypic evidence of plasma cell neoplasm.

Note: Immunohistochemical studies demonstrate that the tumor cells are positive for CK20 (diffuse) and CK7 (focal) and are negative for GATA-3, CDX-2, PAX8, TTF-1 and Napsin-A. The findings represent adenocarcinoma with mucinous features. Although the origin of the tumor is uncertain, based on the morphology and CK20 positivity, an enteric (GI) origin is favored. Clinical and radiologic correlation is recommended.

The bone marrow evaluation of this biopsy was performed by Dr. Amy Duffield (hematopathology).

BONE MARROW BIOPSY
Quality: Adequate  
Cellularity: Patchy, approximately 60% of the marrow shows involvement by metastatic carcinoma with patchy necrosis. The remaining 40% of the marrow space contains hypercellular marrow (approximately 70%) with trilineage hematopoiesis
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes: Borderline increased with variable morphology 
Plasma cells: Not increased 

ASPIRATE MORPHOLOGY
Aspirate differential: (Performed by: SS)
Blasts                1%
Promyelocytes           1%
Myelocytes           4%
Metamyelocytes           1%
Neutrophils/Bands      48%
Monocytes           5%
Eosinophils           1%
Erythroid Precursors      14%
Plasma Cells           1%
Lymphocytes           24%
Number of Cells Counted 200
M:E Ratio           4.3

Morphology: 
Marrow spicules: Aspicular.
Cellularity: N/A
Plasma cell morphology: Small
Myeloid lineage: Orderly maturation   
Erythroid Lineage: Orderly maturation   
Megakaryocytes: Present    
Other findings: Platelet clumps noted

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, <5% of cellularity. CD138 also highlights viable areas of metastatic carcinoma.
Kappa and lambda immunostains show the plasma cells are polytypic.  
BCMA highlights 80% of plasma cells, (2-3+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-5797) 
Interpretation: 
No abnormal mature B-cell population detected.
No abnormal plasma cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

No evidence of an abnormal plasma cell population is identified by flow cytometry.  Plasma cells comprise 0.32% of the viable cells, following erythroid lysis.
5,363,953 cells acquired.  Please note that flow cytometry studies generally underestimate the number of plasma cells, as compared to morphologic assessment. 

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.30% of WBC.
192,167 of cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

PERIPHERAL BLOOD
CBC (07/28/2020):
WBC 8.9 [4.0-11.0 K/mcL] 
RBC 3.17 L [3.80-5.00 M/mcL] 
HGB 9.0 L [11.2-15.4 g/dL] 
HCT 28.9 L [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 28.4 [27.0-33.0 pg] 
MCHC 31.1 [31.0-36.5 g/dL] 
RDW 15.4 H [12.2-15.1 %] 
Platelets. 611 H [160-400 K/mcL] 

Neutrophil 62.2 [32.5-74.8 %] 
Mono 5.7 [0.0-12.3 %] 
Eos 0.7 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 30.5 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 5.5 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 2.7 [0.9-3.2 K/mcL]

Morphology:
WBC: Unremarkalbe. No circulating plasma cells seen on scanning
RBC: Normochromic, nomocytic anemia
Platelets: Increased

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-3518, CG20-3519.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-22687.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-6596;S17;MSKI - 2023-06-07 00.36.36.ndpi,Peripheral Blood Smear,2023-06-07,"{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch31506\stshfhich31506\stshfbi31506\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri{\*\falt Calibri};}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE{\*\falt Calibri};}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr{\*\falt Calibri};}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek{\*\falt Calibri};}
{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur{\*\falt Calibri};}{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew){\*\falt Calibri};}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic){\*\falt Calibri};}
{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic{\*\falt Calibri};}{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese){\*\falt Calibri};}
{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;
\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;
\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;\red0\green0\blue0;}{\*\defchp \f31506\fs22 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 
\f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31506\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused Normal Table;}{
\s15\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 
\f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext15 \spriority0 \styrsid3935487 CoPath Text;}}{\*\rsidtbl \rsid3935487\rsid6516144\rsid8395730\rsid10561362\rsid14957972}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1
\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\author Rivera, Wilson J./Pathology}{\operator Chan, Alexander Y./Pathology}{\creatim\yr2020\mo10\dy16\hr13\min52}{\revtim\yr2020\mo10\dy16\hr13\min52}{\version2}{\edmins0}{\nofpages1}
{\nofwords23}{\nofchars144}{\nofcharsws159}{\vern111}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont1\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1440\dgvorigin1440\dghshow1\dgvshow1
\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\rsidroot10561362\newtblstyruls\nogrowautofit\usenormstyforlist\noindnmbrts\felnbrelev\nocxsptable\indrlsweleven\noafcnsttbl\afelev\utinl\hwelev\spltpgpar\notcvasp\notbrkcnstfrctbl\notvatxbx\krnprsnet\cachedcolbal \nouicompat \fet0
{\*\wgrffmtfilter 2450}\nofeaturethrottle1\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang 
{\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}
\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid14760365 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 \f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid14957972 Fanconi anemia. 23 year old woman with history of Fanconi anemia / aplastic anemia, status post allo HCT 2004, in remission since but with worsening anemia recently. \par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}","1-2. Bone marrow, left posterior iliac crest; biopsy and aspirate. 
     - Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD); see comment.
  
COMMENT: The patient's history of Fanconi anemia (s/p allogeneic stem cell transplant in 2004) with worsening anemia (first noted in 07/2020) is noted. The detection of SF3B1, DNMT3A and TET2 mutations in the peripheral blood (M20-20750) are indicative of a clonal process. The marrow is mildly hypercellular with erythroid hyperplasia with left shifted maturation, dysplasia in the erythroid lineage and megakaryocytes, increased mast cells, increased ring sideroblasts (>15%) with no increase in blasts (<5% of cellularity). 

Altogether, these findings are consistent with a low-grade myeloid neoplasm, best classified as myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD). In addition, most recent molecular chimerism study (M20-20775, 7/14/2020) demonstrated engraftment status of 100% donor. When reconciling the 100% donor status with the relatively high VAF of SF3B1 (0.29) and TET2 (0.26), these findings are suggestive of a myeloid neoplasm of donor origin. Correlation with cytogenetic and molecular studies is recommended. 

This case was also reviewed at the Hematopathology Consensus Conference on 10/16/2020, with agreement on the interpretation between the present hematopathology attending staff. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Mildly hypercellular for age (~90% cellularity)
M:E ratio: Decreased
Blasts: Not overtly increased
Myeloid lineage: Decreased, shows progressive maturation     
Erythroid lineage: Increased, shows left shifted progressive maturation     
Megakaryocytes: Adequate in number with some atypical forms with abnormal nuclear lobation (wide separation of nuclear lobes or hypolobation)
Lymphocytes: Interstitially scattered     
Plasma cells: Interstitially scattered     

Special stains: 
Reticulin stain shows no significant increase in reticulin fibrosis (0/3). 

BONE MARROW ASPIRATE SMEAR/TOUCH IMPRINTS
Differential: (Performed by KT)
Blasts                2%
Promyelocytes           1%
Myelocytes           13%
Metamyelocytes           4%
Neutrophils/Bands      25%
Monocytes           3%
Eosinophils           5%
Basophils           1%
Erythroid Precursors      39%
Plasma Cells           1%
Lymphocytes           6%
Number of Cells Counted 100
M:E Ratio           1.3

Special stain 
Iron: Present
Ring sideroblasts: Present >15%

Morphology: The aspirate smears are spicular and cellular demonstrating maturing trilineage hematopoiesis with erythroid predominance. Blasts are not increased, and Auer rods are not seen. Myeloid elements show mildly left shifted maturation and occasional hypogranular forms. Erythroid elements show left shifted maturation with dyspoiesis (megaloblastic change, nuclear irregularity/budding, binucleation, numerous ring sideroblasts). Megakaryocytes are present with atypical forms showing separation of nuclear lobes or hypolobation. Scattered mast cells are present. Touch imprints are cellular and show similar findings.     

PERIPHERAL BLOOD
CBC (10/10/2020):
WBC 6.7 [4.0-11.0 K/mcL] 
RBC 2.72 L [3.80-5.00 M/mcL] 
HGB 6.6 L [11.2-15.4 g/dL] 
HCT 21.5 L [34.3-46.0 %] 
MCV 79 L [80-98 fL] 
MCH 24.3 L [27.0-33.0 pg] 
MCHC 30.7 L [31.0-36.5 g/dL] 
RDW 25.1 H [12.2-15.1 %] 
Platelets 165 [160-400 K/mcL] 

Neutrophil 52.0 [32.5-74.8 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Lymph 37.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 3.5 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Lymph 2.5 [0.9-3.2 K/mcL] 

Morphology:
WBCs: Relative basophilia. Rare atypical monocytes are seen. A few immature granulocytes are present (metamyelocytes, band forms). No circulating blasts seen. 
RBCs: Microcytic to normocytic normochromic anemia with marked anisopoikilocytosis (tear drop cells, elliptocytes, target cells, basophilic stippling), moderate increase in polychromasia and rare nucleated RBC. 
Platelets: Occasional large forms          

IMMUNOHISTOCHEMISTRY
CD34 immunostain shows no increase in blasts (<5% of cellularity). Aberrant CD34 expression is seen in a subset of megakaryocytes. 
CD117 and tryptase highlight increased predominantly scattered mast cells, some of which appear spindled. A subset of the mast cells is CD2 positive. CD25 immunostain is technically suboptimal for evaluation. 
CD117 also highlights increased erythroid and myeloid precursors.
CD3 highlights singly scattered and small clusters of T-cells.     

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-8350)
No definite abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
Basophilia seen, representing 1.8% of WBC.
No abnormal mast cells seen.
No abnormal mature B- or T-cell populations detected.

There is no definite immunophenotypic evidence of a myeloid stem cell neoplasm by flow cytometry. However, in light of blast population having expression of CD7 (partial), CD11b (partial), CD13 (dim) as well as reduced CD16 on major subset of the granulocytic population, a low-grade myeloid stem cell neoplasm cannot be entirely excluded by these studies.  CD34 positive myeloid blasts represent 2.4% of the white blood cells with expression of CD13, CD33, CD34, CD38, CD45, CD71, CD117 and low CD123.  Normal monocytic maturation is present. 352,000 cells acquired. Morphologic, cytogenetic, and molecular genetic assessment is suggested to exclude myeloid stem cell neoplasm. Clinical correlation is also advised. Suggest a peripheral blood sample submitted for PNH analysis.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-5220.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-32746, M20-32747, M20-32748.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-4806;S20;MSKO - 2023-06-07 02.53.14.ndpi,Peripheral Blood Smear,2023-06-07,"Lymphoma
Relapse
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate smears and peripheral blood smear:
     - Mantle cell lymphoma (50% involvement by CD20 immunohistochemistry). 
     - Hypercellular marrow with maturing trilineage hematopoiesis.

BONE MARROW BIOPSY/CLOT SECTION/TOUCH IMPRINTS/ASPIRATE MORPHOLOGY
Adequate core biopsy and paucispicular but cellular aspirate smears and touch imprint show hypercellular bone marrow for age (approximately 70% cellularity) with maturing trilineage hematopoiesis and a nodular atypical lymphoid infiltrate comprised of mostly small to intermediate sized lymphoid cells with irregular nuclei, condensed chromatin and mostly inconspicuous nucleoli. Myeloid and erythroid elements show progressive maturation. Megakaryocytes are approximately adequate in number without overt atypia. Clot section shows rare minute marrow particles morphologically similar to the core biopsy.

Aspirate differential: (Performed by AS)

Myelocytes           2%
Metamyelocytes           1%
Neutrophils/Bands      14%
Monocytes           2%
Eosinophils           1%
Erythroid Precursors      7%
Lymphocytes           30%
Other cells               45% (abnormal lymphoid cells)
Number of Cells Counted  500
M:E Ratio           2.9

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight the nodular atypical lymphoid infiltrate, which comprises ~50% of the marrow cellularity and shows co-expression of CD5, cyclin D1 and SOX11 without expression of CD23 or p53 (<5% cells strongly positive). Ki-67 proliferative index within the lymphoid infiltrate is ~10%. CD23 highlights follicular dendritic cell meshworks associated with the infiltrate. CD3 labels admixed T-cells.

FLOW CYTOMETRIC ANALYSIS
Not submitted.

PERIPHERAL BLOOD
CBC (08/04/2020):
WBC 5.5 [4.0-11.0 K/mcL] 
RBC 2.69 L [3.95-5.54 M/mcL] 
HGB 9.3 L [12.5-16.2 g/dL] 
HCT 26.9 L [37.5-49.3 %] 
MCV 100 H [80-98 fL]
MCH 34.6 H [27.0-33.0 pg] 
MCHC 34.6 [31.0-36.5 g/dL] 
RDW 20.2 H [12.2-15.1 %] 
Platelets 143 L [160-400 K/mcL] 

Neutrophil 28.3 L [32.5-74.8 %] 
Mono 15.2 H [0.0-12.3 %] 
Eos 4.3 [0.0-4.9 %] 
Baso 0.5 [0.0-1.5 %] 
Immature Granulocyte 0.4 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 51.3 H [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 1.6 [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 2.8 [0.9-3.2 K/mcL] 

Morphology:
WBC: Occasional atypical small to intermediate sized lymphocytes with irregular nuclei and condensed chromatin seen.
RBC: Macrocytic anemia.
Platelets: Unremarkable morphology.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-3694.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-662;S2;MSK1 - 2023-06-27 02.25.47.ndpi,Peripheral Blood Smear,2023-06-27,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears: 
    - B-cell acute lymphoblastic leukemia/lymphoma (75% blasts by aspirate differential count). 

COMMENT: Correlation with forthcoming molecular and cytogenetic results is recommended.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Blasts                75%
Neutrophils/Bands      3%
Monocytes           1%
Erythroid Precursors      3%
Lymphocytes           18%
Number of Cells Counted 500
M:E Ratio           1.3

Morphology:
The aspirate smears are spicular, cellular and show an expanded blast population showing cells of intermediate to large size, scant cytoplasm, fine chromatin and distinct nucleolus. Background myeloid and erythroid elements are markedly reduced. Lymphocytes are mostly small and mature appearing. Megakaryocytes are not readily appreciated.

PERIPHERAL BLOOD
CBC (01/22/2020):
WBC 0.3 LL [7.1-15.9 K/mcL] 
RBC 2.44 L [3.89-5.03 M/mcL] 
HGB 7.6 L [10.7-14.5 g/dL] 
HCT 20.8 L [32.2-43.5 %] 
MCV 85 [74-91 fL] 
MCH 31.1 H [22.7-29.5 pg] 
MCHC 36.5 [31.0-36.5 g/dL] 
RDW 12.1 L [12.2-15.1 %] 
Platelets 18 LL [160-400 K/mcL] 

Morphology:
WBCs: Marked leukopenia. Circulating blasts seen. 
RBCs: Normocytic, normochromic anemia.
Platelets: Marked thrombocytopenia.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-811)
Abnormal immature B-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. Virtually no myeloid blasts seen.
No abnormal mature T-cell population detected.

The blasts have abnormal expression of CD10 (bright), CD13, CD20(partial), CD25 (subset), CD34 (dim), CD38 (dim), CD66c/CD123 (partial), CD81 (dim), with normal expression of CD19, CD22, CD24, CD45, and HLA-DR; and without CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD56, CD64, CD66b, CD71, CD86, CD117 or CD73/CD304.The abnormal population represents 18.2% of WBC and 18.2% of mononuclear cells.     The sample may be markedly hemodiluted based on large discrepancy in cell composition between marrow aspirate smear and the flow sample.

14,767 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.     


CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-482, CG20-483.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-3123 to M20-3125.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. PessinMD., PhD., Director.
"
H20-5331;S11;MSKZ - 2023-04-19 10.32.11.ndpi,Peripheral Blood Smear,2023-04-19,"AML. Newly diagnosed AML. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by acute leukemia, immunophenotypically consistent with mixed-phenotype acute leukemia (B/myeloid). See comment.
  
COMMENT:
The morphology and immunophenotypic findings are compatible with a B/myeloid mixed-phenotype acute leukemia; however, clinical, cytogenetic and molecular correlation are needed for definitive subclassifiation.

BONE MARROW BIOPSY
Quality: Limited due to extensive aspiration artifact.
Cellularity: Appears hypercellular (~90%) in the few intact areas
M:E ratio: Not applicable
Blasts: Markedly increased
Myeloid lineage: Limited maturation
Erythroid lineage: Decreased with progressive maturation
Megakaryocytes: Markedly decreased, rare morphologically unremarkable forms.
Lymphocytes: Not increased
Plasma cells: Not increased
Special stains: Reticulin stain shows no increase in reticulin fibrosis

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                75%
Promyelocytes           1%
Myelocytes           1%
Neutrophils/Bands      5%
Monocytes           1%
Erythroid Precursors      6%
Plasma Cells           2%
Lymphocytes           9%
Number of Cells Counted 500
M:E Ratio           1.3

Special stain
Not submitted for review

Morphology:
Spicular smears show increased blasts, which comprise approximately 80% of the cellularity. The blasts are medium-to-large in size with basophilic cytoplasm, occasional clefted nuclear borders, fine chromatin and conspicuous nucleoli. Some of the blasts have ""hand-mirror"" morphology. There are only rare maturing hematopoietic elements, which are too infrequent to adequately evaluate for background dysplastic changes. Rare megakaryocytes are seen.

PERIPHERAL BLOOD
CBC (08/24/2020):
WBC 0.9 L [4.0-11.0 K/mcL] 
RBC 2.58 L [3.80-5.00 M/mcL] 
HGB 7.9 L [11.2-15.4 g/dL] 
HCT 23.8 L [34.3-46.0 %] 
MCV 92 [80-98 fL] 
MCH 30.6 [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 15.7 H [12.2-15.1 %] 
Platelets. 21 L [160-400 K/mcL] 

Neutrophil 9.0 L [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 10.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 72.0 H [12.2-47.4 %] 
Variant Lymph 3.0 [%] 
Nucleated RBC 2 [/100(WBCs)] 

Abs Neut 0.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL]
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology:
WBC: Marked leukopenia with occasional smudged cells. Rare circulating blasts seen.
RBC: Normochromic, normocytic RBCs
Platelets: Thrombocytopenia

IMMUNOHISTOCHEMISTRY
Immunostains show that blasts with variable expression of CD34 and CD117 comprise approximately 70% of the marrow cellularity in intact areas. The blasts also show partial expression of Pax-5 and TdT.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6696)
Interpretation: 
Expanded abnormal blast population with myeloid and B-lineage differentiation detected. 
No abnormal mature B- or T-cell populations detected. 

The blasts have abnormal expression of CD13 (bright), CD19 (small subset on the CD117 negative population), CD25, CD33 (dim on the CD117 negative population), CD34 (bright with a minor subset negative), CD38 (subset absent), cytoplasmic CD79a (subset on the MPO negative population), CD117 (subset dim to negative) with normal expression of CD45, CD71, CD123 and HLA-DR without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD20, CD56, CD64 or surface light chains. MPO expression is present on a subset of blasts. MPO and cytoplasmic CD79a are present in different blast populations. CD34 positive blasts represent 48.9% of WBC. The blasts show myeloid and B-lineage differentiation. The differential diagnosis includes acute myeloid leukemia with recurrent cytogenetic abnormalities, therapy related myeloid neoplasm, acute myeloid leukemia with myelodysplasia related changes, CML with blast crisis, and mixed phenotype acute leukemia. Correlation with clinical history, morphology, pending cytogenetic and molecular findings is required for further classification. 

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-4133.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-26002 to M20-26005.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     
"
H20-2622;S10;MSK8 - 2023-06-27 23.59.52.ndpi,Peripheral Blood Smear,2023-06-28,"ALL
Early T-Cell precursor ALL with 47, XY, + mar (likely chromosome 8), IDH R14Q mutation and NUP214-ABL1 fusion
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears:     
     - T-lymphoblastic leukemia/lymphoma, 94% blast by aspirate differential count.  

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: 90-95%
M:E ratio: N/A
Blasts: Markedly increased, replacing the marrow celluarity 
Myeloid lineage: Markedly decreased
Erythroid lineage: Markedly decreased
Megakaryocytes: Present, decreased, morphologically unremarkable.  
Lymphocytes: Not increased 
Plasma cells: Not increased 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                94%
Neutrophils/Bands      1%
Erythroid Precursors      2%
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           0.5

Morphology:
Spicular and cellular smears show expanded blast population. Blasts are mostly small and have multiple distinct nucleoli and scant cytoplasm. Background trilineage hematopoiesis is markedly suppressed.  

PERIPHERAL BLOOD
CBC (04/15/2020):
WBC 7.4 [4.0-11.0 K/mcL] 
RBC 3.33 L [3.95-5.54 M/mcL] 
HGB 10.6 L [12.5-16.2 g/dL] 
HCT 31.5 L [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 31.8 [27.0-33.0 pg] 
MCHC 33.7 [31.0-36.5 g/dL] 
RDW 22.0 H [12.2-15.1 %] 
Platelets. 170 [160-400 K/mcL] 

Neutrophil 77.0 H [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 10.0 H [0.0-0.0 %] 
Lymph 13.0 [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 5.7 [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.7 H [0.0-0.0 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology: Circulating blasts identified. 

IMMUNOHISTOCHEMISTRY
CD34 and TdT highlights expanded blast population replacing marrow cellularity, comprising >90% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-3130)
Interpretation: 
Abnormal immature T-cell population identified.
An abnormal immature T-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously (F20-863). The abnormal blasts represent 96.2% of the white cells and abnormally express CD2 (partial), surface CD3 (negative), cytoplasmic CD3 (bright), CD7 (bright), CD16/CD56 (majority), CD34,CD38 (dim), CD45 (dim), and CD48 (negative); and without CD4, CD8, or significant CD10. This finding is consistent with persistent/recurrent precursor T-cell lymphoblastic leukemia/lymphoma depending on the clinical context. 

No abnormal mature B-cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-1952.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-13613, M20-13614, M20-13615, M20-13617. 



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-3266;S2;MSK4 - 2023-06-27 23.01.14.ndpi,Peripheral Blood Smear,2023-06-27,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears:
     - B-lymphoblastic leukemia/lymphoma, 99% blasts by aspirate differential count.

 COMMENT: Correlation with pending molecular and cytogenetic studies is also recommended. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Blasts                99%
Neutrophils/Bands      1%
Number of Cells Counted 500
M:E Ratio           0

Morphology:
Spicular and cellular smears show markedly increased blasts (99% by 500-cell aspirate differential count); the blasts are medium to large sized with irregular nuclei, fine chromatin, variably prominent nucleoli and scant cytoplasm. Myeloid and erythroid elements are markedly decreased. Few megakaryocytes are seen with unremarkable morphology. 

PERIPHERAL BLOOD
CBC (06/01/2020):
WBC 4.2 [4.0-11.0 K/mcL] 
RBC 2.71 L [3.95-5.54 M/mcL] 
HGB 8.2 L [12.5-16.2 g/dL] 
HCT 24.2 L [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 30.3 [27.0-33.0 pg] 
MCHC 33.9 [31.0-36.5 g/dL] 
RDW 13.9 [12.2-15.1 %] 
Platelets 119 L [160-400 K/mcL] 

Neutrophil 17.0 L [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 22.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 55.0 H [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 0.7 L [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.9 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 2.3 [0.9-3.2 K/mcL] 

Morphology: 
WBC: Occasional circulating blasts with similar morphology to those seen on the aspirate smears; absolute neutropenia with mild left shift. 
RBC: Normocytic, normochromic anemia.
Platelets: Thrombocytopenia with occasional large forms.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-3987)
Abnormal immature B-cell population detected.

An abnormal immature B-cell population is identified by flow cytometry. The abnormal immature B-cells represent 96.6% of the white cells and 97.5% of the mononuclear cells in the sample and abnormally express CD10 (dim to intermediate), CD19 (bright), CD34 (bright), CD66c/CD123 (partial); with normal expression of CD22, CD24, CD38, CD45 and CD81; and without CD20, CD66b, or CD73/CD304. This finding is consistent with B-lymphoblastic leukemia/lymphoma, depending on the clinical context.  

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-2442, CG20-2443.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-16561, M20-16562.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. PessinMD., PhD., Director.
 
"
H20-4924;S11;MSK6 - 2023-06-07 02.36.45.ndpi,Peripheral Blood Smear,2023-06-07,"Lymphoma 
MCL
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Mantle cell lymphoma (40% involvement by CD20 immunohistochemistry)

This case was also reviewed by Dr. Ahmet Dogan, Chief of Hematopathology Service. 

BONE MARROW BIOPSY/CLOT SECTION/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens showing hypercellular marrow (~50% cellularity) for age with extensive involvement by an atypical interstitial and nodular lymphoid proliferation. The atypical infiltrate is composed of small to medium-sized lymphoid cells with slightly irregular nuclei, dispersed to granular chromatin, variably distinct nuclei and small amount of cytoplasm. The background trilineage hematopoiesis is reduced. Myeloid and erythroid elements show orderly maturation with mostly unremarkable morphology. Megakaryocytes are overall adequate in number with occasional hypolobated and hyperchromatic forms. Blasts are not increased. 

Aspirate differential: 
(Performed on aspirate smears and touch imprints by HM)
Blasts                2%
Promyelocytes           3%
Myelocytes           11%
Metamyelocytes           7%
Neutrophils/Bands      18%
Monocytes           2%
Eosinophils           3%
Erythroid Precursors      15%
Plasma Cells           1%
Lymphocytes           11%
Abnormal Lymphoid Cells      27%
Number of Cells Counted 500
M:E Ratio           2.9

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight the increased number of atypical lymphoid cells (~40% marrow cellularity). 
CD3 highlights small T-cells scattered interstitially and admixed in lymphoid aggregates.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6211) 
Abnormal B-cell population identified.
Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD20 (bright), CD43 (partial dim), and ROR1; normal expression of CD19, CD38, CD40, CD79b, CD81, and CD45; and without CD3, CD10, CD23, or CD200.  The abnormal B cell population represents 19.9% of total white cells.
This immunophenotype is consistent with previously diagnosed mantle cell lymphoma (MCL).

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F20-6251)
Abnormal B-cell population identified.
Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD20 (bright), CD43 (negative to dim), and ROR1 (partial); normal expression of CD19, CD38, CD40, CD79b, CD81, and CD45; and without CD3, CD10, CD23, or CD200. The abnormal B cell population represents 53.2% of total white cells.
This immunophenotype is consistent with previously diagnosed mantle cell lymphoma (MCL).

PERIPHERAL BLOOD
CBC (8/10/2020):
WBC 17.1 H [4.0-11.0 K/mcL] 
RBC 4.95 [3.95-5.54 M/mcL] 
HGB 14.8 [12.5-16.2 g/dL] 
HCT 44.7 [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 29.9 [27.0-33.0 pg] 
MCHC 33.1 [31.0-36.5 g/dL] 
RDW 13.0 [12.2-15.1 %] 
Platelets 113 L [160-400 K/mcL] 

Neutrophil 25.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 44.0 [12.2-47.4 %] 
Abnormal lymphoid cells 24.0 H [0.0-0.0 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 4.3 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.3 H [0.0-0.2 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.3 H [0.0-0.0 K/mcL] 
Abs Lymph 7.5 H [0.9-3.2 K/mcL] 
Abs Others 4.1 H [0.0-0.0 K/mcL] 

Morphology: 
WBC: Absolute lymphocytosis with frequent circulating atypical small to medium-sized lymphoid cells with irregular nuclei, dispersed to condensed chromatin, variably distinct nucleoli and small amount of cytoplasm
RBC: Unremarkable morphology.
Platelet: Unremarkable morphology.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-3791.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-24244.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-4480;S10;MSKL - 2023-06-07 02.58.51.ndpi,Peripheral Blood Smear,2023-06-07,"Lymphoma, Mantle Cell Lymphoma 
","1-3. Bone marrow, right iliac crest biopsy, aspirate and peripheral blood smears: 
     - Involvement by mantle cell lymphoma (20% with CD20 immunohistochemistry).
     - a minute abnormal B-cell population with CLL/SLL-like immunophenotype (0.04% of the white cells) is detected by flow cytometry only in the marrow and in the peripheral blood.

NOTE: This case was also reviewed by Dr. Wenbin Xiao, Hematopathology Service.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show normocellular bone marrow (20% cellularity) with interstitial nodular lymphoid aggregates of small to medium sized cells with condensed chromatin and inconspicuous nucleoli. There istrilineage maturing hematopoiesis. Myeloid and erythroid elements show progressive maturation. Megakaryocytes appear adequate in number and morphology.

Aspirate differential: (Performed by SS)
Blasts                1%
Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           4%
Neutrophils/Bands      27%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      26%
Lymphocytes           30%
Number of Cells Counted      500
M:E Ratio           1.6

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD20, PAX5, Cyclin D1
Do not express: CD3, CD23, CD5
Other: CD3 and CD5 highlight background small T cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-5611) 
Interpretation: 
Two abnormal B-cell populations identified.
No abnormal mature T-cell population detected.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD5 (partial), CD10 (minor subset), CD22 (dim), CD38 (intermediate), ROR1 (partial), and kappa light chain restriction, and normal expression of CD19, CD20, CD40, CD45, CD79b, and CD81; and without CD23 or CD200. The abnormal B-cell population represents 4.7% of the total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

Flow cytometry identified an abnormal B-cell population with CLL/SLL-like immunophenotype having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23, CD43 (partial, dim), CD79b (absent), CD81 (dim), CD200 (bright), ROR1, and lambda surface light chain restriction (dim); normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The abnormal B-cell population comprises 0.040% of the white cells.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F20-5608) 
Interpretation: 
Two abnormal B-cell populations identified.
No abnormal mature T-cell population detected.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD5 (partial), CD10 (minor subset), CD19 (dim), CD22 (dim), CD38 (intermediate), ROR1 (partial)and kappa light chain restriction, and normal expression of CD20, CD40, CD45, cyCD79b, and CD81; and without CD23 or CD200. The abnormal B-cell population represents 2.8% of the total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

The immunophenotypic identification of an abnormal B-cell population having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23, CD43 (partial), CD79b (absent to dim), CD81 (dim), CD200 (bright), ROR1, and lambda surface light chain restriction (dim); normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression is consistent with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or CLL-like monoclonal B-cell lymphocytosis. Quantitative criterion for CLL (>5000 cells/microliter) abnormal CLL clone is not met in the current sample.  The abnormal B-cell population comprises 0.041% of the white cells representing absolute count of 0.002 thousand/microliter of blood. 

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

PERIPHERAL BLOOD
CBC (07/22/2020)
WBC 5.1 [4.0-11.0 K/mcL] 
RBC 3.29 L [3.95-5.54 M/mcL] 
HGB 11.3 L [12.5-16.2 g/dL] 
HCT 34.2 L [37.5-49.3 %] 
MCV 104 H [80-98 fL] 
MCH 34.3 H [27.0-33.0 pg] 
MCHC 33.0 [31.0-36.5 g/dL] 
RDW 14.0 [12.2-15.1 %] 
Platelets. 117 L [160-400 K/mcL] 

Neutrophil 73.9 [32.5-74.8 %] 
Mono 9.9 [0.0-12.3 %] 
Eos 1.2 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.4 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 14.0 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 3.7 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 0.7 L [0.9-3.2 K/mcL]

Morphology:
WBC: Mild lymphopenia. No circulating blasts or atypical lymphoid cells.
RBC: Normocytic anemia. 
PLT: Unremarkable.

CYTOGENETIC STUDIES
Not performed.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-22007.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-673;S11;MSK3 - 2023-06-27 22.25.57.ndpi,Peripheral Blood Smear,2023-06-27,"CML.
Chronic phase CML s/p multiple TKIs on ponatinib.
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Chronic Myeloid Leukemia (CML), (BCR-ABL-positive), Chronic phase (see comment)  

COMMENT: The patient's prior history of CML is noted. The findings of hypercellular bone marrow with megakaryocyte atypia (small hypolobated forms) without additional dysplasia or significant increase in blasts (<10%) in either bone marrow or peripheral blood in the setting of positive t(9;22)(q34.1;q11.2) and BCR-ABL translocation demonstrated by (FISH) (see CG20-502) are consistent with the above diagnosis.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: ~70%
M:E ratio: Normal
Blasts: Not increased
Myeloid lineage: Full maturation with expansion of early maturing forms in paratrabecular areas
Erythroid lineage: Full maturation
Megakaryocytes: Mildly increased with subset of small hypolobated (dwarf) forms present
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1). 


BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Blasts                3%
Promyelocytes           2%
Myelocytes           17%
Metamyelocytes           6%
Neutrophils/Bands      25%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      32%
Plasma Cells           2%
Lymphocytes           9%
Number of Cells Counted 500
M:E Ratio           1.7

Morphology:
-Spicular and cellular smears show maturing trilineage hematopoiesis with no increase in blasts. The myeloid lineage shows full range of maturation. The erythroid series shows progressive maturation with rare elements show nuclear membrane irregularities. Megakaryocytes are present with a subset of small hypolobated forms.

PERIPHERAL BLOOD
CBC (01/22/2020):
WBC 5.3 [4.0-11.0 K/mcL] 
RBC 4.42 [3.80-5.00 M/mcL] 
HGB 13.6 [11.2-15.4 g/dL] 
HCT 42.4 [34.3-46.0 %] 
MCV 96 [80-98 fL] 
MCH 30.8 [27.0-33.0 pg] 
MCHC 32.1 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 104 L [160-400 K/mcL] 

Neutrophil 62.4 [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 0.9 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.4 [0.0-0.6 %] 
Lymph 27.7 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 3.3 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.5 [0.9-3.2 K/mcL] 

Morphology:
WBC: Unremarkable 
Platelet: Thrombocytopenia
RBC: Unremarkable

IMMUNOHISTOCHEMISTRY
Immunostains show for CD34 and CD117 show no increase in blasts, <5%.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-830)
Atypical myeloid blast maturation identified. 

Flow cytometry identified a small atypical blast population with erythroid biased differentiation that has bright CD71, dim CD13, dim to absent CD33, and bright HLA-DR expression. This atypical blast population is approximately 0.5% of WBC. Correlation with molecular testing for BCR-ABL1 is recommended. Total CD34 positive myeloid blast population is 0.78% of WBC. 209,529 cells acquired.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-502.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-3195.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-8498;S11;MSKF - 2023-04-17 16.00.57.ndpi,Peripheral Blood Smear,2023-04-17,"Leukemia.  New presentation, CMML, versus AML.  
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia, therapy-related, 70% blast/blast-equivalent by aspirate differential count, see comment. 
  
COMMENT: Per clinical notes, the patient has a history of breast carcinoma, status post chemotherapy, surgery, and radiation. Therefore, this leukemia is classified as therapy-related myeloid neoplasm by WHO 2016 classification. Expanded monocyte population is present in the bone marrow, and these monocytes have immature morphology with prominent nucleoli, consistent with blast-equivalent monoblasts and promonocytes. Background hematopoiesis shows significant dysplasia.   

This case was discussed with Dr. Abdel-Wahab and Dr. Wu on 12/29/2020. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: 90-95%
M:E ratio: N/A
Blasts: Increased, replacing marrow cellularity 
Myeloid lineage: No maturation seen
Erythroid lineage: Decreased
Megakaryocytes: Virtually absent 
Lymphocytes: Not increased 
Plasma cells: Not increased 
Special stains: Reticulin stain shows no increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                70% (blasts/blast equivalent)
Promyelocytes           3%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      8%
Monocytes           2%
Erythroid Precursors      9% 
Plasma Cells           1%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           1.7


Morphology:
Spicular and hypercellular smears show marked increase in blasts and immature monocytes (blast-equivalent). Immature monocytes have markedly irregular nuclear contours, fine chromatin and distinct nucleoli. Blasts have high N/C ratio, multiple prominent nucleoli and granular cytoplasm. Prominent dysplasia is present in erythroid precursors (multi-nucleation, nuclear budding, megaloblastoid changes, late stage mitosis). 

PERIPHERAL BLOOD
CBC (12/28/2020):
WBC 34.1 H [4.0-11.0 K/mcL] 
RBC 2.38 L [3.80-5.00 M/mcL] 
HGB 8.0 L [11.2-15.4 g/dL] 
HCT 24.6 L [34.3-46.0 %] 
MCV 103 H [80-98 fL] 
MCH 33.6 H [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 21.8 H [12.2-15.1 %] 
Platelets. 11 L [160-400 K/mcL] 

Neutrophil 47.0 [32.5-74.8 %] 
Mono 41.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 7.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 4.0 L [12.2-47.4 %] 
Nucleated RBC 2 [/100(WBCs)] 

Abs Neut 16.0 H [1.5-7.5 K/mcL] 
Abs Mono 14.0 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 2.4 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.3 H [0.0-0.0 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology: Marked leukocytosis and monocytosis. 

IMMUNOHISTOCHEMISTRY
Immature cells are mostly negative for CD34 and CD117. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-10872)
Interpretation: 
Abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
Monocytosis seen, representing 65.1% of WBC.
No abnormal mature B- or T-cell populations detected.

The myeloid blasts have abnormal expression of CD19 (subset), CD33 (negative to intermediate), CD34 (subset negative), CD38 (negative to dim), HLA-DR (subset negative), with normal expression of CD4, CD13, CD45, CD71, CD117, CD123; without CD2, CD3, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD20, CD25, CD56, CD64, or surface light chains. Monocytosis is seen, representing 65.1% of WBC. Granulocytes show decreased side scatter, which may represent hypogranularity. CD117 positive myeloid blasts represent 4.3% of WBC.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F20-10856)
Interpretation: 
Abnormal myeloid blast population detected. 
Monocytosis is seen, representing 60.7% of WBC.
No abnormal B and T cell populations detected.

The myeloid blasts have abnormal expression of CD19 (subset), CD33 (negative to intermediate), CD34 (subset negative), CD38 (negative to dim), HLA-DR (subset negative), with normal expression of CD4, CD13, CD45, CD71, CD117, CD123; without CD2, CD3, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD20, CD25, CD56, CD64, or surface light chains. Monocytosis is seen, representing 60.7% of WBC. Granulocytes show decreased side scatter, which may represent hypogranularity. CD117 positive myeloid blasts represent 2.3% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-6920.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-43335, M20-43336, M20-43337, M20-43338.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-7768;S10;MSKN - 2023-06-15 19.23.59.ndpi,Peripheral Blood Smear,2023-06-15,"ALL. Newly diagnosed T-ALL. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
     - T-lymphoblastic leukemia/lymphoma (~90% marrow involvement by aspirate morphology and TdT immunostain).
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular (~95%)
M:E ratio: Not applicable
Blasts: Markedly increased (approximately 90% of the marrow cellularity) 
Myeloid lineage: Markedly decreased
Erythroid lineage: Markedly decreased
Megakaryocytes: Decreased with variable morphology
Lymphocytes: No prominent aggregates of mature lymphocytes are noted
Plasma cells: Not increased

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                88%
Myelocytes           1%
Neutrophils/Bands      6%
Eosinophils           3%
Erythroid Precursors      2%
Number of Cells Counted 500
M:E Ratio           5

Morphology:
Spiculate and hypercellular smears show sheets of blasts that are medium to large in size. The blasts have a moderate amount of basophilic cytoplasm, occasional cytoplasmic vacuoles, fine chromatin and inconspicuous nucleoli. Maturing myeloid and erythroid elements are present but markedly decreased, limiting evaluation for background dysplasia. Occasional morphologically unremarkable megakaryocytes are present.

PERIPHERAL BLOOD
CBC (11/23/2020):
WBC 76.9 H [4.0-11.0 K/mcL] 
RBC 4.37 [3.95-5.54 M/mcL] 
HGB 11.7 L [12.5-16.2 g/dL] 
HCT 36.6 L [37.5-49.3 %] 
MCV 84 [80-98 fL] 
MCH 26.8 L [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 13.7 [12.2-15.1 %] 
Platelets. 93 L [160-400 K/mcL] 

Neutrophil 19.0 L [32.5-74.8 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 62.0 H [0.0-0.0 %] 
Lymph 13.0 [12.2-47.4 %] 

Abs Neut 14.6 H [1.5-7.5 K/mcL] 
Abs Mono 3.8 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.8 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 47.7 H [0.0-0.0 K/mcL] 
Abs Lymph 10.0 H [0.9-3.2 K/mcL]

Morphology:
WBC: Leukocytosis with markedly increased circulating blasts. Frequent phenotypically unremarkable granulocytes. Scattered smudged cells seen.
RBC: Normochromic, normocytic anemia
Platelets: Decreased 

IMMUNOHISTOCHEMISTRY
Immunostains show that TdT+ and CD34-negative blasts comprise approximately 90% of the marrow cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-9896)
Interpretation: 
Abnormal immature T-cell population identified. No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

The abnormal blasts represent 90.6% of the white cells and abnormally express surface CD3 (negative), cytoplasmic CD3 (bright), CD4 (negative), CD5 (dim), CD7 (bright), CD8 (partial), CD10 (partial), CD11b (partial), CD38 (absent to dim), CD45 (dim), CD48 (negative), and CD117 (partial); with normal expression of CD2; and without CD16, CD34, or CD56. This finding is consistent with persistent/recurrent precursor T-cell lymphoblastic leukemia/lymphoma depending on the clinical context.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.24% of WBC. 468,000 of cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F20-9846)
Interpretation:
T-lymphoblastic leukemia/lymphoma.

The presence of greater than 20% abnormal immature T-cells in the peripheral blood and/or marrow (64.9% of the total white cells) is diagnostic for T-lymphoblastic leukemia/lymphoma (T-ALL) by WHO criteria. The blasts have abnormal expression of surface CD3 (negative), cytoplasmic CD3 (bright), CD7 (bright), CD8 (partial), CD117 (partial, dim), CD10, CD11b (partial), CD38 (bright), CD45 (dim), CD48 (negative), cytoplasmic CD79a; with normal expression of CD2, CD5, and CD71; and without CD1a, CD4, CD13, CD14, CD15, CD16, CD19, CD20, CD25, CD26, CD33, CD34, CD56, CD64, CD123, CD279 (PD1), T-cell receptor gamma/delta, HLA-DR, MPO, or surface light chains.

No abnormal mature B-cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.

No abnormal myeloid blast, monocyte or maturing myeloid population identified.
CD34 positive myeloid blast population with apparent normal immunophenotype is 0.19% of WBC. 306 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-6248.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M20-38988, M20-38989, M20-38990, M20-38991 and M20-38992.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-424;S12;MSKY - 2023-04-20 09.13.15.ndpi,Peripheral Blood Smear,2023-04-20,"CML. 63 yo woman with newly diagnosed CML
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Chronic myeloid leukemia, BCR-ABL1 positive, chronic phase; see comment.

COMMENT: Recent cytogenetic (CG20-332) and molecular testing (M20-2080 and M20-2081) detected BCR-ABL1 fusion with p210 isoform, consistent with the above diagnosis.
  
BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypercellular (>95%)
M:E ratio: Increased 
Blasts: Not overtly increased 
Myeloid lineage: Predominant with full maturation and mild left shift 
Erythroid lineage: Relatively reduced, with full maturation 
Megakaryocytes: Atypical megakaryocytic hyperplasia showing numerous small forms with monolobation 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis. 
Clot section: Cellular and similar to the biopsy 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                5%
Promyelocytes           2%
Myelocytes           14%
Metamyelocytes           3%
Neutrophils/Bands      54%
Monocytes           1%
Eosinophils           7%
Basophils           1%
Erythroid Precursors      9%
Plasma Cells           1%
Lymphocytes           3%
Number of Cells Counted      100
M:E Ratio           9.1

Morphology:
Spicular and hypercellular smears show trilineage hematopoiesis with increased M:E ratio, mildly left shifted myeloid maturation, reduced erythroid elements, increased basophils and eosinophils. Blasts are borderline increased (5%). Megakaryocytes are increased showing small monolobated forms. Platelet clumps are also noted.

PERIPHERAL BLOOD
CBC (1/15/2020):
WBC 38.3 H [4.0-11.0 K/mcL] 
RBC 4.32 [3.80-5.00 M/mcL] 
HGB 12.0 [11.2-15.4 g/dL] 
HCT 39.4 [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 27.8 [27.0-33.0 pg] 
MCHC 30.5 L [31.0-36.5 g/dL] 
RDW 14.5 [12.2-15.1 %] 
Platelets 550 H [160-400 K/mcL] 

Neutrophil 67.0 [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 7.0 H [0.0-1.5 %] 
Myelocyte 7.0 H [0.0-0.0 %] 
Metamyelocyte 5.0 H [0.0-0.0 %] 
Lymph 9.0 L [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 25.6 H [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.5 H [0.0-0.7 K/mcL] 
Absolute Basophil 2.7 H [0.0-0.2 K/mcL] 
Abs Myelocytes 2.7 H [0.0-0.0 K/mcL] 
Abs Meta 1.9 H [0.0-0.0 K/mcL] 
Abs Lymph 3.4 H [0.9-3.2 K/mcL]

Morphology:
WBCs: Marked leukocytosis with left shifted granulocytes. Basophilia.
RBCs: Normocytic, normochromic RBCs.
Platelets: Mild thrombocytosis seen.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show few scattered blasts, overall slightly less than 5% of total cellularity of a markedly hypercellular bone marrow, focally up to 5%.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-545)
Abnormal myeloid blast population detected.
Basophilia seen, representing 2.5% of WBC.
No abnormal B or T cell population detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD2 (partial), CD7 (partial), CD25 (partial), CD56 (partial), CD11b (subset), CD33 (bright), CD38 (slightly dim), CD117 (slightly bright), HLADR (bright) with normal expression of CD4, CD13, CD34, CD45, CD71 and CD123; without CD5, CD14, CD15, CD16, CD19 or CD64. CD34 positive myeloid blasts represent 2.9% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-332.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-2079 to M20-2081.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-4241;S13;MSK- - 2023-06-05 11.28.06.ndpi,Peripheral Blood Smear,2023-06-05,"Myelodysplastic Syndrome 
Progressive leukopenia and anemia of unclear etiology 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD), 2% blast by aspirate differential count. 
  
COMMENT: Trilineage dysplasia, including ring sideroblasts, is present. With the exclusion of other possible causes of dysplastic changes and ring sideroblasts (medication, toxins etc.), the findings are consistent with MDS-RS-MLD. Correlation with pending cytogenetic and molecular results is also recommended.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Approximately 40% 
M:E ratio: Decreased (erythroid predominance) 
Blasts: Not increased 
Myeloid lineage: Decreased. Orderly maturation. 
Erythroid lineage: Relatively increased. Orderly maturation. 
Megakaryocytes: Adequate in number. Small monolobated forms present. 
Lymphocytes: Not increased. 
Plasma cells: Not increased. 
Special stains: Reticulin stain shows focal mild increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                2%
Promyelocytes           3%
Myelocytes           12%
Metamyelocytes           7%
Neutrophils/Bands      20%
Monocytes           2%
Eosinophils           5%
Erythroid Precursors      40%
Plasma Cells           1%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           1.2

Special stain
Iron: Present
Ring sideroblasts: Present, >15%

Morphology:
Paucispicular and cellular smears show erythroid predominant hematopoiesis. Blasts are not increased. Myeloid cells show maturation, and mature neutrophils present occasional dysplastic features (hypogranular cytoplasm, pseudo Pelger-Huet anomaly). Erythroid precursors show occasional karyorrhexis, nuclear membrane irregularity, and nuclear budding. Megakaryocytes are present, and a subset shows small hypolobated morphology.   

PERIPHERAL BLOOD
CBC (7/14/2020):
WBC 3.4 L [4.0-11.0 K/mcL] 
RBC 3.22 L [3.95-5.54 M/mcL] 
HGB 10.8 L [12.5-16.2 g/dL] 
HCT 32.7 L [37.5-49.3 %] 
MCV 102 H [80-98 fL] 
MCH 33.5 H [27.0-33.0 pg] 
MCHC 33.0 [31.0-36.5 g/dL] 
RDW 14.3 [12.2-15.1 %] 
Platelets 168 [160-400 K/mcL]
 
Neutrophil 53.9 [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 1.8 [0.0-4.9 %] 
Baso 1.2 [0.0-1.5 %] 
Immature Granulocyte 0.6 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 34.5 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 1.8 [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.2 [0.9-3.2 K/mcL] 

Morphology: No circulating immature cells. A few hypoglanular neutrophils are noted. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight no increase in blasts (<5%).
CD117 also highlights many immature erythroid cells.
Myeloperoxidase and CD71 highlight myeloid cells and erythroid cells, respectively. M:E ratio is decreased. 
CD61 highlights megakaryocytes, a subset shows small hypolobated morphology. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-5324)
Interpretation: 
Abnormal myeloid blast populations detected. 
No abnormal B or T cell population detected.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD7 (partial), CD11b (partial), CD13 (subset dim), CD34 (slightly bright), CD123 (uniform dim), HLADR (bright) with normal expression of CD4, CD33, CD38, CD45, CD71, CD117; without CD2, CD5, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. The findings suggest involvement by a myeloid stem cell disorder, however correlation with additional studies (morphologic, cytogenetic, and molecular) is required for a more definitive assessment. CD34 positive myeloid blasts represent 1.0% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-3231.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-20959, M20-20960, M20-20961, M20-20962.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H20-5424;S10;MSKA - 2023-06-07 00.07.57.ndpi,Peripheral Blood Smear,2023-06-07,"Lymphoma, Diffuse Mixed Cell
Mantle Cell Lymphoma 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Mantle cell lymphoma, 10% involvement with CD20 immunohistochemistry. 
     - Normocellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show normocellular bone marrow (40% cellularity) with focal small interstitial lymphoid aggregates of small lymphocytes with condensed chromatin and inconspicuous nucleoli. There istrilineage maturing hematopoiesis. Myeloid and erythroid elements show progressive maturation. Megakaryocytes appear adequate in number and morphology.

Aspirate differential: (Performed by SS)
Blasts                1%
Promyelocytes           1%
Myelocytes           5%
Metamyelocytes           2%
Neutrophils/Bands      15%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      20%
Lymphocytes           54%  
Number of Cells Counted 500
M:E Ratio           1.2

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD20 (subset), PAX5, CD5, Cyclin D1, SOX11
Do not express: CD3

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6826) 
Interpretation: 
Abnormal B-cell population identified.
Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD19(dim), CD20(variable from normal to absent, possibly due to therapy), CD38(uniform bright), and lambda light chain restriction normal expression of CD22, CD40, CD79b, CD81, and CD45; and without CD3, CD10, CD23, or CD200. The abnormal B cell population represents 25.3% of total white cells.
This immunophenotype is raises a possibility mantle cell lymphoma, clinical and morphologic correlation is advised.

No abnormal mature T-cell population detected.
No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

PERIPHERAL BLOOD
CBC (08/27/2020)
WBC 5.0 [4.0-11.0 K/mcL] 
RBC 3.96 [3.95-5.54 M/mcL] 
HGB 11.8 L [12.5-16.2 g/dL] 
HCT 37.6 [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH29.8 [27.0-33.0 pg] 
MCHC 31.4 [31.0-36.5 g/dL] 
RDW 13.7 [12.2-15.1 %] 
Platelets. 84 L [160-400 K/mcL] 

Neutrophil 69.0 [32.5-74.8 %]  
Mono 13.0 H [0.0-12.3 %]  
Eos 1.0 [0.0-4.9 %]  
Baso 0.0 [0.0-1.5 %]  
Immature Granulocyte [0.0-0.6] 
Lymph 7.0 L [12.2-47.4 %]  
Other 10.0 H [0.0-0.0 %] 
Abnormal lymphoid cells with blast-like features.
Nucleated RBC 0 [/100(WBCs)] 
 
Abs Neut 3.5 [1.5-7.5 K/mcL]  
Abs Mono 0.7 [0.0-1.3 K/mcL]  
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL]  
Absolute Basophil 0.0 [0.0-0.2 K/mcL]
Absolute Immature Granulocyte [0.0-0.1] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL]  
Abs Others 0.5 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology:
WBC: Mild lymphopenia. No circulating blasts.
RBC: Normocytic anemia. 
PLT: Unremarkable.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-4218.

MOLECULAR STUDIES 
Not submitted. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-4137;S17;MSK8 - 2023-06-05 11.40.05.ndpi,Peripheral Blood Smear,2023-06-05,"Lymphoma, mantle cell. Newly diagnosed MCL, confirm diagnosis and extent of marrow involvement, needs 20+ FFPE slides. Protocol 18-57.
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
     - Involvement by mantle cell lymphoma (80-90%).
     - Hypercellular marrow with decreased trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show hypercellular bone marrow (>95% cellularity) with focal crush artifact. The marrow contains a diffuse atypical lymphoid infiltrate that is largely composed of small to medium sized lymphoid cells with condensed chromatin and inconspicuous nucleoli. There isfocal trilineage maturing hematopoiesis. Myeloid and erythroid elements show progressive maturation. Megakaryocytes are overall decreased in number.

Aspirate differential: (Performed by KT)
Performed on touch imprint smear.
Myelocytes           2%
Metamyelocytes           1%
Neutrophils/Bands      3%
Eosinophils           1%
Erythroid Precursors      8%
Lymphocytes           3%
Other                82% (atypical lymphoid cells)
Number of Cells Counted 500
M:E Ratio           0.9

IMMUNOHISTOCHEMISTRY
The atypical cells
Express: CD20, PAX5, CD5, Cyclin D1, SOX11 
Do not express: CD3, CD23, LEF1, P53
Other: The Ki-67 proliferative index appears low (less than 5%); however, this specimen is suboptimal for evaluation due to decalcification, which may artefactually decrease Ki-67 staining.
CD23 highlights residual follicular dendritic cell meshworks.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW
Not performed.

PERIPHERAL BLOOD
CBC (07/09/2020):
WBC 3.2 L [4.0-11.0 K/mcL] 
RBC 2.83 L [3.95-5.54 M/mcL] 
HGB 8.3 L [12.5-16.2 g/dL] 
HCT 25.3 L [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 29.3 [27.0-33.0 pg] 
MCHC 32.8 [31.0-36.5 g/dL] 
RDW 16.1 H [12.2-15.1 %] 
Platelets 90 L [160-400 K/mcL] 

Neutrophil 54.0 [32.5-74.8] 
Mono 6.0 [0.0-12.3] 
Eos 12.0 H [0.0-4.9] 
Baso 2.0 H [0.0-1.5] 
Myelocyte 4.0 H [0.0-0.0 %] 
Metamyelocyte 4.0 H [0.0-0.0 %] 
Lymph 9.0 L [12.2-47.4] 
Other 9.0 H [0.0-0.0 %] 
Abnormal lymphoid cells with folded- clefted nuclei seen on smear.
Nucleated RBC 1.9 [%]  

Abs Neut 1.7 [1.5-7.5] 
Abs Mono 0.2 [0.0-1.3] 
Absolute Eosinophil 0.4 [0.0-0.7] 
Absolute Basophil 0.1 [0.0-0.2] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2] 
Abs Others 0.3 H [0.0-0.0 K/mcL] 

Morphology:
WBC: Mild leukopenia with a mild lymphopenia. No circulating blasts.
RBC: Normocytic anemia with mild anisocytosis. 
PLT: Unremarkable.

CYTOGENETIC STUDIES
Cytogenetic analysis was not performed.

MOLECULAR STUDIES 
Molecular analysis was not performed.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-7706;S12;MSKH - 2023-04-17 16.17.31.ndpi,Peripheral Blood Smear,2023-04-17,"CML
New diagnosis 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Myeloproliferative neoplasm, consistent with chronic myeloid leukemia (see comment)
  
COMMENT:
The findings of hypercellular bone marrow with myeloid hyperplasia, megakaryocyte proliferation and atypia (small hypolobated forms) without additional dysplasia along with peripheral blood granulocytosis with left shift, mild basophilia without significant increase in blasts along with abnormal flow cytometry studies for myeloid maturation is diagnostic for myeloproliferative neoplasm and is consistent with chronic myeloid leukemia (CML). Confirmation of the diagnosis of CML required demonstration of BCR-ABL translocation. 

Please note that in addition to BCR-ABL, confirmation of the diagnosis of CML-chronic phase requires exclusion of trisomy 8, isochromosome 17q, trisomy 19, complex karyotype and abnormalities of 3q26.2. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Increased for age (70%)
M:E ratio: Increased
Blasts: Not overtly increased 
Myeloid lineage: Full maturation with myeloid hyperplasia and expansion of early maturing forms in paratrabecular areas
Erythroid lineage: Full maturation, hypoplastic 
Megakaryocytes: Mildly increased with many small hypolobated (dwarf) forms present
Lymphocytes: Scattered, lymphoid aggregates are not seen
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                1%
Promyelocytes           2%
Myelocytes           18%
Metamyelocytes           15%
Neutrophils/Bands      37%
Monocytes           1%
Eosinophils           3%
Basophils           2%
Erythroid Precursors      19%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           4.1


Morphology:
-Speicular and cellular marrow with myeloid hyperplasia with left shift and full maturation. Erythroid lineage is relatively reduced and shows orderly maturation. Megakaryocytes are normal in number and show small and hypolobated forms, Blasts are not increased. 

PERIPHERAL BLOOD
CBC (11/20/2020):
WBC 32.4 H [4.0-11.0 K/mcL] 
RBC 3.96 [3.95-5.54 M/mcL] 
HGB 12.1 L [12.5-16.2 g/dL] 
HCT 36.7 L [37.5-49.3 %] 
MCV 93 [80-98 fL] 
MCH 30.6 [27.0-33.0 pg] 
MCHC 33.0 [31.0-36.5 g/dL] 
RDW 14.7 [12.2-15.1 %] 
Platelets. 279 [160-400 K/mcL] 

Neutrophil 63.0 [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Myelocyte 6.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 6.0 H [0.0-0.0 %] 
Lymph 16.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 20.4 H [1.5-7.5 K/mcL] 
Abs Mono 1.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.0 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.3 H [0.0-0.2 K/mcL] 
Abs Myelocytes 1.9 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.3 H [0.0-0.0 K/mcL] 
Abs Meta 1.9 H [0.0-0.0 K/mcL] 
Abs Lymph 5.2 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology: Granulocytosis with left shift, mild basophilia, few blasts seen. 


IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-9840)
Abnormal myeloid blast population detected. 

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD13 (dim), CD33 (dim), CD7 (small subset), HLA-DR (bright) with normal expression of CD4, CD34, CD38, CD45, CD71, CD117, CD123 without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64. CD34 positive myeloid blasts represent 0.91% of WBC. Correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-6229.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-38778 to M20-38780.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-791;S10;MSKC - 2023-06-27 22.20.17.ndpi,Peripheral Blood Smear,2023-06-27,"ALL
Newly diagnosed leukemia 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - T- Acute lymphoblastic leukemia/ lymphoma (T-ALL), 69% blasts by bone marrow aspirate differential, see comment.
  
COMMENT: The concurrent flow cytometric evaluation reveals abnormal immature T-cell population. Though, rare blasts also express MPO; given the overall phenotype, a diagnosis of T-ALL is favored.

The case was also reviewed by Dr. Roshal, who concurs with the diagnosis.

The preliminary findings of the case were communicated to Dr. Park and Dr. Goldberg via email on 01/30/2020.

BONE MARROW BIOPSY
Quality: Adequate, subcortical, fragmented.
Cellularity: Hypercellular for age (approximately 60% cellularity overall).
M:E ratio: NA.
Blasts: Markedly increased, in sheets.
Myeloid lineage: Markedly decreased
Erythroid lineage: Markedly decreased
Megakaryocytes: Present, predominantly unremarkable morphology. 
Lymphocytes: Interstitially scattered. 
Plasma cells: Interstitially scattered. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                69%
Myelocytes           1%
Neutrophils/Bands      2%
Monocytes           1%
Erythroid Precursors      1%
Plasma Cells           1%
Lymphocytes           25%
Number of Cells Counted 500

Morphology:
- Spicular and cellular smears show marked increased blasts (69% by 500 cell aspirate differential count). The blasts are intermediate sized with round to slightly irregular nuclei, fine chromatin, variably prominent nucleoli and scant, occasionally vacuolated cytoplasm. There is marked decrease in background trilineage hematopoiesis. Rare myeloid and erythroid elements noted. Rare Megakaryocytes are seen.

PERIPHERAL BLOOD
CBC (1/28/2020):
WBC 1.4 L [4.0-11.0 K/mcL] 
RBC 2.12 L [3.95-5.54 M/mcL] 
HGB 6.5 L [12.5-16.2 g/dL] 
HCT 19.2 L [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 30.7 [27.0-33.0 pg] 
MCHC 33.9 [31.0-36.5 g/dL] 
RDW 14.6 [12.2-15.1 %] 
Platelets. 64 L [160-400 K/mcL] 

Neutrophil 2.0 L [32.5-74.8 %] 
Mono 6.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 14.0 H [0.0-0.0 %] 
Lymph 78.0 H [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 0.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL]
Absolute Blasts 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL]

Morphology: Pancytopenia. Rare circulating blasts noted. 

IMMUNOHISTOCHEMISTRY
Immunostains for CD34 and TDT show a marked increase in blasts (~70-80% cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-992)
T-lymphoblastic leukemia/lymphoma. 
No abnormal mature B- or T-cell populations detected. 
No abnormal immature B cell population is detected. 
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

The presence of greater than 20% abnormal immature T-cells in the peripheral blood and/or marrow (77.4% of the total white cells) is diagnostic for T-lymphoblastic leukemia/lymphoma (T-ALL) by WHO criteria. The blasts have abnormal expression of CD2 (negative), surface CD3 (negative), cytoplasmic CD3 (bright), CD7 (bright), CD10 (partial), CD13 (partial), CD33 (partial), CD38 (bright), CD45 (dim), CD48 (negative), CD117 (partial), CD123 (partial), CD1a (minute subset); with normal expression of CD5, and CD71; and without CD4, CD8, CD11b, CD14, CD15, CD16, CD19, CD20, CD34, CD56, CD64, convincing cytoplasmic CD79a, HLA-DR, or surface light chains. Rare blasts also express MPO; however, given the overall phenotype, a diagnosis of T-ALL is favored. 

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified. 
Immature B cells with normal immunophenotype by this method account for 0.10% of WBC following erythroid lysis. 767,789 cells acquired. 
Virtually no myeloid blasts seen. 380,149 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-572.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-3791 to M20-3793.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-4977;S11;MSKD - 2023-06-05 10.59.42.ndpi,Peripheral Blood Smear,2023-06-05,"Lymphoma
Pancytopenia
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by low grade B-cell lymphoma, most consistent with marginal zone lymphoma (>90% with CD20 immunohistochemistry).
     - Residual background trilineage maturing hematopoiesis is present.

BONE MARROW BIOPSY/CLOT SECTION/ASPIRATE MORPHOLOGY
Adequate core biopsy, clot section and aspirate specimens show markedly hypercellular bone marrow for age (approximately 100% cellularity) with a diffuse atypical lymphoid infiltrate comprised small to medium sized with round to oval nucleus with occasional irregularity/indentation, condensed chromatin, inconspicuous nucleoli and scant cytoplasm. Background maturing myeloid and erythroid elements and megakaryocytes are markedly reduced; erythroid elements show mild megaloblastoid changes.     

Aspirate differential: (Performed by HM)

Blasts                2% 
Promyelocytes           2%
Myelocytes           2%
Metamyelocytes           1%
Neutrophils/Bands      5%
Eosinophils           1%
Erythroid Precursors      15%
Plasma Cells           1%
Lymphocytes           71%
Number of Cells Counted 500
M:E Ratio           0.7

Special stain
Iron: Present
Ring sideroblasts: Absent

IMMUNOHISTOCHEMISTRY
CD20 and PAX-5 immunostains highlight the diffuse atypical lymphoid infiltrate, while CD3 labels many reactive T-cells in the background. The neoplastic cells show expression of BCL2 (a subset), while they lack expression of CD10, LMO2, p53, MUM1 and CD38. CD138 highlights scattered plasma cells. CD34 and CD117 do not show an increase in blasts (<2% of cellularity). CD117 also highlights scattered mast cells and rare erythroid and myeloid precursors. BCL6 is technically suboptimal.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6265) 
Abnormal B-cell population identified.
No abnormal T cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD38 (absent), kappa light chain restriction, and normal expression of CD19, CD20, CD22 and CD45; and without CD5 or CD10. The abnormal B-cell population represents 60.7% of the total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.087% of WBC.

PERIPHERAL BLOOD
CBC (8/11/2020):
WBC 20.8 H [4.0-11.0 K/mcL] 
RBC 2.40 L [3.95-5.54 M/mcL] 
HGB 7.7 L [12.5-16.2 g/dL] 
HCT 25.8 L [37.5-49.3 %] 
MCV 108 H [80-98 fL] 
MCH 32.1 [27.0-33.0 pg] 
MCHC 29.8 L [31.0-36.5 g/dL] 
RDW 17.3 H [12.2-15.1 %] 
Platelets 83 L [160-400 K/mcL] 

Neutrophil 25.0 L [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 67.0 H [12.2-47.4 %] 
Other 3.0 H [0.0-0.0 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 5.2 [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 14.0 H [0.9-3.2 K/mcL] 
Abs Others 0.6 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 2 [/100(WBCs)] 

Attending Review 
Manual differential, including the presence of occasional abnormal lymphoid cells with convoluted/folded nucleus, moderate size and mature chromatin, is confirmed.
I attest that the above interpretation/recommendation is based
upon my personal examination of the source material and patient
clinical history, if indicated, and that I have reviewed this report.
Melissa S Pessin MD, PhD Prov ID:016204
08/12/2020 9:22 AM EDT

Morphology:
WBCs: Absolute lymphocytosis comprised of many atypical small to medium sized lymphoid cells with round to oval nucleus with occasional indentation, condensed chromatin, inconspicuous nucleoli and scant cytoplasm; a few immature granulocytes.
RBCs: Moderate macrocytic anemia with mild anisocytosis.
Platelets: Moderately reduced; unremarkable morphology. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-3825.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-24410, M20-24411.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-3849;S11;MSKA - 2023-04-19 11.52.42.ndpi,Peripheral Blood Smear,2023-04-19,"{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch31506\stshfhich31506\stshfbi31506\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}
{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}
{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}
{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;
\red0\green0\blue0;}{\*\defchp \f31506\fs22 }{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive 
\ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv 
\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31506\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused 
Normal Table;}{\s15\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 
\f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext15 \spriority0 \styrsid3015573 CoPath Text;}}{\*\rsidtbl \rsid1137952\rsid3015573\rsid5393789\rsid11958777\rsid12671979\rsid15075221\rsid15417116}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0
\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\author Baez, Joseph/Pathology}{\operator Chan, Alexander Y./Pathology}{\creatim\yr2020\mo6\dy30\hr12\min49}{\revtim\yr2020\mo6\dy30\hr12\min49}{\version2}
{\edmins0}{\nofpages1}{\nofwords10}{\nofchars65}{\nofcharsws74}{\vern99}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont1\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1440\dgvorigin1440\dghshow1\dgvshow1
\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\rsidroot11958777\newtblstyruls\nogrowautofit\usenormstyforlist\noindnmbrts\felnbrelev\nocxsptable\indrlsweleven\noafcnsttbl\afelev\utinl\hwelev\spltpgpar\notcvasp\notbrkcnstfrctbl\notvatxbx\krnprsnet\cachedcolbal \nouicompat \fet0
{\*\wgrffmtfilter 2450}\nofeaturethrottle1\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang 
{\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}
\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid11536363 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 \f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid15075221 CMML w/del20q and genomic alterations in ASXL1, NRAS,RUNX1, CBL, and SRSF2\par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Persistent chronic myelomonocytic leukemia, 11% blasts by aspirate differential, consistent with CMML-2.
    - Markedly hypercellular bone marrow with myeloid predominant hematopoiesis, megakaryocytic dysplasia, and erythroid hypoplasia and moderate reticulin fibrosis (MF2+/3); see comment.

COMMENT: Additional trichrome stain for collagen fibrosis evaluation will be reported in an addendum. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypercellular (>90%)
M:E ratio: Increased
Blasts: Mildly increased scattered immature cells seen
Myeloid lineage: Exhibits full maturation 
Erythroid lineage: Exhibits full maturation 
Megakaryocytes: Increased, with dysplastic changes (hyperchromasia, small hypo/monolobated forms)
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows a moderate increase in reticulin fibers (MF2+/3). 

BONE MARROW ASPIRATE SMEAR AND TOUCH IMPRINT
Differential: (Performed on touch imprints by MT)
Blasts                11%
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      27%
Monocytes           23%
Eosinophils           8%
Erythroid Precursors      3%
Plasma Cells           2%
Lymphocytes           21%
Number of Cells Counted 500
M:E Ratio           21

Morphology: The aspirate smears and touch imprint are aspicular, hypocellular and show an expanded population of medium to large sized blasts with small amounts of cytoplasm, irregular nuclei, fine chromatin and distinct nucleoli, in a background of myeloid predominant maturing trilineage hematopoiesis. Erythroid elements are markedly reduced. Myeloid elements show full maturation. Rare megakaryocytes are seen with dysplastic features (hypolobation). Monocytosis is seen.

PERIPHERAL BLOOD
CBC (6/26/2020):
WBC 8.4 [4.0-11.0 K/mcL] 
RBC 2.65 L [3.95-5.54 M/mcL] 
HGB 7.8 L [12.5-16.2 g/dL] 
HCT 23.0 L [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 29.4 [27.0-33.0 pg] 
MCHC 33.9 [31.0-36.5 g/dL] 
RDW 18.6 H [12.2-15.1 %] 
Platelets. 56 L [160-400 K/mcL] 

Neutrophil 28.0 L [32.5-74.8 %] 
Mono 20.0 H [0.0-12.3 %] 
Eos 12.0 H [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 
Blast 3.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Lymph 31.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 2.4 [1.5-7.5 K/mcL] 
Abs Mono 1.6 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.0 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.3 H [0.0-0.2 K/mcL] 
Absolute Blasts 0.3 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 2.6 [0.9-3.2 K/mcL]

Morphology:
WBC: Relative and absolute monocytosis seen; left shifted granulocytes noted; few circulating blasts seen.
RBC: Normocytic, normochromic anemia with anisocytosis.
PLT: Moderate thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains show mildly increased CD34 and CD117 positive blasts (~5-10% of total cellularity). CD117 also highlights mildly increased mast cells, which are scattered without clustering or spindled morphology.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-4793)
Abnormal myeloid blast population detected.
Basophilia detected, representing 4.3% of WBC.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD5 (partial, dim), CD7 (partial), CD11b (partial), CD13 (bright), CD25 (partial), CD34 (uniform), CD117 (bright), CD123 (uniform, bright), and HLA-DR (bright); with normal expression of CD4, CD33, CD38, CD45, and CD71; without CD2, CD14, CD15, CD16, CD19, CD56 or CD64. CD34 positive myeloid blasts represent 1.5% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-2901.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-19081.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-7500;S10;MSKR - 2023-06-15 19.35.51.ndpi,Peripheral Blood Smear,2023-06-15,"ALL. Newly diagnosis ALL. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by B-lymphoblastic leukemia/lymphoma, 92% blasts by aspirate differential count.
     - Limited bone marrow biopsy. See comment.
  
COMMENT: The bone marrow biopsy is largely composed of cortical bone with a minute cellular area showing significant crush artifact. Immunohistology shows diffuse positivity for CD34 and TdT in this focus. The touch imprints show a marked increase in blasts and corresponding flow cytometry is diagnostic for B-ALL. Correlation with the forthcoming cytogenetic and molecular studies is required for final classification of this B-ALL. Marrow cellularity and background hematopoietic marrow cannot be assessed due to the limited biopsy. 

BONE MARROW BIOPSY
Quality: Marginally adequate, small and largely composed of cortical bone, with a minute, significantly crushed area of cellularity
Cellularity: Unable to assess due to the quality of the biopsy
M:E ratio: N/A
Blasts: Increased, in rare foci of intact morphology the blasts are intermediate in size, with round to slightly irregular nuclei, fine chromatin, inconspicuous nucleoli, and scant cytoplasm.
Remaining hematopoietic elements are not appreciated in a limited biopsy and cannot be evaluated. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                92%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      2%
Monocytes           1%
Erythroid Precursors      3%
Number of Cells Counted 500
M:E Ratio           NA

Morphology:
Aspicular and cellular touch imprints showing an expanded blast population. Blasts are intermediate in size, with round to irregular nuclei, fine chromatin, inconspicuous nucleoli, and scant cytoplasm. Auer rods are not seen. Myeloid and erythroid precursors are rare. Megakaryocytes are not seen.

PERIPHERAL BLOOD
CBC (11/13/2020):
WBC 6.0 [4.0-11.0 K/mcL] 
RBC 2.79 L [3.80-5.00 M/mcL] 
HGB 8.7 L [11.2-15.4 g/dL] 
HCT 25.5 L [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 31.2 [27.0-33.0 pg] 
MCHC 34.1 [31.0-36.5 g/dL] 
RDW 18.4 H [12.2-15.1 %] 
Platelets. 36 L [160-400 K/mcL] 

Neutrophil 11.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 34.0 H [0.0-0.0 %] 
Lymph 55.0 H [12.2-47.4 %] 
Nucleated RBC 4 [/100(WBCs)] 

Abs Neut 0.7 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 2.0 H [0.0-0.0 K/mcL] 
Abs Lymph 3.3 H [0.9-3.2 K/mcL]

Morphology:
WBC: Frequent circulating blasts seen, morphologically similar to those on the touch imprints.
RBC: Normocytic, normochromic anemia with anisocytosis. 
Platelets: Thrombocytopenia

IMMUNOHISTOCHEMISTRY
CD34 and TdT are diffusely positive in the crushed cellular areas, focally showing identifiable blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-9566)
Interpretation: 
Abnormal immature B-cell population detected.
No abnormal mature B- or T-cell populations detected. Virtually no mature B cells seen.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow (89.9% of the total white cells and 93.0% of mononuclear) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD10 (variable, absent to bright), CD11b (partial), CD24 (bright), CD38 (bright), CD66c/CD123 (bright), CD73/CD304 (uniform intermediate), cytoplasmic CD79a (dim to intermediate); with normal expression of CD19, CD22, CD34, CD45, CD71, CD81 and HLA-DR; and without CD2, surface CD3, cytoplasmic CD3, CD4, CD5, CD7, CD8, CD13, CD14, CD15, CD16, CD20, CD25, CD33, CD56, CD64, CD66b, CD86, CD117, convincing MPO, or surface light chains.

No immunophenotypic evidence of involvement by mature B- or T-cell lymphoma or leukemia is identified.
CD34 positive myeloid blast population with apparent normal immunophenotype is 0.10% of WBC.

316,539 cells acquired for myeloid analysis. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F20-9566; 11/13/20)
Interpretation: 
Abnormal immature B-cell population detected.
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow (36.5% of the total white cells and 43.3% of mononuclear) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD10 (variable, absent to bright), CD20 (partial), CD24 (bright), CD38 (bright), and CD66c/CD123; with normal expression of CD19, CD22, CD34, CD45, CD71, CD81 and HLA-DR; and without CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD33, CD56, CD64, CD66b, CD86, CD117, CD73/CD304 or surface light chains.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.60% of WBC.
316,539 of cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-6000.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-37514, M20-37517, M20-37518, M20-37519, & M20-37521.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H20-833;S10;MSK0 - 2023-06-27 22.32.00.ndpi,Peripheral Blood Smear,2023-06-27,"ALL
Disease Evaluation 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
     - B lymphoblastic leukemia/lymphoma (B-ALL), 90% blasts by bone marrow aspirate differential.
  
BONE MARROW BIOPSY
Quality: Adequate. 
Cellularity: >95% 
M:E ratio: NA.
Blasts: Markedly increased, in sheets.
Myeloid lineage: Markedly decreased
Erythroid lineage: Markedly decreased
Megakaryocytes: Decreased 
Lymphocytes: Not increased 
Plasma cells: Not increased 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Blasts                90% (several blasts with vacuoles are noted)
Neutrophils/Bands      1%
Erythroid Precursors      2%
Lymphocytes           7%
Number of Cells Counted 500
M:E Ratio           0.5

Morphology:
- Aspicular and cellular smears show marked increased blasts (90% by 500 cell aspirate differential count). The blasts are intermediate sized with round to slightly irregular nuclei, fine chromatin, variably prominent nucleoli and scant, occasionally vacuolated cytoplasm. There is decreased background trilineage hematopoiesis. Occasional myeloid and erythroid elements are noted. Megakaryocytes are not seen.

PERIPHERAL BLOOD
CBC (01/28/2020):
WBC 4.3 L [7.1-15.9 K/mcL] 
RBC 3.34 [2.93-4.75 M/mcL] 
HGB 9.2 [8.9-12.7 g/dL] 
HCT 25.9 L [26.8-37.8 %] 
MCV 78 [70-85 fL] 
MCH 27.5 [22.7-29.5 pg] 
MCHC 35.5 [31.0-36.5 g/dL] 
RDW 15.9 H [12.2-15.1 %] 
Platelets 28 L [160-400 K/mcL] 

Neutrophil 1.0 L [16.9-74.5 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 20.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 77.0 [18.1-79.9 %] 

Abs Neut 0.0 L [1.5-8.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.9 H [0.0-0.0 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 3.3 [1.1-8.1 K/mcL] 

Morphology: 
WBC: Leukopenia with marked absolute neutropenia, circulating blasts noted.
RBC: Mild anisocytosis.
Platelets: Thrombocytopenia with unremarkable morphology.

IMMUNOHISTOCHEMISTRY
Immunostain for TDT shows diffuse sheets of blasts (>90% cellularity). CD34 highlights a large subset of blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-1058)
Abnormal immature B-cell population detected. 

An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously, see F20-959. The abnormal immature B-cells represent 91.5% of the white cells and 91.6% of the mononuclear cells in the sample and abnormally express CD10 (variable, dim to bright), CD19 (bright), CD20 (partial), CD22 (variable, dim to bright), CD34 (absent to bright), CD38 (variable, intermediate to bright), CD45 (variable, absent to bright), and CD73/CD304; normal expression of CD24 and CD81 and without CD66b, CD66c/CD123, or CD86. This finding is consistent with persistent/recurrent B-lymphoblastic leukemia/lymphoma, depending on the clinical context. Clinical and morphologic correlation is recommended.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-624, CG20-625.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-4008 to M20-4010.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-5852;S12;MSK8 - 2023-04-17 16.23.00.ndpi,Peripheral Blood Smear,2023-04-17,"MDS. Newly referred 
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
     - High-grade myeloid neoplasm, most consistent with myelodysplastic syndrome with excess blasts 2 (MDS-EB-2) (~15-19% blasts by CD34 immunohistochemistry) (see comment 1).
     - Abnormal mature B-cell population with a chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)-like immunophenotype detected by flow cytometry only (5.0% of WBC) (see comment 2).
  
COMMENT 1: The patient's reported prior history of MDS with a normal karyotype and multiple mutations (including in SF3B1, RUNX1 and TET2) previously treated with hypomethylating agents is noted. If this history is confirmed, the current findings would be consistent with persistent disease. Accurate blast enumeration is limited in this sample by aspicular and markedly hypocellular aspirate smears. By CD34 immunohistochemistry, blasts show a variable distribution and are estimated to comprise ~15-19% of marrow cellularity overall but as focal areas show a slightly higher number of blasts, an early evolving acute myeloid leukemia cannot be fully excluded. 

COMMENT 2: A definitive morphologic correlate to the abnormal B-cell population detected by flow cytometry is not identified. This population may represent minimal marrow involvement by CLL/SLL or a monoclonal B-cell lymphocytosis. Correlation with clinical and radiologic findings is suggested. In addition, flow cytometry detected a minute atypical T-cell population (0.18% of WBC), the clinical significance of which is uncertain; clinical correlation is advised. 

BONE MARROW BIOPSY
Quality: Adequate with some crush artifact
Cellularity: Hypercellular for age (60-70% cellularity)
M:E ratio: Reduced
Blasts: Increased (best seen with immunohistochemistry described below)
Myeloid lineage: Relatively reduced with left-shifted maturation
Erythroid lineage: Relatively increased with left-shifted maturation
Megakaryocytes: Increased in number with dysplastic morphology (small, hypolobated forms, separated nuclear lobes) and frequent clusters
Lymphocytes: Scattered, no aggregates seen
Plasma cells: Scattered
Special stains: Reticulin stain shows patchy mild reticulin fibrosis (MF-0-1+/3) 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Hypocellular/hemodiluted aspirate devoid of spicules
Blasts                13%
Promyelocytes           1%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      20%
Monocytes           3%
Eosinophils           1%
Erythroid Precursors      18%
Lymphocytes           42%
Number of Cells Counted 200
M:E Ratio           1.5

Special stain 
Iron: Inadequate for evaluation due to a lack of spicules
Ring sideroblasts: Rare (appear <15%, however, enumeration is limited by few erythroid precursors on hypocellular smears) 

Morphology:
Aspirate smears and touch imprint are aspicular, hypocellular, hemodilute and are suboptimal for evaluation. The differential count may not fully reflect the marrow composition. A relatively increased number of intermediate to large sized blasts with rounded to irregular nuclei, fine chromatin, distinct nucleoli and scant to moderate cytoplasm is seen. Scattered myeloid elements at various stages of maturation with a predominance of mature forms, reflecting hemodilution, are seen with many dysplastic hypogranular forms. Scattered erythroid precursors are present with occasional dysplastic forms (nuclear irregularity/budding, nuclear-cytoplasmic dyssynchrony). Rare megakaryocytes are present with a rare form showing separated nuclear lobes noted.

PERIPHERAL BLOOD
CBC (09/14/2020):
WBC 2.3 L [4.0-11.0 K/mcL] 
RBC 3.38 L [3.95-5.54 M/mcL] 
HGB 10.0 L [12.5-16.2 g/dL] 
HCT 30.4 L [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 29.6 [27.0-33.0 pg] 
MCHC 32.9 [31.0-36.5 g/dL] 
RDW 14.7 [12.2-15.1 %] 
Platelets 174 [160-400 K/mcL] 

Neutrophil 33.0 [32.5-74.8 %] 
Mono 14.0 H [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 11.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 39.0 [12.2-47.4 %] 
Variant Lymph 1.0 [%] 
Nucleated RBC 4 [/100(WBCs)] 

Abs Neut 0.8 L [1.5-7.5 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.3 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology:
WBC: Circulating blasts seen (11%). Leukopenia with absolute neutropenia and hypogranular neutrophils.
RBC: Normochromic, normocytic anemia with occasional nucleated RBCs.
Platelets: Adequate with occasional large and giant platelets

IMMUNOHISTOCHEMISTRY
Immunostains show increased interstitial CD34+, CD117+ blasts in a variable distribution scattered singly and in clusters, which are estimated to comprise ~15-19% of the marrow cellularity overall with focal areas reaching ~20-25%.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-7347)
Interpretation: 
Abnormal myeloid blast population detected.
Abnormal B-cell population identified.
Minute abnormal T cell population detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD25 (partial), CD13 (uniform intermediate), CD33 (dim), CD34 (dim), CD38 (dim), CD45 (dim), CD1123 (uniform intermediate) and HLA-DR (uniform intermediate); with normal expression of CD4, CD71, CD117; and without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD56 or CD64. CD34 positive myeloid blasts represent 11.0% of WBC.

Flow cytometry identified an abnormal B-cell population with CLL/SLL-like immunophenotype having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23, CD43, CD79b (dim), CD81 (dim), CD200 (bright), ROR1 and lambda surface light chain restriction (dim); normal expression of CD19, CD40 and CD45; and without CD3, CD38, or CD10 expression. The abnormal B-cell population comprises 5.0% of the white cells.

The majority of T-cells show no phenotypic abnormality; however, there is a minute population of atypical T-cells that comprise 0.18% of WBCs. These T-cells express abnormal CD3 (negative to dim) and CD56 (dim to intermediate); normal CD45, CD2, CD4 and CD7; and absent CD8 and CD279 (PD-1). The clinical significance of this minute population of unusual T-cells is unclear.

This case was also reviewed by Dr. Mikhail Roshal, hematopathology service.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-4567.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-28859, M20-28860, M20-28861, M20-28862.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     
"
H20-8172;S11;MSK5 - 2023-06-15 19.59.48.ndpi,Peripheral Blood Smear,2023-06-15,"AML. New patient. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia.
  
COMMENT:
Preliminary FISH analysis is reportedly negative for t(15;17)/PML/RARA fusion or other RARA variant translocations, and also negative for MLL translocations.

Correlation with a pending karyotype as well as molecular testing is needed.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: >95%
M:E ratio: N/A
Blasts: Increased
Myeloid lineage: Limited maturation
Erythroid lineage: Markedly decreased; progressive maturation
Megakaryocytes: Rare, if any, megakaryocytes seen
Lymphocytes: Not increased
Plasma cells: Not increased
Special stains: Reticulin stain shows mild reticulin fibrosis (MF 0-1/3).

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                89%
Neutrophils/Bands      4%
Erythroid Precursors      5%
Plasma Cells           1%
Lymphocytes           1%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
-Spiculate and hypercellular smears show sheets of blasts. The blasts have a moderate to abundant amount of cytoplasm. Many of the blasts and blast equivalents have prominent eosinophilic granules, and occasional cells have indented nuclei. Myeloid maturation is limited. There are relatively few erythroid precursors, and some of these have irregular nuclear borders. Megakaryocytes are markedly decreased.

PERIPHERAL BLOOD
CBC (12/10/2020):
WBC 16.8 H [4.0-11.0 K/mcL] 
RBC 2.85 L [3.80-5.00 M/mcL] 
HGB 8.1 L [11.2-15.4 g/dL] 
HCT 25.4 L [34.3-46.0 %] 
MCV 89 [80-98 fL] 
MCH 28.4 [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 15.2 H [12.2-15.1 %] 
Platelets 6 LL [160-400 K/mcL] 

Neutrophil 2.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 83.0 H [0.0-0.0 %] 
Promyelocyte 4.0 H [0.0-0.0 %] 
Lymph 8.0 L [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 0.3 L [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 13.9 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.7 H [0.0-0.0 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBC: Increased circulating blasts. The blasts have variable amounts of cytoplasm, ranging from scant to abundant. Occasional blasts have fine eosinophilic granules. Many of the blasts have irregular nuclear borders, including some cells with ""cup-like"" blasts. Mature granulocytes are rare, with one hypersegmented form seen.
RBC: Normochromic anemia with mild anisocytosis.
Platelets: Marked thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunostains demonstrate that the blasts show variable expression of CD117, but are negative for CD34.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-10438)
Expanded abnormal myeloid blast/promyelocyte population detected.
No abnormal B and T cell populations detected.

The blasts/promyelocytes have abnormal expression of CD11b, CD13 (variable, absent to bright), CD15 (subset), CD33 (bright), CD34 (absent), CD38 (absent to dim), CD64, CD71 (variable, absent to bright), CD117 (variable, absent to bright), CD123 (variable, dim to bright), and HLA-DR (absent); with normal expression of CD4 and CD45; and without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD14, CD16, CD19, CD20, CD25, CD56, cytoplasmic CD79a, or surface light chains. MPO expression is present on the blasts. Myeloid blasts/promyelocytes represent 96.0% of WBC. The findings raise concern for APL. Morphologic correlation as well as evaluation for t(15;17) is advised.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate reports, CG20-6606 and CG20-6607.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M20-41367-41369 and M20-41379-41382.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H20-6457;S11;MSK9 - 2023-04-17 17.18.48.ndpi,Peripheral Blood Smear,2023-04-17,"AML.
New questionable AML. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
     - Acute Myeloid Leukemia (AML) (25% Blasts by Aspirate Differential Count) (See Comment)
  
COMMENT: FISH studies performed on the peripheral blood (CG20-5103) showed NO evidence of RARA rearrangement, including t(15;17)/PML-RARA, nor KMT2A/MLL rearrangement. Furthermore, although some degree of dyspoiesis is seen, the morphologic findings are NOT sufficient to meet a diagnosis of AML with myelodysplasia-related changes. Correlation with pending molecular and cytogenetics studies will be helpful for AML classification.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Normocellular for age (40-50% cellularity)
M:E ratio: Decreased/Inverted
Blasts: Increased intermediate- to larger-sized blasts, with irregular nuclei, fine chromatin, indistinct to small visible nucleoli, and small amount of cytoplasm
Myeloid lineage: Proportionally decreased with marked left-shifted maturation
Erythroid lineage: Proportionally increased with left-shifted, progressive maturation
Megakaryocytes: Normal in number with some atypical hyperlobulated forms, and occasional small hypolobated forms.
Lymphocytes: Scattered
Plasma cells: Scattered

Special stains: 
Reticulin stain shows no significant increase in reticulin fibrosis (0/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Auer rods noted
Blasts                25%
Promyelocytes           3%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      6%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      32%
Plasma Cells           2%
Lymphocytes           24%
Number of Cells Counted 500
M:E Ratio           0.5

Morphology:
Cellular, spicular smears, showing an expanded population of intermediate to large-sized blasts, with irregular/folded or indented nuclear contour, dispersed chromatin, distinct nucleoli, and moderate amount of pale-blue cytoplasm. Scattered blasts with Auer rods are seen. The remaining marrow shows erythroid elements with relative hyperplasia, left-shifted maturation, and frequent dyspoietic forms (karyorrhexis, nuclear-cytoplasmic dyssynchrony, megaloblastoid changes, nuclear irregularity/budding) (but <50% of lineage). Myeloid elements shows left-shifted maturation without significant dysplasia. Some mature monocytes, small lymphoid cells and scattered plasma cells are also seen. Megakaryocytes are present, and include some atypical forms, including small hypolobated forms and nuclear lobe separation.

PERIPHERAL BLOOD
CBC (10/06/2020):
WBC 3.6 L [4.0-11.0 K/mcL] 
RBC 3.96 [3.80-5.00 M/mcL] 
HGB 11.9 [11.2-15.4 g/dL] 
HCT 35.1 [34.3-46.0 %] 
MCV 89 [80-98 fL] 
MCH 30.1 [27.0-33.0 pg] 
MCHC 33.9 [31.0-36.5 g/dL] 
RDW 13.7 [12.2-15.1 %] 
Platelets. 115 L [160-400 K/mcL] 

Neutrophil 20.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 27.0 H [0.0-0.0 %] 
Lymph 48.0 H [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 0.7 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 1.0 H [0.0-0.0 K/mcL] 
Abs Lymph 1.7 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology:
WBC: Leukopenia with absolute neutropenia. Frequent intermediate to large sized blasts with distinct nucleoli seen. Also seen are some large granular lymphocytes and reactive lymphocytes.
RBC: Normocytic, normochromic RBC's.
Platelets: Thrombocytopenia with some large platelets seen.

IMMUNOHISTOCHEMISTRY
CD34 highlights a large subset of blasts.
CD117 highlights increased blasts, as well as some early myeloid elements (together comprising ~30% of cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-8176)
Final Report is Pending and will be reported separately.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F20-8117)
Interpretation: 
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD7 (partial), CD13 (negative to dim), CD33 (negative to dim), CD34 (negative to intermediate), CD45 (dim), CD71 (negative to bright), HLA-DR (negative to intermediate), with normal expression of CD4, CD38, CD117, CD123; without CD2, surface CD3, cytoplasmic CD3, CD5, CD8, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cytoplasmic CD79a, or surface light chains. MPO expression is on all blasts. CD117 positive myeloid blasts represent 27.9% of WBC.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-5134.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-31891 to M20-31894.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-152;S12;MSKW - 2023-06-27 22.43.39.ndpi,Peripheral Blood Smear,2023-06-27,"Multiple myeloma. Dara-pom-dex=>relapse.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
~90% involvement by CD138 immunohistochemistry.
70% involvement by aspirate differential
28.4% (99.7% of total plasma cells) involvement by 10-color flow cytometry
     - Hypercellular marrow with minimal trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality: Adequate.
Cellularity: 80-90%
Myeloid lineage: Decreased.
Erythroid lineage: Decreased.
Megakaryocytes: Few seen.
Plasma cells: Markedly Increased, present in sheets replacing the marrow. The plasma cells are intermediate to large in size with ovoid nuclei, finely clumped chromatin and variably conspicuous nucleoli. Few cells with dutcher bodies are noted. 
CLOT SECTION: consists of predominantly peripheral blood and occasional bone marrow elements.

ASPIRATE MORPHOLOGY
Aspirate differential: (Performed by: HM)

Blasts                1%
Promyelocytes           2%
Myelocytes           4%
Metamyelocytes           3%
Neutrophils/Bands      7%
Eosinophils           3%
Erythroid Precursors      8%
Plasma Cells           70% 
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           2.4

Morphology: 
Marrow spicules: Spicular.
Cellularity: Hypercellular.
Plasma cell morphology: Intermediate to large sized with prominent nucleoli. 
Myeloid lineage: Decreased but with full range of maturation.
Erythroid Lineage: Decreased but with full range of maturation. 
Megakaryocytes: Present. 
Other findings: Numerous naked nuclei noted. 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, ~90% of marrow cellularity. 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.  
BCMA highlights 90% of plasma cells, (1-2+) intensity, membranous / Golgi pattern. 
CD61 stains few megakaryocytes
CD71 stains few erythroid islands
MPO stains few myeloid elements

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-223) 
Abnormal plasma cell population detected. 

Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (absent), CD27 (absent), CD56, CD81 (absent), CD117 (partial dim) and monoclonal kappa cytoplasmic light chain restriction; with normal expression of CD45 and CD138. CD38 expression is dim to absent, consistent with anti-CD38 therapy effect. The abnormal population represents 28.4% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 99.7% of total plasma cells in the sample. 

No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.34% of WBC. 327,642 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

PERIPHERAL BLOOD
CBC (1/07/2020):
WBC 7.1 [4.0-11.0 K/mcL] 
RBC 2.22 L [3.80-5.00 M/mcL] 
HGB 6.9 L [11.2-15.4 g/dL] 
HCT 21.3 L [34.3-46.0 %] 
MCV 96 [80-98 fL] 
MCH 31.1 [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL] 
RDW 17.4 H [12.2-15.1 %] 
Platelets 215 [160-400 K/mcL] 

Neutrophil 77.3 H [32.5-74.8 %] 
Mono 12.6 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.1 [0.0-1.5 %] 
Immature Granulocyte 4.9 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 5.1 L [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 5.5 [1.5-7.5 K/mcL] 
Abs Mono 0.9 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.4 H [0.0-0.1 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Plasma cells in circulation are not seen. 
RBC: Anisocytosis (1+) / Poikilocytosis (1+). Rouleaux formation noted. 
Platelets: Adequate with unremarkable morphology.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-146.

MOLECULAR STUDIES 
Not submitted.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

     
"
H20-1216;S20;MSK7 - 2023-04-20 07.55.58.ndpi,Peripheral Blood Smear,2023-04-20,"AML
Protocol, assess for response to therapy
","1-4. Bone marrow, right posterior iliac crest, biopsies; aspirate and peripheral blood smears: 
     - Persistent acute myeloid leukemia, 73% blast by touch imprints differential count. 
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: 95-100% 
M:E ratio: N/A 
Blasts: Markedly increased, replacing marrow cellularity 
Myeloid lineage: Mature forms are rare
Erythroid lineage: Rare
Megakaryocytes: Virtually absent
Lymphocytes: Few scattered
Plasma cells: Few scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR/ TOUCH IMPRINTS
Differential: (Performed by KT)
Performed on touch imprint smear.
Blasts                73%
Promyelocytes           3%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      4%
Erythroid Precursors      4%
Lymphocytes           14%
Number of Cells Counted 500
M:E Ratio           2.2

Morphology:
Hypercellular touch imprints show expanded blast population. Blasts are variable in size, ranging from small forms with high N/C ratio to large forms with moderate amount of cytoplasm. Nucleoli are distinct. Background lineage hematopoiesis is markedly suppressed.

PERIPHERAL BLOOD
CBC (02/10/2020):
WBC 11.2 H [4.0-11.0 K/mcL] 
RBC 3.13 L [3.95-5.54 M/mcL] 
HGB 9.3 L [12.5-16.2 g/dL] 
HCT 28.8 L [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 32.3 [31.0-36.5 g/dL] 
RDW 16.1 H [12.2-15.1 %] 
Platelets 4 LL [160-400 K/mcL]  

Neutrophil 36.0 [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 37.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Promyelocyte 3.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 13.0 [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 4.1 [1.5-7.5 K/mcL] 
Abs Mono 0.9 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 4.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.3 H [0.0-0.0 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 1.5 [0.9-3.2 K/mcL] 

Morphology: Circulating blasts and immature myeloid cells present. Marked thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight a subset of blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-1502; designated as RPIC tissue needle core biopsy)
Interpretation: 
Abnormal myeloid blast population detected.
No abnormal B or T cell population detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype somewhat similar to that seen in prior sample [F20-185] have abnormal expression of CD11b (partial), CD13 (absent to dim), CD33 (uniform bright), CD34 (dim to intermediate), CD38 (dim), CD64 (subset), CD117 (subset dim to absent), HLADR (absent) with normal expression of CD4, CD45, CD71 and CD123; without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD56 or CD279. CD34 positive myeloid blasts represent 56.2% of WBC.

CYTOGENETIC STUDIES
Not submitted. 

MOLECULAR STUDIES 
Not submitted. 



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H20-6211;S11;MSKX - 2023-06-07 00.42.05.ndpi,Peripheral Blood Smear,2023-06-07,"ALL
BALL x/ CNS disease 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Extensive involvement by B-lymphoblastic leukemia/lymphoma (~80-90% of cellularity).
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular for age (~80-90% cellularity)
M:E ratio: Cannot be assessed
Blasts: Markedly increased small to intermediate-sized blasts with round/oval to slightly irregular nuclei, finely dispersed chromatin, conspicuous nucleoli and scant to moderate amount of cytoplasm present as sheets
Myeloid lineage: Present
Erythroid lineage: Present
Megakaryocytes: Present
Lymphocytes: Interstitially scattered
Plasma cells: Not increased

Clot section: Lacks marrow particles but shows blood clot with numerous blasts

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                81%
Promyelocytes           1%
Myelocytes           1%
Neutrophils/Bands      5%
Erythroid Precursors      13%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology: The aspirate smears are aspicular but are markedly hypercellular and show numerous small to intermediate-sized blasts with round/oval to slightly irregular nuclei, finely dispersed chromatin, conspicuous nucleoli and scant to moderate amount of basophilic cytoplasm with occasional vacuoles. The background trilineage hematopoiesis is present. Touch imprints are markedly hypercellular and show similar findings.

PERIPHERAL BLOOD
CBC (9/28/2020):
WBC 38.4 H [4.0-11.0 K/mcL] 
RBC 5.06 [3.95-5.54 M/mcL] 
HGB 13.3 [12.5-16.2 g/dL] 
HCT 42.5 [37.5-49.3 %] 
MCV 84 [80-98 fL] 
MCH 26.3 L [27.0-33.0 pg] 
MCHC 31.3 [31.0-36.5 g/dL] 
RDW 19.5 H [12.2-15.1 %] 
Platelets 21 L [160-400 K/mcL] 

Neutrophil 23.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 70.0 H [0.0-0.0 %] 
Lymph 6.0 L [12.2-47.4 %] 
Nucleated RBC 3 [/100(WBCs)] 

Abs Neut 8.8 H [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 26.9 H [0.0-0.0 K/mcL] 
Abs Lymph 2.3 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBCs: Markedly increased atypical blasts.
RBCs: Normocytic normochromic RBCs and rare nucleated red blood cells.
Platelets: Thrombocytopenia with unremarkable morphology.

IMMUNOHISTOCHEMISTRY
The blasts are positive for CD34 (subset) and TdT (~80-90% of cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-7834)
Abnormal immature B-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature T-cell population detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and or marrow (84.5% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD20 (partial), CD33, CD34 (absent to intermediate), CD38 (slightly dim), CD45 (absent to intermediate),CD66c/CD123, CD73/CD304, with normal expression of CD10, CD19, CD22, CD24, CD71, CD81 and HLA-DR; and without CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD20, CD56, CD64, CD66b, CD86 or CD117.

Very few CD34 positive myeloid blasts seen.
325 thousand cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-4918.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-20828, M20-30829.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H20-4777;S2;MSKB - 2023-06-05 15.06.01.ndpi,Peripheral Blood Smear,2023-06-05,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears:
     - B-lymphoblastic leukemia/lymphoma (35% blasts)

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Blasts                35%
Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           2%
Neutrophils/Bands      12%
Eosinophils           3%
Erythroid Precursors      37%
Lymphocytes           1%
Number of Cells Counted 500
M:E Ratio           0.7

Morphology:
Cellular bone marrow aspirate shows increased blasts. Background progressive trilineage hematopoiesis is also noted .


PERIPHERAL BLOOD
CBC (08/03/2020):
WBC 2.2 L [7.1-15.9 K/mcL] 
RBC 2.32 L [3.70-4.90 M/mcL] 
HGB 8.1 L [10.6-13.3 g/dL] 
HCT 23.1 L [32.4-40.4 %] 
MCV 100 H [74-91 fL] 
MCH 34.9 H [22.7-29.5 pg] 
MCHC 35.1 [31.0-36.5 g/dL] 
RDW 19.2 H [12.2-15.1 %] 
Platelets 19 LL [160-400 K/mcL]  

Neutrophil 63.0 [16.9-74.5 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 7.0 H [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 1.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 27.0 [15.5-57.8 %] 
Nucleated RBC 1 [/100(WBCs)]
 
Abs Neut 1.4 L [1.5-8.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.0 [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.6 L [1.0-4.3 K/mcL] 

Morphology: occasional blasts. pancytopenia. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-5987)
Abnormal immature B-cell population detected.

An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously F20-5263.  The abnormal immature B-cells represent 39.4% of the white cells and 55.2% of the mononuclear cells in the sample and abnormally express CD10 (bright), CD19 (absent to dim), CD20 (bright), CD34 (dim to intermediate), CD45 (absent to dim), CD66c/CD123, CD73/CD304, and CD81 (bright); with normal expression of CD22, CD24, and CD38; and without CD66b.  This finding is consistent with persistent/recurrent B-lymphoblastic leukemia/lymphoma, depending on the clinical context.  Clinical and morphologic correlation is recommended.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-3652, CG20-3653.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-23394, M20-23395.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. Pessin MD., PhD., Director.
"
H20-4205;S12;MSK9 - 2023-04-25 21.33.05.ndpi,Peripheral Blood Smear,2023-04-25,"Myelodysplastic Syndrome 
Leukopenia, anemia 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Myelodysplastic syndrome with excess blast-2 (MDS-EB-2), 18% blast by aspirate differential count, see comment. 
  
COMMENT: Blasts are increased, and background hematopoiesis shows trilineage dysplasia. Concurrent cytogenetic and molecular analysis is in progress. Please correlate with these results to fully characterize the disease.  

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: 60-70% 
M:E ratio: Increased 
Blasts: Increased (confirmed with CD34 stain)
Myeloid lineage: Left-shifted maturation 
Erythroid lineage: Decreased. 
Megakaryocytes: Increased, many small monolobated forms and forms with separate nuclear lobes are present. 
Lymphocytes: Not increased 
Plasma cells: Not increased 
Special stains: Reticulin stain shows no increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: 
Blasts                18%
Promyelocytes           2%
Myelocytes           19%
Metamyelocytes           5%
Neutrophils/Bands      21%
Monocytes           1%
Eosinophils           4%
Erythroid Precursors      19%
Plasma Cells           4%
Lymphocytes           7%
Number of Cells Counted 500
M:E Ratio           2.7

Special stain 
Iron: Present
Ring sideroblasts: Absent 

Morphology:
Spicular and cellular smears show expanded blast population (18% by differential count). Blasts are intermediate sized and have prominent nucleoli and irregular/folded nuclear membrane, occasionally showing cup-shape morphology. Background trilineage hematopoiesis is dysplastic. Myeloid maturation is left-shifted, and mature myeloid cells have hypogranular cytoplasm and abnormal nuclear lobation. Erythroid precursors show frequent dysplastic features (binucleation, megaloblastoid changes). Many megakaryocytes are present, and nuclear lobe separation is frequently seen. Micromegakaryocytes are also identified.   

PERIPHERAL BLOOD
CBC (7/13/2020):
WBC 2.5 L [4.0-11.0 K/mcL] 
RBC 2.43 L [3.95-5.54 M/mcL] 
HGB 8.9 L [12.5-16.2 g/dL] 
HCT 26.6 L [37.5-49.3 %] 
MCV 110 H [80-98 fL] 
MCH 36.6 H [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 15.5 H [12.2-15.1 %] 
Platelets. 292 [160-400 K/mcL] 

Neutrophil 35.8 [32.5-74.8 %] 
Mono 4.9 [0.0-12.3 %] 
Eos 0.4 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 2.0 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 56.5 H [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL]

Morphology: Circulating immature myeloid cells (myelocytes) present. Mature neutrophils have hypogranluar cytoplasm. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight increase in blasts, comprising 15-20% of marrow cellularity.
CD34 also highlights dysplastic megakaryocytes. 
CD117 also highlights immature myeloid and erythroid precursors.  
CD61, CD71, myeloperoxidase stains are in progress, and the results will be reported as an addendum. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-5268)
Interpretation: 
Abnormal myeloid blast and maturing granulocyte populations detected. 
No abnormal B- or T-cell population detected.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD5, CD7 (partial), CD13 (dim), CD33 (dim), CD34 (uniform), CD38 (uniform, slightly dim), CD56 (partial), CD117 (uniform intermediate), CD123 (dim to absent); with normal expression of CD4, CD45, CD71, and HLA-DR without CD2, CD11b, CD14, CD15, CD16, CD19, CD25 or CD64. Granulocytes show abnormal retention of CD14, CD38, and CD64. The findings are consistent with involvement by a myeloid neoplasm. Correlation with morphology is needed for final classification. CD34 positive myeloid blasts represent 5.3% of WBC. 

No immunophenotypic evidence of involvement by B- or T-cell non-Hodgkin lymphoma or leukemia is identified.  

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-3203.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-20737, M20-20738.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-1419;S11;MSK2 - 2023-06-27 02.42.47.ndpi,Peripheral Blood Smear,2023-06-27,"AML. New AML. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
    - Acute Myeloid Leukemia (AML) (75% blasts by aspirate differential count) (See Comment) 

COMMENT: Per communication with Dr. Abdel-Wahab, an outside laboratory detected a t(8;21)(q22;q22.1)/RUNX1-RUNX1T1. If confirmed, this case will be best classified as AML with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1.

BONE MARROW BIOPSY
Quality: Small biopsy
Cellularity: Markedly hypercellular (>90% cellularity)
M:E ratio: Normal (excluding blasts)
Blasts: Diffuse interstitial increase in large-sized blasts with prominent nucleoli, and small to moderate amount of cytoplasm
Myeloid lineage: Show marked left-shifted maturation  
Erythroid lineage: Show progressive maturation 
Megakaryocytes: Reduced in number 
Lymphocytes: Rare
Plasma cells: Rare

Special stains: 
Reticulin stain shows no increase in reticulin fibrosis (0/3)

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                75% 
Myelocytes           10%
Neutrophils/Bands      2%
Eosinophils           1%
Erythroid Precursors      3%
Plasma Cells           1%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           4.3

Morphology:
The aspirate smears are spicular, cellular and show maturing trilineage hematopoiesis. There a prominent expanded blast population showing intermediate to large size, small to moderate amount of cytoplasm with eosinophilic granules, fine chromatin and distinct nucleoli. Erythroid and myeloid elements are reduced in number, showing left-shifted maturation. Scattered megakaryocytes are present.

PERIPHERAL BLOOD
CBC (2/17/2020):
WBC 14.7 H [4.0-11.0 K/mcL] 
RBC 2.61 L [3.80-5.00 M/mcL] 
HGB 8.0 L [11.2-15.4 g/dL] 
HCT 24.5 L [34.3-46.0 %] 
MCV 94 [80-98 fL] 
MCH 30.7 [27.0-33.0 pg] 
MCHC 32.7 [31.0-36.5 g/dL] 
RDW 17.2 H [12.2-15.1 %] 
Platelets 35 L [160-400 K/mcL] 

Neutrophil 1.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 56.0 H [0.0-0.0 %] 
Myelocyte 4.0 H [0.0-0.0 %] 
Promyelocyte 5.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 29.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 0.1 L [1.5-7.5 K/mcL]
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Blasts 8.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.6 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.7 H [0.0-0.0 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 4.3 H [0.9-3.2 K/mcL]

Morphology:
WBC: Absolute neutropenia. Frequent circulating blasts. Left-shifted granulocytes are present (myelocytes, metamyelocytes).
RBC: Normochromic normocytic anemia. 
Platelets: Marked thrombocytopenia.

IMMUNOHISTOCHEMISTRY
CD34 highlights a subset of the blasts.
CD117 highlights a large subset of the blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-1738)
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD19 (small subset, dim), CD25 (small subset, <10% of blasts), CD33 (dim), CD56 (bright), cytoplasmic CD79a (small subset, dim, coexpressed on CD19+ subset of the blast), CD13 (slightly dim), CD34 (uniform bright), CD117 (bright), CD123 (uniform bright); with normal expression of CD4, CD38, CD45, CD71, and HLA-DR; without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD20, CD64 or surface light chains. MPO expression is brightly expressed on the blasts. CD34 positive myeloid blasts represent 34.0% of WBC.
326,267 cells acquired for myeloid analysis.

The expression of dim CD19 and CD79a on the myeloid blasts RAISES THE POSSIBILITY of Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. However, correlation with pending cytogenetics karyotype/FISH studies, as well as Archer Heme panel (M20-6855) is recommended.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F20-1725)
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD13 (bright), CD19 (partial), CD25 (partial), CD33 (dim), CD34 (uniform), CD56 (bright), CD117 (dim), and CD123 (uniform); with normal expression of CD4, CD38, CD45, CD71, and HLA-DR without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD20, CD64, cytoplasmic CD79a or surface light chains. MPO expression is present on the blasts. CD34 positive myeloid blasts represent 47.1% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-1017.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-6850-6855.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-5921;S26;MSK0 - 2023-06-16 00.15.11.ndpi,Peripheral Blood Smear,2023-06-16,"CLL. PB with nonspecific immunophenotype, IgM M spike.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears:
     - CD5+ low-grade B-cell lymphoma, most consistent with marginal zone lymphoma (~50% involvement by CD20 immunohistochemistry) (see comment).
  
COMMENT: Based on the overall morphologic and immunophenotypic findings (including a prior peripheral blood flow cytometric analysis, F20-6416; 8/14/2020) in conjunction with the results of the prior cytogenetic and molecular studies performed on peripheral blood (CG20-3925, CG20-3926, M20-24825; 8/14/2020), a diagnosis of marginal zone lymphoma is favored. 

Case reviewed at the Hematopathology Consensus Conference on 9/21/2020 with agreement.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show mildly hypercellular bone marrow for age (~40% cellularity overall) with a nodular and interstitial atypical lymphoid infiltrate composed predominantly of small to intermediate sized lymphoid cells with rounded to irregular nuclei, condensed chromatin, mostly inconspicuous nucleoli and mostly scant cytoplasm. Occasional admixed intermediate to large sized cells with distinct nucleoli are seen but sheets of large cells are not identified. Occasional scattered plasma cells are seen. Myeloid and erythroid elements show orderly maturation. The M:E ratio appears normal. Megakaryocytes appear adequate in number with mostly unremarkable morphology. Clot section is non-contributory due to a lack of marrow particles.

Aspirate differential: (Performed by KT)
Promyelocytes           1%
Myelocytes           8%
Metamyelocytes           2%
Neutrophils/Bands      24%
Monocytes           1%
Eosinophils           5%
Erythroid Precursors      23%
Lymphocytes           36%
Number of Cells Counted 500
M:E Ratio           1.8

IMMUNOHISTOCHEMISTRY
CD20 highlights an increased number of B-cells (comprise ~50% of the marrow cellularity), which co-express PAX5, CD5 (weak, variable) and CD23 (small subset weak) and do not express LEF1, cyclin D1, CD11c or p53.
CD23 also highlights follicular dendritic cell meshworks associated with the lymphoid nodules.
Ki-67 proliferation index within the lymphoid nodules is <10%.
CD138 highlights occasional plasma cells scattered singly and in small clusters, comprising <5% of marrow cellularity, which show a kappa predominance with kappa and lambda immunostains.
IgM highlights most of the plasma cells while IgG and IgA each highlight smaller subsets of the plasma cells.
IgD is largely negative.
CD3 labels scattered T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW 
Not submitted.

PERIPHERAL BLOOD
CBC (09/16/2020):
WBC 24.0 H [4.0-11.0 K/mcL] 
RBC 3.55 L [3.80-5.00 M/mcL] 
HGB 10.3 L [11.2-15.4 g/dL] 
HCT 31.7 L [34.3-46.0 %] 
MCV 89 [80-98 fL] 
MCH 29.0 [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 13.6 [12.2-15.1 %] 
Platelets 174 [160-400 K/mcL] 

Neutrophil 31.0 L [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 5.0 H [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 50.0 H [12.2-47.4 %] 
Other (Abnormal lymphoid cells) 10.0 H [0.0-0.0 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 7.4 [1.5-7.5 K/mcL] 
Abs Mono 1.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.2 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 12.0 H [0.9-3.2 K/mcL] 
Abs Others 2.4 H [0.0-0.0 K/mcL]

Morphology:
WBC: Absolute lymphocytosis with circulating atypical lymphoid cells morphologically similar to those in the aspirate smears. Mild absolute eosinophilia.
RBC: Normochromic, normocytic anemia.
Platelets: Adequate with unremarkable morphology.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-4621, CG20-4622.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-29125.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-6570;S12;MSKF - 2023-04-17 16.56.10.ndpi,Peripheral Blood Smear,2023-04-17,"AML.  On Protocol: 19-389.
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
      - Persistent acute myeloid leukemia with t(6;9)(p23:q34); DEK-NUP214, 80% blasts by aspirate differential count.     

BONE MARROW BIOPSY/CLOT SECTION
Quality: Adequate
Cellularity: Hypercellular for age (~95% cellularity)
M:E ratio: N/A
Blasts: Increased, with sheets occupying most of the marrow space
Myeloid lineage: Markedly reduced 
Erythroid lineage: Markedly reduced 
Megakaryocytes: Decreased with hypolobation and hyperchromasia 
Lymphocytes: Rare
Plasma cells: Rare
Clot section: The clot section is non-contributory (mostly blood). 

Special stains: 
Reticulin stain shows focal mild increase in reticulin fibrosis (0-1+/3). 

BONE MARROW ASPIRATE SMEAR/TOUCH IMPRINTS
Differential: (Performed by MT)
Blasts                80%
Myelocytes           1%
Neutrophils/Bands      5%
Erythroid Precursors      10%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           0.6

Morphology:
The aspirate smears are spicular and hypercellular demonstrating maturing trilineage hematopoiesis with increased large sized blasts with round to irregular/folded nuclei, fine chromatin, conspicuous nucleoli and moderate amount of cytoplasm with occasional vacuoles and blebs. Myeloid and erythroid elements are markedly decreased. Scattered hypogranular myeloid elements are seen. Erythroid elements are markedly reduced but show significant dysplasia (>10%; binucleation, nuclear irregularity/budding, late-stage mitoses). Megakaryocytes are present and include forms with hypolobation and/or separation of nuclear lobes. 

PERIPHERAL BLOOD
CBC (10/9/2020):
WBC 1.0 L [4.0-11.0 K/mcL] 
RBC 2.85 L [3.80-5.00 M/mcL] 
HGB 8.3 L [11.2-15.4 g/dL] 
HCT 23.8 L [34.3-46.0 %] 
MCV 84 [80-98 fL] 
MCH 29.1 [27.0-33.0 pg] 
MCHC 34.9 [31.0-36.5 g/dL] 
RDW 12.0 L [12.2-15.1 %] 
Platelets. 36 L [160-400 K/mcL] 

Neutrophil 24.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 38.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 34.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 0.2 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.4 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL]

Morphology:
WBCs: Occasional circulating blasts seen. Absolute neutropenia (occasional hypogranular forms) and absolute lymphopenia.
RBCs: Normocytic normochromic anemia.
Platelets: Marked thrombocytopenia

IMMUNOHISTOCHEMISTRY
The blasts are positive for CD117 and CD34 (subset) immunostains, at least 80% of total cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-8290)
Abnormal myeloid blast population detected.
Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD7 (partial), CD11b (partial), CD13 (uniform intermediate), CD15 (partial), CD25 (partial), CD33 (bright), CD34 (absent to bright), CD38 (absent to dim), CD56 (partial), CD64 (partial), CD117 (dim to intermediate), CD123 (uniform bright), HLA-DR (bright) with normal expression of CD4, CD45, CD71; without CD2, CD5, CD14, CD16 or CD19. Myeloid blasts represent 68.0% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-5194.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-32465 to M20-32468.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-4849;S13;MSKD - 2023-06-07 02.47.46.ndpi,Peripheral Blood Smear,2023-06-07,"MDS r/o POD
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears:  
     - Persistent myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD).

BONE MARROW BIOPSY
Quality: Limited (small and fragmented with aspiration artifact)
Cellularity: Difficult to accurately assess due to limited intact marrow spaces, ranges from ~5% to ~90%, overall ~70%
M:E ratio: Markedly reduced
Blasts: Not increased 
Myeloid lineage: Reduced with progressive maturation
Erythroid lineage: Markedly increased with left-shifted maturation
Megakaryocytes: Present with dysplastic forms (small, hypolobated forms, hyperchromasia)
Lymphocytes: Scattered
Plasma cells: Scattered
Clot section: Contains rare minute marrow particles morphologically similar to the core biopsy
Special stains: Reticulin stain shows mild reticulin fibrosis (MF-1/3) 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Hypocellular aspirate devoid of spicules.
Blasts                2%
Myelocytes           3%
Metamyelocytes           2%
Neutrophils/Bands      15%
Eosinophils           2%
Erythroid Precursors      68%
Lymphocytes           8%
Number of Cells Counted 200
M:E Ratio           0.3

Special stain 
Iron: Inadequate for evaluation due to a lack of spicules
Ring sideroblasts: Present, >15% 

Morphology:
Aspirate smears are aspicular, hypocellular and hemodilute. No expanded blast population is seen. Erythroid precursors predominate, are present at various stages of maturation and show dyserythropoiesis (nuclear irregularity/budding, binucleation, nuclear-cytoplasmic dyssynchrony, megaloblastoid change). Myeloid elements are present at various stages of maturation with rare hyposegmented forms seen. Megakaryocytes are not well represented. 

PERIPHERAL BLOOD
CBC (08/06/2020):
WBC 2.8 L [4.0-11.0 K/mcL] 
RBC 2.44 L [3.95-5.54 M/mcL] 
HGB 7.8 L [12.5-16.2 g/dL] 
HCT 24.3 L [37.5-49.3 %] 
MCV 100 H [80-98 fL] 
MCH 32.0 [27.0-33.0 pg] 
MCHC 32.1 [31.0-36.5 g/dL] 
RDW 21.7 H [12.2-15.1 %] 
Platelets 427 H [160-400 K/mcL] 

Neutrophil 58.0 [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 7.0 H [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Lymph 32.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 1.6 [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL] 

Morphology:
WBC: Relative eosinophilia and basophilia with occasional myelocytes and metamyelocytes. No circulating blasts seen.
RBC: Macrocytic anemia with anisopoikilocytosis, increased polychromasia and rare nucleated RBCs.
Platelets: Mild thrombocytosis.

IMMUNOHISTOCHEMISTRY
CD34 shows no increase in blasts (<5% of marrow cellularity).
CD117 highlights relatively increased early erythroid precursors as well as relatively increased mast cells, which are mostly singly distributed and round in shape.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-6108)
Interpretation: 
Abnormal myeloid blast population detected.
Basophilia and eosinophilia are seen (2.3% and 7.4% respectively)

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD7 (partial), CD13 (dim to intermediate), CD34 (dim), and HLA-DR (bright); with normal expression of CD4, CD33, CD34, CD38, CD45, CD117, and CD71; without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 3.5% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-3718.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-23963.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-7969;S20;MSKR - 2023-04-17 17.24.23.ndpi,Peripheral Blood Smear,2023-04-17,"AML. Leukocytosis, circulating blasts, concern for acute leukemia, AML vs APL vs ALL. Newly diagnosis leukemia. Run for DMP, bone marrow core, do not decalcify. Store in formalin. IMPACT, FLT3, P53, BCR-ABL1, RUNX1- RUNX121. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Myelodysplastic/myeloproliferative neoplasm, with increased blasts. See comment.
  
COMMENT: Morphologic review reveals a markedly hypercellular hematopoietic marrow with dysplasia and increased blasts (10% by differential count). Concurrent CBC is remarkable for leukocytosis (44.4 K/mcL), with absolute and relative monocytosis and increased circulating blasts (9%). Cytogenetic analysis performed on a concurrent peripheral blood sample shows absence of BCR/ABL1 rearrangements. The overall morphologic and immunophenotypic features are consistent with a myelodysplastic/myeloproliferative overlap syndrome. Differential diagnosis includes chronic myelomonocytic leukemia (CMML-2) and atypical chronic myeloid leukemia. The concurrent absolute and relative monocytosis at the time of the bone marrow biopsy would be more consistent with a diagnosis of CMML and an exclusion criterion for a diagnosis of aCML. However, it is not possible, at this time, to prove the sustained duration of the peripheral monocytosis and a conclusive distinction cannot be made. Correlation with clinical data and the pending molecular and cytogenetics studies is recommended.

BONE MARROW BIOPSY
Two core biopsies are submitted. The morphologic findings in the 2 separate samples are similar and as follows:
Quality: Adequate
Cellularity: Markedly hypercellular, >95%
M:E ratio: Increased
Blasts: Slightly increased in number, scattered
Myeloid lineage: Hyperplastic, with left-shifted but complete maturation
Erythroid lineage: Hyperplastic, with complete maturation
Megakaryocytes: Increased number, including numerous small forms with hypolobated nuclei or widely separated nuclear lobes
Lymphocytes: Not increased, scattered
Plasma cells: Not increased, scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1). 

BONE MARROW ASPIRATE SMEAR
Differential (performed on touch imprint smear by CB):
Blasts                10%
Promyelocytes           2%
Myelocytes           15%
Metamyelocytes           9%
Neutrophils/Bands      34%
Monocytes           1%
Eosinophils           2%
Basophils           1%
Erythroid Precursors      23%
Plasma Cells           1%
Lymphocytes           2%
Number of Cells Counted      500
M:E Ratio           2.9

Morphology:
Only touch imprints are available for review. Myeloid elements show markedly left-shifted maturation, with only occasional mature forms seen. Erythroid elements show complete maturation and dysplastic features including frequent nuclear irregularities/budding and nuclear/cytoplasmic dyssynchrony. Blasts are increased. Megakaryocytes are present and show frequent nuclear hypolobation and widely separated nuclear lobes.

PERIPHERAL BLOOD
CBC (12/02/2020):
WBC 44.4 H [4.0-11.0 K/mcL] 
RBC 2.41 L [3.95-5.54 M/mcL] 
HGB 8.4 L [12.5-16.2 g/dL] 
HCT 24.4 L [37.5-49.3 %] 
MCV 101 H [80-98 fL] 
MCH 34.9 H [27.0-33.0 pg] 
MCHC 34.4 [31.0-36.5 g/dL] 
RDW 14.5 [12.2-15.1 %] 
Platelets 141 L [160-400 K/mcL] 

Neutrophil 53.0 [32.5-74.8 %] 
Mono 22.0 H [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Blast 9.0 H [0.0-0.0 %] 
Myelocyte 4.0 H [0.0-0.0 %] 
Promyelocyte 3.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Lymph 3.0 L [12.2-47.4 %] 

Nucleated RBC 4 [/100(WBCs)] 
Abs Neut 23.5 H [1.5-7.5 K/mcL] 
Abs Mono 9.8 H [0.0-1.3 K/mcL]
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.9 H [0.0-0.2 K/mcL] 
Absolute Blasts 4.0 H [0.0-0.0 K/mcL] 
Abs Myelocytes 1.8 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 1.3 H [0.0-0.0 K/mcL] 
Abs Meta 0.9 H [0.0-0.0 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology: Review of the peripheral blood smears shows leukocytosis with presence of numerous immature myeloid elements, display dysplastic features including cytoplasmic hypogranularity and uneven granulation. And increased number of monocytes and atypical monocytes is noted. Blasts are increased number. Occasional nucleated red blood cells are also seen.

IMMUNOHISTOCHEMISTRY
CD34 highlights only a rare, scattered immature precursors (<1%). CD117 is positive in a subset of immature erythroid and myeloid precursors. A stain for p53 is negative. CD61 highlights the increased number of megakaryocytes that include frequent small forms with hypolobated nuclei and occasional micro megakaryocytes. CD71 and MPO highlight immature erythroid and myeloid elements, respectively. 

FLOW CYTOMETRIC ANALYSIS, TISSUE NEEDLE CORE BIOPSY (F20-10161)
Abnormal myeloid blast population detected 
Basophilia seen, representing 1.9% of WBC. 
No abnormal B and T cell populations detected.
No abnormal plasma cell population detected.

The blasts have abnormal expression of CD13 (uniform bright), CD33 (uniform bright), CD34 (dim to negative), CD38 (dim), CD117 (uniform intermediate), CD123 (slightly bright), HLADR (dim to negative) with normal expression of CD4, CD45, CD71; without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cytoplasmic CD79a, or surface light chains. MPO expression is present on all the blasts. CD117 positive myeloid blasts represent 12.2% of WBC. 

The phenotype does not fully exclude APL. Clinical and morphologic correlation is advised.

Granulocytic population is left-shifted and shows retention of CD13.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified. 
No evidence of an abnormal plasma cell population is identified by flow cytometry. 89829 cells acquired.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F20-10153)
Abnormal myeloid blast population detected.
Basophilia seen, representing 1.3% of WBC. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD13 (uniform bright), CD33 (absent to dim), CD34 (subset dim, subset absent), CD38 (dim), CD117 (uniform intermediate), CD123 (uniform bright), HLADR (absent to dim); with normal expression of CD4, CD45, CD71; without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cytoplasmic CD79a, or surface light chains. MPO expression is present on a subset of blasts. CD117 positive myeloid blasts represent 11.1% of WBC.

Maturing granulocytes show an abnormal pattern of acquisition of CD13.

CYTOGENETIC STUDIES
Cytogenetic analysis performed on a peripheral blood sample (CG20-6428) showed a normal male karyotype. FISH analysis revealed:
No evidence of PML-RARA fusion/t(15;17).
No evidence of RARA (17q21.2) rearrangement.
No evidence of MLL (11q23) rearrangement.
No evidence of TP53 (17p13.1) deletion or loss of chromosome 17.

MOLECULAR STUDIES 
Not requested.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-3864;S12;MSK9 - 2023-06-05 11.33.59.ndpi,Peripheral Blood Smear,2023-06-05,"Leukemia, Hairy Cell
Evaluate for progression 
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Hairy cell leukemia, extensive involvement, 80-90% involvement by CD20 immunohistochemistry.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypocellular for age (~20%)
M:E ratio: N/A
Blasts: Not increased (<5%) 
Myeloid lineage: Markedly reduced 
Erythroid lineage: Markedly reduced 
Megakaryocytes: Markedly reduced 
Lymphocytes: Extensive interstitial proliferation of small to medium sized atypical lymphoid cells with abundant cytoplasm, irregular nuclei and condensed chromatin.
Plasma cells: Scattered 
Clot section: The clot section is non-contributory (mostly blood). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by KT)
Markedly hypocellular aspirate devoid of spicules.
Myelocytes           1%
Neutrophils/Bands      43%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      5%
Lymphocytes           44%
Hairy cells           5%
Number of Cells Counted 100
M:E Ratio           9.2

Morphology: Aspirate smears are aspicular, hypocellular and hemodiluted, but show lymphocytosis comprised of small atypical lymphoid cells with moderate amounts of cytoplasm and occasional cytoplasmic projections, round to irregular nuclei and condensed chromatin. Blasts are not increased. Background myeloid elements show mostly mature granulocytes. Erythroid elements and megakaryocytes are markedly reduced. Due to hemodilution, findings may not accurately represent actual bone marrow composition. 

PERIPHERAL BLOOD
CBC (06/26/2020):
WBC 2.8 L [4.0-11.0 K/mcL] 
RBC 3.44 L [3.80-5.00 M/mcL] 
HGB 12.2 [11.2-15.4 g/dL] 
HCT 34.6 [34.3-46.0 %] 
MCV 101 H [80-98 fL] 
MCH 35.5 H [27.0-33.0 pg] 
MCHC 35.3 [31.0-36.5 g/dL] 
RDW 13.9 [12.2-15.1 %] 
Platelets 86 L [160-400 K/mcL] 

Neutrophil 31.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 68.0 H [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.9 [0.9-3.2 K/mcL] 

Morphology:
WBC: Leukopenia with absolute/relative neutropenia; occasional atypical lymphoid cells with cytoplasmic projections seen.
RBC: Normocytic, normochromic RBCs.
PLT: Moderate thrombocytopenia.

IMMUNOHISTOCHEMISTRY
CD20 shows extensive B-cell proliferation, ~80-90% of total cellularity. The B-cells express BRAF by IHC. CD3 highlights scattered T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-4818)
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.

Flow cytometry reveals an abnormal mature B-cell population having abnormal expression of CD19 (slightly bright), CD20 (bright), CD11c, CD22 (bright), CD25, CD45 (bright), CD103 and CD200 (bright) with slightly increased forward and side scatter, and lambda light chain restriction (bright); with normal expression of CD38 and without CD5 or CD10.  The immunophenotype of the abnormal B-cell population is consistent with involvement by hairy cell leukemia. The abnormal B cell population represents 6.6% of the total white cells.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-2907, CG20-2908.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-19124.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H20-6002;S11;MSKE - 2023-04-17 16.28.26.ndpi,Peripheral Blood Smear,2023-04-17,"CML
New Dx
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate and peripheral blood smears:  
    - Chronic myeloid leukemia, BCR-ABL1 positive, chronic phase, <5% blasts; see comment.

COMMENT: BCR-ABL1 fusion was detected in previous cytogenetics testing on peripheral blood (CG20-4585). Findings are most consistent with CML in chronic phase. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypercellular (>90%)
M:E ratio: Increased
Blasts: Not increased (<5%) 
Myeloid lineage: Increased, with mildly left shifted maturation seen
Erythroid lineage: Reduced, exhibits full maturation 
Megakaryocytes: Present, with occasional small hypolobated forms
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows no significant increase in reticulin fibers (0/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                1%
Promyelocytes           2%
Myelocytes           18%
Metamyelocytes           13%
Neutrophils/Bands      45%
Monocytes           1%
Eosinophils           5%
Basophils           1%
Erythroid Precursors      12%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           7.1

Morphology: The aspirate smears are spicular, hypercellular and show maturing trilineage hematopoiesis; no expanded blast population is seen. Myeloid elements show full maturation without overt dysplasia. Mild eosinophilia and basophilia is seen. Erythroid elements are relatively decreased. Megakaryocytes are increased, with frequent small/hypolobated forms compatible with so-called 'dwarf' megakaryocytes.

PERIPHERAL BLOOD
CBC (09/18/2020):
WBC 75.7 H [4.0-11.0 K/mcL] 
RBC 4.31 [3.95-5.54 M/mcL] 
HGB 12.8 [12.5-16.2 g/dL] 
HCT 38.3 [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 33.4 [31.0-36.5 g/dL] 
RDW 14.1 [12.2-15.1 %] 
Platelets. 287 [160-400 K/mcL] 

Neutrophil 52.0 [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Blast 1.0 H [0.0-0.0 %] 
Myelocyte 19.0 H [0.0-0.0 %] 
Promyelocyte 9.0 H [0.0-0.0 %] 
Metamyelocyte 7.0 H [0.0-0.0 %] 
Lymph 3.0 L [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 39.4 H [1.5-7.5 K/mcL] 
Abs Mono 3.0 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 2.3 H [0.0-0.7 K/mcL] 
Absolute Basophil 1.5 H [0.0-0.2 K/mcL] 
Absolute Blasts 0.8 H [0.0-0.0 K/mcL] 
Abs Myelocytes 14.4 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 6.8 H [0.0-0.0 K/mcL] 
Abs Meta 5.3 H [0.0-0.0 K/mcL] 
Abs Lymph 2.3 [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBC: Marked leukocytosis with granulocytosis and basophilia; no definite circulating blasts seen.
RBC: Normocytic, normochromic RBCs.
PLT: Unremarkable morphology.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains show no increases in CD34 and/or CD117 positive blasts (<5%). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F20-7553)
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature B- or T-cell populations detected.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.59% of WBC.
454,677 cells acquired. Flow cytometry is generally not a sensitive methodology in the context of myeloproliferative disorders, and correlation with molecular studies for JAK2, CALR, MPL mutation status and BCR-ABL and morphology is advised. 

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG20-4703.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M20-29591.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-1555;S11;MSK1 - 2023-05-10 20.45.26.ndpi,Peripheral Blood Smear,2023-05-10,"AML. Relapsed AML (+RUNX1, TP53, SRSF2, SETBP1) status post alloSCT, now screening for protocol #17-120. 
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Persistent acute myeloid leukemia, 94% blasts by aspirate differential.

BONE MARROW BIOPSY
Quality: Suboptimal (hemorrhagic, aspirated biopsy with extensive crush artifact)
Cellularity: Appears normocellular (20-30%)
M:E ratio: N/A
Blasts: Markedly expanded population of small to medium sized blasts with small amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli 
Myeloid lineage: Markedly reduced 
Erythroid lineage: Markedly reduced 
Megakaryocytes: Markedly reduced 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows a focal, patchy mild increase in reticulin fibers (0-1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                94%
Myelocytes           1%
Lymphocytes           5%
Number of Cells Counted  500
M:E Ratio           0

Morphology: The aspirate smears are spicular and cellular and show a markedly expanded population of medium sized blasts with small amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli, in a background of markedly decreased trilineage hematopoiesis. 

PERIPHERAL BLOOD
CBC (02/26/2019):
WBC 6.2 [4.0-11.0 K/mcL] 
RBC 3.46 L [3.80-5.00 M/mcL] 
HGB 9.9 L [11.2-15.4 g/dL] 
HCT 29.6 L [34.3-46.0 %] 
MCV 86 [80-98 fL] 
MCH 28.6 [27.0-33.0 pg] 
MCHC 33.4 [31.0-36.5 g/dL] 
RDW 13.3 [12.2-15.1 %] 
Platelets. 20 LL [160-400 K/mcL]  

Neutrophil 1.0 L [32.5-74.8 %] 
Lymph 14.0 [12.2-47.4 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 0.1 L [1.5-7.5 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 84.0 H [0.0-0.0 %] 
Absolute Blasts 5.2 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Numerous circulating blasts; marked absolute/relative neutropenia.
RBC: Normocytic, normochromic anemia.
PLT: Marked thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains for CD34 and CD117 show increased blasts, >90% of the bone marrow cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-1823)
Abnormal myeloid blast population detected. 
Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD2 (partial), CD7 (partial), CD13 (dim to intermediate), CD25 (greater than 30%), CD33 (bright), CD38 (dim to absent), CD117 (dim to bright), CD123 (uniform dim); with normal expression of CD4, CD34, CD45, CD71 and HLA-DR without CD5, CD11b, CD14, CD15, CD16, CD19, CD56, CD64. CD34 positive myeloid blasts represent 95.0% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-1315.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-7458, M19-7459.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-704;S11;MSK6 - 2023-06-21 18.13.15.ndpi,Peripheral Blood Smear,2023-06-21,"AML. Pre allo SCT.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Persistent myelodysplastic syndrome with ring-sideroblasts and multilineage dysplasia (MDS-RS-MLD) (1% blasts by aspirate differential count). 
     - Persistent small abnormal immature B-lymphoblast population detected only by flow cytometry (0.51% of WBC).
     - Hypercellular marrow with erythroid predominant trilineage maturing hematopoiesis, dyserythropoiesis and dysmegakaryopoiesis. 

COMMENT: The significance of the immature B lymphoblast population is unclear. Suggest close patient follow-up.

BONE MARROW BIOPSY
Quality: Adequate, small biopsy
Cellularity: Hypercellular for age (~95% cellularity)
M:E ratio: Decreased 
Blasts: Not overtly increased 
Myeloid lineage: Markedly decreased and exhibit full maturation 
Erythroid lineage: Increased and exhibit left shifted maturation 
Megakaryocytes: Increased in number and show dysplastic forms (hypolobated, abnormal nuclear lobe separation)
Lymphocytes: Scattered
Plasma cells: Rare
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)
Blasts                1%
Promyelocytes           1%
Myelocytes           6%
Metamyelocytes           5%
Neutrophils/Bands      14%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      68%
Lymphocytes           2%
Number of Cells Counted  500
M:E Ratio           0.4

Special stain
Iron: Present
Ring sideroblasts: Present; >15%

Morphology:
Spicular and cellular aspirate smears and touch imprint show erythroid predominant trilineage maturing hematopoiesis with no overt increase in blasts. Myeloid elements are decreased and show occasional dysplastic forms with abnormal nuclear lobation. Erythroid elements are increased and show dyspoiesis (>10%, nuclear irregularity and budding, binucleation, nuclear-cytoplasmic asynchrony, cytoplasmic vacuolization). Megakaryocytes are present and show dyspoiesis (>10%, hypolobated forms). Scattered mast cells are present. 

PERIPHERAL BLOOD
CBC (01/28/2019):
WBC 3.5 L [4.0-11.0 K/mcL] 
RBC 2.09 L [3.95-5.54 M/mcL] 
HGB 6.2 L [12.5-16.2 g/dL] 
HCT 19.0 L [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 32.6 [31.0-36.5 g/dL] 
RDW 22.0 H [12.2-15.1 %] 
Platelets 217 [160-400 K/mcL] 

Neutrophil 77.7 H [32.5-74.8 %] 
Lymph 10.3 L [12.2-47.4 %] 
Mono 7.4 [0.0-12.3 %] 
Eos 3.1 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.9 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Nucleated RBC 0.0 [%] 

Abs Neut 2.7 [1.5-7.5 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Morphology:
WBC: No circulating blasts.
RBC: Moderate anisopoikilocytosis.
PLT: Some large and hypogranular forms present. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no overt increase in blasts (<5% cellularity).
CD34 also highlights subset of dysplastic megakaryocytes.
CD117 also highlights the erythroid precursors. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-819)
Abnormal myeloid blast population detected.
Abnormal immature B-cell population detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD5 (partial), CD7 (partial), CD15 (subset), CD34 (subset dim), CD71 (bright), and CD117 (bright); with normal expression of CD4, CD13, CD33, CD38, CD45, CD123 and HLA-DR; without CD2, CD11b, CD14, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 2.4% of WBC.

In addition, an abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously F18-10168.  The abnormal immature B-cells represent 0.51% of the white cells and 1.5% of the mononuclear cells in the sample and abnormally express CD4 (bright), CD10 (bright), CD11b (partial), CD19 (bright), CD20, CD25 (partial), CD34 (bright), CD58 (bright), and CD123 (bright); with normal expression of CD38, CD45, CD71, and HLA-DR; and without CD2, CD5, CD7, CD13, CD14, CD15, CD33, CD56, CD64, or CD117.  Clinical and morphologic correlation is recommended.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-607.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-3258, M19-3260, M19-3261.




Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-3515;S2;MSKZ - 2023-06-20 11.28.52.ndpi,Peripheral Blood Smear,2023-06-20,[NULL],"1. Bone marrow, right posterior iliac crest, biopsy and aspirate smears: 
     - B-lymphoblastic leukemia/lymphoma, 90% blasts by aspirate differential

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                90%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      1%
Erythroid Precursors      4%
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology: The aspirate smears are spicular and cellular and show an expanded population of small to medium sized blasts with small amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli, in a background of markedly decreased trilineage hematopoiesis. 

PERIPHERAL BLOOD
CBC (05/02/2019):
WBC 3.2 L [7.1-15.9 K/mcL] 
RBC 3.24 L [3.70-4.90 M/mcL] 
HGB 10.2 L [10.6-13.3 g/dL] 
HCT 29.8 L [32.4-40.4 %] 
MCV 92 H [74-91 fL] 
MCH 31.5 H [22.7-29.5 pg] 
MCHC 34.2 [31.0-36.5 g/dL] 
RDW 13.5 [12.2-15.1 %] 
Platelets 125 L [160-400 K/mcL] 

Neutrophil 2.0 L [16.9-74.5 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 26.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 70.0 H [15.5-57.8 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 0.1 L [1.5-8.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.8 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 2.2 [1.0-4.3 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBC: Many circulating blasts with similar morphology to the aspirate smears; absolute neutropenia
RBC: Mildly macrocytic anemia
Platelets: Mild thrombocytopenia

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-4051)
Abnormal immature B-cell population detected.
No abnormal mature T-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (96.7% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD10 (bright), CD11b (partial), CD13 (partial), CD20 (partial), CD33 (partial), CD34 (dim to bright), CD38 (dim), CD45 (absent to dim), CD58 (bright), CD123 (very bright); with normal expression of CD19, cyCD79a, and HLA-DR; and without CD2, convincing surface CD3, cytoplasmic CD3, CD4, CD5, CD7, CD8, CD14, CD15, CD16, CD56, CD64, CD71, or CD117.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.033% of WBC.
203,985 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-2894-5.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-16221-3.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. Pessin MD., PhD., Director.
"
H19-4503;S15;MSKA - 2023-07-19 09.22.34.ndpi,Peripheral Blood Smear,2023-07-19,"CLL. Rule out progression of disease.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:     
     - Chronic lymphocytic leukemia (CLL/SLL), ~60% by CD20 immunohistochemistry.
     - Hypercellular marrow with trilineage maturing hematopoiesis. 
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular for age (~90% cellularity)
M:E ratio: NA
Blasts: Not increased 
Myeloid lineage: Present with maturation  
Erythroid lineage: Present with maturation  
Megakaryocytes: Present and show mostly unremarkable morphology 
Lymphocytes: Markedly increased and form interstitial nodular and sheets, composed predominantly small lymphoid cells with round to irregular nuclei, clumped chromatin and inconspicuous nucleoli 
Plasma cells: Rare

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Myelocytes           2%
Metamyelocytes           1%
Neutrophils/Bands      5%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      10%
Lymphocytes           80%
Number of Cells Counted  500
M:E Ratio           1

Morphology:
Spicular and cellular aspirate smears show markedly expanded monotonous lymphoid population, composed predominantly of small cells with round nuclei, clumped chromatin, inconspicuous nucleoli and scant cytoplasm. Maturing myeloid and erythroid elements are markedly reduced. Megakaryocytes are present. Blasts are not increased.  

PERIPHERAL BLOOD
CBC (06/05/2019):
WBC 4.9 [4.0-11.0 K/mcL] 
RBC 4.53 [3.95-5.54 M/mcL] 
HGB 14.3 [12.5-16.2 g/dL] 
HCT 42.8 [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 31.6 [27.0-33.0 pg] 
MCHC 33.4 [31.0-36.5 g/dL] 
RDW 13.1 [12.2-15.1 %] 
Platelets 235 [160-400 K/mcL] 

Neutrophil 71.4 [32.5-74.8 %] 
Mono 7.1 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.4 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 19.5 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 3.5 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL]

Morphology:
WBC: Few atypical lymphoid cells. 
RBC: Unremarkable morphology. 
PLT: Unremarkable morphology.

IMMUNOHISTOCHEMISTRY
The neoplastic cells (comprising ~80% marrow cellularity)
Express: CD20, CD5, CD23 (partial weak), LEF1 and PAX5  
Do not express: CyclinD1  
Others:
CD3 highlights scattered small T cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-5163)
Interpretation: 
Abnormal B-cell population identified.

Flow cytometry identified an abnormal B-cell population having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23 (partial), CD200 (bright) and lambda surface light chain restriction (dim); with normal expression of CD19, CD45; and without FMC7, CD10, or CD38 expression. The immunophenotype is diagnostic of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). The abnormal B-cell population comprises 21.4% of the white cells.

CYTOGENETIC STUDIES
Not requested. 

MOLECULAR STUDIES 
Not requested. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-5276;S12;MSK6 - 2023-04-19 09.21.43.ndpi,Peripheral Blood Smear,2023-04-19,"CMML
Assess response to therapy 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent myeloid neoplasm, 4% blasts.
     - Hypercellular marrow with myeloid predominance, left shifted myeloid maturation, adequate erythroid elements and increased megakaryocytic elements with dysplasia and myelofibrosis (MF1-2).  

BONE MARROW BIOPSY
Quality: Adequate. 
Cellularity: Hypercellular (~80-90%)
M:E ratio: Normal 
Blasts: 4%. 
Myeloid lineage: Show left shifted maturation. 
Erythroid lineage: Show full maturation.
Megakaryocytes: Increased and show small and hypolobated dysplastic forms 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows mild to moderate increase in reticulin fibrosis (MF1-2). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Blasts                4% 
Promyelocytes           15%
Myelocytes           25%
Metamyelocytes           13%
Neutrophils/Bands      12%
Monocytes           3%
Erythroid Precursors      19%
Plasma Cells           2%
Lymphocytes           7%
Number of Cells Counted 500
M:E Ratio           3.6

Special stain
Iron: Absent
Ring sideroblasts: Absent

Morphology:
Paucispicular and cellular smears show mildly increased M:E ratio, myeloid precursors with dysplastic and hypogranular morphology and left shifted maturation and erythroid precursors. Few megakaryocytes are seen. 

PERIPHERAL BLOOD
CBC (07/01/2019):
WBC 2.2 L [4.0-11.0 K/mcL] 
RBC 2.79 L [3.95-5.54 M/mcL] 
HGB 8.9 L [12.5-16.2 g/dL] 
HCT 28.7 L [37.5-49.3 %] 
MCV 103 H [80-98 fL] 
MCH 31.9 [27.0-33.0 pg] 
MCHC 31.0 [31.0-36.5 g/dL] 
RDW 17.0 H [12.2-15.1 %] 
Platelets 30 L [160-400 K/mcL] 

Neutrophil 62.0 [32.5-74.8 %] 
Mono 17.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 20.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 1.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBC: Leukopenia, hypogranular neutrophils seen, myeloid left shift with few myelocytes. Circulating blasts are not seen. Relative monocytosis noted. 

IMMUNOHISTOCHEMISTRY
Immunostain for CD117 highlights myeloid and erythroid progenitors and increased mast cells. CD34 highlights endothelial cells and scattered blasts (less than 5%). Tryptase shows mildly increased mast cells. CD61 highlights increased dysplastic megakaryocytes. CD71 highlights adequate erythroid elements.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-6028)
Abnormal myeloid blast and monocyte populations detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in the prior sample (F18-11052) having abnormal expression of CD7 (partial), CD13 (bright), CD33 (dim), CD117 (bright), CD38 (subset bright, subset dim) and HLA-DR (bright); with normal expression of CD4, CD34, CD45, CD71, and CD123; without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 1.8% of WBC. In addition, monocytes are relatively expanded (represent 23.9% of the WBC) and show abnormal CD13 (dim) and CD56 expression.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-4257.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-23648.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-2114;S12;MSKU - 2023-06-20 22.16.21.ndpi,Peripheral Blood Smear,2023-06-20,"MDS. Characterize and stage disease. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     -Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thromobocytosis 
    - Hypercellular marrow with trilineage maturing hematopoiesis, megakaryocytic proliferation and mild to moderate myelofibrosis.
  

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Increased for age (80-90%)
M:E ratio: Normal
Blasts: Not increased
Myeloid lineage: Full maturation
Erythroid lineage: Full maturation
Megakaryocytes: Present in increased numbers, many large forms with hyperchromatic nuclei forming clusters
Lymphocytes: Scattered
Plasma cells: Scattered
Special stain: A reticulin stain reveals a mild to moderate diffuse increase in reticulin fibers (overall moderate 2+/3)

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Hemodilute/hypocellular aspirate devoid of spicules
Numerous platelet clumps are noted.

Blasts                1%
Promyelocytes           1%
Myelocytes           6%
Metamyelocytes           5%
Neutrophils/Bands      47%
Monocytes           3%
Eosinophils           2%
Basophils           1%
Erythroid Precursors      19%
Lymphocytes           15%
Number of Cells Counted 500
M:E Ratio           3.4

Special stain
Iron: Suboptimal for evaluation; devoid of spicules
Ring sideroblasts: >15% 

Morphology:
- Hemodilute/hypocellular aspirate devoid of spicules show trilineage maturing hematopoiesis with no increase in blast. Erythroid dysplasia is seen

PERIPHERAL BLOOD
CBC (03/18/2019):
WBC 9.7 [4.0-11.0 K/mcL] 
RBC 3.03 L [3.95-5.54 M/mcL] 
HGB 9.2 L [12.5-16.2 g/dL] 
HCT 30.3 L [37.5-49.3 %] 
MCV 100 H [80-98 fL] 
MCH 30.4 [27.0-33.0 pg] 
MCHC 30.4 L [31.0-36.5 g/dL] 
RDW 31.1 H [12.2-15.1 %] 
Platelets. 476 H [160-400 K/mcL] 

Neutrophil 61.0 [32.5-74.8 %] 
Lymph 27.0 [12.2-47.4 %] 
Mono 6.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 

Abs Neut 5.9 [1.5-7.5 K/mcL] 
Abs Lymph 2.6 [0.9-3.2 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.4 H [0.0-0.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 8 [/100(WBCs)] 
Morphology: Thrombocytosis, macrocytic anemia with pronounced anisocytosis, poikilocytosis, and polychromasia. Basophilia is seen.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 do not show an increase in blasts 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-2499)
Abnormal myeloid blast populations detected. 
Basophilia seen, representing 2.3% of WBC.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD13(dim), CD25, CD38(dim) with normal expression of CD4, CD33, CD34, CD45, CD71, CD117, CD123 and HLA-DR without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64. CD34 positive myeloid blasts represent 0.57% of WBC.
338,080 cells acquired.
Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition.


No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.


CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-1782.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-10128.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-1422;S11;MSKU - 2023-05-10 20.28.53.ndpi,Peripheral Blood Smear,2023-05-10,"AML.  MDS now new diagnosis of AML (20% circulating blasts) with t(6;9) per report.
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Acute Myeloid Leukemia (AML) (22% blasts by aspirate differential count) (See Comment)
    - Hypercellular bone marrow with trilineage dysplasia and no increase in reticulin fibrosis

COMMENT: Per clinical note, prior cytogenetics studies at an outside lab detected t(6;9)(p22;q34); DEK-NUP214. If confirmed at MSKCC, this case will be best classified as AML with t(6;9)(p22;q34); DEK-NUP214. This subtype of AML is associated with morphologic dysplasia. Of note, the 2017 Update to the W.H.O. classification of myeloid neoplasms mentioned that it remains controversial as to whether cases with this translocation but <20% blasts should be classified as AML. The patient's prior outside marrow biopsy (H19-1298; 2/6/19) showed <20% blasts; however, considering the short time course between that prior biopsy and the current biopsy with >20% blasts, this tumor is likely more biologically similar to a de novo AML case.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (~90% cellularity)
M:E ratio: Normal
Blasts: Expanded population of medium to large sized blasts with irregular nuclei, fine/dispersed chromatin, distinct nucleoli, and small to moderate amount of cytoplasm  
Myeloid lineage: Exhibits left-shifted maturation
Erythroid lineage: Exhibits progressive maturation 
Megakaryocytes: Adequate in number with dysmegakaryopoiesis (hypolobation, hyperchromasia, nuclear lobe separation)
Lymphocytes: Scattered 
Plasma cells: Scattered 

Special stains: A reticulin stain shows no significant increase in reticulin fibers (0/3). 

BONE MARROW ASPIRATE SMEAR/ TOUCH PREPARATION
Differential: (Performed by SS)
Blasts                22% (14%-30%)
Promyelocytes           3%
Myelocytes           12%
Metamyelocytes           8%
Neutrophils/Bands      25%
Monocytes           3%
Basophils           1%
Erythroid Precursors      22%
Plasma Cells           1%
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           2.4

Special stain
Iron: Trace
Ring sideroblasts: Absent

Morphology: 
The aspirate smears are spicular and cellular and show an expanded population of medium to large sized blasts with small amounts of grey-blue cytoplasm, round/ovoid to slightly folded nuclei, dispersed chromatin and distinct nucleoli, in a background of trilineage hematopoiesis. Myeloid elements show left shifted maturation and dysgranulopoiesis (hypogranularity, pseudo Pelger-Huet forms). Erythroid elements show progressive maturation with mild dyserythropoiesis (nuclear irregularities, <10% of lineage). Megakaryocytes are present and show frequent dysmegakaryopoiesis (hypolobation, nuclear lobe separation). 

PERIPHERAL BLOOD
CBC (02/20/2019):
WBC 8.1 [4.0-11.0 K/mcL] 
RBC 3.42 L [3.80-5.00 M/mcL] 
HGB 11.0 L [11.2-15.4 g/dL] 
HCT 33.9 L [34.3-46.0 %] 
MCV 99 H [80-98 fL] 
MCH 32.2 [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL] 
RDW 16.1 H [12.2-15.1 %] 
Platelets. 72 L [160-400 K/mcL] 

Neutrophil 47.0 [32.5-74.8 %] 
Lymph 21.0 [12.2-47.4 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Myelocyte 3.0 H [0.0-0.0 %] 
Promyelocyte 2.0 H [0.0-0.0 %] 
Blast 20.0 H [0.0-0.0 %] 

Abs Neut 3.8 [1.5-7.5 K/mcL] 
Abs Lymph 1.7 [0.9-3.2 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.2 H [0.0-0.0 K/mcL] 
Absolute Blasts 1.6 H [0.0-0.0 K/mcL] 

Megakaryocyte Fragment 2 [/100(WBCs)] 
Nucleated RBC 1 [/100(WBCs)]

Morphology:
WBC: Frequent circulating blasts seen. Granulocytes show frequent dysplastic features (hypogranularity, lobation abnormalities), and left-shifted forms. 
RBC: Mild macrocytic anemia
PLT: Moderate thrombocytopenia.

IMMUNOHISTOCHEMISTRY
CD34-positive blasts comprise ~15% of cellularity.
CD117 highlights blasts, as well as some early myeloid and erythroid precursors.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-1684)
Interpretation: 
Abnormal myeloid blast and granulocyte populations detected. 
No abnormal B and T cell populations detected.

Flow cytometry identified a population of myeloid blasts with similar immunophenotype as the blood sample (F19-1663), and have abnormal expression of CD11b (partial), CD13 (uniform, bright), CD19 (partial dim), CD33 (uniform bright), CD34 (slightly bright), CD117 (bright), and CD123 (uniform bright), HLA-DR (variable, bright to absent); with normal expression of CD4, CD38, CD45, and CD71; without CD2, sCD3, cCD3, CD5, CD7, CD8, CD10, CD14, CD15, CD16, CD20, CD25, CD56, CD64, cCD79a or surface light chains. MPO expression is present on a subset of blasts. The CD34-positive abnormal blasts represent 17.1% of WBC.

In addition, the granulocytes show discontinuity in maturation pattern and brighter expression of CD14.
413,629 cells acquired for myeloid analysis.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified. Hodgkin lymphoma would not be detected by these studies.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F19-1663)
Interpretation: 
Expanded abnormal myeloid blast and maturing granulocyte populations detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD11b (partial dim), CD19 (partial), CD13 (uniform bright), CD33 (uniform bright), CD34 (uniform), CD38 (slightly dim), CD123 (uniform bright) with normal expression of CD4, CD45, CD71, CD117 and HLA-DR without CD2, sCD3, cCD3, CD5, CD7, CD8, CD10, CD14, CD15, CD16, CD20, CD25, CD56, CD64, cCD79a or surface light chains. MPO expression is present on a subset of blasts. In addition, granulocytic population shows discontinuity in maturation pattern as well as brighter expression of CD14. CD34 positive myeloid blasts represent 23.7% of WBC. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-1207.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M19-6730, M19-6731, M19-6732, M19-6734, M19-6736.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-4694;S15;MSKB - 2023-05-19 08.53.04.ndpi,Peripheral Blood Smear,2023-05-19,"CLL now with atypical CML.  Rule out progression of disease.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent therapy related myeloproliferative neoplasm/myelodysplastic syndrome (t-MDS/MPN) (2% blasts on aspirate). See comment. 
     - No morphologic or immunophenotypic evidence of involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Comment: 
Cytogenetic and molecular studies have ruled out CML. Recent molecular genetic study (see M19-10368) has demonstrated CSF3R mutations in combination with ASXL1 and ZRSR2. Such mutational profile is common in chronic neutrophilic leukemia (CNL) or atypical CML, however presence of left shifted myeloid forms (>10%) argue against CNL, a diagnosis of atypical CML is favored in the current sample. Clinical correlation is recommended. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (90-95%)
M:E ratio: Increased 
Blasts: Not increased in number 
Myeloid lineage: Markedly increased in number and show left shifted maturation 
Erythroid lineage: Markedly reduced 
Megakaryocytes: Reduced in number and show no overt atypia 
Lymphocytes: Rare 
Plasma cells: Rare. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by AS)
Blasts                2%
Promyelocytes           9%
Myelocytes           19%
Metamyelocytes           12%
Neutrophils/Bands      53%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      2%
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           47.5

Morphology:
-Spicular and cellular aspirate smears show markedly myeloid hyperplasia. There is no expanded blast population. The M:E ratio is overtly increased. Myeloid elements are overtly increased and show left shifted maturation with occasional dyspoiesis (hypogranulation and abnormal segmentation). Erythroid elements are relatively reduced in number and show progressive maturation. Megakaryocytes are seen with no overt atypia. 

PERIPHERAL BLOOD
CBC (06/11/2019):
WBC 109.6 H [4.0-11.0 K/mcL] 
RBC 2.81 L [3.95-5.54 M/mcL] 
HGB 9.5 L [12.5-16.2 g/dL] 
HCT 28.2 L [37.5-49.3 %] 
MCV 100 H [80-98 fL] 
MCH 33.8 H [27.0-33.0 pg] 
MCHC 33.7 [31.0-36.5 g/dL] 
RDW 22.4 H [12.2-15.1 %] 
Platelets 49 L [160-400 K/mcL] 

Neutrophil 66.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 1.0 H [0.0-0.0 %] 
Myelocyte 13.0 H [0.0-0.0 %] 
Promyelocyte 8.0 H [0.0-0.0 %] 
Metamyelocyte 8.0 H [0.0-0.0 %] 
Lymph 1.0 L [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 72.3 H [1.5-7.5 K/mcL] 
Abs Mono 2.2 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 1.1 H [0.0-0.2 K/mcL] 
Absolute Blasts 1.1 H [0.0-0.0 K/mcL] 
Abs Myelocytes 14.2 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 8.8 H [0.0-0.0 K/mcL] 
Abs Meta 8.8 H [0.0-0.0 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 

Morphology:
WBC: Leukocytosis with absolute neutrophilia, significant left shift, a subset hypogranular neutrophils and rare blasts seen. Mild basophilia. 
RBC: Macrocytic anemia with anisopoikilocytosis; nucleated RBC's seen  
Platelets: Thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 are negative 
CD3 and CD5 highlight scattered small reactive T-cells 
LEF1 highlights subset of T-cells
CD23 highlights rare scattered cells 
CyclinD1 highlight scattered histiocytes and endothelial cells
CD34 and CD117 shows no increase in blasts (<5% positivity of bone marrow cellularity)
CD34 also highlights vasculature 
CD117 also highlights myeloid, erythroid precursors and scattered mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-5392)
Abnormal myeloid blast population detected. 
No abnormal mature B- cell populations detected. 

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD25 (subset, >40%, also on CD38 positive cells), CD56 (partial, on the CD25 positive cells), CD13 (slightly bright), CD33 (bright), CD117 (slightly bright), HLADR (bright) with normal expression of CD4, CD34, CD38, CD45, CD71 and CD123; without CD2, CD7, CD11b, CD14, CD15, CD16, CD19 or CD64. CD34 positive myeloid blasts represent 0.12% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-3832.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-21145.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-8719;S13;MSKB - 2023-06-20 10.03.13.ndpi,Peripheral Blood Smear,2023-06-20,"Multiple myeloma. Staging. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
90% involvement by CD138 immunohistochemistry.
Comment: no flow cytometry sample was sent, the phenotype of the plasma cells could not be determined

BONE MARROW BIOPSY
Quality: Inadequate, hemorrhage  
Cellularity: Cannot be precisely estimated
Myeloid lineage: Few
Erythroid lineage: Few
Megakaryocytes: Present
Plasma cells: Increased    
Clot section: Some crushed marrow elements present

ASPIRATE MORPHOLOGY

Aspirate differential: (Not performed: SS)
Only 1 aspirate and 2 touch prep slides available for evaluation
The majority of cells seen are plasma cells and lymphocytes.  

Morphology: 
Marrow spicules: Aspicular.
Cellularity: N/A
Plasma cell morphology: Small to intermediate, bi/multi nucleated, Nucleolated  
Myeloid lineage: Orderly maturation, decreased   
Erythroid Lineage: rare seen
Megakaryocytes: N/A
Other findings: Osteoblasts, osteoclasts seen on touch imprints

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 90% of cellularity. 
Kappa and lambda immunostains show the plasma cells are lambda light chain restricted.  
BCMA highlights 100% of plasma cells, (2+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW 
Not requested

PERIPHERAL BLOOD
CBC (10/29/2019):
WBC 4.7 [4.0-11.0 K/mcL] 
RBC 2.79 L [3.80-5.00 M/mcL] 
HGB 8.7 L [11.2-15.4 g/dL] 
HCT 25.7 L [34.3-46.0 %] 
MCV 92 [80-98 fL] 
MCH 31.2 [27.0-33.0 pg] 
MCHC 33.9 [31.0-36.5 g/dL] 
RDW 13.9 [12.2-15.1 %] 
Platelets. 61 L [160-400 K/mcL] 

Neutrophil 50.1 [32.5-74.8 %] 
Mono 14.7 H [0.0-12.3 %] 
Eos 1.7 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 1.1 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 32.0 [12.2-47.4 %] 
Nucleated RBC 0.4 [%]
 
Abs Neut 2.4 [1.5-7.5 K/mcL] 
Abs Mono 0.7 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.5 [0.9-3.2 K/mcL]

Morphology:
No circulating plasma cells seen on scanning
Rouleaux formation

CYTOGENETIC STUDIES
Not requested

MOLECULAR STUDIES 
Not requested

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

     
"
H19-6497;S12;MSKB - 2023-04-25 15.38.46.ndpi,Peripheral Blood Smear,2023-04-25,"CML. pb remission.
","1-3. Bone marrow, right posterior iliac crest, biopsy, clot section, aspirate and peripheral blood smears: 
     - Persistent low-level involvement by chronic myeloid leukemia, BCR-ABL1 positive, 4% blasts by aspirate differential count. 
     - Hypercellular marrow with trilineage maturing hematopoiesis.
 
COMMENT: Fluorescence in situ hybridization (FISH) detected BCR-ABL1 fusion/t(9;22) in 1.3% of cells (CG19-5219), and quantitative polymerase chain reaction (PCR) detected BCR-ABL1 p210 fusion gene transcript, approximately 1.85992% (IS) (M19-29317). The findings are consistent with low-level involvement by chronic myeloid leukemia. 

BONE MARROW BIOPSY
Quality: Adequate. 
Cellularity: Hypercellular for age, approximately 60-70% cellularity.  
M:E ratio: Within normal limits. 
Blasts: Not increased.
Myeloid lineage: Orderly maturation. 
Erythroid lineage: Orderly maturation.
Megakaryocytes: Adequate in number with occaisonal small, hypolobated forms.
Lymphocytes: Scattered. 
Plasma cells: Not increased. 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (0-1+/3). 
Clot section: Consists predominantly of blood with minimal marrow elements.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                4% 
Promyelocytes           9%
Myelocytes           12%
Metamyelocytes           6%
Neutrophils/Bands      20%
Monocytes           4%
Eosinophils           12%
Basophils           2%
Erythroid Precursors      19%
Plasma Cells           4%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           3.4

Morphology:
Spicular and cellular bone marrow aspirate shows trilineage maturing hematopoiesis. There is no increase in blasts. Myeloid are adequate in proportion with slightly left shifted bu progressive maturation and unremarkable morphology. Erythroid elements are adequate in proportion with orderly maturation and mostly unremarkable morphology. Megakaryocytes are present with mostly unremarkable morphology and few small, hypolobated forms.

PERIPHERAL BLOOD
CBC (08/13/2019):
WBC 4.2 [4.0-11.0 K/mcL] 
RBC 3.19 L [3.95-5.54 M/mcL] 
HGB 9.7 L [12.5-16.2 g/dL] 
HCT 29.6 L [37.5-49.3 %] 
MCV 93 [80-98 fL] 
MCH 30.4 [27.0-33.0 pg] 
MCHC 32.8 [31.0-36.5 g/dL] 
RDW 16.5 H [12.2-15.1 %] 
Platelets 383 [160-400 K/mcL]
 
Neutrophil 63.3 [32.5-74.8 %] 
Mono 11.6 [0.0-12.3 %] 
Eos 1.7 [0.0-4.9 %] 
Baso 2.7 H [0.0-1.5 %] 
Immature Granulocyte 1.4 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 19.3 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 2.6 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 

Morphology:
RBC: Normocytic, normochromic anemia 
WBC: Relative basophilia, slight left shift present, no circulating blasts seen.
PLT: Occasional large forms present. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 immunohistochemical stains show no increase in blasts (<5%).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-7535)
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal immature B-cell population is detected. 

CD34 positive myeloid blast population with apparent normal immunophenotype is 2.1% of WBC.
361,080 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Immature B-cells with normal immunophenotype by this method account for 0.19% of WBC following erythroid lysis. 
4,027,952 cells acquired.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available.

CYTOGENETIC STUDIES (CG19-5219)
FISH ANALYSIS:
BCR-ABL1 fusion/t(9;22) detected in 1.3% of cells.

Chromosome analysis is in progress and will be reported as an addendum separately in CG19-5219.

MOLECULAR STUDIES (M19-29317)
BCR-ABL1 p210 fusion gene transcript DETECTED.

After normalization and standardization to the international scale (IS), the level of positivity for BCR-ABL1 transcript (p210) is approximately 1.85992% (IS).

Additional molecular analysis will be reported separately. See separate report, M19-29316.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-8975;S11;MSKD - 2023-06-20 11.34.44.ndpi,Peripheral Blood Smear,2023-06-20,"AML. AML status post double cord blood transplant on 5/4/18. 
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - No diagnostic morphologic or immunophenotypic evidence of acute myeloid leukemia.
    - Normocellular bone marrow with maturing trilineage hematopoiesis and mildly increased hematogones; see comment.

COMMENT: The findings of mildly increased hematogones (immature B-cell precursors) is nonspecific and can be seen post-transplant for myeloid neoplasia. No definite evidence of acute myeloid leukemia is seen. 

BONE MARROW BIOPSY
Quality: Suboptimal (small fragmented biopsy) 
Cellularity: Normocellular (~50%)
M:E ratio: Reduced
Blasts: Not increased (<5%) 
Myeloid lineage: Relatively decreased, exhibits full maturation 
Erythroid lineage: Relatively increased, exhibits full maturation 
Megakaryocytes: Mildly reduced with occasional hyperchromasia 
Lymphocytes: Mildly increased, with focal small lymphoid aggregates seen
Plasma cells: Scattered 
Special stains: A reticulin stain shows a minimal to mild increase in reticulin fibers (0-1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)
Blasts                3% 
Promyelocytes           1%
Myelocytes           4%
Metamyelocytes           5%
Neutrophils/Bands      17%
Monocytes           1%
Eosinophils           3%
Erythroid Precursors      22%
Plasma Cells           1%
Lymphocytes           43%  
Number of Cells Counted 500
M: E Ratio           1.4

Morphology: The aspirate smears are spicular, cellular and show maturing trilineage hematopoiesis; no expanded blast population is seen. There is mild lymphocytosis with focally increased hematogones. Erythroid and myeloid elements show progressive maturation with relative erythroid hyperplasia. Megakaryocytes are reduced but morphologically unremarkable. 

PERIPHERAL BLOOD
CBC (11/07/2019):
WBC 5.7 [4.0-11.0 K/mcL] 
RBC 3.29 L [3.80-5.00 M/mcL] 
HGB 11.5 [11.2-15.4 g/dL] 
HCT 33.3 L [34.3-46.0 %] 
MCV 101 H [80-98 fL] 
MCH 35.0 H [27.0-33.0 pg] 
MCHC 34.5 [31.0-36.5 g/dL] 
RDW 12.0 L [12.2-15.1 %] 
Platelets 91 L [160-400 K/mcL] 

Neutrophil 39.0 [32.5-74.8 %] 
Mono 13.0 H [0.0-12.3 %] 
Eos 6.0 H [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 41.0 [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 2.2 [1.5-7.5 K/mcL] 
Abs Mono 0.7 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Lymph 2.3 [0.9-3.2 K/mcL]

Morphology:
WBC: Unremarkable morphology.
RBC: Mild macrocytosis.
PLT: Mild thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains show no increases in CD34 and/or CD117 positive myeloid blasts (<5%). 
CD34 and TdT highlight a focal mild increase in hematogones (immature B-cell precursors), which co-express PAX5. CD3 highlights scattered T-cells and small T-cell aggregates.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-10590)
No abnormal myeloid blast population identified. 

CD34 positive myeloid blast population with apparent normal immunophenotype is 2.6% of WBC.
276,250 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with cytogenetic and molecular genetic studies may provide additional information on minimal residual disease status.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7111.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-41181, M19-41182.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-8548;S10;MSKI - 2023-05-31 12.14.27.ndpi,Peripheral Blood Smear,2023-05-31,"Lymphoma
MCL, Most- Recently Treated with Ibrutinib, with POD
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involved by mantle cell lymphoma (60% with CD20 immunohistochemistry)
     - Normocellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show normocellular bone marrow (~40% cellularity). There istrilineage maturing hematopoiesis with diffuse interstitial infiltrate of intermediate sized lymphocytes with irregular nuclei, fine to clumped chromatin and variably conspicuous nucleoli.

Aspirate differential: (Performed by CB)
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      10%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      18%
Plasma Cells           1%
Lymphocytes           4%
Other cells              59% 
Number of Cells Counted 500
M:E Ratio           1

IMMUNOHISTOCHEMISTRY
CD20 and PAX-5 immunostains highlight the increased number of lymphoid cells throughout the interstitium focally in a sinusoidal pattern (~60% of total cellularity). CyclinD1 is positive in tumor cells. CD3 labels background reactive T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-10021) 
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD20 (bright), CD23 (partial) and Lambda surface light chain restriction (bright); normal expression of CD19, CD22, CD38, CD45, FMC7; and without CD10 or CD200. The abnormal B cell population represents 45.7% of total white cells. This immunophenotype is compatible with previously diagnosed mantle cell lymphoma (MCL).

PERIPHERAL BLOOD
CBC (10/23/2019)
WBC 26.3 H [4.0-11.0 K/mcL] 
RBC 3.79 L [3.80-5.00 M/mcL] 
HGB 11.3 [11.2-15.4 g/dL] 
HCT 36.1 [34.3-46.0 %] 
MCV 95 [80-98 fL] 
MCH 29.8 [27.0-33.0 pg] 
MCHC 31.3 [31.0-36.5 g/dL] 
RDW 14.7 [12.2-15.1 %] 
Platelets 161 [160-400 K/mcL] 

Neutrophil 19.0 L [32.5-74.8 %] 
Mono 6.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 5.0 L [12.2-47.4 %] 
Other 70.0 H [0.0-0.0 %] 
Abnormal lymphoid cells.
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 5.0 [1.5-7.5 K/mcL] 
Abs Mono 1.6 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 
Abs Others 18.4 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBCs: Leukocytosis with frequent circulating lymphomatous cells with fine chromatin and distinct nucleoli. 
RBCs: Normocytic, normochromic RBCs 
Platelets: Unremarkable.  

CYTOGENETIC STUDIES
Not performed 

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-39042.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-9623;S17;MSKA - 2023-06-20 13.26.24.ndpi,Peripheral Blood Smear,2023-06-20,"CLL. CLL with new pancytopenia, questionable MDS. 
","1-3. Bone marrow left posterior iliac crest, biopsy; aspirate and peripheral blood smears:  
     - High grade myeloid neoplasm morphologically consistent with chronic myelomonocytic leuekemia-2 (11% blasts by aspirate differential count), see comment. 
     -Low level involvement by previously diagnosed B cell neoplasm, by flow cytometry only.

Comment: Previous therapy for reported CLL is unclear (also see flow cytometry report for diagnostic consideration of the B cell neoplasm, review of original diagnostic sample would be helpful). If the patient is known to have received therapy associated with increased risk of myeloid malignancy, the myeloid neoplasm would be best classified as therapy related with further classification irrelevant to the clinical behavior. Clusters of plasmacytoid dendritic cells are seen, which have been previously described in CMML and may be associated with more aggressive clinical behavior. See ref below.

Ref: Leukemia. 2019 Oct;33(10):2466-2480.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Approximately 80-90% cellularity, hypercellular for age
M:E ratio: N/A
Blasts: Not increased
Myeloid lineage: Orderly maturation
Erythroid lineage: Markedly reduced
Megakaryocytes: Markedly reduced with small hyperchromatic, hypolobated forms
Lymphocytes: No increased, small, favor reactive aggregates seen.
Plasma cells: Not increased
Other: several clusters of plasmacytoid dendritic cells are seen, best visualized by CD123 stain
Clot section: Similar to biopsy

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)

Blasts                11%
Promyelocytes           5%
Myelocytes           19%
Metamyelocytes           2%
Neutrophils/Bands      44%
Monocytes           4%
Eosinophils           1%
Basophils           2%
Erythroid Precursors      4%
Plasma Cells           1%
Lymphocytes           7%
Number of Cells Counted 500
M:E Ratio           19.2

Special stain:
Iron: Suboptimal; devoid of spicules.
Ring Sideroblasts: Suboptimal for evaluation due to limited erythroid activity.

Morphology:
- Blasts are increased. Myeloid precursors are orderly maturing with no overt dysplasia. Erythroid elements are markedly reduced with occasional atypical forms (binucleation, megaloblastic changes). Megakaryocytes are rare. 

PERIPHERAL BLOOD
CBC (12/02/2019):
WBC 3.9 L [4.0-11.0 K/mcL] 
RBC 2.98 L [3.95-5.54 M/mcL] 
HGB 9.0 L [12.5-16.2 g/dL] 
HCT 27.5 L [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 30.2 [27.0-33.0 pg] 
MCHC 32.7 [31.0-36.5 g/dL] 
RDW 20.5 H [12.2-15.1 %] 
Platelets. 39 L [160-400 K/mcL] 

Neutrophil 24.0 L [32.5-74.8 %] 
Mono 44.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 3.0 H [0.0-1.5 %] 
Lymph 29.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 1.7 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL]

Morphology:
WBC: Neutropenia with left shift, monocytosis, blasts noted <5%, basophilia. 
RBC: Normocytic anemia.
PLT: Marked thrombocytopenia

IMMUNOHISTOCHEMISTRY
CD34 highlights increased blasts (approximately 10%), CD117 shows similar number of blasts with weak staining. CD123 shows several plasmacytoid dendritic cell aggregates. CD61 shows rare megakaryocytes, including small forms

CD3 and CD5 highlight T cells. CD20 and PAX5 highlights rare B cells. CD23, LEF1 are non-contributory, Cyclin D1 does not highlight lymphoid cells. The lymphoid aggregates are composed by predominantly T cells with a few B cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-11455)
Abnormal myeloid blast population detected. Monocytosis is seen (15% WBC)
Abnormal B cell population detected.
No abnormal mature T-cell population detected.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD34 (bright), CD38 (negative to intermediate), CD56 (major subset), with normal expression of CD4, CD13, CD33, CD45, CD71 and HLADR, and without CD2, CD7, CD5, CD14, CD15, CD16, CD19, CD64. CD34 positive myeloid blasts represent 8.9% of WBC. 

Plasmacytoid dendritic cell population exceeds 1% of WBC, which in this laboratory's experience is associated with more aggressive clinical course.  

In addition, flow cytometry reveals a very small abnormal mature B-cell population with abnormal expression of CD5 and lambda light chain restriction (dim), and normal expression of CD19, CD20, CD22, CD38 and CD45; and without CD10, CD23 or CD200. The abnormal B-cell population represents 0.0061% of the total white cells. The phenotype is NOT diagnostic for CLL and raises a possibility of a different lymphoproliferative neoplasm including mantle cells lymphoma, although CLL/SLL is not excluded. Clinical correlation is advised. 

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.
FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7621, CG19-7622.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-44454, M19-44455 and M19-44457. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-8483;S11;MSK8 - 2023-05-31 12.26.26.ndpi,Peripheral Blood Smear,2023-05-31,"Multiple myeloma. Multiple myeloma status post multiple therapies including T-cells. Screen, pre-t, d11, d29. Protocol#: 18-043. 
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
30% involvement by CD138 immunohistochemistry
20% involvement by aspirate differential
6.5% involvement by 10-color flow cytometry
     - Variably cellular marrow with maturing trilineage hematopoiesis.

BONE MARROW BIOPSY
Quality: Adequate with some aspiration artifact
Cellularity: Variably cellular (range <5% to 70%, overall ~40%)
Myeloid lineage: Progressive maturation    
Erythroid lineage: Progressive maturation    
Megakaryocytes: Adequate in number with few hypolobated forms and bare nuclei 
Plasma cells: Increased    

ASPIRATE MORPHOLOGY
Aspirate differential: (Performed by: SS)

Blasts                1%
Promyelocytes           1%
Myelocytes           8%
Metamyelocytes           4%
Neutrophils/Bands      30%
Monocytes           2%
Eosinophils           7%
Erythroid Precursors      18%
Plasma Cells           20% 
Lymphocytes           9%
Number of Cells Counted 500
M:E Ratio           2.9

Morphology: 
Marrow spicules: Spicular    
Cellularity: Cellular
Plasma cell morphology: Range from small to large in size with occasional prominent nucleoli, occasional bi/multinucleated forms and occasional Dutcher bodies   
Myeloid lineage: Progressive maturation. Eosinophils appear mildly increased.   
Erythroid Lineage: Progressive maturation with rare forms showing nuclear irregularity/budding or karyorrhexis 
Megakaryocytes: Present with few small, hypolobated forms and forms with disjointed nuclear lobes
Other: Scattered mast cells are seen

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells present in a patchy distribution as single cells and in variably sized clusters comprising ~30% of the marrow cellularity overall. 
Kappa and lambda immunostains show the plasma cells are lambda light chain restricted.  
BCMA highlights ~80% of plasma cells, (1-2+) intensity, membranous, cytoplasmic and Golgi patterns. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-9954) 
Interpretation: 
Abnormal plasma cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
Eosinophilia is seen.

Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (absent), CD27 (absent to dim), CD45 (major subset absent), CD56, CD81 (absent), CD117 (partial dim) and monoclonal lambda cytoplasmic light chain restriction; with normal expression of CD38 and CD138. The abnormal population represents 6.5% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 96.4% of total plasma cells in the sample. 

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.53% of WBC.
395430 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required. 

Eosinophilia is noted, representing 8.5% of the WBC.

PERIPHERAL BLOOD
CBC (10/21/2019):
WBC 3.4 L [4.0-11.0 K/mcL] 
RBC 2.94 L [3.80-5.00 M/mcL] 
HGB 8.3 L [11.2-15.4 g/dL] 
HCT 26.8 L [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 28.2 [27.0-33.0 pg] 
MCHC 31.0 [31.0-36.5 g/dL] 
RDW 15.8 H [12.2-15.1 %] 
Platelets 150 L [160-400 K/mcL] 

Neutrophil 60.9 [32.5-74.8 %] 
Mono 10.4 [0.0-12.3 %] 
Eos 11.5 H [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 16.3 [12.2-47.4 %] 

Nucleated RBC 0.0 [%] 

Abs Neut 2.1 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 0.6 L [0.9-3.2 K/mcL]

Morphology:
WBC: Leukopenia with relative eosinophilia. No plasma cells seen on scanning.
RBC: Normochromic, normocytic anemia.
Platelets: Mild thrombocytopenia.

CYTOGENETIC STUDIES
Not requested

MOLECULAR STUDIES 
Not requested

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-475;S12;MSK2 - 2023-06-21 17.43.15.ndpi,Peripheral Blood Smear,2023-06-21,"Myelodysplastic Syndrome.  MDS, status post decitabine, pre-transplant. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent myeloid neoplasm with 8% blasts, marked megakaryocytic dysplasia and increased ring sideroblasts. See comment.

Comment:
Per clinical notes, the patient had persistent monocytosis from 5/18 to 7/2018, favoring CMML-1. 

BONE MARROW BIOPSY
Quality: adequate 
Cellularity: 90%
M:E ratio: reduced
Blasts: increased
Myeloid lineage: reduced
Erythroid lineage: increased
Megakaryocytes: increased, marked dysplasia
Lymphocytes: rare 
Plasma cells: rare 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1/3). 
Clot section: blood only

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Hypo/hemodiluted aspirate devoid of spicules
Blasts                8%
Promyelocytes           2%
Myelocytes           6%
Metamyelocytes           3%
Neutrophils/Bands      24%
Monocytes           4%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      34%
Lymphocytes           17%
Number of Cells Counted 500
M:E Ratio           1.2

Special stain
Iron: Suboptimal for evaluation due to poor quality of smears
Ring sideroblasts: Present >15% 

Morphology: 
Aspicular smear with scattered precursors. Blasts are mildly increased. Erythroid precursors show mild dysplasia (nuclear irregularity). Megakaryocytes are not seen. Myeloid precursors are left shifted. 

PERIPHERAL BLOOD
CBC (01/17/2019):
WBC 2.4 L [4.0-11.0 K/mcL] 
RBC 3.22 L [3.95-5.54 M/mcL] 
HGB 9.0 L [12.5-16.2 g/dL] 
HCT 29.7 L [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 28.0 [27.0-33.0 pg] 
MCHC 30.3 L [31.0-36.5 g/dL] 
RDW 21.2 H [12.2-15.1 %] 
Platelets. 38 L [160-400 K/mcL] 

Neutrophil 27.0 L [32.5-74.8 %] 
Lymph 47.0 [12.2-47.4 %] 
Mono 17.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 3.0 H [0.0-1.5 %] 

Abs Neut 0.6 L [1.5-7.5 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 

Myelocyte 1.0 H [0.0-0.0 %] 
Blast 5.0 H [0.0-0.0 %] 

Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 

Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 3 [/100(WBCs)]

Morphology: many circulating blasts; pancytopenia

IMMUNOHISTOCHEMISTRY
CD34 stains predominantly Megakaryocytes. A minor subset of blasts are dimly positive for CD34. CD117 stains scattered mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-543)
Abnormal myeloid blast population detected.
Mild basophilia observed.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample (F18-10702) have abnormal expression of CD7 (minute subset), CD19 (minute subset), CD25 (minute subset), CD56 (partial), CD13 (dim to normal), CD33 (absent), CD34 (dim), CD38 (dim), CD117 (dim) and HLA-DR (absent); with normal expression of CD4, CD45, CD71 and CD123; without CD2, CD5, CD11b, CD14, CD15, CD16 or CD64. CD34 positive myeloid blasts represent 7.4% of WBC. In addition, increased basophils are seen representing 2.2% of the WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-418.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-2109.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-607;S11;MSK8 - 2023-05-10 19.46.20.ndpi,Peripheral Blood Smear,2023-05-10,"CML. 47-year-old man with low grade pancreatic cancer, now with likely CML. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia, chronic phase (CML, 1% blasts by aspirate differential count). 

Comment: 
Preliminary results (CG19-531) showed t(9;22)/BCR-ABL1 translocation. 
  
BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (70-80%)
M:E ratio: Increased 
Blasts: Not increased in number 
Myeloid lineage: Increased in proportion and show left shift in maturation 
Erythroid lineage: Decreased in proportion and show progressive maturation 
Megakaryocytes: Increased in number and show small hypo segmented forms 
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                1%
Promyelocytes           9%
Myelocytes           21%
Metamyelocytes           10%
Neutrophils/Bands      32%
Monocytes           3%
Eosinophils           6%
Basophils           3%
Erythroid Precursors      10%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           8.4

Morphology:
- Aspirate smears (spicular and cellular) show maturing trilineage hematopoiesis. There is no expanded blast population. Myeloid elements are increased in proportion and show left shifted maturation with unremarkable morphology. Erythroid elements are decreased in proportion and show progressive maturation. Megakaryocytes are increased in number and show small hypo segmented forms. There is an increase in eosinophils and basophils.  

PERIPHERAL BLOOD
CBC (01/23/2019):
WBC 88.4 H [4.0-11.0 K/mcL] 
RBC 3.76 L [3.95-5.54 M/mcL] 
HGB 10.5 L [12.5-16.2 g/dL] 
HCT 33.8 L [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 27.9 [27.0-33.0 pg] 
MCHC 31.1 [31.0-36.5 g/dL] 
RDW 20.5 H [12.2-15.1 %] 
Platelets 512 H [160-400 K/mcL]
 
Neutrophil 53.0 [32.5-74.8 %] 
Lymph 8.0 L [12.2-47.4 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 6.0 H [0.0-1.5 %] 

Abs Neut 46.8 H [1.5-7.5 K/mcL] 
Abs Lymph 7.1 H [0.9-3.2 K/mcL] 
Abs Mono 6.2 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.8 H [0.0-0.7 K/mcL] 
Absolute Basophil 5.3 H [0.0-0.2 K/mcL] 

Metamyelocyte 9.0 H [0.0-0.0 %] 
Myelocyte 15.0 H [0.0-0.0 %] 

Abs Meta 8.0 H [0.0-0.0 K/mcL] 
Abs Myelocytes 13.3 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Leukocytosis with absolute neutrophilia, lymphocytosis and monocytosis 
       Absolute basophilia and eosinophilia 
       Left shifted granulopoiesis with occasional blasts seen (<1%)
RBC:  Normocytic normochromic anemia with anisopoikilocytosis; nucleated RBC's seen  
Platelets: Thrombocytosis

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlights scattered blasts (<5% positivity of bone marrow cellularity)
CD34 also highlights prominent vasculature 
CD117 also highlights myeloid/erythroid precursors. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-708)
Abnormal myeloid blast population detected. 
Mild eosinophilia and basophilia observed.
No abnormal mature B- or T-cell populations detected.

Flow cytometry identifies an abnormal erythroid biased myeloid blast population having abnormal expression of CD13 (major subset absent, minute subset bright), CD15 (minute subset), CD33 (major subset dim, minor subset bright), CD34 (dim), CD38 (uniform), CD71 (bright), CD117 (partial dim), CD123 (dim) and HLA-DR (dim to bright); with normal expression of CD4 and CD45; without CD2, CD5, CD7, CD11b, CD14, CD16, CD19, CD25, CD56 or CD64. The abnormal myeloid blasts represent 3.0% of WBC. In addition, increased eosinophils and basophils are seen representing 5.3% and 1.3% of the WBC respectively.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not submitted. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-531 and CG19-536.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-2774, M19-2776, M19-2777, M19-2779, M19-2787 and M19-2970. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-5716;S12;MSK5 - 2023-04-25 15.44.35.ndpi,Peripheral Blood Smear,2023-04-25,"MDS/MPN
Leukocytosis suspect CMML vs CML 
","AMENDMENT DETAIL:
Reason for Amendment:          change in molecular profile

Report Section Changed:     Diagnosis Interpretation  

Description of Change:           Please review changes below by Dr. Sen

Note: This document represents an amended version of the Hematopathology report originally issued on 7/18/2019.


1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Hypercellular marrow with myeloid hyperplasia with left shifted maturation, myeloid and megakaryocytic dyspoiesis, absolute peripheral blood monocytosis and increased ring sideroblasts consistent with myeloid neoplasm. 
     - BCR-ABL1 fusion/t(9;22) detected in 94.7% of cells by cytogenetic studies.
     - Abnormal B-cell population identified (0.069% of total white cells) by flow cytometry.
     - Abnormal plasma cell population detected (0.0014% of the total white cells) by flow cytometry.
      
COMMENT: The findings are consistent with chronic myeloid leukemia, BCR-ABL1 positive. 

BONE MARROW BIOPSY
Small subcortical biopsy with limited marrow space showing hypercellular marrow (100%) with increased megakaryocytes with dysplastic features, erythroid elements present, myeloid elements with left shifted but complete maturation. 
Special stains: Reticulin stain in limited marrow available shows no increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                12%
Promyelocytes           8%
Myelocytes           28%
Metamyelocytes           12%
Neutrophils/Bands      22%
Monocytes           10%
Eosinophils           1%
Erythroid Precursors      3%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           27

Special stain
Iron: Present
Ring sideroblasts: Present >15% 

Morphology:
-Spicular and cellular smears show predominantly myeloid elements with left shifted maturation, dyspoietic changes including abnormal nuclear lobation and cytoplasmic hypogranulation, reduced erythroid elements and few megakaryocytes. 

PERIPHERAL BLOOD
CBC (07/16/2019):
WBC 81.5 H [4.0-11.0 K/mcL] 
RBC 3.09 L [3.95-5.54 M/mcL] 
HGB 9.2 L [12.5-16.2 g/dL] 
HCT 29.8 L [37.5-49.3 %] 
MCV 96 [80-98 fL] 
MCH 29.8 [27.0-33.0 pg] 
MCHC 30.9 L [31.0-36.5 g/dL] 
RDW 23.4 H [12.2-15.1 %] 
Platelets 166 [160-400 K/mcL] 

Neutrophil 54.0 [32.5-74.8 %] 
Mono 20.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 6.0 H [0.0-0.0 %] 
Metamyelocyte 16.0 H [0.0-0.0 %] 
Lymph 4.0 L [12.2-47.4 %] 

Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 44.0 H [1.5-7.5 K/mcL] 
Abs Mono 16.3 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 4.9 H [0.0-0.0 K/mcL] 
Abs Meta 13.0 H [0.0-0.0 K/mcL] 
Abs Lymph 3.3 H [0.9-3.2 K/mcL]

Morphology: Leukocytosis, neutrophils with abnormal nuclear lobation and hypogranulation, myeloid precursors, monocytosis

IMMUNOHISTOCHEMISTRY
Immunostains for CD34 and CD117 show no increase in blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-6569)
Abnormal myeloid blast and monocyte populations detected. 
Abnormal B-cell population identified.
Abnormal plasma cell population detected.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD7 (small subset), CD25 (subset), CD56 (subset), CD33 (subset dim, subset bright), CD38 (subset dim), CD117 (bright), CD123 (subset bright), HLADR (subset bright) with normal expression of CD4, CD13, CD34, CD45, CD71; without CD2, CD5, CD11b, CD14, CD15, CD16, CD19 or CD64. Monocytes show partial expression of CD56. CD34 positive myeloid blasts represent 0.15% of WBC.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, and kappa surface light chain restriction (low); normal expression of CD19, CD20, CD22, FMC7, CD38 (absent) and CD45; and without CD10, CD23 or CD200. The abnormal B cell population represents 0.069% of total white cells.
While the immunophenotype is not fully specific, it raises the possibility of mantle cell lymphoma. Cell sorting will be attempted and if successful, the sorted cells will be sent for cytogenetic FISH testing for CCND1 rearrangement.  

Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (absent), CD45 (absent), and monoclonal lambda cytoplasmic light chain restriction; with normal expression of CD27, CD38, CD81 and CD138; and without CD20, CD56, or CD117 expression. The abnormal population represents 0.0014% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 28.1% of total plasma cells in the sample.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
BCR-ABL1 fusion/t(9;22) detected in 94.7% of cells by cytogenetic studies. 

MOLECULAR STUDIES 
BCR-ABL1 p210 fusion gene transcript DETECTED

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-10014;S12;MSKB - 2023-06-20 16.27.24.ndpi,Peripheral Blood Smear,2023-06-20,"MDS-EB2. Bone marrow RPIC, day +97 status post matched related CD34+ alloHCT for MDS-EB2 vs AML pretransplant. 
Protocol #: treatment plan. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - No morphologic or immunophenotypic involvement by myelodysplastic syndrome
     - Cellular marrow with trilineage maturing hematopoiesis with increased hematogones.
  
BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Normocellular for age (~40%)
M:E ratio: Normal 
Blasts: Not increased
Myeloid lineage: Shows progressive maturation 
Erythroid lineage: Shows progressive maturation
Megakaryocytes: Adequate in number with unremarkable morphology 
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0/3).

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM) 

Blasts                2%
Promyelocytes           3%
Myelocytes           10%
Metamyelocytes           7%
Neutrophils/Bands      22%
Monocytes           1%
Eosinophils           4%
Erythroid Precursors      30%
Plasma Cells           1%
Lymphocytes           20%
Number of Cells Counted 500
M:E Ratio           1.6

Special stain 
Iron: Absent
Ring sideroblasts: Absent 

Morphology:
- The aspirate smears are spicular, cellular and show maturing trilineage hematopoiesis. There is no increase in blasts. Erythroid and myeloid elements are adequate in proportion with progressive maturation and unremarkable morphology. Megakaryocytes are present with predominantly unremarkable morphology. There is mild lymphocytosis with increased hematogones.

PERIPHERAL BLOOD
CBC (12/16/2019):
WBC 5.2 [4.0-11.0 K/mcL] 
RBC 4.04 [3.95-5.54 M/mcL] 
HGB 13.0 [12.5-16.2 g/dL] 
HCT 39.9 [37.5-49.3 %] 
MCV 99 H [80-98 fL] 
MCH 32.2 [27.0-33.0 pg] 
MCHC 32.6 [31.0-36.5 g/dL] 
RDW 14.4 [12.2-15.1 %] 
Platelets 258 [160-400 K/mcL]
 
Neutrophil 64.3 [32.5-74.8 %] 
Mono 18.1 H [0.0-12.3 %] 
Eos 2.7 [0.0-4.9 %] 
Baso 0.6 [0.0-1.5 %] 
Immature Granulocyte 1.0 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 13.3 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 3.3 [1.5-7.5 K/mcL] 
Abs Mono 0.9 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 

Morphology: Unremarkable.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts (<5% cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-11922)
No abnormal myeloid blast population identified. 
CD34 positive myeloid blast population with apparent normal immunophenotype is 0.42% of WBC.
352,358 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with cytogenetic and molecular genetic studies may provide additional information on minimal residual disease status.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7911.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-46404, M19-46411, M19-46412.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-8399;S13;MSKF - 2023-05-31 12.20.34.ndpi,Peripheral Blood Smear,2023-05-31,"Leukemia, hairy cell. Pancytopenia, ?HCL vs. other B-cell lymphoma.  
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Hairy cell leukemia (40-50% by CD20 stain)
     -Small CLL-like clone, likely CLL-like monoclonal B cell lymphocytosis 
     - Cellular marrow with trilineage maturing hematopoiesis.

Comment: While BRAF molecular genetic testing was reported at negative on peripheral blood, only a small population of hairy cells was present in that sample at that time. The marrow appears to be positive for BRAF(VE) staining. BRAF testing on the marrow is recommended.

BONE MARROW BIOPSY
Quality: Mildly fragmented
Cellularity: Hypocellular (10%)
M:E ratio: Normal
Blasts: Not increased
Myeloid lineage: Shows full maturation
Erythroid lineage: Shows full maturation
Megakaryocytes: Reduced
Lymphocytes: Scattered
Plasma cells: Scattered

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Promyelocytes           2%
Myelocytes           2%
Metamyelocytes           1%
Neutrophils/Bands      27%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      12%
Plasma Cells           1%
Lymphocytes           35%
Hairy cells           16%
Number of Cells Counted 500
M:E Ratio           3

Special stain
Iron: Inadequate for evaluation; devoid of spicules.
Ring sideroblasts: Absent 

Morphology:
- Spicular and cellular aspirate specimens shows trilineage maturing hematopoiesis. M:E ratio is normal. Myeloid and erythroid element show full maturation. No dysplastic features are identified. Megakaryocytes are normal in number and morphology. Increase in hairy cells (lymphoid cells with abundant cytoplasm and cytoplasmic projections) are noted.

PERIPHERAL BLOOD
CBC (10/18/2019):
WBC 2.6 L [4.0-11.0 K/mcL] 
RBC 2.17 L [3.95-5.54 M/mcL] 
HGB 7.1 L [12.5-16.2 g/dL] 
HCT 22.9 L [37.5-49.3 %] 
MCV 106 H [80-98 fL] 
MCH 32.7 [27.0-33.0 pg] 
MCHC 31.0 [31.0-36.5 g/dL] 
RDW 22.5 H [12.2-15.1 %] 
Platelets. 44 L [160-400 K/mcL] 

Neutrophil 36.5 [32.5-74.8 %] 
Mono 3.8 [0.0-12.3 %] 
Eos 0.8 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Immature Granulocyte 0.4 [0.0-0.6 %] 
Lymph 58.5 H [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 1.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.5 [0.9-3.2 K/mcL]

Morphology: Thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
Immunostain for CD20 stains approximately 40-50% cellularity, many cells with abundant cytoplasm. BRAF(VE) appears to be positive on at least a subset of the abnormal cells. CD3 stains background T cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-8399)
Interpretation: 
Three abnormal B-cell populations identified. 

Flow cytometry reveals an abnormal mature B-cell population having abnormal expression of CD10, CD19 (bright), CD20 (bright), CD11c, CD22 (bright), CD23, CD25, CD45 (bright), CD103 and CD200 (bright) with slightly increased forward and side scatter and kappa light chain restriction (bright); with normal expression of FMC7, CD38 and without CD5.  The immunophenotype of the abnormal B-cell population is consistent with involvement by hairy cell leukemia. The abnormal B cell population represents 6.4% of the total white cells.

In addition, flow cytometry identified an abnormal minute, bi-clonal B-cell population with CLL/SLL-like immunophenotype having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23, and CD200 (bright); normal expression of FMC7, CD19 and CD45; and without CD38 or CD10 expression. Both light chain subsets, lambda and kappa, are dim in expression. The abnormal B-cell population comprises 0.03% of the white cells.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-6666.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-38362, M19-38363.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-10279;S2;MSKD - 2023-06-20 16.21.51.ndpi,Peripheral Blood Smear,2023-06-20,[NULL],"1-2.  Bone marrow, left posterior iliac crest, aspirate and peripheral blood smears:
     - B-lymphoblastic leukemia/lymphoma (B-ALL), 98% blasts by aspirate differential count. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                98%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           0

Morphology:
-Aspicular and cellular bone marrow aspirate shows predominantly blasts which are medium in size, with irregular nuclei, fine chromatin, inconspicuous nucleoli and scant cytoplasm. Trilineage hematopoiesis is absent. 
 
PERIPHERAL BLOOD
CBC (12/24/2019):
WBC 1.2 L [7.1-15.9 K/mcL] 
RBC 2.83 L [3.70-4.90 M/mcL] 
HGB 8.0 L [10.6-13.3 g/dL] 
HCT 24.1 L [32.4-40.4 %] 
MCV 85 [74-91 fL] 
MCH 28.3 [22.7-29.5 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 12.6 [12.2-15.1 %] 
Platelets 53 L [160-400 K/mcL] 

Neutrophil 20.0 [16.9-74.5 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 4.0 H [0.0-0.0 %] 
Lymph 75.0 H [15.5-57.8 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 0.2 L [1.5-8.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.9 L [1.0-4.3 K/mcL] 
Megakaryocyte Fragment 1 [/100(WBCs)] 

Morphology:
WBC: Marked leukopenia. Occasional circulating blasts seen. 
RBC: Normocytic anemia.
PLT: Marked thrombocytopenia. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-12247)
Expanded abnormal immature B-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. Too few myeloid blasts seen for definite analysis.
No abnormal mature T-cell population detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (93.8% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD8 (minor subset), CD10 (bright), CD45 (dim to absent), CD66c/CD123, CD73/CD304 (partial) with normal expression of CD19, CD22, CD24, CD34, CD38, CD71, cyCD79, CD81 and HLA-DR; and without CD2, sCD3, cyCD3, CD4, CD5, CD7, CD11b, CD13, CD14, CD15, CD16, CD20, CD33, CD56, CD64, CD66b, CD86, CD117 or MPO.

414,182 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-8106, CG19-8107.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-47669, M19-47670 and M19-47671. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. PessinMD., PhD., Director.
"
H19-3488;S11;MSK8 - 2023-06-27 23.12.56.ndpi,Peripheral Blood Smear,2023-06-27,"R.O AML vs CMML 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Acute myeloid leukemia with monocytic features, 59% blasts by aspirate differential
  
COMMENT: Correlation with clinical history, cytogenetic and molecular studies is required for further classification. Although there are mildly increased lymphocytic infiltrate, morphologic evidence of lymphoma is not identified. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular for age (90%)
M:E ratio: N/A
Blasts: Increased in sheets and large clusters; blasts have moderate cytoplasm, irregular nuclei, fine chromatin with prominent nucleoli
Myeloid lineage: Markedly reduced; progressive maturation 
Erythroid lineage: Markedly reduced; progressive maturation 
Megakaryocytes: Adequate in number, occasional small clusters
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed on touch imprints by HM)

Blasts                59% 
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      3%
Monocytes           9%
Eosinophils           1%
Erythroid Precursors      4%
Plasma Cells           2%
Lymphocytes           17%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology: The aspirate smears are spicular and cellular and show an expanded population of medium to large sized blasts with moderate amounts of light blue/grey cytoplasm, folded to irregular nuclei, fine chromatin and distinct nucleoli, in a background of reduced trilineage hematopoiesis. Background myeloid and erythroid elements are markedly reduced. Megakaryocytes are present with unremarkable morphology. 

PERIPHERAL BLOOD
CBC (05/02/2019):
WBC 5.4 [4.0-11.0 K/mcL] 
RBC 2.51 L [3.80-5.00 M/mcL] 
HGB 8.7 L [11.2-15.4 g/dL] 
HCT 25.0 L [34.3-46.0 %] 
MCV 100 H [80-98 fL] 
MCH 34.7 H [27.0-33.0 pg] 
MCHC 34.8 [31.0-36.5 g/dL] 
RDW 14.3 [12.2-15.1 %] 
Platelets 61 L [160-400 K/mcL] 

Neutrophil 1.0 L [32.5-74.8 %] 
Mono 54.0 H [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 44.0 [12.2-47.4 %] 

Abs Neut 0.1 L [1.5-7.5 K/mcL] 
Abs Mono 2.9 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 2.4 [0.9-3.2 K/mcL] 

Morphology:
Pancytopenia with atypical monocytosis and occasionally circulating blast equivalents. There is no significant dysplasia in granulocytes. 

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains show no increases in CD34 and/or CD117 positive blasts (<5%). 
CD20 highlights few scattered lymphoid aggregates. CD3 highlights T cells within aggregates and clustered. The CD20 positive B cells do not appear to co-express CD5 or cyclinD1. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-4015)
Abnormal myeloid blast and immature monocyte population detected. No abnormal B and T cell populations detected.
Monocytosis noted.
The blasts have abnormal expression of CD7 (subset), CD25 (subset, >10% of CD34+ blasts), CD13 (dim to bright), CD15(partial), CD33 (bright), CD34 (largely negative), CD117 (bright), CD123 (bright), HLA-DR (bright), with normal expression of CD4, CD38, CD45, CD71, without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cytoplasmic CD79a, MPO or surface light chains. CD117 positive myeloid blasts represent 1.2% of WBC.

In addition, monocytosis noted and the expanded monoytes with atypical expanded expression of CD56 comprise 52.9% of WBC. A subset of immature monocytes having expression of CD13 (negative), CD64 (bright), HLA-Dr (bright) and lacking CD14 represents 3.0% of WBC. Total blasts account for 4.2% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-2868.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-16107, M19-16108, M19-16109, M19-16110.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-10083;S13;MSKI - 2023-06-20 13.14.56.ndpi,Peripheral Blood Smear,2023-06-20,"Leukemia, Hairy cell. Reassess disease for worsening cytopenias.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Extensive involvement by Hairy cell leukemia, 70-80% by CD20 immunostain. 

BONE MARROW BIOPSY
Quality: adequate but with crush artifacts precluding detailed cytologic evaluation
Cellularity: variable, 40-80%
M:E ratio:  not applicable 
Blasts: not increased 
Myeloid lineage: markedly reduced
Erythroid lineage: markedly reduced
Megakaryocytes: markedly reduced
Lymphocytes: markedly increased, interstitial infiltrate by atypical lymphoid cells that are small to medium in size
Plasma cells: rare 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Promyelocytes           1%
Myelocytes           2%
Metamyelocytes           1%
Neutrophils/Bands      8%
Eosinophils           1%
Erythroid Precursors      15%
Plasma Cells           1%
Lymphocytes           14%
Hairy cells           57%
Number of Cells Counted 500
M:E Ratio           0.9

Special stain
Iron: Absent
Ring sideroblasts: Suboptimal for evaluation due to rare erythroid elements 

Morphology:
Spicular and paucicellular smears show many scattered atypical lymphoid cells that are medium in size and have pale chromatin and ample cytoplasm, consistent with Hairy cells. Normal hematopoietic precursors are rare. 

PERIPHERAL BLOOD
CBC (12/17/2019):
WBC 2.5 L [4.0-11.0 K/mcL] 
RBC 3.30 L [3.80-5.00 M/mcL] 
HGB 10.8 L [11.2-15.4 g/dL] 
HCT 32.8 L [34.3-46.0 %] 
MCV 99 H [80-98 fL] 
MCH 32.7 [27.0-33.0 pg] 
MCHC 32.9 [31.0-36.5 g/dL] 
RDW 16.8 H [12.2-15.1 %] 
Platelets. 101 L [160-400 K/mcL] 

Neutrophil 42.0 [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 56.0 H [12.2-47.4 %] 
Hairy Cell 2.0 H [0.0-0.0 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 1.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL] 
Abs Hairy Cells 0.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Morphology: Monocytopenia, occasional Hairy cells. 

IMMUNOHISTOCHEMISTRY
CD20 stains numerous B cells, approximately 70-80% of total cells. BRAF is weakly positive in B cells. CD3 stains scattered T cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-12032)
Abnormal B-cell population identified.
No abnormal plasma cell population detected.

Flow cytometry reveals an abnormal mature B-cell population having abnormal expression of CD19 (bright), CD20 (bright), CD11c, CD22 (bright), CD25, CD45 (bright), CD103 and CD200 (bright) with increased forward and side scatter and no definite light chain restriction expression; with normal expression of CD38 and without CD5 or CD10.  The immunophenotype of the abnormal B-cell population is consistent with involvement by hairy cell leukemia. The abnormal B cell population represents 5.0% of the total white cells.     

No evidence of an abnormal plasma cell population is identified by flow cytometry. 171,300 cells acquired.     

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7981, CG19-7982.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-46750.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-3801;S12;MSK8 - 2023-05-10 22.14.37.ndpi,Peripheral Blood Smear,2023-05-10,"AML. Low dose cytarabine/ Venetoclax.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:     
     - Persistent acute myeloid leukemia (69% blasts by aspirate differential count). See comment. 
     - Hypocellular marrow with megakaryocytic hypoplasia/aplasia. 

Comment: Patient previous cytogenetic reports showed PDGFRA gene rearrangement (CG16-3981; CG16-4401; CG18-1504 and CG18-6664). The fusion partner has not been clear. Cytogenetic evaluation will be attempted and reported in addendum. Formally a possibility that the AML represents progression of Lymphoid/Myeloid neoplasm with eosinophilia could not be excluded.
  
BONE MARROW BIOPSY
Quality: Adequate (partially aspirated) 
Cellularity: Hypocellular for age (20-30%) 
M:E ratio: N/A
Blasts: Overtly increased in number forming sheets consisting of medium to large sized blasts with scant to moderate cytoplasm, round to oval nuclei, fine lacy chromatin and prominent nucleoli 
Myeloid lineage: Show left shifted maturation 
Erythroid lineage: Reduced in number 
Megakaryocytes: Rare to absent 
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0+/3) 
Clot section: Aspirate smears are adequate and show morphology similar to the core and aspirate smears
Other: Hemosiderin laden macrophages seen. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)
Blasts                69%
Plasma Cells           2%
Lymphocytes           29%
Number of Cells Counted 500
M:E Ratio           0

Morphology:
-Spicular and cellular aspirate smears show expanded blast population of medium to large sized blasts with moderate amount of basophilic cytoplasm with small vacuoles, round to oval nuclei, fine lacy chromatin and prominent nucleoli. Background hematopoiesis is markedly reduced. Small mature appearing lymphocytes are seen.  

PERIPHERAL BLOOD
CBC (05/13/2019):
WBC 0.8 L [4.0-11.0 K/mcL] 
RBC 3.23 L [3.80-5.00 M/mcL] 
HGB 9.5 L [11.2-15.4 g/dL] 
HCT 29.7 L [34.3-46.0 %] 
MCV 92 [80-98 fL] 
MCH 29.4 [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 14.3 [12.2-15.1 %] 
Platelets. 5 LL [160-400 K/mcL]
  
Neutrophil 0.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 10.0 H [0.0-0.0 %] 
Lymph 87.0 H [12.2-47.4 %] 

Abs Neut 0.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 

Morphology:
WBC: Leukopenia with absolute neutropenia and lymphopenia; circulating blasts seen (10%)
RBC: Normocytic normochromic anemia 
Platelets: Marked thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlights increased number of blasts (80-90% positivity of bone marrow cellularity)
CD71 also highlights subset of blasts 
CD61 highlights rare megakaryocytes
MPO shows reduced myeloid precursors. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-4364)
Abnormal myeloid blast population detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD7 (subset), CD34 (bright), CD38 (variable, absent to bright), CD56 (subset), CD71 (bright), CD117 (bright), HLA-DR (variably dim, subset negative); with normal expression of CD4, CD33, CD123, CD13, CD45; without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, or CD64. CD34 positive myeloid blasts represent 46.5% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not submitted. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-3116.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-17516.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-1067;S22;MSKA - 2023-04-17 08.51.10.ndpi,Peripheral Blood Smear,2023-04-17,"Myelodysplastic Syndrome.  Pre- transplant.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Persistent involvement by systemic mastocytosis with an associated hematological neoplasm (SM-AHN) in the form of chronic myelomonocytic leukemia (CMML-1), 9% blasts by aspirate differential count, see comment 
 
COMMENT: Current bone marrow biopsy shows overall similar morphologic features to that seen in H18-8072 and H18-9865.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (70% cellularity) 
M:E ratio: Normal to slightly decreased  
Blasts: No large clusters or sheets seen, better evaluated by aspirate smears and immunohistology (see below)
Myeloid lineage: Mildly left-shifted maturation 
Erythroid lineage: Exhibits full maturation
Megakaryocytes: Adequate in number with focal loose clusters and frequent dysplastic forms (small hypolobated, hyperchromatic bare nuclei, micromegakaryocytes) 
Lymphocytes: Scattered 
Plasma cells: Scattered
Other: A large focal area atypical aggregate of spindled cells and partial crush artifact is present, accounting for approximately 10-20% of the marrow composition. Osteosclerosis is also seen.
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0) outside of the spindled areas. 


BONE MARROW ASPIRATE SMEAR
Differential: (Performed on touch imprint and aspirate smears by HM)
Blasts                9%
Promyelocytes           6%
Myelocytes           13%
Metamyelocytes           5%
Neutrophils/Bands      18%
Monocytes           22%
Eosinophils           1%
Erythroid Precursors      14%
Plasma Cells           2%
Lymphocytes           10%
Number of Cells Counted  500
M:E Ratio           4.7

Special stain
Iron: Aspicular, suboptimal for evaluation.
Ring sideroblasts: Absent 

Morphology:
Spicular and cellular aspirate smears show maturing trilineage hematopoiesis with an increase in blasts and promonocytes (blasts equivalents), which show a patchy distribution with an overall count of 9%. Blasts are medium to large in size, with round to slightly irregular nuclei, fine chromatin, variably distinct nucleoli, and scant to moderate amount of cytoplasm. Myeloid elements show left shifted maturation with dyspoiesis (hypogranular and hyposegmented neutrophils, nuclear to cytoplasmic asynchrony). Increased monocytes are present. Erythroid elements show full maturation without overt atypia. Megakaryocytes are present and show few hypolobated forms. Occasional mast cells are seen associated with spicules.

PERIPHERAL BLOOD
CBC (01/28/2019):
WBC 3.5 L [4.0-11.0 K/mcL] 
RBC 4.23 [3.80-5.00 M/mcL] 
HGB 13.2 [11.2-15.4 g/dL] 
HCT 37.9 [34.3-46.0 %] 
MCV 90 [80-98 fL] 
MCH 31.2 [27.0-33.0 pg] 
MCHC 34.8 [31.0-36.5 g/dL] 
RDW 11.9 L [12.2-15.1 %] 
Platelets 180 [160-400 K/mcL] 

Neutrophil 18.0 L [32.5-74.8 %] 
Lymph 55.0 H [12.2-47.4 %] 
Mono 26.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 

Abs Neut 0.6 L [1.5-7.5 K/mcL] 
Abs Lymph 1.9 [0.9-3.2 K/mcL] 
Abs Mono 0.9 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Rare circulating promonocytes (~1%) and monocytosis.
RBC: Unremarkable morphology 
PLT: Adequate in number with occasional large forms present. 

IMMUNOHISTOCHEMISTRY
CD117 highlights increased mast cells, forming a focal dense aggregate as well as scattered interstitially with bright expression.
The mast cells are also positive for tryptase and show aberrant expression of weak CD2 and CD25.
CD117 also highlights increased blasts (~5-9%), which are scattered singly interstitially and show intermediate intensity of expression, while early erythroid cells are present in small clusters and show dim expression. 
CD34 shows that increased blasts are largely CD34 negative. 
MPO highlights myeloid elements, and CD71 highlights erythroid elements, which show a slightly decreased M:E ratio.  
CD61 is positive in the megakaryocytes, including some micromegakaryocytic forms.
CD68(PGM1) highlights increased myelomonocytic cells, while CD14 highlights increased mature monocytes.
CD3 highlights few scattered T-cells.
CD20 highlights rare scattered B-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-1314)
Interpretation:  
Abnormal myeloid blast population detected.
Expanded atypical monocyte population detected.
Atypical mast cell population detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample (F18-10831) having abnormal expression of CD33 (variable, absent to intermediate), CD34 (uniform), CD38 (uniform), CD64 (subset dim), CD71 (subset bright), CD117 (uniform bright), CD123 (bright), HLA-DR (bright); with normal expression of CD4, CD13, CD45; without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56. CD34 positive myeloid blasts represent 1.2% of WBC. 
Maturing (CD14 absent) and mature monocytic cells are expanded (29.2% of WBC) show atypical expression of CD56 and CD2.

In addition, flow cytometry identifies an atypical mast cell population with expression of CD25 and subset with dim CD2. The atypical mast cell population represents 0.17% of WBC.
The immature monocytic cells (CD14 absent, HLD-DR positive, CD64-positive) account for 10.6% of the WBC. Thus overall, blasts and blast equivalents (immature monocytes) account for 11.8% of WBC. 

CYTOGENETIC STUDIES
Not submitted.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-5234.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-1570;S21;MSK9 - 2023-05-12 11.55.04.ndpi,Peripheral Blood Smear,2023-05-12,"MDS. Evaluation of cellularity; also history of NB, evaluate for extrinsic cells. RUSH. 
","1, 3. Bone marrow, right posterior iliac crest; biopsy and aspirate smears: 
    - Therapy related myeloid neoplasm (20% blasts on the aspirate, 5-10% based on CD34 immunostain); see comment.
    - No diagnostic morphologic evidence of metastatic neuroblastoma.

COMMENT: In the context of a patient previously treated with chemotherapy for neuroblastoma, the findings of morphologic megakaryocytic dysplasia, mild dyserythropoiesis and increased blasts is consistent with a therapy related myeloid neoplasm. The blast counts vary from 5-10% based on immunostains but reach up to 20% on the aspirate indicating an evolving acute myeloid leukemia. Correlation with pending cytogenetic and molecular studies is recommended.

BONE MARROW BIOPSY
Quality: Suboptimal (small subcortical biopsy) 
Cellularity: Appears mildly hypocellular for age (~50%)
M:E ratio: Decreased
Blasts: Scattered immature cells seen
Myeloid lineage: Reduced, exhibits left-shifted maturation 
Erythroid lineage: Exhibits left-shifted maturation 
Megakaryocytes: Increased with dysplastic monolobated forms and hyperchromasia 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows no significant increase in reticulin fibers (0/3). 

BONE MARROW ASPIRATE SMEAR 
Differential: (Performed by HWH)
Blasts                20% 
Promyelocytes           2%
Myelocytes           5%
Metamyelocytes           7%
Neutrophils/Bands      22%
Monocytes           5%
Erythroid Precursors      30%
Lymphocytes           9%
Number of Cells Counted 500
M: E Ratio           1.4

No extrinsic cells present. 

Special stain
Iron: Present
Ring sideroblasts: Absent

Morphology: The aspirate smears are spicular and cellular and show a mildly increased population of medium to large sized blasts with small amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli, in a background of trilineage hematopoiesis. Background myeloid elements are reduced and show left shifted maturation while background erythroid elements show mild dyserythropoiesis (nuclear irregularities, nuclear cytoplasmic dyssynchrony). Megakaryocytes are present and show dysmegakaryopoiesis (lobation abnormalities). No extrinsic cells are seen.

PERIPHERAL BLOOD
CBC (02/26/2019):
WBC 2.4 L [7.1-15.9 K/mcL] 
RBC 3.01 L [3.70-4.90 M/mcL] 
HGB 8.8 L [10.6-13.3 g/dL] 
HCT 25.1 L [32.4-40.4 %] 
MCV 83 [74-91 fL] 
MCH 29.2 [24.8-30.2 pg] 
MCHC 35.1 [31.0-36.5 g/dL] 
RDW 12.6 [12.2-15.1 %] 
Platelets 108 L [160-400 K/mcL] 

Neutrophil 58.0 [32.5-74.8 %] 
Lymph 19.0 [12.2-47.4 %] 
Mono 23.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 1.4 L [1.5-7.5 K/mcL] 
Abs Lymph 0.5 L [0.9-3.2 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Leukopenia with absolute lymphopenia, neutropenia and relative monocytosis; no circulating blasts seen. No significant dysplasia is seen. 
RBC: Normocytic, normochromic anemia. 
PLT: Mild thrombocytopenia.

IMMUNOHISTOCHEMISTRY
CD34 highlights mildly increased blasts, 5-10% of total cellularity. CD34 also highlights the megakaryocytes. CD117 highlights blasts as well as left shifted erythroid elements. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-1838)
Abnormal myeloid blast population detected. 
No abnormal B or T cell population detected.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD7 (major subset), CD11b (partial), CD19 (partial), CD13 (dim), CD33 (uniform intermediate), CD34 (bright), CD38 (uniform dim), CD45 (bright), CD117 (bright), CD123 (intermediate to bright), HLADR (major subset bright) with normal expression of CD4 and CD71; without CD2, CD5, CD14, CD15, CD16, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 3.7% of WBC. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-1328.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-7510.


2.4. Bone marrow, left posterior iliac; biopsy and aspirate smears: 
    - Therapy related myeloid neoplasm (5-15% based on CD34 immunostain); see part 1.
    - No diagnostic morphologic evidence of metastatic neuroblastoma.

BONE MARROW BIOPSY
Quality: Suboptimal (small subcortical biopsy) 
Cellularity: Appears mildly hypocellular for age (~50%)
M:E ratio: Decreased / inverted
Blasts: Scattered immature cells seen
Myeloid lineage: Reduced, exhibits left-shifted maturation 
Erythroid lineage: Exhibits left-shifted maturation 
Megakaryocytes: Increased with dysplastic monolobated forms and hyperchromasia 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows no significant increase in reticulin fibers (0/3). 

BONE MARROW ASPIRATE SMEAR
No extrinsic cells present.

Morphology: The aspirate smears are aspicular, hypocellular and hemodiluted. Due to hemodilution, findings may not accurately represent actual bone marrow composition. Aspirate differential count is not performed. Scattered blasts are identified. Megakaryocytes are not readily identifiable. Few maturing myeloid and erythroid elements are seen. No extrinsic cells are seen.

IMMUNOHISTOCHEMISTRY
CD34 highlights mildly increased blasts, 5-9% of total cellularity overall, focally ~15%. There is frequent clustering of blasts. CD34 also highlights the megakaryocytes. CD117 highlights blasts as well as left shifted erythroid elements. 
"
H19-19;S2;MSKV - 2023-06-27 03.05.46.ndpi,Peripheral Blood Smear,2023-06-27,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears: 
     - Cellular marrow aspirates with trilineage maturing hematopoiesis and increased hematogones.
     - No morphologic evidence of involvement by lymphoblastic leukemia.
     
COMMENT: Suggest correlation with flow cytometry studies for MRD status.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                1%
Promyelocytes           1%
Myelocytes           7%
Metamyelocytes           5%
Neutrophils/Bands      23%
Monocytes           2%
Eosinophils           1%
Erythroid Precursors      42%
Lymphocytes           18%
Number of Cells Counted  500
M:E Ratio           0.9

Morphology:
-Spicular and cellular smears show maturing trilineage hematopoiesis and increased hematogones.

PERIPHERAL BLOOD
CBC (01/02/2019):
WBC 2.8 L [7.1-15.9 K/mcL] 
RBC 2.52 L [3.70-4.90 M/mcL] 
HGB 8.4 L [10.6-13.3 g/dL] 
HCT 24.1 L [32.4-40.4 %] 
MCV 96 H [74-91 fL] 
MCH 33.3 H [22.7-29.5 pg] 
MCHC 34.9 [31.0-36.5 g/dL] 
RDW 24.0 H [12.2-15.1 %] 
Platelets 39 L [160-400 K/mcL] 

Neutrophil 55.2 [16.9-74.5 %] 
Lymph 32.0 [15.5-57.8 %] 
Mono 11.6 [0.0-12.3 %] 
Eos 0.4 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 0.4 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 1.6 [1.5-8.5 K/mcL] 
Abs Lymph 0.9 L [1.0-4.3 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Morphology: No circulating blasts

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-23)
Pending

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-33.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-207.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. PessinMD., PhD., Director.
"
H19-3533;S12;MSK- - 2023-06-20 11.23.09.ndpi,Peripheral Blood Smear,2023-06-20,"MF.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Persistent post-essential thrombocytopenia myelofibrosis (post-ET MF) with no increase in blasts.
     - Abnormal B-cell population detected suggestive of a monoclonal B-lymphocytosis with marginal zone phenotype. 
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: N/A
M:E ratio: N/A
Blasts: Not increased
Myeloid lineage: Decreased
Erythroid lineage: Decreased
Megakaryocytes: Atypical forms seen
Lymphocytes: Scattered, not increased, no aggregates seen
Plasma cells: Scattered 
Special stains: Reticulin stain shows marked increase in reticulin fibrosis (MF-2-3/3). 
Clot section: Clot section shows scattered minute hematopoietic marrow fragments 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Aspicular / hemodiluted aspirate.

Blasts                2%
Neutrophils/Bands      52%
Monocytes           6%
Eosinophils           3%
Erythroid Precursors      5%
Lymphocytes           32%
Number of Cells Counted 500
M:E Ratio           12.2

Morphology:
Aspicular and hypocellular smears and touch preparation show hemodilution and mainly peripheral blood elements. Very few scattered hematopoietic precursors are seen. Blasts are not increased. 

PERIPHERAL BLOOD
CBC (05/03/2019):
WBC 4.0 [4.0-11.0 K/mcL] 
RBC 2.65 L [3.80-5.00 M/mcL] 
HGB 8.9 L [11.2-15.4 g/dL] 
HCT 26.9 L [34.3-46.0 %] 
MCV 102 H [80-98 fL] 
MCH 33.6 H [27.0-33.0 pg] 
MCHC 33.1 [31.0-36.5 g/dL] 
RDW 17.1 H [12.2-15.1 %] 
Platelets 119 L [160-400 K/mcL]
 
Neutrophil 58.0 [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 3.0 H [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 32.0 [12.2-47.4 %] 
Nucleated RBC 3 [/100(WBCs)] 

Abs Neut 2.3 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 

Morphology:
WBC: Relative basophilia. No circulating blasts seen.
RBC: Macrocytic anemia.
PLT: Thrombocytopenia.


IMMUNOHISTOCHEMISTRY
Immunohistochemical stains show no increases in CD34 and/or CD117 positive blasts (<5%). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-4075)
Abnormal myeloid blast population detected.
Abnormal B-cell population identified.
Basophilia detected, representing 1.5% of WBC.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD25 (subset, greater than 10% of blasts), CD34 (uniform), CD38 (absent to dim), CD117 (bright), and CD123 (uniform); with normal expression of CD4, CD13, CD33, CD45, CD71, and HLA-DR; without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD56 or CD64. CD34 positive myeloid blasts represent 1.1% of WBC.

Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition. 

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD20 (bright), CD22 (bright), and lambda light chain restriction; with normal expression of CD19, CD38 and CD45; and without CD5 or CD100. The abnormal B-cell population represents 2.7% of the total white cells.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-2912.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-16334, M19-16335.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-497;S11;MSK5 - 2023-06-20 21.08.35.ndpi,Peripheral Blood Smear,2023-06-20,"MDS. Metastatic breast cancer; MDS. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Metastatic carcinoma. See note. 
     - Minute focus of bone marrow elements, inadequate for evaluation of MDS. 
     - Hypogranular neutrophils and rare blasts seen on PB smear. See comment

Comment: The patients history of invasive lobular carcinoma is noted. Immunohistochemical staining shows that the tumor cells are positive for GATA3 and AR (99%, strong intensity), and negative for ER, PR and Her2. These findings are not specific but suggestive of mammary origin. The original breast carcinoma is not available for reviewed and comparison. Patient previous history of ""myelodysplastic syndrome"" is noted in the electronic medical record, however current bone marrow biopsy is focally replaced by metastatic carcinoma; touch imprints are acellular and inadequate for evaluation. Although peripheral blood shows pancytopenia with some hypogranular neutrophils and rare blast raising the possibility of myelodysplastic syndrome, these findings can also be seen in metastatic carcinoma. If clinical suspicion of MDS remains high, a repeat biopsy with adequate material is suggested.  
Dr. Wenbin Xiao at the Hematopathology service has also reviewed this case and concurs. 

Note: The interpretation of these results is based in part on the decalcification procedure performed. 
  
BONE MARROW BIOPSY
Quality: Adequate (mostly consists of bone with few cellular areas)
Cellularity: Cannot be assessed 
M:E ratio: N/A
Blasts: N/A
Myeloid lineage: Cannot be assessed 
Erythroid lineage: Cannot be assessed 
Megakaryocytes: Cannot be assessed 
Lymphocytes: Cannot be assessed 
Plasma cells: Cannot be assessed 
Special stains: Reticulin stain shows moderate increase in reticulin fibrosis (MF-2-3+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (not performed by CB)

Only touch imprints are available for evaluation
Rare peripheral blood cells are present

Special stain
Iron: Suboptimal for evaluation
Ring sideroblasts: Suboptimal for evaluation

PERIPHERAL BLOOD
CBC (01/18/2019):
WBC 2.2 L [4.0-11.0 K/mcL] 
RBC 3.31 L [3.80-5.00 M/mcL] 
HGB 9.0 L [11.2-15.4 g/dL] 
HCT 27.4 L [34.3-46.0 %] 
MCV 83 [80-98 fL] 
MCH 27.2 [27.0-33.0 pg] 
MCHC 32.8 [31.0-36.5 g/dL] 
RDW 16.5 H [12.2-15.1 %] 
Platelets. 55 L [160-400 K/mcL] 

Neutrophil 70.0 [32.5-74.8 %] 
Lymph 25.0 [12.2-47.4 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 1.5 [1.5-7.5 K/mcL] 
Abs Lymph 0.5 L [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 2 [/100(WBCs)] 

Morphology:
WBC: Leukopenia with absolute lymphopenia; hypogranular neutrophils seen; rare blasts seen  
RBC: Normocytic normochromic anemia with anisopoikilocytosis 
Platelets: Thrombocytopenia.  

IMMUNOHISTOCHEMISTRY
Immunostains CD34 and CD117 are negative. 
OSCAR is positive in metastatic carcinoma.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW
Not submitted. 

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not submitted.

CYTOGENETIC STUDIES
Not submitted.

MOLECULAR STUDIES 
Not submitted.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-710;S2;MSK3 - 2023-06-22 02.20.15.ndpi,Peripheral Blood Smear,2023-06-22,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma (B-ALL) with PBX1-TCF3 fusion/t(1;19) (99% blasts by aspirate differential count). 


BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Blasts                99%
Lymphocytes           1%
Number of Cells Counted  500
M:E Ratio           N/A

Morphology:
Paucispicular and hypercellular aspirate smears show markedly expanded population of medium sized blasts with slightly irregular to convoluted nuclei, fine chromatin, indistinct nucleoli, scant basophilic cytoplasm with frequent cytoplasmic vacuoles. Background maturing trilineage hematopoiesis is markedly reduced to absent. 

PERIPHERAL BLOOD
CBC (01/28/2019):
WBC 2.0 L [7.1-15.9 K/mcL] 
RBC 3.54 [2.93-4.75 M/mcL] 
HGB 10.5 [8.9-12.7 g/dL] 
HCT 29.3 [26.8-37.8 %] 
MCV 83 [70-85 fL] 
MCH 29.7 H [22.7-29.5 pg] 
MCHC 35.8 [31.0-36.5 g/dL] 
RDW 13.7 [12.2-15.1 %] 
Platelets 6 LL [160-400 K/mcL]

Neutrophil 2.0 L [16.9-74.5 %] 
Lymph 61.0 [18.1-79.9 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 36.0 H [0.0-0.0 %] 

Abs Neut 0.0 L [1.5-8.5 K/mcL] 
Abs Lymph 1.2 [1.1-8.1 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.7 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology: Numerous circulating blasts present. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-853)
Expanded abnormal immature B-cell population detected.
No abnormal mature T-cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (88.6% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD15 (partial dim), CD19 (bright), CD20 (partial), CD34 (absent), CD38 (bright), CD45 (absent), CD58 (bright), CD123 (dim) with normal expression of CD10, CD22, CD24, CD71, cyCD79a and HLA-DR; and without CD2, sCD3, cyCD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD16, CD20, CD33, CD56, CD64, CD66b, CD117 or convincing MPO.
CD25 is not expressed by the blasts.

CYTOGENETIC STUDIES (CG19-627)
FISH ANALYSIS:
PBX1-TCF3 fusion/t(1;19) with a signal pattern of one fusion, two signals for PBX1 (1q23) and one signal for TCF3 (19p13.3) detected in 97% of cells.

No evidence of IKZF1 (7p12.2) deletion.
No evidence of BCR-ABL1 fusion/t(9;22).
No diagnostic evidence of MLL (11q23) rearrangement.
No evidence ETV6-RUNX1 fusion/t(12;21) or gain of RUNX1 (21q22).

Karyotype analysis is pending and will be reported in an addendum. 

CG19-628 is pending.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-3393.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. PessinMD., PhD., Director.
"
H19-8367;S12;MSK0 - 2023-05-31 12.44.10.ndpi,Peripheral Blood Smear,2023-05-31,"HCL. Screen for protocol. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent hairy cell leukemia, 70% involvement by CD20 immunostain.
     - Hypercellular marrow with residual trilineage maturing hematopoiesis.
  

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular (70%)
M:E ratio: Reduced
Blasts: Not increased
Myeloid lineage: Reduced
Erythroid lineage: Predominant
Megakaryocytes: Adequate in number and morphology
Lymphocytes: Marked diffuse interstitial lymphoid infiltrate composed of small to intermediate sized lymphoid cells with round to irregular nuclei, condensed chromatin, mostly inconspicuous nucleoli and scant to abundant eosinophilic to clear cytoplasm
Plasma cells: Scattered

BONE MARROW ASPIRATE SMEAR
Differential: (Performed on Touch Imprints by HM)

Aspicular / hemodiluted aspirate smears with scattered hairy cells (~9%) in circulation.

Blasts                2%
Promyelocytes           4%
Myelocytes           7%
Metamyelocytes           3%
Neutrophils/Bands      12%
Eosinophils           2%
Erythroid Precursors      40%
Plasma Cells           1%
Lymphocytes           14%
Hairy cells           15%
Number of Cells Counted 500
M:E Ratio           0.7

Morphology:
- Aspirate smears are paucispicular and paucicellular with frequent bare nuclei and are suboptimal for evaluation. A population of atypical lymphoid cells is seen composed predominantly of small to intermediate sized cells with rounded, ovoid, reniform, cleaved or irregular/folded nuclei, some of which are eccentrically located, moderately condensed chromatin, occasional small nucleoli and scant to abundant cytoplasm with occasional cytoplasmic projections. Scattered myeloid and erythroid elements at various stages of maturation are present. Megakaryocytes are present and show no overt atypia. No expanded blast population is seen

PERIPHERAL BLOOD
CBC (10/15/2019):
WBC 2.3 L [4.0-11.0 K/mcL] 
RBC 3.78 L [3.95-5.54 M/mcL] 
HGB 13.4 [12.5-16.2 g/dL] 
HCT 39.3 [37.5-49.3 %] 
MCV 104 H [80-98 fL] 
MCH 35.4 H [27.0-33.0 pg] 
MCHC 34.1 [31.0-36.5 g/dL] 
RDW 14.0 [12.2-15.1 %] 
Platelets 123 L [160-400 K/mcL] 

Neutrophil 40.1 [32.5-74.8 %] 
Mono 6.1 [0.0-12.3 %] 
Eos 0.4 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 0.0 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 53.0 H [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.2 [0.9-3.2 K/mcL] 

Morphology: Mild anemia and thrombocytopenia

IMMUNOHISTOCHEMISTRY
Immunostains for CD20 and BRAF shows increase in hairy cells (70% of marrow cellularity). CD3 shows scattered T cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-9826)
Interpretation: 
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.

Flow cytometry reveals an abnormal mature B-cell population having abnormal expression of CD10, CD19 (bright), CD20 (bright), CD11c, CD22 (bright), CD25, CD45 (normal to bright), CD103 and CD200 (bright) with slightly increased forward and side scatter and lambda light chain restriction (minor subset bright); with normal expression of CD38 and without CD5. The abnormal B cell population represents 14.4% of the total white cells.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-6634.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-38183, M19-38184, M19-38185.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-9571;S11;MSK7 - 2023-06-20 12.57.42.ndpi,Peripheral Blood Smear,2023-06-20,"AML. Newly diagnosed. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia, 56% blasts by aspirate differential count. 
     - Minute CLL-like B cell population detected by flow cytometry (0.077% of WBC)
Comment: Molecular genetic and cytogenetic information is required for precise classification and further prognostic and therapeutic target information. The finding raise of a possibility (but is not diagnostic for) of AML with t(8;21), correlation with molecular genetic and cytogenetic studies is advised. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Approximately 80-90%, hypercellular for age 
M:E ratio: N/A
Blasts: Markedly increased  
Myeloid lineage: Left shifted with scant maturation
Erythroid lineage: Markedly decreased
Megakaryocytes: Markedly decreased 
Lymphocytes: Scattered
Plasma cells: Not increased
Special stains: Reticulin stain shows no increase in reticulin fibrosis

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)

Blasts                56%
Promyelocytes           2%
Myelocytes           7%
Metamyelocytes           1%
Neutrophils/Bands      7%
Eosinophils           4%
Erythroid Precursors      14%
Plasma Cells           2%
Lymphocytes           7%
Number of Cells Counted 500
M:E Ratio           1.5

Morphology:
-Spicular and cellular bone marrow aspirate shows predominantly blasts with intermediate to large size, round to oval nuclei with perinuclear clearing, fine chromatin, prominent nucleoli and intermediate amount of cytoplasm. Auer rods are seen in blasts. Myeloid and erythroid maturation are markedly reduced with no overt dysplasia. Megakaryocytes are rare. 

PERIPHERAL BLOOD
CBC (11/27/2019):
WBC 7.2 [4.0-11.0 K/mcL] 
RBC 1.71 L [3.95-5.54 M/mcL] 
HGB 6.5 L [12.5-16.2 g/dL] 
HCT 18.9 L [37.5-49.3 %] 
MCV 111 H [80-98 fL] 
MCH 38.0 H [27.0-33.0 pg] 
MCHC 34.4 [31.0-36.5 g/dL] 
RDW 19.9 H [12.2-15.1 %] 
Platelets. 44 L [160-400 K/mcL] 

Neutrophil 10.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 63.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Promyelocyte 4.0 H [0.0-0.0 %] 
Lymph 20.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 0.7 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 4.5 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.3 H [0.0-0.0 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL]

Morphology:
WBC: Many circulating blasts with similar morphology seen in aspirate smear.
RBC: Macrocytic anemia.
PLT: Marked thrombocytopenia 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 immunohistochemical stains show no marked increase in blasts (60-70% of cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-11402)
Expanded abnormal myeloid blast population detected. 
Minute abnormal B-cell population identified.
No abnormal T cell populations detected.

The blasts have abnormal expression of CD11b (partial dim), CD13 (uniform intermediate), CD15 (small subset), CD19 (partial dim), CD33 (uniform bright), CD34 (variable, intermediate to dim), CD38 (variable, bright to dim), CD56 (small subset), cyCD79a (minor subset), CD117 (bright), CD123 (uniform intermediate), HLA-DR (variable, intermediate to absent),  with normal expression of CD4, CD45, CD71; without CD2, sCD3, cCD3, CD5, CD7, CD8, CD10, CD14, CD16, CD20, CD25, CD64, or surface light chains. MPO expression is present on most of the blasts. CD34 positive myeloid blasts represent 59.0% of WBC. The finding raise of a possibility of AML with t(8;21), correlation with molecular genetic studies is advised. 

In addition, flow cytometry identified an abnormal mature B-cell population with CLL-like phenotype having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23, CD45 (dim), CD200; normal expression of CD19 and without FMC7, CD38, or CD10 expression. The abnormal B-cell population comprises 0.077% of the white cells.  

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F19-11397)
Expanded abnormal myeloid blast population detected. 
Minute abnormal B-cell population identified.
No abnormal T-cell populations detected.

The blasts have abnormal expression of CD11b (partial dim), CD13 (variable, intermediate to absent), CD15 (small subset), CD19 (partial dim), CD34 (variable, bright to dim), CD38 (variable, bright to dim), CD56 (small subset), cyCD79a (minor subset), CD117 (bright), CD123 (uniform), HLA-DR (variable, bright to absent), with normal expression of CD4, CD33, CD45, and CD71; without CD2, sCD3, cCD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD16, CD20, CD25, CD56, CD64, or surface light chains. MPO expression is present on most of the blasts. CD34 positive myeloid blasts represent 54.8% of WBC.

In addition, flow cytometry identified an abnormal B-cell population having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23, CD45 (dim), CD200, predominantly lambda light chain restricted; normal expression of CD19 and without FMC7, CD38, or CD10 expression. The abnormal B-cell population comprises 0.13% of the white cells representing absolute count of 0.012 thousand/microliter of blood. Such immunophenotype is consistent with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or CLL-like monoclonal B-cell lymphocytosis. Quantitative criterion for CLL (>5000 cells/microliter) abnormal CLL clone is not met in the current sample.  

These findings are consistent with involvement by acute myeloid leukemia (AML), and the immunophenotype raises the possibility of AML with t(8;21). Correlation with the forthcoming cytogenetic and molecular genetic studies as well as the forthcoming bone marrow biopsy report is recommended.

Peripheral blood smear review showed many blasts, with a subset harboring slender Auer rods with pointed ends.
Discussed with Dr. Kelly Bolton, Department of Medicine, and peripheral smear reviewed at the microscope on 11/27/19.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7584.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-44226, M19-44227, M19-44228, M19-44229, M19-44230.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H19-1283;S11;MSKZ - 2023-06-20 17.58.37.ndpi,Peripheral Blood Smear,2023-06-20,"CML. Initial diagnosis. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia, BCR-ABL positive (see comment)
  
COMMENT:
This is a somewhat unusual CML presentation. While myeloid hyperplasia and left shift are seen in the marrow, no basophilia is appreciated in either marrow or peripheral blood. Megakaryocytes do not show the typical dwarf forms. Peripheral blood is essentially morphologically unremarkable with only slight granulocytosis and myeloid left shift. Nonetheless demonstration of high allele burden BCR-ABL positivity in this morphologic context argues strongly for CML, that is consistent with chronic phase morphologically. Cytogenetic and molecular genetic correlation is advised.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Increased (90-95%)
M: E ratio: Increased
Blasts: Not increased
Myeloid lineage: Left shifted and hyperplastic
Erythroid lineage: Full maturation 
Megakaryocytes: Normal in number and appearance
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blasts                1%
Promyelocytes           1%
Myelocytes           16%
Metamyelocytes           15%
Neutrophils/Bands      52%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      11%
Lymphocytes           1%
Number of Cells Counted 500
M: E Ratio           7.9


Morphology:
-Hypercellular smears show myeloid left shift and hyperplasia with no overt increase in blast, trilineage maturation is seen.

PERIPHERAL BLOOD
CBC (02/15/2019):
WBC 12.2 H [4.0-11.0 K/mcL] 
RBC 4.04 [3.95-5.54 M/mcL] 
HGB 12.8 [12.5-16.2 g/dL] 
HCT 38.9 [37.5-49.3 %] 
MCV 96 [80-98 fL] 
MCH 31.7 [27.0-33.0 pg] 
MCHC 32.9 [31.0-36.5 g/dL] 
RDW 18.1 H [12.2-15.1 %] 
Platelets 146 L [160-400 K/mcL] 

Neutrophil 80.0 H [32.5-74.8 %] 
Lymph 5.0 L [12.2-47.4 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Abs Neut 9.8 H [1.5-7.5 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 
Abs Mono 0.9 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 

Myelocyte 4.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Variant Lymph 1.0 [%] 
Abs Myelocytes 0.5 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)]

Morphology:
See comment section
IMMUNOHISTOCHEMISTRY
CD34 show no increased blasts, CD117 shows mild increase in early myeloid precursors.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-1535)
Abnormal myeloid blast population detected. 
No abnormal mature B- or T-cell populations detected. Very few mature B cells seen.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD7 (subset) CD11b (subset), CD13 (dim), CD25 (minute subset), CD38 (uniform bright), CD56 (minute subset), CD117 (bright), HLA-DR (bright); with normal expression of CD4, CD33, CD34, CD45, CD71, CD123; without CD2, CD5, CD14, CD15, CD16, CD19, CD64. CD34 positive myeloid blasts represent 0.28% of WBC.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified. Hodgkin lymphoma would not be detected by these studies.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-1097.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-6130, 6131, 6138, 6139



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-9629;S11;MSKA - 2023-04-25 12.28.18.ndpi,Peripheral Blood Smear,2023-04-25,"CML, blast phase. Hypercaved A/B and blinatmonab.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate smear, touch imprint and peripheral blood smears: 
     -Persistent lymphoid blast phase of CML, 18-20% blasts.   

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Approximately 50-60%, slightly hypocellular for age 
M:E ratio: Increased 
Blasts: Increased 
Myeloid lineage: Orderly maturation
Erythroid lineage: Orderly maturation
Megakaryocytes: Present with few small, hyperchromatic, hypolobated forms
Lymphocytes: Scattered
Plasma cells: Not increased
Special stains: Reticulin stain shows no increase in reticulin fibrosis

BONE MARROW ASPIRATE SMEAR AND TOUCH IMPRINT
Differential: (Performed by MT)

Blasts                18%
Promyelocytes           2%
Myelocytes           12%
Metamyelocytes           2%
Neutrophils/Bands      19%
Monocytes           2%
Eosinophils           5%
Erythroid Precursors      31%
Lymphocytes           9%
Number of Cells Counted 500
M:E Ratio           1.4

Morphology:
-Spicular and cellular bone marrow aspirate smears and touch imprints show trilineage hematopoiesis. Blasts are increased. The blasts are intermediate to large in size, with irregular nuclei, fine chromatin, prominent nucleoli and very scant cytoplasm. Myeloid elements show orderly maturation. Erythroid elements show orderly maturation with occasional atypical forms (binucleation, nuclear budding, irregular nuclear contour). Megakaryocytes are present with occasional small hyperchromatic, hypolobated forms.

PERIPHERAL BLOOD
CBC (12/02/2019):
WBC 6.6 [4.0-11.0 K/mcL] 
RBC 4.60 [3.95-5.54 M/mcL] 
HGB 12.7 [12.5-16.2 g/dL] 
HCT 39.5 [37.5-49.3 %] 
MCV 86 [80-98 fL] 
MCH 27.6 [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 15.2 H [12.2-15.1 %] 
Platelets. 17 LL [160-400 K/mcL] 

Neutrophil 57.0 [32.5-74.8 %] 
Mono 12.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 7.0 H [0.0-0.0 %] 
Lymph 20.0 [12.2-47.4 %] 
Nucleated RBC 3 [/100(WBCs)] 

Abs Neut 3.8 [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Blasts 0.5 H [0.0-0.0 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL]

Morphology:
WBC: Circulating blasts present. 
RBC: Unremarkable. 
PLT: Marked thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD34 shows increased in blasts (approx.. 20% of cellularity). Blasts are negative for CD117. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-11461)
Abnormal immature B-cell population detected.
The B cell blasts have abnormal expression of CD10 (bright), CD20, CD22 (bright), CD24 (dim), CD33 (partial), CD38 (dim), CD45 (absent to intermediate), CD123 with normal expression of CD19, CD34, CD71, CD81 and HLA-DR; and without CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD56, CD64, CD66b, CD86, CD117 or CD73/CD304. The population represents 24.8% of WBC.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 1.0% of WBC.
332,560 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.


CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7630.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-37049-M19-37051. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-10360;S12;MSKF - 2023-06-20 12.28.02.ndpi,Peripheral Blood Smear,2023-06-20,"MDS.  Pre-transplant.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent previously diagnosed myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T), 1% blasts by aspirate differential count. 
Comment: Increased plasma cells were noted in the prior biopsy, flow cytometry for plasma cells will be performed and reported in addendum.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Approximately 70-80%, hypercellular for age 
M:E ratio: Slightly decreased
Blasts: No overt increase
Myeloid lineage: Orderly maturation
Erythroid lineage: left shifted maturation
Megakaryocytes: Increased in number forming small loose clusters, and many atypical forms 
Lymphocytes: Scattered
Plasma cells: Not increased
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                1%
Promyelocytes           2%
Myelocytes           10%
Metamyelocytes           3%
Neutrophils/Bands      27%
Monocytes           1%
Eosinophils           6%
Erythroid Precursors      37%
Plasma Cells           1%
Lymphocytes           12%
Number of Cells Counted 500
M:E Ratio           1.3

Special stain
Iron: Present
Ring sideroblasts: Present, >15% 

Morphology:
-Spicular and cellular bone marrow aspirate shows progressive trilineage hematopoiesis. Blasts are not increased. Myeloid precursors show hypogranulation. Erythroid precursors show left shifted maturation with dysplastic forms (binucleation, nuclear irregularity and budding) and marked megaloblastic change. Megakaryocytes are present with dysplastic forms (abnormal lobation, both hypolobated and occasionally hyperlobated forms with atypical nuclear distribution).  

PERIPHERAL BLOOD
CBC (12/27/2019):
WBC 2.5 L [4.0-11.0 K/mcL] 
RBC 2.29 L [3.95-5.54 M/mcL] 
HGB 7.0 L [12.5-16.2 g/dL] 
HCT 22.5 L [37.5-49.3 %] 
MCV 98 [80-98 fL] 
MCH 30.6 [27.0-33.0 pg] 
MCHC 31.1 [31.0-36.5 g/dL] 
RDW 18.7 H [12.2-15.1 %] 
Platelets. 239 [160-400 K/mcL] 

Neutrophil 32.8 [32.5-74.8 %] 
Mono 8.5 [0.0-12.3 %] 
Eos 12.6 H [0.0-4.9 %] 
Baso 2.4 H [0.0-1.5 %] 
Immature Granulocyte 0.0 [0.0-0.6 %] 
Lymph 43.7 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 0.8 L [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL]
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL]

Morphology:
WBC: Mild neutropenia. No circulating blasts.
RBC: Normocytic anemia.
PLT: Occasional giant platelets. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 immunohistochemical stains show no increase in blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-12334)
Abnormal myeloid blast population detected. 
Mastocytosis (0.82% of WBC) and mild basophilia (1.1% of WBC) noted.
Flow cytometry identifies an abnormal myeloid blast population with erythroid precursor like immunophenotype having abnormal expression of CD11b, CD117 (dim), retention of CD34, CD13, and CD33, with normal expression of CD38, CD45, CD71, HLA-DR without CD2, CD5, CD7, CD14, CD15, CD16, CD19, CD25, CD56, CD64 or CD123. CD34 positive myeloid blasts represent 1.3% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-8179.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-47996. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-79;S11;MSK1 - 2023-06-20 22.56.36.ndpi,Peripheral Blood Smear,2023-06-20,"CML.  59 years old woman, p/w leukocytosis, thrombocytosis, 15% blasts, circulating immature myeloid elements, +t(9;22) concerning for CML in accelerated phase.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Chronic Myeloid Leukemia (CML), (BCR-ABL-positive), (see comment)

COMMENT:
The findings of hypercellular bone marrow with marked myeloid hyperplasia, megakaryocyte atypia (many small hypolobated forms) along with peripheral blood granulocytosis with left shift, marked thrombocytosis and marked basophilia (however <20% of WBC) without significant increase in blasts (<10%) in either bone marrow or peripheral blood in the setting of documented t(9;22)(q34.1;q11.2) and/or BCR-ABL translocation demonstrated by (FISH and/or molecular genetic analysis) are consistent with diagnosis above. While the current evaluation does not meet morphologic criteria for accelerated phase, reported blasts >10% on peripheral blood evaluation on a prior examination were noted. If confirmed, accelerated phase CML would be diagnosed at presentation. Close clinical follow up is advised
Please note that further classification requires exclusion of additional cytogenetic abnormalities developing while on therapy and exclusion of trisomy 8, isochromosome 17q, trisomy 19, complex karyotype and abnormalities of 3q26.2. In edition exclusion of lack of clinical response to TKI including persistent elevation of WBC (>10X109/L), persistent splenomegaly, thromobocytosis (>1000X109/L) or thrombocytopenia (<100X109/L) is required. Presence of any of the factors listed or of hematological, cytogenetic or molecular resistance to two sequential TKI would be diagnostic for accelerated phase CML.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Increased for age (80-90%)
M:E ratio: Increased
Blasts: Not overtly increased 
Myeloid lineage: Full maturation with myeloid hyperplasia and expansion of early maturing forms and eosinophilia
Erythroid lineage: Full maturation, hypoplastic 
Megakaryocytes: Moderately increased with many small hypolobated (dwarf) forms present, clustering observed
Lymphocytes: Scattered, lymphoid aggregates are not seen
Plasma cells: Scattered 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Touch imprint
Blasts                5%
Promyelocytes           2%
Myelocytes           6%
Metamyelocytes           6%
Neutrophils/Bands      47%
Monocytes           1%
Eosinophils           11%
Basophils           12%
Erythroid Precursors      9%
Lymphocytes           1%
Number of Cells Counted 500
M: E Ratio           9.4


Morphology:
-Spicular and cellular with many platelet clumps, moderate increase in blasts, basophilia, myeloid left shift, erythroid dyspoiesis. Touch preparation shows numerous atypical megakaryocytes

PERIPHERAL BLOOD
CBC (01/03/2019):
WBC 28.8 H [4.0-11.0 K/mcL] 
RBC 3.75 L [3.80-5.00 M/mcL] 
HGB 11.2 [11.2-15.4 g/dL] 
HCT 35.3 [34.3-46.0 %] 
MCV 94 [80-98 fL] 
MCH 29.9 [27.0-33.0 pg] 
MCHC 31.7 [31.0-36.5 g/dL] 
RDW 18.6 H [12.2-15.1 %] 
Platelets 1202 H [160-400 K/mcL] 

Neutrophil 63.0 [32.5-74.8 %] 
Lymph 15.0 [12.2-47.4 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 15.0 H [0.0-1.5 %] 
Abs Neut 18.1 H [1.5-7.5 K/mcL] 
Abs Lymph 4.3 H [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.9 H [0.0-0.7 K/mcL] 
Absolute Basophil 4.3 H [0.0-0.2 K/mcL] 

Myelocyte 1.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Blast 2.0 H [0.0-0.0 %] 
Abs Myelocytes 0.3 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.3 H [0.0-0.0 K/mcL] 
Absolute Blasts 0.6 H [0.0-0.0 K/mcL]

Morphology: Marked thrombocytosis, myeloid left shift with mild increase in blast, marked basophilia

IMMUNOHISTOCHEMISTRY
CD34 and CD117 do not show an increase in blasts

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-84)
Abnormal myeloid blast population detected. 
Basophilia is observed. 
No abnormal mature B- or T-cell populations detected.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD2 (partial), CD5 (partial), CD7 (partial), CD25(partial, dim), CD56 (partial), CD11b (partial), CD38 (dim to intermediate), CD117 (dim), CD123 (uniform) with normal expression of CD4, CD13, CD33, CD34, CD45, CD71, and HLA-DR; without CD14, CD15, CD16, CD19, or CD64. CD34 positive myeloid blasts represent 3.4% of WBC. In addition, increased basophils are seen, representing 15.6% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-82.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M????.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-1881;S11;MSK3 - 2023-06-27 01.34.32.ndpi,Peripheral Blood Smear,2023-06-27,"ALL.  25 years old with newly diagnosed ALL.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/ lymphoma, 87% blasts by aspirate differential count 
  
BONE MARROW BIOPSY
Quality: Crushed; aspiration artifact
Cellularity: Hypercellular (100%)
M:E ratio: N/A
Blasts: Increased; sheets of small sized blasts with irregular to round nuclei and dispersed chromatin
Myeloid lineage: Reduced
Erythroid lineage: Reduced
Megakaryocytes: Reduced
Lymphocytes: Scattered 
Plasma cells: Scattered 
Clot section: Clot section shows scattered hematopoietic marrow fragments with findings similar to biopsy 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by AS)

Blasts                87%
Neutrophils/Bands      2%
Erythroid Precursors      4%
Lymphocytes           7%
Number of Cells Counted 500
M:E Ratio           0.5

Morphology: Adequate, spicular and cellular aspirate smears show a markedly expanded blast population comprised of small to medium sized blasts with scant cytoplasm, round to oval nuclei, fine chromatin and indistinct distinct conspicuous prominent nucleoli, in a background of markedly reduced trilineage hematopoiesis. 

PERIPHERAL BLOOD
CBC (03/08/2019):
WBC 32.8 H [4.0-11.0 K/mcL] 
RBC 4.89 [3.95-5.54 M/mcL] 
HGB 14.5 [12.5-16.2 g/dL] 
HCT 42.0 [37.5-49.3 %] 
MCV 86 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 34.5 [31.0-36.5 g/dL] 
RDW 13.0 [12.2-15.1 %] 
Platelets 59 L [160-400 K/mcL] 

Neutrophil 13.0 L [32.5-74.8 %] 
Lymph 14.0 [12.2-47.4 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 

Abs Neut 4.3 [1.5-7.5 K/mcL] 
Abs Lymph 4.6 H [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.3 H [0.0-0.2 K/mcL] 

Blast 73.0 H [0.0-0.0 %] 
Absolute Blasts 23.9 H [0.0-0.0 K/mcL] 

Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
Numerous circulating blasts. 

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains shows increased in CD34 and TdT positive blasts (90-95%). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-2213)
Abnormal immature B-cell population detected.
No abnormal mature T-cell population detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (95.3% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD4 (partial), CD10 (absent to intermediate), CD19 (slightly bright), CD33 (partial dim), CD34 (absent to bright), CD123 with normal expression of CD38, CD45, CD71, cCD79a and HLA-DR; and without CD2, sCD3, cCD3, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, convincing CD20, CD56, CD64, CD117 or MPO.
CD25 is not expressed by the blasts.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F19-2214)
Abnormal immature B-cell population detected.
No abnormal mature T-cell population detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (65.6% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD4 (partial), CD10 (absent to intermediate), CD19 (slightly bright), CD20 (partial), CD33 (partial dim), CD34 (absent to intermediate), CD123 with normal expression of CD38, CD45, CD71, cCD79a and HLA-DR; and without CD2, sCD3, cCD3, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD56, CD64, CD117 or MPO.
CD25 is not expressed by the blasts.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-1567.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-9056, M19-9061, M19-9065.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-9574;S10;MSKI - 2023-06-20 18.04.13.ndpi,Peripheral Blood Smear,2023-06-20,"Lymphoma. 
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Mantle cell lymphoma, >95% involvement with CD20 immunohistochemistry

COMMENT: Marrow is replaced by mantle cell lymphoma. Trilineage hematopoiesis is markedly suppressed. 

BONE MARROW BIOPSY MORPHOLOGY
The core biopsy is subcortical and shows markedly hypercellular marrow for age (>90% cellularity) with practical replacement by small atypical lymphoid cells. Trilineage hematopoiesis is markedly reduced. 

ASPIRATE SMEAR MORPHOLOGY
Cellular smears show expanded small atypical lymphocytes with markedly irregular nuclear contours and cytoplasmic vacuoles. Myeloid and erythroid elements are markedly reduced. Megakaryocytes are not represented.

Aspirate differential: (Performed by MT)
Blasts               0%
Promyelocytes          0% 
Myelocytes           3%
Neutrophils/Bands      2%
Eosinophils           1%
Erythroid Precursors      3%
Lymphocytes           91% (Many with vacuoles)
Number of Cells Counted 500
M:E Ratio           2

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 show markedly increased B cells, replacing marrow cellularity (>95% of cellularity). 
These B-cells co-express CD5 (subset, dim), TP53 (strong) and Cyclin D1.
SOX11 is largely negative. 
cMYC is negative. 
CD3 labels few reactive T-cells

FLOW CYTOMETRIC ANALYSIS, BONE MARROW 
Not performed.

PERIPHERAL BLOOD
CBC (11/27/2019):
WBC 60.9 H [4.0-11.0 K/mcL] 
RBC 3.97 [3.95-5.54 M/mcL] 
HGB 12.3 L [12.5-16.2 g/dL] 
HCT 37.3 L [37.5-49.3 %] 
MCV 94 [80-98 fL] 
MCH 31.0 [27.0-33.0 pg] 
MCHC 33.0 [31.0-36.5 g/dL] 
RDW 13.9 [12.2-15.1 %] 
Platelets. 30 L [160-400 K/mcL] 

Neutrophil 7.0 L [32.5-74.8 %] 
Mono 6.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 19.0 [12.2-47.4 %] 
Other 67.0 H [0.0-0.0 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 4.3 [1.5-7.5 K/mcL] 
Abs Mono 3.7 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.6 H [0.0-0.2 K/mcL] 
Abs Lymph 11.6 H [0.9-3.2 K/mcL] 
Abs Others 40.8 H [0.0-0.0 K/mcL]

Morphology: Numerous circulating lymphoma cells with markedly irregular nuclear contours and cytoplasmic vacuoles.  Thrombocytopenia. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7585.

MOLECULAR STUDIES 
Not requested.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-2389;S2;MSK7 - 2023-06-20 15.11.49.ndpi,Peripheral Blood Smear,2023-06-20,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears:
     - Chronic myeloid leukemia (CML), BCRABL1-positive in chronic phase.
     - Hypercellular marrow aspirate with myeloid predominant-maturing trilineage hematopoiesis, left shifted myeloid maturation, atypical megakaryopoiesis, and 4% blasts. See comment.

 COMMENT: A bone marrow core biopsy is not provided for review. Corresponding flow cytometric analysis (F192787) detected a small abnormal myeloid blast population (1.3% of WBC). Peripheral blood cytogenetic (CG19-1962) and molecular studies (M19-11100) revealed BCRABL1 fusion [t(9;22)] in 95.3% of cells and p210 fusion transcripts, respectively. These findings are diagnostic for CML. Blasts account for <10% supporting chronic phase of the disease. Correlation with results of a complete karyotype (CG192006) is recommended.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                4%
Promyelocytes           2%
Myelocytes           28%
Metamyelocytes           15%
Neutrophils/Bands      38%
Monocytes           2%
Eosinophils           5%
Erythroid Precursors      3%
Plasma Cells           1%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           30

Morphology:
Adequate, spicular and hypercellular aspirate smears with marked myeloid predominant maturing trilineage hematopoiesis. Blasts account for 4% of the cellularity. The M:E ratio is markedly increased. Myeloid elements are markedly increased, with left shifted maturation and increased myelocyte proportion, and show no significant dysplasia. Erythroid cells are markedly decreased. Many megakaryocytes are seen with atypical forms, including ""dwarf"" morphology with small size and nuclear hypersegmentation. 

PERIPHERAL BLOOD
CBC (03/25/2019):
WBC 130.6 H [4.0-11.0 K/mcL] 
RBC 3.76 L [3.80-5.00 M/mcL] 
HGB 11.3 [11.2-15.4 g/dL] 
HCT 36.0 [34.3-46.0 %] 
MCV 96 [80-98 fL] 
MCH 30.1 [27.0-33.0 pg] 
MCHC 31.4 [31.0-36.5 g/dL] 
RDW 14.8 [12.2-15.1 %] 
Platelets. 527 H [160-400 K/mcL] 

Neutrophil 64.0 [32.5-74.8 %] 
Lymph 8.0 L [12.2-47.4 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 

Abs Neut 83.6 H [1.5-7.5 K/mcL] 
Abs Lymph 10.4 H [0.9-3.2 K/mcL] 
Abs Mono 10.4 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 2.6 H [0.0-0.7 K/mcL] 
Absolute Basophil 1.3 H [0.0-0.2 K/mcL] 

Metamyelocyte 7.0 H [0.0-0.0 %] 
Myelocyte 10.0 H [0.0-0.0 %] 
Abs Meta 9.1 H [0.0-0.0 K/mcL] 
Abs Myelocytes 13.1 H [0.0-0.0 K/mcL] 

Morphology:
WBC: Marked leukocytosis with marked neutrophilia and circulating immature granulocytes, including myelocytes and metamyelocytes. No definite circulating blasts seen. Absolute basophilia. Granulocytic dysplasia is not identified.
RBC: Normocytic normochromic RBCs. Occasional nucleated RBCs present.
Platelets: Thrombocytosis

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-2787)
Interpretation: 
Small abnormal myeloid blast population detected. 
No abnormal B- and T- cell populations detected.

The myeloid blasts have abnormal expression of CD7 (subset dim), CD11b (subset, dim), CD34 (bright), CD56 (minute subset dim), CD117 (variable, subset dim to absent), HLA-DR (slightly bright); with normal expression of CD4, CD13, CD33, CD38, CD45, CD71, CD123; without CD2, CD3, CD5, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD25, CD64 or surface light chains. CD34 positive myeloid blasts represent 1.3% of WBC.

Flow cytometry is generally not a sensitive methodology in the context of myeloproliferative disorders, correlation with molecular studies for BCR-ABL1 and morphology is advised.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-2006.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-11295.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. Pessin MD., PhD., Director.
"
H19-863;S11;MSK2 - 2023-06-20 14.06.36.ndpi,Peripheral Blood Smear,2023-06-20,"MDS. Evaluate disease.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Metastatic carcinoma, consistent with prostatic primary, see note
     - No definitive morphologic and immunophenotypic evidence of myeloid neoplasm.

Note: The immunohistochemical stains show the tumor is positive for OSCAR and NKX3.1, confirming the above diagnosis.
  
COMMENT: Mild thrombocytopenia and anemia of the patient are likely due to the extensive bone marrow involvement by metastatic carcinoma. Morphologic and immunophenotypic evaluation of any underlying myeloid neoplasm is insensitive in this setting. Dr. Mikhail Roshal from hematopathology service reviewed the case. 

BONE MARROW BIOPSY
Small and hemorrhagic biopsy shows extensive involvement by metastatic carcinoma with interstitial nested growth pattern and associated desmoplastic changes. Scanty hematopoietic elements are seen in focally uninvolved marrow spaces. 

Special stains: Reticulin stain shows desmoplastic changes associated with metastatic carcinoma.  

BONE MARROW ASPIRATE SMEAR
Aspicular, hemodilute and markedly hypocellular aspirate smears show frequent small and large cohesive clusters of epithelial cells. Scattered maturing myeloid and erythroid elements are present. Megakaryocytes are not identified. No increased blast is seen.  

Special stain
Iron: Aspicular smear, suboptimal for evaluation.
Ring sideroblasts: Absent 

PERIPHERAL BLOOD
CBC (02/01/2019):
WBC 6.3 [4.0-11.0 K/mcL] 
RBC 3.32 L [3.95-5.54 M/mcL] 
HGB 10.4 L [12.5-16.2 g/dL] 
HCT 32.7 L [37.5-49.3 %] 
MCV 99 H [80-98 fL] 
MCH 31.3 [27.0-33.0 pg] 
MCHC 31.8 [31.0-36.5 g/dL] 
RDW 13.7 [12.2-15.1 %] 
Platelets 146 L [160-400 K/mcL] 

Neutrophil 67.0 [32.5-74.8 %] 
Lymph 28.0 [12.2-47.4 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %]
Metamyelocyte 1.0 H [0.0-0.0 %] 
 
Abs Neut 4.2 [1.5-7.5 K/mcL] 
Abs Lymph 1.8 [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: No circulating blasts; few plasmacytoid lymphocytes seen.
RBC: Basophilic stippling occasionally seen.
PLT: Few giant and hypochromatic forms present. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts.
CD117 highlights scattered mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-1046)
No definite abnormal myeloid blast, monocyte or maturing granulocyte populations detected. 
There is no definite immunophenotypic evidence of a myeloid stem cell disorder by flow cytometry. However, in light of the left shift in myeloid blast maturation with unusual di expression of CD33 a low-grade myelodysplastic syndrome or myeloproliferative disorder cannot be entirely excluded by these studies.  CD34 positive myeloid blasts represent 0.33% of the white blood cells with expression of CD13, CD34, CD38, CD45, CD71, CD117 and low CD123.  Normal myelomonocytic maturation is present.
222885 cells acquired. Clinical and morphologic correlation will be required to evaluate for the possibility of MDS.  Cytogenetic analysis is also recommended to rule out a clonal stem cell abnormality. 
Not all myeloid stem cell disorders show abnormal immunophenotyped with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-757.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-4105, M19-4109 to M19-4111.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-4336;S11;MSK1 - 2023-05-19 08.41.18.ndpi,Peripheral Blood Smear,2023-05-19,"AML. New diagnosis of AML at outside hospital. 
","AMENDMENT DETAIL:
Reason for Amendment:          supplemental diagnosis due to additional material not received

Report Section Changed:     Diagnosis 

Description of Change:           Dr. Filiz Sen has re-reviewed. See changes below.


Note: This document represents an amended version of the Hematopathology report originally issued on 6/3/2019. Dr. Martin Tallman has been notified via e-mail.


1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Mixed phenotype leukemia with myeloid/T/partial B phenotype, 58% blasts by aspirate differential count. 
  
COMMENT: Correlation with molecular genetic and cytogenetic studies as well as clinical history is required for further classification (including BCR-ABL, MLL, PDGFRA and PDGFRB, FGFR, JAK2-PCM1 abnormalities). 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Normocellular for age (~50-60% cellularity)
M:E ratio: NA
Blasts: Markedly increased and form interstitial aggregates or sheets 
Myeloid lineage: Markedly decreased 
Erythroid lineage: Relatively increased and exhibits full maturation 
Megakaryocytes: Adequate in number and form focal loose clusters; show occasional hyperlobated nuclei 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows mild to moderate increase in reticulin fibrosis (MF-1/2). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                58%
Promyelocytes           1%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      3%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      20%
Plasma Cells           2%
Lymphocytes           12%
Number of Cells Counted  500
M:E Ratio           0.4


Morphology:
Spicular and cellular aspirate smears and touch imprint show markedly expanded population of blasts with size ranging from small to large with oval to irregular/folded nuclei, fine chromatin and scant to moderate cytoplasmic with frequent cytoplasmic blebs. Maturing myeloid elements are rare. Erythroid elements show full maturation with mild dyspoiesis (<50%, nuclear-cytoplasmic asynchrony, karyorrhexis). Megakaryocytes are present and show hyperlobated forms. 

PERIPHERAL BLOOD
CBC (05/30/2019):
WBC 2.0 L [4.0-11.0 K/mcL] 
RBC 3.15 L [3.95-5.54 M/mcL] 
HGB 10.9 L [12.5-16.2 g/dL] 
HCT 32.0 L [37.5-49.3 %] 
MCV 102 H [80-98 fL] 
MCH 34.6 H [27.0-33.0 pg] 
MCHC 34.1 [31.0-36.5 g/dL] 
RDW 12.7 [12.2-15.1 %] 
Platelets 195 [160-400 K/mcL] 

Neutrophil 14.0 L [32.5-74.8 %] 
Mono 21.0 H [0.0-12.3 %] Updated
Eos 2.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Blast 20.0 H [0.0-0.0 %] 
Lymph 42.0 [12.2-47.4 %] 

Abs Neut 0.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.4 H [0.0-0.0 K/mcL] Updated
Abs Lymph 0.8 L [0.9-3.2 K/mcL]

Morphology:
WBC: Frequent circulating blasts with similar morphology to those on aspirate smear; relative monocytosis. 
RBC: Macrocytic RBCs.
PLT: Unremarkable. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show expanded blast population (comprising ~50% of marrow cellularity). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-4974)
Expanded abnormal blast population with myeloid, T and at least partial B lineage maturation detected. 
No abnormal mature B and T cell populations detected.
The blasts have abnormal expression of CD2 (variable, dim to bright), cytoplasmic CD3 (subset, dim, distinct from the myeloid subset), CD7 (subset, dim), CD11b (subset), CD15 (subset), CD19 (partial, dim, distinct from either a clearly myeloid and T cell subsets and expressing bright CD79a), CD13 (variable, dim to bright), CD33 (dim to negative), CD34 (bright), CD48 (negative), CD64 (subset), cytoplasmic CD79a (subset, bright), CD117 (variable, negative to bright), CD123 (bright), HLA-DR (variable, negative to bright), with normal expression of CD4, CD38, CD45 and CD71, without surface CD3, CD5, CD8, CD10, CD14, CD16, CD20, CD25, CD56, or surface light chains. MPO expression is present on a subset of blasts (not positive for cytoplasmic CD3 or cytoplasmic CD79a). CD34 positive blasts represent 72.1% of WBC. Clinical correlation to exclude antecedent myeloid neoplasm, as well as correlation with cytogenetic studies will be required for precise classification.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-3518.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-19683.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H19-1734;S2;MSK- - 2023-06-20 14.54.26.ndpi,Peripheral Blood Smear,2023-06-20,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears:
     - B-lymphoblastic leukemia/ lymphoma, 95% blast by aspirate differential count. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                95%
Neutrophils/Bands      2%
Eosinophils           1%
Plasma Cells           1%
Lymphocytes           1%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
Spicular and hypercellular smears show expanded blast population, small to intermediate in size with high N/E ratio. Megakaryocytes are present. Myeloid and erythroid cells are rare. 

PERIPHERAL BLOOD
CBC (03/04/2019):
WBC 6.2 L [7.1-15.9 K/mcL] 
RBC 3.21 L [3.70-4.90 M/mcL] 
HGB 9.1 L [10.6-13.3 g/dL] 
HCT 25.6 L [32.4-40.4 %] 
MCV 80 [74-91 fL] 
MCH 28.3 [24.8-30.2 pg] 
MCHC 35.5 [31.0-36.5 g/dL] 
RDW 16.0 H [12.2-15.1 %] 
Platelets 200 [160-400 K/mcL]
 
Neutrophil 15.0 L [32.5-74.8 %] 
Lymph 48.0 H [12.2-47.4 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %]
Myelocyte 1.0 H [0.0-0.0 %] 
Blast 35.0 H [0.0-0.0 %] 
 
Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Lymph 3.0 [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Absolute Blasts 2.2 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology: Circulating blasts seen. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-2040)
Interpretation: 
Abnormal immature B-cell population detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (95.1% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD2, CD10 (dim to intermediate), CD11b (small subset), CD19 (bright), CD38 (dim to intermediate), CD45 (absent), CD56, CD58 (bright), CD123, HLA-DR (dim), with normal expression of CD34, CD71, and cCD79a; and without CD3, cCD3, CD4, CD5, CD7, CD8, CD13, CD14, CD15, CD16, CD20, convincing CD33, CD64, CD117 or MPO.
CD25 is expressed by less than 10% of the blasts.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. Very few CD34 positive myeloid blast seen.
318,358 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No abnormal immature or mature T-cell population detected.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-1449, CG19-1450.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-8430, M19-8431, M19-8432. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. Pessin MD., PhD., Director.
  
"
H19-997;S14;MSKC - 2023-06-20 14.48.32.ndpi,Peripheral Blood Smear,2023-06-20,"Pancytopenia, MDS diagnosed elsewhere.
","1-2. Bone marrow, right posterior iliac crest, biopsy and aspirate smears: 
     - Myelodysplastic syndrome with ring sideroblasts and at least single lineage dysplasia (MDS-RS-SLD)
      - Hypercellular marrow with trilineage maturing hematopoiesis, dyserythropoiesis with ring sideroblasts, borderline dysgranulopoiesis and dysmegakarypoiesis and no overt increased blasts (4% by aspirate differential count)
  
COMMENT: Morphologic findings of the current marrow biopsy (ring sideroblasts and dysplasia approaching, but not exceeding 10% in granulocytes and megakaryocytes), in combination with mild patient's pancytopenia (meeting diagnostic cutoffs for neutropenia only), and TET2 and U2AF1 mutations and gain of chromosome 8 detected in peripheral blood (M18-32949, CG18-6831), are consistent with MDS-RS-SLD, although the distinction between MDS-RS-SLD and MDS-RS with multilineage dysplasia is somewhat arbitrary in this case. Please correlate with concurrent molecular and cytogenetic studies for further assessment.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (~50-60% cellularity) 
M:E ratio: Normal 
Blasts: Mildly increased 
Myeloid lineage: Exhibits full maturation 
Erythroid lineage: Exhibits left shifted maturation 
Megakaryocytes: Adequate in number with focal loose clusters; show occasional forms with hyperchromatic and bare nuclei 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                4%
Promyelocytes           3%
Myelocytes           11%
Metamyelocytes           6%
Neutrophils/Bands      40%
Monocytes           4%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      17%
Plasma Cells           1%
Lymphocytes           12%
Number of Cells Counted  500
M:E Ratio           3.8

Special stain
Iron: Present
Ring sideroblasts: Present: (>15%)

Morphology:
Spicular and cellular aspirate show trilineage maturing hematopoiesis with no overt increase in blasts. Myeloid elements show full maturation with dysplasia (<10%, hypogranular and hyposegmented). No Auer rods seen. Erythroid elements show full maturation with dyspoietic forms (>10%, nuclear irregularity, karyorrhexis, ring sideroblasts). Megakaryocytes are present and show few hypolobated forms and forms with atypical lobe separation (approaching 10%)

PERIPHERAL BLOOD
CBC (02/06/2019):
WBC 2.6 L [4.0-11.0 K/mcL] 
RBC 3.07 L [3.95-5.54 M/mcL] 
HGB 12.2 L [12.5-16.2 g/dL] 
HCT 33.9 L [37.5-49.3 %] 
MCV 110 H [80-98 fL] 
MCH 39.7 H [27.0-33.0 pg] 
MCHC 36.0 [31.0-36.5 g/dL] 
RDW 12.3 [12.2-15.1 %] 
Platelets 104 L [160-400 K/mcL] 

Neutrophil 26.7 L [32.5-74.8 %] 
Lymph 50.4 H [12.2-47.4 %] 
Mono 21.8 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Immature Granulocyte 1.1 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Nucleated RBC 0.0 [%] 

Abs Neut 0.7 L [1.5-7.5 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Morphology: no circulating blasts, neutropenia with left-shifted granulocytic forms seen. Borderline anemia with macrocytosis. Borderline thrombocytopenia. 
IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no overt increase in blasts (<5%). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-1223)
Abnormal myeloid blast populations detected. 
No abnormal B or T cell population detected.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD34(dim), CD117(slightly bright), CD71(bright, consistent with abnormal precursors), CD123(bright for erythroid precursors) with normal expression of CD4, CD123, CD33, CD45; without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64. CD34 positive myeloid blasts represent 1.2% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-887.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-4917.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-8637;S12;MSK0 - 2023-06-15 22.35.39.ndpi,Peripheral Blood Smear,2023-06-15,"MDS / MF. 
Assess response to therapy. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent high grade myeloid neoplasm with marked myelofibrosis previously characterized as MDS/MPN with ring sideroblasts and thrombocytosis (however see comment)  
  
COMMENT:
Given reported radiation therapy for prostate cancer the neoplasm may be therapy related. Please note that the blast count on the aspirate smear is approaching 20% concerning for impending progression to AML.

BONE MARROW BIOPSY
Quality: Adequate, fibrotic
Cellularity: Hypercellular for age (80%), however most cellularity replaced by fibrosis
M:E ratio: Unclear due to fibrosis 
Blasts: Increased
Myeloid lineage: Shows progressive maturation 
Erythroid lineage: Shows progressive maturation
Megakaryocytes: Increased in number with tight clusters, dysplastic in appearance 
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered 
Special stains: Reticulin stain shows marked increase in reticulin fibrosis (MF3+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                18%
Promyelocytes           1%
Myelocytes           1%
Neutrophils/Bands      40%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      2%
Lymphocytes           36%
Number of Cells Counted 200
M:E Ratio           22

Special stain 
Iron: Suboptimal for evaluation due to lack of spicules
Ring sideroblasts: Suboptimal for evaluation due to lack of erythroids

Morphology:
- Hypo/hemodiluted aspirate devoid of spicules with increase in blasts (18%). Myeloid and erythroid lineages show full maturation. Megakaryocytes are not represented.

PERIPHERAL BLOOD
CBC (10/28/2019):
WBC 2.1 L [4.0-11.0 K/mcL] 
RBC 2.28 L [3.95-5.54 M/mcL] 
HGB 6.8 L [12.5-16.2 g/dL] 
HCT 21.1 L [37.5-49.3 %] 
MCV 93 [80-98 fL] 
MCH 29.8 [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 17.5 H [12.2-15.1 %] 
Platelets. 93 L [160-400 K/mcL] 

Neutrophil 50.0 [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 13.0 H [0.0-0.0 %] 
Lymph 36.0 [12.2-47.4 %] 

Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 1.1 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.3 H [0.0-0.0 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 

Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology: Pancytopenia, circulating blasts are increased (13%).

IMMUNOHISTOCHEMISTRY
Immunostains for CD34 and CD117 are difficult to interpret due to fibrosis, at least a moderate increase is seen.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-10174)
Abnormal myeloid blast population detected.
Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample (F19-6211) have abnormal expression of CD7 (partial), CD13 (bright), CD33 (dim to negative), CD38 (bright), HLA-DR (bright) with normal expression of CD4, CD34, CD45, CD71, CD117 and CD123 without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 26.7% of WBC. The findings are highly concerning for transformation to acute myeloid leukemia, although morphologic blast count is required for confirmation. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-6853.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-39650.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H19-10284;S12;MSKA - 2023-06-20 17.41.35.ndpi,Peripheral Blood Smear,2023-06-20,"AML. Newly diagnosed AML. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia, 45% blasts by aspirate differential count, best classified as therapy-related acute myeloid leukemia. See comment. 

Comment: 
Per clinical note, the patient had a history of squamous cell carcinoma of the tongue and has received 40 fractions of radiation therapy in 2014, supporting the above diagnosis. Correlation with cytogenetic and molecular studies are recommended for further classification.  

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Approximately 80-90% 
M:E ratio: N/A
Blasts: Markedly increased 
Myeloid lineage: Markedly reduced
Erythroid lineage: Markedly reduced 
Megakaryocytes: Decreased in number with unremarkable morphology
Lymphocytes: Scattered
Plasma cells: Not increased
Special stains: Reticulin stain shows no increase in reticulin fibrosis
Clot section: Similar to biopsy

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by MT)
Blasts                45%
Myelocytes           1%
Neutrophils/Bands      2%
Erythroid Precursors      23%
Lymphocytes           29%
Number of Cells Counted 500
M:E Ratio           0.1

Morphology:
-Spicular and cellular bone marrow aspirate markedly increased blasts with intermediate to large size, round to oval nuclei, fine chromatin, prominent nucleoli and scant cytoplasm. Myeloid maturation is markedly reduced. Erythroid precursors are orderly maturing. Megakaryocytes are present with unremarkable morphology.

PERIPHERAL BLOOD
CBC (12/25/2019):
WBC 7.3 [4.0-11.0 K/mcL] 
RBC 3.06 L [3.95-5.54 M/mcL] 
HGB 9.7 L [12.5-16.2 g/dL] 
HCT 29.7 L [37.5-49.3 %] 
MCV 97 [80-98 fL] 
MCH 31.7 [27.0-33.0 pg] 
MCHC 32.7 [31.0-36.5 g/dL] 
RDW 21.0 H [12.2-15.1 %] 
Platelets. 157 L [160-400 K/mcL] 

Neutrophil 8.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 25.0 H [0.0-0.0 %] 
Lymph 63.0 H [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 0.6 L [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 1.8 H [0.0-0.0 K/mcL] 
Abs Lymph 4.6 H [0.9-3.2 K/mcL]

Morphology:
WBC: Neutropenia. Frequent circulating blasts with morphology similar described in bone marrow aspirate smear
RBC: Normocytic anemia with anisopoikilocytosis.
PLT: Unremarkable.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 immunohistochemical stains show marked increase in blasts (approximately 70% of cellularity). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-12270)
Expanded abnormal myeloid blast population detected. 
No abnormal T cell populations detected.

The blasts have abnormal expression of CD25 (>10% of blasts), CD13 (absent to intermediate), CD15 (partial), CD33 (absent to intermediate), CD34 (uniform), CD38 (absent to dim), cytoplasmic CD79a (partial, dim), CD117 (absent to intermediate), CD123 (uniform intermediate); with normal expression of CD4, CD45, CD71 and HLA-DR without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD16, CD19, CD20, CD25, CD56, CD64 or surface light chains. MPO expression is not present on the blasts. CD34 positive myeloid blasts represent 90.0% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-8132.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-47628, M19-47629, M19-47630, M19-47631, M19-47633.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-8925;S12;MSK0 - 2023-06-20 10.14.28.ndpi,Peripheral Blood Smear,2023-06-20,"Multiple myeloma. SMM vs. MM.
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
 50% involvement by CD138 immunohistochemistry.
45% involvement by aspirate differential
15.8% involvement by 10-color flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality: Limited, hemorrhage, cortical bones
Cellularity: 40-50% at the preserved areas
Myeloid lineage: Orderly 
Erythroid lineage: Orderly maturation   
Megakaryocytes: Present  
Plasma cells: Increased
Clot section: The majority of cells seen are peripheral blood elements    

ASPIRATE MORPHOLOGY

Aspirate differential: (Performed by: SS)
Blasts                1%
Promyelocytes           1%
Myelocytes           8%
Metamyelocytes           3%
Neutrophils/Bands      14%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      20%
Plasma Cells           45% (patchy distribution ranging from 30%-60%)
Lymphocytes           6%
Number of Cells Counted 500
M:E Ratio           1.4

Morphology: 
Marrow spicules: Spicular    
Cellularity: Hypercellular  
Plasma cell morphology: Small to large, bi-nucleated, nucleolated, Dutcher bodies (nuclear pseudo-inclusion)
Myeloid lineage: Orderly maturation   
Erythroid Lineage: Orderly maturation   
Megakaryocytes:  Present    

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 50% of cellularity. 
Kappa and lambda immunostains show the plasma cells are lambda light chain restricted.  
BCMA highlights 90% of plasma cells, (2+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-10531) 
Abnormal plasma cell population detected.
No abnormal mature B-cell population detected.

Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (absent), CD27 (absent to dim), CD45 (major subset absent), CD56, CD81 (absent), CD117, and monoclonal lambda cytoplasmic light chain restriction; with normal expression of CD38 and CD138; and without CD20 expression.  The abnormal population represents 15.8% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 99.0% of total plasma cells in the sample.

No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.
PERIPHERAL BLOOD
CBC (11/06//2019):
WBC 5.2 [4.0-11.0 K/mcL] 
RBC 3.80 [3.80-5.00 M/mcL] 
HGB 12.6 [11.2-15.4 g/dL] 
HCT 39.1 [34.3-46.0 %] 
MCV 103 H [80-98 fL] 
MCH 33.2 H [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 13.6 [12.2-15.1 %] 
Platelets. 182 [160-400 K/mcL] 

Neutrophil 47.4 [32.5-74.8 %] 
Mono 7.6 [0.0-12.3 %] 
Eos 1.7 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 0.6 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 42.3 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 2.5 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 2.2 [0.9-3.2 K/mcL]

Morphology:

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7076, CG19-7077.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-40975



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-9752;S10;MSKG - 2023-06-20 18.09.45.ndpi,Peripheral Blood Smear,2023-06-20,"Lymphoma. CLL vs marginal zone lymphoma. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Mantle cell lymphoma, favor blastoid variant. see comment.

Comment:
The morphology on the biopsy is suboptimal but the cytologic features on the aspirate suggest blastoid variant. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
The biopsy is fragmented, suboptimal for evaluation. It shows multiple small lymphoid aggregates, intertrabecular and paratrabecular, composed of medium sized atypical lymphoid cells that have blastic nuclear features. The aspirate specimens show sheets of atypical lymphoid cells with intermediate size, slightly irregular nuclei, dispersed chromatin, small conspicuous nucleoli and intermediate amount of cytoplasm. Background trilineage hematopoiesis is markedly reduced.  

Aspirate differential: (Performed by CB)

Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           2%
Neutrophils/Bands      6%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      12%
Lymphocytes           4%
Other cells               70% (medium sized lymphoid cells with blast-like features)
Number of Cells Counted 500
M:E Ratio           1.2

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD20, PAX5, CD5, cyclinD1 (partial dim), SOX11 (partial). The lymphoma cells is approximately 30-40% of the total cells. 
Do not express: CD3, CD23, LEF1, P53, CMYC 
Other: Ki67 proliferation index is difficult to interpret but approximately 30-40% in focus with obvious involvement. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-11621) 
Abnormal B-cell population identified.
Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD20 (bright), CD23 (partial) and kappa surface light chain restriction (bright); normal expression of CD19, CD22, FMC7, CD38 and CD45; and without CD10 or CD200. The abnormal B cell population represents 29.2% of total white cells. This immunophenotype is compatible with mantle cell lymphoma.

No abnormal plasma cell population detected.
No evidence of an abnormal plasma cell population is identified by flow cytometry. 618450 cells acquired.

PERIPHERAL BLOOD
CBC (12/04/2019):
WBC 7.0 [4.0-11.0 K/mcL] 
RBC 3.72 L [3.80-5.00 M/mcL] 
HGB 9.8 L [11.2-15.4 g/dL] 
HCT 32.8 L [34.3-46.0 %] 
MCV 88 [80-98 fL] 
MCH 26.3 L [27.0-33.0 pg] 
MCHC 29.9 L [31.0-36.5 g/dL] 
RDW 20.1 H [12.2-15.1 %] 
Platelets. 105 L [160-400 K/mcL] 

Neutrophil 21.0 L [32.5-74.8 %] 
Mono 11.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Lymph 37.0 [12.2-47.4 %] 
Other 28.0 H [0.0-0.0 %] 
Abnormal lymphoid cells.

Nucleated RBC 0 [/100(WBCs)] 
Abs Neut 1.5 [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 2.6 [0.9-3.2 K/mcL] 
Abs Others 2.0 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBC: Many atypical lymphoid cells with similar morphology seen in marrow. 
RBC: Normocytic anemia.
PLT: Thrombocytopenia. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7726.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-45138, M19-45139, M19-45141.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-9090;S11;MSKM - 2023-06-20 10.59.52.ndpi,Peripheral Blood Smear,2023-06-20,"Myeloproliferative disorder. Newly diagnosed.
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Cellular marrow with trilineage maturing hematopoiesis and mild myeloid predominance and mild myeloid and erythroid dyspoiesis, see comment. 
  
COMMENT: The core biopsy is limited and insufficient for adequate evaluation of a myeloproliferative neoplasm (MPN). Aspirate smears are adequate but do not show overt dysplasia (<10% in each lineage), and flow cytometry does not detect an abnormal myeloid blast population. However, cytogenetic analysis detected an abnormal clone in all twenty metaphase cells with an unbalanced translocation der(2)t(1q;2q), which results in a partial gain of the long arm of chromosome 1 (CG19-7198), concerning for, but not diagnostic of, the presence of an underlying myeloid neoplasm (such as low-grade MDS or MDS/MPN). Currently the biopsy does not meet criteria for myelodysplastic syndrome (MDS) or an MDS/MPN and may be best classified as clonal cytopenia of undetermined significance (CCUS). Close clinical monitoring and a repeat biopsy is recommended if clinically indicated. Correlation with pending molecular studies may also be helpful for additional evaluation. An iron stain to fully rule out MDS with ring sideroblasts and multilineage dysplasia is in progress, and the results will be reported as an addendum. This case was reviewed with Dr. Mariko Yabe, who agrees with the diagnosis. 

BONE MARROW BIOPSY
Quality: Limited (subcortical, fragmented, aspiration artifact) with only small areas of marrow cellularity present. 
Cellularity: Cannot be assessed in the limited biopsy.  
M:E ratio: Appears increased in the limited biopsy. 
Blasts: Not increased in the limited biopsy. 
Myeloid lineage: Relatively increased, with progressive maturation. 
Erythroid lineage: Relatively decreased, with progressive maturation.
Megakaryocytes: Adequate in number with mostly unremarkable morphology and no significant cluster formation
Lymphocytes: Interstitially scattered. 
Plasma cells: Interstitially scattered.
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                3%
Promyelocytes           7%
Myelocytes           16%
Metamyelocytes           10%
Neutrophils/Bands      25%
Monocytes           18%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      14%
Plasma Cells           2%
Lymphocytes           3%
Number of Cells Counted 500
M:E Ratio           5.6

Morphology:
Spicular and cellular smears show trilineage maturing hematopoiesis. There is no increase in blasts. Myeloid elements are slightly increased in proportion with left-shifted and occasional hypogranularity (<10%). Erythroid elements are slightly decreased in proportion with progressive maturation and occasional irregular nuclear contours, nuclear budding (<10%). Megakaryocytes are present with occasional atypical forms (small, monolobated/ hypolobated).

PERIPHERAL BLOOD
CBC (11/12/2019):
WBC 8.1 [4.0-11.0 K/mcL] 
RBC 2.23 L [3.95-5.54 M/mcL] 
HGB 7.3 L [12.5-16.2 g/dL] 
HCT 24.0 L [37.5-49.3 %] 
MCV 108 H [80-98 fL] 
MCH 32.7 [27.0-33.0 pg] 
MCHC 30.4 L [31.0-36.5 g/dL] 
RDW 23.3 H [12.2-15.1 %] 
Platelets 73 L [160-400 K/mcL] 

Neutrophil 51.0 [32.5-74.8 %] 
Mono 29.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 6.0 H [0.0-0.0 %] 
Promyelocyte 2.0 H [0.0-0.0 %] 
Metamyelocyte 4.0 H [0.0-0.0 %] 
Lymph 8.0 L [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 4.2 [1.5-7.5 K/mcL] 
Abs Mono 2.4 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.5 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Meta 0.3 H [0.0-0.0 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBCs: Left-shifted present with occasional hypogranular neutrophils. No circulating blasts seen. 
RBCs: Macrocytic anemia with anisocytosis.
Platelets: Thrombocytopenia with occasional large and giant forms.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 stains show no increase in blasts (<5% total cellularity) in the limited biopsy. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-10746)
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature B- or T-cell populations detected.

CD34 positive myeloid blast population with apparent normal immunophenotype is 1.1% of WBC.
372,332 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.

CYTOGENETIC STUDIES (CG19-7198)
KARYOTYPE ANALYSIS:
Chromosome analysis of this sample revealed an abnormal clone in all twenty metaphase cells with an unbalanced translocation der(2)t(1q;2q), which results in a partial gain of the long arm of chromosome 1, and was observed in a previous bone marrow sample (7/22/2019) by an outside laboratory. Gain of 1q is frequently observed in myeloid neoplasm.

FISH ANALYSIS:
Gain of ANGPTL1 (1q25.2) detected in 96% of cells, consistent with the der(2)(1q;2q) observed by chromosome analysis.

No evidence of TP73 (1p36.3) deletion.
No evidence of RARA (17q21.2) gain.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-41730.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-1173;S11;MSKX - 2023-06-27 01.28.44.ndpi,Peripheral Blood Smear,2023-06-27,"Multiple Myeloma.  Newly diagnosed.  Protocol #: 17-352.
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
30% involvement by CD138 immunohistochemistry.
20% involvement by aspirate differential
4.2% involvement by 10-color flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality:  Adequate, Fragmented, Hemorrhage
Cellularity: 40%
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes:  Adequate   
Plasma cells: Increased    

ASPIRATE MORPHOLOGY
Aspirate differential: (Performed by: SS )
Patchy aspirate
Blasts                1%
Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           4%
Neutrophils/Bands      25%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      26%
Plasma Cells           20%(Area with up to 70% noted)
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           1.7

Morphology: 
Marrow spicules: Spicular    
Cellularity: Cellular   
Plasma cell morphology: Small to intermediate, Rare bi/multi nucleated, Few with nucleoli, Dutcher bodies (nuclear pseudo-inclusion),   
Myeloid lineage: Orderly maturation   
Erythroid Lineage: Orderly maturation   
Megakaryocytes:  Present    

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, patchy infiltration, overall 30% of cellularity. 
Kappa and lambda immunostains show the plasma cells are kappa restricted.  
BCMA highlights 100% of plasma cells, (2+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-1417) 
Abnormal plasma cell population detected.
No abnormal B cell population detected.

Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (absent), CD20 (partial), CD27 (absent), CD38 (dim), CD45 (absent), CD81 (absent) and monoclonal kappa cytoplasmic light chain restriction; with normal expression of CD138; and without CD56 or CD117 expression. The abnormal population represents 4.2% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 93.0% of total plasma cells in the sample.

PERIPHERAL BLOOD
CBC (02/12/2019):
WBC 7.2 [4.0-11.0 K/mcL] 
RBC 4.10 [3.80-5.00 M/mcL] 
HGB 11.3 [11.2-15.4 g/dL] 
HCT 36.4 [34.3-46.0 %] 
MCV 89 [80-98 fL] 
MCH 27.6 [27.0-33.0 pg] 
MCHC 31.0 [31.0-36.5 g/dL] 
RDW 12.9 [12.2-15.1 %] 
Platelets. 336 [160-400 K/mcL

Neutrophil 62.3 [32.5-74.8 %] 
Lymph 28.9 [12.2-47.4 %] 
Mono 8.1 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 4.5 [1.5-7.5 K/mcL] 
Abs Lymph 2.1 [0.9-3.2 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Nucleated RBC 0.0 [%]

Morphology:
No plasma cells seen on scanning

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-1011, CG19-1012.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-5619.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-937;S12;MSK5 - 2023-06-20 09.51.42.ndpi,Peripheral Blood Smear,2023-06-20,"Myelodysplastic syndrome. Rule out progression AML given severe thrombocytopenia following Azacacitidine on 12/10/18.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent myelodysplastic syndrome with ring sideroblasts, 2% blasts by aspirate differential count. 
     - Limited marrow biopsy with erythroid predominant hematopoiesis, granulocytic and megakaryocytic hypoplasia, and dyserythropoiesis.
  
BONE MARROW BIOPSY
Quality: Small, fragmented and hemorrhagic biopsy 
Cellularity: Appears normocellular for age (20-30% cellularity) 
M:E ratio: Markedly decreased 
Blasts: Not increased 
Myeloid lineage: Markedly decreased 
Erythroid lineage: Increased and show full maturation 
Megakaryocytes: Rare
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 
Clot section: Few marrow particles present with similar morphology to the core biopsy 
Others: Hemosiderin deposition and scattered mast cells present

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                2%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      4%
Monocytes           2%
Eosinophils           1%
Erythroid Precursors      55%
Plasma Cells           5%
Lymphocytes           29%
Number of Cells Counted  200
M:E Ratio           0.2

Special stain
Iron: Suboptimal for evaluation due to lack of spicules
Ring sideroblasts: Present >15% 

Morphology:
Paucispicular and hypocellular aspirate smears and touch imprint show erythroid predominant hematopoiesis with no increase in blasts. Erythroid elements show full maturation with dysplastic forms (binucleation, karyorrhexis, nuclear-cytoplasmic asynchrony, ring sideroblasts). Scattered maturing myeloid elements and rare megakaryocytes are present. Scattered mast cells are seen. 

PERIPHERAL BLOOD
CBC (02/05/2019):
WBC 1.6 L [4.0-11.0 K/mcL] 
RBC 2.81 L [3.80-5.00 M/mcL] 
HGB 8.4 L [11.2-15.4 g/dL] 
HCT 24.7 L [34.3-46.0 %] 
MCV 88 [80-98 fL] 
MCH 29.9 [27.0-33.0 pg] 
MCHC 34.0 [31.0-36.5 g/dL] 
RDW 14.1 [12.2-15.1 %] 
Platelets 4 LL [160-400 K/mcL] 

Neutrophil 17.5 L [32.5-74.8 %] 
Lymph 70.3 H [12.2-47.4 %] 
Mono 9.0 [0.0-12.3 %] 
Eos 1.3 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Immature Granulocyte 1.9 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Nucleated RBC 0.0 [%] 

Abs Neut 0.3 L [1.5-7.5 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Morphology: Pancytopenia with no circulating blasts. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts (<5%).
CD117 also highlights mildly increased and scattered mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-1127)
Abnormal myeloid blast population detected.
Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype somewhat similar to that seen in a prior sample (F18-9060) withabnormal expression of CD7 (partial), CD25, CD13 (uniform intermediate), CD33 (dim), CD38 (absent to dim), CD123 (uniform bright), HLADR (uniform, bright) with normal expression of CD4, CD34, CD45, CD71, CD117; without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD56 or CD64. CD34 positive myeloid blasts represent 1.7% of WBC.

While mast cells are mildly relatively increased they do not show abnormal expression of CD2 or CD25

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-809.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-4423, M19-4425, M19-4426, M19-4429.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-3215;S12;MSKX - 2023-05-10 21.53.43.ndpi,Peripheral Blood Smear,2023-05-10,"Leukemia.  PMH of MF + MDS treated with Jakafi and Revlimid, new pancytopenia with peripheral blasts.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - MDS with excess blasts-2 based on peripheral blood (16% blasts) and bone marrow (10% blasts)
  

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular (~95%)
M:E ratio: Reduced
Blasts: Increased
Myeloid lineage: Reduced with full maturation
Erythroid lineage: Left shifted with full maturation
Megakaryocytes: Reduced
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                10%
Promyelocytes           4%
Myelocytes           9%
Metamyelocytes           5%
Neutrophils/Bands      19%
Monocytes           3%
Eosinophils           3%
Erythroid Precursors      44%
Plasma Cells           1%
Lymphocytes           2%
Number of Cells Counted 500
M: E Ratio           1

Special stain
Iron: Absent
Ring sideroblasts: Absent

Morphology:
The aspirate smears are spicular and cellular and show an expanded population of medium to large sized blasts with moderate to scant basophilic cytoplasm, round to slightly irregular nuclei, fine chromatin and distinct nucleoli. Erythroid precursors show left shifted maturation with dysplastic features including megaloblastic changes, binucleation, irregular nuclei, nuclear budding, and karyorrhectic forms (>50%). The megakaryocytes show dysplastic features including nuclear separation and monolobation. Myeloid precursors show dysplastic features including atypical giant bands and hypogranular forms. 

PERIPHERAL BLOOD
CBC (04/24/2019):
WBC 24.8 H [4.0-11.0 K/mcL] 
RBC 2.67 L [3.80-5.00 M/mcL] 
HGB 8.2 L [11.2-15.4 g/dL] 
HCT 26.0 L [34.3-46.0 %] 
MCV 97 [80-98 fL] 
MCH 30.7 [27.0-33.0 pg] 
MCHC 31.5 [31.0-36.5 g/dL] 
RDW 24.2 H [12.2-15.1 %] 
Platelets 15 LL [160-400 K/mcL]

Neutrophil 37.0 [32.5-74.8 %] 
Mono 9.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 16.0 H [0.0-0.0 %] 
Myelocyte 15.0 H [0.0-0.0 %] 
Metamyelocyte 8.0 H [0.0-0.0 %] 
Lymph 14.0 [12.2-47.4 %] 
Nucleated RBC 10 [/100(WBCs)] 

Abs Neut 9.2 H [1.5-7.5 K/mcL] 
Abs Mono 2.2 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 4.0 H [0.0-0.0 K/mcL] 
Abs Myelocytes 3.7 H [0.0-0.0 K/mcL] 
Abs Meta 2.0 H [0.0-0.0 K/mcL] 
Abs Lymph 3.5 H [0.9-3.2 K/mcL] 

Morphology:
WBC: Left shift with frequent circulating blasts.
RBC: Anemia with anisopoikilocytosis
Platelet: Thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD117 highlights early erythroid and blasts. CD34 highlights blasts (less than 5% of cellularity). CD71 highlights erythroid precursors and E Cadherin highlights early erythroid precursors. MPO highlights myeloid cells. M:E ratio is approximately 1:1. 
CD61 highlights megakaryocytes including micromegakaryocytes forms. The blasts are negative for CD61. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-3747)
Interpretation: 
Abnormal myeloid blast and granulocyte populations detected. 
No abnormal mature B and T cell populations detected.

The myeloid blasts have abnormal expression of CD11b (partial), CD13 (uniform bright), CD25 (partial dim, <10% of blasts), CD33 (dim to absent), CD34 (uniform bright), CD38 (dim to absent), CD64 (partial), CD117 (uniform bright), CD123 (uniform bright), HLA-DR (bright); with normal expression of CD4, CD45, CD71; without CD2, surface CD3, CD5, CD7, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD56, or surface light chains. CD34 positive myeloid blasts represent 11.7% of WBC.

In addition, granulocytic population shows abnormal retention of CD13, CD64 and bright expression of CD14.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-2704.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-15072, M19-15073, M19-15074, and M19-15076.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-6853;S11;MSK7 - 2023-04-25 15.04.18.ndpi,Peripheral Blood Smear,2023-04-25,"Lymphoma. Follicular lymphoma vs DLBCL, needed to determine bone marrow involvement. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Minimal involvement by follicular lymphoma (<5%).
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show normocellular bone marrow (40%cellularity). There istrilineage maturing hematopoiesis with small interstitial aggregates of lymphoid cells. M:E ratio is preserved. Myeloid and erythroid lineages show full maturation. Megakaryocytes are unremarkable.

Aspirate differential: (Performed by CB)

Blasts                1%
Promyelocytes           1%
Myelocytes           10%
Metamyelocytes           13%
Neutrophils/Bands      43%
Monocytes           3%
Eosinophils           2%
Erythroid Precursors      24%
Plasma Cells           1%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           3

IMMUNOHISTOCHEMISTRY
Lymphoid aggregates consist of predominantly CD3 positive T cells with intermixed CD20 and PAX5 positive B cells. B cell accounts for <5% of marrow.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-7946) 
Interpretation: 
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD10, CD19 (dim to normal), CD20 (normal to bright), and kappa light chain restriction, and normal expression of CD22, CD38, and CD45; and without CD5. The abnormal B-cell population represents 0.060% of the total white cells.

PERIPHERAL BLOOD
CBC (08/26/2019):
WBC 8.0 [4.0-11.0 K/mcL] 
RBC 4.70 [3.80-5.00 M/mcL] 
HGB 12.6 [11.2-15.4 g/dL] 
HCT 39.5 [34.3-46.0 %] 
MCV 84 [80-98 fL] 
MCH 26.8 L [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 13.1 [12.2-15.1 %] 
Platelets. 188 [160-400 K/mcL] 

Neutrophil 74.9 H [32.5-74.8 %] 
Mono 9.8 [0.0-12.3 %] 
Eos 1.1 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 13.6 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 6.0 [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 1.1 [0.9-3.2 K/mcL] 

Morphology: Unremarkable

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-5500.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-31115.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-7951;S12;MSK8 - 2023-04-25 13.42.32.ndpi,Peripheral Blood Smear,2023-04-25,"MDS vs AML.  73 years old with history of ovarian cancer status post chemotherapy now with anemia and circulating blasts.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Therapy-Related Myeloid Neoplasm (t-MN) with Increased Blasts and monocytosis (6% Blasts by aspirate smear differential count) (See Comment)
     - Hypocellular marrow with trilineage maturing hematopoiesis and relative myeloid hyperplasia
  
COMMENT: Considering the patient's history of serous carcinoma of Mullerian primary, with treatment regimens including Carboplatin, paclitaxel, and gemcitabine since 2013, the findings are consistent with therapy-Related Myeloid Neoplasm (t-MN). Leukocytosis and relative/absolute monocytosis is noted, with the monocytosis present since at least 7/2019. In this context, a further classification of Therapy-Related Chronic Myelomonocytic Leukemia-1 (t-CMML-1) is favored.  

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Variably cellular, overall hypocellular for age (10-20% cellularity).
M:E ratio: Increased
Blasts: Increased interstitial blasts
Myeloid lineage: Proportionally increased with left-shifted, progressive maturation
Erythroid lineage: Proportionally decreased with mildly left-shifted maturation
Megakaryocytes: Small hypolobated forms seen
Lymphocytes: Scattered
Plasma cells: Scattered

Special stains: 
Reticulin stain shows no significant reticulin fibrosis (0/3). 

BONE MARROW ASPIRATE SMEAR/ TOUCH PREPARATION
Differential: (Performed by CB)
Hemodilute/hypocellular aspirate devoid of spicules. Extrinsic cells are not seen
Blasts                6%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      19%
Monocytes           56%
Eosinophils           1%
Erythroid Precursors      5%
Lymphocytes           9%
Number of Cells Counted 500
M:E Ratio           16

Special stain
Iron: Cannot evaluate storage iron in a smear devoid of spicules
Ring sideroblasts: Not identified. However, sensitivity is limited due to paucity of erythroid elements 

Morphology:
Hypocellular, aspicular, and hemodiluted smears with maturing myeloid elements, with an increase in intermediate- to large-sized blasts and promonocytes (blast equivalent). There is also a marked increase in mature monocytes, but a marked decrease in erythroid elements. Scattered mature-appearing small lymphoid cells are seen. Megakaryocytes are not readily identified.
The touch preparation shows similar findings.

PERIPHERAL BLOOD
CBC (10/03/2019):
WBC 11.8 H [4.0-11.0 K/mcL] 
RBC 2.44 L [3.80-5.00 M/mcL] 
HGB 9.1 L [11.2-15.4 g/dL] 
HCT 29.3 L [34.3-46.0 %] 
MCV 120 H [80-98 fL] 
MCH 37.3 H [27.0-33.0 pg] 
MCHC 31.1 [31.0-36.5 g/dL] 
RDW 15.8 H [12.2-15.1 %] 
Platelets. 245 [160-400 K/mcL] 

Neutrophil 33.0 [32.5-74.8 %] 
Mono 32.0 H [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 2.0 H [0.0-0.0 %] 
Lymph 32.0 [12.2-47.4 %] 
Nucleated RBC 8 [/100(WBCs)] 

Abs Neut 3.9 [1.5-7.5 K/mcL] 
Abs Mono 3.8 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 3.8 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBC: Leukocytosis with absolute and relative monocytosis. Scattered circulating blasts/blast equivalent seen.
RBC: Macrocytic anemia with moderate anisopoikilocytosis. Scattered nucleated RBC's seen.
Platelets: Some large platelets seen.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight increased interstitial blasts (5-9% of cellularity), with small cluster formation.
CD61, CD71 and MPO stains are pending and will be reported in an addendum.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-9318)
Interpretation: 
Abnormal myeloid blast population detected.
No abnormal B and T cell populations detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD2 (subset dim), CD5 (minute subset dim), CD11b (negative to dim), CD13 (bright), CD25 (negative to intermediate), CD33 (bright), CD117 (bright),with normal expression of CD4, CD34, CD38, CD45, CD71, CD123 and HLA-DR; without surface CD3, cytoplasmic CD3, CD7, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD56, CD64, cytoplasmic CD79a or surface light chains. MPO expression is present on a subset of blasts. CD34 positive myeloid blasts represent 7.5% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-6344.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-36153, M19-36154, M19-36155, M19-36156, M19-36157.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-8904;S10;MSKO - 2023-06-20 10.26.07.ndpi,Peripheral Blood Smear,2023-06-20,"Burkitt lymphoma. Asses Burkitt lymphoma.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by high grade B cell lymphoma consistent with Burkitt lymphoma (80% with CD20 immunohistochemistry)
     - Cellular marrow with trilineage maturing hematopoiesis.

COMMENT:
As per outside report, c-MYC rearrangement was detected in the molecular studies performed in a previous specimen not available for review (Foundation Medicine report ORD-674680)

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Inadequate biopsy specimen shows variably cellular bone marrow for age (10-60% cellularity) with paratrabecular and interstitital  lymphoid aggregates composed of medium sized cells with condensed chromatin. There istrilineage maturing hematopoiesis. The aspirate smear is paucispicular and cellular and shows trilineage maturing hematopoiesis with atypical lymphoid cells, which are small to medium in size and display basophilic cytoplasm with vacuoles.

Aspirate differential: (Performed by MT)
Erythroid Precursors      2%
Plasma Cells           1%
Lymphocytes           2%
Other cells          95% (atypical lymphoid cells with vacuoles)
Number of Cells Counted 500 
M: E Ratio           0

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD20, PAX5
Do not express: CD3
CD3 highlight background T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-10507) 
Interpretation: 
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD10, CD38 (bright), CD45 (dim to normal), increased forward and side scatter suggestive of larger size, kappa light chain restriction (bright), and normal expression of CD19, CD20, and CD22; and without CD5. The abnormal B-cell population represents 84.1% of the total white cells.  

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

PERIPHERAL BLOOD
CBC (11/04/2019):
WBC 0.8 L [4.0-11.0 K/mcL] 
RBC 3.19 L [3.95-5.54 M/mcL] 
HGB 9.5 L [12.5-16.2 g/dL] 
HCT 29.3 L [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 29.8 [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL] 
RDW 17.2 H [12.2-15.1 %] 
Platelets. 20 LL [160-400 K/mcL]  

Neutrophil 4.0 L [32.5-74.8 %] 
Mono 12.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 60.0 H [12.2-47.4 %] 
Other 21.0 H [0.0-0.0 %] 
Abnormal lymphoid cells.
Nucleated RBC 4 [/100(WBCs)] 

Abs Neut 0.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.5 L [0.9-3.2 K/mcL] 
Abs Others 0.2 H [0.0-0.0 K/mcL]

Attending Review Final 
Cells designated ""Other"" are intermediate to large sized abnormal lymphoid cells with moderately coarse chromatin and deep basophilic cytoplasm with cytoplasmic vacuoles. Correlate with flow cytometry for further characterization if indicated. I attest that the above interpretation/recommendation is based upon my personal examination of the source material and patient clinical history, if indicated, and that I have reviewed this report.
Maly Fenelus MD Prov ID: 023085
11/05/2019 1:02 PM EST

Morphology:

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. 

MOLECULAR STUDIES 
Not requested


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-1212;S11;MSKR - 2023-06-20 09.45.52.ndpi,Peripheral Blood Smear,2023-06-20,"Breast ca. Pancytopenia, concern for breast ca. Breast ca marrow involvement, HER2. ER/ PR. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Metastatic poorly differentiated carcinoma (see note)
     - Hypercellular marrow with markedly reduced hematopoiesis.

Note: The tumor shows focal morphologic overlap with patient's prior left breast carcinoma (S18-72104). Immunohistochemical stains demonstrate the tumor cells are diffusely positive for OSCAR and focally, weakly positive for GATA3. The case was seen in consultation with Dr. K. Petrova-Drus, of the hematopathology service, who rendered the assessment below.

Immunohistochemical stains for ER, PR, and HER2 will be performed and the results reported in an addendum. 

BONE MARROW BIOPSY
Bone marrow biopsy shows extensive involvement by metastatic carcinoma. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HH)
Blasts                1%
Promyelocytes           1%
Myelocytes           11%
Metamyelocytes           6%
Neutrophils/Bands      29%
Monocytes           4%
Eosinophils           2%
Erythroid Precursors      9%
Plasma Cells           2%
Lymphocytes           35%
Number of Cells Counted  200
M:E Ratio           5.9

Morphology:
Aspirate smears are aspicular, hemodilute and hypocellular with scattered maturing hematopoietic elements. Cohesive clusters of epithelial cells are present.  

PERIPHERAL BLOOD
CBC (02/13/2019):
WBC 4.4 [4.0-11.0 K/mcL] 
RBC 2.41 L [3.80-5.00 M/mcL] 
HGB 6.9 L [11.2-15.4 g/dL] 
HCT 22.7 L [34.3-46.0 %] 
MCV 94 [80-98 fL] 
MCH 28.6 [27.0-33.0 pg] 
MCHC 30.4 L [31.0-36.5 g/dL] 
RDW 16.4 H [12.2-15.1 %] 
Platelets 17 LL [160-400 K/mcL] 

Neutrophil 67.0 [32.5-74.8 %] 
Lymph 20.0 [12.2-47.4 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 2.9 [1.5-7.5 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Metamyelocyte 4.0 H [0.0-0.0 %] 
Myelocyte 5.0 H [0.0-0.0 %] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 5 [/100(WBCs)] 

Morphology: No circulating blasts. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increased blasts. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H19-2314;S13;MSKX - 2023-06-20 19.11.36.ndpi,Peripheral Blood Smear,2023-06-20,"AML.  MDS/AML status post Cytarabine/Daunorubicin, Day 14.
","1-3. Bone marrow, left posterior iliac crest, core biopsy, clot section, aspirate and peripheral blood smears: 
     - Acute myeloid leukemia with myelodysplasia related changes (AML-MRC), 55% blasts by aspirate differential, see comment.
  
Comment: The current biopsy shows scattered, round mast cells without cluster formation or significantly increased atypical spindled forms. However, an atypical mast cell population with bright CD25 expression but without convincing CD2 was detected by flow cytometry. Clinical follow-up is advised. This case was reviewed with Dr. Mariko Yabe, who agrees with the diagnosis. 

BONE MARROW BIOPSY
Quality: Adequate (aspiration artifact). 
Cellularity: Hypocellular for age (20%).
M:E ratio: N/A
Blasts: Increased, scattered interstitially and forming small clusters; intermediate sized blasts with irregular nuclei, dispersed chromatin and prominent nucleoli.
Myeloid lineage: Reduced.
Erythroid lineage: Reduced.
Megakaryocytes: Rare.
Lymphocytes: Scattered. 
Plasma cells: Scattered. 
Special stains: Reticulin stain shows no increase in reticulin fibrosis. 
Clot section: Consists mostly of blood with minimal scattered hematopoietic elements.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)

Blasts                55%
Promyelocytes           1%
Neutrophils/Bands      2%
Basophils           2%
Erythroid Precursors      1%
Plasma Cells           12%
Lymphocytes           27%
Number of Cells Counted 500
M:E Ratio           5

Morphology: The aspirate smears are spicular and cellular and show an expanded population of medium to large sized blasts with irregular to indented nuclei, fine chromatin, variably prominent nucleoli and scant cytoplasm with rare small vacuoles, in a background of decreased trilineage hematopoiesis. Myeloid and erythroid elements are markedly decreased in proportion. Megakaryocytes are rare. Plasma cells with mature morphology are increased in proportion. Rare mast cells are also seen.

PERIPHERAL BLOOD
CBC (03/25/2019):
WBC <0.1 LL [4.0-11.0 K/mcL].
RBC 2.25 L [3.95-5.54 M/mcL] 
HGB 7.4 L [12.5-16.2 g/dL] 
HCT 21.6 L [37.5-49.3 %] 
MCV 96 [80-98 fL] 
MCH 32.9 [27.0-33.0 pg] 
MCHC 34.3 [31.0-36.5 g/dL] 
RDW 14.8 [12.2-15.1 %] 
Platelets. 22 L [160-400 K/mcL]

Morphology: Pancytopenia.
WBCs: Marked leukopenia with virtually no white blood cells seen.
RBCs: Normocytic, normochromic anemia with slight anisopoikilocytosis (occasional echinocytes).  
Platelets: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 stains show increased blasts, approximately 50% of marrow cellularity. 
CD117 stain brightly highlights predominantly the blasts. The CD117 stain also highlights mast cells; however, the mast cells are difficult to differentiate due to the high involvement by blasts.   
Tryptase stain highlights scattered, predominantly round mast cells without cluster formation and few atypical spindled forms. 
The mast cells express CD25 (weak) but do not express CD2. 
CD2 and CD3 stains highlight scattered small T-cells in similar distribution patterns. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-2705)
Abnormal myeloid blast population detected. 
Atypical mast cell population seen.

The blasts have abnormal expression of CD13 (uniform, bright), CD25, CD33 (bright), CD71 (dim), CD117 (bright), CD123 (uniform intermediate) and HLA-DR (bright); with normal expression of CD4, CD34, CD38, CD45; without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD56, CD64. CD34 positive myeloid blasts represent 15.9% of WBC. 

In addition, atypical mast cell population is present, with bright CD117 and bright CD25 expression, without convincing CD2, representing 0.82% of the WBC by flow cytometry.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available. 

CYTOGENETIC STUDIES
Not requested/performed. 

MOLECULAR STUDIES 
Not requested/performed. 



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-3560;S2;MSK9 - 2023-05-10 22.04.05.ndpi,Peripheral Blood Smear,2023-05-10,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears:
     - Acute myeloid leukemia, 52% blasts, see comment

COMMENT: Clinical history, Cytogenetic and molecular studies are required for further classification. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                52%
Promyelocytes           4%
Myelocytes           8%
Metamyelocytes           2%
Neutrophils/Bands      5%
Monocytes           2%
Eosinophils           1%
Erythroid Precursors      16%
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           1.4

Morphology: The aspirate smears are spicular and cellular and show an expanded population of medium to large sized blasts with moderate amounts of light blue cytoplasm with azurophilic granules and frequent Auer rods, round to irregular nuclei, fine chromatin and distinct nucleoli, in a background of trilineage hematopoiesis. Background myeloid elements show left shifted maturation while background erythroid elements show are reduced and show rare nuclear irregularities. Megakaryocytes are present and unremarkable. 

PERIPHERAL BLOOD
CBC (05/03/2019):
WBC 0.6 L [4.0-11.0 K/mcL] 
RBC 2.41 L [3.95-5.54 M/mcL] 
HGB 7.8 L [12.5-16.2 g/dL] 
HCT 21.8 L [37.5-49.3 %] 
MCV 91 [80-98 fL] 
MCH 32.4 [27.0-33.0 pg] 
MCHC 35.8 [31.0-36.5 g/dL] 
RDW 13.8 [12.2-15.1 %] 
Platelets. 32 L [160-400 K/mcL] 

Neutrophil 33.0 [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 12.0 H [0.0-0.0 %] 
Lymph 53.0 H [12.2-47.4 %] 
Nucleated RBC 2 [/100(WBCs)] 

Abs Neut 0.2 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 

Morphology:
Pancytopenia with occasional circulating blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-4083)
Abnormal myeloid blast population detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample F19-4043 have abnormal expression of CD13 (bright), CD15, CD33 (dim to bright), CD34 (subset absent, subset dim), and CD123 (uniform, bright); with normal expression of CD4, CD38, CD45, CD71, CD117, and HLA-DR without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD11b, CD14, CD16, CD19, CD25, CD56, CD64, or cyCD79a. MO expression is present on a subset of blasts. CD117 positive myeloid blasts represent 43.0% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-2913, CG19-2914.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-16336 to M19-16338.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. Pessin MD., PhD., Director.
"
H19-1965;S11;MSK6 - 2023-05-10 21.12.06.ndpi,Peripheral Blood Smear,2023-05-10,"T-LGL, MDS.  68 years old man with persistent neutropenia, thrombocytopenia despite T-LGL treatment.  Also has MDS.  +IDH2 and SRSF2 mutations on Impact heme.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Myelodysplastic syndrome with excess blasts-2 (MDS-EB-2), 17% blast by aspirate differential, see comment. 
  
COMMENT: Corresponding flow cytometric analysis is in progress, and the results will be reported separately (F19-2317). Morphologically, large granular lymphocytes are not increased in this bone marrow sample. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: 50-60%
M:E ratio: Decreased
Blasts: Increased
Myeloid lineage: Progressive maturation 
Erythroid lineage: Progressive maturation 
Megakaryocytes: Present with occasional small hypolobated forms  
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                17%
Promyelocytes           6%
Myelocytes           4%
Metamyelocytes           3%
Neutrophils/Bands      9%
Monocytes           10%
Eosinophils           1%
Erythroid Precursors      40%
Plasma Cells           1%
Lymphocytes           9%
Number of Cells Counted 500
M:E Ratio           0.8

Special stain
Iron: Present
Ring sideroblasts: Present 5% to 15%  

Morphology: The aspirate smears are spicular and cellular and show an expanded population of small to medium sized blasts with scant amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli, in a background of erythroid predominant trilineage hematopoiesis. Background myeloid elements show progressive maturation and hypogranular neutrophils while background erythroid elements show megaloblastic changes, few with vacuolated cytoplasm and rare binucleation. Megakaryocytes are present and occasional small hypolobated forms.  

PERIPHERAL BLOOD
CBC (03/13/2019):
WBC 1.9 L [4.0-11.0 K/mcL] 
RBC 3.23 L [3.95-5.54 M/mcL] 
HGB 10.1 L [12.5-16.2 g/dL] 
HCT 32.0 L [37.5-49.3 %] 
MCV 99 H [80-98 fL] 
MCH 31.3 [27.0-33.0 pg] 
MCHC 31.6 [31.0-36.5 g/dL] 
RDW 20.7 H [12.2-15.1 %] 
Platelets 36 L [160-400 K/mcL]
 
Neutrophil 19.1 L [32.5-74.8 %] 
Lymph 55.7 H [12.2-47.4 %] 
Mono 22.7 H [0.0-12.3 %] 
Eos 1.5 [0.0-4.9 %] 
Baso 0.5 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 0.4 L [1.5-7.5 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Nucleated RBC 1.0 [%] 

Morphology:
Pancytopenia with several hypogranular and hypolobated neutrophils. A few large granular lymphocytes are seen.     

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains for CD34 and CD117 show increased blasts, approximately 10-15% of the bone marrow cellularity. 
CD34 also highlights megakaryocytes. 
CD117 also highlights erythroid precursors.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-2317)
Flow cytometric analysis will be reported separately. See separate report, F19-2317.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-1652.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-9574.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-2098;S11;MSKD - 2023-05-12 12.12.31.ndpi,Peripheral Blood Smear,2023-05-12,"AML. Vidaza/Enasidenib.
","1-3. Bone marrow, right posterior iliac crest,biopsy; aspirate and peripheral blood smears: 
     - Persistent acute myeloid leukemia (35% blasts on aspirate)

BONE MARROW BIOPSY
Quality: Adequate, aspiration artifact seen
Cellularity: Normal to slightly decreased
M:E ratio: Increased
Blasts: Increased
Myeloid lineage: Maturation is seen
Erythroid lineage: Maturation is seen, proportionally decreased
Megakaryocytes: Few seen
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                35%
Promyelocytes           2%
Myelocytes           5%
Metamyelocytes           3%
Neutrophils/Bands      22%
Monocytes           10%
Eosinophils           1%
Basophils           2%
Erythroid Precursors      7%
Plasma Cells           1%
Lymphocytes           12%
Number of Cells Counted 500
M:E Ratio           6.4


Morphology:
-Spicular and cellular with marked increase in blasts, pronounced granulocytic dysplasia (hypogranulation, hypolobation), some granulocytes may represent markedly hypogranular basophils based on flow cytometry findings, basiohilia, megakaryocytic dysplasia (hypolobation) and reduced erythroid forms 

PERIPHERAL BLOOD
CBC (03/18/2019):
WBC 5.0 [4.0-11.0 K/mcL] 
RBC 2.67 L [3.80-5.00 M/mcL] 
HGB 8.2 L [11.2-15.4 g/dL] 
HCT 26.1 L [34.3-46.0 %] 
MCV 98 [80-98 fL] 
MCH 30.7 [27.0-33.0 pg] 
MCHC 31.4 [31.0-36.5 g/dL] 
RDW 15.9 H [12.2-15.1 %] 
Platelets 43 L [160-400 K/mcL] 

Neutrophil 51.0 [32.5-74.8 %] 
Lymph 21.0 [12.2-47.4 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 6.0 H [0.0-1.5 %]
 
Abs Neut 2.6 [1.5-7.5 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.3 H [0.0-0.2 K/mcL] 

Metamyelocyte 2.0 H [0.0-0.0 %] 
Blast 14.0 H [0.0-0.0 %] 

Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Absolute Blasts 0.7 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 2 [/100(WBCs)] 
Nucleated RBC 1 [/100(WBCs)] 
Morphology: Numerous blasts seen, basophilia, thromobocytopenia, anemia, dysplastic granulocytes

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight increased blasts (30-40%)

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-2480)
Abnormal myeloid blast population detected. 
Basophlia seen, representing 19.6% of WBC.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD7 (subset), CD56 (subset), CD34 (bright), CD38 (dim), CD71 (bright), CD117 (bright), CD123(bright), HLADR (bright) with normal expression of CD4, CD13, CD33, CD45; without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25 or CD64. CD34 positive myeloid blasts represent 26.3% of WBC.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     
"
H19-9111;S12;MSKY - 2023-06-26 21.55.40.ndpi,Peripheral Blood Smear,2023-06-26,"MDS.  POD.
","1-3. Bone marrow, right posterior iliac crest; biopsy. aspirate and peripheral blood smears: 
    - Hypercellular bone marrow with dyserythropoiesis and ring sideroblasts, consistent with myelodysplastic syndrome with single lineage dysplasia and ring sideroblasts (MDS-SLD-RS), 2% blasts by aspirate differential count; see comment.

COMMENT: Given the history of anemia and concurrent SF3B1 mutation detected in peripheral blood, the findings of dyserythropoiesis and ring sideroblasts is consistent with MDS-SLD-RS. Peripheral blood shows hypochromasia and numerous elliptocytes in the RBC lineage, and iron storage in the marrow appears mildly reduced; findings raise the possibility of an additional component of iron deficiency contributing to the patient's anemia. Correlation with additional laboratory studies to exclude concurrent iron deficiency anemia is recommended. In addition, correlation with pending cytogenetic and molecular studies is required. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular (~70%)
M:E ratio: Mildly decreased
Blasts: Not increased (<5%) 
Myeloid lineage: Exhibits full maturation 
Erythroid lineage: Exhibits left-shifted maturation, relatively increased 
Megakaryocytes: Present with occasional small hypolobated forms 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows no significant increase in reticulin fibers (0/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                2%
Promyelocytes           2%
Myelocytes           5%
Metamyelocytes           4%
Neutrophils/Bands      30%
Monocytes           2%
Eosinophils           2%
Basophils           1%
Erythroid Precursors      34% (several aggregates noted)
Plasma Cells           1%
Lymphocytes           17%
Number of Cells Counted 500
M:E Ratio           1.4

Special stain
Iron: Present, reduced
Ring sideroblasts: Present >15% 

Morphology: The aspirate smears are spicular, cellular and show maturing trilineage hematopoiesis; no expanded blast population is seen. The M:E ratio is mildly reduced, and the smears are focally erythroid predominant. Myeloid elements show full maturation without overt dysplasia. Erythroid elements show dyserythropoiesis (nuclear irregularities, polylobation, binucleation, late stage mitoses, innumerable ring sideroblasts seen on iron stain). Megakaryocytes are present and predominantly unremarkable. 

PERIPHERAL BLOOD
CBC (11/12/2019):
WBC 4.9 [4.0-11.0 K/mcL] 
RBC 2.77 L [3.95-5.54 M/mcL] 
HGB 8.6 L [12.5-16.2 g/dL] 
HCT 25.8 L [37.5-49.3 %] 
MCV 93 [80-98 fL] 
MCH 31.0 [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 31.2 H [12.2-15.1 %] 
Platelets. 255 [160-400 K/mcL] 

Neutrophil 68.7 [32.5-74.8 %] 
Mono 10.4 [0.0-12.3 %] 
Eos 2.2 [0.0-4.9 %] 
Baso 1.8 H [0.0-1.5 %] 
Immature Granulocyte 0.2 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 16.7 [12.2-47.4 %] 
Nucleated RBC 0.6 [%] 

Abs Neut 3.4 [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Abs Lymph 0.8 L [0.9-3.2 K/mcL]

Morphology:
WBC: Unremarkable morphology; no circulating blasts seen; no significant dysplasia is seen.
RBC: Normocytic, hypochromic anemia with anisopoikilocytosis. Frequent elliptocytes seen. 
PLT: Unremarkable morphology. 

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains show no increases in CD34 and/or CD117 positive blasts (<5%). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-10775)
Please see separate report, F19-10775.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F19-10780)
Please see separate report, F19-10780.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7212.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports from peripheral blood, M19-41849 and M19-41851.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-9670;S11;MSKG - 2023-06-20 13.20.41.ndpi,Peripheral Blood Smear,2023-06-20,"Lymphoma. Anemia, r/o involvement by MCL. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Mantle cell lymphoma, 10-15% involvement with CD20 immunohistochemistry, see comment 
     - Mildly hypercellular marrow for age with trilineage maturing hematopoiesis.

COMMENT: Morphologic and immunophenotypic findings are consistent with involvement by the patient's previously diagnosed mantle cell lymphoma. Cyclin D1 and SOX11 immunohistochemistry are in progress, and the results will be reported as an addendum. Confirmation of Cyclin D1 translocation by FISH analysis is in progress, and the result will be reported separately (CG19-7662).   

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
The core biopsy shows mildly hypercellular marrow for age (50-60% cellularity) with maturing trilineage hematopoiesis. There are a few lymphoid aggregates composed mostly of small lymphoid cells with irregular nuclear contours.

Aspirate smear morphology:
Spicular and cellular smears showing maturing trilineage hematopoiesis, with no increase in blasts. Myeloid and erythroid elements exhibit progressive maturation with no significant dysplasia. Megakaryocytes are adequate in number with predominantly unremarkable morphology. The lymphoid cells comprise mostly of small and mature-appearing lymphocytes.

Aspirate differential: (Performed by MT)

Blasts                1%
Promyelocytes           2%
Myelocytes           10%
Metamyelocytes           4%
Neutrophils/Bands      35%
Monocytes           2%
Eosinophils           3%
Erythroid Precursors      33%
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           1.7

Special stain:
Iron: Absent
Ring Sideroblasts: Absent

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlights increase in B-cells, comprising 10-15% of cellularity. 
CD3 labels reactive T-cells
Cyclin D1 and SOX11 immunohistochemistry are in progress, and the results will be reported as an addendum.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-11518) 
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD19 (dim), CD22 (dim) and kappa surface light chain restriction; normal expression of CD20, FMC7, CD38 and CD45; and without CD10, CD23 or significant CD200.  The abnormal B cell population represents 20.5% of total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with immunohistochemical or cytogenetic studies for Cyclin D1 is recommended to rule out mantle cell lymphoma.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.
Also see F19-11488 submitted on the same day.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F19-11488) 
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD19 (dim), CD20 (bright), CD22 (dim to normal), and kappa surface light chain restriction; normal expression of FMC7, CD38 and CD45; and without CD10, CD23 or significant CD200.  The abnormal B cell population represents 10.3% of total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with immunohistochemical or cytogenetic studies for Cyclin D1 is recommended to rule out mantle cell lymphoma.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

PERIPHERAL BLOOD
CBC (12/03/2019):
WBC 7.0 [4.0-11.0 K/mcL] 
RBC 2.64 L [3.80-5.00 M/mcL] 
HGB 8.0 L [11.2-15.4 g/dL] 
HCT 25.6 L [34.3-46.0 %] 
MCV 97 [80-98 fL] 
MCH 30.3 [27.0-33.0 pg] 
MCHC 31.3 [31.0-36.5 g/dL] 
RDW 14.7 [12.2-15.1 %] 
Platelets. 160 [160-400 K/mcL] 

Neutrophil 58.0 [32.5-74.8 %] 
Mono 9.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 11.0 L [12.2-47.4 %] 
Other 21.0 H [0.0-0.0 %] 
Abnormal lymphoid cells with folded- clefted nuclei.
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 4.1 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 
Abs Others 1.5 H [0.0-0.0 K/mcL]

Attending Review 
Cells designated ""Other"" are abnormal lymphoid cells with moderately coarse chromatin and irregular nuclear contours. Correlate with flow cytometry for further characterization if indicated. I attest that the above interpretation/recommendation is based upon my personal examination of the source material and patient clinical history, if indicated, and that I have reviewed this report.
Maly Fenelus MD Prov ID: 023085
12/03/2019 4:25 PM EST

Morphology: 
WBC: Abnormal lymphoid cells with folded/clefted nuclei seen. No increase in blasts.
RBC: Normocytic anemia
Platelets: Unremarkable.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7662.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-44694, M19-44695.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-2145;S10;MSK6 - 2023-06-20 17.47.14.ndpi,Peripheral Blood Smear,2023-06-20,"ALL.  Relapsed ALL status post transplant, screening for CD19 CAR T cells.  Protocol # 17-621.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma
     - Hypercellular marrow with virtually no residual hematopoiesis 
  
COMMENT:

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly increased (replaced by blasts), >90%

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                96%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           0

Morphology:
-Hypercellular smears show replacement of hematopoiesis by blasts 

PERIPHERAL BLOOD
CBC (03/19/2019):
WBC 0.6 L [4.0-11.0 K/mcL] 
RBC 2.57 L [3.80-5.00 M/mcL] 
HGB 8.4 L [11.2-15.4 g/dL] 
HCT 24.5 L [34.3-46.0 %] 
MCV 95 [80-98 fL] 
MCH 32.7 [27.0-33.0 pg] 
MCHC 34.3 [31.0-36.5 g/dL] 
RDW 17.5 H [12.2-15.1 %] 
Platelets. 12 LL [160-400 K/mcL] 

Neutrophil 18.0 L [32.5-74.8 %] 
Lymph 57.0 H [12.2-47.4 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 0.1 L [1.5-7.5 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Metamyelocyte 1.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Blast 23.0 H [0.0-0.0 %] 

Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 

Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)]

Morphology: Pancytopenia, many blasts seen

IMMUNOHISTOCHEMISTRY
CD34 and TdT highlight blasts

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-2540)
Abnormal immature B-cell population detected.
An abnormal immature B-cell population is identified by flow cytometry. The abnormal immature B-cells represent 90.6% of the white cells and 93.4% of the mononuclear cells in the sample and abnormally express CD10 (absent to intermediate), CD19 (slightly bright), CD22 (absent to intermediate), CD33 (partial), CD34 (bright), CD38 (dim to negative), CD45 (absent to intermediate), CD58 (bright); with normal expression of CD24; and without CD20 or CD66b.  This finding is consistent with persistent/recurrent B-lymphoblastic leukemia/lymphoma, depending on the clinical context.  Clinical and morphologic correlation is recommended.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-1810.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-10240 and 10241.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-7324;S10;MSK0 - 2023-04-25 14.23.22.ndpi,Peripheral Blood Smear,2023-04-25,"Lymphoma, Follicular
Eval for Lymphoma 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by follicular lymphoma (60-70% with PAX5 immunohistochemistry)
     - Background cellular marrow with erythroid predominant hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show hypercellular bone marrow (90%cellularity). There are prominent para-trabecular lymphoid aggregates predominantly composed of small cleaved cells. Background hematopoiesis shows erythroid predominance. Megakaryocytes are unremarkable.

Aspirate differential: (Performed by MT)

Blasts                1%
Promyelocytes           2%
Myelocytes           4%
Neutrophils/Bands      2%
Monocytes           1%
Eosinophils           3%
Erythroid Precursors      15%
Lymphocytes           26%
Others                46% (Large lymphoid cells with prominent nucleoli)
Number of Cells Counted 500
M:E Ratio           0.8

IMMUNOHISTOCHEMISTRY
PAX5 immunostain highlights the para-trabecular lymphoid aggregates. CD20 is negative. CD3 labels reactive T-cells

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-8520) 
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. Very few CD34 positive blasts seen.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD5 (partial, dim), CD19 (slightly bright), CD20 (absent, consistent with anti-CD20 therapy), CD38 (absent), kappa light chain restriction, and normal expression of CD22 and CD45; and without CD5 or CD10. The abnormal B-cell population represents 41.6% of the total white cells.

344,385 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition.

PERIPHERAL BLOOD
CBC (9/12/2019):
WBC 6.5 [4.0-11.0 K/mcL] 
RBC 2.57 L [3.95-5.54 M/mcL] 
HGB 8.5 L [12.5-16.2 g/dL] 
HCT 26.6 L [37.5-49.3 %] 
MCV 104 H [80-98 fL] 
MCH 33.1 H [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 19.8 H [12.2-15.1 %] 
Platelets. 20 LL [160-400 K/mcL

Neutrophil 22.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 5.0 H [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Lymph 54.0 H [12.2-47.4 %] 
Other 16.0 H [0.0-0.0 %] 
Abnormal lymphoid cells.
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 1.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Abs Lymph 3.5 H [0.9-3.2 K/mcL] 
Abs Others 1.0 H [0.0-0.0 K/mcL] 

Morphology: Absolute and relative lymphocytosis with atypical lymphocytes. Macrocytic anemia. Thrombocytopenia.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-5857.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-33291.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-4266;S13;MSK5 - 2023-07-19 12.43.27.ndpi,Peripheral Blood Smear,2023-07-19,"Pancytopenia
51 yo man w/ Pancytopenia, low- level circulating blasts. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Acute myeloid leukemia (22% myeloid blasts)
 
COMMENT:
Correlation with clinical history (length of cytopenias to exclude prior MDS), as well as cytogenetic and molecular genetic studies is advised for further diagnostic and prognostic information 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Slightly increased (60-70%)
M:E ratio: Normal 
Blasts: Increased
Myeloid lineage: Full maturation 
Erythroid lineage: Full maturation 
Megakaryocytes: Present without frank dysmorphology, slightly reduced 
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows mild to focally moderate increase in reticulin fibrosis (MF-1-2+/3). 
Clot section:

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Aspirate with scanty spiculated material present.

Blasts                22%
Promyelocytes           4%
Myelocytes           6%
Metamyelocytes           3%
Neutrophils/Bands      28%
Monocytes           4%
Eosinophils           1%
Erythroid Precursors      23%
Lymphocytes           9%
Number of Cells Counted 500
M:E Ratio           2


Morphology:
- Paucispicular and cellular showing trilineage hematopoiesis, granulocytic dysplasia (hypogranulation) and increased blasts

PERIPHERAL BLOOD
CBC (05/29/2019):
WBC 2.0 L [4.0-11.0 K/mcL] 
RBC 2.06 L [3.95-5.54 M/mcL] 
HGB 7.9 L [12.5-16.2 g/dL] 
HCT 23.7 L [37.5-49.3 %] 
MCV 115 H [80-98 fL] 
MCH 38.3 H [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 16.6 H [12.2-15.1 %] 
Platelets 24 L [160-400 K/mcL] 

Neutrophil 20.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 79.0 H [12.2-47.4 %] 

Abs Neut 0.4 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 1.6 [0.9-3.2 K/mcL] 

Morphology: Marked pancytopenia with rare blasts seen, Occasional hypogranular neutrophil noted

IMMUNOHISTOCHEMISTRY
CD34 and CD117 stain blasts (20-25%)

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-4897)
Abnormal myeloid blast population detected. 

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD5 (partial dim), CD13 (bright), CD15 (partial), CD33 (dim to bright), CD34 (bright), CD117 (bright), CD123 (uniform intermediate), HLADR (bright) with normal expression of CD4, CD38, CD45, CD71; without CD2, CD7, CD11b, CD14, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 14.3% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F19-4820)
Abnormal myeloid blast population detected. No abnormal B and T cell populations detected.
The blasts have abnormal expression of CD25 (subset, 10% of blasts), CD13 (bright), CD33 (dim to negative), CD34 (bright), CD45 (dim), CD117 (bright), HLA-DR (bright), with normal expression of CD4, CD38, CD71 and CD123 without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD56, CD64, cytoplasmic CD79a or surface light chains. MPO expression is present on a subset of blasts. CD34 positive myeloid blasts represent 0.74% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-3478.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-19285, M19-19286, M19-19287, M19-19289.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-10150;S10;MSKK - 2023-06-20 13.03.29.ndpi,Peripheral Blood Smear,2023-06-20,"Lymphoma. Rule out POD. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent involvement by previously diagnosed blastic plasmacytoid dendritic cell neoplasm (approximately ~30-40% by CD56/ CD123 immunohistology). See comment. 
     - Approximately hypercellular marrow with erythroid predominant maturing trilineage hematopoiesis.
  
COMMENT: The core biopsy is disrupted, partially aspirated, and with crush artifact; thus, the blast involvement in an approximation.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Quality: Adequate, although fragmented, disrupted, partially aspirated with intramedullary hemorrhage and crush artifact
Cellularity: Difficult to assess accurately due to the quality of the biopsy, appears hypercellular for age (70%)
M:E ratio: NA
Blasts: Markedly increased, present in focal sheets and large clusters, with partial crush artifact. They are intermediate to large in size, with oval to irregular nuclei, fine chromatin, multiple small nucleoli, and scant amount of pale cytoplasm.
Myeloid lineage: Appears decreased, actively maturing 
Erythroid lineage: Relatively increased, actively maturing
Megakaryocytes: Decreased in number with occasional atypia (nuclear hyperchromasia and ""bare nuclei"" morphology)
Lymphocytes: Few, scattered
Plasma cells: Rare, scattered

Aspirate differential: (Performed by MT)
Blasts                29%
Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           5%
Neutrophils/Bands      23%
Erythroid Precursors      25%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           1.5

Morphology:
Adequate, spicular and cellular aspirate smears demonstrate an expanded population of intermediate to large size immature cells with round to irregular nuclei, fine chromatin, variably distinct nucleoli, and generally moderate amount of cytoplasm with eccentric cytoplasmic ""tails"" and occasional cytoplasmic vacuoles. Background trilineage hematopoiesis is present. Myeloid elements are relatively decreased, present at various stages of maturation, and show no significant dysplasia. Erythroid cells are relatively increased, and show occasional binucleation, megaloblastoid features, and late stage mitoses. Megakaryocytes are seen with occasional small and hypolobated forms. Few small mature-appearing lymphocytes are seen.

IMMUNOHISTOCHEMISTRY
CD56 highlights the neoplastic blasts, which are present predominantly in large clusters and crushed paratrabecular collections, and account for approximately 30-40% of the total marrow cellularity. They also express CD123, CD33, PAX5 (weak, subset), and CD117 (dim), while being negative for TCL1, TdT, and CD34.
CD68 (PGM1) highlights the monocytic cells.
CD117 also highlights few scattered mast cells.
CD33 also highlights the myeloid cells.
CD20 and PAX5 highlight rare scattered B cells.
CD3 highlights few scattered T cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-12108) 
Interpretation: 
Abnormal plasmacytoid dendritic cells present.
Flow cytometry identifies an abnormal plasmacytoid dendritic population having abnormal expression of CD5 (partial, dim), CD56 (bright), CD33, CD117 (partial, dim), with normal expression of CD38, CD45, HLA-DR, CD123, CD4 without CD2, CD7, CD13, CD14, CD15, CD19, CD11b, CD25, CD34, CD64, CD303, TCL1 or TdT. This finding is consistent for persistent involvement by blastic plasmacytoid dendritic cells neoplasm. Total plasmacytoid dendritic cells present 25.6% of WBC.

PERIPHERAL BLOOD
CBC (12/19/2019):
WBC 4.6 [4.0-11.0 K/mcL] 
RBC 2.97 L [3.80-5.00 M/mcL] 
HGB 9.5 L [11.2-15.4 g/dL] 
HCT 28.7 L [34.3-46.0 %] 
MCV 97 [80-98 fL] 
MCH 32.0 [27.0-33.0 pg] 
MCHC 33.1 [31.0-36.5 g/dL] 
RDW 16.9 H [12.2-15.1 %] 
Platelets. 40 L [160-400 K/mcL] 

Neutrophil 71.6 [32.5-74.8 %] 
Mono 8.7 [0.0-12.3 %] 
Eos 0.2 [0.0-4.9 %] 
Baso 0.2 [0.0-1.5 %] 
Immature Granulocyte 5.6 H [0.0-0.6 %] 
Lymph 13.7 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 3.3 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.3 H [0.0-0.1 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL]

Morphology:
WBC: Occasional circulating immature cells morphologically similar to those on the aspirate smear. Atypical granulocytes with seeming apoptotic degeneration and hypogranularity are seen.
RBC: Normochromic, normocytic anemia with few nucleated RBCs. 
Platelets: Thrombocytopenia.

CYTOGENETIC STUDIES
Not submitted

MOLECULAR STUDIES 
Not submitted

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-8268;S12;MSK0 - 2023-05-31 12.50.02.ndpi,Peripheral Blood Smear,2023-05-31,"Multiple myeloma. Hypercalcemia, anemia, thrombocytopenia, history of lung nodules, complex nodules, complex cytogenetics, questionable myeloma vs MDS vs lymphoma-see outside report from Elaine Jaffe.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - CD5-positive B-cell lymphoma with plasmacytic differentiation, involving 5-10% of marrow cellularity, see comment 

Comment: Overall morphologic and immunophenotypic findings support the diagnosis of B-cell lymphoma with plasmacytic differentiation. Findings do not support the presence of plasma cell myeloma. 
Bone marrow findings are not enough to render a diagnosis of large B-cell lymphoma; however, a few scattered large B-cells are seen admixed with small B-cell lymphoma. Per clinical notes, the patient has multiple lytic bone lesions which is unusual feature of B-cell lymphoma with plasmacytic differentiation. Please consider a biopsy of these lesions to see if these show higher grade lymphoma, or different pathology. 
Major differential diagnosis of B-cell lymphoma with plasmacytic differentiation includes marginal zone lymphoma and lymphoplasmacytic lymphoma. Chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) is less likely. Please correlate with forthcoming molecular results (MYD88 mutational status). 

This case was discussed at the hematopathology consensus conference on 10/18/2019.
Flow cytometric findings were discussed with Dr. Mikhail Roshal, Hematopathology Service.
Cytogenetic findings were discussed with Dr. Yanming Zhang, Cytogenetic laboratory. 
Above findings were discussed with Dr. Aaron Goldberg via e-mail.  

BONE MARROW BIOPSY
Quality:  Adequate 
Cellularity: Overall 20-30%
Myeloid lineage: Orderly maturation 
Erythroid lineage: Orderly maturation 
Megakaryocytes: Slightly decreased  
Plasma cells: Increased in adjacent to the lymphoid aggregates.  
Additional findings: A few paratrabecular lymphoid aggregates present. These aggregates are mostly composed of small cells. Few larger cells are noted admixed with small cells; however, sheets of large cells are not present. 

ASPIRATE MORPHOLOGY
Aspirate differential: (Performed by: HWH)

Blasts               0% 
Promyelocytes           1%
Myelocytes           11%
Metamyelocytes           7%
Neutrophils/Bands      32%
Monocytes           5%
Eosinophils           3%
Erythroid Precursors      27%
Plasma Cells           1%
Lymphocytes           13%
Number of Cells Counted 500
M: E Ratio           2.2

Special stain
Iron: Absent
Ring sideroblasts: Absent

Morphology: 
Marrow spicules: Spicular   
Cellularity: Cellular   
Plasma cell morphology: Small
Myeloid lineage: Orderly maturation   
Erythroid Lineage: Orderly maturation   
Megakaryocytes:  Present     
Lymphocytes: Not increased. Morphologically unremarkable. 

IMMUNOHISTOCHEMISTRY
CD20 highlights paratrabecular B-lymphoid aggregates, comprising approximately 5% of marrow celluarity.
CD3 highlights numerous T-cells within these paratrabecular lymphoid aggregates. 
These B-cells express MUM1, PAX5, CD23, and do not express CD10 or Cyclin D1. 
Interpretation of BCL2. LEF1, CD5 is difficult due to the presence of numerous T-cells.
CD138 immunostain highlights plasma cells locating mostly associated with paratrabecular B-lymphoid aggregates, overall less than 5% of cellularity. 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.  
BCMA highlights >90% of plasma cells, (2+) intensity, membranous/ Golgi pattern. 
BCL6 is non-contributory. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-9719) 
Interpretation: 
Abnormal plasma cell population detected.
Abnormal B-cell population identified.

Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (dim to normal), CD45 (bright), CD81 (absent) and monoclonal kappa cytoplasmic light chain restriction; with normal expression of CD27, CD38 and CD138; and without CD20, CD56, or CD117 expression.  The abnormal population represents 0.057% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 18.3% of total plasma cells in the sample.

In addition, flow cytometry identified an abnormal B-cell population with having abnormal expression of CD5, CD19 (bright), CD20 (bright), CD22 (normal to bright), CD23, CD200 (bright) and kappa surface light chain restriction; normal expression of FMC7, CD38, and CD45; and without CD10 expression. The abnormal B-cell population comprises 2.2% of the white cells.This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

PERIPHERAL BLOOD
CBC (10/14/2019):
WBC 7.2 [4.0-11.0 K/mcL] 
RBC 3.75 L [3.80-5.00 M/mcL] 
HGB 11.0 L [11.2-15.4 g/dL] 
HCT 33.7 L [34.3-46.0 %] 
MCV 90 [80-98 fL] 
MCH 29.3 [27.0-33.0 pg] 
MCHC 32.6 [31.0-36.5 g/dL] 
RDW 12.8 [12.2-15.1 %] 
Platelets 104 L [160-400 K/mcL] 

Neutrophil 70.4 [32.5-74.8 %] 
Mono 10.7 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.7 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 16.9 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 5.1 [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 1.2 [0.9-3.2 K/mcL]

Morphology: No circulating plasma cells seen. WBCs, RBCs and platelets are morphologically unremarkable. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-6565.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-37692, M19-37693, M19-37697, M19-37700.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.

     
"
H19-7030;S11;MSKE - 2023-04-25 14.46.46.ndpi,Peripheral Blood Smear,2023-04-25,"CML.  New diagnosed of CML.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Chronic Myeloid Leukemia (CML), (BCR-ABL-positive), consistent with chronic phase (see comment)

COMMENT:
The findings of hypercellular bone marrow with marked myeloid hyperplasia, megakaryocyte atypia (small hypolobated forms) without additional dysplasia along with peripheral blood granulocytosis and basophilia (<20% of WBC) without significant increase in blasts (<10%) in either bone marrow or peripheral blood in the setting of documented t(9;22)(q34.1;q11.2), BCR-ABL translocation demonstrated by FISH are consistent with diagnosis above. 
Please note that confirmation of the diagnosis requires exclusion of additional cytogenetic abnormalities developing while on therapy and exclusion of trisomy 8, isochromosome 17q, trisomy 19, complex karyotype and abnormalities of 3q26.2. In addition, exclusion of lack of clinical response to TKI including persistent elevation of WBC (>10X109/L), persistent splenomegaly, thromobocytosis (>1000X109/L) or thrombocytopenia (<100X109/L) is required. Presence of any of the factors listed or of hematological, cytogenetic or molecular resistance to two sequential TKI would be diagnostic for accelerated phase CML.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular (>95%)
M:E ratio: Markedly increased
Blasts: Not increased
Myeloid lineage: Show left shifted maturation
Erythroid lineage: Reduced
Megakaryocytes: Normal in number with small hypolobated (""dwarf"") forms
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1). 

BONE MARROW ASPIRATE SMEAR
Differential: (performed by HWH)
Promyelocytes           5%
Myelocytes           29%
Metamyelocytes           9%
Neutrophils/Bands      41%
Monocytes           2%
Eosinophils           3%
Basophils           7%
Erythroid Precursors      2%
Lymphocytes           2%
Number of Cells Counted 500
M: E Ratio           48

Morphology:
-Spicular and cellular marrow with marked myeloid hyperplasia and scant erythroid elements. There is increase in basophils and eosinophils identified. No increase in blasts. Erythroid lineage shows progressive maturation. Megakaryocytes are atypical; hypolobated and small.

PERIPHERAL BLOOD
CBC (08/30/2019):
WBC 255.3 H [4.0-11.0 K/mcL] 
RBC 4.39 [3.95-5.54 M/mcL] 
HGB 14.1 [12.5-16.2 g/dL] 
HCT 40.3 [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 32.1 [27.0-33.0 pg] 
MCHC 35.0 [31.0-36.5 g/dL] 
RDW 17.8 H [12.2-15.1 %] 
Platelets 97 L [160-400 K/mcL] 

Neutrophil 52.0 [32.5-74.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 
Blast 3.0 H [0.0-0.0 %] 
Myelocyte 15.0 H [0.0-0.0 %] 
Promyelocyte 8.0 H [0.0-0.0 %] 
Metamyelocyte 9.0 H [0.0-0.0 %] 
Lymph 3.0 L [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 132.7 H [1.5-7.5 K/mcL] 
Abs Mono 10.2 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 5.1 H [0.0-0.7 K/mcL] 
Absolute Basophil 10.2 H [0.0-0.2 K/mcL] 
Absolute Blasts 7.7 H [0.0-0.0 K/mcL] 
Abs Myelocytes 38.3 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 20.4 H [0.0-0.0 K/mcL] 
Abs Meta 23.0 H [0.0-0.0 K/mcL] 
Abs Lymph 7.7 H [0.9-3.2 K/mcL]

Morphology: Marked leukocytosis with left shift, myelocyte bulge. Increased basophils and eosinophils. Occasional circulating blasts seen (<5%).

IMMUNOHISTOCHEMISTRY
Immunostains for CD117 and CD34 shows no increase in blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-8142)
Interpretation: 

Abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
Basophilia seen, representing 3.5% of WBC.
No abnormal mature B- or T-cell populations detected.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD7 (partial), CD25 (subset), CD56 (subset), CD11b (partial), CD13 (subset dim), CD33 (bright), CD38 (uniform bright), CD117 (absent to intermediate), HLADR (bright), CD123 (atypical pattern, likely due to abnormal erythroid precursors without CD123, but with bright CD33, HLA-DR, and dim CD71), with normal expression of CD4, CD34, CD45, without CD2, CD5, CD14, CD15, CD16, CD19 or CD64. Granulocytes show expression of CD56, monocytes show uniform expression of CD56. CD34 positive myeloid blasts represent 0.39% of WBC.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-5627.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-31889.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-8316;S10;MSKB - 2023-05-31 12.38.06.ndpi,Peripheral Blood Smear,2023-05-31,"Lymphoma. Diagnosis. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by low grade B-cell lymphoma consistent with marginal zone lymphoma with increased large cells. (20% with 
      CD20 immunohistochemistry)
     - Cellular marrow with trilineage maturing hematopoiesis.

COMMENT:
Although no diagnostic features of large cell transformation is seen, the presence of a population of large cells in the marrow and peripheral blood raises the possibility of emerging higher risk genetics such mutations of TP53 which can be seen in disease progression of marginal zone lymphoma. Comprehensive genomic profiling may be helpful if clinically indicated.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show mildly hypercellular bone marrow for age (30-40% cellularity overall) with atypical lymphoid infiltrate in nodules and sinusoids (best seen with CD20) composed of a mixture of small to intermediate sized cells and larger cells with irregular nuclei, vesicular chromatin and conspicuous nucleoli. There istrilineage maturing hematopoiesis. Myeloid and erythroid elements show progressive maturation. The M:E ratio is normal. Megakaryocytes appear adequate in number and morphology. 

Aspirate differential: (Performed by MT)
Blasts                1%
Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           3%
Neutrophils/Bands      17%
Monocytes           1%
Eosinophils           9%
Erythroid Precursors      21%
Lymphocytes           38% (Several atypical ones noted)
Number of Cells Counted 500
M:E Ratio           1.9

IMMUNOHISTOCHEMISTRY
The atypical cells
Express: CD20, PAX5, IgM (accounting for 20% of marrow cellularity)
Do not express: CD3, IgD, P53
Other: Ki-67 proliferative index is approximately 20%.
CD3 highlights background T-cells.
Kappa and lambda chains highlight scattered plasma cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-9766) 
Interpretation: 
Abnormal B-cell population identified.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD19 (dim), CD20 (dim), CD22 (slightly dim), lambda light chain restriction, and normal expression of CD22, CD38, and CD45; and without CD5 or CD10. The abnormal B-cell population represents 37.9% of the total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

PERIPHERAL BLOOD
CBC (10/15/2019):
WBC 20.0 H [4.0-11.0 K/mcL] 
RBC 3.54 L [3.80-5.00 M/mcL] 
HGB 11.1 L [11.2-15.4 g/dL] 
HCT 35.6 [34.3-46.0 %] 
MCV 101 H [80-98 fL] 
MCH 31.4 [27.0-33.0 pg] 
MCHC 31.2 [31.0-36.5 g/dL] 
RDW 16.5 H [12.2-15.1 %] 
Platelets. 338 [160-400 K/mcL] 

Neutrophil 31.0 L [32.5-74.8 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 12.0 H [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 23.0 [12.2-47.4 %] 
Other 31.0 H [0.0-0.0 %] 
Abnormal lymphoid cells.

Nucleated RBC 0 [/100(WBCs)] 
Abs Neut 6.2 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 2.4 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 4.6 H [0.9-3.2 K/mcL] 
Abs Others 6.2 H [0.0-0.0 K/mcL]

Morphology: Marked lymphocytosis with medium to large sized lymphoid cells, some with prominent nucleoli.

MOLECULAR STUDIES 
Molecular analysis for IgH gene rearrangement will be reported separately. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-9784;S11;MSKC - 2023-06-20 15.17.19.ndpi,Peripheral Blood Smear,2023-06-20,"Lymphoma. Confirm diagnosis. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B cell lymphoma, most consistent with mantle cell lymphoma (60-70% with CD20 immunohistochemistry). See comment. 
     - Cellular marrow with trilineage maturing hematopoiesis.

COMMENT: Correlation with pending cytogenetic findings is recommended.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show hypercellular bone marrow (80%cellularity). There istrilineage maturing hematopoiesis with marked interstitial lymphoid infiltrate composed of atypical lymphoid cells with small to intermediate size, round nuclei, dense chromatin and inconspicuous nucleoli.  

Aspirate differential: (Performed by HM)

Blasts                2%
Promyelocytes           2%
Myelocytes           7%
Metamyelocytes           5%
Neutrophils/Bands      9%
Eosinophils           4%
Erythroid Precursors      9%
Plasma Cells           2%
Lymphocytes           60%
Number of Cells Counted 500
M:E Ratio           3

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD20, PAX5, cyclinD1, SOX11 (partial dim, likely due to decalcification)
Do not express: CD3, CD5, LEF1
CD23 stains scattered cells. 


FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-11646) 
Abnormal B-cell population identified.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD5 (large subset negative, minor subset positive), CD23 (partial), and kappa light chain restriction, and normal expression of CD19, CD20, CD22, CD38, CD45, and FMC7; and without CD5, CD10, or CD200. The abnormal B-cell population represents 75.2% of the total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with morphologic, cytogenetic, and molecular genetic studies will be needed for classification.

PERIPHERAL BLOOD
CBC (12/04/2019):
WBC 59.8 H [4.0-11.0 K/mcL] 
RBC 3.86 L [3.95-5.54 M/mcL] 
HGB 10.9 L [12.5-16.2 g/dL] 
HCT 34.2 L [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 28.2 [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW16.2 H [12.2-15.1 %] 
Platelets 146 L [160-400 K/mcL] 

Neutrophil 4.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 93.0 H [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 2.4 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.2 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 55.6 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBC: lymphocytosis with similar morphology described in aspirate smear
RBC: Normocytic anemia.
PLT: Unremarkable.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7738.

MOLECULAR STUDIES 
Not submitted. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-2616;S12;MSK1 - 2023-05-10 21.22.26.ndpi,Peripheral Blood Smear,2023-05-10,"MDS.  Newly noted pancytopenia.
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Acute myeloid leukemia (57% blasts by aspirate differential count) (see comment 1).
     - Small abnormal B-cell population with a chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)-like immunophenotype detected by flow cytometry only (1.8% of WBC) (see comment 2).
  
COMMENT 1: Per clinical notes, the patient has a long-standing history of macrocytosis, previously without cytopenias, and no prior confirmed diagnosis of a myelodysplastic syndrome. In the current specimen, morphologic criteria for a diagnosis of acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) are not met, however, few myeloid elements or megakaryocytes are present for evaluation of dysplasia. Recent peripheral blood FISH study showed evidence of a gain of chromosome 8, however, a full karyotype was not performed (CG19-2073; 3/28/19). This cytogenetic abnormality alone is insufficient to render a diagnosis of AML-MRC. Thus, correlation with the forthcoming corresponding cytogenetic and molecular genetic studies (including full karyotype) is required for further characterization. 

COMMENT 2: No significant lymphoid infiltrate is seen on the core biopsy. The small abnormal B-cell population detected by flow cytometry is thus favored to represent a monoclonal B-cell lymphocytosis, however, clinical and radiologic correlation is suggested for definitive characterization.

BONE MARROW BIOPSY
Quality: Adequate but small and subcortical
Cellularity: Hypercellular for age (~40% cellularity)
M:E ratio: N/A
Blasts: Markedly increased, present in sheets, predominantly intermediate in size with round to irregular nuclei, fine chromatin, distinct nucleoli and scant cytoplasm 
Myeloid lineage: Markedly reduced
Erythroid lineage: Reduced, present at various stages of maturation 
Megakaryocytes: Reduced in number without overt atypia
Lymphocytes: Scattered; no lymphoid aggregates seen 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                57%
Metamyelocytes           1%
Neutrophils/Bands      2%
Erythroid Precursors      24%
Plasma Cells           1%
Lymphocytes           15%
Number of Cells Counted  500
M:E Ratio           0.1

Special stain
Iron: Present
Ring sideroblasts: <5% 

Morphology:
The aspirate smears are paucispicular and somewhat paucicellular. They show an expanded population of blasts, which range from small to large in size with round to irregular nuclei, fine chromatin, distinct nucleoli and scant basophilic cytoplasm. Erythroid elements are present at various stages of maturation and show occasional dyspoietic forms (nuclear budding, binucleation, nuclear irregularity, megaloblastoid change; <50%). Rare scattered myeloid elements are seen. Few megakaryocytes are identified, which show no significant atypia. Scattered predominantly small, mature-appearing lymphoid cells are present.

PERIPHERAL BLOOD
CBC (04/03/2019):
WBC 2.6 L [4.0-11.0 K/mcL] 
RBC 2.04 L [3.80-5.00 M/mcL] 
HGB 8.6 L [11.2-15.4 g/dL] 
HCT 26.0 L [34.3-46.0 %] 
MCV 128 H [80-98 fL] 
MCH 42.2 H [27.0-33.0 pg] 
MCHC 33.1 [31.0-36.5 g/dL] 
RDW 15.9 H [12.2-15.1 %] 
Platelets 85 L [160-400 K/mcL] 

Neutrophil 16.0 L [32.5-74.8 %] 
Lymph 83.0 H [12.2-47.4 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 0.4 L [1.5-7.5 K/mcL] 
Abs Lymph 2.2 [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Morphology:
WBC: Leukopenia with absolute neutropenia and rare hypogranular neutrophils. A rare possible circulating blast is seen.
RBC: Macrocytic anemia.
Platelets: Thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD34 highlights a markedly increased number of blasts (~80% of cellularity).
The blasts co-express CD117. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-3065)
Interpretation: 
Expanded abnormal myeloid blast population detected.
Small abnormal B-cell population identified.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD2 (partial), CD11b (partial), CD13 (variable, absent to bright), CD15, CD19 (partial), CD25 (partial, >10% of blasts), CD33 (variable, absent to bright), CD34 (uniform, bright), CD38 (absent to dim), CD117 (variable, absent to bright), CD64 (partial dim), CD123 (uniform, bright), and HLA-DR (variable, absent to bright); with normal expression of CD4, CD45, and CD71; without convincing CD5, CD7, CD14, CD16, or CD56. CD34 positive myeloid blasts represent 49.7% of WBC.

Flow cytometry identifies an abnormal mature B-cell population with a chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)-like immunophenotype having abnormal expression of CD5, CD20 (dim), CD22 (dim), CD23, CD200 (majority bright), and kappa surface light chain restriction (dim); normal expression of CD19 and CD45; and without convincing FMC7, CD38, or CD10 expression. The abnormal B-cell population comprises 1.8% of the white cells.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-2196.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M19-12371, M19-12372, M19-12373, M19-12374, M19-12375.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-3509;S12;MSKC - 2023-06-27 22.55.24.ndpi,Peripheral Blood Smear,2023-06-27,"Myelodysplastic Syndrome.  Pancytopenia.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:
    - Metastatic large cell neuroendocrine carcinoma, see note
    - Cellular marrow with decreased trilineage maturing hematopoiesis.

Note: Immunohistochemical stains show the tumor cells are positive for synaptophysin, chromogranin, INSM1, and Neuro D1, while negative for CD56, ASCL-1 and TTF-1. Rb expression is heterogenous, showing both positive and negative cells. Ki-67 proliferation index is 70%. The morphology is compared and found to be similar to patient`s known large cell neuroendocrine carcinoma (S18-39301). 

This biopsy was also reviewed by Dr Xiao (hematopathology service), who found CD117 and CD34 stains to be non-contributory, and that reticulin stain showed mild increase in reticulin fibrosis.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-1859;S11;MSK8 - 2023-05-12 12.19.15.ndpi,Peripheral Blood Smear,2023-05-12,"Leukemia, Acute Promyelocytic. New possible APL vs AML. 
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
     - Acute myeloid leukemia with inv(16)(p13.1q22); CBFB-MYH11, 82% blasts by aspirate differential count, see comment
  
COMMENT: The patient has a history of a thymoma treated with radiation in 12/2017. This raises the possibility of a therapy related myeloid neoplasm, however the localization and extent of the radiation is unclear and clinical correlation in this regard is necessary. 

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular (95%)
M:E ratio: N/A
Blasts: Sheets of large cells with dispersed chromatin
Myeloid lineage: Reduced; few eosinophilic precursors
Erythroid lineage: Reduced
Megakaryocytes: Reduced
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no in reticulin fibrosis (MF-0). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                82%
Promyelocytes           6%
Myelocytes           1%
Neutrophils/Bands      1%
Monocytes           2%
Eosinophils           4%
Erythroid Precursors      2%
Lymphocytes           2%
Number of Cells Counted      500
M:E Ratio           7

Morphology: The aspirate smears are spicular and cellular and show a markedly expanded population of small to medium sized blasts with small amounts of deep blue cytoplasm with azurophilic granules, round to irregular nuclei, fine chromatin and distinct nucleoli, in a background of markedly decreased trilineage hematopoiesis.

PERIPHERAL BLOOD
CBC (03/08/2019):
WBC 59.3 H [4.0-11.0 K/mcL] 
RBC 2.50 L [3.95-5.54 M/mcL] 
HGB 8.0 L [12.5-16.2 g/dL] 
HCT 24.2 L [37.5-49.3 %] 
MCV 97 [80-98 fL] 
MCH 32.0 [27.0-33.0 pg] 
MCHC 33.1 [31.0-36.5 g/dL] 
RDW 19.9 H [12.2-15.1 %] 
Platelets 66 L [160-400 K/mcL] 

Neutrophil 10.0 L [32.5-74.8 %] 

Lymph 0.0 L [12.2-47.4 %] 
Mono 14.0 H [0.0-12.3 %] 
Eos 7.0 H [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 

Abs Neut 5.9 [1.5-7.5 K/mcL] 
Abs Lymph 0.0 L [0.9-3.2 K/mcL] 
Abs Mono 8.3 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 4.2 H [0.0-0.7 K/mcL] 
Absolute Basophil 1.2 H [0.0-0.2 K/mcL] 

Metamyelocyte 2.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Promyelocyte 8.0 H [0.0-0.0 %] 
Blast 55.0 H [0.0-0.0 %] 

Abs Meta 1.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 1.2 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 4.7 H [0.0-0.0 K/mcL] 
Absolute Blasts 32.6 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology: Numerous circulating blasts and left shifted myeloid elements. 

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains for CD34 and CD117 show increased blasts, approximately 90% of the bone marrow cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-2179)
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD5 (partial dim), CD25 (partial, >10% of blasts), CD56 (partial), CD13 (uniform bright), CD33 (bright), CD38 (dim), CD123 (bright), HLADR (dim to absent) with normal expression of CD4, CD34, CD45, CD71 and CD117; without CD2, sCD3, cCD3, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD64, cCD79a or surface light chains. MPO expression is present on a subset of blasts. CD34 positive myeloid blasts represent 45.4% of WBC. Findings are consistent with an acute myeloid leukemia. Reviewing the peripheral blood smear identified eosinophilia and basophilia. Therefore, the possibility of blast crisis of an underlying CML should be ruled out. Correlation with clinical history and pending cytogenetic/molecular results is suggested.

CYTOGENETIC STUDIES (CG19-1538)

KARYOTYPE ANALYSIS:
46,XY,del(7)(q11.2q36),inv(16)(p13.1q22)[20]
Chromosome analysis revealed deletion of 7q and inversion 16 in all twenty metaphase cells, consistent with this patient's AML.

FISH ANALYSIS:
No evidence of PML-RARA fusion/t(15;17).
No evidence of RARA (17q21.2) rearrangement.
Rearrangement of CBFB (16q22) detected in 74% of cells, consistent with inversion 16 observed in chromosome studies.
No evidence of RUNX1T1-RUNX1 fusion/t(8;21).
No evidence of BCR-ABL1 fusion/t(9;22).
No evidence of MLL (11q23) rearrangement.
No evidence of TP53 (17p13.1) deletion or loss of chromosome 17.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M19-8914, M19-8917, M19-8918, M19-8920, M19-8921.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-6815;S2;MSK5 - 2023-04-25 15.27.32.ndpi,Peripheral Blood Smear,2023-04-25,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears:
     - Relapsed acute myeloid leukemia (83% blasts by aspirate differential); see comment

COMMENT: Correlation with cytogenetic and molecular studies is recommended. See corresponding peripheral blood flow cytometry (F19-7843). Corresponding bone marrow flow cytometry is in progress, and the results will be reported separately. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                83%
Promyelocytes           1%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      4%
Eosinophils           1%
Erythroid Precursors      3%
Lymphocytes           6%
Number of Cells Counted  500
M:E Ratio           2.7

Morphology:
Paucispicular and hypercellular aspirate smears show markedly reduced maturing trilineage hematopoiesis. Blasts are markedly increased showing scant amphiphilic cytoplasm without Auer rods, and open, fine chromatin with conspicuous nucleoli. Myeloid and erythroid cells are markedly reduced and show progressive maturation. Megakaryocytes are rare with unremarkable morphology. Lymphocytes are small and mature. 

PERIPHERAL BLOOD
CBC (08/23/2019):
WBC 33.7 H [7.1-15.9 K/mcL] 
RBC 4.10 [3.89-5.03 M/mcL] 
HGB 12.1 [10.7-14.5 g/dL] 
HCT 36.3 [32.2-43.5 %] 
MCV 89 [74-91 fL] 
MCH 29.5 [24.8-30.2 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 109 L [160-400 K/mcL] 

Neutrophil 38.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 44.0 H [0.0-0.0 %] 
Lymph 16.0 [12.2-47.4 %] 

Nucleated RBC 0 [/100(WBCs)]

Abs Neut 12.8 H [1.5-7.5 K/mcL] 
Abs Mono 0.7 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 14.8 H [0.0-0.0 K/mcL] 
Abs Lymph 5.4 H [0.9-3.2 K/mcL] 

Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology:
WBC: Leukopenia with excess circulating blasts. 
RBC: Normochromic normocytic RBCs.
Platelets: Thrombocytopenia. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-7895)
Flow cytometric analysis will be reported separately. See separate report, F19-7895.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-5466.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-30857, M19-30870. 

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. PessinMD., PhD., Director.
 
"
H19-1581;S12;MSK1 - 2023-06-20 12.33.50.ndpi,Peripheral Blood Smear,2023-06-20,"CML.  New diagnosed.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia, chronic phase. 

BONE MARROW BIOPSY
Quality: adequate 
Cellularity: hypercellular particularly on clot section, 90%
M:E ratio: increased 
Blasts: not increased 
Myeloid lineage: marked increase with maturation
Erythroid lineage: relatively decreased 
Megakaryocytes: increased with dwarf morphology
Lymphocytes: rare 
Plasma cells: rare 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                2%
Promyelocytes           1%
Myelocytes           18%
Metamyelocytes           12%
Neutrophils/Bands      46%
Monocytes           1%
Eosinophils           2%
Basophils           2%
Erythroid Precursors      12%
Lymphocytes           4%
Number of Cells Counted 500
M:E Ratio           6.8

Morphology:
Spicular and markedly hypercellular bone marrow aspirate shows marked granulocytic hyperplasia. Blasts are not increased. Myeloid precursors are increased with maturation. Erythroid precursors are decreased. Megakaryocytes are present with atypical morphology.


PERIPHERAL BLOOD
CBC (02/26/2019):
WBC 63.5 H [4.0-11.0 K/mcL] 
RBC 5.43 H [3.80-5.00 M/mcL] 
HGB 11.8 [11.2-15.4 g/dL] 
HCT 41.9 [34.3-46.0 %] 
MCV 77 L [80-98 fL] 
MCH 21.7 L [27.0-33.0 pg] 
MCHC 28.2 L [31.0-36.5 g/dL] 
RDW 23.2 H [12.2-15.1 %] 
Platelets. 719 H [160-400 K/mcL] 

Neutrophil 74.0 [32.5-74.8 %] 
Lymph 7.0 L [12.2-47.4 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 

Abs Neut 47.0 H [1.5-7.5 K/mcL] 
Abs Lymph 4.4 H [0.9-3.2 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.3 H [0.0-0.7 K/mcL] 
Absolute Basophil 2.5 H [0.0-0.2 K/mcL] 

Metamyelocyte 5.0 H [0.0-0.0 %] 
Myelocyte 6.0 H [0.0-0.0 %] 
Promyelocyte 2.0 H [0.0-0.0 %] 

Abs Meta 3.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 3.8 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 1.3 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 
Morphology: leukocytosis, left shift and basophilia, thrombocytosis

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-1864)
Abnormal myeloid blast population detected. 
Basophilia seen, representing 1.5% of WBC.

Flow cytometry identifies an erythroid biased abnormal myeloid blast population having abnormal expression of CD7 (partial), CD11b (partial), CD33 (bright), CD38 (subset dim), CD71 (bright), CD117 (variable, dim to intermediate); with normal expression of CD4, CD13, CD34, CD45, CD123 and HLA-DR without CD2, CD5, CD14, CD15, CD16, CD19, CD25, CD56, CD64. CD34 positive myeloid blasts represent 1.1% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-1333.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-7568.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-3586;S10;MSKF - 2023-06-20 11.17.11.ndpi,Peripheral Blood Smear,2023-06-20,"{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch31506\stshfhich31506\stshfbi31506\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}








{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}
{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;}{\*\defchp \f31506\fs22 
}{\*\defpap \ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa160\sl259\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 
\rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\trcbpat1\trcfpat1\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa160\sl259\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31506\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused Normal Table;}{
\s15\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 
\f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext15 \spriority0 \styrsid2431169 CoPath Text;}}{\*\rsidtbl \rsid464994\rsid2431169\rsid3490063\rsid6439856\rsid8523658\rsid10058196\rsid10892955\rsid11343253\rsid13583424\rsid15669327
\rsid16526161}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\author Alcaraz, Von Jerome/Pathology}{\operator Kumar, Priyadarshini/Graduate Medical Education}
{\creatim\yr2019\mo5\dy8\hr9\min31}{\revtim\yr2019\mo5\dy8\hr9\min31}{\version2}{\edmins0}{\nofpages1}{\nofwords5}{\nofchars34}{\nofcharsws38}{\vern55}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}
\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont1\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1440\dgvorigin1440\dghshow1\dgvshow1
\jexpand\viewkind1\viewscale200\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\rsidroot10892955\newtblstyruls\nogrowautofit\usenormstyforlist\noindnmbrts\felnbrelev\nocxsptable\indrlsweleven\noafcnsttbl\afelev\utinl\hwelev\spltpgpar\notcvasp\notbrkcnstfrctbl\notvatxbx\krnprsnet\cachedcolbal \nouicompat \fet0
{\*\wgrffmtfilter 2450}\nofeaturethrottle1\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang 
{\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}
\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid6439856 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 \f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid13583424 ALL. Day 24 Cytoxan. Protocol: 17-621.\par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma, 95% blasts by aspirate differential
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular for age (90%)
M:E ratio: N/A
Blasts: Increased in sheets; intermediate sized blasts with irregular nuclear borders, fine chromatin and prominent nucleoli
Myeloid lineage: Markedly reduced 
Erythroid lineage: Markedly reduced 
Megakaryocytes: Markedly reduced 
Lymphocytes: Scattered 
Plasma cells: Scattered 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                95%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology: The aspirate smears are aspicular and hypocellular and show an expanded population of small to medium sized blasts with scant amounts of dark blue cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli, in a background of reduced trilineage hematopoiesis. 

PERIPHERAL BLOOD
CBC (05/06/2019):
WBC 1.0 L [4.0-11.0 K/mcL] 
RBC 2.35 L [3.95-5.54 M/mcL] 
HGB 6.7 L [12.5-16.2 g/dL] 
HCT 19.6 L [37.5-49.3 %] 
MCV 83 [80-98 fL] 
MCH 28.5 [27.0-33.0 pg] 
MCHC 34.2 [31.0-36.5 g/dL] 
RDW 11.8 L [12.2-15.1 %] 
Platelets 38 L [160-400 K/mcL] 

Neutrophil 0.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 46.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 52.0 H [12.2-47.4 %] 
Variant Lymph 1.0 [%] 

Abs Neut 0.0 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.5 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Lymph 0.5 L [0.9-3.2 K/mcL] 

Morphology:
Pancytopenia with circulating blasts

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains show increased CD34 and TdT positive blasts (~100%). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-4109)
Interpretation: 
Abnormal immature B-cell population detected.
An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously [F19-3211]. The abnormal immature B-cells represent 90.2% of the white cells and 93.0% of the mononuclear cells in the sample and abnormally express CD19 (bright), CD20 (partial), CD34 (variable, negative to bright), CD38 (slightly dim), CD45 (negative), CD58 (bright), CD24 (bright); with normal expression of CD10, CD22; and without CD33. This finding is consistent with persistent/recurrent B-lymphoblastic leukemia/lymphoma, depending on the clinical context. Clinical and morphologic correlation is recommended.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-2931.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-16542-3.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-2836;S15;MSK8 - 2023-06-20 11.11.40.ndpi,Peripheral Blood Smear,2023-06-20,"Leukemia, chronic lymphoid. Splenomegaly. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Extensive involvement by Mantle Cell Lymphoma (80% involvement by CD20 immunohistochemistry)
     - Hypercellular marrow with markedly reduced trilineage maturing hematopoiesis
  
COMMENT: Although cytogenetics studies performed in 2006 did not detect any t(11;14)/CCND1-IGH, the positivity of the neoplastic cells for SOX-11 and Cyclin D1 immunostains support the above diagnosis. Correlation with pending cytogenetics studies on the current marrow is also recommended. 

The left-over flow cytometry sample has been sent to the molecular lab for Clonal IGH gene rearrangement studies and IGHV somatic hypermutation determination by a NGS assay (Lymphotrack). The results will be reported separately.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular for age (70-80% cellularity)
M:E ratio: N/A
Blasts: Not increased
Myeloid lineage: Markedly reduced in number, progressive maturation
Erythroid lineage: Markedly reduced in number, progressive maturation
Megakaryocytes: Adequate in number with occasional atypical forms
Lymphocytes: Markedly increased aggregates of atypical small lymphoid cells with slightly irregular nuclei, condensed chromatin, and scant cytoplasm
Plasma cells: Scattered 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                1%
Myelocytes           2%
Metamyelocytes           1%
Neutrophils/Bands      3%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      8%
Lymphocytes           83%( folded/irregular nuclei)
Number of Cells Counted 500
M:E Ratio           1

Morphology: 
The aspirate smears are spicular and cellular and show a markedly expanded population of monotonous-appearing, small-sized, mature appearing atypical lymphoid cells with scant cytoplasm, round nuclei and condensed chromatin, in a background of markedly decreased maturing trilineage hematopoiesis. Maturing myeloid and erythroid elements are seen. Megakaryocytes are present with unremarkable morphology.

PERIPHERAL BLOOD
CBC (04/11/2019):
WBC 157.0 H [4.0-11.0 K/mcL] 
RBC 3.16 L [3.80-5.00 M/mcL] 
HGB 7.9 L [11.2-15.4 g/dL] 
HCT 28.8 L [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 25.0 L [27.0-33.0 pg] 
MCHC 27.4 L [31.0-36.5 g/dL] 
RDW 17.5 H [12.2-15.1 %] 
Platelets. 83 L [160-400 K/mcL] 

Neutrophil 2.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 95.0 H [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 3.1 [1.5-7.5 K/mcL] 
Abs Mono 1.6 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.6 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 1.6 H [0.0-0.0 K/mcL] 
Abs Lymph 149.2 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBC: Marked leukocytosis with predominantly atypical monotonous-appearing lymphoid cells similar to those seen in the marrow aspirate. Many naked nuclei cells and smudged cells are present. Some left-shifted granulocytes (band forms, metamyelocytes, myelocytes) are seen.
RBC: Normocytic, normochromic anemia.
PLT: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
The neoplastic cells (~80% cellularity)
Express: CD20 (Strong), PAX-5, CD5, Cyclin D1, SOX-11 (subset)
Do not express: CD3, CD23, LEF-1
P53 is negative (result may be affected by decalcification of core biopsy)
CD3 highlights small T cells scattered interstitially and in small aggregates.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-3319)
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5 (major subset), CD22 (dim), and kappa surface light chain restriction (low); normal expression of CD20, FMC7, CD38 and CD45; and without CD10, CD23 or CD200.  The abnormal B cell population represents 72.9% of total white cells.

While the immunophenotyped is not fully specific it is highly concerning for involvement by mantle cell lymphoma. Correlation with immunohistochemical or cytogenetic studies for Cyclin D1 is necessary for confirmation of the diagnosis.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-2384.

MOLECULAR STUDIES 
The left-over flow cytometry sample has been sent to the molecular lab for Clonal IGH gene rearrangement studies and IGHV somatic hypermutation determination by a NGS assay (Lymphotrack). The results will be reported separately.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H19-1336;S11;MSKY - 2023-06-20 12.39.34.ndpi,Peripheral Blood Smear,2023-06-20,"CML. Diagnosis. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Chronic Myeloid Leukemia (CML), (BCR-ABL-positive), consistent with chronic phase (see comment)

COMMENT:
The findings of hypercellular bone marrow with marked myeloid hyperplasia, megakaryocyte atypia (small hypolobated forms) without additional dysplasia along with peripheral blood granulocytosis, thrombocytosis and basophilia (<20% of WBC) without significant increase in blasts (<10%) in either bone marrow or peripheral blood in the setting of BCR-ABL translocation demonstrated by molecular genetic analysis) are consistent with diagnosis above. 
Please note that confirmation of the chronic phase diagnosis requires exclusion of additional cytogenetic abnormalities developing while on therapy and exclusion of trisomy 8, isochromosome 17q, trisomy 19, complex karyotype and abnormalities of 3q26.2. In edition exclusion of lack of clinical response to TKI including persistent elevation of WBC (>10X109/L), persistent splenomegaly, thromobocytosis (>1000X109/L) or thrombocytopenia (<100X109/L) is required. Presence of any of the factors listed or of hematological, cytogenetic or molecular resistance to two sequential TKI would be diagnostic for accelerated phase CML.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Increased for age (80-90%)
M:E ratio: Increased
Blasts: Not overtly increased 
Myeloid lineage: Full maturation with myeloid hyperplasia and expansion of early maturing forms in paratrabecular areas
Erythroid lineage: Full maturation, hypoplastic 
Megakaryocytes: Moderately increased with many small hypolobated (dwarf) forms present
Lymphocytes: Scattered, lymphoid aggregates are not seen
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                2%
Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           11%
Neutrophils/Bands      59%
Monocytes           1%
Eosinophils           4%
Basophils           3%
Erythroid Precursors      8%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           11


Morphology:
-Hypercellular smears show marked myeloid hyperplasia, mild basophilia without increase in blasts. Dwarf megakaryocytes are seen

PERIPHERAL BLOOD
CBC (02/18/2019):
WBC 105.8 H [4.0-11.0 K/mcL] 
RBC 4.07 [3.95-5.54 M/mcL] 
HGB 12.1 L [12.5-16.2 g/dL] 
HCT 37.9 [37.5-49.3 %] 
MCV 93 [80-98 fL] 
MCH 29.7 [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 16.9 H [12.2-15.1 %] 
Platelets. 1249 H [160-400 K/mcL] 

Neutrophil 73.0 [32.5-74.8 %] 
Lymph 5.0 L [12.2-47.4 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 

Abs Neut 77.2 H [1.5-7.5 K/mcL] 
Abs Lymph 5.3 H [0.9-3.2 K/mcL] 
Abs Mono 3.2 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.1 H [0.0-0.7 K/mcL] 
Absolute Basophil 4.2 H [0.0-0.2 K/mcL] 

Metamyelocyte 7.0 H [0.0-0.0 %] 
Myelocyte 4.0 H [0.0-0.0 %] 
Promyelocyte 2.0 H [0.0-0.0 %] 
Blast 1.0 H [0.0-0.0 %] 

Abs Meta 7.4 H [0.0-0.0 K/mcL] 
Abs Myelocytes 4.2 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 2.1 H [0.0-0.0 K/mcL] 
Absolute Blasts 1.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 2 [/100(WBCs)] 
Morphology: Marked granulocytosis and thrombocytosis. Myeloid left shift is seen, but blasts are few. Basophilia is present. Occasional nucleated RBC seen

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-1590)
Abnormal myeloid blast population detected. 
Basophilia is seen.
No abnormal mature B or T cell population detected.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD7 (partial), CD11b (partial dim), CD13 (uniform dim), CD34 (subset dim), CD38 (slightly bright), CD117 (bright), HLA-DR (slightly bright); with normal expression of CD4, CD33, CD45, CD71 and CD123; without CD2, sCD3, CD5, CD8, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 1.7% of WBC.

Basophilia is seen, with basophils representing 1.8% of WBC.
464,531 cells acquired for myeloid analysis.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-1135.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-6322


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-8592;S20;MSKI - 2023-05-31 12.32.11.ndpi,Peripheral Blood Smear,2023-05-31,"Leukemia, NOS. Leukemia workup. Leukemia/lymphoma evaluation. Do not decalcify, store in formalin. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B lymphoblastic leukemia/lymphoma

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (>90%)
M:E ratio: N/A 
Blasts: Markedly increased, practically replacing the marrow cellularity
Myeloid lineage: Reduced 
Erythroid lineage: Reduced
Megakaryocytes: Reduced with hyperchromatic forms 
Lymphocytes: Rare 
Plasma cells: Rare 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed on touch prep by SS)
Blasts                82%
Promyelocytes           1%
Myelocytes           2%
Neutrophils/Bands      4%
Monocytes           1%
Erythroid Precursors      2%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           4

Morphology:
- Only touch prep slides available for evaluation which shows marked increase in blasts. Blasts have high N:C ratio, fine chromatin, and scant cytoplasm. Myeloid and erythroid elements are reduced.

PERIPHERAL BLOOD
CBC (10/24/2019):
WBC 17.5 H [4.0-11.0 K/mcL] 
RBC 3.19 L [3.95-5.54 M/mcL] 
HGB 9.1 L [12.5-16.2 g/dL] 
HCT 25.7 L [37.5-49.3 %] 
MCV 81 [80-98 fL] 
MCH 28.5 [27.0-33.0 pg] 
MCHC 35.4 [31.0-36.5 g/dL] 
RDW 18.2 H [12.2-15.1 %] 
Platelets. 66 L [160-400 K/mcL] 

Neutrophil 35.0 [32.5-74.8 %] 
Mono 10.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Lymph 34.0 [12.2-47.4 %] 
Variant Lymph 2.0 [%]
Other 18.0 H [0.0-0.0 %] 
Abnormal lymphoid cells with blast-like features.

Nucleated RBC 2 [/100(WBCs)] 

Abs Neut 6.1 [1.5-7.5 K/mcL] 
Abs Mono 1.8 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Lymph 6.3 H [0.9-3.2 K/mcL] 
Abs Others 3.2 H [0.0-0.0 K/mcL] 

Megakaryocyte Fragment 0 [/100(WBCs)]

Morphology: Circulating blasts noted. Anemia and thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunostain CD117 is non-contributory. CD34 is negative.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-10100)
Abnormal immature B-cell population detected.
No abnormal mature B- or T-cell populations detected.

An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously in blood (F19-10038). The abnormal immature B-cells represent 93.7% of the white cells and 93.5% of the mononuclear cells in the sample and abnormally express CD34 (absent), CD73/CD304 (uniform dim); with normal expression of CD10, CD19, CD22, CD24, CD38, CD45 and CD81; and without CD20, CD66b, CD66c/CD123, CD86 or surface light chain. This finding is consistent with involvement by patient's known B-lymphoblastic leukemia/lymphoma, depending on the clinical context.  Clinical and morphologic correlation is recommended. 

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F19-10038)
Abnormal immature B-cell population detected.
No abnormal mature T-cell population detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (21.5% of the total white cells) is diagnostic for lymphoblastic leukemia/lymphoma (ALL) by WHO criteria. The blasts have abnormal expression of CD34 (negative), CD66c/CD123 (partial dim), TdT, increased forward and side scatter suggestive of larger size; with normal expression of CD10, CD19, CD22, CD24, CD38, CD45, CD81; and without CD2, CD3, CD4, CD5, CD7, CD8, CD20, CD56, CD66b, CD86, CD73/CD304 or surface light chains.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

Bone marrow biopsy and aspirate with flow cytometry, cytogenetic and molecular studies is recommended.

This case was also reviewed on 10/24/19 with Dr. Mikhail Roshal (Director, cell marker / flow cytometry laboratory). 

CYTOGENETIC STUDIES
Not available

MOLECULAR STUDIES 
Not available.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-2728;S13;MSK6 - 2023-06-20 17.52.52.ndpi,Peripheral Blood Smear,2023-06-20,"MDS.  Newly referred. 
","AMENDMENT DETAIL:
     Reason for Amendment:     Change in diagnosis due to additional clinical information not recieved

Report Section Changed:     Diagnosis 

Description of Change:           To be reviewed by Dr. Roshal. See the below changes.

Note: This document represents an amended version of the Hematopathology report originally issued on 4/11/2019. 
Dr. Eytan Stein has been notified via e-mail.


1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent acute myeloid leukemia with MDS-related changes based on prior diagnosis of AML (see H19-2264) 
    - CD10-/CD5- kappa restricted abnormal B-cell population (3.1% of cells) detected by flow cytometry consistent with B cell lymphoproliferative neoplasm..  
    - Slightly expanded LGL population representing 17.1% of WBC detected by flow cytometry (possibly reactive).   

Comment: 
Based on subsequent MSKCC evaluation, the patient carries the diagnosis of AML, therefore the current findings are consistent with the revised diagnosis. Prior comment is below.

The aspirate smears are aspicular, hemodiluted, and inadequate for evaluation of dysplasia or accurate bone marrow blast enumeration. Bone marrow biopsy findings of megakaryocytic hyperplasia with atypia and increased in blasts,10-20% by CD34 and somewhat higher by CD117 (20-30%), which also stains myeloid and erythroid precursors is consistent with at least MDS-EB2, however AML could not be fully excluded due to imprecision of the IHC-based estimate. Close clinical follow-up and correlation with pending cytogenetic and molecular studies is recommended. In addition, a CD10-/CD5- kappa restricted B-cell population (3.1% of cells) was also identified by flow cytometry with atypical B cell distribution seen by morphology suggesting of marginal zone lymphoma like B cell LPD. Clinical correlation is needed with imaging studies to exclude the possibility of extramedullary involvement by a B-cell lymphoproliferative disorder such as splenic marginal zone lymphoma.  

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Normocellular to mildly hypocellular for age (15-20%)
M:E ratio: Increased 
Blasts: Increased in number 
Myeloid lineage: Relatively increased in number and show left shifted maturation 
Erythroid lineage: Proportionally reduced in number and show progressive maturation 
Megakaryocytes: Increased in number and show few hypolobated forms 
Lymphocytes: Small interstitial lymphoid aggregate composed of small lymphocytes is seen, scattered forms are also seen
Plasma cells: Interstitially scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0+/3) 
Clot section: Clot is inadequate and show predominantly peripheral blood elements
Other: Hemosiderin laden macrophages seen. Few lymphoid aggregates composed small lymphoid cells are seen.  

BONE MARROW ASPIRATE SMEAR
Differential: (Not performed: SS)

Aspirate smears are aspicular, hypocellular, hemodiluted and predominantly composed of peripheral blood elements, platelet clumps with rare blasts. Touch imprints are suboptimal for evaluation. 

Special stain: touch prep slide
Iron: Suboptimal for evaluation
Ring sideroblasts: Suboptimal for evaluation. 

PERIPHERAL BLOOD
CBC (04/08/2019):
WBC 1.9 L [4.0-11.0 K/mcL] 
RBC 2.42 L [3.80-5.00 M/mcL] 
HGB 7.4 L [11.2-15.4 g/dL] 
HCT 22.3 L [34.3-46.0 %] 
MCV 92 [80-98 fL] 
MCH 30.6 [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 13.9 [12.2-15.1 %] 
Platelets. 309 [160-400 K/mcL] 

Neutrophil 49.0 [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Lymph 48.0 H [12.2-47.4 %] 

Abs Neut 0.9 L [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL]

Morphology:
WBC: Leukopenia with absolute neutropenia; few hypogranulated neutrophils seen; no circulating blasts seen
RBC: Normocytic normochromic anemia 
Platelets: Unremarkable 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlights increased number of blasts (10-20% by CD34 and 20-30 by CD117 which also stains myeloid and erythroid precursors)

CD20 highlights B-cells scattered and in lymphoid aggregate, some CD20 positive B cells show sinusoidal distribution concerning for neoplasm 
CD3 and CD5 highlights T-cells scattered and in lymphoid aggregate. There is a mild increase in T cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-3202)
Abnormal myeloid blast population detected. 
Abnormal B-cell population identified.
No abnormal mature T-cell population detected. Slightly expanded LGL population seen, representing 17.1% of WBC.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD5, CD7, CD34 (uniform bright), CD38 (dim); with normal expression of CD4, CD13, CD33, CD45, CD71, CD117, CD123 and HLA-DR without CD2, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 1.0% of WBC.

Flow cytometry reveals an abnormal mature B-cell population with expression of CD19 (dim), CD22 (dim), CD38 (uniform bright), kappa light chain restriction, and normal expression of CD20 and CD45; and without CD5 or CD10. The abnormal B-cell population represents 3.1% of the total white cells.

Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Results may not be indicative of bone marrow composition.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not submitted. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-2280.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-13004 and M19-13005.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H19-5907;S13;MSKH - 2023-04-19 09.15.41.ndpi,Peripheral Blood Smear,2023-04-19,"CMML. New monocytosis and neutrophilia. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Compatible with chronic myelomonocytic leukemia-0 (CMML-0).
     - Hypercellular marrow with myeloid predominant maturing trilineage hematopoiesis, myeloid left shifted maturation, increased monocytic forms, and mild dyserythropoiesis.
  
COMMENT: Per clinical notes, the patient has had relative and absolute monocytosis persisting for >3 months (CBC on 2/16/19 reportedly showed 21% monocytes, with absolute count of 4.6 K/mcL). Concurrent karyotype analysis (CG19-4748) revealed a normal karyotype and an RNA-Seq panel for common hematological fusions (M19-26320) is negative. Together with the morphology, these findings are compatible with chronic myelomonocytic leukemia-0 (CMML-0) if other causes of reactive monocytosis (e.g. other malignancy, infection, and inflammation) have been excluded. Correlation with the forthcoming molecular studies (IMPACT heme) is recommended to further provide support for a neoplastic etiology of the expanded monocyte population.
Mild to moderate fibrosis is noted, which is associated with a more aggressive disease course (PMID: 29262560). Close clinical follow-up is advised.

BONE MARROW BIOPSY
Quality: Marginally adequate, partially aspirated and with intramedullary hemorrhage
Cellularity: Actively hypercellular for age (90%)
M:E ratio: Markedly increased
Blasts: Not overtly increased
Myeloid lineage: Markedly increased, with left shifted maturation
Erythroid lineage: Relatively decreased, actively maturing
Megakaryocytes: Adequate in number, with occasional forms showing nuclear hyperchromasia, small and hypolobated forms.
Lymphocytes: Few, scattered
Plasma cells: Rare, scattered
Special stains: Reticulin stain shows mild to focally moderate increase in reticulin fibrosis (MF-1 to MF-2). 
Clot section: Contains small foci of marrow particles with similar morphology as the core biopsy.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                4%
Promyelocytes           1%
Myelocytes           15%
Metamyelocytes           10%
Neutrophils/Bands      34%
Monocytes           26%
Eosinophils           1%
Erythroid Precursors      8%
Lymphocytes           1%
Number of Cells Counted 500
M:E Ratio           10.9

Special stain
Iron: Trace iron present
Ring sideroblasts: Absent 

Morphology:
Adequate, spicular and cellular aspirate smears with myeloid predominant maturing trilineage hematopoiesis and no expanded blast population. The M:E ratio is markedly increased. Myeloid elements are increased, show left shifted maturation, and occasional hypogranular neutrophils. Monocytes are markedly expanded, with some atypical forms (lacking nuclear folds). Erythroid cells are relatively decreased, present at various stages of maturation, and show mild dysplasia (~10%, megaloblastoid features, abnormal nuclear contours, and karyorrhexis). Megakaryocytes are seen with occasional small and hypolobated forms. Few small mature-appearing lymphocytes are seen.

PERIPHERAL BLOOD
CBC (07/22/2019):

WBC 42.9 H [4.0-11.0 K/mcL] 
RBC 3.83 L [3.95-5.54 M/mcL] 
HGB 12.1 L [12.5-16.2 g/dL] 
HCT 37.4 L [37.5-49.3 %] 
MCV 98 [80-98 fL] 
MCH 31.6 [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL] 
RDW 15.4 H [12.2-15.1 %] 
Platelets. 173 [160-400 K/mcL] 

Neutrophil 59.0 [32.5-74.8 %] 
Mono 21.0 H [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 7.0 H [0.0-0.0 %] 
Metamyelocyte 3.0 H [0.0-0.0 %] 
Lymph 9.0 L [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 25.3 H [1.5-7.5 K/mcL] 
Abs Mono 9.0 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 3.0 H [0.0-0.0 K/mcL] 
Abs Meta 1.3 H [0.0-0.0 K/mcL] 
Abs Lymph 3.9 H [0.9-3.2 K/mcL] 

Morphology:
WBC: Leukocytosis with marked absolute and relative monocytosis; few atypical monocytes seen, lacking nuclear folding. Absolute neutrophilia is present, with granulocytic forms showing borderline dysplastic features (~10%, hypogranularity and abnormally segmented forms). Few immature granulocytes (myelocytes, metamyelocytes, and bands) are seen. No circulating blasts or promonocytes seen.
RBC: Normochromic, normocytic RBCs. 
Platelets: Adequate in number, with occasional large forms.

IMMUNOHISTOCHEMISTRY
CD34 shows no increase in blasts (<5%). 
CD117 is positive in the myeloid and erythroid cells, which are present in a paratrabecular distribution.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-6775)
Interpretation: 
Abnormal myeloid blast and monocyte populations detected. 
No abnormal mature B- or T-cell populations detected.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD11b (partial), CD13 (subset dim), CD38 (dim), CD117 (bright), HLADR (bright), with normal expression of CD4, CD33, CD34, CD45, CD71, CD123; without CD2, CD5, CD7, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. Monocytosis seen (23.1% of WBC) with expanded abnormal immature monocytes (5.8% of WBC) with expression of CD11b. CD34 positive myeloid blasts represent 0.44% of WBC. In total, blast equivalents (blast and immature monocyte) represent 6.2% of WBC. 

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-4748.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M19-26316, M19-26317, M19-26318, & M19-26320.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-9933;S12;MSK0 - 2023-06-20 13.32.11.ndpi,Peripheral Blood Smear,2023-06-20,"MDS/ MF
Assess Response to Therapy 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
- Cellular marrow with fibrosis and no increase in blasts. 
- Abnormal myeloid blasts detected by flow cytometry consistent with persistent involvement by the patient's previously characterized MDS/MPN with ring sideroblasts and thrombocytosis. See comment.

Comment:
Although the biopsy is suboptimal and aspirate is inadequate for evaluation, the PB smear did not show increased blasts and CD34 immunostain on the biopsy showed no increased blasts, as compared to the prior specimen (H19-8637, 10/28/2019) with increased blasts (18% on aspirate and 13% in blood), suggesting a remarkable therapeutic response. 

BONE MARROW BIOPSY
Quality: suboptimal, fragmented, crushed
Cellularity: difficult to evaluate but appears 50-60%
M:E ratio: unable to assess
Blasts: not increased 
Myeloid lineage: present
Erythroid lineage: present
Megakaryocytes: atypical
Lymphocytes: scattered
Plasma cells: rare 
Special stains: Reticulin stain shows moderate increase in reticulin fibrosis (MF-2 out of 3). 

BONE MARROW ASPIRATE SMEAR
Differential was not performed (HM)

Aspicular / hemodiluted aspirate smears. Touch imprints of the bone marrow biopsy contain too few cells for evaluation. The cellular elements present are composed primarily of peripheral blood elements.

Special stain
Iron: Suboptimal for evaluation; devoid of spicules.
Ring sideroblasts: Absent. 

PERIPHERAL BLOOD
CBC (12/12/2019):
WBC 1.6 L [4.0-11.0 K/mcL] 
RBC 2.79 L [3.95-5.54 M/mcL] 
HGB 7.9 L [12.5-16.2 g/dL] 
HCT 24.3 L [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 28.3 [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 13.9 [12.2-15.1 %] 
Platelets 76 L [160-400 K/mcL] 

Neutrophil 50.0 [32.5-74.8 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 40.0 [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 0.8 L [1.5-7.5 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology: pancytopenia with reactive lymphocytosis. No blasts seen. 

IMMUNOHISTOCHEMISTRY
CD34 shows no increased blasts. CD117 stains scattered cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-11804)
Interpretation: 
Abnormal myeloid blast population detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample [F19-10174, 10/28/2019] having abnormal expression of CD7 (subset), CD13 (uniform bright), CD33 (absent to dim), CD38 (bright), CD117 (uniform intermediate), CD123 (uniform intermediate), HLA-DR (uniform bright); with normal expression of CD4, CD34, CD45, CD71; and without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 1.0% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available or INSERT FROM F

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7842.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-46033.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-3804;S11;MSK0 - 2023-06-27 23.06.54.ndpi,Peripheral Blood Smear,2023-06-27,"Lymphoma, MCL. 77-year-old male with relapsed MCL.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:     
     - Involvement by previously diagnosed mantle cell lymphoma (~20% with CD20 immunohistochemistry). 
     - Normocellular marrow with trilineage maturing hematopoiesis.

COMMENT: The biopsy specimen is limited. The morphology of the lymphoid cells is best evaluated on the aspirate smears and show blastoid features. The findings are consistent with mantle cell lymphoma, blastoid variant. 


BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Small biopsy and adequate aspirate specimens show normocellular bone marrow (~20-30% cellularity) with involvement by an interstitial lymphoid infiltrate. The morphology of the lymphoid proliferation is best evaluated on the aspirate smears and show a population composed predominately of medium to large sized cells with irregular nuclei, finely stippled chromatin, mostly distinct to prominent nucleoli and moderate cytoplasm.The background maturing trilineage hematopoiesis is present with mostly unremarkable morphology. Blasts are not increased. Clots section shows predominantly blood with rare marrow particles showing similar morphology to the biopsy. 

Aspirate differential: (Performed by CB)
Blasts                1%
Promyelocytes           1%
Myelocytes           8%
Metamyelocytes           5%
Neutrophils/Bands      25%
Monocytes           2%
Eosinophils           3%
Erythroid Precursors      21%
Plasma Cells           1%
Lymphocytes           3%
Miscellaneous cells      30% 
(large lymphoid cells with fine chromatin)
Number of Cells Counted  500
M:E Ratio           2.1

IMMUNOHISTOCHEMISTRY
The neoplastic cells (comprising ~20% marrow cellularity)
Express: CD20, PAX5, CD5 and Cyclin D1 
Do not express: SOX11, CD23 and LEF1
Others:
CD3 highlights intermixed small T-cells. 
CD34 and CD117 show no increase in blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-4369) 
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD19, CD20 (slightly bright), CD45 (dimmer), increased forward and side scatter suggestive of larger cell size, and kappa surface light chain restriction; normal expression of CD22, FMC7 and CD38; and without CD10, CD23 or CD200.  The abnormal B cell population represents 10.5% of total white cells.

While the immunophenotype is not fully specific it is highly concerning for involvement by mantle cell lymphoma. Correlation with immunohistochemical or cytogenetic studies for Cyclin D1 is necessary for confirmation of the diagnosis.

PERIPHERAL BLOOD
CBC (05/13/2019):
WBC 9.0 [4.0-11.0 K/mcL] 
RBC 4.33 [3.95-5.54 M/mcL] 
HGB 14.0 [12.5-16.2 g/dL] 
HCT 41.0 [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 32.3 [27.0-33.0 pg] 
MCHC 34.1 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 81 L [160-400 K/mcL] 

Neutrophil 65.0 [32.5-74.8 %] 
Mono 9.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 9.0 L [12.2-47.4 %] 
Other 14.0 H [0.0-0.0 %] 
Abnormal lymphoid cells.

Abs Neut 5.8 [1.5-7.5 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 
Abs Others 1.3 H [0.0-0.0 K/mcL] 

Morphology:
WBC: Atypical lymphoid cells with similar morphology to the biopsy. 
RBC: Unremarkable morphology. 
PLT: Unremarkable morphology.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-3115.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-17509.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-9947;S10;MSKM - 2023-06-20 13.38.04.ndpi,Peripheral Blood Smear,2023-06-20,"Lymphoma. MCL possible progression. 
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears:  
     - Mantle cell lymphoma, involving approximately 40-50% of marrow cellularity by CD20 immunohistochemical stain.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Suboptimal biopsy (fragmented, aspiration artifact) and adequate aspirate (spicular, cellular) specimens show a cellular bone marrow (approximately 20-30% cellularity in the intact areas) with increased atypical lymphocytes, scattered interstitially and forming dense clusters, occasionally in a paratrabecular pattern. The atypical lymphocytes are mostly small with irregular nuclei, condensed chromatin, inconspicuous nucleoli and scant cytoplasm. There is background residual trilineage maturing hematopoiesis; myeloid and erythroid elements are adequate in proportion with progressive maturation and mostly unremarkable morphology; megakaryocytes are present with unremarkable morphology.  

Aspirate differential: (Performed by CB)

Blasts                1%
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           5%
Neutrophils/Bands      23%
Eosinophils           1%
Erythroid Precursors      27%
Plasma Cells           1%
Lymphocytes           38%
Number of Cells Counted 500
M:E Ratio           1.2

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD5, CD20, CD23 (dim, small subset), CyclinD1, PAX5. 
Do not express: CD3, CD10, P53, SOX11.
Other: Ki67 proliferation index is low (approximately <5% within the lymphoid aggregates).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-11835) 
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD19 (dim), CD20 (bright), CD22 (slightly dim), CD23 (partial), and lambda surface light chain restriction (bright); normal expression of FMC7, CD38 and CD45; and without CD10 or CD200. The abnormal B-cell population represents 78.4% of total white cells.

PERIPHERAL BLOOD
CBC (12/12/2019):
WBC 45.6 H [4.0-11.0 K/mcL] 
RBC 3.33 L [3.80-5.00 M/mcL] 
HGB 8.9 L [11.2-15.4 g/dL] 
HCT 28.6 L [34.3-46.0 %] 
MCV 86 [80-98 fL] 
MCH 26.7 L [27.0-33.0 pg] 
MCHC 31.1 [31.0-36.5 g/dL] 
RDW 16.7 H [12.2-15.1 %] 
Platelets. 130 L [160-400 K/mcL] 

Neutrophil 8.0 L [32.5-74.8 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Lymph 91.0 H [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 3.6 [1.5-7.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.5 H [0.0-0.2 K/mcL] 
Abs Lymph 41.5 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
WBC: Marked leukocytosis with absolute lymphocytosis; the lymphocytes are mostly small with round to irregular nuclei, condensed chromatin, inconspicuous nucleoli and scant cytoplasm. No circulating blasts seen. 
RBC: Normocytic, normochromic anemia.
PLT: Mild thrombocytopenia with unremarkable morphology.  

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7859.

MOLECULAR STUDIES 
Not requested.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-2370;S11;MSK7 - 2023-06-20 14.12.27.ndpi,Peripheral Blood Smear,2023-06-20,"Leukemia. Thrombocytopenia, circulating blasts. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     -B lymphoblastic leukemia/lymphoma (BALL), 90% of the cellularity by CD34 immunohistology. See comment
  
COMMENT: Correlation with the forthcoming cytogenetic studies is needed for final subclassification of this neoplasm. Additional immunohistology to further characterize the blasts and the lymphoid aggregate will be reported in an addendum.
The corresponding flow cytometry was reviewed with Dr. Mikhail Roshal, division of Hematopathology, who agrees.

Preliminary results provided to Dr. Ellin Berman, Department of Medicine, on 3/27/19.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular for age (>95%)
M:E ratio: N/A
Blasts: Markedly increased, nearly completely replacing the normal marrow cellularity. Blasts are medium to large in size with round to slightly irregular nuclei, fine chromatin, small, variably conspicuous nucleoli, and scant cytoplasm. Mitotic figures are identified.
Myeloid lineage: Markedly decreased
Erythroid lineage: Markedly decreased
Megakaryocytes: Decreased, without overt atypia
Lymphocytes: A single interstitial lymphoid aggregate is present composed of small lymphocytes with round nuclei, and condensed chromatin, favor reactive. 
Plasma cells: Rare
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1). 


BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                85%
Neutrophils/Bands      3%
Eosinophils           1%
Erythroid Precursors      10%
Lymphocytes           1%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
Paucispicular and hypercellular aspirate smears show an expanded blast population. Blasts are medium to large in size, with round to slightly irregular nuclei, fine chromatin, inconspicuous nucleoli, and scant cytoplasm. Auer rods are not seen. Myeloid and erythroid precursors are markedly decreased. Few megakaryocytes are noted with overall unremarkable morphology. Rare small mature-appearing lymphocytes are seen.

PERIPHERAL BLOOD
CBC (03/26/2019):
WBC 15.4 H [4.0-11.0 K/mcL] 
RBC 4.68 [3.95-5.54 M/mcL] 
HGB 13.5 [12.5-16.2 g/dL] 
HCT 40.2 [37.5-49.3 %] 
MCV 86 [80-98 fL] 
MCH 28.8 [27.0-33.0 pg] 
MCHC 33.6 [31.0-36.5 g/dL] 
RDW 18.2 H [12.2-15.1 %] 
Platelets 14 LL [160-400 K/mcL]
  
Neutrophil 33.0 [32.5-74.8 %] 
Lymph 13.0 [12.2-47.4 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 52.0 H [0.0-0.0 %] 

Abs Neut 5.1 [1.5-7.5 K/mcL] 
Abs Lymph 2.0 [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 8.0 H [0.0-0.0 K/mcL] 
Nucleated RBC 1 [/100(WBCs)] 

Morphology:
WBC: Frequent circulating blasts seen, with similar morphology as that on the aspirate smear. Occasional hypogranular and pseudo-Pelger Huet neutrophils are seen.
RBC: Anisocytosis 
Platelets: Marked thrombocytopenia

IMMUNOHISTOCHEMISTRY
CD34 is positive in blasts, which nearly completely replace the normal marrow cellularity, accounting for approximately 90% of the cellularity, and are present in sheets and large clusters.
Blasts are negative for CD117, which highlights few scattered mast cells.
 
FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-2763)
Interpretation: 
Abnormal immature B-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature B- or T-cell populations detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (35.2% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD10 (variable, absent to bright), CD11b (minute subset, dim), CD13 (minute subset, dim), CD20 (variable, absent to intermediate), CD33 (partial, dim), CD34 (bright), CD38 (variable, absent to dim), CD45 (variable, absent to dim), CD58, CD123 (uniform bright); with normal expression of CD19, CD71, cCD79a, and HLA-DR; and without CD2, sCD3, cCD3, CD4, CD5, CD7, CD8, CD14, CD15, CD16, CD25, CD56, CD64, CD117, MPO or surface light chains.

CD34 positive myeloid blast population with apparent normal immunophenotype is 1.4% of WBC.
174,861 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-1996.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M19-11303, M19-11396, M19-11399, M19-11400, M19-11402.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-9152;S2;MSK2 - 2023-06-20 11.05.45.ndpi,Peripheral Blood Smear,2023-06-20,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma, 88% blasts by aspirate differential count. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                88%
Myelocytes           1%
Neutrophils/Bands      1%
Erythroid Precursors      5%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           0.4

Morphology:
Spicular and cellular smears show markedly increased blasts (88% on 500 cell aspirate differential count). The blasts are intermediate in size with irregular nuclei, fine chromatin, indistinct nucleoli and scant cytoplasm. Background trilineage hematopoiesis is decreased. Myeloid and erythroid elements are markedly reduced. Megakaryocytes are present with mostly unremarkable morphology.    

PERIPHERAL BLOOD
CBC (11/13/2019):
WBC 3.6 L [7.1-15.9 K/mcL] 
RBC 3.41 L [3.89-5.03 M/mcL] 
HGB 10.1 L [10.7-14.5 g/dL] 
HCT 28.7 L [32.2-43.5 %] 
MCV 84 [74-91 fL] 
MCH 29.6 H [22.7-29.5 pg] 
MCHC 35.2 [31.0-36.5 g/dL] 
RDW 14.6 [12.2-15.1 %] 
Platelets. 61 L [160-400 K/mcL] 

Neutrophil 22.0 [16.9-74.5 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 3.0 H [0.0-0.0 %] 
Lymph 73.0 H [15.5-57.8 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 0.8 L [1.5-8.5 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Abs Lymph 2.6 [1.0-4.3 K/mcL]

Morphology:
WBCs: Leukopenia with absolute neutropenia. Circulating blasts are present. 
RBCs: Normocytic, normochromic anemia with occasional circulating nucleated red blood cells. 
Platelets: Thrombocytopenia with rare giant forms. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-10809)
Abnormal immature B-cell population detected.
No abnormal mature T-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (89.8% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD10 (bright), CD24 (bimodal, negative to bright), CD33 (partial, dim), CD34 (variable, dim to bright), CD38 (dim), CD45 (negative to dim), CD73/CD304 (negative to bright), with normal expression of CD19, CD22, CD71, cytoplasmic CD79a, CD81 and HLA-DR; and without CD2, cytoplasmic and surface CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD20, CD56, CD64, CD66b, CD86, CD117, MPO, surface light chains, or convincing CD123/CD66c.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.15% of WBC.
476,458 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Also see F19-10808 submitted on the same day.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7238.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-42012, M19-42013, M19-42014.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. PessinMD., PhD., Director.
"
H19-3679;S11;MSK0 - 2023-04-19 09.44.48.ndpi,Peripheral Blood Smear,2023-04-19,"CML. 
CML, progressive leukocytosis, want to rule out conversion to acute leukemia. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears:     
     - Chronic myeloid leukemia, accelerated phase, 12% blasts
     - Hypercellular marrow with myeloid predominant trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality: Suboptimal (small, hemorrhagic)
Cellularity: Hypercellular for age (95%)
M:E ratio: Increased
Blasts: Increased
Myeloid lineage: Left shifted maturation
Erythroid lineage: Markedly reduced 
Megakaryocytes: Decreased to absent
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed on touch imprints by HM)

Blasts                12%
Promyelocytes           32%
Myelocytes           6%
Metamyelocytes           3%
Neutrophils/Bands      28%
Monocytes           2%
Basophils           1%
Erythroid Precursors      1%
Lymphocytes           15%
Number of Cells Counted 500
M:E Ratio           75

Morphology:
Paucispicular and paucicellular smears show myeloid predominant hematopoiesis. The myeloid series appears left shifted with increased blasts that are medium to large sized blasts with scant dark blue cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli. The erythroid series is markedly reduced. Megakaryocytes are not well represented.  

PERIPHERAL BLOOD
CBC (05/08/2019):
WBC 24.9 H [4.0-11.0 K/mcL] 
RBC 3.29 L [3.80-5.00 M/mcL] 
HGB 11.0 L [11.2-15.4 g/dL] 
HCT 33.1 L [34.3-46.0 %] 
MCV 101 H [80-98 fL] 
MCH 33.4 H [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 20.5 H [12.2-15.1 %] 
Platelets 83 L [160-400 K/mcL]
 
Neutrophil 37.0 [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 9.0 H [0.0-0.0 %] 
Myelocyte 22.0 H [0.0-0.0 %] 
Promyelocyte 14.0 H [0.0-0.0 %] 
Metamyelocyte 4.0 H [0.0-0.0 %] 
Lymph 12.0 L [12.2-47.4 %] 
Nucleated RBC 1 [/100(WBCs)] 

Abs Neut 9.2 H [1.5-7.5 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 2.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 5.5 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 3.5 H [0.0-0.0 K/mcL] 
Abs Meta 1.0 H [0.0-0.0 K/mcL] 
Abs Lymph 3.0 [0.9-3.2 K/mcL] 

Morphology:
Leukoerythroblastic picture with circulating blasts. 

IMMUNOHISTOCHEMISTRY
CD34 shows rare blasts. CD117 highlights increased mononuclear cells ~15-20% of the marrow space in a limited marrow but likely represents both blasts and myeloid progenitors.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-4226)
Abnormal myeloid blast and maturing granulocyte populations detected.  
Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD7 (partial dim), CD25 (major subset), CD56 (subset), CD11b (partial), CD13 (uniform bright), CD33 (bright), CD34 (subset bright), CD38 (variable, absent to intermediate), HLADR (minor subset absent, major subset bright) with normal expression of CD4, CD45, CD71, CD117, CD123; without CD2, CD5, CD14, CD15, CD16, CD19 orCD64. Granulocytes show markedly left shifted maturation and abnormal retention of CD13 and CD64 as well as discontinuity in maturation pattern. CD34 positive myeloid blasts represent 5.1% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-3017.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-16897.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-8787;S12;MSKF - 2023-06-20 10.09.00.ndpi,Peripheral Blood Smear,2023-06-20,"ALL, like MDS. 68 years old male Ph-negative B-ALL, suspected MDS, 7 months status post allogeneic HCT. 
","1-2. Bone marrow, left posterior iliac crest, biopsy and aspirate. 
     - B-lymphoblastic leukemia/ lymphoma, 55% blast by aspirate differential count. 
  
COMMENT: Dysplasia is not seen in a background trilineage hematopoiesis. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Approximately 80%
M:E ratio: N/A 
Blasts: Markedly increased 
Myeloid lineage: Reduced, shows progressive maturation 
Erythroid lineage: Reduced, shows progressive maturation
Megakaryocytes: Mildly reduced, unremarkable morphology 
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                55%
Promyelocytes           1%
Myelocytes           5%
Metamyelocytes           1%
Neutrophils/Bands      12%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      14%
Plasma Cells           1%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           1.6

Special stain
Iron: Present
Ring sideroblasts: Absent 

Morphology:
The aspirate smears are spicular, cellular and show maturing trilineage hematopoiesis. There is marked increase in blasts, small in size, with irregular nuclear contours, distinct nucleoli and occasional vacuolation. Residual erythroid and myeloid elements show progressive maturation and unremarkable morphology. Megakaryocytes are present and show unremarkable morphology.

PERIPHERAL BLOOD
CBC (11/01/2019):
WBC 3.1 L [4.0-11.0 K/mcL] 
RBC 3.97 [3.95-5.54 M/mcL] 
HGB 12.6 [12.5-16.2 g/dL] 
HCT 38.3 [37.5-49.3 %] 
MCV 97 [80-98 fL] 
MCH 31.7 [27.0-33.0 pg] 
MCHC 32.9 [31.0-36.5 g/dL] 
RDW 12.0 L [12.2-15.1 %] 
Platelets. 49 L [160-400 K/mcL] 

Neutrophil 71.9 [32.5-74.8 %] 
Mono 5.8 [0.0-12.3 %] 
Eos 1.6 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Lymph 20.1 [12.2-47.4 %] 
Nucleated RBC 0.0 [%] 

Abs Neut 2.2 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL]

Morphology: Thrombocytopenia. Mature neutrophils are morphologically unremarkable. 

IMMUNOHISTOCHEMISTRY
CD34 highlights marked increase in blasts, comprising 70-80% of marrow cellularity. 
CD117 labels few scattered mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-10378)
Abnormal immature B-cell population detected.
No abnormal myeloid blast population identified. 

An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously, F18-9699.  The abnormal immature B-cells represent 46.8% of the white cells and 45.3% of the mononuclear cells in the sample and abnormally express CD10 (subset absent, subset dim to bright), CD19 (bright), MPO, CD34 (bright), CD38 (slightly dim), CD66c/CD123, CD22 (slightly dim), CD24 (absent), HLA-DR (bright); with normal expression of cyCD79a, CD45 and CD81; and without CD20, CD66b, CD33, CD13, CD117 or CD73/CD304. This finding is consistent with recurrent B-lymphoblastic leukemia/lymphoma with isolated MPO expression.  Clinical and morphologic correlation is recommended.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.26% of WBC.
167479 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-6986.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-40372, M19-40373.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-5274;S16;MSK8 - 2023-04-19 09.33.27.ndpi,Peripheral Blood Smear,2023-04-19,"CLL and MDS
57 yo woman with both CLL and MDS
","1.  Bone marrow; right posterior iliac crest, biopsy:
    - Myelodysplastic syndrome with del(5q).
    - Chronic lymphocytic leukemia/small lymphocytic lymphoma (10-20% involvement by CD20 immunohistochemistry).

See comment. 

COMMENT: Per clinical notes, and recent cytogenetic analysis of peripheral blood (CG19-3568; 6/3/2019), deletion of 5q31 was detected (10% of cells). Suggest correlation with pending cytogenetic studies of the marrow sample for further characterization (whether this represents a myelodysplastic syndrome with isolated del5q). 

  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Normocellular for age (30-40%)
M:E ratio: Normal
Blasts: Not increased
Myeloid lineage: Full maturation
Erythroid lineage: Full maturation
Megakaryocytes: Increased in number with frequent small, hypolobated forms and rare small clusters
Lymphocytes: Multiple interstitial lymphoid aggregates composed predominantly of small lymphoid cells with round to irregular nuclei, condensed chromatin, inconspicuous nucleoli and scant cytoplasm are present. Few scattered admixed intermediate to large, variably nucleolated cells are seen. No sheets of large cells are identified.
Plasma cells: Scattered

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)

Blasts                1%
Promyelocytes           1%
Myelocytes           7%
Metamyelocytes           8%
Neutrophils/Bands      27%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      15%
Plasma Cells           1%
Lymphocytes           38% 
Number of Cells Counted 500
M:E Ratio           3.1

Special stain 
Iron: Absent
Ring sideroblasts: Absent 

Morphology:
- Spicular and cellular. Hypercellular smears show no increase in blasts (1%). Megakaryocytes show dysplastic features including micro-megakaryocytes and hypolobated and non lobated forms. Erythroid precursors show full maturation and megaloblastoid changes. Myeloid lineage shows hypogranular forms.

PERIPHERAL BLOOD
CBC (07/01/2019):
WBC 20.6 H [4.0-11.0 K/mcL] 
RBC 1.87 L [3.80-5.00 M/mcL] 
HGB 8.0 L [11.2-15.4 g/dL] 
HCT 25.1 L [34.3-46.0 %] 
MCV 134 H [80-98 fL] 
MCH 42.8 H [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 16.0 H [12.2-15.1 %] 
Platelets 302 [160-400 K/mcL] 

Neutrophil 13.0 L [32.5-74.8 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 6.0 H [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 79.0 H [12.2-47.4 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 2.7 [1.5-7.5 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.2 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 16.2 H [0.9-3.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Morphology: No circulating blasts noted. Neutrophilia with few hypolobated and occasional hypogranular neutrophils. Macrocytic anemia observed. Relative and absolute lymphocytosis seen. Absolute eosinophil count is slightly increased. 

IMMUNOHISTOCHEMISTRY
The lymphoid infiltrate (~10-20% of the marrow cellularity) is positive for CD20, PAX5, CD5, CD23 and LEF1 and negative for Cyclin D1. Rare cells show weak CyclinD1 expression in the proliferation centers. CD3 highlights scattered T-cells.
CD34 shows blasts in the range of 4% of marrow cellularity overall.
CD117 highlights scattered immature myeloid/erythroid precursors and mast cells.
P53 highlights approximately 1% of cells showing strong nuclear expression.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-6029)
Abnormal myeloid blast population detected.
Abnormal B-cell population identified.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD7 (partial), CD38 (partial dim), CD56 (partial), CD117 (bright), CD123 (uniform), and HLA-DR (bright); with normal expression of CD4, CD13, CD33, CD34, CD45, and CD71; without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, or CD64. CD34 positive myeloid blasts represent 1.0% of WBC.

Flow cytometry identifies an abnormal B-cell population with a CLL/SLL-like immunophenotype having abnormal expression of CD5, CD19 (dim), CD20 (dim), CD22 (dim), CD23, CD200 (bright), and kappa surface light chain restriction (dim); normal expression of CD45; and without CD38, FMC7 or CD10 expression. The abnormal B-cell population comprises 33.2% of the white cells.

Mild eosinophilia and basophilia are seen, representing 6.6% and 1.0% of the WBCs, respectively.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-4256.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-23645, M19-23646, M19-23647.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-604;S11;MSK5 - 2023-05-10 19.41.00.ndpi,Peripheral Blood Smear,2023-05-10,"41-year-old with CML and del (7) in same clone as to (9;22), appears to be responding to nilotinib.
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia (CML, 2% blasts by aspirate differential count). 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (80-90%) 
M:E ratio: Normal 
Blasts: Not increased in number
Myeloid lineage: Show progressive maturation 
Erythroid lineage: Show progressive maturation
Megakaryocytes: Adequate in number and show small atypical hypo segmented megakaryocytes 
Lymphocytes: Interstitially scattered
Plasma cells: Interstitially scattered 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                2%
Promyelocytes           1%
Myelocytes           7%
Metamyelocytes           4%
Neutrophils/Bands      40%
Monocytes           3%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      18%
Lymphocytes           23%
Number of Cells Counted 500
M:E Ratio           3.2

Morphology:
- Aspirate smears are paucispicular and hypocellular and show trilineage maturing hematopoiesis. There is no expanded blast population. Myeloid elements are adequate in number and show progressive maturation with unremarkable morphology. Erythroid elements are adequate in number and show progressive maturation. Megakaryocytes are poorly represented. 

PERIPHERAL BLOOD
CBC (01/23/2019):
WBC 8.5 [4.0-11.0 K/mcL] 
RBC 4.50 [3.80-5.00 M/mcL] 
HGB 12.0 [11.2-15.4 g/dL] 
HCT 36.4 [34.3-46.0 %] 
MCV 81 [80-98 fL] 
MCH 26.7 L [27.0-33.0 pg] 
MCHC 33.0 [31.0-36.5 g/dL] 
RDW 17.1 H [12.2-15.1 %] 
Platelets. 223 [160-400 K/mcL] 

Neutrophil 70.1 [32.5-74.8 %] 
Lymph 22.9 [12.2-47.4 %] 
Mono 4.6 [0.0-12.3 %] 
Eos 1.4 [0.0-4.9 %] 
Baso 0.5 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 5.9 [1.5-7.5 K/mcL] 
Abs Lymph 1.9 [0.9-3.2 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Morphology:
WBC: Occasional blasts seen 
RBC: Unremarkable 
Platelets: Unremarkable 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlights scattered blasts (<5% positivity). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-699)
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature B- or T-cell populations detected.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.64% of WBC.
237,905 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not submitted. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-538.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-2780, M19-2783.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-9340;S11;MSKA - 2023-06-20 11.40.26.ndpi,Peripheral Blood Smear,2023-06-20,"Lymphoma. Mantle cell lymphoma. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by plasma cell neoplasm. See comment.
     60% by CD138 immunohistochemistry
71% by aspirate count
28% by flow cytometry
    - Minimal involvement by CD5 positive B-cell lymphoma (1.7% by flow cytometry). See comment
    - Cellular marrow with trilineage maturing hematopoiesis.

COMMENT:
The marrow shows extensive involvement by a plasma cell neoplasm, and a CD5 positive B-cell lymphoma based on flow cytometric studies. Given the patient has documented lymph node involvement by a blastoid mantle cell lymphoma, and the FISH findings on sorted CD5 positive B-cell showing IGH/CCND1 fusion, this most likely represents minimal involvement by mantle cell lymphoma. The predominant plasma cell component shows phenotypic features most consistent with a primary plasma cell neoplasm/myeloma but also shows IGH/CCND1 fusion. Therefore, whether these two neoplasms represent two distinct clonal processes or clonal evolution of mantle cell lymphoma cannot be ascertained. Additional molecular studies are in progress to establish the clonal relationship between these disorders. These will be resulted separately.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy, clot and aspirate specimens show hypercellular bone marrow (60% cellularity) with maturing trilineage hematopoiesis and focal aggregates of atypical plasma cells and rare lymphoid cells. Myeloid and erythroid cells show progressive maturation. The M:E ratio is normal. Megakaryocytes appear adequate in number and morphology.

Aspirate differential: (Performed by HM)

The bone marrow aspiration yielded a dry tap.

Myelocytes           4%
Metamyelocytes           1%
Neutrophils/Bands      10%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      9%
Plasma Cells           71%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           2

IMMUNOHISTOCHEMISTRY
The atypical plasma cells
Express: CD20, CD19, PAX5 (small subset), IgM, CyclinD1
Do not express: IgA, IgG, Kappa (IHC), Lambda (IHC), Kappa (ISH), Lambda (ISH)
Other:
CD138 and CD38 highlight plasma cells.
CD34 and CD117 show no increase in blasts.
CD3 and CD5 highlight background T cells.
Small CD5 positive B-cell component identified by flow cytometry cannot be visualized by immunohistochemistry.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-11062) 
Abnormal plasma cell population detected.
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.

Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (absent), CD20 (partial), CD27 (absent), CD45 (absent), CD81 (dim to normal)) and no definite cytoplasmic light chain expression; with normal expression of CD38 and CD138; and without CD56 or CD117 expression.  The abnormal population represents 28.3% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 94.7% of total plasma cells in the sample.

In addition, flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD19 (dim), CD20 (normal to bright), CD22 (dim to normal), CD45 (dim to bright), and lambda surface light chain restriction (bright); normal expression of FMC7 and CD38 and without CD10, significant CD23 or CD200.  The abnormal B cell population represents 1.7% of total white cells. This immunophenotype is not entirely specific and does not allow for full classification by flow cytometry. Correlation with immunohistochemical or cytogenetic studies for Cyclin D1 is recommended to rule out mantle cell lymphoma.

No immunophenotypic evidence of involvement by T-cell lymphoma or leukemia is identified.

PERIPHERAL BLOOD
CBC (11/19/2019):
WBC 9.4 [4.0-11.0 K/mcL] 
RBC 4.53 [3.95-5.54 M/mcL] 
HGB 14.7 [12.5-16.2 g/dL] 
HCT 43.4 [37.5-49.3 %] 
MCV 96 [80-98 fL] 
MCH 32.5 [27.0-33.0 pg] 
MCHC 33.9 [31.0-36.5 g/dL] 
RDW 13.6 [12.2-15.1 %] 
Platelets 240 [160-400 K/mcL]
 
Neutrophil 68.0 [32.5-74.8 %] 
Mono 6.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 20.0 [12.2-47.4 %] 
Plasma Cell 2.0 H [0.0-0.0 %] 
Other 3.0 H [0.0-0.0 %] 
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 6.4 [1.5-7.5 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.9 [0.9-3.2 K/mcL] 
Abs Plasma Cells 0.2 H [0.0-0.0 K/mcL] 
Abs Others 0.3 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
Atypical lymphoid cells and circulating plasma cells are seen.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate reports, CG19-7383, CG19-7502, CG19-7518.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-42844.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H19-8767;S11;MSKC - 2023-06-20 10.20.31.ndpi,Peripheral Blood Smear,2023-06-20,"Leukemia. Newly diagnosed. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia with myelodysplasia related changes (AML-MRC), 55% blast by aspirate differential, see comment 
     - Small abnormal bi-clonal B-cell population identified by flow cytometry, see separate report F19-10341. 
  
COMMENT: Trilineage dysplasia is present which fulfills the morphological criteria of AML-MRC. Corresponding cytogenetic and molecular tests are in progress. Please correlate with these results. Per clinical notes, the patient has a history of prostate carcinoma. Please correlate with clinical/treatment history to rule out therapy-related myeloid neoplasm (per WHO classification, diagnosis of therapy-related myeloid neoplasm trumps AML-MRC).  

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Approximately 20%
M:E ratio: Decreased. Erythroid predominance. 
Blasts: Increased. 
Myeloid lineage: Mature forms are decreased. 
Erythroid lineage: Megaloblastoid maturation 
Megakaryocytes: Increased. Numerous small/mono-lobated dysplastic forms present. 
Lymphocytes: Not increased 
Plasma cells: Not increased 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                55%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      5%
Eosinophils           1%
Erythroid Precursors      27%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           0.4

Morphology:
Spicular and cellular smears show increase in blasts. These blasts are small to intermediate in size and have distinct nucleoli. Auer rods are not present. Background myeloid and erythroid hematopoiesis show dysplasia (>50%).   

PERIPHERAL BLOOD
CBC (10/28/2019):
WBC 1.9 L [4.0-11.0 K/mcL] 
RBC 2.49 L [3.95-5.54 M/mcL] 
HGB 8.9 L [12.5-16.2 g/dL] 
HCT 25.1 L [37.5-49.3 %] 
MCV 101 H [80-98 fL] 
MCH 35.7 H [27.0-33.0 pg] 
MCHC 35.5 [31.0-36.5 g/dL] 
RDW 16.7 H [12.2-15.1 %] 
Platelets 24 L [160-400 K/mcL] 

Neutrophil 39.0 [32.5-74.8 %]  
Mono 2.0 [0.0-12.3 %]  
Eos 2.0 [0.0-4.9 %]  
Baso 0.0 [0.0-1.5 %]  
Blast 4.0 H [0.0-0.0 %] 
Immature Granulocyte [0.0-0.6] 
Lymph 53.0 H [12.2-47.4 %]  
Nucleated RBC 0 [/100(WBCs)]  

Abs Neut 0.7 L [1.5-7.5 K/mcL]  
Abs Mono 0.0 [0.0-1.3 K/mcL]  
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL]  
Absolute Basophil 0.0 [0.0-0.2 K/mcL]  
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Absolute Immature Granulocyte [0.0-0.1] 
Abs Lymph 1.0 [0.9-3.2 K/mcL]  
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology: Circulating blasts and immature myeloid cells present. A subset of mature granulocytes shows abnormal nuclear lobation. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight increase in blasts, approximately 30% of marrow cellularity. 
CD61 highlights numerous small dysplastic megakaryocytes.
TP53 immunohistochemistry is negative.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-10341)
Interpretation: 
Expanded abnormal myeloid blast population detected. 
Abnormal bi-clonal B-cell population identified.
No abnormal mature T-cell population detected.

The myeloid blasts have abnormal expression of CD11b (subset dim), CD19 (subset dim), CD25 (subset), CD13 (negative to dim), CD33 (negative to dim), CD117 (bright), CD123 (uniform intermediate); with normal expression of CD4, CD34, CD38, CD45, CD71, and HLA-DR; without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD10, CD14, CD15, CD16, CD20, CD56, CD64, cytoplasmic CD79a or surface light chains. The blasts show uniform dim expression of MPO. CD34 positive myeloid blasts represent 32.2% of WBC.

In addition, flow cytometry identified a biclonal abnormal B-cell population with CLL/SLL-like immunophenotype having abnormal expression of CD5, CD20 (dim), CD22 (dim); normal expression of CD19, CD38 and CD45; and without CD10 expression. The population is too minute to be confidently assessed for the expression of CD23, CD200 and FMC7. The dim lambda light chain restricted subset represents 0.036% of the WBC, and the dim kappa light chain restricted subset represents 0.025% of the WBC. Overall, the abnormal B-cell population comprises 0.061% of the white cells.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-6959.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M19-40214, M19-40215, M19-40216, M19-40217.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H19-9313;S10;MSK0 - 2023-06-20 09.57.19.ndpi,Peripheral Blood Smear,2023-06-20,"Lymphoma. MCL patient completed treatment with rituximab on 09/29/19, now possible POD. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by mantle cell lymphoma (30% with CD20 immunohistochemistry)
     - Cellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show normocellular bone marrow (30% cellularity overall) with a lymphoid infiltrate composed of small cells with condensed chromatin and inconspicuous nucleoli. There istrilineage maturing hematopoiesis. Myeloid and erythroid elements show progressive maturation. Megakaryocytes appear adequate in number and morphology.

Aspirate differential: (Performed by HM)

Patchy cellular distribution noted.
Numerous naked nuclei noted.

Blasts                2%
Promyelocytes           3%
Myelocytes           8%
Metamyelocytes           5%
Neutrophils/Bands      12%
Monocytes           1%
Eosinophils           5%
Basophils           1%
Erythroid Precursors      22%
Plasma Cells           1%
Lymphocytes           40% (range from ~30% to ~60%)
Number of Cells Counted 500
M:E Ratio           1.6

IMMUNOHISTOCHEMISTRY
The neoplastic cells
Express: CD20, PAX5, CD5, CyclinD1 (weak)
Do not express: CD3, SOX11
Other:
CD3 highlights background T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F19-11026) 
Interpretation: 
Abnormal B-cell population identified.
Flow cytometry identifies an abnormal B-cell population having abnormal expression of CD5, CD19 (dim), CD20 (bright), CD22 (dim), CD38 (uniform intermediate), CD45 (bright), FMC7 (uniform intermediate), and lambda surface light chain restriction (bright); and without convincing CD10, CD23 or CD200.  The abnormal B cell population represents 29.7% of total white cells.

This immunophenotype is consistent with previously diagnosed mantle cell lymphoma (MCL).

PERIPHERAL BLOOD
CBC (11/19/2019):
WBC 18.3 H [4.0-11.0 K/mcL] 
RBC 3.29 L [3.95-5.54 M/mcL] 
HGB 8.6 L [12.5-16.2 g/dL] 
HCT 27.2 L [37.5-49.3 %] 
MCV 83 [80-98 fL] 
MCH 26.1 L [27.0-33.0 pg]
MCHC 31.6 [31.0-36.5 g/dL] 
RDW 14.2 [12.2-15.1 %] 
Platelets 52 L [160-400 K/mcL] 

Neutrophil 12.0 L [32.5-74.8 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Lymph 7.0 L [12.2-47.4 %] 
Other 80.0 H [0.0-0.0 %] 
Abnormal small to medium lymphoid cells with folded nuclei, finely clumped chromatin and
occasional nucleoli.
Nucleated RBC 0 [/100(WBCs)] 

Abs Neut 2.2 [1.5-7.5 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 
Abs Others 14.6 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 

Morphology:
Lymphocytosis with atypical small lymphocytes, normochromic normocytic anemia and thrombocytopenia.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG19-7377.

MOLECULAR STUDIES 
Not performed.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9303;S11;MSK9 - 2023-04-25 11.37.47.ndpi,Peripheral Blood Smear,2023-04-25,"MDS.  Evaluate for progression of disease. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Acute myeloid leukemia with myelodysplasia related changes (AML-MRC, 22% blasts by aspirate differential count).
  
COMMENT: Patient's previous diagnosis of myelodysplastic syndrome is noted; the leukemia is best classified as acute myeloid leukemia with myelodysplasia related changes. Correlation with cytogenetic and molecular genetic findings is recommended. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (90-95%) 
M:E ratio: N/A 
Blasts: Overtly increased in number 
Myeloid lineage: Reduced 
Erythroid lineage: Increased and show left shift in maturation
Megakaryocytes: Increased in number and show dysplastic forms (hypolobated forms)
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered
Special stains: Reticulin stain shows marked increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                22%
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      15%
Monocytes           2%
Erythroid Precursors      44%
Plasma Cells           1%
Lymphocytes           11%
Number of Cells Counted 500
M:E Ratio           0.5

Special stains
Iron: Present
Ring sideroblasts: Present; >15%

Morphology: 
Spicular and cellular aspirate smears show numerous naked nuclei and an increased number of blasts. Myeloid elements are reduced. Erythroid elements are increased and show left shift in maturation (megaloblastoid forms). Megakaryocytes are adequate in number and show dysplastic forms. 

PERIPHERAL BLOOD
CBC (11/26/2018):
WBC 2.0 L [4.0-11.0 K/mcL] 
RBC 2.48 L [3.80-5.00 M/mcL] 
HGB 7.4 L [11.2-15.4 g/dL] 
HCT 22.6 L [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 29.8 [27.0-33.0 pg] 
MCHC 32.7 [31.0-36.5 g/dL] 
RDW 16.1 H [12.2-15.1 %] 
Platelets 68 L [160-400 K/mcL] 

Neutrophil 48.0 [32.5-74.8 %] 
Lymph 37.0 [12.2-47.4 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 

Abs Neut 1.0 L [1.5-7.5 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 10.0 H [0.0-0.0 %] 

Absolute Blasts 0.2 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 1 [/100(WBCs)] 

Morphology:
WBC: Leukopenia with circulating blasts (10%) 
RBC: Normocytic normochromic anemia with anisopoikilocytosis 
Platelets: Thrombocytopenia 

IMMUNOHISTOCHEMISTRY
Immunostains for CD34 and CD117 (weak) highlight increased blasts (~15-20%)
CD61 highlights increased dysplastic megakaryocytes 
CD71, Spectrin and E-cadherin highlights the increased erythroid lineage. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10134)
Expanded abnormal myeloid blast population detected. 

The blasts have abnormal expression of CD7 (partial), CD11b (partial), CD13 (absent to bright), CD25, CD34 (bright), CD38 (dim to negative), CD71 (dim to negative), CD117 (uniform),  HLA-DR (bright) with normal expression of CD4, CD33, CD45, without CD2, sCD3, CD5, CD7, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD56, CD64, cCD79a or surface light chains. MPO expression is present on a subset of blasts. A small subset of the blasts co-expresses cCD3. CD34 positive myeloid blasts represent 16.9% of WBC.
CD25 is expressed by greater than 10 percent of the blasts.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not submitted. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7268.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-36670.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6360;S13;MSKA - 2023-06-26 22.06.59.ndpi,Peripheral Blood Smear,2023-06-26,"Lymphoplasmacytic disorder ass with PRCA / ITP, status post allo SCT. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Mildly hypercellular marrow with trilineage maturing hematopoiesis. See comment. 
     - No evidence of B-cell lymphoma. 

Comment:
The etiology of eosinphilia is uncertain but can be seen in GVHD. Clinical correlation is suggested. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show hypercellular bone marrow (60-70%cellularity). There istrilineage maturing hematopoiesis. Myeloid to erythroid ratio is normal. Myeloid and erythroid elements show progressive maturation. Megakaryocytes are slightly increased in number and show occasional hypolobated forms. 

Aspirate differential: (Performed by HM)

Blasts                3%
Promyelocytes           5%
Myelocytes           15%
Metamyelocytes           10%
Neutrophils/Bands      25%
Monocytes           3%
Eosinophils           10%
Basophils           1%
Erythroid Precursors      17%
Plasma Cells           1%
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           4.1

IMMUNOHISTOCHEMISTRY
CD20 and PAX-5 immunostains highlights few B cells
CD3 labels reactive T-cells 
CD138 show few scattered plasma cells 
Kappa and lambda immunostains are noncontributory

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-6807) 
Interpretation: 
No abnormal mature B- or T-cell populations detected.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified. Increase of CD8 LGL (CD5 and CD7 dim with CD57 expression) population seen. Vß fragment analysis demonstrates polytypic expression of Vß chains consistent with polyclonal population. Hodgkin lymphoma would not be detected by these studies.

PERIPHERAL BLOOD
CBC (08/13/2018):
WBC 21.7 H [4.0-11.0 K/mcL] 
RBC 4.00 [3.95-5.54 M/mcL] 
HGB 12.4 L [12.5-16.2 g/dL] 
HCT 38.1 [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 31.0 [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 15.9 H [12.2-15.1 %] 
Platelets 311 [160-400 K/mcL] 

Neutrophil 31.0 L [32.5-74.8 %] 
Lymph 25.0 [12.2-47.4 %] 
Mono 6.0 [0.0-12.3 %] 
Eos 36.0 H [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 

Abs Neut 6.7 [1.5-7.5 K/mcL] 
Abs Lymph 5.4 H [0.9-3.2 K/mcL] 
Abs Mono 1.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 7.8 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.4 H [0.0-0.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Leukocytosis with absolute lymphocytosis and eosinophilia; increased large granular lymphocytes 
RBC: Unremarkable 
Platelets: Unremarkable 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-4905.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-24801.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9303;S11;MSK9 - 2023-03-23 23.08.24.ndpi,Peripheral Blood Smear,2023-04-25,"MDS.  Evaluate for progression of disease. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Acute myeloid leukemia with myelodysplasia related changes (AML-MRC, 22% blasts by aspirate differential count).
  
COMMENT: Patient's previous diagnosis of myelodysplastic syndrome is noted; the leukemia is best classified as acute myeloid leukemia with myelodysplasia related changes. Correlation with cytogenetic and molecular genetic findings is recommended. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (90-95%) 
M:E ratio: N/A 
Blasts: Overtly increased in number 
Myeloid lineage: Reduced 
Erythroid lineage: Increased and show left shift in maturation
Megakaryocytes: Increased in number and show dysplastic forms (hypolobated forms)
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered
Special stains: Reticulin stain shows marked increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                22%
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      15%
Monocytes           2%
Erythroid Precursors      44%
Plasma Cells           1%
Lymphocytes           11%
Number of Cells Counted 500
M:E Ratio           0.5

Special stains
Iron: Present
Ring sideroblasts: Present; >15%

Morphology: 
Spicular and cellular aspirate smears show numerous naked nuclei and an increased number of blasts. Myeloid elements are reduced. Erythroid elements are increased and show left shift in maturation (megaloblastoid forms). Megakaryocytes are adequate in number and show dysplastic forms. 

PERIPHERAL BLOOD
CBC (11/26/2018):
WBC 2.0 L [4.0-11.0 K/mcL] 
RBC 2.48 L [3.80-5.00 M/mcL] 
HGB 7.4 L [11.2-15.4 g/dL] 
HCT 22.6 L [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 29.8 [27.0-33.0 pg] 
MCHC 32.7 [31.0-36.5 g/dL] 
RDW 16.1 H [12.2-15.1 %] 
Platelets 68 L [160-400 K/mcL] 

Neutrophil 48.0 [32.5-74.8 %] 
Lymph 37.0 [12.2-47.4 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 

Abs Neut 1.0 L [1.5-7.5 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 10.0 H [0.0-0.0 %] 

Absolute Blasts 0.2 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 1 [/100(WBCs)] 

Morphology:
WBC: Leukopenia with circulating blasts (10%) 
RBC: Normocytic normochromic anemia with anisopoikilocytosis 
Platelets: Thrombocytopenia 

IMMUNOHISTOCHEMISTRY
Immunostains for CD34 and CD117 (weak) highlight increased blasts (~15-20%)
CD61 highlights increased dysplastic megakaryocytes 
CD71, Spectrin and E-cadherin highlights the increased erythroid lineage. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10134)
Expanded abnormal myeloid blast population detected. 

The blasts have abnormal expression of CD7 (partial), CD11b (partial), CD13 (absent to bright), CD25, CD34 (bright), CD38 (dim to negative), CD71 (dim to negative), CD117 (uniform),  HLA-DR (bright) with normal expression of CD4, CD33, CD45, without CD2, sCD3, CD5, CD7, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD56, CD64, cCD79a or surface light chains. MPO expression is present on a subset of blasts. A small subset of the blasts co-expresses cCD3. CD34 positive myeloid blasts represent 16.9% of WBC.
CD25 is expressed by greater than 10 percent of the blasts.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not submitted. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7268.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-36670.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9401;S11;MSK8 - 2023-03-23 23.03.49.ndpi,Peripheral Blood Smear,2023-04-25,"Erythrocytosis. 61-year-old with history of prostate cancer and now erythrocytosis. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Hypercellular marrow with panmyelosis and atypical pleomorphic megakaryopoiesis consistent with polycythemia vera (JAK2 V617F positive). See comment. 
  
COMMENT: Patient is noted to have high hemoglobin (up to 18.8 g/dL) and hematocrit (57.4%) levels since 7/2018. The overall findings are consistent with polycythemia vera. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (60-70%)
M:E ratio: Normal 
Blasts: Not increased in number 
Myeloid lineage: Increased in number and show progressive maturation 
Erythroid lineage: Increased in number and show progressive maturation 
Megakaryocytes: Increased in number and show pleomorphism 
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered
Special stains: Reticulin stain shows focal increase in reticulin fibrosis (0-1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HH)

Blasts                1%
Promyelocytes           1%
Myelocytes           14%
Metamyelocytes           5%
Neutrophils/Bands      34%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      26%
Plasma Cells           1%
Lymphocytes           14%
Number of Cells Counted 500
M:E Ratio           2.2

Morphology:
- Paucispicular, cellular aspirate smears show maturing trilineage hematopoiesis. There is no expanded blast population. Myeloid and erythroid elements are increased in number and show progressive maturation. Megakaryocytes are increased in number and show pleomorphism. Extrinsic cells are not seen

PERIPHERAL BLOOD
CBC (11/28/2018):
WBC 11.3 H [4.0-11.0 K/mcL] 
RBC 5.19 [3.95-5.54 M/mcL] 
HGB 16.3 H [12.5-16.2 g/dL] 
HCT 49.6 H [37.5-49.3 %] 
MCV 96 [80-98 fL] 
MCH 31.4 [27.0-33.0 pg] 
MCHC 32.9 [31.0-36.5 g/dL] 
RDW 14.8 [12.2-15.1 %] 
Platelets 431 H [160-400 K/mcL] 

Neutrophil 84.1 H [32.5-74.8 %] 
Lymph 10.7 L [12.2-47.4 %] 
Mono 2.4 [0.0-12.3 %] 
Eos 1.3 [0.0-4.9 %] 
Baso 0.8 [0.0-1.5 %] 
Immature Granulocyte 0.7 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 9.5 H [1.5-7.5 K/mcL] 
Abs Lymph 1.2 [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] 

Morphology:
WBC: Mild leukocytosis with absolute neutrophilia; no circulating blasts seen 
RBC: Erythrocytosis 
Platelets: Thrombocytosis 

IMMUNOHISTOCHEMISTRY
Immunostains CD34 and CD117 highlights immature cells (<5% positivity)
CD117 also highlights scattered mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10268)
Interpretation: 
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.64% of WBC.
292,159 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not submitted. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7378.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-37134, M18-37135.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6780;S11;MSKE - 2023-06-26 17.07.44.ndpi,Peripheral Blood Smear,2023-06-26,"Mult Myeloma. Status post induction, pre-auto.
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Limited bone marrow biopsy with minute cellular marrow particles showing trilineage maturing hematopoiesis.
     - No morphologic or immunophenotypic evidence of plasma cell neoplasm, see comment.

Comment: No morphologic or immunophenotypic evidence of plasma cell neoplasm is seen, although core biopsy and aspirate smears are limited for evaluation. Corresponding flow cytometric analysis is negative for abnormal plasma cell population (see F18-7315). 

BONE MARROW BIOPSY
Quality: Limited. Mostly composed of bone, soft tissue, and blood clot. Minute cellular marrow particles are present. 
Cellularity: Approximately 30% in evaluable area 
Myeloid lineage: Orderly maturation    
Erythroid lineage: Orderly maturation   
Megakaryocytes: Present
Plasma cells: Not increased 

ASPIRATE MORPHOLOGY
Aspirate differential: (Not performed by CB)

The smears are aspicular
Peripheral blood elements are mainly present

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, <5% of cellularity 
Kappa and lambda immunostains show no definitive light chain restriction  
BCMA highlights ~100% of plasma cells, (1-2+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7315) 
No abnormal plasma cell population detected, virtually very few plasma cells seen.

No evidence of an abnormal plasma cell population is identified by flow cytometry.  Plasma cells comprise 0.006 % of the viable cells, following erythroid lysis.
3475373 cells acquired.  Please note that flow cytometry studies generally underestimate the number of plasma cells, as compared to morphologic assessment.

PERIPHERAL BLOOD
CBC (08/29/2018):
WBC 3.4 L [4.0-11.0 K/mcL] 
RBC 4.60 [3.95-5.54 M/mcL] 
HGB 13.2 [12.5-16.2 g/dL] 
HCT 39.9 [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 28.7 [27.0-33.0 pg] 
MCHC 33.1 [31.0-36.5 g/dL] 
RDW 17.1 H [12.2-15.1 %] 
Platelets 122 L [160-400 K/mcL] 

Neutrophil 59.6 [32.5-74.8 %] 
Lymph 30.5 [12.2-47.4 %] 
Mono 6.4 [0.0-12.3 %] 
Eos 1.2 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 2.0 [1.5-7.5 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 

Morphology: No circulating plasma cells seen. Neutrophils, monocytes, lymphocytes, red blood cells, and platelets are morphologically unremarkable. Large granular lymphocytes are mildly increased. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5268, CG18-5269.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-26526. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7306;S10;MSKI - 2023-04-20 10.03.54.ndpi,Peripheral Blood Smear,2023-04-20,"ALL. Likely B cell ALL per peripheral flow. 
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - B lymphoblastic leukemia/lymphoma (89% blasts by aspirate differential count).
  
BONE MARROW BIOPSY
Quality: Adequate. 
Cellularity: Hypercellular (more than 90%)
M:E ratio: NA
Blasts: Markedly increased. 
Myeloid lineage: Markedly reduced. 
Erythroid lineage: Markedly reduced.
Megakaryocytes: Reduced and show atypical enlarged forms.
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blasts                89%
Promyelocytes           1%
Myelocytes           1%
Neutrophils/Bands      1%
Erythroid Precursors      2%
Lymphocytes           6%
Number of Cells Counted 500
M: E Ratio           1.5

Morphology:
The aspirate smears are spicular and cellular and show a markedly expanded population of small to medium sized blasts with scant cytoplasm, round to irregular nuclei, fine chromatin and multiple indistinct nucleoli, in a background of markedly decreased trilineage hematopoiesis. Erythroid elements show megaloblastoid changes. Neutrophils with abnormal nuclear lobation and hypogranulation are seen.

PERIPHERAL BLOOD
CBC (09/18/2018):

WBC 383.5 H [4.0-11.0 K/mcL] 
RBC 2.55 L [3.95-5.54 M/mcL] 
HGB 7.7 L [12.5-16.2 g/dL] 
HCT 24.5 L [37.5-49.3 %] 
MCV 96 [80-98 fL] 
MCH 30.2 [27.0-33.0 pg] 
MCHC 31.4 [31.0-36.5 g/dL] 
RDW 16.8 H [12.2-15.1 %] 
Platelets 72 L [160-400 K/mcL] 

Neutrophil 2.0 L [32.5-74.8 %] 
Lymph 2.0 L [12.2-47.4 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Abs Neut 7.7 H [1.5-7.5 K/mcL] 
Abs Lymph 7.7 H [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 96.0 H [0.0-0.0 %] 
Absolute Blasts 368.2 H [0.0-0.0 K/mcL] 

Morphology:
WBC: Markedly increased white blood cell count which represents a marked increase in blasts of variable size, ranging from small to large with round to cleaved nuclei and some with cytoplasmic granularity.
RBC: Normocytic normochromic anemia.
Platelet: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
The blasts express TdT and CD34 (more than 95% of cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7943)
Abnormal immature B-cell population detected.
An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously [F18-7870].  The abnormal immature B-cells represent 86.4% of the white cells and 94% of the mononuclear cells in the sample and abnormally express CD10(bright), CD20(partial), CD38(absent), CD45(dim to absent), CD58(bright) ; with normal expression of CD19, CD34, CD38; and without convincing CD33.  This finding is consistent with B-lymphoblastic leukemia/lymphoma. Clinical and morphologic correlation is recommended.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F18-7870)
Abnormal immature B-cell population detected, diagnostic for B-lymphoblastic leukemia/lymphoma.
No abnormal mature B or T-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. Very few CD34 positive myeloid blasts seen.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood (94.7% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD10 (bright), CD13 (variable, normal to dim), CD15 (small subset), CD20 (partial), CD33 (partial dim), CD34 (bright), CD38 (dim to absent), CD45 (dim to absent), CD58 (slightly bright), CD123 (uniform bright), with normal expression of CD19, CD71, cyCD79a and HLA-DR; and without CD2, sCD3, cyCD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD16, CD20, CD56, CD64, CD117, convincing MPO or surface light chains.
CD25 is expressed by greater than 10% of the blasts.

432,413 cells acquired. Correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5702.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-28708, M18-28709, M18-28710.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6308;S11;MSKA - 2023-06-26 22.01.23.ndpi,Peripheral Blood Smear,2023-06-26,"AML, status post 2 cycles of decitabine + entospletinib. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent acute myeloid leukemia with myelodysplasia related changes (10% blasts by CD34 immunostain).
     - Hypercellular marrow with erythroid predominant hematopoiesis, markedly reduced myeloid elements and multilineage dysplasia. 

BONE MARROW BIOPSY
Quality: Fragmented 
Cellularity: Hypercellular for age, 70% in intact areas
M:E ratio: Decreased 
Blasts: Increased, interstitial, patchy and clustered distribution 
Myeloid lineage: Markedly reduced and left-shifted
Erythroid lineage: Increased and left-shifted 
Megakaryocytes: Increased with dysplastic changes (pleomorphic, hyperchromatic and small hypolobated or multi-nucleated forms)
Lymphocytes: Interstitial lymphoid aggregate of small lymphoid cells
Plasma cells: Scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blasts                2%
Promyelocytes           1%
Myelocytes           4%
Metamyelocytes           2%
Neutrophils/Bands      3%
Monocytes           1%
Eosinophils           2%
Basophils           1%
Erythroid Precursors      45% (30% to 60%)
Plasma Cells           2%
Lymphocytes           37% (25% to 50%)
Number of Cells Counted 500
M: E Ratio           0.3

Morphology:
Spicular and cellular aspirate smears show marked erythroid hyperplasia and dyserythropoiesis (megaloblastic changes and nuclear irregularities). Markedly reduced myeloid maturation is seen. Few neutrophils with dysplastic changes are seen. Megakaryocytes are increased and show dysplastic changes (hypolobated and multi-nucleated forms). Blasts are not overtly increased. Lymphoid cells are increased with unremarkable morphology. 

PERIPHERAL BLOOD
CBC (08/13/2018):
WBC 1.8 L [4.0-11.0 K/mcL] 
RBC 2.79 L [3.95-5.54 M/mcL] 
HGB 8.1 L [12.5-16.2 g/dL] 
HCT 24.8 L [37.5-49.3 %] 
MCV 89 [80-98 fL] 
MCH 29.0 [27.0-33.0 pg] 
MCHC 32.7 [31.0-36.5 g/dL] 
RDW 13.5 [12.2-15.1 %] 
Platelets 39 L [160-400 K/mcL] 

Neutrophil 1.0 L [32.5-74.8 %] 
Lymph 97.0 H [12.2-47.4 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 2.0 H [0.0-0.0 %] 

Abs Neut 0.0 L [1.5-7.5 K/mcL] 
Abs Lymph 1.7 [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.0 [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)]

Morphology:
WBC: Large granular lymphocytes seen. No circulating blasts.
RBC: Unremarkable morphology. 
PLT: Few large forms seen. 

IMMUNOHISTOCHEMISTRY
CD34 highlights increased blasts (~10%) in interstitial patchy and clustered distribution. A subset is also highlighted by CD117. 
CD34 also highlights dysplastic megakaryocytes. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-6767)
Abnormal myeloid blast population detected.
Eosinophilia is observed.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample (F18-5587) have abnormal expression of CD5 (subset), CD7 (subset), CD11b (dim), CD56 (subset), CD13 (dim to bright), CD33 (bright), CD38 (dim to absent), CD117 (absent to normal) and HLA-DR (absent to bright);with normal expression of CD4, CD34, CD45, CD71 and CD123; without CD2, CD14, CD15, CD16, CD19, CD25 or CD64. CD34 positive myeloid blasts represent 10.4% of WBC. In addition, eosinophilia is seen representing 2.1% of the WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-4864.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-24600, M18-24601, M18-24602.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7472;S11;MSK4 - 2023-06-26 21.20.19.ndpi,Peripheral Blood Smear,2023-06-26,"Multiple myeloma. MM 4 years post auto. 
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
    - Minimal involvement by plasma cell neoplasm, lambda-restricted
  <5% involvement by CD138 immunohistochemistry.
<5% involvement by aspirate differential
1.3% (72.9% of plasma cells) involvement by 10-color flow cytometry
     - Small subcortical biopsy with cellular marrow with trilineage maturing hematopoiesis

BONE MARROW BIOPSY
Quality: Small, hemorrhagic, subcortical 
Cellularity: Cannot accurately assess
Myeloid lineage: Progressive maturation
Erythroid lineage: Progressive maturation
Megakaryocytes: Present 
Plasma cells: Scattered
Lymphoid cells: Scattered 

ASPIRATE MORPHOLOGY

Aspirate differential: (Performed by CB)

Blasts                1%
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           4%
Neutrophils/Bands      22%
Monocytes           2%
Eosinophils           4%
Erythroid Precursors      49%
Plasma Cells           2%
Lymphocytes           12%
Number of Cells Counted  200
M:E Ratio           0.7

Morphology: 
Marrow spicules: Paucispicular
Cellularity: Hypocellular
Plasma cell morphology: Intermediate-sized. Occasional Russell bodies seen.
Myeloid lineage: Progressive maturation
Erythroid Lineage: Left-shifted, progressive maturation
Lymphoid cells: Small, mature-appearing
Megakaryocytes: Present, rare 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights scattered plasma cells (<5% cellularity)
Kappa and lambda immunostains show high staining background, and no definitive monotypic plasma cells.
BCMA highlights 100% of plasma cells, (1+) intensity (membranous/ Golgi pattern). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8103) 
Interpretation: 
Abnormal plasma cell population detected.

Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (negative), CD45 (majority negative), CD56, CD81 (dim to negative), CD117 and monoclonal lambda cytoplasmic light chain restriction; with normal expression of CD27, CD38 and CD138. The abnormal population represents 1.3% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 72.9% of total plasma cells in the sample.
4,137,936 cells acquired.

PERIPHERAL BLOOD
CBC (09/24/2018):
WBC 4.3 [4.0-11.0 K/mcL] 
RBC 4.05 [3.80-5.00 M/mcL] 
HGB 12.5 [11.2-15.4 g/dL] 
HCT 37.3 [34.3-46.0 %] 
MCV 92 [80-98 fL] 
MCH 30.9 [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 14.9 [12.2-15.1 %] 
Platelets 251 [160-400 K/mcL] 

Neutrophil 45.4 [32.5-74.8 %] 
Lymph 26.9 [12.2-47.4 %] 
Mono 12.2 [0.0-12.3 %] 
Eos 14.1 H [0.0-4.9 %] 
Baso 1.2 [0.0-1.5 %] 
Immature Granulocyte 0.2 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 1.9 [1.5-7.5 K/mcL] 
Abs Lymph 1.2 [0.9-3.2 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.6 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Morphology:
WBC: Eosinophilia. Large granular lymphocytes seen.
RBC: Normocytic, normochromic RBC's.
Platelet: Some large platelets seen.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5820, CG18-5821.

MOLECULAR STUDIES 
Not requested.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-8200;S11;MSKD - 2023-06-26 18.54.59.ndpi,Peripheral Blood Smear,2023-06-26,"MDS, confirm diagnosis.  Also with low grade lymphoma and plasma cell disorder with prior BM.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Myelodysplastic syndrome with ring sideroblasts with multilineage dysplasia (MDS-RS-MLD), 1% blast by aspirate differential.  
     - Plasma cell neoplasm, kappa light chain restricted, approximately 5% involvement by CD138 immunostain
     - Small abnormal B cell population detected by flow cytometry only, see separate flow report (F18-8853) 
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular for age (approximately 70%)
M:E ratio: Normal
Blasts: Not increased
Myeloid lineage: Progressive maturation 
Erythroid lineage: Progressive maturation 
Megakaryocytes: Adequate in number; a subset shows small hypolobated/hyperchromatic forms (>10%) 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blasts                1%
Promyelocytes           2%
Myelocytes           8%
Metamyelocytes           9%
Neutrophils/Bands      39%
Monocytes           5%
Eosinophils           1%
Erythroid Precursors      27%
Plasma Cells           1%
Lymphocytes           7%
Number of Cells Counted 500
M: E Ratio           2.4

Special stain
Iron: Present
Ring sideroblasts: >15%

Morphology:
Spicular and cellular smears show maturing trilineage hematopoiesis. The myeloid series shows progressive maturation with a subset of neutrophils showing hypogranulation and abnormal chromatin pattern (<10% of myeloid lineages). The erythroid series shows megaloblastoid changes, rare binucleate forms and karyorrhectic bodies. Megakaryocytes show frequent small monolobated forms (>10%). No expanded blast population is identified. No expanded lymphoid population is seen.

PERIPHERAL BLOOD
CBC (10/16/2018):
WBC 8.1 [4.0-11.0 K/mcL] 
RBC 2.63 L [3.95-5.54 M/mcL] 
HGB 9.4 L [12.5-16.2 g/dL] 
HCT 28.9 L [37.5-49.3 %] 
MCV 110 H [80-98 fL] 
MCH 35.7 H [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 16.3 H [12.2-15.1 %] 
Platelets. 191 [160-400 K/mcL] 

Neutrophil 49.5 [32.5-74.8 %] 
Lymph 34.6 [12.2-47.4 %] 
Mono 13.8 H [0.0-12.3 %] 
Eos 1.2 [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 4.0 [1.5-7.5 K/mcL] 
Abs Lymph 2.8 [0.9-3.2 K/mcL] 
Abs Mono 1.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 

Morphology:
WBC: Unremarkable morphology. No circulating blasts seen.
RBC: Macrocytic anemia.
PLT: Unremarkable morphology.

IMMUNOHISTOCHEMISTRY
CD34 does not highlight increased blasts (<5%) and dimly highlights megakaryocytes.
CD117 highlights scattered mast cells. 
CD138 highlights plasma cells, approximately 5% of cellularity, that appear kappa predominant by kappa/lambda staining. 
CD3 highlights scattered T cells. 
CD20 highlights rare scattered B cells, 1-2% of cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8853)
Interpretation: 
Abnormal myeloid blast population detected 
Abnormal plasma cell population detected.
Abnormal B-cell populations identified.
No abnormal T-cell population identified.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD13 (dim), CD38 (bright), CD71 (dim), CD123 (bright), and HLA-DR (bright) with normal expression of CD4, CD33, CD34, CD45, CD117, and without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64. CD34 positive myeloid blasts represent 0.37% of WBC. The findings are consistent with the patient's previously diagnosed myelodysplastic syndrome, per clinical notes.
299,908 cells acquired.

Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (absent), CD20 (partial), CD45 (dim to absent), CD56, CD81 (subset absent, subset intermediate) and monoclonal kappa cytoplasmic light chain restriction; with normal expression of CD27, CD38 and CD138; and without CD117 expression. The abnormal population represents 1.0% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 65.9% of total plasma cells in the sample. 

Two abnormal B-cell populations identified
The larger abnormal mature B-cell population has abnormal expression of CD19 (slightly bright), CD20 (slightly bright), CD22 (slightly bright), CD38 (absent), and kappa light chain restriction; with normal expression of CD45; and without CD5 or CD10. The abnormal B-cell population represents approximately 3.5% of the total white cells. The phenotype is non-specific and is suggestive of a low grade B cell lymphoma (marginal vs. LPL vs. other) or non-CLL-like monoclonal B cell lymphocytosis.  While the population shares the same light chain type (kappa) with the abnormal plasma cell population, it is unclear if they are clonally related. The phenotype of the abnormal plasma cells favors primary plasma cell neoplasm (myeloma/MGUS), rather than a B cell lymphoma with plasmacytic differentiation, favoring unrelated diseases. The populations were sorted in an attempt to valuate clonal relationship. The results will be reported in addendum.

In additional a small abnormal B cell population with lambda light chain restriction and reduced expression of CD22 without CD38 is seen. The population shows normal expression of CD19, CD20, CD45, without CD5 or CD10. The population represents 0.11% of WBC. The phenotype is non-specific and may represent non-CLL type MBL.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6398.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-32105, M18-32593, M18-32594.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-9809;S11;MSKJ - 2023-03-23 21.36.55.ndpi,Peripheral Blood Smear,2023-04-25,"AML. New AML. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute Myeloid Leukemia (45% blasts by aspirate differential count) (See Comment)
     - Hypercellular marrow with erythroid predominant maturing hematopoiesis and dysmegakaryopoiesis and dyserythropoiesis 
  
COMMENT: Per clinical note, the patient has a history of colonic adenocarcinoma and prostate adenocarcinoma, but no prior documented cytotoxic chemotherapy. The marrow findings of dysmegakaryopoiesis and dyserythropoiesis do raise the possibility of Acute Myeloid Leukemia with Myelodysplasia-Related changes (AML-MRC). However, this degree of morphologic dysplasia is insufficient to meet the criteria for this diagnosis (>50% dysplasia in two lineages). Nevertheless, correlation with cytogenetics and molecular findings is recommended for final classification.

BONE MARROW BIOPSY
Quality: Adequate, hemorrhagic biopsy
Cellularity: Mildly hypercellular for age (~30-40% cellularity) in areas away from subcortical region.
M:E ratio: Decreased 
Blasts: Increased interstitial medium-sized blasts with dispersed chromatin, one or more nucleoli, and small amount of cytoplasm.
Myeloid lineage: Relatively decreased and exhibits left shifted maturation 
Erythroid lineage: Relatively increased and exhibits left shifted maturation
Megakaryocytes: Decreased in number with many atypical forms (small hypolobated forms and abnormal nuclear lobe separation)
Lymphocytes: Scattered
Plasma cells: Scattered 

Special stains: Reticulin stain shows no increase in reticulin fibrosis (0/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                45%
Promyelocytes           1%
Myelocytes           4%
Metamyelocytes           2%
Neutrophils/Bands      10%
Eosinophils           1%
Erythroid Precursors      19%
Plasma Cells           9%
Lymphocytes           9%
Number of Cells Counted  500
M:E Ratio           0.9

Morphology:
Spicular and cellular aspirate smears showing erythroid predominant maturing trilineage hematopoiesis with expanded population of medium to large sized blasts with oval to slightly irregular nuclei, dispersed chromatin, distinct nucleoli and scant basophilic cytoplasm with occasional cytoplasmic blebs. No Auer rods are seen. Myeloid elements are relatively decreased and show marked left shifted maturation. Erythroid elements are relatively increased and show left shifted maturation with frequent dyspoietic forms (nuclear irregularity and budding, nuclear-cytoplasmic dyssynchrony, megaloblastoid changes, karyorrhexis), but <50% of lineage. Megakaryocytes are present, appears decreased in number and show frequent dyspoietic forms (abnormal nuclear lobation, abnormal nuclear lobe separation, >50%). Plasma cells are mildly increased.

PERIPHERAL BLOOD
CBC (12/12/2018):
WBC 0.8 L [4.0-11.0 K/mcL] 
RBC 2.01 L [3.95-5.54 M/mcL] 
HGB 7.2 L [12.5-16.2 g/dL] 
HCT 21.4 L [37.5-49.3 %] 
MCV 107 H [80-98 fL] 
MCH 35.8 H [27.0-33.0 pg] 
MCHC 33.6 [31.0-36.5 g/dL] 
RDW 21.8 H [12.2-15.1 %] 
Platelets 45 L [160-400 K/mcL] 

Neutrophil 20.0 L [32.5-74.8 %] 
Lymph 74.0 H [12.2-47.4 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 0.2 L [1.5-7.5 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)]

Morphology:
WBC: Marked leukopenia with absolute neutropenia and relative lymphocytosis. Rare circulating blasts present. 
RBC: Macrocytic anemia with mild anisocytosis. 
PLT: Marked thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show expanded blast population (20-25% cellularity). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10742)
Abnormal myeloid blast population detected. 
No abnormal mature B and T cell population identified. 

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD5 (partial dim), CD13 (uniform bright), CD33 (dim to absent), CD38 (uniform), CD56 (subset), CD117 (uniform bright), CD123 (uniform intermediate), and HLA-DR (uniform bright) with normal expression of CD4, CD34, CD45, CD71, without CD2, sCD3, cyCD3, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD64, cyCD79 or surface light chains. MPO expression is expressed in a subset of blasts. CD34 positive blasts represent 14.6% of WBCs.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.
94,661 cells acquired.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7696.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-38997 to M18-39001.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-8949;S11;MSKD - 2023-03-24 07.12.35.ndpi,Peripheral Blood Smear,2023-03-24,"CML. 82-year-old man with CML currently on Imatinib with POD / intolerant to prior TKI treatment now with peripheral blasts concern for blast phase. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia, blast phase (myeloid) (20% blasts by aspirate differential count). 
  
BONE MARROW BIOPSY
Quality: Adequate (aspiration artifact present)
Cellularity: Hypercellular for age (70-80%)
M:E ratio: Decreased 
Blasts: Increased in number 
Myeloid lineage: Show left shift in maturation 
Erythroid lineage: Show progressive maturation 
Megakaryocytes: Adequate in number and show small hypolobated forms 
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blasts                20%
Promyelocytes           3%
Myelocytes           16%
Metamyelocytes           2%
Neutrophils/Bands      7%
Monocytes           1%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      41%
Plasma Cells           1%
Lymphocytes           7%
Number of Cells Counted 500
M: E Ratio           0.8

Morphology:
- Spicular and cellular aspirate smear show maturing trilineage hematopoiesis. Myeloid elements are adequate in number and show left shift in maturation. Blasts are increased. Blasts are medium to large, with scant cytoplasm, round to oval nuclei, fine lacy chromatin and prominent nucleoli. Erythroid are adequate in number and show progressive maturation. Megakaryocytes are adequate in number and show small, hypolobated forms. 

PERIPHERAL BLOOD
CBC (11/12/2018):
WBC 3.8 L [4.0-11.0 K/mcL] 
RBC 3.11 L [3.95-5.54 M/mcL] 
HGB 8.7 L [12.5-16.2 g/dL] 
HCT 27.1 L [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 28.0 [27.0-33.0 pg] 
MCHC 32.1 [31.0-36.5 g/dL] 
RDW 18.2 H [12.2-15.1 %] 
Platelet. 56 L [160-400 K/mcL] 

Neutrophil 51.0 [32.5-74.8 %] 
Lymph 33.0 [12.2-47.4 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Abs Neut 1.9 [1.5-7.5 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 14.0 H [0.0-0.0 %] 
Absolute Blasts 0.5 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)]

Morphology:
WBC: Leukopenia; increased circulating blasts seen (14%)
RBC: Normocytic normochromic anemia with anisopoikilocytosis 
Platelets: Thrombocytopenia 

IMMUNOHISTOCHEMISTRY
CD34 shows increased blasts, approximately 10% of total cells. CD117 stains more blasts, approximately 20%. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-9716)
Interpretation: 
Expanded abnormal myeloid blast population detected. 
Minute abnormal B-cell population identified.
No abnormal mature T-cell population detected.

The blasts have abnormal expression of CD2 (partial), CD11b (subset), CD13 (dim to bright), CD33 (bright), CD34 (dim to absent), CD38 (dim), CD117 (bright), HLA-DR (dim to normal); with normal expression of CD4, CD45, CD71, CD123 and without sCD3, cCD3, CD5, CD7, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cCD79a or surface light chains. MPO expression is present on the major subset of blasts. CD117 positive myeloid blasts represent 25.8% of WBC.

In addition, flow cytometry also reveals a minute abnormal mature B-cell population with abnormal expression of CD10, CD22 (slightly dim), increased forward and side scatter suggestive of larger size, lambda light chain restriction, and normal expression of CD19, CD38 and CD45; and without CD5. The abnormal B-cell population represents 0.067% of the total white cells.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F18-9718)
Interpretation: 
Abnormal myeloid blast population detected. 
Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD2 (partial), CD7 (partial), CD25 (partial), CD56 (partial), CD11b (subset), CD13 (dim), CD33 (uniform bright), CD34 (dim to intermediate), CD38 (subset absent, subset dim), CD64, CD71 (dim), CD117 (dim to intermediate), CD123 (uniform intermediate), with normal expression of CD4, CD45 and HLA-DR without sCD3, cyCD3, CD5, CD14, CD15, CD16, CD19, CD25 or cyCD79a. MPO is present on subset of the blasts. CD34 positive myeloid blasts represent 14.2% of WBC.

No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6987.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-35237, M18-35239, M18-35250.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6162;S11;MSKZ - 2023-07-06 08.09.41.ndpi,Peripheral Blood Smear,2023-07-06,"Multiple Myeloma. Pancytopenia.
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate smears and peripheral blood smears:
     - Mildly hypercellular marrow with erythroid predominance, multilineage dysplasia, rare ring sideroblasts (2%) and blasts (3%) consistent with myelodysplastic syndrome with multilineage dysplasia (MDS-MLD).
     - No morphologic or immunophenotypic evidence of plasma cell neoplasm.

COMMENT: Further characterization requires correlation with cytogenetic and genetic studies and detailed clinical history. Patient's history of therapy for multiple myeloma and possibly for breast carcinoma is noted. The overall findings may represent therapy related myeloid neoplasm in the form of myelodysplastic syndrome (MDS). 

Relative monocytosis is noted in the peripheral blood smear. 

FISH studies for MDS panel are initiated. 
 
BONE MARROW BIOPSY
Mildly hypercellular (50%) marrow shows erythroid predominance, reduced myeloid elements with maturation, increased megakaryocytes with small hypolobated and dysplastic forms. Plasma cells are not increased. 

ASPIRATE MORPHOLOGY
Aspirate differential: (Performed by: HWH)

Blasts                3%
Promyelocytes           2%
Myelocytes           7%
Metamyelocytes           4%
Neutrophils/Bands      16%
Monocytes           5%
Eosinophils           5%
Erythroid Precursors      47%
Plasma Cells           1%
Lymphocytes           10%
Number of Cells Counted  500
M: E Ratio           0.8

Special stain
Iron: Present
Ring sideroblasts: 2% of erythroid elements

Morphology: 
Spicular and cellular aspirate smears show reduced M:E ratio, erythroid predominance, erythroid dysplasia (nuclear cytoplasmic asynchrony), myeloid elements reduced and show dysplastic changes (abnormal nuclear lobation and hypogranulation), megakaryocytes are increased and show numerous small hypolobated dysplastic forms. Blasts are mildly increased (3%). Plasma cells are not increased. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show mildly increased blasts (3%). CD71 and MPO highlight increased erythroid and reduced myeloid elements. CD61 highlights increased megakaryocytes that show predominantly small and dysplastic morphology. 

CD138 immunostain highlights plasma cells, <5% of cellularity. 
Kappa and lambda immunostains show the plasma cells are polytypic.  
BCMA highlights 90% of plasma cells, (1-2+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-6589) 
Interpretation: 
No abnormal plasma cell population detected.

No evidence of an abnormal plasma cell population is identified by flow cytometry.  Plasma cells comprise 0.63% of the white cells, following erythroid lysis. 2544224 cells acquired. Less than target number of cells acquired for plasma cell neoplasm followup. Target sensitivity is not achieved.
Please note that flow cytometry studies generally underestimate the number of plasma cells, as compared to morphologic assessment.

PERIPHERAL BLOOD
CBC (08/07/2018):
WBC 2.9 L [4.0-11.0 K/mcL] 
RBC 3.31 L [3.80-5.00 M/mcL] 
HGB 10.2 L [11.2-15.4 g/dL] 
HCT 31.4 L [34.3-46.0 %] 
MCV 95 [80-98 fL] 
MCH 30.8 [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 18.6 H [12.2-15.1 %] 
Platelets 141 L [160-400 K/mcL] 

Neutrophil 41.4 [32.5-74.8 %] 
Lymph 35.2 [12.2-47.4 %] 
Mono 20.7 H [0.0-12.3 %] 
Eos 1.7 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.7 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 1.2 L [1.5-7.5 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Morphology: Red blood cells moderate anisopoikilocytosis. Platelets show enlarged forms and a subset with hypogranulation. No circulating blasts are seen. Neutrophils and monocytes show cytoplasmic vacuolization. Neutrophils with abnormal nuclear lobation are seen.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-4732, CG18-4733.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-23951, M18-23952.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-8637;S11;MSK8 - 2023-06-22 00.48.55.ndpi,Peripheral Blood Smear,2023-06-22,"Breast Cancer. Metastatic breast cancer, assess marrow involvement, rule out MDS.
","1.  Bone marrow, RPIC; biopsy:  
- Metastatic mammary carcinoma with lobular features (see note)
- Immunohistochemical stains were performed on formalin-fixed tissue with the following results for metastatic carcinoma (block 1_1BM):

Pan-Cytokeratin: Positive
ESTROGEN RECEPTOR (clone 6F11, Leica): 1% nuclear staining with weak intensity
PROGESTERONE RECEPTOR (clone 16; Leica): Negative (no nuclear staining)
ANDROGEN RECEPTOR (clone SP107, Ventana): 50% nuclear staining with moderate to strong intensity
HER2 (4B5, Ventana):Negative (1+) 

Note, part #1: The patient's primary breast tumor(s) are not immediately available for review/comparison however the carcinoma in this material shows morphologic similarities to the metastatic carcinoma seen in the prior ""right pubic bone"" (S17-31335) and ""left iliac bone"" (S17-45946) biopsies. The morphology and immunohistochemical profile support a metastatic carcinoma of mammary origin. 

The interpretation of the biopsy/immunohistochemical results is based in part on the decalcification procedure performed. 


2, 3.  Bone Marrow Aspirate, RPIC and Peripheral Blood Smear:

Comment: Bone marrow touch imprints and peripheral smear reviewed by Hematopathologist Dr. Wenbin Xiao. 

BONE MARROW Touch imprints

Special stain
Iron: Aspicular/absent
Ring sideroblasts: Absent 

Morphology:
-Touch imprints show atypical mononuclear cells suspicious for metastatic carcinoma and rare bone marrow elements. 

PERIPHERAL BLOOD

Morphology:
WBC: Left shifted granulopoiesis seen; no circulating blasts seen. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW 
Not submitted. 

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not submitted. 

CYTOGENETIC STUDIES
Not submitted. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.



"
H18-9809;S11;MSKJ - 2023-04-25 09.52.53.ndpi,Peripheral Blood Smear,2023-04-25,"AML. New AML. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute Myeloid Leukemia (45% blasts by aspirate differential count) (See Comment)
     - Hypercellular marrow with erythroid predominant maturing hematopoiesis and dysmegakaryopoiesis and dyserythropoiesis 
  
COMMENT: Per clinical note, the patient has a history of colonic adenocarcinoma and prostate adenocarcinoma, but no prior documented cytotoxic chemotherapy. The marrow findings of dysmegakaryopoiesis and dyserythropoiesis do raise the possibility of Acute Myeloid Leukemia with Myelodysplasia-Related changes (AML-MRC). However, this degree of morphologic dysplasia is insufficient to meet the criteria for this diagnosis (>50% dysplasia in two lineages). Nevertheless, correlation with cytogenetics and molecular findings is recommended for final classification.

BONE MARROW BIOPSY
Quality: Adequate, hemorrhagic biopsy
Cellularity: Mildly hypercellular for age (~30-40% cellularity) in areas away from subcortical region.
M:E ratio: Decreased 
Blasts: Increased interstitial medium-sized blasts with dispersed chromatin, one or more nucleoli, and small amount of cytoplasm.
Myeloid lineage: Relatively decreased and exhibits left shifted maturation 
Erythroid lineage: Relatively increased and exhibits left shifted maturation
Megakaryocytes: Decreased in number with many atypical forms (small hypolobated forms and abnormal nuclear lobe separation)
Lymphocytes: Scattered
Plasma cells: Scattered 

Special stains: Reticulin stain shows no increase in reticulin fibrosis (0/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                45%
Promyelocytes           1%
Myelocytes           4%
Metamyelocytes           2%
Neutrophils/Bands      10%
Eosinophils           1%
Erythroid Precursors      19%
Plasma Cells           9%
Lymphocytes           9%
Number of Cells Counted  500
M:E Ratio           0.9

Morphology:
Spicular and cellular aspirate smears showing erythroid predominant maturing trilineage hematopoiesis with expanded population of medium to large sized blasts with oval to slightly irregular nuclei, dispersed chromatin, distinct nucleoli and scant basophilic cytoplasm with occasional cytoplasmic blebs. No Auer rods are seen. Myeloid elements are relatively decreased and show marked left shifted maturation. Erythroid elements are relatively increased and show left shifted maturation with frequent dyspoietic forms (nuclear irregularity and budding, nuclear-cytoplasmic dyssynchrony, megaloblastoid changes, karyorrhexis), but <50% of lineage. Megakaryocytes are present, appears decreased in number and show frequent dyspoietic forms (abnormal nuclear lobation, abnormal nuclear lobe separation, >50%). Plasma cells are mildly increased.

PERIPHERAL BLOOD
CBC (12/12/2018):
WBC 0.8 L [4.0-11.0 K/mcL] 
RBC 2.01 L [3.95-5.54 M/mcL] 
HGB 7.2 L [12.5-16.2 g/dL] 
HCT 21.4 L [37.5-49.3 %] 
MCV 107 H [80-98 fL] 
MCH 35.8 H [27.0-33.0 pg] 
MCHC 33.6 [31.0-36.5 g/dL] 
RDW 21.8 H [12.2-15.1 %] 
Platelets 45 L [160-400 K/mcL] 

Neutrophil 20.0 L [32.5-74.8 %] 
Lymph 74.0 H [12.2-47.4 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 0.2 L [1.5-7.5 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)]

Morphology:
WBC: Marked leukopenia with absolute neutropenia and relative lymphocytosis. Rare circulating blasts present. 
RBC: Macrocytic anemia with mild anisocytosis. 
PLT: Marked thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show expanded blast population (20-25% cellularity). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10742)
Abnormal myeloid blast population detected. 
No abnormal mature B and T cell population identified. 

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD5 (partial dim), CD13 (uniform bright), CD33 (dim to absent), CD38 (uniform), CD56 (subset), CD117 (uniform bright), CD123 (uniform intermediate), and HLA-DR (uniform bright) with normal expression of CD4, CD34, CD45, CD71, without CD2, sCD3, cyCD3, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD64, cyCD79 or surface light chains. MPO expression is expressed in a subset of blasts. CD34 positive blasts represent 14.6% of WBCs.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.
94,661 cells acquired.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7696.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-38997 to M18-39001.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-8554;S12;MSK7 - 2023-05-12 16.20.16.ndpi,Peripheral Blood Smear,2023-05-12,"MDS/ Mantle Cell Lymphoma.  Patient with remote history of mantle cell lymphoma status post autoHSCT 2011 and with MDS status post alloSCT on 10/26/16.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Therapy related acute myeloid leukemia (20-25% by CD34 and CD117 immunostains)      - Hypocellular marrow with trilineage maturing hematopoiesis.

Comment: Bone marrow aspirates are aspicular, but the blast counts based on the immunostains are greater than 20%.  

BONE MARROW BIOPSY
Quality: Short biopsy mostly consists of bone with few marrow spaces 
Cellularity: Unable to assess
M:E ratio: Normal 
Blasts: A small cluster of blasts seen  
Myeloid lineage: Show progressive maturation 
Erythroid lineage: Show progressive maturation
Megakaryocytes: Poorly represented (rare) 
Lymphocytes: Interstitially scattered
Plasma cells: Interstitially scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0+/3). 
Clot section: Adequate and show bone marrow elements with 40-50% cellularity; sheets of immature myeloid elements are seen  

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HH)

Hemodilute/hypocellular aspirate devoid of spicules
Differential count from touch imprint smear

Blasts                2%
Promyelocytes           2%
Myelocytes           11%
Metamyelocytes           5%
Neutrophils/Bands      23%
Monocytes           4%
Eosinophils           2%
Erythroid Precursors      15%
Lymphocytes           36%
Number of Cells Counted 500
M:E Ratio           3.1

Morphology:
-Aspicular, hypocellular and hemodiluted aspirate smears show predominantly peripheral blood elements. Myeloid elements are reduced in number and show left shift in maturation. Erythroid elements are reduced in number and show progressive maturation. Megakaryocytes are poorly represented.  

PERIPHERAL BLOOD
CBC (10/29/2018):
WBC 4.0 [4.0-11.0 K/mcL] 
RBC 3.48 L [3.80-5.00 M/mcL] 
HGB 13.1 [11.2-15.4 g/dL] 
HCT 38.3 [34.3-46.0 %] 
MCV 110 H [80-98 fL] 
MCH 37.6 H [27.0-33.0 pg] 
MCHC 34.2 [31.0-36.5 g/dL] 
RDW 14.1 [12.2-15.1 %] 
Platelets 140 L [160-400 K/mcL] 

Neutrophil 32.7 [32.5-74.8 %] 
Lymph 47.0 [12.2-47.4 %] 
Mono 13.2 H [0.0-12.3 %] 
Eos 6.7 H [0.0-4.9 %] 
Baso 0.2 [0.0-1.5 %] 
Immature Granulocyte 0.2 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 1.3 L [1.5-7.5 K/mcL] 
Abs Lymph 1.9 [0.9-3.2 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 

Morphology:
WBC: Absolute neutropenia; no definitive circulating blasts seen 
RBC: Unremarkable 
Platelets: Thrombocytopenia 

IMMUNOHISTOCHEMISTRY
Immunostains CD34 and CD117 were performed on both biopsy and clot section. The biopsy shows a small cluster of and the clot section shows many blasts (20-25%).  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-9249)
Abnormal myeloid blast population detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample (F17-4162) have abnormal expression of CD11b (partial), CD13 (bright), CD25 (partial, 20% of the blasts), CD33 (uniform, intermediate), CD34 (bright), CD38 (absent to dim), CD56 (partial), CD71 (uniform), CD117 (bright), CD123 (uniform, bright), HLA-DR (absent), with normal expression of  CD4, CD45 without CD2, CD5, CD7, CD14, CD15, CD16, CD19 and CD64. CD34 positive myeloid blasts represent 1.6% of WBC.

No abnormal mature B-cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified. Hodgkin lymphoma would not be detected by these studies.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not submitted. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6665.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-33584.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9196;S11;MSK9 - 2023-06-21 21.36.14.ndpi,Peripheral Blood Smear,2023-06-21,"MDS. Relapse post-transplant; on supportive care. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent myelodysplastic syndrome with excess blasts (7% by aspirate differential, 6% in peripheral blood) and ring sideroblasts. 
     - Hypercellular marrow with multilineage dysplasia.
  
COMMENT: Correlation with forthcoming cytogenetic and molecular studies is recommended. 
 
BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (80-90%)
M:E ratio: Decreased 
Blasts: Slightly increased in number 
Myeloid lineage: Show left shift in maturation 
Erythroid lineage: Show progressive maturation 
Megakaryocytes: Adequate in number and show dysplastic forms (hypolobated and forms with widely separated nuclei)
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered
Special stains: Reticulin stain shows marked increase in reticulin fibrosis (MF-3+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed on touch imprints by HM)

Aspicular / hemodiluted aspirate

Blasts                7%
Promyelocytes           9%
Myelocytes           7%
Metamyelocytes           1%
Neutrophils/Bands      10%
Eosinophils           2%
Basophils           1%
Erythroid Precursors      50%
Lymphocytes           13%
Number of Cells Counted 500
M:E Ratio           0.6

Special stain
Iron: Present appear Increased
Ring sideroblasts: Present  

Morphology:
- Aspicular, hypocellular and hemodiluted aspirate smears are seen. Touch imprints show maturing trilineage hematopoiesis. Myeloid elements are adequate in number and show left shift in maturation with dysgranulopoiesis (hypogranulation and abnormal segmentation). Erythroid elements are adequate in number and show dyspoiesis (nuclear irregularities, nuclear budding and binucleation). Megakaryocytes are poorly represented. 

PERIPHERAL BLOOD
CBC (11/19/2018):
WBC 7.0 [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 2.60 L [3.95-5.54 M/mcL] 
HGB 7.3 L [12.5-16.2 g/dL] 
HCT 23.6 L [37.5-49.3 %] 
Mean Corpuscular Volume 91 [80-98 fL] 
(MCV)
Mean Corpuscular 28.1 [27.0-33.0 pg] 
Hemoglobin (MCH)
Mean Corpuscular 30.9 L [31.0-36.5 g/dL] 
Hemoglobin Conc (MCHC)
Red Blood Cell Distribution 19.9 H [12.2-15.1 %] 
Width (RDW)
Platelets 116 L [160-400 K/mcL] 

Neutrophil 59.0 [32.5-74.8 %] 
Lymph 22.0 [12.2-47.4 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 

Abs Neut 4.2 [1.5-7.5 K/mcL] 
Abs Lymph 1.6 [0.9-3.2 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 

Metamyelocyte 1.0 H [0.0-0.0 %] 
Myelocyte 8.0 H [0.0-0.0 %] 
Blast 6.0 H [0.0-0.0 %] 

Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.6 H [0.0-0.0 K/mcL] 
Absolute Blasts 0.4 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 21 [/100(WBCs)] 

Morphology:
WBC: Left shifted granulocytes with dysplastic hypogranular and hypolobated granulocytes; increased blasts seen (6%) 
RBC: Normocytic normochromic anemia with anisopoikilocytosis and nucleated red blood cells 
Platelets: Thrombocytopenia, occasional megakaryocyte nuclear fragment seen. 

IMMUNOHISTOCHEMISTRY
Immunostains CD34 and CD117 highlights slightly increased blasts 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10028)
Interpretation: 
Abnormal myeloid blast population detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample (F18-4427) having abnormal expression of CD7 (negative to dim), CD13 (negative to dim), CD38 (negative to dim), CD117 (major subset bright, minor subset negative to dim), CD123 (uniform bright), HLA-DR (uniform bright); with normal expression of CD4, CD33, CD34, CD45, CD71; without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 10.0% of WBC. 

Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7180.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-36257, M18-36258.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-8642;S11;MSK4 - 2023-04-17 15.29.25.ndpi,Peripheral Blood Smear,2023-04-17,"Leukemia. 70 year old with newly diagnosed acute leukemia. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia (20% blasts in peripheral blood), best classified as acute myeloid leukemia with myelodysplasia-related changes (AML-MRC). See comment. 
  
COMMENT: The marked dysplasia in megakaryocytic and myeloid lineages supports the above diagnosis. Although the patient has no history, the morphologic findings also raise the possibility of a leukemic transformation from an underlying myeloproliferative/myelodysplastic overlap syndrome. Correlation with clinical findings, cytogenetic and molecular studies is recommended. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (70-80%)
M:E ratio: N/A
Blasts: Overtly increased in number 
Myeloid lineage: Show left shift in maturation 
Erythroid lineage: Markedly reduced and show progressive maturation 
Megakaryocytes: Increased in number and show dysplastic forms with hyperchromatic nuclei, clumped chromatin, plump lobation forming large tight clusters 
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered
Special stains: Reticulin stain shows moderate increase in reticulin fibrosis (MF-2-3+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blasts                20%
Promyelocytes           5%
Myelocytes           15%
Metamyelocytes           6%
Neutrophils/Bands      33%
Monocytes           2%
Erythroid Precursors      5%
Lymphocytes           14%
Number of Cells Counted 200
M: E Ratio           12.2

Morphology:
- Aspicular and hypocellular smears shows an expanded blast population. The differential count may represent peripheral blood. Blasts are medium to large sized, with scant cytoplasm, round to irregular nuclei and prominent nucleoli. Erythroid elements are markedly reduced and show progressive maturation. Megakaryocytes are poorly represented. 

PERIPHERAL BLOOD
CBC (10/31/2018):
WBC 5.2 [4.0-11.0 K/mcL] 
RBC 2.34 L [3.95-5.54 M/mcL] 
HGB 6.7 L [12.5-16.2 g/dL] 
HCT 21.4 L [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 28.6 [27.0-33.0 pg] 
MCHC 31.3 [31.0-36.5 g/dL] 
RDW 21.1 H [12.2-15.1 %] 
Platelets. 18 LL [160-400 K/mcL] 

Morphology:
WBC: Leukoerythroblastic smear with markedly increased circulating blasts seen (20% by manual differential count). Neutrophils are hypogranular and dysplastic. 
RBC: Normocytic normochromic anemia with anisopoikilocytosis (tear drops, fragments), nRBCs 
Platelets: Thrombocytopenia 

IMMUNOHISTOCHEMISTRY
Immunostains CD34 and CD117 highlights increased blast population, focally up to 15% but overall 5-10%.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW 
Not submitted. 

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F18-9345)
Interpretation: 
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD2 (subset), CD11b (partial), CD15 (partial), CD33 (dim), CD34 (slightly bright), CD38 (bright to absent), CD56 (partial bright), CD71 (dim to absent), CD117 (intermediate to bright), and CD123 (uniform dim); with normal expression of CD4, CD13, CD45, and HLA-DR without sCD3, cCD3, CD5, CD7, CD8, CD10, CD14, CD16, CD19, CD20, CD25, CD64, cCD79a or surface light chains. MPO expression is present on a subset of blasts. CD34 positive myeloid blasts represent 20.5% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6757.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-33986, M18-33987, M18-33988, M18-33989, M18-33990.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-8484;S28;MSKF - 2023-06-20 15.00.17.ndpi,Peripheral Blood Smear,2023-06-20,"Lymphoma.  Questionable MZL vs other indolent NHL.
","1-4. Bone marrow, left posterior iliac crest, biopsy, and aspirate smears, and peripheral blood smear: 
     - Extensive involvement by low grade B cell lymphoma, favor marginal zone lymphoma (more than 90% with CD20 immunohistochemistry)
     - Cellular marrow with reduced trilineage hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy shows hypercellular bone marrow for age (~100%cellularity). Interstitial diffuse lymphoid infiltrate comprised of small lymphocytes are seen. Myeloid and erythroid lineages are reduced. Megakaryocytes are present and appear reduced. Granulomas are not seen. The clot shows similar findings. 

Aspirate differential: (Performed by SS )
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      8%
Monocytes           1%
Eosinophils           1%
Lymphocytes           85%
Number of Cells Counted 500
M:E Ratio           0

The touch imprints show predominantly small lymphoid cells. Erythroid and myeloid lineages are reduced and show maturation. Megakaryocytes are seen. 

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlight neoplastic B cells (more than 90% of marrow cellularity). The neoplastic cells express BCL2, and do not express BCL6, MUM1, CD10, LMO2, Cyclin D1, or P53. CD138 highlights scattered plasma cells. Ki67 proliferation index is approximately 10%. CD3 highlights scattered and aggregated T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW 
Not requested/performed. 

PERIPHERAL BLOOD
CBC (10/25/2018)
WBC 57.1 H [4.0-11.0 K/mcL] 
RBC 3.19 L [3.80-5.00 M/mcL] 
HGB 9.7 L [11.2-15.4 g/dL] 
HCT 30.5 L [34.3-46.0 %] 
MCV 96 [80-98 fL] 
MCH 30.4 [27.0-33.0 pg] 
MCHC 31.8 [31.0-36.5 g/dL] 
RDW 14.0 [12.2-15.1 %] 
Platelets. 109 L [160-400 K/mcL] 

Neutrophil 11.0 L [32.5-74.8 %] 
Lymph 87.0 H [12.2-47.4 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 

Abs Neut 6.3 [1.5-7.5 K/mcL] 
Abs Lymph 49.7 H [0.9-3.2 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.6 [0.0-0.7 K/mcL] 
Absolute Basophil 0.6 H [0.0-0.2 K/mcL] 

Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)]

Morphology:
WBC: Lymphocytosis. The lymphocytes are medium sized with clumped chromatin and indistinct nucleoli. Many smudge cells are seen.
RBC: Normocytic normochromic anemia.
Platelet: Mild thrombocytopenia. 

CYTOGENETIC STUDIES
Not requested/performed. 

MOLECULAR STUDIES 
Not requested/performed. 



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9554;S12;MSK8 - 2023-07-19 09.35.49.ndpi,Peripheral Blood Smear,2023-07-19,"Leukemia, hairy Cell. Reassess disease for worsening cytopenias. 
","1-3. Bone marrow, left posterior iliac crest, biopsy, clot section, touch imprint, aspirate and peripheral blood smears: 
     - Hairy cell leukemia, 40-50% by CD20 immunohistochemical stain. 
     - Normocellular marrow with trilineage maturing hematopoiesis.

BONE MARROW BIOPSY
Quality: Adequate.
Cellularity: Normocellular for age (50-60% cellularity).
M:E ratio: Within normal limit.
Blasts: Not increased.
Myeloid lineage: Relatively decreased and exhibits full maturation. 
Erythroid lineage: Exhibits full maturation.
Megakaryocytes: Adequate in number and show unremarkable morphology.
Lymphocytes: Increased, scattered interstitially, best appreciated by immunohistochemistry (see below). The lymphoid cells are predominantly small in size, with round nuclei, condensed chromatin, indistinct nucleoli and moderate amount of cytoplasm.
Plasma cells: Scattered. 
Special stains: Reticulin stain shows mild focal increase in reticulin fibrosis. 
Clot section: Predominantly blood with scattered marrow elements and no marrow particles.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Blasts                1%
Promyelocytes           2%
Myelocytes           9%
Metamyelocytes           8%
Neutrophils/Bands      29%
Monocytes           3%
Eosinophils           1%
Erythroid Precursors      23%
Plasma Cells           1%
Lymphocytes           20%
Hairy cells           3%
Number of Cells Counted  500
M:E Ratio           2.3

Morphology:
The aspirate smears and touch imprint are aspicular and hypocellular and may not be fully representative of marrow composition. Maturing myeloid and erythroid elements are present and show predominantly unremarkable morphology. Rare megakaryocytes are present with unremarkable morphology. There are atypical lymphoid cells identified, composed predominantly of small to medium cells with round to mildly irregular nuclei, condensed chromatin and scant to moderate cytoplasm. 

PERIPHERAL BLOOD
CBC (12/04/2018):
WBC 2.5 L [4.0-11.0 K/mcL] 
RBC 4.09 [3.80-5.00 M/mcL] 
HGB 13.7 [11.2-15.4 g/dL] 
HCT 38.7 [34.3-46.0 %] 
MCV 95 [80-98 fL] 
MCH 33.5 H [27.0-33.0 pg] 
MCHC 35.4 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 110 L [160-400 K/mcL]
 
Neutrophil 50.5 [32.5-74.8 %] 
Lymph 45.1 [12.2-47.4 %] 
Mono 3.2 [0.0-12.3 %] 
Eos 0.4 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Immature Granulocyte 0.8 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Nucleated RBC 0.0 [%] 

Abs Neut 1.3 L [1.5-7.5 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 

Morphology:
WBC: Absolute neutropenia; occasional large granular lymphocytes; rare circulating atypical lymphoid cells present.   
RBC: Normocytic, normochromic red blood cells.
PLT: Thrombocytopenia with occasional large forms. 

IMMUNOHISTOCHEMISTRY
CD20, PAX5 and BRAF stains highlight increased atypical lymphoid cells (40-50% marrow cellularity).
CD3 stain highlights scattered background small T cells.   
CD34 and CD117 stains show no increase in blasts (<5%).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10437)
Abnormal B-cell population identified.
No abnormal mature T-cell population detected. 

Flow cytometry reveals an abnormal mature B-cell population having abnormal expression of CD19 (bright), CD20 (bright), CD11c, CD22 (bright), CD25, CD45 (bright), CD103 and CD200 (bright), with slightly increased forward and side scatter, and lambda light chain restriction; with normal expression of CD38; and without CD5 or CD10. The immunophenotype of the abnormal B-cell population is consistent with involvement by hairy cell leukemia. The abnormal B cell population represents 3.6% of the total white cells.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7493.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-37798, M18-37799.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-10005;S11;MSKJ - 2023-04-25 22.39.50.ndpi,Peripheral Blood Smear,2023-04-25,"ALL.  Newly diagnosed.
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma (B-ALL) with t(9;22); BCR-ABL1, 96% blasts by aspirate differential count. See comment.
  
COMMENT: FISH studies (CG18-7851) performed on the peripheral blood revealed BCR-ABL1 fusion/ t(9;22), diagnostic for this subtype of B-ALL. The morphologic findings are similar to a recent right-sided biopsy (H18-9966; 12/18/18). 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypercellular for age (100% cellularity)
M:E ratio: N/A
Blasts: Markedly increased present as sheets nearly completely replacing the marrow cellularity; blasts are predominantly medium in size, with oval to slightly irregular nuclei, open chromatin, predominantly inconspicuous nucleoli, and scant cytoplasm. 
Myeloid lineage: Markedly decreased 
Erythroid lineage: Markedly decreased 
Megakaryocytes: Markedly decreased to absent 
Lymphocytes: Rare, scattered 
Plasma cells: Rare
Clot section: Rare minute marrow particles showing similar morphology as the core biopsy. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH on touch imprint)
Blasts                96%
Erythroid Precursors      1%
Lymphocytes           3%
Number of Cells Counted  500
M: E Ratio           NA

Morphology:
Aspicular and cellular aspirate smears and touch imprint show a markedly expanded population of blasts, which are predominantly medium in size, with round to slightly irregular nuclei, fine chromatin, predominantly indistinct nucleoli, and scant basophilic cytoplasm. Auer rods are not seen. Background hematopoiesis is virtually absent. Rare erythroid cells are seen. Megakaryocytes are not identified. Rare mature appearing lymphocytes are seen.

PERIPHERAL BLOOD
CBC (12/19/2018):
WBC 4.2 [4.0-11.0 K/mcL] 
RBC 3.41 L [3.80-5.00 M/mcL] 
HGB 10.2 L [11.2-15.4 g/dL] 
HCT 29.9 L [34.3-46.0 %] 
MCV 88 [80-98 fL] 
MCH 29.9 [27.0-33.0 pg] 
MCHC 34.1 [31.0-36.5 g/dL] 
RDW 17.9 H [12.2-15.1 %] 
Platelets 10 LL [160-400 K/mcL]  

Neutrophil 13.0 L [32.5-74.8 %] 
Lymph 61.0 H [12.2-47.4 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Blast 20.0 H [0.0-0.0 %]

Abs Neut 0.5 L [1.5-7.5 K/mcL] 
Abs Lymph 2.6 [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL]
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Absolute Blasts 0.8 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 7 [/100(WBCs)]

Morphology:
WBC: Frequent circulating blasts present which are morphologically similar to those on aspirate smears; neutropenia and relative lymphocytosis.  
RBC: Normocytic and normochromic anemia with anisocytosis; increased reticulocytes; and few nucleated RBCs present. 
PLT: Marked thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD34 and TdT are positive in blasts, which are present in diffuse sheets and account for 95% of the marrow cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10986)
Abnormal immature B-cell population detected.
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (60.6% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD8 (subset), CD10 (intermediate to bright), CD13 (partial dim), CD20 (subset dim), CD25 (partial, greater than 10% of blasts), CD33 (partial), CD34 (bright), CD38 (absent), CD45 (major subset absent, minor subset dim), CD56 (partial), and CD123 (partial); with normal expression of CD19,CD58, cyCD79a, and HLA-DR; and without CD2, sCD3, cyCD3, CD4, CD5, CD7, CD11b, CD14, CD15, CD16, CD64, CD71, CD117, or MPO.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

CD34 positive myeloid blast population with apparent normal immunophenotype is 1.2% of WBC.
292,104 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7880.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M18-39946, M18-39947, and M18-36649.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9084;S11;MSKE - 2023-06-22 01.03.52.ndpi,Peripheral Blood Smear,2023-06-22,"Leukemia. 4% blasts, systemic mastocytosis.
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Systemic mastocytosis, favor to be associated with underlying myeloid neoplasm (see comment)
     - Hypercellular marrow with marked myeloid hyperplasia, granulocytic and erythroid dysplasia and no overt increase in blasts and trilineage maturing hematopoiesis.
      -Peripheral blood with left shifted granulocytosis, anemia, thrombocytopenia, granulocytic dysplasia and increased blasts (approximately 2-4%). 
  
COMMENT:
Bone marrow shows extensive infiltration by abnormal mast cells, approaching, but not yet exceeding 20% of cellularity (diagnostic criterion for mast cell leukemia is not met at this point). The findings appear to fit criteria for aggressive systemic mastocytosis (although marrow failure may well be due to underlying myeloid neoplasm). There is marked granulocytosis with peripheral blood showing left shift (>10% immature forms) as well as pronounced granulocytic dysplasia and mild erythroid dysplasia. Abnormal immunophenotype of the blasts have been demonstrated by flow cytometry, both in peripheral blood and bone marrow of the patient. While there is absolute, there is no relative monocytosis, arguing against but not fully excluding CMML. The results support the diagnosis of underlying myeloid neoplasm meeting criteria for atypical chronic myeloid leukemia (MDS/MPN). While the diagnosis is favored, reactive causes (infection/inflammation/drug reaction) should be formally excluded. Persistence of granulocytic left shift and dysgranulopoiesis without reactive explanation would support the diagnosis of MDS/MPN with associated systemic mastocytosis. Should monocytosis progress, diagnosis of CMML would be favored. 

BONE MARROW BIOPSY
Quality: Small biopsy with few examinable marrow spaces
Cellularity: Increased (70-80%)
M:E ratio: Markedly increased
Blasts: Not overtly increased
Myeloid lineage: Full maturation 
Erythroid lineage: Full maturation, decreased in proportion
Megakaryocytes: Moderately decreased in proportion
Lymphocytes: Scattered and associated with mast cell aggregates
Plasma cells: Scattered
Extensive mast cell aggregates are seen
Special stains: Reticulin stain shows focal moderate increase in reticulin fibrosis, largely associated with mast cell aggregates, rest of the marrow shows no to mild reticulin fibrosis    

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)
Blasts                4%
Promyelocytes           3%
Myelocytes           18%
Metamyelocytes           13%
Neutrophils/Bands      45%
Monocytes           4%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      6%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           14.2

Morphology:
-Spicular/ and cellular bone marrow aspirates with marked myeloid hyperplasia, granulocytic and erythroid dysplasia and no overt increase in blasts and trilineage maturing hematopoiesis. Aggregates of mast cells present

PERIPHERAL BLOOD
CBC (11/15/2018):
WBC 31.2 H [4.0-11.0 K/mcL] 
RBC 2.70 L [3.95-5.54 M/mcL] 
HGB 7.7 L [12.5-16.2 g/dL] 
HCT 23.7 L [37.5-49.3 %] 
MCV 88 [80-98 fL] 
MCH 28.5 [27.0-33.0 pg] 
MCHC 32.5 [31.0-36.5 g/dL] 
RDW 18.4 H [12.2-15.1 %] 
Platelets 45 L [160-400 K/mcL] 

Neutrophil 72.0 [32.5-74.8 %] 
Lymph 5.0 L [12.2-47.4 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 22.4 H [1.5-7.5 K/mcL] 
Abs Lymph 1.6 [0.9-3.2 K/mcL] 
Abs Mono 2.5 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Metamyelocyte 6.0 H [0.0-0.0 %] 
Myelocyte 7.0 H [0.0-0.0 %] 
Blast 2.0 H [0.0-0.0 %] 
Abs Meta 1.9 H [0.0-0.0 K/mcL] 
Abs Myelocytes 2.2 H [0.0-0.0 K/mcL] 
Absolute Blasts 0.6 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology: left shifted granulocytosis, anemia, thrombocytopenia, granulocytic dysplasia (marked hypogranulation) and increased blasts (approximately 2-4%)

IMMUNOHISTOCHEMISTRY
CD34 shows no overt increase in blasts. 
Tryptase, CD117 and CD25 show large mast cell aggregates
CD2 is negative in mast cells, stains T cells
MPO highlights myeloid precursors 
CD71 highlights reduced erythroid precursors
CD123 highlights plasmacytoid dendritic cells, mostly associated with mast cell aggregates, no aggregates of dendritic cells seen.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-9885)
Abnormal myeloid blast population detected.
Atypical mast cell population detected.
Plasmacytoid dendritic cells are mildly increased, 1.7% of WBC. 
Erythroid precursors are markedly decreased. 

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample (F18-9806) have abnormal expression of CD25 (80% of the blasts), CD13 (bright), CD33 (bright), CD34 (dim), CD38 (partial dim), CD117 (dim) and HLA-DR (bright); with normal expression of CD4, CD45, CD71 and CD123; without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD56 or CD64. CD34 positive myeloid blasts represent 3.1% of WBC. 
In addition, mast cell population with atypical expression of CD25 (bright) and without CD2 is seen representing 0.16% of the WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Abnormal myeloid blast population detected.
Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD13(bright), CD25(uniformly positive), CD38(variably dim), CD56 (partial), CD123(bright) with normal expression of CD4, CD33, CD34, CD45, CD71, CD117, and HLA-DR without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD56 or CD64. CD34 positive myeloid blasts represent 4.4% of WBC. The findings are consistent with myeloid neoplasm.
Extremely rare (<0.01%) abnormal mast cells with abnormal expression of CD25 present.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7101.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-35787.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9632;S11;MSK4 - 2023-03-23 21.54.55.ndpi,Peripheral Blood Smear,2023-04-25,"MDS vs. AML.  New MDS vs. AML.
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by Acute Myeloid Leukemia with Monocytic Differentiation (85% blasts by aspirate differential count) (See Comment)
     - Hypercellular marrow with markedly decreased trilineage hematopoiesis
  
COMMENT: Per clinical notes, the patient has a history of myelodysplastic syndrome (MDS) diagnosed a year ago. If confirmed, the current marrow findings will be consistent with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC). Correlation with cytogenetics and molecular results will also be helpful in the final classification.  

BONE MARROW BIOPSY
Quality: Adequate, fragmented 
Cellularity: Hypercellular for age (80% cellularity)
M:E ratio: N/A
Blasts: Markedly increased medium- to large-sized blasts with irregular or slightly folded nuclei, dispersed chromatin, and one or more distinct nucleoli. 
Myeloid lineage: Markedly decreased 
Erythroid lineage: Markedly decreased 
Megakaryocytes: Mildly increased in number with frequent dysplastic forms (small hypolobated forms, abnormal nuclear lobe separation)
Lymphocytes: Scattered 
Plasma cells: Scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Blasts/Promonocytes     85%
Neutrophils/Bands      3%
Monocytes           3%
Eosinophils           2%
Erythroid Precursors      5%
Plasma Cells           1%
Lymphocytes           1%
Number of Cells Counted  500
M:E Ratio           N/A

Special stain
Iron: Present
Ring sideroblasts: Absent 

Morphology:
Spicular and hypocellular aspirate smears showing markedly expanded population of medium to large-sized blasts with slightly irregular to folded nuclei, fine chromatin, distinct nucleoli and moderate amount of basophilic cytoplasm with occasional cytoplasmic vacuoles. No Auer rod is seen. Maturing myeloid elements are markedly reduced and show some dyspoietic forms (hypogranular forms). Maturing erythroid elements are markedly reduced. Megakaryocytes are present and show frequent dyspoietic forms (abnormal nuclear lobe separation, hypolobated forms). 

PERIPHERAL BLOOD
CBC (12/06/2018):
WBC 74.2 H [4.0-11.0 K/mcL] 
RBC 2.97 L [3.80-5.00 M/mcL] 
HGB 9.4 L [11.2-15.4 g/dL] 
HCT 30.3 L [34.3-46.0 %] 
MCV 102 H [80-98 fL] 
MCH 31.6 [27.0-33.0 pg] 
MCHC 31.0 [31.0-36.5 g/dL] 
RDW 21.3 H [12.2-15.1 %] 
Platelets 173 [160-400 K/mcL] 

Neutrophil 6.0 L [32.5-74.8 %] 
Lymph 6.0 L [12.2-47.4 %] 
Mono 67.0 H [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %]
Metamyelocyte 1.0 H [0.0-0.0 %] 
Blast 18.0 H [0.0-0.0 %] 
 
Abs Neut 4.5 [1.5-7.5 K/mcL] 
Abs Lymph 4.5 H [0.9-3.2 K/mcL] 
Abs Mono 49.7 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 2.2 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Meta 0.7 H [0.0-0.0 K/mcL] 
Absolute Blasts 13.4 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Attending Review
Manual differential is confirmed including the presence of numerous circulating blasts and monocytosis. Correlate with flow cytometry for further characterization.
I attest that the above interpretation/recommendation is based
upon my personal examination of the source material and patient
clinical history, if indicated, and that I have reviewed this report.
Maly Fenelus MD Prov ID: 023085
12/06/2018 5:00 PM EST

Morphology:
WBC: Leukocytosis with numerous circulating blasts/promonocytes present. There is also relative and absolute monocytosis. Hypogranular granulocytes are also seen. 
RBC: Macrocytic anemia with anisopoikilocytosis.
PLT: Frequent giant and large forms present. 

IMMUNOHISTOCHEMISTRY
The blasts are negative for CD34, and only a very small subset is positive for CD117. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10513)
Final report is pending.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7550.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-38125 to M18-38128, M18-38380.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-8004;S11;MSKF - 2023-06-26 10.46.47.ndpi,Peripheral Blood Smear,2023-06-26,"T-LGL, MDS. 68 year old man with worsening neutropenia, thrombocytopenia; T-LGL population in PB, suspect MDS in BM. +IDH2 and SRSF2 mutations in IMPACT HEME. 
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Normocellular subcortical bone marrow with maturing trilineage hematopoiesis, erythroid predominance, myeloid hypoplasia, dysmegakaryopoiesis and 4% blasts by aspirate differential count, suggestive of myelodysplastic syndrome; see comment.
    - Mildly increased large granular lymphocytes (T-LGL, 14.4% of WBC by flow cytometry)

COMMENT: The findings of dysmegakaryopoiesis and abnormal myeloid blast population seen by flow cytometry, in conjunction with prior molecular findings of IDH2 and SRSF2 are suggestive of a low grade myelodysplastic syndrome. However, the absence of anemia in current CBC is slightly against this possibility and the leukopenia and thrombocytopenia can partly be due to the LGL population identified (see below). In addition, ring sideroblasts are seen in the range of 5%. Correlation with cytogenetic studies and comprehensive genomic profiling (including SF3B1 mutation analysis) will be helpful to further characterize this complex case.  

The findings of mildly increased T-LGL in the peripheral blood and bone marrow aspirate raise the possibility of a T-LGL leukemia, especially in the presence of clonal TCR rearrangements (see M18-27984). However, the level of T-LGL in the peripheral blood is well below 2 x 109 /L, and molecular genetic testing revealed no mutations associated with T-LGL (ie STAT3, STAT5B). Given the findings of myelodysplastic changes, the LGL population may represent a reactive population. However, an evolving T-LGL leukemia cannot be entirely excluded, so continued monitoring of this population with peripheral blood flow cytometry is recommended. 

BONE MARROW BIOPSY
Quality: Suboptimal (small subcortical biopsy) 
Cellularity: Appears normocellular (50%) 
M:E ratio: Reduced
Blasts: Not increased (<5%) 
Myeloid lineage: Exhibits full maturation, decreased
Erythroid lineage: Predominant and exhibits full maturation 
Megakaryocytes: Increased and show small hypolobated forms 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows no significant increase in reticulin fibers (0/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                4%
Promyelocytes           1%
Myelocytes           7%
Metamyelocytes           4%
Neutrophils/Bands      25%
Monocytes           2%
Eosinophils           1%
Erythroid Precursors      40%
Plasma Cells           1%
Lymphocytes           15%
Number of Cells Counted 500
M:E Ratio           1

Special stain
Iron: Suboptimal for evaluation due to lack of spicules 
Ring sideroblasts: 5%

Morphology: The aspirate smears are aspicular, hypocellular and mildly hemodiluted, and show predominantly maturing myeloid and erythroid elements without increased blasts. Erythroid and myeloid elements show progressive maturation. Megakaryocytes are present and show occasional dysmegakaryopoiesis (hypolobation, micromegakaryocytes). Occasional large granular lymphocytes are seen. Touch imprints show erythroid predominance with maturation and mild dyserythropoiesis and megaloblastoid changes. Myeloid elements show progressive maturation. Few small and hypolobated megakaryocytes are seen.  

PERIPHERAL BLOOD
CBC (10/10/2018):
WBC 2.3 L [4.0-11.0 K/mcL] 
RBC 4.29 [3.95-5.54 M/mcL] 
HGB 12.9 [12.5-16.2 g/dL] 
HCT 38.8 [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 30.1 [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 16.8 H [12.2-15.1 %] 
Platelets 49 L [160-400 K/mcL] 

Neutrophil 18.3 L [32.5-74.8 %] 
Lymph 58.7 H [12.2-47.4 %] 
Mono 20.9 H [0.0-12.3 %] 
Eos 1.7 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Immature Granulocyte 0.4 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 0.4 L [1.5-7.5 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Morphology:
WBC: Leukopenia with absolute neutropenia, relative lymphocytosis and increased large granular lymphocytes.
RBC: Mild anisocytosis.
PLT: Moderate thrombocytopenia with giant platelets.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains show no increases in CD34 and/or CD117 positive blasts (slightly under 5%). Megakaryocytes also show occasional positivity for CD34. 
Immunohistochemical stain for CD3 highlights scattered T cells (~5% of total cellularity). CD4 and CD8 stains show an inverted CD4/CD8 ratio (CD8 > CD4). CD5 also highlights T cells. A small subset of the T cells appears to be found in an intrasinusoidal distribution. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8661)
Abnormal myeloid blast population detected.
Mildly large granular lymphocyte population detected.

Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD7 (partial), CD11b (partial), CD13 (dim to absent), CD25 (partial, greater than 10% of blasts), CD33 (intermediate to absent), CD34 (uniform, bright), CD38 (intermediate to absent), CD117 (uniform, bright), CD123 (uniform), and HLA-DR (bright); with normal expression of CD4, CD45, and CD71; without CD2, CD5, CD14, CD15, CD16, CD19, CD56 or CD64. CD34 positive myeloid blasts represent 1.9% of WBC.

No definite immunophenotypic evidence of T-cell lymphoma is identified. However, an expanded population of large granular lymphocytes (CD8-positive T cells with decreased CD5 and CD7) is present that are estimated to represent 14.4% of the leukocytes. The clinical significance of this population is unclear, but expansions of large granular lymphocytes may be seen in a variety of inflammatory or infectious conditions, as well as large granular lymphoproliferative disorder (LGLD).

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6252.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-31378.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7408;S11;MSKC - 2023-04-25 18.14.02.ndpi,Peripheral Blood Smear,2023-04-25,"Possible AML.  Rule out AML.
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate and peripheral blood smears:
    - Acute myeloid leukemia, 53% blasts by aspirate differential.

COMMENT: 
Per clinical note, the patient's cytogenetics showed inv(16); morphologically this specimen is compatible with AML with inv(16), but correlation with in-house cytogenetics is advised. In light of the reported clinical histories of ulcerative colitis and prostate carcinoma, correlation with the patient's prior therapy history is advised to rule out a therapy related acute leukemia. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypercellular for age (~80-90%)
M:E ratio: Normal
Blasts: Expanded sheet-like proliferation of medium sized blasts small amounts of cytoplasm, irregular nuclei, fine chromatin and distinct nucleoli.
Myeloid lineage: Background myeloid elements show full maturation. Eosinophilia is seen. Eosinophils show abnormal nuclear lobation. 
Erythroid lineage: Markedly reduced 
Megakaryocytes: Present with occasional nuclear separation 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows no significant increase in reticulin fibers (0/3).  
Clot section: Not submitted. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by AS)

Blasts                53% (blast/blasts equivalents)
Promyelocytes           2%
Myelocytes           1%
Metamyelocytes           2%
Neutrophils/Bands      6%
Monocytes           13%
Eosinophils           5%
Erythroid Precursors      8%
Plasma Cells           3%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           3.6

Morphology: The aspirate smears are spicular and cellular and show a markedly expanded population of medium sized blasts with small amounts of cytoplasm, irregular to folded nuclei, fine chromatin and distinct nucleoli, in a background of decreased trilineage hematopoiesis. Background myeloid elements show borderline eosinophilia with atypical eosinophils with nuclear lobation abnormalities. Erythroid elements are reduced but show full maturation. Megakaryocytes are decreased.

PERIPHERAL BLOOD
CBC (09/20/2018):
WBC 5.5 [4.0-11.0 K/mcL] 
RBC 3.30 L [3.95-5.54 M/mcL] 
HGB 12.0 L [12.5-16.2 g/dL] 
HCT 33.0 L [37.5-49.3 %] 
MCV 100 H [80-98 fL] 
MCH 36.4 H [27.0-33.0 pg] 
MCHC 36.4 [31.0-36.5 g/dL] 
RDW 14.9 [12.2-15.1 %] 
Platelets 49 L [160-400 K/mcL] 

Neutrophil 9.0 L [32.5-74.8 %] 
Lymph 28.0 [12.2-47.4 %] 
Mono 35.0 H [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 0.5 L [1.5-7.5 K/mcL] 
Abs Lymph 1.5 [0.9-3.2 K/mcL] 
Abs Mono 1.9 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Blast 27.0 H [0.0-0.0 %] 
Absolute Blasts 1.5 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Increased circulating blasts with morphology similar to aspirate smears.  
RBC: Mild macrocytic anemia.
PLT: Marked thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stain for CD117 highlights the increased blasts, approximately 50-60% of total cellularity. CD34 is positive in a subset of blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8047)
Expanded abnormal myeloid blast and immature monocyte population detected. No abnormal B and T cell populations detected. 

The blasts have abnormal expression of CD13 (dim), CD33 (uniform dim), CD34 (dim to negative), with normal expression of CD4, CD38, CD45, CD71, CD117, CD123 and HLA-DR without CD2, sCD3, cCD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cCD79a or surface light chains. MPO expression is present on all blasts. CD117 positive myeloid blasts represent 51.7% of WBC. In addition, an immature monocyte population is seen (HLA-DR bright, CD15 bright, CD11b dim to negative, CD13 dim to negative, CD14 negative) (13.6% of WBC). Blast and blast equivalents are 65.3% of WBC. Mild eosinophilia is noted (approximately 5% of WBC).

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5778.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-29024, M18-29025, M18-29026, M18-29028, M18-29029.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-8230;S11;MSK7 - 2023-04-17 10.51.36.ndpi,Peripheral Blood Smear,2023-04-17,"Leukemia, Acute Promyelocytic.  Untreated, suspected APL.
","1-2. Bone marrow, right posterior iliac crest, biopsy and aspirate smears: 
     - Acute promyelocytic leukemia, with PML-RARA, 90% promyelocytes by aspirate differential count 
  
BONE MARROW BIOPSY
Quality: Adequate
Cellularity: 95-100% 
M:E ratio: N/A
Blasts: Large immature cells with cytoplasmic granules, consistent with promyelocytes, are replacing marrow cellularity 
Myeloid lineage: Maturation arrest 
Erythroid lineage: Markedly decreased 
Megakaryocytes: Markedly decreased
Lymphocytes: Not increased 
Plasma cells: Not increased
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Atypical
Promyelocytes           90%
Erythroid Precursors      5%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
Paucispicular and cellular smears show expanded population of promyelocytes with prominent cytoplasmic granules. Occasional faggot cells with several Auer rods are noted. 
Normal trilineage hematopoiesis is markedly suppressed. 

PERIPHERAL BLOOD
CBC (10/16/2018):

WBC 0.5 LL [4.0-11.0 K/mcL] 
RBC 2.09 L [3.95-5.54 M/mcL] 
HGB 6.9 L [12.5-16.2 g/dL] 
HCT 19.8 L [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 33.0 [27.0-33.0 pg] 
MCHC 34.8 [31.0-36.5 g/dL] 
RDW 16.4 H [12.2-15.1 %] 
Platelets 43 L [160-400 K/mcL] 

Neutrophil 10.0 L [32.5-74.8 %]  
Lymph 72.0 H [12.2-47.4 %]  
Mono 3.0 [0.0-12.3 %]  
Eos 0.0 [0.0-4.9 %] 
Corrected from 1.0 % on 10/17/18 9:44:34 EDT by Wroblewski, Monika.
Baso 1.0 [0.0-1.5 %]  

Abs Neut 0.1 L [1.5-7.5 K/mcL]  
Abs Lymph 0.4 L [0.9-3.2 K/mcL]  
Abs Mono 0.0 [0.0-1.3 K/mcL]  
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL]  
Absolute Basophil 0.0 [0.0-0.2 K/mcL]  

Metamyelocyte 2.0 H [0.0-0.0 %] 
Corrected from 2.0 % [HI] on 10/17/18 9:44:34 EDT by Wroblewski, Monika.
Myelocyte 3.0 H [0.0-0.0 %] 
Promyelocyte 6.0 H [0.0-0.0 %] 
Corrected from 6.0 % [HI] on 10/17/18 11:46:31 EDT by Wroblewski, Monika.
Corrected from 2.0 % [HI] on 10/17/18 9:44:34 EDT by Wroblewski, Monika.
Blast 3.0 H [0.0-0.0 %] 
Variant Lymph 0.0 [%] 
Corrected from 5.0 % [NA] on 10/17/18 9:44:34 EDT by Wroblewski, Monika.

Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Absolute Blasts 0.0 [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 16 [/100(WBCs)]  
Absolute Immature Granulocyte [0.0-0.1 K/mcL] 

IMMUNOHISTOCHEMISTRY
CD117 dimly highlights immature cells, replacing marrow cellularity.
CD34 is negative. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8881)
Interpretation: 
Abnormal myeloid blast/promyelocyte population detected. 
No abnormal B and T cell populations detected.

The myeloid blast/promyelocyte population have abnormal expression of CD11b, CD13 (bright), CD15, CD33 (bright), CD34 (absent), CD38 (uniform dim), CD45 (bright), CD64, CD117 (uniform), CD123 (uniform bright), and HLA-DR (dim); with normal expression of CD4 and CD71; without CD2, sCD3, cCD3, CD5, CD7, CD8, CD10, convincing CD14, CD16, CD19, CD20, CD25, CD56, cCD79a or surface light chains. MPO expression is present on a subset of blasts. CD117 positive myeloid blasts represent 16.8% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6418.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-32295, M18-32296.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-9901;S11;MSKC - 2023-07-05 15.18.43.ndpi,Peripheral Blood Smear,2023-07-05,"MDS. Outside diagnosis of MDS. Please confirm.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Compatible with myelodysplastic syndrome with excess blasts-2 (MDS-EB-2) (11% blasts by aspirate differential count). 
     - Approximately normocellular marrow with erythroid-predominant maturing trilineage hematopoiesis and multilineage dysplasia. See comment.
  
COMMENT: The bone marrow findings of increased blasts (11% by aspirate differential count) and presence of Auer rods are consistent with the above diagnosis. Correlation with cytogenetics studies is needed. In addition, correlation with molecular studies is also recommended. 

BONE MARROW BIOPSY
Quality: Marginally adequate, fragmented, partially aspirated and hemorrhagic biopsy
Cellularity: Difficult to assess due to few intact marrow spaces, appears approximately normocellular for age (40% cellularity)
M:E ratio: Decreased 
Blasts: Increased, interstitially scattered (best appreciated by immunohistology, see below)
Myeloid lineage: Relatively decreased and appear left shifted 
Erythroid lineage: Relatively increased and exhibits full maturation 
Megakaryocytes: Mildly increased in number with loose clusters and dyspoiesis (>10%, small, hypolobated, abnormal nuclear lobe separation)
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0) 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                11% 
Promyelocytes           2%
Myelocytes           16%
Metamyelocytes           6%
Neutrophils/Bands      14%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      38%
Plasma Cells           1%
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           1.1

Special stain:
Iron: Present
Ring sideroblasts: Rare seen on scanning, <5%

Morphology:
Spicular and cellular aspirate smears show maturing trilineage hematopoiesis with an expanded population of medium to large size blasts with round nuclei, fine chromatin, distinct nucleoli and scant basophilic cytoplasm. Few blasts with Auer rods are seen. The M:E ratio is decreased due to an erythroid predominance. Myeloid elements are proportionally decreased with dyspoiesis (>10%), including frequent hyposegmented forms with nuclear-cytoplasmic dyssynchrony. Erythroid elements are relatively increased and show full maturation and dyspoiesis (>10%, nuclear irregularity, budding, binucleation, megaloblastoid features, and karyorrhexis). Megakaryocytes are present and show dyspoiesis (>10%, small, hyper- and hypolobated, abnormal nuclear lobe separation). 

PERIPHERAL BLOOD
CBC (12/17/2018)
WBC 1.5 L [4.0-11.0 K/mcL] 
RBC 2.57 L [3.95-5.54 M/mcL] 
HGB 9.5 L [12.5-16.2 g/dL] 
HCT 28.0 L [37.5-49.3 %] 
MCV 109 H [80-98 fL] 
MCH 37.0 H [27.0-33.0 pg] 
MCHC 33.9 [31.0-36.5 g/dL] 
RDW 14.6 [12.2-15.1 %] 
Platelets 121 L [160-400 K/mcL] 

Neutrophil 44.0 [32.5-74.8 %] 
Lymph 55.0 H [12.2-47.4 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 

Abs Neut 0.7 L [1.5-7.5 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 1 [/100(WBCs)] 
Nucleated RBC 5 [/100(WBCs)]

Morphology:
WBC: No circulating blasts. Leukopenia with neutropenia and lymphopenia; few hypogranular and pseudo-Pelger-Huet granulocytes present.
RBC: Macrocytic anemia with polychromasia and anisopoikilocytosis (microcytic and elliptical cells); few nucleated RBCs present. 
PLT: Mild thrombocytopenia with occasional giant forms and those with abnormal granulation. 

IMMUNOHISTOCHEMISTRY
CD34 highlights an increase in blasts, present singly and in small clusters, accounting for 10% of the marrow cellularity. 
CD117 appears technically suboptimal with dim expression in blasts, and moderately strong expression in rare scattered mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10858)
Interpretation: 
Abnormal myeloid blast and maturing granulocyte populations detected. 
No abnormal mature B- or T-cell populations detected.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD13 (uniform, slightly bright), CD33 (uniform bright), CD117 (uniform intermediate), CD123 (uniform intermediate), HLA-DR (variable, dim to intermediate); with normal expression of CD4, CD34, CD38, CD45, CD71; without CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64 or surface light chains. 
Granulocytes show discontinuous pattern of maturation, with decreased expression of CD16. CD34 positive myeloid blasts represent 10.0% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7780.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M18-39422, M18-39424, M18-39425, & M18-39426.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7849;S11;MSKB - 2023-04-17 11.18.32.ndpi,Peripheral Blood Smear,2023-04-17,"MDS transformed to AML.
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Acute myeloid leukemia, 52% blasts by aspirate differential. 

Comment: Per the clinical notes, the patient has a history of myelodysplastic syndrome (MDS) with progression to acute myeloid leukemia. The current marrow shows 52% blasts as well as dysplastic features in the myeloid and megakaryocyte lineages. If the previous diagnosis of MDS is confirmed, the findings are consistent with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Additional correlation with molecular and cytogenetic studies is recommended. 
 
BONE MARROW BIOPSY
Quality: Adequate.
Cellularity: 80-90%. 
M:E ratio: Increased. 
Blasts: Increased immature cells.
Myeloid lineage: Increased with left shifted maturation and increased eosinophils.
Erythroid lineage: Decreased. 
Megakaryocytes: Increased (3 - 9 per high power field) with some atypical forms (small, hypolobated, disjointed nuclei). 
Lymphocytes: Scattered.
Plasma cells:Scattered.
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (1+/3). 
Clot section: Not submitted. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by AS)

Blasts                52%
Neutrophils/Bands      10%
Monocytes           6%
Eosinophils           8%
Basophils           5%
Lymphocytes           19%
Number of Cells Counted 200
M:E Ratio           N/A

Special stain
Iron: Storage iron cannot be assessed due to lack of spicules. 
Ring sideroblasts: Cannot be assessed due to paucity of erythroid elements. 

Morphology:
The aspirate smears are aspicular and hypocellular. Blasts are increased (52% by aspirate differential) and are intermediate in size with round to irregular nuclei, finely dispersed chromatin, distinct nucleoli and scant cytoplasm. The myeloid lineage is decreased in proportion with occasional dysgranulopoiesis (hypogranularity). The erythroid lineage is markedly decreased in proportion. Megakaryocytes are present with multiple atypical forms (disjointed nuclei, small, hypolobated). 

PERIPHERAL BLOOD
CBC (10/03/2018):
WBC 3.5 L [4.0-11.0 K/mcL] 
Adjusted for Megakaryocyte Fragments.
RBC 2.99 L [3.80-5.00 M/mcL] 
HGB 8.8 L [11.2-15.4 g/dL] 
HCT 27.3 L [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 29.4 [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 15.8 H [12.2-15.1 %] 
Platelets 244 [160-400 K/mcL] 

Neutrophil 18.0 L [32.5-74.8 %] 
Lymph 38.0 [12.2-47.4 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 6.0 H [0.0-4.9 %] 
Baso 9.0 H [0.0-1.5 %] 

Abs Neut 0.6 L [1.5-7.5 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.3 H [0.0-0.2 K/mcL] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 

Blast 23.0 H [0.0-0.0 %] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Absolute Blasts 0.8 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 17 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBCs: Leukopenia with slight left shift and increased circulating blasts (23% by differential count). Many granulocytes with hypogranularity. 
RBCs: Normocytic, normochromic anemia. 
Platelets: Large and giant forms present. 

IMMUNOHISTOCHEMISTRY
Immunostains for CD117 shows a marked increase in blasts (approximately 30-40% of total cellularity). The blasts are predominantly negative for CD34. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8485)
Expanded abnormal myeloid blast population detected. 
Basophilia and eosinophilia detected, representing 5.9% and 6.6% of WBC respectively.
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD2 (partial), CD11b (small subset on CD34 absent), CD15 (dim), CD19 (partial), CD25 (partial, greater than 10% of blasts), CD33 (bright), CD34 (subset absent, subset dim), CD38 (absent to dim), CD123 (bright), and HLA-DR (bright); with normal expression of CD4, CD13, CD45, CD71, CD117; without sCD3, cCD3, CD5, CD7, CD8, CD10, CD14, CD16, CD20, CD56, CD64, cCD79a or surface light chains. MPO expression is present on a large subset of blasts. The myeloid blasts represent 36.4% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F18-8392)
Expanded abnormal myeloid blast population detected. 
Basophilia and eosinophilia are observed.
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD2 (partial), CD11b (partial), CD15 (partial), CD19 (partial), CD13 (absent to normal), CD33 (bright), CD34 (major subset absent, minor subset dim), CD38 (absent to dim), CD117 (dim), CD123 (bright) and HLA-DR (bright);with normal expression of CD4, CD45 and CD71; without sCD3, cCD3, CD5, CD7, CD8, CD10, CD14, CD16, CD20, CD56, CD64, cCD79a or surface light chains. MPO expression is present on a subset of blasts. CD34 positive myeloid blasts represent 28.4% of WBC. Increased basophils and eosinophils are seen representing 6.8% and 3.2% of the WBC respectively.
CD25 is expressed by greater than 10 percent of the blasts.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6118.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-30674, M18-30675, M18-30676, M18-30677. 



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7360;S10;MSKI - 2023-04-25 17.27.10.ndpi,Peripheral Blood Smear,2023-04-25,"Lymphoma. Prior MZL with increasing FDG avidity, LN biopsy concerning for histiocytic or non-heme neoplasm. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - High grade myelo-monocytic neoplasm, most consistent with acute myeloid leukemia. 

COMMENT:
The marrow shows extensive involvement by high grade myeloid neoplasm with myelo-monocytic phenotype. Given the extent of marrow involvement and phenotype this lesion would be best classified as acute myeloid leukemia. Genetic studies will be required for further refinement of the diagnosis. The background hematopoietic cells show some dyspoiesis but diagnostic morphological or immunophenotypic features of myelodysplasia is not identified.

Case was seen with Dr Mikhail Roshal and reviewed in hematopathology consensus conference, 9/21/2018.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show normocellular bone marrow (40% cellularity) with diffuse infiltration of large atypical cells forming small cohesive group with background stromal reaction. Background trilineage maturing hematopoiesis is present and markedly reduced. Megakaryocytes are focally increased and loosely clustered with some dysplastic forms (abnormal nuclear separation, small and hypolobated forms). Myeloid elements show maturation with some hypogranular forms. Erythroid elements show maturation with occasional atypical forms (nuclear irregularity and budding). 

Aspirate differential: 
Many large and giant atypical cells are present with frequent convoluted to folded nuclei, granular chromatin, prominent eosinophilic nuclei, moderate to abundant eosinophilic cytoplasm with frequent large perinuclear clear vacuoles. These cells show patchy distribution but overall account for 50% of all cells. Occasional hemophagocytic histiocytes are seen. 

IMMUNOHISTOCHEMISTRY
Neoplastic cells:
Express: CD33, lysozyme, CD68, MPO, CD14, CD56, CD45, Pending CD13. 
Do not express: CD34, CD117, CD11c, S100, CD1a, CD123, CD4, CD3, CD20, PAX-5. 
Others: BRAF V600E equivocal
CD3 highlights mildly increased interstitial T-lymphocytes.
CD20 and PAX-5 highlight rare B-lymphocytes. 
CD34 and CD117 show no increased blasts. 
CD13, CD30, CD61 and CD71 immunostains will reported as an addendum.  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7997) 
No definite abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
There is no definite immunophenotypic evidence of a myeloid stem cell disorder by flow cytometry. However, in light of the relatively bright expression of CD117, HLA-DR and CD123 on myeloid blasts and a prominent monocytic population with expression of CD56 and relatively bright CD15, myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm cannot be excluded by these studies.  CD34 positive myeloid blasts represent 0.42% of the white blood cells. 
339394 cells acquired. Clinical and morphologic correlation will be required to evaluate for the possibility of MDS or MDS/MPN.  Cytogenetic and molecular genetic analysis is also recommended to rule out a clonal stem cell abnormality. 

No abnormal mature B-cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

PERIPHERAL BLOOD
CBC (09/19/2018):
WBC 2.4 L [4.0-11.0 K/mcL] 
RBC 2.50 L [3.95-5.54 M/mcL] 
HGB 7.3 L [12.5-16.2 g/dL] 
HCT 22.4 L [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 29.2 [27.0-33.0 pg] 
MCHC 32.6 [31.0-36.5 g/dL] 
RDW 15.9 H [12.2-15.1 %] 
Platelets 56 L [160-400 K/mcL] 

Neutrophil 53.0 [32.5-74.8 %] 
Lymph 12.0 L [12.2-47.4 %] 
Mono 14.0 H [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 

Abs Neut 1.3 L [1.5-7.5 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Metamyelocyte 10.0 H [0.0-0.0 %] 
Myelocyte 8.0 H [0.0-0.0 %] 
Promyelocyte 2.0 H [0.0-0.0 %] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 1 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Leukopenia with absolute neutropenia and lymphopenia; mild relative monocytosis; some left shifted granulocytes and few hypogranular neutrophils are present; rare large atypical cells morphologically similar to aspirate smears are seen.
RBC: Normocytic and normochromic anemia with mild anisopoikilocytosis.
PLT: Thrombocytopenia with few large forms seen. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5744.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-28843.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-8921;S24;MSK8 - 2023-06-20 15.06.15.ndpi,Peripheral Blood Smear,2023-06-20,"MDS.  History of breast ca status post chemo, now with cytopenias, PB blasts; rule out t-MDS.
","1-2. Bone marrow, right posterior iliac crest, biopsy and smears: 
     - Metastatic carcinoma.
     - Limited uninvolved marrow with erythroid predominant hematopoiesis, relatively reduced myeloid elements and frequent megakaryocytes.
  
COMMENT: The specimen is limited. Therefore, the evaluation may not be entirely representative. It is not clear if the metastatic carcinoma is the sole underlying etiology of the patient's reported cytopenias. Remarkable findings in the limited uninvolved marrow are erythroid predominance and frequent megakaryocytes some with hyperchromatic atypical nuclei and bare nuclei. The findings may represent reactive changes secondary to treatment, peripheral sequestration/destruction. However, the possibility of an evolving myeloid neoplasm cannot be entirely ruled out. Suggest correlation with genetic studies and new marrow studies if clinically indicated. 

BONE MARROW BIOPSY&CLOT
Small subcortical and fragmented biopsy (cellularity difficult to assess). The biopsy and the clot sections show small fragments of marrow show clusters of atypical cohesive cells some with signet ring cell morphology. Uninvolved marrow is limited and shows erythroid predominance, relatively reduced myeloid elements and frequent (possibly increased) megakaryocytes some of which shows hyperchromatic atypical nuclei and bare megakaryocytic nuclei. 
 
Special stains: Reticulin stain is non-contributory. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)
Blasts                1%
Promyelocytes           1%
Myelocytes           5%
Metamyelocytes           4%
Neutrophils/Bands      56%
Monocytes           7%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      8%
Lymphocytes           16%
Number of Cells Counted 500
M:E Ratio           9.4

Special stain
Iron: inevaluable; lacks spicules
Ring sideroblasts: Suboptimal for evaluation due to rare erythroid elements 

Morphology:
- Hemodilute/hypocellular aspirate devoid of spicules; inadequate for full evaluation.

PERIPHERAL BLOOD
CBC (11/12/2018):
WBC 4.2 [4.0-11.0 K/mcL] 
RBC 2.17 L [3.80-5.00 M/mcL] 
HGB 7.5 L [11.2-15.4 g/dL] 
HCT 23.3 L [34.3-46.0 %] 
MCV 107 H [80-98 fL] 
MCH 34.6 H [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 24.0 H [12.2-15.1 %] 
Platelets 48 L [160-400 K/mcL] 

Neutrophil 70.0 [32.5-74.8 %] 
Lymph 10.0 L [12.2-47.4 %] 
Mono 9.0 [0.0-12.3 %] 
Eos 6.0 H [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %] 

Abs Neut 3.0 [1.5-7.5 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.2 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 

Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 2 [/100(WBCs)]

Morphology: Circulating myeloid precursors and nucleated red blood cells are seen. 

IMMUNOHISTOCHEMISTRY
Immunostains show the tumor clusters are positive for OSCAR (cytokeratin). CD71 and MPO highlight erythroid predominance and reduced myeloid elements. CD61 highlights small hypolobated appearing megakaryocytes. CD34 and CD117 highlight no increase in blasts. CD20, CD3 and CD138 highlight mildly increased interstitial B and T cells and plasma cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-9691)
Interpretation: 
No abnormal myeloid blast, monocyte or maturing myeloid population identified. Very few CD34 positive blasts seen.
266,793 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6971.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-35207.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7252;S11;MSK- - 2023-06-26 21.44.10.ndpi,Peripheral Blood Smear,2023-06-26,"Myelodysplastic Syndrome.  Pancytopenia.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Metastatic adenocarcinoma extensively involving bone marrow. 
     - No hematopoietic elements are seen.
  
COMMENT: ER, PR and HER2 immunohistochemical studies will be performed and reported in an addendum.

BONE MARROW BIOPSY
Histologic section shows a core biopsy with markedly replaced by cohesive epithelioid cells forming aggregates and glandular structures in a fibrotic desmoplastic background. No hematopoietic elements are seen. The bone is osteosclerotic.
Reticulin stain shows marked increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: Not performed 
Markedly hypocellular touch imprints with extrinsic cells seen both singly and in clumps.

Special stains
Iron: Non-contributory due to lack of spicules
Ring sideroblasts: Non-contributory due to lack of erythroid elements

PERIPHERAL BLOOD
CBC (09/12/2018):
WBC 4.6 [4.0-11.0 K/mcL] 
RBC 2.86 L [3.80-5.00 M/mcL] 
HGB 8.1 L [11.2-15.4 g/dL] 
HCT 25.5 L [34.3-46.0 %] 
MCV 89 [80-98 fL] 
MCH 28.3 [27.0-33.0 pg] 
MCHC 31.8 [31.0-36.5 g/dL] 
RDW 16.9 H [12.2-15.1 %] 
Platelets 128 L [160-400 K/mcL] 

Neutrophil 66.0 [32.5-74.8 %] 
Lymph 16.0 [12.2-47.4 %] 
Mono 9.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 

Abs Neut 3.0 [1.5-7.5 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Metamyelocyte 5.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Blast 1.0 H [0.0-0.0 %] 

Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Absolute Blasts 0.0 [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 5 [/100(WBCs)] 

Morphology: Circulating myeloid precursors and nucleated red blood cells are seen

IMMUNOHISTOCHEMISTRY
Immunostains for CD34 and CD117 show no increase in blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7898)
No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.42% of WBC.
25,058 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required. Less than target number of cells acquired for MDS. Target sensitivity is not achieved.

No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5674.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-28505.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7417;S11;MSK3 - 2023-04-17 10.35.03.ndpi,Peripheral Blood Smear,2023-04-17,"AML. MDS with progressing to AML. 
","1-3. Bone marrow, left posterior iliac crest; biopsy, aspirate and peripheral blood smear: 
    - Therapy-related acute myeloid leukemia, 65% blasts by touch imprint differential.

COMMENT: Additional immunohistochemical stains are pending and will be reported in an addendum.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypercellular (>90%)
M:E ratio: N/A
Blasts: Markedly expanded, sheet-like proliferation of blasts with variable cytoplasm, ovoid nuclei, fine chromatin and distinct nucleoli, approximately 70% of total cellularity by morphology.
Myeloid lineage: Background myeloid elements are reduced with left shifted maturation
Erythroid lineage: Markedly reduced 
Megakaryocytes: Markedly reduced 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows a moderate to focally marked increase in reticulin fibers (2-3+/3). 
Clot section: Not submitted. 
Other: Hemosiderin laden macrophages are seen

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HH)
Only touch imprint smears are available for evaluation

Blasts                65%
Promyelocytes           2%
Myelocytes           5%
Metamyelocytes           1%
Neutrophils/Bands      10%
Monocytes           1%
Erythroid Precursors      1%
Lymphocytes           15%
Number of Cells Counted 500
M:E Ratio           19

Special stain
Iron: Suboptimal for evaluation, cannot be accurately assessed due to lack of spicules
Ring sideroblasts: Cannot be fully evaluated due to limited erythroid elements

Morphology: Only touch imprints were submitted for review. The imprints show a markedly expanded population of medium to large sized blasts with moderate amounts of cytoplasm, round to ovoid nuclei, fine chromatin and distinct nucleoli, in a background of markedly decreased erythroid and myeloid elements. Myeloid elements show dysgranulopoiesis (hypogranularity and nuclear lobation abnormalities). Erythroid elements are rare. Megakaryocytes are not seen on the touch imprints. 

PERIPHERAL BLOOD
CBC (09/20/2018):
WBC 15.1 H [4.0-11.0 K/mcL] 
RBC 2.90 L [3.80-5.00 M/mcL] 
HGB 8.5 L [11.2-15.4 g/dL] 
HCT 25.6 L [34.3-46.0 %] 
MCV 88 [80-98 fL] 
MCH 29.3 [27.0-33.0 pg] 
MCHC 33.2 [31.0-36.5 g/dL] 
RDW 14.9 [12.2-15.1 %] 
Platelets 18 LL [160-400 K/mcL]  

Neutrophil 25.0 L [32.5-74.8 %] 
Lymph 27.0 [12.2-47.4 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 3.8 [1.5-7.5 K/mcL] 
Abs Lymph 4.2 H [0.9-3.2 K/mcL] 
Abs Mono 1.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Metamyelocyte 5.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Blast 34.0 H [0.0-0.0 %] 
Variant Lymph 1.0 [%] 

Abs Meta 0.8 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.3 H [0.0-0.0 K/mcL] 
Absolute Blasts 5.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Expanded circulating blast population, with morphology similar to touch imprints. Background granulocytic elements show occasional pseudo Pelger-Huet forms.
RBC: Normocytic, normochromic anemia with anisocytosis.
PLT: Marked thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stain for CD117 highlights a subset of the blasts. CD117+ blasts are approximately 20-30% of total cellularity. CD34 is negative in the blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8063)
Abnormal blast population detected.

Flow cytometry identifies an abnormal blast population with an immunophenotype similar to that seen in prior sample F18-4671 have abnormal expression of CD2, CD4 (bright), CD7 (bright), CD11b (partial), CD34 (absent), CD71(bright), CD117 (intermediate to absent), CD123 (dim), and HLA-DR (dim to absent), with normal expression of CD13, CD33, CD38, CD45; without CD5, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. The blasts represent 61.4% of WBC.

Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be indicative of bone marrow composition.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5789.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M18-29041, M18-29043, M18-29044.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-9240;S11;MSK9 - 2023-06-20 14.42.49.ndpi,Peripheral Blood Smear,2023-06-20,"MDS. ESA 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
    - Hypercellular marrow with trilineage maturing hematopoiesis with mild dyserythropoiesis and increased ring sideroblasts (>15%). 

See comment.
  
Comment: It is noted that the patient has been on ESA's and Filgastrim. The morphological findings represent effects of these treatments. In addition, mild dyserythropoiesis, increased ring sideroblasts and abnormal myeloid population by flow cytometry are seen consistent with patient's known myelodysplastic syndrome; best classified as myelodysplastic syndrome with single lineage dysplasia with ringed sideroblasts (MDS-RS-SLD). Correlation with cytogenetic and molecular genetic studies is advised to evaluate for a clonal genetic mutation, including SF3B1.
Megakaryocytes are increased and show predominantly unremarkable morphology and few bare nuclei. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (80-90%)
M:E ratio: Normal 
Blasts: Not overtly increased 
Myeloid lineage: Shows left shift in maturation 
Erythroid lineage: Show left shift in maturation  
Megakaryocytes: Increased in number and show predominantly unremarkable morphology and few bare megakaryocytic nuclei are seen 
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                3%
Promyelocytes           6%
Myelocytes           16%
Metamyelocytes           10%
Neutrophils/Bands      28%
Monocytes           3%
Eosinophils           4%
Erythroid Precursors      20%
Plasma Cells           2%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           3.4

Special stain
Iron: Present
Ring sideroblasts: Present >15%  

Morphology:
-Spicular and cellular aspirate smears show maturing trilineage hematopoiesis. There is no expanded blast population. Myeloid elements are adequate in number and show left shift in maturation. Erythroid elements are adequate in number and show mild dyspoiesis (megaloblastoid forms, vacuolation and nuclear irregularities). Megakaryocytes are adequate in number and show no overt atypia. 

PERIPHERAL BLOOD
CBC (11/21/2018):
WBC 8.2 [4.0-11.0 K/mcL] 
RBC 3.98 [3.95-5.54 M/mcL] 
HGB 13.5 [12.5-16.2 g/dL] 
HCT 37.9 [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 33.9 H [27.0-33.0 pg] 
MCHC 35.6 [31.0-36.5 g/dL] 
RDW 17.2 H [12.2-15.1 %] 
Platelets 116 L [160-400 K/mcL]
 
Neutrophil 75.8 H [32.5-74.8 %] 
Lymph 10.3 L [12.2-47.4 %] 
Mono 12.8 H [0.0-12.3 %] 
Eos 0.7 [0.0-4.9 %] 
Baso 0.2 [0.0-1.5 %] 
Immature Granulocyte 0.2 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 6.2 [1.5-7.5 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 
Abs Mono 1.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Morphology:
WBC: No circulating blasts seen
RBC: Unremarkable 
Platelets: Thrombocytopenia 

IMMUNOHISTOCHEMISTRY
Immunostains CD34 and CD117 highlights scattered blast population (<5% positivity). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10070)
Interpretation: 
Abnormal myeloid blast populations detected. 
Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD13 (dim), CD33 (absent to intermediate), CD38 (dim to intermediate), CD117 (bright) with normal expression of CD4, CD34, CD45, CD71, CD123 and HLA-DR without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 0.92% of WBC.

No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not submitted. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7216.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-36360.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7709;S10;MSKP - 2023-04-25 19.24.45.ndpi,Peripheral Blood Smear,2023-04-25,"Lymphoma, Diffuse large cell. Richter's transformation from CLL status post CAR T cells. ScreenB, 4wk, 12wk.
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Recurrent/persistent involvement by CD5+ Large B-cell Lymphoma (30% with PAX-5 immunohistochemistry)
     - Variably cellular marrow with markedly reduced trilineage hematopoiesis and stromal fibrosis (See Comment) 

COMMENT: A portion of the marrow spaces are diffusely infiltrated by B-cell lymphoma, while the rest of the marrow shows marked hypocellularity with stromal fibrosis, consistent with therapy effect. 

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy showing variable marrow cellularity (Overall 30%, range: 0-100% cellularity). A smaller portion of the marrow spaces are entirely replaced by dense atypical lymphoid infiltrate with crush artifact, associated with necrosis and many apoptotic bodies. The lymphoid cells appear pleomorphic, intermediate- to large-sized, with irregular nuclear contour, vesicular chromatin, indistinct nucleoli, and small amount of cytoplasm. Normal marrow maturing hematopoiesis is markedly reduced. A larger portion of the marrow is entirely acellular, with stromal fibrosis and absence of marrow hematopoiesis, consistent with treatment effect.

Aspirate differential: (Performed by AS)
Myelocytes           2%
Metamyelocytes           2%
Neutrophils/Bands      64%
Monocytes           2%
Eosinophils           1%
Lymphocytes           12%
Abnormal lymphoid cells      17%
Number of Cells Counted  500
M:E Ratio           NA

Aspirate smears are aspicular, hemodiluted and hypocellular. Differential count performed may not accurately reflect the marrow composition. Atypical lymphoid cells are seen, comprised of intermediate- to large-sized cells with fine to slightly dispersed chromatin, nucleoli, and small to moderate amount of basophilic cytoplasm. Maturing myeloid and erythroid elements are seen, with no increase in blasts. Megakaryocytes are not readily identified.
The touch preparation shows similar findings.

IMMUNOHISTOCHEMISTRY
The atypical lymphoid cells express PAX-5 diffusely, but mostly negative for CD20.
CD3 highlights scattered small T-cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8345) 
Interpretation: 
Abnormal B cell population identified.

Flow cytometry identified abnormal B cell population with abnormal expression of CD5, CD19 (absent, likely due to anti-CD19 therapy), CD20 (negative to dim), CD22 (negative to dim), CD23 (subset), CD38 (absent), CD45 (dim), CD200 (bright); normal expression of cyCD79a, CD24, HLA-DR, increased forward and side scatter suggestive of larger size, and kappa surface light chain restriction (dim). The immunophenotype of the population is similar to that identified previously in marrow (F18-3568; 5/3/18), with the exception of CD19-negativity in this sample. The abnormal B cell population comprises 4.7% of the white cells.

PERIPHERAL BLOOD
CBC (10/01/2018):
WBC 12.1 H [4.0-11.0 K/mcL] 
RBC 2.75 L [3.95-5.54 M/mcL] 
HGB 10.2 L [12.5-16.2 g/dL] 
HCT 30.4 L [37.5-49.3 %] 
MCV 111 H [80-98 fL] 
MCH 37.1 H [27.0-33.0 pg] 
MCHC 33.6 [31.0-36.5 g/dL] 
RDW 14.0 [12.2-15.1 %] 
Platelets 18 LL [160-400 K/mcL] 
 
Neutrophil 79.0 H [32.5-74.8 %] 
Lymph 9.0 L [12.2-47.4 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Other 3.0 H [0.0-0.0 %] 
Abnormal lymphoid cells.

Abs Neut 9.5 H [1.5-7.5 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.5 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Others 0.4 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 1 [/100(WBCs)] 

Morphology:
WBC: Leukocytosis with some left shifted granulocytes present (bands, metamyelocytes, myelocytes), but no circulating blasts. There are scattered medium to large sized atypical lymphoid cells with similar morphology as the aspirate smear. 
RBC: Macrocytic anemia; mild increase in reticulocytes, rare nucleated RBCs seen.
PLT: Marked thrombocytopenia. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6019, CG18-6021.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-30210, M18-30211.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9742;S11;MSK6 - 2023-04-20 09.47.22.ndpi,Peripheral Blood Smear,2023-04-20,"MDS. 9 month post cord BMT on 17-616.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) (25% blasts by aspirate differential count)
     - Normocellular marrow with myeloid predominant trilineage maturing hematopoiesis

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Normocellular for age (40-50% cellularity)
M:E ratio: Increased 
Blasts: Increased, interstitially scattered or in small clusters, medium to large in size with slightly irregular nuclei, fine chromatin, and distinct nucleoli 
Myeloid lineage: Exhibits left shifted maturation 
Erythroid lineage: Exhibits left shifted maturation
Megakaryocytes: Decreased in number and show some small hypolobated forms
Lymphocytes: Scattered 
Plasma cells: Scattered
Other: hemosiderin deposition is seen.
Special stains: Reticulin stain shows no significant reticulin fibrosis (0/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)
Blasts                25%
Promyelocytes           6%
Myelocytes           7%
Metamyelocytes           4%
Neutrophils/Bands      22%
Monocytes           4%
Eosinophils           1%
Basophils           9%
Erythroid Precursors      6%
Plasma Cells           1%
Lymphocytes           15%
Number of Cells Counted  500
M: E Ratio           8.8

Special stain
Iron: Cannot evaluate for storage iron in a smear devoid of spicules
Ring sideroblasts: Absent

Morphology:
Paucispicular and hypocellular aspirate smears and touch imprint showing myeloid predominant trilineage hematopoiesis with an expanded population of medium to large sized blasts with round to slightly irregular nuclei, dispersed chromatin, mostly distinct nucleoli, and scant to moderate cytoplasm with occasional cytoplasmic vacuoles. Myeloid elements are relatively increased and show left shifted maturation with very mild dyspoiesis (hypogranular forms). Erythroid elements are relatively decreased and show maturation with mild dyspoiesis (karyorrhexis). Megakaryocytes are present and show occasional hypolobated forms. Basophilia is present. 

PERIPHERAL BLOOD
CBC (12/10/2018):
WBC 5.5 [4.0-11.0 K/mcL] 
RBC 2.94 L [3.80-5.00 M/mcL] 
HGB 10.3 L [11.2-15.4 g/dL] 
HCT 30.9 L [34.3-46.0 %] 
MCV 105 H [80-98 fL] 
MCH 35.0 H [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 14.0 [12.2-15.1 %] 
Platelets 85 L [160-400 K/mcL] 

Neutrophil 53.0 [32.5-74.8 %] 
Lymph 19.0 [12.2-47.4 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 23.0 H [0.0-1.5 %] 
Blast 2.0 H [0.0-0.0 %] 

Abs Neut 2.9 [1.5-7.5 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 1.3 H [0.0-0.2 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)]

Morphology:
WBC: Basophilia; few circulating blasts present. 
RBC: Macrocytic anemia. 
PLT: Thrombocytopenia with some large forms. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show expanded blasts population (~20% marrow cellularity).  

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10654)
Abnormal myeloid blast population detected.
Marked basophilia seen.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior marrow sample (F18-9717) have abnormal expression of CD7 (major subset), CD11b (partial dim), CD13 (variable, intermediate to dim), CD15 (small subset), CD25 (small subset, <10% of blasts), CD33 (uniform bright), CD38 (intermediate to absent), CD117 (bright), CD123 (bright), HLA-DR (dim); with normal expression of CD4, CD34, CD45, CD71; without CD2, CD5, CD14, CD16, CD19, CD56 or CD64. CD34 positive myeloid blasts represent 18.5% of WBC. 

There is also marked basophilia, with basophils comprising 14.6% of WBC.

344,899 cells acquired.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7628.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-38606, M18-38607.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9601;S11;MSK0 - 2023-04-17 15.39.54.ndpi,Peripheral Blood Smear,2023-04-17,"AML. Relapsed AML (+RUNX1, TP53, SRSF2, SETBP1), status post allo SCT. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Relapsed acute myeloid leukemia, 40-50% blasts by immunohistochemical stains.

BONE MARROW BIOPSY
Quality: Adequate, fragmented with aspirate effect.
Cellularity: Hypocellular for age (10-20% cellularity).
M:E ratio: N/A
Blasts: Increased. 
Myeloid lineage: Decreased and exhibits left shifted maturation. 
Erythroid lineage: Decreased and exhibits full maturation. 
Megakaryocytes: Decreased with predominantly unremarkable morphology.
Lymphocytes: Scattered. 
Plasma cells: Rare.
Special stains: Reticulin stain shows no increase in reticulin fibrosis.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Blasts                50%
Promyelocytes           2%
Myelocytes           6%
Metamyelocytes           3%
Neutrophils/Bands      18%
Eosinophils           1%
Erythroid Precursors      10%
Lymphocytes           10%
Number of Cells Counted  500
M:E Ratio           N/A

Morphology:
Aspicular and hypocellular aspirate smears and touch imprint show increased blasts with irregular nuclei, variably prominent nucleoli, fine chromatin, and scant to moderate cytoplasm. Maturing myeloid and erythroid elements are present and show no overt dysplasia. Megakaryocytes are not seen. 

PERIPHERAL BLOOD
CBC (12/05/2018):
WBC 1.8 L [4.0-11.0 K/mcL] 
RBC 2.36 L [3.80-5.00 M/mcL] 
HGB 7.9 L [11.2-15.4 g/dL] 
HCT 23.6 L [34.3-46.0 %] 
MCV 100 H [80-98 fL] 
MCH 33.5 H [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 24.3 H [12.2-15.1 %] 
Platelets 100 L [160-400 K/mcL] 

Neutrophil 65.0 [32.5-74.8 %] 
Lymph 22.0 [12.2-47.4 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Blast 3.0 H [0.0-0.0 %] 

Abs Neut 1.2 L [1.5-7.5 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 1 [/100(WBCs)] 

Morphology:
WBC: Rare circulating blasts present; absolute neutropenia and lymphopenia; rare large granular lymphocytes present.
RBC: Normocytic, normochromic anemia with moderate anisocytosis.
PLT: Thrombocytopenia with few large forms. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show increased blasts (40-50% marrow cellularity). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10481)
Abnormal myeloid blast population detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample (F18-8926) having abnormal expression of CD2 (small subset dim), CD7 (subset dim), CD13 (uniform, bright), CD19 (subset dim), CD25 (negative to intermediate), CD33 (bright), CD34 (bright), CD38 (dim to intermediate), CD117 (dim to bright), HLA-DR (bright); with normal expression of CD4, CD45, CD71, CD123; without CD5, CD11b, CD14, CD15, CD16, CD56 or CD64. CD34 positive myeloid blasts represent 29.4% of WBC. The findings are consistent with relapsed acute myeloid leukemia.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7526.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-37991 to M18-37794, M18-38005.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-8234;S11;MSK1 - 2023-04-25 20.05.05.ndpi,Peripheral Blood Smear,2023-04-25,"Myelodysplastic syndrome. Status post allo SCT. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) (40% blasts by CD34 immunohistology and 20% by aspirate differential count). See comment.
     - Minute abnormal B-cell population detected by flow cytometry only (0.13%).
     - Cellular marrow with maturing trilineage hematopoiesis and multilineage dysplasia.
  
COMMENT: The core biopsy is fragmented, largely aspirated, and suboptimal. Few evaluable marrow areas show hypocellular marrow with markedly increased blasts (~40%) highlighted by CD34 immunohistology. The aspirate smears show a cellular marrow with 20% blasts, and the discrepancy may be due to sampling and patchy disease involvement. The patient has a prior history of myelodysplastic syndrome status post stem cell transplant. The current findings are most consistent with relapse of the meyloid neoplasm and progression to AML.
A minute abnormal B-cell population is also detected by flow cytometry without a morphologic correlate. Although it shares a similar light chain restriction (kappa) with the low-grade B-cell lymphoma previously diagnosed (see H17-3836; 6/5/17), the immunophenotype shows some dissimilarities. Thus, it is not clear if this represents minimal involvement the same low-grade B-cell lymphoma or another process. Clinical correlation is advised.

BONE MARROW BIOPSY
Quality: Suboptimal, fragmented, largely aspirated, with intact intertrabecular spaces available for evaluation
Cellularity: Hypocellular for age (10%)
M:E ratio: N/A
Blasts: Increased, present in small interstitial clusters and singly distributed. Blasts are medium to large in size, with oval to irregular nuclei, fine chromatin, variably conspicuous nucleoli, and scant cytoplasm.
Myeloid lineage: Decreased
Erythroid lineage: Decreased
Megakaryocytes: Adequate for cellularity, with dysplastic forms (separation of nuclear lobes, hypolobation, nuclear hyperchromasia)
Lymphocytes: Scattered, lymphoid aggregates are not identified
Plasma cells: Scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blasts                20%
Promyelocytes           2%
Myelocytes           13%
Metamyelocytes           8%
Neutrophils/Bands      20%
Monocytes           1%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      25% 
Plasma Cells           1%
Lymphocytes           8%
Number of Cells Counted 500
M: E Ratio           1.8

Special stain
Iron: Present
Ring sideroblasts: Absent 

Morphology:
Adequate, spicular and cellular aspirate smears with maturing trilineage hematopoiesis and an expanded blast population. Blasts are medium to large in size, with round to ovoid nuclei, fine chromatin, variably conspicuous nucleoli, and scant to occasionally relatively moderate cytoplasm. Auer rods are not seen. Myeloid precursors show progressive maturation with some hyposegmented forms. Erythroid precursors, are present in patchy distribution, and show progressive maturation with frequent megaloblastoid features, nuclear budding, and karyorrhexis. Megakaryocytes are seen with frequent dysplastic forms (disjointed nuclear lobes, small, hypolobated forms).   Few small mature-appearing lymphocytes are seen.

PERIPHERAL BLOOD
CBC (10/17/2018):
WBC 2.2 L [4.0-11.0 K/mcL] 
RBC 2.43 L [3.95-5.54 M/mcL] 
HGB 8.6 L [12.5-16.2 g/dL] 
HCT 27.3 L [37.5-49.3 %] 
MCV 112 H [80-98 fL] 
MCH 35.4 H [27.0-33.0 pg] 
MCHC 31.5 [31.0-36.5 g/dL] 
RDW 14.8 [12.2-15.1 %] 
Platelets 50 L [160-400 K/mcL] 

Neutrophil 64.0 [32.5-74.8 %] 
Lymph 29.0 [12.2-47.4 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Abs Neut 1.4 L [1.5-7.5 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 4.0 H [0.0-0.0 %] 
Variant Lymph 1.0 [%] 
Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 

Morphology:
WBC: Few blasts seen with similar morphology as that on the aspirate smears. Leukopenia with absolute neutropenia and lymphopenia.
RBC: Macrocytic anemia.
Platelets: Thrombocytopenia

IMMUNOHISTOCHEMISTRY
CD34 highlights blasts, with strong expression. They account for ~40% of the marrow composition in a hypocellular marrow.
The blasts are also positive for CD117.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8894)
Interpretation: 
Abnormal myeloid blast population detected.

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD11b (partial), CD19 (minute subset), CD25 (partial), CD56 (partial), CD13 (bright), CD33 (bright), CD34 (bright), CD38 (absent to dim) and CD117 (bright);with normal expression of CD4, CD45, CD71, CD123 and HLA-DR without CD2, CD5, CD7, CD14, CD15, CD16 or CD64. CD34 positive myeloid blasts represent 15.7% of WBC.

Abnormal B-cell population identified.

Flow cytometry reveals an abnormal mature B-cell population similar to that seen previously in [F18-5365] with abnormal expression of CD10, kappa light chain restriction, and normal expression of CD19, CD20, CD22, CD38 and CD45; and without CD5. The abnormal B-cell population represents 0.13% of the total white cells.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6429.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-32291 and M18-32293.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7697;S11;MSKC - 2023-06-26 20.39.06.ndpi,Peripheral Blood Smear,2023-06-26,"Myelodysplastic Syndrome. Pancytopenia.
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Metastatic adenocarcinoma, consistent with prostate origin, see note.

COMMENT: The metastatic carcinoma is positive for pan-cytokeratin, PSA, PSMA and NKX3.1 by immunohistochemistry, consistent with prostatic origin. The patient's pancytopenia is most likely secondary to extensive bone marrow infiltration by metastatic prostatic adenocarcinoma.

This case was also reviewed by Dr. Quesada (Hematopathologist); see detailed hematopathology examination description below.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Cannot be accurately assessed, virtually no hematopoietic elements seen
M:E ratio: Cannot be accurately assessed 
Blasts: Not increased (<5%) 
Myeloid lineage: Markedly reduced  
Erythroid lineage: Markedly reduced 
Megakaryocytes: Rare 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows a mild increase in reticulin fibers (1+/3). 
Other: Extensive infiltration by metastatic adenocarcinoma seen.

BONE MARROW ASPIRATE SMEAR
Differential from touch imprint smear: (Performed by HWH)

Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           7%
Neutrophils/Bands      28%
Monocytes           4%
Eosinophils           3%
Erythroid Precursors      40%
Lymphocytes           8%
Number of Cells Counted  500
M: E Ratio           1.3
Positive for extrinsic cells seen.

Morphology: The touch imprints are aspicular, hypocellular and show a markedly expanded population of extrinsic cells in clusters and glands consistent with adenocarcinoma. Blasts are not increased. Trilineage hematopoiesis is seen but is markedly reduced. 

PERIPHERAL BLOOD
CBC (10/01/2018):
WBC 1.3 L [4.0-11.0 K/mcL] 
RBC 2.56 L [3.95-5.54 M/mcL] 
HGB 8.0 L [12.5-16.2 g/dL] 
HCT 23.9 L [37.5-49.3 %] 
MCV 93 [80-98 fL] 
MCH 31.3 [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 16.3 H [12.2-15.1 %] 
Platelets 24 L [160-400 K/mcL] 

Neutrophil 28.0 L [32.5-74.8 %] 
Lymph 48.5 H [12.2-47.4 %] 
Mono 19.7 H [0.0-12.3 %] 
Eos 1.5 [0.0-4.9 %] 
Baso 0.8 [0.0-1.5 %] 
Immature Granulocyte 1.5 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 0.4 L [1.5-7.5 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 1.5 [%] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Morphology:
WBC: Leukopenia with marked absolute/relative neutropenia. No circulating blasts seen.  
RBC: Normocytic, normochromic anemia with anisocytosis.
PLT: Marked thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
The metastatic carcinoma is positive for pan-cytokeratin, PSA, PSMA and NKX3.1 by immunohistochemistry.
Immunohistochemical stains show no increases in CD34 and/or CD117 positive blasts (<5%).

FLOW CYTOMETRIC ANALYSIS
Not submitted.  

CYTOGENETIC/MOLECULAR STUDIES
Not submitted. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6657;S12;MSK9 - 2023-06-29 00.24.47.ndpi,Peripheral Blood Smear,2023-06-29,"Merkel Cell. Thrombocytopenia, c/f marrow invasion of metastatic Merkel Cell vs progression of historical plasma cell neoplasia. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Metastatic Merkel cell carcinoma, see note
     - No morphologic or immunophenotypic evidence of plasma cell neoplasm
  
Note: Prior pathology (S18-42382) has been reviewed and tumor cells have similar morphology. This case was also reviewed by Dr. Mariko Yabe, Hematopathology service, whose interpretation is below:


BONE MARROW BIOPSY/ ASPIRATE SMEAR
Differential: (Performed by HH)

Blasts                3%
Promyelocytes           2%
Myelocytes           10%
Metamyelocytes           5%
Neutrophils/Bands      17%
Monocytes           1%
Eosinophils           2%
Erythroid Precursors      54%
Plasma Cells           1%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           0.7

Biopsy and aspirate smear Morphology:
Biopsy shows hypercellular marrow with extensive involvement by non-hematopoietic elements. Spicular and cellular smears show trilineage maturing hematopoiesis with numerous extrinsic cells singly as well as forming clusters. 

PERIPHERAL BLOOD
CBC (08/23/2018):
WBC 2.7 L [4.0-11.0 K/mcL] 
RBC 2.95 L [3.95-5.54 M/mcL] 
HGB 8.1 L [12.5-16.2 g/dL] 
HCT 23.6 L [37.5-49.3 %] 
MCV 80 [80-98 fL] 
MCH 27.5 [27.0-33.0 pg] 
MCHC 34.3 [31.0-36.5 g/dL] 
RDW 18.6 H [12.2-15.1 %] 
Platelets 15 LL [160-400 K/mcL]  

Neutrophil 69.0 [32.5-74.8 %] 
Lymph 24.0 [12.2-47.4 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 1.9 [1.5-7.5 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Metamyelocyte 1.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Blast 1.0 H [0.0-0.0 %] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Absolute Blasts 0.0 [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 4 [/100(WBCs)] 

Morphology: Circulating immature myeloid cells and nucleated RBCs seen, consistent with leukoerythroblastosis. 

IMMUNOHISTOCHEMISTRY/SPECIAL STAIN 
OSCAR, CK20, synaptophysin and CD138 highlight carcinoma, and these cells do not express CD45. 
Kappa and lambda stains are non-contributory due to high background stain.
CD34 and CD117 highlight no increase in blasts. 
Reticulin stain shows increased reticulin fibers associated with metastatic tumor. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7162)
Interpretation: 
No abnormal mature B-cell population detected.
No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

No abnormal plasma cell population detected.
No evidence of an abnormal plasma cell population is identified by flow cytometry.  Plasma cells comprise 0.19% of the viable cells, following erythroid lysis.
5291875 cells acquired.  Please note that flow cytometry studies generally underestimate the number of plasma cells, as compared to morphologic assessment.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5152.

MOLECULAR STUDIES 
Not submitted. 



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-8229;S2;MSK5 - 2023-06-20 17.18.18.ndpi,Peripheral Blood Smear,2023-06-20,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears:
     - B-lymphoblastic leukemia/ lymphoma, 37% blasts by aspirate differential count.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                37%
Promyelocytes           1%
Myelocytes           4%
Metamyelocytes           3%
Neutrophils/Bands      27%
Monocytes           1%
Erythroid Precursors      17%
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           2.1

Morphology:
Spicular and cellular smears show increased blasts, small in size and with high N/C ratio. Nunerous smudge cells are present in a background. 

PERIPHERAL BLOOD
CBC (10/17/2018):
WBC 10.1 [7.1-15.9 K/mcL] 
RBC 3.56 L [3.89-5.03 M/mcL] 
HGB 10.3 L [10.7-14.5 g/dL] 
HCT 30.5 L [32.2-43.5 %] 
MCV 86 [74-91 fL] 
MCH 28.9 [24.8-30.2 pg] 
MCHC 33.8 [31.0-36.5 g/dL] 
RDW 13.3 [12.2-15.1 %] 
Platelets. 51 L [160-400 K/mcL] 

Neutrophil 63.0 [32.5-74.8 %] 
Lymph 16.0 [12.2-47.4 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 6.3 [1.5-7.5 K/mcL] 
Abs Lymph 1.6 [0.9-3.2 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL]
 
Metamyelocyte 5.0 H [0.0-0.0 %] 
Myelocyte 7.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 

Abs Meta 0.5 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.7 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.1 H [0.0-0.0 K/mcL] 

Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 2 [/100(WBCs)]

Morphology: Circulating immature myeloid cells (myelocytes, metamyelocytes) are present. Blasts are not overtly increased. Nucleated RBCs are seen. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8886)
Interpretation: 
Abnormal immature B-cell population detected.

An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously [F18-8106]. The abnormal immature B-cells represent 6.8% of the white cells and 23.9% of the mononuclear cells in the sample and abnormally express CD10 (variable, absent to dim), CD34 (variable, absent to normal), CD38 (slightly bright), CD45 (absent to dim), CD58 (uniform, bright); with normal expression of CD19, CD22, CD24 and HLA-DR; and without CD20, CD13, CD33 or CD66b. This finding is consistent with persistent/recurrent B-lymphoblastic leukemia/lymphoma, depending on the clinical context. Clinical and morphologic correlation is recommended.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.14% of WBC.
391656 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6430.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-32287.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. Pessin MD., PhD., Director.
  
"
H18-10086;S11;MSKI - 2023-04-17 09.35.06.ndpi,Peripheral Blood Smear,2023-04-17,"AML.  Newly diagnosed acute leukemia.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     -Acute myeloid leukemia (95% blasts count by aspirate differential count), see comment.
     -B cell lymphoproliferative neoplasm with marginal zone lymphoma phenotype detected by flow cytometry only (clinical and radiologic correlation is advised)
COMMENT:
Correlation with molecular genetic studies and karyotype is suggested for further classification.

BONE MARROW BIOPSY
Quality: Adequate. 
Cellularity: Hypercellular (~95%)
M:E ratio: N/A
Blasts: Markedly increased. 
Myeloid lineage: Reduced.
Erythroid lineage: Reduced.
Megakaryocytes: Reduced.
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Blasts                95%
Neutrophils/Bands      1%
Erythroid Precursors      4%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
The aspirate smears are spicular and cellular and show a markedly expanded population of variable size (small to large) blasts with scant cytoplasm, indented nuclei (cup and saucer shaped), fine chromatin and occasional distinct nucleoli. Occasional bilobed forms are seen. Auer rods are not seen. There is markedly decreased trilineage hematopoiesis. 

PERIPHERAL BLOOD
CBC (12/21/2018):
WBC 73.8 H [4.0-11.0 K/mcL] 
RBC 2.25 L [3.80-5.00 M/mcL] 
HGB 6.4 L [11.2-15.4 g/dL] 
HCT 20.2 L [34.3-46.0 %] 
MCV 90 [80-98 fL] 
MCH 28.4 [27.0-33.0 pg] 
MCHC 31.7 [31.0-36.5 g/dL] 
RDW 19.9 H [12.2-15.1 %] 
Platelets.12 LL [160-400 K/mcL] Fina

Neutrophil 1.0 L [32.5-74.8 %] 
Lymph 8.0 L [12.2-47.4 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 0.7 L [1.5-7.5 K/mcL] 
Abs Lymph 5.9 H [0.9-3.2 K/mcL] 
Abs Mono 1.5 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 89.0 H [0.0-0.0 %] 

Absolute Blasts 65.6 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 4 [/100(WBCs)] 

Morphology:
WBC: Many circulating blasts seen.
RBC: Normocytic normochromic anemia.
Platelet: Thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD117 highlights marked increase in blasts (~95% of overall marrow cellularity). CD34 is not expressed on blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW F18-11071
Interpretation: 
Expanded abnormal myeloid blast population detected. 
Abnormal B cell population detected.

The blasts have abnormal expression of CD117 without CD34, CD13(absent), CD15(absent), CD25(low level, partial), HLA-DR(absent), CD38(slightly dim), CD56 (partial), CD64(dim), with normal expression of  CD4, CD33, CD45, CD71, and CD123 without CD2, sCD3, cCD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD16, CD19, CD20, cCD79a or surface light chains. MPO expression is present on all of the blasts. CD117 positive myeloid blasts represent approximately 97% of WBC.
While not diagnostic, the finding do not exclude acute promyelocytic leukemia, particularly hypogranular variant, however AML with FLT3 mutations and/or NPM1 mutations may have a very similar phenotype. Correlation with the tandem cytogenetic evaluation is required.

Abnormal B-cell population identified.
Flow cytometry reveals an abnormal mature B-cell population with abnormal bright expression of CD19, CD20, CD22, lambda light chain restriction, and normal expression of CD45 and variably dim expression of CD11c; and without CD5, CD25, CD103, CD38 or CD10. The abnormal B-cell population represents 0.56% of the total white cells. 

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available.

CYTOGENETIC STUDIES

Cytogenetic analysis will be reported separately. See separate report, CG18-7939
Cytogenetic analysis performed on peripheral blood (F18-7930):
FISH ANALYSIS:
No evidence of PML-RARA fusion/t(15;17).
No evidence of rearrangement of RARA (17q21.2).
MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-40262 and M18-40264 to M18-40267.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-8643;S11;MSK5 - 2023-05-12 09.37.41.ndpi,Peripheral Blood Smear,2023-05-12,"Leukemia. Suspected acute leukemia. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma (B-ALL), 91% by aspirate differential count. 
     - Hypercellular marrow with reduced myeloid and erythropoiesis.
  
COMMENT: Correlation with cytogenetic and molecular studies is recommended. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (80-90%) 
M:E ratio: N/A
Blasts: Overtly increased in number 
Myeloid lineage: Markedly reduced in number 
Erythroid lineage: Markedly reduced in number
Megakaryocytes: Adequate in number and show no overt atypia 
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blasts                91%
Myelocytes           1%
Erythroid Precursors      6%
Lymphocytes           2%
Number of Cells Counted 500
M: E Ratio           0.2

Morphology:
- Spicular and cellular aspirate smear shows an expanded blast population. Blasts are medium to large size, with scant cytoplasm, round to oval nuclei, fine lacy chromatin and prominent nucleoli. The blasts have hand mirror morphology. Erythroid and myeloid elements are markedly reduced. Megakaryocytes are adequate in number and show no overt atypia. 

PERIPHERAL BLOOD
CBC (10/31/2018):
WBC 7.7 [4.0-11.0 K/mcL] 
RBC 4.77 [3.95-5.54 M/mcL] 
HGB 14.2 [12.5-16.2 g/dL] 
HCT 39.1 [37.5-49.3 %] 
MCV 82 [80-98 fL] 
MCH 29.8 [27.0-33.0 pg] 
MCHC 36.3 [31.0-36.5 g/dL] 
RDW 13.4 [12.2-15.1 %] 
Platelets 69 L [160-400 K/mcL] 

Neutrophil 13.0 L [32.5-74.8 %] 
Lymph 49.0 H [12.2-47.4 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Abs Neut 1.0 L [1.5-7.5 K/mcL] 
Abs Lymph 3.8 H [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 37.0 H [0.0-0.0 %] 
Absolute Blasts 2.8 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 3 [/100(WBCs)]

Morphology:
WBC: Absolute neutropenia and lymphocytosis; Numerous circulating blasts seen
RBC: Unremarkable 
Platelets: Thrombocytopenia  

IMMUNOHISTOCHEMISTRY
Immunostain CD34 highlights sheets of blasts (80-90%) The blasts are positive for TdT. 
CD117 is negative in blasts and highlights scattered mast cells 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-9371)
Abnormal immature B-cell population detected.
No abnormal mature B or T-cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow 95.3% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD10 (slightly bright), CD20 (partial dim), CD33 (partial dim), CD38 (dim to absent), CD45 (dim to absent), CD58 (uniform), CD123 (partial), with normal expression of CD19, CD71 and HLA-DR; and without CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD56, CD64, CD117 or surface light chains.
CD25 is expressed by greater than 10% of the blasts.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.050% of WBC.
358,467 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F18-9355)
Interpretation:

Abnormal immature B-cell population detected.
No abnormal mature B or T-cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (41.4% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD10 (slightly bright), CD20 (partial dim), CD33 (partial dim), CD38 (dim to absent), CD45 (dim to absent), CD123 (partial), with normal expression of CD19, CD71, cyCD79a and HLA-DR; and without CD2, CD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD56, CD64, CD117 or surface light chains.
CD25 is expressed by greater than 10% of the blasts.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.22% of WBC.
382,824 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6756.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-33993, M18-33995, M18-33996.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-6315;S11;MSKZ - 2023-06-26 22.18.49.ndpi,Peripheral Blood Smear,2023-06-26,"Myelodysplastic syndrome. Untreated. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
    - Normocellular marrow with erythroid predominant trilineage maturing hematopoiesis with no increase in blasts (see comment).
  
COMMENT:
Megakaryocytes and erythroid elements show mild atypical change (<10%); however, diagnostic morphologic features of involvement by myelodysplastic syndrome are not seen. The patient's cytogenetic abnormalities (-Y and +15) are not currently considered to be defining for MDS in the absence of morphologic criteria. 

Due to the patient's longstanding history of cytopenias, TET1 somatic mutation and blast count <5%, the differential diagnosis includes clonal cytopenia of undetermined significance (CCUS). Clonal expansions such as CHIP, ARCH, ICUS and CCUS, can be seen in approximately 10% of persons older than 70 years of age. Mutations in DNMT3A, TET2 and ASXL1 account for the vast majority of these cases. Clonal expansions of TET1 have not been well described in the literature, but nonetheless may represent underlying CCUS.      

References: 
1. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015 Jul 2;126(1):9-16.

2. Bowman RL, Busque L, Levine RL. Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. Cell Stem Cell. 2018 Feb 1;22(2):157-170.

3. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL.
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017 Jul 13;377(2):111-121. 

BONE MARROW BIOPSY
Quality: Fragmented biopsy
Cellularity: Normocellular for age, 20%
M:E ratio: Decreased 
Blasts: Not increased 
Myeloid lineage: Decreased with full maturation
Erythroid lineage: Increased with full maturation
Megakaryocytes: Present with few hypolobated forms 
Lymphocytes: Scattered
Plasma cells: Scattered 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1) 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blasts                1%
Promyelocytes           1%
Myelocytes           14%
Metamyelocytes           6%
Neutrophils/Bands      21%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      45%
Plasma Cells           2%
Lymphocytes           6%
Number of Cells Counted 500
M: E Ratio           1

Special stain
Iron: Absent
Ring sideroblasts: Rare (1%) 

Morphology:
Spicular and cellular aspirate smears show erythroid predominant maturing trilineage hematopoiesis with no increased blasts. myeloid elements show full maturation with no overt dysplasia. Erythroid elements show full maturation with rare binucleated forms. Megakaryocytes are present with few small hypo/monolobated forms.

PERIPHERAL BLOOD
CBC (08/13/2018):
WBC 3.6 L [4.0-11.0 K/mcL] 
RBC 4.26 [3.95-5.54 M/mcL] 
HGB 13.3 [12.5-16.2 g/dL] 
HCT 40.0 [37.5-49.3 %] 
MCV 94 [80-98 fL] 
MCH 31.2 [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 14.1 [12.2-15.1 %] 
Platelets 96 L [160-400 K/mcL] 

Neutrophil 68.2 [32.5-74.8 %] 
Lymph 20.9 [12.2-47.4 %] 
Mono 8.1 [0.0-12.3 %] 
Eos 2.2 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.3 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 2.4 [1.5-7.5 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Morphology:
WBC: No circulating blasts.
RBC: Unremarkable morphology.
PLT: Unremarkable morphology.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts (<5%). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-6770)
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.25% of WBC.
347,874 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-4877.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-24634.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7477;S11;MSK9 - 2023-06-26 21.14.30.ndpi,Peripheral Blood Smear,2023-06-26,"Amyloid. Long term f/u BMA on protocol 11-061.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Normocellular marrow with trilineage maturing hematopoiesis
     - No morphologic or immunophenotypic evidence of plasma cell neoplasm

BONE MARROW BIOPSY
Quality: Small, subcortical
Cellularity: Appears normocellular for age (~40% cellularity)
Myeloid lineage: Progressive maturation
Erythroid lineage: Progressive maturation
Megakaryocytes: Adequate in number, occasional small hypolobated forms 
Plasma cells: Scattered
Lymphoid cells: Scattered

ASPIRATE/ TOUCH PREPARATION MORPHOLOGY
Aspirate differential: (Performed by CB)

Blasts                1%
Promyelocytes           2%
Myelocytes           12%
Metamyelocytes           9%
Neutrophils/Bands      26%
Monocytes           5%
Eosinophils           2%
Erythroid Precursors      36%
Plasma Cells           1%
Lymphocytes           6%
Number of Cells Counted 500
M:E Ratio           1.6

Morphology: 
Marrow spicules: Spicular 
Cellularity: Cellular
Plasma cell morphology: Small to intermediate-sized 
Myeloid lineage: Progressive maturation
Erythroid Lineage: Progressive maturation
Megakaryocytes: Present, unremarkable morphology
Lymphoid cells: Small and mature-appearing.

IMMUNOHISTOCHEMISTRY/SPECIAL STAINS
CD138 immunostain highlights scattered plasma cells (<5% of cellularity). 
Kappa and lambda immunostains show high staining background and no definitive monotypic plasma cells.  
Congo Red stain is negative for amyloid deposition. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8113) 
Interpretation: 
No abnormal plasma cell population detected.

No evidence of an abnormal plasma cell population is identified by flow cytometry. Plasma cells comprise 0.080% of the viable cells, following erythroid lysis.

5,296,054 cells acquired. Please note that flow cytometry studies generally underestimate the number of plasma cells, as compared to morphologic assessment.

PERIPHERAL BLOOD
CBC (09/24/2018):
WBC 5.2 [4.0-11.0 K/mcL] 
RBC 5.16 [3.95-5.54 M/mcL] 
HGB 14.0 [12.5-16.2 g/dL] 
HCT 43.7 [37.5-49.3 %] 
MCV 85 [80-98 fL] 
MCH 27.1 [27.0-33.0 pg] 
MCHC 32.0 [31.0-36.5 g/dL] 
RDW 13.4 [12.2-15.1 %] 
Platelets 160 [160-400 K/mcL] 

Neutrophil 79.0 H [32.5-74.8 %] 
Lymph 12.2 [12.2-47.4 %] 
Mono 6.2 [0.0-12.3 %] 
Eos 0.8 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Immature Granulocyte 0.8 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 4.1 [1.5-7.5 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Morphology:
WBC: Scattered large granular lymphocytes seen. No circulating plasma cells
RBC: Normocytic, normochromic RBC'sPlatelet: Unremarkable morphology

CYTOGENETIC STUDIES
Not requested.

MOLECULAR STUDIES 
Not requested.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9582;S12;MSK9 - 2023-04-25 10.19.21.ndpi,Peripheral Blood Smear,2023-04-25,"AML. Newly diagnosed. 
","{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch31506\stshfhich31506\stshfbi31506\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fhimajor\f31502\fbidi \froman\fcharset0\fprq2{\*\panose 00000000000000000000}Cambria;}
{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri{\*\falt Calibri};}
{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}









{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhimajor\f31528\fbidi \froman\fcharset238\fprq2 Cambria CE;}{\fhimajor\f31529\fbidi \froman\fcharset204\fprq2 Cambria Cyr;}{\fhimajor\f31531\fbidi \froman\fcharset161\fprq2 Cambria Greek;}{\fhimajor\f31532\fbidi \froman\fcharset162\fprq2 Cambria Tur;}
{\fhimajor\f31535\fbidi \froman\fcharset186\fprq2 Cambria Baltic;}{\fhimajor\f31536\fbidi \froman\fcharset163\fprq2 Cambria (Vietnamese);}{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE{\*\falt Calibri};}
{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr{\*\falt Calibri};}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek{\*\falt Calibri};}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur{\*\falt Calibri};}
{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic{\*\falt Calibri};}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red192\green0\blue0;}
{\*\defchp \f31506\fs22 }{\*\defpap \ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa200\sl276\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive 
\ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv 
\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31506\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused 
Normal Table;}{\s15\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 
\snext15 \slink16 \sqformat \spriority1 \styrsid1407877 No Spacing;}{\*\cs16 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \dbch\af31505 \sbasedon10 \slink15 \slocked \spriority1 \styrsid1407877 No Spacing Char;}{\s17\ql \li0\ri0\widctlpar
\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 
\f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext17 \spriority0 \styrsid882823 CoPath Text;}}{\*\rsidtbl \rsid67849\rsid882823\rsid1407877\rsid2042514\rsid2244535\rsid2384879\rsid2631653\rsid3440157\rsid3692237\rsid4135798\rsid4349262
\rsid4405459\rsid4611041\rsid5570980\rsid5712722\rsid6766448\rsid6967677\rsid7345479\rsid7682242\rsid7801243\rsid7941751\rsid8093638\rsid8211225\rsid8327408\rsid8547255\rsid9375557\rsid10486192\rsid11625837\rsid11880241\rsid11935605\rsid12266937
\rsid13046825\rsid13703865\rsid13781310\rsid13842715\rsid14895546\rsid14950412\rsid16198884\rsid16476786}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info
{\author Melo, Heydi L./Pathology}{\operator Quesada, Andres E./Pathology}{\creatim\yr2018\mo12\dy13\hr12\min43}{\revtim\yr2018\mo12\dy13\hr12\min43}{\version2}{\edmins0}{\nofpages4}{\nofwords703}{\nofchars4284}{\nofcharsws4881}{\vern55}}
{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont1\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1440\dgvorigin1440\dghshow1\dgvshow1
\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\rsidroot3692237\newtblstyruls\nogrowautofit\usenormstyforlist\noindnmbrts\felnbrelev\nocxsptable\indrlsweleven\noafcnsttbl\afelev\utinl\hwelev\spltpgpar\notcvasp\notbrkcnstfrctbl\notvatxbx\krnprsnet\cachedcolbal \nouicompat \fet0
{\*\wgrffmtfilter 2450}\nofeaturethrottle1\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang 
{\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}
\pard\plain \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid2631653 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\ul\insrsid4405459\charrsid2631653 AMENDMENT DETAIL:}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid2631653 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459\charrsid2631653 Reason for Amendment:\~}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459 \tab \tab }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\caps\f1\fs18\insrsid4405459 correction to clinical history provided}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\caps\f1\fs18\insrsid4405459\charrsid2631653  }{\rtlch\fcs1 \ab\af0 \ltrch\fcs0 \b\insrsid4405459 \par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid2244535 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459\charrsid2244535 R}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459 eport Section Changed:\tab Diagnosis (Comments)}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459\charrsid2244535  \par }\pard \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid6967677 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459\charrsid2244535 \par }\pard \ltrpar\ql \fi-2880\li2880\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin2880\itap0\pararsid11625837 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459 Description of Change: \tab }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\ul\cf2\insrsid4405459 Portion of comment removed due to clarification of patient\rquote s history provided by the treating physician.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\fs18\cf17\insrsid4405459\charrsid2244535 \par }\pard\plain \ltrpar\s17\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid2384879 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 \f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid4405459 \par \par }\pard \ltrpar\s17\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid11625837 {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459\charrsid11625837 Note: This document represents an amended version of the}{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459  Hemato}{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459\charrsid11625837 pathology report originally issued on }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459 12/6/2018. Renier Brentjens, MD}{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459\charrsid11625837  has been notified via e-mail on }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459 12/6/2018}{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459\charrsid11625837 . \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \insrsid4405459\charrsid7682242 \par }\pard\plain \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid7801243 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par 1-3}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\insrsid4405459\charrsid7345479 . }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid7345479 Bone marrow, }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459 left posterior iliac crest,}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid7345479  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459 biopsy,}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid9375557  aspirate and peripheral blood smears:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid7345479  \~\~}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459      }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 - }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 Acute myeloid leukemia, 59% blasts by aspirate differential count, see comment.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\insrsid4405459\charrsid3440157 COMMENTS:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Correlation with concurrent cytogenetic and molecular studies is required for further classification. \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479   \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 BONE MARROW BIOPSY}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Quality:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Excellent.  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Cellularity:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Normocellular for age (~70% cellularity).}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par M:E ratio:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  N/A}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Blasts:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Markedly increased, forming dense clusters and focal sheets.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Myeloid lineage:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Markedly reduced. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Erythroid lineage:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Present and exhibits full maturation.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Megakaryocytes:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Decreased (0-2 per high power field) with few atypical forms (small, mono/hypolobated). }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Lymphocytes:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Scattered. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Plasma cells:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Rare.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Special stains:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid4611041 Reticulin stain shows no }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 increase in reticulin fibrosis}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid4611041 .}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Clot section:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Predominantly blood with few marrow elements showing similar morphology to the biopsy.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 BONE MARROW ASPIRATE SMEAR}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Differential:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  (Performed by HWH)}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192 Blasts \tab \tab \tab 59%\par Promyelocytes \tab \tab 1%\par Myelocytes \tab \tab 1%\par Metamyelocytes \tab \tab 1%\par Neutrophils/Bands \tab 2%\par Eosinophils \tab \tab 2%\par Erythroid Precursors \tab 26%\par Lymphocytes \tab \tab 8%\par Number of Cells Counted }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192 500\par M:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192 E Ratio \tab \tab 0.3}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Morphology:\par Spicular and cellular}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  aspirate smears show a markedly expanded blast population, composed of medium to large cells with oval to slightly irregular nuclei, fine chromatin, prominent nucleoli and scant to moderate cytoplasm with few showing perinuclear hofs. Occasional Auer rods are identified. Maturing myeloid elements are markedly decreased in proportion. Erythroid elements are adequate in proportion and show full maturation with few dyspoietic forms (nuclear irregularity, binucleation). Megakaryocytes are present with predominantly unremarkable morphology.   }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 \par PERIPHERAL BLOOD}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 CBC (12/04/2018}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 ):\par }\pard \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid7801243 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192 WBC 2.7 L [4.0-11.0 K/mcL] \par RBC 3.09 L [3.95-5.54 M/mcL] \par HGB 10.1 L [12.5-16.2 g/dL] \par HCT 28.6 L [37.5-49.3 %] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 MCV}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192  93 [80-98 fL] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 MCH}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192  32.7 [27.0-33.0 pg] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 MCHC}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192  35.3 [31.0-36.5 g/dL] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 RDW}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192  13.5 [12.2-15.1 %] \par Platelets 122 L [160-400 K/mcL] \par \par Neutrophil 14.0 L [32.5-74.8 %] \par Lymph 57.0 H [12.2-47.4 %] \par Mono 2.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Blast 26.0 H [0.0-0.0 %] \par Variant Lymph 1.0 [%] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192 Abs Neut 0.4 L [1.5-7.5 K/mcL] \par Abs Lymph 1.6 [0.9-3.2 K/mcL] \par Abs Mono 0.1 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolut}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 e Basophil 0.0 [0.0-0.2 K/mcL] \par }\pard \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid7801243 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192 Absolute Blasts 0.7 H [0.0-0.0 K/mcL]\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Morphology:\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 WBC: Frequent circulating blasts (26% by differential count) with similar morphology to those of the aspirate smear; absolute neutropenia and relative lymphocytosis.\par RBC: Normocytic, normochromic anemia.\par PLT: Thrombocytopenia. \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 IMMUNOHISTOCHEMISTRY}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 CD34 and CD117 show an expanded blast population (50-60% marrow cellularity). }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid4611041 FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10462)}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid6766448 Expanded abnormal myeloid blast population detected. \par \par The blasts have abnormal expression of CD5 (partial), CD7 (partial), CD13 (absent to intermediate), CD33 (dim), CD34 (variable, dim to intermediate), CD38 (uniform), CD45 (dim), CD71 (partial absent), CD117 (uniform), HLA-DR (absent to intermediate); with normal expression of CD4 and CD123, without CD2, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64. CD34 positive myeloid blasts represent 66.1% of WBC.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459  (F18-10400)}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid13703865 Expanded abnormal myeloid blast population detected. \par No abnormal B and T cell populations detected.\par \par The blasts have abnormal expression of CD5 (partial), CD7 (partial), CD11b (partial), CD13 (absent to dim), CD33 (dim), CD34 (variable, dim to intermediate), CD38 (uniform), CD45 (dim), CD117 (uniform intermediate); with normal expression of CD4, CD71, CD123 and HLA-DR without CD2, sCD3, cCD3, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cCD79a or surface light chains. MPO expression is present on majority of the blasts. CD34 positive myeloid blasts represent 46.7% of WBC.\par CD25 is not expressed by the blasts.\~\~\~\~\~}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 CYTOGENETIC STUDIES}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Cytogenetic analysis will be reported separately. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid7345479 See separate report, CG}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459 18-7507}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid7345479 .}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par \~\par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 MOLECULAR STUDIES}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479  \par Molecular analysis will be reported separately. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459 See separate report, M18-37885, M18-37887, M18-37888, M18-37889}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid7345479 .}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par \par \par }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid7801243 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\af31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid4405459 \par }{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid4405459\charrsid4349262 \hich\af1\dbch\af31505\loch\f1 Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 \hich\af1\dbch\af31505\loch\f1 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin}{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid4405459 \hich\af1\dbch\af31505\loch\f1  }{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid4405459\charrsid4349262 \hich\af1\dbch\af31505\loch\f1 MD.,}{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid4405459 \hich\af1\dbch\af31505\loch\f1  }{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid4405459\charrsid4349262 \hich\af1\dbch\af31505\loch\f1 PhD., Director.\par \par \hich\af1\dbch\af31505\loch\f1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid8093638 \par }\pard \ltrpar\s15\ql \li-180\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin-180\itap0\pararsid7801243 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par }\pard\plain \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid7801243 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid4405459\charrsid13842715 \par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}"
H18-7381;S11;MSK3 - 2023-06-26 12.59.36.ndpi,Peripheral Blood Smear,2023-06-26,"Myelodysplastic Syndrome. Relapsed after transplant, treated with DLI. 
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Hypercellular marrow for age with dysgranulopoiesis, dyserythropoiesis and rare ring sideroblasts, consistent with persistent myelodysplastic syndrome with <5% blasts 

Comment: Dysplasia does not exceed 10% of any lineage, CBC counts are not overtly reduced and only very rare ring sideroblasts are seen. However, the presence of documented SF3B1 mutation, documented mixed chimerism (with evidence of mixed chimerism in myeloid lineage also seen by flow cytometry) supports the diagnosis of at least low level abnormal clone present.  

BONE MARROW BIOPSY
Quality: Suboptimal (small fragmented biopsy)
Cellularity: Hypercellular for age (~60-70%)
M:E ratio: Normal
Blasts: Not increased (<5%) 
Myeloid lineage: Exhibits full maturation 
Erythroid lineage: Exhibits full maturation 
Megakaryocytes: Present in adequate numbers without significant dysplasia
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows no significant increase in reticulin fibers (0/3). 
Clot section: Not submitted. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)
Blasts                1%
Promyelocytes           2%
Myelocytes           8%
Metamyelocytes           5%
Neutrophils/Bands      23%
Monocytes           5%
Eosinophils           2%
Erythroid Precursors      38%
Lymphocytes           16%
Number of Cells Counted 500
M:E Ratio           1.2

Special stain
Iron: Inadequate for evaluation: devoid of spicules
Ring sideroblasts: Rare, <1%

Morphology: The aspirate smears are spicular, cellular and show maturing trilineage hematopoiesis; no expanded blast population is seen. Myeloid elements show full maturation and mild dysgranulopoiesis (hypogranularity, approaching 10%). Erythroid elements show mild dyserythropoiesis (nuclear cytoplasmic dyssynchrony, binucleation, megaloblastic changes, approaching 10%). Megakaryocytes are present and without significant dysplasia.  Mast cells are mildly increased, but do not show significant atypia.

PERIPHERAL BLOOD
CBC (09/20/2018):
WBC 6.5 [4.0-11.0 K/mcL] 
RBC 3.38 L [3.80-5.00 M/mcL] 
HGB 11.5 [11.2-15.4 g/dL] 
HCT 34.5 [34.3-46.0 %] 
MCV 102 H [80-98 fL] 
MCH 34.0 H [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 150 L [160-400 K/mcL] 

Neutrophil 61.5 [32.5-74.8 %] 
Lymph 24.4 [12.2-47.4 %] 
Mono 12.7 H [0.0-12.3 %] 
Eos 0.6 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 4.0 [1.5-7.5 K/mcL] 
Abs Lymph 1.6 [0.9-3.2 K/mcL] 
Abs Mono 0.8 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Morphology:
WBC: Unremarkable morphology. No circulating blasts seen.
RBC: Mild macrocytosis.
PLT: Unremarkable morphology, borderline minimal thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains show no increases in CD34 and/or CD117 positive blasts (<5%). 
CD117 highlights increased mast cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8009)
No definite abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
There is no definite immunophenotypic evidence of a myeloid stem cell disorder by flow cytometry.  No significant immunophenotypic abnormalities are seen on myeloid CD34 positive blasts. However, monocytes show bi-modal CD33 expression with a minor component (dim) consistent with mixed chimerism (donor/host).  Therefore a low level low-grade myelodysplastic syndrome cannot be entirely excluded by these studies.  CD34 positive myeloid blasts represent 0.35% of the white blood cells with expression of CD13, CD33, CD34, CD38, CD45, CD71, CD117 and low CD123.  Normal myelomonocytic maturation is present.
394324 cells acquired. Clinical and morphologic correlation will be required to evaluate for the possibility of MDS. 
Mast cell evaluation will be reported in addendum.
 

Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.



FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5755.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-28952, M18-28956.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6717;S12;MSK6 - 2023-06-26 13.28.54.ndpi,Peripheral Blood Smear,2023-06-26,"MDS/Myelofibrosis. Assess for progression to AML.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent involvement by myeloid neoplasm with increased reticulin fibrosis (MF-3), 5-10% blasts by CD34 immunohistochemistry, and 15% circulating blasts. See comment. 
     - Markedly hypocellular marrow with reduced maturing trilineage hematopoiesis, dysmegakaryopoiesis, and severe fibrosis.

Comment: The patient's myeloid neoplasm was initially classified as myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD). Subsequently a JAK2 V617F mutation had been detected and associated with increasing fibrosis. Current findings are in course of treatment with ruxolitinib, show increased in circulating blasts (15%) indicating progression to MDS with excess blasts-2 and fibrosis (MDS-EB-2-F). Touch imprint smears are inadequate precluding evaluation for ring sideroblasts, dysplasia, and a differential count. The bone marrow biopsy shows ~5-10% blasts by CD34 immunohistology in a markedly hypocellular marrow. Close clinical follow-up is advised.
  
BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypocellular for age (<10% cellularity)
M:E ratio: N/A
Blasts: Mildly increased, best appreciated by immunohistology (see below) 
Myeloid lineage: Markedly reduced 
Erythroid lineage: Markedly reduced
Megakaryocytes: Adequate in number with occasional hyperchromatic forms
Lymphocytes: Scattered 
Plasma cells: Scattered
Clot section: Contains no marrow particles and is inadequate for evaluation.
Others: Stromal changes consistent with fibrosis and hemosiderin deposition present

Special stains: 
Reticulin stain is technically suboptimal but shows increased reticulin fibrosis (difficult to grade accurately due to quality, appears MF-3). 
Trichrome stain shows diffuse deposition of collagen (Grade 3). 

BONE MARROW ASPIRATE SMEAR
The touch imprints are markedly hypocellular. They are suboptimal for evaluation due to virtually absent hematopoietic elements. The differential count is therefore not performed. 

Special stain 
Iron: Suboptimal for evaluation.
Ring sideroblasts: Suboptimal for evaluation due to lack of erythroid elements.

PERIPHERAL BLOOD
CBC (08/27/2018):
WBC 1.9 L [4.0-11.0 K/mcL] 
RBC 2.33 L [3.95-5.54 M/mcL] 
HGB 6.6 L [12.5-16.2 g/dL] 
HCT 20.2 L [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 28.3 [27.0-33.0 pg] 
MCHC 32.7 [31.0-36.5 g/dL] 
RDW 15.1 [12.2-15.1 %] 
Platelets 40 L [160-400 K/mcL] 

Neutrophil 31.0 L [32.5-74.8 %] 
Lymph 41.0 [12.2-47.4 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 
Metamyelocyte 1.0 H [0.0-0.0 %] 
Myelocyte 4.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Blast 15.0 H [0.0-0.0 %] 
Variant Lymph 2.0 [%] 

Abs Neut 0.6 L [1.5-7.5 K/mcL] 
Abs Lymph 0.8 L [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Absolute Blasts 0.3 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 7 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Few circulating blasts are seen (15% by manual differential). Blasts are large in size, with round to irregular nuclei fine chromatin, occasional prominent nucleoli, and scant cytoplasm.  Leukopenia with neutropenia, lymphopenia, and mild relative basophilia. Immature granulocytes (metamyelocytes, myelocytes and promyelocytes) are seen. 
RBC: Normochromic, normocytic anemia. 
PLT: Thrombocytopenia with occasional large forms. 

IMMUNOHISTOCHEMISTRY
CD34 shows ~5-10% blasts in a markedly hypocellular marrow.
CD34 also highlights increased vasculature. 
CD117 highlights scattered mast cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW
Not requested 

CYTOGENETIC STUDIES
Not requested

MOLECULAR STUDIES 
Not requested


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-9986;S11;MSKF - 2023-04-25 09.14.44.ndpi,Peripheral Blood Smear,2023-04-25,"MF. Newly diagnosed. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Hypercellular marrow with erythroid-predominant maturing trilineage hematopoiesis, megakaryocytic hyperplasia and significant atypia, moderate myelofibrosis (MF-2), and no increase in blasts, compatible with involvement by a myeloproliferative neoplasm (MPN). See comment. 
  
COMMENT: Based on the megakaryocytic morphology, primary myelofibrosis (PMF) is favored. While the observed erythroid predominance is less common in this entity, its presence does not exclude this diagnosis. However, based on the WHO criteria, demonstration of a clonal marker (such as JAK2, CALR, or MPL mutations) is required for this diagnosis. Furthermore, clinical correlation is needed to exclude the possibility of a prior polycythemia vera (PV) or essential thrombocytosis (ET). In addition, the diagnosis of overt fibrotic phase of PMF requires presence of one minor criterion that must be confirmed in two consecutive determinations (elevated LDH, anemia, leukocytosis, palpable splenomegaly, or leukoerythroblastosis). By clinical notes, the patient has had documented elevated LDH since March, which would satisfy this requirement. Clinical correlation with the forthcoming molecular and cytogenetic studies is needed.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (~95% cellularity) 
M:E ratio: Decreased 
Blasts: Not overtly increased 
Myeloid lineage: Relatively decreased, actively maturing
Erythroid lineage: Relatively increased, actively maturing
Megakaryocytes: Increased in number with focal tight clustering, and frequent markedly atypical forms (hyperchromatic nuclei, hyperlobated and hypolobated forms, bulbous nuclei, forms with high nuclear to cytoplasmic ratio)
Lymphocytes: Scattered 
Plasma cells: Rare
Others: Sinusoids are dilated and intra-sinusoidal hematopoiesis is present. 
Special stains: Reticulin stain shows at least moderate increase in reticulin fibrosis (MF-2).
Trichrome stain shows focal paratrabecular and central collagen deposition with no connecting meshwork (Grade 1).  

BONE MARROW ASPIRATE SMEAR
Differential: (Performed on touch imprint: SS)
Blasts                3%
Promyelocytes           3%
Myelocytes           8%
Metamyelocytes           8%
Neutrophils/Bands      30%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      40%
Lymphocytes           6%
Number of Cells Counted  500
M:E Ratio           1.3

Morphology:
Aspicular, hemodilute and hypocellular aspirate smears and touch imprint show maturing trilineage hematopoiesis with no overt increase in blasts. Myeloid elements are mildly decreased and show full maturation without overt dysplasia. Erythroid elements are relatively increased and show full maturation and mild atypia (nuclear irregularity and karyorrhexis). Megakaryocytes are present and show occasional hypolobated forms. Platelet clumps are seen.

PERIPHERAL BLOOD
CBC (12/19/2018):
WBC 3.2 L [4.0-11.0 K/mcL] 
RBC 3.06 L [3.95-5.54 M/mcL] 
HGB 7.6 L [12.5-16.2 g/dL] 
HCT 24.1 L [37.5-49.3 %] 
MCV 79 L [80-98 fL] 
MCH 24.8 L [27.0-33.0 pg] 
MCHC 31.5 [31.0-36.5 g/dL] 
RDW 20.8 H [12.2-15.1 %] 
Platelets 298 [160-400 K/mcL] 

Neutrophil 85.0 H [32.5-74.8 %] 
Lymph 14.0 [12.2-47.4 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 

Abs Neut 2.7 [1.5-7.5 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 3 [/100(WBCs)]

Morphology:
WBC: No circulating blasts seen. Leukopenia with lymphopenia and relative neutrophilia.
RBC: Hypochromic anemia with anisopoikilocytosis, frequent tear-drop cells, and polychromasia; few nucleated RBCs present. 
PLT: Adequate in number, occasional large forms seen. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts (<5% of marrow cellularity).
CD117 also highlights scattered erythroid precursors and mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10960)
No definite abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
No abnormal mature B- or T-cell populations detected.

There is no definite immunophenotypic evidence of a myeloid stem cell disorder by flow cytometry. However, in light of the myeloid blasts with expression of CD7 (negative to dim) and CD56 (minute subset dim), along with reduction of CD71 a low-grade myelodysplastic syndrome cannot be entirely excluded by these studies. CD34 positive myeloid blasts represent 0.73% of the white blood cells. Normal myelomonocytic maturation is present. 348514 cells acquired. Clinical and morphologic correlation will be required to evaluate for the possibility of MDS or MPN. Cytogenetic analysis is also recommended to rule out a clonal stem cell abnormality. 
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7857.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-39888.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6286;S2;MSK6 - 2023-04-19 16.08.29.ndpi,Peripheral Blood Smear,2023-04-19,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears:
      - B lymphoblastic leukemia/lymphoma, (91% blasts by aspirate differential). 
 
BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                91%
Neutrophils/Bands      3%
Monocytes           1%
Lymphocytes           5%
Number of Cells Counted 500
M:E Ratio           N/A

Morphology:
Aspicular and hypercellular aspirate smears show markedly expanded blast population, which are small to medium in size, with fine chromatin, inconspicuous nucleoli and scant basophilic cytoplasm with vacuoles. Trilineage hematopoiesis is virtually absent.

PERIPHERAL BLOOD
CBC (08/10/2018):

WBC 5.4 L [7.1-15.9 K/mcL] 
RBC 2.73 L [3.89-5.03 M/mcL] 
HGB 7.8 L [10.7-14.5 g/dL] 
HCT 22.3 L [32.2-43.5 %] 
MCV 82 [74-91 fL] 
MCH 28.6 [22.7-29.5 pg] 
MCHC 35.0 [31.0-36.5 g/dL] 
RDW 15.3 H [12.2-15.1 %] 
Platelets 45 L [160-400 K/mcL] 

Neutrophil 36.0 [16.9-74.5 %] 
Lymph 45.0 [15.5-57.8 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %]
 
Abs Neut 1.9 [1.5-8.5 K/mcL] 
Abs Lymph 2.4 [1.0-4.3 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL]
 
Metamyelocyte 3.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Blast 9.0 H [0.0-0.0 %] 

Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Absolute Blasts 0.5 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 1 [/100(WBCs)] 

Morphology:
WBC: Circulating blasts seen.
RBC: Normocytic and normochromic anemia.
PLT: Thrombocytopenia. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-6745)
Abnormal immature B-cell population detected.
The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (75.2% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD10 (variable, dim to negative), CD19 (bright), CD34 (negative), CD38 (slightly dim), CD45 (dim to negative), with normal expression of CD58, cyCD79a, CD71 and HLA-DR; and without CD2, sCD3, cCD3, CD4, CD5, CD7, CD8, CD11b, CD13, CD14, CD15, CD16, CD20, CD25, CD33, CD56, CD64, CD117, CD123 or MPO.

No abnormal mature T-cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.15% of WBC.
243863 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-4830, CG18-4831.

MOLECULAR STUDIES 
Not available


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. Pessin MD., PhD., Director.
"
H18-7498;S11;MSKB - 2023-06-26 21.38.22.ndpi,Peripheral Blood Smear,2023-06-26,"Leukemia. History of breast cancer, status post chemo, persistent with new leukemia. 
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - T-lymphoblastic leukemia/lymphoma.
     - Hypercellular marrow with scant residual hematopoiesis and no evidence of metastatic carcinoma
 
Comment: Disease may be therapy-related given prior treatment for breast cancer. It is not entirely clear if prior therapy affects prognosis in T-ALL.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Increased (90%)
M:E ratio: N/A
Blasts: Markedly increased, diffusely replacing bone marrow
Myeloid lineage: Scant maturation
Erythroid lineage: Scant maturation
Megakaryocytes: Few seen
Lymphocytes: No aggregates seen
Plasma cells: Few seen.
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blasts                72%
Neutrophils/Bands      1%
Erythroid Precursors      1%
Lymphocytes           26%
Number of Cells Counted 500
M: E Ratio           1

No extrinsic cells seen.


Morphology:
-Spicular and cellular aspirates show markedly increased blasts (large to small with variably prominent nucleoli). Residual hematopoiesis is markedly reduced. 

PERIPHERAL BLOOD
CBC (09/24/2018):
WBC 10.8 [4.0-11.0 K/mcL] 
RBC 2.82 L [3.80-5.00 M/mcL] 
HGB 8.4 L [11.2-15.4 g/dL] 
HCT 26.4 L [34.3-46.0 %] 
MCV 94 [80-98 fL] 
MCH 29.8 [27.0-33.0 pg] 
MCHC 31.8 [31.0-36.5 g/dL] 
RDW 13.0 [12.2-15.1 %] 
Platelets 85 L [160-400 K/mcL] 

Neutrophil 24.0 L [32.5-74.8 %] 
Lymph 30.0 [12.2-47.4 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Abs Neut 2.6 [1.5-7.5 K/mcL] 
Abs Lymph 3.2 [0.9-3.2 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Metamyelocyte 4.0 H [0.0-0.0 %] 
Blast 38.0 H [0.0-0.0 %] 
Abs Meta 0.4 H [0.0-0.0 K/mcL] 
Absolute Blasts 4.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 1 [/100(WBCs)]

Morphology: Numerous blasts present. Pancytopenia

IMMUNOHISTOCHEMISTRY
Blasts are negative for CD34 and CD117

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8145)
T-lymphoblastic leukemia/lymphoma.
No abnormal B cell population detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

The presence of greater than 20% abnormal immature T-cells in the bone marrow (96.0% of the total white cells) is diagnostic for T-lymphoblastic leukemia/lymphoma (T-ALL) by WHO criteria. The blasts have abnormal expression of CD2 (absent to intermediate), CD7 (dim to bright), CD8 (partial dim), CD10 (partial dim), CD34 (absent), CD45 (bimodal, absent to bright), CD48 (dim to absent); with normal expression of cyCD3, CD4, CD5, CD38 and CD71; and without sCD3, CD11b, CD13, CD14, CD15, CD16, CD19, CD20, CD33, CD56, CD64, CD117, CD123, HLA-DR or surface light chains.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.044% of WBC.
466,518 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5849.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-29428, M18-29429, M18-29431, M18-29432, M18-29433.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6392;S12;MSK5 - 2023-06-26 22.24.39.ndpi,Peripheral Blood Smear,2023-06-26,"Leukemia, chronic myeloid. Evaluate for MDS/AML. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Mildly hypercellular marrow with trilineage maturing hematopoiesis, mild dyspoietic changes, and ring sideroblasts (4%). 

See comment.
  
COMMENT: Mild multilineage dyspoiesis seen in the marrow does not fulfill the morphologic diagnostic criteria for myelodysplastic syndrome (MDS). Reported SF3B1 mutation detected (M18-29151) in peripheral blood along with the marrow findings may represent a clonal cytopenia of undetermined significance (CCUS). Suggest close patient follow up with serial CBC's and a new marrow biopsy/aspirate at an interval to evaluate for possible evolution into a MDS. Correlation with cytogenetic studies is also recommended. 

In addition, some of the morphologic findings such as small hypolobated megakaryocytes may be due to patient's known chronic myeloid leukemia (CML). Suggest correlation with BCR-ABL1 status. 

Flow cytometry studies show two abnormal B-cell populations (0.037% (kappa restricted) and 0.027% (lambda restricted) of WBC) which likely represent monoclonal B cell lymphocytosis (MBL). Suggest correlation with clinical findings.


BONE MARROW BIOPSY
Quality: Small subcortical biopsy
Cellularity: Mildly hypercellular for age, 50%
M:E ratio: Normal 
Blasts: Not increased
Myeloid lineage: Exhibit full maturation 
Erythroid lineage: Exhibit full maturation
Megakaryocytes: Mildly increased with frequent small hypolobated and occasional forms with widely separated nuclei
Lymphocytes: Scattered
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 
Clot section: Predominantly blood

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by AS)

Blasts                1%
Promyelocytes           2%
Myelocytes           17%
Metamyelocytes           8%
Neutrophils/Bands      30%
Monocytes           3%
Eosinophils           4%
Erythroid Precursors      22%
Plasma Cells           1%
Lymphocytes           12%
Number of Cells Counted  500
M:E Ratio           2.9

Special stain
Iron: Present
Ring sideroblasts: Present; 4%

Morphology:
Spicular and cellular aspirate smears show trilineage maturing hematopoiesis with no increased blasts. Myeloid elements show full maturation with occasional hypogranular forms. Erythroid elements show full maturation with mild dyspoietic changes including binucleation and nuclear budding (<10%). Megakaryocytes are present and show few small hypolobated forms. 

PERIPHERAL BLOOD
CBC (08/10/2018):
WBC 9.1 [4.0-11.0 K/mcL] 
RBC 2.98 L [3.95-5.54 M/mcL] 
HGB 9.6 L [12.5-16.2 g/dL] 
HCT 29.7 L [37.5-49.3 %] 
MCV 100 H [80-98 fL] 
MCH 32.2 [27.0-33.0 pg] 
MCHC 32.3 [31.0-36.5 g/dL] 
RDW 14.2 [12.2-15.1 %] 
Platelets 253 [160-400 K/mcL] 

Neutrophil 72.4 [32.5-74.8 %] 
Lymph 9.9 L [12.2-47.4 %] 
Mono 12.2 [0.0-12.3 %] 
Eos 4.7 [0.0-4.9 %] 
Baso 0.3 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 6.6 [1.5-7.5 K/mcL] 
Abs Lymph 0.9 [0.9-3.2 K/mcL] 
Abs Mono 1.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Morphology:
WBC: Few large granular lymphocytes and hypogranular neutrophils seen. No circulating blasts.
RBC: Macrocytic RBCs.
PLT: Few large forms seen. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increased blasts (<2%). CD34 also highlights a subset of the megakaryocytes. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-6848)
Abnormal myeloid blast population detected. 
Two abnormal B-cell populations identified.
No abnormal mature T-cell population detected.

The blasts have abnormal expression of CD33 (dim), HLA-DR (subset absent), with normal expression of CD4, CD13, CD34, CD38, CD45, CD71, CD117 and CD123 without CD2, CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 1.2% of WBC.

Flow cytometry reveals an abnormal B-cell population having abnormal expression of CD5, CD20 (dim), CD22 (dim) and kappa surface light chain restriction (dim); normal expression of CD19, CD38 and CD45; and without CD10 expression. In addition, another abnormal B cell population with similar immunophenotype as the first abnormal B cell population but with lambda light chain restriction detected. Both the populations show CD23 and CD200 (variable) expression and without FMC7. The immunophenotype is consistent with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or CLL-like monoclonal B-cell lymphocytosis. The abnormal B-cell population comprises 0.037% (kappa restricted) and 0.027% (lambda restricted) of the white cells.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-4929.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-24836.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7175;S21;MSK5 - 2023-04-17 12.45.06.ndpi,Peripheral Blood Smear,2023-04-17,"AML. New leukemia. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Hypocellular marrow with erythroid predominance, reduced myeloid and megakaryocytic elements and increased blasts (34% by aspirate differential count), consistent with acute myeloid leukemia.   

See comment.

Comment: History of breast cancer s/p AC/taxol treatment is noted. The findings would be consistent with therapy related myeloid neoplasm, blast count in the range of therapy related acute myeloid leukemia (t-AML) if this . Suggest correlation with clinical findings and genetic studies. 

BONE MARROW BIOPSY
Quality: Fragmented with aspiration artifact 
Cellularity: Acellular to hypocellular for age (approximately 5-10%)
M:E ratio: Reduced
Blasts: Increased. 
Myeloid lineage: Reduced. 
Erythroid lineage: Predominant
Megakaryocytes: Rare
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HH)

Blasts                34%
Promyelocytes           1%
Myelocytes           2%
Metamyelocytes           2%
Neutrophils/Bands      3%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      32% 
Plasma Cells           1%
Lymphocytes           23%
Number of Cells Counted 500
M:E Ratio           0.3

Morphology:
The aspirate smears are spicular and cellular and show an expanded population of small to large sized blasts in a background of erythroid predominant hematopoiesis. Erythroid elements show dysplastic changes. Myeloid elements are markedly reduced and show maturation. Rare megakaryocytes seen.

PERIPHERAL BLOOD
CBC (09/13/2018):
WBC 2.4 L [4.0-11.0 K/mcL] 
RBC 1.94 L [3.80-5.00 M/mcL] 
HGB 6.9 L [11.2-15.4 g/dL] 
HCT 20.0 L [34.3-46.0 %] 
MCV 103 H [80-98 fL] 
MCH 35.6 H [27.0-33.0 pg] 
MCHC 34.5 [31.0-36.5 g/dL] 
RDW Not Measured [12.2-15.1 %] 
Platelets 14 LL [160-400 K/mcL]  

Neutrophil 15.0 L [32.5-74.8 %] 
Lymph 84.0 H [12.2-47.4 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 0.4 L [1.5-7.5 K/mcL] 
Abs Lymph 2.0 [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Leukopenia. 
RBC: Anemia with moderate anisopoikilocytosis. 
Platelet: Thrombocytopenia. 

IMMUNOHISTOCHEMISTRY.
CD117 and CD34 highlight the blasts (approximately 50-60% of cellularity).

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7792)
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD7 (partial), CD13 (uniform bright), CD33 (uniform dim), CD34 (uniform bright), CD38 (dim to absent), CD123 (uniform bright), HLADR (bright) with normal expression of CD4, CD45, CD71, CD117; without CD2, sCD3, cCD3, convincing CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cCD79a or surface light chains. MPO expression is present on a minor subset of blasts. CD34 positive myeloid blasts represent 19.0% of WBC.
CD25 is not expressed by the blasts.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F18-7765)
Abnormal myeloid blast population detected.
No abnormal mature B- or T-cell populations detected.

Flow cytometry identifies an abnormal myeloid blast population have abnormal expression of CD13 (bright), CD33 (dim to negative), CD38 (negative), HLA-DR (bright) with normal expression of CD4, CD34, CD45, CD71, CD117, and CD123 without CD2, CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 1.7% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5586.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-28178, M18-28179, M18-28180, M18-28181.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6163;S12;MSK1 - 2023-07-06 08.15.46.ndpi,Peripheral Blood Smear,2023-07-06,"Multiple Myeloma.  Newly diagnosed.
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
20% involvement by CD138 immunohistochemistry.
21% involvement by aspirate differential
4.9% involvement by 10-color flow cytometry
     - Cellular marrow with trilineage maturing hematopoiesis.


BONE MARROW BIOPSY
Quality:  Limited biopsy with hemorrhage
Cellularity: Less than 10%
Myeloid lineage: Present
Erythroid lineage:Present
Megakaryocytes:  Present
Plasma cells: Increased 
Other findings: Mainly peripheral blood elements

ASPIRATE MORPHOLOGY

Aspirate differential: (Performed by: HWH)

Promyelocytes           1%
Myelocytes           8%
Metamyelocytes           6%
Neutrophils/Bands      28%
Monocytes           2%
Eosinophils           4%
Erythroid Precursors      26%
Plasma Cells           21% 
Lymphocytes           4%
Number of Cells Counted  500
M: E Ratio           1.9

Morphology: 
Marrow spicules: Spicular    
Cellularity: Hypocellular
Plasma cell morphology: Intermediate to large in size, atypical plasma cells with binucleation, nucleoli, Dutcher bodies (nuclear pseudo-inclusion), Russel bodies (cytoplasmic inclusions)
Myeloid lineage: Orderly maturation  
Erythroid Lineage: Orderly maturation 
Megakaryocytes:  Present 

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, 20% of cellularity. 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.  
BCMA highlights 90% of plasma cells, (2+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-6591) 
Abnormal plasma cell population detected.
No abnormal mature B-cell population detected.

Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (absent), CD27 (absent), CD38 (dim), CD45 (absent), CD56 (bright), CD81 (dim) and monoclonal kappa cytoplasmic light chain restriction; with normal expression of CD138; and without CD20 or CD117 expression.  The abnormal population represents 4.9% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 95.7% of total plasma cells in the sample.

No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

PERIPHERAL BLOOD
CBC (08/07/2018):
WBC 5.2 [4.0-11.0 K/mcL] 
RBC 3.93 [3.80-5.00 M/mcL] 
HGB 12.5 [11.2-15.4 g/dL] 
HCT 38.1 [34.3-46.0 %] 
MCV 97 [80-98 fL] 
MCH 31.8 [27.0-33.0 pg] 
MCHC 32.8 [31.0-36.5 g/dL] 
RDW13.2 [12.2-15.1 %] 
Platelets 345 [160-400 K/mcL] 

Neutrophil 76.2 H [32.5-74.8 %] 
Lymph 14.2 [12.2-47.4 %] 
Mono 7.2 [0.0-12.3 %] 
Eos 1.4 [0.0-4.9 %] 
Baso 0.8 [0.0-1.5 %] 
Immature Granulocyte 0.2 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 3.9 [1.5-7.5 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Morphology: No circulating plasma cells. Rouleaux formation noted.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-4734, CG18-4735.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-23960.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-10005;S11;MSKJ - 2023-03-24 00.34.32.ndpi,Peripheral Blood Smear,2023-04-25,"ALL.  Newly diagnosed.
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma (B-ALL) with t(9;22); BCR-ABL1, 96% blasts by aspirate differential count. See comment.
  
COMMENT: FISH studies (CG18-7851) performed on the peripheral blood revealed BCR-ABL1 fusion/ t(9;22), diagnostic for this subtype of B-ALL. The morphologic findings are similar to a recent right-sided biopsy (H18-9966; 12/18/18). 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypercellular for age (100% cellularity)
M:E ratio: N/A
Blasts: Markedly increased present as sheets nearly completely replacing the marrow cellularity; blasts are predominantly medium in size, with oval to slightly irregular nuclei, open chromatin, predominantly inconspicuous nucleoli, and scant cytoplasm. 
Myeloid lineage: Markedly decreased 
Erythroid lineage: Markedly decreased 
Megakaryocytes: Markedly decreased to absent 
Lymphocytes: Rare, scattered 
Plasma cells: Rare
Clot section: Rare minute marrow particles showing similar morphology as the core biopsy. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH on touch imprint)
Blasts                96%
Erythroid Precursors      1%
Lymphocytes           3%
Number of Cells Counted  500
M: E Ratio           NA

Morphology:
Aspicular and cellular aspirate smears and touch imprint show a markedly expanded population of blasts, which are predominantly medium in size, with round to slightly irregular nuclei, fine chromatin, predominantly indistinct nucleoli, and scant basophilic cytoplasm. Auer rods are not seen. Background hematopoiesis is virtually absent. Rare erythroid cells are seen. Megakaryocytes are not identified. Rare mature appearing lymphocytes are seen.

PERIPHERAL BLOOD
CBC (12/19/2018):
WBC 4.2 [4.0-11.0 K/mcL] 
RBC 3.41 L [3.80-5.00 M/mcL] 
HGB 10.2 L [11.2-15.4 g/dL] 
HCT 29.9 L [34.3-46.0 %] 
MCV 88 [80-98 fL] 
MCH 29.9 [27.0-33.0 pg] 
MCHC 34.1 [31.0-36.5 g/dL] 
RDW 17.9 H [12.2-15.1 %] 
Platelets 10 LL [160-400 K/mcL]  

Neutrophil 13.0 L [32.5-74.8 %] 
Lymph 61.0 H [12.2-47.4 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Blast 20.0 H [0.0-0.0 %]

Abs Neut 0.5 L [1.5-7.5 K/mcL] 
Abs Lymph 2.6 [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL]
Abs Promyelocytes 0.0 [0.0-0.0 K/mcL] 
Absolute Blasts 0.8 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 7 [/100(WBCs)]

Morphology:
WBC: Frequent circulating blasts present which are morphologically similar to those on aspirate smears; neutropenia and relative lymphocytosis.  
RBC: Normocytic and normochromic anemia with anisocytosis; increased reticulocytes; and few nucleated RBCs present. 
PLT: Marked thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD34 and TdT are positive in blasts, which are present in diffuse sheets and account for 95% of the marrow cellularity.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10986)
Abnormal immature B-cell population detected.
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (60.6% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD8 (subset), CD10 (intermediate to bright), CD13 (partial dim), CD20 (subset dim), CD25 (partial, greater than 10% of blasts), CD33 (partial), CD34 (bright), CD38 (absent), CD45 (major subset absent, minor subset dim), CD56 (partial), and CD123 (partial); with normal expression of CD19,CD58, cyCD79a, and HLA-DR; and without CD2, sCD3, cyCD3, CD4, CD5, CD7, CD11b, CD14, CD15, CD16, CD64, CD71, CD117, or MPO.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

CD34 positive myeloid blast population with apparent normal immunophenotype is 1.2% of WBC.
292,104 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7880.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M18-39946, M18-39947, and M18-36649.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6632;S11;MSK1 - 2023-06-28 22.31.23.ndpi,Peripheral Blood Smear,2023-06-28,"Thrombocytopenia, rule out MDS. 
","1-2. Bone marrow, right posterior iliac crest, biopsy and smears: 
     - Overall normocellular marrow with maturing trilineage hematopoiesis, mild myeloid left-shifted maturation, and mild atypia in megakaryopoiesis and granulopoiesis.
     - No diagnostic morphologic or immunophenotypic evidence of involvement by previously diagnosed classical Hodgkin lymphoma.

COMMENT: Mild atypia is noted in megakaryocytes and the granulocytic lineage, which are not diagnostic for myelodysplastic syndrome (MDS) based on morphology alone. There is no increase in blasts and no significant ring sideroblasts are noted. The morphologic findings are overall similar to those reported in a prior bone marrow sampling from 6/15/16 (H16-3909). Correlation with the forthcoming cytogenetic and molecular analyses is needed for a complete diagnostic evaluation. Other causes of persistent thrombocytopenia should also be explored, such as autoimmune etiologies or medication.
No diagnostic evidence of involvement by previously diagnosed classical Hodgkin lymphoma.

Reviewed at Hematopathology service consensus conference on 8/27/18 with all in agreement.

BONE MARROW BIOPSY
Quality: Adequate with partial aspiration and hemorrhage
Cellularity: Appears overall normocellular to mildly hypocellular for age (60% cellularity) 
M:E ratio: Normal 
Blasts: Not increased 
Myeloid lineage: Exhibit progressive maturation 
Erythroid lineage: Exhibit progressive maturation
Megakaryocytes: Adequate in number and show occasional atypical forms (small hypolobated and those nuclear hyperchromasia)
Lymphocytes: Scattered 
Plasma cells: Scattered 

Special stains: 
Reticulin stain shows no increase in reticulin fibrosis (MF-0). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Blasts                3%
Promyelocytes           6%
Myelocytes           15%
Metamyelocytes           10%
Neutrophils/Bands      21%
Monocytes           4%
Eosinophils           5%
Basophils           1%
Erythroid Precursors      21%
Plasma Cells           4%
Lymphocytes           10%
Number of Cells Counted  500
M:E Ratio            3

Special stain
Iron: Present
Ring sideroblasts: Rare present, <1%

Morphology:
Spicular and cellular aspirate smears show maturing trilineage hematopoiesis with no increase in blasts. The M:E ratio is normal. Erythroid elements show progressive maturation with occasional atypical forms, including late stage mitoses, karyorrhexis, and nuclear irregularities. Myeloid elements show mild left shift with occasional hypogranular and hypolobated granulocytic forms. Megakaryocytes are present and show occasional atypical forms (small with nuclear hypolobation). Few scattered small mature-appearing lymphocytes are seen. Scattered plasma cells are present.

PERIPHERAL BLOOD
CBC (08/14/2018):
WBC 7.0 [4.0-11.0 K/mcL] 
RBC 3.86 [3.80-5.00 M/mcL] 
HGB 12.1 [11.2-15.4 g/dL] 
HCT 36.2 [34.3-46.0 %] 
MCV 94 [80-98 fL] 
MCH 31.3 [27.0-33.0 pg] 
MCHC 33.4 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 88 L [160-400 K/mcL] 

Neutrophil 43.7 [32.5-74.8 %] 
Lymph 43.6 [12.2-47.4 %] 
Mono 6.6 [0.0-12.3 %] 
Eos 5.6 H [0.0-4.9 %] 
Baso 0.4 [0.0-1.5 %] 
Immature Granulocyte 0.1 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Nucleated RBC 0.0 [%] 

Abs Neut 3.0 [1.5-7.5 K/mcL] 
Abs Lymph 3.0 [0.9-3.2 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.4 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

WBC: No circulating blasts seen. Mild relative eosinophilia. Large granular lymphocytes are seen. 
RBC: Normochromic, normocytic RBCs.
Platelets: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increased blasts (<5% cellularity).
CD117 also highlights scattered mast cells.
CD61 highlights megakaryocytes which are adequate in number.  
CD138 highlights few scattered plasma cells which are polytypic by kappa and lambda immunostains. 
CD30 is negative.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7130)
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified. Hodgkin lymphoma would not be detected by these studies.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.63% of WBC.

330,456 cells acquired for myeloid analysis.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5131.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-25860.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6795;S12;MSKB - 2023-04-17 12.12.04.ndpi,Peripheral Blood Smear,2023-04-17,"AML.  Anemia with peripheral blasts, new diagnosis of acute leukemia.
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia (AML) (80% blasts by aspirate differential count), See Comment
     - Markedly hypercellular marrow with reduced myeloid and erythroid hematopoiesis, increased megakaryopoiesis, dysmegakaryopoiesis, and mild to focally moderate fibrosis. 

COMMENT: Per conversion with Dr. M. Mauro, the patient has no prior history of chemotherapy treatment. The marrow is extensively involved by AML with markedly reduced myelo- and erythropoiesis, limiting confident evaluation of dysplasia in these two lineages. Significant dysmegakaryopoiesis (>50%) and borderline dysgranulopoiesis (~50%) is present, which may suggest that this AML represents AML with myelodysplasia-related changes (AML-MRC). However, correlation with cytogenetic findings is needed. In addition, correlation with molecular genetic studies is necessary for definitive classification of this AML, as presence of NPM1 mutations (suspected in this case based on the immunoprofile) and biallelic CEBPA mutations can similarly present with multilineage dysplasia.

Case reviewed with Dr. M. Mauro at the microscope on 8/31/18.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Markedly hypercellular for age (>95% cellularity) 
M:E ratio: N/A
Blasts: Markedly increased and nearly replacing the marrow. Present in sheets, composed of medium to large size blasts, with oval to irregular nuclei, fine chromatin, single to multiple prominent nucleoli, and scant cytoplasm.   
Myeloid lineage: Markedly reduced 
Erythroid lineage: Markedly reduced
Megakaryocytes: Increased in number with frequent dysplastic forms (>50%, small hypolobated, separation of nuclear lobes, forms with hyperchromatic or hyperlobated nuclei) 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Clot section: Adequate, with morphology similar to that on the core biopsy.

Special stains: 
Reticulin stain shows mild to focally moderate increase in reticulin fibrosis (MF-1 to focal MF-2). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                80% 
Promyelocytes           1%
Myelocytes           1%
Neutrophils/Bands      5%
Eosinophils           1%
Erythroid Precursors      3%
Plasma Cells           1%
Lymphocytes           8%
Number of Cells Counted  500
M:E Ratio           N/A

Morphology:
Spicular and hypercellular smears show a markedly expanded population of blasts, which are medium to large in size, with oval to slightly irregular nuclei, fine chromatin, single to multiple prominent nucleoli, and scant to moderate basophilic to amphophilic cytoplasm.  Occasional blasts shows minute area of perinuclear clearing. Rare short Auer rods are seen. Myeloid elements are markedly reduced with borderline evidence of dyspoiesis (~50%, hyposegmented forms, hypogranular neutrophils and occasional pseudo-Pelger-Huët neutrophils). Erythroid elements are markedly reduced limiting evaluation of dysplasia. Megakaryocytes are present with frequent dysplastic forms (small and large, hypo- and hyperlobated forms). 

PERIPHERAL BLOOD
CBC (08/29/2018):
WBC 8.5 [4.0-11.0 K/mcL] 
RBC 2.00 L [3.80-5.00 M/mcL] 
HGB 6.9 L [11.2-15.4 g/dL] 
HCT 19.5 L [34.3-46.0 %] 
MCV 98 [80-98 fL] 
MCH 34.5 H [27.0-33.0 pg] 
MCHC 35.4 [31.0-36.5 g/dL] 
RDW 18.0 H [12.2-15.1 %] 
Platelets 148 L [160-400 K/mcL] 

Neutrophil 18.0 L [32.5-74.8 %] 
Lymph 50.0 H [12.2-47.4 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 31.0 H [0.0-0.0 %] 

Abs Neut 1.5 [1.5-7.5 K/mcL] 
Abs Lymph 4.3 H [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Blasts 2.6 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 1 [/100(WBCs)] 

Morphology:
WBC: Many circulating blasts morphologically similar to those seen in the aspirate smears. Absolute neutropenia and relative lymphocytosis; few hypogranular neutrophils present.
RBC: Normocytic and hyperchromic anemia with mild anisopoikilocytosis.
PLT: Occasional large platelets seen.   

IMMUNOHISTOCHEMISTRY
CD117 highlights sheets of blasts comprising ~80% of marrow cellularity. The blasts are negative for CD34. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7330)
Interpretation: 
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

The blasts show a similar immunophenotype as prior (F18-7261) having abnormal expression of CD7 (partial), CD19 (partial), CD25 (partial, >10% of blasts), CD33 (bright), CD34 (absent), CD38 (variable, bright to absent), CD71 (bright), and CD123 (intermediate to bright); with normal expression of CD4, CD13, CD45, CD117, and HLA-DR; without CD2, sCD3, cCD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD20, CD56, CD64, CD79a or surface light chains. MPO expression is present on all the blasts. CD117 positive myeloid blasts represent 74.6% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F18-7261, 8/28/18)
Interpretation: 
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD7, CD19 (partial), CD25 (85% of blasts), CD33 (bright), CD34 (negative), CD123 (bright), HLA-DR (bright), with normal expression of CD4, CD13, CD38, CD45, CD71 and CD117, without CD2, sCD3, cCD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD56, CD64, cCD79a or surface light chains. MPO expression is present on all of blasts. CD117 positive myeloid blasts represent 57.8% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5272.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M18-26518, M18-26520.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-7792;S10;MSKH - 2023-04-25 19.47.38.ndpi,Peripheral Blood Smear,2023-04-25,"Leukemia, Acute Lymphoid. New acute leukemia. 
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - B lymphoblastic leukemia/lymphoma, approximately 90% blasts by CD34 and TdT immunohistochemistry.

BONE MARROW BIOPSY
Quality: Excellent. 
Cellularity: Markedly hypercellular (>90%).
M:E ratio: N/A.
Blasts: Sheets of large blasts with small amounts of cytoplasm, round nuclei, fine chromatin and distinct nucleoli. 
Myeloid lineage: Markedly reduced. 
Erythroid lineage: Markedly reduced. 
Megakaryocytes: Markedly reduced. 
Lymphocytes: Scattered. 
Plasma cells: Scattered. 
Special stains: A reticulin stain shows a mild increase in reticulin fibers (1+/3).  
Clot section: Not submitted. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by AS)

Blasts                67%
Promyelocytes           1%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      6%
Monocytes           1%
Eosinophils           0%
Erythroid Precursors      2%
Plasma Cells           0%
Lymphocytes           21%
Number of Cells Counted 500
M:E Ratio           6

Morphology: The aspirate smears are spicular and cellular and show a markedly expanded population of medium sized blasts with scant cytoplasm, round nuclei, fine chromatin and distinct nucleoli, in a background of markedly decreased trilineage hematopoiesis. Smaller more mature appearing lymphocytes are also seen.  

PERIPHERAL BLOOD
CBC (10/03/2018):
WBC 52.6 H [4.0-11.0 K/mcL] 
RBC 3.60 L [3.80-5.00 M/mcL] 
HGB 10.9 L [11.2-15.4 g/dL] 
HCT 32.5 L [34.3-46.0 %] 
MCV 90 [80-98 fL] 
MCH 30.3 [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 14.6 [12.2-15.1 %] 
Platelets 65 L [160-400 K/mcL] 

Neutrophil 11.0 L [32.5-74.8 %] 
Lymph 8.0 L [12.2-47.4 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 

Abs Neut 5.8 [1.5-7.5 K/mcL] 
Abs Lymph 4.7 H [0.9-3.2 K/mcL] 
Abs Mono 4.2 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.5 H [0.0-0.2 K/mcL] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 

Blast 69.0 H [0.0-0.0 %] 
Variant Lymph 1.0 [%] 
Abs Meta 1.1 H [0.0-0.0 K/mcL] 
Abs Promyelocytes 0.5 H [0.0-0.0 K/mcL] 
Absolute Blasts 36.3 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 1 [/100(WBCs)] 

Morphology:
WBC: Marked leukocytosis with many circulating blasts with irregular to round nuclei, fine chromatin, distinct nuceoli and scant cytoplasm. Absolute lymphocytosis and monocytosis. 
RBC: Normocytic, normochromic anemia.
PLT: Thrombocytopenia with unremarkable morphology.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains for CD34 and TdT show markedly increased blasts, approximately 90% of total cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8430)
Abnormal immature B-cell population detected.

An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously in the peripheral blood (F18-8355). The abnormal immature B-cells represent 83.4% of the white cells and 88.7% of the mononuclear cells in the sample and abnormally express CD10 (bright to absent), CD20 (partial), CD34 (bright), CD38 (dim); with normal expression of CD19, CD58, and CD45. This finding is diagnostic for B-lymphoblastic leukemia/lymphoma.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F18-8355)
Abnormal immature B-cell population detected.
No abnormal T or myeloid population detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (68.2% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD10 (absent to bright), CD11b (partial dim), CD13 (partial dim), CD20 (dim), CD33 (partial dim), CD34 (mostly bright), CD38 (absent to intermediate), CD45 (intermediate to absent), CD123 with normal expression of CD19, CD71, cyCD79a and HLA-DR; and without CD2, sCD3, cyCD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD56, CD64, CD117, MPO or surface light chains.
CD25 is expressed by greater than 10% of the blasts.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6086.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M18-30541, M18-30542.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-8967;S13;MSKF - 2023-06-20 15.52.23.ndpi,Peripheral Blood Smear,2023-06-20,"Multiple Myeloma. Receiving chemotherapy.
","1-3. Bone marrow, left posterior iliac crest, core biopsy, clot section, touch imprints, aspirate and peripheral blood smears: 
     - Plasma cell neoplasm, 
30-40% involvement by CD138 immunohistochemistry.
1% involvement by aspirate differential.
0.038% (83.2% of plasma cells) involvement by 10-color flow cytometry, see comment.
     - Cellular marrow with erythroid predominant trilineage maturing hematopoiesis with fibrosis.
     - No morphologic or immunophenotypic support for involvement by metastatic carcinoma.      

COMMENT: Flow cytometry also detected atypical features in CD34 positive blasts (F18-9734). The current bone marrow does not meet criteria for a diagnosis of myelodysplastic syndrome at this time; however, morphologic evaluation is limited by the hypocellular aspirate smear and touch imprint slides. Furthermore, there is fibrosis present in the bone marrow. This may be related to therapy effect but has also been reported to be associated with plasma cell neoplasms (1,2). Clinical correlation, follow-up and additional special studies (cytogenetics and molecular) on peripheral blood are recommended.

This case was reviewed with Dr. Mariko Yabe, who agrees with the diagnosis. 

References: 
1. Hallgrimsdottir T, Porwit A, Björkholm M, Rossmann E, Steingrimsdottir H, Lund SH and Kristinsson SY. Bone Marrow Fibrosis In Patients With Multiple Myeloma: A New Prognostic Factor For Survival? Blood 2013 122:1946 (Abstract).    
2. Subramanian R, Basu D, Dutta TK. Significance of bone marrow fibrosis in multiple myeloma. Pathology 2007;39(5):512-5.

BONE MARROW BIOPSY
Quality: Short, subcortical. 
Cellularity: Hypercellular, 60-70%.
Myeloid lineage: Orderly maturation.   
Erythroid lineage: Relatively increased, orderly maturation.   
Megakaryocytes: Adequate in number, occasional atypical forms (small, hypolobated, hyperchromatic).    
Plasma cells: Increased in patchy distribution. 
Other: Increased fibrosis.     
Clot: Minimal marrow elements present, consists predominantly of blood. 

Special stains:
Reticulin: Mild increase in reticulin fibrosis (1+ of 3).
Trichrome: Mild increase in collagen deposition. 

TOUCH IMPRINT MORPHOLOGY

Touch imprint differential: (Performed by: HH)
Only touch imprint smears are available for evaluation.

Blasts                1%
Promyelocytes           1%
Myelocytes           5%
Metamyelocytes           4%
Neutrophils/Bands      33%
Monocytes           2%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      41%
Plasma Cells           1%
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           1.1

Morphology: 
Marrow spicules: N/A
Cellularity: Hypocellular.    
Plasma cell morphology: Few seen, small to intermediate.
Myeloid lineage: Orderly maturation, no significant dysplasia.   
Erythroid Lineage: Orderly maturation, no significant dysplasia.    
Megakaryocytes: Few present, unremarkable morphology.      

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells in a patchy distribution, overall 30-40% of cellularity. 
Kappa and lambda immunostains show the plasma cells are kappa light chain restricted.  
BCMA highlights approximately 90% of plasma cells, (2+) intensity, membranous/ Golgi pattern.
There is no increase in blasts (<5%) by CD34 or CD117 immunostains.
CD61 stain highlights megakaryocytes, no micromegakaryocytes are seen.
Pankeratin stain (Oscar) is negative. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-9734) 

Abnormal plasma cell population detected.
Flow cytometry reveals an abnormal plasma cell population having abnormal expression of CD19 (absent), CD27 (absent), CD45 (absent), CD56, CD81 (dim), CD138 (dim) and monoclonal kappa cytoplasmic light chain restriction; with normal expression of CD38; and without CD117 expression. The abnormal population represents 0.038% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 83.2% of total plasma cells in the sample.

Atypical myeloid blast population detected. 
Flow cytometry identifies an atypical myeloid blast population having abnormal expression of CD11b, CD38 (dim), and CD56 (subset bright), with normal expression of CD4, CD13, CD33, CD34, CD38, CD45, CD71, CD117, CD123 and HLA-DR without CD2, CD5, CD7, CD14, CD15, CD16, CD19, CD25, CD64. CD34 positive myeloid blasts represent 0.039% of WBC. Basophilia is also seen, representing 1.7% of WBC. While a reactive etiology cannot be excluded, the findings raise concern for a myeloid neoplasm. Clinical and morphologic correlation is required for further evaluation. Cytogenetic and molecular analysis is also recommended. 

365,176 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

Mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm is reduced. Results may not be fully indicative of bone marrow composition.
This case was reviewed with Dr. Mikhail Roshal, who agrees with the interpretation.

PERIPHERAL BLOOD
CBC (11/12/2018):
WC 5.2 [4.0-11.0 K/mcL] 
RBC 3.05 L [3.80-5.00 M/mcL] 
HGB 9.5 L [11.2-15.4 g/dL] 
HCT 30.6 L [34.3-46.0 %] 
MCV 100 H [80-98 fL] 
MCH 31.1 [27.0-33.0 pg] 
MCHC 31.0 [31.0-36.5 g/dL] 
RDW 19.7 H [12.2-15.1 %] 
Platelets 483 H [160-400 K/mcL] 

Neutrophil 66.0 [32.5-74.8 %] 
Lymph 27.0 [12.2-47.4 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 2.0 H [0.0-1.5 %] 

Abs Neut 3.4 [1.5-7.5 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology: 
WBCs: Neutrophils with toxic granulation; no significant dysplasia and no circulating blasts; rare basophils present. No circulating plasma cells are seen.
RBCs: Normocytic, normochromic anemia with anisocytosis and poikilocytosis.   
Platelets: Increased with large forms present. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7000, CG18-7001.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-35256.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7848;S11;MSKA - 2023-06-26 15.29.55.ndpi,Peripheral Blood Smear,2023-06-26,"MDS with monosomy 7, IHD2 mutation status post allo SCT now with circulating blasts.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Relapsed myelodysplastic syndrome with excess blasts, 7% blasts by aspirate differential count. 
     - Cellular marrow with trilineage dysplasia and erythroid predominance.
  
COMMENT: The patient has a history of MDS-EB-2 (H17-3922) status post stem cell transplant 10/31/2017. A bone marrow on 8/8/2018 (H18-6187) were suspicious for early relapse of myeloid neoplasm based on flow cytometry findings (F18-6611). The current bone marrow and flow cytometry findings are diagnostic for relapsed MDS.   

BONE MARROW BIOPSY
Quality: Suboptimal (fragmented, aspirate artifact). 
Cellularity: Cannot be accurately assessed, appears approximately 50% in the areas of cellularity. 
M:E ratio: Inverted.  
Blasts: Slight increase in immature cells. 
Myeloid lineage: Decreased.
Erythroid lineage: Increased, full maturation. 
Megakaryocytes: Present, occasional dysplastic forms (small, hypolobated, hyperchromatic).
Lymphocytes: Scattered.
Plasma cells: Scattered. 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (0/3). 
Clot section: Not submitted.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by AS)

Blasts                7%
Promyelocytes           2%
Myelocytes           12%
Metamyelocytes           8%
Neutrophils/Bands      11%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      48%
Lymphocytes           8%
Number of Cells Counted 500
M:E Ratio           0.8

Special stain
Iron: Present.
Ring sideroblasts: None seen. 

Morphology:
The aspirate smears are spicular and cellular. Blasts are increased (7% by differential count) and are intermediate in size with round to irregular nuclei, finely dispersed chromatin, distinct nucleoli and scant cytoplasm. The myeloid lineage is decreased in proportion with progressive maturation and dysplasia (hypogranularity, monolobated). The erythroid lineage is increased in proportion with progressive maturation and dysplasia (irregular nuclear contours, binucleation, nuclear to cytoplasmic asynchrony, late stage mitoses). Megakaryocytes are present with occasional dysplastic forms (small, hypolobated).    

PERIPHERAL BLOOD
CBC (10/01/2018):
WBC 0.7 L [4.0-11.0 K/mcL] 
RBC 2.98 L [3.95-5.54 M/mcL] 
HGB 10.1 L [12.5-16.2 g/dL] 
HCT 29.4 L [37.5-49.3 %] 
MCV 99 H [80-98 fL] 
MCH 33.9 H [27.0-33.0 pg] 
MCHC 34.4 [31.0-36.5 g/dL] 
RDW 15.6 H [12.2-15.1 %] 
Platelets 221 [160-400 K/mcL] 

Neutrophil 45.0 [32.5-74.8 %] 
Lymph 41.0 [12.2-47.4 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 4.0 H [0.0-1.5 %] 

Abs Neut 0.3 L [1.5-7.5 K/mcL] 
Abs Lymph 0.3 L [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Metamyelocyte 3.0 H [0.0-0.0 %] 

Blast 4.0 H [0.0-0.0 %] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Absolute Blasts 0.0 [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBCs: Marked leukopenia with absolute neutropenia. Left shift with increased blasts (4% by differential count). Granulocytes with dysplasia (hypogranularity, pseudo Pelger-Huet cells) are occasionally seen.  
RBCs: Normocytic, normochromic anemia with anisopoikilocytosis (elliptocytes) and polychromasia. No circulating nucleated RBCs are seen. 
Platelets: Unremarkable. 

IMMUNOHISTOCHEMISTRY
Immunostains for CD34 and CD117 show increased blasts, approximately 5-10% of the marrow cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8486)
Abnormal myeloid blast population detected. 

Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD2, CD13 (dim to absent), CD15 (early acquisition of), CD25 (partial), CD33 (dim), CD34 (bright), CD38 (dim), CD123 (bright and uniform), with normal expression of CD4, CD45, CD71, CD117, and HLA-DR without CD5, CD7, CD11b, CD14, CD15, CD16, CD19, CD56 or CD64. CD34 positive myeloid blasts represent 9.9% of WBC. This is a similar phenotype to the small population seen on F18-6611. 

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6121.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-30679, M18-30680, M18-30681, M18-30682, M18-37028



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9401;S11;MSK8 - 2023-04-25 10.57.51.ndpi,Peripheral Blood Smear,2023-04-25,"Erythrocytosis. 61-year-old with history of prostate cancer and now erythrocytosis. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Hypercellular marrow with panmyelosis and atypical pleomorphic megakaryopoiesis consistent with polycythemia vera (JAK2 V617F positive). See comment. 
  
COMMENT: Patient is noted to have high hemoglobin (up to 18.8 g/dL) and hematocrit (57.4%) levels since 7/2018. The overall findings are consistent with polycythemia vera. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (60-70%)
M:E ratio: Normal 
Blasts: Not increased in number 
Myeloid lineage: Increased in number and show progressive maturation 
Erythroid lineage: Increased in number and show progressive maturation 
Megakaryocytes: Increased in number and show pleomorphism 
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered
Special stains: Reticulin stain shows focal increase in reticulin fibrosis (0-1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HH)

Blasts                1%
Promyelocytes           1%
Myelocytes           14%
Metamyelocytes           5%
Neutrophils/Bands      34%
Monocytes           2%
Eosinophils           2%
Erythroid Precursors      26%
Plasma Cells           1%
Lymphocytes           14%
Number of Cells Counted 500
M:E Ratio           2.2

Morphology:
- Paucispicular, cellular aspirate smears show maturing trilineage hematopoiesis. There is no expanded blast population. Myeloid and erythroid elements are increased in number and show progressive maturation. Megakaryocytes are increased in number and show pleomorphism. Extrinsic cells are not seen

PERIPHERAL BLOOD
CBC (11/28/2018):
WBC 11.3 H [4.0-11.0 K/mcL] 
RBC 5.19 [3.95-5.54 M/mcL] 
HGB 16.3 H [12.5-16.2 g/dL] 
HCT 49.6 H [37.5-49.3 %] 
MCV 96 [80-98 fL] 
MCH 31.4 [27.0-33.0 pg] 
MCHC 32.9 [31.0-36.5 g/dL] 
RDW 14.8 [12.2-15.1 %] 
Platelets 431 H [160-400 K/mcL] 

Neutrophil 84.1 H [32.5-74.8 %] 
Lymph 10.7 L [12.2-47.4 %] 
Mono 2.4 [0.0-12.3 %] 
Eos 1.3 [0.0-4.9 %] 
Baso 0.8 [0.0-1.5 %] 
Immature Granulocyte 0.7 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 9.5 H [1.5-7.5 K/mcL] 
Abs Lymph 1.2 [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature Granulocyte 0.1 [0.0-0.1 K/mcL] 

Morphology:
WBC: Mild leukocytosis with absolute neutrophilia; no circulating blasts seen 
RBC: Erythrocytosis 
Platelets: Thrombocytosis 

IMMUNOHISTOCHEMISTRY
Immunostains CD34 and CD117 highlights immature cells (<5% positivity)
CD117 also highlights scattered mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10268)
Interpretation: 
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.64% of WBC.
292,159 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not submitted. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7378.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-37134, M18-37135.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6851;S11;MSK4 - 2023-06-26 17.59.59.ndpi,Peripheral Blood Smear,2023-06-26,"Breast, Malignant Neoplasm.  Breast cancer, pancytopenia.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Metastatic adenocarcinoma involving marrow. 
     
  
COMMENT: The tumor cells do not express ER, PR or HER2 on decalcified biopsy.

BONE MARROW BIOPSY
Core biopsy shows osteosclerosis, new bone formation and limited fibrotic marrow spaces with scattered and small clusters of large atypical cells with mucinous material.

BONE MARROW ASPIRATE SMEAR
Differential: Not performed. Markedly hypocellular aspirate devoid of spicules.
Smears and touch imprint are markedly hypocellular and show scattered small lymphocytes and few hematopoietic elements. 

Special stain 
Iron: Inadequate for evaluation due to lack of spicules.

PERIPHERAL BLOOD
CBC (08/30/2018):
WBC 4.3 [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 3.13 L [3.80-5.00 M/mcL] 
HGB 9.6 L [11.2-15.4 g/dL] 
HCT 28.5 L [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 30.7 [27.0-33.0 pg] 
MCHC 33.7 [31.0-36.5 g/dL] 
RDW 19.5 H [12.2-15.1 %] 
Platelets 102 L [160-400 K/mcL] 

Neutrophil 54.0 [32.5-74.8 %] 
Lymph 32.0 [12.2-47.4 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Blast 1.0 H [0.0-0.0 %] 

Abs Neut 2.3 [1.5-7.5 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Absolute Blasts 0.0 [0.0-0.0 K/mcL] 

Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 18 [/100(WBCs)] 

Morphology:
WBC: Left shift. 
RBC: Normocytic normochromic anemia with moderate anisopoikilocytosis.
Platelet: Thrombocytopenia. No morphologic abnormalities. 

IMMUNOHISTOCHEMISTRY
The neoplastic cells express OSCAR, and do not express ER, PR, and HER2.
CD117 highlights rare scattered blasts.
CD34 highlights rare scattered blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7394)
No definite abnormal myeloid blast populations detected. 
Mild basophilia noted.
No abnormal mature B- or T-cell populations detected.

There is no definite immunophenotypic evidence of a myeloid stem cell disorder by flow cytometry. Overall, very few blasts detected, and mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm therefore is reduced. Results may not be indicative of bone marrow composition. However, in light of the blasts show expression of CD25 (subset, >10% of blasts), CD13 (slightly dim), CD123 (slightly bright), with mild basophilia (1.2% of WBC), a low-grade myelodysplastic syndrome or myeloproliferative disorder cannot be entirely excluded by these studies.  CD34 positive myeloid blasts represent 0.31% of the white blood cells with expression of CD33, CD34, CD38, CD45, CD71, CD117 and HLA-DR. 
270683 cells acquired. 
Clinical and morphologic correlation will be required to evaluate for the possibility of MDS.  Cytogenetic analysis is also recommended to rule out a clonal stem cell abnormality. 
Not all myeloid stem cell disorders show abnormal immunophenotyped with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5308.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-26660.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-6773;S11;MSK7 - 2023-06-26 16.50.24.ndpi,Peripheral Blood Smear,2023-06-26,"MDS on erythropoietin also history MGUS rule out myeloma now worsening anemia.

","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent involvement by myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD). See comment.
     - Hypercellular marrow with erythroid predominant maturing trilineage hematopoiesis, multilineage dysplasia, increased ring sideroblasts, and 3% blasts (by aspirate differential count).
     - Persistent minute abnormal plasma cell population (0.0446% of WBC, and 14.1% of total plasma cells) detected by flow cytometry.
  
COMMENT: Overall, the findings are similar to those reported for the prior biopsy from 2/14/18 (H18-1197). Currently, by aspirate differential count, blasts account for 3% and by CD34 immunohistology, overall, they represent <5% of the cellularity, although focal areas show approximately 5% blasts. Auer rods are not identified and circulating blasts represent <1%. By WHO criteria, blast enumeration is evaluated on the aspirate smears, indicating that criteria for MDS with excess blasts (MDS-EB) is not yet fulfilled. Nonetheless, close clinical follow-up is advised. 
In addition, a minute abnormal plasma cell population (0.0446%) is detected by flow cytometry, which likely represents monoclonal gammopathy of undetermined significance (MGUS). However, correlation with clinical findings including metabolic and CBC parameters, serum/ urine protein electrophoresis and immunofixation, and imaging studies is needed to further classify this plasma cell neoplasm. Immunohistology to evaluate the plasma cells will be reported in an addendum.

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Hypercellular for age (90%)
M:E ratio: Decreased
Blasts: Not overtly increased, best appreciated by immunohistology (see below)
Myeloid lineage: Relatively decreased, with mildly left-shifted maturation
Erythroid lineage: Increased, actively maturing with megaloblastoid features
Megakaryocytes: Adequate in number with dysplastic forms (small, hyperchromatic, hypolobated, widely separated nuclear lobes)
Lymphocytes: Scattered
Plasma cells: Scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blasts                3%
Promyelocytes           1%
Myelocytes           9%
Metamyelocytes           7%
Neutrophils/Bands      16%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      56%
Lymphocytes           6%
Number of Cells Counted 500
M: E Ratio           0.6

Special stain 
Iron: Present
Ring sideroblasts: >5%

Morphology:
Adequate, spicular and cellular aspirate smears with maturing trilineage hematopoiesis. Blasts account for 3% of the cellularity. Auer rods are not seen. The M:E ratio is decreased. Myeloid elements are relatively decreased with mildly left shifted maturation and dysplastic forms (pseudo-Pelger-Huët, hypogranular, and hyposegmented forms). Erythroid cells are relatively increased, present at various stages of maturation and show megaloblastoid features, binucleation, and nuclear irregularities. Megakaryocytes are seen with frequent dysplastic forms (small, hypolobated, widely separated nuclear lobes).  Rare small mature-appearing lymphocytes are seen.

PERIPHERAL BLOOD
CBC (08/29/2018):
WBC 3.6 L [4.0-11.0 K/mcL] 
RBC 2.31 L [3.95-5.54 M/mcL] 
HGB 8.2 L [12.5-16.2 g/dL] 
HCT 25.3 L [37.5-49.3 %] 
MCV 110 H [80-98 fL] 
MCH 35.5 H [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL] 
RDW 23.9 H [12.2-15.1 %] 
Platelets 136 L [160-400 K/mcL] 

Neutrophil 83.0 H [32.5-74.8 %] 
Lymph 11.3 L [12.2-47.4 %] 
Mono 4.4 [0.0-12.3 %] 
Eos 0.5 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Immature Granulocyte 0.8 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 3.0 [1.5-7.5 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 

Morphology:
WBC: Rare circulating blasts seen (<1%). Dysplastic granulocytes present, including hypogranular neutrophils and pseudo-Pelger-Huët forms. Occasional immature monocytic forms are present. Large granular lymphocytes are noted.
RBC: Macrocytic anemia with anisopoikilocytosis (pencil cells present). 
Platelets: Mild thrombocytopenia with occasional giant forms seen. 

IMMUNOHISTOCHEMISTRY
CD34 highlights scattered blasts, which overall account for <5% of the cellularity, however, focally areas are noted where blasts represent approximately 5% of the marrow cellularity.
CD117 also highlights a subset of blasts, as well as rare scattered mast cells, early erythroid cells, and promyelocytes.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7300)
Interpretation: 
Abnormal myeloid blast population detected.
Abnormal plasma cell population detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotyped similar to that seen in prior sample (F18-5292) have abnormal expression of CD25 (>10% of blasts), CD11b (partial), CD13 (bright), CD34 (uniform), CD117 (intermediate to dim), HLA-DR (partial bright), with normal expression of CD4, CD38, CD45, CD71, and CD123 and without CD2, CD5, CD7, CD14, CD15, CD16, CD19, convincing CD56 or CD64. CD34 positive myeloid blasts represent 5.2% of WBC.

In addition, flow cytometry reveals an abnormal plasma cell population seen in prior sample (F18-1276) having abnormal expression of CD19 (dim to absent), CD38 (dim), CD45 (subset absent), CD81 (absent), CD117 and monoclonal kappa cytoplasmic light chain restriction; with normal expression of CD27, and CD138; and without CD56 expression.  The abnormal population represents 0.0446% of the total white cells by flow cytometry, and almost certainly will be an underestimate in comparison with morphology. Abnormal plasma cells represent 14.1% of total plasma cells in the sample.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5257.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-26509.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7605;S11;MSKB - 2023-07-06 08.27.23.ndpi,Peripheral Blood Smear,2023-07-06,"Newly dx CMML vs MDS. 
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Myeloid neoplasm, best classified as myelodysplastic syndrome with excess blasts 2 (MDS-EB-2), 12% blast by aspirate differential; see comment.
    - Hypercellular marrow with trilineage hematopoiesis and trilineage dysplasia. 

COMMENT: Per the clinical notes, a previous bone marrow biopsy performed on 7/5/2018 elsewhere was suggestive of chronic myelomonocytic leukemia 1 (CMML-1). However, the current bone marrow biopsy does not show increased monocytes and the peripheral blood does not show monocytosis. Review of the original biopsy material would be of additional benefit. 

The current biopsy shows trilineage dysplasia and increased blasts. Overall, these findings together with the previous cytogenetics and molecular testing results favor a diagnosis of MDS-EB-2. By immunohistochemical stains, there are focal areas in which the blasts approach the 15-20% range, concerning for early progression to acute myeloid leukemia. Close clinical follow-up is recommended.

This case was reviewed with Dr. Caleb Ho, who agrees with the diagnosis. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular (~80%)
M:E ratio: Markedly increased
Blasts: Increased immature cells seen
Myeloid lineage: Exhibits left-shifted maturation, relatively increased 
Erythroid lineage: Exhibits left-shifted maturation, relatively decreased 
Megakaryocytes: Present with dysmegakaryopoiesis (small, hypolobated forms)
Lymphocytes: Scattered 
Plasma cells: Scattered 

Special stains: A reticulin stain shows a mild to moderate increase in reticulin fibers (MF1-2+/3) 

Clot section: Not submitted

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                12%
Promyelocytes           7%
Myelocytes           13%
Metamyelocytes           11%
Neutrophils/Bands      29%
Monocytes           6%
Erythroid Precursors      8%
Plasma Cells           3%
Lymphocytes           11%
Number of Cells Counted 500
M:E Ratio           8.6

Special stain 
Iron: Suboptimal for evaluation; devoid of spicules
Ring sideroblasts: <5% 

Morphology: The aspirate smears are spicular and cellular and show an expanded population of medium to large sized blasts with small amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli. The background consists of maturing trilineage hematopoiesis with marked relative myeloid hyperplasia. Myeloid elements show left shifted maturation with dysgranulopoiesis (hypogranularity, >10%). Erythroid elements are reduced and show dyserythropoiesis (nuclear irregularities, polylobation, >10%). Megakaryocytes are present and show dysmegakaryopoiesis (small hypolobated forms, >10%).

PERIPHERAL BLOOD
CBC (09/26/2018):

WBC 5.8 [4.0-11.0 K/mcL] 
RBC 2.56 L [3.95-5.54 M/mcL] 
HGB 7.7 L [12.5-16.2 g/dL] 
HCT 22.9 L [37.5-49.3 %] 
MCV 90 [80-98 fL] 
MCH 30.1 [27.0-33.0 pg] 
MCHC 33.6 [31.0-36.5 g/dL] 
RDW 15.9 H [12.2-15.1 %] 
Platelets 105 L [160-400 K/mcL]
 
Neutrophil 55.2 [32.5-74.8 %] 
Lymph 33.3 [12.2-47.4 %] 
Mono 6.3 [0.0-12.3 %] 
Eos 0.2 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Immature Granulocyte 5.0 H [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 3.2 [1.5-7.5 K/mcL] 
Abs Lymph 1.9 [0.9-3.2 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.3 H [0.0-0.1 K/mcL] 
Granulocyte

Morphology:
WBC: Left shifted granulocytes with hypogranularity and occasional pseudo-Pelger Huet forms. Rare circulating blasts are seen.
RBC: Normocytic, normochromic anemia with anisocytosis and poikilocytosis (elliptocytes). 
PLT: Thrombocytopenia with unremarkable platelet morphology. 

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains for CD34 shows increased blasts, overall approximately 10% of the bone marrow cellularity, and focally slightly higher (15-19%). CD117 also highlights blasts and early erythroid precursors.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8231)
Abnormal myeloid blast population detected.
Flow cytometry identifies an abnormal myeloid blast population with abnormal expression of CD7, CD13(bright), CD117(bright), CD38(uniform), CD123(bright) with normal expression of CD4, CD33, CD34, CD38, CD45, CD71, and HLA-DR without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 4.3% of WBC. No monocytosis is seen.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5945.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-29757, M18-29758, M18-29759, M18-29761.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-8957;S12;MSKD - 2023-07-19 10.59.16.ndpi,Peripheral Blood Smear,2023-07-19,"Multiple myeloma. Status post 8 cycles of KRD. 
","1-3. Bone marrow, right posterior iliac crest, core biopsy, clot section, aspirate and peripheral blood smears: 
     - Normocellular marrow with trilineage maturing hematopoiesis.
     - No morphologic or immunophenotypic support for involvement by plasma cell neoplasm.

BONE MARROW BIOPSY
Quality: Adequate. 
Cellularity: Variably cellular, 30-60%; overall approximately 50%.
Myeloid lineage: Orderly maturation.    
Erythroid lineage: Orderly maturation.   
Megakaryocytes: Adequate in number, unremarkable morphology.    
Plasma cells: Not increased.
Clot section: Aspicular; trilineage hematopoietic elements are present with similar morphologic findings to those of the core biopsy. 

ASPIRATE MORPHOLOGY
Aspirate differential: (Performed by: SS)
Blasts                2%
Promyelocytes           2%
Myelocytes           11%
Metamyelocytes           6%
Neutrophils/Bands      25%
Monocytes           4%
Eosinophils           3%
Basophils           1%
Erythroid Precursors      33%
Plasma Cells           3%
Lymphocytes           10%
Number of Cells Counted 500
M:E Ratio           1.6

Morphology: 
Marrow spicules: Spicular.    
Cellularity: Cellular.   
Plasma cell morphology: Small to intermediate, few binucleated and rare multi-nucleated forms.     
Myeloid lineage: Orderly maturation, no dyspoiesis.   
Erythroid Lineage: Orderly maturation, no dyspoiesis.    
Megakaryocytes: Present, unremarkable morphology.     

IMMUNOHISTOCHEMISTRY
CD138 immunostain highlights plasma cells, <5% of cellularity. 
Kappa and lambda immunostains show no definitive light chain restriction.  
BCMA highlights approximately 80% of plasma cells, (2-3+) intensity, membranous/ Golgi pattern. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-9724) 
No abnormal plasma cell population detected.

No evidence of an abnormal plasma cell population is identified by flow cytometry. Plasma cells comprise 0.68% of the viable cells, following erythroid lysis.

4,111,920 cells acquired. Please note that flow cytometry studies generally underestimate the number of plasma cells, as compared to morphologic assessment.

PERIPHERAL BLOOD
CBC (11/12/2018):
WBC 4.3 [4.0-11.0 K/mcL] 
RBC 3.93 L [3.95-5.54 M/mcL] 
HGB 12.0 L [12.5-16.2 g/dL] 
HCT 38.0 [37.5-49.3 %] 
MCV 97 [80-98 fL] 
MCH 30.5 [27.0-33.0 pg] 
MCHC 31.6 [31.0-36.5 g/dL] 
RDW 14.4 [12.2-15.1 %] 
Platelets. 151 L [160-400 K/mcL] 

Neutrophil 48.6 [32.5-74.8 %] 
Lymph 34.8 [12.2-47.4 %] 
Mono 13.8 H [0.0-12.3 %] 
Eos 1.9 [0.0-4.9 %] 
Baso 0.7 [0.0-1.5 %] 
Immature Granulocyte 0.2 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 2.1 [1.5-7.5 K/mcL] 
Abs Lymph 1.5 [0.9-3.2 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.5 [%]

Morphology:
WBCs: Unremarkable morphology; no circulating plasma cells seen.
RBCs: Normocytic, normochromic red blood cells. 
Platelets: Unremarkable morphology.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6993, CG18-6994.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-35236.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9180;S10;MSKK - 2023-06-27 03.11.27.ndpi,Peripheral Blood Smear,2023-06-27,"Lymphoma.  POD, biopsy per protocol 18-157.
","1-3. Bone marrow, left posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by mantle cell lymphoma (30% with CD20 immunohistochemistry)
     - Variably cellular marrow with decreased to decreased trilineage maturing hematopoiesis.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy and aspirate specimens show variably cellular bone marrow (50-100%cellularity). There isdecreased trilineage maturing hematopoiesis with increased numbers of lymphocytes arranged in paratrabecular and interstitial aggregates. The lymphocytes are small with condensed chromatin.

Aspirate differential: (Performed by HM)

Blasts                2%
Promyelocytes           4%
Myelocytes           14%
Metamyelocytes           10%
Neutrophils/Bands      20%
Monocytes           6%
Eosinophils           3%
Erythroid Precursors      25%
Plasma Cells           1%
Lymphocytes           15% (range from ~15% to ~95%)
Number of Cells Counted  500
M:E Ratio           2.3

IMMUNOHISTOCHEMISTRY
CD20 immunostain highlights the increased number of lymphoid cells (30% of cellularity). CyclinD1 highlights a major subset of the CD20 lymphocytes. CD5 highlights only a small subset of the lymphocytes. CD3 labels reactive T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10001) 
Abnormal B-cell population identified.
No abnormal mature T-cell population detected.

Flow cytometry identifies an abnormal B-cell population with immunophenotype similar to the patient's prior blood sample (F18-9508), having abnormal expression of CD5 (small subset), FMC-7 (dim), and kappa surface light chain restriction; normal expression of CD19, CD20, CD22, and CD45; and without CD10, CD23, CD38, or CD200. The abnormal B cell population represents 14.6% of total white cells.

The immunophenotype is consistent with involvement by patient's known Mantle Cell Lymphoma

PERIPHERAL BLOOD
CBC (11/19/2018):
WBC 8.3 [4.0-11.0 K/mcL] 
RBC 3.35 L [3.80-5.00 M/mcL] 
HGB 10.3 L [11.2-15.4 g/dL] 
HCT 31.8 L [34.3-46.0 %] 
MCV 95 [80-98 fL] 
MCH 30.7 [27.0-33.0 pg] 
MCHC 32.4 [31.0-36.5 g/dL] 
RDW 15.9 H [12.2-15.1 %] 
Platelets 75 L [160-400 K/mcL] 

Neutrophil 70.5 [32.5-74.8 %] 
Lymph 14.3 [12.2-47.4 %] 
Mono 12.2 [0.0-12.3 %] 
Eos 0.7 [0.0-4.9 %] 
Baso 0.7 [0.0-1.5 %] 
Immature Granulocyte 1.6 H [0.0-0.6 %] 

Abs Neut 5.8 [1.5-7.5 K/mcL] 
Abs Lymph 1.2 [0.9-3.2 K/mcL] 
Abs Mono 1.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.1 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.1 [0.0-0.1 K/mcL] 
Granulocyte

CYTOGENETIC STUDIES
Not requested/performed.

MOLECULAR STUDIES 
Not requested/performed.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-8425;S11;MSK3 - 2023-06-20 16.55.59.ndpi,Peripheral Blood Smear,2023-06-20,"MDS. Rule out AML. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Myelodysplastic syndrome with excess blasts (MDS-EB2), with ring sideroblasts, 13% blasts by aspirate differential
     - Normocellular marrow with multilineage dysplasia (limited marrow)
  
COMMENT: Although core biopsy is small and subcortical, aspirate smears are adequate for evaluation. Per clinical notes the patient has a history of MDS-EB1, the current findings support progression of disease. Close clinical follow up is advised.

BONE MARROW BIOPSY
Quality: Suboptimal (small, subcortical)
Cellularity: Normocellular for age (10-20%)
M:E ratio: Normal
Blasts: Increased (best seen by IHC)
Myeloid lineage: Left shifted and reduced
Erythroid lineage: Progressive maturation 
Megakaryocytes: Adequate, small with separated nuclear lobes and hypolobated
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blasts                13% 
Promyelocytes           3%
Myelocytes           15%
Metamyelocytes           9%
Neutrophils/Bands      18%
Monocytes           6%
Eosinophils           4%
Erythroid Precursors      22% 
Plasma Cells           1%
Lymphocytes           9%
Number of Cells Counted  500
M: E Ratio           2.5

Special stain
Iron: Present
Ring sideroblasts: Present >5%

Morphology:
Spicular and cellular smears show an expanded blast population composed of large sized blasts with blue cytoplasm, irregular, scalloped nuclei, fine chromatin and distinct nucleoli. The myeloid series shows progressive maturation with irregular chromatin clumping and few with nuclear:cytoplasmic dyssynchrony. The erythroid series shows megaloblastoid changes. Megakaryocytes are present, occasional small and hypolobated with separated nuclear lobes.

PERIPHERAL BLOOD
CBC (10/24/2018):
WBC 0.9 L [4.0-11.0 K/mcL] 
RBC 1.90 L [3.95-5.54 M/mcL] 
HGB 7.3 L [12.5-16.2 g/dL] 
HCT 22.6 L [37.5-49.3 %] 
MCV 119 H [80-98 fL] 
MCH 38.4 H [27.0-33.0 pg] 
MCHC 32.3 [31.0-36.5 g/dL] 
RDW 22.5 H [12.2-15.1 %] 
Platelets. 29 L [160-400 K/mcL] 

Neutrophil 26.0 L [32.5-74.8 %] 
Lymph 62.0 H [12.2-47.4 %] 
Mono 7.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Abs Neut 0.2 L [1.5-7.5 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Metamyelocyte 1.0 H [0.0-0.0 %] 
Abs Meta 0.0 [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
Pancytopenia, numerous hypogranular neutrophils and rare circulating blast


IMMUNOHISTOCHEMISTRY
CD34 highlights a subset of blasts. CD117 highlights increased blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-9120)
Abnormal myeloid blast and immature monocytic populations detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD7 (partial), CD13 (bright), CD33 (bright), CD38 (partial dim), CD117 (bright) and HLA-DR (bright); with normal expression of CD4, CD34, CD45, CD71 and CD123; without CD2, CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 6.9% of WBC. In addition, immature monocytes expressing bright CD64 and HLA-DR without CD14 are present representing 6.9% of the WBC. In total, the blast equivalents (myeloid blasts and immature monocytes) represent 13.8% of the WBC.  

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6592.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-33102, M18-33103.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7791;S10;MSKG - 2023-06-26 14.21.22.ndpi,Peripheral Blood Smear,2023-06-26,"Assess Burkitt lymphoma. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Hypocellular marrow with trilineage maturing hematopoiesis and non-necrotizing granulomas (See Comment)
     - No diagnostic morphologic and immunophenotypic evidence of B cell lymphoma 

COMMENT: Although no stainable AFB or fungal organisms were identified by special stains, microbiology cultures and serologic studies will likely be more helpful in fully evaluating for any infectious processes.

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
Adequate biopsy showing mildly hypocellular bone marrow for age (~50% cellularity) withtrilineage maturing hematopoiesis. Myeloid elements show full maturation with no increase in blasts. Erythroid elements show left shifted maturation. Megakaryocytes are adequate in number with mostly unremarkable morphology. Lymphocytes are not increased, and no atypical lymphoid aggregates/infiltrate seen. A few non-paratrabecular and paratrabecular non-necrotizing granulomas are seen. Hemosiderin is seen.

Aspirate differential: (Performed by HH)
Blasts                2%
Promyelocytes           1%
Myelocytes           7%
Metamyelocytes           4%
Neutrophils/Bands      35%
Monocytes           5%
Eosinophils           2%
Erythroid Precursors      35%
Lymphocytes           9%
Number of Cells Counted  500
M:E Ratio           1.5

Aspirate Smear morphology:
Spicular and cellular aspirate smears and touch imprint showing trilineage maturing hematopoiesis with no increased blasts. Myeloid elements show full maturation with no significant dysplasia. Erythroid show left-shifted maturation with no significant dysplasia. Megakaryocytes are present with mostly unremarkable morphology. Lymphocytes are not increased with mostly small and mature-appearing in morphology.

IMMUNOHISTOCHEMISTRY/ SPECIAL STAINS
CD3 highlights interstitially scattered small T-cells.
PAX5 highlights scattered B-cells.
CD20 is negative.
GMS and AFB stains are negative for stainable fungal and AFB organisms, respectively.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8427) 
Interpretation: 
No abnormal mature B-cell population detected.
Very few mature B cells are seen.

No immunophenotypic evidence of involvement by B-cell lymphoma or leukemia is identified. Hodgkin lymphoma would not be detected by these studies.

PERIPHERAL BLOOD
CBC (10/03/2018):
WBC 8.3 [4.0-11.0 K/mcL] 
RBC 3.06 L [3.95-5.54 M/mcL] 
HGB 9.5 L [12.5-16.2 g/dL] 
HCT 29.8 L [37.5-49.3 %] 
MCV 97 [80-98 fL] 
MCH 31.0 [27.0-33.0 pg] 
MCHC 31.9 [31.0-36.5 g/dL] 
RDW 19.7 H [12.2-15.1 %] 
Platelets 161 [160-400 K/mcL] 

Neutrophil 70.8 [32.5-74.8 %] 
Lymph 5.9 L [12.2-47.4 %] 
Mono 19.6 H [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 0.2 [0.0-1.5 %] 
Immature Granulocyte 0.5 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.
Nucleated RBC 0.0 [%] 

Abs Neut 5.9 [1.5-7.5 K/mcL] 
Abs Lymph 0.5 L [0.9-3.2 K/mcL] 
Abs Mono 1.6 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature Granulocyte 0.0 [0.0-0.1 K/mcL] 

Morphology:
WBC: Absolute and relative monocytosis and lymphopenia. Scattered large granular lymphocytes are present. No circulating blasts or abnormal lymphoid cells seen.
RBC: Normocytic and normochromic anemia; mild anisopoikilocytosis.
PLT: Unremarkable morphology.  

CYTOGENETIC STUDIES
Not requested. 

MOLECULAR STUDIES 
Not requested.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9120;S12;MSK7 - 2023-03-24 06.59.02.ndpi,Peripheral Blood Smear,2023-04-25,"Leukemia.  New diagnosis of leukemia with 22% circulating blasts.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Acute myeloid leukemia (95% blasts by aspirate differential count).
     - Cellular marrow with markedly reduced trilineage maturing hematopoiesis.
  
COMMENT: Please correlate with cytogenetic and molecular findings for further classification of AML. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (60-70%)
M:E ratio: N/A
Blasts: Overtly increased 
Myeloid lineage: Almost no maturation seen 
Erythroid lineage: Markedly reduced and show progressive maturation 
Megakaryocytes: Adequate in number and show no overt atypia 
Lymphocytes: Rare 
Plasma cells: Rare
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0+/3). 
Clot section: Morphological findings are similar to biopsy 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Differential performed on touch imprints
Blasts                95%
Erythroid Precursors      3%
Plasma Cells           1%
Lymphocytes           1%
Number of Cells Counted 500
M:E Ratio               N/A          

Morphology:
- Aspicular and cellular aspirate smears shows an expanded blast population. Blasts are medium to large sized, with scant blue cytoplasm, fine lacy chromatin and prominent nucleoli. There is markedly reduced trilineage hematopoiesis. 

PERIPHERAL BLOOD
CBC (11/15/2018):

WBC 2.4 L [4.0-11.0 K/mcL] 
RBC 3.78 L [3.80-5.00 M/mcL] 
HGB 12.7 [11.2-15.4 g/dL] 
HCT 36.6 [34.3-46.0 %] 
MCV 97 [80-98 fL] 
MCH 33.6 H [27.0-33.0 pg] 
MCHC 34.7 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 152 L [160-400 K/mcL] 

Neutrophil 9.0 L [32.5-74.8 %] 
Lymph 46.0 [12.2-47.4 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 5.0 H [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %]
 
Abs Neut 0.2 L [1.5-7.5 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 39.0 H [0.0-0.0 %] 

Absolute Blasts 0.9 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Leukopenia with absolute neutropenia; circulating blasts seen (39%)
RBC: Unremarkable 
Platelets: Thrombocytopenia 

IMMUNOHISTOCHEMISTRY
CD34 is negative in blasts 
CD117 highlights expanded blast population (80-90%) 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-9923)
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

Expanded abnormal myeloid blast population detected. No abnormal B and T cell populations detected.
The blasts have abnormal expression of CD4(dim to absent), HLA-DR (absent), CD13(dim to absent), CD33(bright), CD38(dim to absent), CD34(absent), CD45 (dim to absent), CD56, CD71(dim to absent) with normal expression of  CD117, CD123 and without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD64, cCD79a or surface light chains. MPO is uniformly expressed on the blasts. CD117 positive myeloid blasts represent 83.5% of WBC.
FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F18-9905)
Interpretation: 
Expanded abnormal myeloid blast population detected. No abnormal B and T cell populations detected.
The blasts have abnormal expression of CD4(dim to absent), HLA-DR (absent), CD13(dim to absent), CD33(bright), CD38(absent), CD34(absent), CD45 (dim to absent), CD56, CD71(dim to absent) with normal expression of  CD117, CD123 and without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD64, cCD79a or surface light chains. MPO is uniformly expressed on the blasts. CD117 positive myeloid blasts represent 52% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7123.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-35925, M18-35926, M18-35927, M18-35928.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9120;S12;MSK7 - 2023-04-25 11.43.31.ndpi,Peripheral Blood Smear,2023-04-25,"Leukemia.  New diagnosis of leukemia with 22% circulating blasts.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Acute myeloid leukemia (95% blasts by aspirate differential count).
     - Cellular marrow with markedly reduced trilineage maturing hematopoiesis.
  
COMMENT: Please correlate with cytogenetic and molecular findings for further classification of AML. 

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (60-70%)
M:E ratio: N/A
Blasts: Overtly increased 
Myeloid lineage: Almost no maturation seen 
Erythroid lineage: Markedly reduced and show progressive maturation 
Megakaryocytes: Adequate in number and show no overt atypia 
Lymphocytes: Rare 
Plasma cells: Rare
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0+/3). 
Clot section: Morphological findings are similar to biopsy 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Differential performed on touch imprints
Blasts                95%
Erythroid Precursors      3%
Plasma Cells           1%
Lymphocytes           1%
Number of Cells Counted 500
M:E Ratio               N/A          

Morphology:
- Aspicular and cellular aspirate smears shows an expanded blast population. Blasts are medium to large sized, with scant blue cytoplasm, fine lacy chromatin and prominent nucleoli. There is markedly reduced trilineage hematopoiesis. 

PERIPHERAL BLOOD
CBC (11/15/2018):

WBC 2.4 L [4.0-11.0 K/mcL] 
RBC 3.78 L [3.80-5.00 M/mcL] 
HGB 12.7 [11.2-15.4 g/dL] 
HCT 36.6 [34.3-46.0 %] 
MCV 97 [80-98 fL] 
MCH 33.6 H [27.0-33.0 pg] 
MCHC 34.7 [31.0-36.5 g/dL] 
RDW 13.2 [12.2-15.1 %] 
Platelets 152 L [160-400 K/mcL] 

Neutrophil 9.0 L [32.5-74.8 %] 
Lymph 46.0 [12.2-47.4 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 5.0 H [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %]
 
Abs Neut 0.2 L [1.5-7.5 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 39.0 H [0.0-0.0 %] 

Absolute Blasts 0.9 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Leukopenia with absolute neutropenia; circulating blasts seen (39%)
RBC: Unremarkable 
Platelets: Thrombocytopenia 

IMMUNOHISTOCHEMISTRY
CD34 is negative in blasts 
CD117 highlights expanded blast population (80-90%) 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-9923)
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

Expanded abnormal myeloid blast population detected. No abnormal B and T cell populations detected.
The blasts have abnormal expression of CD4(dim to absent), HLA-DR (absent), CD13(dim to absent), CD33(bright), CD38(dim to absent), CD34(absent), CD45 (dim to absent), CD56, CD71(dim to absent) with normal expression of  CD117, CD123 and without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD64, cCD79a or surface light chains. MPO is uniformly expressed on the blasts. CD117 positive myeloid blasts represent 83.5% of WBC.
FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F18-9905)
Interpretation: 
Expanded abnormal myeloid blast population detected. No abnormal B and T cell populations detected.
The blasts have abnormal expression of CD4(dim to absent), HLA-DR (absent), CD13(dim to absent), CD33(bright), CD38(absent), CD34(absent), CD45 (dim to absent), CD56, CD71(dim to absent) with normal expression of  CD117, CD123 and without CD2, surface CD3, cytoplasmic CD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD22, CD25, CD64, cCD79a or surface light chains. MPO is uniformly expressed on the blasts. CD117 positive myeloid blasts represent 52% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7123.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-35925, M18-35926, M18-35927, M18-35928.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6694;S11;MSK9 - 2023-04-17 08.29.50.ndpi,Peripheral Blood Smear,2023-04-17,"AML, newly dx
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute meyloid leukemia (AML), 80% blasts by aspirate differential count. See comment.
  
COMMENT: Bone marrow aspirate specimen was not submitted for flow cytometric assessment. Corresponding flow cytometry of peripheral blood detected abnormal circulating myeloid blasts, diagnostic for AML. Background trilineage hematopoiesis is markedly decreased, precluding morphologic assessment of dysplasia. Correlation with the forthcoming cytogenetic studies is required to evaluate for the possibility of recurrent cytogenetic abnormalities and those seen in AML with myelodysplasia related changes (AML-MRC). Clinical correlation is needed to exclude any history of prior chemotherapy. Correlation with the forthcoming molecular studies is advised.   

BONE MARROW BIOPSY
Quality: Adequate
Cellularity: Markedly hypercellular for age (>95%)
M:E ratio: N/A
Blasts: Markedly increased, present as sheets nearly completely replacing the marrow composition with frequent apoptotic bodies. Blasts are large size, with irregular nuclei, fine chromatin, prominent nucleoli, and scant to moderate amount of cytoplasm.
Myeloid lineage: Decreased
Erythroid lineage: Decreased
Megakaryocytes: Decreased
Lymphocytes: Few scattered
Plasma cells: Few scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                80%
Promyelocytes           5%
Myelocytes           1%
Neutrophils/Bands      1%
Monocytes           5%
Eosinophils           1%
Plasma Cells           1%
Lymphocytes           6%
Number of Cells Counted  500
M:E Ratio           N/A

Morphology:
Spicular and hypercellular aspirate smears show an expanded blast population, which are medium to large in size, with round to irregular nuclei, fine chromatin, prominent nucleoli, and scant to moderate amount of cytoplasm with rare vacuoles. Auer rods are not seen. Maturing myeloid and erythroid elements are markedly decreased. Rare megakaryocytes are seen. Few small mature-appearing lymphocytes are present.

PERIPHERAL BLOOD
CBC (08/25/2018):
WBC 56.0 H [4.0-11.0 K/mcL] 
RBC 2.66 L [3.80-5.00 M/mcL] 
HGB 8.7 L [11.2-15.4 g/dL] 
HCT 25.9 L [34.3-46.0 %] 
MCV 97 [80-98 fL] 
MCH 32.7 [27.0-33.0 pg] 
MCHC 33.6 [31.0-36.5 g/dL] 
RDW 15.9 H [12.2-15.1 %] 
Platelets 61 L [160-400 K/mcL] 

Neutrophil 0.0 L [32.5-74.8 %] 
Lymph 6.0 L [12.2-47.4 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %]
 
Abs Neut 0.0 L [1.5-7.5 K/mcL] 
Abs Lymph 3.4 H [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Metamyelocyte 1.0 H [0.0-0.0 %] 
Blast 93.0 H [0.0-0.0 %] 

Abs Meta 0.6 H [0.0-0.0 K/mcL] 
Absolute Blasts 52.1 H [0.0-0.0 K/mcL] 

Morphology:
WBC: Frequent circulating blasts seen, which are large in size, with irregular nuclei, fine chromatin with occasional fine folds, prominent nucleoli, moderate amount of cytoplasm with occasional vacuoles. No Auer rods seen.
RBC: Normocytic, normochromic anemia.
Platelets: Thrombocytopenia.

IMMUNOHISTOCHEMISTRY
CD34 and CD117 are positive in blasts, which are present in large clusters and sheets, and account for ~70-80% of the cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW 
Not submitted.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F18-7155)
Interpretation: 
Expanded abnormal myeloid blast population detected.
No abnormal B and T cell populations detected.

The blasts have abnormal expression CD11b (partial), CD13 (absent to bright), CD33 (bright), CD34(dim), CD117 (dim), CD123 (bright); with normal expression of CD4, CD38, CD45, HLA-DR and CD71; without CD2, sCD3, cCD3, CD5, CD7, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD56, CD64, cCD79a or surface light chains. MPO expression is present on a subset of blasts. CD34 positive myeloid blasts represent 80.1% of WBC. The findings are diagnostic for AML.
CD25 is expressed by greater than 10 percent (65%) of the blasts.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5182.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-25888 - M18-25891.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9986;S11;MSKF - 2023-03-24 02.14.05.ndpi,Peripheral Blood Smear,2023-04-25,"MF. Newly diagnosed. 
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Hypercellular marrow with erythroid-predominant maturing trilineage hematopoiesis, megakaryocytic hyperplasia and significant atypia, moderate myelofibrosis (MF-2), and no increase in blasts, compatible with involvement by a myeloproliferative neoplasm (MPN). See comment. 
  
COMMENT: Based on the megakaryocytic morphology, primary myelofibrosis (PMF) is favored. While the observed erythroid predominance is less common in this entity, its presence does not exclude this diagnosis. However, based on the WHO criteria, demonstration of a clonal marker (such as JAK2, CALR, or MPL mutations) is required for this diagnosis. Furthermore, clinical correlation is needed to exclude the possibility of a prior polycythemia vera (PV) or essential thrombocytosis (ET). In addition, the diagnosis of overt fibrotic phase of PMF requires presence of one minor criterion that must be confirmed in two consecutive determinations (elevated LDH, anemia, leukocytosis, palpable splenomegaly, or leukoerythroblastosis). By clinical notes, the patient has had documented elevated LDH since March, which would satisfy this requirement. Clinical correlation with the forthcoming molecular and cytogenetic studies is needed.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular for age (~95% cellularity) 
M:E ratio: Decreased 
Blasts: Not overtly increased 
Myeloid lineage: Relatively decreased, actively maturing
Erythroid lineage: Relatively increased, actively maturing
Megakaryocytes: Increased in number with focal tight clustering, and frequent markedly atypical forms (hyperchromatic nuclei, hyperlobated and hypolobated forms, bulbous nuclei, forms with high nuclear to cytoplasmic ratio)
Lymphocytes: Scattered 
Plasma cells: Rare
Others: Sinusoids are dilated and intra-sinusoidal hematopoiesis is present. 
Special stains: Reticulin stain shows at least moderate increase in reticulin fibrosis (MF-2).
Trichrome stain shows focal paratrabecular and central collagen deposition with no connecting meshwork (Grade 1).  

BONE MARROW ASPIRATE SMEAR
Differential: (Performed on touch imprint: SS)
Blasts                3%
Promyelocytes           3%
Myelocytes           8%
Metamyelocytes           8%
Neutrophils/Bands      30%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      40%
Lymphocytes           6%
Number of Cells Counted  500
M:E Ratio           1.3

Morphology:
Aspicular, hemodilute and hypocellular aspirate smears and touch imprint show maturing trilineage hematopoiesis with no overt increase in blasts. Myeloid elements are mildly decreased and show full maturation without overt dysplasia. Erythroid elements are relatively increased and show full maturation and mild atypia (nuclear irregularity and karyorrhexis). Megakaryocytes are present and show occasional hypolobated forms. Platelet clumps are seen.

PERIPHERAL BLOOD
CBC (12/19/2018):
WBC 3.2 L [4.0-11.0 K/mcL] 
RBC 3.06 L [3.95-5.54 M/mcL] 
HGB 7.6 L [12.5-16.2 g/dL] 
HCT 24.1 L [37.5-49.3 %] 
MCV 79 L [80-98 fL] 
MCH 24.8 L [27.0-33.0 pg] 
MCHC 31.5 [31.0-36.5 g/dL] 
RDW 20.8 H [12.2-15.1 %] 
Platelets 298 [160-400 K/mcL] 

Neutrophil 85.0 H [32.5-74.8 %] 
Lymph 14.0 [12.2-47.4 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 

Abs Neut 2.7 [1.5-7.5 K/mcL] 
Abs Lymph 0.4 L [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 3 [/100(WBCs)]

Morphology:
WBC: No circulating blasts seen. Leukopenia with lymphopenia and relative neutrophilia.
RBC: Hypochromic anemia with anisopoikilocytosis, frequent tear-drop cells, and polychromasia; few nucleated RBCs present. 
PLT: Adequate in number, occasional large forms seen. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts (<5% of marrow cellularity).
CD117 also highlights scattered erythroid precursors and mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10960)
No definite abnormal myeloid blast, monocyte and maturing granulocyte populations detected. 
No abnormal mature B- or T-cell populations detected.

There is no definite immunophenotypic evidence of a myeloid stem cell disorder by flow cytometry. However, in light of the myeloid blasts with expression of CD7 (negative to dim) and CD56 (minute subset dim), along with reduction of CD71 a low-grade myelodysplastic syndrome cannot be entirely excluded by these studies. CD34 positive myeloid blasts represent 0.73% of the white blood cells. Normal myelomonocytic maturation is present. 348514 cells acquired. Clinical and morphologic correlation will be required to evaluate for the possibility of MDS or MPN. Cytogenetic analysis is also recommended to rule out a clonal stem cell abnormality. 
Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7857.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-39888.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-8703;S2;MSKB - 2023-04-17 15.18.56.ndpi,Peripheral Blood Smear,2023-04-17,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears: 
     - B-lymphoblastic leukemia/lymphoma (90% blasts by aspirate differential count). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Blasts                90%
Lymphocytes           10%
Number of Cells Counted  500
M:E Ratio           N/A

Morphology:
Spicular and cellular aspirate smears show a markedly expanded population of blasts, which range from small to large in size with round to irregular nuclei, moderately condensed to fine chromatin, occasional prominent nucleoli and scant basophilic cytoplasm with occasional cytoplasmic vacuoles. Background trilineage hematopoiesis is markedly reduced. 

PERIPHERAL BLOOD
CBC (11/02/2018):
WBC 12.9 [7.1-15.9 K/mcL] 
RBC 2.00 L [2.93-4.75 M/mcL] 
HGB 5.3 LL [9.2-12.7 g/dL]  
HCT 15.2 L [27.7-37.9 %] 
MCV 76 [70-85 fL] 
MCH 26.5 [22.7-29.5 pg] 
MCHC 34.9 [31.0-36.5 g/dL] 
RDW 14.9 [12.2-15.6 %] 
Platelet 99 L [160-400 K/mcL] 

Neutrophil 1.0 L [16.9-74.5 %] 
Lymph 66.0 [18.1-79.9 %] 
Mono 1.0 L [3.8-15.5 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %]
 
Abs Neut 0.1 L [1.5-8.5 K/mcL] 
Abs Lymph 8.5 H [1.1-8.1 K/mcL] 
Abs Mono 0.1 L [0.2-1.2 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL]
 
Blast 32.0 H [0.0-0.0 %] 

Absolute Blasts 4.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Absolute neutropenia with frequent circulating blasts morphologically similar to those in the aspirate smears. 
RBC: Normochromic, normocytic anemia. 
Platelets: Thrombocytopenia. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW ASPIRATE, LEFT TIBIA (F18-9443)
Interpretation: 
Abnormal immature B-cell population detected.
No abnormal immature or mature T-cell population detected. 
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (34.2 % of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD10 (major subset negative, minor subset dim), CD11b (minor subset dim), CD13 (negative to dim), CD15 (subset positive), CD33 (minor subset dim), CD38 (intermediate to bright), CD45 (negative to dim), cyCD79a (dim to intermediate), CD123 (negative to bright); with normal expression of CD19, CD34, CD71 and HLA-DR; and without CD2, sCD3, cCD3, CD4, CD5, CD7, CD8, CD14, CD16, CD20, CD56, CD64, CD117 or MPO.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.27% of WBC.
221647 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate reports, CG18-6810, CG18-6811.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M18-34231, M18-34232, M18-34234.

NOTE: The case was reviewed with Dr. M. Yabe, Hematopathology service, who agrees.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. PessinMD., PhD., Director.
"
H18-7702;S11;MSK0 - 2023-06-26 09.50.30.ndpi,Peripheral Blood Smear,2023-06-26,"Neuroendocrine carcinoma. Anemia, pancytopenia- widely metastatic thymic neuroendocrine tumor. Evaluate for marrow infiltration vs MDS/AML.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Metastatic neuroendocrine carcinoma involving marrow. 
     - Cellular marrow with trilineage maturing hematopoiesis.


BONE MARROW BIOPSY
Histologic section shows a core biopsy with cohesive nests of neoplastic cells associated with calcifications and in a desmoplastic background. Uninvolved marrow shows maturing trilineage hematopoiesis with erythroid predominance, mildly increased megakaryocytes with forms showing small and hypolobated morphology. 
Special stains: Reticulin stain shows increase in reticulin fibrosis.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)
Blasts                1%
Promyelocytes           1%
Myelocytes           5%
Metamyelocytes           3%
Neutrophils/Bands      36%
Monocytes           3%
Eosinophils           2%
Erythroid Precursors      22%
Lymphocytes           27%
Number of Cells Counted  200
M:E Ratio           2.3

Morphology:
Aspicular and hypocellular smears and touch imprints show scattered aggregates of extrinsic cells and scattered hematopoietic elements. 

PERIPHERAL BLOOD
CBC (09/28/2018):
WBC 4.8 [4.0-11.0 K/mcL] 
RBC 2.63 L [3.95-5.54 M/mcL] 
HGB 8.3 L [12.5-16.2 g/dL] 
HCT 26.3 L [37.5-49.3 %] 
MCV 100 H [80-98 fL] 
MCH 31.6 [27.0-33.0 pg] 
MCHC 31.6 [31.0-36.5 g/dL] 
RDW 17.2 H [12.2-15.1 %] 
Platelets 150 L [160-400 K/mcL] 

Neutrophil 77.6 H [32.5-74.8 %] 
Lymph 10.7 L [12.2-47.4 %] 
Mono 10.3 [0.0-12.3 %] 
Eos 0.6 [0.0-4.9 %] 
Baso 0.2 [0.0-1.5 %] 
Immature Granulocyte 0.6 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 3.8 [1.5-7.5 K/mcL] 
Abs Lymph 0.5 L [0.9-3.2 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Nucleated RBC 0.0 [%] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte
Morphology: No diagnostic abnormalities

IMMUNOHISTOCHEMISTRY
Immunostains show the tumor cells are positive for OSCAR (cytokeratin), Synaptophysin, Chromogranin and CD117. CD34 and CD117 highlight scattered immature cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8341)
No abnormal mature B- or T-cell populations detected.
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

CD34 positive myeloid blast population with apparent normal immunophenotype is 0.18% of WBC.
257,713 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6011.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-30202.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6851;S11;MSK4 - 2023-06-26 16.27.15.ndpi,Peripheral Blood Smear,2023-06-26,"Breast, Malignant Neoplasm.  Breast cancer, pancytopenia.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Metastatic adenocarcinoma involving marrow. 
     
  
COMMENT: The tumor cells do not express ER, PR or HER2 on decalcified biopsy.

BONE MARROW BIOPSY
Core biopsy shows osteosclerosis, new bone formation and limited fibrotic marrow spaces with scattered and small clusters of large atypical cells with mucinous material.

BONE MARROW ASPIRATE SMEAR
Differential: Not performed. Markedly hypocellular aspirate devoid of spicules.
Smears and touch imprint are markedly hypocellular and show scattered small lymphocytes and few hematopoietic elements. 

Special stain 
Iron: Inadequate for evaluation due to lack of spicules.

PERIPHERAL BLOOD
CBC (08/30/2018):
WBC 4.3 [4.0-11.0 K/mcL] 
Adjusted for NRBC.
RBC 3.13 L [3.80-5.00 M/mcL] 
HGB 9.6 L [11.2-15.4 g/dL] 
HCT 28.5 L [34.3-46.0 %] 
MCV 91 [80-98 fL] 
MCH 30.7 [27.0-33.0 pg] 
MCHC 33.7 [31.0-36.5 g/dL] 
RDW 19.5 H [12.2-15.1 %] 
Platelets 102 L [160-400 K/mcL] 

Neutrophil 54.0 [32.5-74.8 %] 
Lymph 32.0 [12.2-47.4 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Myelocyte 1.0 H [0.0-0.0 %] 
Blast 1.0 H [0.0-0.0 %] 

Abs Neut 2.3 [1.5-7.5 K/mcL] 
Abs Lymph 1.4 [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Meta 0.1 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Absolute Blasts 0.0 [0.0-0.0 K/mcL] 

Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 18 [/100(WBCs)] 

Morphology:
WBC: Left shift. 
RBC: Normocytic normochromic anemia with moderate anisopoikilocytosis.
Platelet: Thrombocytopenia. No morphologic abnormalities. 

IMMUNOHISTOCHEMISTRY
The neoplastic cells express OSCAR, and do not express ER, PR, and HER2.
CD117 highlights rare scattered blasts.
CD34 highlights rare scattered blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7394)
No definite abnormal myeloid blast populations detected. 
Mild basophilia noted.
No abnormal mature B- or T-cell populations detected.

There is no definite immunophenotypic evidence of a myeloid stem cell disorder by flow cytometry. Overall, very few blasts detected, and mostly mature granulocytes and monocytes seen in the sample, suggestive of hemodilution. Sensitivity of analysis for myeloid neoplasm therefore is reduced. Results may not be indicative of bone marrow composition. However, in light of the blasts show expression of CD25 (subset, >10% of blasts), CD13 (slightly dim), CD123 (slightly bright), with mild basophilia (1.2% of WBC), a low-grade myelodysplastic syndrome or myeloproliferative disorder cannot be entirely excluded by these studies.  CD34 positive myeloid blasts represent 0.31% of the white blood cells with expression of CD33, CD34, CD38, CD45, CD71, CD117 and HLA-DR. 
270683 cells acquired. 
Clinical and morphologic correlation will be required to evaluate for the possibility of MDS.  Cytogenetic analysis is also recommended to rule out a clonal stem cell abnormality. 
Not all myeloid stem cell disorders show abnormal immunophenotyped with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5308.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-26660.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
     

"
H18-8589;S12;MSKE - 2023-06-20 16.50.18.ndpi,Peripheral Blood Smear,2023-06-20,"MDS-EB2 with worsening cytopenias.
","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia with myelodysplasia related changes (AML-MRC, 45% blasts by aspirate differential count). See comment.

Comment:
Correlation with cytogenetic results is recommended. 
     
BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Normocellular for age (20-30%) 
M:E ratio: N/A
Blasts: overtly increased in number
Myeloid lineage: Show left shift in maturation 
Erythroid lineage: Markedly reduced in number 
Megakaryocytes: adequate in number and show numerous hypolobated forms 
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered
Special stains: Reticulin stain shows no increase in reticulin fibrosis (MF-0+/3). 
Clot section: Shows peripheral blood elements 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Aspirate with scanty / hypocellular material present

Blasts                45%
Neutrophils/Bands      15%
Monocytes           10%
Eosinophils           1%
Erythroid Precursors      6%
Plasma Cells           5%
Lymphocytes           18%
Number of Cells Counted 500
M:E Ratio           4.3

Special stain
Iron: Present / Increased
Ring sideroblasts: Absent 

Morphology:
- Aspirate is paucispicular and hypocellular. There is an expanded blast population with blasts of medium to large size, scant cytoplasm, fine lacy chromatin and prominent nucleoli. No auer rods are seen. Myeloid cells show hypogranularity.  Megakaryocytes and erythroid elements are poorly represented. 

PERIPHERAL BLOOD
CBC (10/30/2018):

WBC 2.6 L [4.0-11.0 K/mcL] 
RBC 2.23 L [3.80-5.00 M/mcL] 
HGB 8.1 L [11.2-15.4 g/dL] 
HCT 23.8 L [34.3-46.0 %] 
MCV 107 H [80-98 fL] 
MCH 36.3 H [27.0-33.0 pg] 
MCHC 34.0 [31.0-36.5 g/dL] 
RDW 19.3 H [12.2-15.1 %] 
Platelets 74 L [160-400 K/mcL]
 
Neutrophil 51.0 [32.5-74.8 %] 
Lymph 38.0 [12.2-47.4 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 1.3 L [1.5-7.5 K/mcL] 
Abs Lymph 1.0 [0.9-3.2 K/mcL] 
Abs Mono 0.2 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 3.0 H [0.0-0.0 %] 

Absolute Blasts 0.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Leukopenia; rare circulating blasts seen; hypogranular neutrophils
RBC: Macrocytic anemia with anisopoikilocytosis 
Platelets: Thrombocytopenia 

IMMUNOHISTOCHEMISTRY
Immunostains CD34 and CD117 shows increased number of blasts (40-50%) 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-9295)
Interpretation: 
Expanded abnormal myeloid blast population detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample (F18-5075) have abnormal expression of CD7, CD13 (bright), CD38 (dim), CD123 (bright), with normal expression of CD4, CD33, CD34, CD45, CD71, CD117, and HLA-DR without CD2, CD5, CD11b, CD14, CD15, CD16, CD19, CD25, CD56 or CD64. CD34 positive myeloid blasts represent 29.4% of WBC. While morphologic count is required, the findings are highly concerning for progression to AML-MRC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not submitted. 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6707.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-33758.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7228;S12;MSK4 - 2023-04-17 12.39.39.ndpi,Peripheral Blood Smear,2023-04-17,"AML. Newly dx.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Acute myeloid leukemia with monocytic differentiation (85% blasts by aspirate differential count).

See comment. 
  
COMMENT: Suggest correlation with molecular and cytogenetic studies for further classification. Additional immunohistochemical studies are pending for further characterization.

BONE MARROW BIOPSY
Quality: Fragmented with aspiration artifact 
Cellularity: Approximately 80% in the limited preserved area.
M:E ratio: NA
Blasts: Markedly increased. 
Myeloid lineage: Reduced.
Erythroid lineage: Reduced.
Megakaryocytes: Reduced.
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blast/blast equivalents      85%
Promyelocytes           2%
Myelocytes           1%
Metamyelocytes           1%
Neutrophils/Bands      1%
Monocytes           3%
Eosinophils           1%
Erythroid Precursors      1%
Plasma Cells           1%
Lymphocytes           4%
Number of Cells Counted 500
M: E Ratio           9

Morphology:
The aspirate smears are paucispicular and cellular and show a markedly expanded population of medium to large sized blasts with round to folded nuclei (promonocytes), moderate cytoplasm, cytoplasmic granules and occasional Auer rods in a background of markedly decreased hematopoiesis. 

PERIPHERAL BLOOD
CBC (09/14/2018):
WBC 7.2 [4.0-11.0 K/mcL] 
RBC 2.87 L [3.80-5.00 M/mcL] 
HGB 8.8 L [11.2-15.4 g/dL] 
HCT 26.9 L [34.3-46.0 %] 
MCV 94 [80-98 fL] 
MCH 30.7 [27.0-33.0 pg] 
MCHC 32.7 [31.0-36.5 g/dL] 
RDW 15.7 H [12.2-15.1 %] 
Platelets 60 L [160-400 K/mcL] 

Neutrophil 4.0 L [32.5-74.8 %] 
Lymph 50.0 H [12.2-47.4 %] 
Mono 6.0 [0.0-12.3 %] 
Eos 4.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Abs Neut 0.3 L [1.5-7.5 K/mcL] 
Abs Lymph 3.7 H [0.9-3.2 K/mcL] 
Abs Mono 0.4 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.3 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 35.0 H [0.0-0.0 %] 
Variant Lymph 1.0 [%] 
Absolute Blasts 2.5 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 1 [/100(WBCs)]

Morphology:
WBC: Many circulating blasts seen.
RBC: Normocytic normochromic anemia with mild anisocytosis.
Platelet: Thrombocytopenia. Some giant platelets are seen. 

IMMUNOHISTOCHEMISTRY
CD117 is dimly expressed on blasts (approximately 80% of total cellularity). CD34 is not expressed on blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7845)
Expanded abnormal myeloid blast and immature monocyte populations detected.
Abnormal B-cell population identified.
Flow cytometry identifies an abnormal myeloid blast population similar to that of the prior peripheral blood sample (F18-7712), with an abnormal expression of CD7 (partial), CD19 (partial dim), CD25 (partial, >10%), CD13 (uniform bright), CD33 (uniform bright), CD34 (absent), CD38 (dim), CD117 (uniform intermediate), CD123 (uniform bright), HLA-DR (uniform bright) with normal expression of CD4, CD45, CD71; without CD2, CD5, CD10, CD11b, CD14, CD15, CD16, CD20, CD56, CD64, or surface light chains. CD117 positive myeloid blasts represent 60.1% of WBC. In addition, immature monocyte population lacking CD14 is expanded with abnormal expression of CD11b, representing 23.7% of WBC. In total, blast equivalents (CD117 positive blast and immature monocyte) represent 83.8% of WBC.
Flow cytometry also reveals an abnormal mature B-cell population with abnormal expression of CD19 (slightly bright), CD20 (slightly bright), CD38 (absent), CD22 (bright), kappa light chain restriction, and normal expression of CD45; and without CD5 or CD10. The abnormal B-cell population represents 2.8% of the total white cells.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD F18-7712
Expanded abnormal myeloid blast population detected.
Abnormal B-cell population identified.
No abnormal T cell populations detected.

The blasts have abnormal expression of CD7 (partial), CD19 (partial dim), CD25 (partial, >10%), CD13 (uniform bright), CD33 (uniform bright), CD34 (absent), CD38 (dim), CD117 (uniform intermediate), CD123 (uniform bright), HLA-DR (uniform bright) with normal expression of  CD4, CD45, CD71; without CD2, surface CD3, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD20, CD56, CD64, or surface light chains. CD117 positive myeloid blasts represent 49.2% of WBC. The findings are diagnostic for AML. Additional phenotyping will be reported in addendum.

Flow cytometry reveals an abnormal mature B-cell population with abnormal expression of CD19 (slightly dim), CD20 (slightly bright), CD38 (absent), kappa light chain restriction, and normal expression of CD22, CD38 and CD45; and without CD5 or CD10. The abnormal B-cell population represents 4.5% of the total white cells.The findings are consistent with B cell lymphoproliferative neoplasm. Clinical and morphologic correlation is advised.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5641.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-28362, M18-28363, M18-28364, and M18-28365.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9499;S10;MSKN - 2023-06-21 17.37.59.ndpi,Peripheral Blood Smear,2023-06-21,"Lymphoma.  Protocol 14-023.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Involvement by follicular lymphoma (approximately 530% with CD20 immunohistochemistry)

BONE MARROW BIOPSY/ASPIRATE MORPHOLOGY
The biopsy is fragmented and shows intertrabecular and paratrabecular lymphoid aggregates comprised of small lymphocytes. Myeloid and erythroid lineages are actively maturing with no evidence of dysplasia. Megakaryocytes are present in adequate amount with no morphologic abnormalities. Granulomas are not seen. 

Aspirate differential: (Performed by CB)
Mast cells are noted
Promyelocytes           1%
Myelocytes           3%
Metamyelocytes           2%
Neutrophils/Bands      7%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      11%
Lymphocytes           74% (majority of them have clefted/irregular nuclei)
Number of Cells Counted 500
M:E Ratio           1.4

The aspirate is spicular and adequate. Small lymphocytes with cleaved nuclei are increased. Erythroid and myeloid lineages show progressive maturation. Megakaryocytes are seen. Blasts are not increased. 

IMMUNOHISTOCHEMISTRY
CD20 and PAX5 highlights neoplastic B cells (approximately 50% of marrow cellularity). CD3 highlights scattered T-cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10369) 
Interpretation: 
Abnormal B-cell population identified.

Flow cytometry reveals an abnormal mature B-cell population similar to that seen previously in [F18-9486] with abnormal expression of CD10, CD19 (dim), CD20 (dim), CD22 (dim), CD38 (mostly absent), lambda light chain restriction, and normal expression of CD45; and without CD5. The abnormal B-cell population represents 48.1% of the total white cells.

PERIPHERAL BLOOD
CBC (11/27/2018):
WBC 17.2 H [4.0-11.0 K/mcL] 
RBC 4.48 [3.95-5.54 M/mcL] 
HGB 13.7 [12.5-16.2 g/dL] 
HCT 41.2 [37.5-49.3 %] 
MCV 92 [80-98 fL] 
MCH 30.6 [27.0-33.0 pg] 
MCHC 33.3 [31.0-36.5 g/dL] 
RDW 11.9 L [12.2-15.1 %] 
Platelets. 197 [160-400 K/mcL] 

Neutrophil 33.0 [32.5-74.8 %] 
Lymph 13.0 [12.2-47.4 %] 
Mono 3.0 [0.0-12.3 %] 
Eos 1.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 5.7 [1.5-7.5 K/mcL] 
Abs Lymph 2.2 [0.9-3.2 K/mcL] 
Abs Mono 0.5 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.2 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Other 50.0 H [0.0-0.0 %] 
Abnormal lymphoid cells with folded- clefted nuclei.
Abs Others 8.6 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Lymphocytosis. The lymphocytes are small with cleaved nuclei.
RBC: Unremarkable..
Platelet: Unremarkable. 


CYTOGENETIC STUDIES
Not requested/performed. 

MOLECULAR STUDIES 
Not requested/performed. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD.,PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7973;S2;MSK0 - 2023-06-26 09.44.43.ndpi,Peripheral Blood Smear,2023-06-26,[NULL],"1-2.  Bone marrow, right posterior iliac crest, aspirate and peripheral blood smears:
     - T-lymphoblastic leukemia/lymphoma, 85% blasts by aspirate differential, see comment. 

COMMENT: In addition to the primary population of T-lymphoblastic leukemia/lymphoma (T-ALL), flow cytometry also detected a small population of blasts (<1% of total blasts) which is favored to represent at least partial myeloid maturation of the abnormal clone (see F18-8620 for full report). While T-ALL is the most appropriate classification at this time, the possibility of mixed phenotype acute leukemia cannot be fully ruled out, and the myeloid component will be monitored subsequently. Correlation with molecular and cytogenetic results will also be beneficial. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)

Blasts                85%
Promyelocytes           3%
Myelocytes           2%
Neutrophils/Bands      2%
Erythroid Precursors      7%
Lymphocytes           1%
Number of Cells Counted  500
M:E Ratio           N/A

Morphology:
The aspirate smears are spicular and cellular. Blasts are markedly increased (85% by aspirate differential) and are intermediate to large with round to irregular nuclei, finely dispersed chromatin, inconspicuous nucleoli and scant cytoplasm. The myeloid and erythroid lineages are markedly decreased in proportion. Megakaryocytes are rare and show unremarkable morphology. 

PERIPHERAL BLOOD
CBC (10/09/2018):
WBC 37.1 H [7.1-15.9 K/mcL] 
RBC 2.32 L [3.70-4.90 M/mcL] 
HGB 7.3 L [10.6-13.3 g/dL] 
HCT 21.7 L [32.4-40.4 %] 
MCV 94 H [74-91 fL] 
MCH 31.5 H [24.8-30.2 pg] 
MCHC 33.6 [31.0-36.5 g/dL] 
RDW 18.6 H [12.2-15.1 %] 
Platelets 88 L [160-400 K/mcL]
 
Neutrophil 5.0 L [32.5-74.8 %] 
Lymph 3.0 L [12.2-47.4 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %]
 
Abs Neut 1.9 [1.5-7.5 K/mcL] 
Abs Lymph 1.1 [0.9-3.2 K/mcL] 
Abs Mono 0.7 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 90.0 H [0.0-0.0 %] 
Absolute Blasts 33.4 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBCs: Leukocytosis with a marked increase in blasts (90% by differential count) with similar morphology to that seen on the bone marrow aspirate. There is relative neutropenia and relative lymphopenia.  
RBCs: Normocytic, normochromic anemia with mild anisocytosis. 
Platelets: Thrombocytopenia with rare large forms. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8620)
T-lymphoblastic leukemia/lymphoma.

The presence of greater than 20% abnormal immature T-cells in the bone marrow (88.7% of the total white cells) is diagnostic for T-lymphoblastic leukemia/lymphoma (T-ALL) by WHO criteria. The blasts have abnormal expression of CD2 (absent to dim), sCD3 (absent), cyCD3 (dim), CD5 (dim), CD7 (absent), CD11b, CD13, CD25 (small subset), CD33, CD34 (absent to bright), CD38 (bright), CD45 (bright), CD48 (absent), HLA-DR (absent to bright); with normal expression of CD71; and without CD4, CD8, CD14, CD15, CD16, CD19, CD20, CD22, CD56, CD64, CD117, CD123, or surface light chains.

In addition, a small population of blasts (<1% of total blasts) shows lower expression of CD7, no cytoplasmic CD3, bright CD33, HLA-DR, CD117 (intermediate), CD34 and CD11c. The population is favored to represent at least partial myeloid maturation of the abnormal clone. While T-ALL is likely the most appropriate classification at this time a possibility of mixed phenotype acute leukemia is not excluded, and myeloid component will be monitored subsequently.

No abnormal mature B-cell population detected.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. Virtually no myeloid blast cells seen.

398,256 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (cytogenetic and molecular) is required.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6226, CG18-6227.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-31230, M18-31231.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-7474, Melissa S. Pessin MD., PhD., Director.
"
H18-7019;S12;MSKB - 2023-04-20 10.42.10.ndpi,Peripheral Blood Smear,2023-04-20,"AML.  New diagnosis.
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia (38% blasts by aspirate differentiation count), consistent with therapy-related AML. See comment. 
  
COMMENT:
The patient had a history of Langerhans cell histiocytosis and is status post cytotoxic chemotherapy in 2000. Therefore, this is best classified as therapy-related AML. On the other hand, a subset of histiocytic neoplasms can be associated with clonally related myeloid neoplasms. Molecular studies are required to address clonal relatedness. 

BONE MARROW BIOPSY
Quality: Limited (fragmented with aspiration artifacts)
Cellularity: Difficult to assess. 
M:E ratio: NA 
Blasts: Increased. 
Myeloid lineage: Decreased.
Erythroid lineage: Decreased.
Megakaryocytes: Decreased.
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis. 
Clot section: Non-contributory 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by AS)
Blasts                38%
Promyelocytes           2%
Myelocytes           6%
Metamyelocytes           7%
Neutrophils/Bands      23%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      2%
Plasma Cells           1%
Lymphocytes           19%
Number of Cells Counted 500
M:E Ratio           20

Morphology:
The aspirate smears are spicular and cellular and show an expanded population of medium to large sized blasts with moderate to scant cytoplasm, round nuclei, fine chromatin and distinct nucleoli. Auer rods are not seen. Myeloid precursors are orderly maturing with no overt dysplasia. Erythroid precursors are virtually absent. Scattered Megakaryocytes are seen with dysplastic morphology. 

PERIPHERAL BLOOD
CBC (09/07/2018):
WBC 1.5 L [4.0-11.0 K/mcL] 
RBC 2.37 L [3.95-5.54 M/mcL] 
HGB 7.5 L [12.5-16.2 g/dL] 
HCT 20.5 L [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 31.6 [27.0-33.0 pg] 
MCHC 36.6 H [31.0-36.5 g/dL] 
RDW 13.9 [12.2-15.1 %] 
Platelets 26 L [160-400 K/mcL] 

Neutrophil 30.0 L [32.5-74.8 %] 
Lymph 48.0 H [12.2-47.4 %] 
Mono 8.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 

Abs Neut 0.4 L [1.5-7.5 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Blast 14.0 H [0.0-0.0 %] 
Absolute Blasts 0.2 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Leukopenia with hypogranular and pelgeroid neutrophils and rare circulating blasts seen.
RBC: Normocytic normochromic anemia.
Platelet: Thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 highlight blasts (approximately 20% of cellularity). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7587)
Abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD5 (partial), CD7, CD33 (dim to absent), CD13 (uniform bright), CD34 (uniform bright), CD45 (variable, dim to intermediate), CD117 (slightly bright), CD123 (uniform bright), HLADR (uniform bright) with normal expression of CD4, CD38 and CD71; without CD2, sCD3, cCD3, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cCD79a or surface light chains. MPO expression is present on a small subset of blasts. CD34 positive myeloid blasts represent 10.6% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD F18-7547)
Abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD5 (partial), CD7, CD25 (partial, <10%), CD33 (dim), CD13 (uniform bright), CD34 (uniform intermediate), CD38 (dim), CD45 (variable, dim to intermediate), CD117 (slightly bright), CD123 (uniform bright), HLADR (uniform bright) with normal expression of CD4 and CD71; without CD2, sCD3, cCD3, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD56, CD64, cCD79a or surface light chains. MPO expression is present on a subset of blasts. CD34 positive myeloid blasts represent 7.2% of WBC.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5444.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-27423, M18-27424, M18-27425, M18-27426, M18-27427. 


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-8949;S11;MSKD - 2023-04-25 12.11.35.ndpi,Peripheral Blood Smear,2023-03-24,"CML. 82-year-old man with CML currently on Imatinib with POD / intolerant to prior TKI treatment now with peripheral blasts concern for blast phase. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Chronic myeloid leukemia, blast phase (myeloid) (20% blasts by aspirate differential count). 
  
BONE MARROW BIOPSY
Quality: Adequate (aspiration artifact present)
Cellularity: Hypercellular for age (70-80%)
M:E ratio: Decreased 
Blasts: Increased in number 
Myeloid lineage: Show left shift in maturation 
Erythroid lineage: Show progressive maturation 
Megakaryocytes: Adequate in number and show small hypolobated forms 
Lymphocytes: Interstitially scattered 
Plasma cells: Interstitially scattered 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HWH)

Blasts                20%
Promyelocytes           3%
Myelocytes           16%
Metamyelocytes           2%
Neutrophils/Bands      7%
Monocytes           1%
Eosinophils           1%
Basophils           1%
Erythroid Precursors      41%
Plasma Cells           1%
Lymphocytes           7%
Number of Cells Counted 500
M: E Ratio           0.8

Morphology:
- Spicular and cellular aspirate smear show maturing trilineage hematopoiesis. Myeloid elements are adequate in number and show left shift in maturation. Blasts are increased. Blasts are medium to large, with scant cytoplasm, round to oval nuclei, fine lacy chromatin and prominent nucleoli. Erythroid are adequate in number and show progressive maturation. Megakaryocytes are adequate in number and show small, hypolobated forms. 

PERIPHERAL BLOOD
CBC (11/12/2018):
WBC 3.8 L [4.0-11.0 K/mcL] 
RBC 3.11 L [3.95-5.54 M/mcL] 
HGB 8.7 L [12.5-16.2 g/dL] 
HCT 27.1 L [37.5-49.3 %] 
MCV 87 [80-98 fL] 
MCH 28.0 [27.0-33.0 pg] 
MCHC 32.1 [31.0-36.5 g/dL] 
RDW 18.2 H [12.2-15.1 %] 
Platelet. 56 L [160-400 K/mcL] 

Neutrophil 51.0 [32.5-74.8 %] 
Lymph 33.0 [12.2-47.4 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 2.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Abs Neut 1.9 [1.5-7.5 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.1 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 

Blast 14.0 H [0.0-0.0 %] 
Absolute Blasts 0.5 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)]

Morphology:
WBC: Leukopenia; increased circulating blasts seen (14%)
RBC: Normocytic normochromic anemia with anisopoikilocytosis 
Platelets: Thrombocytopenia 

IMMUNOHISTOCHEMISTRY
CD34 shows increased blasts, approximately 10% of total cells. CD117 stains more blasts, approximately 20%. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-9716)
Interpretation: 
Expanded abnormal myeloid blast population detected. 
Minute abnormal B-cell population identified.
No abnormal mature T-cell population detected.

The blasts have abnormal expression of CD2 (partial), CD11b (subset), CD13 (dim to bright), CD33 (bright), CD34 (dim to absent), CD38 (dim), CD117 (bright), HLA-DR (dim to normal); with normal expression of CD4, CD45, CD71, CD123 and without sCD3, cCD3, CD5, CD7, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cCD79a or surface light chains. MPO expression is present on the major subset of blasts. CD117 positive myeloid blasts represent 25.8% of WBC.

In addition, flow cytometry also reveals a minute abnormal mature B-cell population with abnormal expression of CD10, CD22 (slightly dim), increased forward and side scatter suggestive of larger size, lambda light chain restriction, and normal expression of CD19, CD38 and CD45; and without CD5. The abnormal B-cell population represents 0.067% of the total white cells.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F18-9718)
Interpretation: 
Abnormal myeloid blast population detected. 
Flow cytometry identifies an abnormal myeloid blast population having abnormal expression of CD2 (partial), CD7 (partial), CD25 (partial), CD56 (partial), CD11b (subset), CD13 (dim), CD33 (uniform bright), CD34 (dim to intermediate), CD38 (subset absent, subset dim), CD64, CD71 (dim), CD117 (dim to intermediate), CD123 (uniform intermediate), with normal expression of CD4, CD45 and HLA-DR without sCD3, cyCD3, CD5, CD14, CD15, CD16, CD19, CD25 or cyCD79a. MPO is present on subset of the blasts. CD34 positive myeloid blasts represent 14.2% of WBC.

No abnormal mature B- or T-cell populations detected.
No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6987.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-35237, M18-35239, M18-35250.

Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6504;S11;MSK9 - 2023-06-26 22.12.40.ndpi,Peripheral Blood Smear,2023-06-26," 72 male with AML from antecedent MDS, with relapse after allograft now status post MEC re induction with peripheral count recovery.

","1-3. Bone marrow, right posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Persistent involvement by Acute Myeloid Leukemia with Myelodysplasia-Related Changes (5% blasts by aspirate differential count)
     - Hypercellular marrow with maturing trilineage hematopoiesis and mild eosinophilia   

BONE MARROW BIOPSY
Quality: Subcortical fragmented biopsy 
Cellularity: Hypercellular for age (~60% cellularity) 
M:E ratio: Mildly increased 
Blasts: Not overtly increased 
Myeloid lineage: Mildly relatively increased and exhibit full maturation 
Erythroid lineage: Mildly relatively decreased and exhibit left-shifted maturation 
Megakaryocytes: Adequate in number with frequent atypical forms (abnormal nuclear lobation and hyperchromatic forms)
Lymphocytes: Scattered
Plasma cells: Scattered 

Special stains: 
Reticulin stain shows focal mild increase in reticulin fibrosis (1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Blasts                5%
Promyelocytes           4%
Myelocytes           11%
Metamyelocytes           11%
Neutrophils/Bands      28%
Monocytes           4%
Eosinophils           7%
Basophils           1%
Erythroid Precursors      10%
Plasma Cells           1%
Lymphocytes           18%
Number of Cells Counted  500
M:E Ratio           6.6

Morphology:
Paucispicular, hemodiluted, hypocellular aspirate smears and touch imprint showing trilineage hematopoiesis with a borderline increase in large-sized blasts. Myeloid elements show full maturation with occasional hyposegmented forms (<10% lineage). Erythroid elements are relatively reduced with mildly left-shifted maturation and some dysplastic forms (nuclear irregularity/budding, karyorrhexis, nuclear-cytoplasmic dyssynchrony). Rare megakaryocytes are present. Eosinophils are mildly increased with mostly unremarkable morphology.

PERIPHERAL BLOOD
CBC (08/20/2018):
WBC 11.2 H [4.0-11.0 K/mcL] 
RBC 2.95 L [3.95-5.54 M/mcL] 
HGB 8.4 L [12.5-16.2 g/dL] 
HCT 26.0 L [37.5-49.3 %] 
MCV 88 [80-98 fL] 
MCH 28.5 [27.0-33.0 pg] 
MCHC 32.3 [31.0-36.5 g/dL] 
RDW 14.4 [12.2-15.1 %] 
Platelets 189 [160-400 K/mcL] 

Neutrophil 53.0 [32.5-74.8 %] 
Lymph 31.0 [12.2-47.4 %] 
Mono 5.0 [0.0-12.3 %] 
Eos 10.0 H [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 1.0 H [0.0-0.0 %]
 
Abs Neut 6.0 [1.5-7.5 K/mcL] 
Abs Lymph 3.5 H [0.9-3.2 K/mcL] 
Abs Mono 0.6 [0.0-1.3 K/mcL] 
Absolute Eosinophil 1.1 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.1 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Mild eosinophilia. Some large granular lymphocytes and hyposegmented neutrophils present. Immature granulocytes are present (metamyelocytes/bands) with no circulating blasts. 
RBC: Normocytic normochromic anemia with mild anisocytosis.
Platelets: Few large and hypogranular forms seen. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show no increase in blasts (<5% cellularity).
CD117 also highlights scattered mast cells.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-6993)
Abnormal myeloid blast population detected.
Eosinophilia detected.

Flow cytometry identifies an abnormal myeloid blast population similar to that of the prior bone marrow sample (F18-6200), with abnormal expression of CD7 (partial, bright), CD11b (partial), CD13 (slightly bright), CD15 (subset), CD25 (subset, greater than 10% of blasts), CD33 (bright), CD34 (bright), CD38 (slightly bright), CD64 (minor subset), CD117 (intermediate to absent), and CD123 (uniform, bright); with normal expression of CD4, CD45, CD71, and HLA-DR; without CD2, CD5, CD14, CD16, CD19, CD56. CD34 positive myeloid blasts represent 2.2% of WBC. 

In addition, eosinophilia is detected, representing 7.0% of WBC.
403,383 cells acquired.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5025.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-25422, M18-25424.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6587;S12;MSKA - 2023-04-17 08.35.00.ndpi,Peripheral Blood Smear,2023-04-17,"MDS to AML, status post azacitidine. 
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - Acute Myeloid Leukemia (72% blasts by aspirate differential count) (See Comment)
     - Hypercellular marrow with reduced trilineage hematopoiesis, mild erythroid and megakaryocytic dyspoiesis
  
COMMENT: Per clinical note, the patient presented previously with cytopenias and was diagnosed with myelodysplastic syndrome (MDS) in an outside marrow biopsy. If confirmed, the current marrow findings are consistent with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC). 

BONE MARROW BIOPSY/ CLOT SECTION
Quality: Fragmented and hemorrhagic biopsy
Cellularity: Hypercellular for age (60-70% cellularity) 
M:E ratio: Difficult to assess
Blasts: Markedly increased, in interstitial clusters, medium to large in size, with oval to indented/folded nuclei, fine to dispersed chromatin, prominent nucleoli, and scant to moderate cytoplasm   
Myeloid lineage: Exhibit left-shifted maturation
Erythroid lineage: Reduced in number and show progressive maturation 
Megakaryocytes: Moderately reduced with few atypical forms (hypolobated and hyperchromic forms) 
Lymphocytes: Scattered 
Plasma cells: Scattered 

Clot section: Several marrow fragments present with similar morphology to biopsy 

Special stains: 
Reticulin stain shows no increase in reticulin fibrosis (0/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)
Blasts                72%
Erythroid Precursors      19%
Plasma Cells           2%
Lymphocytes           7%
Number of Cells Counted  500
M:E Ratio           N/A

Special Stain:
Iron: Increased storage iron
Ring sideroblast: Present (between 5-15% of erythroid elements)

Morphology:
Spicular and hypercellular aspirate smear showing expanded blasts population, composed predominantly of medium to large-sized blasts with oval to slightly irregular/indented nuclei, fine chromatin, single to multiple prominent nucleoli, scant pale blue to amphophilic cytoplasm. Rare Auer Rods are seen. Maturing myeloid elements are reduced and left-shifted. Erythroid elements are reduced in number and show full maturation and mild dyspoiesis (nuclear irregularity, binucleation, karyorrhexis, nuclear-cytoplasmic dyssynchrony). Megakaryocytes are present and show atypical forms (hyperlobated forms and abnormal nuclear lobe separation). 

PERIPHERAL BLOOD
CBC (08/22/2018):
WBC 1.2 L [4.0-11.0 K/mcL] 
RBC 2.77 L [3.95-5.54 M/mcL] 
HGB 8.0 L [12.5-16.2 g/dL] 
HCT 25.9 L [37.5-49.3 %] 
MCV 94 [80-98 fL] 
MCH 28.9 [27.0-33.0 pg] 
MCHC 30.9 L [31.0-36.5 g/dL] 
RDW 18.3 H [12.2-15.1 %] 
Platelets 22 L [160-400 K/mcL] 

Neutrophil 0.0 L [32.5-74.8 %] 
Lymph 56.0 H [12.2-47.4 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Myelocyte 2.0 H [0.0-0.0 %] 
Blast 40.0 H [0.0-0.0 %] 
Variant Lymph 1.0 [%] 

Abs Neut 0.0 L [1.5-7.5 K/mcL] 
Abs Lymph 0.7 L [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Absolute Blasts 0.5 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Morphology:
WBC: Leukopenia with marked neutropenia and expanded population of large-sized blasts morphologically similar to those in marrow aspirate. 
RBC: Normocytic and normochromic anemia. Mild anisopoikilocytosis. 
PLT: Marked thrombocytopenia. 

IMMUNOHISTOCHEMISTRY
CD34 and CD117 show expanded blast population (60-70% cellularity). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7095)
Interpretation: 
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.
No abnormal plasma cell population detected.

The blasts have abnormal expression of CD5 (partial dim), CD33 (bright), CD34 (bright), CD38 (dim), CD117 (bright), HLA-DR (variable, bright to absent); with normal expression of CD4, CD13, CD45, CD71, CD123; without CD2, sCD3, cCD3, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cCD79a or surface light chains. MPO expression is present on the blasts. CD34 positive myeloid blasts represent 86.2% of WBC. The findings are diagnostic for AML.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.
No evidence of an abnormal plasma cell population is identified by flow cytometry.

418,474 cells acquired for myeloid analysis.
446,747 cells acquired for plasma cell analysis.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5096.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-25607, M18-25608.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9632;S11;MSK4 - 2023-04-25 09.58.11.ndpi,Peripheral Blood Smear,2023-04-25,"MDS vs. AML.  New MDS vs. AML.
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Involvement by Acute Myeloid Leukemia with Monocytic Differentiation (85% blasts by aspirate differential count) (See Comment)
     - Hypercellular marrow with markedly decreased trilineage hematopoiesis
  
COMMENT: Per clinical notes, the patient has a history of myelodysplastic syndrome (MDS) diagnosed a year ago. If confirmed, the current marrow findings will be consistent with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC). Correlation with cytogenetics and molecular results will also be helpful in the final classification.  

BONE MARROW BIOPSY
Quality: Adequate, fragmented 
Cellularity: Hypercellular for age (80% cellularity)
M:E ratio: N/A
Blasts: Markedly increased medium- to large-sized blasts with irregular or slightly folded nuclei, dispersed chromatin, and one or more distinct nucleoli. 
Myeloid lineage: Markedly decreased 
Erythroid lineage: Markedly decreased 
Megakaryocytes: Mildly increased in number with frequent dysplastic forms (small hypolobated forms, abnormal nuclear lobe separation)
Lymphocytes: Scattered 
Plasma cells: Scattered
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (1+/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HM)
Blasts/Promonocytes     85%
Neutrophils/Bands      3%
Monocytes           3%
Eosinophils           2%
Erythroid Precursors      5%
Plasma Cells           1%
Lymphocytes           1%
Number of Cells Counted  500
M:E Ratio           N/A

Special stain
Iron: Present
Ring sideroblasts: Absent 

Morphology:
Spicular and hypocellular aspirate smears showing markedly expanded population of medium to large-sized blasts with slightly irregular to folded nuclei, fine chromatin, distinct nucleoli and moderate amount of basophilic cytoplasm with occasional cytoplasmic vacuoles. No Auer rod is seen. Maturing myeloid elements are markedly reduced and show some dyspoietic forms (hypogranular forms). Maturing erythroid elements are markedly reduced. Megakaryocytes are present and show frequent dyspoietic forms (abnormal nuclear lobe separation, hypolobated forms). 

PERIPHERAL BLOOD
CBC (12/06/2018):
WBC 74.2 H [4.0-11.0 K/mcL] 
RBC 2.97 L [3.80-5.00 M/mcL] 
HGB 9.4 L [11.2-15.4 g/dL] 
HCT 30.3 L [34.3-46.0 %] 
MCV 102 H [80-98 fL] 
MCH 31.6 [27.0-33.0 pg] 
MCHC 31.0 [31.0-36.5 g/dL] 
RDW 21.3 H [12.2-15.1 %] 
Platelets 173 [160-400 K/mcL] 

Neutrophil 6.0 L [32.5-74.8 %] 
Lymph 6.0 L [12.2-47.4 %] 
Mono 67.0 H [0.0-12.3 %] 
Eos 3.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %]
Metamyelocyte 1.0 H [0.0-0.0 %] 
Blast 18.0 H [0.0-0.0 %] 
 
Abs Neut 4.5 [1.5-7.5 K/mcL] 
Abs Lymph 4.5 H [0.9-3.2 K/mcL] 
Abs Mono 49.7 H [0.0-1.3 K/mcL] 
Absolute Eosinophil 2.2 H [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Meta 0.7 H [0.0-0.0 K/mcL] 
Absolute Blasts 13.4 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 0 [/100(WBCs)] 

Attending Review
Manual differential is confirmed including the presence of numerous circulating blasts and monocytosis. Correlate with flow cytometry for further characterization.
I attest that the above interpretation/recommendation is based
upon my personal examination of the source material and patient
clinical history, if indicated, and that I have reviewed this report.
Maly Fenelus MD Prov ID: 023085
12/06/2018 5:00 PM EST

Morphology:
WBC: Leukocytosis with numerous circulating blasts/promonocytes present. There is also relative and absolute monocytosis. Hypogranular granulocytes are also seen. 
RBC: Macrocytic anemia with anisopoikilocytosis.
PLT: Frequent giant and large forms present. 

IMMUNOHISTOCHEMISTRY
The blasts are negative for CD34, and only a very small subset is positive for CD117. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10513)
Final report is pending.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7550.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-38125 to M18-38128, M18-38380.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-7964;S11;MSK0 - 2023-06-06 01.24.09.ndpi,Peripheral Blood Smear,2023-06-06,"AML.  New diagnosis. 
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - Acute myeloid leukemia, 85% blasts by aspirate differential; see comment.

COMMENT: Complete subclassification requires correlation with cytogenetic and molecular genetic findings.

BONE MARROW BIOPSY
Quality: Suboptimal (aspirated/hemorrhagic biopsy) 
Cellularity: Cannot be accurately assessed 
M:E ratio: Cannot be accurately assessed 
Blasts: Markedly expanded population of medium to large sized blasts with small amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli 
Myeloid lineage: Markedly reduced to absent
Erythroid lineage: Markedly reduced to absent
Megakaryocytes: Markedly reduced to absent
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows no significant increase in reticulin fibers (0/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                85%
Promyelocytes           1%
Myelocytes           1%
Neutrophils/Bands      1%
Eosinophils           1%
Erythroid Precursors      4%
Plasma Cells           1%
Lymphocytes           6%
Number of Cells Counted 500
M:E Ratio           1

Morphology: The aspirate smears are spicular and hypercellular and show a markedly expanded population of medium to large sized blasts with small amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli, in a background of near absent maturing myeloid elements, rare scattered erythroid elements and rare megakaryocyte. 


PERIPHERAL BLOOD
CBC (10/09/2018):
WBC 0.5 LL [4.0-11.0 K/mcL] 
RBC 2.18 L [3.80-5.00 M/mcL] 
HGB 7.7 L [11.2-15.4 g/dL] 
HCT 23.0 L [34.3-46.0 %] 
MCV 106 H [80-98 fL] 
MCH 35.3 H [27.0-33.0 pg] 
MCHC 33.5 [31.0-36.5 g/dL] 
RDW 15.1 [12.2-15.1 %] 
Platelets. 24 L [160-400 K/mcL]

Morphology:
WBC: Marked leukopenia with neutropenia; rare circulating blasts seen 
RBC: Macrocytic anemia
PLT: Marked thrombocytopenia

IMMUNOHISTOCHEMISTRY
Immunohistochemical stains for CD34 and CD117 show increased blasts, approximately 80-90% of the bone marrow cellularity. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8607)
Expanded abnormal myeloid blast population detected. 
No abnormal B and T cell populations detected.

The blasts have abnormal expression of CD13 (uniform bright), CD33 (subset dim to absent), CD34 (subset absent), CD71 (absent), CD117 (subset dim to absent) and HLA-DR (dim to absent) with normal expression of CD4, CD38, CD45 and CD123 and without CD2, sCD3, cCD3, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cCD79a or surface light chains. MPO expression is present on a major subset of blasts. Abnormal myeloid blasts represent 71.1% of WBC. CD25 is expressed by less than 10 percent of the blasts.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6205.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M18-31199 to M18-31203.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9582;S12;MSK9 - 2023-03-23 22.36.37.ndpi,Peripheral Blood Smear,2023-04-25,"AML. Newly diagnosed. 
","{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch31506\stshfhich31506\stshfbi31506\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial{\*\falt Arial};}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fhimajor\f31502\fbidi \froman\fcharset0\fprq2{\*\panose 00000000000000000000}Cambria;}
{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}
{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri{\*\falt Calibri};}
{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman{\*\falt Times New Roman};}









{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}
{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}
{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}
{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}
{\fhimajor\f31528\fbidi \froman\fcharset238\fprq2 Cambria CE;}{\fhimajor\f31529\fbidi \froman\fcharset204\fprq2 Cambria Cyr;}{\fhimajor\f31531\fbidi \froman\fcharset161\fprq2 Cambria Greek;}{\fhimajor\f31532\fbidi \froman\fcharset162\fprq2 Cambria Tur;}
{\fhimajor\f31535\fbidi \froman\fcharset186\fprq2 Cambria Baltic;}{\fhimajor\f31536\fbidi \froman\fcharset163\fprq2 Cambria (Vietnamese);}{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE{\*\falt Calibri};}
{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr{\*\falt Calibri};}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek{\*\falt Calibri};}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur{\*\falt Calibri};}
{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic{\*\falt Calibri};}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE{\*\falt Times New Roman};}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr{\*\falt Times New Roman};}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek{\*\falt Times New Roman};}
{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur{\*\falt Times New Roman};}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew){\*\falt Times New Roman};}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic){\*\falt Times New Roman};}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic{\*\falt Times New Roman};}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese){\*\falt Times New Roman};}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red192\green0\blue0;}
{\*\defchp \f31506\fs22 }{\*\defpap \ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa200\sl276\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive 
\ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv 
\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31506\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused 
Normal Table;}{\s15\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\f31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 
\snext15 \slink16 \sqformat \spriority1 \styrsid1407877 No Spacing;}{\*\cs16 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \dbch\af31505 \sbasedon10 \slink15 \slocked \spriority1 \styrsid1407877 No Spacing Char;}{\s17\ql \li0\ri0\widctlpar
\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 
\f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext17 \spriority0 \styrsid882823 CoPath Text;}}{\*\rsidtbl \rsid67849\rsid882823\rsid1407877\rsid2042514\rsid2244535\rsid2384879\rsid2631653\rsid3440157\rsid3692237\rsid4135798\rsid4349262
\rsid4405459\rsid4611041\rsid5570980\rsid5712722\rsid6766448\rsid6967677\rsid7345479\rsid7682242\rsid7801243\rsid7941751\rsid8093638\rsid8211225\rsid8327408\rsid8547255\rsid9375557\rsid10486192\rsid11625837\rsid11880241\rsid11935605\rsid12266937
\rsid13046825\rsid13703865\rsid13781310\rsid13842715\rsid14895546\rsid14950412\rsid16198884\rsid16476786}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info
{\author Melo, Heydi L./Pathology}{\operator Quesada, Andres E./Pathology}{\creatim\yr2018\mo12\dy13\hr12\min43}{\revtim\yr2018\mo12\dy13\hr12\min43}{\version2}{\edmins0}{\nofpages4}{\nofwords703}{\nofchars4284}{\nofcharsws4881}{\vern55}}
{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont1\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1440\dgvorigin1440\dghshow1\dgvshow1
\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\rsidroot3692237\newtblstyruls\nogrowautofit\usenormstyforlist\noindnmbrts\felnbrelev\nocxsptable\indrlsweleven\noafcnsttbl\afelev\utinl\hwelev\spltpgpar\notcvasp\notbrkcnstfrctbl\notvatxbx\krnprsnet\cachedcolbal \nouicompat \fet0
{\*\wgrffmtfilter 2450}\nofeaturethrottle1\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang 
{\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}
\pard\plain \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid2631653 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\ul\insrsid4405459\charrsid2631653 AMENDMENT DETAIL:}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid2631653 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459\charrsid2631653 Reason for Amendment:\~}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459 \tab \tab }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\caps\f1\fs18\insrsid4405459 correction to clinical history provided}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\caps\f1\fs18\insrsid4405459\charrsid2631653  }{\rtlch\fcs1 \ab\af0 \ltrch\fcs0 \b\insrsid4405459 \par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid2244535 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459\charrsid2244535 R}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459 eport Section Changed:\tab Diagnosis (Comments)}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459\charrsid2244535  \par }\pard \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid6967677 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459\charrsid2244535 \par }\pard \ltrpar\ql \fi-2880\li2880\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin2880\itap0\pararsid11625837 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\insrsid4405459 Description of Change: \tab }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\fs18\ul\cf2\insrsid4405459 Portion of comment removed due to clarification of patient\rquote s history provided by the treating physician.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\fs18\cf17\insrsid4405459\charrsid2244535 \par }\pard\plain \ltrpar\s17\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid2384879 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 \f1\fs18\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid4405459 \par \par }\pard \ltrpar\s17\ql \li0\ri0\widctlpar\tx720\tx1440\tx2160\tx2880\tx3600\tx4320\tx5040\tx5760\tx6480\tx7200\tx7920\tx8640\tx9360\tx10080\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid11625837 {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459\charrsid11625837 Note: This document represents an amended version of the}{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459  Hemato}{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459\charrsid11625837 pathology report originally issued on }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459 12/6/2018. Renier Brentjens, MD}{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459\charrsid11625837  has been notified via e-mail on }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459 12/6/2018}{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\insrsid4405459\charrsid11625837 . \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \insrsid4405459\charrsid7682242 \par }\pard\plain \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid7801243 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par 1-3}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\insrsid4405459\charrsid7345479 . }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid7345479 Bone marrow, }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459 left posterior iliac crest,}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid7345479  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459 biopsy,}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid9375557  aspirate and peripheral blood smears:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid7345479  \~\~}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459      }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 - }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 Acute myeloid leukemia, 59% blasts by aspirate differential count, see comment.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\insrsid4405459\charrsid3440157 COMMENTS:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Correlation with concurrent cytogenetic and molecular studies is required for further classification. \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479   \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 BONE MARROW BIOPSY}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Quality:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Excellent.  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Cellularity:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Normocellular for age (~70% cellularity).}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par M:E ratio:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  N/A}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Blasts:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Markedly increased, forming dense clusters and focal sheets.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Myeloid lineage:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Markedly reduced. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Erythroid lineage:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Present and exhibits full maturation.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Megakaryocytes:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Decreased (0-2 per high power field) with few atypical forms (small, mono/hypolobated). }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Lymphocytes:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Scattered. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Plasma cells:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Rare.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Special stains:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid4611041 Reticulin stain shows no }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 increase in reticulin fibrosis}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid4611041 .}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Clot section:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  Predominantly blood with few marrow elements showing similar morphology to the biopsy.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 BONE MARROW ASPIRATE SMEAR}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Differential:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  (Performed by HWH)}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192 Blasts \tab \tab \tab 59%\par Promyelocytes \tab \tab 1%\par Myelocytes \tab \tab 1%\par Metamyelocytes \tab \tab 1%\par Neutrophils/Bands \tab 2%\par Eosinophils \tab \tab 2%\par Erythroid Precursors \tab 26%\par Lymphocytes \tab \tab 8%\par Number of Cells Counted }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192 500\par M:}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192 E Ratio \tab \tab 0.3}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Morphology:\par Spicular and cellular}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459  aspirate smears show a markedly expanded blast population, composed of medium to large cells with oval to slightly irregular nuclei, fine chromatin, prominent nucleoli and scant to moderate cytoplasm with few showing perinuclear hofs. Occasional Auer rods are identified. Maturing myeloid elements are markedly decreased in proportion. Erythroid elements are adequate in proportion and show full maturation with few dyspoietic forms (nuclear irregularity, binucleation). Megakaryocytes are present with predominantly unremarkable morphology.   }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 \par PERIPHERAL BLOOD}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 CBC (12/04/2018}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 ):\par }\pard \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid7801243 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192 WBC 2.7 L [4.0-11.0 K/mcL] \par RBC 3.09 L [3.95-5.54 M/mcL] \par HGB 10.1 L [12.5-16.2 g/dL] \par HCT 28.6 L [37.5-49.3 %] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 MCV}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192  93 [80-98 fL] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 MCH}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192  32.7 [27.0-33.0 pg] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 MCHC}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192  35.3 [31.0-36.5 g/dL] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 RDW}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192  13.5 [12.2-15.1 %] \par Platelets 122 L [160-400 K/mcL] \par \par Neutrophil 14.0 L [32.5-74.8 %] \par Lymph 57.0 H [12.2-47.4 %] \par Mono 2.0 [0.0-12.3 %] \par Eos 0.0 [0.0-4.9 %] \par Baso 1.0 [0.0-1.5 %] \par Blast 26.0 H [0.0-0.0 %] \par Variant Lymph 1.0 [%] \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192 Abs Neut 0.4 L [1.5-7.5 K/mcL] \par Abs Lymph 1.6 [0.9-3.2 K/mcL] \par Abs Mono 0.1 [0.0-1.3 K/mcL] \par Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] \par Absolut}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 e Basophil 0.0 [0.0-0.2 K/mcL] \par }\pard \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid7801243 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid10486192 Absolute Blasts 0.7 H [0.0-0.0 K/mcL]\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Morphology:\par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 WBC: Frequent circulating blasts (26% by differential count) with similar morphology to those of the aspirate smear; absolute neutropenia and relative lymphocytosis.\par RBC: Normocytic, normochromic anemia.\par PLT: Thrombocytopenia. \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 IMMUNOHISTOCHEMISTRY}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 CD34 and CD117 show an expanded blast population (50-60% marrow cellularity). }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid4611041 FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10462)}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid6766448 Expanded abnormal myeloid blast population detected. \par \par The blasts have abnormal expression of CD5 (partial), CD7 (partial), CD13 (absent to intermediate), CD33 (dim), CD34 (variable, dim to intermediate), CD38 (uniform), CD45 (dim), CD71 (partial absent), CD117 (uniform), HLA-DR (absent to intermediate); with normal expression of CD4 and CD123, without CD2, CD11b, CD14, CD15, CD16, CD19, CD25, CD56, CD64. CD34 positive myeloid blasts represent 66.1% of WBC.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459  (F18-10400)}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid13703865 Expanded abnormal myeloid blast population detected. \par No abnormal B and T cell populations detected.\par \par The blasts have abnormal expression of CD5 (partial), CD7 (partial), CD11b (partial), CD13 (absent to dim), CD33 (dim), CD34 (variable, dim to intermediate), CD38 (uniform), CD45 (dim), CD117 (uniform intermediate); with normal expression of CD4, CD71, CD123 and HLA-DR without CD2, sCD3, cCD3, CD8, CD10, CD14, CD15, CD16, CD19, CD20, CD25, CD56, CD64, cCD79a or surface light chains. MPO expression is present on majority of the blasts. CD34 positive myeloid blasts represent 46.7% of WBC.\par CD25 is not expressed by the blasts.\~\~\~\~\~}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 CYTOGENETIC STUDIES}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par Cytogenetic analysis will be reported separately. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid7345479 See separate report, CG}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459 18-7507}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid7345479 .}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par \~\par }{\rtlch\fcs1 \ab\af1\afs18 \ltrch\fcs0 \b\f1\fs18\ul\insrsid4405459\charrsid7345479 MOLECULAR STUDIES}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479  \par Molecular analysis will be reported separately. }{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459 See separate report, M18-37885, M18-37887, M18-37888, M18-37889}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\cgrid0\insrsid4405459\charrsid7345479 .}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid7345479 \par \par \par }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid7801243 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \fs22\lang1033\langfe1033\loch\af31506\hich\af31506\dbch\af31505\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid4405459 \par }{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid4405459\charrsid4349262 \hich\af1\dbch\af31505\loch\f1 Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 \hich\af1\dbch\af31505\loch\f1 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin}{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid4405459 \hich\af1\dbch\af31505\loch\f1  }{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid4405459\charrsid4349262 \hich\af1\dbch\af31505\loch\f1 MD.,}{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid4405459 \hich\af1\dbch\af31505\loch\f1  }{\rtlch\fcs1 \af1\afs14 \ltrch\fcs0 \f1\fs14\cf1\insrsid4405459\charrsid4349262 \hich\af1\dbch\af31505\loch\f1 PhD., Director.\par \par \hich\af1\dbch\af31505\loch\f1 The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459\charrsid8093638 \par }\pard \ltrpar\s15\ql \li-180\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin-180\itap0\pararsid7801243 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid4405459 \par }\pard\plain \ltrpar\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid7801243 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid4405459\charrsid13842715 \par }{\*\noop}{\*\noop}{\*\noop}{\*\noop}}"
H18-8008;S10;MSKS - 2023-06-26 09.56.11.ndpi,Peripheral Blood Smear,2023-06-26,"ALL.  New diagnosis.
","1-3. Bone marrow, right posterior iliac crest; biopsy, aspirate and peripheral blood smears: 
    - B lymphoblastic leukemia/lymphoma, >90% blasts by TdT immunostain; see comment.

COMMENT: For complete subclassification, correlation with molecular genetic and cytogenetic findings is required.

BONE MARROW BIOPSY
Quality: Adequate 
Cellularity: Hypercellular (>90%)
M:E ratio: N/A
Blasts: Markedly expanded sheetlike population of medium sized blasts with small amounts of cytoplasm, round to irregular nuclei, fine chromatin and distinct nucleoli 
Myeloid lineage: Markedly reduced 
Erythroid lineage: Markedly reduced 
Megakaryocytes: Markedly reduced 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: A reticulin stain shows a mild to moderate increase in reticulin fibers. 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by CB)
Blasts                28%
Myelocytes           3%
Metamyelocytes           1%
Neutrophils/Bands      15%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      21%
Lymphocytes           30%
Number of Cells Counted  500
M:E Ratio           1

Morphology: The aspirate smears are suboptimal (aspicular, hypocellular and hemodiluted) but show an expanded blast population comprised of small to medium sized blasts with scant cytoplasm, round to oval nuclei, fine chromatin and distinct nucleoli, in a background of reduced trilineage hematopoiesis. Occasional erythroid and myeloid elements are seen. Megakaryocytes are rare to absent. The aspirates are markedly hemodiluted, findings may not accurately reflect actual bone marrow content.

PERIPHERAL BLOOD
CBC (10/10/2018):
WBC 9.8 [4.0-11.0 K/mcL] 
RBC 2.82 L [3.80-5.00 M/mcL] 
HGB 8.3 L [11.2-15.4 g/dL] 
HCT 25.8 L [34.3-46.0 %] 
MCV 92 [80-98 fL] 
MCH 29.4 [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 15.0 [12.2-15.1 %] 
Platelets 100 L [160-400 K/mcL] 

Neutrophil 35.0 [32.5-74.8 %] 
Lymph 55.0 H [12.2-47.4 %] 
Mono 0.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Blast 6.0 H [0.0-0.0 %] 
Metamyelocyte 2.0 H [0.0-0.0 %] 
Myelocyte 2.0 H [0.0-0.0 %] 

Abs Neut 3.4 [1.5-7.5 K/mcL] 
Abs Lymph 5.4 H [0.9-3.2 K/mcL] 
Abs Mono 0.0 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Meta 0.2 H [0.0-0.0 K/mcL] 
Abs Myelocytes 0.2 H [0.0-0.0 K/mcL] 
Absolute Blasts 0.6 H [0.0-0.0 K/mcL] 

Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 5 [/100(WBCs)] 

Morphology:
WBC: Circulating blasts.
RBC: Normocytic, normochromic anemia.
PLT: Mild thrombocytopenia.

IMMUNOHISTOCHEMISTRY
Immunohistochemical stain for TdT highlights the increased blasts, >90% of total cellularity. CD34 is predominantly negative in the blasts. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-8668)
Abnormal immature B-cell population detected.
An abnormal immature B-cell population is identified by flow cytometry with an immunophenotype similar to that identified previously [F15-8582].  The abnormal immature B-cells represent 22.3% of the white cells and 30.8% of the mononuclear cells in the sample and abnormally express CD10 (absent to dim), CD20 (partial), CD34 (absent), CD58 (uniform bright), CD45 (slightly dim); with normal expression of CD19, CD38; and without CD33. This finding is consistent with persistent/recurrent B-lymphoblastic leukemia/lymphoma, depending on the clinical context.  Clinical and morphologic correlation is recommended.

In addition, myeloid blasts show an expanded expression of CD25 (~50% of blasts) and CD33 (dim to negative) with otherwise normal immunophenotype seen. Significance of this finding is not entirely clear and may favor reactive changes. CD34 positive myeloid blast population is 0.24% of WBC.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD
Not available 

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-6256, CG18-6257.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M18-31401 to M18-31403.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6946;S10;MSKH - 2023-04-20 10.52.58.ndpi,Peripheral Blood Smear,2023-04-20,"Patient with Ph chromosome + ALL.
","1-3. Bone marrow, right posterior iliac crest, biopsy, aspirate and peripheral blood smears: 
     - B lymphoblastic leukemia/lymphoma (blasts 85%).

BONE MARROW BIOPSY
Quality: Adequate. 
Cellularity: Hypercellular (approximately 90%)
M:E ratio: NA 
Blasts: Markedly increased. 
Myeloid lineage: Reduced.
Erythroid lineage: Present and show maturation
Megakaryocytes: Reduced.
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows no increase in reticulin fibrosis.

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HH)
Blasts                85%
Myelocytes           1%
Neutrophils/Bands      1%
Erythroid Precursors      11%
Lymphocytes           2%
Number of Cells Counted 500
M:E Ratio           0.2

Morphology:
The aspirate smears are paucispicular and cellular and show markedly expanded population of small to large sized blasts with scant cytoplasm, round to irregular nuclei, fine chromatin and occasional distinct nucleoli, in a background of markedly decreased trilineage hematopoiesis. 

PERIPHERAL BLOOD
CBC (09/05/2018):
WBC 10.6 [4.0-11.0 K/mcL] 
RBC 2.54 L [3.95-5.54 M/mcL] 
HGB 7.8 L [12.5-16.2 g/dL] 
HCT 24.2 L [37.5-49.3 %] 
MCV 95 [80-98 fL] 
MCH 30.7 [27.0-33.0 pg] 
MCHC 32.2 [31.0-36.5 g/dL] 
RDW 19.3 H [12.2-15.1 %] 
Platelets 25 L [160-400 K/mcL] 

Neutrophil 3.0 L [32.5-74.8 %] 
Lymph 32.0 [12.2-47.4 %] 
Mono 1.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 0.0 [0.0-1.5 %] 
Promyelocyte 1.0 H [0.0-0.0 %] 
Blast 64.0 H [0.0-0.0 %] 

Abs Neut 0.3 L [1.5-7.5 K/mcL] 
Abs Lymph 3.4 H [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Promyelocytes 0.1 H [0.0-0.0 K/mcL] 
Absolute Blasts 6.8 H [0.0-0.0 K/mcL] 

Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 1 [/100(WBCs)] 

Morphology:
WBC: Markedly increased circulating blasts.
RBC: Normocytic normochromic anemia with moderate anisopoikilocytosis. 
Platelet: Thrombocytopenia  

IMMUNOHISTOCHEMISTRY
The blasts express TdT and CD34 (approximately 90% of marrow cellularity). 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7507)
Abnormal immature B-cell population detected.
No abnormal mature T-cell population detected.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (93.5% of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria.  The blasts have abnormal expression of CD10 (variable, negative to bright), CD19 (dim to bright), CD45 (negative to dim), CD11b (partial, dim), CD13 (intermediate), CD20 (partial), CD25 (negative to bright, 90% of blasts), CD33 (intermediate), CD34 (dim to bright), CD38 (negative to dim), CD58 (uniform, bright), CD123 (bright), with normal expression of cCD79a, CD71 and HLA-DR; and without CD2, CD3, CD4, CD5, CD7, CD8, CD13, CD14, CD15, CD16, CD56, CD64, CD117 or MPO.

No abnormal myeloid blast, monocyte or maturing myeloid population identified. CD34 positive myeloid blast population with apparent normal immunophenotype is 0.07% of WBC.
311591 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotyped with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

FLOW CYTOMETRIC ANALYSIS, PERIPHERAL BLOOD (F18-7434)
Abnormal immature B-cell population detected.
No abnormal mature T-cell population detected. 
No abnormal myeloid blast, monocyte or maturing myeloid population identified. Virtually no myeloid blasts are seen.

The presence of greater than 20% abnormal immature B-cells in the peripheral blood and/or marrow (57.1 % of the total white cells) is diagnostic for B-lymphoblastic leukemia/lymphoma (B-ALL) by WHO criteria. The blasts have abnormal expression of CD10 (subset negative, subset dim to  bright), CD13 (dim), CD19 (dim to intermediate), CD20 (minute subset dim), CD25 (negative to bright), CD33 (negative to intermediate), CD34 (dim to intermediate), CD38 (negative to intermediate), CD45 (negative to intermediate), CD58 (bright), CD123 (dim to bright); with normal expression of CD71, cCD79a and HLA-DR; and without CD2, sCD3, cCD3, CD4, CD5, CD7, CD8, CD11b, CD14, CD15, CD16, CD56, CD64, CD117 or MPO. CD25 is expressed by greater than 10% of the blasts.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5388.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-27134, M18-27135, M18-27136, M18-27137.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-6936;S11;MSK8 - 2023-04-17 12.17.47.ndpi,Peripheral Blood Smear,2023-04-17,"Myeloproliferative Neoplasm.  Progressive thrombocytosis, 2016 BM biopsy reportedly pre-fibrotic MF.  Now worsened thrombocytosis.
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Normocellular to mildly hypercellular marrow for age with normal M:E ratio, atypical megakaryocytic proliferation and mild fibrosis consistent with myeloproliferative neoplasm, see comment.
  
COMMENT: The overall morphologic findings are consistent with a myeloproliferative neoplasm favor essential thrombocythemia (also see H18-6855; 3/9/2016). However, correlation with clinical findings and genetic studies is recommended for further characterization.  

BONE MARROW BIOPSY
Quality: Adequate with fragmentation and hemorrhage
Cellularity: Normocellular to mildly hypercellular marrow (40-60%) for age 
M:E ratio: Adequate. 
Blasts: Not increased. 
Myeloid lineage: Full maturation. 
Erythroid lineage: Full maturation. 
Megakaryocytes: Increased with atypical enlarged and some hyperchromatic forms 
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows mild increase in reticulin fibrosis (MF-0-1/3). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by SS)
Blasts                3%
Promyelocytes           1%
Myelocytes           11%
Metamyelocytes           6%
Neutrophils/Bands      40%
Monocytes           1%
Eosinophils           4%
Erythroid Precursors      20%
Plasma Cells           1%
Lymphocytes           13%
Number of Cells Counted 500
M:E Ratio           3.2

Morphology:
The aspirate is spicular and adequate. Blasts are not increased. Megakaryocytes are increased and some with hypersegmentation. Erythroid and myeloid lineages are adequately maturing. 

PERIPHERAL BLOOD
CBC (09/05/2018):
WBC 7.3 [4.0-11.0 K/mcL] 
RBC 4.09 [3.80-5.00 M/mcL] 
HGB 12.9 [11.2-15.4 g/dL] 
HCT 39.4 [34.3-46.0 %] 
MCV 96 [80-98 fL] 
MCH 31.5 [27.0-33.0 pg] 
MCHC 32.7 [31.0-36.5 g/dL] 
RDW ed Blood 13.4 [12.2-15.1 %] 
Platelets 1018 H [160-400 K/mcL] 

Neutrophil 77.2 H [32.5-74.8 %] 
Lymph 17.5 [12.2-47.4 %] 
Mono 4.0 [0.0-12.3 %] 
Eos 0.5 [0.0-4.9 %] 
Baso 0.7 [0.0-1.5 %] 
Immature Granulocyte 0.1 [0.0-0.6 %] 
Immature Granulocytes include metamyelocytes, myelocytes and promyelocytes.

Abs Neut 5.6 [1.5-7.5 K/mcL] 
Abs Lymph 1.3 [0.9-3.2 K/mcL] 
Abs Mono 0.3 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Absolute Immature 0.0 [0.0-0.1 K/mcL] 
Granulocyte

Nucleated RBC 0.0 [%] 

Morphology:
WBC: No blasts seen. No circulating myeloid precursors are seen.
RBC: No morphologic abnormalities. 
Platelet: Thrombocytosis. 

IMMUNOHISTOCHEMISTRY
CD117 highlights rare scattered blasts.
CD34 highlights rare scattered blasts.

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-7503)
No abnormal myeloid blast, monocyte or maturing myeloid population identified. 
No abnormal mature B- or T-cell populations detected.

CD34 positive myeloid blast population with apparent normal immunophenotype is 1.1% of WBC.
375,853 cells acquired. Not all myeloid stem cell disorders show abnormal immunophenotype with this assessment and correlation with additional studies (morphologic, cytogenetic, and molecular) is required.

No immunophenotypic evidence of involvement by B- or T-cell lymphoma or leukemia is identified.  Hodgkin lymphoma would not be detected by these studies.

Flow cytometry is generally not a sensitive methodology in the context of myeloproliferative disorders, correlation with molecular studies for JAK2 mutation status and/or BCR-ABL and morphology is advised if clinically indicated.

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-5386.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate report, M18-27111, M18-27112.



Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
H18-9860;S11;MSKG - 2023-05-12 11.22.26.ndpi,Peripheral Blood Smear,2023-05-12,"Myelodysplastic Syndrome on erythropoietin- also history of MGUS rule out myeloma; now worsening anemia and increased peripheral blasts.
","1-3. Bone marrow, left posterior iliac crest, biopsy; aspirate and peripheral blood smears: 
     - Acute myeloid leukemia, most compatible with AML with myelodysplasia-related changes (AML-MRC) (41% blasts by aspirate differential count), see comment. 
     - Persistent minute abnormal plasma cell population detected by flow cytometry (0.003% of WBCs and 1% of total plasma cells). 
     - Markedly hypercellular marrow with erythroid predominant trilineage hematopoiesis and multilineage dysplasia.
  
COMMENT: In light of the patient's prior documented history of myelodysplastic syndrome (MDS), specifically MDS with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD), the current findings are compatible with AML-MRC. However, correlation with cytogenetic and molecular genetic studies is needed to exclude recurrent cytogenetic abnormalities. 
In addition, a minute abnormal plasma cell population (0.003% of WBC) is detected by flow cytometry with a similar immunophenotype as previously detected and likely represents monoclonal gammopathy of undetermined significance (MGUS). Correlation with clinical findings is advised. Immunohistology to evaluate the plasma cells will be reported in an addendum.

BONE MARROW BIOPSY
Quality: Fragmented but adequate 
Cellularity: Markedly hypercellular for age (95% cellularity)
M:E ratio: N/A
Blasts: Increased and present as interstitial small and large clusters. The blasts are large in size, with oval to irregular nuclei, dispersed chromatin, large prominent eosinophilic nucleoli, and scant to moderate amount of cytoplasm. 
Myeloid lineage: Decreased with left shifted maturation 
Erythroid lineage: Relatively increased 
Megakaryocytes: Adequate in number with occasional loose clusters and frequent dysplastic forms (>50%, small size, hypolobated/hyperlobated and hyperchromatic nuclei)
Lymphocytes: Scattered 
Plasma cells: Scattered 
Special stains: Reticulin stain shows focal mild increase in reticulin fibrosis (MF-0 to MF-1). 

BONE MARROW ASPIRATE SMEAR
Differential: (Performed by HH)
Blasts                41%
Promyelocytes           1%
Myelocytes           4%
Metamyelocytes           2%
Neutrophils/Bands      4%
Monocytes           1%
Eosinophils           1%
Erythroid Precursors      36%
Plasma Cells           1%
Lymphocytes           9%
Number of Cells Counted  500
M:E Ratio           0.4

Special stain
Iron: Present
Ring sideroblasts: Present (>15%) 

Morphology:
Spicular and markedly hypercellular aspirate smears show erythroid predominant maturing trilineage hematopoiesis with an expanded population of blasts, which are large in size, with oval to irregular nuclei, fine chromatin, distinct lage nucleoli and scant to moderate basophilic cytoplasm. Auer rods are not seen. Myeloid elements are decreased with left shifted maturation and dysplastic forms (hypogranular and hyposegmented forms). Erythroid elements are relatively increased and show left-shifted maturation and dysplastic forms (nuclear irregularities, budding, bi-nucleation, megaloblastoid features, nuclear-cytoplasmic dyssynchrony, and karyorrhexis). Megakaryocytes are present and show frequent dysplastic forms (small and hypolobated forms). Rare scattered plasma cells are seen without overt atypia.

PERIPHERAL BLOOD
CBC (12/13/2018):
WBC 3.4 L [4.0-11.0 K/mcL] 
RBC 2.23 L [3.95-5.54 M/mcL] 
HGB 7.3 L [12.5-16.2 g/dL] 
HCT 22.6 L [37.5-49.3 %] 
MCV 101 H [80-98 fL] 
MCH 32.7 [27.0-33.0 pg] 
MCHC 32.3 [31.0-36.5 g/dL] 
RDW 23.6 H [12.2-15.1 %] 
Platelets 133 L [160-400 K/mcL] 

Neutrophil 64.0 [32.5-74.8 %] 
Lymph 17.0 [12.2-47.4 %] 
Mono 2.0 [0.0-12.3 %] 
Eos 0.0 [0.0-4.9 %] 
Baso 1.0 [0.0-1.5 %]
Myelocyte 1.0 H [0.0-0.0 %] 
Blast 16.0 H [0.0-0.0 %] 

Abs Neut 2.2 [1.5-7.5 K/mcL] 
Abs Lymph 0.6 L [0.9-3.2 K/mcL] 
Abs Mono 0.1 [0.0-1.3 K/mcL] 
Absolute Eosinophil 0.0 [0.0-0.7 K/mcL] 
Absolute Basophil 0.0 [0.0-0.2 K/mcL] 
Abs Myelocytes 0.0 [0.0-0.0 K/mcL] 
Absolute Blasts 0.5 H [0.0-0.0 K/mcL] 
Megakaryocyte Fragment 0 [/100(WBCs)] 
Nucleated RBC 2 [/100(WBCs)] 

Morphology:
WBC: Frequent circulating blasts with similar morphology as on the aspirate smears are seen.  Leukopenia with absolute lymphopenia; hypogranular, hyposegmented and pseudo-Pelger-Huët neutrophils present.
RBC: Macrocytic anemia with anisopoikilocytosis (microspherocytes and pencil cells present); rare nucleated RBCs seen. 
PLT: Thrombocytopenia, mild, with few large forms. 

IMMUNOHISTOCHEMISTRY
CD34 highlights increased blasts, present as interstitial small and large clusters, which account for 30-40% of the marrow cellularity.
CD117 appears technically suboptimal, and highlights somewhat weakly scattered mast cells. 

FLOW CYTOMETRIC ANALYSIS, BONE MARROW (F18-10806)
Expanded abnormal myeloid blast population detected.
Minute abnormal plasma cell population detected.

Flow cytometry identifies an abnormal myeloid blast population with an immunophenotype similar to that seen in prior sample (F18-7300) have abnormal expression of CD7 (partial), CD11b, CD25 (major subset, >10% of blasts), CD56 (partial dim), CD13 (variable, absent to bright), and CD117 (variable, absent to intermediate); with normal expression of CD4, CD33, CD34, CD38, CD45, CD71, CD123 and HLA-DR; without CD2, sCD3, cyCD3, CD5, CD14, CD15, CD16, CD19, CD64, or cyCD79a expression. Partial dim MPO expression is seen in the blasts. CD34 positive myeloid blasts represent 42.6% of WBC.     

In addition, flow cytometry also reveals an abnormal plasma cell population similar to that seen in prior sample (F18-7300) having abnormal expression of CD19 (absent), CD38 (dim), CD81 (absent), CD117 and monoclonal kappa cytoplasmic light chain restriction; with normal expression of CD27, CD45 and CD138; and without CD56 expression. The abnormal population represents 0.003% of the total white cells by flow cytometry, and may be an underestimate in comparison with morphology. Abnormal plasma cells represent 1.0% of total plasma cells in the sample.     

CYTOGENETIC STUDIES
Cytogenetic analysis will be reported separately. See separate report, CG18-7746.

MOLECULAR STUDIES 
Molecular analysis will be reported separately. See separate reports, M18-39166 to M18-39169.


Peripheral Blood Analysis Performed By: Hematology Laboratory, Dept. of Laboratory Medicine, Memorial Hospital for Cancer and Allied Diseases, 1275 York Avenue, New York, NY 10065, Telephone 212-639-6457, Melissa S. Pessin MD., PhD., Director.

The interpretation of bone marrow biopsy results is based in part on the decalcification procedure performed.
"
